# ::id PMC1234335.0
# ::snt Rapid Estrogen-Induced Phosphorylation of the SRC-3 Coactivator Occurs in an Extranuclear Complex Containing Estrogen Receptor
# ::tok Rapid Estrogen @-@ Induced Phosphorylation of the SRC @-@ 3 Coactivator Occurs in an Extranuclear Complex Containing Estrogen Receptor
(x9 / be-located-at-91
      :mod (x1 / rapid)
      :ARG1 (x5 / phosphorylate-01
            :ARG2-of (x4 / induce-01
                  :ARG0 (x2 / small-molecule
                        :name (x3 / name :op1 "Estrogen")
                        :xref (x / xref :value "PUBCHEM:5757" :prob "10.921484")))
            :ARG1 (x6 / amino-acid
                  :name (x7 / name :op1 "SRC")
                  :mod "3"
                  :name (x8 / name :op1 "Coactivator")
                  :xref (x15 / xref :value "PUBCHEM:21781" :prob "9.856016")))
      :ARG2 (x11 / macro-molecular-complex
            :name (x10 / name :op1 "Extranuclear")
            :ARG0-of (x12 / contain-01
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "Estrogen" :op2 "Receptor")))))


# ::id PMC1234335.2
# ::snt SRC-3/AIB1/ACTR/pCIP/RAC3/TRAM1 is a primary transcriptional coregulator for estrogen receptor (ER).
# ::tok SRC @-@ 3/AIB1/ACTR/pCIP/RAC3/TRAM1 is a primary transcriptional coregulator for estrogen receptor ( ER ) .
(x4 / transcribe-01
      :ARG0 (x3 / primary
            :domain (x1 / protein
                  :name (x2 / name :op1 "SRC" :op2 "3/AIB1/ACTR/pCIP/RAC3/TRAM1")))
      :ARG1 (x5 / and
            :op1 (x6 / enzyme
                  :name (x7 / name :op1 "estrogen" :op2 "receptor"))
            :op2 (x8 / protein
                  :name (x9 / name :op1 "erα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))))


# ::id PMC1234335.3
# ::snt Six SRC-3 phosphorylation sites have been identified, and these can be induced by steroids, cytokines, and growth factors, involving multiple kinase signaling pathways.
# ::tok Six SRC @-@ 3 phosphorylation sites have been identified , and these can be induced by steroids , cytokines , and growth factors , involving multiple kinase signaling pathways .
(x6 / and
      :op1 (x5 / identify-01
            :ARG1 (x4 / site
                  :quant "6"
                  :ARG0-of (x3 / phosphorylate-01
                        :ARG1 (x1 / protein
                              :name (x2 / name :op1 "SRC-3")))))
      :op2 (x7 / possible-01
            :ARG1 (x9 / induce-01
                  :ARG1 (x8 / this)
                  :ARG0 (x12 / and
                        :op1 (x10 / steroid)
                        :op2 (x11 / cytokine)
                        :op2 (x13 / growth-factor)))
            :ARG0-of (x14 / involve-01
                  :ARG1 (x18 / pathway
                        :mod (x15 / disease
                              :name (x16 / name :op1 "multiple" :op2 "kinase"))
                        :ARG0-of (x17 / signal-07)))))


# ::id PMC1234335.4
# ::snt Using phosphospecific antibodies for six phosphorylation sites, we investigated the mechanisms involved in estradiol (E2)-induced SRC-3 phosphorylation and found that this occurs only when either activated estrogen receptor α (ERα) or activated ERβ is present.
# ::tok Using phosphospecific antibodies for six phosphorylation sites , we investigated the mechanisms involved in estradiol ( E2 ) -induced SRC @-@ 3 phosphorylation and found that this occurs only when either activated estrogen receptor α ( ERα ) or activated ERβ is present .
(x7 / investigate-01
      :manner (x1 / use-01
            :ARG1 (x3 / antibody
                  :name (x2 / name :op1 "phosphospecific"))
            :ARG2 (x5 / site
                  :quant "6"
                  :mod (x4 / phosphorylate-01)))
      :ARG0 (x6 / we)
      :ARG1 (x8 / mechanism
            :ARG0-of (x16 / find-01
                  :ARG1 (x9 / involve-01
                        :ARG2 (x15 / and
                              :op1 (x10 / small-molecule
                                    :name (x11 / name :op1 "estradiol")
                                    :xref (x31 / xref :value "PUBCHEM:5757" :prob "13.090267"))
                              :op2 (x14 / phosphorylate-01
                                    :ARG1 (x12 / protein
                                          :name (x13 / name :op1 "SRC-3")))))
                  :ARG1 (x17 / this)
                  :mod (x18 / only)
                  :time (x29 / present-02
                        :ARG1 (x19 / or
                              :op1 (x20 / activate-01
                                    :ARG1 (x21 / enzyme
                                          :name (x22 / name
                                                :op1 "estrogen"
                                                :op2 "receptor"
                                                :op3 "α")
                                          :ARG1-of (x23 / describe-01
                                                :ARG0 (x24 / protein
                                                      :name (x25 / name :op1 "ERα")
                                                      :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))))
                              :op2 (x26 / enzyme
                                    :ARG1-of (x27 / activate-01)
                                    :name (x28 / name :op1 "ERβ")
                                    :xref (x30 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))))))


# ::id PMC1234335.6
# ::snt Mutations in the coactivator binding groove of the ERα ligand binding domain inhibit E2-stimulated SRC-3 phosphorylation, as do mutations in the nuclear receptor-interacting domain of SRC-3, suggesting that ERα must directly contact SRC-3 for this posttranslational modification to take place.
# ::tok Mutations in the coactivator binding groove of the ERα ligand binding domain inhibit E2 @-@ stimulated SRC @-@ 3 phosphorylation , as do mutations in the nuclear receptor @-@ interacting domain of SRC @-@ 3 , suggesting that ERα must directly contact SRC @-@ 3 for this posttranslational modification to take place .
(x1 / multi-sentence
      :snt1 (x5 / bind-01
            :ARG1 (x2 / mutate-01
                  :ARG1 (x3 / gene
                        :name (x4 / name :op1 "coactivator")
                        :xref (x40 / xref :value "UNIPROT:NCOA5_HUMAN" :prob "0.242")))
            :ARG1 (x6 / groove)
            :ARG2 (x7 / protein
                  :name (x8 / name :op1 "ERα")
                  :xref (x41 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
      :snt2 (x12 / inhibit-01
            :ARG0 (x11 / domain
                  :ARG0-of (x10 / bind-01
                        :ARG1 (x9 / ligand)))
            :ARG1 (x18 / phosphorylate-01
                  :ARG1-of (x15 / stimulate-01
                        :ARG0 (x13 / protein
                              :name (x14 / name :op1 "E2")))
                  :ARG1 (x16 / protein
                        :name (x17 / name :op1 "SRC-3")))
            :ARG1-of (x37 / modify-01
                  :ARG0 (x19 / mutate-01
                        :location (x23 / domain
                              :ARG0-of (x22 / interact-01
                                    :ARG1 (x21 / receptor
                                          :mod (x20 / nucleus
                                                :xref (x42 / xref :value "GO:0005634" :prob "0.8"))))
                              :part-of (x24 / protein
                                    :name (x25 / name :op1 "SRC-3")))
                        :ARG0-of (x26 / suggest-01
                              :ARG1 (x29 / obligate-01
                                    :ARG1 (x27 / protein
                                          :name (x28 / name :op1 "ERα")
                                          :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                                    :ARG2 (x31 / contact-01
                                          :ARG1-of (x30 / direct-02)
                                          :ARG1 (x32 / protein
                                                :name (x33 / name :op1 "SRC-3"))))
                              :ARG0 (x34 / this)))
                  :time (x35 / after
                        :op1 (x36 / translate-02))
                  :ARG1 (x38 / take-01
                        :ARG1 (x39 / place)))))


# ::id PMC1234335.7
# ::snt A transcriptionally inactive ERα mutant which localizes to the cytoplasm supports E2-induced SRC-3 phosphorylation.
# ::tok A transcriptionally inactive ERα mutant which localizes to the cytoplasm supports E2 @-@ induced SRC @-@ 3 phosphorylation .
(x8 / support-01
      :ARG0 (x2 / activate-01
            :mod (x1 / transcribe-01)
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "ERα")
                  :ARG2-of (x5 / mutate-01)
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
            :ARG0-of (x6 / localize-01)
            :ARG2 (x7 / cytoplasm
                  :xref (x15 / xref :value "GO:0005737" :prob "0.8")))
      :ARG1 (x14 / phosphorylate-01
            :ARG2-of (x11 / induce-01
                  :ARG0 (x9 / enzyme
                        :name (x10 / name :op1 "E2")))
            :ARG1 (x12 / protein
                  :name (x13 / name :op1 "SRC-3"))))


# ::id PMC1234335.8
# ::snt Mutations of the ERα DNA binding domain did not block this rapid E2-dependent SRC-3 phosphorylation.
# ::tok Mutations of the ERα DNA binding domain did not block this rapid E2 @-@ dependent SRC @-@ 3 phosphorylation .
(x8 / block-01
      :ARG0 (x1 / mutate-01
            :ARG1 (x7 / domain
                  :mod (x2 / protein
                        :name (x3 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                  :mod (x6 / bind-01
                        :ARG1 (x4 / nucleic-acid
                              :wiki "dna"
                              :name (x5 / name :op1 "DNA")))))
      :polarity "-"
      :ARG1 (x16 / phosphorylate-01
            :mod (x9 / this)
            :mod (x10 / rapid)
            :ARG0-of (x13 / depend-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "E2")))
            :ARG1 (x14 / protein
                  :name (x15 / name :op1 "SRC-3"))))


# ::id PMC1234335.10
# ::snt Our results provide evidence for an early nongenomic action of ER on SRC-3 that supports the well-established downstream genomic roles of estrogen and coactivators.
# ::tok Our results provide evidence for an early nongenomic action of ER on SRC @-@ 3 that supports the well @-@ established downstream genomic roles of estrogen and coactivators .
(x4 / provide-01
      :ARG0 (x2 / thing
            :poss (x1 / we)
            :ARG2-of (x3 / result-01))
      :ARG1 (x5 / evidence-01
            :ARG1 (x9 / act-01
                  :time (x6 / early)
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "nongenomic"))
                  :ARG0 (x10 / protein
                        :name (x11 / name :op1 "erα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593")))
            :location (x12 / protein
                  :name (x13 / name :op1 "SRC-3"))
            :ARG0-of (x14 / support-01
                  :ARG1 (x19 / role
                        :ARG0-of (x17 / downstream
                              :ARG1-of (x16 / establish-01
                                    :ARG1-of (x15 / well-09)))
                        :mod (x18 / genome)
                        :poss (x20 / small-molecule
                              :name (x21 / name :op1 "estrogen")
                              :xref (x23 / xref :value "PUBCHEM:5757" :prob "10.921484"))))
            :ARG0-of (x22 / coactivate-01)))


# ::id PMC1234335.12
# ::snt Estradiol induces a mobility change of SRC-3 on SDS-PAGE gels in an ER-dependent manner.
# ::tok Estradiol induces a mobility change of SRC @-@ 3 on SDS @-@ PAGE gels in an ER @-@ dependent manner .
(x3 / induce-01
      :ARG0 (x1 / small-molecule
            :name (x2 / name :op1 "Estradiol")
            :xref (x13 / xref :value "PUBCHEM:5757" :prob "13.090267"))
      :ARG2 (x5 / change-01
            :ARG1 (x4 / mobility)
            :ARG1 (x6 / protein
                  :name (x7 / name :op1 "SRC-3"))
            :location (x9 / gel
                  :name (x8 / name :op1 "SDS-PAGE"))
            :manner (x12 / depend-01
                  :ARG1 (x10 / protein
                        :name (x11 / name :op1 "erα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593")))))


# ::id PMC1234335.13
# ::snt It is well known that posttranslational modifications of proteins (e.g., phosphorylation) can change their electrophoretic mobility on SDS-PAGE gels.
# ::tok It is well known that posttranslational modifications of proteins ( e.g . , phosphorylation ) can change their electrophoretic mobility on SDS @-@ PAGE gels .
(x9 / change-01
      :ARG1-of (x2 / know-01
            :mod (x1 / well)
            :ARG1 (x5 / modify-01
                  :time (x3 / after
                        :op1 (x4 / translate-02))
                  :ARG1 (x6 / protein))
            :example (x8 / possible-01
                  :ARG1 (x7 / phosphorylate-01)))
      :ARG1 (x15 / gel
            :ARG1-of (x12 / mobility
                  :ARG0 (x10 / enzyme
                        :name (x11 / name :op1 "electrophoretic"))
                  :location (x13 / thing
                        :name (x14 / name :op1 "SDS-PAGE")))))


# ::id PMC1234335.14
# ::snt Protein modification pathways can be activated by various stimuli including hormones and growth factors.
# ::tok Protein modification pathways can be activated by various stimuli including hormones and growth factors .
(x1 / possible-01
      :ARG1 (x6 / activate-01
            :ARG1 (x5 / pathway
                  :ARG0-of (x4 / modify-01
                        :ARG1 (x2 / enzyme
                              :name (x3 / name :op1 "Protein")
                              :xref (x / xref :value "UNIPROT:S45A3_HUMAN" :prob "0.372"))))
            :ARG0 (x8 / stimulus
                  :mod (x7 / various)
                  :ARG2-of (x9 / include-01
                        :ARG1 (x11 / and
                              :op1 (x10 / hormone)
                              :op2 (x12 / growth-factor))))))


# ::id PMC1234335.15
# ::snt To investigate the effect of estradiol (E2) on the migration pattern of SRC-3 on an SDS-PAGE gel, E2 induction (10 nM, 1 h) was performed in HEK293T cells transiently transfected with Flag-tagged wild-type SRC-3 (SRC-3) with or without ERs.
# ::tok To investigate the effect of estradiol ( E2 ) on the migration pattern of SRC @-@ 3 on an SDS @-@ PAGE gel , E2 induction ( 10 nM , 1 h ) was performed in HEK293T cells transiently transfected with Flag @-@ tagged wild @-@ type SRC @-@ 3 ( SRC @-@ 3 ) with or without ERs .
(x1 / multi-sentence
      :snt1 (x25 / perform-02
            :purpose (x2 / investigate-01
                  :ARG1 (x3 / affect-01
                        :ARG0 (x4 / and
                              :op1 (x5 / small-molecule
                                    :name (x6 / name :op1 "estradiol")
                                    :xref (x41 / xref :value "PUBCHEM:5757" :prob "13.090267"))
                              :op2 (x7 / enzyme
                                    :name (x8 / name :op1 "E2")))
                        :ARG1 (x9 / pattern-01
                              :ARG1 (x10 / migrate-01
                                    :ARG2 (x11 / protein
                                          :name (x12 / name :op1 "SRC-3")))
                              :ARG2 (x15 / gel
                                    :mod (x13 / thing
                                          :name (x14 / name :op1 "SDS-PAGE"))))))
            :ARG1 (x18 / induce-01
                  :ARG2 (x16 / protein
                        :name (x17 / name :op1 "E2"))
                  :ARG1 (x19 / small-molecule
                        :quant (x20 / concentration-quantity
                              :quant "10"
                              :unit (x21 / nanomolar))
                        :ARG1-of (x22 / mean-01
                              :ARG2 (x23 / temporal-quantity
                                    :quant "1"
                                    :unit (x24 / hour)))))
            :location (x26 / cell-line
                  :name (x27 / name :op1 "HEK293T")))
      :snt2 (x29 / transfect-01
            :ARG1-of (x28 / transient-02)
            :ARG2 (x33 / enzyme
                  :ARG1-of (x32 / tag-01
                        :ARG2 (x30 / protein
                              :name (x31 / name :op1 "Flag")))
                  :mod (x34 / wild-type)
                  :name (x35 / name :op1 "SRC")
                  :mod "3"
                  :xref (x / xref :value "UNIPROT:SRC_HUMAN" :prob "1.004"))
            :ARG1-of (x36 / describe-01
                  :ARG0 (x37 / protein
                        :name (x38 / name :op1 "SRC-3")))
            :ARG2 (x39 / or
                  :manner (x40 / ers))))


# ::id PMC1234335.16
# ::snt As shown in Fig. , E2 treatment caused an upward smearing migration pattern of SRC-3 in the presence of ERα or ERβ (lanes 4 and 6).
# ::tok As shown in Fig . , E2 treatment caused an upward smearing migration pattern of SRC @-@ 3 in the presence of ERα or ERβ ( lanes 4 and 6 ) .
(x6 / cause-01
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure))
      :ARG0 (x5 / treat-04
            :ARG2 (x3 / small-molecule
                  :name (x4 / name :op1 "E2")
                  :xref (x22 / xref :value "PUBCHEM:5757" :prob "13.96532")))
      :ARG1 (x8 / migrate-01
            :ARG0 (x7 / smear-01)
            :ARG1 (x9 / pattern-01
                  :ARG1 (x10 / protein
                        :name (x11 / name :op1 "SRC-3")))
            :condition (x12 / present-02
                  :ARG1 (x15 / or
                        :op1 (x13 / protein
                              :name (x14 / name :op1 "ERα")
                              :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                        :op2 (x16 / protein
                              :name (x17 / name :op1 "ERβ")
                              :xref (x21 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))))
            :ARG1-of (x18 / compare-01
                  :ARG1 (x19 / lane :mod "4")
                  :ARG2 (x20 / lane :mod "6"))))


# ::id PMC1234335.17
# ::snt The mobility shift was not observed in the absence of ER (Fig. , lane 2).
# ::tok The mobility shift was not observed in the absence of ER ( Fig . , lane 2 ) .
(x3 / observe-01
      :ARG1 (x2 / shift-01
            :ARG1 (x1 / mobility))
      :polarity "-"
      :condition (x4 / absent-01
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "erα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593")))
      :ARG1-of (x7 / describe-01
            :ARG0 (x9 / lane
                  :part-of (x8 / figure)
                  :mod "2")))


# ::id PMC1234335.18
# ::snt Treatment with E2 did not change the mobility pattern of an A6 SRC-3 mutated at all six phosphorylation sites (Fig. , lanes 7 and 8).
# ::tok Treatment with E2 did not change the mobility pattern of an A6 SRC @-@ 3 mutated at all six phosphorylation sites ( Fig . , lanes 7 and 8 ) .
(x4 / change-01
      :ARG0 (x1 / treat-04
            :ARG2 (x2 / small-molecule
                  :name (x3 / name :op1 "E2")
                  :xref (x / xref :value "PUBCHEM:5757" :prob "13.96532")))
      :polarity "-"
      :ARG1 (x6 / pattern-01
            :ARG1 (x5 / mobility)
            :ARG1 (x7 / enzyme
                  :name (x8 / name :op1 "a6-integrin")
                  :ARG2-of (x11 / mutate-01
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "SRC-3"))))
            :location (x14 / site
                  :mod (x12 / all)
                  :quant "6"
                  :mod (x13 / phosphorylate-01))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / figure :mod "8b")))
      :ARG0-of (x17 / compare-01
            :ARG1 (x18 / lane :mod "7")
            :ARG2 (x19 / lane :mod "8")))


# ::id PMC1234335.19
# ::snt These results indicated that E2 could alter the electrophoretic mobility of the wild-type SRC-3 but not its phosphorylation-site A6 mutant, implying that the E2-induced mobility change of SRC-3 is the result of SRC-3 phosphorylation.
# ::tok These results indicated that E2 could alter the electrophoretic mobility of the wild @-@ type SRC @-@ 3 but not its phosphorylation @-@ site A6 mutant , implying that the E2 @-@ induced mobility change of SRC @-@ 3 is the result of SRC @-@ 3 phosphorylation .
(x4 / indicate-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x5 / possible-01
            :ARG1 (x8 / alter-01
                  :ARG0 (x6 / small-molecule
                        :name (x7 / name :op1 "E2")
                        :xref (x / xref :value "PUBCHEM:5757" :prob "13.96532"))
                  :ARG1 (x10 / mobility
                        :name (x9 / name :op1 "electrophoretic"))))
      :ARG1 (x24 / change-01
            :mod (x11 / wild-type
                  :ARG1-of (x14 / contrast-01
                        :ARG2 (x12 / protein
                              :name (x13 / name :op1 "SRC-3"))
                        :ARG2 (x15 / phosphorylate-01 :polarity "-")
                        :ARG1 (x16 / protein-segment
                              :name (x17 / name :op1 "a6-integrin")
                              :ARG2-of (x18 / mutate-01))
                        :ARG0-of (x19 / imply-01
                              :ARG1 (x22 / induce-01
                                    :ARG0 (x20 / protein
                                          :name (x21 / name :op1 "E2"))))))
            :ARG1-of (x23 / mobility)
            :ARG1 (x25 / protein
                  :name (x26 / name :op1 "SRC-3"))
            :ARG2-of (x27 / result-01
                  :ARG1 (x30 / phosphorylate-01
                        :ARG1 (x28 / protein
                              :name (x29 / name :op1 "SRC-3"))))))


# ::id PMC1234335.20
# ::snt Since this was observed only in the presence of an ER, the E2-induced SRC-3 mobility shift depends on expression of either ERα or ERβ.
# ::tok Since this was observed only in the presence of an ER , the E2 @-@ induced SRC @-@ 3 mobility shift depends on expression of either ERα or ERβ.
(x1 / cause-01
      :ARG0 (x3 / observe-01
            :ARG1 (x2 / this)
            :mod (x4 / only)
            :condition (x5 / present-02
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "ERα")
                        :xref (x23 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))))
      :ARG1 (x15 / depend-01
            :ARG0 (x14 / shift-01
                  :ARG2-of (x10 / induce-01
                        :ARG0 (x8 / enzyme
                              :name (x9 / name :op1 "E2")))
                  :ARG1 (x13 / mobility
                        :op1 (x11 / protein
                              :name (x12 / name :op1 "SRC-3"))))
            :ARG1 (x16 / express-03
                  :ARG2 (x19 / or
                        :op1 (x17 / protein
                              :name (x18 / name :op1 "ERα")
                              :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                        :op2 (x20 / enzyme
                              :name (x21 / name :op1 "ERβ.")
                              :xref (x22 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.613"))))))


# ::id PMC1234335.21
# ::snt Estradiol-induced SRC-3 phosphorylation requires ER.
# ::tok Estradiol @-@ induced SRC @-@ 3 phosphorylation requires ER .
(x7 / require-01
      :ARG0 (x6 / phosphorylate-01
            :ARG2-of (x3 / induce-01
                  :ARG0 (x1 / small-molecule
                        :name (x2 / name :op1 "Estradiol")
                        :xref (x10 / xref :value "PUBCHEM:5757" :prob "13.090267")))
            :ARG1 (x4 / protein
                  :name (x5 / name :op1 "SRC-3")))
      :ARG1 (x8 / protein
            :name (x9 / name :op1 "erα")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593")))


# ::id PMC1234335.22
# ::snt In cells that express ERα, E2 induces SRC-3 phosphorylation at all six phosphorylation sites identified ().
# ::tok In cells that express ERα, E2 induces SRC @-@ 3 phosphorylation at all six phosphorylation sites identified ( ) .
(x12 / identify-01
      :location (x1 / cell
            :ARG0-of (x5 / induce-01
                  :ARG0 (x2 / express-03
                        :ARG2 (x3 / enzyme
                              :name (x4 / name :op1 "E2")))
                  :ARG2 (x8 / phosphorylate-01
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "SRC-3"))
                        :location (x11 / site
                              :mod (x9 / all)
                              :quant "6"
                              :mod (x10 / phosphorylate-01)))))
      :ARG1 (x13 / statistical-test-91
            :ARG2 (x14 / less-than :op1 "0.02")))


# ::id PMC1234335.23
# ::snt To determine whether E2-induced SRC-3 phosphorylation is dependent on the presence of ER, HEK293T cells transfected with SRC-3 together with or without either ERα or ERβ were treated with E2.
# ::tok To determine whether E2 @-@ induced SRC @-@ 3 phosphorylation is dependent on the presence of ER , HEK293T cells transfected with SRC @-@ 3 together with or without either ERα or ERβ were treated with E2 .
(x14 / transfect-01
      :purpose (x1 / determine-01
            :ARG1 (x8 / depend-01
                  :mode "interrogative"
                  :ARG2 (x7 / phosphorylate-01
                        :ARG2-of (x4 / induce-01
                              :ARG0 (x2 / enzyme
                                    :name (x3 / name :op1 "E2")))
                        :ARG1 (x5 / protein
                              :name (x6 / name :op1 "SRC-3")))
                  :ARG1 (x9 / present-02
                        :ARG1 (x10 / protein
                              :name (x11 / name :op1 "ERα")
                              :xref (x29 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))))
      :ARG0 (x12 / cell-line
            :name (x13 / name :op1 "HEK293T"))
      :ARG2 (x15 / protein
            :name (x16 / name :op1 "SRC-3"))
      :mod (x17 / together)
      :ARG2 (x18 / or
            :op1 (x25 / treat-04
                  :polarity "-"
                  :ARG1 (x22 / or
                        :mod (x19 / either)
                        :op1 (x20 / protein
                              :name (x21 / name :op1 "ERα")
                              :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                        :op2 (x23 / protein
                              :name (x24 / name :op1 "ERβ")
                              :xref (x28 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
                  :ARG2 (x26 / small-molecule
                        :name (x27 / name :op1 "E2")
                        :xref (x30 / xref :value "PUBCHEM:5757" :prob "13.96532")))))


# ::id PMC1234335.25
# ::snt As shown in Fig. , E2 induced SRC-3 phosphorylation at all six sites (T24, S505, S543, S857, S860, and S867) in cells transfected with an expression vector for wild-type ERα (Fig. , lanes 3 and 4, rows 1 to 6) or ERβ (Fig. , rows 1 to 6), but not in cells transfected with an empty expression vector (Fig. , lanes 1 and 2, rows 1 to 6).
# ::tok As shown in Fig . , E2 induced SRC @-@ 3 phosphorylation at all six sites ( T24 , S505 , S543 , S857 , S860 , and S867 ) in cells transfected with an expression vector for wild @-@ type ERα ( Fig . , lanes 3 and 4 , rows 1 to 6 ) or ERβ ( Fig . , rows 1 to 6 ) , but not in cells transfected with an empty expression vector ( Fig . , lanes 1 and 2 , rows 1 to 6 ) .
(x1 / multi-sentence
      :snt1 (x6 / induce-01
            :ARG1-of (x2 / show-01
                  :ARG0 (x3 / figure))
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "E2"))
            :ARG2 (x9 / phosphorylate-01
                  :ARG1 (x7 / protein
                        :name (x8 / name :op1 "SRC-3"))
                  :location (x11 / protein-segment
                        :mod (x10 / all)
                        :quant "6"
                        :ARG1-of (x12 / mean-01
                              :ARG2 (x23 / and
                                    :op1 (x13 / amino-acid
                                          :mod "24"
                                          :name (x14 / name :op1 "threonine")
                                          :xref (x65 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                    :op2 (x15 / amino-acid
                                          :mod "505"
                                          :name (x16 / name :op1 "serine")
                                          :xref (x66 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x17 / amino-acid
                                          :mod "543"
                                          :name (x18 / name :op1 "serine")
                                          :xref (x67 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x19 / amino-acid
                                          :mod "857"
                                          :name (x20 / name :op1 "serine")
                                          :xref (x64 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x21 / amino-acid
                                          :mod "860"
                                          :name (x22 / name :op1 "serine")
                                          :xref (x63 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x24 / amino-acid
                                          :mod "867"
                                          :name (x25 / name :op1 "serine")
                                          :xref (x62 / xref :value "PUBCHEM:5951" :prob "11.218784"))))))
            :location (x26 / cell
                  :ARG1-of (x27 / transfect-01
                        :ARG2 (x28 / vector
                              :ARG2-of (x29 / express-03
                                    :ARG1 (x30 / enzyme
                                          :mod (x31 / wild-type)
                                          :name (x32 / name :op1 "ERα")
                                          :xref (x61 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))))))
            :ARG1-of (x33 / describe-01
                  :ARG0 (x34 / figure :mod "4a")))
      :snt2 (x48 / contrast-01
            :ARG1 (x46 / row
                  :ARG1 (x35 / and
                        :op1 (x38 / and
                              :op1 (x36 / lane :mod "3")
                              :op2 (x37 / lane :mod "4")
                              :op2 (x39 / row))
                        :op2 (x41 / or
                              :op1 (x40 / value-interval :op1 "1" :op2 "6")
                              :op2 (x42 / protein
                                    :name (x43 / name :op1 "ERβ")
                                    :ARG1-of (x44 / describe-01
                                          :ARG0 (x45 / figure :mod "3c"))
                                    :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))))
                  :mod "1"
                  :ARG2 (x47 / figure :mod "6"))
            :ARG2 (x50 / transfect-01
                  :polarity "-"
                  :ARG1 (x49 / cell)
                  :ARG2 (x58 / and
                        :op1 (x53 / vector
                              :ARG1-of (x51 / empty-02)
                              :mod (x52 / express-03)
                              :ARG1-of (x54 / describe-01
                                    :ARG0 (x55 / figure)))
                        :op1 (x56 / lane :mod "1")
                        :op2 (x57 / lane :mod "2")
                        :op2 (x59 / row))
                  :ARG2 (x60 / value-interval :op1 "1" :op2 "6"))))


# ::id PMC1234335.26
# ::snt As a negative control, E2-induced SRC-3 phosphorylation was not observed when the SRC-3 phosphorylation mutant A6 was used (Fig. , lanes 5 and 6, rows 1 to 6), even though the A6 form of SRC-3, like wild-type SRC-3, could still bind to ERα in response to E2 (Fig. , lane 6, row 7).
# ::tok As a negative control , E2 @-@ induced SRC @-@ 3 phosphorylation was not observed when the SRC @-@ 3 phosphorylation mutant A6 was used ( Fig . , lanes 5 and 6 , rows 1 to 6 ) , even though the A6 form of SRC @-@ 3 , like wild @-@ type SRC @-@ 3 , could still bind to ERα in response to E2 ( Fig . , lane 6 , row 7 ) .
(x1 / multi-sentence
      :snt1 (x22 / and
            :op1 (x10 / observe-01
                  :ARG1-of (x3 / control-01
                        :ARG2-of (x2 / negative-01))
                  :ARG1 (x9 / phosphorylate-01
                        :ARG2-of (x6 / induce-01
                              :ARG0 (x4 / enzyme
                                    :name (x5 / name :op1 "E2")))
                        :ARG1 (x7 / protein
                              :name (x8 / name :op1 "SRC-3")))
                  :polarity "-"
                  :time (x17 / use-01
                        :ARG1 (x14 / enzyme
                              :ARG0-of (x13 / phosphorylate-01
                                    :ARG1 (x11 / protein
                                          :name (x12 / name :op1 "SRC-3")))
                              :ARG2-of (x15 / mutate-01)
                              :name (x16 / name :op1 "a6-integrin")))
                  :ARG1-of (x18 / describe-01
                        :ARG0 (x19 / figure :mod "1b")))
            :op1 (x20 / lane :mod "5")
            :op2 (x21 / lane :mod "6")
            :op2 (x23 / row))
      :snt2 (x25 / have-concession-91
            :ARG1 (x24 / value-interval :op1 "1" :op2 "6")
            :ARG2 (x46 / in-a-row
                  :op1 (x31 / resemble-01
                        :ARG1 (x28 / form
                              :mod (x26 / protein
                                    :name (x27 / name :op1 "a6-integrin"))
                              :mod (x29 / protein
                                    :name (x30 / name :op1 "SRC-3")))
                        :ARG2 (x37 / bind-01
                              :ARG0 (x35 / possible-01
                                    :mod (x32 / wild-type)
                                    :mod (x33 / protein
                                          :name (x34 / name :op1 "SRC-3"))
                                    :mod (x36 / still))
                              :ARG2 (x38 / protein
                                    :name (x39 / name :op1 "ERα")
                                    :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                              :ARG2-of (x40 / respond-01
                                    :ARG1 (x41 / small-molecule
                                          :name (x42 / name :op1 "E2")
                                          :xref (x47 / xref :value "PUBCHEM:5757" :prob "13.96532")))
                              :ARG1-of (x43 / describe-01
                                    :ARG0 (x44 / figure :mod "1b"))))
                  :op2 (x45 / lane :mod "6")
                  :mod "7")))


# ::id PMC1234335.27
# ::snt These results indicated that E2-induced SRC-3 phosphorylation requires either form of ER.
# ::tok These results indicated that E2 @-@ induced SRC @-@ 3 phosphorylation requires either form of ER .
(x4 / indicate-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x11 / require-01
            :ARG0 (x10 / phosphorylate-01
                  :ARG2-of (x7 / induce-01
                        :ARG0 (x5 / enzyme
                              :name (x6 / name :op1 "E2")))
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "SRC-3")))
            :ARG1 (x13 / form
                  :mod (x12 / either)
                  :mod (x14 / protein
                        :name (x15 / name :op1 "erα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593")))))


# ::id PMC1234335.28
# ::snt Estradiol-induced SRC-3 phosphorylation requires the presence of ER.
# ::tok Estradiol @-@ induced SRC @-@ 3 phosphorylation requires the presence of ER .
(x7 / require-01
      :ARG0 (x6 / phosphorylate-01
            :ARG2-of (x3 / induce-01
                  :ARG0 (x1 / small-molecule
                        :name (x2 / name :op1 "Estradiol")
                        :xref (x11 / xref :value "PUBCHEM:5757" :prob "13.090267")))
            :ARG1 (x4 / protein
                  :name (x5 / name :op1 "SRC-3")))
      :ARG1 (x8 / present-02
            :ARG1 (x9 / protein
                  :name (x10 / name :op1 "erα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))))


# ::id PMC1234335.29
# ::snt (A) HEK293T cells were transfected with Flag-tagged SRC-3 (SRC-3) or its phosphorylation mutant (A6), in the absence or presence of ERα.
# ::tok ( A ) HEK293T cells were transfected with Flag @-@ tagged SRC @-@ 3 ( SRC @-@ 3 ) or its phosphorylation mutant ( A6 ) , in the absence or presence of ERα.
(x3 / transfect-01
      :ARG1 (x1 / cell-line
            :name (x2 / name :op1 "HEK293T"))
      :ARG2 (x11 / or
            :ARG1-of (x6 / tag-01
                  :ARG2 (x4 / protein
                        :name (x5 / name :op1 "Flag")))
            :op1 (x7 / protein
                  :name (x8 / name :op1 "SRC-3"))
            :op1 (x9 / protein
                  :name (x10 / name :op1 "SRC-3"))
            :op2 (x12 / phosphorylate-01
                  :ARG1 (x13 / enzyme
                        :ARG2-of (x14 / mutate-01)
                        :ARG1-of (x15 / mutate-01 :mod "-/-")))
            :op2 (x21 / mediate-01
                  :location (x16 / or
                        :op2 (x17 / present-02)
                        :op1 (x18 / absent-01
                              :ARG1 (x19 / protein
                                    :name (x20 / name :op1 "e-cadherin")
                                    :xref (x / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703"))))
                  :ARG0 (x22 / protein-segment
                        :name (x23 / name :op1 "riα")))))


# ::id PMC1234335.30
# ::snt Forty-eight hours later, 10 nM E2 (+) ...
# ::tok Forty @-@ eight hours later , 10 nM E2 ( + ) ...
(x1 / and
      :op1 (x5 / late
            :op1 (x2 / temporal-quantity
                  :quant (x3 / value-interval :op1 "40" :op2 "8")
                  :unit (x4 / hour))
            :degree (x6 / more))
      :op2 (x7 / small-molecule
            :quant (x8 / concentration-quantity
                  :quant "10"
                  :unit (x9 / nanomolar))
            :name (x10 / name :op1 "E2")
            :mod (x11 / and)
            :xref (x / xref :value "PUBCHEM:5757" :prob "13.96532")))


# ::id PMC1234335.31
# ::snt In order to confirm the ER dependence with endogenous proteins, siRNA against ERα (siERα) was transfected into MCF-7 cells to reduce the expression of endogenous ERα.
# ::tok In order to confirm the ER dependence with endogenous proteins , siRNA against ERα ( siERα ) was transfected into MCF @-@ 7 cells to reduce the expression of endogenous ERα.
(x15 / reduce-01
      :purpose (x1 / confirm-01
            :ARG1 (x4 / depend-01
                  :ARG0 (x2 / protein
                        :name (x3 / name :op1 "ERα")
                        :xref (x20 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                  :ARG1 (x6 / protein
                        :mod (x5 / endogenous))))
      :ARG1 (x8 / nucleic-acid
            :name (x7 / name :op1 "siRNA")
            :ARG0-of (x9 / counter-01
                  :ARG1 (x10 / protein
                        :name (x11 / name :op1 "ERα" :op2 "siERα"))))
      :ARG1-of (x12 / transfect-01
            :ARG1 (x14 / cell-line
                  :name (x13 / name :op1 "MCF-7")))
      :ARG1 (x16 / express-03
            :ARG2 (x17 / enzyme
                  :mod (x18 / endogenous)
                  :name (x19 / name :op1 "ERα.")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.613"))))


# ::id PMC1234335.33
# ::snt As shown in Fig. , in the presence of siERα, expression of endogenous ERα was greatly reduced (lanes 3 and 4, row 4), and E2-induced phosphorylation of endogenous SRC-3 was abolished (lanes 3 and 4, rows 1 to 3).
# ::tok As shown in Fig . , in the presence of siERα, expression of endogenous ERα was greatly reduced ( lanes 3 and 4 , row 4 ) , and E2 @-@ induced phosphorylation of endogenous SRC @-@ 3 was abolished ( lanes 3 and 4 , rows 1 to 3 ) .
(x1 / multi-sentence
      :snt1 (x12 / reduce-01
            :ARG1-of (x2 / show-01
                  :ARG0 (x3 / figure))
            :ARG1 (x7 / express-03
                  :condition (x4 / present-02
                        :ARG1 (x5 / small-molecule
                              :name (x6 / name :op1 "siERα,")))
                  :ARG2 (x8 / enzyme
                        :mod (x9 / endogenous)
                        :name (x10 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
            :ARG2 (x11 / great)
            :ARG1-of (x13 / compare-01
                  :ARG1 (x14 / lane :mod "3")
                  :ARG2 (x15 / lane :mod "4")))
      :snt2 (x17 / and
            :op1 (x16 / in-a-row :mod "4")
            :op2 (x24 / abolish-01
                  :ARG1 (x21 / phosphorylate-01
                        :ARG2-of (x20 / induce-01
                              :ARG0 (x18 / enzyme
                                    :name (x19 / name :op1 "E2")))
                        :ARG1 (x22 / protein
                              :name (x23 / name :op1 "SRC-3")))
                  :ARG1-of (x25 / describe-01
                        :ARG0 (x28 / and
                              :op1 (x26 / lane :mod "3")
                              :op2 (x27 / lane :mod "4")
                              :op2 (x29 / row)
                              :op1 (x30 / value-interval :op1 "1" :op2 "3"))))))


# ::id PMC1234335.34
# ::snt In contrast, SRC-3 phosphorylation was still induced when a control siRNA against luciferase (siLuc) was used (lanes 1 and 2, rows 1 to 3).
# ::tok In contrast , SRC @-@ 3 phosphorylation was still induced when a control siRNA against luciferase ( siLuc ) was used ( lanes 1 and 2 , rows 1 to 3 ) .
(x1 / contrast-01
      :ARG2 (x6 / induce-01
            :ARG1 (x4 / phosphorylate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "SRC-3")))
            :mod (x5 / still)
            :time (x14 / use-01
                  :ARG1 (x7 / control-01
                        :ARG0 (x8 / nucleic-acid
                              :name (x9 / name :op1 "siRNA")
                              :ARG0-of (x10 / counter-01
                                    :ARG1 (x11 / enzyme
                                          :name (x12 / name :op1 "luciferase"))))
                        :ARG1-of (x13 / siluc))))
      :ARG1-of (x15 / describe-01
            :ARG0 (x18 / and
                  :op1 (x16 / lane :mod "1")
                  :op2 (x17 / lane :mod "2")
                  :op2 (x19 / row
                        :ARG2 (x20 / value-interval :op1 "1" :op2 "3")))))


# ::id PMC1234335.35
# ::snt This confirmed the data from transient-transfection experiments indicating that E2-induced phosphorylation of SRC-3 requires ER.
# ::tok This confirmed the data from transient @-@ transfection experiments indicating that E2 @-@ induced phosphorylation of SRC @-@ 3 requires ER .
(x7 / indicate-01
      :ARG0 (x6 / experiment-01
            :mod (x1 / this)
            :ARG1-of (x2 / confirm-01
                  :ARG1 (x3 / data
                        :source (x5 / transfect-01
                              :ARG1-of (x4 / transient-02)))))
      :ARG1 (x14 / require-01
            :ARG0 (x11 / phosphorylate-01
                  :ARG2-of (x10 / induce-01
                        :ARG0 (x8 / enzyme
                              :name (x9 / name :op1 "E2")))
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "SRC-3")))
            :ARG1 (x15 / protein
                  :name (x16 / name :op1 "erα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))))


# ::id PMC1234335.36
# ::snt The kinetics of E2-induced SRC-3 phosphorylation also were assessed in HEK293T cells cotransfected with Flag-tagged SRC-3 and ERα.
# ::tok The kinetics of E2 @-@ induced SRC @-@ 3 phosphorylation also were assessed in HEK293T cells cotransfected with Flag @-@ tagged SRC @-@ 3 and ERα.
(x12 / cotransfect-01
      :ARG1 (x9 / assess-01
            :ARG1 (x1 / kinetics
                  :mod (x7 / phosphorylate-01
                        :ARG2-of (x4 / induce-01
                              :ARG0 (x2 / enzyme
                                    :name (x3 / name :op1 "E2")))
                        :ARG1 (x5 / protein
                              :name (x6 / name :op1 "SRC-3"))
                        :mod (x8 / also)))
            :location (x10 / cell-line
                  :name (x11 / name :op1 "HEK293T")))
      :ARG2 (x18 / and
            :op1 (x13 / enzyme
                  :ARG1-of (x16 / tag-01
                        :ARG2 (x14 / protein
                              :name (x15 / name :op1 "Flag")))
                  :name (x17 / name :op1 "SRC")
                  :xref (x / xref :value "UNIPROT:SRC_HUMAN" :prob "1.004"))
            :op2 (x19 / enzyme
                  :name (x20 / name :op1 "ERα.")
                  :xref (x21 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.613"))))


# ::id PMC1234335.37
# ::snt As shown in Fig. , SRC-3 phosphorylation could be observed by 15 min after E2 treatment, represented by phosphorylation at sites T24, S505, and S543 (lanes 3 to 7, rows 1 to 3).
# ::tok As shown in Fig . , SRC @-@ 3 phosphorylation could be observed by 15 min after E2 treatment , represented by phosphorylation at sites T24 , S505 , and S543 ( lanes 3 to 7 , rows 1 to 3 ) .
(x3 / possible-01
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure))
      :ARG1 (x7 / observe-01
            :ARG1 (x6 / phosphorylate-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "SRC-3")))
            :ARG0 (x21 / and
                  :op1 (x10 / after
                        :quant (x8 / temporal-quantity
                              :quant "15"
                              :unit (x9 / minute))
                        :op1 (x13 / treat-04
                              :ARG2 (x11 / small-molecule
                                    :name (x12 / name :op1 "E2")
                                    :xref (x30 / xref :value "PUBCHEM:5757" :prob "13.96532"))))
                  :op2 (x14 / represent-01
                        :ARG0 (x15 / phosphorylate-01
                              :ARG1 (x16 / protein-segment
                                    :mod (x17 / amino-acid
                                          :mod "24"
                                          :name (x18 / name :op1 "threonine")
                                          :xref (x31 / xref :value "PUBCHEM:205" :prob "11.848252")))))
                  :op2 (x19 / amino-acid
                        :mod "505"
                        :name (x20 / name :op1 "serine")
                        :xref (x29 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :op2 (x22 / amino-acid
                        :mod "543"
                        :name (x23 / name :op1 "serine")
                        :xref (x / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :ARG1-of (x24 / describe-01
                        :ARG0 (x25 / lane
                              :mod (x26 / value-interval :op1 "3" :op2 "7")))
                  :ARG0-of (x27 / row))
            :location (x28 / value-interval :op1 "1" :op2 "3")))


# ::id PMC1234335.38
# ::snt Selectivity of hormones and nuclear receptors for induction of SRC-3 phosphorylation.
# ::tok Selectivity of hormones and nuclear receptors for induction of SRC @-@ 3 phosphorylation .
(x1 / select-01
      :ARG1 (x3 / and
            :op1 (x2 / hormone)
            :op2 (x5 / receptor
                  :mod (x4 / nucleus
                        :xref (x / xref :value "GO:0005634" :prob "0.8"))))
      :ARG2 (x6 / induce-01
            :ARG2 (x9 / phosphorylate-01
                  :ARG1 (x7 / protein
                        :name (x8 / name :op1 "SRC-3")))))


# ::id PMC1234335.39
# ::snt It has been shown that E2 and the synthetic androgen R1881 can induce SRC-3 phosphorylation in the presence of ER and androgen receptor, respectively (Fig. ) ().
# ::tok It has been shown that E2 and the synthetic androgen R1881 can induce SRC @-@ 3 phosphorylation in the presence of ER and androgen receptor , respectively ( Fig . ) ( ) .
(x1 / show-01
      :ARG1 (x2 / possible-01
            :ARG1 (x9 / induce-01
                  :ARG0 (x5 / and
                        :op1 (x3 / enzyme
                              :name (x4 / name :op1 "E2"))
                        :op2 (x7 / androgen
                              :mod (x6 / synthetic)
                              :name (x8 / name :op1 "R1881")))
                  :ARG2 (x12 / phosphorylate-01
                        :ARG1 (x10 / protein
                              :name (x11 / name :op1 "SRC-3")))
                  :condition (x13 / present-02
                        :ARG1 (x15 / and
                              :mod (x14 / er :mode "expressive")
                              :op2 (x17 / receptor
                                    :ARG1 (x16 / androgen))
                              :mod (x18 / respective)
                              :ARG1-of (x19 / describe-01
                                    :ARG0 (x20 / figure))
                              :ARG1-of (x21 / statistical-test-91
                                    :ARG2 (x22 / less-than :op1 "0.02")))))))


# ::id PMC1234335.40
# ::snt In order to investigate whether other hormones and their cognate nuclear receptors can induce SRC-3 phosphorylation, HEK293T cells transfected with an SRC-3 expression vector in the absence or presence of progesterone receptor B (PR-B) plasmid were treated with progesterone (P; 10 nM, 1 h).
# ::tok In order to investigate whether other hormones and their cognate nuclear receptors can induce SRC @-@ 3 phosphorylation , HEK293T cells transfected with an SRC @-@ 3 expression vector in the absence or presence of progesterone receptor B ( PR @-@ B ) plasmid were treated with progesterone ( P ; 10 nM , 1 h ) .
(x1 / multi-sentence
      :snt1 (x16 / transfect-01
            :purpose (x2 / investigate-01
                  :ARG1 (x3 / possible-01
                        :mode "interrogative"
                        :ARG1 (x10 / induce-01
                              :ARG0 (x6 / and
                                    :op1 (x5 / hormone
                                          :mod (x4 / other))
                                    :op2 (x9 / receptor
                                          :mod (x7 / cognate)
                                          :mod (x8 / nucleus
                                                :xref (x40 / xref :value "GO:0005634" :prob "0.8"))))
                              :ARG2 (x13 / phosphorylate-01
                                    :ARG1 (x11 / protein
                                          :name (x12 / name :op1 "SRC-3"))))))
            :ARG0 (x14 / cell-line
                  :name (x15 / name :op1 "HEK293T"))
            :ARG2 (x20 / vector
                  :ARG1-of (x19 / express-03
                        :ARG2 (x17 / protein
                              :name (x18 / name :op1 "SRC-3"))))
            :condition (x21 / or
                  :op2 (x22 / present-02)
                  :op1 (x23 / absent-01
                        :ARG1 (x24 / protein
                              :name (x25 / name
                                    :op1 "progesterone"
                                    :op2 "receptor"
                                    :op3 "B")))))
      :snt2 (x32 / treat-04
            :ARG1-of (x26 / describe-01
                  :ARG0 (x27 / thing
                        :ARG2-of (x28 / respond-01
                              :degree (x29 / part))
                        :name (x30 / name :op1 "B")))
            :ARG1 (x31 / plasmid)
            :ARG2 (x33 / and
                  :op1 (x34 / enzyme
                        :name (x35 / name :op1 "progesterone")
                        :xref (x / xref :value "UNIPROT:3BHS1_HUMAN" :prob "0.332"))
                  :op2 (x36 / concentration-quantity
                        :quant "10"
                        :unit (x37 / nanomolar)))
            :duration (x38 / temporal-quantity
                  :quant "1"
                  :unit (x39 / hour))))


# ::id PMC1234335.41
# ::snt As shown in Fig. did not induce SRC-3 phosphorylation in the presence of PR-B (lanes 5 and 6), although in parallel experiments E2 induced ER-dependent SRC-3 phosphorylation (lanes 3 and 4).
# ::tok As shown in Fig . did not induce SRC @-@ 3 phosphorylation in the presence of PR @-@ B ( lanes 5 and 6 ) , although in parallel experiments E2 induced ER @-@ dependent SRC @-@ 3 phosphorylation ( lanes 3 and 4 ) .
(x14 / have-concession-91
      :ARG1 (x4 / induce-01
            :ARG0 (x1 / and
                  :ARG1-of (x2 / show-01
                        :medium (x3 / figure)))
            :polarity "-"
            :ARG2 (x7 / phosphorylate-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "SRC-3")))
            :condition (x8 / present-02
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "PR-B")))
            :ARG1-of (x11 / compare-01
                  :ARG1 (x12 / lane :mod "5")
                  :ARG2 (x13 / lane :mod "6")))
      :ARG2 (x19 / induce-01
            :ARG0 (x16 / experiment-01
                  :ARG0-of (x15 / parallel-01)
                  :ARG1 (x17 / enzyme
                        :name (x18 / name :op1 "E2")))
            :ARG2 (x25 / phosphorylate-01
                  :ARG0-of (x22 / depend-01
                        :ARG1 (x20 / protein
                              :name (x21 / name :op1 "erα")
                              :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593")))
                  :ARG1 (x23 / protein
                        :name (x24 / name :op1 "SRC-3"))))
      :ARG1-of (x26 / describe-01
            :ARG0 (x29 / and
                  :op1 (x27 / lane :mod "3")
                  :op2 (x28 / lane :mod "4"))))


# ::id PMC1234335.42
# ::snt Representative data for SRC-3 phosphorylation at S505 and S867 were shown, and other sites had a similar pattern (data not shown).
# ::tok Representative data for SRC @-@ 3 phosphorylation at S505 and S867 were shown , and other sites had a similar pattern ( data not shown ) .
(x15 / have-03
      :ARG0 (x1 / data
            :ARG0-of (x2 / represent-01
                  :ARG1 (x12 / and
                        :op1 (x11 / show-01
                              :ARG0 (x3 / protein
                                    :name (x4 / name :op1 "SRC-3"))
                              :ARG1 (x5 / phosphorylate-01
                                    :ARG1 (x6 / and
                                          :op1 (x7 / amino-acid
                                                :mod "505"
                                                :name (x8 / name :op1 "serine")
                                                :xref (x21 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                          :op2 (x9 / amino-acid
                                                :mod "867"
                                                :name (x10 / name :op1 "serine")
                                                :xref (x / xref :value "PUBCHEM:5951" :prob "11.218784")))))
                        :op2 (x14 / site
                              :mod (x13 / other)))))
      :ARG1 (x17 / pattern
            :ARG1-of (x16 / resemble-01))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / data
                  :ARG1-of (x20 / show-01 :polarity "-"))))


# ::id PMC1234335.43
# ::snt As in the case of PR-B, dexamethasone did not induce SRC-3 phosphorylation in cells expressing the glucocorticoid receptor (data not shown).
# ::tok As in the case of PR @-@ B , dexamethasone did not induce SRC @-@ 3 phosphorylation in cells expressing the glucocorticoid receptor ( data not shown ) .
(x1 / cause-01
      :ARG0 (x6 / induce-01
            :topic (x2 / protein
                  :name (x3 / name :op1 "PR-B"))
            :ARG0 (x4 / small-molecule
                  :name (x5 / name :op1 "dexamethasone")
                  :xref (x / xref :value "PUBCHEM:5743" :prob "14.701785"))
            :polarity "-"
            :ARG2 (x9 / phosphorylate-01
                  :ARG1 (x7 / protein
                        :name (x8 / name :op1 "SRC-3"))
                  :location (x10 / cell
                        :ARG3-of (x11 / express-03
                              :ARG2 (x13 / receptor
                                    :op1 (x12 / glucocorticoid)
                                    :ARG1-of (x14 / describe-01
                                          :ARG0 (x15 / data
                                                :ARG1-of (x16 / show-01 :polarity "-")))))))))


# ::id PMC1234335.44
# ::snt These data indicated that different steroids and their receptors have differential effects on SRC-3 phosphorylation.
# ::tok These data indicated that different steroids and their receptors have differential effects on SRC @-@ 3 phosphorylation .
(x3 / indicate-01
      :ARG0 (x2 / data
            :mod (x1 / this))
      :ARG1 (x9 / affect-01
            :ARG1-of (x4 / differ-02)
            :ARG1 (x6 / and
                  :op1 (x5 / steroid)
                  :op2 (x7 / receptor))
            :mod (x8 / differential)
            :ARG1 (x12 / phosphorylate-01
                  :ARG1 (x10 / protein
                        :name (x11 / name :op1 "SRC-3")))))


# ::id PMC1234335.45
# ::snt Effects of different agonists and antagonists and their receptors on SRC-3 phosphorylation.
# ::tok Effects of different agonists and antagonists and their receptors on SRC @-@ 3 phosphorylation .
(x1 / affect-01
      :ARG0 (x6 / and
            :op1 (x4 / and
                  :ARG1-of (x2 / differ-02)
                  :op1 (x3 / agonist)
                  :op2 (x5 / antagonist))
            :op2 (x7 / receptor))
      :ARG1 (x10 / phosphorylate-01
            :ARG1 (x8 / protein
                  :name (x9 / name :op1 "SRC-3"))))


# ::id PMC1234335.46
# ::snt HEK293T cells were transfected with Flag-tagged wild-type SRC-3 (SRC-3) or its phosphorylation-site mutant (A6) together with either ERα (A and B), ERβ ...
# ::tok HEK293T cells were transfected with Flag @-@ tagged wild @-@ type SRC @-@ 3 ( SRC @-@ 3 ) or its phosphorylation @-@ site mutant ( A6 ) together with either ERα ( A and B ) , ERβ ...
(x1 / and
      :op1 (x4 / transfect-01
            :ARG1 (x2 / cell-line
                  :name (x3 / name :op1 "HEK293T"))
            :ARG2 (x14 / or
                  :op1 (x8 / enzyme
                        :ARG1-of (x7 / tag-01
                              :ARG2 (x5 / protein
                                    :name (x6 / name :op1 "Flag")))
                        :mod (x9 / wild-type)
                        :name (x10 / name :op1 "SRC")
                        :mod "3"
                        :ARG1-of (x11 / mean-01
                              :ARG2 (x12 / protein
                                    :name (x13 / name :op1 "SRC-3")))
                        :xref (x29 / xref :value "UNIPROT:SRC_HUMAN" :prob "1.004"))
                  :op2 (x16 / site
                        :mod (x15 / phosphorylate-01)
                        :ARG0-of (x17 / mutate-01)
                        :ARG1-of (x21 / or
                              :ARG0 (x18 / protein
                                    :name (x19 / name :op1 "a6-integrin")
                                    :ARG2-of (x20 / together-with))
                              :op2 (x22 / protein
                                    :name (x23 / name :op1 "ERα")
                                    :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                              :ARG1-of (x24 / describe-01
                                    :ARG0 (x26 / and
                                          :op1 (x25 / figure :mod "a")
                                          :op2 (x27 / figure :mod "4b"))))
                        :name (x28 / name :op1 "ERβ")))))


# ::id PMC1234335.47
# ::snt SERMs do not induce SRC-3 phosphorylation.
# ::tok SERMs do not induce SRC @-@ 3 phosphorylation .
(x2 / induce-01
      :ARG0 (x1 / serms)
      :polarity "-"
      :ARG2 (x5 / phosphorylate-01
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "SRC-3"))))


# ::id PMC1234335.48
# ::snt In order to investigate whether selective estrogen receptor modulators (SERMs) such as 4HT and Ral and pure antagonists such as ICI 182,780 (ICI) can induce SRC-3 phosphorylation, drug treatment (10 nM, 1 h) was performed in HEK293T cells cotransfected with plasmids for Flag-tagged SRC-3 and ERα (Fig. ) or ERβ (Fig. ).
# ::tok In order to investigate whether selective estrogen receptor modulators ( SERMs ) such as 4HT and Ral and pure antagonists such as ICI 182,780 ( ICI ) can induce SRC @-@ 3 phosphorylation , drug treatment ( 10 nM , 1 h ) was performed in HEK293T cells cotransfected with plasmids for Flag @-@ tagged SRC @-@ 3 and ERα ( Fig . ) or ERβ ( Fig . ) .
(x1 / multi-sentence
      :snt1 (x29 / perform-02
            :purpose (x2 / investigate-01
                  :ARG1 (x17 / induce-01
                        :mode "interrogative"
                        :ARG1 (x9 / and
                              :op1 (x3 / select-01
                                    :ARG1 (x6 / and
                                          :op1 (x4 / protein
                                                :name (x5 / name
                                                      :op1 "estrogen"
                                                      :op2 "receptor"
                                                      :op3 "modulators"
                                                      :op1 "SERMs"))
                                          :op1 (x7 / enzyme
                                                :name (x8 / name :op1 "4HT"))))
                              :op2 (x10 / protein
                                    :name (x11 / name :op1 "Ral")
                                    :xref (x49 / xref :value "UNIPROT:RALA_HUMAN" :prob "0.603"))
                              :op2 (x13 / antagonist
                                    :mod (x12 / pure)
                                    :example (x14 / ici)
                                    :quant "182780"
                                    :ARG1-of (x16 / possible-01
                                          :name (x15 / name :op1 "ICI"))))
                        :ARG2 (x20 / phosphorylate-01
                              :ARG1 (x18 / protein
                                    :name (x19 / name :op1 "SRC-3")))))
            :ARG1 (x22 / treat-04
                  :ARG2 (x21 / drug)
                  :ARG1 (x23 / small-molecule
                        :quant (x24 / concentration-quantity
                              :quant "10"
                              :unit (x25 / nanomolar))
                        :ARG1-of (x26 / mean-01
                              :ARG2 (x27 / temporal-quantity
                                    :quant "1"
                                    :unit (x28 / hour)))))
            :location (x30 / cell-line
                  :name (x31 / name :op1 "HEK293T")))
      :snt2 (x32 / cotransfect-01
            :ARG2 (x43 / or
                  :op1 (x33 / plasmid
                        :purpose (x39 / and
                              :op1 (x36 / tag-01
                                    :ARG2 (x34 / protein
                                          :name (x35 / name :op1 "Flag")))
                              :op1 (x37 / protein
                                    :name (x38 / name :op1 "SRC-3"))
                              :op2 (x40 / protein
                                    :name (x41 / name :op1 "ERα")
                                    :xref (x48 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                              :ARG1-of (x42 / describe-01)))
                  :op2 (x44 / protein
                        :name (x45 / name :op1 "ERβ")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
            :ARG1-of (x46 / describe-01
                  :ARG0 (x47 / figure))))


# ::id PMC1234335.49
# ::snt Tamoxifen and ICI (Fig. ) and 4HT and Ral (Fig. ), unlike E2, did not noticeably induce SRC-3 phosphorylation at sites S505 and S867 in the presence of ERα and ERβ, respectively (lanes 3 and 4, rows 1 and 2).
# ::tok Tamoxifen and ICI ( Fig . ) and 4HT and Ral ( Fig . ) , unlike E2 , did not noticeably induce SRC @-@ 3 phosphorylation at sites S505 and S867 in the presence of ERα and ERβ, respectively ( lanes 3 and 4 , rows 1 and 2 ) .
(x1 / multi-sentence
      :snt1 (x17 / notice-01
            :ARG0 (x4 / and
                  :op1 (x2 / small-molecule
                        :name (x3 / name :op1 "Tamoxifen")
                        :xref (x48 / xref :value "PUBCHEM:2733526" :prob "14.823483"))
                  :op2 (x5 / protein
                        :name (x6 / name :op1 "ICI")
                        :location (x8 / and
                              :op1 (x7 / figure)
                              :op2 (x9 / enzyme
                                    :name (x10 / name :op1 "4HT")))
                        :xref (x44 / xref :value "UNIPROT:IL1RA_HUMAN" :prob "0.202"))
                  :op3 (x11 / peptide
                        :ARG1-of (x12 / describe-01
                              :ARG0 (x13 / figure))
                        :ARG1-of (x14 / resemble-01
                              :polarity "-"
                              :ARG2 (x15 / enzyme
                                    :name (x16 / name :op1 "E2")))))
            :polarity "-"
            :ARG1 (x18 / induce-01
                  :ARG2 (x21 / phosphorylate-01
                        :ARG1 (x19 / protein
                              :name (x20 / name :op1 "SRC-3"))
                        :location (x22 / site))))
      :snt2 (x23 / and
            :op1 (x24 / amino-acid
                  :mod "505"
                  :name (x25 / name :op1 "serine")
                  :xref (x46 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :op2 (x26 / amino-acid
                  :mod "867"
                  :name (x27 / name :op1 "serine")
                  :xref (x47 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :location (x31 / and
                  :op1 (x28 / present-02
                        :ARG1 (x29 / protein
                              :name (x30 / name :op1 "ERα")
                              :xref (x43 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
                  :op2 (x32 / enzyme
                        :name (x33 / name :op1 "ERβ,")
                        :xref (x45 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.613"))
                  :mod (x34 / respective)
                  :ARG1-of (x35 / describe-01
                        :ARG0 (x40 / and
                              :op1 (x38 / and
                                    :op1 (x36 / lane :mod "3")
                                    :op2 (x37 / lane :mod "4"))
                              :op2 (x39 / row :mod "1")
                              :op3 (x41 / enzyme
                                    :name (x42 / name :op1 "erk2")
                                    :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.603")))))))


# ::id PMC1234335.50
# ::snt ICI treatment significantly reduced the level of total ERα (Fig. , lane 4, row 3) as reported previously (, , ).
# ::tok ICI treatment significantly reduced the level of total ERα ( Fig . , lane 4 , row 3 ) as reported previously ( , , ) .
(x14 / row
      :ARG1 (x1 / and
            :op1 (x6 / reduce-01
                  :ARG0 (x4 / treat-04
                        :ARG2 (x2 / small-molecule
                              :name (x3 / name :op1 "ICI")
                              :xref (x18 / xref :value "PUBCHEM:2955" :prob "13.850034")))
                  :ARG2 (x5 / significant-02)
                  :ARG1 (x7 / level
                        :quant-of (x8 / enzyme
                              :mod (x9 / total)
                              :name (x10 / name :op1 "ERα")
                              :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
                  :ARG1-of (x11 / describe-01
                        :ARG0 (x12 / figure :mod "2b")))
            :op2 (x13 / lane :mod "4"))
      :mod "3"
      :ARG1-of (x15 / report-01
            :time (x16 / previous)
            :mod (x17 / nanomolar)))


# ::id PMC1234335.51
# ::snt Since SERMs do not promote interaction between SRC coactivators and ER in HEK293T (data not shown) and other cell lines (, ), the data are consistent with a requirement for a direct binding between ER and SRC-3 for induction of coactivator phosphorylation.
# ::tok Since SERMs do not promote interaction between SRC coactivators and ER in HEK293T ( data not shown ) and other cell lines ( , ) , the data are consistent with a requirement for a direct binding between ER and SRC @-@ 3 for induction of coactivator phosphorylation .
(x1 / cause-01
      :ARG0 (x3 / promote-02
            :ARG0 (x2 / serms)
            :polarity "-"
            :ARG1 (x8 / and
                  :op1 (x4 / interact-01
                        :ARG0 (x5 / protein
                              :name (x6 / name :op1 "SRC")
                              :xref (x35 / xref :value "UNIPROT:SRC_HUMAN" :prob "1.004"))
                        :ARG0-of (x7 / coactivate-01))
                  :op2 (x9 / protein
                        :name (x10 / name :op1 "erα")
                        :xref (x34 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593")))
            :location (x16 / and
                  :op1 (x11 / cell-line
                        :name (x12 / name :op1 "HEK293T")
                        :ARG1-of (x13 / describe-01
                              :ARG0 (x14 / data
                                    :ARG1-of (x15 / show-01 :polarity "-"))))
                  :op2 (x18 / cell-line
                        :mod (x17 / other)
                        :ARG1-of (x19 / statistical-test-91
                              :ARG2 (x20 / less-than :op1 "0.02")))))
      :ARG1 (x21 / data
            :ARG1-of (x22 / consistent-01
                  :ARG2 (x23 / require-01
                        :ARG1 (x25 / bind-01
                              :ARG1-of (x24 / direct-02)
                              :ARG1 (x26 / protein
                                    :name (x27 / name :op1 "erα")
                                    :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
                              :ARG2 (x28 / protein
                                    :name (x29 / name :op1 "SRC-3")))))
            :topic (x30 / induce-01
                  :ARG2 (x33 / phosphorylate-01
                        :ARG1 (x31 / enzyme
                              :name (x32 / name :op1 "coactivator")
                              :xref (x36 / xref :value "UNIPROT:NCOA5_HUMAN" :prob "0.242"))))))


# ::id PMC1234335.52
# ::snt AF-1 and LBD/AF-2 of ERα are required for maximal induction of SRC-3 phosphorylation.
# ::tok AF @-@ 1 and LBD @/@ AF @-@ 2 of ERα are required for maximal induction of SRC @-@ 3 phosphorylation .
(x10 / require-01
      :ARG1 (x3 / and
            :op1 (x1 / protein
                  :name (x2 / name :op1 "AF")
                  :xref (x16 / xref :value "UNIPROT:PSMD4_HUMAN" :prob "1.002"))
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "LBD"))
            :op2 (x6 / amino-acid
                  :name (x7 / name :op1 "AF")
                  :mod "2"
                  :part-of (x8 / protein
                        :name (x9 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                  :xref (x17 / xref :value "PUBCHEM:1983" :prob "6.800189")))
      :ARG0 (x12 / induce-01
            :mod (x11 / maximal)
            :ARG2 (x15 / phosphorylate-01
                  :ARG1 (x13 / protein
                        :name (x14 / name :op1 "SRC-3")))))


# ::id PMC1234335.53
# ::snt The results above demonstrated that ER is required for E2-induced SRC-3 phosphorylation and implied that an interaction, either direct or indirect, between ER and SRC-3 is required.
# ::tok The results above demonstrated that ER is required for E2 @-@ induced SRC @-@ 3 phosphorylation and implied that an interaction , either direct or indirect , between ER and SRC @-@ 3 is required .
(x4 / demonstrate-01
      :ARG0 (x1 / thing
            :ARG2-of (x2 / result-01))
      :time (x3 / above)
      :ARG1 (x7 / require-01
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "erα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
            :ARG0 (x13 / phosphorylate-01
                  :ARG2-of (x10 / induce-01
                        :ARG0 (x8 / enzyme
                              :name (x9 / name :op1 "E2")))
                  :ARG1 (x11 / protein
                        :name (x12 / name :op1 "SRC-3"))))
      :ARG0-of (x14 / imply-01)
      :ARG1 (x23 / require-01
            :ARG1 (x15 / interact-01
                  :ARG1 (x16 / or
                        :op1 (x17 / direct-02)
                        :op2 (x18 / direct-02 :polarity "-"))
                  :ARG0 (x19 / protein
                        :name (x20 / name :op1 "erα")
                        :xref (x24 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
                  :ARG2 (x21 / protein
                        :name (x22 / name :op1 "SRC-3")))))


# ::id PMC1234335.54
# ::snt In order to investigate the contribution of the AF-1 and AF-2 domains of ERα for E2-induced SRC-3 phosphorylation, wild-type full-length ERα and an ERα truncation mutant, ERα1-282 (N282) lacking AF-2/LBD or ERα179-595 (179C) lacking AF-1, together with Flag-tagged SRC-3, were transfected into HEK293T cells.
# ::tok In order to investigate the contribution of the AF @-@ 1 and AF @-@ 2 domains of ERα for E2 @-@ induced SRC @-@ 3 phosphorylation , wild @-@ type full @-@ length ERα and an ERα truncation mutant , ERα1 @-@ 282 ( N282 ) lacking AF @-@ 2/LBD or ERα179 @-@ 595 ( 179C ) lacking AF @-@ 1 , together with Flag @-@ tagged SRC @-@ 3 , were transfected into HEK293T cells .
(x1 / multi-sentence
      :snt1 (x22 / and
            :purpose (x2 / investigate-01
                  :ARG1 (x3 / contribute-01
                        :ARG0 (x6 / and
                              :op1 (x4 / enzyme
                                    :name (x5 / name :op1 "AF")
                                    :xref (x53 / xref :value "UNIPROT:PSMD4_HUMAN" :prob "1.002"))
                              :op2 (x7 / enzyme
                                    :name (x8 / name :op1 "AF" :op2 "domain")))
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "ERα")
                              :xref (x52 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                        :ARG2 (x16 / phosphorylate-01
                              :ARG2-of (x13 / induce-01
                                    :ARG0 (x11 / enzyme
                                          :name (x12 / name :op1 "E2")))
                              :ARG1 (x14 / protein
                                    :name (x15 / name :op1 "SRC-3")))))
            :ARG1 (x17 / enzyme
                  :mod (x18 / wild-type)
                  :ARG1-of (x20 / long-03
                        :ARG1-of (x19 / full-09))
                  :name (x21 / name :op1 "ERα")
                  :xref (x55 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
            :ARG2 (x25 / truncate-01
                  :ARG1 (x23 / protein
                        :name (x24 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))))
      :snt2 (x49 / transfect-01
            :ARG1 (x31 / lack-01
                  :ARG1 (x26 / mutate-01
                        :ARG2 (x27 / enzyme
                              :name (x28 / name :op1 "ERα1" :op2 "282"))
                        :ARG1 (x29 / amino-acid
                              :mod "282"
                              :name (x30 / name :op1 "asparagine")))
                  :ARG1 (x32 / protein
                        :name (x33 / name :op1 "AF")
                        :xref (x54 / xref :value "UNIPROT:PSMD4_HUMAN" :prob "1.002"))
                  :ARG2 (x36 / or
                        :op1 (x34 / enzyme
                              :name (x35 / name :op1 "2/LBD"))
                        :op2 (x37 / enzyme
                              :name (x38 / name :op1 "ERα179"))
                        :op2 "595")
                  :ARG1-of (x40 / lack-01
                        :ARG0 (x39 / 179c)
                        :ARG1 (x41 / and
                              :op1 (x42 / amino-acid
                                    :name (x43 / name :op1 "AF")
                                    :mod "1"
                                    :xref (x56 / xref :value "PUBCHEM:1983" :prob "6.800189"))
                              :op2 (x46 / tag-01
                                    :ARG2 (x44 / protein
                                          :name (x45 / name :op1 "Flag"))))
                        :ARG1 (x47 / protein
                              :name (x48 / name :op1 "SRC-3"))))
            :ARG2 (x50 / cell-line
                  :name (x51 / name :op1 "HEK293T"))))


# ::id PMC1234335.55
# ::snt Cells were then treated, and SRC-3 phosphorylation was examined.
# ::tok Cells were then treated , and SRC @-@ 3 phosphorylation was examined .
(x4 / and
      :op1 (x3 / treat-04
            :ARG1 (x1 / cell)
            :time (x2 / then))
      :op2 (x8 / examine-01
            :ARG1 (x7 / phosphorylate-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "SRC-3")))))


# ::id PMC1234335.56
# ::snt As shown in Fig. , N282 did not support E2-induced SRC-3 phosphorylation (lanes 3 and 4), which is not surprising since N282 lacks an LBD and is not responsive to E2.
# ::tok As shown in Fig . , N282 did not support E2 @-@ induced SRC @-@ 3 phosphorylation ( lanes 3 and 4 ) , which is not surprising since N282 lacks an LBD and is not responsive to E2 .
(x5 / support-01
      :ARG1-of (x1 / show-01
            :medium (x2 / figure))
      :ARG0 (x3 / amino-acid
            :mod "282"
            :name (x4 / name :op1 "asparagine"))
      :polarity "-"
      :ARG1 (x11 / phosphorylate-01
            :ARG2-of (x8 / induce-01
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "E2")))
            :ARG1 (x9 / protein
                  :name (x10 / name :op1 "SRC-3")))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / compare-01
                  :ARG1 (x14 / lane :mod "3")
                  :ARG2 (x15 / lane :mod "4")))
      :ARG0-of (x20 / lack-01
            :ARG1 (x16 / surprise-01
                  :polarity "-"
                  :ARG1-of (x17 / cause-01
                        :ARG0 (x18 / amino-acid
                              :mod "282"
                              :name (x19 / name :op1 "asparagine")))))
      :ARG1 (x23 / and
            :op1 (x21 / enzyme
                  :name (x22 / name :op1 "LBD"))
            :op2 (x24 / respond-01
                  :polarity "-"
                  :ARG1 (x25 / small-molecule
                        :name (x26 / name :op1 "E2")
                        :xref (x / xref :value "PUBCHEM:5757" :prob "13.96532")))))


# ::id PMC1234335.57
# ::snt The 179C mutant supported only minimal E2-induced SRC-3 phosphorylation at S505 but not at other sites as represented by T24, S543, and S867 (Fig. , lanes 5 and 6).
# ::tok The 179C mutant supported only minimal E2 @-@ induced SRC @-@ 3 phosphorylation at S505 but not at other sites as represented by T24 , S543 , and S867 ( Fig . , lanes 5 and 6 ) .
(x4 / support-01
      :ARG0 (x3 / mutate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "179C")))
      :ARG1 (x6 / minimal-02
            :mod (x5 / only)
            :ARG1 (x12 / phosphorylate-01
                  :ARG2-of (x9 / induce-01
                        :ARG0 (x7 / enzyme
                              :name (x8 / name :op1 "E2")))
                  :ARG1 (x10 / protein
                        :name (x11 / name :op1 "SRC-3"))
                  :ARG1 (x13 / amino-acid
                        :mod "505"
                        :name (x14 / name :op1 "serine")
                        :xref (x34 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :ARG1-of (x15 / contrast-01
                        :ARG2 (x16 / be-located-at-91
                              :polarity "-"
                              :ARG2 (x18 / protein-segment
                                    :mod (x17 / other))
                              :ARG1-of (x19 / represent-01
                                    :ARG0 (x20 / and
                                          :op1 (x21 / amino-acid
                                                :mod "24"
                                                :name (x22 / name :op1 "threonine")
                                                :xref (x32 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                          :op2 (x23 / amino-acid
                                                :mod "543"
                                                :name (x24 / name :op1 "serine")
                                                :xref (x33 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                          :op2 (x25 / amino-acid
                                                :mod "867"
                                                :name (x26 / name :op1 "serine")
                                                :xref (x / xref :value "PUBCHEM:5951" :prob "11.218784"))))
                              :ARG1-of (x27 / describe-01
                                    :ARG0 (x28 / figure :mod "1b")))))
            :ARG0-of (x29 / compare-01
                  :ARG1 (x30 / lane :mod "5")
                  :ARG2 (x31 / lane :mod "6"))))


# ::id PMC1234335.58
# ::snt Similarly, an ERβ truncation mutant, 143C (aa 143 to 530), lacking AF-1, supported only minimal E2-induced SRC-3 phosphorylation at S505 and S543 but not at other sites as represented by T24 and S867 (Fig. ).
# ::tok Similarly , an ERβ truncation mutant , 143C ( aa 143 to 530 ) , lacking AF @-@ 1 , supported only minimal E2 @-@ induced SRC @-@ 3 phosphorylation at S505 and S543 but not at other sites as represented by T24 and S867 ( Fig . ) .
(x1 / multi-sentence
      :snt1 (x14 / support-01
            :ARG1-of (x2 / resemble-01)
            :ARG0 (x6 / mutate-01
                  :ARG1-of (x5 / truncate-01
                        :ARG2 (x3 / protein
                              :name (x4 / name :op1 "ERβ")
                              :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
                  :ARG2 (x7 / enzyme
                        :name (x8 / name :op1 "143C")
                        :xref (x40 / xref :value "UNIPROT:1433B_HUMAN" :prob "0.203"))
                  :ARG1-of (x9 / describe-01
                        :ARG0 (x10 / value-interval :op1 "143" :op2 "530"))
                  :ARG0-of (x11 / lack-01
                        :ARG1 (x12 / gene
                              :name (x13 / name :op1 "AF")
                              :xref (x41 / xref :value "UNIPROT:PSMD4_HUMAN" :prob "1.002"))))
            :mod (x15 / only)
            :ARG1-of (x16 / minimal-02
                  :ARG1 (x22 / phosphorylate-01
                        :ARG2-of (x19 / induce-01
                              :ARG0 (x17 / enzyme
                                    :name (x18 / name :op1 "E2")))
                        :ARG1 (x20 / protein
                              :name (x21 / name :op1 "SRC-3"))))
            :ARG1 (x23 / and
                  :op1 (x24 / amino-acid
                        :mod "505"
                        :name (x25 / name :op1 "serine")
                        :xref (x42 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :op2 (x26 / amino-acid
                        :mod "543"
                        :name (x27 / name :op1 "serine")
                        :xref (x43 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
      :snt2 (x28 / contrast-01
            :ARG2 (x29 / be-located-at-91
                  :polarity "-"
                  :ARG2 (x31 / protein-segment
                        :mod (x30 / other))
                  :ARG1-of (x32 / represent-01
                        :ARG0 (x33 / and
                              :op1 (x34 / amino-acid
                                    :mod "24"
                                    :name (x35 / name :op1 "threonine")
                                    :xref (x45 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x36 / amino-acid
                                    :mod "867"
                                    :name (x37 / name :op1 "serine")
                                    :xref (x44 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
                  :ARG1-of (x38 / describe-01
                        :ARG0 (x39 / figure :mod "3c")))))


# ::id PMC1234335.59
# ::snt These data reveal that the AF-1 or LBD/AF-2 domains are required for maximal induction of E2-induced coactivator phosphorylation.
# ::tok These data reveal that the AF @-@ 1 or LBD @/@ AF @-@ 2 domains are required for maximal induction of E2 @-@ induced coactivator phosphorylation .
(x3 / reveal-01
      :ARG0 (x2 / data
            :mod (x1 / this))
      :ARG1 (x11 / require-01
            :ARG1 (x6 / or
                  :op1 (x4 / protein
                        :name (x5 / name :op1 "AF")
                        :xref (x20 / xref :value "UNIPROT:PSMD4_HUMAN" :prob "1.002"))
                  :op2 (x7 / enzyme
                        :name (x8 / name :op1 "LBD"))
                  :op2 (x9 / enzyme
                        :name (x10 / name :op1 "AF" :op2 "domain")))
            :ARG0 (x13 / induce-01
                  :mod (x12 / maximal)
                  :ARG2 (x19 / phosphorylate-01
                        :ARG2-of (x16 / induce-01
                              :ARG0 (x14 / enzyme
                                    :name (x15 / name :op1 "E2")))
                        :ARG1 (x17 / enzyme
                              :name (x18 / name :op1 "coactivator")
                              :xref (x / xref :value "UNIPROT:NCOA5_HUMAN" :prob "0.242"))))))


# ::id PMC1234335.60
# ::snt Both AF-1 and LBD/AF-2 domains of ERα are required for maximal induction of SRC-3 phosphorylation in response to E2.
# ::tok Both AF @-@ 1 and LBD @/@ AF @-@ 2 domains of ERα are required for maximal induction of SRC @-@ 3 phosphorylation in response to E2 .
(x1 / and
      :op2 (x11 / require-01
            :ARG1 (x4 / and
                  :op1 (x2 / protein
                        :name (x3 / name :op1 "AF")
                        :xref (x20 / xref :value "UNIPROT:PSMD4_HUMAN" :prob "1.002"))
                  :op2 (x5 / enzyme
                        :name (x6 / name :op1 "LBD"))
                  :op2 (x7 / amino-acid
                        :name (x8 / name :op1 "AF")
                        :mod "2"
                        :part-of (x9 / protein
                              :name (x10 / name :op1 "ERα")
                              :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                        :xref (x21 / xref :value "PUBCHEM:1983" :prob "6.800189")))
            :ARG0 (x13 / induce-01
                  :mod (x12 / maximal)
                  :ARG2 (x16 / phosphorylate-01
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "SRC-3")))
                  :ARG2-of (x17 / respond-01
                        :ARG1 (x18 / small-molecule
                              :name (x19 / name :op1 "E2")
                              :xref (x22 / xref :value "PUBCHEM:5757" :prob "13.96532"))))))


# ::id PMC1234335.61
# ::snt HEK293T cells were cotransfected with either Flag-SRC-3 (SRC-3) or Flag-SRC-3 phosphorylation mutant (A6) together with either ...
# ::tok HEK293T cells were cotransfected with either Flag @-@ SRC @-@ 3 ( SRC @-@ 3 ) or Flag @-@ SRC @-@ 3 phosphorylation mutant ( A6 ) together with either ...
(x3 / cotransfect-01
      :ARG1 (x1 / cell-line
            :name (x2 / name :op1 "HEK293T"))
      :ARG2 (x4 / or
            :op2 (x5 / protein
                  :name (x6 / name :op1 "SRC-3")))
      :ARG1-of (x12 / phosphorylate-01
            :ARG0 (x9 / or
                  :op1 (x7 / protein
                        :name (x8 / name :op1 "SRC-3"))
                  :op2 (x10 / protein
                        :name (x11 / name :op1 "SRC-3")))
            :ARG1 (x17 / or
                  :op1 (x13 / enzyme
                        :ARG2-of (x14 / mutate-01)
                        :ARG1-of (x15 / mutate-01 :mod "-/-"))
                  :ARG0-of (x16 / together-with))))


# ::id PMC1234335.62
# ::snt To further test the role of AF-1 in SRC-3 phosphorylation, an ERα phosphorylation mutant (S104A/S106A/S118A as 3A) was used to determine whether phosphorylation of AF-1 is required.
# ::tok To further test the role of AF @-@ 1 in SRC @-@ 3 phosphorylation , an ERα phosphorylation mutant ( S104A/S106A/S118A as 3A ) was used to determine whether phosphorylation of AF @-@ 1 is required .
(x11 / phosphorylate-01
      :purpose (x2 / test-01
            :degree (x1 / further)
            :ARG1 (x3 / role
                  :poss (x4 / protein
                        :name (x5 / name :op1 "AF" :op2 "1"))
                  :topic (x8 / phosphorylate-01
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "SRC-3")))))
      :ARG1 (x9 / protein
            :name (x10 / name :op1 "ERα")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
      :ARG1-of (x12 / mutate-01)
      :ARG1-of (x17 / use-01
            :ARG1 (x15 / and
                  :op1 (x13 / enzyme
                        :name (x14 / name :op1 "S104A/S106A/S118A"))
                  :op2 (x16 / figure :mod "3a"))
            :ARG2 (x18 / determine-01
                  :ARG1 (x22 / require-01
                        :mode "interrogative"
                        :ARG1 (x19 / phosphorylate-01
                              :ARG1 (x20 / amino-acid
                                    :name (x21 / name :op1 "AF")
                                    :mod "1"
                                    :xref (x23 / xref :value "PUBCHEM:1983" :prob "6.800189")))))))


# ::id PMC1234335.63
# ::snt HEK293T cells were transfected with either wild-type ERα or its mutant 3A together with Flag-tagged SRC-3 and treated as described above.
# ::tok HEK293T cells were transfected with either wild @-@ type ERα or its mutant 3A together with Flag @-@ tagged SRC @-@ 3 and treated as described above .
(x3 / transfect-01
      :ARG1 (x1 / cell-line
            :name (x2 / name :op1 "HEK293T"))
      :ARG2 (x7 / or
            :op1 (x4 / enzyme
                  :mod (x5 / wild-type)
                  :name (x6 / name :op1 "ERα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
            :op2 (x8 / mutate-01
                  :ARG1 (x9 / gene
                        :name (x10 / name :op1 "3A"))
                  :ARG2 (x13 / tag-01
                        :ARG2 (x11 / protein
                              :name (x12 / name :op1 "Flag")))
                  :ARG1 (x16 / and
                        :op1 (x14 / protein
                              :name (x15 / name :op1 "SRC-3"))
                        :op2 (x17 / treat-04))))
      :ARG1-of (x18 / describe-01
            :location (x19 / above)))


# ::id PMC1234335.64
# ::snt Interestingly, this ERα AF-1 phosphorylation mutant could still induce SRC-3 phosphorylation, at a level comparable to the wild-type ERα (Fig. ), suggesting that phosphorylation of ERα is not a prerequisite for promoting SRC-3 phosphorylation.
# ::tok Interestingly , this ERα AF @-@ 1 phosphorylation mutant could still induce SRC @-@ 3 phosphorylation , at a level comparable to the wild @-@ type ERα ( Fig . ) , suggesting that phosphorylation of ERα is not a prerequisite for promoting SRC @-@ 3 phosphorylation .
(x1 / multi-sentence
      :snt1 (x8 / phosphorylate-01
            :ARG2-of (x2 / interest-01)
            :ARG0 (x4 / protein
                  :mod (x3 / this)
                  :name (x5 / name :op1 "ERα")
                  :xref (x33 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
            :ARG1 (x6 / protein
                  :name (x7 / name :op1 "AF")
                  :xref (x32 / xref :value "UNIPROT:PSMD4_HUMAN" :prob "1.002")))
      :snt2 (x9 / possible-01
            :ARG1 (x12 / induce-01
                  :ARG0 (x10 / mutate-01)
                  :mod (x11 / still)
                  :ARG2 (x15 / phosphorylate-01
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "SRC-3")))
                  :time (x16 / level
                        :ARG1-of (x17 / comparable-03
                              :ARG2 (x18 / enzyme
                                    :mod (x19 / wild-type)
                                    :name (x20 / name :op1 "ERα")
                                    :xref (x34 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))))
                  :ARG1-of (x21 / describe-01
                        :ARG0 (x22 / figure))
                  :ARG0-of (x23 / suggest-01
                        :ARG1 (x27 / require-01
                              :ARG0 (x24 / phosphorylate-01
                                    :ARG1 (x25 / protein
                                          :name (x26 / name :op1 "ERα")
                                          :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
                              :polarity "-"
                              :ARG1 (x28 / promote-01
                                    :ARG1 (x31 / phosphorylate-01
                                          :ARG1 (x29 / protein
                                                :name (x30 / name :op1 "SRC-3")))))))))


# ::id PMC1234335.65
# ::snt The coactivator-binding groove of ERα is required for E2-induced SRC-3 phosphorylation.
# ::tok The coactivator @-@ binding groove of ERα is required for E2 @-@ induced SRC @-@ 3 phosphorylation .
(x8 / require-01
      :ARG1 (x4 / protein-segment
            :ARG0-of (x3 / bind-01
                  :ARG1 (x1 / enzyme
                        :name (x2 / name :op1 "coactivator")
                        :xref (x / xref :value "UNIPROT:NCOA5_HUMAN" :prob "0.242")))
            :name (x5 / name :op1 "groove")
            :part-of (x6 / protein
                  :name (x7 / name :op1 "ERα")
                  :xref (x15 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
      :ARG0 (x14 / phosphorylate-01
            :ARG2-of (x11 / induce-01
                  :ARG0 (x9 / enzyme
                        :name (x10 / name :op1 "E2")))
            :ARG1 (x12 / protein
                  :name (x13 / name :op1 "SRC-3"))))


# ::id PMC1234335.66
# ::snt It has been shown that the amino acids K362, V376, and L539 of the ERα LBD are among the residues critical for forming a coactivator-binding groove in response to E2 ().
# ::tok It has been shown that the amino acids K362 , V376 , and L539 of the ERα LBD are among the residues critical for forming a coactivator @-@ binding groove in response to E2 ( ) .
(x1 / multi-sentence
      :snt1 (x2 / show-01
            :ARG1 (x8 / and
                  :op1 (x3 / amino-acid
                        :mod (x4 / amino-acid
                              :mod "362"
                              :name (x5 / name :op1 "lysine")))
                  :op2 (x6 / amino-acid
                        :mod "376"
                        :name (x7 / name :op1 "valine"))
                  :op2 (x9 / enzyme
                        :name (x10 / name :op1 "L539")
                        :xref (x / xref :value "UNIPROT:RM53_HUMAN" :prob "0.202"))))
      :snt2 (x13 / include-91
            :ARG1 (x11 / protein
                  :name (x12 / name :op1 "ERα" :op2 "LBD"))
            :ARG2 (x14 / residue
                  :ARG1-of (x15 / critical-02
                        :ARG2 (x16 / form-01
                              :ARG1 (x19 / bind-01
                                    :ARG1 (x17 / enzyme
                                          :name (x18 / name :op1 "coactivator")
                                          :xref (x26 / xref :value "UNIPROT:NCOA5_HUMAN" :prob "0.242")))
                              :ARG1-of (x20 / groove)
                              :ARG2-of (x21 / respond-01
                                    :ARG1 (x22 / small-molecule
                                          :name (x23 / name :op1 "E2")
                                          :xref (x27 / xref :value "PUBCHEM:5757" :prob "13.96532")))
                              :ARG1-of (x24 / statistical-test-91
                                    :ARG2 (x25 / less-than :op1 "0.02")))))))


# ::id PMC1234335.67
# ::snt In order to investigate whether this surface is essential for E2-induced SRC-3 phosphorylation, several mutations which disrupt the direct interaction of ERα with coactivator were examined for their ability to impact E2 induction of SRC-3 phosphorylation in HEK293T cells.
# ::tok In order to investigate whether this surface is essential for E2 @-@ induced SRC @-@ 3 phosphorylation , several mutations which disrupt the direct interaction of ERα with coactivator were examined for their ability to impact E2 induction of SRC @-@ 3 phosphorylation in HEK293T cells .
(x26 / induce-01
      :purpose (x1 / investigate-01
            :ARG1 (x2 / possible-01
                  :mode "interrogative"
                  :ARG1 (x5 / essential
                        :domain (x4 / surface
                              :mod (x3 / this))
                        :purpose (x11 / phosphorylate-01
                              :ARG2-of (x8 / induce-01
                                    :ARG0 (x6 / enzyme
                                          :name (x7 / name :op1 "E2")))
                              :ARG1 (x9 / protein
                                    :name (x10 / name :op1 "SRC-3"))))))
      :ARG0 (x13 / mutate-01
            :quant (x12 / several)
            :ARG0-of (x21 / examine-01
                  :ARG1 (x14 / disrupt-01
                        :ARG1 (x16 / interact-01
                              :ARG1-of (x15 / direct-02)
                              :ARG0 (x17 / protein
                                    :name (x18 / name :op1 "ERα")
                                    :xref (x32 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
                        :ARG2 (x19 / protein
                              :name (x20 / name :op1 "coactivator")
                              :xref (x / xref :value "UNIPROT:NCOA5_HUMAN" :prob "0.242")))
                  :ARG2 (x22 / capable-01
                        :ARG2 (x23 / impact-01
                              :ARG1 (x24 / enzyme
                                    :name (x25 / name :op1 "E2"))))))
      :ARG2 (x29 / phosphorylate-01
            :ARG1 (x27 / protein
                  :name (x28 / name :op1 "SRC-3")))
      :location (x30 / cell-line
            :name (x31 / name :op1 "HEK293T")))


# ::id PMC1234335.68
# ::snt The mutants (the single mutants K362D [K], V376D [V], and L539A [L]; the double mutant K362D/V376D [KV]; and the triple mutant K362D/V376D/L539A [KVL]) were transcriptionally impaired as demonstrated in a luciferase reporter assay (Fig. ), consistent with previous reports on the effect of the single mutations ().
# ::tok The mutants ( the single mutants K362D [ K ] , V376D [ V ] , and L539A [ L ] ; the double mutant K362D @/@ V376D [ KV ] ; and the triple mutant K362D/V376D/L539A [ KVL ] ) were transcriptionally impaired as demonstrated in a luciferase reporter assay ( Fig . ) , consistent with previous reports on the effect of the single mutations ( ) .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op1 (x14 / and
                  :ARG0-of (x3 / mutate-01
                        :ARG1-of (x4 / single-02
                              :op2 (x5 / enzyme
                                    :ARG2-of (x6 / mutate-01)
                                    :name (x7 / name :op1 "K362D")
                                    :xref (x51 / xref :value "UNIPROT:KRT36_HUMAN" :prob "0.232"))
                              :ARG1-of (x10 / cite-01
                                    :ARG2 (x8 / enzyme
                                          :name (x9 / name :op1 "k-ras")
                                          :xref (x50 / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.701"))))
                        :ARG0-of (x11 / mutate-01 :value "V376D")
                        :ARG1-of (x12 / small-molecule
                              :name (x13 / name :op1 "vemurafenib")
                              :xref (x52 / xref :value "PUBCHEM:42611257" :prob "17.762056")))
                  :op1 (x15 / enzyme
                        :name (x16 / name :op1 "L539A"))
                  :ARG1-of (x17 / describe-01
                        :ARG0 (x18 / figure :mod "l")))
            :op2 (x20 / mutate-01
                  :mod (x19 / double)
                  :ARG1 (x23 / slash
                        :op1 (x21 / enzyme
                              :name (x22 / name :op1 "K362D")
                              :xref (x / xref :value "UNIPROT:KRT36_HUMAN" :prob "0.232"))
                        :op2 (x24 / enzyme
                              :name (x25 / name :op1 "V376D"))))
            :ARG1-of (x28 / describe-01
                  :ARG0 (x26 / protein
                        :name (x27 / name :op1 "KV"))))
      :snt2 (x36 / impair-01
            :ARG1 (x29 / and
                  :op1 (x30 / macro-molecular-complex
                        :ARG0-of (x31 / mutate-01
                              :ARG1 (x32 / enzyme
                                    :name (x33 / name :op1 "K362D/V376D/L539A")))
                        :ARG1-of (x34 / kvl)))
            :ARG0-of (x35 / transcribe-01)
            :ARG1-of (x37 / demonstrate-01
                  :ARG0 (x41 / assay-01
                        :ARG1 (x40 / report-01
                              :ARG1 (x38 / enzyme
                                    :name (x39 / name :op1 "luciferase")))
                        :ARG1-of (x42 / describe-01
                              :ARG0 (x43 / figure))
                        :ARG1-of (x44 / consistent-01
                              :ARG2 (x46 / report-01
                                    :time (x45 / previous))
                              :ARG1 (x47 / affect-01
                                    :ARG1 (x49 / mutate-01
                                          :ARG1-of (x48 / single-02))))))))


# ::id PMC1234335.69
# ::snt As shown in Fig. , the ERα single mutants (K, V, or L) were severely compromised in their ability to support E2-induced SRC-3 phosphorylation (lanes 5 to 10, row 1), while the triple mutant (KVL) was unable to induce any phosphorylation of SRC-3 (lanes 3 and 4, row 1).
# ::tok As shown in Fig . , the ERα single mutants ( K , V, or L ) were severely compromised in their ability to support E2 @-@ induced SRC @-@ 3 phosphorylation ( lanes 5 to 10 , row 1 ) , while the triple mutant ( KVL ) was unable to induce any phosphorylation of SRC @-@ 3 ( lanes 3 and 4 , row 1 ) .
(x1 / multi-sentence
      :snt1 (x17 / compromise-02
            :ARG1-of (x2 / show-01
                  :ARG0 (x3 / figure))
            :ARG1 (x7 / mutate-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "ERα")
                        :xref (x44 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                  :ARG1-of (x6 / single-02)
                  :ARG1-of (x8 / mean-01
                        :ARG2 (x9 / enzyme
                              :name (x10 / name :op1 "k-ras")
                              :xref (x / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.701")))
                  :ARG1 (x13 / or
                        :op1 (x11 / enzyme
                              :name (x12 / name :op1 "V,"))
                        :op2 (x14 / cell-line
                              :name (x15 / name :op1 "l-540"))))
            :degree (x16 / severe)
            :ARG3 (x18 / capable-01
                  :ARG2 (x19 / support-01
                        :ARG1 (x25 / phosphorylate-01
                              :ARG2-of (x22 / induce-01
                                    :ARG0 (x20 / enzyme
                                          :name (x21 / name :op1 "E2")))
                              :ARG1 (x23 / protein
                                    :name (x24 / name :op1 "SRC-3")))))
            :ARG1-of (x26 / describe-01
                  :ARG0 (x27 / lane
                        :mod (x28 / value-interval :op1 "5" :op2 "10"))))
      :snt2 (x30 / contrast-01
            :ARG1 (x29 / row :mod "1")
            :ARG2 (x43 / row
                  :ARG0 (x32 / mutate-01
                        :mod (x31 / triple)
                        :ARG1-of (x33 / kvl))
                  :ARG1-of (x35 / induce-01
                        :ARG1-of (x34 / possible-01 :polarity "-")
                        :ARG2 (x37 / phosphorylate-01
                              :mod (x36 / any)
                              :ARG1 (x38 / protein
                                    :name (x39 / name :op1 "SRC-3"))
                              :ARG1-of (x40 / compare-01
                                    :ARG1 (x41 / lane :mod "3")
                                    :ARG2 (x42 / lane :mod "4"))))
                  :mod "1")))


# ::id PMC1234335.70
# ::snt As predicted, the E2-induced interaction between these ERα mutants and SRC-3 was greatly reduced or totally abolished (Fig. , lanes 3 to 10, row 2) in comparison to the positive control (lanes 1 and 2, row 2).
# ::tok As predicted , the E2 @-@ induced interaction between these ERα mutants and SRC @-@ 3 was greatly reduced or totally abolished ( Fig . , lanes 3 to 10 , row 2 ) in comparison to the positive control ( lanes 1 and 2 , row 2 ) .
(x1 / multi-sentence
      :snt1 (x5 / induce-01
            :ARG1-of (x2 / predict-01)
            :ARG0 (x3 / protein
                  :name (x4 / name :op1 "E2")))
      :snt2 (x14 / reduce-01
            :ARG1 (x6 / interact-01
                  :ARG0 (x8 / protein
                        :mod (x7 / this)
                        :name (x9 / name :op1 "ERα")
                        :ARG2-of (x10 / mutate-01)
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                  :ARG1 (x11 / protein
                        :name (x12 / name :op1 "SRC-3")))
            :degree (x13 / great)
            :ARG1 (x15 / and
                  :op1 (x16 / or
                        :op2 (x18 / abolish-01
                              :mod (x17 / total)
                              :ARG1-of (x19 / describe-01
                                    :ARG0 (x20 / figure :mod "2b"))))
                  :op2 (x21 / lane
                        :mod (x22 / value-interval :op1 "3" :op2 "10")))
            :ARG0-of (x23 / row
                  :mod "2"
                  :location (x31 / row
                        :ARG1-of (x24 / compare-01
                              :ARG2 (x26 / control
                                    :mod (x25 / positive))
                              :ARG1-of (x27 / describe-01
                                    :ARG0 (x28 / compare-01
                                          :ARG1 (x29 / lane :mod "1")
                                          :ARG2 (x30 / lane :mod "2"))))
                        :mod "2"))))


# ::id PMC1234335.72
# ::snt The coactivator-binding groove of ERα is required for estradiol-induced and ER-dependent SRC-3 phosphorylation.
# ::tok The coactivator @-@ binding groove of ERα is required for estradiol @-@ induced and ER @-@ dependent SRC @-@ 3 phosphorylation .
(x12 / and
      :op1 (x8 / require-01
            :ARG1 (x4 / protein-segment
                  :ARG1-of (x3 / bind-01
                        :ARG2 (x1 / enzyme
                              :name (x2 / name :op1 "coactivator")
                              :xref (x19 / xref :value "UNIPROT:NCOA5_HUMAN" :prob "0.242")))
                  :name (x5 / name :op1 "groove")
                  :part-of (x6 / protein
                        :name (x7 / name :op1 "ERα")
                        :xref (x20 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
            :ARG0 (x11 / induce-01
                  :ARG0 (x9 / small-molecule
                        :name (x10 / name :op1 "estradiol")
                        :xref (x21 / xref :value "PUBCHEM:5757" :prob "13.090267"))))
      :op2 (x18 / phosphorylate-01
            :ARG0-of (x15 / depend-01
                  :ARG1 (x13 / protein
                        :name (x14 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
            :ARG1 (x16 / protein
                  :name (x17 / name :op1 "SRC-3"))))


# ::id PMC1234335.73
# ::snt (A) HEK293T cells were cotransfected with pERE-E1b-Luc and either the empty vector (Vector), the ERα wild type (WT), the ERα ...
# ::tok ( A ) HEK293T cells were cotransfected with pERE @-@ E1b @-@ Luc and either the empty vector ( Vector ) , the ERα wild type ( WT ) , the ERα ...
(x3 / cotransfect-01
      :li "a"
      :ARG0 (x1 / cell-line
            :name (x2 / name :op1 "HEK293T"))
      :ARG1 (x4 / protein
            :name (x5 / name :op1 "pERE" :op2 "E1b"))
      :ARG2-of (x6 / efficient-01)
      :ARG1-of (x7 / and
            :op2 (x8 / or
                  :op1 (x10 / vector
                        :ARG1-of (x9 / empty-02))
                  :ARG1-of (x11 / mean-01
                        :ARG2 (x13 / or
                              :op1 (x12 / vector)
                              :op1 (x14 / protein
                                    :name (x15 / name :op1 "ERα")
                                    :mod (x16 / wild-type)
                                    :xref (x19 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                              :op2 (x17 / protein
                                    :name (x18 / name :op1 "ERα")
                                    :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))))))


# ::id PMC1234335.74
# ::snt The LXXLL motifs of SRC-3 are required for E2-induced SRC-3 phosphorylation.
# ::tok The LXXLL motifs of SRC @-@ 3 are required for E2 @-@ induced SRC @-@ 3 phosphorylation .
(x4 / require-01
      :ARG1 (x1 / protein-segment
            :part-of (x2 / protein
                  :name (x3 / name :op1 "SRC-3")))
      :ARG0 (x10 / phosphorylate-01
            :ARG2-of (x7 / induce-01
                  :ARG0 (x5 / enzyme
                        :name (x6 / name :op1 "E2")))
            :ARG1 (x8 / protein
                  :name (x9 / name :op1 "SRC-3"))))


# ::id PMC1234335.75
# ::snt SRC family members contain several LXXLL motifs located in their receptor-interacting domains that mediate their direct binding to the LBD of nuclear receptors such as ERα.
# ::tok SRC family members contain several LXXLL motifs located in their receptor @-@ interacting domains that mediate their direct binding to the LBD of nuclear receptors such as ERα.
(x5 / contain-01
      :ARG0 (x4 / member
            :ARG1-of (x1 / include-91
                  :ARG2 (x3 / protein-family
                        :name (x2 / name :op1 "SRC"))))
      :ARG1 (x11 / domain
            :quant (x6 / several)
            :mod (x8 / protein-segment
                  :name (x7 / name :op1 "LXXLL")
                  :location (x10 / interact-01
                        :ARG1 (x9 / receptor)))
            :ARG0-of (x12 / mediate-01
                  :ARG1 (x14 / bind-01
                        :ARG1-of (x13 / direct-02)
                        :ARG2 (x15 / protein
                              :name (x16 / name :op1 "LBD"))
                        :ARG1 (x18 / receptor
                              :mod (x17 / nucleus
                                    :xref (x / xref :value "GO:0005634" :prob "0.8"))
                              :example (x19 / small-molecule
                                    :name (x20 / name :op1 "ERα.")
                                    :xref (x21 / xref :value "PUBCHEM:1727" :prob "9.13859")))))))


# ::id PMC1234335.76
# ::snt The SRC-3-AAA mutant has two amino acid substitutions within each of its three NR boxes, such that the LXXLL motifs are mutated to LXXAA (); this abolishes the ligand-dependent binding between SRC-3 and the ERα LBD (, , , ).
# ::tok The SRC @-@ 3 @-@ AAA mutant has two amino acid substitutions within each of its three NR boxes , such that the LXXLL motifs are mutated to LXXAA ( ) ; this abolishes the ligand @-@ dependent binding between SRC @-@ 3 and the ERα LBD ( , , , ) .
(x1 / multi-sentence
      :snt1 (x5 / and
            :op1 (x4 / mutate-01
                  :ARG2 (x2 / protein
                        :name (x3 / name :op1 "SRC-3-AAA")))
            :op2 (x7 / substitute-01
                  :quant "2"
                  :ARG1 (x6 / amino-acid)
                  :location (x9 / protein-segment
                        :mod (x8 / each)
                        :mod "3")))
      :snt2 (x10 / and
            :op1 (x16 / mutate-01
                  :ARG1 (x13 / and
                        :op1 (x11 / enzyme
                              :name (x12 / name :op1 "NR" :op2 "box"))
                        :op2 (x15 / protein-segment
                              :name (x14 / name :op1 "LXXLL")))
                  :ARG2 (x17 / amino-acid
                        :name (x18 / name :op1 "LXXAA"))
                  :ARG1-of (x19 / statistical-test-91
                        :ARG2 (x20 / less-than :op1 "0.02")))
            :op2 (x22 / abolish-01
                  :ARG0 (x21 / this)
                  :ARG1 (x25 / bind-01
                        :ARG1 (x24 / depend-01
                              :ARG0 (x23 / ligand))
                        :ARG1 (x26 / protein
                              :name (x27 / name :op1 "SRC-3"))
                        :ARG2 (x30 / and
                              :op1 (x28 / protein
                                    :name (x29 / name :op1 "ERα")
                                    :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                              :op2 (x31 / enzyme
                                    :name (x32 / name :op1 "LBD")
                                    :ARG1-of (x33 / statistical-test-91
                                          :ARG2 (x34 / less-than :op1 "0.02"))))))))


# ::id PMC1234335.77
# ::snt To investigate whether the SRC-3-AAA mutant can be phosphorylated in response to E2, plasmids for the SRC-3 mutant and ERα were transfected into HEK293T cells.
# ::tok To investigate whether the SRC @-@ 3 @-@ AAA mutant can be phosphorylated in response to E2 , plasmids for the SRC @-@ 3 mutant and ERα were transfected into HEK293T cells .
(x17 / transfect-01
      :purpose (x1 / investigate-01
            :ARG1 (x2 / possible-01
                  :mode "interrogative"
                  :ARG1 (x6 / phosphorylate-01
                        :ARG1 (x5 / mutate-01
                              :ARG2 (x3 / protein
                                    :name (x4 / name :op1 "SRC-3-AAA")))
                        :ARG2-of (x7 / respond-01
                              :ARG1 (x8 / small-molecule
                                    :name (x9 / name :op1 "E2")
                                    :xref (x20 / xref :value "PUBCHEM:5757" :prob "13.96532"))))))
      :ARG1 (x10 / plasmid
            :ARG2 (x14 / and
                  :op1 (x13 / mutate-01
                        :ARG2 (x11 / protein
                              :name (x12 / name :op1 "SRC-3")))
                  :op2 (x15 / protein
                        :name (x16 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))))
      :ARG2 (x18 / cell-line
            :name (x19 / name :op1 "HEK293T")))


# ::id PMC1234335.78
# ::snt As shown in Fig. , unlike the wild-type SRC-3 (lanes 2 and 3), the AAA mutant could not be phosphorylated in response to E2 treatment (lanes 4 and 5), substantiating the notion that a direct ligand-induced interaction between coactivator and ERα is necessary for E2-dependent SRC-3 phosphorylation.
# ::tok As shown in Fig . , unlike the wild @-@ type SRC @-@ 3 ( lanes 2 and 3 ) , the AAA mutant could not be phosphorylated in response to E2 treatment ( lanes 4 and 5 ) , substantiating the notion that a direct ligand @-@ induced interaction between coactivator and ERα is necessary for E2 @-@ dependent SRC @-@ 3 phosphorylation .
(x1 / multi-sentence
      :snt1 (x10 / and
            :ARG1-of (x2 / show-01
                  :ARG0 (x3 / figure)
                  :ARG1-of (x4 / resemble-01
                        :polarity "-"
                        :ARG2 (x5 / enzyme
                              :mod (x6 / wild-type)
                              :name (x7 / name :op1 "SRC")
                              :mod "3"
                              :xref (x / xref :value "UNIPROT:SRC_HUMAN" :prob "1.004"))))
            :op1 (x8 / lane :mod "2")
            :op2 (x9 / lane :mod "3")
            :op2 (x13 / mutate-01
                  :ARG1 (x11 / protein
                        :name (x12 / name :op1 "AAA")))
            :ARG1-of (x15 / phosphorylate-01
                  :ARG1-of (x14 / possible-01 :polarity "-")
                  :ARG2-of (x16 / respond-01
                        :ARG1 (x19 / treat-04
                              :ARG2 (x17 / small-molecule
                                    :name (x18 / name :op1 "E2")
                                    :xref (x44 / xref :value "PUBCHEM:5757" :prob "13.96532"))))
                  :ARG1-of (x20 / describe-01
                        :ARG0 (x21 / compare-01
                              :ARG1 (x22 / lane :mod "4")
                              :ARG2 (x23 / lane :mod "5")))
                  :ARG0-of (x24 / substantiate-01)))
      :snt2 (x35 / need-01
            :ARG1 (x25 / notion
                  :topic (x32 / and
                        :op1 (x29 / interact-01
                              :ARG2-of (x28 / induce-01
                                    :ARG0 (x27 / ligand
                                          :ARG1-of (x26 / direct-02)))
                              :ARG0 (x30 / protein
                                    :name (x31 / name :op1 "coactivator")
                                    :xref (x43 / xref :value "UNIPROT:NCOA5_HUMAN" :prob "0.242")))
                        :op2 (x33 / protein
                              :name (x34 / name :op1 "ERα")
                              :xref (x42 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))))
            :ARG0 (x41 / phosphorylate-01
                  :ARG0-of (x38 / depend-01
                        :ARG1 (x36 / enzyme
                              :name (x37 / name :op1 "E2")))
                  :ARG1 (x39 / protein
                        :name (x40 / name :op1 "SRC-3")))))


# ::id PMC1234335.79
# ::snt The interaction observed between the AAA mutant and ERα in the absence of E2 (Fig. , lane 4, row 7) likely reflects a hormone- and LXXLL-independent interaction of the ERα AF-1 domain with SRC-3 (), which is inhibited by E2 as a result of ligand-induced interactions of the N and C termini of the receptor ().
# ::tok The interaction observed between the AAA mutant and ERα in the absence of E2 ( Fig . , lane 4 , row 7 ) likely reflects a hormone @- and LXXLL @-@ independent interaction of the ERα AF @-@ 1 domain with SRC @-@ 3 ( ) , which is inhibited by E2 as a result of ligand @-@ induced interactions of the N and C termini of the receptor ( ) .
(x1 / multi-sentence
      :snt1 (x18 / reflect-01
            :ARG1 (x16 / in-a-row
                  :op1 (x3 / observe-01
                        :ARG1 (x2 / interact-01)
                        :ARG1 (x7 / and
                              :op1 (x6 / mutate-01
                                    :ARG2 (x4 / protein
                                          :name (x5 / name :op1 "AAA")))
                              :op2 (x8 / protein
                                    :name (x9 / name :op1 "ERα")
                                    :xref (x50 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
                        :condition (x10 / absent-01
                              :ARG1 (x11 / enzyme
                                    :name (x12 / name :op1 "E2")))
                        :ARG1-of (x13 / describe-01
                              :ARG0 (x14 / figure :mod "4b")))
                  :op2 (x15 / lane :mod "4")
                  :mod "7")
            :ARG1-of (x17 / likely-01)
            :ARG2 (x20 / and
                  :op1 (x19 / hormone)
                  :op2 (x23 / depend-01
                        :ARG1 (x21 / enzyme
                              :name (x22 / name :op1 "LXXLL"))
                        :polarity "-"))
            :ARG1 (x24 / interact-01
                  :ARG0 (x25 / protein
                        :name (x26 / name :op1 "ERα")
                        :xref (x49 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                  :ARG2 (x27 / protein
                        :name (x28 / name :op1 "AF" :op2 "domain"))
                  :ARG1 (x29 / protein
                        :name (x30 / name :op1 "SRC-3"))))
      :snt2 (x31 / and
            :op1 (x32 / statistical-test-91
                  :ARG2 (x33 / less-than :op1 "0.02"))
            :op2 (x34 / inhibit-01
                  :ARG0 (x35 / small-molecule
                        :name (x36 / name :op1 "E2")
                        :mod (x37 / result-01
                              :ARG1 (x39 / induce-01
                                    :ARG0 (x38 / ligand)))
                        :xref (x51 / xref :value "PUBCHEM:5757" :prob "13.96532"))
                  :ARG1 (x40 / interact-01
                        :ARG0 (x43 / and
                              :op1 (x41 / enzyme
                                    :name (x42 / name :op1 "n-ras")
                                    :xref (x / xref :value "UNIPROT:Q9UM97_HUMAN" :prob "0.701"))
                              :op2 (x44 / figure :mod "c"))
                        :ARG1 (x46 / receptor
                              :mod (x45 / terminus)
                              :ARG1-of (x47 / statistical-test-91
                                    :ARG2 (x48 / less-than :op1 "0.02")))))))


# ::id PMC1234335.80
# ::snt The receptor-interacting domain of SRC-3 is required for estradiol-induced SRC-3 phosphorylation.
# ::tok The receptor @-@ interacting domain of SRC @-@ 3 is required for estradiol @-@ induced SRC @-@ 3 phosphorylation .
(x6 / require-01
      :ARG1 (x3 / domain
            :ARG0-of (x2 / interact-01
                  :ARG1 (x1 / receptor))
            :part-of (x4 / protein
                  :name (x5 / name :op1 "SRC-3")))
      :ARG0 (x12 / phosphorylate-01
            :ARG2-of (x9 / induce-01
                  :ARG0 (x7 / small-molecule
                        :name (x8 / name :op1 "estradiol")
                        :xref (x / xref :value "PUBCHEM:5757" :prob "13.090267")))
            :ARG1 (x10 / protein
                  :name (x11 / name :op1 "SRC-3"))))


# ::id PMC1234335.81
# ::snt HEK293T cells were transfected with either wild-type Flag-SRC-3 (SRC-3) or SRC-3 mutant (AAA) having all three LXXLL motifs in the receptor-interacting domain ...
# ::tok HEK293T cells were transfected with either wild @-@ type Flag @-@ SRC @-@ 3 ( SRC @-@ 3 ) or SRC @-@ 3 mutant ( AAA ) having all three LXXLL motifs in the receptor @-@ interacting domain ...
(x3 / transfect-01
      :ARG1 (x1 / cell-line
            :name (x2 / name :op1 "HEK293T"))
      :ARG2 (x4 / or
            :op1 (x5 / enzyme
                  :mod (x6 / wild-type)
                  :name (x7 / name :op1 "Flag"))
            :op2 (x8 / protein
                  :name (x9 / name :op1 "SRC-3")))
      :ARG1-of (x15 / mutate-01
            :ARG0 (x12 / or
                  :op1 (x10 / protein
                        :name (x11 / name :op1 "SRC-3"))
                  :op2 (x13 / protein
                        :name (x14 / name :op1 "SRC-3")))
            :ARG1-of (x17 / have-03
                  :ARG0 (x16 / aaa)
                  :ARG1 (x21 / motif
                        :mod (x18 / all)
                        :quant "3"
                        :mod (x19 / enzyme
                              :name (x20 / name :op1 "LXXLL"))))
            :ARG2 (x23 / interact-01
                  :ARG1 (x22 / receptor))
            :ARG1 (x24 / domain)))


# ::id PMC1234335.82
# ::snt Nuclear localization of ERα is not required for E2-induced SRC-3 phosphorylation.
# ::tok Nuclear localization of ERα is not required for E2 @-@ induced SRC @-@ 3 phosphorylation .
(x5 / require-01
      :ARG1 (x2 / be-located-at-91
            :ARG2 (x1 / nucleus
                  :xref (x12 / xref :value "GO:0005634" :prob "0.8"))
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "ERα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
      :polarity "-"
      :ARG0 (x11 / phosphorylate-01
            :ARG2-of (x8 / induce-01
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "E2")))
            :ARG1 (x9 / protein
                  :name (x10 / name :op1 "SRC-3"))))


# ::id PMC1234335.83
# ::snt To determine whether phosphorylation of SRC-3 can take place in the cytoplasm, an ERα mutant (ERαΔNLS) lacking amino acids 250 to 303, which encompass the ERα NLS, was used.
# ::tok To determine whether phosphorylation of SRC @-@ 3 can take place in the cytoplasm , an ERα mutant ( ERαΔNLS ) lacking amino acids 250 to 303 , which encompass the ERα NLS , was used .
(x14 / lack-01
      :purpose (x1 / determine-01
            :ARG1 (x2 / possible-01
                  :mode "interrogative"
                  :ARG1 (x6 / take-01
                        :ARG0 (x3 / phosphorylate-01
                              :ARG1 (x4 / protein
                                    :name (x5 / name :op1 "SRC-3")))
                        :ARG1 (x7 / place
                              :location (x8 / cytoplasm
                                    :xref (x23 / xref :value "GO:0005737" :prob "0.8"))))))
      :ARG1-of (x9 / protein-segment
            :part-of (x10 / protein
                  :name (x11 / name :op1 "ERα")
                  :ARG2-of (x12 / mutate-01)
                  :xref (x22 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
            :name (x13 / name :op1 "ERαΔNLS"))
      :ARG1 (x21 / use-01
            :ARG1 (x15 / amino-acid
                  :mod (x16 / value-interval :op1 "250" :op2 "303")
                  :ARG0-of (x17 / encompass-01
                        :ARG1 (x18 / protein
                              :name (x19 / name :op1 "ERα")
                              :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
                  :name (x20 / name :op1 "NLS"))))


# ::id PMC1234335.84
# ::snt This mutant was transcriptionally impaired in a luciferase reporter assay and is localized predominantly in the cytoplasm in the absence of ligand ().
# ::tok This mutant was transcriptionally impaired in a luciferase reporter assay and is localized predominantly in the cytoplasm in the absence of ligand ( ) .
(x10 / and
      :op1 (x5 / impair-01
            :ARG1 (x2 / gene
                  :mod (x1 / this)
                  :ARG2-of (x3 / mutate-01))
            :ARG1-of (x4 / transcribe-01)
            :location (x9 / assay-01
                  :ARG0-of (x8 / report-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "luciferase")))))
      :op2 (x11 / localize-01
            :ARG1-of (x12 / predominate-01)
            :location (x13 / cytoplasm
                  :condition (x14 / absent-01
                        :ARG1 (x15 / ligand))
                  :xref (x / xref :value "GO:0005737" :prob "0.8"))
            :ARG1-of (x16 / statistical-test-91
                  :ARG2 (x17 / less-than :op1 "0.02"))))


# ::id PMC1234335.85
# ::snt In order to determine whether SRC-3 overexpression or ligand would affect the mutant vs subcellular localization, cells were transfected with vectors for Flag-tagged SRC-3 and either wild-type or mutant ERα and then treated with either E2 or vehicle.
# ::tok In order to determine whether SRC @-@ 3 overexpression or ligand would affect the mutant vs subcellular localization , cells were transfected with vectors for Flag @-@ tagged SRC @-@ 3 and either wild @-@ type or mutant ERα and then treated with either E2 or vehicle .
(x12 / transfect-01
      :purpose (x1 / determine-01
            :ARG1 (x7 / affect-01
                  :mode "interrogative"
                  :ARG0 (x5 / or
                        :op1 (x4 / overexpress-01
                              :ARG1 (x2 / protein
                                    :name (x3 / name :op1 "SRC-3")))
                        :op2 (x6 / ligand))
                  :ARG1 (x8 / mutate-01)
                  :ARG1 (x10 / localize-01
                        :mod (x9 / subcellular))))
      :ARG1 (x11 / cell)
      :ARG2 (x13 / vector)
      :purpose (x24 / and
            :op1 (x19 / or
                  :op1 (x14 / enzyme
                        :ARG1-of (x17 / tag-01
                              :ARG2 (x15 / protein
                                    :name (x16 / name :op1 "Flag")))
                        :name (x18 / name :op1 "SRC")
                        :xref (x30 / xref :value "UNIPROT:SRC_HUMAN" :prob "1.004"))
                  :op1 (x20 / wild-type)
                  :op2 (x21 / enzyme
                        :ARG2-of (x22 / mutate-01)
                        :name (x23 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
            :op2 (x25 / treat-04
                  :ARG2 (x28 / or
                        :op1 (x26 / enzyme
                              :name (x27 / name :op1 "E2"))
                        :op2 (x29 / vehicle)))))


# ::id PMC1234335.86
# ::snt In the presence of ligand, GFP-ERαΔNLS was localized in the cytoplasm, as opposed to the wild-type ERα (GFP-hERαWT), which was localized primarily in the nucleus (Fig. ), regardless of the presence or absence (data not shown) of ligand.
# ::tok In the presence of ligand , GFP @-@ ERαΔNLS was localized in the cytoplasm , as opposed to the wild @-@ type ERα ( GFP @-@ hERαWT ) , which was localized primarily in the nucleus ( Fig . ) , regardless of the presence or absence ( data not shown ) of ligand .
(x1 / multi-sentence
      :snt1 (x7 / be-located-at-91
            :condition (x2 / present-02
                  :ARG1 (x3 / ligand
                        :mod (x4 / protein
                              :name (x5 / name :op1 "GFP")
                              :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))
                        :name (x6 / name :op1 "ERαΔNLS")))
            :ARG2 (x8 / cytoplasm
                  :ARG1-of (x9 / instead-of-91
                        :ARG2 (x11 / protein
                              :mod (x10 / wild-type)
                              :name (x12 / name :op1 "ERα")
                              :mod (x13 / protein
                                    :name (x14 / name :op1 "GFP")
                                    :xref (x32 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))
                              :name (x15 / name :op1 "hERαWT")
                              :xref (x31 / xref :value "UNIPROT:ERAL1_HUMAN" :prob "0.202")))
                  :time (x16 / amr-unknown)
                  :xref (x30 / xref :value "GO:0005737" :prob "0.8")))
      :snt2 (x17 / be-located-at-91
            :ARG2 (x18 / primary
                  :location (x19 / nucleus
                        :xref (x33 / xref :value "GO:0005634" :prob "0.8"))
                  :ARG1-of (x20 / describe-01
                        :ARG0 (x21 / figure))
                  :ARG1-of (x22 / regardless-91
                        :ARG2 (x23 / or
                              :op2 (x24 / absent-01
                                    :ARG1-of (x25 / describe-01
                                          :ARG0 (x26 / data
                                                :ARG1-of (x27 / show-01 :polarity "-"))))
                              :op1 (x28 / present-02
                                    :ARG1 (x29 / ligand)))))))


# ::id PMC1234335.87
# ::snt Next, the ability of the mutant to promote coactivator phosphorylation was tested.
# ::tok Next , the ability of the mutant to promote coactivator phosphorylation was tested .
(x8 / test-01
      :time (x1 / next)
      :ARG1 (x2 / capable-01
            :ARG1 (x3 / mutate-01)
            :ARG2 (x4 / promote-01
                  :ARG1 (x7 / phosphorylate-01
                        :ARG1 (x5 / enzyme
                              :name (x6 / name :op1 "coactivator")
                              :xref (x / xref :value "UNIPROT:NCOA5_HUMAN" :prob "0.242"))))))


# ::id PMC1234335.88
# ::snt As for wild-type ERα, the mutant was able to induce SRC-3 phosphorylation at all six sites (Fig. ), indicating that nuclear localization of ERα may not be required for inducing SRC-3 phosphorylation in response to E2.
# ::tok As for wild @-@ type ERα, the mutant was able to induce SRC @-@ 3 phosphorylation at all six sites ( Fig . ) , indicating that nuclear localization of ERα may not be required for inducing SRC @-@ 3 phosphorylation in response to E2 .
(x1 / multi-sentence
      :snt1 (x2 / cause-01
            :ARG1 (x3 / enzyme
                  :mod (x4 / wild-type)
                  :name (x5 / name :op1 "ERα,")
                  :xref (x30 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.613")))
      :snt2 (x7 / capable-01
            :ARG1 (x6 / mutate-01)
            :ARG2 (x8 / induce-01
                  :ARG2 (x11 / phosphorylate-01
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "SRC-3")))
                  :location (x13 / protein-segment
                        :mod (x12 / all)
                        :quant "6"))
            :ARG1-of (x14 / describe-01
                  :ARG0 (x15 / figure))
            :ARG0-of (x16 / indicate-01
                  :ARG1 (x17 / possible-01
                        :ARG1 (x22 / require-01
                              :ARG0 (x19 / localize-01
                                    :mod (x18 / nucleus
                                          :xref (x31 / xref :value "GO:0005634" :prob "0.8"))
                                    :ARG1 (x20 / protein
                                          :name (x21 / name :op1 "ERα")
                                          :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
                              :polarity "-"
                              :purpose (x23 / induce-01
                                    :ARG2 (x26 / phosphorylate-01
                                          :ARG1 (x24 / protein
                                                :name (x25 / name :op1 "SRC-3")))
                                    :ARG2-of (x27 / respond-01
                                          :ARG1 (x28 / small-molecule
                                                :name (x29 / name :op1 "E2")
                                                :xref (x32 / xref :value "PUBCHEM:5757" :prob "13.96532")))))))))


# ::id PMC1234335.89
# ::snt Furthermore, the mutant could still bind to SRC-3 in the presence of E2 (Fig. , lanes 5 and 6, row 7).
# ::tok Furthermore , the mutant could still bind to SRC @-@ 3 in the presence of E2 ( Fig . , lanes 5 and 6 , row 7 ) .
(x1 / and
      :op2 (x2 / possible-01
            :ARG1 (x5 / bind-01
                  :ARG0 (x3 / mutate-01)
                  :mod (x4 / still)
                  :ARG2 (x6 / protein
                        :name (x7 / name :op1 "SRC-3"))
                  :condition (x8 / present-02
                        :ARG1 (x9 / enzyme
                              :name (x10 / name :op1 "E2")))))
      :ARG1-of (x11 / describe-01
            :ARG1 (x14 / and
                  :op1 (x12 / lane :mod "5")
                  :op2 (x13 / lane :mod "6")
                  :op2 (x15 / in-a-row :mod "7"))))


# ::id PMC1234335.90
# ::snt It is possible that there is a small amount of the ΔNLS mutant receptor localized in the nucleus () which may contribute to SRC-3 phosphorylation.
# ::tok It is possible that there is a small amount of the ΔNLS mutant receptor localized in the nucleus ( ) which may contribute to SRC @-@ 3 phosphorylation .
(x1 / possible-01
      :ARG1 (x2 / contrast-01
            :ARG1 (x10 / localize-01
                  :ARG0 (x4 / amount
                        :mod (x3 / small)
                        :quant-of (x5 / enzyme
                              :name (x6 / name :op1 "ΔNLS")
                              :ARG2-of (x7 / mutate-01
                                    :ARG1 (x8 / enzyme
                                          :name (x9 / name :op1 "receptor")
                                          :xref (x / xref :value "UNIPROT:CIR1_HUMAN" :prob "0.243")))
                              :xref (x19 / xref :value "UNIPROT:NLS1_HUMAN" :prob "0.242")))
                  :location (x11 / nucleus
                        :xref (x20 / xref :value "GO:0005634" :prob "0.8"))
                  :ARG1-of (x12 / statistical-test-91
                        :ARG2 (x13 / less-than :op1 "0.02")))
            :ARG0-of (x15 / contribute-01
                  :ARG1-of (x14 / possible-01)
                  :ARG2 (x18 / phosphorylate-01
                        :ARG1 (x16 / protein
                              :name (x17 / name :op1 "SRC-3"))))))


# ::id PMC1234335.91
# ::snt However, it should be noted that, under the conditions used for these assays, there is insufficient nuclear ERαΔNLS to induce the transcription of an ERE-containing reporter gene (data not shown) consistent with a previous report ().
# ::tok However , it should be noted that , under the conditions used for these assays , there is insufficient nuclear ERαΔNLS to induce the transcription of an ERE @-@ containing reporter gene ( data not shown ) consistent with a previous report ( ) .
(x1 / multi-sentence
      :snt1 (x2 / have-concession-91
            :ARG1 (x3 / recommend-01
                  :ARG1 (x4 / note-01
                        :ARG1 (x5 / that)))
            :condition (x6 / condition))
      :snt2 (x10 / cause-01
            :ARG1-of (x7 / use-01
                  :ARG2 (x9 / assay-01
                        :mod (x8 / this)))
            :ARG0 (x11 / suffice-01
                  :ARG1 (x15 / induce-01
                        :ARG0 (x12 / enzyme
                              :mod (x13 / nucleus
                                    :xref (x28 / xref :value "GO:0005634" :prob "0.8"))
                              :name (x14 / name :op1 "ERαΔNLS"))
                        :ARG2 (x16 / transcribe-01
                              :ARG1 (x21 / gene
                                    :ARG1 (x19 / contain-01
                                          :ARG1 (x17 / enzyme
                                                :name (x18 / name :op1 "ERE")
                                                :xref (x / xref :value "UNIPROT:EREG_HUMAN" :prob "0.263")))
                                    :ARG0-of (x20 / report-01)
                                    :ARG1-of (x22 / describe-01
                                          :ARG0 (x23 / data
                                                :ARG1-of (x24 / show-01 :polarity "-")))
                                    :ARG1-of (x25 / consistent-01
                                          :ARG2 (x27 / report-01
                                                :time (x26 / previous)))))))))


# ::id PMC1234335.92
# ::snt Nuclear localization of ERα is not required for estradiol-induced SRC-3 phosphorylation.
# ::tok Nuclear localization of ERα is not required for estradiol @-@ induced SRC @-@ 3 phosphorylation .
(x5 / require-01
      :ARG1 (x2 / be-located-at-91
            :ARG2 (x1 / nucleus
                  :xref (x12 / xref :value "GO:0005634" :prob "0.8"))
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "ERα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
      :polarity "-"
      :ARG0 (x11 / phosphorylate-01
            :ARG2-of (x8 / induce-01
                  :ARG0 (x6 / small-molecule
                        :name (x7 / name :op1 "estradiol")
                        :xref (x13 / xref :value "PUBCHEM:5757" :prob "13.090267")))
            :ARG1 (x9 / protein
                  :name (x10 / name :op1 "SRC-3"))))


# ::id PMC1234335.93
# ::snt (A) HEK293T cells were cotransfected with GFP-tagged wild-type ERα (GFP-WT) or ERα NLS deletion mutant lacking aa 250 to 303 (GFP-ΔNLS), ...
# ::tok ( A ) HEK293T cells were cotransfected with GFP @-@ tagged wild @-@ type ERα ( GFP @-@ WT ) or ERα NLS deletion mutant lacking aa 250 to 303 ( GFP-ΔNLS ) , ...
(x3 / cotransfect-01
      :li "a"
      :ARG0 (x1 / cell-line
            :name (x2 / name :op1 "HEK293T"))
      :ARG2 (x4 / enzyme
            :ARG1-of (x7 / tag-01
                  :ARG2 (x5 / protein
                        :name (x6 / name :op1 "GFP")
                        :xref (x28 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
            :mod (x8 / wild-type)
            :name (x9 / name :op1 "ERα")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
      :ARG1-of (x10 / describe-01
            :ARG0 (x11 / and
                  :op1 (x20 / delete-01
                        :ARG0 (x15 / or
                              :op1 (x12 / protein
                                    :name (x13 / name :op1 "GFP")
                                    :mod (x14 / wild-type)
                                    :xref (x30 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))
                              :op2 (x16 / protein
                                    :name (x17 / name :op1 "ERα")
                                    :xref (x31 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
                        :ARG1 (x18 / protein
                              :name (x19 / name :op1 "NLS")
                              :xref (x29 / xref :value "UNIPROT:NLS1_HUMAN" :prob "0.262"))
                        :ARG2 (x21 / enzyme
                              :ARG2-of (x22 / mutate-01)
                              :ARG0-of (x23 / lack-01
                                    :ARG1 (x24 / protein
                                          :name (x25 / name :op1 "6-aa")
                                          :mod (x26 / value-interval :op1 "250" :op2 "303")))
                              :name (x27 / name :op1 "GFP-ΔNLS"))))))


# ::id PMC1234335.94
# ::snt ERα DNA binding activity is not required for E2-induced SRC-3 phosphorylation.
# ::tok ERα DNA binding activity is not required for E2 @-@ induced SRC @-@ 3 phosphorylation .
(x7 / require-01
      :ARG1 (x6 / activity-06
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "ERα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
            :ARG1 (x5 / bind-01
                  :ARG1 (x3 / nucleic-acid
                        :wiki "dna"
                        :name (x4 / name :op1 "DNA"))))
      :polarity "-"
      :ARG0 (x13 / phosphorylate-01
            :ARG2-of (x10 / induce-01
                  :ARG0 (x8 / enzyme
                        :name (x9 / name :op1 "E2")))
            :ARG1 (x11 / protein
                  :name (x12 / name :op1 "SRC-3"))))


# ::id PMC1234335.95
# ::snt Previous data indicated that E2-induced SRC-3 phosphorylation requires the formation of a complex containing SRC-3 and ER.
# ::tok Previous data indicated that E2 @-@ induced SRC @-@ 3 phosphorylation requires the formation of a complex containing SRC @-@ 3 and ER .
(x3 / indicate-01
      :ARG0 (x2 / data
            :mod (x1 / previous))
      :ARG1 (x10 / require-01
            :ARG0 (x9 / phosphorylate-01
                  :ARG2-of (x6 / induce-01
                        :ARG0 (x4 / enzyme
                              :name (x5 / name :op1 "E2")))
                  :ARG1 (x7 / protein
                        :name (x8 / name :op1 "SRC-3")))
            :ARG1 (x11 / form-01
                  :ARG1 (x12 / macro-molecular-complex
                        :ARG0-of (x13 / contain-01
                              :ARG1 (x16 / and
                                    :op1 (x14 / protein
                                          :name (x15 / name :op1 "SRC-3"))
                                    :op2 (x17 / protein
                                          :name (x18 / name :op1 "erα")
                                          :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))))))))


# ::id PMC1234335.96
# ::snt Assembly of ERα, coactivators, and general transcription factors at target gene promoters is associated with recruitment of protein kinases and receptor phosphorylation (, ).
# ::tok Assembly of ERα, coactivators , and general transcription factors at target gene promoters is associated with recruitment of protein kinases and receptor phosphorylation ( , ) .
(x12 / associate-01
      :ARG1 (x4 / and
            :op1 (x1 / assemble-01
                  :ARG1 (x3 / coactivate-01
                        :name (x2 / name :op1 "ERα,")))
            :op2 (x11 / molecular-physical-entity
                  :ARG1-of (x5 / general-02)
                  :ARG0-of (x10 / promote-01
                        :ARG1 (x9 / gene
                              :mod (x7 / factor
                                    :ARG0-of (x6 / transcribe-01))
                              :ARG1-of (x8 / target-01)))))
      :ARG2 (x16 / and
            :op1 (x13 / recruit-01
                  :ARG1 (x14 / enzyme
                        :name (x15 / name :op1 "protein" :op2 "kinase")))
            :op2 (x19 / phosphorylate-01
                  :ARG1 (x17 / enzyme
                        :name (x18 / name :op1 "receptor")
                        :xref (x / xref :value "UNIPROT:CIR1_HUMAN" :prob "0.243"))
                  :ARG1-of (x20 / statistical-test-91
                        :ARG2 (x21 / less-than :op1 "0.02")))))


# ::id PMC1234335.97
# ::snt Whether E2-dependent SRC-3 phosphorylation requires ERα to be bound to DNA was investigated.
# ::tok Whether E2 @-@ dependent SRC @-@ 3 phosphorylation requires ERα to be bound to DNA was investigated .
(x13 / investigate-01
      :ARG1 (x7 / require-01
            :mode "interrogative"
            :ARG0 (x6 / phosphorylate-01
                  :ARG0-of (x3 / depend-01
                        :ARG1 (x1 / enzyme
                              :name (x2 / name :op1 "E2")))
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "SRC-3")))
            :ARG1 (x10 / bind-01
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                  :ARG2 (x11 / nucleic-acid
                        :wiki "dna"
                        :name (x12 / name :op1 "DNA")))))


# ::id PMC1234335.98
# ::snt The receptor binds directly to estrogen response elements mainly through the P box in the first of the two functionally distinct cysteine-cysteine zinc fingers located within the DBD.
# ::tok The receptor binds directly to estrogen response elements mainly through the P box in the first of the two functionally distinct cysteine @-@ cysteine zinc fingers located within the DBD .
(x20 / locate-01
      :ARG1 (x2 / bind-01
            :ARG1 (x1 / receptor)
            :ARG1-of (x3 / direct-02)
            :ARG2 (x7 / element
                  :ARG0-of (x6 / respond-01
                        :ARG1 (x4 / small-molecule
                              :name (x5 / name :op1 "estrogen")
                              :xref (x23 / xref :value "PUBCHEM:5757" :prob "10.921484")))
                  :mod (x8 / main))
            :ARG0 (x9 / enzyme
                  :ARG3-of (x10 / phosphorylate-01)
                  :name (x11 / name :op1 "box"))
            :location (x16 / amino-acid
                  :ord (x12 / ordinal-entity :value "1")
                  :ARG1-of (x13 / include-91
                        :ARG2 (x14 / function-01
                              :quant "2"
                              :mod (x15 / distinct)))
                  :name (x17 / name :op1 "cysteine")
                  :name (x18 / name :op1 "cysteine")
                  :name (x19 / name :op1 "zinc" :op2 "fingers")
                  :xref (x22 / xref :value "PUBCHEM:594" :prob "11.272514")))
      :location (x21 / dbd))


# ::id PMC1234335.99
# ::snt Two ERα DBD mutants were tested, ERαCC and ERαEG, each containing a double mutation in different regions of the P box (C202H/C205H as CC and E203A/G204A as EG, respectively).
# ::tok Two ERα DBD mutants were tested , ERαCC and ERαEG , each containing a double mutation in different regions of the P box ( C202H/C205H as CC and E203A @/@ G204A as EG , respectively ) .
(x13 / contain-01
      :ARG1 (x6 / test-01
            :quant "2"
            :ARG1 (x5 / mutate-01
                  :ARG1 (x1 / protein
                        :name (x2 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                  :ARG2 (x3 / enzyme
                        :name (x4 / name :op1 "DBD")))
            :ARG0 (x9 / and
                  :op1 (x7 / enzyme
                        :name (x8 / name :op1 "ERαCC")
                        :xref (x31 / xref :value "UNIPROT:ERCC1_HUMAN" :prob "0.252"))
                  :op2 (x10 / enzyme
                        :name (x11 / name :op1 "ERαEG")
                        :xref (x32 / xref :value "UNIPROT:EREG_HUMAN" :prob "0.673")))
            :mod (x12 / each))
      :ARG1 (x15 / mutate-01
            :mod (x14 / double))
      :location (x17 / region
            :ARG1-of (x16 / differ-02)
            :part-of (x18 / enzyme
                  :ARG3-of (x19 / phosphorylate-01)
                  :name (x20 / name :op1 "box"))
            :name (x21 / name :op1 "C202H/C205H")
            :mod (x24 / and
                  :mod (x22 / disease
                        :wiki "cervical_cancer"
                        :name (x23 / name :op1 "cervical" :op2 "cancer"))
                  :op2 (x27 / slash
                        :op1 (x25 / enzyme
                              :name (x26 / name :op1 "E203A"))
                        :op2 (x28 / enzyme
                              :name (x29 / name :op1 "G204A")))
                  :ARG0-of (x30 / exemplify-01))))


# ::id PMC1234335.100
# ::snt Neither of the two ERα DBD mutants could activate ERE-dependent transcription in a luciferase reporter assay (Fig. ).
# ::tok Neither of the two ERα DBD mutants could activate ERE @-@ dependent transcription in a luciferase reporter assay ( Fig . ) .
(x7 / activate-01
      :polarity "-"
      :ARG0 (x5 / mutate-01
            :quant "2"
            :mod (x1 / protein
                  :name (x2 / name :op1 "ERα")
                  :xref (x18 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
            :ARG2 (x3 / enzyme
                  :name (x4 / name :op1 "DBD"))
            :ARG1-of (x6 / possible-01))
      :ARG1 (x11 / transcribe-01
            :ARG0-of (x10 / depend-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "ERE")
                        :xref (x / xref :value "UNIPROT:EREG_HUMAN" :prob "0.263"))))
      :location (x15 / assay-01
            :ARG0-of (x14 / report-01
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "luciferase")))
            :ARG1-of (x16 / describe-01
                  :ARG0 (x17 / figure))))


# ::id PMC1234335.101
# ::snt However, both of the CC and EG ERα DBD mutants induced SRC-3 phosphorylation, represented by sites S505, S543, and S867 (Fig. , lanes 5 and 6 and lanes 7 and 8, respectively).
# ::tok However , both of the CC and EG ERα DBD mutants induced SRC @-@ 3 phosphorylation , represented by sites S505 , S543 , and S867 ( Fig . , lanes 5 and 6 and lanes 7 and 8 , respectively ) .
(x1 / contrast-01
      :ARG2 (x29 / and
            :mod (x2 / both)
            :mod (x3 / disease
                  :wiki "cervical_cancer"
                  :name (x4 / name :op1 "cervical" :op2 "cancer"))
            :ARG0-of (x5 / exemplify-01
                  :ARG1 (x11 / induce-01
                        :ARG0 (x10 / mutate-01
                              :ARG1 (x6 / protein
                                    :name (x7 / name :op1 "ERα")
                                    :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                              :ARG2 (x8 / enzyme
                                    :name (x9 / name :op1 "DBD")))
                        :ARG2 (x14 / phosphorylate-01
                              :ARG1 (x12 / protein
                                    :name (x13 / name :op1 "SRC-3")))
                        :ARG0-of (x15 / represent-01
                              :ARG0 (x16 / protein-segment)
                              :ARG1 (x17 / and
                                    :op1 (x18 / amino-acid
                                          :mod "505"
                                          :name (x19 / name :op1 "serine")
                                          :xref (x36 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x20 / amino-acid
                                          :mod "543"
                                          :name (x21 / name :op1 "serine")
                                          :xref (x34 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x22 / amino-acid
                                          :mod "867"
                                          :name (x23 / name :op1 "serine")
                                          :xref (x35 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
                        :ARG1-of (x24 / describe-01
                              :ARG0 (x25 / figure :mod "1b"))))
            :ARG0-of (x26 / compare-01
                  :ARG1 (x27 / lane :mod "5")
                  :ARG2 (x28 / lane :mod "6"))
            :op2 (x32 / and
                  :op1 (x30 / lane :mod "7")
                  :op2 (x31 / lane :mod "8"))
            :mod (x33 / respective)))


# ::id PMC1234335.102
# ::snt The CC mutant appeared to be less effective at supporting SRC-3 phosphorylation than wild-type ERα was (lanes 3 and 4) or the EG mutant, even though the CC mutant binds to SRC-3 as well as does the wild-type receptor.
# ::tok The CC mutant appeared to be less effective at supporting SRC @-@ 3 phosphorylation than wild @-@ type ERα was ( lanes 3 and 4 ) or the EG mutant , even though the CC mutant binds to SRC @-@ 3 as well as does the wild @-@ type receptor .
(x1 / multi-sentence
      :snt1 (x2 / appear-02
            :ARG1 (x7 / effective-04
                  :ARG1 (x5 / mutate-01
                        :mod (x3 / disease
                              :wiki "cervical_cancer"
                              :name (x4 / name :op1 "cervical" :op2 "cancer")))
                  :degree (x6 / less)
                  :ARG1 (x8 / support-01
                        :ARG1 (x11 / phosphorylate-01
                              :ARG1 (x9 / protein
                                    :name (x10 / name :op1 "SRC-3"))))
                  :compared-to (x19 / or
                        :op1 (x15 / be-located-at-91
                              :ARG1 (x12 / enzyme
                                    :mod (x13 / wild-type)
                                    :name (x14 / name :op1 "ERα")
                                    :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                              :ARG1-of (x16 / compare-01
                                    :ARG1 (x17 / lane :mod "3")
                                    :ARG2 (x18 / lane :mod "4")))
                        :op2 (x22 / mutate-01
                              :ARG1 (x20 / enzyme
                                    :name (x21 / name :op1 "EG")))))
            :concession (x25 / mutate-01
                  :mod (x23 / disease
                        :wiki "cervical_cancer"
                        :name (x24 / name :op1 "cervical" :op2 "cancer"))))
      :snt2 (x29 / and
            :op1 (x26 / bind-01
                  :ARG2 (x27 / protein
                        :name (x28 / name :op1 "SRC-3")))
            :op2 (x31 / receptor
                  :mod (x30 / wild-type))))


# ::id PMC1234335.103
# ::snt In contrast, a weaker interaction between the EG mutant and SRC-3 was noted (Fig. , row 4).
# ::tok In contrast , a weaker interaction between the EG mutant and SRC @-@ 3 was noted ( Fig . , row 4 ) .
(x1 / contrast-01
      :ARG2 (x13 / row
            :ARG1 (x10 / note-02
                  :ARG1-of (x2 / weak-02
                        :degree (x3 / more))
                  :ARG1 (x4 / interact-01
                        :ARG0 (x5 / enzyme
                              :name (x6 / name :op1 "EG")
                              :ARG2-of (x7 / mutate-01))
                        :ARG2 (x8 / protein
                              :name (x9 / name :op1 "SRC-3")))
                  :ARG1-of (x11 / describe-01
                        :ARG0 (x12 / figure :mod "3c")))
            :mod "4"))


# ::id PMC1234335.104
# ::snt It was observed that E2 treatment resulted in decreased SRC-3 levels in cells transfected with either ERα DBD mutant (Fig. , lanes 5 to 8, row 6); the reason for this is unknown, but it does suggest that ERα can exert control over SRC-3 levels in some contexts.
# ::tok It was observed that E2 treatment resulted in decreased SRC @-@ 3 levels in cells transfected with either ERα DBD mutant ( Fig . , lanes 5 to 8 , row 6 ) ; the reason for this is unknown , but it does suggest that ERα can exert control over SRC @-@ 3 levels in some contexts .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op1 (x3 / and
                  :op1 (x4 / observe-01
                        :ARG1 (x8 / result-01
                              :ARG1 (x7 / treat-04
                                    :ARG2 (x5 / protein
                                          :name (x6 / name :op1 "E2")))
                              :ARG2 (x12 / level
                                    :ARG1-of (x9 / decrease-01)
                                    :quant-of (x10 / protein
                                          :name (x11 / name :op1 "SRC-3")))
                              :location (x13 / cell
                                    :ARG1-of (x14 / transfect-01
                                          :ARG2 (x15 / or
                                                :op1 (x16 / protein
                                                      :name (x17 / name :op1 "ERα")
                                                      :xref (x41 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                                                :op2 (x20 / mutate-01
                                                      :ARG2 (x18 / enzyme
                                                            :name (x19 / name :op1 "DBD"))))))
                              :ARG1-of (x21 / describe-01
                                    :ARG0 (x22 / figure :mod "8b"))))
                  :op2 (x23 / lane
                        :mod (x24 / value-interval :op1 "5" :op2 "8")))
            :op2 (x25 / in-a-row :mod "6"))
      :snt2 (x29 / contrast-01
            :ARG1 (x28 / know-01
                  :ARG1 (x26 / cause-01
                        :ARG1 (x27 / this))
                  :polarity "-")
            :ARG2 (x30 / suggest-01
                  :ARG1 (x31 / possible-01
                        :ARG1 (x34 / exert-01
                              :ARG0 (x32 / protein
                                    :name (x33 / name :op1 "ERα")
                                    :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                              :ARG1 (x35 / control-01
                                    :ARG1 (x38 / level
                                          :quant-of (x36 / protein
                                                :name (x37 / name :op1 "SRC-3"))
                                          :location (x39 / some)))
                              :ARG0-of (x40 / context))))))


# ::id PMC1234335.105
# ::snt Estradiol-induced and ER-dependent SRC-3 phosphorylation does not require ER DNA binding.
# ::tok Estradiol @-@ induced and ER @-@ dependent SRC @-@ 3 phosphorylation does not require ER DNA binding .
(x4 / and
      :op1 (x3 / induce-01
            :ARG0 (x1 / small-molecule
                  :name (x2 / name :op1 "Estradiol")
                  :xref (x18 / xref :value "PUBCHEM:5757" :prob "13.090267")))
      :op2 (x11 / require-01
            :ARG0 (x10 / phosphorylate-01
                  :ARG0-of (x7 / depend-01
                        :ARG1 (x5 / protein
                              :name (x6 / name :op1 "erα")
                              :xref (x17 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593")))
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "SRC-3")))
            :polarity "-"
            :ARG1 (x16 / bind-01
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "erα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
                  :ARG2 (x14 / nucleic-acid
                        :name (x15 / name :op1 "DNA")))))


# ::id PMC1234335.106
# ::snt (A) HEK293T cells were cotransfected with pERE-E1b-Luc, and either the empty vector (Vector), or vectors for wild-type ERα (WT), or the EG (E203A/G204A) ...
# ::tok ( A ) HEK293T cells were cotransfected with pERE @-@ E1b @-@ Luc , and either the empty vector ( Vector ) , or vectors for wild @-@ type ERα ( WT ) , or the EG ( E203A/G204A ) ...
(x1 / and
      :op1 (x8 / and
            :mod (x4 / cotransfect-01
                  :li "a"
                  :ARG1 (x2 / cell-line
                        :name (x3 / name :op1 "HEK293T"))
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "pERE" :op2 "E1b"))
                  :ARG2-of (x7 / efficient-01))
            :op1 (x9 / or
                  :op1 (x11 / vector
                        :ARG1-of (x10 / empty-02)
                        :name (x12 / name :op1 "con.-vector"))
                  :op2 (x13 / vector
                        :ARG1 (x14 / enzyme
                              :mod (x15 / wild-type)
                              :name (x16 / name :op1 "ERα")
                              :mod (x17 / wild-type)
                              :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))))
      :op2 (x18 / or
            :op1 (x19 / exemplify-01
                  :ARG2 (x20 / small-molecule
                        :name (x21 / name :op1 "E203A/G204A")))))


# ::id PMC3178447.0
# ::snt RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
# ::tok RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild @-@ type BRAF
(x11 / signal-07
      :ARG1 (x4 / molecular-physical-entity
            :ARG0-of (x3 / inhibit-01
                  :ARG1 (x1 / enzyme
                        :name (x2 / name :op1 "RAF")
                        :xref (x15 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))
            :name (x5 / name :op1 "transactivate"))
      :ARG0 (x8 / and
            :op1 (x7 / dimer
                  :name (x6 / name :op1 "RAF"))
            :op2 (x9 / enzyme
                  :name (x10 / name :op1 "ERK")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
      :location (x12 / cell
            :mod (x13 / wild-type)
            :name (x14 / name :op1 "BRAF")))


# ::id PMC3178447.180
# ::snt RAF inhibitors rapidly activate MEK/ERK in cells with wild-type BRAF
# ::tok RAF inhibitors rapidly activate MEK @/@ ERK in cells with wild @-@ type BRAF
(x6 / activate-01
      :ARG0 (x4 / molecular-physical-entity
            :ARG0-of (x3 / inhibit-01
                  :ARG1 (x1 / enzyme
                        :name (x2 / name :op1 "RAF")
                        :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))
      :manner (x5 / rapid)
      :ARG1 (x7 / pathway
            :name (x8 / name :op1 "MEK/ERK"))
      :location (x9 / cell
            :mod (x10 / wild-type)
            :name (x11 / name :op1 "BRAF")))


# ::id PMC3178447.181
# ::snt a , Calu-6 cells (BRAF wild-type /K-RAS Q61K ) were treated with increasing doses of the indicated RAF inhibitors and the effects on ERK signaling were determined by immunoblotting for pMEK and pERK.
# ::tok a , Calu @-@ 6 cells ( BRAF wild @-@ type /K @-@ RAS Q61K ) were treated with increasing doses of the indicated RAF inhibitors and the effects on ERK signaling were determined by immunoblotting for pMEK and pERK .
(x16 / and
      :li "a"
      :op1 (x8 / treat-04
            :ARG1 (x1 / amino-acid
                  :name (x2 / name :op1 "Calu")
                  :mod "6"
                  :name (x3 / name :op1 "BRAF")
                  :xref (x32 / xref :value "PUBCHEM:53438230" :prob "11.787919"))
            :ARG1 (x4 / enzyme
                  :mod (x5 / wild-type)
                  :name (x6 / name :op1 "/K")
                  :ARG2-of (x7 / mutate-01 :value "Q61K"))
            :ARG2 (x10 / dose-01
                  :ARG1-of (x9 / increase-01))
            :ARG2 (x15 / molecular-physical-entity
                  :ARG1-of (x11 / indicate-01)
                  :ARG0-of (x14 / inhibit-01
                        :ARG1 (x12 / enzyme
                              :name (x13 / name :op1 "RAF")
                              :xref (x31 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))))
      :op2 (x21 / determine-01
            :ARG1 (x17 / affect-01
                  :ARG1 (x20 / signal-07
                        :ARG0 (x18 / enzyme
                              :name (x19 / name :op1 "ERK")
                              :xref (x30 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
            :ARG2 (x22 / immunoblot-01
                  :ARG3 (x23 / and
                        :op1 (x24 / enzyme
                              :name (x25 / name :op1 "mek")
                              :ARG3-of (x26 / phosphorylate-01)
                              :xref (x / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.243"))
                        :op2 (x27 / enzyme
                              :name (x28 / name :op1 "ERK")
                              :xref (x29 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))))


# ::id PMC3178447.182
# ::snt b , Cells with wild-type BRAF (Calu-6) or mutant BRAF (Malme-3M) were treated with vehicle or PLX4720 (1μM/1 hour).
# ::tok b , Cells with wild @-@ type BRAF ( Calu @-@ 6 ) or mutant BRAF ( Malme @-@ 3M ) were treated with vehicle or PLX4720 ( 1μM/1 hour ) .
(x12 / treat-04
      :li "b"
      :ARG1 (x1 / cell
            :mod (x2 / wild-type)
            :name (x3 / name :op1 "BRAF")
            :ARG1-of (x6 / or
                  :op1 (x4 / protein
                        :name (x5 / name :op1 "Calu-6"))
                  :op2 (x10 / amino-acid
                        :mod (x7 / gene
                              :ARG2-of (x8 / mutate-01)
                              :name (x9 / name :op1 "BRAF")
                              :xref (x / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004"))
                        :name (x11 / name :op1 "Malme")
                        :mod "3m"
                        :xref (x20 / xref :value "PUBCHEM:354616" :prob "7.2248"))))
      :ARG2 (x14 / or
            :op1 (x13 / vehicle)
            :op2 (x15 / small-molecule
                  :name (x16 / name :op1 "PLX4720")
                  :ARG0-of (x18 / hour
                        :name (x17 / name :op1 "1μM/1"))
                  :xref (x19 / xref :value "PUBCHEM:24180719" :prob "18.572987"))))


# ::id PMC3178447.183
# ::snt Phosphorylation and expression of the indicated proteins were assayed by immunoblotting.
# ::tok Phosphorylation and expression of the indicated proteins were assayed by immunoblotting .
(x2 / and
      :op1 (x1 / phosphorylate-01)
      :op2 (x6 / assay-01
            :ARG1 (x3 / express-03
                  :ARG2 (x5 / protein
                        :ARG0-of (x4 / indicate-01)))
            :ARG0 (x7 / immunoblot-01)))


# ::id PMC3178447.184
# ::snt c , Calu-6 cells treated with 1μM PLX4720 for the indicated time points.
# ::tok c , Calu @-@ 6 cells treated with 1μM PLX4720 for the indicated time points .
(x8 / point
      :mod (x1 / cell-line
            :name (x2 / name :op1 "c" :op2 "Calu")
            :ARG1-of (x3 / treat-04
                  :ARG2 (x4 / small-molecule
                        :name (x5 / name :op1 "PLX4720")
                        :xref (x / xref :value "PUBCHEM:24180719" :prob "18.572987"))
                  :duration (x7 / time
                        :ARG1-of (x6 / indicate-01)))))


# ::id PMC3178447.185
# ::snt d , Calu-6 cells were treated with 1μM PLX4720 for 60 minutes, then medium was replaced with medium containing 1μM PLX4720 (lanes 3-5) or vehicle (lanes 8-10) for the indicated time points.
# ::tok d , Calu @-@ 6 cells were treated with 1μM PLX4720 for 60 minutes , then medium was replaced with medium containing 1μM PLX4720 ( lanes 3 @-@ 5 ) or vehicle ( lanes 8 @-@ 10 ) for the indicated time points .
(x11 / replace-01
      :ARG1 (x4 / treat-04
            :ARG1 (x3 / cell-line
                  :ARG1 (x1 / protein
                        :name (x2 / name :op1 "d" :op2 "Calu")))
            :ARG2 (x5 / small-molecule
                  :name (x6 / name :op1 "PLX4720")
                  :xref (x / xref :value "PUBCHEM:24180719" :prob "18.572987"))
            :duration (x7 / temporal-quantity
                  :quant "60"
                  :unit (x8 / minute)))
      :time (x9 / then)
      :ARG1 (x10 / medium)
      :ARG2 (x20 / or
            :op1 (x12 / medium
                  :ARG0-of (x13 / contain-01
                        :ARG1 (x14 / enzyme
                              :name (x15 / name :op1 "1μM")))
                  :name (x16 / name :op1 "PLX4720")
                  :ARG1-of (x17 / describe-01
                        :ARG0 (x18 / lane
                              :mod (x19 / value-interval :op1 "3" :op2 "5"))))
            :op2 (x21 / vehicle))
      :ARG1-of (x22 / describe-01
            :ARG0 (x23 / lane
                  :mod (x24 / value-interval :op1 "8" :op2 "10")))
      :ARG2 (x27 / point
            :mod (x26 / time
                  :ARG1-of (x25 / indicate-01))))


# ::id PMC3178447.186
# ::snt MEK/ERK activation requires binding of drug to the catalytic domain of RAF
# ::tok MEK @/@ ERK activation requires binding of drug to the catalytic domain of RAF
(x4 / require-01
      :ARG0 (x3 / activate-01
            :ARG1 (x1 / pathway
                  :name (x2 / name :op1 "MEK/ERK")))
      :ARG1 (x5 / bind-01
            :ARG2 (x7 / domain
                  :mod (x6 / catalytic)
                  :part-of (x8 / enzyme
                        :name (x9 / name :op1 "RAF")
                        :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))))


# ::id PMC3178447.187
# ::snt a , 293H cells transfected with EGFP (control), HA-tagged RAS G12V , the catalytic domain of CRAF (V5-tagged catC) and catC carrying a mutation at the gatekeeper residue (V5-tagged catC T421M ), treated with vehicle or PLX4720 (1μM/1 hour).
# ::tok a , 293H cells transfected with EGFP ( control ) , HA @-@ tagged RAS G12V , the catalytic domain of CRAF ( V5 @-@ tagged catC ) and catC carrying a mutation at the gatekeeper residue ( V5 @-@ tagged catC T421M ) , treated with vehicle or PLX4720 ( 1μM/1 hour ) .
(x1 / multi-sentence
      :snt1 (x2 / and
            :li "a"
            :op1 (x5 / transfect-01
                  :ARG1 (x3 / cell-line
                        :name (x4 / name :op1 "293H"))
                  :ARG2 (x6 / small-molecule
                        :name (x7 / name :op1 "EGFP")
                        :ARG0-of (x8 / control-01)))
            :op2 (x9 / enzyme
                  :ARG1-of (x12 / tag-01
                        :ARG2 (x10 / protein
                              :name (x11 / name :op1 "HA")
                              :xref (x48 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
                  :name (x13 / name :op1 "RAS")
                  :ARG2-of (x14 / mutate-01 :value "G12V")
                  :xref (x46 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
            :op3 (x16 / domain
                  :mod (x15 / catalytic)
                  :mod (x17 / enzyme
                        :name (x18 / name :op1 "CRAF")
                        :xref (x49 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
                  :ARG1-of (x19 / mean-01
                        :ARG2 (x25 / and
                              :op1 (x20 / enzyme
                                    :ARG1-of (x23 / tag-01
                                          :ARG2 (x21 / protein
                                                :name (x22 / name :op1 "V5")))
                                    :name (x24 / name :op1 "catC")
                                    :xref (x45 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))
                              :op2 (x26 / enzyme
                                    :name (x27 / name :op1 "catC")
                                    :xref (x / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))))
                  :ARG0-of (x28 / carry-01
                        :ARG1 (x29 / mutate-01
                              :ARG1 (x31 / residue
                                    :name (x30 / name :op1 "gatekeeper"))))
                  :ARG1-of (x34 / tag-01
                        :ARG2 (x32 / protein
                              :name (x33 / name :op1 "V5")))))
      :snt2 (x38 / treat-04
            :ARG1 (x35 / enzyme
                  :name (x36 / name :op1 "catC")
                  :ARG2-of (x37 / mutate-01 :value "T421M")
                  :xref (x47 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))
            :ARG2 (x40 / or
                  :op1 (x39 / vehicle)
                  :op2 (x41 / small-molecule
                        :name (x42 / name :op1 "PLX4720")
                        :ARG0-of (x44 / hour
                              :name (x43 / name :op1 "1μM/1"))
                        :xref (x50 / xref :value "PUBCHEM:24180719" :prob "18.572987")))))


# ::id PMC3178447.188
# ::snt Lysates were subjected to immunoblot analysis for pMEK and pERK.
# ::tok Lysates were subjected to immunoblot analysis for pMEK and pERK .
(x2 / subject-01
      :ARG1 (x1 / lysate)
      :ARG2 (x4 / analyze-01
            :manner (x3 / immunoblot-01)
            :ARG1 (x5 / and
                  :op1 (x6 / enzyme
                        :name (x7 / name :op1 "mek")
                        :ARG3-of (x8 / phosphorylate-01)
                        :xref (x11 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.243"))
                  :op2 (x9 / enzyme
                        :name (x10 / name :op1 "erk")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))


# ::id PMC3178447.189
# ::snt b , Wild-type (+/+), BRAF knock-out (BRAF −/−) or CRAF knock-out (CRAF −/−) mouse embryonic fibroblasts (MEFs) were treated with the indicated concentrations of PLX4720 for 1 hour.
# ::tok b , Wild @-@ type ( +/+ ) , BRAF knock @-@ out ( BRAF −/− ) or CRAF knock @-@ out ( CRAF −/− ) mouse embryonic fibroblasts ( MEFs ) were treated with the indicated concentrations of PLX4720 for 1 hour .
(x25 / treat-04
      :ARG1-of (x1 / describe-01
            :ARG0 (x2 / figure :mod "b"))
      :ARG1 (x22 / fibroblast
            :mod (x3 / wild-type
                  :ARG1-of (x4 / describe-01
                        :ARG2 (x5 / name :op1 "+/+"))
                  :ARG0-of (x8 / knock-down-02
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "BRAF")
                              :xref (x32 / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004")))
                  :location (x12 / or
                        :op1 (x9 / enzyme
                              :name (x10 / name :op1 "BRAF")
                              :ARG2-of (x11 / mutate-01 :mod "−/−")
                              :xref (x / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004"))
                        :op2 (x13 / enzyme
                              :name (x14 / name :op1 "CRAF")
                              :xref (x33 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))))
            :ARG1-of (x15 / knock-out-03
                  :ARG1-of (x16 / mean-01
                        :ARG2 (x17 / enzyme
                              :name (x18 / name :op1 "CRAF")
                              :ARG2-of (x19 / mutate-01 :mod "−/−")
                              :xref (x34 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))))
            :mod (x21 / embryo
                  :mod (x20 / mouse))
            :ARG1-of (x23 / describe-01
                  :ARG2 (x24 / name :op1 "mef")))
      :ARG2 (x27 / concentrate-02
            :ARG1-of (x26 / indicate-01)
            :ARG1 (x28 / small-molecule
                  :name (x29 / name :op1 "PLX4720")
                  :xref (x35 / xref :value "PUBCHEM:24180719" :prob "18.572987")))
      :duration (x30 / temporal-quantity
            :quant "1"
            :unit (x31 / hour)))


# ::id PMC3178447.190
# ::snt c , Sorafenib inhibits the gatekeeper mutant catC T421M protein in vitro ( Supplementary Fig. 8c ) and activates MEK/ERK in cells expressing it.
# ::tok c , Sorafenib inhibits the gatekeeper mutant catC T421M protein in vitro ( Supplementary Fig . 8c ) and activates MEK @/@ ERK in cells expressing it .
(x15 / and
      :op1 (x5 / inhibit-01
            :ARG0 (x1 / and
                  :op1 (x2 / figure :mod "c")
                  :op2 (x3 / small-molecule
                        :name (x4 / name :op1 "Sorafenib")
                        :xref (x / xref :value "PUBCHEM:216239" :prob "16.740406")))
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "gatekeeper")
                  :ARG2-of (x8 / mutate-01
                        :ARG1 (x10 / protein
                              :name (x9 / name :op1 "T421M"))))
            :manner (x11 / in-vitro)
            :ARG1-of (x12 / describe-01
                  :ARG0 (x14 / figure
                        :ARG2-of (x13 / supplement-01)
                        :mod "8c")))
      :op2 (x16 / activate-01
            :ARG1 (x17 / pathway
                  :name (x18 / name :op1 "MEK/ERK"))
            :location (x19 / cell
                  :ARG3-of (x20 / express-03))))


# ::id PMC3178447.191
# ::snt 293H cells overexpressing catC T421M were treated with the indicated concentrations of sorafenib for 1 hour.
# ::tok 293H cells overexpressing catC T421M were treated with the indicated concentrations of sorafenib for 1 hour .
(x7 / treat-04
      :ARG0 (x3 / overexpress-01
            :mod (x1 / cell-line
                  :name (x2 / name :op1 "293H")))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "catC")
            :ARG2-of (x6 / mutate-01 :value "T421M")
            :xref (x / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))
      :ARG2 (x9 / concentrate-02
            :ARG1-of (x8 / indicate-01)
            :ARG1 (x10 / small-molecule
                  :name (x11 / name :op1 "sorafenib")
                  :xref (x14 / xref :value "PUBCHEM:216239" :prob "16.740406")))
      :duration (x12 / temporal-quantity
            :quant "1"
            :unit (x13 / hour)))


# ::id PMC3178447.192
# ::snt Lysates were subjected to analysis for pMEK and pERK.
# ::tok Lysates were subjected to analysis for pMEK and pERK .
(x2 / subject-01
      :ARG1 (x1 / lysate)
      :ARG2 (x3 / analyze-01
            :ARG1 (x4 / and
                  :op1 (x5 / enzyme
                        :name (x6 / name :op1 "mek")
                        :ARG3-of (x7 / phosphorylate-01)
                        :xref (x10 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.243"))
                  :op2 (x8 / enzyme
                        :name (x9 / name :op1 "erk")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))


# ::id PMC3178447.193
# ::snt RAF inhibitor induces the active, phosphorylated state of wild-type and kinase-dead RAF
# ::tok RAF inhibitor induces the active , phosphorylated state of wild @-@ type and kinase @-@ dead RAF
(x4 / induce-01
      :ARG0 (x3 / inhibit-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "RAF")
                  :xref (x16 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))
      :ARG2 (x12 / die-01
            :ARG1 (x6 / state
                  :ARG1-of (x5 / activate-01)
                  :mod (x7 / phosphorylate-01
                        :ARG1 (x9 / and
                              :op1 (x8 / wild-type)
                              :op2 (x10 / enzyme
                                    :name (x11 / name :op1 "kinase")
                                    :xref (x15 / xref :value "UNIPROT:ITK_HUMAN" :prob "0.293")))))
            :ARG2 (x13 / enzyme
                  :name (x14 / name :op1 "RAF")
                  :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))


# ::id PMC3178447.194
# ::snt a , 293H cells over-expressing catC were treated with the indicated amounts of PLX4720 for 1 hour.
# ::tok a , 293H cells over @-@ expressing catC were treated with the indicated amounts of PLX4720 for 1 hour .
(x8 / treat-04
      :ARG1 (x4 / overexpress-01
            :ARG1-of (x1 / mean-01
                  :ARG2 (x2 / cell-line
                        :name (x3 / name :op1 "293H")))
            :ARG1 (x5 / express-03
                  :ARG2 (x6 / enzyme
                        :name (x7 / name :op1 "catC")
                        :xref (x / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))))
      :ARG2 (x10 / amount
            :ARG1-of (x9 / indicate-01)
            :quant-of (x11 / small-molecule
                  :name (x12 / name :op1 "PLX4720")
                  :xref (x15 / xref :value "PUBCHEM:24180719" :prob "18.572987")))
      :duration (x13 / temporal-quantity
            :quant "1"
            :unit (x14 / hour)))


# ::id PMC3178447.196
# ::snt Kinase activity was determined by immunoblotting for pMEK.
# ::tok Kinase activity was determined by immunoblotting for pMEK .
(x3 / determine-01
      :ARG1 (x2 / activity-06
            :ARG0 (x1 / kinase))
      :ARG2 (x4 / immunoblot-01
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "mek")
                  :xref (x / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.243"))))


# ::id PMC3178447.197
# ::snt b , Calu-6 cells were treated with PLX4720 (1μM/1 hour).
# ::tok b , Calu @-@ 6 cells were treated with PLX4720 ( 1μM/1 hour ) .
(x3 / treat-04
      :li "b"
      :ARG1 (x1 / amino-acid
            :name (x2 / name :op1 "Calu")
            :mod "6")
      :ARG2 (x4 / small-molecule
            :name (x5 / name :op1 "PLX4720" :op2 "1μM/1"))
      :time (x6 / hour))


# ::id PMC3178447.199
# ::snt c , Treatment with RAF inhibitor results in elevated phosphorylation at activating phosphorylation sites on RAF.
# ::tok c , Treatment with RAF inhibitor results in elevated phosphorylation at activating phosphorylation sites on RAF .
(x1 / and
      :op1 (x2 / figure :mod "5c")
      :op2 (x7 / result-01
            :ARG1 (x3 / treat-04
                  :ARG2 (x6 / inhibit-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "RAF")
                              :xref (x15 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))
            :ARG2 (x9 / phosphorylate-01
                  :ARG1-of (x8 / elevate-01)
                  :ARG1 (x12 / protein-segment
                        :ARG0-of (x10 / activate-01)
                        :ARG1-of (x11 / phosphorylate-01)
                        :location (x13 / enzyme
                              :name (x14 / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))))


# ::id PMC3178447.200
# ::snt V5-tagged wild-type CRAF or kinase-dead CRAF D486N were overexpressed in 293H cells.
# ::tok V5 @-@ tagged wild @-@ type CRAF or kinase @-@ dead CRAF D486N were overexpressed in 293H cells .
(x14 / overexpress-01
      :ARG0 (x7 / or
            :ARG1-of (x3 / tag-01
                  :ARG2 (x1 / protein
                        :name (x2 / name :op1 "V5")))
            :op1 (x4 / enzyme
                  :mod (x5 / wild-type)
                  :name (x6 / name :op1 "CRAF")
                  :xref (x18 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
            :op2 (x8 / enzyme
                  :name (x9 / name :op1 "kinase")
                  :ARG1-of (x10 / die-01)
                  :xref (x / xref :value "UNIPROT:ITK_HUMAN" :prob "0.293")))
      :ARG1 (x11 / enzyme
            :name (x12 / name :op1 "CRAF")
            :ARG2-of (x13 / mutate-01 :value "D486N")
            :xref (x17 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
      :location (x15 / cell-line
            :name (x16 / name :op1 "293H")))


# ::id PMC3178447.201
# ::snt After 24 hours cells were treated with vehicle or PLX4720 (5μM/1hour) and lysates were immunoblotted for p338CRAF and p621CRAF.
# ::tok After 24 hours cells were treated with vehicle or PLX4720 ( 5μM/1 hour ) and lysates were immunoblotted for p338CRAF and p621CRAF .
(x13 / and
      :op1 (x12 / hour
            :time (x1 / after
                  :quant (x2 / temporal-quantity
                        :quant "24"
                        :unit (x3 / hour))
                  :op1 (x5 / treat-04
                        :ARG1 (x4 / cell)
                        :ARG2 (x7 / or
                              :op1 (x6 / vehicle)
                              :op2 (x8 / small-molecule
                                    :name (x9 / name :op1 "PLX4720")
                                    :xref (x21 / xref :value "PUBCHEM:24180719" :prob "18.572987"))))
                  :op2 (x10 / small-molecule
                        :name (x11 / name :op1 "5μM/1"))))
      :op2 (x15 / immunoblot-01
            :ARG1 (x14 / lysate)
            :ARG3 (x18 / and
                  :op1 (x16 / enzyme
                        :name (x17 / name :op1 "p338CRAF"))
                  :op2 (x19 / enzyme
                        :name (x20 / name :op1 "p621CRAF")
                        :xref (x / xref :value "UNIPROT:MCAF1_HUMAN" :prob "0.232")))))


# ::id PMC3178447.202
# ::snt The gatekeeper mutant CRAF T421M was used as negative control.
# ::tok The gatekeeper mutant CRAF T421M was used as negative control .
(x7 / use-01
      :ARG0 (x3 / mutate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "gatekeeper")))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "CRAF")
            :ARG2-of (x6 / mutate-01 :value "T421M")
            :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
      :ARG2 (x9 / control-01
            :ARG2-of (x8 / negative-01)))


# ::id PMC3178447.204
# ::snt Samples as in Fig. 1a , immunoblotted for pS338CRAF.
# ::tok Samples as in Fig . 1a , immunoblotted for pS338CRAF .
(x1 / thing
      :ARG1-of (x2 / sample-01)
      :ARG1-of (x3 / possible-01
            :ARG1-of (x4 / describe-01
                  :ARG0 (x5 / figure :mod "1a"))
            :ARG1 (x6 / immunoblot-01
                  :ARG3 (x7 / protein
                        :name (x8 / name :op1 "pS338CRAF")))))


# ::id PMC3178447.206
# ::snt MEK/ERK induction occurs via transactivation of RAF dimers
# ::tok MEK @/@ ERK induction occurs via transactivation of RAF dimers
(x3 / induce-01
      :ARG0 (x1 / pathway
            :name (x2 / name :op1 "MEK/ERK"))
      :ARG1 (x4 / occur-01)
      :manner (x5 / transactivate-01
            :ARG1 (x7 / dimer
                  :name (x6 / name :op1 "RAF"))))


# ::id PMC3178447.207
# ::snt a , Similarly to RAF inhibitors, JAB34 inhibits MEK/ERK at higher concentrations.
# ::tok a , Similarly to RAF inhibitors , JAB34 inhibits MEK @/@ ERK at higher concentrations .
(x8 / inhibit-01
      :ARG0 (x1 / person
            :ARG1-of (x2 / resemble-01
                  :ARG2 (x6 / molecular-physical-entity
                        :ARG0-of (x5 / inhibit-01
                              :ARG1 (x3 / enzyme
                                    :name (x4 / name :op1 "RAF")
                                    :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))
                        :name (x7 / name :op1 "JAB34"))))
      :ARG1 (x9 / pathway
            :name (x10 / name :op1 "MEK/ERK"))
      :time (x13 / concentrate-02
            :ARG1-of (x11 / high-02
                  :degree (x12 / more))))


# ::id PMC3178447.208
# ::snt 293H cells expressing V5-tagged catC or catC S428C were treated with either vehicle or 10μM JAB34 for 1 hour.
# ::tok 293H cells expressing V5 @-@ tagged catC or catC S428C were treated with either vehicle or 10μM JAB34 for 1 hour .
(x13 / treat-04
      :ARG0 (x1 / cell-line
            :name (x2 / name :op1 "293H"))
      :ARG1 (x3 / express-03
            :ARG2 (x9 / or
                  :op1 (x4 / enzyme
                        :ARG1-of (x7 / tag-01
                              :ARG2 (x5 / protein
                                    :name (x6 / name :op1 "V5")))
                        :name (x8 / name :op1 "catC")
                        :xref (x20 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))
                  :op2 (x10 / enzyme
                        :name (x11 / name :op1 "catC")
                        :ARG2-of (x12 / mutate-01 :value "S428C")
                        :xref (x / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))))
      :ARG2 (x15 / or
            :op1 (x14 / vehicle)
            :op2 (x16 / enzyme
                  :name (x17 / name :op1 "10μM" :op2 "JAB34")))
      :duration (x18 / temporal-quantity
            :quant "1"
            :unit (x19 / hour)))


# ::id PMC3178447.209
# ::snt b , Coexpression of drug-sensitive V5-tagged catC with drug-resistant FLAG-catC reveals that activation in the homodimer occurs in trans .
# ::tok b , Coexpression of drug @-@ sensitive V5 @-@ tagged catC with drug @-@ resistant FLAG @-@ catC reveals that activation in the homodimer occurs in trans .
(x16 / reveal-01
      :li "b"
      :ARG0 (x1 / express-03
            :ARG2 (x2 / and
                  :op1 (x3 / enzyme
                        :ARG1-of (x8 / tag-01
                              :ARG2 (x4 / cell-line
                                    :ARG0-of (x6 / sensitive-03
                                          :ARG1 (x5 / drug))
                                    :name (x7 / name :op1 "V5")))
                        :name (x9 / name :op1 "catC")
                        :xref (x21 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))
                  :op2 (x11 / resist-01
                        :ARG1 (x10 / drug))))
      :ARG1-of (x12 / cell-line
            :mod (x13 / protein
                  :name (x14 / name :op1 "FLAG")
                  :xref (x / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222"))
            :name (x15 / name :op1 "catC"))
      :ARG1 (x19 / be-located-at-91
            :ARG1 (x17 / activate-01
                  :ARG1 (x18 / homodimer))
            :ARG2 (x20 / trans)))


# ::id PMC3178447.210
# ::snt 293H cells expressing the indicated mutants V5-tagged catC and FLAG-tagged catC were treated with a dose of JAB34 (10μM/1 hour) that inhibits catC S428C when expressed alone.
# ::tok 293H cells expressing the indicated mutants V5 @-@ tagged catC and FLAG @-@ tagged catC were treated with a dose of JAB34 ( 10μM/1 hour ) that inhibits catC S428C when expressed alone .
(x17 / treat-04
      :ARG1 (x11 / and
            :op1 (x3 / express-03
                  :ARG1 (x1 / cell-line
                        :name (x2 / name :op1 "293H"))
                  :ARG2 (x4 / enzyme
                        :ARG1-of (x9 / tag-01
                              :ARG2 (x5 / indicate-01
                                    :ARG1 (x6 / enzyme
                                          :ARG2-of (x7 / mutate-01)
                                          :name (x8 / name :op1 "V5"))))
                        :name (x10 / name :op1 "catC")
                        :xref (x29 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603")))
            :op2 (x12 / enzyme
                  :ARG1-of (x15 / tag-01
                        :ARG2 (x13 / protein
                              :name (x14 / name :op1 "FLAG")
                              :xref (x31 / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                  :name (x16 / name :op1 "catC")
                  :xref (x30 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603")))
      :ARG2 (x18 / dose-01
            :ARG2 (x19 / small-molecule
                  :name (x20 / name :op1 "JAB34"))
            :ARG4 (x22 / hour
                  :name (x21 / name :op1 "10μM/1"))
            :ARG1 (x23 / inhibit-01
                  :ARG1 (x24 / enzyme
                        :name (x25 / name :op1 "catC")
                        :ARG2-of (x26 / mutate-01 :value "S428C")
                        :xref (x / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))
                  :condition (x27 / express-03
                        :mod (x28 / alone)))))


# ::id PMC3178447.211
# ::snt c , Activation in the context of the heterodimer BRAF/CRAF occurs in trans .
# ::tok c , Activation in the context of the heterodimer BRAF @/@ CRAF occurs in trans .
(x3 / activate-01
      :ARG1-of (x1 / describe-01
            :ARG0 (x2 / figure :mod "4c"))
      :ARG1 (x4 / context
            :mod (x5 / heterodimer
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "BRAF")
                        :mod (x8 / enzyme
                              :name (x9 / name :op1 "CRAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
                        :xref (x11 / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004")))
            :location (x10 / trans)))


# ::id PMC3178447.212
# ::snt 293H cells co-expressing FLAG-tagged wild-type BRAF and V5- tagged kinase-dead catC (catC D486N ) (lanes 3,4) or JAB34-sensitive/kinase-dead catC (catC S428C/D486N ) (lanes 5,6) treated with vehicle or 10μM JAB34 for 1 hour.
# ::tok 293H cells co @-@ expressing FLAG @-@ tagged wild @-@ type BRAF and V5 @- tagged kinase @-@ dead catC ( catC D486N ) ( lanes 3,4 ) or JAB34 @-@ sensitive @/@ kinase @-@ dead catC ( catC S428C @/@ D486N ) ( lanes 5,6 ) treated with vehicle or 10μM JAB34 for 1 hour .
(x1 / multi-sentence
      :snt1 (x4 / express-03
            :ARG0 (x2 / cell-line
                  :name (x3 / name :op1 "293H"))
            :ARG2 (x11 / and
                  :op1 (x5 / enzyme
                        :ARG1-of (x8 / tag-01
                              :ARG2 (x6 / protein
                                    :name (x7 / name :op1 "FLAG")
                                    :xref (x47 / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                        :mod (x9 / wild-type)
                        :name (x10 / name :op1 "BRAF")
                        :xref (x48 / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004"))
                  :op2 (x17 / die-01
                        :ARG2 (x14 / tag-01
                              :op1 (x12 / enzyme
                                    :name (x13 / name :op1 "V5"))
                              :op2 (x15 / enzyme
                                    :name (x16 / name :op1 "kinase")
                                    :xref (x52 / xref :value "UNIPROT:ITK_HUMAN" :prob "0.293")))))
            :ARG1 (x24 / or
                  :op1 (x18 / protein
                        :name (x19 / name :op1 "catC")
                        :ARG1-of (x20 / mutate-01 :value "D486N")
                        :ARG1-of (x21 / describe-01
                              :ARG0 (x22 / lane))
                        :name (x23 / name :op1 "3,4")
                        :xref (x51 / xref :value "UNIPROT:AMZ1_HUMAN" :prob "0.562"))
                  :op2 (x27 / sensitive-03
                        :ARG1 (x25 / small-molecule
                              :name (x26 / name :op1 "JAB34"))))
            :ARG1 (x28 / enzyme
                  :name (x29 / name :op1 "kinase")
                  :ARG1-of (x30 / die-01)
                  :xref (x / xref :value "UNIPROT:ITK_HUMAN" :prob "0.293")))
      :snt2 (x40 / treat-04
            :ARG0 (x34 / slash
                  :mod (x31 / protein
                        :name (x32 / name :op1 "catC")
                        :ARG1-of (x33 / mutate-01 :value "S428C")
                        :xref (x49 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))
                  :op2 (x35 / enzyme
                        :name (x36 / name :op1 "D486N"))
                  :ARG1-of (x37 / describe-01
                        :ARG0 (x38 / lane
                              :name (x39 / name :op1 "5,6"))))
            :ARG2 (x42 / or
                  :op1 (x41 / vehicle)
                  :op2 (x43 / enzyme
                        :name (x44 / name :op1 "10μM" :op2 "JAB34")))
            :duration (x45 / temporal-quantity
                  :quant "1"
                  :unit (x46 / hour))))


# ::id PMC3178447.213
# ::snt d , HT-29 cells (colorectal – BRAF V600E ) were transfected with EGFP or HA-tagged N-RAS G12V and treated with PLX4720 (1μM/1hour).
# ::tok d , HT @-@ 29 cells ( colorectal – BRAF V600E ) were transfected with EGFP or HA @-@ tagged N @-@ RAS G12V and treated with PLX4720 ( 1μM/1 hour ) .
(x8 / transfect-01
      :li "d"
      :ARG1 (x2 / cell-line
            :name (x1 / name :op1 "HT-29")
            :mod (x3 / disease
                  :wiki "colorectal_cancer"
                  :name (x4 / name :op1 "colorectal" :op2 "47")))
      :ARG1 (x5 / enzyme
            :name (x6 / name :op1 "BRAF")
            :ARG2-of (x7 / mutate-01 :value "V600E")
            :xref (x24 / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004"))
      :ARG2 (x11 / or
            :op1 (x9 / enzyme
                  :name (x10 / name :op1 "EGFP")
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "0.263"))
            :op2 (x14 / tag-01
                  :ARG2 (x12 / protein
                        :name (x13 / name :op1 "HA")
                        :xref (x25 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002"))))
      :ARG2 (x18 / and
            :op1 (x15 / enzyme
                  :name (x16 / name :op1 "N-RAS")
                  :ARG2-of (x17 / mutate-01 :value "G12V")
                  :xref (x26 / xref :value "UNIPROT:RASN_HUMAN" :prob "0.673"))
            :op2 (x19 / treat-04
                  :ARG2 (x20 / small-molecule
                        :name (x21 / name :op1 "PLX4720")
                        :xref (x27 / xref :value "PUBCHEM:24180719" :prob "18.572987"))))
      :ARG1-of (x23 / hour
            :name (x22 / name :op1 "1μM/1")))


# ::id PMC3178447.214
# ::snt Lysates were blotted for pMEK and pERK.
# ::tok Lysates were blotted for pMEK and pERK .
(x2 / immunoblot-01
      :ARG1 (x1 / lysate)
      :ARG3 (x3 / and
            :op1 (x4 / enzyme
                  :name (x5 / name :op1 "mek")
                  :ARG3-of (x6 / phosphorylate-01)
                  :xref (x9 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.243"))
            :op2 (x7 / enzyme
                  :name (x8 / name :op1 "erk")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))


# ::id PMC3690480.0
# ::snt RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
# ::tok RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3 @-@ Kinase Isoforms
(x10 / regulate-01
      :ARG0 (x3 / and
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "RAS")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
            :op2 (x6 / family
                  :mod (x4 / protein
                        :name (x5 / name :op1 "RHO")
                        :xref (x16 / xref :value "UNIPROT:OPSD_HUMAN" :prob "1.002"))
                  :consist-of (x7 / enzyme
                        :name (x8 / name :op1 "gtpase")
                        :xref (x15 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252"))))
      :ARG1-of (x9 / direct-02)
      :ARG1 (x14 / isoform
            :mod (x11 / distinct)
            :mod (x12 / enzyme
                  :name (x13 / name :op1 "Phosphoinositide" :op2 "3-Kinase"))))


# ::id PMC3690480.3
# ::snt RAS proteins are important direct activators of p110α, p110γ, and p110δ type I phosphoinositide 3-kinases (PI3Ks), interacting via an amino-terminal RAS-binding domain (RBD).
# ::tok RAS proteins are important direct activators of p110α, p110γ, and p110δ type I phosphoinositide 3 @-@ kinases ( PI3Ks ) , interacting via an amino @-@ terminal RAS @-@ binding domain ( RBD ) .
(x10 / and
      :op1 (x5 / activate-01
            :ARG0 (x2 / protein-family
                  :name (x1 / name :op1 "RAS"))
            :mod (x3 / important)
            :ARG1-of (x4 / direct-02)
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "p110α,")
                  :xref (x26 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242"))
            :ARG1 (x8 / isoform
                  :name (x9 / name :op1 "p110α")))
      :op2 (x21 / protein-segment
            :ARG0-of (x18 / interact-01
                  :ARG1 (x11 / protein
                        :name (x12 / name
                              :op1 "p110δ"
                              :op2 "type"
                              :op3 "I"))
                  :ARG1 (x13 / and
                        :op1 (x14 / enzyme
                              :name (x15 / name :op1 "phosphoinositide" :op2 "3-kinase"))
                        :op2 (x16 / enzyme
                              :name (x17 / name :op1 "pi3k")
                              :xref (x27 / xref :value "UNIPROT:PK3CB_HUMAN" :prob "0.203")))
                  :instrument (x19 / protein-segment
                        :name (x20 / name :op1 "amino-terminus")))
            :ARG0-of (x24 / bind-01
                  :ARG1 (x22 / enzyme
                        :name (x23 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
            :name (x25 / name :op1 "RBD")))


# ::id PMC3690480.4
# ::snt Here, we investigate the regulation of the ubiquitous p110β isoform of PI3K, implicated in G-protein-coupled receptor (GPCR) signaling, PTEN-loss-driven cancers, and thrombocyte function.
# ::tok Here , we investigate the regulation of the ubiquitous p110β isoform of PI3K , implicated in G @-@ protein @-@ coupled receptor ( GPCR ) signaling , PTEN @-@ loss @-@ driven cancers , and thrombocyte function .
(x3 / investigate-01
      :medium (x1 / here)
      :ARG0 (x2 / we)
      :ARG1 (x11 / implicate-01
            :ARG2 (x4 / regulate-01
                  :ARG1 (x5 / ubiquity))
            :ARG1 (x8 / isoform
                  :mod (x6 / protein
                        :name (x7 / name :op1 "p110β")
                        :xref (x26 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                  :mod (x9 / enzyme
                        :name (x10 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
            :ARG2 (x12 / protein
                  :name (x13 / name :op1 "G-protein-coupled" :op2 "receptor"))
            :ARG1-of (x14 / describe-01
                  :ARG0 (x23 / and
                        :op1 (x16 / signal-07
                              :name (x15 / name :op1 "GPCR"))
                        :op2 (x20 / drive-02
                              :ARG0 (x19 / lose-02
                                    :ARG1 (x17 / protein
                                          :name (x18 / name :op1 "PTEN")
                                          :xref (x27 / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004")))
                              :ARG1 (x21 / disease
                                    :wiki "cancer"
                                    :name (x22 / name :op1 "cancer")))
                        :op2 (x25 / function-01
                              :ARG0 (x24 / thrombocyte))))))


# ::id PMC3690480.5
# ::snt Unexpectedly, RAS is unable to interact with p110β, but instead RAC1 and CDC42 from the RHO subfamily of small GTPases bind and activate p110β via its RBD.
# ::tok Unexpectedly , RAS is unable to interact with p110β, but instead RAC1 and CDC42 from the RHO subfamily of small GTPases bind and activate p110β via its RBD .
(x8 / contrast-01
      :ARG1-of (x1 / expect-01 :polarity "-")
      :ARG1 (x2 / possible-01
            :polarity "-"
            :ARG1 (x5 / interact-01
                  :ARG0 (x3 / enzyme
                        :name (x4 / name :op1 "RAS")
                        :xref (x27 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "p110β,")
                        :xref (x28 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242"))))
      :ARG2 (x9 / instead-of-91
            :ARG1 (x12 / and
                  :op1 (x10 / protein
                        :name (x11 / name :op1 "RAC1")
                        :xref (x29 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x13 / protein
                        :name (x14 / name :op1 "CDC42")
                        :xref (x30 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))
      :ARG2 (x15 / protein
            :name (x16 / name :op1 "RHO" :op2 "subfamily"))
      :ARG1 (x21 / and
            :op1 (x20 / bind-01
                  :ARG2 (x17 / enzyme
                        :mod (x18 / small)
                        :name (x19 / name :op1 "gtpase")
                        :xref (x31 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252")))
            :op2 (x22 / activate-01
                  :ARG1 (x23 / enzyme
                        :name (x24 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                  :instrument (x25 / protein-segment
                        :name (x26 / name :op1 "RBD")))))


# ::id PMC3690480.6
# ::snt In fibroblasts, GPCRs couple to PI3K through Dock180/Elmo1-mediated RAC activation and subsequent interaction with p110β.
# ::tok In fibroblasts , GPCRs couple to PI3K through Dock180 @/@ Elmo1 @-@ mediated RAC activation and subsequent interaction with p110β.
(x4 / couple-01
      :location (x1 / fibroblast)
      :ARG0 (x2 / small-molecule
            :name (x3 / name :op1 "GPCRs"))
      :ARG2 (x5 / enzyme
            :name (x6 / name :op1 "PI3K")
            :xref (x24 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
      :manner (x16 / and
            :op1 (x15 / activate-01
                  :ARG1-of (x12 / mediate-01
                        :ARG0 (x9 / slash
                              :op1 (x7 / enzyme
                                    :name (x8 / name :op1 "Dock180")
                                    :xref (x22 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
                              :op2 (x10 / enzyme
                                    :name (x11 / name :op1 "Elmo1")
                                    :xref (x23 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))))
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "RAC")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003")))
            :op2 (x18 / interact-01
                  :time (x17 / subsequent)
                  :ARG1 (x19 / protein
                        :name (x20 / name :op1 "p110β.")
                        :xref (x21 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242")))))


# ::id PMC3690480.7
# ::snt Cells from mice carrying mutations in the p110β RBD show reduced PI3K activity and defective chemotaxis, and these mice are resistant to experimental lung fibrosis.
# ::tok Cells from mice carrying mutations in the p110β RBD show reduced PI3K activity and defective chemotaxis , and these mice are resistant to experimental lung fibrosis .
(x16 / and
      :op1 (x8 / show-01
            :ARG0 (x1 / cell
                  :source (x2 / mouse
                        :ARG0-of (x3 / carry-01
                              :ARG1 (x4 / mutate-01
                                    :ARG1 (x5 / gene
                                          :name (x6 / name :op1 "p110β")
                                          :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))))
                  :name (x7 / name :op1 "RBD"))
            :ARG1 (x13 / and
                  :op1 (x9 / reduce-01
                        :ARG1 (x12 / activity-06
                              :ARG0 (x10 / enzyme
                                    :name (x11 / name :op1 "PI3K")
                                    :xref (x23 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))
                  :op2 (x15 / chemotaxis
                        :mod (x14 / defective))))
      :op2 (x19 / resist-01
            :ARG0 (x18 / mouse
                  :mod (x17 / this))
            :ARG1 (x20 / experiment-01
                  :ARG1 (x21 / disease
                        :wiki "lung_cancer"
                        :name (x22 / name :op1 "lung" :op2 "fibrosis")))))


# ::id PMC3690480.8
# ::snt These findings revise our understanding of the regulation of type I PI3K by showing that both RAS and RHO family GTPases directly regulate distinct ubiquitous PI3K isoforms and that RAC activates p110β downstream of GPCRs.
# ::tok These findings revise our understanding of the regulation of type I PI3K by showing that both RAS and RHO family GTPases directly regulate distinct ubiquitous PI3K isoforms and that RAC activates p110β downstream of GPCRs .
(x4 / revise-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG1-of (x3 / find-01))
      :ARG1 (x6 / understand-01
            :ARG0 (x5 / we)
            :ARG1 (x12 / show-01
                  :ARG0 (x7 / regulate-01
                        :ARG1 (x8 / disease
                              :mod (x9 / type
                                    :ord (x10 / ordinal-entity :value "1"))
                              :name (x11 / name :op1 "PI3K")))
                  :ARG1 (x13 / and
                        :op1 (x20 / regulate-01
                              :ARG0 (x14 / and
                                    :op1 (x15 / enzyme
                                          :name (x16 / name :op1 "RAS")
                                          :xref (x38 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                                    :op2 (x17 / protein-family
                                          :name (x18 / name :op1 "RHO" :op2 "gtpase")))
                              :ARG1-of (x19 / direct-02)
                              :ARG1 (x25 / isoform
                                    :mod (x21 / distinct)
                                    :mod (x22 / ubiquity
                                          :ARG1 (x23 / enzyme
                                                :name (x24 / name :op1 "PI3K")
                                                :xref (x36 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))))
                        :op2 (x28 / activate-01
                              :ARG0 (x26 / enzyme
                                    :name (x27 / name :op1 "RAC")
                                    :xref (x35 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                              :ARG1 (x29 / enzyme
                                    :name (x30 / name :op1 "p110β")
                                    :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                              :ARG2 (x31 / relative-position
                                    :direction (x32 / downstream)
                                    :op1 (x33 / enzyme
                                          :name (x34 / name :op1 "GPCRs")
                                          :xref (x37 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311"))))))))


# ::id PMC3690480.13
# ::snt Unlike p110α, p110γ, and p110δ PI3K isoforms, RAS is unable to interact with p110β
# ::tok Unlike p110α, p110γ, and p110δ PI3K isoforms , RAS is unable to interact with p110β
(x1 / resemble-01
      :ARG1 (x9 / isoform
            :op1 (x4 / and
                  :op1 (x2 / enzyme
                        :name (x3 / name :op1 "p110α")
                        :xref (x17 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                  :op2 (x5 / enzyme
                        :name (x6 / name :op1 "p110δ")
                        :xref (x19 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
            :mod (x7 / enzyme
                  :name (x8 / name :op1 "PI3K")
                  :xref (x18 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
      :ARG1-of (x10 / possible-01
            :polarity "-"
            :ARG1 (x13 / interact-01
                  :ARG0 (x11 / enzyme
                        :name (x12 / name :op1 "RAS")
                        :xref (x16 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :ARG1 (x14 / protein
                        :name (x15 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))))


# ::id PMC3690480.14
# ::snt The RHO family GTPases RAC1 and CDC42 directly bind and activate p110β via its RBD
# ::tok The RHO family GTPases RAC1 and CDC42 directly bind and activate p110β via its RBD
(x10 / and
      :op1 (x9 / bind-01
            :ARG1 (x5 / and
                  :op1 (x1 / protein-family
                        :name (x2 / name :op1 "RHO" :op2 "gtpase"))
                  :op2 (x3 / protein
                        :name (x4 / name :op1 "RAC1")
                        :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op3 (x6 / protein
                        :name (x7 / name :op1 "CDC42")
                        :xref (x17 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
            :ARG1-of (x8 / direct-02))
      :op2 (x11 / activate-01
            :ARG1 (x12 / enzyme
                  :name (x13 / name :op1 "p110β")
                  :xref (x16 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
            :instrument (x14 / protein-segment
                  :name (x15 / name :op1 "RBD"))))


# ::id PMC3690480.15
# ::snt GPCRs couple to PI3K via Dock180/Elmo1-mediated RAC activation and binding to p110β
# ::tok GPCRs couple to PI3K via Dock180 @/@ Elmo1 @-@ mediated RAC activation and binding to p110β
(x3 / couple-01
      :ARG2 (x1 / enzyme
            :name (x2 / name :op1 "GPCRs")
            :xref (x22 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311"))
      :ARG2 (x4 / enzyme
            :name (x5 / name :op1 "PI3K")
            :xref (x23 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
      :instrument (x15 / and
            :op1 (x14 / activate-01
                  :ARG1-of (x11 / mediate-01
                        :ARG0 (x8 / slash
                              :op1 (x6 / enzyme
                                    :name (x7 / name :op1 "Dock180")
                                    :xref (x19 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
                              :op2 (x9 / enzyme
                                    :name (x10 / name :op1 "Elmo1")
                                    :xref (x20 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))))
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "RAC")
                        :xref (x21 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003")))
            :op2 (x16 / bind-01
                  :ARG2 (x17 / protein
                        :name (x18 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))))


# ::id PMC3690480.16
# ::snt Mice with RBD mutant p110β are resistant to experimental lung fibrosis
# ::tok Mice with RBD mutant p110β are resistant to experimental lung fibrosis
(x7 / resist-01
      :ARG0 (x1 / mouse
            :ARG0-of (x2 / have-03
                  :ARG1 (x4 / enzyme
                        :name (x3 / name :op1 "RBD")
                        :ARG2-of (x5 / mutate-01)))
            :name (x6 / name :op1 "p110β"))
      :ARG1 (x8 / experiment-01
            :ARG1 (x9 / disease
                  :wiki "lung_cancer"
                  :name (x10 / name :op1 "lung" :op2 "fibrosis"))))


# ::id PMC3690480.18
# ::snt RAS proteins bind and activate multiple PI3K isoforms.
# ::tok RAS proteins bind and activate multiple PI3K isoforms .
(x3 / bind-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "RAS")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
      :ARG2 (x4 / and
            :op2 (x5 / activate-01
                  :ARG1 (x9 / isoform
                        :quant (x6 / multiple)
                        :mod (x7 / enzyme
                              :name (x8 / name :op1 "PI3K")
                              :xref (x10 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))))


# ::id PMC3690480.19
# ::snt The p110β isoform of PI3K, however, is instead activated by the binding of RHO family members RAC and CDC42.
# ::tok The p110β isoform of PI3K , however , is instead activated by the binding of RHO family members RAC and CDC42 .
(x1 / contrast-01
      :ARG2 (x6 / be-located-at-91
            :ARG0 (x3 / isoform
                  :name (x2 / name :op1 "p110β")
                  :mod (x4 / enzyme
                        :name (x5 / name :op1 "PI3K")
                        :xref (x21 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
            :ARG2 (x7 / instead-of-91
                  :ARG1 (x8 / activate-01
                        :ARG0 (x13 / member
                              :ARG1-of (x12 / include-91
                                    :ARG2 (x9 / bind-01
                                          :ARG1 (x10 / protein
                                                :name (x11 / name :op1 "RHO")
                                                :xref (x20 / xref :value "UNIPROT:OPSD_HUMAN" :prob "1.002")))))
                        :ARG1 (x16 / and
                              :op1 (x14 / enzyme
                                    :name (x15 / name :op1 "RAC")
                                    :xref (x19 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                              :op2 (x17 / protein
                                    :name (x18 / name :op1 "CDC42")
                                    :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))))))


# ::id PMC3690480.20
# ::snt Blocking this interaction blunts GPCR-mediated cellular chemotaxis and confers resistance to lung fibrosis.
# ::tok Blocking this interaction blunts GPCR @-@ mediated cellular chemotaxis and confers resistance to lung fibrosis .
(x6 / confer-02
      :ARG1 (x5 / chemotaxis
            :ARG1-of (x3 / mediate-01
                  :ARG0 (x1 / enzyme
                        :name (x2 / name :op1 "GPCR")
                        :xref (x / xref :value "UNIPROT:Q76L88_HUMAN" :prob "1.001")))
            :mod (x4 / cell))
      :ARG0 (x7 / block-01
            :ARG1 (x9 / interact-01
                  :mod (x8 / this))
            :ARG2 (x10 / resist-01
                  :ARG1 (x11 / disease
                        :wiki "lung_cancer"
                        :name (x12 / name :op1 "lung" :op2 "fibrosis")))))


# ::id PMC3690480.47
# ::snt PI3K p110β Is Not a RAS Target Protein
# ::tok PI3K p110β Is Not a RAS Target Protein
(x5 / target-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "PI3K" :op2 "p110β"))
      :polarity "-"
      :ARG2 (x3 / enzyme
            :name (x4 / name :op1 "RAS")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
      :ARG1 (x6 / enzyme
            :name (x7 / name :op1 "Protein")
            :xref (x8 / xref :value "UNIPROT:S45A3_HUMAN" :prob "0.372")))


# ::id PMC3690480.48
# ::snt To investigate the role of RAS in regulating p110β, we set out to characterize the biochemical interaction between the two in vitro.
# ::tok To investigate the role of RAS in regulating p110β, we set out to characterize the biochemical interaction between the two in vitro .
(x9 / set-out-06
      :purpose (x1 / investigate-01
            :ARG1 (x2 / role
                  :poss (x3 / enzyme
                        :name (x4 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :topic (x5 / regulate-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "p110β,")
                              :xref (x14 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242")))))
      :ARG0 (x8 / we)
      :ARG1 (x10 / characterize-01
            :ARG1 (x12 / interact-01
                  :mod (x11 / biochemistry)
                  :ARG0 (x13 / in-vitro :quant "2"))))


# ::id PMC3690480.49
# ::snt In glutathione S-transferase (GST) pull-down studies using recombinant, GTPγS-loaded HRAS, KRAS, and NRAS as baits, we found strong and specific interaction between all three RAS proteins and p110α ( Figure 1 A).
# ::tok In glutathione S @-@ transferase ( GST ) pull @-@ down studies using recombinant , GTPγS @-@ loaded HRAS , KRAS , and NRAS as baits , we found strong and specific interaction between all three RAS proteins and p110α ( Figure 1 A ) .
(x1 / multi-sentence
      :snt1 (x24 / find-01
            :medium (x9 / study-01
                  :ARG0 (x2 / and
                        :op1 (x3 / enzyme
                              :name (x4 / name :op1 "glutathione" :op2 "S-transferase"))
                        :op2 (x5 / enzyme
                              :name (x6 / name :op1 "GST")
                              :xref (x39 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "GST")
                        :xref (x38 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))
                  :ARG0-of (x10 / use-01
                        :ARG1 (x19 / and
                              :op1 (x11 / enzyme
                                    :ARG1-of (x15 / load-01
                                          :ARG2 (x12 / enzyme
                                                :ARG0-of (x13 / recombine-01)
                                                :name (x14 / name :op1 "GTPγS")))
                                    :name (x16 / name :op1 "HRAS")
                                    :xref (x41 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
                              :op2 (x17 / gene
                                    :name (x18 / name :op1 "KRAS")
                                    :xref (x42 / xref :value "UNIPROT:RASK_HUMAN" :prob "1.003"))
                              :op2 (x20 / gene
                                    :name (x21 / name :op1 "NRAS")
                                    :xref (x37 / xref :value "UNIPROT:RASN_HUMAN" :prob "1.003"))))
                  :ARG1-of (x22 / bait))
            :ARG0 (x23 / we)
            :ARG1 (x27 / interact-01
                  :ARG1-of (x25 / strong-02)
                  :ARG1-of (x26 / specific-02)
                  :ARG0 (x31 / protein
                        :mod (x28 / all)
                        :quant "3"
                        :mod (x29 / enzyme
                              :name (x30 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))
      :snt2 (x32 / and
            :op2 (x33 / enzyme
                  :name (x34 / name :op1 "p110α")
                  :xref (x40 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
            :ARG1-of (x35 / describe-01
                  :ARG0 (x36 / figure :mod "1"))))


# ::id PMC3690480.50
# ::snt In contrast, p110β bound to none of the RAS proteins, but did bind to RAB5, a previously identified GTPase interactor of p110β ( Christoforidis et al., 1999 ).
# ::tok In contrast , p110β bound to none of the RAS proteins , but did bind to RAB5 , a previously identified GTPase interactor of p110β ( Christoforidis et al. , 1999 ) .
(x1 / contrast-01
      :ARG2 (x8 / contrast-01
            :ARG1 (x4 / bind-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                  :ARG2 (x5 / none
                        :poss (x7 / protein-family
                              :name (x6 / name :op1 "RAS"))))
            :ARG2 (x9 / bind-01
                  :ARG2 (x10 / protein
                        :name (x11 / name :op1 "RAB5")
                        :ARG1-of (x13 / identify-01
                              :time (x12 / previous)
                              :ARG2 (x14 / enzyme
                                    :name (x15 / name :op1 "GTPase")
                                    :xref (x30 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.312"))
                              :ARG1 (x17 / amino-acid
                                    :name (x16 / name :op1 "interactor")
                                    :part-of (x18 / enzyme
                                          :name (x19 / name :op1 "p110β")
                                          :xref (x28 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))
                        :xref (x29 / xref :value "UNIPROT:RAB5A_HUMAN" :prob "1.003"))))
      :ARG1-of (x20 / describe-01
            :ARG0 (x21 / publication-91
                  :ARG0 (x24 / and
                        :op1 (x22 / person
                              :name (x23 / name :op1 "Christoforidis"))
                        :op2 (x25 / person
                              :mod (x26 / other)))
                  :time (x27 / date-entity :year "1999"))))


# ::id PMC3690480.51
# ::snt Mutating key residues within the RBD of p110α (T208D/K227A) abrogated RAS binding, whereas introduction of analogous mutations (see below for details) into p110β did not affect RAB5 binding.
# ::tok Mutating key residues within the RBD of p110α ( T208D/K227A ) abrogated RAS binding , whereas introduction of analogous mutations ( see below for details ) into p110β did not affect RAB5 binding .
(x8 / abrogate-01
      :ARG1 (x3 / residue
            :mod (x1 / mutate-01)
            :ARG1-of (x2 / key-02)
            :location (x4 / protein-segment
                  :name (x5 / name :op1 "RBD")
                  :part-of (x6 / enzyme
                        :name (x7 / name :op1 "p110α" :op2 "T208D/K227A"))))
      :ARG1 (x12 / contrast-01
            :ARG1 (x11 / bind-01
                  :ARG1 (x9 / enzyme
                        :name (x10 / name :op1 "RAS")
                        :xref (x25 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
            :ARG2 (x13 / introduce-02
                  :ARG1 (x15 / mutate-01
                        :mod (x14 / analogous)))
            :ARG1-of (x16 / see-01
                  :location (x17 / below))
            :ARG2 (x18 / detail-01))
      :ARG2 (x21 / affect-01
            :ARG0 (x19 / small-molecule
                  :name (x20 / name :op1 "p110β")
                  :xref (x26 / xref :value "PUBCHEM:6511" :prob "9.430335"))
            :polarity "-"
            :ARG1 (x24 / bind-01
                  :ARG2 (x22 / protein
                        :name (x23 / name :op1 "RAB5")
                        :xref (x / xref :value "UNIPROT:RAB5A_HUMAN" :prob "1.003")))))


# ::id PMC3690480.52
# ::snt Similar results were obtained when we used recombinant full-length GST-p110/p85 complexes to pull down active RAS or RAB5 proteins ( Figure 1 B).
# ::tok Similar results were obtained when we used recombinant full @-@ length GST @-@ p110 @/@ p85 complexes to pull down active RAS or RAB5 proteins ( Figure 1 B ) .
(x4 / obtain-01
      :ARG1 (x2 / thing
            :ARG1-of (x1 / resemble-01)
            :ARG2-of (x3 / result-01))
      :time (x6 / use-01
            :ARG0 (x5 / we)
            :ARG1 (x13 / complex
                  :mod (x8 / protein
                        :ARG1-of (x7 / recombine-01)
                        :ARG1-of (x10 / long-03
                              :ARG1-of (x9 / full-09)))
                  :mod (x11 / protein
                        :name (x12 / name :op1 "GST-p110/p85")))
            :ARG2 (x18 / or
                  :op1 (x14 / pull-down-08
                        :ARG1 (x15 / enzyme
                              :ARG0-of (x16 / activity-06)
                              :name (x17 / name :op1 "RAS")
                              :xref (x23 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
                  :op2 (x20 / protein
                        :name (x19 / name :op1 "RAB5")
                        :xref (x / xref :value "UNIPROT:RAB5A_HUMAN" :prob "1.003"))))
      :ARG1-of (x21 / describe-01
            :ARG0 (x22 / figure :mod "1b")))


# ::id PMC3690480.53
# ::snt Moreover, when we expressed constitutively active RAS or RAB5, along with p110α/p85 or p110β/p85 in COS7 cells, and measured PIP 3 -levels ( Figure 1 C) or steady-state phospho-AKT ( Figure S1 A available online) as indicators of PI3K activity, HRAS and KRAS strongly enhanced p110α activity, whereas p110β was not stimulated by either RAS proteins or RAB5.
# ::tok Moreover , when we expressed constitutively active RAS or RAB5 , along with p110α/p85 or p110β/p85 in COS7 cells , and measured PIP 3 -@ levels ( Figure 1 C ) or steady @-@ state phospho @-@ AKT ( Figure S1 A available online ) as indicators of PI3K activity , HRAS and KRAS strongly enhanced p110α activity , whereas p110β was not stimulated by either RAS proteins or RAB5 .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op2 (x19 / and
                  :time (x4 / express-03
                        :ARG0 (x3 / we)
                        :ARG2 (x9 / or
                              :op1 (x5 / enzyme
                                    :ARG0-of (x7 / activity-06
                                          :mod (x6 / constitutive))
                                    :name (x8 / name :op1 "RAS")
                                    :xref (x63 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                              :op2 (x10 / enzyme
                                    :name (x11 / name :op1 "RAB5")
                                    :xref (x67 / xref :value "UNIPROT:RAB5A_HUMAN" :prob "1.003"))
                              :accompanier (x14 / or
                                    :op1 (x12 / enzyme
                                          :name (x13 / name :op1 "p110α/p85"))
                                    :op2 (x15 / enzyme
                                          :name (x16 / name :op1 "p110β/p85"))))
                        :location (x18 / cell
                              :name (x17 / name :op1 "COS7")))
                  :op2 (x20 / measure-01
                        :ARG1 (x21 / protein
                              :name (x22 / name :op1 "PIP" :op2 "3"))
                        :ARG2 (x23 / level))
                  :ARG1-of (x24 / describe-01
                        :ARG0 (x25 / figure :mod "1"))))
      :snt2 (x51 / contrast-01
            :li "c"
            :ARG1 (x47 / enhance-01
                  :ARG1 (x43 / and
                        :op1 (x26 / or
                              :op2 (x28 / state
                                    :ARG1-of (x27 / steady-01))
                              :ARG1-of (x29 / phosphorylate-01
                                    :ARG2 (x30 / enzyme
                                          :name (x31 / name :op1 "AKT")
                                          :xref (x64 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                              :ARG1-of (x32 / describe-01
                                    :ARG0 (x33 / figure :mod "s1")
                                    :ARG1 (x34 / available-02
                                          :medium (x35 / online))
                                    :ARG2 (x36 / thing
                                          :ARG0-of (x37 / indicate-01))
                                    :ARG1 (x40 / activity-06
                                          :ARG0 (x38 / enzyme
                                                :name (x39 / name :op1 "PI3K")
                                                :xref (x65 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))))
                        :op2 (x41 / enzyme
                              :name (x42 / name :op1 "HRAS")
                              :xref (x61 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
                        :op3 (x44 / enzyme
                              :name (x45 / name :op1 "KRAS")
                              :xref (x60 / xref :value "UNIPROT:RASK_HUMAN" :prob "1.003")))
                  :ARG1-of (x46 / strong-02)
                  :ARG1 (x50 / activity-06
                        :ARG0 (x48 / enzyme
                              :name (x49 / name :op1 "p110α")
                              :xref (x62 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))
            :ARG2 (x52 / protein
                  :name (x53 / name :op1 "p110β")
                  :ARG1-of (x54 / stimulate-01
                        :polarity "-"
                        :ARG0 (x55 / or
                              :op1 (x57 / protein-family
                                    :name (x56 / name :op1 "RAS"))
                              :op2 (x58 / enzyme
                                    :name (x59 / name :op1 "RAB5")
                                    :xref (x66 / xref :value "UNIPROT:RAB5A_HUMAN" :prob "1.003"))))
                  :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))


# ::id PMC3690480.54
# ::snt An Intact RBD Is Essential for p110β Activity in Cells
# ::tok An Intact RBD Is Essential for p110β Activity in Cells
(x4 / essential
      :domain (x1 / temporal-quantity
            :quant "1"
            :mod (x2 / intact)
            :name (x3 / name :op1 "RBD"))
      :purpose (x7 / activity-06
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "p110β")
                  :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
            :location (x8 / cell)))


# ::id PMC3690480.55
# ::snt The modest RBD sequence similarity among the four paralogs of type I PI3K is shown in Figure 1 D.
# ::tok The modest RBD sequence similarity among the four paralogs of type I PI3K is shown in Figure 1 D .
(x5 / resemble-01
      :ARG1 (x4 / sequence
            :mod (x1 / modest)
            :part-of (x2 / protein-segment
                  :name (x3 / name :op1 "RBD")))
      :ARG2 (x6 / include-91
            :ARG2 (x7 / paralog
                  :quant "4"
                  :mod (x8 / type
                        :ord (x9 / ordinal-entity :value "1"))
                  :mod (x10 / enzyme
                        :name (x11 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                  :ARG1-of (x12 / show-01
                        :ARG0 (x13 / figure :mod "5d")))))


# ::id PMC3690480.56
# ::snt Even though the overall structural organization of the p110β RBD is conserved ( Zhang et al., 2011 ), we speculated that because we cannot detect any interaction with RAS, it might have lost or altered its function.
# ::tok Even though the overall structural organization of the p110β RBD is conserved ( Zhang et al. , 2011 ) , we speculated that because we cannot detect any interaction with RAS , it might have lost or altered its function .
(x16 / speculate-01
      :concession (x2 / structure
            :mod (x1 / overall)
            :ARG1-of (x3 / organize-01
                  :ARG1 (x6 / conserve-01
                        :ARG1 (x4 / protein-segment
                              :name (x5 / name :op1 "RBD"))
                        :ARG1-of (x7 / describe-01
                              :ARG0 (x8 / publication-91
                                    :ARG0 (x11 / and
                                          :op1 (x9 / person
                                                :name (x10 / name :op1 "Zhang"))
                                          :op2 (x12 / person
                                                :mod (x13 / other)))
                                    :time (x14 / date-entity :year "2011"))))))
      :ARG0 (x15 / we)
      :ARG1 (x17 / cause-01
            :ARG0 (x18 / possible-01
                  :polarity "-"
                  :ARG1 (x20 / detect-01
                        :ARG0 (x19 / we)
                        :ARG1 (x22 / interact-01
                              :mod (x21 / any)
                              :ARG1 (x23 / enzyme
                                    :name (x24 / name :op1 "RAS")
                                    :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                              :ARG1-of (x25 / possible-01
                                    :ARG1 (x26 / lose-02
                                          :ARG1 (x27 / or
                                                :op2 (x28 / alter-01)))))))
            :ARG1 (x29 / function-01)))


# ::id PMC3690480.57
# ::snt We therefore mutated two highly conserved key residues within the p110β RBD to generate a p110β-S205D/K224A double mutant (p110β-RBD-DM; Figure 1 E).
# ::tok We therefore mutated two highly conserved key residues within the p110β RBD to generate a p110β-S205D/K224A double mutant ( p110β-RBD @-@ DM ; Figure 1 E ) .
(x1 / multi-sentence
      :snt1 (x10 / generate-01
            :ARG0 (x2 / we)
            :ARG1 (x3 / mutate-01
                  :ARG1 (x7 / residue
                        :quant "2"
                        :ARG1-of (x5 / conserve-01
                              :degree (x4 / high-02))
                        :ARG1-of (x6 / key-02)
                        :location (x8 / protein-segment
                              :name (x9 / name :op1 "RBD"))))
            :ARG1 (x11 / enzyme
                  :name (x12 / name :op1 "p110β-S205D/K224A")
                  :ARG2-of (x14 / mutate-01
                        :mod (x13 / double)))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / protein
                        :name (x17 / name :op1 "p110β-RBD")
                        :mod (x18 / dm)
                        :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))))
      :snt2 (x19 / and
            :op2 (x20 / figure :mod "3e")))


# ::id PMC3690480.58
# ::snt Analogous mutations in p110α and p110γ disrupt RAS binding ( Gupta et al., 2007 ; Pacold et al., 2000 ).
# ::tok Analogous mutations in p110α and p110γ disrupt RAS binding ( Gupta et al. , 2007 ; Pacold et al. , 2000 ) .
(x8 / disrupt-01
      :ARG0 (x2 / mutate-01
            :mod (x1 / analogous)
            :location (x5 / and
                  :op1 (x3 / cell-line
                        :name (x4 / name :op1 "p110α"))
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "p110γ")
                        :xref (x28 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))
      :ARG1 (x11 / bind-01
            :ARG1 (x9 / enzyme
                  :name (x10 / name :op1 "RAS")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / and
                  :op1 (x14 / publication-91
                        :ARG0 (x17 / and
                              :op1 (x15 / person
                                    :name (x16 / name :op1 "Gupta"))
                              :op2 (x18 / person
                                    :mod (x19 / other)))
                        :time (x20 / date-entity :year "2007"))
                  :op2 (x21 / publication-91
                        :ARG0 (x24 / and
                              :op1 (x22 / person
                                    :name (x23 / name :op1 "Pacold"))
                              :op2 (x25 / person
                                    :mod (x26 / other)))
                        :time (x27 / date-entity :year "2000")))))


# ::id PMC3690480.59
# ::snt In vitro, the basal lipid kinase activity of purified recombinant p110β-RBD-DM protein was indistinguishable from its wild-type counterpart prepared in parallel ( Figure 1 F).
# ::tok In vitro , the basal lipid kinase activity of purified recombinant p110β-RBD @-@ DM protein was indistinguishable from its wild @-@ type counterpart prepared in parallel ( Figure 1 F ) .
(x13 / prepare-01
      :ARG0 (x5 / activity-06
            :manner (x1 / in-vitro)
            :ARG0 (x4 / kinase
                  :mod (x2 / basal)
                  :mod (x3 / lipid))
            :ARG1 (x10 / protein
                  :ARG1-of (x6 / purify-01)
                  :ARG3-of (x7 / recombine-01
                        :name (x8 / name :op1 "p110β-RBD")
                        :ARG1-of (x9 / dm)))
            :polarity "-"
            :ARG1 (x12 / counterpart
                  :mod (x11 / wild-type)))
      :ARG2 (x14 / parallel-01)
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / figure :mod "4f")))


# ::id PMC3690480.60
# ::snt Moreover, p110β-RBD-DM was still stimulated by the addition of purified recombinant Gβγ subunits, alone or in combination with a platelet-derived growth factor receptor (PDGFR)-derived phosphotyrosine peptide (pY740), indicating that the RBD mutations had no intrinsic effect on p110β lipid kinase activity or RBD-independent stimulatory input ( Figure 1 G).
# ::tok Moreover , p110β-RBD @-@ DM was still stimulated by the addition of purified recombinant Gβγ subunits , alone or in combination with a platelet @-@ derived growth factor receptor ( PDGFR ) -derived phosphotyrosine peptide ( pY740 ) , indicating that the RBD mutations had no intrinsic effect on p110β lipid kinase activity or RBD @-@ independent stimulatory input ( Figure 1 G ) .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op2 (x7 / stimulate-01
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "p110β-RBD")
                        :ARG1-of (x5 / dm)
                        :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
                  :mod (x6 / still)
                  :ARG0 (x15 / or
                        :op1 (x8 / add-02
                              :ARG1 (x13 / subunit
                                    :mod (x10 / enzyme
                                          :ARG1-of (x9 / purify-01)
                                          :ARG0-of (x11 / recombine-01)
                                          :name (x12 / name :op1 "Gβγ")
                                          :xref (x41 / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.58"))
                                    :mod (x14 / alone)))
                        :op2 (x16 / combine-01))
                  :ARG2 (x17 / protein
                        :name (x18 / name
                              :op1 "platelet-derived"
                              :op2 "growth"
                              :op3 "factor"
                              :op4 "receptor"))
                  :ARG1-of (x20 / phosphotyrosine
                        :name (x19 / name :op1 "PDGFR" :op2 "-derived"))))
      :snt2 (x37 / stimulate-01
            :ARG0 (x21 / peptide
                  :ARG1-of (x22 / py740)
                  :ARG0-of (x23 / indicate-01
                        :ARG1 (x26 / mutate-01
                              :ARG1 (x24 / enzyme
                                    :name (x25 / name :op1 "RBD"))))
                  :ARG0-of (x27 / have-03
                        :polarity "-"
                        :ARG1 (x29 / affect-01
                              :mod (x28 / intrinsic)
                              :ARG1 (x33 / or
                                    :op1 (x32 / activity-06
                                          :ARG0 (x31 / lipid
                                                :name (x30 / name :op1 "p110β")))
                                    :op2 (x36 / depend-01
                                          :ARG1 (x34 / enzyme
                                                :name (x35 / name :op1 "RBD"))
                                          :polarity "-")))))
            :ARG0 (x38 / input)
            :ARG1-of (x39 / describe-01
                  :ARG0 (x40 / figure :mod "1g"))))


# ::id PMC3690480.61
# ::snt However, RBD mutant p110β was much less active than wild-type when expressed in COS7 cells ( Figures 1 H and S1 B) even when Gβγ subunits were coexpressed or a myristoylation signal was added, pointing to a critical role of the RBD for p110β activity in living cells.
# ::tok However , RBD mutant p110β was much less active than wild @-@ type when expressed in COS7 cells ( Figures 1 H and S1 B ) even when Gβγ subunits were coexpressed or a myristoylation signal was added , pointing to a critical role of the RBD for p110β activity in living cells .
(x1 / multi-sentence
      :snt1 (x2 / have-concession-91
            :ARG1 (x22 / even-when
                  :op1 (x10 / activity-06
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "RBD")
                              :ARG2-of (x5 / mutate-01
                                    :ARG1 (x6 / enzyme
                                          :name (x7 / name :op1 "p110β")
                                          :xref (x41 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))
                        :degree (x9 / less
                              :degree (x8 / much))
                        :compared-to (x19 / and
                              :mod (x11 / wild-type)
                              :time (x12 / express-03
                                    :ARG3 (x14 / cell
                                          :name (x13 / name :op1 "COS7")
                                          :ARG1-of (x15 / describe-01
                                                :ARG0 (x16 / figure :mod "1")))
                                    :ARG2 (x17 / enzyme
                                          :name (x18 / name :op1 "h-ras")
                                          :xref (x43 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601")))
                              :op2 (x20 / enzyme
                                    :name (x21 / name :op1 "S1")
                                    :xref (x / xref :value "UNIPROT:B1N8M6_HUMAN" :prob "1.001"))))
                  :op2 (x25 / coexpress-01
                        :ARG1 (x24 / subunit
                              :name (x23 / name :op1 "Gβγ")))))
      :snt2 (x31 / point-01
            :ARG1 (x30 / add-02
                  :ARG1 (x26 / or
                        :op1 (x29 / signal-07
                              :ARG0 (x27 / enzyme
                                    :name (x28 / name :op1 "myristoylation")))))
            :ARG2 (x33 / role
                  :ARG1-of (x32 / critical-02)
                  :poss (x34 / protein-segment
                        :name (x35 / name :op1 "RBD"))
                  :purpose (x38 / activity-06
                        :ARG0 (x36 / enzyme
                              :name (x37 / name :op1 "p110β")
                              :xref (x42 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
                  :location (x40 / cell
                        :ARG0-of (x39 / live-01)))))


# ::id PMC3690480.62
# ::snt p110β Interacts with Distinct RAS Subfamily GTPases
# ::tok p110β Interacts with Distinct RAS Subfamily GTPases
(x3 / interact-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "p110β")
            :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
      :ARG1 (x5 / enzyme
            :mod (x4 / distinct)
            :name (x6 / name :op1 "RAS")
            :ARG0-of (x7 / subfamily)
            :name (x8 / name :op1 "gtpase")
            :xref (x10 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252")))


# ::id PMC3690480.63
# ::snt To identify RBD interactors of p110β, we probed all 34 murine members of the RAS subfamily of small GTPases (RFGs) for binding to p110β/p85 ( Figure S1 C).
# ::tok To identify RBD interactors of p110β, we probed all 34 murine members of the RAS subfamily of small GTPases ( RFGs ) for binding to p110β/p85 ( Figure S1 C ) .
(x4 / interact-01
      :purpose (x1 / identify-01
            :ARG1 (x2 / protein-segment
                  :name (x3 / name :op1 "RBD")))
      :ARG1 (x5 / protein
            :name (x6 / name :op1 "p110β,")
            :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242"))
      :ARG1-of (x8 / probe-01
            :ARG0 (x7 / we)
            :ARG1 (x12 / member
                  :mod (x9 / all)
                  :quant "34"
                  :mod (x10 / organism
                        :name (x11 / name :op1 "muridae"))
                  :ARG1-of (x13 / include-91
                        :ARG2 (x14 / protein-family
                              :name (x15 / name :op1 "RAS")))
                  :mod (x16 / subfamily))
            :ARG2 (x17 / enzyme
                  :mod (x18 / small)
                  :name (x19 / name :op1 "gtpase")
                  :xref (x26 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252"))
            :ARG1-of (x20 / rfgs)
            :ARG2 (x21 / bind-01
                  :ARG2 (x22 / protein
                        :name (x23 / name :op1 "p110β/p85")))
            :ARG1-of (x24 / describe-01
                  :ARG0 (x25 / figure :mod "s1"))))


# ::id PMC3690480.64
# ::snt Parallel experiments were performed with p110α/p85, p110γ/p101, and p110δ/p85, respectively ( Figure S1 D).
# ::tok Parallel experiments were performed with p110α/p85 , p110γ/p101 , and p110δ/p85 , respectively ( Figure S1 D ) .
(x3 / perform-01
      :ARG0 (x1 / parallel-01)
      :ARG1 (x2 / experiment-01)
      :ARG2 (x8 / and
            :op1 (x4 / enzyme
                  :name (x5 / name :op1 "p110α/p85"))
            :op2 (x6 / cell-line
                  :name (x7 / name :op1 "p110γ/p101"))
            :op2 (x9 / enzyme
                  :name (x10 / name :op1 "p110δ/p85"))
            :mod (x11 / respective))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / figure :mod "s1")))


# ::id PMC3690480.65
# ::snt Strikingly, whereas all non-β isoforms interacted with the three prototypical RAS proteins and a partially overlapping subset of closely related RFGs (RRAS1, RRAS2, MRAS, and ERAS), p110β bound to none of those ( Figure 2 A).
# ::tok Strikingly , whereas all non-β isoforms interacted with the three prototypical RAS proteins and a partially overlapping subset of closely related RFGs ( RRAS1 , RRAS2 , MRAS , and ERAS ) , p110β bound to none of those ( Figure 2 A ) .
(x1 / multi-sentence
      :snt1 (x3 / contrast-01
            :ARG1-of (x2 / strike-04)
            :ARG2 (x8 / interact-01
                  :ARG0 (x7 / isoform
                        :mod (x4 / all)
                        :mod (x5 / enzyme
                              :name (x6 / name :op1 "non-β")))
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "3")
                        :xref (x / xref :value "UNIPROT:AB12B_HUMAN" :prob "0.572")))
            :ARG0 (x11 / prototypical))
      :snt2 (x14 / and
            :op1 (x13 / protein-family
                  :name (x12 / name :op1 "RAS"))
            :op2 (x16 / overlap-01
                  :degree (x15 / part)
                  :ARG1-of (x17 / subset
                        :consist-of (x27 / and
                              :op1 (x18 / enzyme
                                    :ARG1-of (x20 / relate-01
                                          :ARG1-of (x19 / close-10))
                                    :name (x21 / name :op1 "RFGs")
                                    :name (x22 / name :op1 "RRAS1")
                                    :xref (x39 / xref :value "UNIPROT:RRAS_HUMAN" :prob "0.313"))
                              :op2 (x23 / protein
                                    :name (x24 / name :op1 "RRAS2"))
                              :op2 (x25 / protein
                                    :name (x26 / name :op1 "MRAS"))
                              :op2 (x28 / protein
                                    :name (x29 / name :op1 "ERAS")))))
            :op2 (x32 / bind-01
                  :ARG1 (x30 / enzyme
                        :name (x31 / name :op1 "p110β")
                        :xref (x37 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                  :ARG2 (x33 / none
                        :mod (x34 / that)))
            :ARG1-of (x35 / describe-01
                  :ARG0 (x36 / figure :mod "2"))))


# ::id PMC3690480.66
# ::snt Instead, p110β exclusively bound to the more distantly related DIRAS1 and DIRAS2 proteins in a GTP-dependent manner ( Figure S1 C).
# ::tok Instead , p110β exclusively bound to the more distantly related DIRAS1 and DIRAS2 proteins in a GTP @-@ dependent manner ( Figure S1 C ) .
(x4 / bind-01
      :ARG2-of (x1 / instead-of-91)
      :ARG0 (x3 / exclusive-02
            :name (x2 / name :op1 "p110β"))
      :ARG2 (x13 / protein
            :ARG1-of (x7 / relate-01
                  :degree (x5 / more)
                  :mod (x6 / distant)
                  :ARG2 (x10 / and
                        :op1 (x8 / protein
                              :name (x9 / name :op1 "DIRAS1")
                              :xref (x / xref :value "UNIPROT:DIRA1_HUMAN" :prob "1.002"))
                        :op2 (x11 / protein
                              :name (x12 / name :op1 "DIRAS2")
                              :xref (x19 / xref :value "UNIPROT:DIRA2_HUMAN" :prob "1.002")))))
      :manner (x16 / depend-01
            :ARG1 (x14 / small-molecule
                  :name (x15 / name :op1 "GTP")
                  :xref (x20 / xref :value "PUBCHEM:6830" :prob "15.470645")))
      :ARG1-of (x17 / describe-01
            :ARG0 (x18 / figure :mod "s1")))


# ::id PMC3690480.67
# ::snt DIRAS selectively bound wild-type and not RBD mutant p110β ( Figure S2 B), suggesting binding to the RBD.
# ::tok DIRAS selectively bound wild @-@ type and not RBD mutant p110β ( Figure S2 B ) , suggesting binding to the RBD .
(x4 / bind-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "DIRAS"))
      :mod (x3 / selective)
      :ARG1-of (x6 / and
            :mod (x5 / wild-type))
      :polarity "-"
      :ARG2 (x8 / enzyme
            :name (x7 / name :op1 "RBD")
            :ARG2-of (x9 / mutate-01)
            :name (x10 / name :op1 "p110β")
            :ARG1-of (x11 / describe-01
                  :ARG0 (x12 / figure :mod "s2"))
            :xref (x19 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
      :ARG1 (x13 / enzyme
            :name (x14 / name :op1 "b-raf")
            :xref (x / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.701"))
      :ARG0-of (x15 / suggest-01
            :ARG1 (x16 / bind-01
                  :ARG2 (x17 / protein-segment
                        :name (x18 / name :op1 "RBD")))))


# ::id PMC3690480.68
# ::snt However, DIRAS failed to stimulate p110β lipid kinase activity in vitro ( Figure 2 C) and in cells, where constitutively active DIRAS proteins seemed to repress rather than elevate phospho-AKT when coexpressed along with p110β ( Figure 2 B), making DIRAS an unlikely in vivo activator of p110β.
# ::tok However , DIRAS failed to stimulate p110β lipid kinase activity in vitro ( Figure 2 C ) and in cells , where constitutively active DIRAS proteins seemed to repress rather than elevate phospho @-@ AKT when coexpressed along with p110β ( Figure 2 B ) , making DIRAS an unlikely in vivo activator of p110β.
(x1 / multi-sentence
      :snt1 (x2 / contrast-01
            :ARG2 (x5 / fail-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "DIRAS"))
                  :ARG2 (x6 / stimulate-01
                        :ARG1 (x9 / lipid
                              :op1 (x7 / enzyme
                                    :name (x8 / name :op1 "p110β")
                                    :xref (x44 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                              :op2 (x11 / activity-06
                                    :ARG0 (x10 / kinase))))
                  :manner (x12 / in-vitro))
            :ARG1-of (x13 / describe-01
                  :ARG0 (x14 / figure :mod "2")))
      :snt2 (x23 / seem-01
            :ARG1 (x15 / and
                  :op1 (x16 / figure :mod "5c")
                  :op2 (x17 / cell-line
                        :ARG1-of (x18 / mean-01
                              :ARG2 (x20 / activity-06
                                    :mod (x19 / constitutive)))))
            :ARG0 (x21 / protein
                  :name (x22 / name :op1 "DIRAS"))
            :ARG1 (x24 / repress-01)
            :ARG1-of (x25 / instead-of-91
                  :ARG2 (x26 / elevate-01
                        :ARG1 (x27 / enzyme
                              :ARG3-of (x28 / phosphorylate-01)
                              :name (x29 / name :op1 "AKT")
                              :xref (x43 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :time (x30 / coexpress-01
                              :ARG2 (x31 / protein
                                    :name (x32 / name :op1 "p110β")
                                    :ARG1-of (x33 / describe-01
                                          :ARG0 (x34 / figure :mod "2b"))
                                    :xref (x45 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))))
            :ARG0-of (x35 / make-02
                  :ARG1 (x38 / likely-01
                        :ARG1 (x36 / protein
                              :name (x37 / name :op1 "DIRAS"))
                        :polarity "-"
                        :mod (x39 / in-vivo)
                        :ARG0-of (x40 / activate-01
                              :ARG1 (x41 / enzyme
                                    :name (x42 / name :op1 "p110β.")
                                    :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242")))))))


# ::id PMC3690480.69
# ::snt p110β Is a Direct RAC/CDC42 Target Protein
# ::tok p110β Is a Direct RAC @/@ CDC42 Target Protein
(x10 / protein
      :domain (x1 / protein
            :name (x2 / name :op1 "p110β")
            :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
      :ARG0-of (x9 / target-01
            :ARG1-of (x3 / direct-02)
            :ARG0 (x6 / slash
                  :op1 (x4 / enzyme
                        :name (x5 / name :op1 "RAC")
                        :xref (x12 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                  :op2 (x7 / enzyme
                        :name (x8 / name :op1 "CDC42")
                        :xref (x11 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))))


# ::id PMC3690480.70
# ::snt When comparing DIRAS with RAS, an obvious difference is the substitution of Asp33 within the G2 box of RAS with Ile37 in DIRAS ( Figure 2 D).
# ::tok When comparing DIRAS with RAS , an obvious difference is the substitution of Asp33 within the G2 box of RAS with Ile37 in DIRAS ( Figure 2 D ) .
(x7 / differ-02
      :time (x1 / compare-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "DIRAS"))
            :ARG2 (x4 / small-molecule
                  :name (x5 / name :op1 "RAS")
                  :ARG1-of (x6 / obvious-01)
                  :xref (x21 / xref :value "PUBCHEM:3052776" :prob "16.868237")))
      :ARG1 (x8 / substitute-01
            :ARG1 (x9 / amino-acid
                  :mod "33"
                  :name (x10 / name :op1 "aspartic" :op2 "acid"))
            :location (x11 / protein-segment
                  :name (x12 / name :op1 "G2" :op2 "box")
                  :part-of (x13 / enzyme
                        :name (x14 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
            :ARG1 (x15 / amino-acid
                  :mod "37"
                  :name (x16 / name :op1 "isoleucine")))
      :location (x17 / protein
            :name (x18 / name :op1 "DIRAS"))
      :ARG1-of (x19 / describe-01
            :ARG0 (x20 / figure :mod "2d")))


# ::id PMC3690480.71
# ::snt This substitution is relevant to PI3K binding because an HRAS-D33I mutant showed attenuated binding to p110α and DIRAS1-I37D showed reduced binding to p110β, even though exchange of this residue did not enable RAS binding to p110β or DIRAS binding to p110α ( Figure S2 A), pointing to additional, G2-box-independent determinants of PI3K isoform specificity.
# ::tok This substitution is relevant to PI3K binding because an HRAS @-@ D33I mutant showed attenuated binding to p110α and DIRAS1 @-@ I37D showed reduced binding to p110β, even though exchange of this residue did not enable RAS binding to p110β or DIRAS binding to p110α ( Figure S2 A ) , pointing to additional , G2 @-@ box @-@ independent determinants of PI3K isoform specificity .
(x1 / multi-sentence
      :snt1 (x4 / relevant-01
            :ARG1 (x3 / substitute-01
                  :mod (x2 / this))
            :ARG2 (x8 / cause-01
                  :ARG0 (x7 / bind-01
                        :ARG1 (x5 / enzyme
                              :name (x6 / name :op1 "PI3K")
                              :xref (x59 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                  :ARG1 (x13 / show-01
                        :ARG0 (x9 / enzyme
                              :name (x10 / name :op1 "HRAS")
                              :ARG1-of (x11 / mutate-01 :value "D33I")
                              :ARG2-of (x12 / mutate-01)
                              :xref (x58 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
                        :ARG1 (x14 / attenuate-01
                              :ARG1 (x22 / show-01
                                    :ARG1 (x18 / and
                                          :op1 (x15 / bind-01
                                                :ARG2 (x16 / protein
                                                      :name (x17 / name :op1 "p110α")
                                                      :xref (x63 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
                                          :op2 (x19 / protein
                                                :name (x20 / name :op1 "DIRAS1")
                                                :xref (x62 / xref :value "UNIPROT:DIRA1_HUMAN" :prob "1.002")))
                                    :ARG0 (x21 / mutate-01 :value "I37D")))
                        :ARG1 (x23 / reduce-01))
                  :ARG1 (x24 / bind-01
                        :ARG2 (x25 / protein
                              :name (x26 / name :op1 "p110β,")
                              :xref (x57 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242")))))
      :snt2 (x51 / determine-01
            :concession (x46 / point-01
                  :ARG1 (x27 / exchange-01
                        :ARG1 (x30 / enable-01
                              :ARG0 (x29 / residue
                                    :mod (x28 / this))
                              :polarity "-"
                              :ARG1 (x39 / bind-01
                                    :ARG0 (x33 / bind-01
                                          :ARG1 (x31 / enzyme
                                                :name (x32 / name :op1 "RAS")
                                                :xref (x60 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                                          :ARG2 (x36 / or
                                                :op1 (x34 / enzyme
                                                      :name (x35 / name :op1 "p110β")
                                                      :xref (x61 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                                                :op2 (x37 / protein
                                                      :name (x38 / name :op1 "DIRAS"))))
                                    :ARG2 (x40 / protein
                                          :name (x41 / name :op1 "p110α")
                                          :xref (x56 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
                              :ARG1-of (x42 / describe-01
                                    :ARG0 (x43 / figure :mod "s2"))
                              :ARG1-of (x44 / describe-01
                                    :ARG0 (x45 / figure :mod "a"))))
                  :ARG2 (x47 / add-02))
            :ARG0 (x50 / depend-01
                  :ARG1 (x48 / enzyme
                        :name (x49 / name :op2 "G2" :op1 "box"))
                  :polarity "-")
            :ARG1 (x54 / isoform
                  :op1 (x52 / enzyme
                        :name (x53 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                  :ARG1-of (x55 / specific-02))))


# ::id PMC3690480.72
# ::snt Several members of the RHO subfamily of small GTPases harbor a hydrophobic isoleucine or valine residue in this position ( Figure S2 C), which prompted us to test p110β for binding to representative RHO family GTPases ( Figure S2 D).
# ::tok Several members of the RHO subfamily of small GTPases harbor a hydrophobic isoleucine or valine residue in this position ( Figure S2 C ) , which prompted us to test p110β for binding to representative RHO family GTPases ( Figure S2 D ) .
(x10 / harbor-01
      :ARG0 (x2 / member
            :quant (x1 / several)
            :ARG1-of (x3 / include-91
                  :ARG2 (x4 / protein-family
                        :name (x5 / name :op1 "RHO")))
            :ARG1-of (x6 / subfamily)
            :part-of (x7 / enzyme
                  :mod (x8 / small)
                  :name (x9 / name :op1 "gtpase")
                  :xref (x35 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252")))
      :ARG1 (x14 / or
            :mod (x11 / hydrophobic)
            :mod (x12 / amino-acid
                  :name (x13 / name :op1 "isoleucine"))
            :op2 (x15 / residue
                  :mod (x16 / amino-acid
                        :name (x17 / name :op1 "valine")))
            :location (x19 / position
                  :mod (x18 / this))
            :ARG1-of (x20 / describe-01
                  :ARG0 (x21 / figure
                        :mod "s2"
                        :ARG1-of (x22 / describe-01
                              :ARG0 (x23 / figure :mod "c"))))
            :ARG0-of (x24 / prompt-02
                  :ARG1 (x25 / we)
                  :ARG2 (x26 / test-01
                        :ARG1 (x27 / enzyme
                              :name (x28 / name :op1 "p110β")
                              :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))
            :purpose (x29 / bind-01
                  :ARG2 (x30 / represent-01
                        :ARG1 (x31 / protein-family
                              :name (x32 / name :op1 "RHO" :op2 "gtpase")))))
      :ARG1-of (x33 / describe-01
            :ARG0 (x34 / figure :mod "s2")))


# ::id PMC3690480.74
# ::snt Weaker binding to RHOG and minimal binding to RHOA was also observed ( Figure 2 E).
# ::tok Weaker binding to RHOG and minimal binding to RHOA was also observed ( Figure 2 E ) .
(x12 / observe-01
      :ARG1 (x6 / and
            :op1 (x3 / bind-01
                  :ARG1-of (x1 / weak-02
                        :degree (x2 / more))
                  :ARG2 (x4 / protein
                        :name (x5 / name :op1 "RHOG")
                        :xref (x15 / xref :value "UNIPROT:RHOG_HUMAN" :prob "1.004")))
            :op2 (x8 / bind-01
                  :ARG1-of (x7 / minimal-02)
                  :ARG2 (x9 / protein
                        :name (x10 / name :op1 "RHOA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "1.004"))))
      :mod (x11 / also)
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure :mod "3e")))


# ::id PMC3690480.75
# ::snt Importantly, RAC1, CDC42, RHOG, and RHOA preparations bound similar amounts of GTP, indicating proper folding and functionality ( Figure 2 E, right lower graph), and a RAC1-I33D mutant showed reduced binding to p110β ( Figure S2 E), confirming a key role of this residue in GTPase binding to p110β.
# ::tok Importantly , RAC1 , CDC42 , RHOG , and RHOA preparations bound similar amounts of GTP , indicating proper folding and functionality ( Figure 2 E , right lower graph ) , and a RAC1 @-@ I33D mutant showed reduced binding to p110β ( Figure S2 E ) , confirming a key role of this residue in GTPase binding to p110β.
(x1 / multi-sentence
      :snt1 (x34 / show-01
            :mod (x2 / important)
            :ARG0 (x27 / graph
                  :ARG1-of (x12 / prepare-01
                        :ARG2 (x9 / and
                              :op1 (x3 / protein
                                    :name (x4 / name :op1 "RAC1")
                                    :xref (x55 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                              :op2 (x5 / protein
                                    :name (x6 / name :op1 "CDC42")
                                    :xref (x57 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
                              :op2 (x7 / protein
                                    :name (x8 / name :op1 "RHOG")
                                    :xref (x56 / xref :value "UNIPROT:RHOG_HUMAN" :prob "1.004"))
                              :op2 (x10 / protein
                                    :name (x11 / name :op1 "RHOA")
                                    :xref (x60 / xref :value "UNIPROT:RHOA_HUMAN" :prob "1.004")))
                        :ARG1 (x13 / bind-01
                              :ARG1 (x15 / amount
                                    :ARG1-of (x14 / resemble-01)
                                    :quant-of (x16 / small-molecule
                                          :name (x17 / name :op1 "GTP")
                                          :xref (x61 / xref :value "PUBCHEM:6830" :prob "15.470645"))))
                        :ARG0-of (x18 / indicate-01
                              :ARG1 (x21 / functionality
                                    :mod (x19 / proper)
                                    :mod (x20 / folding)
                                    :ARG1-of (x22 / describe-01
                                          :ARG0 (x23 / figure :mod "e"))
                                    :ARG1-of (x24 / right-04))))
                  :ARG1-of (x25 / low-04
                        :degree (x26 / more)))
            :ARG0 (x28 / and
                  :op1 (x29 / protein
                        :name (x30 / name :op1 "RAC1")
                        :xref (x54 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x31 / enzyme
                        :name (x32 / name :op1 "I33D")
                        :ARG2-of (x33 / mutate-01)))
            :ARG1 (x35 / reduce-01
                  :ARG1 (x36 / bind-01
                        :ARG2 (x37 / protein
                              :name (x38 / name :op1 "p110β")
                              :xref (x58 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))
            :ARG1-of (x39 / describe-01
                  :ARG0 (x40 / figure :mod "s2")))
      :snt2 (x43 / confirm-01
            :ARG0 (x41 / protein
                  :name (x42 / name :op1 "e-cadherin")
                  :xref (x / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703"))
            :ARG1 (x45 / role
                  :ARG1-of (x44 / key-01)
                  :poss (x47 / residue
                        :mod (x46 / this))
                  :topic (x50 / bind-01
                        :ARG1 (x48 / enzyme
                              :name (x49 / name :op1 "GTPase")
                              :xref (x53 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.312"))
                        :ARG2 (x51 / protein
                              :name (x52 / name :op1 "p110β.")
                              :xref (x59 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242"))))))


# ::id PMC3690480.76
# ::snt The RAC1/CDC42-p110β interaction was isoform specific because neither RAC1 nor CDC42 significantly bound non-β isoforms under parallel conditions ( Figures 2 F and S2 F).
# ::tok The RAC1 @/@ CDC42 @-@ p110β interaction was isoform specific because neither RAC1 nor CDC42 significantly bound non-β isoforms under parallel conditions ( Figures 2 F and S2 F ) .
(x6 / isoform
      :ARG1 (x5 / interact-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "RAC1")
                  :xref (x26 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "CDC42" :op2 "p110β")))
      :ARG1-of (x7 / specific-02)
      :ARG1-of (x8 / cause-01
            :ARG0 (x15 / bind-01
                  :polarity "-"
                  :ARG0 (x9 / and
                        :op1 (x10 / protein
                              :name (x11 / name :op1 "RAC1")
                              :xref (x27 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                        :op2 (x12 / protein
                              :name (x13 / name :op1 "CDC42")
                              :xref (x28 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                  :ARG1-of (x14 / significant-02)
                  :ARG1 (x18 / isoform
                        :mod (x16 / enzyme
                              :name (x17 / name :op1 "non-β")))
                  :condition (x19 / parallel-01)
                  :ARG1-of (x20 / describe-01
                        :ARG0 (x21 / and
                              :op1 (x22 / figure :mod "2")
                              :op2 (x23 / figure :mod "s2")))
                  :ARG1 (x24 / protein
                        :name (x25 / name :op1 "f-actin")
                        :xref (x / xref :value "UNIPROT:NEXN_HUMAN" :prob "0.232")))))


# ::id PMC3690480.77
# ::snt Strikingly, GTPγS-loaded RAC1 or CDC42 strongly stimulated p110β lipid kinase activity in vitro ( Figure 2 G), alone and in cooperation with a phosphotyrosine peptide (pY740), or when p110β was complexed with a less inhibitory, truncated p85 (Δp85 schematic in Figure 3 C).
# ::tok Strikingly , GTPγS @-@ loaded RAC1 or CDC42 strongly stimulated p110β lipid kinase activity in vitro ( Figure 2 G ) , alone and in cooperation with a phosphotyrosine peptide ( pY740 ) , or when p110β was complexed with a less inhibitory , truncated p85 ( Δp85 schematic in Figure 3 C ) .
(x1 / multi-sentence
      :snt1 (x2 / contrast-01
            :ARG1 (x5 / load-01
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "GTPγS")))
            :ARG2 (x12 / stimulate-01
                  :ARG0 (x8 / or
                        :op1 (x6 / protein
                              :name (x7 / name :op1 "RAC1")
                              :xref (x43 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                        :op2 (x9 / protein
                              :name (x10 / name :op1 "CDC42")
                              :xref (x42 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                  :ARG1-of (x11 / strong-02)
                  :ARG1 (x16 / activity-06
                        :ARG1 (x15 / kinase
                              :mod (x14 / lipid
                                    :name (x13 / name :op1 "p110β"))))
                  :manner (x17 / in-vitro)
                  :ARG1-of (x18 / describe-01
                        :ARG0 (x19 / figure :mod "2"))))
      :snt2 (x36 / truncate-01
            :ARG1 (x33 / macro-molecular-complex
                  :ARG1 (x30 / or
                        :op1 (x20 / protein
                              :name (x21 / name :op1 "G")
                              :xref (x / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.601"))
                        :op2 (x23 / and
                              :op1 (x22 / alone)
                              :op2 (x28 / peptide
                                    :ARG0-of (x24 / cooperate-01
                                          :ARG2 (x25 / amino-acid
                                                :name (x26 / name :op1 "threonine")
                                                :ARG3-of (x27 / phosphorylate-01)
                                                :xref (x46 / xref :value "PUBCHEM:205" :prob "11.848252")))
                                    :name (x29 / name :op1 "pY740")))
                        :op3 (x31 / enzyme
                              :name (x32 / name :op1 "p110β")
                              :xref (x44 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
                  :ARG0-of (x35 / inhibit-01
                        :degree (x34 / less)))
            :ARG2 (x37 / protein
                  :name (x38 / name :op1 "p85")
                  :xref (x45 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))
            :ARG1-of (x40 / schematic
                  :name (x39 / name :op1 "Δp85")
                  :location (x41 / figure :mod "3"))))


# ::id PMC3690480.78
# ::snt Stimulation of p110β by active RAC1 and CDC42 was dose dependent ( Figure 2 H).
# ::tok Stimulation of p110β by active RAC1 and CDC42 was dose dependent ( Figure 2 H ) .
(x11 / depend-01
      :ARG1 (x1 / stimulate-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "p110β")
                  :xref (x14 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
            :ARG0 (x4 / activate-01)
            :ARG1 (x7 / and
                  :op1 (x5 / protein
                        :name (x6 / name :op1 "RAC1")
                        :xref (x15 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x8 / protein
                        :name (x9 / name :op1 "CDC42")
                        :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))
      :ARG1 (x10 / dose-01)
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / figure :mod "h")))


# ::id PMC3690480.79
# ::snt Coexpression of constitutively active RAC1 or CDC42 ( Figure S2 G, lanes 4–6), but not RHOA ( Figure S2 H), along with p110β/p85 in COS7 cells strongly elevated cellular phospho-AKT and PIP 3 levels ( Figure 2 I), indicating that both GTPases activate p110β in transfected cells.
# ::tok Coexpression of constitutively active RAC1 or CDC42 ( Figure S2 G , lanes 4–6 ) , but not RHOA ( Figure S2 H ) , along with p110β/p85 in COS7 cells strongly elevated cellular phospho @-@ AKT and PIP 3 levels ( Figure 2 I ) , indicating that both GTPases activate p110β in transfected cells .
(x1 / multi-sentence
      :snt1 (x17 / contrast-01
            :ARG1 (x2 / express-03
                  :ARG2 (x7 / or
                        :op1 (x5 / enzyme
                              :ARG0-of (x4 / activity-06
                                    :mod (x3 / constitutive))
                              :name (x6 / name :op1 "RAC1")
                              :xref (x52 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                        :op2 (x8 / protein
                              :name (x9 / name :op1 "CDC42")
                              :xref (x51 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                  :ARG1-of (x10 / describe-01
                        :ARG0 (x11 / figure :mod "s2"))
                  :ARG1 (x12 / and
                        :op1 (x13 / protein
                              :name (x14 / name :op1 "G")
                              :xref (x56 / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.601"))
                        :op2 (x15 / lane
                              :mod (x16 / value-interval :op1 "4" :op2 "6"))))
            :ARG2 (x30 / elevate-01
                  :polarity "-"
                  :ARG1 (x18 / and
                        :op1 (x19 / protein
                              :name (x20 / name :op1 "RHOA")
                              :ARG1-of (x21 / describe-01
                                    :ARG0 (x22 / figure :mod "s2")
                                    :ARG1 (x23 / enzyme
                                          :name (x24 / name :op1 "h-ras")
                                          :xref (x50 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601")))
                              :xref (x55 / xref :value "UNIPROT:RHOA_HUMAN" :prob "1.004"))
                        :op2 (x25 / enzyme
                              :name (x26 / name :op1 "p110β/p85")
                              :location (x28 / cell
                                    :name (x27 / name :op1 "COS7"))))
                  :ARG1-of (x29 / strong-02)
                  :ARG1 (x31 / cell)))
      :snt2 (x35 / and
            :op1 (x32 / enzyme
                  :ARG3-of (x33 / phosphorylate-01)
                  :name (x34 / name :op1 "AKT")
                  :xref (x53 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :op2 (x38 / level
                  :quant-of (x36 / protein
                        :name (x37 / name :op1 "pip3")
                        :xref (x54 / xref :value "UNIPROT:MTMRC_HUMAN" :prob "0.222")))
            :ARG1-of (x39 / describe-01
                  :ARG0 (x40 / figure :mod "i"))
            :ARG0-of (x41 / indicate-01
                  :ARG1 (x44 / activate-01
                        :ARG1 (x42 / enzyme
                              :name (x43 / name :op1 "gtpase")
                              :xref (x49 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252"))
                        :ARG1 (x45 / enzyme
                              :name (x46 / name :op1 "p110β")
                              :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                        :location (x48 / cell
                              :ARG1-of (x47 / transfect-01))))))


# ::id PMC3690480.80
# ::snt PIP 3 levels were further enhanced by coexpression of Gβ 1 /Gγ 2 subunits or by myristoylation of p110β ( Figure 2 I).
# ::tok PIP 3 levels were further enhanced by coexpression of Gβ 1 /Gγ 2 subunits or by myristoylation of p110β ( Figure 2 I ) .
(x5 / enhance-01
      :ARG1 (x3 / level
            :quant-of (x1 / protein
                  :name (x2 / name :op1 "pip3")
                  :xref (x19 / xref :value "UNIPROT:MTMRC_HUMAN" :prob "0.222")))
      :degree (x4 / further)
      :ARG0 (x6 / coexpress-01
            :ARG2 (x7 / enzyme
                  :name (x8 / name :op1 "Gβ")
                  :xref (x20 / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.58")))
      :ARG1 (x12 / or
            :op1 (x11 / subunit
                  :mod "1"
                  :part-of (x9 / enzyme
                        :name (x10 / name :op1 "/Gγ" :op2 "2")))
            :op2 (x14 / amino-acid
                  :name (x13 / name :op1 "myristoylation")
                  :part-of (x15 / enzyme
                        :name (x16 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))
      :ARG1-of (x17 / describe-01
            :ARG0 (x18 / figure :mod "i")))


# ::id PMC3690480.81
# ::snt In contrast, GTPγS-loaded RAC1/CDC42 did not stimulate p110α in vitro ( Figure S2 I), nor did V12-RAC1/CDC42 cooperate with p110α, p110γ, or p110δ to elevate cellular phospho-AKT levels ( Figure S2 J).
# ::tok In contrast , GTPγS @-@ loaded RAC1 @/@ CDC42 did not stimulate p110α in vitro ( Figure S2 I ) , nor did V12 @-@ RAC1 @/@ CDC42 cooperate with p110α, p110γ, or p110δ to elevate cellular phospho @-@ AKT levels ( Figure S2 J ) .
(x1 / multi-sentence
      :snt1 (x10 / stimulate-01
            :location (x2 / contrast-01
                  :ARG2 (x5 / load-01
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "GTPγS"))))
            :ARG0 (x6 / protein
                  :name (x7 / name :op1 "RAC1")
                  :mod (x8 / protein
                        :name (x9 / name :op1 "CDC42")
                        :xref (x41 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
                  :xref (x42 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :polarity "-"
            :ARG1 (x11 / enzyme
                  :name (x12 / name :op1 "p110α")
                  :xref (x45 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
            :manner (x13 / in-vitro)
            :ARG1-of (x14 / describe-01
                  :ARG0 (x15 / figure :mod "s2")))
      :snt2 (x29 / elevate-01
            :ARG0 (x16 / i)
            :ARG1-of (x17 / do-02
                  :polarity "-"
                  :ARG1 (x23 / cooperate-01
                        :ARG2 (x18 / enzyme
                              :ARG2-of (x19 / mutate-01 :value "V12")
                              :name (x20 / name :op1 "RAC1")
                              :xref (x44 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                        :ARG1 (x21 / protein
                              :name (x22 / name :op1 "CDC42")
                              :xref (x40 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                  :ARG2 (x26 / or
                        :op1 (x24 / enzyme
                              :name (x25 / name :op1 "p110α")
                              :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                        :op2 (x27 / enzyme
                              :name (x28 / name :op1 "p110δ")
                              :xref (x39 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))
            :ARG1 (x34 / level
                  :mod (x30 / cell)
                  :quant-of (x31 / enzyme
                        :ARG3-of (x32 / phosphorylate-01)
                        :name (x33 / name :op1 "AKT")
                        :xref (x43 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :ARG1-of (x35 / describe-01
                  :ARG0 (x36 / figure :mod "s2"))
            :ARG1-of (x37 / describe-01
                  :ARG0 (x38 / figure :mod "j"))))


# ::id PMC3690480.83
# ::snt RAC and CDC42 Are RBD Interactors of p110β
# ::tok RAC and CDC42 Are RBD Interactors of p110β
(x8 / interact-01
      :ARG1 (x3 / and
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "RAC")
                  :xref (x11 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :op2 (x4 / protein
                  :name (x5 / name :op1 "CDC42")
                  :xref (x12 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :ARG0 (x6 / protein-segment
            :name (x7 / name :op1 "RBD"))
      :ARG1 (x9 / protein
            :name (x10 / name :op1 "p110β")
            :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))


# ::id PMC3690480.84
# ::snt We next aimed to confirm that RAC and CDC42 are RBD interactors of p110β.
# ::tok We next aimed to confirm that RAC and CDC42 are RBD interactors of p110β.
(x3 / aim-01
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x4 / confirm-01
            :ARG1 (x12 / interact-01
                  :ARG0 (x7 / and
                        :op1 (x5 / enzyme
                              :name (x6 / name :op1 "RAC")
                              :xref (x16 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                        :op2 (x8 / protein
                              :name (x9 / name :op1 "CDC42")
                              :xref (x15 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                  :ARG1 (x10 / enzyme
                        :name (x11 / name :op1 "RBD"))
                  :ARG0 (x13 / protein
                        :name (x14 / name :op1 "p110β.")
                        :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242")))))


# ::id PMC3690480.85
# ::snt Purified recombinant wild-type p110β/p85 bound to RAC1 and CDC42 in a concentration-dependent manner, whereas p110β-RBD-DM/p85 complexes showed no binding ( Figure 3 A).
# ::tok Purified recombinant wild @-@ type p110β/p85 bound to RAC1 and CDC42 in a concentration @-@ dependent manner , whereas p110β-RBD @-@ DM @/@ p85 complexes showed no binding ( Figure 3 A ) .
(x14 / contrast-01
      :ARG1 (x6 / bind-01
            :ARG0 (x2 / enzyme
                  :ARG1-of (x1 / purify-01)
                  :ARG0-of (x3 / recombine-01)
                  :mod (x4 / wild-type)
                  :name (x5 / name :op1 "p110β/p85"))
            :ARG2 (x9 / and
                  :op1 (x7 / protein
                        :name (x8 / name :op1 "RAC1")
                        :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x10 / protein
                        :name (x11 / name :op1 "CDC42")
                        :xref (x26 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
            :manner (x13 / depend-01
                  :ARG1 (x12 / concentrate-02)))
      :ARG2 (x21 / show-01
            :ARG0 (x20 / macro-molecular-complex
                  :part (x15 / enzyme
                        :name (x16 / name :op1 "p110β-RBD")
                        :ARG1-of (x17 / dm)
                        :xref (x27 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
                  :part (x18 / enzyme
                        :name (x19 / name :op1 "p85")
                        :xref (x25 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003")))
            :ARG1 (x22 / bind-01 :polarity "-")
            :ARG1-of (x23 / describe-01
                  :ARG0 (x24 / figure :mod "3"))))


# ::id PMC3690480.86
# ::snt Similarly, RBD mutant p110β was not stimulated by active RAC1 or CDC42 in vitro ( Figure 3 B) or in cells ( Figure S2 E, lanes 7–9).
# ::tok Similarly , RBD mutant p110β was not stimulated by active RAC1 or CDC42 in vitro ( Figure 3 B ) or in cells ( Figure S2 E , lanes 7–9 ) .
(x1 / resemble-01
      :ARG2 (x17 / or
            :op1 (x7 / stimulate-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "RBD")
                        :ARG2-of (x4 / mutate-01))
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "p110β")
                        :xref (x23 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                  :polarity "-"
                  :ARG0 (x11 / or
                        :op1 (x8 / enzyme
                              :ARG0-of (x9 / activity-06)
                              :name (x10 / name :op1 "RAC1")
                              :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                        :op2 (x12 / protein
                              :name (x13 / name :op1 "CDC42")
                              :xref (x24 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                  :manner (x14 / in-vitro)
                  :ARG1-of (x15 / describe-01
                        :ARG0 (x16 / figure :mod "3")))
            :op2 (x18 / cell))
      :ARG1-of (x19 / describe-01
            :ARG0 (x20 / figure
                  :mod "s2"
                  :mod "3e"
                  :part (x21 / lane
                        :mod (x22 / value-interval :op1 "7" :op2 "9")))))


# ::id PMC3690480.87
# ::snt To test whether the BCR homology domain (BHD) on p85, which had previously been shown to bind RAC and CDC42 ( Bokoch et al., 1996 ; Zheng et al., 1994 ), is required for RAC/CDC42 binding to p110β, we truncated p85 (Δp85 schematic in Figure 3 C) and probed for binding of p110β/Δp85 to RAC1 and CDC42 in vitro.
# ::tok To test whether the BCR homology domain ( BHD ) on p85 , which had previously been shown to bind RAC and CDC42 ( Bokoch et al. , 1996 ; Zheng et al. , 1994 ) , is required for RAC @/@ CDC42 binding to p110β, we truncated p85 ( Δp85 schematic in Figure 3 C ) and probed for binding of p110β/Δp85 to RAC1 and CDC42 in vitro .
(x1 / multi-sentence
      :snt1 (x41 / bind-01
            :ARG2 (x2 / test-01
                  :ARG1 (x35 / require-01
                        :mode "interrogative"
                        :ARG1 (x6 / domain
                              :mod (x3 / protein
                                    :name (x4 / name :op1 "BCR")
                                    :xref (x63 / xref :value "UNIPROT:BCR_HUMAN" :prob "1.004"))
                              :mod (x5 / homologous)
                              :name (x7 / name :op1 "BHD")
                              :part-of (x8 / enzyme
                                    :name (x9 / name :op1 "p85")
                                    :xref (x62 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))
                              :ARG0-of (x10 / have-03
                                    :ARG1 (x16 / and
                                          :ARG1-of (x12 / show-01
                                                :time (x11 / previous)
                                                :ARG1 (x13 / bind-01
                                                      :ARG2 (x14 / enzyme
                                                            :name (x15 / name :op1 "RAC")
                                                            :xref (x67 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))))
                                          :op2 (x17 / protein
                                                :name (x18 / name :op1 "CDC42")
                                                :xref (x68 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                                    :ARG1-of (x19 / describe-01
                                          :ARG0 (x20 / and
                                                :op1 (x21 / publication-91
                                                      :ARG0 (x24 / and
                                                            :op1 (x22 / person
                                                                  :name (x23 / name :op1 "Bokoch"))
                                                            :op2 (x25 / person
                                                                  :mod (x26 / other)))
                                                      :time (x27 / date-entity :year "1996"))
                                                :op2 (x28 / publication-91
                                                      :ARG0 (x31 / and
                                                            :op1 (x29 / person
                                                                  :name (x30 / name :op1 "Zheng"))
                                                            :op2 (x32 / person
                                                                  :mod (x33 / other)))
                                                      :time (x34 / date-entity :year "1994"))))))
                        :ARG0 (x38 / slash
                              :op1 (x36 / enzyme
                                    :name (x37 / name :op1 "RAC")
                                    :xref (x64 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                              :op2 (x39 / enzyme
                                    :name (x40 / name :op1 "CDC42")
                                    :xref (x65 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))))
      :snt2 (x51 / probe-01
            :purpose (x43 / truncate-01
                  :ARG0 (x42 / we)
                  :ARG1 (x44 / protein
                        :name (x45 / name :op1 "p85")
                        :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))
                  :ARG1-of (x47 / schematic
                        :name (x46 / name :op1 "Δp85"))
                  :location (x50 / and
                        :op1 (x48 / figure :mod "3")
                        :op2 (x49 / figure :mod "5c")))
            :ARG0 (x52 / bind-01
                  :ARG1 (x53 / protein
                        :name (x54 / name :op1 "p110β/Δp85"))
                  :ARG2 (x57 / and
                        :op1 (x55 / protein
                              :name (x56 / name :op1 "RAC1")
                              :xref (x61 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                        :op2 (x58 / protein
                              :name (x59 / name :op1 "CDC42")
                              :xref (x66 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                  :manner (x60 / in-vitro))))


# ::id PMC3690480.88
# ::snt Intriguingly, binding was unaffected by removal of the BHD but completely disrupted when full-length p85 was in complex with RBD mutant p110β, strongly arguing for the RBD as the RAC/CDC42-binding site.
# ::tok Intriguingly , binding was unaffected by removal of the BHD but completely disrupted when full @-@ length p85 was in complex with RBD mutant p110β, strongly arguing for the RBD as the RAC @/@ CDC42 @-@ binding site .
(x1 / intrigue-01
      :ARG1 (x20 / argue-01
            :ARG0 (x3 / affect-01
                  :ARG1 (x2 / bind-01)
                  :polarity "-"
                  :ARG0 (x4 / remove-01
                        :ARG1 (x7 / contrast-01
                              :ARG1 (x5 / enzyme
                                    :name (x6 / name :op1 "BHD")
                                    :xref (x30 / xref :value "UNIPROT:FLCN_HUMAN" :prob "1.002"))
                              :ARG2 (x9 / disrupt-01
                                    :ARG1-of (x8 / complete-02)
                                    :ARG0 (x10 / protein
                                          :ARG1-of (x12 / long-03
                                                :ARG1-of (x11 / full-09))
                                          :name (x13 / name :op1 "p85")
                                          :xref (x31 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))))))
            :ARG1-of (x19 / strong-02
                  :location (x14 / macro-molecular-complex
                        :part (x15 / enzyme
                              :name (x16 / name :op1 "RBD")
                              :ARG2-of (x17 / mutate-01))
                        :name (x18 / name :op1 "p110β,")))
            :ARG1 (x28 / protein-segment
                  :name (x21 / name :op1 "RBD")
                  :ARG0-of (x27 / bind-01
                        :ARG1 (x22 / and
                              :op1 (x23 / enzyme
                                    :name (x24 / name :op1 "RAC")
                                    :xref (x29 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                              :op2 (x25 / protein
                                    :name (x26 / name :op1 "CDC42")
                                    :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))))))


# ::id PMC3690480.89
# ::snt To further corroborate these findings, we generated 43 single point mutations covering 37 residues across the p110β RBD and assayed these mutants for binding to RAC1 and CDC42 ( Figures 3 D, S3 A, and S3B).
# ::tok To further corroborate these findings , we generated 43 single point mutations covering 37 residues across the p110β RBD and assayed these mutants for binding to RAC1 and CDC42 ( Figures 3 D , S3 A , and S3B ) .
(x7 / generate-01
      :purpose (x2 / corroborate-01
            :degree (x1 / further)
            :ARG1 (x4 / thing
                  :mod (x3 / this)
                  :ARG1-of (x5 / find-01)))
      :ARG0 (x6 / we)
      :ARG1 (x13 / mutate-01
            :ARG1-of (x8 / describe-01
                  :ARG0 (x9 / publication
                        :ARG1-of (x10 / cite-01 :ARG2 "43")))
            :ARG1-of (x11 / single-02)
            :mod (x12 / point))
      :ARG1 (x37 / and
            :op1 (x14 / cover-01
                  :ARG1 (x21 / and
                        :op1 (x18 / residue
                              :ARG1-of (x15 / describe-01
                                    :ARG0 (x16 / publication
                                          :ARG1-of (x17 / cite-01 :ARG2 "37")))
                              :location (x19 / protein-segment
                                    :name (x20 / name :op1 "RBD")))
                        :op2 (x22 / assay-01
                              :mod (x23 / this)
                              :ARG2-of (x24 / mutate-01)))
                  :ARG2 (x25 / bind-01
                        :ARG2 (x28 / and
                              :op1 (x26 / protein
                                    :name (x27 / name :op1 "RAC1")
                                    :xref (x39 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                              :op2 (x29 / protein
                                    :name (x30 / name :op1 "CDC42")
                                    :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))
                  :ARG1-of (x31 / describe-01
                        :ARG0 (x32 / value-interval
                              :op1 (x33 / figure :mod "3")
                              :op2 (x34 / figure :mod "d"))))
            :op3 (x35 / protein
                  :name (x36 / name :op1 "S3" :op2 "A"))
            :op2 (x38 / figure :mod "s3b")))


# ::id PMC3690480.90
# ::snt Of those, 17 mutations of 14 RBD residues affected binding to both GTPases without affecting p110β protein stability.
# ::tok Of those , 17 mutations of 14 RBD residues affected binding to both GTPases without affecting p110β protein stability .
(x7 / residue
      :mod (x1 / that)
      :ARG0 (x2 / person
            :quant "17"
            :ARG0-of (x3 / mutate-01
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "14")))
            :name (x6 / name :op1 "RBD"))
      :ARG0-of (x8 / affect-01
            :ARG1 (x9 / bind-01
                  :ARG2 (x10 / and
                        :op1 (x11 / enzyme
                              :name (x12 / name :op1 "gtpase")
                              :xref (x / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252"))
                        :op2 (x13 / affect-01
                              :polarity "-"
                              :ARG1 (x16 / stability
                                    :mod (x15 / protein
                                          :name (x14 / name :op1 "p110β")
                                          :xref (x17 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))))))


# ::id PMC3690480.91
# ::snt Several of these residues were part of the RBDβ1 and β2 sheets or the loop adjacent to the RBDα1 helix ( Zhang et al., 2011 ), areas known to be important for RAS binding in non-β isoforms ( Pacold et al., 2000 ).
# ::tok Several of these residues were part of the RBDβ1 and β2 sheets or the loop adjacent to the RBDα1 helix ( Zhang et al. , 2011 ) , areas known to be important for RAS binding in non-β isoforms ( Pacold et al. , 2000 ) .
(x1 / multi-sentence
      :snt1 (x5 / have-part-91
            :ARG1 (x4 / residue
                  :quant (x2 / several)
                  :mod (x3 / this))
            :ARG2 (x8 / and
                  :op1 (x6 / enzyme
                        :name (x7 / name :op1 "RBDβ1"))
                  :op2 (x9 / protein
                        :name (x10 / name :op1 "β2")
                        :xref (x41 / xref :value "UNIPROT:FKRP_HUMAN" :prob "0.552"))))
      :snt2 (x25 / know-02
            :ARG1 (x12 / or
                  :op1 (x11 / sheet)
                  :op2 (x13 / loop
                        :ARG2-of (x14 / border-01
                              :ARG2 (x15 / helix))
                        :ARG1-of (x16 / describe-01
                              :ARG0 (x17 / publication-91
                                    :ARG0 (x20 / and
                                          :op1 (x18 / person
                                                :name (x19 / name :op1 "Zhang"))
                                          :op2 (x21 / person
                                                :mod (x22 / other)))
                                    :time (x23 / date-entity :year "2011")))))
            :mod (x24 / also)
            :ARG2 (x26 / important
                  :purpose (x29 / bind-01
                        :ARG1 (x27 / enzyme
                              :name (x28 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                        :ARG2 (x32 / isoform
                              :mod (x30 / enzyme
                                    :name (x31 / name :op1 "non-β")))))
            :ARG1-of (x33 / describe-01
                  :ARG0 (x34 / publication-91
                        :ARG0 (x37 / and
                              :op1 (x35 / person
                                    :name (x36 / name :op1 "Pacold"))
                              :op2 (x38 / person
                                    :mod (x39 / other)))
                        :time (x40 / date-entity :year "2000")))))


# ::id PMC3690480.92
# ::snt Finally, we employed isothermal titration calorimetry (ITC) to study thermodynamics of the RAC1/CDC42-p110β interaction.
# ::tok Finally , we employed isothermal titration calorimetry ( ITC ) to study thermodynamics of the RAC1 @/@ CDC42 @-@ p110β interaction .
(x2 / employ-02
      :li "-1"
      :ARG0 (x1 / we)
      :ARG1 (x4 / titrate-01
            :op1 (x3 / isothermal)
            :op2 (x5 / calorimetry))
      :ARG1-of (x6 / itc)
      :purpose (x7 / study-01
            :ARG0 (x8 / thermodynamics)
            :ARG1 (x13 / interact-01
                  :ARG0 (x9 / protein
                        :name (x10 / name :op1 "RAC1")
                        :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :ARG1 (x11 / protein
                        :name (x12 / name :op1 "CDC42" :op2 "p110β")))))


# ::id PMC3690480.93
# ::snt In solution, RAC1⋅GTPγS bound to p110β/Δp85 with a molar ratio close to 1 and an average K d of 1.42 μM, whereas the affinity measured for CDC42⋅GTPγS was 3.1 μM ( Figures 3 E and 3F).
# ::tok In solution , RAC1⋅GTPγS bound to p110β/Δp85 with a molar ratio close to 1 and an average K d of 1.42 μM , whereas the affinity measured for CDC42⋅GTPγS was 3.1 μM ( Figures 3 E and 3F ) .
(x1 / multi-sentence
      :snt1 (x5 / bind-01
            :location (x2 / solve-01)
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "RAC1⋅GTPγS")
                  :xref (x29 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.243"))
            :ARG2 (x6 / protein
                  :name (x7 / name :op1 "p110β/Δp85"))
            :ARG2 (x8 / molar))
      :snt2 (x17 / contrast-01
            :ARG1 (x9 / ratio-of
                  :quant (x10 / close-10
                        :ARG2 (x11 / and
                              :op1 "1"
                              :op2 (x12 / average-01
                                    :ARG1 (x13 / enzyme
                                          :name (x14 / name :op1 "k-ras")
                                          :xref (x30 / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.701")))))
                  :op1 (x15 / concentration-quantity
                        :quant "1.42"
                        :unit (x16 / micromolar)))
            :ARG2 (x18 / affinity
                  :ARG1-of (x19 / measure-01
                        :ARG2 (x22 / small-molecule
                              :ARG2 (x20 / gene
                                    :name (x21 / name :op1 "CDC42⋅GTPγS")
                                    :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "0.263"))
                              :quant (x23 / concentration-quantity
                                    :quant "3.1"
                                    :unit (x24 / micromolar)))))
            :ARG1-of (x25 / describe-01
                  :ARG0 (x26 / and
                        :op1 (x27 / figure :mod "3")
                        :op2 (x28 / figure :mod "3f")))))


# ::id PMC3690480.94
# ::snt Similar affinities have been reported for the RAS-p110α and RAS-p110γ interactions ( Pacold et al., 2000 ; Rodriguez-Viciana et al., 1996 ), indicating that RAC1 and CDC42 are plausible RBD interactors of p110β.
# ::tok Similar affinities have been reported for the RAS @-@ p110α and RAS @-@ p110γ interactions ( Pacold et al. , 2000 ; Rodriguez @-@ Viciana et al. , 1996 ) , indicating that RAC1 and CDC42 are plausible RBD interactors of p110β.
(x1 / multi-sentence
      :snt1 (x4 / report-01
            :ARG1 (x3 / affinity
                  :ARG1-of (x2 / resemble-01))
            :ARG1 (x10 / and
                  :op1 (x5 / macro-molecular-complex
                        :part (x6 / enzyme
                              :name (x7 / name :op1 "RAS")
                              :xref (x44 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                        :part (x8 / small-molecule
                              :name (x9 / name :op1 "p110α")
                              :xref (x49 / xref :value "PUBCHEM:6511" :prob "9.430335")))
                  :op2 (x15 / interact-01
                        :ARG1 (x11 / enzyme
                              :name (x12 / name :op1 "RAS")
                              :xref (x47 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                        :ARG0 (x13 / enzyme
                              :name (x14 / name :op1 "p110γ")
                              :xref (x48 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))
            :ARG1-of (x16 / describe-01
                  :ARG0 (x17 / and
                        :op1 (x18 / publication-91
                              :ARG0 (x21 / and
                                    :op1 (x19 / person
                                          :name (x20 / name :op1 "Pacold"))
                                    :op2 (x22 / person
                                          :mod (x23 / other)))
                              :time (x24 / date-entity :year "2000"))
                        :op2 (x25 / publication-91
                              :ARG0 (x28 / and
                                    :op1 (x26 / person
                                          :name (x27 / name :op1 "Rodriguez-Viciana"))
                                    :op2 (x29 / person
                                          :mod (x30 / other)))
                              :time (x31 / date-entity :year "1996"))))
            :ARG0-of (x32 / indicate-01
                  :ARG1 (x38 / plausible
                        :domain (x35 / and
                              :op1 (x33 / protein
                                    :name (x34 / name :op1 "RAC1")
                                    :xref (x45 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                              :op2 (x36 / protein
                                    :name (x37 / name :op1 "CDC42")
                                    :xref (x46 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))))
      :snt2 (x41 / interact-01
            :ARG0 (x39 / protein
                  :name (x40 / name :op1 "RBD"))
            :ARG1 (x42 / protein
                  :name (x43 / name :op1 "p110β.")
                  :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242"))))


# ::id PMC3690480.95
# ::snt No binding was observed between GTPγS-loaded RAC1/CDC42 and p110α or p110β-RBD-DM, respectively ( Figure S3 C).
# ::tok No binding was observed between GTPγS @-@ loaded RAC1 @/@ CDC42 and p110α or p110β-RBD @-@ DM , respectively ( Figure S3 C ) .
(x13 / or
      :ARG0 (x10 / and
            :op1 (x1 / enzyme
                  :ARG1-of (x6 / load-01
                        :ARG2 (x3 / observe-01
                              :polarity "-"
                              :ARG1 (x2 / bind-01)
                              :ARG0 (x4 / enzyme
                                    :name (x5 / name :op1 "GTPγS"))))
                  :name (x7 / name :op1 "RAC1")
                  :xref (x21 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :op2 (x8 / protein
                  :name (x9 / name :op1 "CDC42")
                  :xref (x19 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :op1 (x11 / enzyme
            :name (x12 / name :op1 "p110α")
            :xref (x20 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
      :op2 (x14 / enzyme
            :name (x15 / name :op1 "p110β-RBD")
            :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
      :op2 (x16 / dm)
      :ARG1-of (x17 / describe-01
            :ARG0 (x18 / figure :mod "s3")))


# ::id PMC3690480.96
# ::snt p110β-RBD-DM Mice Show Signs of Reduced PI3K Activity
# ::tok p110β-RBD @-@ DM Mice Show Signs of Reduced PI3K Activity
(x5 / show-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "p110β-RBD")
            :xref (x11 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
      :ARG0 (x4 / mouse
            :mod (x3 / dm))
      :ARG1 (x6 / signal-07
            :ARG1 (x7 / reduce-01
                  :ARG1 (x10 / activity-06
                        :ARG0 (x8 / enzyme
                              :name (x9 / name :op1 "PI3K")
                              :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))))


# ::id PMC3690480.97
# ::snt To study the role of interactor binding to the p110β RBD for PI3K signaling in vivo, we generated mice harboring the two p110β RBD point mutations (S205D/K224A) within their germline.
# ::tok To study the role of interactor binding to the p110β RBD for PI3K signaling in vivo , we generated mice harboring the two p110β RBD point mutations ( S205D/K224A ) within their germline .
(x13 / generate-01
      :purpose (x1 / study-01
            :ARG1 (x2 / role
                  :poss (x3 / enzyme
                        :name (x4 / name :op1 "interactor")
                        :ARG1-of (x5 / bind-01
                              :ARG2 (x6 / protein-segment
                                    :name (x7 / name :op1 "RBD")))
                        :xref (x21 / xref :value "UNIPROT:CABL1_HUMAN" :prob "0.283"))
                  :topic (x10 / signal-07
                        :ARG0 (x8 / enzyme
                              :name (x9 / name :op1 "PI3K")
                              :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))
            :manner (x11 / in-vivo))
      :ARG0 (x12 / we)
      :ARG1 (x14 / mouse
            :ARG0-of (x15 / harbor-01
                  :ARG1 (x18 / mutate-01
                        :quant "2"
                        :mod (x17 / point
                              :name (x16 / name :op1 "RBD"))))
            :name (x19 / name :op1 "S205D/K224A"))
      :location (x20 / germline))


# ::id PMC3690480.98
# ::snt Homologous recombination in embryonic stem (ES) cells was employed to replace exon 6 of the murine Pik3cb gene ( Figure S4 A), and germline transmission was achieved by eight-cell embryo injection ( Figures S4 B and S4C).
# ::tok Homologous recombination in embryonic stem ( ES ) cells was employed to replace exon 6 of the murine Pik3 cb gene ( Figure S4 A ) , and germline transmission was achieved by eight @-@ cell embryo injection ( Figures S4 B and S4C ) .
(x7 / employ-02
      :ARG1 (x6 / cell
            :mod (x1 / homologous)
            :mod (x3 / embryo
                  :mod (x2 / recombination))
            :mod (x4 / protein
                  :name (x5 / name :op1 "stem" :op2 "ES")))
      :purpose (x8 / replace-01
            :ARG1 (x9 / exon
                  :mod "6"
                  :part-of (x13 / gene
                        :mod (x10 / organism
                              :name (x11 / name :op1 "muridae"))
                        :name (x12 / name :op1 "pik3/mtor"))))
      :ARG1-of (x14 / describe-01
            :ARG0 (x17 / and
                  :op1 (x15 / figure :mod "s4")
                  :op2 (x16 / figure :mod "a")
                  :op3 (x20 / achieve-01
                        :ARG0 (x18 / germline)
                        :ARG1 (x19 / transmit-01)
                        :manner (x23 / inject-01
                              :ARG1 (x21 / cell
                                    :quant "8"
                                    :mod (x22 / embryo)))
                        :ARG1-of (x24 / describe-01
                              :ARG0 (x25 / figure :mod "s4"))
                        :ARG1 (x28 / and
                              :op1 (x26 / enzyme
                                    :name (x27 / name :op1 "b-raf")
                                    :xref (x / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.701"))
                              :op2 (x29 / protein
                                    :name (x30 / name :op1 "S4C")))))))


# ::id PMC3690480.99
# ::snt p110β-RBD-DM mice were viable and fertile, although numbers of homozygous animals at the time of biopsy (around day 14) were moderately reduced (73 where 105 were expected; p < 0.02; Figure 4 A), indicating incomplete lethality for undetermined reasons.
# ::tok p110β-RBD @-@ DM mice were viable and fertile , although numbers of homozygous animals at the time of biopsy ( around day 14 ) were moderately reduced ( 73 where 105 were expected ; p
(x5 / fertile
      :ARG1 (x1 / gene
            :name (x2 / name :op1 "p110β-RBD")
            :ARG2-of (x3 / dm)
            :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
      :ARG1 (x4 / viable)
      :concession (x6 / number
            :quant-of (x8 / animal
                  :mod (x7 / homozygous)))
      :time (x15 / reduce-01
            :ARG1 (x9 / and
                  :op1 (x10 / biopsy)
                  :op2 (x11 / around
                        :op1 (x12 / temporal-quantity
                              :unit (x13 / day)
                              :quant "14")))
            :ARG1-of (x14 / moderate-03)
            :ARG1-of (x16 / describe-01
                  :ARG0 (x17 / publication
                        :ARG1-of (x18 / cite-01 :ARG2 "73")))
            :ARG0 (x19 / person
                  :quant "105"
                  :ARG0-of (x20 / expect-01))
            :ARG1-of (x21 / statistical-test-91
                  :ARG2 (x22 / less-than :op1 "0.05"))))


# ::id PMC3690480.100
# ::snt Newborn homozygous p110β-RBD-DM pups were smaller than their wild-type littermates ( Figure 4 B).
# ::tok Newborn homozygous p110β-RBD @-@ DM pups were smaller than their wild @-@ type littermates ( Figure 4 B ) .
(x7 / small
      :ARG0 (x2 / homozygous
            :ARG1-of (x1 / new-01))
      :ARG1 (x3 / enzyme
            :name (x4 / name :op1 "p110β-RBD")
            :mod (x5 / enzyme
                  :name (x6 / name :op1 "pups"))
            :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
      :degree (x8 / more)
      :compared-to (x10 / littermate
            :mod (x9 / wild-type))
      :ARG1-of (x11 / describe-01
            :ARG0 (x12 / figure :mod "4")))


# ::id PMC3690480.101
# ::snt The size difference in adult mice was subtle but remained significant when same-sex litter- and cage-mates were compared ( Figure 4 C).
# ::tok The size difference in adult mice was subtle but remained significant when same @-@ sex litter @- and cage @-@ mates were compared ( Figure 4 C ) .
(x6 / contrast-01
      :ARG1 (x2 / differ-02
            :mod (x1 / size)
            :location (x4 / mouse
                  :mod (x3 / adult)))
      :degree (x5 / subtle)
      :ARG2 (x7 / remain-01
            :ARG3 (x8 / significant-02)
            :time (x10 / sex
                  :ARG1-of (x9 / same-01))
            :ARG1-of (x17 / compare-01
                  :ARG2 (x13 / and
                        :op1 (x11 / enzyme
                              :name (x12 / name :op1 "litter"))
                        :op2 (x14 / enzyme
                              :name (x15 / name :op1 "cage")
                              :xref (x / xref :value "UNIPROT:DDX53_HUMAN" :prob "0.602")))
                  :ARG1 (x16 / mate)))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / figure :mod "4c")))


# ::id PMC3690480.102
# ::snt MEFs homozygous for the p110β RBD mutation proliferated at a significantly slower rate than their wild-type counterparts ( Figure 4 D), which was reflected by a higher percentage of cells in G1 (1% fetal calf serum [FCS]: 56.7% ± 0.32% versus 64.2% ± 0.53%, n = 4, p < 0.001; 10% FCS: 47.5% ± 3.0% versus 52.2% ± 3.9%, n = 4, p < 0.05), fewer cells in G2 (1% FCS: 24.5% ± 1.4% versus 21.0% ± 1.9%, n = 4, p < 0.05; 10% FCS: 23.9% ± 1.4% versus 21.1% ± 1.6%, n = 4, p < 0.05) and fewer cells in S phase for 1% FCS (1% FCS: 13.3% ± 1.0% versus 11.0% ± 169%, n = 4, p < 0.05) ( Figure 4 E).
# ::tok MEFs homozygous for the p110β RBD mutation proliferated at a significantly slower rate than their wild @-@ type counterparts ( Figure 4 D ) , which was reflected by a higher percentage of cells in G1 ( 1 % fetal calf serum [ FCS ] : 56.7 % ± 0.32 % versus 64.2 % ± 0.53 % , n = 4 , p
(x1 / multi-sentence
      :snt1 (x4 / homozygous
            :ARG1 (x2 / cell
                  :name (x3 / name :op1 "mef"))
            :topic (x10 / proliferate-01
                  :ARG0 (x5 / enzyme
                        :name (x6 / name :op1 "p110β")
                        :ARG2-of (x9 / mutate-01
                              :ARG1 (x7 / gene
                                    :name (x8 / name :op1 "RBD")))
                        :xref (x42 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
            :location (x13 / rate
                  :mod (x12 / slow-05
                        :ARG1-of (x11 / significant-02))
                  :compared-to (x15 / counterpart
                        :mod (x14 / wild-type))
                  :ARG1-of (x16 / describe-01
                        :ARG0 (x17 / figure :mod "4d")))
            :ARG1-of (x18 / reflect-01
                  :ARG2 (x21 / percentage
                        :ARG1-of (x19 / high-02
                              :degree (x20 / more))
                        :quant-of (x22 / cell
                              :mod (x23 / event
                                    :name (x24 / name :op1 "G1"))))
                  :ARG1-of (x28 / serum
                        :mod (x25 / percentage-entity :value "1")
                        :source (x26 / fetus
                              :mod (x27 / calf)))
                  :ARG1-of (x31 / describe-01
                        :ARG0 (x29 / protein
                              :name (x30 / name :op1 "FCS")
                              :xref (x / xref :value "UNIPROT:FCSD1_HUMAN" :prob "0.232")))))
      :snt2 (x33 / and
            :ARG0 (x32 / percentage-entity :value "56.7")
            :op1 (x34 / add-02
                  :ARG1 (x35 / percentage-entity :value "0.32"))
            :op2 (x36 / percentage-entity :value "64.2")
            :ARG2-of (x37 / add-02
                  :ARG1 (x38 / percentage-entity :value "0.53"))
            :ARG1-of (x39 / sample-01
                  :quant "4"
                  :ARG1-of (x40 / statistical-test-91
                        :ARG2 (x41 / less-than :op1 "0.05")))))


# ::id PMC3690480.103
# ::snt Moreover, p110β-RBD-DM MEFs showed lower steady-state phospho-AKT levels ( Figure 4 F), suggesting that stimulatory signaling to p110β via its RBD contributes to PI3K activity in vivo.
# ::tok Moreover , p110β-RBD @-@ DM MEFs showed lower steady @-@ state phospho @-@ AKT levels ( Figure 4 F ) , suggesting that stimulatory signaling to p110β via its RBD contributes to PI3K activity in vivo .
(x1 / and
      :op2 (x6 / show-01
            :ARG0 (x2 / enzyme
                  :name (x3 / name :op1 "p110β-RBD")
                  :mod (x4 / enzyme
                        :name (x5 / name :op1 "mef")
                        :xref (x30 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :xref (x29 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :ARG1 (x14 / level
                  :ARG1-of (x7 / low-04
                        :degree (x8 / more))
                  :mod (x10 / state
                        :ARG1-of (x9 / steady-01))
                  :quant-of (x11 / enzyme
                        :ARG3-of (x12 / phosphorylate-01)
                        :name (x13 / name :op1 "AKT")
                        :xref (x31 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / figure :mod "4f"))
            :ARG0-of (x17 / suggest-01
                  :ARG1 (x18 / stimulate-01
                        :ARG1 (x19 / signal-07
                              :ARG1 (x20 / small-molecule
                                    :name (x21 / name :op1 "p110β")
                                    :xref (x32 / xref :value "PUBCHEM:6511" :prob "9.430335"))
                              :instrument (x24 / contribute-01
                                    :ARG1 (x22 / enzyme
                                          :name (x23 / name :op1 "RBD"))
                                    :ARG2 (x27 / activity-06
                                          :ARG1 (x25 / enzyme
                                                :name (x26 / name :op1 "PI3K")
                                                :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                                          :manner (x28 / in-vivo))))))))


# ::id PMC3690480.104
# ::snt Expression levels of p110β, p110α, and p85 were indistinguishable among the genotypes ( Figure S4 D), and the stoichiometry of p110 subunit binding to p85 was undisturbed ( Figure S4 E).
# ::tok Expression levels of p110β, p110α, and p85 were indistinguishable among the genotypes ( Figure S4 D ) , and the stoichiometry of p110 subunit binding to p85 was undisturbed ( Figure S4 E ) .
(x9 / include-91
      :ARG1 (x1 / level
            :degree-of (x2 / express-03
                  :ARG2 (x5 / and
                        :op1 (x3 / enzyme
                              :name (x4 / name :op1 "p110α,")
                              :xref (x26 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242"))
                        :op2 (x6 / enzyme
                              :name (x7 / name :op1 "p85")
                              :xref (x27 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003")))))
      :ARG1-of (x8 / possible-01 :polarity "-")
      :ARG2 (x10 / genotype)
      :ARG1-of (x11 / describe-01
            :ARG0 (x12 / figure :mod "s4"))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / and
                  :op1 (x15 / figure :mod "3d")
                  :op2 (x16 / and
                        :op1 (x17 / stoichiometry
                              :mod (x20 / bind-01
                                    :ARG1 (x18 / protein
                                          :name (x19 / name :op1 "p110" :op2 "subunit"))
                                    :ARG2 (x21 / protein
                                          :name (x22 / name :op1 "p85")
                                          :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))))
                        :op2 (x23 / disturb-01 :polarity "-"))
                  :ARG1-of (x24 / describe-01
                        :ARG0 (x25 / figure :mod "s4")))))


# ::id PMC3690480.105
# ::snt RAC and CDC42 Regulate p110β In Vivo
# ::tok RAC and CDC42 Regulate p110β In Vivo
(x6 / regulate-01
      :ARG0 (x3 / and
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "RAC")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :op2 (x4 / protein
                  :name (x5 / name :op1 "CDC42")
                  :xref (x11 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :ARG1 (x7 / enzyme
            :name (x8 / name :op1 "p110β")
            :xref (x10 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
      :manner (x9 / in-vivo))


# ::id PMC3690480.106
# ::snt To determine whether RAC and CDC42 are upstream activators of p110β in vivo, we transfected wild-type and p110β-RBD-DM MEFs with small interfering RNA (siRNA) pools (Dharmacon On-target plus) targeting these GTPases ( Figure 4 G).
# ::tok To determine whether RAC and CDC42 are upstream activators of p110β in vivo , we transfected wild @-@ type and p110β-RBD @-@ DM MEFs with small interfering RNA ( siRNA ) pools ( Dharmacon On @-@ target plus ) targeting these GTPases ( Figure 4 G ) .
(x1 / multi-sentence
      :snt1 (x14 / transfect-01
            :purpose (x2 / determine-01
                  :ARG1 (x9 / activate-01
                        :mode "interrogative"
                        :ARG1 (x5 / and
                              :op1 (x3 / enzyme
                                    :name (x4 / name :op1 "RAC")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                              :op2 (x6 / protein
                                    :name (x7 / name :op1 "CDC42")
                                    :xref (x34 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                        :mod (x8 / upstream)
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "p110β")
                              :xref (x37 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                        :manner (x12 / in-vivo)))
            :ARG0 (x13 / we)
            :ARG1 (x16 / and
                  :op1 (x15 / wild-type)
                  :op2 (x17 / enzyme
                        :name (x18 / name :op1 "p110β-RBD")
                        :mod (x19 / enzyme
                              :name (x20 / name :op1 "mef")
                              :xref (x36 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                        :xref (x38 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212")))
            :ARG2 (x21 / nucleic-acid
                  :name (x22 / name
                        :op1 "small"
                        :op2 "interfering"
                        :op3 "RNA"))
            :ARG1-of (x23 / nucleic-acid
                  :name (x24 / name :op1 "siRNA")
                  :mod (x25 / protein
                        :name (x26 / name :op1 "pools" :op2 "Dharmacon"))))
      :snt2 (x29 / target-01
            :ARG0 (x28 / and
                  :ARG1-of (x27 / target-01))
            :ARG1 (x30 / enzyme
                  :name (x31 / name :op1 "gtpase")
                  :xref (x35 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252"))
            :ARG1-of (x32 / describe-01
                  :ARG0 (x33 / figure :mod "1g"))))


# ::id PMC3690480.107
# ::snt Although single knockdowns had only minor effects, combined knockdown of RAC1 and CDC42 significantly lowered phospho-AKT levels in wild-type, but not in p110β-RBD-DM cells, closing the gap in steady-state phospho-AKT levels between the genotypes and suggesting that endogenous RAC1 and CDC42 cooperatively activate p110β via its RBD.
# ::tok Although single knockdowns had only minor effects , combined knockdown of RAC1 and CDC42 significantly lowered phospho @-@ AKT levels in wild @-@ type , but not in p110β-RBD @-@ DM cells , closing the gap in steady @-@ state phospho @-@ AKT levels between the genotypes and suggesting that endogenous RAC1 and CDC42 cooperatively activate p110β via its RBD .
(x1 / multi-sentence
      :snt1 (x2 / have-concession-91
            :ARG2 (x7 / affect-01
                  :ARG1-of (x3 / single-02)
                  :ARG0 (x4 / knockdown)
                  :mod (x5 / only)
                  :ARG1-of (x6 / minor-01))
            :ARG1 (x8 / combine-01
                  :ARG1 (x20 / level
                        :ARG0 (x9 / knock-down-02
                              :ARG1 (x12 / and
                                    :op1 (x10 / protein
                                          :name (x11 / name :op1 "RAC1")
                                          :xref (x54 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                                    :op2 (x13 / protein
                                          :name (x14 / name :op1 "CDC42")
                                          :xref (x55 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))
                        :ARG1-of (x16 / low-04
                              :ARG1-of (x15 / significant-02))
                        :quant-of (x17 / enzyme
                              :ARG3-of (x18 / phosphorylate-01)
                              :name (x19 / name :op1 "AKT")
                              :xref (x56 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :location (x21 / wild-type))))
      :snt2 (x22 / contrast-01
            :ARG2 (x43 / cooperate-01
                  :polarity "-"
                  :ARG1-of (x26 / close-01
                        :location (x23 / enzyme
                              :name (x24 / name :op1 "p110β-RBD")
                              :ARG1-of (x25 / dm)
                              :xref (x51 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
                        :ARG1 (x27 / protein
                              :name (x28 / name :op1 "gap")
                              :xref (x50 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.603"))
                        :location (x34 / level
                              :mod (x30 / state
                                    :ARG1-of (x29 / steady-01))
                              :quant-of (x31 / enzyme
                                    :ARG3-of (x32 / phosphorylate-01)
                                    :name (x33 / name :op1 "AKT")
                                    :xref (x52 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                        :ARG0 (x36 / and
                              :op1 (x35 / genotype)
                              :op2 (x37 / suggest-01
                                    :ARG1 (x40 / and
                                          :op1 (x38 / protein
                                                :name (x39 / name :op1 "RAC1")
                                                :xref (x53 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                                          :op2 (x41 / protein
                                                :name (x42 / name :op1 "CDC42")
                                                :xref (x49 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))))
                  :ARG1 (x44 / activate-01
                        :ARG1 (x45 / enzyme
                              :name (x46 / name :op1 "p110β")
                              :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                        :instrument (x47 / protein-segment
                              :name (x48 / name :op1 "RBD"))))))


# ::id PMC3690480.108
# ::snt We next acutely expressed constitutively active mutants of RAC1 and CDC42 in wild-type, p110α-, and p110β-knockout MEFs ( Figures 4 H and S4 F).
# ::tok We next acutely expressed constitutively active mutants of RAC1 and CDC42 in wild @-@ type , p110α-, and p110β-knockout MEFs ( Figures 4 H and S4 F ) .
(x4 / express-03
      :ARG0 (x1 / we)
      :time (x2 / next)
      :mod (x3 / acute)
      :ARG2 (x5 / enzyme
            :ARG0-of (x7 / activity-06
                  :mod (x6 / constitutive))
            :ARG2-of (x8 / mutate-01))
      :ARG1 (x11 / and
            :op1 (x9 / protein
                  :name (x10 / name :op1 "RAC1")
                  :xref (x29 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :op2 (x12 / protein
                  :name (x13 / name :op1 "CDC42")
                  :xref (x30 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :ARG2 (x17 / and
            :op1 (x14 / enzyme
                  :mod (x15 / wild-type)
                  :name (x16 / name :op1 "p110α-,")
                  :xref (x31 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.232"))
            :op2 (x18 / cell
                  :name (x19 / name :op1 "mef")))
      :ARG1-of (x20 / describe-01
            :ARG0 (x21 / figure :mod "4"))
      :ARG1 (x24 / and
            :op1 (x22 / enzyme
                  :name (x23 / name :op1 "h-ras")
                  :xref (x28 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601"))
            :op2 (x25 / figure :mod "s4"))
      :ARG1 (x26 / protein
            :name (x27 / name :op1 "f-actin")
            :xref (x / xref :value "UNIPROT:NEXN_HUMAN" :prob "0.232")))


# ::id PMC3690480.109
# ::snt Both RAC1 and CDC42 increased steady-state phospho-AKT levels in wild-type and p110α-deleted cells but not in p110β-knockout MEFs.
# ::tok Both RAC1 and CDC42 increased steady @-@ state phospho @-@ AKT levels in wild @-@ type and p110α-deleted cells but not in p110β-knockout MEFs .
(x1 / and
      :op2 (x7 / increase-01
            :ARG0 (x4 / and
                  :op1 (x2 / protein
                        :name (x3 / name :op1 "RAC1")
                        :xref (x20 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x5 / protein
                        :name (x6 / name :op1 "CDC42")
                        :xref (x21 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
            :ARG1 (x13 / level
                  :mod (x9 / state
                        :mod (x8 / steady))
                  :quant-of (x10 / enzyme
                        :ARG3-of (x11 / phosphorylate-01)
                        :name (x12 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :location (x16 / cell-line
                  :mod (x14 / wild-type)
                  :name (x15 / name :op1 "p110α-deleted")
                  :ARG1-of (x17 / contrast-01
                        :ARG2 (x18 / cell
                              :name (x19 / name :op1 "mef"))))))


# ::id PMC3690480.110
# ::snt Moreover, expression of V12-RAC1 and V12-CDC42 failed to elevate phospho-AKT levels in p110β-RBD-DM MEFs, whereas V12-HRAS did so in both wild-type and p110β-RBD-DM MEFs ( Figure 4 I).
# ::tok Moreover , expression of V12 @-@ RAC1 and V12 @-@ CDC42 failed to elevate phospho @-@ AKT levels in p110β-RBD @-@ DM MEFs , whereas V12 @-@ HRAS did so in both wild @-@ type and p110β-RBD @-@ DM MEFs ( Figure 4 I ) .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op2 (x11 / fail-01
                  :ARG1 (x3 / express-03
                        :ARG2 (x7 / and
                              :op1 (x4 / enzyme
                                    :ARG2-of (x5 / mutate-01 :value "V12")
                                    :name (x6 / name :op1 "RAC1")
                                    :xref (x35 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                              :op2 (x8 / enzyme
                                    :ARG2-of (x9 / mutate-01 :value "V12")
                                    :name (x10 / name :op1 "CDC42")
                                    :xref (x34 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))
                  :ARG2 (x16 / level
                        :ARG1-of (x12 / elevate-01)
                        :quant-of (x13 / enzyme
                              :ARG3-of (x14 / phosphorylate-01)
                              :name (x15 / name :op1 "AKT")
                              :xref (x36 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :location (x17 / cell-line
                              :name (x18 / name :op1 "p110β-RBD"))
                        :name (x19 / name :op1 "mef"))
                  :ARG1-of (x23 / cause-01
                        :ARG0 (x20 / enzyme
                              :ARG2-of (x21 / mutate-01 :value "V12")
                              :name (x22 / name :op1 "HRAS")
                              :xref (x33 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003")))
                  :location (x24 / wild-type)))
      :snt2 (x25 / and
            :op1 (x26 / enzyme
                  :name (x27 / name :op1 "p110β-RBD")
                  :xref (x32 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :op2 (x28 / enzyme
                  :name (x29 / name :op1 "mef")
                  :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
            :ARG1-of (x30 / describe-01
                  :ARG0 (x31 / figure :mod "i"))))


# ::id PMC3690480.111
# ::snt Taken together, these findings indicate that RAC1 and CDC42 activate PI3K in living cells by isoform-specific regulation of p110β through its RBD.
# ::tok Taken together , these findings indicate that RAC1 and CDC42 activate PI3K in living cells by isoform @-@ specific regulation of p110β through its RBD .
(x6 / indicate-01
      :ARG0 (x4 / thing
            :ARG1-of (x1 / take-01
                  :mod (x2 / together))
            :mod (x3 / this)
            :ARG1-of (x5 / find-01))
      :ARG1 (x12 / activate-01
            :ARG0 (x9 / and
                  :op1 (x7 / protein
                        :name (x8 / name :op1 "RAC1")
                        :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x10 / protein
                        :name (x11 / name :op1 "CDC42")
                        :xref (x24 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
            :ARG1 (x13 / enzyme
                  :name (x14 / name :op1 "PI3K")
                  :xref (x25 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
            :location (x15 / live-01)
            :manner (x17 / specific-02
                  :ARG2 (x16 / isoform)))
      :ARG1 (x18 / regulate-01
            :ARG1 (x19 / protein
                  :name (x20 / name :op1 "p110β")
                  :xref (x23 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
            :instrument (x21 / protein-segment
                  :name (x22 / name :op1 "RBD"))))


# ::id PMC3690480.112
# ::snt Activation of p110β Downstream of GPCRs Requires an Intact RBD
# ::tok Activation of p110β Downstream of GPCRs Requires an Intact RBD
(x8 / require-01
      :ARG0 (x1 / activate-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "p110β")
                  :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
            :ARG2 (x4 / relative-position
                  :direction (x5 / downstream)
                  :op1 (x6 / enzyme
                        :name (x7 / name :op1 "GPCRs")
                        :xref (x12 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311"))))
      :ARG1 (x9 / nucleic-acid
            :wiki "dna"
            :mod (x10 / intact)
            :name (x11 / name :op1 "RBD")))


# ::id PMC3690480.113
# ::snt To study whether the p110β RBD is required for coupling p110β to GPCRs, we stimulated wild-type and p110β-RBD-DM MEFs with the lipid growth factors and GPCR agonists LPA and S1P.
# ::tok To study whether the p110β RBD is required for coupling p110β to GPCRs , we stimulated wild @-@ type and p110β-RBD @-@ DM MEFs with the lipid growth factors and GPCR agonists LPA and S1P .
(x1 / multi-sentence
      :snt1 (x14 / stimulate-01
            :purpose (x2 / study-01
                  :ARG1 (x7 / require-01
                        :mode "interrogative"
                        :ARG0 (x3 / small-molecule
                              :name (x4 / name :op1 "p110β")
                              :xref (x34 / xref :value "PUBCHEM:6511" :prob "9.430335"))
                        :ARG1 (x5 / protein-segment
                              :name (x6 / name :op1 "RBD"))
                        :ARG0 (x8 / couple-01
                              :ARG2 (x9 / enzyme
                                    :name (x10 / name :op1 "p110β")
                                    :xref (x31 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))
                  :ARG2 (x11 / protein
                        :name (x12 / name :op1 "GPCRs")
                        :xref (x32 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311")))
            :ARG0 (x13 / we)
            :ARG1 (x16 / and
                  :mod (x15 / wild-type)
                  :op1 (x17 / enzyme
                        :name (x18 / name :op1 "p110β-RBD")
                        :xref (x33 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
                  :name (x19 / name :op1 "mef"))
            :ARG2 (x22 / and
                  :op1 (x21 / growth-factor
                        :mod (x20 / lipid))
                  :op2 (x23 / enzyme
                        :name (x24 / name :op1 "GPCR")
                        :xref (x30 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "1.001"))))
      :snt2 (x27 / and
            :op1 (x25 / agonist
                  :name (x26 / name :op1 "LPA"))
            :op2 (x28 / protein
                  :name (x29 / name :op1 "S1P")
                  :xref (x / xref :value "UNIPROT:MBTP1_HUMAN" :prob "1.002"))))


# ::id PMC3690480.114
# ::snt LPA and S1P dose-dependently induced both AKT and ERK phosphorylation in wild-type cells ( Figures 5 A and S5 A).
# ::tok LPA and S1P dose @-@ dependently induced both AKT and ERK phosphorylation in wild @-@ type cells ( Figures 5 A and S5 A ) .
(x8 / induce-01
      :ARG0 (x3 / and
            :op1 (x1 / small-molecule
                  :name (x2 / name :op1 "LPA")
                  :xref (x23 / xref :value "PUBCHEM:62707" :prob "9.981436"))
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "S1P")
                  :xref (x22 / xref :value "UNIPROT:MBTP1_HUMAN" :prob "1.002")))
      :ARG0-of (x7 / depend-01
            :ARG1 (x6 / dose))
      :ARG1 (x11 / and
            :op1 (x9 / enzyme
                  :name (x10 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :op2 (x14 / phosphorylate-01
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "ERK")
                        :xref (x21 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :location (x16 / cell
                        :mod (x15 / wild-type))))
      :ARG1-of (x17 / describe-01
            :ARG0 (x18 / and
                  :op1 (x19 / figure :mod "5")
                  :op2 (x20 / figure :mod "s5"))))


# ::id PMC3690480.115
# ::snt These responses were sensitive to pertussis toxin ( Figure S5 B), confirming GPCR involvement.
# ::tok These responses were sensitive to pertussis toxin ( Figure S5 B ) , confirming GPCR involvement .
(x4 / sensitive-03
      :ARG1 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / respond-01))
      :ARG1 (x5 / small-molecule
            :name (x6 / name :op1 "pertussis" :op2 "toxin"))
      :ARG1-of (x7 / describe-01
            :ARG0 (x8 / figure :mod "s5"))
      :ARG1-of (x9 / describe-01
            :ARG0 (x10 / figure :mod "b"))
      :ARG0-of (x11 / confirm-01
            :ARG1 (x14 / involve-01
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "GPCR")
                        :xref (x / xref :value "UNIPROT:Q76L88_HUMAN" :prob "1.001")))))


# ::id PMC3690480.116
# ::snt In p110β-RBD-DM MEFs, LPA- and S1P-induced phosphorylation of AKT was strongly diminished, whereas ERK phosphorylation was undisturbed ( Figures 5 A and S5 A).
# ::tok In p110β-RBD @-@ DM MEFs , LPA @- and S1P @-@ induced phosphorylation of AKT was strongly diminished , whereas ERK phosphorylation was undisturbed ( Figures 5 A and S5 A ) .
(x16 / contrast-01
      :location (x15 / diminish-01
            :mod (x1 / enzyme
                  :name (x2 / name :op1 "p110β-RBD")
                  :mod (x3 / enzyme
                        :name (x4 / name :op1 "mef")
                        :xref (x25 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :xref (x26 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :ARG2 (x11 / phosphorylate-01
                  :ARG2-of (x10 / induce-01
                        :ARG0 (x7 / and
                              :op1 (x5 / small-molecule
                                    :name (x6 / name :op1 "LPA")
                                    :xref (x29 / xref :value "PUBCHEM:62707" :prob "9.981436"))
                              :op2 (x8 / protein
                                    :name (x9 / name :op1 "S1P")
                                    :xref (x / xref :value "UNIPROT:MBTP1_HUMAN" :prob "1.002"))))
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "AKT")
                        :xref (x27 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :ARG1-of (x14 / strong-02))
      :ARG2 (x19 / phosphorylate-01
            :ARG1 (x17 / enzyme
                  :name (x18 / name :op1 "ERK")
                  :xref (x28 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :ARG2 (x20 / disturbed :polarity "-"))
      :ARG1-of (x21 / describe-01
            :ARG0 (x22 / and
                  :op1 (x23 / figure :mod "5")
                  :op2 (x24 / figure :mod "s5"))))


# ::id PMC3690480.117
# ::snt Also, in time course experiments, AKT phosphorylation was more transient when the p110β RBD was mutated ( Figure 5 B and not shown).
# ::tok Also , in time course experiments , AKT phosphorylation was more transient when the p110β RBD was mutated ( Figure 5 B and not shown ) .
(x15 / and
      :mod (x1 / also)
      :op1 (x4 / experiment-01
            :ARG0 (x3 / course
                  :mod (x2 / time))
            :ARG1-of (x9 / transient-02
                  :ARG1 (x7 / phosphorylate-01
                        :ARG1 (x5 / enzyme
                              :name (x6 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                  :degree (x8 / more))
            :time (x12 / mutate-01
                  :ARG1 (x10 / enzyme
                        :name (x11 / name :op1 "RBD"))
                  :ARG1-of (x13 / describe-01
                        :ARG0 (x14 / figure :mod "5b"))))
      :ARG1-of (x16 / show-01 :polarity "-"))


# ::id PMC3690480.118
# ::snt In contrast, p110β-RBD-DM MEFs responded normally to epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and insulin in dose-response ( Figure S5 C) and time course experiments (data not shown).
# ::tok In contrast , p110β-RBD @-@ DM MEFs responded normally to epidermal growth factor ( EGF ) , platelet @-@ derived growth factor ( PDGF ) , and insulin in dose @-@ response ( Figure S5 C ) and time course experiments ( data not shown ) .
(x1 / multi-sentence
      :snt1 (x26 / and
            :op1 (x2 / contrast-01
                  :ARG2 (x7 / respond-01
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "p110β-RBD")
                              :mod (x5 / enzyme
                                    :name (x6 / name :op1 "mef")
                                    :xref (x33 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                              :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
                        :ARG1-of (x8 / normal-02)
                        :ARG2 (x9 / protein
                              :name (x10 / name
                                    :op1 "epidermal"
                                    :op2 "growth"
                                    :op3 "factor")))
                  :ARG1-of (x11 / describe-01
                        :ARG0 (x18 / and
                              :op1 (x12 / protein
                                    :name (x13 / name :op1 "EGF")
                                    :xref (x35 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                              :op2 (x14 / protein
                                    :name (x15 / name
                                          :op1 "platelet-derived"
                                          :op2 "growth"
                                          :op3 "factor"))
                              :op2 (x16 / protein
                                    :name (x17 / name :op1 "PDGF")
                                    :xref (x36 / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313"))
                              :op3 (x22 / respond-01
                                    :ARG0 (x21 / dose-01
                                          :ARG2 (x19 / protein
                                                :name (x20 / name :op1 "insulin")
                                                :xref (x34 / xref :value "UNIPROT:INS_HUMAN" :prob "0.703"))))
                              :ARG1-of (x23 / describe-01
                                    :ARG0 (x24 / figure :mod "s5")))))
            :op2 (x25 / figure :mod "5c"))
      :snt2 (x29 / experiment-01
            :ARG1 (x28 / course
                  :mod (x27 / time))
            :ARG1-of (x30 / describe-01
                  :ARG0 (x31 / data
                        :ARG1-of (x32 / show-01 :polarity "-")))))


# ::id PMC3690480.119
# ::snt Notably, in p110β-knockout cells, AKT phosphorylation in response to LPA was completely abolished ( Figure 5 C), indicating that the RBD is essential for much but not all p110β activation downstream of GPCRs.
# ::tok Notably , in p110β-knockout cells , AKT phosphorylation in response to LPA was completely abolished ( Figure 5 C ) , indicating that the RBD is essential for much but not all p110β activation downstream of GPCRs .
(x1 / multi-sentence
      :snt1 (x12 / abolish-01
            :ARG1-of (x2 / notable-04)
            :ARG1 (x7 / phosphorylate-01
                  :location (x4 / cell-line
                        :name (x3 / name :op1 "p110β-knockout"))
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "AKT")
                        :xref (x29 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :ARG2-of (x8 / respond-01
                        :ARG1 (x9 / small-molecule
                              :name (x10 / name :op1 "LPA")
                              :xref (x30 / xref :value "PUBCHEM:62707" :prob "9.981436"))))
            :ARG1-of (x11 / complete-02)
            :ARG1-of (x13 / describe-01
                  :ARG0 (x14 / figure :mod "5c"))
            :ARG0-of (x15 / indicate-01
                  :ARG1 (x18 / essential
                        :domain (x16 / protein-segment
                              :name (x17 / name :op1 "RBD"))
                        :purpose (x19 / much))))
      :snt2 (x20 / contrast-01
            :ARG2 (x24 / activate-01
                  :polarity "-"
                  :mod (x21 / all)
                  :ARG1 (x22 / enzyme
                        :name (x23 / name :op1 "p110β")
                        :xref (x28 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                  :mod (x25 / downstream)
                  :ARG1 (x26 / enzyme
                        :name (x27 / name :op1 "GPCRs")
                        :xref (x / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311")))))


# ::id PMC3690480.120
# ::snt Activation of p110β Downstream of GPCRs Requires RAC
# ::tok Activation of p110β Downstream of GPCRs Requires RAC
(x8 / require-01
      :ARG0 (x1 / activate-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "p110β")
                  :xref (x11 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
            :ARG2 (x4 / relative-position
                  :direction (x5 / downstream)
                  :op1 (x6 / enzyme
                        :name (x7 / name :op1 "GPCRs")
                        :xref (x12 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311"))))
      :ARG1 (x9 / enzyme
            :name (x10 / name :op1 "RAC")
            :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003")))


# ::id PMC3690480.121
# ::snt To test whether the identified p110β RBD interactors are required for linking p110β to GPCRs, we knocked down RAC1 and CDC42 in wild-type MEFs.
# ::tok To test whether the identified p110β RBD interactors are required for linking p110β to GPCRs , we knocked down RAC1 and CDC42 in wild @-@ type MEFs .
(x13 / knock-down-02
      :purpose (x1 / test-01
            :ARG1 (x6 / require-01
                  :mode "interrogative"
                  :ARG1 (x2 / identify-01
                        :ARG1 (x5 / interact-01
                              :ARG1 (x3 / enzyme
                                    :name (x4 / name :op1 "RBD"))))
                  :ARG0 (x7 / link-01
                        :ARG1 (x8 / enzyme
                              :name (x9 / name :op1 "p110β")
                              :xref (x24 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                        :ARG2 (x10 / protein
                              :name (x11 / name :op1 "GPCRs")
                              :xref (x23 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311")))))
      :ARG0 (x12 / we)
      :ARG1 (x16 / and
            :op1 (x14 / protein
                  :name (x15 / name :op1 "RAC1")
                  :xref (x22 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :op2 (x17 / protein
                  :name (x18 / name :op1 "CDC42")
                  :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :location (x19 / cell
            :mod (x20 / wild-type)
            :name (x21 / name :op1 "mef")))


# ::id PMC3690480.122
# ::snt Knockdown of RAC1 strongly impacted LPA/S1P-induced AKT phosphorylation, knockdown of CDC42 had only minor effects, and combination knockdown of both RAC1 and CDC42 had little additional effect compared to RAC1 knockdown alone ( Figure 5 D).
# ::tok Knockdown of RAC1 strongly impacted LPA @/@ S1P @-@ induced AKT phosphorylation , knockdown of CDC42 had only minor effects , and combination knockdown of both RAC1 and CDC42 had little additional effect compared to RAC1 knockdown alone ( Figure 5 D ) .
(x18 / and
      :op1 (x5 / impact-01
            :ARG0 (x1 / knock-down-02
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "RAC1")
                        :xref (x38 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004")))
            :ARG1-of (x4 / strong-02)
            :ARG1 (x17 / affect-01
                  :ARG1 (x11 / phosphorylate-01
                        :ARG2-of (x8 / induce-01
                              :ARG0 (x6 / small-molecule
                                    :name (x7 / name :op1 "LPA" :op2 "S1P")))
                        :ARG1 (x9 / enzyme
                              :name (x10 / name :op1 "AKT")
                              :xref (x37 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                  :ARG0 (x12 / knock-down-02
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "CDC42")
                              :xref (x40 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                  :mod (x15 / only)
                  :ARG1-of (x16 / minor-01)))
      :op2 (x19 / combine-01
            :ARG1 (x28 / affect-01
                  :ARG0 (x20 / knock-down-02
                        :ARG1 (x21 / and
                              :op1 (x22 / protein
                                    :name (x23 / name :op1 "RAC1")
                                    :xref (x36 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                              :op2 (x24 / protein
                                    :name (x25 / name :op1 "CDC42")
                                    :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))
                  :degree (x26 / little)
                  :mod (x27 / additional)
                  :ARG1-of (x29 / compare-01
                        :ARG2 (x32 / knock-down-02
                              :ARG1 (x30 / protein
                                    :name (x31 / name :op1 "RAC1")
                                    :xref (x39 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004")))))
            :mod (x33 / alone))
      :ARG1-of (x34 / describe-01
            :ARG0 (x35 / figure :mod "5d")))


# ::id PMC3690480.123
# ::snt Deconvolution experiments using single siRNA oligonucleotides confirmed the leading role of RAC1 in this pathway ( Figure S5 D).
# ::tok Deconvolution experiments using single siRNA oligonucleotides confirmed the leading role of RAC1 in this pathway ( Figure S5 D ) .
(x9 / confirm-01
      :ARG0 (x3 / experiment-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "Deconvolution")
                  :xref (x18 / xref :value "UNIPROT:PGS2_HUMAN" :prob "0.202"))
            :ARG0-of (x4 / use-01
                  :ARG1 (x8 / oligonucleotide
                        :ARG1-of (x5 / single-02)
                        :mod (x6 / nucleic-acid
                              :name (x7 / name :op1 "siRNA")))))
      :ARG1 (x10 / lead-03
            :ARG1 (x11 / role
                  :poss (x12 / protein
                        :name (x13 / name :op1 "RAC1")
                        :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :topic (x15 / pathway
                        :mod (x14 / this))))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / figure :mod "s5")))


# ::id PMC3690480.124
# ::snt Neither RAC1 nor CDC42 knockdown affected LPA/S1P-induced phosphorylation of ERK or activation of either pathway induced by tyrosine kinase receptor agonists (EGF, PDGF, and insulin; Figure S5 E).
# ::tok Neither RAC1 nor CDC42 knockdown affected LPA @/@ S1P @-@ induced phosphorylation of ERK or activation of either pathway induced by tyrosine kinase receptor agonists ( EGF , PDGF , and insulin ; Figure S5 E ) .
(x7 / affect-01
      :polarity "-"
      :ARG0 (x6 / knock-down-02
            :ARG1 (x3 / or
                  :op1 (x1 / protein
                        :name (x2 / name :op1 "RAC1")
                        :xref (x33 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x4 / protein
                        :name (x5 / name :op1 "CDC42")
                        :xref (x34 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))
      :ARG1 (x14 / or
            :op1 (x11 / phosphorylate-01
                  :ARG2-of (x10 / induce-01
                        :ARG0 (x8 / enzyme
                              :name (x9 / name :op1 "LPA" :op2 "S1P")))
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "ERK")
                        :xref (x35 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :op2 (x15 / activate-01
                  :ARG1 (x16 / pathway)
                  :ARG2-of (x17 / induce-01
                        :ARG0 (x19 / agonist
                              :name (x18 / name
                                    :op1 "tyrosine"
                                    :op2 "kinase"
                                    :op3 "receptor")))))
      :ARG1-of (x24 / and
            :op1 (x20 / protein
                  :name (x21 / name :op1 "EGF")
                  :xref (x31 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :op2 (x22 / protein
                  :name (x23 / name :op1 "PDGF")
                  :xref (x32 / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313"))
            :op2 (x25 / protein
                  :name (x26 / name :op1 "insulin")
                  :xref (x30 / xref :value "UNIPROT:INS_HUMAN" :prob "0.703"))
            :op2 (x27 / figure :mod "s5")
            :op2 (x28 / protein
                  :name (x29 / name :op1 "e-cadherin")
                  :xref (x / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703"))))


# ::id PMC3690480.125
# ::snt Similarly, EHT1864, a direct inhibitor of RAC but not CDC42 activation, dose-dependently inhibited AKT phosphorylation induced by LPA/S1P ( Figure 5 E), but not EGF, PDGF, or insulin ( Figure S5 F).
# ::tok Similarly , EHT1864 , a direct inhibitor of RAC but not CDC42 activation , dose @-@ dependently inhibited AKT phosphorylation induced by LPA @/@ S1P ( Figure 5 E ) , but not EGF , PDGF , or insulin ( Figure S5 F ) .
(x8 / contrast-01
      :ARG1-of (x1 / resemble-01)
      :ARG1 (x4 / small-molecule
            :name (x2 / name :op1 "EHT1864")
            :ARG1-of (x3 / direct-02)
            :ARG0-of (x5 / inhibit-01
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "RAC")
                        :xref (x41 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))))
      :ARG2 (x11 / activate-01
            :polarity "-"
            :ARG1 (x9 / protein
                  :name (x10 / name :op1 "CDC42")
                  :xref (x40 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
            :ARG0-of (x14 / inhibit-01
                  :ARG0-of (x13 / depend-01
                        :ARG1 (x12 / dose))
                  :ARG1 (x21 / slash
                        :op1 (x17 / phosphorylate-01
                              :ARG1 (x15 / enzyme
                                    :name (x16 / name :op1 "AKT")
                                    :xref (x44 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                              :ARG2-of (x18 / induce-01
                                    :ARG0 (x19 / small-molecule
                                          :name (x20 / name :op1 "LPA")
                                          :xref (x45 / xref :value "PUBCHEM:62707" :prob "9.981436"))))
                        :op2 (x22 / enzyme
                              :name (x23 / name :op1 "S1P")
                              :xref (x39 / xref :value "UNIPROT:MBTP1_HUMAN" :prob "1.002")))
                  :ARG1-of (x24 / describe-01
                        :ARG0 (x25 / figure :mod "e"))
                  :ARG1-of (x26 / contrast-01
                        :ARG2 (x31 / or
                              :op1 (x27 / protein
                                    :name (x28 / name :op1 "EGF")
                                    :xref (x38 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                              :op2 (x29 / protein
                                    :name (x30 / name :op1 "PDGF")
                                    :xref (x / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313"))
                              :op2 (x32 / protein
                                    :name (x33 / name :op1 "insulin")
                                    :xref (x42 / xref :value "UNIPROT:INS_HUMAN" :prob "0.703")))))
            :ARG1-of (x34 / describe-01
                  :ARG0 (x35 / figure :mod "s5"))
            :ARG1 (x36 / protein
                  :name (x37 / name :op1 "f-actin")
                  :xref (x43 / xref :value "UNIPROT:NEXN_HUMAN" :prob "0.232"))))


# ::id PMC3690480.126
# ::snt Therefore, acute loss or inhibition of RAC phenocopied the signaling defect observed in p110β-RBD-DM MEFs.
# ::tok Therefore , acute loss or inhibition of RAC phenocopied the signaling defect observed in p110β-RBD @-@ DM MEFs .
(x1 / cause-01
      :ARG1 (x8 / phenocopy-00
            :ARG0 (x4 / or
                  :op1 (x3 / lose-02
                        :mod (x2 / acute))
                  :op2 (x5 / inhibit-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "RAC")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))))
            :ARG1 (x9 / signal-07
                  :ARG1 (x10 / defect
                        :ARG1-of (x11 / observe-01
                              :location (x12 / cell
                                    :name (x13 / name :op1 "p110β-RBD")))
                        :name (x14 / name :op1 "mef")))))


# ::id PMC3690480.127
# ::snt In line with this, RAC was activated very rapidly upon LPA stimulation, reaching its peak activity within 20 s ( Figure 5 F).
# ::tok In line with this , RAC was activated very rapidly upon LPA stimulation , reaching its peak activity within 20 s ( Figure 5 F ) .
(x11 / reach-01
      :ARG1-of (x1 / resemble-01
            :ARG2 (x2 / this))
      :ARG0 (x5 / activate-01
            :ARG1 (x3 / enzyme
                  :name (x4 / name :op1 "RAC")
                  :xref (x20 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :mod (x7 / rapid
                  :degree (x6 / very))
            :condition (x10 / stimulate-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "LPA")
                        :xref (x / xref :value "UNIPROT:APOA_HUMAN" :prob "1.002"))))
      :ARG1 (x12 / peak
            :ARG0-of (x13 / activity-06
                  :ARG1-of (x14 / describe-01
                        :ARG0 (x15 / publication
                              :ARG1-of (x16 / cite-01 :ARG2 "20")))
                  :name (x17 / name :op1 "s")))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / figure :mod "4f")))


# ::id PMC3690480.128
# ::snt Dock180/Elmo1 Activates RAC Downstream of GPCRs and Upstream of p110β
# ::tok Dock180 @/@ Elmo1 Activates RAC Downstream of GPCRs and Upstream of p110β
(x5 / activate-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "Dock180")
            :xref (x19 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
      :ARG0 (x3 / protein
            :name (x4 / name :op1 "Elmo1")
            :xref (x18 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))
      :ARG1 (x6 / enzyme
            :name (x7 / name :op1 "RAC")
            :xref (x20 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
      :ARG1 (x12 / and
            :op1 (x8 / relative-position
                  :direction (x9 / downstream)
                  :op1 (x10 / enzyme
                        :name (x11 / name :op1 "GPCRs")
                        :xref (x17 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311")))
            :op2 (x13 / relative-position
                  :direction (x14 / upstream)
                  :op1 (x15 / enzyme
                        :name (x16 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))))


# ::id PMC3690480.129
# ::snt To provide further mechanistic insight into the GPCR-RAC-p110β pathway, we performed a small candidate siRNA screen to identify the guanine nucleotide exchange factor (RAC-GEF) involved.
# ::tok To provide further mechanistic insight into the GPCR @-@ RAC @-@ p110β pathway , we performed a small candidate siRNA screen to identify the guanine nucleotide exchange factor ( RAC @-@ GEF ) involved .
(x12 / perform-01
      :purpose (x1 / provide-01
            :ARG1 (x4 / insight
                  :mod (x3 / mechanistic
                        :degree (x2 / further))
                  :topic (x5 / enzyme
                        :name (x6 / name :op1 "GPCR")
                        :mod (x7 / enzyme
                              :name (x8 / name :op1 "RAC")
                              :xref (x27 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                        :xref (x28 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "1.001")))
            :ARG2 (x10 / pathway
                  :name (x9 / name :op1 "p110β")))
      :ARG0 (x11 / we)
      :ARG1 (x16 / screen-01
            :ARG1 (x13 / small-molecule
                  :mod (x14 / candidate)
                  :name (x15 / name :op1 "siRNA"))
            :ARG2 (x17 / identify-01
                  :ARG1 (x18 / protein
                        :name (x19 / name
                              :op1 "guanine"
                              :op2 "nucleotide"
                              :op3 "exchange"
                              :op4 "factor")
                        :ARG1-of (x25 / involve-01
                              :ARG2 (x20 / macro-molecular-complex
                                    :part (x21 / enzyme
                                          :name (x22 / name :op1 "RAC")
                                          :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                                    :part (x23 / protein
                                          :name (x24 / name :op1 "GEF")
                                          :xref (x26 / xref :value "UNIPROT:S2A4R_HUMAN" :prob "1.002"))))))))


# ::id PMC3690480.130
# ::snt Transfection of wild-type MEFs with siRNA pools targeting the Dbl family RAC-GEFs Vav1-3, PREX1/2, and α-/β-PIX had no clear effect on LPA/S1P-induced AKT phosphorylation ( Figures 6 A and S6 A).
# ::tok Transfection of wild @-@ type MEFs with siRNA pools targeting the Dbl family RAC @-@ GEFs Vav1 @-@ 3 , PREX1 @/@ 2 , and α-/β-PIX had no clear effect on LPA @/@ S1P @-@ induced AKT phosphorylation ( Figures 6 A and S6 A ) .
(x1 / multi-sentence
      :snt1 (x8 / pool
            :ARG0-of (x2 / transfect-01
                  :ARG1 (x3 / enzyme
                        :mod (x4 / wild-type)
                        :name (x5 / name :op1 "mef")
                        :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :ARG2 (x6 / nucleic-acid
                        :name (x7 / name :op1 "siRNA")))
            :ARG0-of (x9 / target-01
                  :ARG1 (x11 / protein-family
                        :name (x10 / name :op1 "Dbl")))
            :ARG0-of (x14 / activate-01
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "RAC")
                        :xref (x38 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                  :ARG0 (x15 / protein
                        :name (x16 / name :op1 "gef")
                        :xref (x39 / xref :value "UNIPROT:S2A4R_HUMAN" :prob "0.602"))))
      :snt2 (x24 / have-03
            :ARG0 (x21 / and
                  :op1 (x17 / protein
                        :name (x18 / name :op1 "Vav1-3"))
                  :op2 (x19 / protein
                        :name (x20 / name :op1 "PREX1/2"))
                  :op2 (x22 / enzyme
                        :name (x23 / name :op1 "α-/β-PIX")))
            :polarity "-"
            :ARG1 (x26 / affect-01
                  :ARG1-of (x25 / clear-06)
                  :ARG1 (x32 / phosphorylate-01
                        :ARG2-of (x29 / induce-01
                              :ARG0 (x27 / small-molecule
                                    :name (x28 / name :op1 "LPA" :op2 "S1P")))
                        :ARG1 (x30 / enzyme
                              :name (x31 / name :op1 "AKT")
                              :xref (x37 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
            :ARG1-of (x33 / describe-01
                  :ARG0 (x34 / and
                        :op1 (x35 / figure :mod "6")
                        :op2 (x36 / figure :mod "s6")))))


# ::id PMC3690480.131
# ::snt In contrast, knockdown of the Dock family RAC-GEF Dock180 or its adaptor protein Elmo1 interfered with AKT phosphorylation induced by LPA and S1P ( Figure 6 B and S6 B), but not by EGF, PDGF, and insulin ( Figure S6 C).
# ::tok In contrast , knockdown of the Dock family RAC @-@ GEF Dock180 or its adaptor protein Elmo1 interfered with AKT phosphorylation induced by LPA and S1P ( Figure 6 B and S6 B ) , but not by EGF , PDGF , and insulin ( Figure S6 C ) .
(x1 / contrast-01
      :ARG2 (x14 / interfere-01
            :ARG0 (x2 / knock-down-02
                  :ARG1 (x11 / or
                        :op1 (x3 / dock-01
                              :ARG1 (x4 / protein-family
                                    :mod (x5 / macro-molecular-complex
                                          :part (x6 / enzyme
                                                :name (x7 / name :op1 "RAC")
                                                :xref (x42 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                                          :part (x8 / protein
                                                :name (x9 / name :op1 "GEF")
                                                :xref (x41 / xref :value "UNIPROT:S2A4R_HUMAN" :prob "1.002")))
                                    :name (x10 / name :op1 "Dock180")))
                        :op2 (x12 / protein
                              :name (x13 / name
                                    :op1 "adaptor"
                                    :op2 "protein"
                                    :op3 "Elmo1"))))
            :ARG1 (x21 / and
                  :op1 (x17 / phosphorylate-01
                        :ARG1 (x15 / enzyme
                              :name (x16 / name :op1 "AKT")
                              :xref (x46 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :ARG2-of (x18 / induce-01
                              :ARG0 (x19 / small-molecule
                                    :name (x20 / name :op1 "LPA")
                                    :xref (x47 / xref :value "PUBCHEM:62707" :prob "9.981436"))))
                  :op2 (x22 / protein
                        :name (x23 / name :op1 "S1P")
                        :xref (x40 / xref :value "UNIPROT:MBTP1_HUMAN" :prob "1.002")))
            :ARG1-of (x24 / describe-01
                  :ARG0 (x26 / and
                        :op1 (x25 / figure :mod "6a")
                        :op2 (x27 / figure :mod "s6")))
            :ARG1 (x35 / and
                  :op1 (x28 / enzyme
                        :name (x29 / name :op1 "b-raf")
                        :xref (x / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.701"))
                  :op2 (x30 / contrast-01
                        :ARG2 (x31 / protein
                              :name (x32 / name :op1 "EGF")
                              :xref (x44 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :op3 (x33 / protein
                        :name (x34 / name :op1 "PDGF")
                        :xref (x43 / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313"))
                  :op4 (x36 / protein
                        :name (x37 / name :op1 "insulin")
                        :xref (x45 / xref :value "UNIPROT:INS_HUMAN" :prob "0.703"))))
      :ARG1-of (x38 / describe-01
            :ARG0 (x39 / figure :mod "s6")))


# ::id PMC3690480.132
# ::snt Specificity of results was confirmed in deconvolution experiments using individual siRNA oligonucleotides targeting Dock180 and Elmo1 ( Figures S6 D and S6E).
# ::tok Specificity of results was confirmed in deconvolution experiments using individual siRNA oligonucleotides targeting Dock180 and Elmo1 ( Figures S6 D and S6E ) .
(x4 / confirm-01
      :ARG1 (x1 / specific-02
            :ARG1 (x2 / thing
                  :ARG2-of (x3 / result-01)))
      :location (x23 / and
            :op1 (x7 / experiment-01
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "deconvolution"))
                  :ARG0-of (x8 / use-01
                        :ARG1 (x12 / oligonucleotide
                              :mod (x9 / individual)
                              :mod (x10 / nucleic-acid
                                    :name (x11 / name :op1 "siRNA"))
                              :ARG0-of (x13 / target-01
                                    :ARG1 (x16 / and
                                          :op1 (x14 / enzyme
                                                :name (x15 / name :op1 "Dock180")
                                                :xref (x26 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
                                          :op2 (x17 / protein
                                                :name (x18 / name :op1 "Elmo1")
                                                :xref (x27 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))))))
                  :ARG1-of (x19 / describe-01
                        :ARG0 (x20 / value-interval
                              :op1 (x21 / figure :mod "s6")
                              :op2 (x22 / figure :mod "5d"))))
            :op2 (x24 / enzyme
                  :name (x25 / name :op1 "S6E")
                  :xref (x / xref :value "UNIPROT:S6EWF0_HUMAN" :prob "0.211"))))


# ::id PMC3690480.133
# ::snt Knockdown of Elmo2 had no effect ( Figure S6 F).
# ::tok Knockdown of Elmo2 had no effect ( Figure S6 F ) .
(x4 / affect-01
      :ARG0 (x1 / knock-down-02
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "Elmo2")
                  :xref (x / xref :value "UNIPROT:ELMO2_HUMAN" :prob "0.603")))
      :polarity "-"
      :ARG1-of (x5 / describe-01
            :ARG0 (x6 / figure
                  :mod "s6"
                  :name (x7 / name :op1 "f-actin"))))


# ::id PMC3690480.134
# ::snt Moreover, knockdown of Dock180 abolished LPA- but not EGF-induced RAC activation ( Figure 6 C), firmly placing Dock180/Elmo1 downstream of the LPA receptor and upstream of RAC and p110β.
# ::tok Moreover , knockdown of Dock180 abolished LPA @- but not EGF @-@ induced RAC activation ( Figure 6 C ) , firmly placing Dock180 @/@ Elmo1 downstream of the LPA receptor and upstream of RAC and p110β.
(x1 / and
      :op2 (x5 / abolish-01
            :ARG1-of (x2 / knock-down-02
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "Dock180")
                        :xref (x37 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633")))
            :ARG1 (x8 / contrast-01
                  :ARG0 (x6 / small-molecule
                        :name (x7 / name :op1 "LPA")
                        :xref (x42 / xref :value "PUBCHEM:62707" :prob "9.981436")))
            :polarity "-"
            :ARG1 (x14 / activate-01
                  :ARG2-of (x11 / induce-01
                        :ARG0 (x9 / protein
                              :name (x10 / name :op1 "EGF")
                              :xref (x36 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "RAC")
                        :xref (x41 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003")))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / figure :mod "6c"))
            :ARG1-of (x17 / firm-03
                  :ARG1 (x18 / place-01
                        :ARG1 (x21 / slash
                              :op1 (x19 / enzyme
                                    :name (x20 / name :op1 "Dock180")
                                    :xref (x40 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
                              :op2 (x22 / enzyme
                                    :name (x23 / name :op1 "Elmo1")
                                    :xref (x / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604")))
                        :ARG2 (x24 / relative-position
                              :direction (x25 / downstream)
                              :op1 (x28 / and
                                    :op1 (x27 / receptor
                                          :name (x26 / name :op1 "LPA"))
                                    :op2 (x29 / relative-position
                                          :direction (x30 / upstream)
                                          :op1 (x33 / and
                                                :op1 (x31 / enzyme
                                                      :name (x32 / name :op1 "RAC")
                                                      :xref (x38 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                                                :op2 (x34 / protein
                                                      :name (x35 / name :op1 "p110β.")
                                                      :xref (x39 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242"))))))))))


# ::id PMC3690480.135
# ::snt The DHR-1 domain of Dock180 has been shown to bind PIP 3 ( Côté et al., 2005 ), raising the possibility of a PIP 3 -driven feedback loop, in which RAC would be upstream and downstream of p110β.
# ::tok The DHR @-@ 1 domain of Dock180 has been shown to bind PIP 3 ( Côté et al. , 2005 ) , raising the possibility of a PIP 3 -@ driven feedback loop , in which RAC would be upstream and downstream of p110β.
(x1 / multi-sentence
      :snt1 (x6 / show-01
            :ARG1 (x2 / amino-acid
                  :name (x3 / name :op1 "DHR")
                  :mod "1"
                  :part-of (x4 / protein
                        :name (x5 / name :op1 "Dock180")
                        :xref (x34 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
                  :xref (x36 / xref :value "PUBCHEM:440104" :prob "18.167522"))
            :ARG1 (x7 / bind-01
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "PIP" :op2 "3")))
            :ARG1-of (x10 / describe-01
                  :ARG0 (x11 / and
                        :op1 (x12 / publication-91
                              :ARG0 (x15 / and
                                    :op1 (x13 / person
                                          :name (x14 / name :op1 "Côté"))
                                    :op2 (x16 / person
                                          :mod (x17 / other)))
                              :time (x18 / date-entity :year "2005"))
                        :op2 (x25 / loop
                              :ARG0-of (x19 / raise-01
                                    :ARG1 (x20 / possible-01
                                          :ARG1 (x23 / drive-02
                                                :ARG2 (x21 / protein
                                                      :name (x22 / name :op1 "PIP" :op2 "3")))))
                              :mod (x24 / feedback))
                        :location-of (x28 / upstream
                              :ARG1 (x26 / enzyme
                                    :name (x27 / name :op1 "RAC")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))))))
      :snt2 (x29 / and
            :op1 (x30 / relative-position
                  :direction (x31 / downstream)
                  :op1 (x32 / enzyme
                        :name (x33 / name :op1 "p110β.")
                        :xref (x35 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242")))))


# ::id PMC3690480.136
# ::snt However, whereas sensitive to pertussis toxin, LPA-induced RAC activation was entirely insensitive to PI3K inhibition by GDC0941, a pan type I PI3K inhibitor, placing all detectable RAC activation upstream of p110β ( Figure 6 D).
# ::tok However , whereas sensitive to pertussis toxin , LPA @-@ induced RAC activation was entirely insensitive to PI3K inhibition by GDC0941 , a pan type I PI3K inhibitor , placing all detectable RAC activation upstream of p110β ( Figure 6 D ) .
(x1 / have-concession-91
      :ARG1 (x2 / contrast-01
            :ARG2 (x3 / sensitive-03
                  :ARG1 (x4 / small-molecule
                        :name (x5 / name :op1 "pertussis" :op2 "toxin"))
                  :ARG0-of (x13 / sensitive-03
                        :ARG1 (x11 / activate-01
                              :ARG2-of (x8 / induce-01
                                    :ARG0 (x6 / small-molecule
                                          :name (x7 / name :op1 "LPA")
                                          :xref (x43 / xref :value "PUBCHEM:62707" :prob "9.981436")))
                              :ARG1 (x9 / enzyme
                                    :name (x10 / name :op1 "RAC")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003")))
                        :degree (x12 / entire)
                        :polarity "-"
                        :ARG1 (x16 / inhibit-01
                              :ARG1 (x14 / enzyme
                                    :name (x15 / name :op1 "PI3K")
                                    :xref (x42 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                              :ARG0 (x17 / small-molecule
                                    :name (x18 / name :op1 "GDC0941")
                                    :xref (x44 / xref :value "PUBCHEM:17755052" :prob "18.349844"))))
                  :ARG0 (x21 / disease
                        :mod (x19 / enzyme
                              :name (x20 / name :op1 "pan-raf"))
                        :mod (x22 / type
                              :ord (x23 / ordinal-entity :value "1")))
                  :ARG1 (x26 / inhibit-01
                        :ARG1 (x24 / protein-family
                              :name (x25 / name :op1 "PI3K"))))
            :ARG1 (x27 / place-01
                  :ARG1 (x33 / activate-01
                        :mod (x28 / all)
                        :ARG1-of (x29 / detect-01
                              :ARG1-of (x30 / possible-01))
                        :ARG1 (x31 / enzyme
                              :name (x32 / name :op1 "RAC")
                              :xref (x40 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003")))
                  :ARG2 (x34 / relative-position
                        :direction (x35 / upstream)
                        :op1 (x36 / enzyme
                              :name (x37 / name :op1 "p110β")
                              :xref (x41 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))
            :ARG1-of (x38 / describe-01
                  :ARG0 (x39 / figure :mod "5d"))))


# ::id PMC3690480.137
# ::snt Recently, Dictyostelium ElmoE has been reported to be a direct Gβγ effector ( Yan et al., 2012 ).
# ::tok Recently , Dictyostelium ElmoE has been reported to be a direct Gβγ effector ( Yan et al. , 2012 ) .
(x2 / report-01
      :time (x1 / recent)
      :ARG1 (x5 / direct-01
            :ARG2 (x3 / enzyme
                  :name (x4 / name :op1 "Dictyostelium" :op2 "ElmoE"))
            :ARG1 (x7 / effector
                  :name (x6 / name :op1 "Gβγ")))
      :ARG1-of (x8 / describe-01
            :ARG0 (x9 / publication-91
                  :ARG0 (x12 / and
                        :op1 (x10 / person
                              :name (x11 / name :op1 "Yan"))
                        :op2 (x13 / person
                              :mod (x14 / other)))
                  :time (x15 / date-entity :year "2012"))))


# ::id PMC3690480.138
# ::snt We thus probed Gβγ subunits for direct binding to purified recombinant Elmo1 ( Figure 6 E) and found Gβγ to strongly bind to full-length Elmo and several N-terminal fragments.
# ::tok We thus probed Gβγ subunits for direct binding to purified recombinant Elmo1 ( Figure 6 E ) and found Gβγ to strongly bind to full @-@ length Elmo and several N @-@ terminal fragments .
(x1 / cause-01
      :ARG1 (x3 / probe-01
            :ARG0 (x2 / we)
            :ARG1 (x14 / and
                  :op1 (x5 / subunit
                        :name (x4 / name :op1 "Gβγ")
                        :purpose (x7 / bind-01
                              :ARG1-of (x6 / direct-02)
                              :ARG2 (x8 / enzyme
                                    :ARG1-of (x9 / purify-01)
                                    :ARG1-of (x10 / recombine-01)
                                    :name (x11 / name :op1 "Elmo1")
                                    :xref (x29 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604")))
                        :ARG1-of (x12 / describe-01
                              :ARG0 (x13 / figure :mod "e")))
                  :op2 (x15 / find-01
                        :ARG1 (x24 / and
                              :op1 (x16 / enzyme
                                    :name (x17 / name :op1 "Gβγ")
                                    :ARG1-of (x19 / bind-01
                                          :ARG1-of (x18 / strong-02)
                                          :ARG2 (x20 / protein
                                                :ARG1-of (x22 / long-03
                                                      :ARG1-of (x21 / full-09))
                                                :name (x23 / name :op1 "Elmo")
                                                :xref (x / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.233")))
                                    :xref (x30 / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.58"))
                              :op2 (x28 / protein-segment
                                    :quant (x25 / several)
                                    :mod (x26 / protein-segment
                                          :name (x27 / name :op1 "n-terminus"))))))))


# ::id PMC3690480.139
# ::snt This altogether suggests a model in which Dock180 is recruited downstream of GPCRs, possibly through binding of Gβγ to the N terminus of Elmo1.
# ::tok This altogether suggests a model in which Dock180 is recruited downstream of GPCRs , possibly through binding of Gβγ to the N terminus of Elmo1 .
(x3 / suggest-01
      :ARG0 (x1 / this)
      :degree (x2 / altogether)
      :ARG1 (x4 / model
            :mod (x7 / recruit-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "Dock180")
                        :xref (x22 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
                  :ARG2 (x8 / relative-position
                        :direction (x9 / downstream)
                        :op1 (x10 / enzyme
                              :name (x11 / name :op1 "GPCRs")
                              :xref (x21 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311")))))
      :ARG1-of (x12 / possible-01
            :ARG1 (x13 / bind-01
                  :ARG1 (x14 / protein
                        :name (x15 / name :op1 "Gβγ")
                        :xref (x / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.58"))
                  :ARG2 (x16 / protein-segment
                        :name (x17 / name :op1 "n-terminus")
                        :part-of (x18 / protein
                              :name (x19 / name :op1 "Elmo1")
                              :xref (x20 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))))))


# ::id PMC3690480.140
# ::snt At the same time, p110β is directly recruited by Gβγ.
# ::tok At the same time , p110β is directly recruited by Gβγ.
(x6 / recruit-01
      :time (x2 / time
            :ARG1-of (x1 / same-01))
      :ARG1 (x3 / protein
            :name (x4 / name :op1 "p110β")
            :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
      :ARG1-of (x5 / direct-02)
      :ARG0 (x7 / enzyme
            :name (x8 / name :op1 "Gβγ.")
            :xref (x9 / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.57")))


# ::id PMC3690480.141
# ::snt RAC is activated in proximity to p110β and binds to the RBD to fully activate p110β lipid kinase activity (schematic in Figure 6 F).
# ::tok RAC is activated in proximity to p110β and binds to the RBD to fully activate p110β lipid kinase activity ( schematic in Figure 6 F ) .
(x3 / activate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "RAC")
            :xref (x21 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
      :ARG1-of (x4 / close-10
            :ARG2 (x15 / lipid
                  :op1 (x12 / activate-01
                        :ARG0 (x7 / and
                              :op1 (x5 / enzyme
                                    :name (x6 / name :op1 "p110β")
                                    :xref (x22 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                              :op2 (x8 / bind-01
                                    :ARG2 (x9 / protein-segment
                                          :name (x10 / name :op1 "RBD"))))
                        :degree (x11 / full)
                        :ARG1 (x13 / enzyme
                              :name (x14 / name :op1 "p110β")
                              :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
                  :op2 (x17 / activity-06
                        :ARG0 (x16 / kinase)))
            :ARG1-of (x18 / schematic
                  :location (x19 / figure :mod "6")
                  :name (x20 / name :op1 "f-actin"))))


# ::id PMC3690480.142
# ::snt We could not detect any tyrosine phosphorylation on p85 in response to LPA ( Figure S6 G), and the tyrosine kinase inhibitors dasatinib, erlotinib, and PP2 (all at 1 μM) had no effect on the signaling pathway studied (data not shown).
# ::tok We could not detect any tyrosine phosphorylation on p85 in response to LPA ( Figure S6 G ) , and the tyrosine kinase inhibitors dasatinib , erlotinib , and PP2 ( all at 1 μM ) had no effect on the signaling pathway studied ( data not shown ) .
(x1 / multi-sentence
      :snt1 (x2 / possible-01
            :ARG1 (x4 / detect-01
                  :ARG0 (x3 / we)
                  :polarity "-"
                  :ARG1 (x7 / phosphorylate-01
                        :ARG1 (x5 / amino-acid
                              :name (x6 / name :op1 "tyrosine")
                              :xref (x41 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :ARG2 (x8 / enzyme
                              :name (x9 / name :op1 "p85")
                              :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))
                        :ARG2-of (x10 / respond-01
                              :ARG1 (x11 / small-molecule
                                    :name (x12 / name :op1 "LPA")
                                    :xref (x42 / xref :value "PUBCHEM:62707" :prob "9.981436")))))
            :ARG1-of (x13 / describe-01
                  :ARG0 (x14 / figure :mod "s6")))
      :snt2 (x35 / study-01
            :ARG0 (x17 / and
                  :op1 (x15 / protein
                        :name (x16 / name :op1 "G")
                        :xref (x39 / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.601"))
                  :op2 (x32 / affect-01
                        :ARG0 (x25 / and
                              :op1 (x21 / molecular-physical-entity
                                    :ARG0-of (x20 / inhibit-01
                                          :ARG1 (x18 / enzyme
                                                :name (x19 / name :op1 "tyrosine" :op2 "kinase")))
                                    :name (x22 / name :op1 "dasatinib"))
                              :op2 (x23 / small-molecule
                                    :name (x24 / name :op1 "erlotinib")
                                    :xref (x40 / xref :value "PUBCHEM:176870" :prob "16.13064"))
                              :op3 (x26 / protein
                                    :name (x27 / name :op1 "PP2"))
                              :op2 (x29 / small-molecule
                                    :mod (x28 / all)
                                    :quant (x30 / concentration-quantity
                                          :quant "1"
                                          :unit (x31 / micromolar))))
                        :polarity "-"
                        :ARG1 (x34 / pathway
                              :ARG0-of (x33 / signal-07))))
            :ARG1-of (x36 / describe-01
                  :ARG0 (x37 / data
                        :ARG1-of (x38 / show-01 :polarity "-")))))


# ::id PMC3690480.143
# ::snt Disruption of the LPA-Dock180/Elmo1-RAC-p110β Axis Affects Fibroblast Chemotaxis
# ::tok Disruption of the LPA @-@ Dock180 @/@ Elmo1 @-@ RAC @-@ p110β Axis Affects Fibroblast Chemotaxis
(x14 / affect-01
      :ARG0 (x1 / disrupt-01
            :ARG1 (x13 / axis
                  :mod (x2 / small-molecule
                        :name (x3 / name :op1 "LPA")
                        :xref (x20 / xref :value "PUBCHEM:62707" :prob "9.981436"))
                  :mod (x8 / macro-molecular-complex
                        :part (x4 / protein
                              :name (x5 / name :op1 "Dock180")
                              :xref (x19 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
                        :part (x6 / enzyme
                              :name (x7 / name :op1 "Elmo1")
                              :xref (x18 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))
                        :part (x9 / enzyme
                              :name (x10 / name :op1 "RAC")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                        :part (x11 / enzyme
                              :name (x12 / name :op1 "p110β")
                              :xref (x17 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))))
      :ARG1 (x16 / chemotaxis
            :name (x15 / name :op1 "Fibroblast")))


# ::id PMC3690480.144
# ::snt To assess the functional importance of the Dock180/Elmo1-RAC-p110β signaling axis for fibroblast chemotaxis, we employed transwell filter assays to study migration in gradients of LPA and PDGF.
# ::tok To assess the functional importance of the Dock180 @/@ Elmo1 @-@ RAC @-@ p110β signaling axis for fibroblast chemotaxis , we employed transwell filter assays to study migration in gradients of LPA and PDGF .
(x18 / employ-02
      :purpose (x1 / assess-01
            :ARG1 (x2 / function-01
                  :mod (x3 / important)
                  :ARG0 (x6 / slash
                        :op1 (x4 / enzyme
                              :name (x5 / name :op1 "Dock180")
                              :xref (x32 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
                        :op2 (x7 / enzyme
                              :name (x8 / name :op1 "Elmo1")
                              :xref (x31 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604")))
                  :ARG1 (x14 / axis
                        :ARG0-of (x13 / signal-07
                              :ARG1 (x9 / enzyme
                                    :name (x10 / name :op1 "RAC")
                                    :xref (x30 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                              :ARG0 (x11 / protein
                                    :name (x12 / name :op1 "p110β")
                                    :xref (x33 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
                        :ARG0-of (x16 / chemotaxis
                              :name (x15 / name :op1 "fibroblast")))))
      :ARG0 (x17 / we)
      :ARG1 (x21 / assay-01
            :ARG1 (x20 / filter-02
                  :mod (x19 / transwell)))
      :purpose (x22 / study-01
            :ARG1 (x23 / migrate-01
                  :location (x24 / gradient)))
      :ARG1 (x27 / and
            :op1 (x25 / small-molecule
                  :name (x26 / name :op1 "LPA")
                  :xref (x34 / xref :value "PUBCHEM:62707" :prob "9.981436"))
            :op2 (x28 / protein
                  :name (x29 / name :op1 "PDGF")
                  :xref (x / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313"))))


# ::id PMC3690480.145
# ::snt p110β-RBD-DM MEFs showed significantly reduced migration in LPA but not PDGF gradients ( Figure 7 A).
# ::tok p110β-RBD @-@ DM MEFs showed significantly reduced migration in LPA but not PDGF gradients ( Figure 7 A ) .
(x5 / show-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "p110β-RBD")
            :mod (x3 / enzyme
                  :name (x4 / name :op1 "mef")
                  :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
            :xref (x18 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
      :ARG1 (x7 / reduce-01
            :ARG1-of (x6 / significant-02)
            :ARG1 (x8 / migrate-01)
            :location (x11 / contrast-01
                  :ARG1 (x9 / small-molecule
                        :name (x10 / name :op1 "LPA")
                        :xref (x19 / xref :value "PUBCHEM:62707" :prob "9.981436"))
                  :ARG2 (x12 / protein
                        :name (x13 / name :op1 "PDGF")
                        :xref (x17 / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313"))))
      :ARG1-of (x14 / gradient)
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / figure :mod "7")))


# ::id PMC3690480.146
# ::snt Similarly, wild-type MEFs transfected with siRNA pools targeting Dock180, Elmo1, or RAC1 showed defective migration in gradients of LPA but not PDGF ( Figure 7 B), pointing to the specificity of this pathway for GPCR-induced chemotaxis.
# ::tok Similarly , wild @-@ type MEFs transfected with siRNA pools targeting Dock180 , Elmo1 , or RAC1 showed defective migration in gradients of LPA but not PDGF ( Figure 7 B ) , pointing to the specificity of this pathway for GPCR @-@ induced chemotaxis .
(x9 / target-01
      :ARG1-of (x1 / resemble-01)
      :ARG0 (x8 / pool
            :mod (x2 / enzyme
                  :mod (x3 / wild-type)
                  :name (x4 / name :op1 "mef")
                  :xref (x36 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
            :ARG0-of (x5 / transfect-01
                  :ARG2 (x6 / nucleic-acid
                        :name (x7 / name :op1 "siRNA"))))
      :ARG1 (x10 / enzyme
            :name (x11 / name :op1 "Dock180")
            :xref (x38 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
      :ARG0-of (x17 / show-01
            :ARG1 (x14 / or
                  :op1 (x12 / protein
                        :name (x13 / name :op1 "Elmo1")
                        :xref (x39 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))
                  :op2 (x15 / protein
                        :name (x16 / name :op1 "RAC1")
                        :xref (x40 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004")))
            :ARG1 (x19 / migrate-01
                  :mod (x18 / defective))
            :location (x20 / gradient))
      :ARG1 (x23 / contrast-01
            :ARG0 (x21 / small-molecule
                  :name (x22 / name :op1 "LPA")
                  :xref (x41 / xref :value "PUBCHEM:62707" :prob "9.981436"))
            :polarity "-"
            :ARG2 (x24 / protein
                  :name (x25 / name :op1 "PDGF")
                  :xref (x / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313"))
            :ARG1-of (x26 / describe-01
                  :ARG0 (x27 / figure :mod "1b"))
            :ARG0-of (x28 / point-01
                  :ARG2 (x29 / specific-02
                        :ARG1 (x31 / pathway
                              :mod (x30 / this)))
                  :purpose (x34 / induce-01
                        :ARG0 (x32 / enzyme
                              :name (x33 / name :op1 "GPCR")
                              :xref (x37 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "1.001"))))
            :ARG1 (x35 / chemotaxis)))


# ::id PMC3690480.147
# ::snt In contrast, PI3K activity was required for normal migration in either gradient, because pretreatment of wild-type cells with GDC0941 strongly affected migration toward LPA and PDGF, whereas pretreatment of cells with pertussis toxin selectively blocked migration in LPA gradients ( Figure S7 A).
# ::tok In contrast , PI3K activity was required for normal migration in either gradient , because pretreatment of wild @-@ type cells with GDC0941 strongly affected migration toward LPA and PDGF , whereas pretreatment of cells with pertussis toxin selectively blocked migration in LPA gradients ( Figure S7 A ) .
(x1 / contrast-01
      :ARG2 (x5 / require-01
            :ARG0 (x4 / activity-06
                  :ARG0 (x2 / enzyme
                        :name (x3 / name :op1 "PI3K")
                        :xref (x37 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
            :ARG1 (x8 / or
                  :op1 (x7 / migrate-01
                        :ARG0 (x6 / cell))
                  :op2 (x9 / gradient))
            :ARG1-of (x10 / cause-01
                  :ARG0 (x24 / contrast-01
                        :ARG0 (x11 / pretreat-01
                              :ARG1 (x13 / cell
                                    :mod (x12 / wild-type))
                              :ARG3 (x17 / affect-01
                                    :ARG0 (x14 / small-molecule
                                          :name (x15 / name :op1 "GDC0941")
                                          :xref (x40 / xref :value "PUBCHEM:17755052" :prob "18.349844"))
                                    :ARG1-of (x16 / strong-02)
                                    :ARG1 (x18 / migrate-01
                                          :ARG2 (x21 / and
                                                :op1 (x19 / small-molecule
                                                      :name (x20 / name :op1 "LPA")
                                                      :xref (x39 / xref :value "PUBCHEM:62707" :prob "9.981436"))
                                                :op2 (x22 / protein
                                                      :name (x23 / name :op1 "PDGF")
                                                      :xref (x / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313"))))))
                        :ARG2 (x30 / block-01
                              :ARG0 (x25 / pretreat-01
                                    :ARG1 (x26 / cell)
                                    :ARG3 (x27 / small-molecule
                                          :name (x28 / name :op1 "pertussis" :op2 "toxin")))
                              :manner (x29 / selective)
                              :ARG1 (x31 / migrate-01
                                    :ARG0 (x32 / small-molecule
                                          :name (x33 / name :op1 "LPA")
                                          :xref (x38 / xref :value "PUBCHEM:62707" :prob "9.981436"))
                                    :ARG1 (x34 / gradient)))
                        :ARG1-of (x35 / describe-01
                              :ARG0 (x36 / figure :mod "s7"))))))


# ::id PMC3690480.148
# ::snt In agreement with a key role of RAC upstream of p110β in fibroblast migration, acute expression of constitutively active RAC (V12-RAC1) stimulated migration of wild-type but not p110β-RBD-DM MEFs in the absence of chemoattractant and in the presence of a low concentration of LPA (10 nM) in the lower chamber, whereas migration toward 1% FCS was largely unaffected ( Figure S7 B).
# ::tok In agreement with a key role of RAC upstream of p110β in fibroblast migration , acute expression of constitutively active RAC ( V12 @-@ RAC1 ) stimulated migration of wild @-@ type but not p110β-RBD @-@ DM MEFs in the absence of chemoattractant and in the presence of a low concentration of LPA ( 10 nM ) in the lower chamber , whereas migration toward 1 % FCS was largely unaffected ( Figure S7 B ) .
(x1 / multi-sentence
      :snt1 (x14 / express-03
            :ARG1-of (x2 / agree-01
                  :ARG2 (x4 / role
                        :ARG1-of (x3 / key-01)
                        :poss (x5 / enzyme
                              :name (x6 / name :op1 "RAC")
                              :ARG1-of (x7 / relative-position
                                    :direction (x8 / upstream)
                                    :op1 (x9 / enzyme
                                          :name (x10 / name :op1 "p110β")
                                          :xref (x54 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
                              :xref (x55 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                        :topic (x12 / migrate-01
                              :ARG0 (x11 / fibroblast))))
            :mod (x13 / acute)
            :ARG2 (x17 / enzyme
                  :ARG0-of (x16 / activity-06
                        :mod (x15 / constitutive))
                  :name (x18 / name :op1 "RAC")
                  :xref (x58 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :ARG1-of (x22 / stimulate-01
                  :ARG0 (x19 / enzyme
                        :ARG2-of (x20 / mutate-01 :value "V12")
                        :name (x21 / name :op1 "RAC1")
                        :xref (x57 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :ARG1 (x23 / migrate-01
                        :ARG0 (x24 / enzyme
                              :mod (x25 / wild-type)
                              :ARG1-of (x26 / contrast-01
                                    :ARG2 (x27 / protein
                                          :name (x28 / name :op1 "p110β-RBD")
                                          :xref (x53 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212")))
                              :name (x29 / name :op1 "mef")
                              :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))))
      :snt2 (x44 / contrast-01
            :mod (x33 / and
                  :op1 (x30 / absent-01
                        :ARG1 (x31 / protein
                              :name (x32 / name :op1 "chemokine")
                              :xref (x56 / xref :value "UNIPROT:CCL15_HUMAN" :prob "0.332")))
                  :op2 (x34 / present-02
                        :ARG1 (x36 / concentrate-02
                              :ARG1-of (x35 / low-04)
                              :ARG1 (x37 / small-molecule
                                    :name (x38 / name :op1 "LPA")
                                    :quant (x39 / concentration-quantity
                                          :quant "10"
                                          :unit (x40 / nanomolar))
                                    :xref (x60 / xref :value "PUBCHEM:62707" :prob "9.981436"))
                              :location (x43 / chamber
                                    :ARG1-of (x41 / low-04
                                          :degree (x42 / more))))))
            :ARG2 (x50 / affect-01
                  :ARG1 (x45 / migrate-01
                        :ARG2 (x46 / small-molecule
                              :quant (x47 / percentage-entity :value "1")
                              :name (x48 / name :op1 "FCS")
                              :xref (x59 / xref :value "PUBCHEM:3040269" :prob "11.608116")))
                  :degree (x49 / large)
                  :polarity "-")
            :ARG1-of (x51 / describe-01
                  :ARG0 (x52 / figure :mod "s7"))))


# ::id PMC3690480.150
# ::snt LPA has been identified as important fibroblast chemoattractant in bleomycin-induced lung fibrosis, a well-studied mouse model of human fibrotic lung disease, and was found to be elevated in patients with idiopathic lung fibrosis ( Tager et al., 2008 ).
# ::tok LPA has been identified as important fibroblast chemoattractant in bleomycin @-@ induced lung fibrosis , a well @-@ studied mouse model of human fibrotic lung disease , and was found to be elevated in patients with idiopathic lung fibrosis ( Tager et al. , 2008 ) .
(x22 / elevate-01
      :ARG0 (x3 / identify-01
            :ARG1 (x1 / small-molecule
                  :name (x2 / name :op1 "LPA")
                  :xref (x37 / xref :value "PUBCHEM:62707" :prob "9.981436"))
            :ARG2 (x4 / important)
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "fibroblast" :op2 "chemoattractant"))
            :location (x11 / fibrosis
                  :ARG1-of (x9 / induce-01
                        :ARG0 (x7 / enzyme
                              :name (x8 / name :op1 "bleomycin")
                              :xref (x / xref :value "UNIPROT:BLMH_HUMAN" :prob "0.282")))
                  :mod (x10 / lung)
                  :ARG1-of (x13 / study-01
                        :ARG1-of (x12 / well-09))))
      :ARG1 (x20 / and
            :op1 (x15 / model
                  :mod (x14 / mouse)
                  :topic (x19 / disease
                        :mod (x16 / human)
                        :name (x17 / name :op1 "fibrotic")
                        :mod (x18 / lung)))
            :op2 (x21 / find-01))
      :location (x23 / person
            :ARG0-of (x24 / have-rel-role-91
                  :ARG2 (x25 / patient))
            :ARG0-of (x26 / have-03
                  :ARG1 (x27 / disease
                        :wiki "lung_cancer"
                        :name (x28 / name :op1 "lung" :op2 "fibrosis"))))
      :ARG1-of (x29 / describe-01
            :ARG0 (x30 / publication-91
                  :ARG0 (x33 / and
                        :op1 (x31 / person
                              :name (x32 / name :op1 "Tager"))
                        :op2 (x34 / person
                              :mod (x35 / other)))
                  :time (x36 / date-entity :year "2008"))))


# ::id PMC3690480.151
# ::snt We therefore wondered whether the disruption of p110β activation by LPA in p110β-RBD-DM mice would be sufficient to affect experimental lung fibrosis.
# ::tok We therefore wondered whether the disruption of p110β activation by LPA in p110β-RBD @-@ DM mice would be sufficient to affect experimental lung fibrosis .
(x1 / cause-01
      :ARG1 (x3 / wonder-01
            :ARG0 (x2 / we)
            :ARG1 (x14 / suffice-01
                  :mode "interrogative"
                  :ARG0 (x4 / disrupt-01
                        :ARG1 (x7 / activate-01
                              :ARG1 (x5 / enzyme
                                    :name (x6 / name :op1 "p110β")
                                    :xref (x19 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                              :ARG0 (x8 / small-molecule
                                    :name (x9 / name :op1 "LPA")
                                    :xref (x20 / xref :value "PUBCHEM:62707" :prob "9.981436")))
                        :location (x13 / mouse
                              :mod (x10 / enzyme
                                    :name (x11 / name :op1 "p110β-RBD")
                                    :ARG1-of (x12 / dm)
                                    :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))))
                  :ARG1 (x15 / affect-01
                        :ARG0 (x16 / experiment-01)
                        :ARG1 (x17 / disease
                              :wiki "lung_cancer"
                              :name (x18 / name :op1 "lung" :op2 "fibrosis"))))))


# ::id PMC3690480.152
# ::snt Following a single intratracheal application of bleomycin, a quarter of all wild-type animals died or had to be culled according to local animal welfare regulations, whereas all p110β-RBD-DM mice survived ( Figure 7 C).
# ::tok Following a single intratracheal application of bleomycin , a quarter of all wild @-@ type animals died or had to be culled according to local animal welfare regulations , whereas all p110β-RBD @-@ DM mice survived ( Figure 7 C ) .
(x19 / contrast-01
      :ARG1-of (x1 / follow-01
            :ARG2 (x4 / apply-02
                  :ARG1-of (x2 / single-02
                        :name (x3 / name :op1 "intratracheal"))
                  :ARG1 (x6 / quarter
                        :name (x5 / name :op1 "bleomycin")
                        :part-of (x9 / animal
                              :mod (x7 / all)
                              :mod (x8 / wild-type))
                        :ARG0-of (x11 / or
                              :op1 (x10 / die-01)
                              :op2 (x12 / obligate-01
                                    :ARG2 (x13 / cull-01)))
                        :ARG1-of (x14 / conform-01
                              :ARG2 (x18 / regulate-01
                                    :part-of (x17 / welfare
                                          :ARG1-of (x15 / local-02)
                                          :mod (x16 / animal)))))))
      :ARG2 (x24 / mouse
            :mod (x20 / all)
            :mod (x21 / enzyme
                  :name (x22 / name :op1 "p110β-RBD")
                  :ARG1-of (x23 / dm)
                  :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :ARG0-of (x25 / survive-01))
      :ARG1-of (x26 / describe-01
            :ARG0 (x27 / figure :mod "7")))


# ::id PMC3690480.153
# ::snt Also, wild-type but not p110β-RBD-DM mice significantly lost body weight ( Figure 7 D) upon bleomycin treatment.
# ::tok Also , wild @-@ type but not p110β-RBD @-@ DM mice significantly lost body weight ( Figure 7 D ) upon bleomycin treatment .
(x9 / lose-02
      :mod (x1 / also)
      :ARG0 (x7 / mouse
            :mod (x2 / wild-type)
            :ARG1-of (x3 / contrast-01
                  :ARG2 (x4 / enzyme
                        :name (x5 / name :op1 "p110β-RBD")
                        :ARG1-of (x6 / dm)
                        :xref (x17 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))))
      :ARG1-of (x8 / significant-02)
      :ARG1 (x11 / weight-01
            :ARG1 (x10 / body))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / figure :mod "7d"))
      :time (x16 / treat-04
            :ARG2 (x14 / protein
                  :name (x15 / name :op1 "bleomycin")
                  :xref (x / xref :value "UNIPROT:BLMH_HUMAN" :prob "0.282"))))


# ::id PMC3690480.154
# ::snt Lung weights increased in both groups, but to a significantly lesser extent in p110β-RBD-DM mice ( Figure S7 C).
# ::tok Lung weights increased in both groups , but to a significantly lesser extent in p110β-RBD @-@ DM mice ( Figure S7 C ) .
(x6 / contrast-01
      :ARG1 (x3 / increase-01
            :ARG1 (x1 / disease
                  :wiki "lung_cancer"
                  :name (x2 / name :op1 "Lung" :op2 "weights"))
            :location (x5 / group
                  :mod (x4 / both)))
      :ARG2 (x7 / significant-02
            :ARG1 (x9 / extent
                  :degree (x8 / less)))
      :location (x12 / mouse
            :name (x10 / name :op1 "p110β-RBD")
            :ARG1-of (x11 / dm))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure :mod "s7")))


# ::id PMC3690480.155
# ::snt Histology of lungs 14 days after bleomycin challenge revealed extended areas of fibrotic changes in wild-type animals ( Figure 7 E, hematoxylin and eosin staining [H&E], top), characterized by accumulation of activated, smooth muscle antigen-positive fibroblasts ( Figure 7 E, middle) and deposition of crosslinked collagen fibers ( Figure 7 E, Sirius red, bottom).
# ::tok Histology of lungs 14 days after bleomycin challenge revealed extended areas of fibrotic changes in wild @-@ type animals ( Figure 7 E , hematoxylin and eosin staining [ H&E ] , top ) , characterized by accumulation of activated , smooth muscle antigen @-@ positive fibroblasts ( Figure 7 E , middle ) and deposition of crosslinked collagen fibers ( Figure 7 E , Sirius red , bottom ) .
(x1 / multi-sentence
      :snt1 (x10 / reveal-01
            :ARG0 (x2 / histology
                  :part-of (x3 / lung))
            :ARG1 (x6 / after
                  :quant (x4 / temporal-quantity
                        :quant "14"
                        :unit (x5 / day))
                  :op1 (x9 / challenge-01
                        :ARG1 (x7 / enzyme
                              :name (x8 / name :op1 "bleomycin")
                              :xref (x58 / xref :value "UNIPROT:BLMH_HUMAN" :prob "0.282"))))
            :ARG1 (x12 / area
                  :ARG1-of (x11 / extend-01)
                  :ARG0-of (x15 / change-01
                        :ARG1 (x13 / enzyme
                              :name (x14 / name :op1 "fibrotic")
                              :xref (x59 / xref :value "UNIPROT:FINC_HUMAN" :prob "0.233"))))
            :location (x17 / animal
                  :mod (x16 / wild-type))
            :ARG1-of (x18 / describe-01
                  :ARG0 (x19 / and
                        :part-of (x20 / figure :mod "7")
                        :op1 (x21 / figure :mod "3e")
                        :op2 (x27 / stain-01
                              :ARG2 (x24 / and
                                    :op1 (x22 / small-molecule
                                          :name (x23 / name :op1 "hematoxylin")
                                          :xref (x62 / xref :value "PUBCHEM:10603" :prob "16.740406"))
                                    :op2 (x25 / small-molecule
                                          :name (x26 / name :op1 "eosin")
                                          :xref (x61 / xref :value "PUBCHEM:11048" :prob "9.837358"))))))
            :ARG1-of (x30 / describe-01
                  :mod (x28 / small-molecule
                        :name (x29 / name :op1 "hematoxylin")
                        :xref (x60 / xref :value "PUBCHEM:10603" :prob "16.740406"))
                  :location (x31 / top)))
      :snt2 (x50 / fiber
            :ARG1-of (x32 / characterize-01
                  :ARG2 (x33 / accumulate-01
                        :ARG1 (x34 / activate-01)))
            :ARG0 (x45 / and
                  :op1 (x39 / fibroblast
                        :ARG1-of (x36 / muscle
                              :ARG1-of (x35 / smooth-06))
                        :mod (x37 / antigen
                              :mod (x38 / positive))
                        :ARG1-of (x40 / describe-01
                              :ARG0 (x41 / and
                                    :part-of (x42 / figure :mod "7")
                                    :op1 (x43 / figure :mod "3e")
                                    :op2 (x44 / middle))))
                  :op2 (x46 / deposit-01
                        :ARG1 (x47 / crosslink-00
                              :ARG0 (x48 / protein
                                    :name (x49 / name :op1 "collagen")
                                    :xref (x / xref :value "UNIPROT:COLLAGEN_I_HUMAN" :prob "1.002")))))
            :ARG1-of (x51 / describe-01
                  :ARG0 (x52 / and
                        :part-of (x53 / figure :mod "7")
                        :op1 (x54 / figure :mod "3e")
                        :op2 (x56 / red-02
                              :name (x55 / name :op1 "Sirius"))))
            :mod (x57 / bottom)))


# ::id PMC3690480.156
# ::snt Changes in p110β-RBD-DM mice were milder, with some mice showing almost normal lungs and others showing more limited areas of fibrosis.
# ::tok Changes in p110β-RBD @-@ DM mice were milder , with some mice showing almost normal lungs and others showing more limited areas of fibrosis .
(x1 / and
      :op1 (x2 / change-01
            :ARG1 (x3 / gene
                  :name (x4 / name :op1 "p110β-RBD")
                  :ARG2-of (x5 / dm)
                  :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :mod (x6 / mild
                  :degree (x7 / more)))
      :op2 (x10 / show-01
            :ARG0 (x9 / mouse
                  :quant (x8 / some))
            :ARG1 (x14 / and
                  :ARG1-of (x12 / normal-02
                        :degree (x11 / almost))
                  :mod (x13 / lung)
                  :op2 (x15 / person
                        :mod (x16 / other))
                  :ARG0-of (x17 / show-01
                        :ARG1 (x20 / area
                              :ARG1-of (x19 / limit-01
                                    :degree (x18 / more))
                              :ARG0-of (x21 / fibrosis))))))


# ::id PMC3690480.157
# ::snt Morphometric analysis of multiple nonoverlapping lung areas confirmed the differences between the genotypes: transparent lung areas were significantly reduced ( Figures 7 F and S7 D) and SMA-positive areas significantly increased ( Figure 7 G and S7 E) in wild-type but not p110β-RBD-DM mice when compared to saline controls.
# ::tok Morphometric analysis of multiple nonoverlapping lung areas confirmed the differences between the genotypes : transparent lung areas were significantly reduced ( Figures 7 F and S7 D ) and SMA @-@ positive areas significantly increased ( Figure 7 G and S7 E ) in wild @-@ type but not p110β-RBD @-@ DM mice when compared to saline controls .
(x1 / multi-sentence
      :snt1 (x7 / confirm-01
            :ARG0 (x2 / analyze-01
                  :ARG1 (x6 / area
                        :mod (x5 / lung
                              :mod (x3 / disease
                                    :name (x4 / name :op1 "multiple" :op2 "nonoverlapping")))))
            :ARG1 (x14 / reduce-01
                  :ARG1 (x8 / differ-02
                        :ARG1 (x9 / genotype)
                        :ARG2 (x12 / area
                              :mod (x10 / transparent)
                              :mod (x11 / lung)))
                  :ARG2 (x13 / significant-02))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / and
                        :op1 (x17 / figure :mod "7")
                        :op2 (x18 / figure :mod "s7"))))
      :snt2 (x26 / increase-01
            :ARG0 (x20 / and
                  :op1 (x19 / figure :mod "3d")
                  :op2 (x24 / area
                        :mod (x23 / positive
                              :mod (x21 / protein
                                    :name (x22 / name :op1 "SMA")
                                    :xref (x44 / xref :value "UNIPROT:SMAKA_HUMAN" :prob "0.332")))))
            :ARG2 (x25 / significant-02)
            :ARG1-of (x27 / describe-01
                  :ARG0 (x28 / figure :mod "7"))
            :ARG1 (x31 / and
                  :op1 (x29 / protein
                        :name (x30 / name :op1 "G")
                        :xref (x / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.601"))
                  :op2 (x32 / figure :mod "s7")
                  :op2 (x33 / protein
                        :name (x34 / name :op1 "e-cadherin")
                        :xref (x45 / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703")))
            :location (x40 / mouse
                  :mod (x35 / wild-type)
                  :ARG1-of (x36 / contrast-01
                        :ARG2 (x37 / enzyme
                              :name (x38 / name :op1 "p110β-RBD")
                              :ARG1-of (x39 / dm)
                              :xref (x46 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))))
            :time (x41 / compare-01
                  :ARG2 (x43 / control-01
                        :ARG0 (x42 / saline)))))


# ::id PMC3690480.159
# ::snt RAS Proteins Do Not Regulate the Ubiquitous p110β Isoform
# ::tok RAS Proteins Do Not Regulate the Ubiquitous p110β Isoform
(x3 / regulate-01
      :ARG0 (x2 / protein-family
            :name (x1 / name :op1 "RAS"))
      :polarity "-"
      :ARG1 (x7 / isoform
            :mod (x4 / ubiquity
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))))


# ::id PMC3690480.168
# ::snt RAC and CDC42 Are Isoform-Specific RBD Interactors of p110β
# ::tok RAC and CDC42 Are Isoform @-@ Specific RBD Interactors of p110β
(x10 / interact-01
      :ARG1 (x3 / and
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "RAC")
                  :xref (x13 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :op2 (x4 / protein
                  :name (x5 / name :op1 "CDC42")
                  :xref (x14 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :ARG1-of (x7 / specific-02
            :ARG2 (x6 / isoform))
      :ARG1 (x8 / enzyme
            :name (x9 / name :op1 "RBD"))
      :ARG0 (x11 / protein
            :name (x12 / name :op1 "p110β")
            :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))


# ::id PMC3690480.178
# ::snt RAC/CDC42 Binding to p110β Controls PI3K Activity In Vivo
# ::tok RAC @/@ CDC42 Binding to p110β Controls PI3K Activity In Vivo
(x8 / control-01
      :ARG0 (x5 / bind-01
            :ARG2 (x1 / enzyme
                  :name (x2 / name :op1 "RAC")
                  :xref (x14 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "CDC42")
                  :xref (x13 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
            :ARG2 (x6 / protein
                  :name (x7 / name :op1 "p110β")
                  :xref (x15 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
      :ARG1 (x11 / activity-06
            :ARG0 (x9 / enzyme
                  :name (x10 / name :op1 "PI3K")
                  :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
      :manner (x12 / in-vivo))


# ::id PMC3690480.183
# ::snt GPCRs Activate p110β through its RBD
# ::tok GPCRs Activate p110β through its RBD
(x1 / activate-01
      :ARG1 (x2 / enzyme
            :name (x3 / name :op1 "p110β")
            :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
      :instrument (x4 / protein-segment
            :name (x5 / name :op1 "RBD")))


# ::id PMC3690480.190
# ::snt Dock180/Elmo1 Couples GPCRs to RAC and p110β
# ::tok Dock180 @/@ Elmo1 Couples GPCRs to RAC and p110β
(x6 / couple-01
      :ARG1 (x3 / slash
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "Dock180")
                  :xref (x15 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "Elmo1")
                  :xref (x17 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604")))
      :ARG1 (x7 / enzyme
            :name (x8 / name :op1 "GPCRs")
            :xref (x16 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311"))
      :ARG2 (x11 / and
            :op1 (x9 / enzyme
                  :name (x10 / name :op1 "RAC")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :op2 (x12 / protein
                  :name (x13 / name :op1 "p110β")
                  :xref (x14 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))


# ::id PMC3690480.207
# ::snt Other GTPase Interactors of p110β
# ::tok Other GTPase Interactors of p110β
(x4 / interact-01
      :mod (x1 / other)
      :ARG1 (x2 / enzyme
            :name (x3 / name :op1 "GTPase")
            :xref (x / xref :value "UNIPROT:RAN_HUMAN" :prob "0.312"))
      :ARG0 (x5 / protein
            :name (x6 / name :op1 "p110β")
            :xref (x7 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))


# ::id PMC3690480.226
# ::snt p110β-RBD-DM Mice Are Resistant to Bleomycin-Induced Lung Fibrosis
# ::tok p110β-RBD @-@ DM Mice Are Resistant to Bleomycin @-@ Induced Lung Fibrosis
(x4 / resist-01
      :ARG0 (x1 / gene
            :name (x2 / name :op1 "p110β-RBD")
            :ARG2-of (x3 / dm)
            :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
      :ARG1 (x7 / induce-01
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "Bleomycin")
                  :xref (x10 / xref :value "UNIPROT:BLMH_HUMAN" :prob "0.292"))
            :ARG2 (x8 / disease
                  :wiki "lung_cancer"
                  :name (x9 / name :op1 "Lung" :op2 "Fibrosis"))))


# ::id PMC3690480.239
# ::snt Bleomycin-Induced Lung Fibrosis
# ::tok Bleomycin @-@ Induced Lung Fibrosis
(x3 / induce-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "Bleomycin")
            :xref (x / xref :value "UNIPROT:BLMH_HUMAN" :prob "0.292"))
      :ARG2 (x4 / disease
            :wiki "lung_cancer"
            :name (x5 / name :op1 "Lung" :op2 "Fibrosis")))


# ::id PMC3690480.244
# ::snt Reagents and Antibodies
# ::tok Reagents and Antibodies
(x2 / and
      :op1 (x1 / reagent)
      :op2 (x3 / antibody))


# ::id PMC3690480.249
# ::snt Plasmids and Cloning
# ::tok Plasmids and Cloning
(x2 / and
      :op1 (x1 / plasmid)
      :op2 (x3 / clone-01))


# ::id PMC3690480.278
# ::snt Lipid Kinase Assays
# ::tok Lipid Kinase Assays
(x3 / assay-01
      :ARG1 (x2 / kinase
            :mod (x1 / lipid)))


# ::id PMC3690480.282
# ::snt Lipid Extraction and PIP 3 Quantification
# ::tok Lipid Extraction and PIP 3 Quantification
(x6 / quantify-01
      :ARG0 (x3 / and
            :op1 (x2 / extract-01
                  :ARG1 (x1 / lipid))
            :op2 (x4 / protein
                  :name (x5 / name :op1 "PIP" :op2 "3"))))


# ::id PMC3690480.294
# ::snt Generation of p110β-RBD-DM Mice
# ::tok Generation of p110β-RBD @-@ DM Mice
(x1 / generate-01
      :ARG1 (x5 / mouse
            :mod (x2 / enzyme
                  :name (x3 / name :op1 "p110β-RBD")
                  :ARG1-of (x4 / dm)
                  :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))))


# ::id PMC3690480.308
# ::snt Mouse Embryonic Fibroblasts
# ::tok Mouse Embryonic Fibroblasts
(x3 / fibroblast
      :part-of (x2 / embryo
            :mod (x1 / mouse)))


# ::id PMC3690480.316
# ::snt Cell Culture, Plasmid, and siRNA Transfections
# ::tok Cell Culture , Plasmid , and siRNA Transfections
(x4 / and
      :op1 (x2 / culture-01
            :ARG1 (x1 / cell))
      :op2 (x3 / plasmid)
      :op3 (x7 / transfect-01
            :ARG2 (x5 / nucleic-acid
                  :name (x6 / name :op1 "siRNA"))))


# ::id PMC3690480.333
# ::snt Quantitative Real-Time PCR
# ::tok Quantitative Real @-@ Time PCR
(x3 / react-01
      :mod (x1 / quantitative)
      :mod (x2 / real-time)
      :ARG0 (x4 / polymerase)
      :ARG1-of (x5 / chain-01))


# ::id PMC3690480.337
# ::snt Growth Factor and Lysophospholipid Signaling Assays
# ::tok Growth Factor and Lysophospholipid Signaling Assays
(x2 / and
      :op1 (x1 / growth-factor)
      :op2 (x6 / assay-01
            :ARG1 (x5 / signal-07
                  :ARG0 (x3 / enzyme
                        :name (x4 / name :op1 "Lysophospholipid")
                        :xref (x / xref :value "UNIPROT:PA24A_HUMAN" :prob "0.362")))))


# ::id PMC3690480.353
# ::snt RAC Activation Assay
# ::tok RAC Activation Assay
(x4 / assay-01
      :ARG1 (x3 / activate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "RAC")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))))


# ::id PMC3690480.364
# ::snt Histology and Morphometric Analysis
# ::tok Histology and Morphometric Analysis
(x2 / and
      :op1 (x1 / histology)
      :op2 (x5 / analyze-01
            :ARG1 (x3 / enzyme
                  :name (x4 / name :op1 "Morphometric"))))


# ::id PMC3690480.374
# ::snt Article plus Supplemental Information
# ::tok Article plus Supplemental Information
(x2 / and
      :op1 (x1 / article)
      :op2 (x4 / information
            :ARG2-of (x3 / supplement-01)))


# ::id PMC3690480.375
# ::snt PI 3-Kinase p110β Is Unable to Interact with RAS
# ::tok PI 3 @-@ Kinase p110β Is Unable to Interact with RAS
(x1 / possible-01
      :polarity "-"
      :ARG1 (x6 / interact-01
            :ARG0 (x2 / enzyme
                  :mod (x3 / enzyme
                        :name (x4 / name :op1 "PI" :op2 "3-Kinase"))
                  :name (x5 / name :op1 "p110β")
                  :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
            :ARG1 (x7 / enzyme
                  :name (x8 / name :op1 "RAS")
                  :xref (x9 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))


# ::id PMC3690480.376
# ::snt Purified recombinant, GTPγS-loaded HRAS, KRAS, NRAS, and RAB5 were incubated with lysates from COS7 cells expressing FLAG-p110α/p85 or FLAG-p110β/p85, wild-type (WT), or RBD double mutant (DM).
# ::tok Purified recombinant , GTPγS @-@ loaded HRAS , KRAS , NRAS , and RAB5 were incubated with lysates from COS7 cells expressing FLAG @-@ p110α/p85 or FLAG @-@ p110β/p85 , wild @-@ type ( WT ) , or RBD double mutant ( DM ) .
(x1 / multi-sentence
      :snt1 (x17 / incubate-01
            :ARG1 (x14 / and
                  :op1 (x6 / load-01
                        :ARG2 (x3 / enzyme
                              :ARG1-of (x2 / purify-01)
                              :ARG0-of (x4 / recombine-01)
                              :name (x5 / name :op1 "GTPγS"))
                        :ARG1 (x9 / and
                              :op1 (x7 / enzyme
                                    :name (x8 / name :op1 "HRAS")
                                    :xref (x36 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
                              :op1 (x10 / gene
                                    :name (x11 / name :op1 "KRAS")
                                    :xref (x37 / xref :value "UNIPROT:RASK_HUMAN" :prob "1.003"))
                              :op2 (x12 / gene
                                    :name (x13 / name :op1 "NRAS")
                                    :xref (x38 / xref :value "UNIPROT:RASN_HUMAN" :prob "1.003"))))
                  :op2 (x15 / protein
                        :name (x16 / name :op1 "RAB5")
                        :xref (x39 / xref :value "UNIPROT:RAB5A_HUMAN" :prob "1.003")))
            :ARG2 (x18 / lysate
                  :source (x19 / organism
                        :name (x20 / name :op1 "COS7"))))
      :snt2 (x30 / or
            :op2 (x26 / or
                  :op1 (x21 / cell
                        :ARG3-of (x22 / express-03
                              :ARG2 (x23 / protein
                                    :name (x24 / name :op1 "FLAG")
                                    :xref (x / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                        :name (x25 / name :op1 "p110α/p85"))
                  :op2 (x27 / small-molecule
                        :name (x28 / name :op1 "p110β/p85")
                        :mod (x29 / wild-type)))
            :op3 (x31 / enzyme
                  :name (x32 / name :op1 "RBD")
                  :ARG2-of (x34 / mutate-01
                        :mod (x33 / double)))
            :ARG1-of (x35 / dm)))


# ::id PMC3690480.377
# ::snt Purified recombinant GST-p110α/p85 and GST-p110β/p85 were incubated with lysates from COS7 cells expressing Myc-tagged, constitutively active HRAS, KRAS, NRAS, and RAB5.
# ::tok Purified recombinant GST @-@ p110α/p85 and GST @-@ p110β/p85 were incubated with lysates from COS7 cells expressing Myc @-@ tagged , constitutively active HRAS , KRAS , NRAS , and RAB5 .
(x26 / and
      :op1 (x9 / incubate-01
            :ARG1 (x6 / and
                  :mod (x2 / enzyme
                        :ARG1-of (x1 / purify-01)
                        :ARG0-of (x3 / recombine-01))
                  :op1 (x4 / protein
                        :name (x5 / name :op1 "GST-p110α/p85"))
                  :op2 (x7 / protein
                        :name (x8 / name :op1 "GST-p110β/p85")))
            :ARG2 (x10 / lysate
                  :source (x12 / cell
                        :name (x11 / name :op1 "COS7")
                        :ARG3-of (x13 / express-03
                              :ARG2 (x21 / and
                                    :op1 (x16 / tag-01
                                          :ARG2 (x14 / protein
                                                :name (x15 / name :op1 "Myc")
                                                :xref (x32 / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604")))
                                    :op2 (x19 / enzyme
                                          :ARG0-of (x18 / activity-06
                                                :mod (x17 / constitutive))
                                          :name (x20 / name :op1 "HRAS")
                                          :xref (x31 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
                                    :op1 (x22 / gene
                                          :name (x23 / name :op1 "KRAS")
                                          :xref (x30 / xref :value "UNIPROT:RASK_HUMAN" :prob "1.003"))
                                    :op2 (x24 / gene
                                          :name (x25 / name :op1 "NRAS")
                                          :xref (x / xref :value "UNIPROT:RASN_HUMAN" :prob "1.003")))))))
      :op2 (x27 / protein
            :name (x28 / name :op1 "RAB5")
            :xref (x29 / xref :value "UNIPROT:RAB5A_HUMAN" :prob "1.003")))


# ::id PMC3690480.378
# ::snt Lipids were extracted and PIP 3 levels measured from COS7 cells expressing constitutively active mutants of HRAS, KRAS, NRAS, and RAB5, alone or in combination with p110α/p85 or p110β/p85 (n = 3; mean with SD; one-way ANOVA).
# ::tok Lipids were extracted and PIP 3 levels measured from COS7 cells expressing constitutively active mutants of HRAS , KRAS , NRAS , and RAB5 , alone or in combination with p110α/p85 or p110β/p85 ( n = 3; mean with SD ; one @-@ way ANOVA ) .
(x1 / multi-sentence
      :snt1 (x8 / measure-01
            :ARG1 (x4 / and
                  :op1 (x3 / extract-01
                        :ARG1 (x2 / lipid))
                  :op2 (x7 / level
                        :quant-of (x5 / protein
                              :name (x6 / name :op1 "pip3")
                              :xref (x39 / xref :value "UNIPROT:MTMRC_HUMAN" :prob "0.222"))))
            :ARG2 (x10 / cell
                  :name (x9 / name :op1 "COS7")
                  :ARG3-of (x11 / express-03
                        :ARG2 (x12 / enzyme
                              :ARG0-of (x14 / activity-06
                                    :mod (x13 / constitutive))
                              :ARG2-of (x15 / mutate-01))))
            :ARG1 (x23 / and
                  :op1 (x18 / and
                        :op1 (x16 / enzyme
                              :name (x17 / name :op1 "HRAS")
                              :xref (x41 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
                        :op1 (x19 / gene
                              :name (x20 / name :op1 "KRAS")
                              :xref (x40 / xref :value "UNIPROT:RASK_HUMAN" :prob "1.003"))
                        :op2 (x21 / gene
                              :name (x22 / name :op1 "NRAS")
                              :xref (x38 / xref :value "UNIPROT:RASN_HUMAN" :prob "1.003")))
                  :op2 (x24 / protein
                        :name (x25 / name :op1 "RAB5")
                        :xref (x / xref :value "UNIPROT:RAB5A_HUMAN" :prob "1.003")))
            :manner (x27 / or
                  :op1 (x26 / alone)
                  :op2 (x28 / combine-01
                        :ARG2 (x29 / small-molecule
                              :name (x30 / name :op1 "p110α/p85")))))
      :snt2 (x31 / or
            :op2 (x32 / disease
                  :name (x33 / name :op1 "p110β/p85")
                  :ARG1-of (x34 / mean-01
                        :ARG2 (x35 / name :op1 "SD")))
            :op2 (x36 / way :quant "1")
            :ARG1-of (x37 / anova)))


# ::id PMC3690480.379
# ::snt Alignment of amino acid sequences of all four type I PI3K RBDs (PIK3CB = p110β, PIK3CD = p110δ, PIK3CA = p110α, PIK3CG = p110γ).
# ::tok Alignment of amino acid sequences of all four type I PI3K RBDs ( PIK3CB = p110β, PIK3CD = p110δ, PIK3CA = p110α, PIK3CG = p110γ ) .
(x5 / type-03
      :ARG1 (x1 / align-01
            :ARG1 (x2 / amino-acid
                  :part-of (x4 / cell-line
                        :mod (x3 / all)
                        :quant "4")))
      :ARG2 (x6 / enzyme
            :name (x7 / name
                  :op1 "PI3K"
                  :op2 "RBDs"
                  :op1 "PIK3CB"))
      :ARG1-of (x8 / equal-01
            :ARG1 (x9 / enzyme
                  :name (x10 / name :op1 "p110β," :op2 "PIK3CD"))
            :ARG2 (x13 / mutate-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "p110δ,")
                        :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242"))
                  :ARG2 (x14 / enzyme
                        :name (x15 / name :op1 "=" :op2 "p110γ")))))


# ::id PMC3690480.380
# ::snt Orange represents RAS-binding residues in p110γ, and arrows represent conserved “RAS-binding” residues.
# ::tok Orange represents RAS @-@ binding residues in p110γ, and arrows represent conserved “ RAS @-@ binding ” residues .
(x2 / represent-01
      :ARG0 (x1 / orange)
      :ARG1 (x11 / represent-01
            :ARG0 (x9 / and
                  :op1 (x6 / residue
                        :ARG1-of (x5 / bind-01
                              :ARG2 (x3 / enzyme
                                    :name (x4 / name :op1 "RAS")
                                    :xref (x19 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
                        :location (x7 / cell-line
                              :name (x8 / name :op1 "p110α")))
                  :op2 (x10 / arrow))
            :ARG1 (x18 / residue
                  :ARG1-of (x12 / conserve-01)
                  :ARG0-of (x15 / bind-01
                        :ARG1 (x13 / enzyme
                              :name (x14 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
                  :mod (x16 / amino-acid
                        :name (x17 / name :op1 "”")))))


# ::id PMC3690480.381
# ::snt The two point mutations are shown together with hypothetical interactor residues modeled on the RAS-p110γ interaction.
# ::tok The two point mutations are shown together with hypothetical interactor residues modeled on the RAS @-@ p110γ interaction .
(x3 / show-01
      :ARG1 (x2 / mutate-01
            :quant "2"
            :mod (x1 / point))
      :mod (x4 / together)
      :ARG2 (x9 / model-01
            :ARG1-of (x5 / hypothetical-02
                  :ARG1 (x8 / residue
                        :mod (x6 / amino-acid
                              :name (x7 / name :op1 "interactor"))))
            :ARG1 (x14 / interact-01
                  :ARG1 (x10 / enzyme
                        :name (x11 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :ARG0 (x12 / enzyme
                        :name (x13 / name :op1 "p110γ")
                        :xref (x15 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))))


# ::id PMC3690480.382
# ::snt Lipid kinase assay assessing basal activities of purified recombinant p110β/p85 complexes (n = 3; mean with SEM).
# ::tok Lipid kinase assay assessing basal activities of purified recombinant p110β/p85 complexes ( n = 3; mean with SEM ) .
(x11 / macro-molecular-complex
      :ARG0 (x3 / assay-01
            :mod (x1 / lipid)
            :ARG1 (x2 / kinase)
            :ARG0-of (x4 / assess-01))
      :ARG0-of (x6 / activity-06
            :mod (x5 / basal)
            :ARG0 (x7 / enzyme
                  :ARG1-of (x8 / purify-01)
                  :ARG1-of (x9 / recombine-01)
                  :name (x10 / name :op1 "p110β/p85")))
      :ARG1-of (x12 / sample-01
            :ARG2 (x15 / mean-01
                  :ARG1 (x13 / protein
                        :name (x14 / name :op1 "3;")
                        :xref (x / xref :value "UNIPROT:AB12B_HUMAN" :prob "0.552"))
                  :ARG2 (x16 / enzyme
                        :name (x17 / name :op1 "SEM")
                        :xref (x18 / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.332")))))


# ::id PMC3690480.383
# ::snt A representative lipid kinase assay assessing effect of recombinant Gβγ and a PDGFR-derived phosphotyrosine peptide (pY740) on the activity of purified recombinant p85/p110β-WT and p85/p110β-RBD-DM is shown.
# ::tok A representative lipid kinase assay assessing effect of recombinant Gβγ and a PDGFR @-@ derived phosphotyrosine peptide ( pY740 ) on the activity of purified recombinant p85/p110β-WT and p85/p110β-RBD @-@ DM is shown .
(x1 / multi-sentence
      :snt1 (x15 / activity-06
            :ARG1 (x7 / affect-01
                  :ARG0 (x5 / assay-01
                        :ARG0-of (x2 / represent-01)
                        :mod (x3 / lipid)
                        :ARG1 (x4 / kinase))
                  :ARG1-of (x6 / assess-01)
                  :ARG0 (x11 / and
                        :op1 (x8 / protein
                              :ARG3-of (x9 / recombine-01)
                              :name (x10 / name :op1 "Gβγ")
                              :xref (x / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.58"))
                        :op2 (x12 / protein
                              :name (x13 / name
                                    :op1 "PDGFR-derived"
                                    :op2 "phosphotyrosine"
                                    :op3 "peptide")))
                  :ARG1-of (x14 / py740))
            :ARG0 (x16 / enzyme
                  :ARG1-of (x17 / purify-01)
                  :ARG1-of (x18 / recombine-01)
                  :name (x19 / name :op1 "p85/p110β-WT")))
      :snt2 (x24 / show-01
            :ARG1 (x20 / and
                  :op1 (x21 / enzyme
                        :name (x22 / name :op1 "p85/p110β-RBD"))
                  :op2 (x23 / dm))))


# ::id PMC3690480.384
# ::snt Lipids were extracted and PIP 3 levels measured from COS7 cells expressing wild-type or RBD mutant p110β/p85.
# ::tok Lipids were extracted and PIP 3 levels measured from COS7 cells expressing wild @-@ type or RBD mutant p110β/p85 .
(x17 / mutate-01
      :ARG0 (x3 / and
            :op1 (x2 / extract-01
                  :ARG1 (x1 / lipid))
            :op2 (x7 / measure-01
                  :ARG1 (x6 / level
                        :quant-of (x4 / protein
                              :name (x5 / name :op1 "pip3")
                              :xref (x20 / xref :value "UNIPROT:MTMRC_HUMAN" :prob "0.222"))))
            :source (x9 / cell
                  :name (x8 / name :op1 "COS7")
                  :ARG3-of (x10 / express-03
                        :ARG2 (x14 / or
                              :op1 (x11 / enzyme
                                    :mod (x12 / wild-type)
                                    :name (x13 / name :op1 "braf")
                                    :xref (x / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.671"))
                              :op2 (x15 / enzyme
                                    :name (x16 / name :op1 "RBD"))))))
      :ARG1 (x18 / gene
            :name (x19 / name :op1 "p110β/p85")))


# ::id PMC3690480.385
# ::snt Gβγ, coexpression of Gβ 2 and Gγ 1 ; Myr, myristoylated p110β (n = 3; mean with SEM; paired t test).
# ::tok Gβγ, coexpression of Gβ 2 and Gγ 1 ; Myr , myristoylated p110β ( n = 3; mean with SEM ; paired t test ) .
(x20 / test-01
      :ARG0 (x9 / and
            :op1 (x1 / express-03
                  :ARG2 (x4 / and
                        :op1 (x2 / enzyme
                              :name (x3 / name :op1 "erk2")
                              :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.603"))
                        :op2 (x5 / enzyme
                              :name (x6 / name :op1 "Gγ")
                              :xref (x21 / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.58"))
                        :op2 "1"
                        :op3 (x7 / protein
                              :name (x8 / name :op1 "Myr"))))
            :op2 (x10 / medical-condition
                  :name (x11 / name :op1 "p110β")
                  :ARG1-of (x12 / mean-01
                        :ARG2 (x13 / slash
                              :op1 (x14 / error
                                    :ARG1-of (x15 / standard-02))
                              :op2 (x16 / error :polarity "-"))
                        :ARG1-of (x17 / pair-01))))
      :mod (x18 / cell
            :name (x19 / name :op1 "t")))


# ::id PMC3690480.386
# ::snt See also Figure S1 .
# ::tok See also Figure S1 .
(x1 / see-01
      :mode "imperative"
      :ARG0 (x2 / you)
      :mod (x3 / also)
      :ARG2 (x4 / figure :mod "s1"))


# ::id PMC3690480.387
# ::snt RAC and CDC42 Directly Bind and Active p110β
# ::tok RAC and CDC42 Directly Bind and Active p110β
(x11 / direct-02
      :ARG1 (x6 / bind-01
            :ARG1 (x3 / and
                  :op1 (x1 / enzyme
                        :name (x2 / name :op1 "RAC")
                        :xref (x12 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                  :op2 (x4 / protein
                        :name (x5 / name :op1 "CDC42")
                        :xref (x13 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
            :ARG2 (x7 / and
                  :op1 (x8 / enzyme
                        :ARG0-of (x9 / activity-06)
                        :name (x10 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))))


# ::id PMC3690480.388
# ::snt Table summarizes results from GST pull-down assays ( Figures S1 C and S1D) probing 34 murine RAS subfamily GTPases for GTP-dependent binding of type I PI3K isoforms (−, no binding; +, specific binding; ++, strong binding; +++, very strong binding).
# ::tok Table summarizes results from GST pull @-@ down assays ( Figures S1 C and S1D ) probing 34 murine RAS subfamily GTPases for GTP @-@ dependent binding of type I PI3K isoforms ( −, no binding ; +, specific binding ; ++, strong binding ; +++, very strong binding ) .
(x1 / multi-sentence
      :snt1 (x12 / probe-01
            :ARG0 (x2 / table
                  :ARG1-of (x4 / result-01
                        :ARG2-of (x3 / summarize-01)
                        :ARG2 (x7 / assay-01
                              :ARG1 (x5 / enzyme
                                    :name (x6 / name :op1 "GST")
                                    :xref (x40 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
                        :ARG1-of (x8 / describe-01
                              :ARG0 (x11 / and
                                    :op1 (x9 / figure :mod "s1c")
                                    :op2 (x10 / figure :mod "s1d")))))
            :ARG1 (x13 / person
                  :quant "34"
                  :mod (x14 / organism
                        :name (x15 / name :op1 "muridae"))
                  :name (x16 / name :op1 "RAS")
                  :ARG0-of (x17 / subfamily)
                  :name (x18 / name :op1 "gtpase"))
            :ARG1 (x32 / bind-01
                  :ARG1-of (x22 / bind-01
                        :ARG0 (x21 / depend-01
                              :ARG1 (x19 / small-molecule
                                    :name (x20 / name :op1 "GTP")
                                    :xref (x41 / xref :value "PUBCHEM:6830" :prob "15.470645")))
                        :ARG1 (x27 / isoform
                              :mod (x23 / type
                                    :ord (x24 / ordinal-entity :value "1"))
                              :mod (x25 / enzyme
                                    :name (x26 / name :op1 "PI3K")
                                    :xref (x39 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                        :ARG1-of (x28 / bind-01 :polarity "-")
                        :ARG2 (x29 / protein
                              :name (x30 / name :op1 "igf-1r")
                              :xref (x / xref :value "UNIPROT:IGF1R_HUMAN" :prob "0.593")))
                  :ARG1-of (x31 / specific-02)))
      :snt2 (x35 / bind-01
            :ARG0 (x34 / strong-02
                  :name (x33 / name :op1 "++,"))
            :ARG1-of (x38 / bind-01
                  :ARG1-of (x37 / strong-02
                        :degree (x36 / very)))))


# ::id PMC3690480.389
# ::snt Constitutively active DIRAS1 or DIRAS2 were coexpressed with FLAG-p110β/p85 in COS7 cells.
# ::tok Constitutively active DIRAS1 or DIRAS2 were coexpressed with FLAG @-@ p110β/p85 in COS7 cells .
(x8 / coexpress-01
      :ARG1 (x5 / or
            :ARG0-of (x2 / activity-06
                  :mod (x1 / constitutive))
            :op1 (x3 / protein
                  :name (x4 / name :op1 "DIRAS1")
                  :xref (x / xref :value "UNIPROT:DIRA1_HUMAN" :prob "1.002"))
            :op2 (x6 / enzyme
                  :name (x7 / name :op1 "DIRAS2")
                  :xref (x13 / xref :value "UNIPROT:DIRA2_HUMAN" :prob "1.002")))
      :ARG2 (x9 / protein
            :name (x10 / name :op1 "FLAG" :op2 "p110β/p85"))
      :location (x12 / cell
            :name (x11 / name :op1 "COS7")))


# ::id PMC3690480.390
# ::snt Shown is a lipid kinase assay assessing the effect of purified recombinant, GTPγS-loaded DIRAS1 on p85/p110β (WT) and p85/p110β-RBD-DM (DM) activity (n = 3; mean with SEM).
# ::tok Shown is a lipid kinase assay assessing the effect of purified recombinant , GTPγS @-@ loaded DIRAS1 on p85/p110β ( WT ) and p85/p110β-RBD @-@ DM ( DM ) activity ( n = 3; mean with SEM ) .
(x1 / multi-sentence
      :snt1 (x2 / show-01
            :ARG0 (x5 / assay-01
                  :ARG1 (x3 / lipid)
                  :ARG1 (x4 / kinase)
                  :ARG1-of (x6 / assess-01))
            :ARG1 (x7 / affect-01
                  :ARG0 (x8 / enzyme
                        :ARG1-of (x13 / load-01
                              :ARG2 (x10 / enzyme
                                    :ARG1-of (x9 / purify-01)
                                    :ARG0-of (x11 / recombine-01)
                                    :name (x12 / name :op1 "GTPγS")))
                        :name (x14 / name :op1 "DIRAS1")
                        :xref (x31 / xref :value "UNIPROT:DIRA1_HUMAN" :prob "1.002"))
                  :ARG1 (x18 / and
                        :op1 (x15 / cell-line
                              :name (x16 / name :op1 "p85/p110β")
                              :mod (x17 / wild-type))
                        :op2 (x19 / enzyme
                              :name (x20 / name :op1 "p85/p110β-RBD")
                              :ARG1-of (x21 / dm)))))
      :snt2 (x23 / activity-06
            :ARG1-of (x22 / dm)
            :ARG1-of (x24 / sample-01
                  :ARG2 (x25 / enzyme
                        :name (x26 / name :op1 "3;")
                        :ARG1-of (x27 / mean-01)
                        :xref (x30 / xref :value "UNIPROT:AB12B_HUMAN" :prob "0.552")))
            :ARG2 (x28 / protein
                  :name (x29 / name :op1 "SEM")
                  :xref (x / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.332"))))


# ::id PMC3690480.391
# ::snt Color-coded amino acid sequence alignment of the N termini of indicated small GTPases.
# ::tok Color @-@ coded amino acid sequence alignment of the N termini of indicated small GTPases .
(x8 / indicate-01
      :ARG1 (x5 / align-01
            :ARG1 (x4 / dna-sequence
                  :ARG1-of (x2 / code-01
                        :ARG0 (x1 / color))
                  :mod (x3 / amino-acid))
            :ARG2 (x6 / enzyme
                  :name (x7 / name :op1 "n-ras" :op2 "termini")))
      :ARG0 (x9 / enzyme
            :mod (x10 / small)
            :name (x11 / name :op1 "gtpase")
            :xref (x / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252")))


# ::id PMC3690480.392
# ::snt A square frame highlights the G2 box sequence, and the variant residue (D33 in RAS) is shown in gray.
# ::tok A square frame highlights the G2 box sequence , and the variant residue ( D33 in RAS ) is shown in gray .
(x4 / highlight-01
      :ARG1 (x3 / frame
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "square")))
      :ARG1 (x7 / sequence
            :mod (x5 / thing
                  :name (x6 / name :op1 "G2" :op2 "box")))
      :ARG0-of (x15 / show-01
            :ARG1 (x8 / and
                  :op1 (x10 / residue
                        :mod (x9 / variant)
                        :mod (x11 / amino-acid
                              :mod "33"
                              :name (x12 / name :op1 "aspartic" :op2 "acid"))
                        :mod (x13 / enzyme
                              :name (x14 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
            :ARG0 (x16 / gray-02)))


# ::id PMC3690480.393
# ::snt Purified recombinant, GDP/GTPγS-loaded RHO GTPases were incubated with purified recombinant p110β/p85 (50 nM).
# ::tok Purified recombinant , GDP/GTPγS @-@ loaded RHO GTPases were incubated with purified recombinant p110β/p85 ( 50 nM ) .
(x8 / incubate-01
      :ARG1 (x1 / enzyme
            :ARG1-of (x6 / load-01
                  :ARG2 (x3 / enzyme
                        :ARG1-of (x2 / purify-01)
                        :ARG0-of (x4 / recombine-01)
                        :name (x5 / name :op1 "GDP/GTPγS")))
            :name (x7 / name :op1 "RHO" :op2 "gtpase"))
      :ARG2 (x9 / enzyme
            :ARG1-of (x10 / purify-01)
            :ARG1-of (x11 / recombine-01)
            :name (x12 / name :op1 "p110β/p85")
            :quant (x13 / concentration-quantity
                  :quant "50"
                  :unit (x14 / nanomolar))))


# ::id PMC3690480.394
# ::snt Top: representative experiment; left: quantification (n = 2; mean with SEM); right: 3 [H]-GTP uptake of GTPase preparations (n = 2; mean with SEM).
# ::tok Top : representative experiment ; left : quantification ( n = 2; mean with SEM ) ; right : 3 [ H ] -GTP uptake of GTPase preparations ( n = 2; mean with SEM ) .
(x1 / and
      :op1 (x7 / quantify-01
            :ARG1 (x2 / and
                  :op1 (x4 / represent-01
                        :location (x3 / top)
                        :mod (x5 / experiment-01))
                  :op2 (x6 / left-20))
            :ARG1-of (x8 / sample-01
                  :ARG2 (x9 / enzyme
                        :name (x10 / name :op1 "2;")
                        :ARG1-of (x11 / mean-01)
                        :xref (x / xref :value "UNIPROT:FKRP_HUMAN" :prob "0.552")))
            :ARG2 (x12 / protein
                  :name (x13 / name :op1 "SEM")
                  :xref (x29 / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.332")))
      :op2 (x20 / take-up-13
            :ARG1-of (x14 / right-04 :mod "3")
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / enzyme
                        :name (x17 / name :op1 "h-ras")
                        :xref (x30 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601")))
            :ARG1 (x18 / enzyme
                  :name (x19 / name :op1 "-GTP")
                  :xref (x28 / xref :value "UNIPROT:GTPB1_HUMAN" :prob "0.202"))
            :ARG2 (x21 / small-molecule
                  :name (x22 / name :op1 "GTPase")
                  :xref (x32 / xref :value "PUBCHEM:71464389" :prob "9.633067"))
            :ARG1 (x23 / medical-condition
                  :name (x24 / name :op1 "preparations")
                  :ARG1-of (x25 / mean-01))
            :ARG2 (x26 / small-molecule
                  :name (x27 / name :op1 "SEM")
                  :xref (x31 / xref :value "PUBCHEM:2724271" :prob "10.871458"))))


# ::id PMC3690480.395
# ::snt Purified recombinant GDP/GTPγS-loaded RAC1 and CDC42 were incubated with lysates from COS7 cells expressing FLAG-tagged p110α/p85, p110β/p85, p110γ/p101, and p110δ/p85.
# ::tok Purified recombinant GDP/GTPγS @-@ loaded RAC1 and CDC42 were incubated with lysates from COS7 cells expressing FLAG @-@ tagged p110α/p85 , p110β/p85 , p110γ/p101 , and p110δ/p85 .
(x1 / multi-sentence
      :snt1 (x12 / incubate-01
            :ARG1 (x6 / load-01
                  :ARG1 (x3 / enzyme
                        :ARG1-of (x2 / purify-01)
                        :ARG0-of (x4 / recombine-01)
                        :name (x5 / name :op1 "GDP/GTPγS"))
                  :ARG2 (x9 / and
                        :op1 (x7 / protein
                              :name (x8 / name :op1 "RAC1")
                              :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                        :op2 (x10 / protein
                              :name (x11 / name :op1 "CDC42")
                              :xref (x30 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))
            :ARG2 (x13 / lysate
                  :source (x15 / cell
                        :name (x14 / name :op1 "COS7"))))
      :snt2 (x26 / and
            :op1 (x16 / express-03
                  :ARG2 (x17 / protein
                        :ARG1-of (x20 / tag-01
                              :ARG2 (x18 / protein
                                    :name (x19 / name :op1 "FLAG")
                                    :xref (x29 / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                        :name (x21 / name :op1 "p110α/p85")))
            :op2 (x22 / enzyme
                  :name (x23 / name :op1 "p110β/p85"))
            :op3 (x24 / protein
                  :name (x25 / name :op1 "p110γ/p101"))
            :op2 (x27 / enzyme
                  :name (x28 / name :op1 "p110δ/p85"))))


# ::id PMC3690480.396
# ::snt Purified recombinant GTPγS-loaded RAC1/CDC42 (1 μM) were added to purified recombinant p110β/p85, and lipid kinase activity was assessed in vitro.
# ::tok Purified recombinant GTPγS @-@ loaded RAC1 @/@ CDC42 ( 1 μM ) were added to purified recombinant p110β/p85 , and lipid kinase activity was assessed in vitro .
(x20 / assess-01
      :ARG0 (x5 / load-01
            :ARG2 (x1 / enzyme
                  :ARG1-of (x2 / purify-01)
                  :ARG1-of (x3 / recombine-01)
                  :name (x4 / name :op1 "GTPγS")))
      :ARG1 (x19 / activity-06
            :ARG0 (x17 / and
                  :op1 (x6 / protein
                        :name (x7 / name :op1 "RAC1")
                        :xref (x22 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x12 / add-02
                        :ARG1 (x8 / protein
                              :name (x9 / name :op1 "CDC42")
                              :quant (x10 / concentration-quantity
                                    :quant "1"
                                    :unit (x11 / micromolar))
                              :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
                        :ARG2 (x13 / enzyme
                              :ARG1-of (x14 / purify-01)
                              :ARG1-of (x15 / recombine-01)
                              :name (x16 / name :op1 "p110β/p85")))
                  :op3 (x18 / lipid)))
      :manner (x21 / in-vitro))


# ::id PMC3690480.397
# ::snt pTyr, phosphotyrosine peptide (pY740, 10 μM); Δp85, truncated p85, schematic in Figure 3 C (n = 2; mean with SD).
# ::tok pTyr , phosphotyrosine peptide ( pY740 , 10 μM ) ; Δp85 , truncated p85 , schematic in Figure 3 C ( n = 2; mean with SD ) .
(x1 / and
      :op1 (x4 / peptide
            :mod (x2 / enzyme
                  :name (x3 / name :op1 "pTyr"))
            :ARG1-of (x5 / small-molecule
                  :name (x6 / name :op1 "pY740")
                  :quant (x7 / concentration-quantity
                        :quant "10"
                        :unit (x8 / micromolar))))
      :op2 (x10 / truncate-01
            :name (x9 / name :op1 "Δp85")
            :ARG1 (x11 / protein
                  :name (x12 / name :op1 "p85")
                  :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))
            :ARG0-of (x13 / schematic
                  :location (x14 / figure :mod "3")
                  :name (x15 / name :op1 "C"))
            :ARG1-of (x16 / mean-01
                  :ARG2 (x17 / name :op1 "SD"))))


# ::id PMC3690480.398
# ::snt Increasing concentrations of purified recombinant GTPγS-loaded RAC1/CDC42 were added to purified recombinant p110β/Δp85, and lipid kinase activity was assessed in vitro (n = 3; mean with SEM).
# ::tok Increasing concentrations of purified recombinant GTPγS @-@ loaded RAC1 @/@ CDC42 were added to purified recombinant p110β/Δp85 , and lipid kinase activity was assessed in vitro ( n = 3; mean with SEM ) .
(x17 / and
      :op1 (x12 / add-02
            :ARG2 (x1 / enzyme
                  :ARG1-of (x8 / load-01
                        :ARG2 (x3 / concentrate-02
                              :ARG1-of (x2 / increase-01)
                              :ARG1 (x5 / enzyme
                                    :ARG1-of (x4 / purify-01)
                                    :ARG0-of (x6 / recombine-01)
                                    :name (x7 / name :op1 "GTPγS"))))
                  :name (x9 / name :op1 "RAC1")
                  :xref (x30 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :ARG1 (x10 / protein
                  :name (x11 / name :op1 "CDC42")
                  :xref (x31 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
            :ARG2 (x13 / enzyme
                  :ARG1-of (x14 / purify-01)
                  :ARG1-of (x15 / recombine-01)
                  :name (x16 / name :op1 "p110β/Δp85")))
      :op2 (x21 / assess-01
            :ARG1 (x18 / lipid
                  :ARG1-of (x20 / activity-06
                        :ARG0 (x19 / kinase)))
            :manner (x22 / in-vitro))
      :ARG1-of (x23 / sample-01
            :ARG2 (x26 / mean-01
                  :ARG1 (x24 / protein
                        :name (x25 / name :op1 "3;")
                        :xref (x / xref :value "UNIPROT:AB12B_HUMAN" :prob "0.552"))
                  :ARG2 (x27 / enzyme
                        :name (x28 / name :op1 "SEM")
                        :xref (x29 / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.332")))))


# ::id PMC3690480.399
# ::snt Lipids were extracted and PIP 3 levels measured from COS7 cells expressing constitutively active RAC1 or CDC42, alone or in combination with FLAG-p110β/p85.
# ::tok Lipids were extracted and PIP 3 levels measured from COS7 cells expressing constitutively active RAC1 or CDC42 , alone or in combination with FLAG @-@ p110β/p85 .
(x7 / measure-01
      :ARG1 (x3 / and
            :op1 (x2 / extract-01
                  :ARG1 (x1 / lipid))
            :op2 (x6 / level
                  :quant-of (x4 / protein
                        :name (x5 / name :op1 "pip3")
                        :xref (x25 / xref :value "UNIPROT:MTMRC_HUMAN" :prob "0.222"))))
      :ARG2 (x10 / cell
            :mod (x8 / protein
                  :name (x9 / name :op1 "COS7")
                  :xref (x / xref :value "UNIPROT:COSA1_HUMAN" :prob "0.202"))
            :ARG3-of (x11 / express-03
                  :ARG2 (x16 / or
                        :op1 (x12 / enzyme
                              :ARG0-of (x14 / activity-06
                                    :mod (x13 / constitutive))
                              :name (x15 / name :op1 "RAC1")
                              :xref (x26 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                        :op2 (x20 / or
                              :op1 (x17 / protein
                                    :name (x18 / name :op1 "CDC42")
                                    :mod (x19 / alone)
                                    :xref (x27 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
                              :op2 (x21 / combine-01
                                    :ARG2 (x22 / small-molecule
                                          :name (x23 / name :op1 "FLAG")
                                          :xref (x28 / xref :value "PUBCHEM:122124" :prob "11.354702"))))))
            :name (x24 / name :op1 "p110β/p85")))


# ::id PMC3690480.400
# ::snt Gβγ, coexpression of Gβ 2 and Gγ 1 ; Myr, myristoylated p110β (n = 2; mean with SD).
# ::tok Gβγ, coexpression of Gβ 2 and Gγ 1 ; Myr , myristoylated p110β ( n = 2; mean with SD ) .
(x9 / and
      :op1 (x1 / express-03
            :ARG2 (x4 / and
                  :op1 (x2 / enzyme
                        :name (x3 / name :op1 "erk2")
                        :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.603"))
                  :op2 (x5 / enzyme
                        :name (x6 / name :op1 "Gγ")
                        :xref (x14 / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.58"))
                  :op2 "1"
                  :op3 (x7 / protein
                        :name (x8 / name :op1 "Myr"))))
      :op2 (x10 / medical-condition
            :name (x11 / name :op1 "p110β")
            :ARG1-of (x12 / mean-01
                  :ARG2 (x13 / name :op1 "SD"))))


# ::id PMC3690480.401
# ::snt Western blots show expression levels of FLAG-p110β and Myc-tagged GTPases.
# ::tok Western blots show expression levels of FLAG @-@ p110β and Myc @-@ tagged GTPases .
(x8 / and
      :op1 (x1 / immunoblot-01
            :ARG0-of (x2 / show-01
                  :ARG1 (x3 / level
                        :degree-of (x4 / express-03
                              :ARG2 (x5 / protein
                                    :name (x6 / name :op1 "FLAG")
                                    :xref (x15 / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))))
            :name (x7 / name :op1 "p110β"))
      :op2 (x9 / enzyme
            :ARG1-of (x12 / tag-01
                  :ARG2 (x10 / protein
                        :name (x11 / name :op1 "Myc")
                        :xref (x / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604")))
            :name (x13 / name :op1 "gtpase")
            :xref (x14 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252")))


# ::id PMC3690480.402
# ::snt See also Figure S2 .
# ::tok See also Figure S2 .
(x1 / see-01
      :mode "imperative"
      :ARG0 (x2 / you)
      :mod (x3 / also)
      :ARG2 (x4 / figure :mod "s2"))


# ::id PMC3690480.403
# ::snt RAC and CDC42 Are Interactors of the p110β RAS-Binding Domain
# ::tok RAC and CDC42 Are Interactors of the p110β RAS @-@ Binding Domain
(x6 / interact-01
      :ARG1 (x3 / and
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "RAC")
                  :xref (x12 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :op2 (x4 / protein
                  :name (x5 / name :op1 "CDC42")
                  :xref (x13 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :ARG0 (x8 / protein-segment
            :name (x7 / name :op1 "p110β")
            :ARG0-of (x11 / bind-01
                  :ARG1 (x9 / enzyme
                        :name (x10 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))


# ::id PMC3690480.404
# ::snt Purified recombinant p85/p110β (WT) and p85/p110β-RBD-DM (DM) protein complexes, at the indicated concentrations, were incubated with GST-tagged, GDP/GTPγS-loaded RAC1 and CDC42.
# ::tok Purified recombinant p85/p110β ( WT ) and p85/p110β-RBD @-@ DM ( DM ) protein complexes , at the indicated concentrations , were incubated with GST @-@ tagged , GDP/GTPγS @-@ loaded RAC1 and CDC42 .
(x1 / multi-sentence
      :snt1 (x7 / and
            :op1 (x2 / enzyme
                  :ARG1-of (x3 / purify-01)
                  :ARG1-of (x4 / recombine-01)
                  :name (x5 / name :op1 "p85/p110β")
                  :mod (x6 / wild-type))
            :op2 (x8 / enzyme
                  :name (x9 / name :op1 "p85/p110β-RBD")
                  :ARG1-of (x10 / dm)))
      :snt2 (x13 / macro-molecular-complex
            :ARG1-of (x11 / dm)
            :ARG0 (x12 / protein)
            :condition (x16 / incubate-01
                  :ARG1 (x15 / concentrate-02
                        :ARG1-of (x14 / indicate-01))
                  :ARG2 (x25 / and
                        :op1 (x17 / enzyme
                              :ARG1-of (x23 / load-01
                                    :ARG2 (x18 / protein
                                          :ARG1-of (x21 / tag-01
                                                :ARG2 (x19 / protein
                                                      :name (x20 / name :op1 "GST")
                                                      :xref (x28 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
                                          :name (x22 / name :op1 "GDP/GTPγS")))
                              :name (x24 / name :op1 "RAC1")
                              :xref (x29 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                        :op2 (x26 / protein
                              :name (x27 / name :op1 "CDC42")
                              :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))))


# ::id PMC3690480.405
# ::snt Purified recombinant GTPγS-loaded RAC1/CDC42 (1 μM) were added to purified recombinant p85/p110β-WT or p85/p110β-RBD-DM in lipid kinase assays (n = 2; mean with SD).
# ::tok Purified recombinant GTPγS @-@ loaded RAC1 @/@ CDC42 ( 1 μM ) were added to purified recombinant p85/p110β-WT or p85/p110β-RBD @-@ DM in lipid kinase assays ( n = 2; mean with SD ) .
(x1 / multi-sentence
      :snt1 (x18 / or
            :op1 (x13 / add-02
                  :ARG1-of (x6 / load-01
                        :ARG2 (x2 / enzyme
                              :ARG1-of (x3 / purify-01)
                              :ARG1-of (x4 / recombine-01)
                              :name (x5 / name :op1 "GTPγS")))
                  :ARG1 (x7 / protein
                        :name (x8 / name :op1 "RAC1")
                        :mod (x9 / protein
                              :name (x10 / name :op1 "CDC42")
                              :quant (x11 / concentration-quantity
                                    :quant "1"
                                    :unit (x12 / micromolar))
                              :xref (x31 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
                        :xref (x32 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :ARG2 (x14 / enzyme
                        :ARG1-of (x15 / purify-01)
                        :ARG1-of (x16 / recombine-01)
                        :name (x17 / name :op1 "p85/p110β-WT")))
            :op2 (x19 / enzyme
                  :name (x20 / name :op1 "p85/p110β-RBD")
                  :ARG1-of (x21 / dm)))
      :snt2 (x22 / lipid
            :op2 (x24 / assay-01
                  :ARG1 (x23 / kinase))
            :ARG1-of (x25 / sample-01
                  :ARG2 (x28 / mean-01
                        :ARG1 (x26 / protein
                              :name (x27 / name :op1 "2;")
                              :xref (x / xref :value "UNIPROT:FKRP_HUMAN" :prob "0.552"))
                        :ARG2 (x29 / small-molecule
                              :name (x30 / name :op1 "SD")
                              :xref (x33 / xref :value "PUBCHEM:3039" :prob "8.722122"))))))


# ::id PMC3690480.406
# ::snt Data are part of experiment shown in Figure 2 G.
# ::tok Data are part of experiment shown in Figure 2 G .
(x2 / participate-01
      :ARG0 (x1 / data)
      :ARG1 (x3 / experiment-01
            :ARG1 (x4 / show-01
                  :ARG0 (x5 / figure :mod "2g"))))


# ::id PMC3690480.407
# ::snt Purified recombinant p110β/p85 protein complexes were incubated with GST-tagged, GDP/GTPγS-loaded RAC1, CDC42 and RAB5.
# ::tok Purified recombinant p110β/p85 protein complexes were incubated with GST @-@ tagged , GDP/GTPγS @-@ loaded RAC1 , CDC42 and RAB5 .
(x6 / incubate-01
      :ARG1 (x5 / macro-molecular-complex
            :ARG1 (x4 / protein
                  :ARG1-of (x1 / purify-01)
                  :ARG3-of (x2 / recombine-01
                        :name (x3 / name :op1 "p110β/p85"))))
      :ARG2 (x7 / enzyme
            :name (x8 / name :op1 "GST")
            :ARG1-of (x9 / tag-01
                  :ARG2 (x12 / load-01
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "GDP/GTPγS")))
                  :ARG0 (x13 / protein
                        :name (x14 / name :op1 "RAC1")
                        :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :ARG1 (x17 / and
                        :op1 (x15 / protein
                              :name (x16 / name :op1 "CDC42")
                              :xref (x20 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
                        :op2 (x18 / protein
                              :name (x19 / name :op1 "RAB5")
                              :xref (x21 / xref :value "UNIPROT:RAB5A_HUMAN" :prob "1.003"))))
            :xref (x22 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))


# ::id PMC3690480.408
# ::snt Lanes 1/2: p85/p110β-WT; lanes 3/4: Δp85/p110β-WT; lanes 5/6: p85/p110β-RBD-DM.
# ::tok Lanes 1 @/@ 2: p85/p110β-WT ; lanes 3 @/@ 4: Δp85/p110β-WT ; lanes 5 @/@ 6: p85/p110β-RBD @-@ DM .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op1 (x3 / lane
                  :mod "1"
                  :mod (x4 / slash)
                  :mod "2"
                  :name (x5 / name :op1 "p85/p110β-WT"))
            :op2 (x6 / lane
                  :mod "3"
                  :mod (x7 / slash)
                  :mod "4"
                  :name (x8 / name :op1 "Δp85/p110β-WT")))
      :snt2 (x10 / slash
            :op1 (x9 / lane :mod "5")
            :op2 (x11 / enzyme
                  :name (x12 / name :op1 "p85/p110β-RBD")
                  :ARG1-of (x13 / dm))))


# ::id PMC3690480.409
# ::snt Δp85 is detailed in the schematic.
# ::tok Δp85 is detailed in the schematic .
(x3 / detail-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "Δp85")
            :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "0.693"))
      :location (x4 / schematic))


# ::id PMC3690480.410
# ::snt Amino acid alignment of type I PI3K RBDs with secondary structure elements of p110β (H, helix; E, β sheet) and color coding to illustrate effect of residue mutation on p110β binding to RAC1/CDC42.
# ::tok Amino acid alignment of type I PI3K RBDs with secondary structure elements of p110β ( H , helix ; E, β sheet ) and color coding to illustrate effect of residue mutation on p110β binding to RAC1/CDC42 .
(x23 / illustrate-01
      :ARG0 (x20 / and
            :op1 (x11 / element
                  :mod (x1 / amino-acid)
                  :ARG1-of (x2 / align-01
                        :ARG1 (x3 / disease
                              :mod (x4 / type
                                    :ord (x5 / ordinal-entity :value "1"))
                              :mod (x6 / enzyme
                                    :name (x7 / name :op1 "PI3K")
                                    :xref (x32 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                              :name (x8 / name :op1 "RBDs"))
                        :ARG2 (x10 / structure
                              :mod (x9 / secondary)))
                  :part-of (x12 / enzyme
                        :name (x13 / name :op1 "p110β")
                        :xref (x33 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                  :example (x16 / and
                        :op1 (x14 / enzyme
                              :name (x15 / name :op1 "h-ras")
                              :xref (x34 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601"))
                        :op1 (x17 / helix)
                        :op2 (x19 / sheet
                              :name (x18 / name :op1 "β"))))
            :op2 (x22 / code-01
                  :ARG0 (x21 / color)))
      :ARG1 (x24 / affect-01
            :ARG0 (x26 / mutate-01
                  :ARG1 (x25 / residue))
            :ARG1 (x29 / bind-01
                  :ARG1 (x27 / enzyme
                        :name (x28 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                  :ARG2 (x30 / protein
                        :name (x31 / name :op1 "RAC1/CDC42")))))


# ::id PMC3690480.411
# ::snt Green, unaltered binding; red, reduced/abolished binding; blue, unstable protein; yellow, p110β-RBD-DM residues; black, not mutated ( Figures S3 A and S3B for pull-down assays and table).
# ::tok Green , unaltered binding ; red , reduced @/@ abolished binding ; blue , unstable protein ; yellow , p110β-RBD @-@ DM residues ; black , not mutated ( Figures S3 A and S3B for pull @-@ down assays and table ) .
(x1 / multi-sentence
      :snt1 (x4 / bind-01
            :ARG1-of (x2 / green-02)
            :ARG1-of (x3 / possible-01))
      :snt2 (x11 / stable-03
            :ARG1-of (x5 / red-02)
            :ARG1 (x6 / reduce-01
                  :ARG1 (x7 / and
                        :op1 (x8 / abolish-01
                              :ARG1 (x9 / bind-01))
                        :op2 (x10 / blue)))
            :op4 (x12 / protein)
            :ARG1-of (x13 / yellow-02)
            :ARG0-of (x16 / residue
                  :name (x14 / name :op1 "p110β-RBD")
                  :ARG1-of (x15 / dm)
                  :ARG1-of (x17 / black-04))
            :ARG1-of (x18 / mutate-01
                  :polarity "-"
                  :ARG1-of (x19 / describe-01
                        :ARG0 (x20 / and
                              :op1 (x21 / figure :mod "s3")
                              :op2 (x22 / figure :mod "s3b")))
                  :ARG2 (x26 / and
                        :op1 (x25 / assay-01
                              :ARG1 (x23 / enzyme
                                    :name (x24 / name :op1 "gst")
                                    :xref (x / xref :value "UNIPROT:SO6A1_HUMAN" :prob "0.602")))
                        :op2 (x27 / table :mod "1")))))


# ::id PMC3690480.412
# ::snt Binding of purified recombinant GTPγS-loaded RAC1 and CDC42 to purified recombinant p110β/Δ85 in solution was studied.
# ::tok Binding of purified recombinant GTPγS @-@ loaded RAC1 and CDC42 to purified recombinant p110β/Δ85 in solution was studied .
(x17 / study-01
      :ARG0 (x6 / load-01
            :ARG2 (x1 / bind-01
                  :ARG2 (x3 / enzyme
                        :ARG1-of (x2 / purify-01)
                        :ARG0-of (x4 / recombine-01)
                        :name (x5 / name :op1 "GTPγS"))))
      :ARG1 (x16 / solve-01
            :ARG1 (x9 / and
                  :op1 (x7 / protein
                        :name (x8 / name :op1 "RAC1")
                        :xref (x18 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x10 / protein
                        :name (x11 / name :op1 "CDC42")
                        :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
            :ARG2 (x12 / enzyme
                  :ARG1-of (x13 / purify-01)
                  :ARG1-of (x14 / recombine-01)
                  :name (x15 / name :op1 "p110β/Δ85"))))


# ::id PMC3690480.413
# ::snt Top: differential power over time; bottom: thermal energy (H) over molar ratio.
# ::tok Top : differential power over time ; bottom : thermal energy ( H ) over molar ratio .
(x1 / and
      :op1 (x4 / power
            :location (x2 / top)
            :mod (x3 / differential)
            :mod (x5 / over
                  :op1 (x6 / time)))
      :op2 (x9 / energy
            :location (x7 / bottom)
            :mod (x8 / thermal)
            :ARG1-of (x15 / ratio
                  :ARG0 (x12 / overexpress-01
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "h-ras")
                              :xref (x / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601")))
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "molar")))))


# ::id PMC3690480.414
# ::snt Numbers represent K d values determined in independent experiments.
# ::tok Numbers represent K d values determined in independent experiments .
(x6 / determine-01
      :ARG0 (x2 / represent-01
            :ARG0 (x1 / number)
            :ARG1 (x5 / value
                  :mod (x3 / enzyme
                        :name (x4 / name :op1 "k-ras" :op2 "d"))))
      :location (x8 / experiment
            :quant "3"
            :ARG0-of (x7 / depend-01 :polarity "-")))


# ::id PMC3690480.415
# ::snt n.b., no binding.
# ::tok n.b . , no binding .
(x3 / bind-01
      :ARG0 (x1 / person
            :wiki "-"
            :name (x2 / name :op1 "n.b"))
      :polarity "-")


# ::id PMC3690480.416
# ::snt See also Figure S3 .
# ::tok See also Figure S3 .
(x1 / see-01
      :mode "imperative"
      :ARG0 (x2 / you)
      :mod (x3 / also)
      :ARG1-of (x4 / describe-01
            :ARG0 (x5 / figure :mod "s3")))


# ::id PMC3690480.417
# ::snt RAC/CDC42 Binding to p110β Regulates PI3K Activity In Vivo
# ::tok RAC @/@ CDC42 Binding to p110β Regulates PI3K Activity In Vivo
(x8 / regulate-01
      :ARG0 (x5 / bind-01
            :ARG2 (x1 / enzyme
                  :name (x2 / name :op1 "RAC")
                  :xref (x14 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "CDC42")
                  :xref (x13 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
            :ARG2 (x6 / protein
                  :name (x7 / name :op1 "p110β")
                  :xref (x15 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
      :ARG1 (x11 / activity-06
            :ARG0 (x9 / enzyme
                  :name (x10 / name :op1 "PI3K")
                  :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
            :manner (x12 / in-vivo)))


# ::id PMC3690480.418
# ::snt Offspring from HET × HET crosses was genotyped at 2 weeks of age (n = 389; p < 0.02, chi-square analysis).
# ::tok Offspring from HET × HET crosses was genotyped at 2 weeks of age ( n = 389; p
(x9 / age-01
      :ARG1 (x1 / offspring
            :source (x3 / person
                  :name (x2 / name :op1 "HET")
                  :quant "30000"
                  :ARG0-of (x4 / cross-01)))
      :ARG2 (x5 / small-molecule
            :name (x6 / name :op1 "genotyped")
            :quant (x7 / temporal-quantity
                  :quant "2"
                  :unit (x8 / week)))
      :ARG1-of (x10 / sample-01
            :ARG2 (x13 / phosphorylate-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "389;")))))


# ::id PMC3690480.419
# ::snt Newborn pups from HET × HET crosses were collected on the morning of birth, weighed, and genotyped (n = 31; mean ±SEM; p = 0.011, t test).
# ::tok Newborn pups from HET × HET crosses were collected on the morning of birth , weighed , and genotyped ( n = 31; mean ±SEM ; p = 0.011 , t test ) .
(x20 / test-01
      :ARG1-of (x1 / new-01
            :name (x2 / name :op1 "pups")
            :source (x9 / and
                  :op1 (x5 / collect-01
                        :ARG0 (x3 / person
                              :quant "30000"
                              :ARG0-of (x4 / cross-01))
                        :ARG1 (x7 / bear-02
                              :ARG1 (x6 / morning)))
                  :op2 (x8 / weigh-01)
                  :op2 (x10 / medical-condition
                        :name (x11 / name :op1 "genotyped")
                        :ARG1-of (x14 / mean-01
                              :ARG2 (x12 / small-molecule
                                    :name (x13 / name :op1 "31;")
                                    :xref (x22 / xref :value "PUBCHEM:85846374" :prob "7.115437"))))
                  :op3 (x15 / enzyme
                        :name (x16 / name :op1 "±SEM")
                        :xref (x / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.292"))
                  :op4 (x17 / phosphorylate-01 :quant "0.011")))
      :ARG1 (x18 / protein
            :name (x19 / name :op1 "t")
            :xref (x21 / xref :value "UNIPROT:BRAC_HUMAN" :prob "0.602")))


# ::id PMC3690480.420
# ::snt Weights of adult homozygous p110β-RBD-DM mice (12–30 weeks old) were compared to same-cage wild-type littermates (n = 39; mean ±SEM; paired t test).
# ::tok Weights of adult homozygous p110β-RBD @-@ DM mice ( 12–30 weeks old ) were compared to same @-@ cage wild @-@ type littermates ( n = 39; mean ±SEM ; paired t test ) .
(x9 / compare-01
      :ARG0 (x3 / homozygous
            :mod (x1 / weight)
            :mod (x2 / adult))
      :ARG2 (x7 / mouse
            :mod (x4 / enzyme
                  :name (x5 / name :op1 "p110β-RBD")
                  :ARG1-of (x6 / dm)
                  :xref (x24 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :mod (x8 / old))
      :ARG1 (x13 / littermate
            :ARG1-of (x10 / same-01
                  :ARG2 (x11 / cage))
            :mod (x12 / wild-type)
            :ARG1-of (x14 / sample-01
                  :ARG2 (x17 / mean-01
                        :ARG1 (x15 / protein
                              :name (x16 / name :op1 "39;"))
                        :ARG2 (x18 / protein
                              :name (x19 / name :op1 "±SEM")
                              :xref (x25 / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.292")))))
      :ARG1-of (x20 / pair-01
            :ARG1 (x23 / test-01
                  :ARG1 (x21 / enzyme
                        :name (x22 / name :op1 "t")
                        :xref (x / xref :value "UNIPROT:BRAC_HUMAN" :prob "0.602")))))


# ::id PMC3690480.421
# ::snt Early passage primary MEFs were grown in culture following a modified 3T3 protocol (n = 2 per genotype).
# ::tok Early passage primary MEFs were grown in culture following a modified 3T3 protocol ( n = 2 per genotype ) .
(x6 / grow-01
      :ARG1 (x3 / cell
            :mod (x2 / passage
                  :mod (x1 / early))
            :mod (x4 / primary)
            :name (x5 / name :op1 "mef"))
      :location (x7 / culture
            :ARG1-of (x8 / follow-01
                  :ARG2 (x12 / protocol
                        :ARG1-of (x9 / modify-01
                              :ARG1 (x10 / enzyme
                                    :name (x11 / name :op1 "3T3"))))))
      :ARG1-of (x13 / sample-01
            :quant "2"
            :ARG1-of (x14 / rate-entity-91
                  :ARG2 (x15 / genotype))))


# ::id PMC3690480.422
# ::snt Population doubling rate was calculated as PDR = log ( n ( d a y 3 ) / n ( s e e d e d ) ) / l o g 2 (mean ±SEM; p < 0.001, two-way ANOVA).
# ::tok Population doubling rate was calculated as PDR = log ( n ( d a y 3 ) / n ( s e e d e d ) ) / l o g 2 ( mean ±SEM ; p
(x1 / and
      :op1 (x5 / calculate-01
            :ARG1 (x4 / rate
                  :mod (x3 / double-01
                        :ARG1 (x2 / population)))
            :ARG1-of (x6 / resemble-01
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "PDR")
                        :xref (x / xref :value "UNIPROT:PDRG1_HUMAN" :prob "0.262"))
                  :ARG2 (x9 / univariate))
            :ARG1-of (x10 / describe-01
                  :ARG0 (x11 / and
                        :op1 (x12 / enzyme
                              :name (x13 / name :op1 "n-ras")
                              :ARG1-of (x14 / describe-01
                                    :ARG0 (x15 / and
                                          :op1 (x16 / figure :mod "a")
                                          :op2 (x17 / amino-acid
                                                :name (x18 / name :op1 "tyrosine")
                                                :mod "3"
                                                :xref (x39 / xref :value "PUBCHEM:1153" :prob "11.081481"))))
                              :xref (x38 / xref :value "UNIPROT:Q9UM97_HUMAN" :prob "0.701"))
                        :op2 (x19 / enzyme
                              :name (x20 / name :op1 "n-ras")
                              :ARG1-of (x21 / mean-01
                                    :ARG2 (x22 / and
                                          :op1 (x23 / protein
                                                :name (x24 / name :op1 "s" :op2 "e"))
                                          :op2 (x25 / and
                                                :op1 (x26 / figure :mod "5d")
                                                :op2 (x27 / figure :mod "d"))))
                              :xref (x37 / xref :value "UNIPROT:Q9UM97_HUMAN" :prob "0.701"))
                        :op3 (x28 / cell-line
                              :name (x29 / name :op1 "hd-lm2")))))
      :op2 (x30 / enzyme
            :name (x31 / name
                  :op1 "o"
                  :op2 "g"
                  :op3 "2")
            :ARG1-of (x32 / mean-01)
            :name (x33 / name :op1 "±SEM")
            :xref (x36 / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.292"))
      :op3 (x34 / statistical-test-91
            :ARG2 (x35 / less-than :op1 "0.05")))


# ::id PMC3690480.423
# ::snt Cell-cycle profiles of early passage wild-type and homozygous p110β-RBD-DM primary MEFs growing in 1% or 10% FCS (n = 4, means; SEM in the Results section).
# ::tok Cell @-@ cycle profiles of early passage wild @-@ type and homozygous p110β-RBD @-@ DM primary MEFs growing in 1 % or 10 % FCS ( n = 4 , means ; SEM in the Results section ) .
(x3 / profile-01
      :ARG1 (x2 / cycle-02
            :ARG1 (x1 / cell))
      :ARG1 (x8 / and
            :op1 (x6 / cell
                  :mod (x5 / passage
                        :mod (x4 / early))
                  :mod (x7 / wild-type))
            :op2 (x9 / enzyme
                  :mod (x10 / homozygous)
                  :name (x11 / name :op1 "p110β-RBD")
                  :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212")))
      :ARG2 (x24 / and
            :op1 (x15 / grow-01
                  :ARG1 (x12 / cell
                        :mod (x13 / primary)
                        :name (x14 / name :op1 "mef"))
                  :location (x17 / or
                        :op1 (x16 / percentage-entity :value "1")
                        :op2 (x18 / small-molecule
                              :quant (x19 / percentage-entity :value "10")
                              :name (x20 / name :op1 "FCS")
                              :ARG1-of (x21 / describe-01
                                    :ARG0 (x22 / publication
                                          :ARG1-of (x23 / cite-01 :ARG2 "4")))
                              :xref (x31 / xref :value "PUBCHEM:3040269" :prob "11.608116"))))
            :op1 (x25 / mean-01)
            :op2 (x30 / thing
                  :location (x26 / sem)
                  :ARG2-of (x29 / section-01
                        :ARG1 (x27 / thing
                              :ARG2-of (x28 / result-01))))))


# ::id PMC3690480.424
# ::snt Wild-type and p110β-RBD-DM MEFs were maintained in cell culture medium supplemented with 0%, 1%, or 10% FCS and harvested for western blot analysis.
# ::tok Wild @-@ type and p110β-RBD @-@ DM MEFs were maintained in cell culture medium supplemented with 0 % , 1 % , or 10 % FCS and harvested for western blot analysis .
(x6 / maintain-01
      :ARG1 (x2 / and
            :mod (x1 / wild-type)
            :op1 (x3 / enzyme
                  :name (x4 / name :op1 "p110β-RBD")
                  :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :name (x5 / name :op1 "mef"))
      :location (x9 / medium
            :mod (x8 / culture
                  :mod (x7 / cell))
            :ARG0-of (x10 / supplement-01))
      :ARG2 (x17 / and
            :op1 (x13 / or
                  :op1 (x11 / percentage-entity :value "0")
                  :op2 (x12 / percentage-entity :value "1")
                  :op3 (x14 / small-molecule
                        :quant (x15 / percentage-entity :value "10")
                        :name (x16 / name :op1 "republican" :op2 "party")))
            :op2 (x18 / harvest-01
                  :ARG1 (x20 / analyze-01
                        :manner (x19 / immunoblot-01)))))


# ::id PMC3690480.425
# ::snt Wild-type and p110β-RBD-DM MEFs were transfected with scrambled duplex or gene-specific siRNA pools targeting RAC1, CDC42, or both and harvested for western blot analysis 30 hr after transfection.
# ::tok Wild @-@ type and p110β-RBD @-@ DM MEFs were transfected with scrambled duplex or gene @-@ specific siRNA pools targeting RAC1 , CDC42 , or both and harvested for western blot analysis 30 hr after transfection .
(x15 / target-01
      :ARG1 (x2 / and
            :mod (x1 / wild-type)
            :op1 (x3 / enzyme
                  :name (x4 / name :op1 "p110β-RBD")
                  :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :name (x5 / name :op1 "mef"))
      :mod (x6 / transfect-01
            :ARG2 (x14 / pool
                  :ARG1-of (x7 / scramble-02)
                  :ARG0-of (x12 / nucleic-acid
                        :ARG1-of (x11 / specific-02
                              :ARG2 (x9 / or
                                    :op1 (x8 / duplex)
                                    :op2 (x10 / gene)))
                        :name (x13 / name :op1 "siRNA"))))
      :ARG1 (x20 / or
            :op1 (x16 / protein
                  :name (x17 / name :op1 "RAC1")
                  :xref (x31 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :op2 (x18 / protein
                  :name (x19 / name :op1 "CDC42")
                  :xref (x30 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
            :op3 (x22 / and
                  :mod (x21 / both)
                  :op2 (x23 / enzyme
                        :name (x24 / name :op1 "harvested"))))
      :purpose (x26 / analyze-01
            :manner (x25 / immunoblot-01))
      :ARG1 (x27 / ratio-of :value "30")
      :time (x28 / after
            :op1 (x29 / transfect-01)))


# ::id PMC3690480.426
# ::snt Graph shows phospho-AKT normalized to total AKT (n = 3; mean with SEM, one-way ANOVA).
# ::tok Graph shows phospho @-@ AKT normalized to total AKT ( n = 3; mean with SEM , one @-@ way ANOVA ) .
(x2 / show-01
      :ARG0 (x1 / graph)
      :ARG1 (x6 / normalize-01
            :ARG1 (x3 / enzyme
                  :ARG3-of (x4 / phosphorylate-01)
                  :name (x5 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :ARG1 (x7 / enzyme
                  :mod (x8 / total)
                  :name (x9 / name :op1 "AKT")
                  :ARG1-of (x10 / mean-01)
                  :xref (x15 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :ARG2 (x11 / small-molecule
                  :name (x12 / name :op1 "SEM")
                  :xref (x16 / xref :value "PUBCHEM:2724271" :prob "10.871458")))
      :ARG0-of (x13 / way :quant "1")
      :ARG1-of (x14 / anova))


# ::id PMC3690480.427
# ::snt Myc-V12-RAC1 and Myc-V12-CDC42 were nucleofected into immortalized wild-type, p110α-knockout, and p110β-knockout MEFs, along with a kinase-dead AKT reporter construct.
# ::tok Myc @-@ V12 @-@ RAC1 and Myc @-@ V12 @-@ CDC42 were nucleofected into immortalized wild @-@ type , p110α-knockout , and p110β-knockout MEFs , along with a kinase @-@ dead AKT reporter construct .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op1 (x3 / protein
                  :name (x4 / name :op1 "Myc")
                  :ARG2-of (x5 / mutate-01 :value "V12")
                  :xref (x34 / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604"))
            :op2 (x8 / and
                  :op1 (x6 / protein
                        :name (x7 / name :op1 "RAC1")
                        :xref (x35 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x9 / protein
                        :name (x10 / name :op1 "Myc")
                        :xref (x33 / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604")))
            :op3 (x11 / gene
                  :ARG2-of (x12 / mutate-01 :value "V12")
                  :name (x13 / name :op1 "CDC42")
                  :xref (x36 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :snt2 (x22 / and
            :op1 (x14 / be-located-at-91
                  :ARG1 (x15 / enzyme
                        :name (x16 / name :op1 "nucleofected")
                        :xref (x37 / xref :value "UNIPROT:NUCL_HUMAN" :prob "0.222"))
                  :ARG2 (x18 / cell
                        :ARG1-of (x17 / immortalize-03)
                        :mod (x19 / wild-type)))
            :op2 (x20 / enzyme
                  :name (x21 / name :op1 "p110α-knockout"))
            :op2 (x23 / cell
                  :name (x24 / name :op1 "mef"))
            :op3 (x31 / construct-01
                  :ARG1 (x25 / enzyme
                        :name (x26 / name :op1 "kinase")
                        :ARG1-of (x27 / die-01)
                        :xref (x32 / xref :value "UNIPROT:ITK_HUMAN" :prob "0.293"))
                  :ARG2 (x30 / report-01
                        :ARG1 (x28 / enzyme
                              :name (x29 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))))


# ::id PMC3690480.428
# ::snt The next day, cells were serum starved and harvested for western blot.
# ::tok The next day , cells were serum starved and harvested for western blot .
(x6 / and
      :op1 (x5 / starve-01
            :time (x2 / day
                  :mod (x1 / next))
            :ARG1 (x3 / cell)
            :ARG2 (x4 / serum))
      :op2 (x7 / harvest-01
            :ARG1 (x8 / immunoblot-01)))


# ::id PMC3690480.429
# ::snt Myc-V12-RAC1, Myc-V12-CDC42, or Myc-V12-HRAS were nucleofected into wild-type and p110β-RBD-DM MEFs as described in (H).
# ::tok Myc @-@ V12 @-@ RAC1 , Myc @-@ V12 @-@ CDC42 , or Myc @-@ V12 @-@ HRAS were nucleofected into wild @-@ type and p110β-RBD @-@ DM MEFs as described in ( H ) .
(x16 / be-located-at-91
      :ARG1 (x10 / or
            :op1 (x1 / protein
                  :name (x2 / name :op1 "Myc")
                  :ARG2-of (x3 / mutate-01 :value "V12")
                  :xref (x29 / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604"))
            :op1 (x4 / protein
                  :name (x5 / name :op1 "RAC1")
                  :mod (x6 / protein
                        :name (x7 / name :op1 "Myc")
                        :ARG2-of (x8 / mutate-01 :value "V12")
                        :xref (x30 / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604"))
                  :name (x9 / name :op1 "CDC42")
                  :xref (x32 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
            :op2 (x11 / protein
                  :name (x12 / name :op1 "Myc")
                  :ARG2-of (x13 / mutate-01 :value "V12")
                  :xref (x33 / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604"))
            :op2 (x14 / enzyme
                  :name (x15 / name :op1 "HRAS")
                  :xref (x34 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003")))
      :ARG1 (x17 / enzyme
            :name (x18 / name :op1 "nucleofected")
            :xref (x35 / xref :value "UNIPROT:NUCL_HUMAN" :prob "0.222"))
      :ARG2 (x20 / and
            :op1 (x19 / wild-type)
            :op2 (x21 / enzyme
                  :name (x22 / name :op1 "p110β-RBD")
                  :mod (x23 / enzyme
                        :name (x24 / name :op1 "mef")
                        :xref (x28 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212")))
      :ARG1-of (x25 / describe-01
            :ARG0 (x26 / publication
                  :wiki "-"
                  :name (x27 / name :op1 "h-ras"))))


# ::id PMC3690480.430
# ::snt See also Figure S4 .
# ::tok See also Figure S4 .
(x1 / see-01
      :mode "imperative"
      :ARG0 (x2 / you)
      :mod (x3 / also)
      :ARG2 (x4 / figure :mod "s4"))


# ::id PMC3690480.431
# ::snt RAC Activates p110β Downstream of GPCRs
# ::tok RAC Activates p110β Downstream of GPCRs
(x6 / downstream
      :ARG1-of (x3 / activate-01
            :ARG0 (x1 / enzyme
                  :name (x2 / name :op1 "RAC")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "p110β")
                  :xref (x10 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
      :mod (x7 / enzyme
            :name (x8 / name :op1 "GPCRs")
            :xref (x9 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311")))


# ::id PMC3690480.432
# ::snt Primary wild-type and homozygous p110β-RBD-DM MEFs were serum starved and stimulated with LPA for 5 min.
# ::tok Primary wild @-@ type and homozygous p110β-RBD @-@ DM MEFs were serum starved and stimulated with LPA for 5 min .
(x10 / and
      :op1 (x9 / starve-01
            :ARG1 (x1 / cell
                  :mod (x2 / primary)
                  :mod (x3 / wild-type)
                  :mod (x4 / enzyme
                        :mod (x5 / homozygous)
                        :name (x6 / name :op1 "p110β-RBD")
                        :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
                  :name (x7 / name :op1 "mef"))
            :ARG2 (x8 / serum))
      :op2 (x11 / stimulate-01
            :ARG2 (x12 / small-molecule
                  :name (x13 / name :op1 "LPA")
                  :xref (x16 / xref :value "PUBCHEM:62707" :prob "9.981436"))
            :duration (x14 / temporal-quantity
                  :quant "5"
                  :unit (x15 / minute))))


# ::id PMC3690480.433
# ::snt Primary wild-type and p110β-RBD-DM MEFs were serum starved and stimulated with LPA (10 μM) for indicated time periods.
# ::tok Primary wild @-@ type and p110β-RBD @-@ DM MEFs were serum starved and stimulated with LPA ( 10 μM ) for indicated time periods .
(x3 / and
      :op1 (x2 / wild-type
            :mod (x1 / primary))
      :op2 (x11 / stimulate-01
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "p110β-RBD")
                  :mod (x6 / enzyme
                        :name (x7 / name :op1 "mef")
                        :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :xref (x19 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :ARG2 (x10 / and
                  :ARG1-of (x9 / starve-01
                        :ARG2 (x8 / serum)))
            :ARG2 (x12 / small-molecule
                  :name (x13 / name :op1 "LPA")
                  :quant (x14 / concentration-quantity
                        :quant "10"
                        :unit (x15 / micromolar))
                  :xref (x20 / xref :value "PUBCHEM:62707" :prob "9.981436"))
            :duration (x18 / period
                  :ARG1-of (x17 / time
                        :ARG1-of (x16 / indicate-01)))))


# ::id PMC3690480.434
# ::snt Immortalized wild-type, p110α-knockout, p110β-knockout, and p110β-RBD-DM MEFs were serum starved and stimulated with indicated doses of LPA for 5 min.
# ::tok Immortalized wild @-@ type , p110α-knockout , p110β-knockout , and p110β-RBD @-@ DM MEFs were serum starved and stimulated with indicated doses of LPA for 5 min .
(x1 / multi-sentence
      :snt1 (x2 / immortalize-03
            :ARG1 (x3 / enzyme
                  :mod (x4 / wild-type)
                  :name (x5 / name :op1 "p110α-knockout")))
      :snt2 (x15 / and
            :op1 (x14 / starve-01
                  :ARG1 (x8 / and
                        :op1 (x6 / enzyme
                              :name (x7 / name :op1 "p110β-knockout"))
                        :op2 (x9 / enzyme
                              :name (x10 / name :op1 "p110β-RBD")
                              :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
                        :op2 (x11 / enzyme
                              :name (x12 / name :op1 "mef")
                              :xref (x23 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))
                  :ARG2 (x13 / serum))
            :op2 (x16 / stimulate-01
                  :ARG2 (x18 / dose-01
                        :ARG1-of (x17 / indicate-01)
                        :ARG2 (x19 / small-molecule
                              :name (x20 / name :op1 "LPA")
                              :xref (x24 / xref :value "PUBCHEM:62707" :prob "9.981436")))
                  :duration (x21 / temporal-quantity
                        :quant "5"
                        :unit (x22 / minute)))))


# ::id PMC3690480.435
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific siRNA pools targeting RAC1, CDC42 or both.
# ::tok Immortalized wild @-@ type MEFs were transfected with scrambled duplex or gene @-@ specific siRNA pools targeting RAC1 , CDC42 or both .
(x5 / transfect-01
      :ARG1 (x2 / cell
            :ARG1-of (x1 / immortalize-03)
            :mod (x3 / wild-type)
            :name (x4 / name :op1 "mef"))
      :ARG2 (x19 / or
            :op1 (x13 / pool
                  :ARG1-of (x6 / scramble-02)
                  :ARG0-of (x11 / nucleic-acid
                        :ARG1-of (x10 / specific-02
                              :ARG2 (x8 / or
                                    :op1 (x7 / duplex)
                                    :op2 (x9 / gene)))
                        :name (x12 / name :op1 "siRNA"))
                  :ARG0-of (x14 / target-01
                        :ARG1 (x15 / protein
                              :name (x16 / name :op1 "RAC1")
                              :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))))
            :op2 (x17 / protein
                  :name (x18 / name :op1 "CDC42")
                  :xref (x21 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
            :op3 (x20 / and)))


# ::id PMC3690480.436
# ::snt Serum-starved cells were stimulated with LPA (10 μM) or S1P (1 μM) for 5 min.
# ::tok Serum @-@ starved cells were stimulated with LPA ( 10 μM ) or S1P ( 1 μM ) for 5 min .
(x4 / stimulate-01
      :ARG1 (x3 / cell
            :ARG1-of (x2 / starve-01
                  :ARG2 (x1 / serum)))
      :ARG2 (x9 / or
            :op1 (x5 / small-molecule
                  :name (x6 / name :op1 "LPA")
                  :quant (x7 / concentration-quantity
                        :quant "10"
                        :unit (x8 / micromolar))
                  :xref (x16 / xref :value "PUBCHEM:62707" :prob "9.981436"))
            :op2 (x10 / protein
                  :name (x11 / name :op1 "S1P")
                  :xref (x / xref :value "UNIPROT:MBTP1_HUMAN" :prob "1.002"))
            :op2 (x12 / concentration-quantity
                  :quant "1"
                  :unit (x13 / micromolar)))
      :duration (x14 / temporal-quantity
            :quant "5"
            :unit (x15 / minute)))


# ::id PMC3690480.437
# ::snt Immortalized wild-type MEFs were serum starved, preincubated with EHT1864 for 30 min, and stimulated with LPA (10 μM) or S1P (1 μM) for 5 min.
# ::tok Immortalized wild @-@ type MEFs were serum starved , preincubated with EHT1864 for 30 min , and stimulated with LPA ( 10 μM ) or S1P ( 1 μM ) for 5 min .
(x12 / and
      :op1 (x6 / starve-01
            :ARG1 (x3 / cell
                  :ARG1-of (x1 / immortalize-03)
                  :mod (x2 / wild-type)
                  :name (x4 / name :op1 "mef"))
            :ARG2 (x5 / serum)
            :ARG1-of (x7 / preincubated)
            :ARG2 (x8 / protein
                  :name (x9 / name :op1 "EHT1864")
                  :xref (x / xref :value "UNIPROT:MTG8R_HUMAN" :prob "0.202"))
            :duration (x10 / temporal-quantity
                  :quant "30"
                  :unit (x11 / minute)))
      :op2 (x13 / stimulate-01
            :ARG2 (x18 / or
                  :op1 (x14 / small-molecule
                        :name (x15 / name :op1 "LPA")
                        :quant (x16 / concentration-quantity
                              :quant "10"
                              :unit (x17 / micromolar))
                        :xref (x26 / xref :value "PUBCHEM:62707" :prob "9.981436"))
                  :op2 (x19 / protein
                        :name (x20 / name :op1 "S1P")
                        :xref (x25 / xref :value "UNIPROT:MBTP1_HUMAN" :prob "1.002"))
                  :op2 (x21 / concentration-quantity
                        :quant "1"
                        :unit (x22 / micromolar)))
            :duration (x23 / temporal-quantity
                  :quant "5"
                  :unit (x24 / minute))))


# ::id PMC3690480.438
# ::snt Serum-starved wild-type and p110β-RBD-DM MEFs were stimulated with LPA (10 μM) for indicated periods of time.
# ::tok Serum @-@ starved wild @-@ type and p110β-RBD @-@ DM MEFs were stimulated with LPA ( 10 μM ) for indicated periods of time .
(x10 / stimulate-01
      :ARG1 (x5 / and
            :op1 (x3 / cell
                  :ARG1-of (x2 / starve-01
                        :ARG2 (x1 / serum))
                  :mod (x4 / wild-type))
            :op2 (x6 / enzyme
                  :name (x7 / name :op1 "p110β-RBD")
                  :mod (x8 / enzyme
                        :name (x9 / name :op1 "mef")
                        :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :xref (x18 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212")))
      :ARG2 (x11 / small-molecule
            :name (x12 / name :op1 "LPA")
            :quant (x13 / concentration-quantity
                  :quant "10"
                  :unit (x14 / micromolar))
            :xref (x19 / xref :value "PUBCHEM:62707" :prob "9.981436"))
      :duration (x16 / period
            :ARG1-of (x15 / indicate-01)
            :consist-of (x17 / time)))


# ::id PMC3690480.439
# ::snt RAC⋅GTP and total RAC were measured as described in the Extended Experimental Procedures (n = 3; mean with SEM).
# ::tok RAC⋅GTP and total RAC were measured as described in the Extended Experimental Procedures ( n = 3; mean with SEM ) .
(x7 / measure-01
      :ARG1 (x3 / and
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "RAC⋅GTP")
                  :xref (x19 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :op2 (x4 / enzyme
                  :mod (x5 / total)
                  :name (x6 / name :op1 "RAC")
                  :xref (x20 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003")))
      :ARG1-of (x8 / describe-01
            :ARG2 (x9 / extend-01
                  :ARG1 (x11 / procedure
                        :mod (x10 / experiment-01)))
            :ARG1-of (x12 / sample-01
                  :ARG2 (x15 / mean-01
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "3;")
                              :xref (x / xref :value "UNIPROT:AB12B_HUMAN" :prob "0.552"))
                        :ARG2 (x16 / enzyme
                              :name (x17 / name :op1 "SEM")
                              :xref (x18 / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.332"))))))


# ::id PMC3690480.440
# ::snt See also Figure S5 .
# ::tok See also Figure S5 .
(x1 / see-01
      :mode "imperative"
      :ARG0 (x2 / you)
      :mod (x3 / also)
      :ARG1-of (x4 / describe-01
            :ARG0 (x5 / figure :mod "s5")))


# ::id PMC3690480.441
# ::snt Dock180/Elmo1 Activate RAC Downstream of GPCRs and Upstream of p110β
# ::tok Dock180 @/@ Elmo1 Activate RAC Downstream of GPCRs and Upstream of p110β
(x6 / activate-01
      :ARG0 (x3 / slash
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "Dock180")
                  :xref (x / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "Elmo1")
                  :xref (x19 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604")))
      :ARG1 (x11 / and
            :op1 (x7 / enzyme
                  :name (x8 / name :op1 "RAC")
                  :mod (x9 / downstream)
                  :name (x10 / name :op1 "GPCRs")
                  :xref (x18 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311"))
            :op2 (x12 / relative-position
                  :direction (x13 / upstream)
                  :op1 (x14 / enzyme
                        :name (x15 / name :op1 "p110β")
                        :xref (x16 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))))


# ::id PMC3690480.443
# ::snt A total of 48 hr after transfection, serum-starved cells were stimulated with LPA (10 μM) for 5 min.
# ::tok A total of 48 hr after transfection , serum @-@ starved cells were stimulated with LPA ( 10 μM ) for 5 min .
(x8 / stimulate-01
      :ARG1 (x2 / ratio-of
            :ARG1-of (x1 / total-01 :ARG2 "48"))
      :time (x3 / after
            :op1 (x4 / transfect-01))
      :ARG1 (x7 / cell
            :ARG1-of (x6 / starve-01
                  :ARG2 (x5 / serum)))
      :ARG2 (x9 / small-molecule
            :name (x10 / name :op1 "LPA")
            :quant (x11 / concentration-quantity
                  :quant "10"
                  :unit (x12 / micromolar))
            :xref (x / xref :value "PUBCHEM:62707" :prob "9.981436"))
      :duration (x13 / temporal-quantity
            :quant "5"
            :unit (x14 / minute)))


# ::id PMC3690480.445
# ::snt Then 48 hr after transfection, serum-starved cells were stimulated with LPA (10 μM) for 5 min.
# ::tok Then 48 hr after transfection , serum @-@ starved cells were stimulated with LPA ( 10 μM ) for 5 min .
(x8 / stimulate-01
      :time (x3 / after
            :quant (x1 / temporal-quantity
                  :quant "48"
                  :unit (x2 / ratio-of))
            :op1 (x4 / transfect-01))
      :ARG1 (x7 / cell
            :ARG1-of (x6 / starve-01
                  :ARG2 (x5 / serum)))
      :ARG2 (x9 / small-molecule
            :name (x10 / name :op1 "LPA")
            :quant (x11 / concentration-quantity
                  :quant "10"
                  :unit (x12 / micromolar))
            :xref (x / xref :value "PUBCHEM:62707" :prob "9.981436"))
      :duration (x13 / temporal-quantity
            :quant "5"
            :unit (x14 / minute)))


# ::id PMC3690480.446
# ::snt Immortalized wild-type MEFs, transfected with scrambled duplex or Dock180-specific siRNA pools, were stimulated with LPA (10 μM) or EGF (10 ng/ml) for 20 s and active RAC was quantified (n = 4; mean with SEM; t test; bottom: a representative experiment).
# ::tok Immortalized wild @-@ type MEFs , transfected with scrambled duplex or Dock180 @-@ specific siRNA pools , were stimulated with LPA ( 10 μM ) or EGF ( 10 ng/ml ) for 20 s and active RAC was quantified ( n = 4; mean with SEM ; t test ; bottom : a representative experiment ) .
(x1 / multi-sentence
      :snt1 (x32 / quantify-01
            :ARG1 (x28 / and
                  :op1 (x6 / transfect-01
                        :ARG1-of (x2 / immortalize-03)
                        :mod (x3 / enzyme
                              :mod (x4 / wild-type)
                              :name (x5 / name :op1 "mef")
                              :xref (x45 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                        :ARG2 (x21 / or
                              :op1 (x16 / stimulate-01
                                    :ARG1 (x15 / pool
                                          :ARG1-of (x7 / scramble-02)
                                          :ARG0-of (x13 / nucleic-acid
                                                :ARG1-of (x12 / specific-02
                                                      :ARG2 (x9 / or
                                                            :op1 (x8 / duplex)
                                                            :op2 (x10 / enzyme
                                                                  :name (x11 / name :op1 "Dock180")
                                                                  :xref (x49 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))))
                                                :name (x14 / name :op1 "siRNA")))
                                    :ARG2 (x17 / small-molecule
                                          :name (x18 / name :op1 "LPA")
                                          :quant (x19 / concentration-quantity
                                                :quant "10"
                                                :unit (x20 / micromolar))
                                          :xref (x50 / xref :value "PUBCHEM:62707" :prob "9.981436")))
                              :op2 (x22 / protein
                                    :name (x23 / name :op1 "EGF")
                                    :quant (x24 / concentration-quantity
                                          :quant "10"
                                          :unit (x25 / nanogram-per-milliliter))
                                    :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                        :duration (x26 / temporal-quantity
                              :quant "20"
                              :unit (x27 / year)))
                  :op2 (x29 / activity-06))
            :ARG0 (x30 / enzyme
                  :name (x31 / name :op1 "RAC")
                  :xref (x46 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :ARG1-of (x33 / sample-01
                  :ARG2 (x36 / mean-01
                        :ARG1 (x34 / protein
                              :name (x35 / name :op1 "4;"))
                        :ARG2 (x37 / enzyme
                              :name (x38 / name :op1 "SEM")
                              :xref (x47 / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.332")))))
      :snt2 (x41 / test-01
            :ARG0 (x39 / protein
                  :name (x40 / name :op1 "t")
                  :xref (x48 / xref :value "UNIPROT:BRAC_HUMAN" :prob "0.602"))
            :ARG1 (x42 / bottom)
            :ARG1-of (x43 / represent-01
                  :ARG0 (x44 / experiment-01))))


# ::id PMC3690480.447
# ::snt Immortalized MEFs were preincubated with PTX (200 ng/ml, 16 hr) or GDC0941 (10 μM, 1 hr) and stimulated with LPA (10 μM) for the indicated time periods (n = 4; mean with SEM; one-way ANOVA; bottom: representative lysates).
# ::tok Immortalized MEFs were preincubated with PTX ( 200 ng/ml , 16 hr ) or GDC0941 ( 10 μM , 1 hr ) and stimulated with LPA ( 10 μM ) for the indicated time periods ( n = 4; mean with SEM ; one @-@ way ANOVA ; bottom : representative lysates ) .
(x1 / multi-sentence
      :snt1 (x13 / or
            :op1 (x2 / immortalize-03
                  :ARG1 (x3 / cell
                        :name (x4 / name :op1 "mef"))
                  :ARG2 (x7 / and
                        :op1 (x5 / enzyme
                              :name (x6 / name :op1 "preincubated"))
                        :op1 (x8 / small-molecule
                              :name (x9 / name :op1 "PTX")
                              :quant (x10 / concentration-quantity
                                    :quant "200"
                                    :unit (x11 / nanogram-per-milliliter))
                              :xref (x42 / xref :value "PUBCHEM:4740" :prob "17.474375"))
                        :op2 (x12 / ratio-of :value "16")))
            :op1 (x14 / small-molecule
                  :name (x15 / name :op1 "GDC0941")
                  :quant (x16 / concentration-quantity
                        :quant "10"
                        :unit (x17 / micromolar))
                  :xref (x43 / xref :value "PUBCHEM:17755052" :prob "18.349844"))
            :op2 (x18 / concentration-quantity
                  :quant "1"
                  :unit (x19 / ratio-of))
            :op2 (x28 / period
                  :ARG1-of (x20 / stimulate-01
                        :ARG2 (x21 / and
                              :op1 (x22 / small-molecule
                                    :name (x23 / name :op1 "LPA")
                                    :xref (x41 / xref :value "PUBCHEM:62707" :prob "9.981436"))
                              :op2 (x24 / concentration-quantity
                                    :quant "10"
                                    :unit (x25 / micromolar)))
                        :duration (x27 / time
                              :ARG1-of (x26 / indicate-01)))
                  :ARG1-of (x29 / sample-01
                        :ARG2 (x32 / mean-01
                              :ARG1 (x30 / protein
                                    :name (x31 / name :op1 "4;"))
                              :ARG2 (x33 / enzyme
                                    :name (x34 / name :op1 "SEM")
                                    :xref (x / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.332"))))))
      :snt2 (x39 / represent-01
            :ARG0 (x36 / and
                  :op1 (x35 / way :quant "1")
                  :op1 (x37 / anova)
                  :op2 (x38 / bottom))
            :ARG1 (x40 / lysate)))


# ::id PMC3690480.448
# ::snt GST-tagged full-length Elmo1 and fragments as shown (schematic) were incubated with lysates from COS7 cells expressing Gβ 2 and Gγ 1 .
# ::tok GST @-@ tagged full @-@ length Elmo1 and fragments as shown ( schematic ) were incubated with lysates from COS7 cells expressing Gβ 2 and Gγ 1 .
(x18 / and
      :op1 (x11 / incubate-01
            :ARG0 (x3 / tag-01
                  :ARG2 (x1 / protein
                        :name (x2 / name :op1 "GST")
                        :xref (x21 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
            :ARG1 (x8 / fragment-01
                  :ARG1-of (x5 / long-03
                        :ARG1-of (x4 / full-09))
                  :mod (x6 / protein
                        :name (x7 / name :op1 "Elmo1")
                        :xref (x22 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))
                  :ARG1-of (x9 / show-01)
                  :ARG1-of (x10 / schematic))
            :ARG2 (x12 / lysate
                  :source (x14 / cell
                        :name (x13 / name :op1 "COS7")
                        :ARG3-of (x15 / express-03
                              :ARG2 (x16 / enzyme
                                    :name (x17 / name :op1 "erk2")
                                    :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.603"))))))
      :op2 (x19 / protein
            :name (x20 / name :op1 "Gγ" :op2 "1")))


# ::id PMC3690480.449
# ::snt Bound Gβ was detected by western blot.
# ::tok Bound Gβ was detected by western blot .
(x4 / detect-01
      :ARG1 (x1 / bind-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "Gβ")
                  :xref (x / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.58")))
      :ARG2 (x5 / immunoblot-01))


# ::id PMC3690480.450
# ::snt See text for details.
# ::tok See text for details .
(x1 / see-01
      :mode "imperative"
      :ARG0 (x2 / you)
      :ARG1 (x3 / text)
      :purpose (x4 / detail-01))


# ::id PMC3690480.451
# ::snt See also Figure S6 .
# ::tok See also Figure S6 .
(x1 / see-01
      :mode "imperative"
      :ARG0 (x2 / you)
      :mod (x3 / also)
      :ARG2 (x4 / figure :mod "s6"))


# ::id PMC3690480.453
# ::snt Migration of wild-type and p110β-RBD-DM MEFs in gradients of LPA and PDGF was assessed in transwell filter assays (n = 3; mean with SD; one-way ANOVA).
# ::tok Migration of wild @-@ type and p110β-RBD @-@ DM MEFs in gradients of LPA and PDGF was assessed in transwell filter assays ( n = 3; mean with SD ; one @-@ way ANOVA ) .
(x1 / multi-sentence
      :snt1 (x15 / assess-01
            :ARG1 (x2 / migrate-01
                  :ARG0 (x4 / and
                        :mod (x3 / wild-type)
                        :op2 (x5 / enzyme
                              :name (x6 / name :op1 "p110β-RBD")
                              :mod (x7 / enzyme
                                    :name (x8 / name :op1 "mef")
                                    :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                              :xref (x24 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
                        :location (x9 / gradient)))
            :ARG1 (x12 / and
                  :op1 (x10 / small-molecule
                        :name (x11 / name :op1 "LPA")
                        :xref (x27 / xref :value "PUBCHEM:62707" :prob "9.981436"))
                  :op2 (x13 / protein
                        :name (x14 / name :op1 "PDGF")
                        :xref (x25 / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313")))
            :location (x17 / assay-01
                  :name (x16 / name :op1 "filter")
                  :ARG1-of (x18 / mean-01))
            :ARG2 (x19 / small-molecule
                  :name (x20 / name :op1 "SD")
                  :xref (x26 / xref :value "PUBCHEM:3039" :prob "8.722122")))
      :snt2 (x21 / small-molecule
            :mod (x22 / way :quant "1")
            :name (x23 / name :op1 "ANOVA")))


# ::id PMC3690480.454
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific siRNA pools targeting Dock180, Elmo1, or RAC1.
# ::tok Immortalized wild @-@ type MEFs were transfected with scrambled duplex or gene @-@ specific siRNA pools targeting Dock180 , Elmo1 , or RAC1 .
(x5 / transfect-01
      :ARG1 (x2 / cell
            :ARG1-of (x1 / immortalize-03)
            :mod (x3 / wild-type)
            :name (x4 / name :op1 "mef"))
      :ARG2 (x19 / or
            :op1 (x13 / pool
                  :ARG1-of (x6 / scramble-02)
                  :ARG0-of (x11 / nucleic-acid
                        :ARG1-of (x10 / specific-02
                              :ARG2 (x8 / or
                                    :op1 (x7 / duplex)
                                    :op2 (x9 / gene)))
                        :name (x12 / name :op1 "siRNA"))
                  :ARG0-of (x14 / target-01
                        :ARG1 (x15 / enzyme
                              :name (x16 / name :op1 "Dock180")
                              :xref (x22 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))))
            :op2 (x17 / protein
                  :name (x18 / name :op1 "Elmo1")
                  :xref (x23 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))
            :op2 (x20 / protein
                  :name (x21 / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))))


# ::id PMC3690480.455
# ::snt Migration in gradients of LPA and PDGF was assessed in transwell filter assays and cell numbers were normalized to control conditions (n = 4; mean with SEM; one-way ANOVA).
# ::tok Migration in gradients of LPA and PDGF was assessed in transwell filter assays and cell numbers were normalized to control conditions ( n = 4; mean with SEM ; one @-@ way ANOVA ) .
(x12 / and
      :op1 (x1 / migrate-01
            :ARG0 (x2 / gradient)
            :ARG1 (x8 / assess-01
                  :ARG1 (x5 / and
                        :op1 (x3 / small-molecule
                              :name (x4 / name :op1 "LPA")
                              :xref (x27 / xref :value "PUBCHEM:62707" :prob "9.981436"))
                        :op2 (x6 / protein
                              :name (x7 / name :op1 "PDGF")
                              :xref (x26 / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313")))
                  :location (x11 / assay-01
                        :ARG1 (x10 / filter-02
                              :mod (x9 / transwell)))))
      :op2 (x15 / normalize-01
            :ARG1 (x14 / number
                  :quant-of (x13 / cell))
            :ARG1 (x16 / control-01)
            :ARG1-of (x17 / sample-01
                  :ARG2 (x18 / and
                        :op1 (x21 / mean-01
                              :ARG1 (x19 / protein
                                    :name (x20 / name :op1 "4;"))
                              :ARG2 (x22 / enzyme
                                    :name (x23 / name :op1 "SEM")
                                    :xref (x / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.332")))
                        :op2 (x24 / way :quant "1")))
            :ARG1-of (x25 / anova)))


# ::id PMC3690480.456
# ::snt Wild-type and homozygous p110β-RBD-DM mice were treated with a single intratracheal dose of bleomycin (1.25 U/kg) and observed for 14 days (n = 16 mice per genotype; Mantel-Cox test).
# ::tok Wild @-@ type and homozygous p110β-RBD @-@ DM mice were treated with a single intratracheal dose of bleomycin ( 1.25 U/kg ) and observed for 14 days ( n = 16 mice per genotype ; Mantel @-@ Cox test ) .
(x3 / homozygous
      :ARG0 (x2 / and
            :mod (x1 / wild-type))
      :op4 (x21 / mouse
            :ARG1-of (x7 / treat-04
                  :ARG1 (x4 / gene
                        :name (x5 / name :op1 "p110β-RBD")
                        :ARG2-of (x6 / dm)
                        :xref (x28 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
                  :ARG2 (x11 / dose-01
                        :ARG1-of (x8 / single-02)
                        :ARG1 (x9 / enzyme
                              :name (x10 / name :op1 "intratracheal"))
                        :ARG2 (x12 / small-molecule
                              :name (x13 / name :op1 "bleomycin")
                              :xref (x29 / xref :value "PUBCHEM:84068" :prob "15.122998"))
                        :ARG1-of (x14 / describe-01
                              :ARG0 (x17 / and
                                    :op1 (x15 / enzyme
                                          :name (x16 / name :op1 "1.25" :op2 "U/kg"))
                                    :op2 (x18 / observe-01))))
                  :duration (x19 / temporal-quantity
                        :quant "14"
                        :unit (x20 / day)))
            :quant "16"
            :ARG1-of (x22 / rate-entity-91
                  :ARG2 (x23 / genotype)))
      :ARG1-of (x27 / test-01
            :ARG1 (x24 / mantel)
            :ARG0 (x25 / enzyme
                  :name (x26 / name :op1 "cox-2")
                  :xref (x / xref :value "UNIPROT:X2D3Z6_HUMAN" :prob "0.671"))))


# ::id PMC3690480.457
# ::snt Wild-type and p110β-RBD-DM mice received a single intratracheal dose of saline (n = 3 per genotype) or bleomycin (n = 10 per genotype) and weights were taken 14 days later (mean ±SEM; one-way ANOVA).
# ::tok Wild @-@ type and p110β-RBD @-@ DM mice received a single intratracheal dose of saline ( n = 3 per genotype ) or bleomycin ( n = 10 per genotype ) and weights were taken 14 days later ( mean ±SEM ; one @-@ way ANOVA ) .
(x1 / multi-sentence
      :snt1 (x6 / mouse
            :mod (x2 / wild-type)
            :mod (x3 / enzyme
                  :name (x4 / name :op1 "p110β-RBD")
                  :ARG1-of (x5 / dm)
                  :xref (x32 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212")))
      :snt2 (x7 / receive-01
            :ARG1 (x11 / dose-01
                  :ARG1-of (x8 / single-02)
                  :mod (x9 / enzyme
                        :name (x10 / name :op1 "intratracheal"))
                  :ARG2 (x14 / rate-entity-91
                        :ARG1 (x13 / temporal-quantity
                              :ARG1-of (x12 / salinity)
                              :quant "3")
                        :ARG2 (x15 / genotype)))
            :ARG2 (x16 / or
                  :op1 (x17 / medical-condition
                        :name (x18 / name :op1 "bleomycin")
                        :ARG1-of (x19 / genotype :value "10"))
                  :op2 (x21 / take-01
                        :ARG1 (x20 / weight)
                        :ARG1 (x24 / late
                              :op1 (x22 / temporal-quantity
                                    :quant "14"
                                    :unit (x23 / day))
                              :degree (x25 / more))
                        :ARG1-of (x26 / mean-01)
                        :ARG2 (x27 / protein
                              :name (x28 / name :op1 "±SEM")
                              :xref (x / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.292"))))
            :ARG1-of (x29 / small-molecule
                  :mod (x30 / way :quant "1")
                  :name (x31 / name :op1 "ANOVA"))))


# ::id PMC3690480.458
# ::snt Representative lung areas from wild-type and homozygous p110β-RBD-DM mice 14 days after treatment with intratracheal bleomycin (×4 magnification).
# ::tok Representative lung areas from wild @-@ type and homozygous p110β-RBD @-@ DM mice 14 days after treatment with intratracheal bleomycin ( ×4 magnification ) .
(x1 / represent-01
      :ARG1 (x3 / area
            :mod (x2 / lung)
            :source (x9 / mouse
                  :mod (x4 / wild-type)
                  :mod (x5 / enzyme
                        :mod (x6 / homozygous)
                        :name (x7 / name :op1 "p110β-RBD")
                        :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
                  :mod (x8 / dm)
                  :ARG1-of (x12 / after
                        :quant (x10 / temporal-quantity
                              :quant "14"
                              :unit (x11 / day))
                        :op1 (x13 / treat-04
                              :ARG2 (x14 / small-molecule
                                    :name (x15 / name :op1 "intratracheal" :op2 "bleomycin"))
                              :ARG1-of (x17 / magnify-01
                                    :name (x16 / name :op1 "×4")))))))


# ::id PMC3690480.459
# ::snt Top: H&E; middle: IHC for α-SMA; bottom: Sirius red.
# ::tok Top : H&E ; middle : IHC for α-SMA ; bottom : Sirius red .
(x1 / and
      :op1 (x2 / top)
      :op2 (x3 / small-molecule
            :name (x4 / name :op1 "hematoxylin")
            :xref (x14 / xref :value "PUBCHEM:10603" :prob "16.740406"))
      :op2 (x5 / and
            :op1 (x6 / middle)
            :op2 (x7 / immunohistochemistry
                  :ARG2 (x8 / enzyme
                        :name (x9 / name :op1 "α-SMA")
                        :xref (x / xref :value "UNIPROT:SMAKA_HUMAN" :prob "0.282"))
                  :ARG1-of (x10 / describe-01
                        :location (x11 / bottom))
                  :ARG1-of (x13 / red-02
                        :name (x12 / name :op1 "Sirius")))))


# ::id PMC3690480.460
# ::snt Lungs were analyzed by H&E 14 days after bleomycin challenge.
# ::tok Lungs were analyzed by H&E 14 days after bleomycin challenge .
(x2 / analyze-01
      :ARG1 (x1 / lung)
      :ARG0 (x3 / and
            :op1 (x4 / small-molecule
                  :name (x5 / name :op1 "hematoxylin")
                  :xref (x12 / xref :value "PUBCHEM:10603" :prob "16.740406"))
            :op2 (x8 / after
                  :quant (x6 / temporal-quantity
                        :quant "14"
                        :unit (x7 / day))
                  :op1 (x11 / challenge-01
                        :ARG1 (x9 / enzyme
                              :name (x10 / name :op1 "bleomycin")
                              :xref (x / xref :value "UNIPROT:BLMH_HUMAN" :prob "0.282"))))))


# ::id PMC3690480.461
# ::snt Multiple nonoverlapping areas of representative sections from each lung were photographed and transparent (white) areas were quantified using Nikon NIS elements software (mean ±SEM; one-way ANOVA; see Figure S7 C for raw data).
# ::tok Multiple nonoverlapping areas of representative sections from each lung were photographed and transparent ( white ) areas were quantified using Nikon NIS elements software ( mean ±SEM ; one @-@ way ANOVA ; see Figure S7 C for raw data ) .
(x8 / photograph-01
      :ARG1 (x5 / section-01
            :ARG1 (x3 / area
                  :mod (x1 / disease
                        :name (x2 / name :op1 "Multiple" :op2 "nonoverlapping"))
                  :ARG0-of (x4 / represent-01))
            :ARG3 (x7 / lung
                  :mod (x6 / each)))
      :ARG1 (x9 / and
            :op1 (x10 / transparent))
      :ARG1-of (x11 / white-03)
      :ARG1-of (x24 / see-01
            :ARG1 (x12 / area)
            :mod (x13 / quantify-01
                  :manner (x14 / use-01
                        :ARG1 (x15 / and
                              :op1 (x18 / element
                                    :mod (x16 / enzyme
                                          :name (x17 / name :op1 "Nikon" :op2 "NIS"))
                                    :mod (x19 / software
                                          :mod (x20 / mean)
                                          :name (x21 / name :op1 "±SEM")))
                              :op2 (x22 / way :quant "1")))
                  :name (x23 / name :op1 "ANOVA"))
            :mod (x25 / figure :mod "s7")
            :duration (x27 / data
                  :mod (x26 / raw))))


# ::id PMC3690480.462
# ::snt Lungs were analyzed by immunohistochemistry for smooth muscle antigen (α-SMA) 14 days after bleomycin challenge.
# ::tok Lungs were analyzed by immunohistochemistry for smooth muscle antigen ( α-SMA ) 14 days after bleomycin challenge .
(x2 / analyze-01
      :ARG1 (x1 / lung)
      :ARG0 (x3 / immunohistochemistry)
      :ARG1 (x6 / antigen
            :mod (x5 / muscle
                  :ARG1-of (x4 / smooth-06))
            :name (x7 / name :op1 "α-SMA"))
      :time (x10 / after
            :quant (x8 / temporal-quantity
                  :quant "14"
                  :unit (x9 / day))
            :op1 (x13 / challenge-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "bleomycin")
                        :xref (x / xref :value "UNIPROT:BLMH_HUMAN" :prob "0.282")))))


# ::id PMC3690480.463
# ::snt Multiple nonoverlapping areas of representative sections from each lung were photographed and SMA-positive (brown) areas were quantified using Nikon NIS elements software (mean ±SEM; one-way ANOVA; see Figure S7 D for raw data).
# ::tok Multiple nonoverlapping areas of representative sections from each lung were photographed and SMA @-@ positive ( brown ) areas were quantified using Nikon NIS elements software ( mean ±SEM ; one @-@ way ANOVA ; see Figure S7 D for raw data ) .
(x8 / photograph-01
      :ARG1 (x5 / section-01
            :ARG1 (x3 / area
                  :mod (x1 / disease
                        :name (x2 / name :op1 "Multiple" :op2 "nonoverlapping"))
                  :ARG0-of (x4 / represent-01))
            :ARG3 (x7 / lung
                  :mod (x6 / each)))
      :ARG1 (x9 / and
            :op1 (x10 / protein
                  :name (x11 / name :op1 "SMA")
                  :mod (x12 / positive)
                  :xref (x / xref :value "UNIPROT:SMAKA_HUMAN" :prob "0.332")))
      :ARG1-of (x16 / quantify-01
            :ARG0 (x13 / person
                  :wiki "gordon_brown"
                  :name (x14 / name :op1 "brown"))
            :ARG1 (x15 / area)
            :ARG1 (x17 / use-01
                  :ARG1 (x24 / and
                        :op1 (x20 / element
                              :mod (x18 / enzyme
                                    :name (x19 / name :op1 "Nikon" :op2 "NIS"))
                              :mod (x21 / software
                                    :mod (x22 / mean)
                                    :name (x23 / name :op1 "±SEM")))
                        :op1 (x25 / small-molecule
                              :mod (x26 / way :quant "1")
                              :name (x27 / name :op1 "ANOVA"))
                        :op2 (x28 / see-01
                              :ARG2 (x29 / figure
                                    :mod "s7"
                                    :ARG1-of (x30 / describe-01
                                          :ARG0 (x31 / figure :mod "d")))))
                  :ARG2 (x33 / data
                        :mod (x32 / raw)))))


# ::id PMC3690480.464
# ::snt See also Figure S7 .
# ::tok See also Figure S7 .
(x1 / see-01
      :mode "imperative"
      :ARG0 (x2 / you)
      :mod (x3 / also)
      :ARG1-of (x4 / describe-01
            :ARG0 (x5 / figure :mod "s7")))


# ::id PMC3690480.465
# ::snt PI 3-Kinase p110β Is Unable to Interact with RAS, Related to Figure 1
# ::tok PI 3 @-@ Kinase p110β Is Unable to Interact with RAS , Related to Figure 1
(x9 / relate-01
      :ARG1 (x1 / possible-01
            :polarity "-"
            :ARG1 (x6 / interact-01
                  :ARG0 (x2 / enzyme
                        :mod (x3 / enzyme
                              :name (x4 / name :op1 "PI" :op2 "3-Kinase"))
                        :name (x5 / name :op1 "p110β")
                        :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "RAS")
                        :xref (x11 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
      :ARG2 (x10 / figure :mod "1"))


# ::id PMC3690480.466
# ::snt Constitutively active mutants of HRAS, KRAS and NRAS were expressed in COS7 cells along with empty vector, p110α/p85 or p110β/p85.
# ::tok Constitutively active mutants of HRAS , KRAS and NRAS were expressed in COS7 cells along with empty vector , p110α/p85 or p110β/p85 .
(x1 / and
      :op1 (x4 / mutate-01
            :mod (x2 / constitutive)
            :ARG0-of (x3 / activity-06)
            :ARG2 (x5 / enzyme
                  :name (x6 / name :op1 "HRAS")
                  :xref (x22 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
            :ARG1-of (x12 / express-03
                  :ARG2 (x9 / and
                        :op1 (x7 / gene
                              :name (x8 / name :op1 "KRAS")
                              :xref (x21 / xref :value "UNIPROT:RASK_HUMAN" :prob "1.003"))
                        :op2 (x10 / gene
                              :name (x11 / name :op1 "NRAS")
                              :xref (x / xref :value "UNIPROT:RASN_HUMAN" :prob "1.003")))
                  :ARG3 (x14 / cell
                        :name (x13 / name :op1 "COS7"))))
      :op2 (x18 / or
            :op1 (x16 / vector
                  :ARG1-of (x15 / empty-02)
                  :name (x17 / name :op1 "p110α/p85"))
            :op2 (x19 / enzyme
                  :name (x20 / name :op1 "p110β/p85"))))


# ::id PMC3690480.468
# ::snt Wild-type p110β or p110β-RBD-DM were expressed at low levels in COS7 cells, along with p85.
# ::tok Wild @-@ type p110β or p110β-RBD @-@ DM were expressed at low levels in COS7 cells , along with p85 .
(x8 / express-03
      :ARG1 (x4 / or
            :op1 (x1 / enzyme
                  :mod (x2 / wild-type)
                  :name (x3 / name :op1 "p110β")
                  :xref (x16 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
            :op2 (x5 / enzyme
                  :name (x6 / name :op1 "p110β-RBD")
                  :ARG1-of (x7 / dm)
                  :xref (x17 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212")))
      :quant (x10 / level
            :ARG1-of (x9 / low-04))
      :location (x11 / and
            :op1 (x13 / cell
                  :name (x12 / name :op1 "COS7"))
            :op2 (x14 / enzyme
                  :name (x15 / name :op1 "p85")
                  :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))))


# ::id PMC3690480.470
# ::snt Gβγ, coexpression of Gβ 2 and Gγ 1 ; Myr, myristoylated p110β.
# ::tok Gβγ, coexpression of Gβ 2 and Gγ 1 ; Myr , myristoylated p110β.
(x9 / and
      :op1 (x1 / express-03
            :ARG2 (x4 / and
                  :op1 (x2 / enzyme
                        :name (x3 / name :op1 "erk2")
                        :xref (x12 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.603"))
                  :op2 (x5 / enzyme
                        :name (x6 / name :op1 "Gγ")
                        :xref (x13 / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.58"))
                  :op2 "1"
                  :op3 (x7 / protein
                        :name (x8 / name :op1 "Myr"))))
      :op2 (x10 / enzyme
            :name (x11 / name :op1 "p110β.")
            :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242")))


# ::id PMC3690480.471
# ::snt cDNAs encoding all 34 murine members of the RAS subfamily of small GTPases (RFGs) were cloned into pGEX-2T and verified by sequencing.
# ::tok cDNAs encoding all 34 murine members of the RAS subfamily of small GTPases ( RFGs ) were cloned into pGEX @-@ 2T and verified by sequencing .
(x19 / verify-01
      :ARG0 (x3 / encode-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "cDNAs")))
      :ARG1 (x7 / member
            :mod (x4 / all)
            :quant "34"
            :mod (x5 / organism
                  :name (x6 / name :op1 "muridae"))
            :ARG1-of (x8 / include-91
                  :ARG2 (x9 / protein-family
                        :name (x10 / name :op1 "RAS")))
            :mod (x11 / subfamily)
            :part-of (x12 / enzyme
                  :mod (x13 / small)
                  :name (x14 / name :op1 "gtpase")
                  :xref (x / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252"))
            :name (x15 / name :op1 "RFGs"))
      :ARG1-of (x16 / clone-01
            :ARG1 (x17 / protein
                  :name (x18 / name :op1 "pGEX" :op2 "2T")))
      :manner (x20 / sequence-01))


# ::id PMC3690480.472
# ::snt GST-tagged RFGs were expressed in E.
# ::tok GST @-@ tagged RFGs were expressed in E .
(x6 / express-03
      :ARG1 (x1 / enzyme
            :ARG1-of (x4 / tag-01
                  :ARG2 (x2 / protein
                        :name (x3 / name :op1 "GST")
                        :xref (x / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
            :name (x5 / name :op1 "RFGs")
            :xref (x9 / xref :value "UNIPROT:NCOA4_HUMAN" :prob "0.262"))
      :ARG2 (x7 / protein
            :name (x8 / name :op1 "e-cadherin")
            :xref (x10 / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703")))


# ::id PMC3690480.473
# ::snt coli , purified on glutathione agarose, loaded with GDP/GTPγS in vitro and incubated with lysates from transfected COS7 cells, expressing FLAG-p110β/p85.
# ::tok coli , purified on glutathione agarose , loaded with GDP/GTPγS in vitro and incubated with lysates from transfected COS7 cells , expressing FLAG @-@ p110β/p85 .
(x6 / load-01
      :ARG1 (x1 / protein
            :name (x2 / name :op1 "coli")
            :ARG1-of (x3 / purify-01
                  :ARG2 (x4 / enzyme
                        :name (x5 / name :op1 "glutathione" :op2 "agarose")))
            :xref (x19 / xref :value "UNIPROT:COLI_HUMAN" :prob "0.603"))
      :ARG2 (x9 / and
            :op1 (x8 / in-vitro
                  :name (x7 / name :op1 "GDP/GTPγS"))
            :op2 (x10 / incubate-01
                  :ARG2 (x11 / lysate
                        :source (x14 / cell
                              :ARG1-of (x12 / transfect-01
                                    :name (x13 / name :op1 "COS7"))
                              :ARG3-of (x15 / express-03
                                    :ARG2 (x16 / protein
                                          :name (x17 / name :op1 "FLAG")
                                          :xref (x / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                              :name (x18 / name :op1 "p110β/p85"))))))


# ::id PMC3690480.474
# ::snt GST-tagged RFGs were purified from E.
# ::tok GST @-@ tagged RFGs were purified from E .
(x6 / purify-01
      :ARG1 (x1 / enzyme
            :ARG1-of (x4 / tag-01
                  :ARG2 (x2 / protein
                        :name (x3 / name :op1 "GST")
                        :xref (x / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
            :name (x5 / name :op1 "RFGs")
            :xref (x9 / xref :value "UNIPROT:NCOA4_HUMAN" :prob "0.262"))
      :ARG2 (x7 / protein
            :name (x8 / name :op1 "e-cadherin")
            :xref (x10 / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703")))


# ::id PMC3690480.475
# ::snt coli lysates and loaded with GDP/GTPγS in vitro.
# ::tok coli lysates and loaded with GDP/GTPγS in vitro .
(x3 / load-01
      :ARG0 (x2 / lysate
            :name (x1 / name :op1 "coli"))
      :ARG2 (x5 / in-vitro
            :name (x4 / name :op1 "GDP/GTPγS")))


# ::id PMC3690480.476
# ::snt FLAG-tagged p110α, p110γ and p110δ were expressed in COS7 cells along with their respective regulatory subunits p85 or p101.
# ::tok FLAG @-@ tagged p110α, p110γ and p110δ were expressed in COS7 cells along with their respective regulatory subunits p85 or p101 .
(x1 / and
      :op1 (x2 / enzyme
            :ARG1-of (x5 / tag-01
                  :ARG2 (x3 / protein
                        :name (x4 / name :op1 "FLAG")
                        :xref (x24 / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
            :name (x6 / name :op1 "p110α,")
            :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242"))
      :op2 (x12 / express-03
            :ARG2 (x9 / and
                  :op1 (x7 / enzyme
                        :name (x8 / name :op1 "p110γ")
                        :xref (x25 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                  :op2 (x10 / enzyme
                        :name (x11 / name :op1 "p110δ")
                        :xref (x27 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
            :ARG3 (x13 / and
                  :op1 (x15 / cell
                        :name (x14 / name :op1 "COS7"))
                  :op2 (x18 / subunit
                        :mod (x16 / respective)
                        :ARG0-of (x17 / regulate-01)
                        :mod (x21 / or
                              :op1 (x19 / enzyme
                                    :name (x20 / name :op1 "p85")
                                    :xref (x26 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))
                              :op2 (x22 / protein
                                    :name (x23 / name :op1 "p101")))))))


# ::id PMC3690480.477
# ::snt COS7 cell lysates were incubated with GTPases for 1 hr and bound p110 was detected by western blot for FLAG.
# ::tok COS7 cell lysates were incubated with GTPases for 1 hr and bound p110 was detected by western blot for FLAG .
(x4 / incubate-01
      :ARG1 (x3 / lysate
            :mod (x2 / cell
                  :name (x1 / name :op1 "COS7")))
      :ARG2 (x5 / enzyme
            :name (x6 / name :op1 "gtpase")
            :xref (x18 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252"))
      :duration (x7 / temporal-quantity
            :quant "1"
            :unit (x8 / ratio-of
                  :op1 (x13 / detect-01
                        :ARG1 (x9 / and
                              :op1 (x10 / bind-01
                                    :ARG1 (x11 / protein
                                          :name (x12 / name :op1 "p110")
                                          :xref (x17 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.262"))))
                        :ARG2 (x14 / immunoblot-01
                              :ARG1 (x15 / protein
                                    :name (x16 / name :op1 "FLAG")
                                    :xref (x / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))))))


# ::id PMC3690480.478
# ::snt RAC and CDC42 Directly Bind and Active p110β, Related to Figure 2
# ::tok RAC and CDC42 Directly Bind and Active p110β, Related to Figure 2
(x12 / relate-01
      :ARG1 (x8 / and
            :op1 (x7 / bind-01
                  :ARG1 (x3 / and
                        :op1 (x1 / enzyme
                              :name (x2 / name :op1 "RAC")
                              :xref (x14 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                        :op2 (x4 / protein
                              :name (x5 / name :op1 "CDC42")
                              :xref (x15 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                  :ARG1-of (x6 / direct-02))
            :op2 (x9 / enzyme
                  :ARG0-of (x10 / activity-06)
                  :name (x11 / name :op1 "p110β,")
                  :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242")))
      :ARG2 (x13 / figure :mod "2"))


# ::id PMC3690480.479
# ::snt Left: GST-tagged wild-type and D33I mutant HRAS were expressed in E.
# ::tok Left : GST @-@ tagged wild @-@ type and D33I mutant HRAS were expressed in E .
(x6 / and
      :ARG1-of (x1 / left-20)
      :op1 (x2 / enzyme
            :name (x3 / name :op1 "GST")
            :ARG1-of (x4 / tag-01
                  :mod (x5 / wild-type))
            :xref (x16 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))
      :op2 (x12 / express-03
            :ARG2 (x7 / enzyme
                  :name (x8 / name :op1 "D33I")
                  :ARG2-of (x9 / mutate-01
                        :ARG2 (x10 / enzyme
                              :name (x11 / name :op1 "HRAS")
                              :xref (x15 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))))
            :ARG3 (x13 / protein
                  :name (x14 / name :op1 "e-cadherin")
                  :xref (x / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703"))))


# ::id PMC3690480.480
# ::snt coli , purified on glutathione agarose beads, loaded with GDP/GTPγS in vitro, and incubated with lysates from transfected COS7 cells expressing FLAG-p110α/p85 or FLAG-p110β/p85.
# ::tok coli , purified on glutathione agarose beads , loaded with GDP/GTPγS in vitro , and incubated with lysates from transfected COS7 cells expressing FLAG @-@ p110α/p85 or FLAG @-@ p110β/p85 .
(x1 / multi-sentence
      :snt1 (x4 / purify-01
            :ARG1 (x2 / cell-line
                  :name (x3 / name :op1 "coli"))
            :ARG2 (x5 / enzyme
                  :name (x6 / name :op1 "glutathione" :op2 "s-transferase")))
      :snt2 (x7 / load-01
            :ARG2 (x10 / and
                  :op1 (x9 / in-vitro
                        :name (x8 / name :op1 "GDP/GTPγS"))
                  :op2 (x11 / incubate-01
                        :ARG2 (x20 / or
                              :op1 (x12 / lysate
                                    :source (x15 / cell
                                          :ARG1-of (x13 / transfect-01
                                                :name (x14 / name :op1 "COS7"))
                                          :ARG3-of (x16 / express-03
                                                :ARG2 (x17 / protein
                                                      :name (x18 / name :op1 "FLAG")
                                                      :xref (x / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                                          :name (x19 / name :op1 "p110α/p85")))
                              :op2 (x21 / protein
                                    :name (x22 / name :op1 "FLAG" :op2 "p110β/p85")))))))


# ::id PMC3690480.481
# ::snt Right: GST-tagged wild-type and I37D mutant DIRAS1 were probed for binding FLAG-p110α/p85 or FLAG-p110β/p85.
# ::tok Right : GST @-@ tagged wild @-@ type and I37D mutant DIRAS1 were probed for binding FLAG @-@ p110α/p85 or FLAG @-@ p110β/p85 .
(x6 / and
      :op1 (x1 / right-04
            :ARG1-of (x4 / tag-01
                  :ARG2 (x2 / protein
                        :name (x3 / name :op1 "GST")
                        :xref (x23 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
            :mod (x5 / wild-type))
      :op2 (x12 / probe-01
            :ARG1 (x7 / enzyme
                  :name (x8 / name :op1 "I37D")
                  :ARG2-of (x9 / mutate-01
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "DIRAS1")
                              :xref (x22 / xref :value "UNIPROT:DIRA1_HUMAN" :prob "1.002"))))
            :ARG2 (x13 / bind-01
                  :ARG1 (x14 / protein
                        :name (x15 / name :op1 "flag-strad")
                        :ARG1-of (x18 / or
                              :op1 (x16 / enzyme
                                    :name (x17 / name :op1 "p110α/p85"))
                              :op2 (x19 / enzyme
                                    :name (x20 / name :op1 "FLAG")
                                    :xref (x / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                        :name (x21 / name :op1 "p110β/p85")))))


# ::id PMC3690480.482
# ::snt Bound p110 was identified by western blot for FLAG.
# ::tok Bound p110 was identified by western blot for FLAG .
(x4 / identify-01
      :ARG1 (x1 / bind-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "p110")
                  :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.262")))
      :ARG0 (x5 / immunoblot-01
            :ARG1 (x6 / protein
                  :name (x7 / name :op1 "FLAG")
                  :xref (x8 / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222"))))


# ::id PMC3690480.483
# ::snt GST pulldown assay assessing binding of purified recombinant p110β/p85 complexes to immobilized, GDP-/GTPγS-loaded DIRAS1.
# ::tok GST pulldown assay assessing binding of purified recombinant p110β/p85 complexes to immobilized , GDP-/GTPγS @-@ loaded DIRAS1 .
(x4 / assess-02
      :ARG0 (x3 / assay-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "pulldown")))
      :ARG1 (x10 / complex
            :ARG1-of (x5 / bind-01
                  :ARG2 (x6 / enzyme
                        :ARG1-of (x7 / purify-01)
                        :ARG1-of (x8 / recombine-01)
                        :name (x9 / name :op1 "p110β/p85"))))
      :ARG2 (x14 / load-01
            :ARG2 (x11 / protein-segment
                  :ARG1-of (x12 / immobilize-01)
                  :name (x13 / name :op1 "GDP-/GTPγS")))
      :ARG1 (x15 / protein
            :name (x16 / name :op1 "DIRAS1")
            :xref (x / xref :value "UNIPROT:DIRA1_HUMAN" :prob "1.002")))


# ::id PMC3690480.484
# ::snt Lanes 1/2: p85/p110β wild-type; Lanes 3/4: Δp85/p110β wild-type; Lanes 5/6: p85/p110β-RBD-DM.
# ::tok Lanes 1 @/@ 2: p85/p110β wild @-@ type ; Lanes 3 @/@ 4: Δp85/p110β wild @-@ type ; Lanes 5 @/@ 6: p85/p110β-RBD @-@ DM .
(x1 / multi-sentence
      :snt1 (x3 / slash
            :op1 (x2 / lane :mod "1")
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "p85/p110β")
                  :mod (x6 / wild-type)))
      :snt2 (x10 / slash
            :op1 (x9 / lane
                  :mod (x7 / lane :mod "3")
                  :mod "4"
                  :mod (x8 / wild-type)
                  :mod "5")
            :op2 (x11 / enzyme
                  :name (x12 / name :op1 "p85/p110β-RBD")
                  :ARG1-of (x13 / dm))))


# ::id PMC3690480.485
# ::snt Δp85 is depicted in Figure 3 C.
# ::tok Δp85 is depicted in Figure 3 C .
(x3 / depict-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "Δp85")
            :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "0.693"))
      :location (x4 / and
            :op1 (x5 / figure :mod "3")
            :op2 (x6 / figure :mod "5c")))


# ::id PMC3690480.486
# ::snt Color-coded amino acid sequence alignment of the G2 boxes of indicated RHO GTPases, frame highlights RAC1-I33 residue.
# ::tok Color @-@ coded amino acid sequence alignment of the G2 boxes of indicated RHO GTPases , frame highlights RAC1 @-@ I33 residue .
(x12 / highlight-01
      :ARG0 (x4 / dna-sequence
            :ARG0-of (x2 / code-01
                  :ARG0 (x1 / color))
            :mod (x3 / amino-acid)
            :ARG0-of (x5 / align-01
                  :ARG1 (x8 / indicate-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "G2" :op2 "box"))
                        :ARG0 (x9 / pathway
                              :name (x10 / name :op1 "RHO" :op2 "gtpase"))))
            :name (x11 / name :op1 "methionine"))
      :ARG1 (x17 / residue
            :ARG2 (x13 / protein
                  :name (x14 / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :mod (x15 / amino-acid
                  :mod "33"
                  :name (x16 / name :op1 "isoleucine"))))


# ::id PMC3690480.487
# ::snt Purified recombinant, GST-tagged and GDP/GTPγS-loaded RHO subfamily GTPases were incubated with lysates from COS7 cells expressing FLAG-p110β/p85.
# ::tok Purified recombinant , GST @-@ tagged and GDP/GTPγS @-@ loaded RHO subfamily GTPases were incubated with lysates from COS7 cells expressing FLAG @-@ p110β/p85 .
(x6 / and
      :op1 (x5 / tag-01
            :ARG2 (x2 / enzyme
                  :ARG1-of (x1 / purify-01)
                  :ARG0-of (x3 / recombine-01)
                  :name (x4 / name :op1 "GST")
                  :xref (x23 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
      :op2 (x14 / incubate-01
            :ARG1 (x7 / enzyme
                  :name (x8 / name :op1 "GDP/GTPγS")
                  :ARG1-of (x9 / load-01
                        :ARG1 (x10 / protein
                              :name (x11 / name :op1 "RHO")
                              :xref (x22 / xref :value "UNIPROT:OPSD_HUMAN" :prob "1.002"))
                        :ARG2 (x12 / subfamily))
                  :name (x13 / name :op1 "gtpase")
                  :xref (x24 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252"))
            :ARG2 (x15 / lysate
                  :source (x17 / cell
                        :name (x16 / name :op1 "COS7"))
                  :ARG1-of (x18 / express-03
                        :ARG2 (x19 / protein
                              :name (x20 / name :op1 "FLAG")
                              :xref (x / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                  :name (x21 / name :op1 "p110β/p85"))))


# ::id PMC3690480.488
# ::snt Purified recombinant wild-type RAC1 and a RAC1-I33D mutant were compared for GTP-dependent binding to purified recombinant p110β/p85 (50 nM).
# ::tok Purified recombinant wild @-@ type RAC1 and a RAC1 @-@ I33D mutant were compared for GTP @-@ dependent binding to purified recombinant p110β/p85 ( 50 nM ) .
(x12 / compare-01
      :ARG1 (x6 / and
            :op1 (x2 / enzyme
                  :ARG1-of (x1 / purify-01)
                  :ARG0-of (x3 / recombine-01)
                  :mod (x4 / wild-type)
                  :name (x5 / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :op2 (x7 / protein
                  :name (x8 / name :op1 "RAC1")
                  :ARG1-of (x11 / mutate-01
                        :ARG2 (x9 / enzyme
                              :name (x10 / name :op1 "I33D")))
                  :xref (x23 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004")))
      :ARG2 (x16 / bind-01
            :ARG0-of (x15 / depend-01
                  :ARG1 (x13 / small-molecule
                        :name (x14 / name :op1 "GTP")
                        :xref (x24 / xref :value "PUBCHEM:6830" :prob "15.470645")))
            :ARG2 (x17 / enzyme
                  :ARG1-of (x18 / purify-01)
                  :ARG1-of (x19 / recombine-01)
                  :name (x20 / name :op1 "p110β/p85")
                  :quant (x21 / concentration-quantity
                        :quant "50"
                        :unit (x22 / nanomolar)))))


# ::id PMC3690480.489
# ::snt Representative experiment and quantification of two independent experiments are shown (mean and SEM).
# ::tok Representative experiment and quantification of two independent experiments are shown ( mean and SEM ) .
(x9 / and
      :op1 (x1 / represent-01
            :ARG1 (x3 / and
                  :op1 (x2 / experiment-01)
                  :op2 (x7 / show-01
                        :ARG0 (x4 / quantify-01
                              :ARG1 (x6 / experiment-01
                                    :quant "2"
                                    :ARG0-of (x5 / depend-01 :polarity "-")))
                        :ARG1-of (x8 / mean-01))))
      :op2 (x10 / enzyme
            :name (x11 / name :op1 "SEM")
            :xref (x / xref :value "UNIPROT:SEM4F_HUMAN" :prob "0.332")))


# ::id PMC3690480.490
# ::snt 11 selected RHO family GTPases were expressed in E.
# ::tok 11 selected RHO family GTPases were expressed in E .
(x4 / select-01
      :ARG1-of (x1 / describe-01
            :ARG0 (x2 / publication
                  :ARG1-of (x3 / cite-01 :ARG2 "11")))
      :ARG1 (x7 / express-03
            :ARG1 (x5 / protein-family
                  :name (x6 / name :op1 "RHO" :op2 "gtpase"))
            :ARG2 (x8 / protein
                  :name (x9 / name :op1 "e-cadherin")
                  :xref (x / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703"))))


# ::id PMC3690480.491
# ::snt coli , purified on glutathione agarose beads and loaded with GDP/GTPγS in vitro.
# ::tok coli , purified on glutathione agarose beads and loaded with GDP/GTPγS in vitro .
(x7 / load-01
      :ARG1 (x1 / protein
            :name (x2 / name :op1 "coli")
            :ARG1-of (x3 / purify-01
                  :ARG2 (x6 / and
                        :op1 (x4 / enzyme
                              :name (x5 / name :op1 "glutathione")
                              :xref (x10 / xref :value "UNIPROT:GSHB_HUMAN" :prob "0.333"))))
            :xref (x / xref :value "UNIPROT:COLI_HUMAN" :prob "0.603"))
      :ARG2 (x9 / in-vitro
            :name (x8 / name :op1 "GDP/GTPγS")))


# ::id PMC3690480.492
# ::snt HRAS was included as positive control.
# ::tok HRAS was included as positive control .
(x3 / include-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "HRAS")
            :xref (x / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
      :condition (x5 / control
            :mod (x4 / positive)))


# ::id PMC3690480.493
# ::snt Pulldown was made from a lysate of transfected COS7 cells expressing FLAG-p110α/p85.
# ::tok Pulldown was made from a lysate of transfected COS7 cells expressing FLAG @-@ p110α/p85 .
(x2 / make-01
      :ARG1 (x1 / pulldown)
      :ARG2 (x3 / lysate
            :mod (x6 / cell
                  :ARG1-of (x4 / transfect-01
                        :name (x5 / name :op1 "COS7"))
                  :ARG3-of (x7 / express-03
                        :ARG2 (x8 / protein
                              :name (x9 / name :op1 "FLAG")
                              :xref (x / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                  :name (x10 / name :op1 "p110α/p85"))))


# ::id PMC3690480.494
# ::snt Constitutively active mutants of RAC1 and CDC42 (Myc-tagged) were expressed in COS7 cells along with empty vector, FLAG-p110β/p85 or FLAG-p110β-RBD-DM/p85.
# ::tok Constitutively active mutants of RAC1 and CDC42 ( Myc @-@ tagged ) were expressed in COS7 cells along with empty vector , FLAG @-@ p110β/p85 or FLAG @-@ p110β-RBD @-@ DM/p85 .
(x12 / express-03
      :ARG1 (x3 / mutate-01
            :mod (x1 / constitutive)
            :ARG0-of (x2 / activity-06)
            :ARG2 (x6 / and
                  :op1 (x4 / protein
                        :name (x5 / name :op1 "RAC1")
                        :xref (x25 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x7 / protein
                        :name (x8 / name :op1 "CDC42")
                        :xref (x24 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
            :ARG1-of (x11 / tag-01
                  :ARG2 (x9 / protein
                        :name (x10 / name :op1 "Myc")
                        :xref (x / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604"))))
      :ARG3 (x13 / and
            :op1 (x15 / cell
                  :name (x14 / name :op1 "COS7"))
            :op2 (x21 / or
                  :op1 (x17 / vector
                        :ARG1-of (x16 / empty-02)
                        :mod (x18 / protein
                              :name (x19 / name :op1 "FLAG")
                              :xref (x26 / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222"))
                        :name (x20 / name :op1 "p110β/p85"))
                  :op2 (x22 / protein
                        :name (x23 / name :op1 "p110β-RBD" :op2 "DM/p85")))))


# ::id PMC3690480.495
# ::snt Constitutively active mutants of RAC1, CDC42 and RHOA (Myc-tagged) were expressed in COS7 cells along with empty vector or FLAG-p110β/p85.
# ::tok Constitutively active mutants of RAC1 , CDC42 and RHOA ( Myc @-@ tagged ) were expressed in COS7 cells along with empty vector or FLAG @-@ p110β/p85 .
(x14 / express-03
      :ARG2 (x1 / enzyme
            :ARG0-of (x3 / activity-06
                  :mod (x2 / constitutive))
            :ARG2-of (x4 / mutate-01)
            :name (x5 / name :op1 "RAC1")
            :xref (x26 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
      :ARG1 (x8 / and
            :op1 (x6 / protein
                  :name (x7 / name :op1 "CDC42")
                  :xref (x27 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
            :op2 (x9 / protein
                  :name (x10 / name :op1 "RHOA")
                  :ARG1-of (x13 / tag-01
                        :ARG2 (x11 / protein
                              :name (x12 / name :op1 "Myc")
                              :xref (x28 / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604")))
                  :xref (x25 / xref :value "UNIPROT:RHOA_HUMAN" :prob "1.004")))
      :ARG3 (x16 / cell
            :name (x15 / name :op1 "COS7"))
      :ARG2 (x17 / gene
            :ARG2-of (x18 / border-01
                  :ARG2 (x21 / or
                        :op1 (x20 / vector
                              :ARG1-of (x19 / empty-02))
                        :op2 (x22 / protein
                              :name (x23 / name :op1 "FLAG")
                              :xref (x / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222"))))
            :name (x24 / name :op1 "p110β/p85")))


# ::id PMC3690480.497
# ::snt Representative lipid kinase assay assessing the effect of increasing concentrations of purified recombinant GTPγS-loaded RAC1 and CDC42 on the activity of purified recombinant p110α/p85 protein complexes.
# ::tok Representative lipid kinase assay assessing the effect of increasing concentrations of purified recombinant GTPγS @-@ loaded RAC1 and CDC42 on the activity of purified recombinant p110α/p85 protein complexes .
(x1 / represent-01
      :ARG0 (x4 / assay-01
            :mod (x2 / lipid)
            :ARG1 (x3 / kinase)
            :ARG0-of (x5 / assess-01))
      :ARG1 (x6 / affect-01
            :ARG0 (x8 / concentrate-02
                  :ARG1-of (x7 / increase-01)
                  :ARG1 (x10 / enzyme
                        :ARG1-of (x9 / purify-01)
                        :ARG1-of (x14 / load-01
                              :ARG2 (x11 / enzyme
                                    :ARG0-of (x12 / recombine-01)
                                    :name (x13 / name :op1 "GTPγS"))))
                  :ARG1 (x17 / and
                        :op1 (x15 / protein
                              :name (x16 / name :op1 "RAC1")
                              :xref (x26 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                        :op2 (x18 / protein
                              :name (x19 / name :op1 "CDC42")
                              :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))
            :ARG1 (x25 / macro-molecular-complex
                  :ARG0-of (x20 / activity-06
                        :ARG1 (x24 / protein
                              :ARG1-of (x21 / purify-01)
                              :ARG3-of (x22 / recombine-01
                                    :name (x23 / name :op1 "p110α/p85")))))))


# ::id PMC3690480.498
# ::snt Constitutively active mutants of RAC1 and CDC42 (Myc-tagged) were expressed in COS7 cells along with empty vector, FLAG-tagged p110α/p85, p110γ/p101 or p110δ/p85.
# ::tok Constitutively active mutants of RAC1 and CDC42 ( Myc @-@ tagged ) were expressed in COS7 cells along with empty vector , FLAG @-@ tagged p110α/p85 , p110γ/p101 or p110δ/p85 .
(x1 / multi-sentence
      :snt1 (x13 / express-03
            :ARG2 (x4 / mutate-01
                  :mod (x2 / constitutive)
                  :ARG0-of (x3 / activity-06)
                  :ARG2 (x7 / and
                        :op1 (x5 / protein
                              :name (x6 / name :op1 "RAC1")
                              :xref (x30 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                        :op2 (x8 / protein
                              :name (x9 / name :op1 "CDC42")
                              :xref (x29 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                  :ARG1-of (x12 / tag-01
                        :ARG2 (x10 / protein
                              :name (x11 / name :op1 "Myc")
                              :xref (x31 / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604"))))
            :ARG3 (x15 / cell
                  :name (x14 / name :op1 "COS7")
                  :ARG1-of (x16 / along-with)))
      :snt2 (x26 / or
            :op1 (x18 / vector
                  :ARG1-of (x17 / empty-02))
            :op2 (x19 / enzyme
                  :ARG1-of (x22 / tag-01
                        :ARG2 (x20 / protein
                              :name (x21 / name :op1 "FLAG")
                              :xref (x / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                  :name (x23 / name :op1 "p110α/p85"))
            :op1 (x24 / enzyme
                  :name (x25 / name :op1 "p110γ/p101"))
            :op2 (x27 / enzyme
                  :name (x28 / name :op1 "p110δ/p85"))))


# ::id PMC3690480.500
# ::snt RAC and CDC42 Are Interactors of the p110β RAS-Binding Domain, Related to Figure 3
# ::tok RAC and CDC42 Are Interactors of the p110β RAS @-@ Binding Domain , Related to Figure 3
(x6 / interact-01
      :ARG1 (x3 / and
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "RAC")
                  :xref (x14 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :op2 (x4 / protein
                  :name (x5 / name :op1 "CDC42")
                  :xref (x15 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :ARG0 (x8 / protein-segment
            :name (x7 / name :op1 "p110β")
            :ARG0-of (x11 / bind-01
                  :ARG1 (x9 / enzyme
                        :name (x10 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
            :ARG1-of (x12 / relate-01
                  :ARG2 (x13 / figure :mod "3"))))


# ::id PMC3690480.501
# ::snt 43 single point mutations of 37 RBD residues were introduced by site-directed mutagenesis.
# ::tok 43 single point mutations of 37 RBD residues were introduced by site @-@ directed mutagenesis .
(x6 / introduce-02
      :ARG1 (x3 / mutate-01
            :quant "43"
            :ARG1-of (x1 / single-02)
            :mod (x2 / point)
            :quant "37"
            :ARG0-of (x5 / residue
                  :name (x4 / name :op1 "RBD")))
      :ARG0 (x7 / protein-segment
            :ARG1-of (x8 / direct-01
                  :ARG2 (x9 / mutagenesis))))


# ::id PMC3690480.502
# ::snt Mutants were expressed in COS7 cells, along with p85, and lysates were incubated with GST-tagged, GTPγS-loaded RAC1 and CDC42.
# ::tok Mutants were expressed in COS7 cells , along with p85 , and lysates were incubated with GST @-@ tagged , GTPγS @-@ loaded RAC1 and CDC42 .
(x8 / and
      :op1 (x2 / express-03
            :ARG2 (x1 / mutate-01)
            :ARG3 (x3 / and
                  :op1 (x5 / cell
                        :name (x4 / name :op1 "COS7"))
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "p85")
                        :xref (x24 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))))
      :op2 (x10 / incubate-01
            :ARG0 (x9 / lysate)
            :ARG2 (x16 / load-01
                  :ARG2 (x11 / protein
                        :ARG1-of (x14 / tag-01
                              :ARG2 (x12 / protein
                                    :name (x13 / name :op1 "GST")
                                    :xref (x23 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
                        :name (x15 / name :op1 "GTPγS")))
            :ARG1 (x19 / and
                  :op1 (x17 / protein
                        :name (x18 / name :op1 "RAC1")
                        :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x20 / protein
                        :name (x21 / name :op1 "CDC42")
                        :xref (x22 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))))


# ::id PMC3690480.503
# ::snt Bound p110β was detected by western blot for FLAG.
# ::tok Bound p110β was detected by western blot for FLAG .
(x4 / detect-01
      :ARG1 (x1 / bind-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "p110β")
                  :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252")))
      :ARG2 (x5 / immunoblot-01
            :ARG1 (x6 / protein
                  :name (x7 / name :op1 "FLAG")
                  :xref (x8 / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222"))))


# ::id PMC3690480.504
# ::snt Mutants with reduced protein expression levels were deemed unstable and excluded from experiments.
# ::tok Mutants with reduced protein expression levels were deemed unstable and excluded from experiments .
(x9 / exclude-01
      :ARG1 (x1 / mutate-01
            :ARG2 (x5 / level
                  :ARG1-of (x2 / reduce-01
                        :ARG1 (x4 / express-03
                              :ARG2 (x3 / protein)))
                  :ARG1-of (x6 / deem-01
                        :ARG1 (x8 / and
                              :ARG1-of (x7 / stable-03 :polarity "-")))))
      :ARG2 (x10 / experiment-01))


# ::id PMC3690480.505
# ::snt Point mutations made are listed along with their impact on binding to RAC1 and CDC42 (+, no effect on binding; (+), reduced binding; −, complete or near complete loss of binding; unst., unstable protein).
# ::tok Point mutations made are listed along with their impact on binding to RAC1 and CDC42 ( +, no effect on binding ; ( + ) , reduced binding ; −, complete or near complete loss of binding ; unst . , unstable protein ) .
(x15 / affect-01
      :ARG0 (x2 / mutate-01
            :mod (x1 / point))
      :degree (x5 / impact-01
            :ARG1 (x3 / and
                  :op1 (x4 / list-01))
            :ARG1 (x6 / bind-01
                  :ARG2 (x9 / and
                        :op1 (x7 / protein
                              :name (x8 / name :op1 "RAC1")
                              :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                        :op2 (x10 / protein
                              :name (x11 / name :op1 "CDC42")
                              :xref (x33 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))
            :ARG1-of (x12 / describe-01
                  :ARG0 (x13 / protein
                        :name (x14 / name :op1 "igf-1r")
                        :xref (x34 / xref :value "UNIPROT:IGF1R_HUMAN" :prob "0.593"))))
      :polarity "-"
      :ARG1 (x16 / and
            :op1 (x17 / bind-01)
            :op2 (x31 / stable-03
                  :ARG2 (x18 / and
                        :op1 (x19 / reduce-01
                              :ARG1 (x20 / bind-01))
                        :op2 (x23 / complete-01
                              :ARG0 (x21 / protein
                                    :name (x22 / name :op1 "−,"))
                              :ARG1 (x24 / or
                                    :op2 (x27 / lose-02
                                          :ARG1-of (x26 / complete-02
                                                :degree (x25 / near))
                                          :ARG1 (x28 / bind-01)))
                              :ARG1 (x29 / protein
                                    :name (x30 / name :op1 "unst"))))
                  :ARG1 (x32 / protein))))


# ::id PMC3690480.506
# ::snt Top: the differential power recorded directly over time; bottom: thermal energy (H) over molar ratio.
# ::tok Top : the differential power recorded directly over time ; bottom : thermal energy ( H ) over molar ratio .
(x4 / record-01
      :mod (x1 / top)
      :ARG0 (x3 / power
            :mod (x2 / differential))
      :ARG1-of (x5 / direct-02)
      :ARG1 (x6 / and
            :op1 (x7 / time)
            :op2 (x10 / energy
                  :location (x8 / bottom)
                  :mod (x9 / heat)
                  :name (x11 / name :op1 "h-ras")))
      :ARG2 (x13 / ratio-of
            :op1 (x12 / molar)))


# ::id PMC3690480.507
# ::snt RAC/CDC42 Binding to p110β Regulates PI3K Activity In Vivo, Related to Figure 4
# ::tok RAC @/@ CDC42 Binding to p110β Regulates PI3K Activity In Vivo , Related to Figure 4
(x9 / regulate-01
      :ARG1 (x1 / and
            :op1 (x2 / enzyme
                  :name (x3 / name :op1 "RAC")
                  :xref (x16 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :op2 (x6 / bind-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "CDC42")
                        :xref (x18 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
                  :ARG2 (x7 / protein
                        :name (x8 / name :op1 "p110β")
                        :xref (x17 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))))
      :ARG1 (x12 / activity-06
            :ARG0 (x10 / enzyme
                  :name (x11 / name :op1 "PI3K")
                  :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
      :manner (x13 / in-vivo)
      :ARG1-of (x14 / relate-01
            :ARG2 (x15 / figure :mod "4")))


# ::id PMC3690480.508
# ::snt An FRT-flanked neomycin selection cassette was inserted into murine genomic DNA provided by a BAC clone, immediately downstream of Pik3cb exon 6, using Red/ET recombination technology (Genebridges).
# ::tok An FRT @-@ flanked neomycin selection cassette was inserted into murine genomic DNA provided by a BAC clone , immediately downstream of Pik3 cb exon 6 , using Red @/@ ET recombination technology ( Genebridges ) .
(x13 / provide-01
      :ARG0 (x7 / insert-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "FRT")
                  :xref (x / xref :value "UNIPROT:VGFR1_HUMAN" :prob "1.002"))
            :ARG1 (x6 / cassette
                  :ARG2-of (x5 / select-01
                        :ARG0 (x3 / flank-01)
                        :ARG1 (x4 / neomycin)))
            :ARG2 (x8 / medical-condition
                  :mod (x9 / organism
                        :name (x10 / name :op1 "muridae"))
                  :mod (x11 / genome)
                  :name (x12 / name :op1 "DNA")))
      :ARG0 (x16 / clone-01
            :ARG1 (x14 / enzyme
                  :name (x15 / name :op1 "BAC")
                  :xref (x27 / xref :value "UNIPROT:BACE1_HUMAN" :prob "0.262")))
      :ARG1 (x21 / use-01
            :ARG1 (x20 / exon
                  :mod (x18 / downstream
                        :mod (x17 / immediate)
                        :name (x19 / name :op1 "pik3/mtor"))
                  :mod "6")
            :ARG2 (x23 / and
                  :op1 (x22 / red-02)
                  :op2 (x25 / technology
                        :mod (x24 / recombination)))
            :ARG1-of (x26 / genebridges)))


# ::id PMC3690480.509
# ::snt Selection cassette and flanking arms of genomic DNA were sub-cloned and mutations (★) introduced by site-directed mutagenesis.
# ::tok Selection cassette and flanking arms of genomic DNA were sub @-@ cloned and mutations ( ★ ) introduced by site @-@ directed mutagenesis .
(x16 / introduce-02
      :ARG1 (x3 / and
            :op1 (x2 / cassette
                  :ARG2-of (x1 / select-01))
            :op2 (x6 / arm
                  :mod (x4 / dna-sequence
                        :name (x5 / name :op1 "5'-flanking"))
                  :mod (x7 / genome)
                  :name (x8 / name :op1 "DNA")))
      :ARG1-of (x11 / clone-01
            :ARG0 (x9 / protein
                  :name (x10 / name :op1 "sub-g1")
                  :xref (x / xref :value "UNIPROT:TCP4_HUMAN" :prob "0.222"))
            :ARG1 (x12 / and
                  :op1 (x13 / mutate-01)
                  :op2 (x14 / small-molecule
                        :name (x15 / name :op1 "★"))))
      :ARG0 (x18 / direct-01
            :ARG0 (x17 / protein-segment))
      :ARG1 (x19 / enzyme
            :name (x20 / name :op1 "mutagenesis")))


# ::id PMC3690480.510
# ::snt Arrows indicate priming sites for ES cell screening and genotyping.
# ::tok Arrows indicate priming sites for ES cell screening and genotyping .
(x2 / indicate-01
      :ARG0 (x1 / arrow)
      :ARG1 (x7 / screen-01
            :ARG1 (x4 / site
                  :mod (x3 / priming)
                  :purpose (x6 / cell
                        :name (x5 / name :op1 "ES")))
            :ARG2 (x8 / genotyping)))


# ::id PMC3690480.511
# ::snt The neomycin selection cassette was later removed by crosses of heterozygous p110β-RBD-DM mice with FLPe mice.
# ::tok The neomycin selection cassette was later removed by crosses of heterozygous p110β-RBD @-@ DM mice with FLPe mice .
(x6 / remove-01
      :ARG1 (x3 / cassette
            :ARG2-of (x2 / select-01
                  :ARG0 (x1 / neomycin)))
      :time (x4 / late
            :degree (x5 / more))
      :ARG0 (x7 / cross-01)
      :ARG1 (x11 / mouse
            :mod (x8 / heterozygous
                  :name (x9 / name :op1 "p110β-RBD"))
            :mod (x10 / dm))
      :ARG2 (x12 / mouse))


# ::id PMC3690480.512
# ::snt Homologous recombination in ES cells was confirmed by long genomic PCR bridging the entire targeting region (top, targeted allele 10kb, wild-type allele 8.5kb).
# ::tok Homologous recombination in ES cells was confirmed by long genomic PCR bridging the entire targeting region ( top , targeted allele 10 kb , wild @-@ type allele 8.5kb ) .
(x5 / confirm-01
      :ARG1 (x1 / homologous
            :mod (x2 / recombination)
            :location (x4 / cell
                  :name (x3 / name :op1 "ES")))
      :ARG0 (x7 / genome
            :ARG1-of (x6 / long-03))
      :ARG2-of (x11 / bridge-01
            :ARG0 (x8 / react-01
                  :ARG0 (x9 / polymerase)
                  :ARG1-of (x10 / chain-01))
            :ARG1 (x21 / allele
                  :ARG1-of (x13 / target-01
                        :degree (x12 / entire)
                        :ARG1 (x14 / region)
                        :ARG1-of (x15 / describe-01
                              :location (x16 / top)
                              :ARG1-of (x17 / target-01))
                        :ARG1 (x18 / allele
                              :mod "10"
                              :name (x19 / name :op1 "kb")))
                  :mod (x20 / wild-type)
                  :mod (x22 / enzyme
                        :name (x23 / name :op1 "8.5kb")))))


# ::id PMC3690480.513
# ::snt After FLP recombination, MEFs (middle) and mice (bottom) were genotyped using primer pairs flanking the remaining FRT adjacent to exon 6.
# ::tok After FLP recombination , MEFs ( middle ) and mice ( bottom ) were genotyped using primer pairs flanking the remaining FRT adjacent to exon 6 .
(x20 / border-01
      :time (x1 / after
            :op1 (x2 / recombination))
      :ARG0 (x17 / remain-01
            :ARG1 (x13 / use-01
                  :ARG1 (x7 / and
                        :op1 (x3 / cell
                              :name (x4 / name :op1 "mef")
                              :ARG1-of (x5 / describe-01
                                    :location (x6 / middle)))
                        :op2 (x8 / mouse
                              :ARG1-of (x9 / describe-01
                                    :location (x10 / bottom))))
                  :ARG2 (x11 / enzyme
                        :name (x12 / name :op1 "genotyped")))
            :ARG2 (x15 / pair
                  :mod (x14 / prime)
                  :name (x16 / name :op1 "5'-flanking"))
            :ARG1 (x18 / enzyme
                  :name (x19 / name :op1 "FRT")
                  :xref (x / xref :value "UNIPROT:VGFR1_HUMAN" :prob "1.002")))
      :ARG1 (x21 / exon :mod "6"))


# ::id PMC3690480.514
# ::snt Genomic DNA from heterozygous and homozygous p110β-RBD-DM mice was isolated and exon 6 was PCR amplified and sequenced using standard techniques.
# ::tok Genomic DNA from heterozygous and homozygous p110β-RBD @-@ DM mice was isolated and exon 6 was PCR amplified and sequenced using standard techniques .
(x17 / use-01
      :ARG0 (x16 / sequence-01
            :mod (x1 / genome
                  :name (x2 / name :op1 "DNA")
                  :source (x10 / and
                        :op1 (x9 / isolate-01
                              :ARG2 (x4 / enzyme
                                    :mod (x3 / heterozygous)
                                    :mod (x5 / homozygous)
                                    :name (x6 / name :op1 "p110β-RBD")
                                    :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
                              :ARG1 (x8 / mouse
                                    :mod (x7 / dm)))
                        :op2 (x15 / amplify-01
                              :ARG1 (x11 / exon :mod "6")
                              :ARG0-of (x12 / react-01
                                    :ARG0 (x13 / polymerase)
                                    :ARG1-of (x14 / chain-01))))))
      :ARG1 (x19 / technique
            :mod (x18 / standard)))


# ::id PMC3690480.515
# ::snt Wild-type and homozygous p110β-RBD-DM MEFs were maintained in 0%, 1% and 10% FCS, respectively.
# ::tok Wild @-@ type and homozygous p110β-RBD @-@ DM MEFs were maintained in 0 % , 1 % and 10 % FCS , respectively .
(x6 / maintain-01
      :ARG1 (x1 / enzyme
            :mod (x2 / wild-type)
            :mod (x3 / homozygous
                  :name (x4 / name :op1 "p110β-RBD"))
            :name (x5 / name :op1 "mef")
            :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
      :location (x9 / and
            :op1 (x7 / percentage-entity :value "0")
            :op2 (x8 / percentage-entity :value "1")
            :op2 (x10 / cell-line
                  :quant (x11 / percentage-entity :value "10")
                  :name (x12 / name :op1 "FCS"))
            :mod (x13 / respective)))


# ::id PMC3690480.516
# ::snt Lysates were made for western blot analysis.
# ::tok Lysates were made for western blot analysis .
(x2 / make-01
      :ARG1 (x1 / lysate)
      :ARG0 (x4 / analyze-01
            :manner (x3 / immunoblot-01)))


# ::id PMC3690480.518
# ::snt The coprecipitation of p110α and p110β along with p85 was assessed by western blot.
# ::tok The coprecipitation of p110α and p110β along with p85 was assessed by western blot .
(x8 / assess-01
      :ARG1 (x1 / protein-segment
            :name (x2 / name :op1 "coprecipitation")
            :part-of (x3 / and
                  :op1 (x4 / enzyme
                        :name (x5 / name :op1 "p110β")
                        :xref (x10 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                  :op2 (x6 / protein
                        :name (x7 / name :op1 "p85")
                        :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))))
      :manner (x9 / immunoblot-01))


# ::id PMC3690480.519
# ::snt Immortalized p110α lox/lox ;CreER +/− and p110β lox/lox ;CreER +/− MEFs were treated with 4-hydroxytamoxifen (1 μM) for 3 consecutive days, prior to use in experiments.
# ::tok Immortalized p110α lox @/@ lox ; CreER +/− and p110β lox @/@ lox ; CreER +/− MEFs were treated with 4 @-@ hydroxytamoxifen ( 1 μM ) for 3 consecutive days , prior to use in experiments .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op1 (x3 / immortalize-03
                  :op2 (x4 / lox)
                  :op1 (x5 / lox))
            :op2 (x8 / and
                  :op1 (x6 / enzyme
                        :name (x7 / name :op1 "+/−"))
                  :op2 (x9 / lox)
                  :op2 (x10 / enzyme
                        :name (x11 / name :op1 "lox-stop-lox")
                        :xref (x / xref :value "UNIPROT:LYOX_HUMAN" :prob "0.202"))))
      :snt2 (x16 / treat-04
            :ARG0 (x12 / protein
                  :name (x13 / name :op1 "CreER" :op2 "+/−"))
            :ARG1 (x14 / cell
                  :name (x15 / name :op1 "mef"))
            :ARG2 (x17 / protein
                  :name (x18 / name :op1 "il-4")
                  :xref (x29 / xref :value "UNIPROT:IL4_HUMAN" :prob "0.653"))
            :ARG2 (x19 / small-molecule
                  :name (x20 / name :op1 "hydroxytamoxifen")
                  :quant (x21 / concentration-quantity
                        :quant "1"
                        :unit (x22 / micromolar))
                  :xref (x30 / xref :value "PUBCHEM:449459" :prob "16.221611"))
            :duration (x23 / temporal-quantity
                  :quant "3"
                  :unit (x25 / day
                        :mod (x24 / consecutive)))
            :time (x26 / prior
                  :op1 (x27 / use-01
                        :ARG1 (x28 / experiment-01)))))


# ::id PMC3690480.520
# ::snt RAC Activates p110β Downstream of G Protein-Coupled Receptors, Related to Figure 5
# ::tok RAC Activates p110β Downstream of G Protein @-@ Coupled Receptors , Related to Figure 5
(x8 / relate-01
      :ARG1 (x3 / activate-01
            :ARG0 (x1 / enzyme
                  :name (x2 / name :op1 "RAC")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :ARG1 (x4 / relative-position
                  :direction (x5 / downstream)
                  :op1 (x6 / protein
                        :name (x7 / name
                              :op1 "G"
                              :op2 "Protein-Coupled"
                              :op3 "receptor"))))
      :ARG2 (x9 / figure :mod "5"))


# ::id PMC3690480.521
# ::snt Primary wild-type and homozygous p110β-RBD-DM MEFs were serum-starved and stimulated with sphingosine 1-phosphate (S1P) at indicated doses.
# ::tok Primary wild @-@ type and homozygous p110β-RBD @-@ DM MEFs were serum @-@ starved and stimulated with sphingosine 1 @-@ phosphate ( S1P ) at indicated doses .
(x14 / phosphate
      :ARG1 (x1 / cell
            :mod (x2 / primary)
            :mod (x3 / wild-type)
            :mod (x4 / enzyme
                  :mod (x5 / homozygous)
                  :name (x6 / name :op1 "p110β-RBD")
                  :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :name (x7 / name :op1 "mef"))
      :ARG2 (x10 / and
            :ARG1-of (x9 / starve-01
                  :ARG2 (x8 / serum))
            :op2 (x11 / stimulate-01
                  :ARG2 (x12 / enzyme
                        :name (x13 / name :op1 "sphingosine" :op2 "1"))))
      :ARG1-of (x15 / s1p)
      :time (x17 / dose-01
            :ARG1-of (x16 / indicate-01)))


# ::id PMC3690480.523
# ::snt Immortalized wild-type MEFs were serum starved overnight and stimulated with EGF, LPA or S1P for 5 min.
# ::tok Immortalized wild @-@ type MEFs were serum starved overnight and stimulated with EGF , LPA or S1P for 5 min .
(x6 / starve-01
      :ARG1 (x3 / cell
            :ARG1-of (x1 / immortalize-03)
            :mod (x2 / wild-type)
            :name (x4 / name :op1 "mef"))
      :ARG2 (x5 / serum)
      :time (x7 / overnight)
      :ARG2 (x14 / or
            :op1 (x8 / and
                  :op2 (x9 / stimulate-01
                        :ARG2 (x10 / protein
                              :name (x11 / name :op1 "EGF")
                              :xref (x19 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :op3 (x12 / small-molecule
                        :name (x13 / name :op1 "LPA")
                        :xref (x20 / xref :value "PUBCHEM:62707" :prob "9.981436")))
            :op2 (x15 / protein
                  :name (x16 / name :op1 "S1P")
                  :xref (x / xref :value "UNIPROT:MBTP1_HUMAN" :prob "1.002")))
      :duration (x17 / temporal-quantity
            :quant "5"
            :unit (x18 / minute)))


# ::id PMC3690480.524
# ::snt Pertussis toxin (PTX, 200 ng/ml) was added 16 prior to stimulation where indicated.
# ::tok Pertussis toxin ( PTX , 200 ng/ml ) was added 16 prior to stimulation where indicated .
(x14 / indicate-01
      :ARG1 (x7 / add-02
            :ARG0 (x1 / small-molecule
                  :name (x2 / name :op1 "Pertussis" :op2 "toxin"))
            :ARG1 (x3 / small-molecule
                  :name (x4 / name :op1 "PTX")
                  :quant (x5 / concentration-quantity
                        :quant "200"
                        :unit (x6 / nanogram-per-milliliter))
                  :xref (x / xref :value "PUBCHEM:4740" :prob "17.474375"))
            :ARG1-of (x8 / describe-01
                  :ARG0 (x9 / publication
                        :ARG1-of (x10 / cite-01 :ARG2 "16")))
            :time (x11 / prior
                  :op1 (x12 / stimulate-01)))
      :ARG0 (x13 / amr-unknown))


# ::id PMC3690480.525
# ::snt Primary wild-type and p110β-RBD-DM MEFs were serum-starved and stimulated with EGF, PDGF or insulin at indicated doses.
# ::tok Primary wild @-@ type and p110β-RBD @-@ DM MEFs were serum @-@ starved and stimulated with EGF , PDGF or insulin at indicated doses .
(x16 / or
      :ARG0 (x3 / and
            :mod (x1 / primary)
            :mod (x2 / wild-type)
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "p110β-RBD")
                  :mod (x6 / enzyme
                        :name (x7 / name :op1 "mef")
                        :xref (x23 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :xref (x24 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :ARG0-of (x10 / and
                  :ARG1-of (x9 / starve-01
                        :ARG2 (x8 / serum))
                  :op1 (x11 / stimulate-01
                        :ARG0 (x12 / protein
                              :name (x13 / name :op1 "EGF")
                              :xref (x22 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :op2 (x14 / protein
                        :name (x15 / name :op1 "PDGF")
                        :xref (x21 / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313"))))
      :op2 (x17 / protein
            :name (x18 / name :op1 "insulin")
            :xref (x / xref :value "UNIPROT:INS_HUMAN" :prob "0.703"))
      :time (x20 / dose-01
            :ARG1-of (x19 / indicate-01)))


# ::id PMC3690480.527
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific individual siRNA oligonucleotides targeting RAC1 or CDC42.
# ::tok Immortalized wild @-@ type MEFs were transfected with scrambled duplex or gene @-@ specific individual siRNA oligonucleotides targeting RAC1 or CDC42 .
(x4 / transfect-01
      :ARG1 (x1 / immortalize-03
            :mod (x2 / wild-type)
            :name (x3 / name :op1 "mef"))
      :ARG2 (x7 / or
            :ARG1-of (x5 / scramble-02)
            :op1 (x6 / duplex)
            :op2 (x10 / individual
                  :ARG1-of (x9 / specific-02
                        :ARG2 (x8 / gene))
                  :ARG0-of (x12 / oligonucleotide
                        :name (x11 / name :op1 "siRNA")
                        :ARG0-of (x13 / target-01
                              :ARG1 (x16 / or
                                    :op1 (x14 / protein
                                          :name (x15 / name :op1 "RAC1")
                                          :xref (x19 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                                    :op2 (x17 / protein
                                          :name (x18 / name :op1 "CDC42")
                                          :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))))))


# ::id PMC3690480.528
# ::snt 48 hr after transfection, serum-starved cells were stimulated with LPA (10 μM) for 5 min.
# ::tok 48 hr after transfection , serum @-@ starved cells were stimulated with LPA ( 10 μM ) for 5 min .
(x8 / stimulate-01
      :time (x3 / after
            :quant (x1 / temporal-quantity
                  :quant "48"
                  :unit (x2 / ratio-of))
            :op1 (x4 / transfect-01))
      :ARG1 (x7 / cell
            :ARG1-of (x6 / starve-01
                  :ARG2 (x5 / serum)))
      :ARG2 (x9 / small-molecule
            :name (x10 / name :op1 "LPA")
            :quant (x11 / concentration-quantity
                  :quant "10"
                  :unit (x12 / micromolar))
            :xref (x / xref :value "PUBCHEM:62707" :prob "9.981436"))
      :duration (x13 / temporal-quantity
            :quant "5"
            :unit (x14 / minute)))


# ::id PMC3690480.529
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific siRNA pools targeting RAC1 or CDC42.
# ::tok Immortalized wild @-@ type MEFs were transfected with scrambled duplex or gene @-@ specific siRNA pools targeting RAC1 or CDC42 .
(x14 / target-01
      :ARG0 (x13 / pool
            :ARG1-of (x1 / immortalize-03)
            :mod (x5 / transfect-01
                  :ARG1 (x2 / enzyme
                        :mod (x3 / wild-type)
                        :name (x4 / name :op1 "mef")
                        :xref (x21 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :ARG2 (x8 / or
                        :ARG1-of (x6 / scramble-02)
                        :ARG0-of (x7 / duplex)))
            :ARG0-of (x11 / nucleic-acid
                  :ARG1-of (x10 / specific-02
                        :ARG2 (x9 / gene))
                  :name (x12 / name :op1 "siRNA")))
      :ARG1 (x17 / or
            :op1 (x15 / protein
                  :name (x16 / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :op2 (x18 / protein
                  :name (x19 / name :op1 "CDC42")
                  :xref (x20 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))


# ::id PMC3690480.530
# ::snt Serum-starved cells were stimulated with EGF (10 ng/ml), PDGF (10 ng/ml) or insulin (5 μg/ml) for 5 min, before they were harvested for western blot.
# ::tok Serum @-@ starved cells were stimulated with EGF ( 10 ng/ml ) , PDGF ( 10 ng/ml ) or insulin ( 5 μg/ml ) for 5 min , before they were harvested for western blot .
(x4 / stimulate-01
      :ARG1 (x3 / cell
            :ARG1-of (x2 / starve-01
                  :ARG2 (x1 / serum)))
      :ARG2 (x13 / or
            :op1 (x5 / protein
                  :name (x6 / name :op1 "EGF")
                  :quant (x7 / concentration-quantity
                        :quant "10"
                        :unit (x8 / nanogram-per-milliliter))
                  :xref (x22 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :op1 (x9 / protein
                  :name (x10 / name :op1 "PDGF")
                  :quant (x11 / concentration-quantity
                        :quant "10"
                        :unit (x12 / nanogram-per-milliliter))
                  :xref (x21 / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313"))
            :op2 (x14 / protein
                  :name (x15 / name :op1 "insulin")
                  :xref (x / xref :value "UNIPROT:INS_HUMAN" :prob "0.703"))
            :op2 "5"
            :op3 "μg/ml")
      :duration (x16 / temporal-quantity
            :quant "5"
            :unit (x17 / minute))
      :time (x18 / before
            :op1 (x19 / harvest-01
                  :ARG2 (x20 / immunoblot-01))))


# ::id PMC3690480.531
# ::snt Immortalized wild-type MEFs were serum-starved and incubated with EHT1864 at the indicated doses for 30 min, before they were stimulated with EGF (10 ng/ml), PDGF (10 ng/ml) or insulin (5 μg/ml) for 5 min.
# ::tok Immortalized wild @-@ type MEFs were serum @-@ starved and incubated with EHT1864 at the indicated doses for 30 min , before they were stimulated with EGF ( 10 ng/ml ) , PDGF ( 10 ng/ml ) or insulin ( 5 μg/ml ) for 5 min .
(x1 / multi-sentence
      :snt1 (x2 / immortalize-03)
      :snt2 (x9 / incubate-01
            :ARG1 (x3 / enzyme
                  :mod (x4 / wild-type)
                  :name (x5 / name :op1 "mef")
                  :xref (x33 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
            :ARG2 (x8 / and
                  :ARG1-of (x7 / starve-01
                        :ARG2 (x6 / serum)))
            :ARG2 (x10 / small-molecule
                  :name (x11 / name :op1 "EHT1864")
                  :ARG1-of (x13 / dose-01
                        :ARG1-of (x12 / indicate-01)))
            :duration (x14 / temporal-quantity
                  :quant "30"
                  :unit (x15 / minute))
            :time (x16 / before
                  :op1 (x17 / stimulate-01
                        :ARG2 (x18 / and
                              :op1 (x19 / protein
                                    :name (x20 / name :op1 "EGF")
                                    :quant (x21 / concentration-quantity
                                          :quant "10"
                                          :unit (x22 / nanogram-per-milliliter))
                                    :xref (x34 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                              :op2 (x23 / protein
                                    :name (x24 / name :op1 "PDGF")
                                    :xref (x / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313")))))
            :ARG1-of (x27 / or
                  :op1 (x25 / concentration-quantity
                        :quant "10"
                        :unit (x26 / nanogram-per-milliliter))
                  :op2 (x28 / small-molecule
                        :name (x29 / name :op1 "insulin")
                        :quant "5"
                        :name (x30 / name :op1 "μg/ml")
                        :xref (x35 / xref :value "PUBCHEM:70678557" :prob "15.003454")))
            :duration (x31 / temporal-quantity
                  :quant "5"
                  :unit (x32 / minute))))


# ::id PMC3690480.532
# ::snt Dock180/Elmo1 Activate RAC Downstream of GPCRs and Upstream of p110β, Related to Figure 6
# ::tok Dock180 @/@ Elmo1 Activate RAC Downstream of GPCRs and Upstream of p110β, Related to Figure 6
(x18 / relate-01
      :ARG1 (x6 / activate-01
            :ARG0 (x3 / slash
                  :op1 (x1 / enzyme
                        :name (x2 / name :op1 "Dock180")
                        :xref (x21 / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
                  :op2 (x4 / enzyme
                        :name (x5 / name :op1 "Elmo1")
                        :xref (x23 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604")))
            :ARG1 (x7 / enzyme
                  :name (x8 / name :op1 "RAC")
                  :xref (x22 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003")))
      :ARG1-of (x9 / relative-position
            :direction (x10 / downstream)
            :op1 (x13 / and
                  :op1 (x11 / enzyme
                        :name (x12 / name :op1 "GPCRs")
                        :xref (x20 / xref :value "UNIPROT:Q76L88_HUMAN" :prob "0.311"))
                  :op2 (x14 / relative-position
                        :direction (x15 / upstream)
                        :op1 (x16 / enzyme
                              :name (x17 / name :op1 "p110β,")
                              :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.242")))))
      :ARG2 (x19 / figure :mod "6"))


# ::id PMC3690480.537
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or siRNA pools targeting Dock180 or Elmo1.
# ::tok Immortalized wild @-@ type MEFs were transfected with scrambled duplex or siRNA pools targeting Dock180 or Elmo1 .
(x12 / target-01
      :ARG0 (x11 / pool
            :ARG1-of (x1 / immortalize-03)
            :mod (x5 / transfect-01
                  :ARG1 (x2 / enzyme
                        :mod (x3 / wild-type)
                        :name (x4 / name :op1 "mef")
                        :xref (x20 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :ARG2 (x8 / or
                        :ARG1-of (x6 / scramble-02)
                        :ARG0-of (x7 / duplex)
                        :op2 (x9 / enzyme
                              :name (x10 / name :op1 "siRNA")
                              :xref (x18 / xref :value "UNIPROT:SHPS1_HUMAN" :prob "0.212")))))
      :ARG1 (x15 / or
            :op1 (x13 / enzyme
                  :name (x14 / name :op1 "Dock180")
                  :xref (x / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633"))
            :op2 (x16 / protein
                  :name (x17 / name :op1 "Elmo1")
                  :xref (x19 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))))


# ::id PMC3690480.538
# ::snt Cells were serum starved and stimulated with EGF (10 ng/ml), PDGF (10 ng/ml) or insulin (5 μg/ml) for 5 min.
# ::tok Cells were serum starved and stimulated with EGF ( 10 ng/ml ) , PDGF ( 10 ng/ml ) or insulin ( 5 μg/ml ) for 5 min .
(x4 / and
      :op1 (x3 / starve-01
            :ARG1 (x1 / cell)
            :ARG2 (x2 / serum))
      :op2 (x5 / stimulate-01
            :ARG2 (x14 / or
                  :op1 (x6 / protein
                        :name (x7 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :op2 (x8 / concentration-quantity
                        :quant "10"
                        :unit (x9 / nanogram-per-milliliter))
                  :op1 (x10 / protein
                        :name (x11 / name :op1 "PDGF")
                        :quant (x12 / concentration-quantity
                              :quant "10"
                              :unit (x13 / nanogram-per-milliliter))
                        :xref (x20 / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313"))
                  :op2 (x15 / protein
                        :name (x16 / name :op1 "insulin")
                        :xref (x19 / xref :value "UNIPROT:INS_HUMAN" :prob "0.703"))
                  :op2 "5"
                  :op3 "μg/ml")
            :duration (x17 / temporal-quantity
                  :quant "5"
                  :unit (x18 / minute))))


# ::id PMC3690480.539
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific individual siRNA oligonucleotides targeting Dock180.
# ::tok Immortalized wild @-@ type MEFs were transfected with scrambled duplex or gene @-@ specific individual siRNA oligonucleotides targeting Dock180 .
(x5 / transfect-01
      :ARG1 (x3 / cell
            :ARG1-of (x1 / immortalize-03)
            :mod (x2 / wild-type)
            :name (x4 / name :op1 "mef"))
      :ARG2 (x8 / or
            :ARG1-of (x6 / scramble-02)
            :op1 (x7 / duplex)
            :op2 (x11 / individual
                  :ARG1-of (x10 / specific-02
                        :ARG2 (x9 / gene))
                  :ARG0-of (x13 / oligonucleotide
                        :name (x12 / name :op1 "siRNA")
                        :ARG0-of (x14 / target-01
                              :ARG1 (x15 / enzyme
                                    :name (x16 / name :op1 "Dock180")
                                    :xref (x / xref :value "UNIPROT:DOCK1_HUMAN" :prob "0.633")))))))


# ::id PMC3690480.541
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific single siRNA oligonucleotides targeting Elmo1.
# ::tok Immortalized wild @-@ type MEFs were transfected with scrambled duplex or gene @-@ specific single siRNA oligonucleotides targeting Elmo1 .
(x5 / transfect-01
      :ARG1 (x3 / cell
            :ARG1-of (x1 / immortalize-03)
            :mod (x2 / wild-type)
            :name (x4 / name :op1 "mef"))
      :ARG2 (x8 / or
            :ARG1-of (x6 / scramble-02)
            :op1 (x7 / duplex)
            :op2 (x9 / gene
                  :ARG1-of (x10 / specific-02)))
      :ARG1-of (x12 / oligonucleotide
            :name (x11 / name :op1 "siRNA")
            :ARG0-of (x13 / target-01
                  :ARG1 (x14 / protein
                        :name (x15 / name :op1 "Elmo1")
                        :xref (x / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604")))))


# ::id PMC3690480.543
# ::snt RNA was extracted in parallel experiments and Elmo1 mRNA levels were compared by qPCR (mean with SEM).
# ::tok RNA was extracted in parallel experiments and Elmo1 mRNA levels were compared by qPCR ( mean with SEM ) .
(x3 / extract-01
      :ARG1 (x1 / nucleic-acid
            :name (x2 / name :op1 "RNA"))
      :ARG2 (x5 / experiment-01
            :ARG0-of (x4 / parallel-01)
            :ARG0-of (x12 / compare-01
                  :ARG1 (x6 / and
                        :op1 (x7 / protein
                              :name (x8 / name :op1 "Elmo1")
                              :xref (x18 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604")))
                  :ARG1 (x11 / level
                        :quant-of (x9 / nucleic-acid
                              :name (x10 / name :op1 "mRNA")))
                  :ARG2 (x13 / enzyme
                        :name (x14 / name :op1 "qPCR")
                        :xref (x / xref :value "UNIPROT:QCR7_HUMAN" :prob "0.202"))
                  :ARG1-of (x15 / mean-01)
                  :ARG2 (x16 / small-molecule
                        :name (x17 / name :op1 "SEM")
                        :xref (x19 / xref :value "PUBCHEM:2724271" :prob "10.871458")))))


# ::id PMC3690480.544
# ::snt Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific siRNA pools targeting Elmo1 or Elmo2, and serum-starved cells were stimulated with LPA for 5 min.
# ::tok Immortalized wild @-@ type MEFs were transfected with scrambled duplex or gene @-@ specific siRNA pools targeting Elmo1 or Elmo2 , and serum @-@ starved cells were stimulated with LPA for 5 min .
(x5 / transfect-01
      :ARG1 (x3 / cell
            :ARG1-of (x1 / immortalize-03)
            :mod (x2 / wild-type)
            :name (x4 / name :op1 "mef"))
      :ARG2 (x20 / and
            :op1 (x14 / target-01
                  :ARG0 (x13 / pool
                        :ARG1-of (x6 / scramble-02)
                        :ARG0-of (x11 / nucleic-acid
                              :ARG1-of (x10 / specific-02
                                    :ARG2 (x8 / or
                                          :op1 (x7 / duplex)
                                          :op2 (x9 / gene)))
                              :name (x12 / name :op1 "siRNA")))
                  :ARG1 (x17 / or
                        :op1 (x15 / protein
                              :name (x16 / name :op1 "Elmo1")
                              :xref (x29 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))
                        :op2 (x18 / protein
                              :name (x19 / name :op1 "Elmo2")
                              :xref (x / xref :value "UNIPROT:ELMO2_HUMAN" :prob "0.603"))))
            :op2 (x24 / stimulate-01
                  :ARG1 (x23 / cell
                        :ARG1-of (x22 / starve-01
                              :ARG2 (x21 / serum)))
                  :ARG2 (x25 / small-molecule
                        :name (x26 / name :op1 "LPA")
                        :xref (x30 / xref :value "PUBCHEM:62707" :prob "9.981436"))
                  :duration (x27 / temporal-quantity
                        :quant "5"
                        :unit (x28 / minute)))))


# ::id PMC3690480.545
# ::snt Elmo1/Elmo2 mRNA levels were assessed by qPCR (mean with SEM).
# ::tok Elmo1 @/@ Elmo2 mRNA levels were assessed by qPCR ( mean with SEM ) .
(x9 / assess-01
      :ARG0 (x3 / slash
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "Elmo1")
                  :xref (x15 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "Elmo2")
                  :xref (x16 / xref :value "UNIPROT:ELMO2_HUMAN" :prob "0.603")))
      :ARG1 (x8 / level
            :quant-of (x6 / nucleic-acid
                  :name (x7 / name :op1 "mRNA")))
      :ARG0 (x10 / protein
            :name (x11 / name :op1 "qPCR")
            :ARG1-of (x12 / mean-01)
            :xref (x / xref :value "UNIPROT:QCR7_HUMAN" :prob "0.202"))
      :ARG2 (x13 / small-molecule
            :name (x14 / name :op1 "SEM")
            :xref (x17 / xref :value "PUBCHEM:2724271" :prob "10.871458")))


# ::id PMC3690480.547
# ::snt p110β-RBD-DM Mice Are Protected from Bleomycin-Induced Lung Fibrosis, Related to Figure 7
# ::tok p110β-RBD @-@ DM Mice Are Protected from Bleomycin @-@ Induced Lung Fibrosis , Related to Figure 7
(x10 / relate-01
      :ARG1 (x4 / protect-01
            :ARG1 (x1 / gene
                  :name (x2 / name :op1 "p110β-RBD")
                  :ARG2-of (x3 / dm)
                  :xref (x / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :ARG2 (x9 / fibrosis
                  :ARG2-of (x7 / induce-01
                        :ARG0 (x5 / protein
                              :name (x6 / name :op1 "Bleomycin")
                              :xref (x12 / xref :value "UNIPROT:BLMH_HUMAN" :prob "0.292")))
                  :mod (x8 / lung)))
      :ARG2 (x11 / figure :mod "7"))


# ::id PMC3690480.548
# ::snt Serum-starved immortalized wild-type MEFs were seeded onto fibronectin-coated membrane inserts and placed into 24-well plates containing serum-free medium and the indicated chemoattractants.
# ::tok Serum @-@ starved immortalized wild @-@ type MEFs were seeded onto fibronectin @-@ coated membrane inserts and placed into 24 @-@ well plates containing serum @-@ free medium and the indicated chemoattractants .
(x22 / and
      :op1 (x7 / seed-02
            :ARG1 (x3 / immortalize-03
                  :ARG1-of (x2 / starve-01
                        :ARG2 (x1 / serum))
                  :op2 (x4 / enzyme
                        :mod (x5 / wild-type)
                        :name (x6 / name :op1 "mef")
                        :xref (x25 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))
            :ARG2 (x11 / membrane
                  :ARG1-of (x10 / coat-01
                        :ARG2 (x8 / protein
                              :name (x9 / name :op1 "fibronectin")
                              :xref (x / xref :value "UNIPROT:FINC_HUMAN" :prob "0.703")))
                  :xref (x27 / xref :value "GO:0016020" :prob "0.8"))
            :ARG1-of (x18 / contain-01
                  :ARG0 (x14 / and
                        :op1 (x12 / enzyme
                              :name (x13 / name :op1 "inserts")
                              :xref (x26 / xref :value "UNIPROT:INS_HUMAN" :prob "0.203"))
                        :op2 (x15 / place-01
                              :ARG2 (x17 / plate
                                    :quant "24"
                                    :mod (x16 / well))))
                  :ARG1 (x21 / medium
                        :ARG1-of (x20 / free-04
                              :ARG2 (x19 / serum)))))
      :op2 (x24 / chemoattractants
            :ARG1-of (x23 / indicate-01)))


# ::id PMC3690480.549
# ::snt Where indicated, GDC0941 (5 μM) or PTX (200 ng/ml) were added 30 min and 16 hr prior to seeding, respectively, and were present throughout experiments.
# ::tok Where indicated , GDC0941 ( 5 μM ) or PTX ( 200 ng/ml ) were added 30 min and 16 hr prior to seeding , respectively , and were present throughout experiments .
(x15 / ratio-of
      :op1 (x1 / indicate-01
            :ARG1 (x14 / and
                  :op1 (x11 / add-02
                        :ARG1 (x6 / or
                              :op1 (x2 / small-molecule
                                    :name (x3 / name :op1 "GDC0941")
                                    :quant (x4 / concentration-quantity
                                          :quant "5"
                                          :unit (x5 / micromolar))
                                    :xref (x / xref :value "PUBCHEM:17755052" :prob "18.349844"))
                              :op2 (x7 / small-molecule
                                    :name (x8 / name :op1 "PTX")
                                    :quant (x9 / concentration-quantity
                                          :quant "200"
                                          :unit (x10 / nanogram-per-milliliter))
                                    :xref (x22 / xref :value "PUBCHEM:4740" :prob "17.474375")))
                        :ARG2 (x12 / temporal-quantity
                              :quant "30"
                              :unit (x13 / minute)))
                  :op2 "16"))
      :op2 (x20 / present-01
            :time (x16 / prior
                  :op1 (x17 / seed-01))
            :ARG1 (x19 / and
                  :mod (x18 / respective))
            :time (x21 / experiment-01)))


# ::id PMC3690480.550
# ::snt After 6 hr, migrated cells were semiautomatically counted and numbers were normalized to control conditions (n = 3; mean with SEM; repeated-measures ANOVA).
# ::tok After 6 hr , migrated cells were semiautomatically counted and numbers were normalized to control conditions ( n = 3; mean with SEM ; repeated @-@ measures ANOVA ) .
(x4 / and
      :time (x1 / after
            :op1 (x2 / ratio-of :mod "6"))
      :op1 (x3 / migrate-01)
      :op1 (x8 / count-01
            :ARG1 (x5 / cell)
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "semiautomatically"))
            :ARG1 (x9 / and
                  :op1 (x10 / number)
                  :op2 (x11 / normalize-01
                        :ARG1-of (x12 / conform-01
                              :ARG2 (x13 / control))))
            :ARG1-of (x14 / sample-01
                  :ARG2 (x15 / enzyme
                        :name (x16 / name :op1 "3;")
                        :ARG1-of (x17 / mean-01)
                        :xref (x24 / xref :value "UNIPROT:AB12B_HUMAN" :prob "0.552")))
            :ARG2 (x18 / small-molecule
                  :name (x19 / name :op1 "SEM")
                  :xref (x25 / xref :value "PUBCHEM:2724271" :prob "10.871458")))
      :op2 (x20 / repeat-01
            :ARG1 (x21 / measure-02
                  :ARG1 (x22 / protein
                        :name (x23 / name :op1 "ANOVA")
                        :xref (x / xref :value "UNIPROT:NOVA2_HUMAN" :prob "1.002")))))


# ::id PMC3690480.551
# ::snt Migration of transfected wild-type and p110β-RBD-DM MEFs in starvation medium and gradients of LPA (10 nM) and FCS (1%) were assessed in transwell filter assays (n = 6 from 2 independent experiments; mean with SEM; 1way ANOVA).
# ::tok Migration of transfected wild @-@ type and p110β-RBD @-@ DM MEFs in starvation medium and gradients of LPA ( 10 nM ) and FCS ( 1 % ) were assessed in transwell filter assays ( n = 6 from 2 independent experiments ; mean with SEM ; 1 way ANOVA ) .
(x1 / multi-sentence
      :snt1 (x6 / and
            :op1 (x2 / migrate-01
                  :ARG0 (x4 / cell
                        :ARG1-of (x3 / transfect-01)
                        :mod (x5 / wild-type)))
            :op2 (x7 / enzyme
                  :name (x8 / name :op1 "p110β-RBD")
                  :mod (x9 / enzyme
                        :name (x10 / name :op1 "mef")
                        :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :xref (x35 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
            :ARG1-of (x11 / starve-01))
      :snt2 (x33 / way
            :ARG0 (x13 / and
                  :op1 (x12 / medium)
                  :op2 (x23 / assess-01
                        :ARG1 (x14 / gradient)
                        :ARG1 (x19 / and
                              :op1 (x15 / small-molecule
                                    :name (x16 / name :op1 "LPA")
                                    :quant (x17 / concentration-quantity
                                          :quant "10"
                                          :unit (x18 / nanomolar))
                                    :xref (x38 / xref :value "PUBCHEM:62707" :prob "9.981436"))
                              :op2 (x20 / small-molecule
                                    :name (x21 / name :op1 "FCS")
                                    :quant (x22 / percentage-entity :value "1")
                                    :xref (x36 / xref :value "PUBCHEM:3040269" :prob "11.608116")))
                        :location (x26 / assay-01
                              :ARG1 (x25 / filter-02
                                    :mod (x24 / transwell)))
                        :ARG1-of (x27 / sample-01
                              :quant "6"
                              :ARG2 (x29 / experiment-01
                                    :quant "2"
                                    :ARG0-of (x28 / depend-01 :polarity "-"))
                              :ARG1-of (x30 / mean-01))
                        :ARG2 (x31 / small-molecule
                              :name (x32 / name :op1 "SEM")
                              :xref (x37 / xref :value "PUBCHEM:2724271" :prob "10.871458"))))
            :mod "1"
            :mod (x34 / anova)))


# ::id PMC3690480.552
# ::snt Age- and sex-matched wild-type and p110β-RBD-DM mice received saline (n = 3 per genotype) or bleomycin (n = 10 per genotype) via intratracheal instillation and were culled 14 days later (mean ± SEM; t test).
# ::tok Age @- and sex @-@ matched wild @-@ type and p110β-RBD @-@ DM mice received saline ( n = 3 per genotype ) or bleomycin ( n = 10 per genotype ) via intratracheal instillation and were culled 14 days later ( mean ± SEM ; t test ) .
(x1 / multi-sentence
      :snt1 (x5 / rate-entity-91
            :ARG2 (x3 / and
                  :op1 (x2 / age-01)
                  :op2 (x4 / sex))
            :ARG2 (x6 / genotype)
            :ARG3 (x20 / temporal-quantity
                  :ARG1-of (x7 / match-01
                        :ARG2 (x17 / or
                              :op1 (x9 / and
                                    :mod (x8 / wild-type)
                                    :op2 (x10 / gene
                                          :name (x11 / name :op1 "p110β-RBD")
                                          :ARG2-of (x12 / dm)
                                          :xref (x36 / xref :value "UNIPROT:BID_HUMAN" :prob "0.212"))
                                    :ARG0-of (x13 / receive-01
                                          :ARG1 (x15 / rate-entity-91
                                                :ARG1-of (x14 / salinity)
                                                :quant "3"
                                                :ARG2 (x16 / genotype))))
                              :op2 (x18 / enzyme
                                    :name (x19 / name :op1 "bleomycin")
                                    :xref (x / xref :value "UNIPROT:BLMH_HUMAN" :prob "0.282"))))
                  :quant "10"))
      :snt2 (x22 / and
            :op1 (x21 / instill-01)
            :op2 (x23 / cull-01)
            :time (x26 / late
                  :op1 (x24 / temporal-quantity
                        :quant "14"
                        :unit (x25 / day))
                  :degree (x27 / more))
            :ARG1-of (x28 / mean-01
                  :ARG2 (x29 / mean
                        :mod (x30 / slash
                              :op1 (x31 / error
                                    :ARG1-of (x32 / standard-02))
                              :op2 (x33 / error :polarity "-"))))
            :op2 (x34 / enzyme
                  :name (x35 / name :op1 "t" :op2 "test"))))


# ::id PMC3690480.554
# ::snt After two weeks, lungs were fixed, sectioned and stained with H&E.
# ::tok After two weeks , lungs were fixed , sectioned and stained with H&E .
(x7 / and
      :time (x1 / after
            :quant (x2 / temporal-quantity
                  :quant "2"
                  :unit (x3 / week))
            :op1 (x5 / fix-02
                  :ARG1 (x4 / lung)))
      :op1 (x6 / section-01)
      :op2 (x8 / stain-01
            :ARG2 (x9 / small-molecule
                  :name (x10 / name :op1 "hematoxylin")
                  :xref (x / xref :value "PUBCHEM:10603" :prob "16.740406"))))


# ::id PMC3690480.555
# ::snt As many as possible nonoverlapping areas (A–L), avoiding artifacts from interlobes and major bronchi/vessels, of representative sections from each lung were photographed at low (4×) magnification and transparent (white) areas within each image were quantified using Nikon NIS elements software.
# ::tok As many as possible nonoverlapping areas ( A–L ) , avoiding artifacts from interlobes and major bronchi/vessels , of representative sections from each lung were photographed at low ( 4× ) magnification and transparent ( white ) areas within each image were quantified using Nikon NIS elements software .
(x1 / multi-sentence
      :snt1 (x2 / as-many-as
            :op1 (x3 / possible-01
                  :ARG1 (x8 / avoid-01
                        :ARG1 (x5 / area
                              :name (x4 / name :op1 "nonoverlapping")
                              :mod (x6 / gene
                                    :name (x7 / name :op1 "A–L")))
                        :ARG1 (x9 / artifact)
                        :ARG2 (x11 / and
                              :name (x10 / name :op1 "interlobes")))))
      :snt2 (x29 / quantify-01
            :ARG1 (x26 / area
                  :ARG1-of (x12 / major-02)
                  :ARG0-of (x17 / section-01
                        :ARG1 (x15 / and
                              :op1 (x13 / enzyme
                                    :name (x14 / name :op1 "bronchi/vessels"))
                              :op2 (x16 / represent-01))
                        :ARG3 (x20 / photograph-01
                              :ARG1 (x19 / lung
                                    :mod (x18 / each))
                              :location (x21 / low-04))
                        :ARG1-of (x23 / magnify-01
                              :name (x22 / name :op1 "2"))
                        :mod (x24 / transparent)
                        :ARG1-of (x25 / white-03))
                  :location (x28 / image
                        :mod (x27 / each)))
            :manner (x30 / use-01
                  :ARG1 (x34 / software
                        :mod (x33 / element
                              :mod (x31 / enzyme
                                    :name (x32 / name :op1 "Nikon" :op2 "NIS")))))))


# ::id PMC3690480.557
# ::snt After two weeks, lungs were fixed, sectioned and stained with immunohistochemistry for smooth muscle antigen (α-SMA).
# ::tok After two weeks , lungs were fixed , sectioned and stained with immunohistochemistry for smooth muscle antigen ( α-SMA ) .
(x7 / and
      :time (x1 / after
            :op1 (x2 / temporal-quantity
                  :quant "2"
                  :unit (x3 / week)))
      :op1 (x5 / fix-02
            :ARG2 (x4 / lung)
            :ARG1 (x6 / section-01))
      :op2 (x8 / stain-01
            :ARG2 (x12 / antigen
                  :mod (x9 / immunohistochemistry
                        :ARG1 (x11 / muscle
                              :ARG1-of (x10 / smooth-06)))
                  :name (x13 / name :op1 "α-SMA"))))


# ::id PMC3690480.558
# ::snt As many as possible nonoverlapping areas (A–N), avoiding artifacts from bronchi and blood vessels, of representative sections from each lung were photographed at low (4×) magnification and positive (brown) areas within each image were quantified using Nikon NIS elements software.
# ::tok As many as possible nonoverlapping areas ( A–N ) , avoiding artifacts from bronchi and blood vessels , of representative sections from each lung were photographed at low ( 4× ) magnification and positive ( brown ) areas within each image were quantified using Nikon NIS elements software .
(x1 / multi-sentence
      :snt1 (x2 / as-many-as)
      :snt2 (x3 / possible-01
            :ARG1 (x8 / avoid-01
                  :ARG0 (x5 / area
                        :name (x4 / name :op1 "nonoverlapping")
                        :mod (x6 / gene
                              :name (x7 / name :op1 "A–N")))
                  :ARG1 (x9 / artifact)
                  :ARG2 (x12 / and
                        :op1 (x10 / enzyme
                              :name (x11 / name :op1 "bronchi"))
                        :op2 (x14 / vessel
                              :mod (x13 / blood)))
                  :ARG1 (x19 / photograph-01
                        :ARG1 (x16 / section-01
                              :ARG1 (x15 / representative)
                              :ARG3 (x18 / lung
                                    :mod (x17 / each)))
                        :location (x34 / software
                              :mod (x23 / positive
                                    :ARG1-of (x20 / low-04
                                          :ARG1-of (x22 / magnify-01
                                                :name (x21 / name :op1 "2")))
                                    :ARG0-of (x29 / quantify-01
                                          :ARG1 (x26 / area
                                                :ARG0 (x24 / person
                                                      :wiki "gordon_brown"
                                                      :name (x25 / name :op1 "brown"))
                                                :location (x28 / image
                                                      :mod (x27 / each)))
                                          :manner (x30 / use-01
                                                :ARG1 (x33 / element
                                                      :mod (x31 / enzyme
                                                            :name (x32 / name :op1 "Nikon" :op2 "NIS")))))))))))


# ::id PMC4345513.0
# ::snt Constitutively active Ras negatively regulates Erk MAP kinase through induction of MAP kinase phosphatase 3 (MKP3) in NIH3T3 cells
# ::tok Constitutively active Ras negatively regulates Erk MAP kinase through induction of MAP kinase phosphatase 3 ( MKP3 ) in NIH3T3 cells
(x5 / downregulate-01
      :ARG0 (x2 / activity-06
            :mod (x1 / constitutive))
      :ARG0 (x3 / enzyme
            :name (x4 / name :op1 "Ras")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
      :ARG1 (x6 / enzyme
            :name (x7 / name
                  :op1 "Erk"
                  :op2 "MAP"
                  :op3 "kinase"))
      :manner (x8 / induce-01
            :ARG2 (x9 / protein
                  :name (x10 / name
                        :op1 "MAP"
                        :op2 "kinase"
                        :op3 "phosphatase"
                        :op4 "3")))
      :ARG1-of (x11 / mkp3)
      :location (x13 / cell-line
            :name (x12 / name :op1 "NIH3T3")))


# ::id PMC4345513.2
# ::snt The Ras/Raf/MEK/Erk signaling pathway is important for regulation of cell growth, proliferation, differentiation, survival, and apoptosis in response to a variety of extracellular stimuli.
# ::tok The Ras/Raf/MEK/Erk signaling pathway is important for regulation of cell growth , proliferation , differentiation , survival , and apoptosis in response to a variety of extracellular stimuli .
(x4 / important
      :domain (x3 / pathway
            :name (x1 / name :op1 "Ras/Raf/MEK/Erk")
            :ARG0-of (x2 / signal-07))
      :purpose (x5 / regulate-01
            :ARG1 (x12 / and
                  :op1 (x7 / grow-01
                        :ARG1 (x6 / cell))
                  :op2 (x8 / and
                        :op1 (x9 / proliferate-01)
                        :op2 (x10 / differentiate-01)
                        :op3 (x11 / survive-01))
                  :op3 (x14 / respond-01
                        :ARG2 (x13 / apoptosis)
                        :ARG1 (x17 / stimulus
                              :mod (x15 / variety)
                              :mod (x16 / extracellular))))))


# ::id PMC4345513.3
# ::snt Lack of Erk MAPK activation is observed in several cancer cells despite active activation of Ras.
# ::tok Lack of Erk MAPK activation is observed in several cancer cells despite active activation of Ras .
(x13 / activate-01
      :ARG0 (x1 / lack-01
            :ARG1 (x6 / activate-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "Erk")
                        :xref (x16 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "MAPK")
                        :xref (x17 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))
                  :ARG1-of (x7 / observe-01
                        :location (x11 / cell
                              :quant (x8 / several)
                              :mod (x9 / disease
                                    :wiki "cancer"
                                    :name (x10 / name :op1 "cancer"))))
                  :concession (x12 / activate-01)))
      :ARG1 (x14 / enzyme
            :name (x15 / name :op1 "Ras")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))


# ::id PMC4345513.4
# ::snt However, little is known about the modulation of Erk1/2 activity by active Ras.
# ::tok However , little is known about the modulation of Erk1 @/@ 2 activity by active Ras .
(x1 / have-concession-91
      :ARG1 (x2 / know-01
            :ARG1 (x3 / little
                  :topic (x4 / modulate-01
                        :ARG1 (x7 / activity-06
                              :ARG0 (x5 / enzyme
                                    :name (x6 / name :op1 "Erk1/2")))))
            :ARG0 (x8 / enzyme
                  :ARG1-of (x9 / activate-01)
                  :name (x10 / name :op1 "Ras")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))


# ::id PMC4345513.5
# ::snt Here, we show that overexpression of active H-Ras (H-RasG12R) in NIH3T3 fibroblasts impaired FGF2-induced Erk1/2 phosphorylation, as compared to wild-type cells.
# ::tok Here , we show that overexpression of active H @-@ Ras ( H @-@ RasG12R ) in NIH3T3 fibroblasts impaired FGF2 @-@ induced Erk1 @/@ 2 phosphorylation , as compared to wild @-@ type cells .
(x3 / show-01
      :medium (x1 / here)
      :ARG0 (x2 / we)
      :ARG1 (x16 / impair-01
            :ARG0 (x4 / overexpress-01
                  :ARG1 (x5 / enzyme
                        :ARG0-of (x6 / activity-06)
                        :name (x7 / name :op1 "H-Ras")
                        :xref (x / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))
                  :ARG1-of (x8 / describe-01
                        :ARG0 (x9 / and
                              :op1 (x10 / enzyme
                                    :name (x11 / name :op1 "H-Ras")
                                    :xref (x26 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))
                              :op2 (x12 / enzyme
                                    :name (x13 / name :op1 "RasG12R")
                                    :xref (x27 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.223"))))
                  :location (x15 / fibroblast
                        :name (x14 / name :op1 "NIH3T3")))
            :ARG1 (x22 / phosphorylate-01
                  :ARG2-of (x19 / induce-01
                        :ARG0 (x17 / enzyme
                              :name (x18 / name :op1 "FGF2")
                              :xref (x28 / xref :value "UNIPROT:FGF2_HUMAN" :prob "1.004")))
                  :ARG1 (x20 / enzyme
                        :name (x21 / name :op1 "Erk1/2"))))
      :ARG1-of (x23 / compare-01
            :ARG2 (x25 / cell
                  :mod (x24 / wild-type))))


# ::id PMC4345513.6
# ::snt Northern blot analysis revealed that prolonged expression of active Ras increased MAP kinase phosphatase 3 (MKP3) mRNA expression, a negative regulator of Erk MAPK.
# ::tok Northern blot analysis revealed that prolonged expression of active Ras increased MAP kinase phosphatase 3 ( MKP3 ) mRNA expression , a negative regulator of Erk MAPK .
(x4 / reveal-01
      :ARG0 (x3 / analyze-01
            :mod (x1 / thing
                  :name (x2 / name :op1 "Northern" :op2 "blot")))
      :ARG1 (x10 / increase-01
            :ARG0 (x6 / express-03
                  :ARG1-of (x5 / prolong-01)
                  :ARG2 (x7 / enzyme
                        :ARG1-of (x8 / activate-01)
                        :name (x9 / name :op1 "Ras")
                        :xref (x22 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG1 (x11 / protein
                  :name (x12 / name
                        :op1 "MAP"
                        :op2 "kinase"
                        :op3 "phosphatase"
                        :op4 "3")))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / protein
                  :name (x15 / name :op1 "MKP3")
                  :ARG2-of (x19 / downregulate-01
                        :manner (x18 / express-03
                              :ARG2 (x16 / nucleic-acid
                                    :name (x17 / name :op1 "mRNA")))
                        :ARG1 (x20 / enzyme
                              :name (x21 / name :op1 "Erk" :op2 "MAPK")))
                  :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))))


# ::id PMC4345513.7
# ::snt Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway abrogated active Ras-induced up-regulation of MKP3 expression, leading to the rescue of Erk1/2 phosphorylation.
# ::tok Inhibition of the phosphatidylinositol 3 @-@ kinase ( PI3K ) /Akt pathway abrogated active Ras @-@ induced up @-@ regulation of MKP3 expression , leading to the rescue of Erk1 @/@ 2 phosphorylation .
(x9 / abrogate-01
      :ARG0 (x1 / inhibit-01
            :ARG1 (x2 / and
                  :op1 (x3 / enzyme
                        :name (x4 / name :op1 "phosphatidylinositol" :op2 "3-kinase"))
                  :op2 (x5 / enzyme
                        :name (x6 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))
      :mod (x8 / pathway
            :name (x7 / name :op1 "/Akt"))
      :ARG1 (x17 / express-03
            :ARG2-of (x13 / induce-01
                  :ARG0 (x10 / enzyme
                        :ARG1-of (x11 / activate-01)
                        :name (x12 / name :op1 "Ras")
                        :xref (x23 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG2 (x14 / upregulate-01
                  :ARG1 (x15 / protein
                        :name (x16 / name :op1 "MKP3")
                        :xref (x24 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))))
      :ARG0-of (x18 / lead-03
            :ARG2 (x19 / rescue-01
                  :ARG1 (x22 / phosphorylate-01
                        :ARG1 (x20 / enzyme
                              :name (x21 / name :op1 "Erk1/2"))))))


# ::id PMC4345513.8
# ::snt Our results demonstrated that the Ras/Raf/MEK/Erk signaling cascade is negatively regulated by the PI3K/Aktdependent transcriptional activation of the MKP3 gene.
# ::tok Our results demonstrated that the Ras/Raf/MEK/Erk signaling cascade is negatively regulated by the PI3K @/@ Aktdependent transcriptional activation of the MKP3 gene .
(x4 / demonstrate-01
      :ARG0 (x2 / thing
            :poss (x1 / we)
            :ARG2-of (x3 / result-01))
      :ARG1 (x15 / activate-01
            :ARG0 (x8 / downregulate-01
                  :ARG1 (x7 / signal-07
                        :ARG0 (x5 / enzyme
                              :name (x6 / name :op1 "Ras/Raf/MEK/Erk")))
                  :ARG2 (x9 / regulate-01
                        :ARG0 (x10 / enzyme
                              :name (x11 / name :op1 "PI3K")
                              :xref (x18 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                        :ARG1 (x14 / transcribe-01
                              :ARG1 (x12 / enzyme
                                    :name (x13 / name :op1 "Aktdependent")))))
            :ARG1 (x17 / gene
                  :name (x16 / name :op1 "MKP3")
                  :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))))


# ::id PMC4345513.26
# ::snt We previously described a NIH3T3 cell line (NIH3T3tet-on/HRasG12R), in which the expression of active Ras (H-RasG12R) can be induced by addition of doxycycline (20) .
# ::tok We previously described a NIH3T3 cell line ( NIH3T3 tet @-@ on/HRasG12R ) , in which the expression of active Ras ( H @-@ RasG12R ) can be induced by addition of doxycycline ( 20 ) .
(x22 / possible-01
      :ARG0 (x1 / we)
      :ARG1-of (x3 / describe-01
            :time (x2 / previous)
            :ARG1 (x5 / cell-line
                  :name (x4 / name :op1 "NIH3T3")
                  :ARG1-of (x6 / mean-01
                        :ARG2 (x7 / cell-line
                              :name (x8 / name :op1 "NIH3T3")
                              :mod (x9 / protein
                                    :name (x10 / name :op1 "tet-crkl"))
                              :name (x11 / name :op1 "on/HRasG12R"))))
            :location-of (x12 / express-03
                  :ARG2 (x13 / enzyme
                        :ARG1-of (x14 / activate-01)
                        :name (x15 / name :op1 "Ras")
                        :xref (x31 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :ARG1-of (x16 / describe-01
                        :ARG0 (x17 / and
                              :op1 (x18 / enzyme
                                    :name (x19 / name :op1 "h-ras")
                                    :xref (x30 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601"))
                              :op2 (x20 / enzyme
                                    :name (x21 / name :op1 "RasG12R")
                                    :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.223"))))))
      :ARG1 (x23 / induce-01
            :ARG0 (x24 / add-02
                  :ARG1 (x25 / small-molecule
                        :name (x26 / name :op1 "doxycycline")
                        :xref (x32 / xref :value "PUBCHEM:54671203" :prob "15.91623"))))
      :ARG1-of (x27 / describe-01
            :ARG0 (x28 / publication
                  :ARG1-of (x29 / cite-01 :ARG2 "20"))))


# ::id PMC4345513.27
# ::snt In this model system, the active Ras protein was detectable 24 h after the addition of 2 μg/ml doxycycline ( Fig. 1 A).
# ::tok In this model system , the active Ras protein was detectable 24 h after the addition of 2 μg/ml doxycycline ( Fig . 1 A ) .
(x7 / detect-01
      :ARG1 (x3 / system
            :mod (x1 / this)
            :mod (x2 / model)
            :ARG0-of (x4 / activity-06))
      :ARG1 (x5 / protein
            :name (x6 / name :op1 "Ras")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
      :time (x10 / after
            :quant (x8 / temporal-quantity
                  :quant "24"
                  :unit (x9 / hour))
            :op1 (x11 / add-02
                  :ARG1 (x12 / small-molecule
                        :name (x13 / name :op1 "2")
                        :xref (x19 / xref :value "PUBCHEM:72670316" :prob "2.248541")))
            :name (x14 / name :op1 "μg/ml"))
      :ARG1 (x15 / small-molecule
            :name (x16 / name :op1 "doxycycline")
            :xref (x20 / xref :value "PUBCHEM:54671203" :prob "15.91623"))
      :ARG1-of (x17 / describe-01
            :ARG0 (x18 / figure :mod "1")))


# ::id PMC4345513.28
# ::snt Despite the continual increase in the level of active Ras, the levels of Erk1/2 phosphorylation gradually decreased after peaking at 12 h after doxycycline addition.
# ::tok Despite the continual increase in the level of active Ras , the levels of Erk1 @/@ 2 phosphorylation gradually decreased after peaking at 12 h after doxycycline addition .
(x12 / decrease-01
      :concession (x2 / increase-01
            :ARG1-of (x1 / continue-01)
            :ARG1 (x3 / level
                  :quant-of (x4 / enzyme
                        :ARG0-of (x5 / activity-06)
                        :name (x6 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))
      :ARG1 (x7 / level
            :degree-of (x10 / phosphorylate-01
                  :ARG2 (x8 / enzyme
                        :name (x9 / name :op1 "Erk1/2"))))
      :manner (x11 / gradual)
      :time (x13 / after
            :op1 (x14 / peak-01
                  :time (x15 / after
                        :op1 (x16 / temporal-quantity
                              :quant "12"
                              :unit (x17 / hour)))))
      :time (x18 / after
            :op1 (x21 / add-02
                  :ARG2 (x19 / small-molecule
                        :name (x20 / name :op1 "doxycycline")
                        :xref (x22 / xref :value "PUBCHEM:54671203" :prob "15.91623")))))


# ::id PMC4345513.29
# ::snt However, Akt and Raf1, an upstream kinase of Erk1/2, phosphorylation was still increased due to expression of active Ras.
# ::tok However , Akt and Raf1 , an upstream kinase of Erk1 @/@ 2 , phosphorylation was still increased due to expression of active Ras .
(x1 / contrast-01
      :ARG2 (x13 / increase-01
            :ARG1 (x11 / phosphorylate-01
                  :ARG1 (x4 / and
                        :op1 (x2 / enzyme
                              :name (x3 / name :op1 "Akt")
                              :xref (x19 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                        :op2 (x5 / enzyme
                              :name (x6 / name :op1 "Raf1")
                              :ARG1-of (x8 / activate-01
                                    :direction (x7 / upstream)
                                    :ARG1 (x9 / enzyme
                                          :name (x10 / name :op1 "Erk1/2")))
                              :xref (x20 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.674"))))
            :mod (x12 / still)
            :ARG1-of (x14 / cause-01
                  :ARG0 (x15 / express-03
                        :ARG2 (x16 / enzyme
                              :ARG1-of (x17 / activate-01)
                              :name (x18 / name :op1 "Ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))))


# ::id PMC4345513.30
# ::snt To determine whether growth factor stimulation of Erk1/2 could also be affected due to sustained activation of Ras, NIH3T3tet-on/H-RasG12R cells were cultured in medium containing 0.5% serum in both the absence and presence of doxycycline, and then stimulated with FGF2 for 30 min ( Fig. 1 B).
# ::tok To determine whether growth factor stimulation of Erk1 @/@ 2 could also be affected due to sustained activation of Ras , NIH3T3 tet @-@ on/H @-@ RasG12R cells were cultured in medium containing 0.5 % serum in both the absence and presence of doxycycline , and then stimulated with FGF2 for 30 min ( Fig . 1 B ) .
(x1 / multi-sentence
      :snt1 (x20 / culture-01
            :purpose (x2 / determine-01
                  :ARG1 (x3 / possible-01
                        :mode "interrogative"
                        :ARG1 (x9 / affect-01
                              :ARG2 (x5 / stimulate-01
                                    :ARG0 (x4 / growth-factor)
                                    :ARG1 (x6 / enzyme
                                          :name (x7 / name :op1 "Erk1/2")))
                              :mod (x8 / also)
                              :ARG1-of (x10 / cause-01
                                    :ARG0 (x12 / activate-01
                                          :ARG1-of (x11 / sustain-01)
                                          :ARG1 (x13 / enzyme
                                                :name (x14 / name :op1 "Ras")
                                                :xref (x39 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))))))
            :ARG1 (x19 / cell
                  :name (x15 / name :op1 "NIH3T3")
                  :mod (x16 / protein
                        :name (x17 / name :op1 "tet-crkl" :op2 "on/H"))
                  :name (x18 / name :op1 "RasG12R"))
            :location (x21 / medium
                  :ARG0-of (x22 / contain-01
                        :ARG1 (x23 / percentage-entity
                              :value "0.5"
                              :quant-of (x24 / serum))))
            :location (x25 / and
                  :op1 (x26 / and
                        :op2 (x27 / present-02)
                        :op1 (x28 / absent-01
                              :ARG1 (x29 / small-molecule
                                    :name (x30 / name :op1 "doxycycline")
                                    :xref (x40 / xref :value "PUBCHEM:54671203" :prob "15.91623"))))))
      :snt2 (x31 / and
            :op2 (x32 / stimulate-01
                  :ARG2 (x33 / protein
                        :name (x34 / name :op1 "FGF2")
                        :xref (x / xref :value "UNIPROT:FGF2_HUMAN" :prob "1.004"))
                  :duration (x35 / temporal-quantity
                        :quant "30"
                        :unit (x36 / minute)))
            :ARG1-of (x37 / describe-01
                  :ARG0 (x38 / figure :mod "1"))))


# ::id PMC4345513.31
# ::snt The level of Erk1/2 phosphorylation was increased by FGF2 in both untreated and treated cells with doxycycline for 12 h, but not in cells treated with doxycycline for 48 h, although the basal Erk1/2 phosphorylation level was similar to that in cells treated with doxycycline for 12 h.
# ::tok The level of Erk1 @/@ 2 phosphorylation was increased by FGF2 in both untreated and treated cells with doxycycline for 12 h , but not in cells treated with doxycycline for 48 h , although the basal Erk1 @/@ 2 phosphorylation level was similar to that in cells treated with doxycycline for 12 h .
(x1 / multi-sentence
      :snt1 (x17 / contrast-01
            :ARG1 (x6 / increase-01
                  :ARG1 (x5 / phosphorylate-01
                        :ARG1 (x2 / level
                              :quant-of (x3 / enzyme
                                    :name (x4 / name :op1 "Erk1/2"))))
                  :ARG0 (x7 / protein
                        :name (x8 / name :op1 "FGF2")
                        :xref (x / xref :value "UNIPROT:FGF2_HUMAN" :prob "1.004"))
                  :location (x9 / and
                        :op1 (x10 / treat-04 :polarity "-")
                        :op2 (x11 / treat-04
                              :ARG1 (x12 / cell)
                              :ARG2 (x13 / small-molecule
                                    :name (x14 / name :op1 "doxycycline")
                                    :xref (x40 / xref :value "PUBCHEM:54671203" :prob "15.91623"))
                              :duration (x15 / temporal-quantity
                                    :quant "12"
                                    :unit (x16 / hour)))))
            :ARG2 (x24 / have-concession-91
                  :polarity "-"
                  :ARG1 (x18 / cell
                        :ARG1-of (x19 / treat-04
                              :ARG2 (x20 / small-molecule
                                    :name (x21 / name :op1 "doxycycline")
                                    :xref (x38 / xref :value "PUBCHEM:54671203" :prob "15.91623"))
                              :duration (x22 / temporal-quantity
                                    :quant "48"
                                    :unit (x23 / hour))))
                  :ARG2 (x28 / phosphorylate-01
                        :mod (x25 / basal)
                        :ARG1 (x26 / enzyme
                              :name (x27 / name :op1 "Erk1/2")))))
      :snt2 (x30 / resemble-01
            :ARG1 (x29 / level)
            :ARG2 (x31 / that)
            :location (x32 / cell
                  :ARG1-of (x33 / treat-04
                        :ARG2 (x34 / small-molecule
                              :name (x35 / name :op1 "doxycycline")
                              :xref (x39 / xref :value "PUBCHEM:54671203" :prob "15.91623"))
                        :duration (x36 / temporal-quantity
                              :quant "12"
                              :unit (x37 / hour))))))


# ::id PMC4345513.32
# ::snt Furthermore, the phosphorylation of Erk1/2 down-stream targets, such as p90 ribosomal S6 kinase (RSK; MAPKAPK1A) and transcription factor Elk-1, was not increased by FGF2 in cells treated with doxycycline for 48 h.
# ::tok Furthermore , the phosphorylation of Erk1 @/@ 2 down @-@ stream targets , such as p90 ribosomal S6 kinase ( RSK ; MAPKAPK1A ) and transcription factor Elk @-@ 1 , was not increased by FGF2 in cells treated with doxycycline for 48 h .
(x1 / and
      :op2 (x19 / increase-01
            :ARG1 (x5 / downregulate-01
                  :ARG0 (x2 / phosphorylate-01
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "Erk1/2")))
                  :ARG1 (x8 / molecular-physical-entity
                        :ARG1-of (x7 / target-01
                              :ARG0 (x6 / stream))
                        :example (x11 / and
                              :op1 (x9 / enzyme
                                    :name (x10 / name
                                          :op1 "p90"
                                          :op2 "ribosomal"
                                          :op3 "S6"
                                          :op4 "kinase"))
                              :op1 (x12 / enzyme
                                    :name (x13 / name :op1 "RSK")
                                    :xref (x28 / xref :value "UNIPROT:KS6A1_HUMAN" :prob "0.262"))
                              :op2 (x14 / protein
                                    :name (x15 / name :op1 "MAPKAPK1A")))
                        :mod (x17 / factor
                              :ARG0-of (x16 / transcribe-01)
                              :name (x18 / name :op1 "Elk-1"))))
            :polarity "-"
            :ARG0 (x20 / protein
                  :name (x21 / name :op1 "FGF2")
                  :xref (x / xref :value "UNIPROT:FGF2_HUMAN" :prob "1.004"))
            :location (x22 / cell
                  :ARG1-of (x23 / treat-04
                        :ARG2 (x24 / small-molecule
                              :name (x25 / name :op1 "doxycycline")
                              :xref (x29 / xref :value "PUBCHEM:54671203" :prob "15.91623"))
                        :duration (x26 / temporal-quantity
                              :quant "48"
                              :unit (x27 / hour))))))


# ::id PMC4345513.33
# ::snt Effect of sustained active Ras expression on Erk1/2 downregulation.
# ::tok Effect of sustained active Ras expression on Erk1 @/@ 2 downregulation .
(x1 / affect-01
      :ARG0 (x3 / activate-01
            :ARG1-of (x2 / sustain-01)
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "Ras")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
      :ARG1 (x9 / downregulate-01
            :ARG1 (x6 / express-03
                  :ARG2 (x7 / enzyme
                        :name (x8 / name :op1 "Erk1/2")))))


# ::id PMC4345513.34
# ::snt Western blot analysis was performed using antibodies against H-Ras, phospho-Erk1/2 (Thr202/Tyr204), phospho-RSK (T573), phospho-Elk1 (Ser383), and GAPDH (internal control).
# ::tok Western blot analysis was performed using antibodies against H @-@ Ras , phospho @-@ Erk1 @/@ 2 ( Thr202/Tyr204 ) , phospho @-@ RSK ( T573 ) , phospho @-@ Elk1 ( Ser383 ) , and GAPDH ( internal control ) .
(x3 / perform-01
      :ARG1 (x2 / analyze-01
            :manner (x1 / immunoblot-01))
      :ARG2-of (x4 / use-01
            :ARG1 (x5 / antibody
                  :ARG0-of (x6 / counter-01
                        :ARG1 (x9 / and
                              :op1 (x7 / enzyme
                                    :name (x8 / name :op1 "H-Ras")
                                    :xref (x28 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))
                              :op1 (x10 / enzyme
                                    :ARG3-of (x11 / phosphorylate-01)
                                    :name (x12 / name :op1 "Erk1/2" :op2 "Thr202/Tyr204"))
                              :op2 (x13 / phosphorylate-01
                                    :ARG2 (x14 / enzyme
                                          :name (x15 / name :op1 "RSK")
                                          :xref (x30 / xref :value "UNIPROT:KS6A1_HUMAN" :prob "0.262")))
                              :ARG1-of (x27 / control-01
                                    :ARG1 (x23 / and
                                          :op1 (x16 / amino-acid
                                                :mod "573"
                                                :name (x17 / name :op1 "threonine")
                                                :xref (x32 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                          :op2 (x18 / enzyme
                                                :ARG3-of (x19 / phosphorylate-01)
                                                :name (x20 / name :op1 "Elk1")
                                                :ARG1-of (x21 / amino-acid
                                                      :mod "383"
                                                      :name (x22 / name :op1 "serine")
                                                      :xref (x31 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                                :xref (x29 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.603"))
                                          :op3 (x24 / enzyme
                                                :name (x25 / name :op1 "GAPDH")
                                                :xref (x / xref :value "UNIPROT:G3P_HUMAN" :prob "1.002")))
                                    :ARG1-of (x26 / internal-02)))))))


# ::id PMC4345513.35
# ::snt We next assessed the nuclear translocation of phosphorylated Erk1/2 following doxycycline treatment.
# ::tok We next assessed the nuclear translocation of phosphorylated Erk1 @/@ 2 following doxycycline treatment .
(x3 / assess-01
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x5 / translocate-01
            :ARG2 (x4 / nucleus
                  :xref (x / xref :value "GO:0005634" :prob "0.8"))
            :ARG1 (x6 / enzyme
                  :ARG3-of (x7 / phosphorylate-01)
                  :name (x8 / name :op1 "Erk1/2")))
      :ARG1-of (x9 / follow-01
            :ARG2 (x12 / treat-04
                  :ARG2 (x10 / small-molecule
                        :name (x11 / name :op1 "doxycycline")
                        :xref (x13 / xref :value "PUBCHEM:54671203" :prob "15.91623")))))


# ::id PMC4345513.36
# ::snt Phopho-Erk1/2 immunoreactivity was highly enriched in the nucleus following FGF2 treatment in control cultures.
# ::tok Phopho @-@ Erk1 @/@ 2 immunoreactivity was highly enriched in the nucleus following FGF2 treatment in control cultures .
(x6 / enrich-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "Phopho")
            :mod (x3 / enzyme
                  :name (x4 / name :op1 "Erk1/2"))
            :xref (x14 / xref :value "UNIPROT:PLM_HUMAN" :prob "0.202"))
      :degree (x5 / high)
      :location (x7 / nucleus
            :ARG1-of (x8 / follow-01
                  :ARG2 (x11 / treat-04
                        :ARG2 (x9 / protein
                              :name (x10 / name :op1 "FGF2")
                              :xref (x / xref :value "UNIPROT:FGF2_HUMAN" :prob "1.004"))))
            :xref (x15 / xref :value "GO:0005634" :prob "0.8"))
      :location (x13 / culture-01
            :mod (x12 / control)))


# ::id PMC4345513.37
# ::snt In contrast, Erk1/2 phosphorylation was marked in the cytosol, but sparse in the nucleus of doxycycline-treated cells ( Fig. 2 ).
# ::tok In contrast , Erk1 @/@ 2 phosphorylation was marked in the cytosol , but sparse in the nucleus of doxycycline @-@ treated cells ( Fig . 2 ) .
(x1 / contrast-01
      :ARG2 (x7 / contrast-01
            :ARG1 (x5 / mark-01
                  :ARG1 (x4 / phosphorylate-01
                        :ARG1 (x2 / enzyme
                              :name (x3 / name :op1 "Erk1/2")))
                  :location (x6 / cytosol
                        :xref (x16 / xref :value "GO:0005829" :prob "0.8")))
            :ARG2 (x8 / sparsity)
            :location (x9 / nucleus
                  :part-of (x13 / cell
                        :ARG1-of (x12 / treat-04
                              :ARG2 (x10 / small-molecule
                                    :name (x11 / name :op1 "doxycycline")
                                    :xref (x17 / xref :value "PUBCHEM:54671203" :prob "15.91623"))))
                  :xref (x / xref :value "GO:0005634" :prob "0.8")))
      :ARG1-of (x14 / describe-01
            :ARG0 (x15 / figure :mod "2")))


# ::id PMC4345513.38
# ::snt These results suggest that prolonged Ras activation impairs the nuclear levels of phosphorylated Erk1/2 in NIH3T3 cells.
# ::tok These results suggest that prolonged Ras activation impairs the nuclear levels of phosphorylated Erk1 @/@ 2 in NIH3T3 cells .
(x4 / suggest-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x9 / impair-01
            :ARG0 (x8 / activate-01
                  :ARG1-of (x5 / prolong-01)
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG1 (x11 / level
                  :mod (x10 / nucleus
                        :xref (x17 / xref :value "GO:0005634" :prob "0.8"))
                  :quant-of (x12 / enzyme
                        :ARG3-of (x13 / phosphorylate-01)
                        :name (x14 / name :op1 "Erk1/2"))
                  :location (x16 / cell-line
                        :name (x15 / name :op1 "NIH3T3")))))


# ::id PMC4345513.39
# ::snt Effect of sustained active Ras expression on the nuclear localization of phosphorylated Erk1/2.
# ::tok Effect of sustained active Ras expression on the nuclear localization of phosphorylated Erk1 @/@ 2 .
(x1 / affect-01
      :ARG0 (x3 / activate-01
            :ARG1-of (x2 / sustain-01)
            :ARG1 (x6 / express-03
                  :ARG2 (x4 / enzyme
                        :name (x5 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG2 (x8 / localize-01
                  :ARG1 (x7 / nucleus
                        :xref (x12 / xref :value "GO:0005634" :prob "0.8"))))
      :ARG1 (x9 / phosphorylate-01
            :ARG1 (x10 / enzyme
                  :name (x11 / name :op1 "Erk1/2"))))


# ::id PMC4345513.40
# ::snt NIH3T3tet-on/H-RasG12R cells were cultured on glass slides and either left untreated (− Doxy ) or treated (+ Doxy ) with doxycycline (2 μg/ml) for 24 h, followed by serum starvation with 0.5% serum for an additional 24 h in the absence or presence of doxycycline.
# ::tok NIH3T3 tet @-@ on/H @-@ RasG12R cells were cultured on glass slides and either left untreated ( − Doxy ) or treated ( + Doxy ) with doxycycline ( 2 μg/ml ) for 24 h , followed by serum starvation with 0.5 % serum for an additional 24 h in the absence or presence of doxycycline .
(x1 / multi-sentence
      :snt1 (x7 / culture-01
            :ARG1 (x6 / cell
                  :name (x2 / name :op1 "NIH3T3")
                  :mod (x3 / protein
                        :name (x4 / name :op1 "tet-crkl" :op2 "on/H"))
                  :name (x5 / name :op1 "RasG12R"))
            :ARG1 (x10 / and
                  :op1 (x8 / glass
                        :ARG1-of (x9 / slide-01))
                  :op2 (x11 / left-20))
            :ARG1-of (x12 / treat-04 :polarity "-"))
      :snt2 (x15 / treat-04
            :ARG1-of (x13 / doxy)
            :ARG2 (x14 / or)
            :ARG1 (x16 / and
                  :op1 (x17 / doxy))
            :ARG2 (x18 / small-molecule
                  :name (x19 / name :op1 "doxycycline")
                  :quant "2"
                  :name (x20 / name :op1 "μg/ml")
                  :xref (x36 / xref :value "PUBCHEM:54671203" :prob "15.91623"))
            :duration (x21 / temporal-quantity
                  :quant "24"
                  :unit (x22 / hour))
            :ARG1-of (x23 / follow-01
                  :ARG2 (x25 / starve-01
                        :ARG2 (x24 / serum))
                  :ARG1 (x26 / percentage-entity
                        :value "0.5"
                        :quant-of (x27 / serum))
                  :ARG2 (x28 / add-02
                        :ARG1 (x29 / temporal-quantity
                              :quant "24"
                              :unit (x30 / hour)))
                  :ARG1 (x31 / or
                        :op2 (x32 / present-02)
                        :op1 (x33 / absent-01
                              :ARG1 (x34 / small-molecule
                                    :name (x35 / name :op1 "doxycycline")
                                    :xref (x / xref :value "PUBCHEM:54671203" :prob "15.91623")))))))


# ::id PMC4345513.41
# ::snt After treatment with 50 ng/mL FGF2 for 30 min, cells were fixed in 4% paraformaldehyde and permeabilized in 0.1% Triton X-100.
# ::tok After treatment with 50 ng @/@ mL FGF2 for 30 min , cells were fixed in 4 % paraformaldehyde and permeabilized in 0.1 % Triton X @-@ 100 .
(x14 / and
      :time (x1 / after
            :op1 (x2 / treat-04
                  :ARG2 (x3 / small-molecule
                        :quant (x4 / concentration-quantity
                              :quant "50"
                              :unit (x5 / nanogram-per-milliliter))
                        :name (x6 / name :op1 "FGF2")
                        :xref (x20 / xref :value "PUBCHEM:71308511" :prob "19.266134"))
                  :duration (x7 / temporal-quantity
                        :quant "30"
                        :unit (x8 / minute))))
      :op1 (x10 / fix-00
            :ARG1 (x9 / cell)
            :ARG2 (x11 / small-molecule
                  :mod (x12 / percentage-entity :value "4")
                  :name (x13 / name :op1 "paraformaldehyde")
                  :xref (x / xref :value "PUBCHEM:712" :prob "16.525295")))
      :op2 (x15 / enzyme
            :name (x16 / name :op1 "permeabilized")
            :location (x17 / small-molecule
                  :quant (x18 / percentage-entity :value "0.1")
                  :name (x19 / name :op1 "Triton" :op2 "X-100"))))


# ::id PMC4345513.42
# ::snt The samples were incubated with primary antibodies against α-tubulin or phosphor-Erk1/2 (Thr 202/Tyr 204) for 90 min, followed by incubation with Alexa Fluor 555- (for α-tubulin) or Alexa Fluor 488-conjugated secondary antibody (for phosphor-Erk1/2) for 30 min.
# ::tok The samples were incubated with primary antibodies against α-tubulin or phosphor @-@ Erk1 @/@ 2 ( Thr 202 @/@ Tyr 204 ) for 90 min , followed by incubation with Alexa Fluor 555 @- ( for α-tubulin ) or Alexa Fluor 488 @-@ conjugated secondary antibody ( for phosphor @-@ Erk1 @/@ 2 ) for 30 min .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op1 (x5 / incubate-01
                  :ARG1 (x3 / thing
                        :ARG1-of (x4 / sample-01))
                  :ARG2 (x7 / antibody
                        :mod (x6 / primary)
                        :ARG0-of (x8 / counter-01
                              :ARG1 (x11 / or
                                    :op1 (x9 / protein
                                          :name (x10 / name :op1 "α-tubulin"))
                                    :op2 (x12 / enzyme
                                          :ARG3-of (x13 / phosphorylate-01)
                                          :name (x14 / name :op1 "Erk1/2"))))
                        :ARG1-of (x15 / describe-01
                              :ARG0 (x16 / and
                                    :op1 (x17 / amino-acid
                                          :mod "202"
                                          :name (x18 / name :op1 "threonine")
                                          :xref (x46 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                    :op2 (x19 / amino-acid
                                          :name (x20 / name :op1 "tyrosine")
                                          :mod "204"
                                          :xref (x45 / xref :value "PUBCHEM:1153" :prob "11.081481")))))
                  :duration (x21 / temporal-quantity
                        :quant "90"
                        :unit (x22 / minute)))
            :op2 (x23 / follow-01
                  :ARG1 (x24 / incubate-01
                        :ARG2 (x25 / small-molecule
                              :name (x26 / name :op1 "Alexa" :op2 "Fluor")))))
      :snt2 (x39 / antibody
            :ARG0 (x32 / or
                  :op1 (x27 / protein
                        :name (x28 / name :op1 "555"))
                  :op1 (x29 / and
                        :op2 (x30 / protein
                              :name (x31 / name :op1 "α-tubulin")))
                  :op2 (x33 / small-molecule
                        :name (x34 / name :op1 "Alexa" :op2 "Fluor")))
            :ARG1-of (x37 / conjugate-02
                  :ARG2 (x35 / small-molecule
                        :name (x36 / name :op1 "488")
                        :xref (x / xref :value "PUBCHEM:765619" :prob "7.620367")))
            :mod (x38 / secondary)
            :ARG2 (x40 / enzyme
                  :ARG3-of (x41 / phosphorylate-01)
                  :name (x42 / name :op1 "Erk1/2"))
            :duration (x43 / temporal-quantity
                  :quant "30"
                  :unit (x44 / minute))))


# ::id PMC4345513.43
# ::snt Nuclear DNA was stained with Hoechst 33258.
# ::tok Nuclear DNA was stained with Hoechst 33258 .
(x4 / stain-01
      :ARG1 (x1 / enzyme
            :mod (x2 / nucleus
                  :xref (x7 / xref :value "GO:0005634" :prob "0.8"))
            :name (x3 / name :op1 "DNA")
            :xref (x / xref :value "UNIPROT:DNS2A_HUMAN" :prob "0.272"))
      :ARG2 (x5 / small-molecule
            :name (x6 / name :op1 "Hoechst" :op2 "33258")))


# ::id PMC4345513.44
# ::snt Stained cells were immediately observed under an EVOSf1 Ⓡ fluorescence microscope (Advance Microscopy Group).
# ::tok Stained cells were immediately observed under an EVOSf1 Ⓡ fluorescence microscope ( Advance Microscopy Group ) .
(x3 / observe-01
      :ARG1 (x1 / stain-01)
      :manner (x2 / immediate)
      :condition (x6 / fluorescence
            :ARG0 (x4 / enzyme
                  :name (x5 / name :op1 "EVOSf1" :op2 "Ⓡ"))
            :ARG1-of (x7 / microscope)
            :ARG1-of (x8 / advance-01
                  :ARG1 (x10 / group
                        :mod (x9 / microscopy)))))


# ::id PMC4345513.45
# ::snt MKP3 is a Thr/Tyr dual-specific phosphatase of Erk1/2 that prevents nuclear translocation of Erk1/2 (18) .
# ::tok MKP3 is a Thr @/@ Tyr dual @-@ specific phosphatase of Erk1 @/@ 2 that prevents nuclear translocation of Erk1 @/@ 2 ( 18 ) .
(x9 / phosphorylate-01
      :ARG2 (x1 / protein
            :name (x2 / name :op1 "MKP3")
            :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
      :ARG1-of (x8 / specific-02
            :ARG2 (x3 / amino-acid
                  :name (x4 / name :op1 "threonine")
                  :mod (x5 / amino-acid
                        :name (x6 / name :op1 "tyrosine")
                        :mod (x7 / dual)
                        :xref (x22 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :xref (x21 / xref :value "PUBCHEM:205" :prob "11.848252")))
      :ARG1 (x10 / enzyme
            :name (x11 / name :op1 "Erk1/2"))
      :ARG0-of (x12 / prevent-01
            :ARG1 (x14 / translocate-01
                  :ARG2 (x13 / nucleus
                        :xref (x20 / xref :value "GO:0005634" :prob "0.8"))
                  :ARG1 (x15 / enzyme
                        :name (x16 / name :op1 "Erk1/2")))
            :ARG1-of (x17 / describe-01
                  :ARG0 (x18 / publication
                        :ARG1-of (x19 / cite-01 :ARG2 "18")))))


# ::id PMC4345513.46
# ::snt It has been reported that MKP3 is induced by Erk1/2 upon fibroblast growth factor 2 (FGF2) stimulation in NIH3T3 cells (21) , suggesting that growth factor-induced Erk1/2 activity could be controlled by negative feedback loops via Erk1/2-specific MKP3 expression.
# ::tok It has been reported that MKP3 is induced by Erk1 @/@ 2 upon fibroblast growth factor 2 ( FGF2 ) stimulation in NIH3T3 cells ( 21 ) , suggesting that growth factor @-@ induced Erk1 @/@ 2 activity could be controlled by negative feedback loops via Erk1 @/@ 2 @-@ specific MKP3 expression .
(x1 / multi-sentence
      :snt1 (x3 / report-01
            :ARG1 (x2 / it)
            :ARG1 (x6 / induce-01
                  :ARG2 (x4 / protein
                        :name (x5 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
                  :ARG0 (x7 / enzyme
                        :name (x8 / name :op1 "Erk1/2")))
            :time (x9 / and
                  :op1 (x10 / protein
                        :name (x11 / name
                              :op1 "fibroblast"
                              :op2 "growth"
                              :op3 "factor"
                              :op4 "2"))
                  :op2 (x12 / protein
                        :name (x13 / name :op1 "FGF2")
                        :xref (x39 / xref :value "UNIPROT:FGF2_HUMAN" :prob "1.004"))))
      :snt2 (x14 / stimulate-01
            :location (x16 / cell-line
                  :name (x15 / name :op1 "NIH3T3"))
            :ARG1-of (x17 / describe-01
                  :ARG0 (x18 / publication
                        :ARG1-of (x19 / cite-01 :ARG2 "21")))
            :ARG0-of (x20 / suggest-01
                  :ARG1 (x21 / possible-01
                        :ARG1 (x28 / control-01
                              :ARG1 (x27 / activity-06
                                    :ARG2-of (x24 / induce-01
                                          :ARG0 (x22 / protein
                                                :name (x23 / name :op2 "growth" :op3 "factor")))
                                    :ARG0 (x25 / enzyme
                                          :name (x26 / name :op1 "Erk1/2")))
                              :ARG0 (x31 / loop-01
                                    :mod (x30 / feedback
                                          :ARG0-of (x29 / negative-03)))))
                  :ARG2 (x37 / express-03
                        :ARG1-of (x34 / specific-02
                              :ARG2 (x32 / enzyme
                                    :name (x33 / name :op1 "Erk1/2")))
                        :ARG2 (x35 / protein
                              :name (x36 / name :op1 "MKP3")
                              :xref (x38 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))))))


# ::id PMC4345513.47
# ::snt To investigate whether sustained Ras activation impairs phosphorylated Erk1/2 levels in the nucleus through induction of MKP3, NIH3T3tet-on/H-RasG12R cells were exposed to doxycycline and MKP3 mRNA levels were examined by Northern blot analysis.
# ::tok To investigate whether sustained Ras activation impairs phosphorylated Erk1 @/@ 2 levels in the nucleus through induction of MKP3 , NIH3T3 tet @-@ on/H @-@ RasG12R cells were exposed to doxycycline and MKP3 mRNA levels were examined by Northern blot analysis .
(x23 / and
      :purpose (x1 / investigate-01
            :ARG1 (x6 / impair-01
                  :mode "interrogative"
                  :ARG0 (x5 / activate-01
                        :ARG1-of (x2 / sustain-01)
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "Ras")
                              :xref (x33 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                  :ARG1 (x10 / level
                        :quant-of (x7 / enzyme
                              :ARG3-of (x8 / phosphorylate-01)
                              :name (x9 / name :op1 "Erk1/2")))
                  :location (x11 / nucleus
                        :xref (x35 / xref :value "GO:0005634" :prob "0.8")))
            :ARG2 (x12 / induce-01
                  :ARG2 (x13 / protein
                        :name (x14 / name :op1 "MKP3")
                        :xref (x34 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))))
      :op1 (x20 / expose-01
            :ARG1 (x19 / cell
                  :name (x15 / name :op1 "NIH3T3")
                  :mod (x16 / protein
                        :name (x17 / name :op1 "tet-crkl" :op2 "on/H"))
                  :name (x18 / name :op1 "RasG12R"))
            :ARG2 (x21 / small-molecule
                  :name (x22 / name :op1 "doxycycline")
                  :xref (x36 / xref :value "PUBCHEM:54671203" :prob "15.91623")))
      :op2 (x29 / examine-01
            :ARG1 (x28 / level
                  :mod (x24 / protein
                        :name (x25 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
                  :quant-of (x26 / nucleic-acid
                        :name (x27 / name :op1 "mRNA")))
            :ARG0 (x32 / analyze-01
                  :mod (x30 / thing
                        :name (x31 / name :op1 "Northern" :op2 "blot")))))


# ::id PMC4345513.48
# ::snt A time kinetic study showed that MKP3 mRNA was detectable within 3 h after doxycycline addition ( Fig. 3 A).
# ::tok A time kinetic study showed that MKP3 mRNA was detectable within 3 h after doxycycline addition ( Fig . 3 A ) .
(x4 / show-01
      :ARG0 (x3 / study-01
            :mod (x1 / time)
            :mod (x2 / kinetic))
      :ARG1 (x9 / detect-01
            :ARG0 (x5 / protein
                  :name (x6 / name :op1 "MKP3")
                  :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
            :ARG1 (x7 / nucleic-acid
                  :name (x8 / name :op1 "mRNA"))
            :time (x13 / after
                  :quant (x10 / up-to
                        :op1 (x11 / temporal-quantity
                              :quant "3"
                              :unit (x12 / hour)))
                  :op1 (x16 / add-02
                        :ARG2 (x14 / small-molecule
                              :name (x15 / name :op1 "doxycycline")
                              :xref (x19 / xref :value "PUBCHEM:54671203" :prob "15.91623"))))
            :ARG1-of (x17 / describe-01
                  :ARG0 (x18 / figure :mod "3"))))


# ::id PMC4345513.49
# ::snt MKP3 protein was also increased by doxycycline treatment and coincided with a reduction in Erk1/2 phosphorylation ( Fig. 3 B).
# ::tok MKP3 protein was also increased by doxycycline treatment and coincided with a reduction in Erk1 @/@ 2 phosphorylation ( Fig . 3 B ) .
(x9 / coincide-01
      :ARG0 (x4 / increase-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "MKP3")
                  :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
            :mod (x3 / also)
            :ARG0 (x7 / treat-04
                  :ARG2 (x5 / small-molecule
                        :name (x6 / name :op1 "doxycycline")
                        :xref (x16 / xref :value "PUBCHEM:54671203" :prob "15.91623")))
            :ARG2 (x8 / and))
      :ARG2 (x10 / reduce-01
            :ARG1 (x13 / phosphorylate-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "Erk1/2"))))
      :ARG1-of (x14 / describe-01
            :ARG0 (x15 / figure :mod "3")))


# ::id PMC4345513.50
# ::snt To determine whether induction of MKP3 mRNA by active Ras occurred at the transcriptional level, the 5'-regulatory region of the MKP3 gene (nucleotides from −1597 to −10 relative to the transcription start site) was isolated and sub-cloned into a pGL3-Luc reporter vector.
# ::tok To determine whether induction of MKP3 mRNA by active Ras occurred at the transcriptional level , the 5 ' @-@ regulatory region of the MKP3 gene ( nucleotides from −1597 to −10 relative to the transcription start site ) was isolated and sub @-@ cloned into a pGL3 @-@ Luc reporter vector .
(x1 / multi-sentence
      :snt1 (x29 / isolate-01
            :purpose (x2 / determine-01
                  :ARG1 (x12 / be-located-at-91
                        :mode "interrogative"
                        :ARG1 (x3 / induce-01
                              :ARG2 (x6 / nucleic-acid
                                    :mod (x4 / protein
                                          :name (x5 / name :op1 "MKP3")
                                          :xref (x39 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
                                    :name (x7 / name :op1 "mRNA")
                                    :ARG0-of (x8 / encode-01))
                              :ARG0 (x9 / enzyme
                                    :ARG1-of (x10 / activate-01)
                                    :name (x11 / name :op1 "Ras")
                                    :xref (x38 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                        :ARG2 (x14 / level
                              :mod (x13 / transcribe-01))))
            :ARG1 (x18 / region
                  :ARG0-of (x17 / regulate-01
                        :ARG1 (x15 / enzyme
                              :name (x16 / name :op1 "5'")))
                  :part-of (x20 / gene
                        :name (x19 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
                  :ARG1-of (x25 / relative-05
                        :ARG1 (x21 / nucleotide
                              :source (x23 / molecular-physical-entity
                                    :name (x22 / name :op1 "−1597"))
                              :name (x24 / name :op1 "−10"))
                        :ARG2 (x28 / protein-segment
                              :location-of (x27 / start-01
                                    :ARG1 (x26 / transcribe-01))))))
      :snt2 (x30 / and
            :op2 (x37 / vector
                  :mod (x33 / clone-01
                        :ARG1 (x31 / enzyme
                              :name (x32 / name :op1 "sub-g1")
                              :xref (x40 / xref :value "UNIPROT:TCP4_HUMAN" :prob "0.222"))
                        :ARG1 (x34 / pgl3)
                        :ARG2-of (x35 / efficient-01))
                  :ARG0-of (x36 / report-01))))


# ::id PMC4345513.51
# ::snt Transient co-transfection of active H-RasV12 and pMkp3-Luc(−1597/−10) into NIH3T3 cells led to a concentration-dependent increase in promoter reporter activity, while dominant-negative RasN17 had no effect ( Fig. 3 C).
# ::tok Transient co @-@ transfection of active H @-@ RasV12 and pMkp3 @-@ Luc ( −1597/−10 ) into NIH3T3 cells led to a concentration @-@ dependent increase in promoter reporter activity , while dominant @-@ negative RasN17 had no effect ( Fig . 3 C ) .
(x1 / multi-sentence
      :snt1 (x16 / lead-03
            :ARG1 (x15 / cell-line
                  :ARG1-of (x2 / transient-02
                        :ARG1 (x3 / cotransfect-01
                              :ARG2 (x4 / activate-01
                                    :ARG1 (x8 / and
                                          :op1 (x5 / enzyme
                                                :name (x6 / name :op1 "h-ras")
                                                :ARG2-of (x7 / mutate-01 :value "v12")
                                                :xref (x32 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601"))
                                          :op2 (x9 / enzyme
                                                :name (x10 / name :op1 "pMkp3")))
                                    :ARG2-of (x11 / efficient-01)
                                    :ARG1-of (x13 / into
                                          :name (x12 / name :op1 "−1597/−10")))))
                  :name (x14 / name :op1 "NIH3T3"))
            :ARG2 (x19 / increase-01
                  :degree (x18 / depend-01
                        :ARG1 (x17 / concentrate-02))
                  :location (x20 / molecular-physical-entity
                        :ARG0-of (x21 / promote-01))))
      :snt2 (x24 / contrast-01
            :ARG1 (x23 / activity-06
                  :ARG0-of (x22 / report-01))
            :ARG2 (x29 / affect-01
                  :ARG0 (x25 / enzyme
                        :ARG0-of (x26 / dominate-01)
                        :ARG2-of (x27 / mutate-01 :mod "-/-")
                        :name (x28 / name :op1 "ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                  :polarity "-")
            :ARG1-of (x30 / describe-01
                  :ARG0 (x31 / figure :mod "3c"))))


# ::id PMC4345513.52
# ::snt Thus, long-term activation of the Ras signaling pathway up-regulates MKP3 expression at the transcriptional level in NIH3T3 fibroblasts.
# ::tok Thus , long @-@ term activation of the Ras signaling pathway up @-@ regulates MKP3 expression at the transcriptional level in NIH3T3 fibroblasts .
(x1 / infer-01
      :ARG1 (x8 / regulate-01
            :ARG1-of (x2 / long-03)
            :mod (x7 / pathway
                  :ARG1-of (x3 / activate-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "Ras")
                              :xref (x16 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                  :ARG0-of (x6 / signal-07))
            :ARG1 (x11 / express-03
                  :ARG2 (x9 / protein
                        :name (x10 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
                  :ARG3 (x13 / level
                        :mod (x12 / transcribe-01)))
            :location (x15 / fibroblast
                  :name (x14 / name :op1 "NIH3T3"))))


# ::id PMC4345513.54
# ::snt After total RNA was isolated, MKP3 or Gapdh mRNA expression was determined using Northern blotting.
# ::tok After total RNA was isolated , MKP3 or Gapdh mRNA expression was determined using Northern blotting .
(x14 / determine-01
      :time (x1 / after
            :op1 (x5 / isolate-01
                  :ARG1 (x2 / enzyme
                        :mod (x3 / total)
                        :name (x4 / name :op1 "RNA")
                        :xref (x18 / xref :value "UNIPROT:RCL1_HUMAN" :prob "0.262"))))
      :ARG0 (x8 / or
            :op1 (x6 / protein
                  :name (x7 / name :op1 "MKP3")
                  :xref (x19 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
            :op2 (x9 / enzyme
                  :name (x10 / name :op1 "Gapdh")
                  :xref (x / xref :value "UNIPROT:G3P_HUMAN" :prob "0.602")))
      :ARG1 (x13 / express-03
            :ARG2 (x11 / nucleic-acid
                  :name (x12 / name :op1 "mRNA")))
      :manner (x15 / use-01
            :ARG1 (x16 / thing
                  :name (x17 / name :op1 "Northern" :op2 "blotting"))))


# ::id PMC4345513.55
# ::snt After 24 h, the cells were treated with doxycycline (2 μg/ml) for an additional 24 h.
# ::tok After 24 h , the cells were treated with doxycycline ( 2 μg/ml ) for an additional 24 h .
(x5 / treat-04
      :time (x1 / after
            :op1 (x2 / temporal-quantity
                  :quant "24"
                  :unit (x3 / hour)))
      :ARG1 (x4 / cell)
      :ARG2 (x6 / small-molecule
            :name (x7 / name :op1 "doxycycline")
            :quant "2"
            :name (x8 / name :op1 "μg/ml")
            :xref (x / xref :value "PUBCHEM:54671203" :prob "15.91623"))
      :duration (x9 / temporal-quantity
            :quant "1"
            :mod (x10 / additional)
            :quant "24"
            :unit (x11 / hour)))


# ::id PMC4345513.57
# ::snt Active Ras can stimulate multiple effector pathways, including Raf and PI3K (22) .
# ::tok Active Ras can stimulate multiple effector pathways , including Raf and PI3K ( 22 ) .
(x5 / stimulate-01
      :ARG0 (x1 / enzyme
            :ARG1-of (x2 / activate-01)
            :name (x3 / name :op1 "Ras")
            :xref (x19 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
      :ARG1-of (x4 / possible-01)
      :ARG1 (x8 / pathway
            :quant (x6 / multiple)
            :mod (x7 / effector)
            :ARG2-of (x9 / include-01
                  :ARG1 (x12 / and
                        :op1 (x10 / enzyme
                              :name (x11 / name :op1 "Raf")
                              :xref (x18 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
                        :op2 (x13 / enzyme
                              :name (x14 / name :op1 "PI3K")
                              :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))))
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / publication
                  :ARG1-of (x17 / cite-01 :ARG2 "22"))))


# ::id PMC4345513.58
# ::snt Numerous reports have demonstrated that MKP3 expression is dependent on Erk1/2 activity in several cell types, including NIH3T3, human pancreatic cancer, and non-small-cell lung cancer cells (21 , 23 - 25) .
# ::tok Numerous reports have demonstrated that MKP3 expression is dependent on Erk1 @/@ 2 activity in several cell types , including NIH3T3 , human pancreatic cancer , and non @-@ small @-@ cell lung cancer cells ( 21 , 23 - 25 ) .
(x4 / demonstrate-01
      :ARG0 (x2 / thing
            :quant (x1 / numerous)
            :ARG1-of (x3 / report-01))
      :ARG1 (x8 / depend-01
            :ARG0 (x7 / express-03
                  :ARG2 (x5 / protein
                        :name (x6 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))
            :ARG1 (x11 / activity-06
                  :ARG0 (x9 / enzyme
                        :name (x10 / name :op1 "Erk1/2"))))
      :location (x26 / cell
            :quant (x12 / several)
            :mod (x14 / type
                  :mod (x13 / cell)
                  :ARG2-of (x15 / include-01
                        :ARG1 (x21 / and
                              :op1 (x17 / cell-line
                                    :name (x16 / name :op1 "NIH3T3")
                                    :mod (x18 / human)
                                    :mod (x19 / disease
                                          :wiki "pancreatic_cancer"
                                          :name (x20 / name :op1 "pancreatic" :op2 "cancer")))
                              :op2 (x23 / cell
                                    :mod (x22 / small :polarity "-")))))
            :mod (x24 / disease
                  :wiki "lung_cancer"
                  :name (x25 / name :op1 "lung" :op2 "cancer")))
      :ARG1-of (x27 / describe-01
            :ARG0 (x28 / publication
                  :ARG1-of (x29 / cite-01
                        :ARG2 (x30 / and
                              :op1 "21"
                              :op2 (x31 / value-interval :op1 "23" :op2 "25"))))))


# ::id PMC4345513.59
# ::snt The PI3K pathway also inhibits Erk1/2 activity through up-regulation of MKP3 expression in response to FGF8 stimulation during limb development (26) .
# ::tok The PI3K pathway also inhibits Erk1 @/@ 2 activity through up @-@ regulation of MKP3 expression in response to FGF8 stimulation during limb development ( 26 ) .
(x15 / stimulate-01
      :ARG0 (x4 / inhibit-01
            :ARG1 (x1 / pathway
                  :name (x2 / name :op1 "PI3K"))
            :mod (x3 / also)
            :ARG1 (x7 / activity-06
                  :ARG0 (x5 / enzyme
                        :name (x6 / name :op1 "Erk1/2")))
            :instrument (x8 / upregulate-01
                  :ARG1 (x11 / express-03
                        :ARG2 (x9 / protein
                              :name (x10 / name :op1 "MKP3")
                              :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))
                  :ARG2-of (x12 / respond-01
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "FGF8")))))
      :time (x17 / develop-02
            :ARG1 (x16 / limb))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / publication
                  :ARG1-of (x20 / cite-01 :ARG2 "26"))))


# ::id PMC4345513.60
# ::snt These studies have suggested that multiple signaling pathways are involved in MKP3 expression.
# ::tok These studies have suggested that multiple signaling pathways are involved in MKP3 expression .
(x3 / suggest-01
      :ARG0 (x2 / study-01
            :mod (x1 / this))
      :ARG1 (x7 / involve-01
            :ARG1 (x6 / pathway
                  :quant (x4 / multiple)
                  :ARG0-of (x5 / signal-07))
            :ARG2 (x10 / express-03
                  :ARG2 (x8 / protein
                        :name (x9 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))))


# ::id PMC4345513.61
# ::snt To determine the downstream signaling pathway of active Ras involved in MKP3 expression, we utilized pharmacological inhibitors.
# ::tok To determine the downstream signaling pathway of active Ras involved in MKP3 expression , we utilized pharmacological inhibitors .
(x13 / utilize-01
      :purpose (x1 / determine-01
            :ARG1 (x4 / pathway
                  :ARG0-of (x3 / signal-07
                        :direction (x2 / downstream)))
            :ARG2 (x8 / involve-01
                  :ARG1 (x5 / enzyme
                        :ARG0-of (x6 / activity-06)
                        :name (x7 / name :op1 "Ras")
                        :xref (x17 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :ARG2 (x11 / express-03
                        :ARG2 (x9 / protein
                              :name (x10 / name :op1 "MKP3")
                              :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))))
      :ARG0 (x12 / we)
      :ARG1 (x15 / molecular-physical-entity
            :mod (x14 / pharmacological)
            :ARG0-of (x16 / inhibit-01)))


# ::id PMC4345513.62
# ::snt Treatment with either the PI3K inhibitor (LY294002) or the Akt inhibitor (API-2) blocked doxycycline-induced accumulation of MKP3, which led to the partial recovery of the phosphorylation status of Erk1/2 ( Fig. 4 A), suggesting the existence of an alternative mechanism.
# ::tok Treatment with either the PI3K inhibitor ( LY294002 ) or the Akt inhibitor ( API @-@ 2 ) blocked doxycycline @-@ induced accumulation of MKP3 , which led to the partial recovery of the phosphorylation status of Erk1 @/@ 2 ( Fig . 4 A ) , suggesting the existence of an alternative mechanism .
(x1 / multi-sentence
      :snt1 (x9 / or
            :op1 (x2 / treat-04
                  :ARG2 (x3 / or
                        :op1 (x7 / small-molecule
                              :ARG0-of (x6 / inhibit-01
                                    :ARG1 (x4 / protein-family
                                          :name (x5 / name :op1 "PI3K")))
                              :name (x8 / name :op1 "LY294002")
                              :xref (x35 / xref :value "PUBCHEM:3973" :prob "18.86067"))))
            :op2 (x10 / enzyme
                  :name (x11 / name :op1 "Akt")
                  :xref (x34 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
      :snt2 (x14 / block-01
            :ARG0 (x12 / small-molecule
                  :name (x13 / name :op1 "API")
                  :mod "2")
            :ARG1 (x18 / accumulate-01
                  :ARG2-of (x17 / induce-01
                        :ARG0 (x15 / small-molecule
                              :name (x16 / name :op1 "doxycycline")
                              :xref (x36 / xref :value "PUBCHEM:54671203" :prob "15.91623")))
                  :ARG1 (x19 / protein
                        :name (x20 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))
            :ARG0-of (x21 / lead-03
                  :ARG2 (x23 / recover-02
                        :degree (x22 / part)
                        :ARG1 (x24 / status
                              :mod (x25 / phosphorylate-01
                                    :ARG1 (x26 / enzyme
                                          :name (x27 / name :op1 "Erk1/2")))))
                  :ARG1-of (x28 / describe-01
                        :ARG0 (x29 / figure :mod "a"))
                  :ARG0-of (x30 / suggest-01
                        :ARG1 (x31 / exist-01
                              :ARG1 (x33 / mechanism
                                    :mod (x32 / alternative)))))))


# ::id PMC4345513.63
# ::snt Interestingly, treatment with the MEK inhibitor (U0126) caused a dramatic reduction in the level of phosphorylated Erk1/2, but only slightly prevented MKP3 accumulation.
# ::tok Interestingly , treatment with the MEK inhibitor ( U0126 ) caused a dramatic reduction in the level of phosphorylated Erk1 @/@ 2 , but only slightly prevented MKP3 accumulation .
(x16 / contrast-01
      :ARG2-of (x1 / interest-01)
      :ARG1 (x2 / treat-04
            :ARG2 (x6 / molecular-physical-entity
                  :ARG0-of (x5 / inhibit-01
                        :ARG1 (x3 / protein-family
                              :name (x4 / name :op1 "MEK"))))
            :ARG1-of (x9 / cause-01
                  :ARG0 (x7 / small-molecule
                        :name (x8 / name :op1 "U0126")
                        :xref (x23 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
                  :ARG1 (x11 / reduce-01
                        :degree (x10 / dramatic)
                        :ARG1 (x12 / level
                              :quant-of (x13 / enzyme
                                    :ARG3-of (x14 / phosphorylate-01)
                                    :name (x15 / name :op1 "Erk1/2"))))))
      :ARG2 (x19 / prevent-01
            :degree (x18 / slight
                  :mod (x17 / only))
            :ARG1 (x22 / accumulate-01
                  :ARG1 (x20 / protein
                        :name (x21 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))))


# ::id PMC4345513.64
# ::snt Moreover, doxycycline-induced MKP3 promoter activity was strongly inhibited by LY294002 or API-2, whereas only slightly, but significantly, inhibited in the presence of U0126 ( Fig. 4 B).
# ::tok Moreover , doxycycline @-@ induced MKP3 promoter activity was strongly inhibited by LY294002 or API @-@ 2 , whereas only slightly , but significantly , inhibited in the presence of U0126 ( Fig . 4 B ) .
(x1 / and
      :op2 (x17 / contrast-01
            :ARG1 (x11 / inhibit-01
                  :ARG1 (x9 / activity-06
                        :ARG2-of (x4 / induce-01
                              :ARG0 (x2 / small-molecule
                                    :name (x3 / name :op1 "doxycycline")
                                    :xref (x29 / xref :value "PUBCHEM:54671203" :prob "15.91623")))
                        :ARG0 (x8 / molecular-physical-entity
                              :ARG0-of (x7 / promote-01
                                    :ARG1 (x5 / protein
                                          :name (x6 / name :op1 "MKP3")
                                          :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))))
                  :ARG1-of (x10 / strong-02)
                  :ARG0 (x14 / or
                        :op1 (x12 / small-molecule
                              :name (x13 / name :op1 "LY294002")
                              :xref (x30 / xref :value "PUBCHEM:3973" :prob "18.86067"))
                        :op2 (x15 / protein
                              :name (x16 / name :op1 "API-2"))))
            :ARG2 (x22 / inhibit-01
                  :mod (x18 / only)
                  :degree (x19 / slight
                        :ARG1-of (x20 / contrast-01
                              :ARG2 (x21 / significant-02)))
                  :location (x23 / present-02
                        :ARG1 (x24 / small-molecule
                              :name (x25 / name :op1 "U0126")
                              :xref (x28 / xref :value "PUBCHEM:3006531" :prob "17.656696"))))
            :ARG1-of (x26 / describe-01
                  :ARG0 (x27 / figure :mod "4b"))))


# ::id PMC4345513.65
# ::snt In contrast, the mTOR inhibitor rapamycin had no significant effect on doxycycline-induced MKP3 promoter activity.
# ::tok In contrast , the mTOR inhibitor rapamycin had no significant effect on doxycycline @-@ induced MKP3 promoter activity .
(x1 / contrast-01
      :ARG2 (x8 / affect-01
            :ARG0 (x2 / small-molecule
                  :ARG0-of (x5 / inhibit-01
                        :ARG1 (x3 / protein
                              :name (x4 / name :op1 "mTOR")
                              :xref (x / xref :value "UNIPROT:MTOR_HUMAN" :prob "1.004")))
                  :name (x6 / name :op1 "rapamycin")
                  :xref (x19 / xref :value "PUBCHEM:5040" :prob "15.003454"))
            :polarity "-"
            :ARG1-of (x7 / significant-02)
            :ARG1 (x16 / activity-06
                  :ARG2-of (x11 / induce-01
                        :ARG0 (x9 / small-molecule
                              :name (x10 / name :op1 "doxycycline")
                              :xref (x18 / xref :value "PUBCHEM:54671203" :prob "15.91623")))
                  :ARG0 (x15 / molecular-physical-entity
                        :ARG0-of (x14 / promote-01
                              :ARG1 (x12 / protein
                                    :name (x13 / name :op1 "MKP3")
                                    :xref (x17 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))))))


# ::id PMC4345513.66
# ::snt We next assessed the effect of forced expression of PI3K.
# ::tok We next assessed the effect of forced expression of PI3K .
(x3 / assess-01
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x4 / affect-01
            :ARG0 (x6 / express-03
                  :ARG1-of (x5 / force-02)
                  :ARG2 (x7 / enzyme
                        :name (x8 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))))


# ::id PMC4345513.67
# ::snt Transient transfection of active RasV12, p110-CAAX (constitutively active p110 subunit of PI3K), or Akt led to a strong increase in reporter activity of the pMkp3-Luc(−1597/−10) construct ( Fig. 4 C).
# ::tok Transient transfection of active RasV12 , p110 @-@ CAAX ( constitutively active p110 subunit of PI3K ) , or Akt led to a strong increase in reporter activity of the pMkp3 @-@ Luc ( −1597/−10 ) construct ( Fig . 4 C ) .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op1 (x4 / transfect-01
                  :ARG1-of (x3 / transient-02)
                  :ARG2 (x5 / activity-06
                        :ARG0 (x6 / and
                              :op1 (x7 / enzyme
                                    :name (x8 / name :op1 "ras")
                                    :ARG2-of (x9 / mutate-01 :value "v12")
                                    :xref (x42 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                              :op2 (x10 / enzyme
                                    :name (x11 / name :op1 "ras")
                                    :ARG2-of (x12 / mutate-01 :value "v12s35")
                                    :xref (x44 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203")))))
            :op2 (x13 / protein
                  :name (x14 / name :op1 "p110")
                  :xref (x45 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.262"))
            :op3 (x16 / enzyme
                  :name (x15 / name :op1 "rlf-caax")
                  :ARG0-of (x18 / activity-06
                        :mod (x17 / constitutive))))
      :snt2 (x27 / lead-03
            :ARG0 (x24 / or
                  :op1 (x21 / subunit
                        :mod (x19 / protein
                              :name (x20 / name :op1 "p110")
                              :xref (x43 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.262"))
                        :part-of (x22 / enzyme
                              :name (x23 / name :op1 "PI3K")
                              :xref (x41 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                  :op2 (x25 / enzyme
                        :name (x26 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :ARG2 (x29 / increase-01
                  :ARG1-of (x28 / strong-02)
                  :ARG1 (x30 / report-01
                        :ARG1 (x31 / activity-06
                              :ARG0 (x32 / protein
                                    :name (x33 / name :op1 "pMkp3")))
                        :ARG2-of (x34 / efficient-01)
                        :ARG1-of (x35 / describe-01
                              :ARG0 (x36 / protein
                                    :name (x37 / name :op1 "−1597/−10")
                                    :ARG2-of (x38 / construct-01)))))
            :ARG1-of (x39 / describe-01
                  :ARG0 (x40 / figure :mod "4"))))


# ::id PMC4345513.68
# ::snt Furthermore, RasV12-induced MKP3 promoter activity was significantly abrogated by expression of dominant negative (DN)-Akt ( Fig. 4 D).
# ::tok Furthermore , RasV12 @-@ induced MKP3 promoter activity was significantly abrogated by expression of dominant negative ( DN ) -Akt ( Fig . 4 D ) .
(x1 / and
      :op2 (x12 / abrogate-01
            :ARG1 (x10 / activity-06
                  :ARG2-of (x5 / induce-01
                        :ARG0 (x2 / enzyme
                              :name (x3 / name :op1 "ras")
                              :ARG2-of (x4 / mutate-01 :value "v12")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203")))
                  :ARG0 (x9 / molecular-physical-entity
                        :ARG0-of (x8 / promote-01
                              :ARG1 (x6 / protein
                                    :name (x7 / name :op1 "MKP3")
                                    :xref (x20 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))))
            :ARG1-of (x11 / significant-02)
            :ARG0 (x13 / express-03
                  :ARG2 (x15 / negative-03
                        :ARG0-of (x14 / dominate-01)
                        :name (x16 / name :op1 "DN")
                        :name (x17 / name :op1 "-Akt"))))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / figure :mod "4")))


# ::id PMC4345513.69
# ::snt These data suggest that the PI3K pathway plays a critical role in MKP3 expression induced by active Ras activation.
# ::tok These data suggest that the PI3K pathway plays a critical role in MKP3 expression induced by active Ras activation .
(x3 / suggest-01
      :ARG0 (x2 / data
            :mod (x1 / this))
      :ARG1 (x6 / play-02
            :ARG0 (x4 / pathway
                  :name (x5 / name :op1 "PI3K"))
            :ARG1 (x7 / role
                  :ARG1-of (x8 / critical-02
                        :ARG2 (x16 / activate-01
                              :ARG1 (x11 / express-03
                                    :ARG2 (x9 / protein
                                          :name (x10 / name :op1 "MKP3")
                                          :xref (x17 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
                                    :ARG2-of (x12 / induce-01
                                          :ARG0 (x13 / enzyme
                                                :ARG1-of (x14 / activate-01)
                                                :name (x15 / name :op1 "Ras")
                                                :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))))))))


# ::id PMC4345513.70
# ::snt Role of PI3K signaling in active Ras-induced MKP3 expression.
# ::tok Role of PI3K signaling in active Ras @-@ induced MKP3 expression .
(x4 / signal-07
      :ARG1 (x1 / role
            :poss (x2 / enzyme
                  :name (x3 / name :op1 "PI3K")
                  :xref (x12 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
      :ARG0-of (x5 / activity-06
            :ARG1 (x11 / express-03
                  :ARG2-of (x8 / induce-01
                        :ARG0 (x6 / enzyme
                              :name (x7 / name :op1 "Ras")
                              :xref (x13 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                  :ARG2 (x9 / protein
                        :name (x10 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))))


# ::id PMC4345513.71
# ::snt The cells were collected and Western blot analysis was performed using antibodies against H-Ras, MKP3, phosphor-Erk1/2 (Thr202/Tyr204) or Erk2 (internal control).
# ::tok The cells were collected and Western blot analysis was performed using antibodies against H @-@ Ras , MKP3 , phosphor @-@ Erk1 @/@ 2 ( Thr202/Tyr204 ) or Erk2 ( internal control ) .
(x3 / and
      :op1 (x2 / collect-01
            :ARG1 (x1 / cell))
      :op2 (x19 / or
            :op1 (x6 / perform-01
                  :ARG1 (x5 / analyze-01
                        :manner (x4 / immunoblot-01))
                  :ARG2-of (x7 / use-01
                        :ARG1 (x8 / antibody
                              :ARG0-of (x9 / counter-01
                                    :ARG1 (x10 / and
                                          :op1 (x11 / enzyme
                                                :name (x12 / name :op1 "H-Ras")
                                                :xref (x24 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))
                                          :op2 (x13 / protein
                                                :name (x14 / name :op1 "MKP3")
                                                :xref (x25 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
                                          :op3 (x15 / enzyme
                                                :ARG3-of (x16 / phosphorylate-01)
                                                :name (x17 / name :op1 "Erk1/2"))))
                              :name (x18 / name :op1 "Thr202/Tyr204"))))
            :op2 (x20 / enzyme
                  :name (x21 / name :op1 "Erk2")
                  :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.603")))
      :ARG1-of (x23 / control-01
            :ARG1-of (x22 / internal-02)))


# ::id PMC4345513.72
# ::snt After 24 h, the cells were treated with doxycycline (2 μg/ml) for an additional 24 h in the absence or presence of U0126 (10 μM), LY294002 (25 μM), API-2 (10 μM), rapamycin (10 μM), or GF109203X (10 μM).
# ::tok After 24 h , the cells were treated with doxycycline ( 2 μg/ml ) for an additional 24 h in the absence or presence of U0126 ( 10 μM ) , LY294002 ( 25 μM ) , API @-@ 2 ( 10 μM ) , rapamycin ( 10 μM ) , or GF109203X ( 10 μM ) .
(x1 / multi-sentence
      :snt1 (x2 / and
            :time (x3 / after
                  :op1 (x4 / temporal-quantity
                        :quant "24"
                        :unit (x5 / hour)))
            :op1 (x7 / treat-04
                  :ARG1 (x6 / cell)
                  :ARG2 (x8 / small-molecule
                        :name (x9 / name :op1 "doxycycline")
                        :quant "2"
                        :name (x10 / name :op1 "μg/ml")
                        :xref (x40 / xref :value "PUBCHEM:54671203" :prob "15.91623"))
                  :duration (x11 / temporal-quantity
                        :quant "1"
                        :mod (x12 / additional)
                        :quant "24"
                        :unit (x13 / hour))
                  :ARG2 (x14 / or
                        :op2 (x15 / present-02)
                        :op1 (x16 / absent-01
                              :ARG1 (x17 / small-molecule
                                    :name (x18 / name :op1 "U0126")
                                    :quant (x19 / concentration-quantity
                                          :quant "10"
                                          :unit (x20 / micromolar))
                                    :xref (x43 / xref :value "PUBCHEM:3006531" :prob "17.656696")))))
            :op2 (x21 / small-molecule
                  :name (x22 / name :op1 "LY294002")
                  :xref (x / xref :value "PUBCHEM:3973" :prob "18.86067"))
            :ARG1-of (x23 / describe-01
                  :ARG0 (x24 / publication
                        :ARG1-of (x25 / cite-01 :ARG2 "25"))))
      :snt2 (x26 / and
            :op2 (x27 / protein
                  :name (x28 / name :op1 "API-2"))
            :ARG1-of (x35 / or
                  :op1 (x29 / concentration-quantity
                        :quant "10"
                        :unit (x30 / micromolar))
                  :op2 (x31 / small-molecule
                        :name (x32 / name :op1 "rapamycin")
                        :quant (x33 / concentration-quantity
                              :quant "10"
                              :unit (x34 / micromolar))
                        :xref (x41 / xref :value "PUBCHEM:5040" :prob "15.003454"))
                  :op3 (x36 / small-molecule
                        :name (x37 / name :op1 "GF109203X")
                        :quant (x38 / concentration-quantity
                              :quant "10"
                              :unit (x39 / micromolar))
                        :xref (x42 / xref :value "PUBCHEM:2396" :prob "19.266134")))))


# ::id PMC4345513.74
# ::snt Firefly luciferase activity was normalized to Renilla luciferase activity.
# ::tok Firefly luciferase activity was normalized to Renilla luciferase activity .
(x3 / activity-06
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "Firefly" :op2 "luciferase"))
      :ARG1-of (x4 / normalize-01
            :ARG1 (x7 / activity-06
                  :ARG0 (x6 / luciferase
                        :name (x5 / name :op1 "Renilla")))))


# ::id PMC4345513.76
# ::snt After 24 h, the cells were collected and assayed for luciferase activity.
# ::tok After 24 h , the cells were collected and assayed for luciferase activity .
(x6 / and
      :time (x1 / after
            :op1 (x2 / temporal-quantity
                  :quant "24"
                  :unit (x3 / hour)))
      :op1 (x5 / collect-01
            :ARG1 (x4 / cell))
      :op2 (x7 / assay-01
            :ARG1 (x9 / activity-06
                  :ARG0 (x8 / luciferase))))


# ::id PMC4345513.77
# ::snt Firefly luciferase activity was normalized to the Renilla luciferase activity.
# ::tok Firefly luciferase activity was normalized to the Renilla luciferase activity .
(x4 / normalize-01
      :ARG1 (x3 / activity-06
            :ARG0 (x1 / enzyme
                  :name (x2 / name :op1 "Firefly" :op2 "luciferase")))
      :ARG2 (x7 / activity-06
            :ARG1 (x6 / luciferase
                  :name (x5 / name :op1 "Renilla"))))


# ::id PMC4345513.79
# ::snt The present study proposes a novel mechanism by which prolonged activation of active Ras can modulate Erk1/2 activity through induction of the MKP3 gene in NIH3T3 cells.
# ::tok The present study proposes a novel mechanism by which prolonged activation of active Ras can modulate Erk1 @/@ 2 activity through induction of the MKP3 gene in NIH3T3 cells .
(x3 / propose-01
      :ARG0 (x2 / study-01
            :time (x1 / present))
      :ARG1 (x5 / mechanism
            :mod (x4 / novel)
            :instrument-of (x6 / possible-01
                  :ARG1 (x12 / modulate-01
                        :ARG0 (x8 / activate-01
                              :ARG1-of (x7 / prolong-01)
                              :ARG1 (x9 / enzyme
                                    :ARG0-of (x10 / activity-06)
                                    :name (x11 / name :op1 "Ras")
                                    :xref (x21 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                        :ARG1 (x15 / activity-06
                              :ARG0 (x13 / enzyme
                                    :name (x14 / name :op1 "Erk1/2"))))
                  :manner (x16 / induce-01
                        :ARG2 (x18 / gene
                              :name (x17 / name :op1 "MKP3")
                              :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
                        :location (x20 / cell-line
                              :name (x19 / name :op1 "NIH3T3"))))))


# ::id PMC4345513.80
# ::snt Activated PI3K converts phosphatidylinositol 4,5-bisphosphate (PIP 2 ) into phosphatidylinositol 3,4,5 phosphate (PIP 3 ), which promotes membrane localization of PI-dependent kinase 1 (PDK1), leading to the activation of Akt, which in turn, can cause the activation or inhibition of specific target proteins involved in transcription, translation, cell growth, and survival.
# ::tok Activated PI3K converts phosphatidylinositol 4,5 @-@ bisphosphate ( PIP 2 ) into phosphatidylinositol 3,4,5 phosphate ( PIP 3 ) , which promotes membrane localization of PI @-@ dependent kinase 1 ( PDK1 ) , leading to the activation of Akt , which in turn , can cause the activation or inhibition of specific target proteins involved in transcription , translation , cell growth , and survival .
(x1 / multi-sentence
      :snt1 (x5 / convert-01
            :ARG1 (x2 / activate-01
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "PI3K")
                        :xref (x49 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "phosphatidylinositol" :op2 "4,5"))
            :ARG2 (x8 / protein
                  :name (x9 / name :op1 "bisphosphate")
                  :xref (x48 / xref :value "UNIPROT:BPNT1_HUMAN" :prob "0.262"))
            :ARG1-of (x14 / phosphate
                  :mod (x10 / amino-acid
                        :name (x11 / name :op1 "pip3")
                        :mod "2"
                        :ARG2 (x12 / enzyme
                              :name (x13 / name :op1 "phosphatidylinositol" :op2 "3,4,5"))
                        :xref (x52 / xref :value "PUBCHEM:3013835" :prob "9.77612"))
                  :name (x15 / name :op1 "pip3")
                  :mod "3")
            :ARG0-of (x16 / promote-01
                  :ARG1 (x18 / be-located-at-91
                        :ARG2 (x17 / membrane
                              :xref (x50 / xref :value "GO:0016020" :prob "0.8"))
                        :ARG1 (x22 / kinase
                              :ARG0-of (x21 / depend-01
                                    :ARG1 (x19 / small-molecule
                                          :name (x20 / name :op1 "pi-103")
                                          :xref (x51 / xref :value "PUBCHEM:9884685" :prob "14.194942")))))
                  :ARG1-of (x23 / describe-01
                        :ARG2 (x24 / enzyme
                              :name (x25 / name :op1 "PDK1")
                              :xref (x47 / xref :value "UNIPROT:PDK1_HUMAN" :prob "1.003"))))
            :ARG0-of (x26 / lead-03
                  :ARG2 (x27 / activate-01
                        :ARG1 (x28 / enzyme
                              :name (x29 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
            :ARG0-of (x32 / cause-01
                  :mod (x30 / in-turn)
                  :ARG1-of (x31 / possible-01)
                  :ARG1 (x33 / activate-01)))
      :snt2 (x34 / or
            :op2 (x35 / inhibit-01
                  :ARG1 (x38 / protein
                        :ARG1-of (x36 / specific-02)
                        :ARG0-of (x37 / target-01)))
            :ARG1-of (x39 / involve-01
                  :ARG2 (x40 / and
                        :op1 (x41 / transcribe-01)
                        :op2 (x42 / translate-02
                              :ARG1 (x45 / and
                                    :op1 (x44 / grow-01
                                          :ARG1 (x43 / cell))
                                    :op2 (x46 / survive-01)))))))


# ::id PMC4345513.81
# ::snt Ras positively cross-talks through direct interaction with the p110 catalytic subunit of PI3K to promote PI3K pathway activation (27) .
# ::tok Ras positively cross @-@ talks through direct interaction with the p110 catalytic subunit of PI3K to promote PI3K pathway activation ( 27 ) .
(x11 / subunit
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "Ras")
            :xref (x22 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
      :mod (x10 / catalysis
            :mod (x3 / positive)
            :ARG0-of (x4 / cross-02
                  :ARG1 (x5 / talk-01
                        :ARG1 (x7 / interact-01
                              :ARG1-of (x6 / direct-02)
                              :ARG1 (x8 / protein
                                    :name (x9 / name :op1 "p110")
                                    :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.262"))))))
      :part-of (x12 / enzyme
            :name (x13 / name :op1 "PI3K")
            :xref (x21 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
      :ARG2 (x14 / promote-01
            :ARG1 (x17 / activate-01
                  :ARG1 (x16 / pathway
                        :name (x15 / name :op1 "PI3K"))))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / publication
                  :ARG1-of (x20 / cite-01 :ARG2 "27"))))


# ::id PMC4345513.82
# ::snt In addition, constitutive Ras activation can promote the down-regulation of PTEN, a lipid phosphatase which counterbalances the effects of PI3K by removing the phosphate from PIP 3 (28) .
# ::tok In addition , constitutive Ras activation can promote the down @-@ regulation of PTEN , a lipid phosphatase which counterbalances the effects of PI3K by removing the phosphate from PIP 3 ( 28 ) .
(x1 / and
      :op2 (x2 / possible-01
            :ARG1 (x7 / promote-01
                  :ARG0 (x6 / activate-01
                        :mod (x3 / constitutive)
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "Ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                  :ARG1 (x14 / affect-01
                        :ARG0 (x8 / downregulate-01
                              :ARG1 (x10 / lipid
                                    :name (x9 / name :op1 "PTEN")
                                    :op2 (x11 / enzyme
                                          :name (x12 / name :op1 "phosphatase")
                                          :xref (x24 / xref :value "UNIPROT:Q59GM9_HUMAN" :prob "0.291"))
                                    :ARG1-of (x13 / counterbalance)))
                        :ARG1 (x15 / enzyme
                              :name (x16 / name :op1 "PI3K")
                              :xref (x25 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                  :manner (x17 / remove-01
                        :ARG1 (x18 / phosphate)
                        :ARG2 (x19 / protein
                              :name (x20 / name :op1 "PIP" :op2 "3")))))
      :ARG1-of (x21 / describe-01
            :ARG0 (x22 / publication
                  :ARG1-of (x23 / cite-01 :ARG2 "28"))))


# ::id PMC4345513.83
# ::snt On the contrary, Akt can inhibit the Raf through phosphorylation on Ser-259 (29 , 30) .
# ::tok On the contrary , Akt can inhibit the Raf through phosphorylation on Ser @-@ 259 ( 29 , 30 ) .
(x1 / contrast-01
      :ARG2 (x2 / possible-01
            :ARG1 (x5 / inhibit-01
                  :ARG0 (x3 / enzyme
                        :name (x4 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "Raf")
                        :xref (x12 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
                  :instrument (x11 / and
                        :op1 (x8 / phosphorylate-01
                              :ARG1 (x9 / amino-acid
                                    :name (x10 / name :op1 "serine")
                                    :mod "259"
                                    :xref (x13 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                        :op1 "29"
                        :op2 "30"))))


# ::id PMC4345513.84
# ::snt These findings suggest that the Ras and PI3K pathways can be mutually regulated by several cross-talk mechanisms in different cellular contexts.
# ::tok These findings suggest that the Ras and PI3K pathways can be mutually regulated by several cross @-@ talk mechanisms in different cellular contexts .
(x4 / suggest-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG1-of (x3 / find-01))
      :ARG1 (x5 / possible-01
            :ARG1 (x12 / regulate-01
                  :ARG1 (x8 / and
                        :op1 (x6 / enzyme
                              :name (x7 / name :op1 "Ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                        :op2 (x9 / pathway
                              :name (x10 / name :op1 "PI3K")))
                  :mod (x11 / mutual)
                  :ARG0 (x13 / several
                        :op1 (x14 / crosstalk-00))
                  :location (x16 / cell
                        :ARG1-of (x15 / differ-02)
                        :ARG1-of (x17 / context)))))


# ::id PMC4345513.86
# ::snt On the contrary, it has been reported that negative feedback regulation of FGF signaling (FGF2/4/8) is not mediated by the PI3K pathway, but by an Erk1/2-dependent Ets transcription factor, in MKP3 expression (21) .
# ::tok On the contrary , it has been reported that negative feedback regulation of FGF signaling ( FGF2 @/@ 4/8 ) is not mediated by the PI3K pathway , but by an Erk1 @/@ 2 @-@ dependent Ets transcription factor , in MKP3 expression ( 21 ) .
(x1 / contrast-01
      :ARG2 (x3 / report-01
            :ARG1 (x2 / it)
            :ARG1 (x6 / regulate-01
                  :mod (x5 / feedback
                        :ARG0-of (x4 / negative-03))
                  :ARG1 (x9 / signal-07
                        :ARG0 (x7 / protein
                              :name (x8 / name :op1 "FGF"))))
            :ARG1-of (x16 / mediate-01
                  :ARG0 (x12 / slash
                        :op1 (x10 / enzyme
                              :name (x11 / name :op1 "FGF2")
                              :xref (x32 / xref :value "UNIPROT:FGF2_HUMAN" :prob "1.004"))
                        :op2 (x13 / enzyme
                              :name (x14 / name :op1 "erk2")
                              :xref (x33 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.603")))
                  :ARG1-of (x15 / e/i)
                  :polarity "-"
                  :ARG0 (x17 / enzyme
                        :name (x18 / name :op1 "PI3K")
                        :xref (x34 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                  :ARG1-of (x19 / contrast-01
                        :ARG2 (x28 / express-03
                              :ARG0-of (x22 / depend-01
                                    :ARG1 (x20 / enzyme
                                          :name (x21 / name :op1 "Erk1/2")))
                              :ARG1 (x23 / and
                                    :op1 (x24 / protein
                                          :name (x25 / name
                                                :op1 "Ets"
                                                :op2 "transcription"
                                                :op3 "factor"))
                                    :op2 (x26 / protein
                                          :name (x27 / name :op1 "MKP3")
                                          :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))))
                        :ARG1-of (x29 / describe-01
                              :ARG0 (x30 / publication
                                    :ARG1-of (x31 / cite-01 :ARG2 "21")))))))


# ::id PMC4345513.87
# ::snt This discrepancy might be due to the different cellular contexts.
# ::tok This discrepancy might be due to the different cellular contexts .
(x2 / possible-01
      :ARG0 (x1 / this)
      :ARG1 (x4 / cause-01
            :ARG1 (x3 / discrepant)
            :ARG0 (x6 / cell
                  :ARG1-of (x5 / differ-02)
                  :ARG1-of (x7 / context))))


# ::id PMC4345513.88
# ::snt High levels of constitutively active Ras may affect multiple signaling pathways that are not activated by normal Ras (31) .
# ::tok High levels of constitutively active Ras may affect multiple signaling pathways that are not activated by normal Ras ( 31 ) .
(x8 / affect-01
      :ARG0 (x2 / level
            :ARG1-of (x1 / high-02)
            :quant-of (x3 / enzyme
                  :ARG0-of (x5 / activity-06
                        :mod (x4 / constitutive))
                  :name (x6 / name :op1 "Ras")
                  :xref (x19 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
      :ARG1-of (x7 / possible-01)
      :ARG1 (x11 / pathway
            :quant (x9 / multiple)
            :ARG0-of (x10 / signal-07)
            :ARG1-of (x12 / activate-01
                  :polarity "-"
                  :ARG0 (x13 / normal-02)
                  :ARG1 (x14 / enzyme
                        :name (x15 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / publication
                  :ARG1-of (x18 / cite-01 :ARG2 "31"))))


# ::id PMC4345513.89
# ::snt It is speculated that transient activation of Ras by growth factor signaling may induce MKP3 expression through an Erk1/2-dependent Ets-family transcription factor, but sustained activation of Ras may preferentially use the PI3K-dependent pathway to induce MKP3 expression.
# ::tok It is speculated that transient activation of Ras by growth factor signaling may induce MKP3 expression through an Erk1 @/@ 2 @-@ dependent Ets @-@ family transcription factor , but sustained activation of Ras may preferentially use the PI3K @-@ dependent pathway to induce MKP3 expression .
(x21 / contrast-01
      :ARG1 (x1 / speculate-01
            :ARG1 (x2 / possible-01
                  :ARG1 (x10 / induce-01
                        :ARG0 (x9 / signal-07
                              :ARG0-of (x4 / activate-01
                                    :ARG1-of (x3 / transient-02)
                                    :ARG1 (x5 / enzyme
                                          :name (x6 / name :op1 "Ras")
                                          :xref (x38 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                                    :ARG0 (x7 / protein
                                          :name (x8 / name :op2 "growth" :op3 "factor"))))
                        :ARG2 (x13 / express-03
                              :ARG1 (x11 / protein
                                    :name (x12 / name :op1 "MKP3")
                                    :xref (x40 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))))
            :manner (x20 / factor
                  :ARG0-of (x16 / depend-01
                        :ARG1 (x14 / enzyme
                              :name (x15 / name :op1 "Erk1/2")))
                  :mod (x18 / protein-family
                        :name (x17 / name :op1 "Ets"))
                  :ARG0-of (x19 / transcribe-01)))
      :ARG2 (x22 / possible-01
            :ARG1 (x27 / prefer-01
                  :ARG0 (x24 / activate-01
                        :ARG1-of (x23 / sustain-01)
                        :ARG1 (x25 / enzyme
                              :name (x26 / name :op1 "Ras")
                              :xref (x37 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                  :ARG1 (x28 / use-01
                        :ARG1 (x32 / pathway
                              :ARG0-of (x31 / depend-01
                                    :ARG1 (x29 / enzyme
                                          :name (x30 / name :op1 "PI3K")
                                          :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))
                        :ARG2 (x33 / induce-01
                              :ARG2 (x36 / express-03
                                    :ARG2 (x34 / protein
                                          :name (x35 / name :op1 "MKP3")
                                          :xref (x39 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))))))))


# ::id PMC4345513.90
# ::snt In summary, we showed that the PI3K-Akt signaling pathway negatively regulates Erk1/2 through induction of MKP3 expression in NIH3T3 cells expressing constitutively active Ras.
# ::tok In summary , we showed that the PI3K @-@ Akt signaling pathway negatively regulates Erk1 @/@ 2 through induction of MKP3 expression in NIH3T3 cells expressing constitutively active Ras .
(x3 / show-01
      :ARG2-of (x1 / summarize-01)
      :ARG0 (x2 / we)
      :ARG1 (x10 / downregulate-01
            :ARG1 (x9 / pathway
                  :ARG0-of (x8 / signal-07
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "PI3K")
                              :xref (x25 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                        :ARG0 (x6 / enzyme
                              :name (x7 / name :op1 "Akt")
                              :xref (x24 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
            :ARG1 (x11 / enzyme
                  :name (x12 / name :op1 "Erk1/2"))
            :manner (x13 / induce-01
                  :ARG2 (x16 / express-03
                        :ARG2 (x14 / protein
                              :name (x15 / name :op1 "MKP3")
                              :xref (x26 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))))
            :location (x18 / cell-line
                  :name (x17 / name :op1 "NIH3T3")
                  :ARG3-of (x19 / express-03
                        :ARG2 (x20 / enzyme
                              :ARG0-of (x22 / activity-06
                                    :mod (x21 / constitutive))
                              :name (x23 / name :op1 "Ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))))


# ::id PMC4345513.91
# ::snt However, it remains possible that other MKPs of the DUSP family could affect active Ras-induced Erk1/2 activity.
# ::tok However , it remains possible that other MKPs of the DUSP family could affect active Ras @-@ induced Erk1 @/@ 2 activity .
(x1 / have-concession-91
      :ARG1 (x2 / remain-01
            :ARG1 (x3 / possible-01
                  :ARG1 (x4 / possible-01
                        :ARG1 (x10 / affect-01
                              :ARG0 (x9 / protein-family
                                    :mod (x5 / other)
                                    :mod (x6 / enzyme
                                          :name (x7 / name :op1 "mkp")
                                          :xref (x18 / xref :value "UNIPROT:DUS1_HUMAN" :prob "0.202"))
                                    :name (x8 / name :op1 "DUSP"))
                              :ARG1 (x17 / activity-06
                                    :ARG2-of (x14 / induce-01
                                          :ARG0 (x11 / enzyme
                                                :ARG1-of (x12 / activate-01)
                                                :name (x13 / name :op1 "Ras")
                                                :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                                    :ARG0 (x15 / enzyme
                                          :name (x16 / name :op1 "Erk1/2"))))))))


# ::id PMC4345513.92
# ::snt An understanding of the precise molecular mechanism of the negative feedback loop induced by active Ras would be beneficial to the design of future therapeutic development against active Ras-mediated tumorigenesis.
# ::tok An understanding of the precise molecular mechanism of the negative feedback loop induced by active Ras would be beneficial to the design of future therapeutic development against active Ras @-@ mediated tumorigenesis .
(x16 / develop-01
      :ARG1 (x1 / understand-01
            :ARG1 (x4 / mechanism
                  :mod (x2 / precise)
                  :mod (x3 / molecule)
                  :ARG0-of (x12 / benefit-01
                        :ARG0 (x7 / loop
                              :mod (x6 / feedback
                                    :ARG0-of (x5 / negative-03))
                              :ARG2-of (x8 / induce-01
                                    :ARG0 (x9 / enzyme
                                          :ARG1-of (x10 / activate-01)
                                          :name (x11 / name :op1 "Ras")
                                          :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))))
            :ARG2 (x13 / design-01
                  :ARG1 (x15 / therapy
                        :time (x14 / future))))
      :ARG2 (x21 / create-01
            :ARG1 (x17 / activity-06)
            :ARG1-of (x20 / mediate-01
                  :ARG0 (x18 / enzyme
                        :name (x19 / name :op1 "Ras")
                        :xref (x23 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG1 (x22 / tumor)))


# ::id PMC4345513.94
# ::snt Cells and reagents
# ::tok Cells and reagents
(x2 / and
      :op1 (x1 / cell)
      :op2 (x3 / reagent))


# ::id PMC4345513.99
# ::snt Western blot analysis
# ::tok Western blot analysis
(x2 / analyze-01
      :manner (x1 / immunoblot-01))


# ::id PMC4345513.102
# ::snt Northern blot analysis
# ::tok Northern blot analysis
(x3 / analyze-01
      :mod (x1 / thing
            :name (x2 / name :op1 "Northern" :op2 "blot")))


# ::id PMC4345513.112
# ::snt Construction of the MKP3 promoter-reporter construct
# ::tok Construction of the MKP3 promoter @-@ reporter construct
(x1 / construct-01
      :ARG1 (x5 / molecular-physical-entity
            :ARG0-of (x4 / promote-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))))
      :ARG1-of (x8 / construct-01
            :ARG0 (x6 / gene
                  :ARG0-of (x7 / report-01))))


# ::id PMC4345513.115
# ::snt Transient transfection and luciferase promoter reporter assay
# ::tok Transient transfection and luciferase promoter reporter assay
(x9 / assay-01
      :ARG1 (x3 / and
            :op1 (x2 / transfect-01
                  :ARG1-of (x1 / transient-02))
            :op2 (x7 / molecular-physical-entity
                  :ARG0-of (x6 / promote-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "luciferase")))))
      :ARG0-of (x8 / report-01))


# ::id PMC5341140.0
# ::snt The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway
# ::tok The docking protein Gab1 is the primary mediator of EGF @-@ stimulated activation of the PI @-@ 3K @/@ Akt cell survival pathway
(x5 / mediate-01
      :ARG0 (x2 / protein
            :ARG0-of (x1 / dock-01)
            :name (x3 / name :op1 "Gab1")
            :domain (x4 / primary)
            :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
      :ARG1 (x8 / stimulate-01
            :ARG0 (x6 / protein
                  :name (x7 / name :op1 "EGF")
                  :xref (x17 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :ARG1 (x9 / activate-01
                  :ARG1 (x10 / and
                        :op1 (x11 / protein
                              :name (x12 / name :op1 "PI" :op2 "3K"))
                        :op2 (x16 / pathway
                              :name (x13 / name :op1 "Akt")
                              :mod (x15 / survive-01
                                    :ARG0 (x14 / cell)))))))


# ::id PMC5341140.3
# ::snt Gab1 is a docking protein that recruits phosphatidylinositol-3 kinase (PI-3 kinase) and other effector proteins in response to the activation of many receptor tyrosine kinases (RTKs).
# ::tok Gab1 is a docking protein that recruits phosphatidylinositol @-@ 3 kinase ( PI @-@ 3 kinase ) and other effector proteins in response to the activation of many receptor tyrosine kinases ( RTKs ) .
(x5 / recruit-01
      :ARG0 (x4 / protein
            :domain (x1 / protein
                  :name (x2 / name :op1 "Gab1")
                  :xref (x22 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG0-of (x3 / dock-01))
      :ARG1 (x6 / protein
            :name (x7 / name :op1 "phosphatidylinositol-3" :op2 "kinase"))
      :ARG1-of (x10 / and
            :op2 (x9 / kinase
                  :name (x8 / name :op1 "PI-3"))
            :op3 (x13 / protein
                  :mod (x11 / other)
                  :mod (x12 / effector))
            :ARG2-of (x14 / respond-01
                  :ARG1 (x15 / and
                        :op1 (x16 / activate-01
                              :ARG1 (x17 / person
                                    :quant (x18 / many)
                                    :name (x19 / name
                                          :op1 "receptor"
                                          :op2 "tyrosine"
                                          :op3 "kinase")))
                        :op2 (x20 / enzyme
                              :name (x21 / name :op1 "rtk")
                              :xref (x / xref :value "UNIPROT:DDR1_HUMAN" :prob "0.202"))))))


# ::id PMC5341140.4
# ::snt As the autophosphorylation sites on EGF-receptor (EGFR) do not include canonical PI-3 kinase binding sites, it is thought that EGF stimulation of PI-3 kinase and its downstream effector Akt is mediated by an indirect mechanism.
# ::tok As the autophosphorylation sites on EGF @-@ receptor ( EGFR ) do not include canonical PI @-@ 3 kinase binding sites , it is thought that EGF stimulation of PI @-@ 3 kinase and its downstream effector Akt is mediated by an indirect mechanism .
(x1 / and
      :op1 (x3 / site
            :ARG1-of (x2 / phosphorylate-01)
            :location (x4 / protein
                  :name (x5 / name :op1 "EGF" :op2 "receptor")))
      :ARG1-of (x8 / include-01
            :ARG2 (x6 / enzyme
                  :name (x7 / name :op1 "EGFR")
                  :xref (x29 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
            :polarity "-"
            :ARG1 (x13 / protein-segment
                  :ARG1-of (x12 / bind-01
                        :ARG2 (x11 / kinase
                              :mod (x9 / canonical)
                              :name (x10 / name :op1 "PI-3"))))
            :ARG1-of (x14 / possible-01
                  :ARG1 (x15 / think-01
                        :ARG1 (x26 / mediate-01
                              :ARG1 (x18 / stimulate-01
                                    :ARG0 (x16 / protein
                                          :name (x17 / name :op1 "EGF")
                                          :xref (x30 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                                    :ARG1 (x21 / and
                                          :op1 (x20 / kinase
                                                :name (x19 / name :op1 "PI-3"))
                                          :op2 (x23 / effector
                                                :mod (x22 / downstream)
                                                :mod (x24 / enzyme
                                                      :name (x25 / name :op1 "Akt")
                                                      :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))
                              :ARG0 (x28 / mechanism
                                    :ARG1-of (x27 / direct-02 :polarity "-")))))))


# ::id PMC5341140.6
# ::snt We used fibroblasts isolated from Gab1-/- mouse embryos to explore the mechanism of EGF stimulation of the PI-3 kinase/Akt anti-apoptotic cell signaling pathway.
# ::tok We used fibroblasts isolated from Gab1-/- mouse embryos to explore the mechanism of EGF stimulation of the PI @-@ 3 kinase @/@ Akt anti @-@ apoptotic cell signaling pathway .
(x2 / use-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / fibroblast
            :ARG1-of (x4 / isolate-01
                  :ARG2 (x6 / embryo
                        :mod (x5 / mouse))))
      :ARG2 (x7 / explore-01
            :ARG1 (x8 / mechanism
                  :poss (x11 / stimulate-01
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :ARG1 (x17 / pathway
            :name (x12 / name :op1 "PI-3" :op2 "kinase/Akt")
            :ARG0-of (x13 / counter-01
                  :ARG1 (x15 / cell
                        :mod (x14 / apoptotic)))
            :ARG0-of (x16 / signal-07)))


# ::id PMC5341140.7
# ::snt We demonstrate that Gab1 is essential for EGF stimulation of PI-3 kinase and Akt in these cells and that these responses are mediated by complex formation between p85, the regulatory subunit of PI-3 kinase, and three canonical tyrosine phosphorylation sites on Gab1.
# ::tok We demonstrate that Gab1 is essential for EGF stimulation of PI @-@ 3 kinase and Akt in these cells and that these responses are mediated by complex formation between p85 , the regulatory subunit of PI @-@ 3 kinase , and three canonical tyrosine phosphorylation sites on Gab1 .
(x2 / demonstrate-01
      :ARG0 (x1 / we)
      :ARG1 (x16 / and
            :op1 (x5 / essential
                  :domain (x3 / protein
                        :name (x4 / name :op1 "Gab1")
                        :xref (x36 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :purpose (x8 / stimulate-01
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "EGF")
                              :xref (x37 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                        :ARG1 (x11 / and
                              :op1 (x10 / kinase
                                    :name (x9 / name :op1 "PI-3"))
                              :op2 (x12 / enzyme
                                    :name (x13 / name :op1 "Akt")
                                    :xref (x39 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                        :location (x15 / cell
                              :mod (x14 / this))))
            :op2 (x20 / mediate-01
                  :ARG1 (x18 / thing
                        :mod (x17 / this)
                        :ARG2-of (x19 / respond-01))
                  :ARG1 (x22 / form-01
                        :ARG1 (x21 / macro-molecular-complex))
                  :ARG0 (x23 / enzyme
                        :name (x24 / name :op1 "p85")
                        :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))))
      :ARG1 (x29 / and
            :op1 (x26 / subunit
                  :ARG0-of (x25 / regulate-01)
                  :part-of (x28 / kinase
                        :name (x27 / name :op1 "PI-3")))
            :op2 (x33 / protein-segment
                  :quant "3"
                  :mod (x30 / canonical
                        :name (x31 / name :op1 "tyrosine"))
                  :ARG1-of (x32 / phosphorylate-01)
                  :location (x34 / protein
                        :name (x35 / name :op1 "Gab1")
                        :xref (x38 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))


# ::id PMC5341140.11
# ::snt The primary mechanism of EGF-induced stimulation of the PI-3 kinase/Akt anti-apoptotic pathway occurs via the docking protein Gab1.
# ::tok The primary mechanism of EGF @-@ induced stimulation of the PI @-@ 3 kinase @/@ Akt anti @-@ apoptotic pathway occurs via the docking protein Gab1 .
(x6 / stimulate-01
      :ARG0 (x2 / mechanism
            :mod (x1 / primary)
            :instrument-of (x5 / induce-01
                  :ARG0 (x3 / protein
                        :name (x4 / name :op1 "EGF")
                        :xref (x15 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
      :ARG1 (x11 / be-located-at-91
            :ARG1 (x10 / pathway
                  :name (x7 / name :op1 "PI-3" :op2 "kinase/Akt")
                  :ARG0-of (x8 / counter-01
                        :ARG1 (x9 / apoptosis)))
            :instrument (x13 / protein
                  :ARG0-of (x12 / dock-01)
                  :name (x14 / name :op1 "Gab1")
                  :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))


# ::id PMC5341140.12
# ::snt However, in cells expressing ErbB3, EGF and neuroregulin can stimulate PI-3 kinase and Akt activation in a Gab1-dependent or Gab1-independent manner.
# ::tok However , in cells expressing ErbB3 , EGF and neuroregulin can stimulate PI @-@ 3 kinase and Akt activation in a Gab1 @-@ dependent or Gab1 @-@ independent manner .
(x1 / have-concession-91
      :ARG2 (x2 / possible-01
            :ARG1 (x12 / stimulate-01
                  :ARG0 (x3 / cell
                        :ARG3-of (x4 / express-03
                              :ARG2 (x9 / and
                                    :op1 (x5 / protein
                                          :name (x6 / name :op1 "ErbB3")
                                          :xref (x27 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
                                    :op2 (x7 / protein
                                          :name (x8 / name :op1 "EGF")
                                          :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                                    :op3 (x10 / protein
                                          :name (x11 / name :op1 "neuroregulin")))))
                  :ARG2 (x15 / and
                        :op1 (x14 / kinase
                              :name (x13 / name :op1 "PI-3"))
                        :op2 (x18 / activate-01
                              :ARG1 (x16 / enzyme
                                    :name (x17 / name :op1 "Akt")
                                    :xref (x29 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
                  :manner (x25 / depend-01
                        :ARG1 (x22 / or
                              :op1 (x21 / depend-01
                                    :ARG1 (x19 / protein
                                          :name (x20 / name :op1 "Gab1")
                                          :xref (x28 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                              :op2 (x23 / protein
                                    :name (x24 / name :op1 "Gab1")
                                    :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                        :polarity "-"))))


# ::id PMC5341140.42
# ::snt Previous studies have suggested that ErbB3 and Gab1 can function as links between EGFR and PI-3 kinase.
# ::tok Previous studies have suggested that ErbB3 and Gab1 can function as links between EGFR and PI @-@ 3 kinase .
(x3 / suggest-01
      :ARG0 (x2 / study-01
            :time (x1 / previous))
      :ARG1 (x4 / possible-01
            :ARG1 (x11 / link-01
                  :ARG0 (x7 / and
                        :op1 (x5 / protein
                              :name (x6 / name :op1 "ErbB3")
                              :xref (x18 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
                        :op2 (x8 / protein
                              :name (x9 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :mod (x10 / function-01)
                  :ARG1 (x14 / and
                        :op1 (x12 / enzyme
                              :name (x13 / name :op1 "EGFR")
                              :xref (x17 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
                        :op2 (x16 / kinase
                              :name (x15 / name :op1 "PI-3"))))))


# ::id PMC5341140.43
# ::snt In this report we use MEFs derived from Gab1 -/- embryos [ 19 ] to explore the contribution of Gab1 and ErbB3 to EGF stimulation of PI-3 kinase and Akt in these cells.
# ::tok In this report we use MEFs derived from Gab1 -/- embryos [ 19 ] to explore the contribution of Gab1 and ErbB3 to EGF stimulation of PI @-@ 3 kinase and Akt in these cells .
(x4 / use-01
      :ARG1 (x2 / report
            :mod (x1 / this))
      :ARG0 (x3 / we)
      :ARG1 (x5 / cell
            :name (x6 / name :op1 "mef")
            :ARG0-of (x7 / derive-01
                  :ARG2 (x11 / embryo
                        :mod (x8 / protein
                              :name (x9 / name :op1 "Gab1")
                              :ARG2-of (x10 / mutate-01 :mod "-/-")
                              :xref (x34 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :ARG1-of (x12 / describe-01
                  :ARG0 (x13 / publication
                        :ARG1-of (x14 / cite-01 :ARG2 "19"))))
      :ARG2 (x15 / explore-01
            :ARG1 (x16 / contribute-01
                  :ARG0 (x19 / and
                        :op1 (x17 / protein
                              :name (x18 / name :op1 "Gab1")
                              :xref (x35 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :op2 (x20 / protein
                              :name (x21 / name :op1 "ErbB3")
                              :xref (x32 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634")))
                  :ARG2 (x24 / stimulate-01
                        :ARG0 (x22 / protein
                              :name (x23 / name :op1 "EGF")
                              :xref (x33 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                        :ARG1 (x27 / and
                              :op1 (x26 / kinase
                                    :name (x25 / name :op1 "PI-3"))
                              :op2 (x28 / enzyme
                                    :name (x29 / name :op1 "Akt")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                        :location (x31 / cell
                              :mod (x30 / this))))))


# ::id PMC5341140.44
# ::snt Gab1 is essential for EGF stimulation of PI-3 kinase and Akt
# ::tok Gab1 is essential for EGF stimulation of PI @-@ 3 kinase and Akt
(x3 / essential
      :domain (x1 / protein
            :name (x2 / name :op1 "Gab1")
            :xref (x12 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
      :purpose (x9 / and
            :op1 (x6 / stimulate-01
                  :ARG0 (x4 / protein
                        :name (x5 / name :op1 "EGF")
                        :xref (x13 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :ARG1 (x8 / kinase
                        :name (x7 / name :op1 "PI-3")))
            :op2 (x10 / enzyme
                  :name (x11 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))


# ::id PMC5341140.45
# ::snt MEFs derived from Gab1-/- or wild type (WT) embryos were stimulated with EGF and assayed for Gab1 tyrosine phosphorylation, for activation of PI-3 kinase and for Akt stimulation.
# ::tok MEFs derived from Gab1-/- or wild type ( WT ) embryos were stimulated with EGF and assayed for Gab1 tyrosine phosphorylation , for activation of PI @-@ 3 kinase and for Akt stimulation .
(x12 / and
      :op1 (x9 / stimulate-01
            :ARG1 (x1 / cell
                  :name (x2 / name :op1 "mef")
                  :ARG1-of (x3 / derive-01
                        :ARG2 (x6 / or
                              :op1 (x4 / enzyme
                                    :name (x5 / name :op1 "Gab1-/-"))
                              :op2 (x8 / embryo
                                    :mod (x7 / wild-type)))))
            :ARG2 (x10 / protein
                  :name (x11 / name :op1 "EGF")
                  :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :op2 (x13 / assay-01
            :purpose (x22 / and
                  :op1 (x18 / phosphorylate-01
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "Gab1")
                              :xref (x27 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :ARG1 (x16 / enzyme
                              :name (x17 / name :op1 "tyrosine")
                              :xref (x28 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
                        :ARG2 (x19 / activate-01
                              :ARG1 (x21 / kinase
                                    :name (x20 / name :op1 "PI-3"))))
                  :op2 (x25 / stimulate-01
                        :ARG1 (x23 / enzyme
                              :name (x24 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))))


# ::id PMC5341140.46
# ::snt As shown in Figure 1A , the endogenous Gab1 present in WT MEFs is tyrosine phosphorylated in response to EGF treatment.
# ::tok As shown in Figure 1A , the endogenous Gab1 present in WT MEFs is tyrosine phosphorylated in response to EGF treatment .
(x1 / show-01
      :ARG0 (x2 / figure :mod "1a")
      :ARG1 (x6 / present-02
            :ARG1 (x3 / enzyme
                  :mod (x4 / endogenous)
                  :name (x5 / name :op1 "Gab1")
                  :xref (x18 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG2 (x12 / phosphorylate-01
                  :ARG1 (x7 / enzyme
                        :mod (x8 / wild-type)
                        :name (x9 / name :op1 "mef")
                        :xref (x19 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :ARG2 (x10 / enzyme
                        :name (x11 / name :op1 "tyrosine")
                        :xref (x17 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
                  :ARG2-of (x13 / respond-01
                        :ARG1 (x16 / treat-04
                              :ARG2 (x14 / protein
                                    :name (x15 / name :op1 "EGF")
                                    :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))))


# ::id PMC5341140.47
# ::snt As shown in Figure 1B , Gab1 -/- MEFs displayed very low levels of EGF-induced PI-3 kinase activity relative to cells expressing Gab1.
# ::tok As shown in Figure 1B , Gab1 -/- MEFs displayed very low levels of EGF @-@ induced PI @-@ 3 kinase activity relative to cells expressing Gab1 .
(x8 / display-01
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "1b"))
      :ARG0 (x3 / cell
            :mod (x4 / protein
                  :name (x5 / name :op1 "Gab1")
                  :ARG2-of (x6 / mutate-01 :mod "-/-")
                  :xref (x23 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :name (x7 / name :op1 "mef"))
      :ARG1 (x11 / level
            :ARG1-of (x10 / low-04
                  :degree (x9 / very))
            :degree-of (x17 / activity-06
                  :ARG0 (x16 / kinase
                        :ARG1-of (x14 / induce-01
                              :ARG0 (x12 / protein
                                    :name (x13 / name :op1 "EGF")
                                    :xref (x24 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                        :name (x15 / name :op1 "PI-3")))
            :ARG1-of (x18 / relative-05
                  :ARG3 (x19 / cell
                        :ARG3-of (x20 / express-03
                              :ARG2 (x21 / protein
                                    :name (x22 / name :op1 "Gab1")
                                    :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))))


# ::id PMC5341140.48
# ::snt We did observe an approximate 2-fold increase in this low-level basal PI-3 kinase activity in Gab1 -/- MEFs, which represents a Gab1-independent signaling pathway.
# ::tok We did observe an approximate 2 @-@ fold increase in this low @-@ level basal PI @-@ 3 kinase activity in Gab1 -/- MEFs , which represents a Gab1 @-@ independent signaling pathway .
(x2 / observe-01
      :ARG0 (x1 / we)
      :ARG1 (x5 / increase-01
            :ARG2 (x3 / approximately
                  :op1 (x4 / product-of :op1 "2"))
            :ARG1 (x12 / activity-06
                  :ARG0 (x11 / kinase
                        :mod (x6 / this)
                        :mod (x8 / level
                              :ARG1-of (x7 / low-04))
                        :mod (x9 / basal)
                        :name (x10 / name :op1 "PI-3")))
            :location (x13 / cell
                  :mod (x14 / protein
                        :name (x15 / name :op1 "Gab1")
                        :ARG2-of (x16 / mutate-01 :mod "-/-")
                        :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :name (x17 / name :op1 "mef")))
      :ARG0-of (x18 / represent-01
            :ARG1 (x23 / pathway
                  :ARG0-of (x21 / depend-01
                        :ARG1 (x19 / protein
                              :name (x20 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :polarity "-")
                  :ARG0-of (x22 / signal-07))))


# ::id PMC5341140.49
# ::snt Gab1 -/- and WT MEFs were additionally stimulated with EGF and the activation of Akt was analyzed by immunoblotting with antibodies which recognize specifically the activated form of Akt.
# ::tok Gab1 -/- and WT MEFs were additionally stimulated with EGF and the activation of Akt was analyzed by immunoblotting with antibodies which recognize specifically the activated form of Akt .
(x16 / analyze-01
      :ARG1 (x4 / and
            :op1 (x1 / protein
                  :name (x2 / name :op1 "Gab1")
                  :ARG2-of (x3 / mutate-01 :mod "-/-")
                  :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :op2 (x5 / enzyme
                  :mod (x6 / wild-type)
                  :name (x7 / name :op1 "mef")
                  :xref (x25 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))
      :mod (x8 / additional)
      :ARG1 (x12 / and
            :op1 (x9 / stimulate-01
                  :ARG2 (x10 / protein
                        :name (x11 / name :op1 "EGF")
                        :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :op2 (x13 / activate-01
                  :ARG1 (x14 / enzyme
                        :name (x15 / name :op1 "Akt")
                        :xref (x27 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
      :manner (x17 / immunoblot-01
            :ARG3 (x18 / antibody
                  :ARG0-of (x19 / recognize-02
                        :ARG1-of (x20 / specific-02)
                        :ARG1 (x21 / enzyme
                              :ARG1-of (x22 / activate-01)
                              :name (x23 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))))


# ::id PMC5341140.50
# ::snt As shown in Figure 1C (top and middle panels), Gab1 -/- cells display no activation of Akt in response to EGF, while WT MEFs show EGF-stimulated Akt activation within two minutes of EGF treatment.
# ::tok As shown in Figure 1C ( top and middle panels ) , Gab1 -/- cells display no activation of Akt in response to EGF , while WT MEFs show EGF @-@ stimulated Akt activation within two minutes of EGF treatment .
(x11 / display-01
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "1c")
            :ARG1-of (x4 / and
                  :op1 (x3 / top)
                  :op2 (x6 / panel
                        :mod (x5 / middle))))
      :ARG0 (x10 / cell
            :mod (x7 / protein
                  :name (x8 / name :op1 "Gab1")
                  :ARG2-of (x9 / mutate-01 :mod "-/-")
                  :xref (x36 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
      :ARG1 (x18 / contrast-01
            :polarity "-"
            :ARG1 (x12 / activate-01
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "Akt")
                        :xref (x39 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                  :ARG2-of (x15 / respond-01
                        :ARG1 (x16 / protein
                              :name (x17 / name :op1 "EGF")
                              :xref (x40 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
            :ARG2 (x22 / show-01
                  :ARG0 (x19 / enzyme
                        :mod (x20 / wild-type)
                        :name (x21 / name :op1 "mef")
                        :xref (x38 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :ARG1 (x25 / stimulate-01
                        :ARG0 (x23 / protein
                              :name (x24 / name :op1 "EGF")
                              :xref (x35 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x28 / activate-01
                        :ARG1 (x26 / enzyme
                              :name (x27 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
            :time (x29 / after
                  :quant (x30 / temporal-quantity
                        :quant "2"
                        :unit (x31 / minute))
                  :op1 (x34 / treat-04
                        :ARG2 (x32 / protein
                              :name (x33 / name :op1 "EGF")
                              :xref (x37 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))


# ::id PMC5341140.51
# ::snt The cDNA encoding the wild type murine Gab1 sequence was cloned into a retroviral vector, and the virus was used to infect Gab1 -/- MEFs.
# ::tok The cDNA encoding the wild type murine Gab1 sequence was cloned into a retroviral vector , and the virus was used to infect Gab1 -/- MEFs .
(x14 / use-01
      :ARG1 (x1 / nucleic-acid
            :wiki "dna"
            :name (x2 / name :op1 "dna")
            :ARG0-of (x3 / encode-01
                  :ARG1 (x12 / and
                        :op1 (x9 / clone-01
                              :ARG1 (x8 / dna-sequence
                                    :mod (x4 / enzyme
                                          :mod (x5 / wild-type)
                                          :name (x6 / name :op1 "muridae"))
                                    :name (x7 / name :op1 "Gab1"))
                              :ARG2 (x11 / vector
                                    :mod (x10 / retrovirus)))
                        :op2 (x13 / virus))))
      :ARG2 (x15 / infect-01
            :ARG1 (x16 / cell
                  :mod (x17 / protein
                        :name (x18 / name :op1 "Gab1")
                        :ARG2-of (x19 / mutate-01 :mod "-/-")
                        :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :name (x20 / name :op1 "mef"))))


# ::id PMC5341140.52
# ::snt Stable cell lines were selected for co-transduction of a puromycin resistance gene and pools of selected cells were used for further analysis.
# ::tok Stable cell lines were selected for co @-@ transduction of a puromycin resistance gene and pools of selected cells were used for further analysis .
(x3 / select-01
      :ARG1 (x2 / cell-line
            :ARG1-of (x1 / stable-03))
      :purpose (x10 / and
            :op1 (x4 / co-culture
                  :ARG1-of (x5 / transduce-01
                        :ARG1 (x9 / gene
                              :ARG0-of (x8 / resist-01
                                    :ARG1 (x6 / small-molecule
                                          :name (x7 / name :op1 "puromycin")
                                          :xref (x / xref :value "PUBCHEM:4984" :prob "16.295719"))))))
            :op2 (x14 / use-01
                  :ARG1 (x11 / pool
                        :consist-of (x13 / cell
                              :ARG1-of (x12 / select-01)))
                  :ARG2 (x16 / analyze-01
                        :degree (x15 / further)))))


# ::id PMC5341140.53
# ::snt As shown in Figure 1A , the ectopic Gab1 protein was expressed at slightly lower levels in the Gab1 -/- MEFs relative to endogenous Gab1 expression seen in the wild type MEFs.
# ::tok As shown in Figure 1A , the ectopic Gab1 protein was expressed at slightly lower levels in the Gab1 -/- MEFs relative to endogenous Gab1 expression seen in the wild type MEFs .
(x6 / express-03
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "1a"))
      :ARG1 (x5 / protein
            :mod (x3 / ectopic)
            :name (x4 / name :op1 "Gab1")
            :xref (x25 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
      :time (x20 / express-03
            :ARG2 (x10 / level
                  :ARG1-of (x9 / low-04
                        :degree (x8 / more
                              :degree (x7 / slight)))
                  :location (x11 / cell
                        :mod (x12 / protein
                              :name (x13 / name :op1 "Gab1")
                              :ARG2-of (x14 / mutate-01 :mod "-/-")
                              :xref (x26 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :name (x15 / name :op1 "mef"))
                  :ARG2-of (x16 / relative-05
                        :ARG3 (x17 / protein
                              :mod (x18 / endogenous)
                              :name (x19 / name :op1 "Gab1")
                              :xref (x27 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :ARG1-of (x21 / see-01
                  :location (x22 / enzyme
                        :mod (x23 / wild-type)
                        :name (x24 / name :op1 "mef")
                        :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))))


# ::id PMC5341140.54
# ::snt Quantitation by densitometry reveals Gab1 expression in wild type MEFs to be 1.4-fold higher than ectopic Gab1 expression in Gab1 -/- MEFs.
# ::tok Quantitation by densitometry reveals Gab1 expression in wild type MEFs to be 1.4 @-@ fold higher than ectopic Gab1 expression in Gab1 -/- MEFs .
(x5 / reveal-01
      :ARG0 (x3 / and
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "Quantitation"))
            :op2 (x4 / densitometry))
      :ARG1 (x13 / high-02
            :ARG1 (x8 / express-03
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "Gab1")
                        :xref (x25 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG2 (x9 / enzyme
                        :mod (x10 / wild-type)
                        :name (x11 / name :op1 "mef")
                        :xref (x24 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))
            :degree (x12 / product-of :op1 "1.4")
            :degree (x14 / more)
            :compared-to (x18 / express-03
                  :mod (x15 / ectopic)
                  :ARG2 (x16 / protein
                        :name (x17 / name :op1 "Gab1")
                        :xref (x26 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :location (x19 / cell
                  :mod (x20 / protein
                        :name (x21 / name :op1 "Gab1")
                        :ARG2-of (x22 / mutate-01 :mod "-/-")
                        :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :name (x23 / name :op1 "mef"))))


# ::id PMC5341140.55
# ::snt Treatment with EGF induced tyrosine phosphorylation of the exogenous Gab1 protein expressed in the Gab1 -/- MEFs at levels similar to endogenous Gab1 in wild type MEFs.
# ::tok Treatment with EGF induced tyrosine phosphorylation of the exogenous Gab1 protein expressed in the Gab1 -/- MEFs at levels similar to endogenous Gab1 in wild type MEFs .
(x11 / express-03
      :ARG1 (x4 / induce-01
            :ARG0 (x1 / treat-04
                  :ARG2 (x2 / small-molecule
                        :name (x3 / name :op1 "EGF")
                        :xref (x28 / xref :value "PUBCHEM:56841751" :prob "18.167522")))
            :ARG2 (x5 / phosphorylate-01
                  :ARG1 (x6 / amino-acid
                        :name (x7 / name :op1 "tyrosine")
                        :part-of (x10 / protein
                              :mod (x8 / exogenous)
                              :name (x9 / name :op1 "Gab1")
                              :xref (x26 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :xref (x29 / xref :value "PUBCHEM:1153" :prob "11.081481"))))
      :ARG3 (x12 / cell
            :mod (x13 / protein
                  :name (x14 / name :op1 "Gab1")
                  :ARG2-of (x15 / mutate-01 :mod "-/-")
                  :xref (x27 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :name (x16 / name :op1 "mef"))
      :ARG2 (x17 / level
            :ARG1-of (x18 / resemble-01
                  :ARG2 (x19 / enzyme
                        :mod (x20 / endogenous)
                        :name (x21 / name :op1 "Gab1")
                        :xref (x25 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
      :location (x22 / enzyme
            :mod (x23 / wild-type)
            :name (x24 / name :op1 "mef")
            :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))


# ::id PMC5341140.56
# ::snt As shown in Figure 1B , expression of exogenous Gab1 in the Gab1 -/- MEFs results in Gab1-associated PI-3 kinase activity that is augmented following EGF treatment.
# ::tok As shown in Figure 1B , expression of exogenous Gab1 in the Gab1 -/- MEFs results in Gab1 @-@ associated PI @-@ 3 kinase activity that is augmented following EGF treatment .
(x11 / result-01
      :ARG1-of (x1 / show-01
            :medium (x2 / figure :mod "1b"))
      :ARG1 (x3 / express-03
            :ARG2 (x4 / protein
                  :name (x5 / name :op1 "Gab1")
                  :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :location (x6 / cell
                  :mod (x7 / protein
                        :name (x8 / name :op1 "Gab1")
                        :ARG2-of (x9 / mutate-01 :mod "-/-")
                        :xref (x23 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :name (x10 / name :op1 "mef")))
      :ARG2 (x17 / activity-06
            :ARG1 (x16 / kinase
                  :ARG1-of (x14 / associate-01
                        :ARG2 (x12 / protein
                              :name (x13 / name :op1 "Gab1")
                              :xref (x25 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :name (x15 / name :op1 "PI-3"))
            :ARG0-of (x18 / augment-01
                  :ARG1-of (x19 / follow-01
                        :ARG2 (x22 / treat-04
                              :ARG2 (x20 / protein
                                    :name (x21 / name :op1 "EGF")
                                    :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))))


# ::id PMC5341140.57
# ::snt The low level of EGF-induced PI-3 kinase activity observed in the Gab1 -/- cells may be due to signaling via an alternate, Gab1-independent mechanism.
# ::tok The low level of EGF @-@ induced PI @-@ 3 kinase activity observed in the Gab1 -/- cells may be due to signaling via an alternate , Gab1 @-@ independent mechanism .
(x21 / mechanism
      :op1 (x1 / possible-01
            :ARG1 (x15 / cause-01
                  :ARG1 (x3 / level
                        :ARG1-of (x2 / low-04)
                        :degree-of (x9 / activity-06
                              :ARG0 (x8 / kinase
                                    :ARG1-of (x6 / induce-01
                                          :ARG0 (x4 / protein
                                                :name (x5 / name :op1 "EGF")
                                                :xref (x23 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                                    :name (x7 / name :op1 "PI-3")))
                        :ARG1-of (x10 / observe-01
                              :location (x14 / cell
                                    :mod (x11 / protein
                                          :name (x12 / name :op1 "Gab1")
                                          :ARG2-of (x13 / mutate-01 :mod "-/-")
                                          :xref (x22 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))
                  :ARG0 (x16 / signal-07))
            :instrument (x17 / alternate-01))
      :ARG0-of (x20 / depend-01
            :ARG1 (x18 / protein
                  :name (x19 / name :op1 "Gab1")
                  :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :polarity "-"))


# ::id PMC5341140.58
# ::snt These cells were additionally treated with EGF over a period of time and the activation of Akt was assayed by immunoblotting with antibodies specific for the Ser473 phosphorylated form of Akt.
# ::tok These cells were additionally treated with EGF over a period of time and the activation of Akt was assayed by immunoblotting with antibodies specific for the Ser473 phosphorylated form of Akt .
(x13 / assay-01
      :ARG1 (x2 / cell
            :mod (x1 / this))
      :mod (x3 / additional)
      :ARG1 (x9 / and
            :op1 (x4 / treat-04
                  :ARG2 (x5 / protein
                        :name (x6 / name :op1 "EGF")
                        :xref (x21 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :duration (x7 / period
                        :consist-of (x8 / time)))
            :op2 (x10 / activate-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
      :manner (x14 / immunoblot-01
            :ARG3 (x15 / antibody
                  :ARG1-of (x16 / specific-02
                        :ARG2 (x19 / phosphorylate-01
                              :ARG1 (x17 / amino-acid
                                    :mod "473"
                                    :name (x18 / name :op1 "serine")
                                    :xref (x22 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
                  :name (x20 / name :op1 "Akt"))))


# ::id PMC5341140.59
# ::snt The experiment presented in Fig 1C shows that ectopic expression of Gab1 in the Gab1 deficient cells rescues EGF-induced Akt activation to levels similar to those observed in EGF-treated wild type MEFs.
# ::tok The experiment presented in Fig 1C shows that ectopic expression of Gab1 in the Gab1 deficient cells rescues EGF @-@ induced Akt activation to levels similar to those observed in EGF @-@ treated wild type MEFs .
(x4 / show-01
      :ARG0 (x1 / experiment-01)
      :ARG1-of (x2 / present-01
            :location (x3 / figure :mod "1c"))
      :ARG1 (x12 / rescue-01
            :ARG0 (x6 / express-03
                  :mod (x5 / ectopic)
                  :ARG2 (x7 / protein
                        :name (x8 / name :op1 "Gab1")
                        :xref (x31 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG2 (x9 / enzyme
                        :name (x10 / name :op1 "Gab1")
                        :ARG2-of (x11 / mutate-01 :mod "-/-")
                        :xref (x30 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :ARG1 (x18 / activate-01
                  :ARG2-of (x15 / induce-01
                        :ARG0 (x13 / protein
                              :name (x14 / name :op1 "EGF")
                              :xref (x32 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x16 / enzyme
                        :name (x17 / name :op1 "Akt")
                        :xref (x33 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :ARG2 (x19 / level
                  :ARG1-of (x20 / resemble-01
                        :ARG2 (x21 / person
                              :ARG0-of (x22 / observe-01
                                    :ARG1 (x25 / treat-04
                                          :ARG2 (x23 / protein
                                                :name (x24 / name :op1 "EGF")
                                                :xref (x29 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
                              :mod (x26 / enzyme
                                    :mod (x27 / wild-type)
                                    :name (x28 / name :op1 "mef")
                                    :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))))))


# ::id PMC5341140.61
# ::snt The canonical p85 binding sites on Gab1 are essential for PI-3 kinase and Akt activation in response to EGF stimulation
# ::tok The canonical p85 binding sites on Gab1 are essential for PI @-@ 3 kinase and Akt activation in response to EGF stimulation
(x10 / and
      :op1 (x7 / essential
            :domain (x4 / site
                  :mod (x1 / canonical
                        :name (x2 / name :op1 "p85"))
                  :ARG2-of (x3 / bind-01)
                  :location (x5 / protein
                        :name (x6 / name :op1 "Gab1")
                        :xref (x19 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :purpose (x9 / kinase
                  :name (x8 / name :op1 "PI-3")))
      :op2 (x13 / activate-01
            :ARG1 (x11 / enzyme
                  :name (x12 / name :op1 "Akt")
                  :xref (x18 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :ARG2-of (x14 / respond-01
                  :ARG1 (x17 / stimulate-01
                        :ARG0 (x15 / protein
                              :name (x16 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))


# ::id PMC5341140.62
# ::snt The cDNA encoding a mutant Gab1 protein, containing tyrosine to phenylalanine point mutations at the three binding sites for the p85 regulatory subunit of PI-3 kinase (Y446F/Y472F/Y589F) (Gab1 F446/472/589 ), was cloned into a retroviral vector and used to generate pools of stable MEF cell lines as described above.
# ::tok The cDNA encoding a mutant Gab1 protein , containing tyrosine to phenylalanine point mutations at the three binding sites for the p85 regulatory subunit of PI @-@ 3 kinase ( Y446F/Y472F/Y589F ) ( Gab1 F446 @/@ 472 @/@ 589 ) , was cloned into a retroviral vector and used to generate pools of stable MEF cell lines as described above .
(x1 / multi-sentence
      :snt1 (x9 / contain-01
            :ARG1 (x2 / nucleic-acid
                  :wiki "dna"
                  :name (x3 / name :op1 "dna")
                  :ARG0-of (x4 / encode-01
                        :ARG1 (x5 / enzyme
                              :ARG1-of (x6 / mutate-01)
                              :name (x7 / name :op1 "Gab1")
                              :xref (x46 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :name (x8 / name :op1 "protein"))
            :ARG1 (x10 / amino-acid
                  :name (x11 / name :op1 "tyrosine")
                  :xref (x48 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :ARG2 (x12 / amino-acid
                  :name (x13 / name :op1 "phenylalanine"))
            :ARG1 (x15 / mutate-01
                  :mod (x14 / point)
                  :location (x21 / subunit
                        :quant "3"
                        :ARG0-of (x20 / regulate-01
                              :ARG1 (x16 / protein-segment
                                    :ARG2-of (x17 / bind-01
                                          :ARG1 (x18 / protein
                                                :name (x19 / name :op1 "p85")
                                                :xref (x47 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003")))))
                        :part-of (x23 / kinase
                              :name (x22 / name :op1 "PI-3"))
                        :name (x24 / name :op1 "Y446F/Y472F/Y589F")))
            :ARG1-of (x25 / describe-01
                  :ARG0 (x26 / protein
                        :name (x27 / name :op1 "Gab1")
                        :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
      :snt2 (x33 / clone-01
            :ARG1 (x30 / slash
                  :op1 (x28 / enzyme
                        :name (x29 / name :op1 "F446"))
                  :op2 (x31 / enzyme
                        :name (x32 / name :op1 "472"))
                  :op2 "589")
            :ARG2 (x36 / and
                  :op1 (x35 / vector
                        :mod (x34 / retrovirus))
                  :op2 (x37 / use-01
                        :ARG2 (x38 / generate-01
                              :ARG1 (x39 / pool
                                    :consist-of (x43 / cell-line
                                          :ARG1-of (x40 / stable-03)
                                          :mod (x41 / disease
                                                :wiki "cancer"
                                                :name (x42 / name :op1 "MEF")))))
                        :ARG1-of (x44 / describe-01
                              :location (x45 / above))))))


# ::id PMC5341140.63
# ::snt We first assayed the cells for Gab1 expression, and for the ability of the mutant Gab1 F446/472/589 protein to become tyrosine phosphorylated in response to EGF treatment.
# ::tok We first assayed the cells for Gab1 expression , and for the ability of the mutant Gab1 F446 @/@ 472 @/@ 589 protein to become tyrosine phosphorylated in response to EGF treatment .
(x8 / and
      :op1 (x3 / assay-01
            :ARG0 (x1 / we)
            :ord (x2 / ordinal-entity :value "1")
            :ARG1 (x4 / cell)
            :ARG1 (x7 / express-03
                  :ARG2 (x5 / protein
                        :name (x6 / name :op1 "Gab1")
                        :xref (x26 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
      :op2 (x18 / become-01
            :ARG1 (x9 / capable-01
                  :ARG1 (x10 / enzyme
                        :ARG2-of (x11 / mutate-01)
                        :name (x12 / name :op1 "Gab1")
                        :xref (x27 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG2 (x15 / slash
                        :op1 (x13 / enzyme
                              :name (x14 / name :op1 "F446"))
                        :op2 (x17 / protein
                              :name (x16 / name :op1 "472" :op2 "589"))))
            :ARG2 (x21 / phosphorylate-01
                  :ARG1 (x19 / amino-acid
                        :name (x20 / name :op1 "tyrosine")
                        :xref (x28 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2-of (x22 / respond-01
                        :ARG1 (x25 / treat-04
                              :ARG2 (x23 / protein
                                    :name (x24 / name :op1 "EGF")
                                    :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))))


# ::id PMC5341140.64
# ::snt As shown in Figure 2A , both wild type Gab1 and Gab1 F446/472/589 undergo tyrosine phosphorylation in response to EGF treatment (upper left panel).
# ::tok As shown in Figure 2A , both wild type Gab1 and Gab1 F446 @/@ 472 @/@ 589 undergo tyrosine phosphorylation in response to EGF treatment ( upper left panel ) .
(x12 / undergo-28
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "2a"))
      :ARG0 (x3 / and
            :op1 (x4 / enzyme
                  :mod (x5 / wild-type)
                  :name (x6 / name :op1 "Gab1")
                  :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :op2 (x7 / and
                  :op1 (x8 / amino-acid
                        :mod "446"
                        :name (x9 / name :op1 "phenylalanine"))
                  :op2 (x10 / enzyme
                        :name (x11 / name :op1 "472" :op2 "589"))))
      :ARG2 (x15 / phosphorylate-01
            :ARG1 (x13 / amino-acid
                  :name (x14 / name :op1 "tyrosine")
                  :xref (x24 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :ARG2-of (x16 / respond-01
                  :ARG1 (x19 / treat-04
                        :ARG2 (x17 / protein
                              :name (x18 / name :op1 "EGF")
                              :xref (x23 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :ARG1-of (x20 / describe-01
            :ARG0 (x22 / panel
                  :ARG1-of (x21 / left-20))))


# ::id PMC5341140.65
# ::snt Quantitation of multiple experiments by densitometry reproducibly demonstrates that Gab1 F446/472/589 is tyrosine phosphorylated following EGF treatment to similar levels when normalized for Gab1 expression levels.
# ::tok Quantitation of multiple experiments by densitometry reproducibly demonstrates that Gab1 F446 @/@ 472 @/@ 589 is tyrosine phosphorylated following EGF treatment to similar levels when normalized for Gab1 expression levels .
(x14 / phosphorylate-01
      :ARG1 (x1 / protein-segment
            :name (x2 / name :op1 "Quantitation")
            :part-of (x7 / demonstrate-01
                  :ARG0 (x4 / experiment-01
                        :quant (x3 / multiple)
                        :ARG0 (x5 / densitometry)
                        :mod (x6 / reproducibly))
                  :ARG1 (x8 / and
                        :op1 (x9 / amino-acid
                              :mod "446"
                              :name (x10 / name :op1 "phenylalanine"))
                        :op2 (x11 / enzyme
                              :name (x12 / name :op1 "472" :op2 "589"))))
            :name (x13 / name :op1 "tyrosine"))
      :time (x15 / after
            :op1 (x18 / treat-04
                  :ARG0 (x16 / protein
                        :name (x17 / name :op1 "EGF")
                        :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :ARG2 (x20 / level
                        :ARG1-of (x19 / resemble-01))
                  :time (x25 / level
                        :ARG1-of (x21 / normalize-01
                              :ARG1 (x24 / express-03
                                    :ARG2 (x22 / protein
                                          :name (x23 / name :op1 "Gab1")
                                          :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))))))


# ::id PMC5341140.67
# ::snt As has been demonstrated previously [ 20 ], wild type Gab1 readily coimmunoprecipitated p85 following EGF treatment, while the Gab1 F446/472/589 mutant protein failed to show an association with p85, confirming that the Gab1 F446/472/589 protein is deficient in p85 binding.
# ::tok As has been demonstrated previously [ 20 ] , wild type Gab1 readily coimmunoprecipitated p85 following EGF treatment , while the Gab1 F446 @/@ 472 @/@ 589 mutant protein failed to show an association with p85 , confirming that the Gab1 F446 @/@ 472 @/@ 589 protein is deficient in p85 binding .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op2 (x3 / demonstrate-01
                  :time (x4 / previous)
                  :ARG1-of (x5 / describe-01
                        :ARG0 (x6 / publication
                              :ARG1-of (x7 / cite-01 :ARG2 "20")))
                  :ARG1-of (x8 / describe-01
                        :ARG2 (x12 / ready
                              :mod (x9 / enzyme
                                    :mod (x10 / wild-type)
                                    :name (x11 / name :op1 "Gab1")
                                    :xref (x43 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
                  :ARG0 (x13 / coimmunoprecipitate-01
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "p85")
                              :xref (x45 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003")))
                  :ARG1-of (x16 / follow-01
                        :ARG2 (x19 / treat-04
                              :ARG2 (x17 / protein
                                    :name (x18 / name :op1 "EGF")
                                    :xref (x46 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
            :ARG1-of (x20 / contrast-01
                  :ARG2 (x21 / and
                        :op1 (x22 / amino-acid
                              :mod "446"
                              :name (x23 / name :op1 "phenylalanine"))
                        :op2 (x24 / enzyme
                              :name (x25 / name :op1 "472" :op2 "589")))))
      :snt2 (x28 / fail-01
            :ARG1 (x27 / protein
                  :ARG2-of (x26 / mutate-01))
            :ARG2 (x29 / show-01
                  :ARG1 (x30 / associate-01
                        :ARG1 (x31 / enzyme
                              :name (x32 / name :op1 "p85")
                              :xref (x44 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))
                        :ARG0-of (x33 / confirm-01
                              :ARG1 (x34 / and
                                    :op1 (x35 / amino-acid
                                          :mod "446"
                                          :name (x36 / name :op1 "phenylalanine"))
                                    :op2 (x38 / protein
                                          :name (x37 / name :op1 "472" :op2 "589"))))
                        :ARG0-of (x39 / lack-01
                              :ARG1 (x42 / bind-01
                                    :ARG2 (x40 / protein
                                          :name (x41 / name :op1 "p85")
                                          :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))))))))


# ::id PMC5341140.68
# ::snt Similar levels of Gab1 expression in these cells were confirmed by reprobing the Gab1 phosphotyrosine blot with anti-Gab1 antibodies (Figure 2A , bottom left panel).
# ::tok Similar levels of Gab1 expression in these cells were confirmed by reprobing the Gab1 phosphotyrosine blot with anti @-@ Gab1 antibodies ( Figure 2A , bottom left panel ) .
(x8 / confirm-01
      :ARG1 (x5 / express-03
            :ARG1-of (x1 / resemble-01)
            :ARG2 (x2 / level
                  :quant-of (x3 / protein
                        :name (x4 / name :op1 "Gab1")
                        :xref (x23 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :ARG3 (x7 / cell
                  :mod (x6 / this)))
      :ARG0 (x12 / immunoblot-01
            :ARG1 (x9 / protein
                  :name (x10 / name :op1 "Gab1")
                  :xref (x22 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG2 (x11 / phosphotyrosine)
            :ARG2 (x16 / antibody
                  :ARG0-of (x13 / counter-01
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :ARG1-of (x17 / describe-01
                  :ARG0 (x18 / figure
                        :mod "2a"
                        :location (x21 / panel
                              :mod (x19 / bottom)
                              :ARG1-of (x20 / left-20))))))


# ::id PMC5341140.69
# ::snt Additionally, total cell lysates of all Gab1 expressing cell lines described in this study were subjected to anti-Gab1 immunoblotting, providing independent evidence for similar levels of Gab1 expression across all cell lines (Figure 2A , right panel).
# ::tok Additionally , total cell lysates of all Gab1 expressing cell lines described in this study were subjected to anti @-@ Gab1 immunoblotting , providing independent evidence for similar levels of Gab1 expression across all cell lines ( Figure 2A , right panel ) .
(x1 / and
      :op2 (x13 / subject-01
            :ARG1 (x4 / lysate
                  :mod (x2 / total)
                  :mod (x3 / cell)
                  :source (x9 / cell-line
                        :mod (x5 / all)
                        :ARG1-of (x8 / express-03
                              :ARG2 (x6 / protein
                                    :name (x7 / name :op1 "Gab1")
                                    :xref (x32 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
                  :ARG1-of (x10 / describe-01
                        :ARG0 (x12 / study-01
                              :mod (x11 / this))))
            :ARG2 (x17 / immunoblot-01
                  :ARG0-of (x14 / counter-01
                        :ARG1 (x15 / protein
                              :name (x16 / name :op1 "Gab1")
                              :xref (x33 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :ARG0-of (x18 / provide-01
                  :ARG1 (x20 / evidence-01
                        :ARG0-of (x19 / depend-01 :polarity "-")
                        :ARG1 (x25 / express-03
                              :ARG1-of (x21 / resemble-01)
                              :ARG2 (x22 / level
                                    :quant-of (x23 / protein
                                          :name (x24 / name :op1 "Gab1")
                                          :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
                        :location (x27 / cell-line
                              :mod (x26 / all))
                        :ARG1-of (x28 / describe-01
                              :ARG0 (x29 / figure
                                    :mod "2a"
                                    :location (x31 / panel
                                          :ARG1-of (x30 / right-04))))))))


# ::id PMC5341140.70
# ::snt Because the substrates of Shp2 are for the most part unknown, we were additionally interested in examining the state of EGFR tyrosine phosphorylation following treatment with EGF in order to determine if the failure of Gab1 to bind p85, and potentially recruit Shp2, would influence levels of EGFR autophosphorylation.
# ::tok Because the substrates of Shp2 are for the most part unknown , we were additionally interested in examining the state of EGFR tyrosine phosphorylation following treatment with EGF in order to determine if the failure of Gab1 to bind p85 , and potentially recruit Shp2 , would influence levels of EGFR autophosphorylation .
(x1 / multi-sentence
      :snt1 (x10 / interest-01
            :ARG1-of (x2 / cause-01
                  :ARG0 (x7 / know-01
                        :ARG0 (x3 / substrate
                              :mod (x4 / enzyme
                                    :name (x5 / name :op1 "Shp2")
                                    :xref (x39 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003")))
                        :ARG1-of (x6 / for-the-most-part)
                        :polarity "-"))
            :ARG0 (x8 / we)
            :mod (x9 / additional)
            :ARG2 (x11 / examine-01
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "EGFR")
                        :xref (x43 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))))
      :snt2 (x16 / phosphorylate-01
            :ARG1 (x14 / amino-acid
                  :name (x15 / name :op1 "tyrosine")
                  :xref (x44 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :ARG1-of (x17 / follow-01
                  :ARG2 (x18 / treat-04
                        :ARG2 (x19 / protein
                              :name (x20 / name :op1 "EGF")
                              :xref (x42 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
            :purpose (x21 / determine-01
                  :ARG1 (x33 / influence-01
                        :ARG0 (x28 / and
                              :op1 (x22 / fail-01
                                    :ARG1 (x23 / protein
                                          :name (x24 / name :op1 "Gab1")
                                          :xref (x38 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                                    :ARG2 (x25 / bind-01
                                          :ARG2 (x26 / protein
                                                :name (x27 / name :op1 "p85")
                                                :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))))
                              :op2 (x30 / recruit-01
                                    :mod (x29 / potential)
                                    :ARG1 (x31 / enzyme
                                          :name (x32 / name :op1 "Shp2")
                                          :xref (x40 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))))
                        :ARG1 (x37 / phosphorylate-01
                              :ARG1 (x34 / level
                                    :quant-of (x35 / enzyme
                                          :name (x36 / name :op1 "EGFR")
                                          :xref (x41 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))))))))


# ::id PMC5341140.71
# ::snt However, stimulation with EGF for varying time intervals revealed no significant differences in the levels of autophosphorylation of EGFR in cells expressing wild type Gab1 versus the Gab1 F446/472/589 mutant (Figure 2B ).
# ::tok However , stimulation with EGF for varying time intervals revealed no significant differences in the levels of autophosphorylation of EGFR in cells expressing wild type Gab1 versus the Gab1 F446 @/@ 472 @/@ 589 mutant ( Figure 2B ) .
(x1 / have-concession-91
      :ARG1 (x2 / stimulate-01
            :ARG2 (x3 / protein
                  :name (x4 / name :op1 "EGF")
                  :xref (x29 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :ARG2 (x5 / vary-01
            :ARG1 (x7 / reveal-01
                  :time (x6 / interval)
                  :ARG1 (x9 / differ-02
                        :polarity "-"
                        :ARG1-of (x8 / significant-02))
                  :ARG1 (x10 / level
                        :degree-of (x11 / phosphorylate-01
                              :ARG1 (x12 / enzyme
                                    :name (x13 / name :op1 "EGFR")
                                    :xref (x30 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004")))))
            :location (x14 / and
                  :op1 (x15 / cell
                        :ARG3-of (x16 / express-03
                              :ARG2 (x17 / enzyme
                                    :mod (x18 / wild-type)
                                    :name (x19 / name :op1 "Gab1")
                                    :xref (x31 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
                  :op2 (x20 / protein
                        :name (x21 / name :op1 "Gab1")
                        :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :op3 (x22 / cell-line
                        :name (x23 / name :op1 "F446")
                        :mod (x24 / gene
                              :name (x25 / name :op1 "472" :op2 "589")
                              :ARG2-of (x26 / mutate-01)))))
      :ARG1-of (x27 / describe-01
            :ARG0 (x28 / figure :mod "2b")))


# ::id PMC5341140.72
# ::snt A linear representation of the EGF-induced EGFR tyrosine phosphorylation following normalization for EGFR expression levels is shown in Figure 2B (bottom).
# ::tok A linear representation of the EGF @-@ induced EGFR tyrosine phosphorylation following normalization for EGFR expression levels is shown in Figure 2B ( bottom ) .
(x2 / represent-01
      :ARG1-of (x1 / linear)
      :ARG1 (x17 / show-01
            :ARG1 (x10 / phosphorylate-01
                  :ARG2-of (x5 / induce-01
                        :ARG0 (x3 / protein
                              :name (x4 / name :op1 "EGF")
                              :xref (x21 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x6 / amino-acid
                        :part-of (x7 / enzyme
                              :name (x8 / name :op1 "EGFR")
                              :xref (x22 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
                        :name (x9 / name :op1 "tyrosine")
                        :xref (x23 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG1-of (x11 / follow-01
                        :ARG2 (x16 / level
                              :ARG1-of (x12 / normalize-01
                                    :ARG1 (x15 / express-03
                                          :ARG2 (x13 / enzyme
                                                :name (x14 / name :op1 "EGFR")
                                                :xref (x / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004")))))))
            :ARG0 (x18 / figure :mod "2b"))
      :ARG1-of (x19 / describe-01
            :location (x20 / bottom)))


# ::id PMC5341140.73
# ::snt These results are consistent with our finding that p85 binding to Gab1 does not influence the recruitment of Shp2 to the Gab1 signaling complex, and are inconsistent with the conclusion that Gab1 mediates a PI-3 kinase-dependent recruitment of Shp2 [ 14 ].
# ::tok These results are consistent with our finding that p85 binding to Gab1 does not influence the recruitment of Shp2 to the Gab1 signaling complex , and are inconsistent with the conclusion that Gab1 mediates a PI @-@ 3 kinase @-@ dependent recruitment of Shp2 [ 14 ] .
(x20 / and
      :op1 (x4 / consistent-01
            :ARG1 (x2 / thing
                  :mod (x1 / this)
                  :ARG2-of (x3 / result-01))
            :ARG2 (x6 / find-01
                  :ARG0 (x5 / we)
                  :ARG1 (x12 / influence-01
                        :ARG0 (x9 / bind-01
                              :ARG1 (x7 / enzyme
                                    :name (x8 / name :op1 "p85")
                                    :xref (x35 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))
                              :ARG2 (x10 / protein
                                    :name (x11 / name :op1 "Gab1")
                                    :xref (x37 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                        :polarity "-"
                        :ARG1 (x13 / recruit-01
                              :ARG1 (x14 / enzyme
                                    :name (x15 / name :op1 "Shp2")
                                    :xref (x38 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
                              :ARG2 (x19 / complex
                                    :mod (x16 / protein
                                          :name (x17 / name :op1 "Gab1")
                                          :xref (x39 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                                    :ARG0-of (x18 / signal-07))))))
      :op2 (x21 / consistent-01
            :polarity "-"
            :ARG2 (x22 / conclude-01
                  :ARG1 (x25 / mediate-01
                        :ARG0 (x23 / protein
                              :name (x24 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :ARG1 (x29 / recruit-01
                              :ARG0-of (x28 / depend-01
                                    :ARG1 (x26 / protein
                                          :name (x27 / name :op1 "PI-3")))
                              :ARG1 (x30 / enzyme
                                    :name (x31 / name :op1 "Shp2")
                                    :xref (x36 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
                              :ARG1-of (x32 / describe-01
                                    :ARG0 (x33 / publication
                                          :ARG1-of (x34 / cite-01 :ARG2 "14"))))))))


# ::id PMC5341140.74
# ::snt We next explored the role of Gab1 in EGF-induced activation of the PI-3 kinase/Akt cell survival pathway utilizing the Gab1 F446/472/589 expressing cells.
# ::tok We next explored the role of Gab1 in EGF @-@ induced activation of the PI @-@ 3 kinase @/@ Akt cell survival pathway utilizing the Gab1 F446 @/@ 472 @/@ 589 expressing cells .
(x3 / explore-01
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x4 / role
            :poss (x5 / protein
                  :name (x6 / name :op1 "Gab1")
                  :xref (x25 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :topic (x10 / activate-01
                  :ARG2-of (x9 / induce-01
                        :ARG0 (x7 / protein
                              :name (x8 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x13 / kinase
                        :mod (x11 / protein
                              :name (x12 / name :op1 "PI-3"))
                        :name (x14 / name :op1 "Akt")
                        :xref (x27 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
      :ARG2 (x17 / utilize-01
            :ARG1 (x16 / survive-01
                  :ARG0 (x15 / cell)))
      :ARG1 (x24 / express-03
            :ARG0 (x18 / protein
                  :name (x19 / name :op1 "Gab1")
                  :xref (x26 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG1 (x20 / amino-acid
                  :mod "446"
                  :name (x21 / name :op1 "phenylalanine"))
            :ARG2 (x22 / enzyme
                  :name (x23 / name :op1 "472" :op2 "589"))))


# ::id PMC5341140.75
# ::snt We first assayed the Gab1-associated PI-3 kinase activity directly through a PI-3 kinase assay.
# ::tok We first assayed the Gab1 @-@ associated PI @-@ 3 kinase activity directly through a PI @-@ 3 kinase assay .
(x3 / assay-01
      :ARG0 (x1 / we)
      :ord (x2 / ordinal-entity :value "1")
      :ARG1 (x9 / activity-06
            :ARG0 (x8 / kinase
                  :ARG1-of (x6 / associate-01
                        :ARG2 (x4 / protein
                              :name (x5 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :name (x7 / name :op1 "PI-3"))
            :ARG1-of (x10 / direct-02))
      :instrument (x13 / kinase
            :mod (x11 / protein
                  :name (x12 / name :op1 "PI-3"))
            :ARG1-of (x14 / assay-01)))


# ::id PMC5341140.76
# ::snt As shown in Figure 2C , immunoprecipitation of wild type Gab1 following EGF treatment brings down associated PI-3 kinase activity.
# ::tok As shown in Figure 2C , immunoprecipitation of wild type Gab1 following EGF treatment brings down associated PI @-@ 3 kinase activity .
(x11 / bring-down-03
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "2c"))
      :ARG0 (x3 / coimmunoprecipitate-01
            :ARG1 (x4 / enzyme
                  :mod (x5 / wild-type)
                  :name (x6 / name :op1 "Gab1")
                  :xref (x16 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG1-of (x7 / follow-01
                  :ARG2 (x10 / treat-04
                        :ARG2 (x8 / protein
                              :name (x9 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :ARG1 (x15 / activity-06
            :ARG1-of (x12 / associate-01)
            :ARG0 (x14 / kinase
                  :name (x13 / name :op1 "PI-3"))))


# ::id PMC5341140.77
# ::snt However immunoprecipitation of Gab1 F446/472/589 is not associated with significant levels of PI-3 kinase in the presence or absence of EGF stimulation.
# ::tok However immunoprecipitation of Gab1 F446 @/@ 472 @/@ 589 is not associated with significant levels of PI @-@ 3 kinase in the presence or absence of EGF stimulation .
(x1 / have-concession-91
      :ARG2 (x20 / stimulate-01
            :ARG0 (x2 / and
                  :op1 (x3 / immunoprecipitate-01
                        :ARG1 (x4 / protein
                              :name (x5 / name :op1 "Gab1")
                              :xref (x21 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :ARG2 (x6 / amino-acid
                              :mod "446"
                              :name (x7 / name :op1 "phenylalanine")))
                  :op2 (x10 / associate-01
                        :ARG1 (x8 / protein
                              :name (x9 / name :op1 "472" :op2 "589"))
                        :polarity "-"
                        :ARG2 (x12 / level
                              :ARG1-of (x11 / significant-02)
                              :quant-of (x13 / protein
                                    :name (x14 / name :op1 "PI-3" :op2 "kinase"))
                              :location (x15 / or
                                    :op2 (x16 / absent-01)
                                    :op1 (x17 / present-02
                                          :ARG1 (x18 / protein
                                                :name (x19 / name :op1 "EGF")
                                                :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))))))


# ::id PMC5341140.78
# ::snt In order to assay the effects of EGF stimulation on signaling downstream of PI-3 kinase, Gab1 -/- MEFs expressing no Gab1, wild type Gab1 or Gab1 F446/472/589 were treated with EGF over varying times and cell lysates were immunoblotted for serine-phosphorylated Akt.
# ::tok In order to assay the effects of EGF stimulation on signaling downstream of PI @-@ 3 kinase , Gab1 -/- MEFs expressing no Gab1 , wild type Gab1 or Gab1 F446 @/@ 472 @/@ 589 were treated with EGF over varying times and cell lysates were immunoblotted for serine @-@ phosphorylated Akt .
(x1 / multi-sentence
      :snt1 (x2 / obligate-01
            :purpose (x3 / assay-01
                  :ARG1 (x4 / affect-01
                        :ARG0 (x7 / stimulate-01
                              :ARG1 (x5 / protein
                                    :name (x6 / name :op1 "EGF")
                                    :xref (x45 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                        :ARG1 (x8 / signal-07
                              :mod (x9 / downstream)
                              :ARG1 (x11 / kinase
                                    :name (x10 / name :op1 "PI-3")
                                    :mod (x12 / protein
                                          :name (x13 / name :op1 "Gab1")
                                          :ARG2-of (x14 / mutate-01 :mod "-/-")
                                          :xref (x49 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                                    :name (x15 / name :op1 "mef")
                                    :xref (x48 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))))
            :ARG2 (x16 / express-03
                  :polarity "-"
                  :ARG1 (x17 / protein
                        :name (x18 / name :op1 "Gab1")
                        :xref (x50 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG2 (x22 / or
                        :op1 (x19 / enzyme
                              :mod (x20 / wild-type)
                              :name (x21 / name :op1 "Gab1")
                              :xref (x47 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :op2 (x23 / protein
                              :name (x24 / name :op1 "Gab1")
                              :xref (x44 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))
      :snt2 (x35 / and
            :op1 (x30 / treat-04
                  :ARG1 (x27 / slash
                        :op1 (x25 / enzyme
                              :name (x26 / name :op1 "F446"))
                        :op2 (x28 / enzyme
                              :name (x29 / name :op1 "472"))
                        :op2 "589")
                  :ARG2 (x31 / protein
                        :name (x32 / name :op1 "EGF")
                        :xref (x46 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :duration (x34 / time
                        :ARG1-of (x33 / vary-01)))
            :op2 (x38 / immunoblot-01
                  :ARG1 (x37 / lysate
                        :mod (x36 / cell))
                  :ARG1 (x39 / amino-acid
                        :name (x40 / name :op1 "serine")
                        :xref (x51 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :ARG2 (x41 / enzyme
                        :ARG3-of (x42 / phosphorylate-01)
                        :name (x43 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))


# ::id PMC5341140.79
# ::snt Mutation of the p85 binding sites on Gab1 essentially eliminated all EGF-induced Akt activation relative to cells expressing wild type Gab1 (Figure 2D ).
# ::tok Mutation of the p85 binding sites on Gab1 essentially eliminated all EGF @-@ induced Akt activation relative to cells expressing wild type Gab1 ( Figure 2D ) .
(x8 / eliminate-01
      :ARG0 (x1 / mutate-01
            :ARG1 (x4 / site
                  :name (x2 / name :op1 "p85")
                  :ARG2-of (x3 / bind-01)
                  :location (x5 / protein
                        :name (x6 / name :op1 "Gab1")
                        :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
      :mod (x7 / essential)
      :ARG1 (x15 / activate-01
            :mod (x9 / all)
            :ARG2-of (x12 / induce-01
                  :ARG0 (x10 / protein
                        :name (x11 / name :op1 "EGF")
                        :xref (x25 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x13 / enzyme
                  :name (x14 / name :op1 "Akt")
                  :xref (x26 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
      :ARG1-of (x16 / relative-05
            :ARG3 (x17 / cell
                  :ARG3-of (x18 / express-03
                        :ARG2 (x19 / enzyme
                              :mod (x20 / wild-type)
                              :name (x21 / name :op1 "Gab1")
                              :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))
      :ARG1-of (x22 / describe-01
            :ARG0 (x23 / figure :mod "2d")))


# ::id PMC5341140.80
# ::snt The binding of p85 is absolutely required for Gab1-mediated activation of PI-3 kinase and Akt following EGF treatment [ 9 ].
# ::tok The binding of p85 is absolutely required for Gab1 @-@ mediated activation of PI @-@ 3 kinase and Akt following EGF treatment [ 9 ] .
(x1 / bind-01
      :ARG1 (x2 / protein
            :name (x3 / name :op1 "p85")
            :xref (x22 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))
      :ARG2 (x4 / absolute
            :ARG0-of (x5 / require-01
                  :ARG0 (x9 / activate-01
                        :ARG1-of (x8 / mediate-01
                              :ARG0 (x6 / protein
                                    :name (x7 / name :op1 "Gab1")
                                    :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                        :ARG1 (x12 / and
                              :op1 (x11 / kinase
                                    :name (x10 / name :op1 "PI-3"))
                              :op2 (x13 / enzyme
                                    :name (x14 / name :op1 "Akt")
                                    :xref (x23 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
                  :ARG1-of (x15 / follow-01
                        :ARG2 (x18 / treat-04
                              :ARG2 (x16 / protein
                                    :name (x17 / name :op1 "EGF")
                                    :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
            :ARG1-of (x19 / describe-01
                  :ARG0 (x20 / publication
                        :ARG1-of (x21 / cite-01 :ARG2 "9")))))


# ::id PMC5341140.81
# ::snt Previous work has indicated that treatment of cells with PI-3 kinase inhibitors reduces levels of EGF-induced complex formation between Gab1 and the protein tyrosine phosphatase Shp2 [ 14 ].
# ::tok Previous work has indicated that treatment of cells with PI @-@ 3 kinase inhibitors reduces levels of EGF @-@ induced complex formation between Gab1 and the protein tyrosine phosphatase Shp2 [ 14 ] .
(x3 / indicate-01
      :ARG0 (x2 / work-01
            :time (x1 / previous))
      :ARG1 (x10 / reduce-01
            :ARG0 (x4 / treat-04
                  :ARG1 (x5 / cell)
                  :ARG2 (x9 / molecular-physical-entity
                        :ARG0-of (x8 / inhibit-01
                              :ARG1 (x7 / kinase
                                    :name (x6 / name :op1 "PI-3")))))
            :ARG1 (x11 / level
                  :quant-of (x14 / induce-01
                        :ARG0 (x12 / protein
                              :name (x13 / name :op1 "EGF")
                              :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1-of (x21 / tyrosine-phosphatase
                        :ARG0-of (x15 / form-01
                              :ARG1 (x16 / macro-molecular-complex
                                    :part (x17 / protein
                                          :name (x18 / name :op1 "Gab1")
                                          :xref (x27 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                                    :part (x19 / enzyme
                                          :name (x20 / name :op1 "protein")
                                          :xref (x / xref :value "UNIPROT:S45A3_HUMAN" :prob "0.342"))))
                        :name (x22 / name :op1 "Shp2")
                        :ARG1-of (x23 / describe-01
                              :ARG0 (x24 / publication
                                    :ARG1-of (x25 / cite-01 :ARG2 "14")))))))


# ::id PMC5341140.82
# ::snt This finding suggests a role for Gab1 in the PI-3 kinase-dependent recruitment of Shp2 following EGF stimulation.
# ::tok This finding suggests a role for Gab1 in the PI @-@ 3 kinase @-@ dependent recruitment of Shp2 following EGF stimulation .
(x4 / suggest-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG1-of (x3 / find-01))
      :ARG1 (x5 / role
            :poss (x6 / protein
                  :name (x7 / name :op1 "Gab1")
                  :xref (x19 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :topic (x11 / recruit-01
                  :ARG0 (x10 / depend-01
                        :ARG1 (x8 / protein
                              :name (x9 / name :op1 "PI-3")))
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "Shp2")
                        :xref (x18 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
                  :ARG1-of (x14 / follow-01
                        :ARG2 (x17 / stimulate-01
                              :ARG2 (x15 / protein
                                    :name (x16 / name :op1 "EGF")
                                    :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))))


# ::id PMC5341140.83
# ::snt We have examined the possibility that mutation of the p85 binding sites on Gab1, which prevents PI-3 kinase activation, altered EGF-induced recruitment of Shp2 as compared to the recruitment of Shp2 by wild type Gab1.
# ::tok We have examined the possibility that mutation of the p85 binding sites on Gab1 , which prevents PI @-@ 3 kinase activation , altered EGF @-@ induced recruitment of Shp2 as compared to the recruitment of Shp2 by wild type Gab1 .
(x2 / examine-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / possible-01
            :ARG1 (x18 / recruit-01
                  :ARG0 (x4 / mutate-01
                        :ARG1 (x7 / site
                              :name (x5 / name :op1 "p85")
                              :ARG2-of (x6 / bind-01)
                              :location (x8 / protein
                                    :name (x9 / name :op1 "Gab1")
                                    :xref (x29 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                              :ARG0-of (x10 / prevent-01
                                    :ARG1 (x13 / activate-01
                                          :ARG1 (x12 / kinase
                                                :name (x11 / name :op1 "PI-3"))
                                          :ARG1-of (x14 / alter-01
                                                :ARG1 (x17 / induce-01
                                                      :ARG0 (x15 / protein
                                                            :name (x16 / name :op1 "EGF")
                                                            :xref (x31 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))))
                  :ARG1 (x19 / enzyme
                        :name (x20 / name :op1 "Shp2")
                        :xref (x30 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
                  :ARG1-of (x21 / compare-01
                        :ARG2 (x22 / recruit-01
                              :ARG1 (x23 / enzyme
                                    :name (x24 / name :op1 "Shp2")
                                    :xref (x28 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
                              :ARG0 (x25 / enzyme
                                    :mod (x26 / wild-type)
                                    :name (x27 / name :op1 "Gab1")
                                    :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))))


# ::id PMC5341140.85
# ::snt The experiment presented in Fig 2A shows that mutation of the p85 binding sites on Gab1 did not affect recruitment of Shp2 by Gab1 following EGF stimulation (Figure 2A , fourth panel from the top).
# ::tok The experiment presented in Fig 2A shows that mutation of the p85 binding sites on Gab1 did not affect recruitment of Shp2 by Gab1 following EGF stimulation ( Figure 2A , fourth panel from the top ) .
(x4 / show-01
      :ARG0 (x1 / experiment-01
            :ARG1-of (x2 / present-01
                  :location (x3 / figure :mod "2a")))
      :ARG1 (x11 / affect-01
            :ARG0 (x5 / mutate-01
                  :ARG1 (x8 / site
                        :name (x6 / name :op1 "p85")
                        :ARG2-of (x7 / bind-01)
                        :location (x9 / protein
                              :name (x10 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :polarity "-"
            :ARG1 (x12 / recruit-01
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "Shp2")
                        :xref (x28 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
                  :ARG0 (x15 / protein
                        :name (x16 / name :op1 "Gab1")
                        :xref (x29 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG1-of (x17 / follow-01
                        :ARG2 (x20 / stimulate-01
                              :ARG2 (x18 / protein
                                    :name (x19 / name :op1 "EGF")
                                    :xref (x27 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))
      :ARG1-of (x21 / describe-01
            :ARG0 (x22 / and
                  :op1 (x23 / figure :mod "2a")
                  :op2 (x25 / panel
                        :mod (x24 / ordinal-entity :value "4")
                        :source (x26 / top)))))


# ::id PMC5341140.86
# ::snt As has been previously observed [ 20 ], we noted a low level of basal association between Shp2 and both Gab1 and Gab1 F446/472/589 , which may be due to incomplete growth factor starvation prior to EGF stimulation in these experiments.
# ::tok As has been previously observed [ 20 ] , we noted a low level of basal association between Shp2 and both Gab1 and Gab1 F446 @/@ 472 @/@ 589 , which may be due to incomplete growth factor starvation prior to EGF stimulation in these experiments .
(x8 / note-01
      :ARG1-of (x3 / observe-01
            :ARG0-of (x1 / have-03
                  :ARG1 (x2 / previous))
            :ARG1-of (x4 / describe-01
                  :ARG0 (x5 / publication
                        :ARG1-of (x6 / cite-01 :ARG2 "20"))))
      :ARG0 (x7 / we)
      :ARG1 (x10 / level
            :ARG1-of (x9 / low-04)
            :mod (x11 / basal)
            :ARG1-of (x12 / associate-01
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "Shp2")
                        :xref (x36 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
                  :ARG2 (x15 / and
                        :op1 (x16 / protein
                              :name (x17 / name :op1 "Gab1")
                              :xref (x37 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :op2 (x18 / protein
                              :name (x19 / name :op1 "Gab1")
                              :xref (x35 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :ARG1 (x20 / amino-acid
                        :mod "446"
                        :name (x21 / name :op1 "phenylalanine"))
                  :ARG2 (x22 / enzyme
                        :name (x23 / name :op1 "472" :op2 "589")))
            :ARG1-of (x25 / cause-01
                  :ARG1-of (x24 / possible-01)
                  :ARG0 (x28 / starve-01
                        :ARG1-of (x26 / complete-01 :polarity "-")
                        :ARG0 (x27 / growth-factor)
                        :time (x29 / prior
                              :op1 (x32 / stimulate-01
                                    :ARG0 (x30 / protein
                                          :name (x31 / name :op1 "EGF")
                                          :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                                    :location (x34 / experiment-01
                                          :mod (x33 / this))))))))


# ::id PMC5341140.87
# ::snt Expression of Gab1 mutant protein deficient in Shp2 binding rescues EGF-induced PI-3 kinase/Akt activation in Gab1 -/- MEFs
# ::tok Expression of Gab1 mutant protein deficient in Shp2 binding rescues EGF @-@ induced PI @-@ 3 kinase @/@ Akt activation in Gab1 -/- MEFs
(x10 / rescue-01
      :ARG0 (x1 / express-03
            :ARG2 (x5 / protein
                  :mod (x2 / protein
                        :name (x3 / name :op1 "Gab1")
                        :ARG2-of (x4 / mutate-01)
                        :xref (x23 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG0-of (x6 / lack-01
                        :ARG1 (x9 / bind-01
                              :ARG2 (x7 / enzyme
                                    :name (x8 / name :op1 "Shp2")
                                    :xref (x24 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))))))
      :ARG1 (x16 / activate-01
            :ARG2-of (x13 / induce-01
                  :ARG0 (x11 / protein
                        :name (x12 / name :op1 "EGF")
                        :xref (x22 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x14 / protein
                  :name (x15 / name :op1 "PI-3")))
      :location (x17 / cell
            :mod (x18 / protein
                  :name (x19 / name :op1 "Gab1")
                  :ARG2-of (x20 / mutate-01 :mod "-/-")
                  :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :name (x21 / name :op1 "mef")))


# ::id PMC5341140.88
# ::snt To assess the role of the protein tyrosine phosphatase Shp2 in Gab1-mediated signaling induced by EGF, two Gab1 mutants were generated and expressed in pools of Gab1 -/- MEFs.
# ::tok To assess the role of the protein tyrosine phosphatase Shp2 in Gab1 @-@ mediated signaling induced by EGF , two Gab1 mutants were generated and expressed in pools of Gab1 -/- MEFs .
(x17 / express-03
      :purpose (x1 / assess-01
            :ARG1 (x2 / role
                  :poss (x3 / protein
                        :name (x4 / name
                              :op1 "protein"
                              :op2 "tyrosine"
                              :op3 "phosphatase"
                              :op4 "Shp2"))
                  :topic (x7 / mediate-01
                        :ARG0 (x5 / protein
                              :name (x6 / name :op1 "Gab1")
                              :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :ARG1 (x8 / signal-07
                              :ARG2-of (x9 / induce-01
                                    :ARG0 (x10 / protein
                                          :name (x11 / name :op1 "EGF")
                                          :xref (x25 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))))
      :ARG0 (x16 / and
            :quant "2"
            :ARG0-of (x15 / generate-01
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "Gab1")
                        :ARG2-of (x14 / mutate-01)
                        :xref (x26 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
      :location (x18 / cell
            :mod (x19 / pool
                  :consist-of (x20 / protein
                        :name (x21 / name :op1 "Gab1")
                        :ARG2-of (x22 / mutate-01 :mod "-/-")
                        :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :name (x23 / name :op1 "mef")))


# ::id PMC5341140.89
# ::snt The first contained tyrosine to phenylalanine point mutations at the two binding sites for the Shp2 protein tyrosine phosphatase (Y627F/Y659F) (designated Gab1 F627/659 ) and the second contained mutations at the Shp2 binding sites as well as at the three PI-3 kinase binding sites described above (designated Gab1 F446/472/589/627/659 ).
# ::tok The first contained tyrosine to phenylalanine point mutations at the two binding sites for the Shp2 protein tyrosine phosphatase ( Y627F/Y659F ) ( designated Gab1 F627 @/@ 659 ) and the second contained mutations at the Shp2 binding sites as well as at the three PI @-@ 3 kinase binding sites described above ( designated Gab1 F446 @/@ 472 @/@ 589 @/@ 627 @/@ 659 ) .
(x1 / multi-sentence
      :snt1 (x9 / mutate-01
            :ARG1 (x8 / point
                  :ord (x2 / ordinal-entity :value "1")
                  :ARG0-of (x3 / contain-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "tyrosine")
                              :xref (x47 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
                        :ARG2 (x6 / amino-acid
                              :name (x7 / name :op1 "phenylalanine"))))
            :location (x22 / and
                  :op1 (x14 / tyrosine-phosphatase
                        :quant "2"
                        :ARG1-of (x10 / protein-segment
                              :ARG2-of (x11 / bind-01
                                    :ARG1 (x12 / enzyme
                                          :name (x13 / name :op1 "Shp2" :op2 "protein"))))
                        :name (x15 / name :op1 "Y627F/Y659F")
                        :ARG1-of (x16 / designate-01
                              :ARG1 (x17 / protein
                                    :name (x18 / name :op1 "Gab1")
                                    :xref (x49 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                              :ARG2 (x19 / amino-acid
                                    :mod "627"
                                    :name (x20 / name :op1 "phenylalanine")))
                        :name (x21 / name :op1 "659"))
                  :op2 (x24 / contain-01
                        :ord (x23 / ordinal-entity :value "2")
                        :ARG1 (x25 / mutate-01
                              :ARG1 (x29 / site
                                    :ARG1-of (x28 / bind-01
                                          :ARG2 (x26 / enzyme
                                                :name (x27 / name :op1 "Shp2")
                                                :xref (x / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))))))))
      :snt2 (x30 / and
            :time (x34 / protein-segment
                  :quant "3"
                  :ARG1-of (x33 / bind-01
                        :ARG2 (x31 / protein
                              :name (x32 / name :op1 "PI-3" :op2 "kinase")))
                  :ARG1-of (x35 / describe-01
                        :location (x36 / above)))
            :ARG1-of (x37 / designate-01
                  :ARG0 (x38 / protein
                        :name (x39 / name :op1 "Gab1")
                        :xref (x48 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG1 (x42 / slash
                        :op1 (x40 / amino-acid
                              :mod "446"
                              :name (x41 / name :op1 "phenylalanine"))
                        :op2 (x43 / enzyme
                              :name (x44 / name :op1 "472" :op2 "589"))
                        :op2 (x45 / amino-acid
                              :mod "627"
                              :name (x46 / name :op1 "659")
                              :xref (x50 / xref :value "PUBCHEM:1183272" :prob "7.366475"))))))


# ::id PMC5341140.90
# ::snt We first assayed the ability of the mutant Gab1 proteins to become tyrosine phosphorylated in response to EGF.
# ::tok We first assayed the ability of the mutant Gab1 proteins to become tyrosine phosphorylated in response to EGF .
(x3 / assay-01
      :ARG0 (x1 / we)
      :ord (x2 / ordinal-entity :value "1")
      :ARG1 (x4 / capable-01
            :ARG1 (x5 / enzyme
                  :ARG2-of (x6 / mutate-01)
                  :name (x7 / name :op1 "Gab1")
                  :xref (x15 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG2 (x8 / become-01
                  :ARG2 (x11 / phosphorylate-01
                        :ARG1 (x9 / amino-acid
                              :name (x10 / name :op1 "tyrosine")
                              :xref (x16 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :ARG2-of (x12 / respond-01
                              :ARG1 (x13 / protein
                                    :name (x14 / name :op1 "EGF")
                                    :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))))


# ::id PMC5341140.91
# ::snt As shown in Figure 3A (top panel) both wild type Gab1 protein and the Gab1 F627/659 protein readily undergo tyrosine phosphorylation when stimulated with EGF.
# ::tok As shown in Figure 3A ( top panel ) both wild type Gab1 protein and the Gab1 F627 @/@ 659 protein readily undergo tyrosine phosphorylation when stimulated with EGF .
(x1 / multi-sentence
      :snt1 (x2 / show-01
            :ARG0 (x3 / figure :mod "3a"))
      :snt2 (x18 / undergo-28
            :ARG0 (x6 / and
                  :op1 (x5 / panel
                        :mod (x4 / top))
                  :op2 (x10 / and
                        :op1 (x7 / enzyme
                              :mod (x8 / wild-type)
                              :name (x9 / name :op1 "Gab1")
                              :xref (x25 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :op2 (x11 / protein
                              :name (x12 / name :op1 "Gab1")
                              :xref (x27 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :op2 (x13 / amino-acid
                        :mod "627"
                        :name (x14 / name :op1 "phenylalanine"))
                  :op1 (x16 / protein
                        :name (x15 / name :op1 "659")))
            :manner (x17 / ready)
            :ARG2 (x21 / phosphorylate-01
                  :ARG1 (x19 / enzyme
                        :name (x20 / name :op1 "tyrosine")
                        :xref (x26 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352")))
            :time (x22 / stimulate-01
                  :ARG2 (x23 / protein
                        :name (x24 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC5341140.92
# ::snt Quantitation following densitometry indicates that Gab1 F627/659 is reproducibly tyrosine phosphorylated to levels approximately 1.5-fold higher than Gab1.
# ::tok Quantitation following densitometry indicates that Gab1 F627 @/@ 659 is reproducibly tyrosine phosphorylated to levels approximately 1.5 @-@ fold higher than Gab1 .
(x5 / indicate-01
      :ARG0 (x3 / after
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "Quantitation"))
            :op2 (x4 / densitometry))
      :ARG1 (x12 / phosphorylate-01
            :ARG1 (x6 / and
                  :op1 (x7 / amino-acid
                        :mod "627"
                        :name (x8 / name :op1 "phenylalanine"))
                  :op2 "659")
            :ARG1-of (x9 / reproducibly)
            :ARG1 (x10 / enzyme
                  :name (x11 / name :op1 "tyrosine")
                  :xref (x20 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
            :degree (x13 / level
                  :degree (x15 / product-of
                        :mod (x14 / approximate)
                        :op1 "1.5")
                  :ARG1-of (x16 / high-02
                        :degree (x17 / more)
                        :compared-to (x18 / protein
                              :name (x19 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))))


# ::id PMC5341140.93
# ::snt This result suggests that Gab1 may be a substrate of Shp2, and that blocking Shp2 binding thereby increases EGF-induced Gab1 tyrosine phosphorylation.
# ::tok This result suggests that Gab1 may be a substrate of Shp2 , and that blocking Shp2 binding thereby increases EGF @-@ induced Gab1 tyrosine phosphorylation .
(x4 / suggest-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x8 / substrate
            :domain (x5 / protein
                  :name (x6 / name :op1 "Gab1")
                  :xref (x26 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG1-of (x7 / possible-01)
            :ARG1 (x9 / enzyme
                  :name (x10 / name :op1 "Shp2")
                  :xref (x25 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
            :ARG0-of (x11 / block-01
                  :ARG1 (x14 / bind-01
                        :ARG1 (x12 / enzyme
                              :name (x13 / name :op1 "Shp2")
                              :xref (x27 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))))
            :ARG1-of (x15 / cause-01
                  :ARG1 (x16 / increase-01
                        :ARG1 (x24 / phosphorylate-01
                              :ARG2-of (x19 / induce-01
                                    :ARG0 (x17 / protein
                                          :name (x18 / name :op1 "EGF")
                                          :xref (x28 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                              :ARG1 (x20 / amino-acid
                                    :part-of (x21 / protein
                                          :name (x22 / name :op1 "Gab1")
                                          :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                                    :name (x23 / name :op1 "tyrosine")
                                    :xref (x29 / xref :value "PUBCHEM:1153" :prob "11.081481")))))))


# ::id PMC5341140.94
# ::snt The Gab1 F446/472/589/627/659 mutant reproducibly displayed lower levels of tyrosine phosphorylation following treatment with EGF suggesting that these five tyrosines are the main phosphorylation sites on Gab1.
# ::tok The Gab1 F446 @/@ 472 @/@ 589 @/@ 627 @/@ 659 mutant reproducibly displayed lower levels of tyrosine phosphorylation following treatment with EGF suggesting that these five tyrosines are the main phosphorylation sites on Gab1 .
(x12 / display-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "Gab1")
            :xref (x32 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
      :ARG1-of (x10 / mutate-01
            :ARG2 (x5 / slash
                  :op1 (x3 / amino-acid
                        :mod "446"
                        :name (x4 / name :op1 "phenylalanine"))
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "472" :op2 "589"))
                  :op2 (x8 / amino-acid
                        :mod "627"
                        :name (x9 / name :op1 "659")
                        :xref (x35 / xref :value "PUBCHEM:1183272" :prob "7.366475"))))
      :mod (x11 / reproducibly)
      :ARG1 (x15 / level
            :ARG1-of (x13 / low-04
                  :degree (x14 / more))
            :degree-of (x18 / phosphorylate-01
                  :ARG1 (x16 / amino-acid
                        :name (x17 / name :op1 "tyrosine")
                        :xref (x36 / xref :value "PUBCHEM:1153" :prob "11.081481")))
            :ARG1-of (x19 / follow-01
                  :ARG2 (x20 / treat-04
                        :ARG2 (x21 / protein
                              :name (x22 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :ARG0-of (x23 / suggest-01
            :ARG1 (x29 / site
                  :mod (x24 / this)
                  :quant "5"
                  :ARG1-of (x28 / phosphorylate-01
                        :ARG1 (x25 / amino-acid
                              :name (x26 / name :op1 "tyrosine")
                              :xref (x34 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :mod (x27 / main))))
      :ARG1 (x30 / protein
            :name (x31 / name :op1 "Gab1")
            :xref (x33 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))


# ::id PMC5341140.95
# ::snt Immunoprecipitation of cell lysates with anti-Gab1 antibodies followed by immunoblotting with anti-Shp2 antibodies demonstrates that wild type Gab1 forms a complex with Shp2 following EGF treatment, while the Gab1 F627/659 mutant proteins fail to show an association with Shp2 thus confirming that phosphorylation of Tyr627 and 659 is required for Shp2 binding (Fig 3A ).
# ::tok Immunoprecipitation of cell lysates with anti @-@ Gab1 antibodies followed by immunoblotting with anti @-@ Shp2 antibodies demonstrates that wild type Gab1 forms a complex with Shp2 following EGF treatment , while the Gab1 F627 @/@ 659 mutant proteins fail to show an association with Shp2 thus confirming that phosphorylation of Tyr627 and 659 is required for Shp2 binding ( Fig 3A ) .
(x1 / multi-sentence
      :snt1 (x15 / demonstrate-01
            :ARG0 (x2 / immunoprecipitate-01
                  :ARG1 (x4 / lysate
                        :mod (x3 / cell))
                  :ARG2 (x8 / antibody
                        :ARG0-of (x5 / counter-01
                              :ARG1 (x6 / protein
                                    :name (x7 / name :op1 "Gab1")
                                    :xref (x54 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
                  :ARG2-of (x9 / follow-01
                        :ARG1 (x10 / immunoblot-01
                              :ARG3 (x14 / antibody
                                    :ARG0-of (x11 / counter-01
                                          :ARG1 (x12 / enzyme
                                                :name (x13 / name :op1 "Shp2")
                                                :xref (x56 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003")))))))
            :ARG1 (x19 / form-01
                  :ARG0 (x16 / enzyme
                        :mod (x17 / wild-type)
                        :name (x18 / name :op1 "Gab1")
                        :xref (x57 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG1 (x20 / macro-molecular-complex
                        :part (x21 / enzyme
                              :name (x22 / name :op1 "Shp2")
                              :ARG1-of (x23 / follow-01
                                    :ARG2 (x26 / treat-04
                                          :ARG1 (x24 / enzyme
                                                :name (x25 / name :op1 "EGF")
                                                :xref (x51 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                                          :ARG2 (x27 / protein
                                                :name (x28 / name :op1 "Gab1")
                                                :xref (x52 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
                              :name (x29 / name :op1 "F627")
                              :xref (x53 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
                        :part (x30 / protein
                              :name (x31 / name :op1 "659")))))
      :snt2 (x32 / cause-01
            :ARG1 (x40 / confirm-01
                  :ARG0 (x35 / fail-01
                        :ARG1 (x34 / protein
                              :ARG2-of (x33 / mutate-01))
                        :ARG2 (x36 / show-01
                              :ARG1 (x37 / associate-01
                                    :ARG2 (x38 / enzyme
                                          :name (x39 / name :op1 "Shp2")
                                          :xref (x55 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003")))))
                  :ARG1 (x45 / require-01
                        :ARG0 (x41 / phosphorylate-01
                              :ARG1 (x42 / amino-acid
                                    :mod "627"
                                    :name (x43 / name :op1 "tyrosine")
                                    :xref (x58 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                        :ARG1 (x44 / and :mod "659")
                        :ARG0 (x48 / bind-01
                              :ARG1 (x46 / enzyme
                                    :name (x47 / name :op1 "Shp2")
                                    :xref (x / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003")))
                        :ARG1-of (x49 / describe-01
                              :ARG0 (x50 / figure :mod "3a"))))))


# ::id PMC5341140.96
# ::snt The basal interaction we observed between Gab1 and Shp2 in the absence of EGF stimulation (Figure 2A ) is absent in the Gab1 F627/659 mutant, even following prolonged exposures of the western blot.
# ::tok The basal interaction we observed between Gab1 and Shp2 in the absence of EGF stimulation ( Figure 2A ) is absent in the Gab1 F627 @/@ 659 mutant , even following prolonged exposures of the western blot .
(x16 / absent-01
      :ARG1 (x2 / interact-01
            :mod (x1 / basal)
            :ARG1 (x7 / and
                  :op1 (x4 / observe-01
                        :ARG0 (x3 / we)
                        :ARG1 (x5 / protein
                              :name (x6 / name :op1 "Gab1")
                              :xref (x25 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :op2 (x8 / enzyme
                        :name (x9 / name :op1 "Shp2")
                        :xref (x / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003")))
            :condition (x10 / absent-01
                  :ARG1 (x13 / stimulate-01
                        :ARG0 (x11 / protein
                              :name (x12 / name :op1 "EGF")
                              :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
            :ARG1-of (x14 / describe-01
                  :ARG0 (x15 / figure :mod "2a")))
      :ARG1 (x17 / and
            :op2 (x18 / amino-acid
                  :mod "627"
                  :name (x19 / name :op1 "phenylalanine"))
            :op1 (x20 / mutate-01 :mod "659"))
      :ARG1-of (x21 / follow-01
            :ARG2 (x23 / expose-01
                  :ARG1-of (x22 / prolong-01))
            :ARG1 (x24 / immunoblot-01)))


# ::id PMC5341140.97
# ::snt We did not detect a change in the tyrosine phosphorylation of EGFR in cells expressing Gab1 proteins that are deficient in recruitment of Shp2.
# ::tok We did not detect a change in the tyrosine phosphorylation of EGFR in cells expressing Gab1 proteins that are deficient in recruitment of Shp2 .
(x2 / detect-01
      :ARG0 (x1 / we)
      :polarity "-"
      :ARG1 (x3 / change-01
            :ARG1 (x4 / phosphorylate-01
                  :ARG1 (x5 / amino-acid
                        :name (x6 / name :op1 "tyrosine")
                        :part-of (x7 / enzyme
                              :name (x8 / name :op1 "EGFR")
                              :xref (x19 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
                        :xref (x20 / xref :value "PUBCHEM:1153" :prob "11.081481"))))
      :location (x9 / cell
            :ARG3-of (x10 / express-03
                  :ARG2 (x11 / protein
                        :name (x12 / name :op1 "Gab1")
                        :xref (x18 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :mod (x13 / protein)
            :ARG0-of (x14 / lack-01
                  :ARG1 (x15 / recruit-01
                        :ARG1 (x16 / enzyme
                              :name (x17 / name :op1 "Shp2")
                              :xref (x / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))))))


# ::id PMC5341140.98
# ::snt The experiment presented in Fig 3B shows cells stimulated with EGF over varying periods of time and cell extracts assayed for levels of EGFR tyrosine autophosphorylation.
# ::tok The experiment presented in Fig 3B shows cells stimulated with EGF over varying periods of time and cell extracts assayed for levels of EGFR tyrosine autophosphorylation .
(x4 / show-01
      :ARG0 (x1 / experiment-01)
      :ARG1-of (x2 / present-01
            :location (x3 / figure :mod "3b"))
      :ARG1 (x22 / phosphorylate-01
            :ARG0 (x5 / cell
                  :ARG1-of (x6 / stimulate-01
                        :ARG0 (x7 / protein
                              :name (x8 / name :op1 "EGF")
                              :xref (x23 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
            :ARG2 (x13 / and
                  :op1 (x9 / over
                        :op1 (x11 / period
                              :ARG1-of (x10 / vary-01)
                              :consist-of (x12 / time)))
                  :op2 (x16 / assay-01
                        :ARG1-of (x15 / extract-01
                              :ARG2 (x14 / cell))
                        :ARG1 (x17 / level
                              :quant-of (x18 / enzyme
                                    :name (x19 / name :op1 "EGFR")
                                    :xref (x24 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004")))))
            :ARG1 (x20 / enzyme
                  :name (x21 / name :op1 "tyrosine")
                  :xref (x / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))))


# ::id PMC5341140.99
# ::snt As has been previously reported [ 15 , 18 , 20 ], recruitment of Shp2 by Gab1 does not alter the magnitude or kinetics of tyrosine autophosphorylation of EGFR (Figure 3B , left panels).
# ::tok As has been previously reported [ 15 , 18 , 20 ] , recruitment of Shp2 by Gab1 does not alter the magnitude or kinetics of tyrosine autophosphorylation of EGFR ( Figure 3B , left panels ) .
(x13 / alter-01
      :ARG0 (x8 / recruit-01
            :ARG1-of (x7 / cite-01
                  :ARG2 (x1 / and
                        :op1 (x3 / report-01
                              :time (x2 / previous)
                              :ARG1-of (x4 / describe-01
                                    :ARG0 (x5 / publication
                                          :ARG1-of (x6 / cite-01 :ARG2 "15"))))
                        :op2 "18"
                        :op3 "20"))
            :ARG1 (x9 / enzyme
                  :name (x10 / name :op1 "Shp2")
                  :xref (x26 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
            :ARG0 (x11 / protein
                  :name (x12 / name :op1 "Gab1")
                  :xref (x27 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
      :polarity "-"
      :ARG1 (x15 / or
            :op1 (x14 / magnitude)
            :op2 (x16 / kinetics
                  :mod (x17 / phosphorylate-01
                        :ARG1 (x18 / amino-acid
                              :name (x19 / name :op1 "tyrosine")
                              :part-of (x20 / enzyme
                                    :name (x21 / name :op1 "EGFR")
                                    :xref (x / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
                              :xref (x28 / xref :value "PUBCHEM:1153" :prob "11.081481"))))
            :ARG1-of (x22 / describe-01
                  :ARG0 (x23 / figure
                        :mod "3b"
                        :location (x25 / panel
                              :ARG1-of (x24 / left-20))))))


# ::id PMC5341140.100
# ::snt Levels of EGFR autophosphorylation are represented linearly following quantitation by densitometry and normalization for protein expression levels (Figure 3B , bottom).
# ::tok Levels of EGFR autophosphorylation are represented linearly following quantitation by densitometry and normalization for protein expression levels ( Figure 3B , bottom ) .
(x5 / represent-01
      :ARG1 (x1 / level
            :degree-of (x4 / phosphorylate-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "EGFR")
                        :xref (x / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))))
      :ARG2 (x12 / normalize-01
            :mod (x6 / linear)
            :ARG1-of (x7 / follow-01
                  :ARG2 (x10 / and
                        :op1 (x8 / enzyme
                              :name (x9 / name :op1 "quantitation"))
                        :op2 (x11 / densitometry)))
            :ARG1 (x15 / level
                  :degree-of (x14 / express-03
                        :ARG2 (x13 / protein)))
            :ARG1-of (x16 / describe-01
                  :ARG0 (x17 / figure
                        :mod "3b"
                        :location (x18 / bottom)))))


# ::id PMC5341140.101
# ::snt Previous work with Shp2 -/- cells demonstrated an elevated and sustained activation of PI-3 kinase and Akt in response to EGF treatment, and it was proposed that Shp2 may act to dephosphorylate Gab1 at one or both of the p85 binding sites [ 18 ].
# ::tok Previous work with Shp2 -/- cells demonstrated an elevated and sustained activation of PI @-@ 3 kinase and Akt in response to EGF treatment , and it was proposed that Shp2 may act to dephosphorylate Gab1 at one or both of the p85 binding sites [ 18 ] .
(x7 / demonstrate-01
      :ARG0 (x2 / work-01
            :time (x1 / previous)
            :ARG2 (x6 / cell
                  :mod (x3 / enzyme
                        :name (x4 / name :op1 "Shp2")
                        :ARG2-of (x5 / mutate-01 :mod "-/-")
                        :xref (x39 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))))
      :ARG1 (x20 / and
            :ARG1-of (x8 / elevate-01)
            :ARG1-of (x19 / treat-04
                  :ARG2 (x10 / activate-01
                        :ARG1-of (x9 / sustain-01)
                        :ARG1 (x13 / and
                              :op1 (x12 / kinase
                                    :name (x11 / name :op1 "PI-3"))
                              :op2 (x14 / enzyme
                                    :name (x15 / name :op1 "Akt")
                                    :xref (x41 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                        :ARG2-of (x16 / respond-01
                              :ARG1 (x17 / protein
                                    :name (x18 / name :op1 "EGF")
                                    :xref (x42 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
            :op2 (x21 / propose-01
                  :ARG1 (x22 / possible-01
                        :ARG1 (x25 / act-02
                              :ARG0 (x23 / enzyme
                                    :name (x24 / name :op1 "Shp2")
                                    :xref (x38 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
                              :purpose (x26 / dephosphorylate-01
                                    :ARG1 (x27 / protein
                                          :name (x28 / name :op1 "Gab1")
                                          :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                                    :ARG2 (x29 / or :quant "1"))))
                  :ARG0-of (x34 / protein-segment
                        :mod (x30 / both)
                        :ARG0-of (x33 / bind-01
                              :ARG1 (x31 / enzyme
                                    :name (x32 / name :op1 "p85")
                                    :xref (x40 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))))
                  :ARG1-of (x35 / describe-01
                        :ARG0 (x36 / publication
                              :ARG1-of (x37 / cite-01 :ARG2 "18"))))))


# ::id PMC5341140.102
# ::snt We utilized the Gab1 proteins deficient in Shp2 binding to assay more directly the role of the Shp2-Gab1 complex in mediating activation of PI-3 kinase and Akt in response to EGF stimulation.
# ::tok We utilized the Gab1 proteins deficient in Shp2 binding to assay more directly the role of the Shp2 @-@ Gab1 complex in mediating activation of PI @-@ 3 kinase and Akt in response to EGF stimulation .
(x2 / utilize-01
      :ARG0 (x1 / we)
      :ARG1 (x5 / protein
            :mod (x3 / protein
                  :name (x4 / name :op1 "Gab1")
                  :xref (x30 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG0-of (x6 / lack-01
                  :ARG1 (x9 / bind-01
                        :ARG1 (x7 / enzyme
                              :name (x8 / name :op1 "Shp2")
                              :xref (x31 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
                        :ARG2 (x10 / assay-01
                              :ARG1-of (x12 / direct-02
                                    :degree (x11 / more))))))
      :ARG1 (x13 / role
            :poss (x14 / enzyme
                  :name (x15 / name :op1 "Shp2")
                  :ARG1-of (x17 / macro-molecular-complex
                        :name (x16 / name :op1 "Gab1"))
                  :xref (x32 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
            :topic (x18 / mediate-01
                  :ARG1 (x19 / activate-01
                        :ARG1 (x22 / and
                              :op1 (x21 / kinase
                                    :name (x20 / name :op1 "PI-3"))
                              :op2 (x23 / enzyme
                                    :name (x24 / name :op1 "Akt")
                                    :xref (x29 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                        :ARG2-of (x25 / respond-01
                              :ARG1 (x28 / stimulate-01
                                    :ARG0 (x26 / protein
                                          :name (x27 / name :op1 "EGF")
                                          :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))))


# ::id PMC5341140.103
# ::snt As shown in Figure 3C , immunoprecipitation of Gab1 F627/659 brings down 1.6-fold higher basal levels of PI-3 kinase activity relative to wild type Gab1 as assayed by PIP3 production.
# ::tok As shown in Figure 3C , immunoprecipitation of Gab1 F627 @/@ 659 brings down 1.6 @-@ fold higher basal levels of PI @-@ 3 kinase activity relative to wild type Gab1 as assayed by PIP3 production .
(x7 / bring-down-03
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "3c"))
      :ARG1 (x3 / immunoprecipitate-01
            :ARG1 (x4 / and
                  :op1 (x5 / amino-acid
                        :mod "627"
                        :name (x6 / name :op1 "phenylalanine"))
                  :op2 "659"))
      :ARG1 (x8 / product-of :op1 "1.6")
      :ARG1-of (x9 / high-02
            :degree (x10 / more)
            :ARG1 (x12 / level
                  :mod (x11 / basal)
                  :quant-of (x15 / activity-06
                        :ARG0 (x14 / kinase
                              :name (x13 / name :op1 "PI-3"))))
            :ARG1-of (x16 / relative-05
                  :ARG3 (x23 / produce-01
                        :ARG0 (x20 / assay-01
                              :ARG1 (x17 / enzyme
                                    :mod (x18 / wild-type)
                                    :name (x19 / name :op1 "Gab1")
                                    :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                        :ARG1 (x21 / protein
                              :name (x22 / name :op1 "PIP3"))))))


# ::id PMC5341140.104
# ::snt Importantly, Gab1 mutants defective for Shp2 binding show approximately 2-fold higher Gab1-associated PI-3 kinase activity in response to EGF treatment.
# ::tok Importantly , Gab1 mutants defective for Shp2 binding show approximately 2 @-@ fold higher Gab1 @-@ associated PI @-@ 3 kinase activity in response to EGF treatment .
(x9 / show-01
      :mod (x1 / important)
      :ARG0 (x2 / protein
            :name (x3 / name :op1 "Gab1")
            :ARG2-of (x4 / mutate-01)
            :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
      :mod (x5 / defective)
      :ARG0 (x8 / bind-01
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "Shp2")
                  :xref (x25 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003")))
      :ARG1 (x13 / high-02
            :degree (x12 / more
                  :quant (x10 / approximately
                        :op1 (x11 / product-of :op1 "2")))
            :ARG1 (x19 / activity-06
                  :ARG0 (x18 / kinase
                        :ARG1-of (x16 / associate-01
                              :ARG2 (x14 / protein
                                    :name (x15 / name :op1 "Gab1")
                                    :xref (x26 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                        :name (x17 / name :op1 "PI-3"))))
      :ARG2-of (x20 / respond-01
            :ARG1 (x23 / treat-04
                  :ARG2 (x21 / protein
                        :name (x22 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC5341140.105
# ::snt Consistent with these findings, previous studies have demonstrated that cells transiently over-expressing Gab1 F627/659 bound more p85 [ 18 ].
# ::tok Consistent with these findings , previous studies have demonstrated that cells transiently over @-@ expressing Gab1 F627 @/@ 659 bound more p85 [ 18 ] .
(x7 / demonstrate-01
      :ARG1-of (x1 / consistent-01
            :ARG2 (x3 / thing
                  :mod (x2 / this)
                  :ARG1-of (x4 / find-01)))
      :ARG0 (x6 / study-01
            :time (x5 / previous))
      :ARG1 (x8 / cell
            :ARG0-of (x10 / overexpress-01
                  :ARG1-of (x9 / transient-02)
                  :ARG1 (x11 / express-03
                        :ARG1 (x12 / protein
                              :name (x13 / name :op1 "Gab1")
                              :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :ARG2 (x14 / amino-acid
                              :mod "627"
                              :name (x15 / name :op1 "phenylalanine")))
                  :ARG2 (x16 / person
                        :quant "659"
                        :ARG0-of (x17 / bind-01
                              :ARG1 (x18 / protein
                                    :quant (x19 / more)
                                    :name (x20 / name :op1 "p85")
                                    :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003")))))
            :ARG1-of (x21 / describe-01
                  :ARG0 (x22 / publication
                        :ARG1-of (x23 / cite-01 :ARG2 "18")))))


# ::id PMC5341140.106
# ::snt In both Gab1 and Gab1 F627/659 expressing cells the Gab1-associated PI-3 kinase activity is augmented by EGF treatment.
# ::tok In both Gab1 and Gab1 F627 @/@ 659 expressing cells the Gab1 @-@ associated PI @-@ 3 kinase activity is augmented by EGF treatment .
(x15 / augment-01
      :time (x1 / and
            :op1 (x2 / protein
                  :name (x3 / name :op1 "Gab1")
                  :xref (x20 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :op2 (x8 / cell
                  :mod (x4 / enzyme
                        :name (x5 / name :op1 "Gab1")
                        :ARG2-of (x7 / express-03
                              :name (x6 / name :op1 "F627")
                              :mod "659")
                        :xref (x21 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
      :ARG1 (x14 / activity-06
            :ARG0 (x13 / kinase
                  :ARG1-of (x11 / associate-01
                        :ARG2 (x9 / protein
                              :name (x10 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :name (x12 / name :op1 "PI-3")))
      :ARG0 (x18 / treat-04
            :ARG2 (x16 / protein
                  :name (x17 / name :op1 "EGF")
                  :xref (x19 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))


# ::id PMC5341140.107
# ::snt As expected, the additional mutation of the p85 binding sites eliminates Gab1-associated PI-3 kinase activity.
# ::tok As expected , the additional mutation of the p85 binding sites eliminates Gab1 @-@ associated PI @-@ 3 kinase activity .
(x8 / eliminate-01
      :ARG1-of (x1 / expect-01)
      :ARG0 (x3 / mutate-01
            :mod (x2 / additional)
            :ARG1 (x7 / protein-segment
                  :ARG1-of (x6 / bind-01
                        :ARG2 (x4 / enzyme
                              :name (x5 / name :op1 "p85")
                              :xref (x15 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003")))))
      :ARG1 (x14 / activity-06
            :ARG0 (x13 / kinase
                  :ARG1-of (x11 / associate-01
                        :ARG2 (x9 / protein
                              :name (x10 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :name (x12 / name :op1 "PI-3"))))


# ::id PMC5341140.108
# ::snt In order to assay the effects of EGF stimulation on signaling downstream of PI-3 kinase, cells were treated with EGF for varying periods of time and cell lysates were assayed for Akt activation by immunoblotting with P-Ser473 Akt antibodies.
# ::tok In order to assay the effects of EGF stimulation on signaling downstream of PI @-@ 3 kinase , cells were treated with EGF for varying periods of time and cell lysates were assayed for Akt activation by immunoblotting with P @-@ Ser473 Akt antibodies .
(x1 / and
      :purpose (x2 / assay-01
            :ARG1 (x3 / affect-01
                  :ARG0 (x6 / stimulate-01
                        :ARG1 (x4 / protein
                              :name (x5 / name :op1 "EGF")
                              :xref (x32 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x7 / signal-07
                        :mod (x8 / downstream)
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "PI-3" :op2 "kinase")))))
      :op1 (x12 / treat-04
            :ARG1 (x11 / cell)
            :ARG2 (x13 / protein
                  :name (x14 / name :op1 "EGF")
                  :xref (x33 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :duration (x16 / period
                  :ARG1-of (x15 / vary-01)
                  :consist-of (x17 / time)))
      :op2 (x20 / assay-01
            :ARG1 (x19 / lysate
                  :mod (x18 / cell))
            :purpose (x23 / activate-01
                  :ARG1 (x21 / enzyme
                        :name (x22 / name :op1 "Akt")
                        :xref (x31 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                  :ARG0 (x24 / immunoblot-01
                        :ARG3 (x30 / antibody
                              :ARG1-of (x25 / statistical-test-91
                                    :ARG2 (x26 / amino-acid
                                          :mod "473"
                                          :name (x27 / name :op1 "serine")
                                          :part-of (x28 / enzyme
                                                :name (x29 / name :op1 "Akt")
                                                :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                                          :xref (x34 / xref :value "PUBCHEM:5951" :prob "11.218784"))))))))


# ::id PMC5341140.109
# ::snt Interestingly, cells expressing the Gab1 F627/659 protein reproducibly showed activation of Akt with significantly sustained kinetics relative to cells expressing wild type Gab1 (Figure 3D , left panels).
# ::tok Interestingly , cells expressing the Gab1 F627 @/@ 659 protein reproducibly showed activation of Akt with significantly sustained kinetics relative to cells expressing wild type Gab1 ( Figure 3D , left panels ) .
(x12 / show-01
      :ARG2-of (x1 / interest-01)
      :ARG0 (x2 / cell-line
            :ARG3-of (x3 / express-03
                  :ARG2 (x4 / protein
                        :name (x5 / name :op1 "Gab1")
                        :xref (x30 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :mod (x8 / slash
                  :op1 (x6 / amino-acid
                        :mod "627"
                        :name (x7 / name :op1 "phenylalanine"))
                  :op2 (x9 / enzyme
                        :name (x10 / name :op1 "erk2")
                        :xref (x29 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.603")))
            :mod "659"
            :name (x11 / name :op1 "reproducibly"))
      :ARG1 (x13 / activate-01
            :ARG1 (x14 / enzyme
                  :name (x15 / name :op1 "Akt")
                  :xref (x31 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :ARG2 (x18 / kinetics
                  :ARG1-of (x16 / significant-02)
                  :ARG1-of (x17 / sustain-01)
                  :ARG1-of (x19 / relative-05
                        :ARG3 (x20 / cell
                              :ARG3-of (x21 / express-03
                                    :ARG2 (x22 / enzyme
                                          :mod (x23 / wild-type)
                                          :name (x24 / name :op1 "Gab1")
                                          :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))))
      :ARG1-of (x25 / describe-01
            :ARG0 (x26 / figure
                  :mod "3d"
                  :location (x28 / panel
                        :ARG1-of (x27 / left-20)))))


# ::id PMC5341140.110
# ::snt As expected, the additional mutation of the p85 binding sites (Gab1 F446/472/589/627/659 ) limited Akt activation to levels similar to those observed in the Gab1 -/- cells, confirming the requirement for PI-3 kinase association with Gab1 to induce EGF-mediated activation of the Akt pathway.
# ::tok As expected , the additional mutation of the p85 binding sites ( Gab1 F446 @/@ 472 @/@ 589 @/@ 627 @/@ 659 ) limited Akt activation to levels similar to those observed in the Gab1 -/- cells , confirming the requirement for PI @-@ 3 kinase association with Gab1 to induce EGF @-@ mediated activation of the Akt pathway .
(x1 / multi-sentence
      :snt1 (x17 / limit-01
            :ARG1-of (x2 / expect-01)
            :ARG0 (x12 / slash
                  :mod (x3 / additional)
                  :ARG0-of (x4 / mutate-01
                        :ARG1 (x8 / protein-segment
                              :ARG0-of (x7 / bind-01
                                    :ARG1 (x5 / enzyme
                                          :name (x6 / name :op1 "p85")
                                          :xref (x43 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003")))
                              :name (x9 / name :op1 "Gab1"))
                        :ARG2 (x10 / amino-acid
                              :mod "446"
                              :name (x11 / name :op1 "phenylalanine")))
                  :op1 (x13 / enzyme
                        :name (x14 / name :op1 "472" :op2 "589"))
                  :op2 (x15 / amino-acid
                        :mod "627"
                        :name (x16 / name :op1 "659")
                        :xref (x47 / xref :value "PUBCHEM:1183272" :prob "7.366475")))
            :ARG1 (x20 / activate-01
                  :ARG1 (x18 / enzyme
                        :name (x19 / name :op1 "Akt")
                        :xref (x46 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
      :snt2 (x29 / confirm-01
            :purpose (x21 / level
                  :ARG1-of (x22 / resemble-01
                        :ARG2 (x23 / that))
                  :ARG1-of (x24 / observe-01
                        :location (x28 / cell
                              :mod (x25 / protein
                                    :name (x26 / name :op1 "Gab1")
                                    :ARG2-of (x27 / mutate-01 :mod "-/-")
                                    :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))
            :ARG1 (x30 / require-01
                  :ARG1 (x33 / associate-01
                        :ARG1 (x31 / protein
                              :name (x32 / name :op1 "PI-3" :op2 "kinase"))
                        :ARG2 (x34 / protein
                              :name (x35 / name :op1 "Gab1")
                              :xref (x45 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :purpose (x36 / induce-01
                        :ARG2 (x40 / activate-01
                              :ARG1-of (x39 / mediate-01
                                    :ARG0 (x37 / protein
                                          :name (x38 / name :op1 "EGF")
                                          :xref (x44 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                              :ARG1 (x41 / pathway
                                    :name (x42 / name :op1 "Akt")))))))


# ::id PMC5341140.112
# ::snt Expression of ErbB3 in Gab1 -/- MEFs enhances activation of the PI-3 kinase signaling pathway
# ::tok Expression of ErbB3 in Gab1 -/- MEFs enhances activation of the PI @-@ 3 kinase signaling pathway
(x9 / enhance-01
      :ARG0 (x1 / express-03
            :ARG2 (x2 / protein
                  :name (x3 / name :op1 "ErbB3")
                  :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
            :location (x4 / cell
                  :mod (x5 / protein
                        :name (x6 / name :op1 "Gab1")
                        :ARG2-of (x7 / mutate-01 :mod "-/-")
                        :xref (x15 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :name (x8 / name :op1 "mef")))
      :ARG1 (x10 / activate-01
            :ARG1 (x14 / pathway
                  :mod (x12 / kinase
                        :name (x11 / name :op1 "PI-3"))
                  :ARG0-of (x13 / signal-07))))


# ::id PMC5341140.113
# ::snt As described above, PI-3 kinase is recruited to the EGFR via the adaptor protein Gab1.
# ::tok As described above , PI @-@ 3 kinase is recruited to the EGFR via the adaptor protein Gab1 .
(x5 / recruit-01
      :ARG1-of (x1 / describe-01
            :location (x2 / above))
      :ARG1 (x3 / protein
            :name (x4 / name :op1 "PI-3" :op2 "kinase"))
      :ARG1 (x6 / enzyme
            :name (x7 / name :op1 "EGFR")
            :xref (x11 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
      :instrument (x9 / protein
            :mod (x8 / adaptor)
            :name (x10 / name :op1 "Gab1")
            :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))


# ::id PMC5341140.114
# ::snt The results presented here demonstrate that Gab1 is required for EGF-induced activation of the PI-3 kinase pathway via the EGFR, presumably because this receptor does not contain binding sites for the p85 regulatory subunit of PI-3 kinase.
# ::tok The results presented here demonstrate that Gab1 is required for EGF @-@ induced activation of the PI @-@ 3 kinase pathway via the EGFR , presumably because this receptor does not contain binding sites for the p85 regulatory subunit of PI @-@ 3 kinase .
(x5 / demonstrate-01
      :ARG0 (x1 / thing
            :ARG2-of (x2 / result-01))
      :ARG1-of (x3 / present-01
            :medium (x4 / here))
      :ARG1 (x8 / require-01
            :ARG1 (x6 / protein
                  :name (x7 / name :op1 "Gab1")
                  :xref (x31 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG0 (x11 / induce-01
                  :ARG0 (x9 / protein
                        :name (x10 / name :op1 "EGF")
                        :xref (x30 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG2 (x12 / activate-01
                  :ARG1 (x14 / pathway
                        :name (x13 / name :op1 "PI-3" :op2 "kinase"))
                  :instrument (x15 / enzyme
                        :name (x16 / name :op1 "EGFR")
                        :ARG1-of (x17 / presume-01)
                        :xref (x32 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004")))
            :ARG1-of (x18 / cause-01
                  :ARG0 (x21 / contain-01
                        :ARG0 (x20 / receptor
                              :mod (x19 / this))
                        :polarity "-"
                        :ARG1 (x22 / protein-segment
                              :ARG2-of (x23 / bind-01
                                    :ARG1 (x29 / kinase
                                          :name (x24 / name :op1 "p85")
                                          :mod (x26 / subunit
                                                :ARG0-of (x25 / regulate-01)
                                                :part-of (x27 / protein
                                                      :name (x28 / name :op1 "PI-3")))
                                          :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))))))))


# ::id PMC5341140.115
# ::snt The catalytically inactive ErbB3 receptor, however, contains at least six binding sites for p85 [ 5 ], and thus may bypass the requirement for Gab1 in response to EGF by heterodimerizing with the catalytically active EGFR.
# ::tok The catalytically inactive ErbB3 receptor , however , contains at least six binding sites for p85 [ 5 ] , and thus may bypass the requirement for Gab1 in response to EGF by heterodimerizing with the catalytically active EGFR .
(x1 / contrast-01
      :ARG2 (x6 / contain-01
            :ARG0 (x5 / receptor
                  :name (x2 / name :op1 "catalytically")
                  :ARG0-of (x3 / activity-06 :polarity "-")
                  :name (x4 / name :op1 "ErbB3"))
            :ARG1 (x8 / site
                  :quant (x7 / at-least :op1 "6")
                  :mod (x9 / bind-01
                        :ARG1 (x15 / and
                              :op1 (x10 / gene
                                    :name (x11 / name :op1 "p85")
                                    :ARG1-of (x12 / describe-01
                                          :ARG0 (x14 / publication
                                                :ARG1-of (x13 / cite-01 :ARG2 "5")))
                                    :xref (x30 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))
                              :op2 (x16 / possible-01
                                    :ARG1 (x17 / bypass-01
                                          :ARG1 (x18 / require-01
                                                :ARG1 (x19 / protein
                                                      :name (x20 / name :op1 "Gab1")
                                                      :xref (x29 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                                                :ARG2-of (x21 / respond-01
                                                      :ARG1 (x22 / protein
                                                            :name (x23 / name :op1 "EGF")
                                                            :xref (x28 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
                                          :ARG0 (x24 / heterodimerize-00))))))
            :ARG2 (x25 / enzyme
                  :ARG0-of (x26 / activity-06)
                  :name (x27 / name :op1 "EGFR")
                  :xref (x / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))))


# ::id PMC5341140.116
# ::snt In order to test this hypothesis, retroviral vectors were used to introduce either the Gab1 or ErbB3 genes into Gab1 -/- MEFs that endogenously express the EGFR but not ErbB3, and pools of stable cell lines were selected for further analysis.
# ::tok In order to test this hypothesis , retroviral vectors were used to introduce either the Gab1 or ErbB3 genes into Gab1 -/- MEFs that endogenously express the EGFR but not ErbB3 , and pools of stable cell lines were selected for further analysis .
(x6 / use-01
      :purpose (x1 / test-01
            :ARG1 (x3 / hypothesize-01
                  :mod (x2 / this)))
      :ARG1 (x5 / vector
            :mod (x4 / retrovirus))
      :ARG2 (x7 / introduce-02
            :ARG1 (x10 / or
                  :op1 (x8 / protein
                        :name (x9 / name :op1 "Gab1")
                        :xref (x34 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :op2 (x12 / gene
                        :name (x11 / name :op1 "ErbB3")
                        :xref (x36 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634")))
            :ARG2 (x13 / cell
                  :mod (x14 / protein
                        :name (x15 / name :op1 "Gab1")
                        :ARG2-of (x16 / mutate-01 :mod "-/-")
                        :xref (x37 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :name (x17 / name :op1 "mef"))
            :ARG0-of (x23 / contrast-01
                  :ARG1 (x20 / express-03
                        :ARG1 (x18 / enzyme
                              :name (x19 / name :op1 "endogenously")
                              :xref (x35 / xref :value "UNIPROT:V9H1F4_HUMAN" :prob "0.241"))
                        :ARG2 (x21 / enzyme
                              :name (x22 / name :op1 "EGFR")
                              :xref (x33 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004")))
                  :ARG2 (x30 / select-01
                        :polarity "-"
                        :ARG1 (x26 / and
                              :op1 (x24 / protein
                                    :name (x25 / name :op1 "ErbB3")
                                    :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
                              :op2 (x27 / pool
                                    :consist-of (x29 / cell-line
                                          :ARG1-of (x28 / stable-03))))
                        :purpose (x32 / analyze-01
                              :degree (x31 / further))))))


# ::id PMC5341140.117
# ::snt We first assayed the ability of the endogenous EGFR to be tyrosine autophosphorylated in response to EGF, as well as the ability of the exogenous ErbB3 receptor to be tyrosine phosphorylated in response to stimulation with either EGF or neuregulin (NRG).
# ::tok We first assayed the ability of the endogenous EGFR to be tyrosine autophosphorylated in response to EGF , as well as the ability of the exogenous ErbB3 receptor to be tyrosine phosphorylated in response to stimulation with either EGF or neuregulin ( NRG ) .
(x1 / and
      :op1 (x4 / assay-01
            :ARG0 (x2 / we)
            :ord (x3 / ordinal-entity :value "1")
            :ARG1 (x5 / capable-01
                  :ARG1 (x6 / enzyme
                        :mod (x7 / endogenous)
                        :name (x8 / name :op1 "EGFR")
                        :xref (x29 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
                  :ARG2 (x11 / phosphorylate-01
                        :ARG1 (x9 / amino-acid
                              :name (x10 / name :op1 "tyrosine")
                              :xref (x31 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :ARG2-of (x12 / respond-01
                              :ARG1 (x13 / protein
                                    :name (x14 / name :op1 "EGF")
                                    :xref (x30 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))
      :op2 (x15 / capable-01
            :ARG1 (x16 / protein
                  :mod (x17 / exogenous)
                  :name (x18 / name :op1 "ErbB3" :op2 "receptor"))
            :ARG2 (x21 / phosphorylate-01
                  :ARG1 (x19 / amino-acid
                        :name (x20 / name :op1 "tyrosine")
                        :xref (x32 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2-of (x22 / respond-01
                        :ARG1 (x23 / stimulate-01
                              :ARG2 (x26 / or
                                    :op1 (x24 / protein
                                          :name (x25 / name :op1 "EGF")
                                          :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                                    :op2 (x27 / protein
                                          :name (x28 / name :op1 "neuregulin" :op2 "."))))))))


# ::id PMC5341140.118
# ::snt The experiment presented in Fig 4A shows that all cell lines exhibit EGFR autophosphorylation in response to EGF treatment (Figure 4A , upper left panel), while only cells expressing the ectopically introduced ErbB3 protein show ErbB3 tyrosine phosphorylation in response to EGF stimulation.
# ::tok The experiment presented in Fig 4A shows that all cell lines exhibit EGFR autophosphorylation in response to EGF treatment ( Figure 4A , upper left panel ) , while only cells expressing the ectopically introduced ErbB3 protein show ErbB3 tyrosine phosphorylation in response to EGF stimulation .
(x4 / show-01
      :ARG0 (x1 / experiment-01)
      :ARG1-of (x2 / present-01
            :location (x3 / figure :mod "4a"))
      :ARG1 (x20 / contrast-01
            :ARG1 (x7 / exhibit-01
                  :ARG0 (x6 / cell-line
                        :mod (x5 / all))
                  :ARG1 (x10 / phosphorylate-01
                        :ARG1 (x8 / enzyme
                              :name (x9 / name :op1 "EGFR")
                              :xref (x37 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
                        :ARG2-of (x11 / respond-01
                              :ARG1 (x14 / treat-04
                                    :ARG2 (x12 / protein
                                          :name (x13 / name :op1 "EGF")
                                          :xref (x39 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
                        :ARG1-of (x15 / describe-01
                              :ARG0 (x16 / figure
                                    :mod "4a"
                                    :part (x19 / panel
                                          :ARG1-of (x18 / left-20
                                                :mod (x17 / upper)))))))
            :ARG2 (x27 / show-01
                  :ARG0 (x22 / cell-line
                        :mod (x21 / only)
                        :ARG3-of (x23 / express-03
                              :ARG2 (x25 / introduce-02
                                    :mod (x24 / ectopic)))
                        :name (x26 / name :op1 "ErbB3"))
                  :ARG1 (x32 / phosphorylate-01
                        :ARG1 (x28 / amino-acid
                              :part-of (x29 / protein
                                    :name (x30 / name :op1 "ErbB3")
                                    :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
                              :name (x31 / name :op1 "tyrosine")
                              :xref (x40 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :ARG2-of (x33 / respond-01
                              :ARG1 (x36 / stimulate-01
                                    :ARG0 (x34 / protein
                                          :name (x35 / name :op1 "EGF")
                                          :xref (x38 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))))


# ::id PMC5341140.120
# ::snt Cells expressing ErbB3 show tyrosine phosphorylation in response to treatment with NRG (Figure 4A , upper and middle right panels).
# ::tok Cells expressing ErbB3 show tyrosine phosphorylation in response to treatment with NRG ( Figure 4A , upper and middle right panels ) .
(x5 / show-01
      :ARG0 (x1 / cell
            :ARG3-of (x2 / express-03
                  :ARG2 (x3 / protein
                        :name (x4 / name :op1 "ErbB3")
                        :xref (x20 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))))
      :ARG1 (x8 / phosphorylate-01
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "tyrosine")
                  :xref (x21 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
            :ARG2-of (x9 / respond-01
                  :ARG1 (x10 / treat-04
                        :ARG2 (x11 / protein
                              :name (x12 / name :op1 "NRG")
                              :xref (x / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.263")))))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure
                  :mod "4a"
                  :location (x15 / and
                        :op1 (x16 / cell-line
                              :name (x17 / name :op1 "middle"))
                        :op2 (x19 / panel
                              :ARG1-of (x18 / right-04))))))


# ::id PMC5341140.121
# ::snt Expression of EGFR and ErbB3 in the appropriate cell lines was confirmed by immunoblotting with antibodies specific for EGFR and ErbB3, respectively (Figure 4A , lower panels).
# ::tok Expression of EGFR and ErbB3 in the appropriate cell lines was confirmed by immunoblotting with antibodies specific for EGFR and ErbB3 , respectively ( Figure 4A , lower panels ) .
(x15 / and
      :op1 (x9 / confirm-01
            :ARG1 (x1 / express-03
                  :ARG2 (x4 / and
                        :op1 (x2 / enzyme
                              :name (x3 / name :op1 "EGFR")
                              :xref (x / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
                        :op2 (x5 / protein
                              :name (x6 / name :op1 "ErbB3")
                              :xref (x24 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634")))
                  :location (x8 / cell-line
                        :ARG1-of (x7 / appropriate-02)))
            :ARG0 (x10 / immunoblot-01
                  :ARG3 (x11 / antibody
                        :ARG1-of (x12 / specific-02
                              :ARG2 (x13 / enzyme
                                    :name (x14 / name :op1 "EGFR")
                                    :xref (x25 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))))))
      :op2 (x16 / protein
            :name (x17 / name :op1 "ErbB3")
            :xref (x26 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / and
                  :op1 (x20 / figure :mod "4a")
                  :op2 (x23 / panel
                        :ARG1-of (x21 / low-04
                              :degree (x22 / more))))))


# ::id PMC5341140.122
# ::snt The apparent decrease in EGFR expression in cells co-expressing EGFR and ErbB3 following EGF treatment was not observed in repetitions of this experiment, and is likely due to a stripping anomaly.
# ::tok The apparent decrease in EGFR expression in cells co @-@ expressing EGFR and ErbB3 following EGF treatment was not observed in repetitions of this experiment , and is likely due to a stripping anomaly .
(x17 / observe-01
      :ARG1 (x10 / and
            :op1 (x2 / decrease-01
                  :ARG1-of (x1 / appear-02)
                  :ARG1 (x5 / express-03
                        :ARG2 (x3 / enzyme
                              :name (x4 / name :op1 "EGFR")
                              :xref (x26 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004")))
                  :location (x6 / cell)
                  :ARG3-of (x7 / express-03
                        :ARG2 (x8 / enzyme
                              :name (x9 / name :op1 "EGFR")
                              :xref (x / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))))
            :op2 (x11 / protein
                  :name (x12 / name :op1 "ErbB3")
                  :xref (x27 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
            :ARG1-of (x13 / follow-01
                  :ARG2 (x16 / treat-04
                        :ARG2 (x14 / protein
                              :name (x15 / name :op1 "EGF")
                              :xref (x28 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :polarity "-"
      :location (x21 / and
            :op1 (x20 / experiment-01
                  :ARG1-of (x18 / repeat-01)
                  :mod (x19 / this))
            :op2 (x23 / cause-01
                  :ARG1-of (x22 / likely-01)
                  :ARG0 (x25 / anomaly
                        :name (x24 / name :op1 "stripping")))))


# ::id PMC5341140.123
# ::snt Additionally, we demonstrated that Gab1 -/- MEFs that express wild type Gab1 display Gab1 tyrosine phosphorylation in response to EGF treatment, while Gab1 -/- control cells or those expressing ErbB3 do not show Gab1 phosphorylation (Figure 4B , upper panel).
# ::tok Additionally , we demonstrated that Gab1 -/- MEFs that express wild type Gab1 display Gab1 tyrosine phosphorylation in response to EGF treatment , while Gab1 -/- control cells or those expressing ErbB3 do not show Gab1 phosphorylation ( Figure 4B , upper panel ) .
(x1 / and
      :op2 (x3 / demonstrate-01
            :ARG0 (x2 / we)
            :ARG1 (x23 / contrast-01
                  :ARG1 (x13 / display-01
                        :ARG0 (x9 / express-03
                              :ARG1 (x4 / cell
                                    :mod (x5 / protein
                                          :name (x6 / name :op1 "Gab1")
                                          :ARG2-of (x7 / mutate-01 :mod "-/-")
                                          :xref (x42 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                                    :name (x8 / name :op1 "mef"))
                              :ARG2 (x10 / protein
                                    :mod (x11 / wild-type)
                                    :name (x12 / name :op1 "Gab1")
                                    :xref (x45 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                        :ARG1 (x18 / phosphorylate-01
                              :ARG1 (x14 / protein
                                    :name (x15 / name :op1 "Gab1")
                                    :xref (x46 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                              :ARG2 (x16 / enzyme
                                    :name (x17 / name :op1 "tyrosine")
                                    :xref (x47 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
                              :ARG2-of (x19 / respond-01
                                    :ARG1 (x22 / treat-04
                                          :ARG2 (x20 / protein
                                                :name (x21 / name :op1 "EGF")
                                                :xref (x41 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))
                  :ARG2 (x33 / show-01
                        :ARG0 (x29 / or
                              :op1 (x28 / cell
                                    :mod (x24 / protein
                                          :name (x25 / name :op1 "Gab1")
                                          :ARG2-of (x26 / mutate-01 :mod "-/-")
                                          :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                                    :ARG0-of (x27 / control-01))
                              :op2 (x30 / express-03
                                    :ARG2 (x31 / protein
                                          :name (x32 / name :op1 "ErbB3")
                                          :xref (x43 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))))
                        :polarity "-"
                        :ARG1 (x36 / phosphorylate-01
                              :ARG1 (x34 / protein
                                    :name (x35 / name :op1 "Gab1")
                                    :xref (x44 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))
            :ARG1-of (x37 / describe-01
                  :ARG0 (x38 / figure
                        :mod "4b"
                        :location (x40 / panel
                              :mod (x39 / upper))))))


# ::id PMC5341140.124
# ::snt In order to test the ability of ErbB3 to rescue the EGF-induced activation of the PI-3 kinase/Akt signaling pathway in Gab1 -/- MEFs, we first assayed these cells for EGF-induced PI-3 kinase activity.
# ::tok In order to test the ability of ErbB3 to rescue the EGF @-@ induced activation of the PI @-@ 3 kinase @/@ Akt signaling pathway in Gab1 -/- MEFs , we first assayed these cells for EGF @-@ induced PI @-@ 3 kinase activity .
(x20 / assay-01
      :purpose (x1 / test-01
            :ARG1 (x2 / capable-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "ErbB3")
                        :xref (x29 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
                  :ARG2 (x5 / rescue-01
                        :ARG1 (x9 / activate-01
                              :ARG2-of (x8 / induce-01
                                    :ARG0 (x6 / protein
                                          :name (x7 / name :op1 "EGF")
                                          :xref (x30 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                              :ARG1 (x12 / signal-07
                                    :ARG0 (x10 / pathway
                                          :name (x11 / name :op1 "PI" :op2 "kinase"))))
                        :location (x13 / cell
                              :mod (x14 / protein
                                    :name (x15 / name :op1 "Gab1")
                                    :ARG2-of (x16 / mutate-01 :mod "-/-")
                                    :xref (x31 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                              :name (x17 / name :op1 "mef")))))
      :ARG0 (x18 / we)
      :ord (x19 / ordinal-entity :value "1")
      :ARG1 (x22 / cell
            :mod (x21 / this))
      :purpose (x28 / activity-06
            :ARG2-of (x25 / induce-01
                  :ARG0 (x23 / protein
                        :name (x24 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG0 (x27 / kinase
                  :name (x26 / name :op1 "PI-3"))))


# ::id PMC5341140.126
# ::snt Phosphotyrosine-associated PI-3 kinase activity was then assayed by analysis of PIP3 production.
# ::tok Phosphotyrosine @-@ associated PI @-@ 3 kinase activity was then assayed by analysis of PIP3 production .
(x9 / assay-01
      :ARG1 (x7 / activity-06
            :ARG0 (x6 / kinase
                  :ARG1-of (x4 / associate-01
                        :ARG2 (x1 / amino-acid
                              :name (x2 / name :op1 "threonine")
                              :ARG3-of (x3 / phosphorylate-01)
                              :xref (x / xref :value "PUBCHEM:205" :prob "11.848252")))
                  :name (x5 / name :op1 "PI-3")))
      :time (x8 / then)
      :ARG0 (x10 / analyze-01
            :ARG1 (x13 / produce-01
                  :ARG1 (x11 / protein
                        :name (x12 / name :op1 "PIP3")))))


# ::id PMC5341140.127
# ::snt As shown in Figure 4C , both cells expressing wild type Gab1 and ErbB3 show PI-3 kinase activity, while Gab1 -/- cells do not.
# ::tok As shown in Figure 4C , both cells expressing wild type Gab1 and ErbB3 show PI @-@ 3 kinase activity , while Gab1 -/- cells do not .
(x11 / show-01
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "4c"))
      :ARG0 (x3 / and
            :op1 (x4 / cell
                  :ARG3-of (x5 / express-03
                        :ARG2 (x6 / enzyme
                              :mod (x7 / wild-type)
                              :name (x8 / name :op1 "Gab1")
                              :xref (x20 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :op2 (x9 / protein
                  :name (x10 / name :op1 "ErbB3")
                  :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634")))
      :ARG1 (x14 / activity-06
            :ARG0 (x13 / kinase
                  :name (x12 / name :op1 "PI-3"))
            :ARG1-of (x15 / contrast-01
                  :ARG2 (x16 / protein
                        :name (x17 / name :op1 "Gab1")
                        :ARG2-of (x18 / mutate-01 :mod "-/-")
                        :xref (x19 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :polarity "-"))


# ::id PMC5341140.128
# ::snt Interestingly, EGF induces PI-3 kinase activity to a greater degree in cells expressing Gab1 relative to cells expressing ErbB3.
# ::tok Interestingly , EGF induces PI @-@ 3 kinase activity to a greater degree in cells expressing Gab1 relative to cells expressing ErbB3 .
(x3 / induce-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "EGF")
            :xref (x20 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :ARG1 (x6 / activity-06
            :ARG0 (x5 / kinase
                  :name (x4 / name :op1 "PI-3")))
      :degree (x9 / degree
            :mod (x7 / great
                  :degree (x8 / more)))
      :location (x10 / cell
            :ARG3-of (x11 / express-03
                  :ARG2 (x12 / protein
                        :name (x13 / name :op1 "Gab1")
                        :xref (x19 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
      :ARG2-of (x14 / relative-05
            :ARG3 (x15 / cell
                  :ARG3-of (x16 / express-03
                        :ARG2 (x17 / protein
                              :name (x18 / name :op1 "ErbB3")
                              :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))))))


# ::id PMC5341140.129
# ::snt In order to assay the effects of EGF stimulation on signaling downstream of PI-3 kinase, cells were treated with EGF over varying periods of time and assayed for the presence of Ser473-phosphorylated Akt.
# ::tok In order to assay the effects of EGF stimulation on signaling downstream of PI @-@ 3 kinase , cells were treated with EGF over varying periods of time and assayed for the presence of Ser473 @-@ phosphorylated Akt .
(x1 / and
      :purpose (x2 / assay-01
            :ARG1 (x3 / affect-01
                  :ARG0 (x6 / stimulate-01
                        :ARG1 (x4 / protein
                              :name (x5 / name :op1 "EGF")
                              :xref (x25 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x7 / signal-07
                        :mod (x8 / downstream)
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "PI-3" :op2 "kinase")))))
      :op1 (x12 / treat-04
            :ARG1 (x11 / cell)
            :ARG2 (x13 / protein
                  :name (x14 / name :op1 "EGF")
                  :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :duration (x16 / period
                  :ARG1-of (x15 / vary-01)
                  :consist-of (x17 / time)))
      :op2 (x18 / assay-01
            :ARG0 (x19 / present-02
                  :ARG1 (x20 / amino-acid
                        :mod "473"
                        :name (x21 / name :op1 "serine")
                        :xref (x27 / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :ARG1 (x22 / enzyme
                  :ARG3-of (x23 / phosphorylate-01)
                  :name (x24 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))


# ::id PMC5341140.130
# ::snt Treatment of cells expressing either wild type Gab1 or ErbB3 with EGF induced rapid activation of Akt, although cells expressing wild type Gab1 reproducibly displaed higher levels of phosphorylated Akt with significantly sustained kinetics relative to Gab1 -/- cells expressing ErbB3 (Figure 4D , left panels).
# ::tok Treatment of cells expressing either wild type Gab1 or ErbB3 with EGF induced rapid activation of Akt , although cells expressing wild type Gab1 reproducibly displaed higher levels of phosphorylated Akt with significantly sustained kinetics relative to Gab1 -/- cells expressing ErbB3 ( Figure 4D , left panels ) .
(x17 / have-concession-91
      :ARG1 (x12 / induce-01
            :ARG0 (x1 / treat-04
                  :ARG1 (x2 / cell
                        :ARG3-of (x3 / express-03
                              :ARG2 (x7 / or
                                    :op1 (x4 / enzyme
                                          :mod (x5 / wild-type)
                                          :name (x6 / name :op1 "Gab1")
                                          :xref (x47 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                                    :op2 (x8 / protein
                                          :name (x9 / name :op1 "ErbB3")
                                          :xref (x46 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634")))))
                  :ARG2 (x10 / protein
                        :name (x11 / name :op1 "EGF")
                        :xref (x50 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG2 (x14 / activate-01
                  :mod (x13 / rapid)
                  :ARG1 (x15 / enzyme
                        :name (x16 / name :op1 "Akt")
                        :xref (x51 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
      :ARG2 (x18 / cell
            :ARG3-of (x19 / express-03
                  :ARG2 (x20 / enzyme
                        :mod (x21 / wild-type)
                        :name (x22 / name :op1 "Gab1")
                        :xref (x45 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :mod (x23 / reproducibly)
            :ARG0-of (x26 / level
                  :ARG1-of (x24 / high-02
                        :degree (x25 / more))
                  :quant-of (x27 / enzyme
                        :ARG3-of (x28 / phosphorylate-01)
                        :name (x29 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :ARG0-of (x32 / kinetics
                  :ARG1-of (x30 / significant-02)
                  :ARG1-of (x31 / sustain-01))
            :ARG1-of (x33 / relative-05
                  :ARG3 (x37 / cell
                        :mod (x34 / protein
                              :name (x35 / name :op1 "Gab1")
                              :ARG2-of (x36 / mutate-01 :mod "-/-")
                              :xref (x48 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :ARG3-of (x38 / express-03
                              :ARG2 (x39 / protein
                                    :name (x40 / name :op1 "ErbB3")
                                    :xref (x49 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))))))
      :ARG1-of (x41 / describe-01
            :ARG0 (x42 / figure
                  :mod "4d"
                  :location (x44 / panel
                        :ARG1-of (x43 / left-20)))))


# ::id PMC5341140.131
# ::snt Equal loading and expression levels of Akt were confirmed by immunoblotting (Figure 4D , right panels).
# ::tok Equal loading and expression levels of Akt were confirmed by immunoblotting ( Figure 4D , right panels ) .
(x8 / confirm-01
      :ARG1 (x3 / and
            :op1 (x2 / load-01
                  :ARG1-of (x1 / equal-01))
            :op2 (x4 / level
                  :degree-of (x5 / express-03
                        :ARG2 (x6 / enzyme
                              :name (x7 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))
      :ARG0 (x9 / immunoblot-01)
      :ARG1-of (x10 / describe-01
            :ARG0 (x11 / figure
                  :mod "4d"
                  :location (x13 / panel
                        :ARG1-of (x12 / right-04)))))


# ::id PMC5341140.132
# ::snt Cells expressing ErbB3 displayed activation of Akt in response to treatment with NRG at levels similar to or greater than that seen in Gab1-expressing cells following EGF treatment, with activation reproducibly observed at longer time points (Figure 4E , left panels).
# ::tok Cells expressing ErbB3 displayed activation of Akt in response to treatment with NRG at levels similar to or greater than that seen in Gab1 @-@ expressing cells following EGF treatment , with activation reproducibly observed at longer time points ( Figure 4E , left panels ) .
(x1 / and
      :op1 (x6 / display-01
            :ARG0 (x2 / cell
                  :ARG3-of (x3 / express-03
                        :ARG2 (x4 / protein
                              :name (x5 / name :op1 "ErbB3")
                              :xref (x43 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))))
            :ARG1 (x14 / level
                  :ARG1-of (x7 / activate-01
                        :ARG1 (x8 / enzyme
                              :name (x9 / name :op1 "Akt")
                              :xref (x42 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                        :ARG2-of (x10 / respond-01
                              :ARG1 (x11 / treat-04
                                    :ARG2 (x12 / small-molecule
                                          :name (x13 / name :op1 "NRG")
                                          :xref (x45 / xref :value "PUBCHEM:440005" :prob "18.86067")))))
                  :ARG1-of (x15 / resemble-01
                        :ARG2 (x16 / or
                              :op1 (x17 / great
                                    :degree (x18 / more)
                                    :compared-to (x19 / thing
                                          :ARG1-of (x20 / see-01
                                                :location (x24 / cell
                                                      :ARG3-of (x23 / express-03
                                                            :ARG2 (x21 / protein
                                                                  :name (x22 / name :op1 "Gab1")
                                                                  :xref (x41 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))))))))
            :ARG1-of (x25 / follow-01
                  :ARG2 (x28 / treat-04
                        :ARG2 (x26 / protein
                              :name (x27 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :op2 (x32 / observe-01
            :ARG1 (x29 / activate-01
                  :ARG1 (x30 / enzyme
                        :name (x31 / name :op1 "reproducibly")
                        :xref (x44 / xref :value "UNIPROT:UBXN8_HUMAN" :prob "0.212")))
            :time (x36 / point
                  :ARG1-of (x33 / long-03
                        :degree (x34 / more))
                  :mod (x35 / time))
            :ARG1-of (x37 / describe-01
                  :ARG0 (x38 / figure
                        :mod "4e"
                        :location (x40 / panel
                              :ARG1-of (x39 / left-20))))))


# ::id PMC5341140.133
# ::snt Again, equal loading and expression levels of Akt were confirmed by immunoblotting (Figure 4E , right panels).
# ::tok Again , equal loading and expression levels of Akt were confirmed by immunoblotting ( Figure 4E , right panels ) .
(x9 / confirm-01
      :mod (x1 / again)
      :ARG0 (x4 / and
            :op1 (x3 / load-01
                  :ARG1-of (x2 / equal-01))
            :op2 (x5 / level
                  :degree-of (x6 / express-03
                        :ARG2 (x7 / enzyme
                              :name (x8 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))
      :ARG0 (x10 / immunoblot-01)
      :ARG1-of (x11 / describe-01
            :ARG0 (x12 / figure
                  :mod "4e"
                  :location (x14 / panel
                        :ARG1-of (x13 / right-04)))))


# ::id PMC5341140.134
# ::snt The phosphorylation of AKT in cells expressing Gab1, which shows modest enhancement following treatment with NRG, may be attributed to alternate signaling pathways including those mediated by ErbB2 and ErbB4.
# ::tok The phosphorylation of AKT in cells expressing Gab1 , which shows modest enhancement following treatment with NRG , may be attributed to alternate signaling pathways including those mediated by ErbB2 and ErbB4 .
(x1 / possible-01
      :ARG1 (x16 / attribute-01
            :ARG1 (x2 / phosphorylate-01
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "AKT")
                        :xref (x28 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :location (x5 / cell
                        :ARG3-of (x6 / express-03
                              :ARG2 (x7 / protein
                                    :name (x8 / name :op1 "Gab1")
                                    :ARG0-of (x9 / show-01
                                          :ARG1 (x11 / enhance-01
                                                :mod (x10 / modest)
                                                :ARG1-of (x12 / follow-01
                                                      :ARG2 (x13 / treat-04
                                                            :ARG2 (x14 / small-molecule
                                                                  :name (x15 / name :op1 "NRG")
                                                                  :xref (x30 / xref :value "PUBCHEM:440005" :prob "18.86067"))))))
                                    :xref (x29 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))
            :ARG2 (x19 / pathway
                  :ARG1-of (x17 / alternate-01)
                  :ARG0-of (x18 / signal-07)
                  :ARG2-of (x20 / include-01
                        :ARG1 (x21 / that))
                  :ARG1-of (x22 / mediate-01
                        :ARG0 (x25 / and
                              :op1 (x23 / protein
                                    :name (x24 / name :op1 "ErbB2")
                                    :xref (x / xref :value "UNIPROT:ERBB2_HUMAN" :prob "0.634"))
                              :op2 (x26 / protein
                                    :name (x27 / name :op1 "ErbB4")))))))


# ::id PMC5341140.135
# ::snt Involvement of these receptors was not explored in this study.
# ::tok Involvement of these receptors was not explored in this study .
(x4 / explore-01
      :ARG1 (x1 / involve-01
            :ARG1 (x3 / receptor
                  :mod (x2 / this)))
      :polarity "-"
      :location (x6 / study-01
            :mod (x5 / this)))


# ::id PMC5341140.136
# ::snt Taken together, these results demonstrate that ErbB3 can partially compensate for Gab1 deficiency in EGF-induced activation of the PI-3 kinase/Akt signaling pathway, although Gab1-mediated activation appears to be more robust, and likely represents the primary mechanism by which EGF stimulates PI-3 kinase and Akt.
# ::tok Taken together , these results demonstrate that ErbB3 can partially compensate for Gab1 deficiency in EGF @-@ induced activation of the PI @-@ 3 kinase @/@ Akt signaling pathway , although Gab1 @-@ mediated activation appears to be more robust , and likely represents the primary mechanism by which EGF stimulates PI @-@ 3 kinase and Akt .
(x1 / multi-sentence
      :snt1 (x7 / demonstrate-01
            :ARG0 (x5 / thing
                  :ARG1-of (x2 / take-01
                        :mod (x3 / together))
                  :mod (x4 / this)
                  :ARG2-of (x6 / result-01))
            :ARG1 (x8 / possible-01
                  :ARG1 (x18 / activate-01
                        :ARG0 (x9 / protein
                              :name (x10 / name :op1 "ErbB3")
                              :xref (x43 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
                        :ARG1-of (x12 / compensate-01
                              :degree (x11 / part)
                              :ARG1 (x13 / protein
                                    :name (x14 / name :op1 "Gab1")
                                    :xref (x45 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                              :ARG2 (x17 / induce-01
                                    :ARG0 (x15 / protein
                                          :name (x16 / name :op1 "EGF")
                                          :xref (x46 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
                        :ARG1 (x21 / pathway
                              :name (x19 / name :op1 "PI-3" :op2 "kinase/Akt")
                              :ARG0-of (x20 / signal-07))
                        :concession (x25 / activate-01
                              :ARG1-of (x24 / mediate-01
                                    :ARG0 (x22 / protein
                                          :name (x23 / name :op1 "Gab1")
                                          :xref (x42 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))))
      :snt2 (x26 / appear-02
            :ARG1 (x29 / and
                  :op1 (x28 / robust
                        :degree (x27 / more))
                  :op2 (x30 / likely-01
                        :ARG1 (x31 / represent-01
                              :ARG1 (x33 / mechanism
                                    :mod (x32 / primary)
                                    :instrument-of (x36 / stimulate-01
                                          :ARG0 (x34 / protein
                                                :name (x35 / name :op1 "EGF")
                                                :xref (x44 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                                          :ARG1 (x39 / and
                                                :op1 (x38 / kinase
                                                      :name (x37 / name :op1 "PI-3"))
                                                :op2 (x40 / enzyme
                                                      :name (x41 / name :op1 "Akt")
                                                      :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))))))))


# ::id PMC5341140.152
# ::snt Cell lines and culture
# ::tok Cell lines and culture
(x2 / and
      :op1 (x1 / cell-line)
      :op2 (x3 / culture))


# ::id PMC5341140.176
# ::snt PI-3 kinase assay
# ::tok PI @-@ 3 kinase assay
(x3 / assay-01
      :ARG1 (x2 / kinase
            :name (x1 / name :op1 "PI-3")))


# ::id PMC5341140.194
# ::snt Figures and Tables
# ::tok Figures and Tables
(x2 / and
      :op1 (x1 / figure)
      :op2 (x3 / table))


# ::id PMC5341140.195
# ::snt Expression of wild type Gab1 rescues EGF-induced PI-3 kinase and Akt activation in Gab1 deficient MEFs.
# ::tok Expression of wild type Gab1 rescues EGF @-@ induced PI @-@ 3 kinase and Akt activation in Gab1 deficient MEFs .
(x5 / rescue-01
      :ARG0 (x1 / express-03
            :ARG2 (x2 / enzyme
                  :mod (x3 / wild-type)
                  :name (x4 / name :op1 "Gab1")
                  :xref (x21 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
      :ARG1 (x14 / activate-01
            :ARG2-of (x8 / induce-01
                  :ARG0 (x6 / protein
                        :name (x7 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x11 / and
                  :op1 (x10 / kinase
                        :name (x9 / name :op1 "PI-3"))
                  :op2 (x12 / enzyme
                        :name (x13 / name :op1 "Akt")
                        :xref (x22 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
      :location (x17 / protein
            :mod (x15 / protein
                  :name (x16 / name :op1 "Gab1")
                  :xref (x20 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG2-of (x18 / mutate-01 :mod "-/-")
            :name (x19 / name :op1 "mef")
            :xref (x23 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))


# ::id PMC5341140.198
# ::snt Cell extracts were prepared and analyzed for Gab1 tyrosine phosphorylation and Gab1 expression.
# ::tok Cell extracts were prepared and analyzed for Gab1 tyrosine phosphorylation and Gab1 expression .
(x4 / and
      :op1 (x3 / prepare-02
            :ARG1 (x2 / extract-01
                  :ARG1 (x1 / cell)))
      :op2 (x5 / analyze-01
            :ARG1 (x10 / phosphorylate-01
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "Gab1")
                        :xref (x15 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG2 (x8 / enzyme
                        :name (x9 / name :op1 "tyrosine")
                        :xref (x / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))))
      :op2 (x13 / express-03
            :ARG2 (x11 / protein
                  :name (x12 / name :op1 "Gab1")
                  :xref (x14 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))


# ::id PMC5341140.199
# ::snt Both WT MEFs and cells expressing exogenous Gab1 show Gab1 tyrosine phosphorylation in response to EGF treatment.
# ::tok Both WT MEFs and cells expressing exogenous Gab1 show Gab1 tyrosine phosphorylation in response to EGF treatment .
(x1 / and
      :op1 (x2 / enzyme
            :mod (x3 / wild-type)
            :name (x4 / name :op1 "mef")
            :xref (x21 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
      :op2 (x10 / show-01
            :ARG0 (x5 / cell
                  :ARG3-of (x6 / express-03
                        :ARG2 (x7 / protein
                              :mod (x8 / exogenous)
                              :name (x9 / name :op1 "Gab1")
                              :xref (x22 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :ARG1 (x15 / phosphorylate-01
                  :ARG0 (x11 / protein
                        :name (x12 / name :op1 "Gab1")
                        :xref (x20 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG1 (x13 / amino-acid
                        :name (x14 / name :op1 "tyrosine")
                        :xref (x23 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2-of (x16 / respond-01
                        :ARG1 (x19 / treat-04
                              :ARG2 (x17 / protein
                                    :name (x18 / name :op1 "EGF")
                                    :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))))


# ::id PMC5341140.206
# ::snt Cell extracts were prepared and analyzed for activation of Akt by using antibodies that specifically recognize the serine473 phosphorylated form of Akt.
# ::tok Cell extracts were prepared and analyzed for activation of Akt by using antibodies that specifically recognize the serine473 phosphorylated form of Akt .
(x4 / and
      :op1 (x3 / prepare-02
            :ARG1 (x2 / extract-01
                  :ARG1 (x1 / cell)))
      :op2 (x5 / analyze-01
            :ARG1 (x6 / activate-01
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :manner (x9 / use-01
                  :ARG1 (x10 / antibody
                        :ARG0-of (x12 / recognize-02
                              :ARG1-of (x11 / specific-02)
                              :ARG1 (x13 / amino-acid
                                    :mod "473"
                                    :name (x14 / name :op1 "serine")
                                    :xref (x17 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                        :ARG1-of (x15 / phosphorylate-01)
                        :name (x16 / name :op1 "Akt")))))


# ::id PMC5341140.208
# ::snt Ectopic expression of Gab1 in Gab1 -/- MEFs rescues the EGF-induced activation of Akt.
# ::tok Ectopic expression of Gab1 in Gab1 -/- MEFs rescues the EGF @-@ induced activation of Akt .
(x10 / rescue-01
      :ARG0 (x2 / express-03
            :mod (x1 / ectopic)
            :ARG2 (x3 / protein
                  :name (x4 / name :op1 "Gab1")
                  :xref (x18 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG3 (x5 / cell
                  :mod (x6 / protein
                        :name (x7 / name :op1 "Gab1")
                        :ARG2-of (x8 / mutate-01 :mod "-/-")
                        :xref (x19 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :name (x9 / name :op1 "mef")))
      :ARG1 (x14 / activate-01
            :ARG2-of (x13 / induce-01
                  :ARG0 (x11 / protein
                        :name (x12 / name :op1 "EGF")
                        :xref (x17 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x15 / enzyme
                  :name (x16 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))


# ::id PMC5341140.209
# ::snt Expression of a Gab1 mutant protein deficient in p85 binding fails to rescue EGF-induced PI-3 kinase/Akt activation in Gab1 deficient MEFs.
# ::tok Expression of a Gab1 mutant protein deficient in p85 binding fails to rescue EGF @-@ induced PI @-@ 3 kinase @/@ Akt activation in Gab1 deficient MEFs .
(x10 / fail-01
      :ARG1 (x1 / express-03
            :ARG2 (x2 / enzyme
                  :name (x3 / name :op1 "Gab1")
                  :ARG2-of (x4 / mutate-01)
                  :xref (x23 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG1 (x5 / protein))
      :ARG0 (x6 / lack-01
            :ARG1 (x9 / bind-01
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "p85")
                        :xref (x24 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))))
      :ARG1 (x11 / rescue-01
            :ARG1 (x17 / activate-01
                  :ARG2-of (x14 / induce-01
                        :ARG0 (x12 / protein
                              :name (x13 / name :op1 "EGF")
                              :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x15 / protein
                        :name (x16 / name :op1 "PI-3"))
                  :location (x20 / protein
                        :mod (x18 / protein
                              :name (x19 / name :op1 "Gab1")
                              :xref (x25 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :ARG2-of (x21 / mutate-01 :mod "-/-")
                        :name (x22 / name :op1 "mef")
                        :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))))


# ::id PMC5341140.213
# ::snt Both Gab1 and Gab1 F446/472/589 are tyrosine phosphorylated in response to EGF treatment, and both form a stable complex with Shp2.
# ::tok Both Gab1 and Gab1 F446 @/@ 472 @/@ 589 are tyrosine phosphorylated in response to EGF treatment , and both form a stable complex with Shp2 .
(x19 / form-01
      :ARG0 (x18 / and
            :op1 (x1 / and
                  :op1 (x2 / protein
                        :name (x3 / name :op1 "Gab1")
                        :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :op2 (x4 / protein
                        :name (x5 / name :op1 "Gab1")
                        :xref (x25 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :op2 (x13 / phosphorylate-01
                  :ARG1 (x8 / slash
                        :op1 (x6 / enzyme
                              :name (x7 / name :op1 "F446"))
                        :op2 (x9 / enzyme
                              :name (x10 / name :op1 "472"))
                        :op2 "589")
                  :mod (x11 / amino-acid
                        :name (x12 / name :op1 "tyrosine")
                        :xref (x27 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2-of (x14 / respond-01
                        :ARG1 (x17 / treat-04
                              :ARG2 (x15 / protein
                                    :name (x16 / name :op1 "EGF")
                                    :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))
      :ARG1 (x21 / macro-molecular-complex
            :ARG1-of (x20 / stable-03))
      :ARG2 (x22 / enzyme
            :name (x23 / name :op1 "Shp2")
            :xref (x / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003")))


# ::id PMC5341140.214
# ::snt However, Gab1 F446/472/589 fails to associate with the p85 subunit of PI-3 kinase.
# ::tok However , Gab1 F446 @/@ 472 @/@ 589 fails to associate with the p85 subunit of PI @-@ 3 kinase .
(x1 / have-concession-91
      :ARG1 (x9 / fail-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "Gab1")
                  :xref (x16 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG1 (x6 / slash
                  :op1 (x4 / enzyme
                        :name (x5 / name :op1 "F446"))
                  :op2 (x7 / enzyme
                        :name (x8 / name :op1 "472"))
                  :op2 "589")
            :ARG2 (x10 / associate-01
                  :ARG2 (x13 / subunit
                        :mod (x11 / protein
                              :name (x12 / name :op1 "p85")
                              :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))
                        :part-of (x15 / kinase
                              :name (x14 / name :op1 "PI-3"))))))


# ::id PMC5341140.215
# ::snt Additionally total cell lysates from the indicated cell lines were immunoblotted with anti-Gab1 antibodies, providing independent evidence that Gab1 is expressed at approximately equal levels in all cell lines.
# ::tok Additionally total cell lysates from the indicated cell lines were immunoblotted with anti @-@ Gab1 antibodies , providing independent evidence that Gab1 is expressed at approximately equal levels in all cell lines .
(x1 / and
      :op1 (x7 / immunoblot-01
            :ARG1 (x4 / lysate
                  :mod (x2 / total)
                  :mod (x3 / cell)
                  :source (x6 / cell-line
                        :ARG1-of (x5 / indicate-01)))
            :ARG2 (x11 / antibody
                  :ARG0-of (x8 / counter-01
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :ARG0-of (x12 / provide-01
                  :ARG1 (x14 / evidence-01
                        :ARG0-of (x13 / depend-01 :polarity "-")
                        :ARG1 (x17 / express-03
                              :ARG1 (x15 / protein
                                    :name (x16 / name :op1 "Gab1")
                                    :xref (x23 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                              :degree (x20 / level
                                    :ARG1-of (x19 / equal-01
                                          :ARG0-of (x18 / approximate-01)))
                              :location (x22 / cell-line
                                    :mod (x21 / all)))))))


# ::id PMC5341140.218
# ::snt Cell extracts were prepared and analyzed for EGFR tyrosine phosphorylation.
# ::tok Cell extracts were prepared and analyzed for EGFR tyrosine phosphorylation .
(x4 / and
      :op1 (x3 / prepare-02
            :ARG1 (x2 / extract-01
                  :ARG1 (x1 / cell)))
      :op2 (x5 / analyze-01
            :ARG1 (x10 / phosphorylate-01
                  :ARG1 (x6 / amino-acid
                        :part-of (x7 / enzyme
                              :name (x8 / name :op1 "EGFR")
                              :xref (x / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
                        :name (x9 / name :op1 "tyrosine")
                        :xref (x11 / xref :value "PUBCHEM:1153" :prob "11.081481")))))


# ::id PMC5341140.219
# ::snt All of the cell lines examined show similar kinetics of EGF-induced EGFR activation.
# ::tok All of the cell lines examined show similar kinetics of EGF @-@ induced EGFR activation .
(x4 / show-01
      :ARG0 (x2 / cell-line
            :mod (x1 / all)
            :ARG1-of (x3 / examine-01))
      :ARG1 (x5 / kinetics
            :ARG1-of (x6 / resemble-01
                  :ARG2 (x12 / activate-01
                        :ARG2-of (x9 / induce-01
                              :ARG0 (x7 / protein
                                    :name (x8 / name :op1 "EGF")
                                    :xref (x13 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "EGFR")
                              :xref (x / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))))))


# ::id PMC5341140.220
# ::snt Immunoblots were quantitated by densitometry, normalized for EGFR expression and represented linearly.
# ::tok Immunoblots were quantitated by densitometry , normalized for EGFR expression and represented linearly .
(x1 / immunoblot-01
      :ARG0-of (x5 / normalize-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "quantitated"))
            :manner (x4 / densitometry)
            :ARG1 (x8 / express-03
                  :ARG2 (x6 / enzyme
                        :name (x7 / name :op1 "EGFR")
                        :xref (x / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))))
      :ARG0-of (x9 / represent-01
            :ARG1 (x10 / linear)))


# ::id PMC5341140.221
# ::snt Diamonds = Gab1 -/-, squares = Gab1, triangles = Gab1 F446/472/589 .
# ::tok Diamonds = Gab1 -/-, squares = Gab1 , triangles = Gab1 F446 @/@ 472 @/@ 589 .
(x1 / equal-01
      :ARG1 (x7 / square
            :ARG1-of (x2 / equal-01
                  :ARG1 (x3 / diamond)
                  :ARG2 (x4 / protein
                        :name (x5 / name :op1 "Gab1")
                        :xref (x16 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :name (x6 / name :op1 "-/-,"))
      :ARG2 (x10 / triangle
            :ARG1 (x8 / protein
                  :name (x9 / name :op1 "Gab1")
                  :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG2 (x11 / and
                  :op1 (x12 / amino-acid
                        :mod "446"
                        :name (x13 / name :op1 "phenylalanine"))
                  :op2 (x14 / enzyme
                        :name (x15 / name :op1 "472" :op2 "589")))))


# ::id PMC5341140.225
# ::snt Ectopic expression of wild type Gab1 restored EGF-induced PI-3 kinase activity, while expression of Gab1 F446/472/589 fails to rescue PI-3 kinase activity in response to EGF treatment.
# ::tok Ectopic expression of wild type Gab1 restored EGF @-@ induced PI @-@ 3 kinase activity , while expression of Gab1 F446 @/@ 472 @/@ 589 fails to rescue PI @-@ 3 kinase activity in response to EGF treatment .
(x13 / contrast-01
      :ARG1 (x6 / restore-01
            :ARG0 (x2 / express-03
                  :mod (x1 / ectopic)
                  :ARG2 (x3 / enzyme
                        :mod (x4 / wild-type)
                        :name (x5 / name :op1 "Gab1")
                        :xref (x30 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :ARG1 (x12 / activity-06
                  :ARG0 (x11 / kinase
                        :ARG1-of (x9 / induce-01
                              :ARG0 (x7 / protein
                                    :name (x8 / name :op1 "EGF")
                                    :xref (x31 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                        :name (x10 / name :op1 "PI-3"))))
      :ARG2 (x21 / fail-01
            :ARG1 (x14 / express-03
                  :ARG2 (x15 / protein
                        :name (x16 / name :op1 "Gab1")
                        :xref (x32 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG1 (x17 / amino-acid
                        :mod "446"
                        :name (x18 / name :op1 "phenylalanine"))
                  :ARG2 (x19 / enzyme
                        :name (x20 / name :op1 "472" :op2 "589")))
            :ARG2 (x22 / rescue-01
                  :ARG1 (x25 / activity-06
                        :ARG1 (x24 / kinase
                              :name (x23 / name :op1 "PI-3"))))
            :ARG2-of (x26 / respond-01
                  :ARG1 (x29 / treat-04
                        :ARG2 (x27 / protein
                              :name (x28 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))


# ::id PMC5341140.230
# ::snt Ectopic expression of Gab1 in Gab1 -/- MEFs rescues activation of Akt in response to EGF treatment, while expression of Gab1 F446/472/589 fails to rescue the EGF-induced Akt activation.
# ::tok Ectopic expression of Gab1 in Gab1 -/- MEFs rescues activation of Akt in response to EGF treatment , while expression of Gab1 F446 @/@ 472 @/@ 589 fails to rescue the EGF @-@ induced Akt activation .
(x18 / contrast-01
      :ARG1 (x10 / rescue-01
            :ARG0 (x2 / express-03
                  :mod (x1 / ectopic)
                  :ARG2 (x3 / protein
                        :name (x4 / name :op1 "Gab1")
                        :xref (x36 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG3 (x5 / cell
                        :mod (x6 / protein
                              :name (x7 / name :op1 "Gab1")
                              :ARG2-of (x8 / mutate-01 :mod "-/-")
                              :xref (x37 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :name (x9 / name :op1 "mef")))
            :ARG1 (x11 / activate-01
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "Akt")
                        :xref (x39 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                  :ARG2-of (x14 / respond-01
                        :ARG1 (x17 / treat-04
                              :ARG2 (x15 / protein
                                    :name (x16 / name :op1 "EGF")
                                    :xref (x40 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))
      :ARG2 (x27 / fail-01
            :ARG1 (x19 / express-03
                  :ARG2 (x20 / protein
                        :name (x21 / name :op1 "Gab1")
                        :xref (x35 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :ARG0 (x24 / slash
                  :op1 (x22 / enzyme
                        :name (x23 / name :op1 "F446"))
                  :op2 (x25 / enzyme
                        :name (x26 / name :op1 "472"))
                  :op2 "589")
            :ARG1 (x28 / rescue-01
                  :ARG1 (x34 / activate-01
                        :ARG2-of (x31 / induce-01
                              :ARG0 (x29 / protein
                                    :name (x30 / name :op1 "EGF")
                                    :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                        :ARG1 (x32 / enzyme
                              :name (x33 / name :op1 "Akt")
                              :xref (x38 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))))


# ::id PMC5341140.235
# ::snt Gab1 F627/659 becomes tyrosine phosphorylated in response to EGF treatment to levels approximately 1.5-fold higher than Gab1 as determined by densitometry, while Gab1 F446/472/589/627/659 does not show EGF-induced tyrosine phosphorylation in this assay.
# ::tok Gab1 F627 @/@ 659 becomes tyrosine phosphorylated in response to EGF treatment to levels approximately 1.5 @-@ fold higher than Gab1 as determined by densitometry , while Gab1 F446 @/@ 472 @/@ 589 @/@ 627 @/@ 659 does not show EGF @-@ induced tyrosine phosphorylation in this assay .
(x24 / contrast-01
      :ARG1 (x10 / phosphorylate-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "Gab1")
                  :xref (x41 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG1 (x5 / slash
                  :op1 (x3 / amino-acid
                        :mod "627"
                        :name (x4 / name :op1 "phenylalanine"))
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "659")))
            :ARG1 (x8 / enzyme
                  :name (x9 / name :op1 "tyrosine")
                  :xref (x40 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
            :ARG2-of (x11 / respond-01
                  :ARG1 (x14 / treat-04
                        :ARG2 (x12 / protein
                              :name (x13 / name :op1 "EGF")
                              :xref (x44 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
            :degree (x15 / level
                  :degree (x17 / product-of
                        :mod (x16 / approximate)
                        :op1 "1.5")
                  :ARG1-of (x18 / high-02
                        :degree (x19 / more)
                        :compared-to (x22 / determine-01
                              :mod (x20 / protein
                                    :name (x21 / name :op1 "Gab1")
                                    :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                              :ARG0 (x23 / densitometry)))))
      :ARG2 (x31 / show-01
            :ARG0 (x25 / and
                  :op2 (x26 / amino-acid
                        :mod "446"
                        :name (x27 / name :op1 "phenylalanine"))
                  :op1 (x29 / amino-acid
                        :name (x28 / name :op1 "472" :op2 "589")
                        :mod "627"
                        :mod (x30 / slash :op1 "202" :op2 "659")))
            :polarity "-"
            :ARG1 (x37 / phosphorylate-01
                  :ARG2-of (x34 / induce-01
                        :ARG0 (x32 / protein
                              :name (x33 / name :op1 "EGF")
                              :xref (x42 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x35 / enzyme
                        :name (x36 / name :op1 "tyrosine")
                        :xref (x43 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
                  :location (x39 / assay-01
                        :mod (x38 / this)))))


# ::id PMC5341140.236
# ::snt Wild type Gab1 forms a stable complex with Shp2 in response to EGF treatment, while Gab1 F627/659 and Gab1 F446/472/589/627/659 do not.
# ::tok Wild type Gab1 forms a stable complex with Shp2 in response to EGF treatment , while Gab1 F627 @/@ 659 and Gab1 F446 @/@ 472 @/@ 589 @/@ 627 @/@ 659 do not .
(x13 / contrast-01
      :ARG1 (x4 / form-01
            :ARG1 (x1 / enzyme
                  :mod (x2 / wild-type)
                  :name (x3 / name :op1 "Gab1")
                  :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG1 (x6 / macro-molecular-complex
                  :ARG1-of (x5 / stable-03)
                  :part (x7 / enzyme
                        :name (x8 / name :op1 "Shp2")
                        :xref (x28 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003")))
            :ARG2-of (x9 / respond-01
                  :ARG1 (x12 / treat-04
                        :ARG2 (x10 / protein
                              :name (x11 / name :op1 "EGF")
                              :xref (x30 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :ARG2 (x27 / possible-01
            :ARG0 (x14 / and
                  :op1 (x15 / amino-acid
                        :mod "627"
                        :name (x16 / name :op1 "phenylalanine"))
                  :op2 (x25 / amino-acid
                        :mod "659"
                        :mod (x22 / slash
                              :op1 (x17 / and
                                    :op2 (x18 / protein
                                          :name (x19 / name :op1 "Gab1")
                                          :xref (x29 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                                    :op3 (x20 / amino-acid
                                          :mod "446"
                                          :name (x21 / name :op1 "phenylalanine")))
                              :op2 (x23 / enzyme
                                    :name (x24 / name :op1 "472" :op2 "589")))
                        :mod "627"
                        :name (x26 / name :op1 "659")
                        :xref (x31 / xref :value "PUBCHEM:1183272" :prob "7.366475")))
            :polarity "-"))


# ::id PMC5341140.239
# ::snt Cell extracts were prepared and analyzed for EGFR tyrosine phosphorylation and EGFR expression.
# ::tok Cell extracts were prepared and analyzed for EGFR tyrosine phosphorylation and EGFR expression .
(x4 / and
      :op1 (x3 / prepare-02
            :ARG1 (x2 / extract-01
                  :ARG1 (x1 / cell)))
      :op2 (x5 / analyze-01
            :ARG1 (x10 / phosphorylate-01
                  :ARG1 (x6 / amino-acid
                        :part-of (x7 / enzyme
                              :name (x8 / name :op1 "EGFR")
                              :xref (x14 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
                        :name (x9 / name :op1 "tyrosine")
                        :xref (x15 / xref :value "PUBCHEM:1153" :prob "11.081481"))))
      :op2 (x13 / express-03
            :ARG2 (x11 / enzyme
                  :name (x12 / name :op1 "EGFR")
                  :xref (x / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))))


# ::id PMC5341140.241
# ::snt Immunoblots were quantitated by densitometry, normalized for EGFR expression, and represented linearly.
# ::tok Immunoblots were quantitated by densitometry , normalized for EGFR expression , and represented linearly .
(x10 / and
      :op1 (x1 / immunoblot-01
            :ARG1 (x4 / and
                  :op1 (x2 / enzyme
                        :name (x3 / name :op1 "quantitated"))
                  :op2 (x5 / densitometry)))
      :op2 (x6 / normalize-01
            :ARG1 (x9 / express-03
                  :ARG2 (x7 / enzyme
                        :name (x8 / name :op1 "EGFR")
                        :xref (x / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))))
      :op2 (x11 / represent-01
            :ARG1 (x12 / linear)))


# ::id PMC5341140.242
# ::snt Diamonds = Gab1 -/-, squares = Gab1, triangles = Gab1 F627/659 , circles = Gab1 F446/472/589/627/659 .
# ::tok Diamonds = Gab1 -/-, squares = Gab1 , triangles = Gab1 F627 @/@ 659 , circles = Gab1 F446 @/@ 472 @/@ 589 @/@ 627 @/@ 659 .
(x1 / equal-01
      :ARG1 (x7 / square
            :ARG1-of (x2 / equal-01
                  :ARG1 (x3 / diamond)
                  :ARG2 (x4 / protein
                        :name (x5 / name :op1 "Gab1")
                        :xref (x23 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :name (x6 / name :op1 "-/-,"))
      :ARG2 (x10 / triangle
            :ARG1 (x8 / protein
                  :name (x9 / name :op1 "Gab1")
                  :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG2 (x11 / and
                  :op1 (x12 / amino-acid
                        :mod "627"
                        :name (x13 / name :op1 "phenylalanine"))
                  :op2 (x21 / amino-acid
                        :mod "659"
                        :ARG1-of (x14 / equal-01
                              :ARG1 (x15 / circle)
                              :ARG2 (x16 / and
                                    :op1 (x17 / amino-acid
                                          :mod "446"
                                          :name (x18 / name :op1 "phenylalanine"))
                                    :op2 (x19 / enzyme
                                          :name (x20 / name :op1 "472" :op2 "589"))))
                        :mod "627"
                        :mod (x22 / slash :op1 "202" :op2 "659")))))


# ::id PMC5341140.246
# ::snt Cells expressing exogenous Gab1 F627/659 display enhanced PI-3 kinase activity relative to cells expressing wild type Gab1.
# ::tok Cells expressing exogenous Gab1 F627 @/@ 659 display enhanced PI @-@ 3 kinase activity relative to cells expressing wild type Gab1 .
(x8 / display-01
      :ARG0 (x1 / cell
            :ARG3-of (x2 / express-03
                  :ARG2 (x3 / protein
                        :mod (x4 / exogenous)
                        :name (x5 / name :op1 "Gab1")
                        :xref (x19 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
      :ARG2 (x6 / enzyme
            :name (x7 / name :op1 "F627" :op2 "659"))
      :ARG1 (x12 / activity-06
            :ARG1-of (x9 / enhance-01)
            :ARG0 (x11 / kinase
                  :name (x10 / name :op1 "PI-3")))
      :ARG1-of (x13 / relative-05
            :ARG3 (x14 / cell
                  :ARG3-of (x15 / express-03
                        :ARG2 (x16 / enzyme
                              :mod (x17 / wild-type)
                              :name (x18 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))))


# ::id PMC5341140.247
# ::snt Expression of exogenous Gab1 F446/472/589/627/659 fails to rescue EGF-induced PI-3 kinase activity in Gab1 deficient MEFs.
# ::tok Expression of exogenous Gab1 F446 @/@ 472 @/@ 589 @/@ 627 @/@ 659 fails to rescue EGF @-@ induced PI @-@ 3 kinase activity in Gab1 deficient MEFs .
(x10 / fail-01
      :ARG0 (x1 / express-03
            :ARG2 (x2 / protein
                  :mod (x3 / exogenous)
                  :name (x4 / name :op1 "Gab1")
                  :xref (x23 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
      :ARG1 (x7 / slash
            :op1 (x5 / enzyme
                  :name (x6 / name :op1 "F446"))
            :op2 (x9 / amino-acid
                  :name (x8 / name :op1 "472" :op2 "589")
                  :mod "627")
            :op2 "659")
      :ARG2 (x11 / rescue-01
            :ARG1 (x17 / activity-06
                  :ARG2-of (x14 / induce-01
                        :ARG0 (x12 / protein
                              :name (x13 / name :op1 "EGF")
                              :xref (x25 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x16 / kinase
                        :name (x15 / name :op1 "PI-3"))
                  :location (x20 / protein
                        :mod (x18 / protein
                              :name (x19 / name :op1 "Gab1")
                              :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :ARG2-of (x21 / mutate-01 :mod "-/-")
                        :name (x22 / name :op1 "mef")
                        :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))))


# ::id PMC5341140.252
# ::snt Cells expressing exogenous Gab1 F627/659 display enhanced activation of Akt with sustained kinetics relative to cells expressing wild type Gab1.
# ::tok Cells expressing exogenous Gab1 F627 @/@ 659 display enhanced activation of Akt with sustained kinetics relative to cells expressing wild type Gab1 .
(x9 / display-01
      :ARG0 (x1 / cell
            :ARG3-of (x2 / express-03
                  :ARG2 (x3 / protein
                        :mod (x4 / exogenous)
                        :name (x5 / name :op1 "Gab1")
                        :xref (x22 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
      :ARG2 (x6 / amino-acid
            :mod "627"
            :name (x7 / name :op1 "phenylalanine"))
      :mod (x8 / slash :op1 "202" :op2 "659")
      :ARG1 (x11 / activate-01
            :ARG1-of (x10 / enhance-01)
            :ARG1 (x12 / enzyme
                  :name (x13 / name :op1 "Akt")
                  :xref (x23 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
      :ARG2 (x15 / kinetics
            :ARG1-of (x14 / sustain-01))
      :ARG1-of (x16 / relative-05
            :ARG2 (x17 / cell
                  :ARG3-of (x18 / express-03
                        :ARG2 (x19 / enzyme
                              :mod (x20 / wild-type)
                              :name (x21 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))))


# ::id PMC5341140.253
# ::snt Expression of exogenous Gab1 F446/472/589/627/659 fails to rescue EGF-induced Akt activation in Gab1 deficient MEFs.
# ::tok Expression of exogenous Gab1 F446 @/@ 472 @/@ 589 @/@ 627 @/@ 659 fails to rescue EGF @-@ induced Akt activation in Gab1 deficient MEFs .
(x10 / fail-01
      :ARG0 (x1 / express-03
            :ARG2 (x2 / protein
                  :mod (x3 / exogenous)
                  :name (x4 / name :op1 "Gab1")
                  :xref (x23 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
      :ARG1 (x7 / slash
            :op1 (x5 / enzyme
                  :name (x6 / name :op1 "F446"))
            :op2 (x9 / amino-acid
                  :name (x8 / name :op1 "472" :op2 "589")
                  :mod "627")
            :op2 "659")
      :ARG2 (x11 / rescue-01
            :ARG1 (x17 / activate-01
                  :ARG2-of (x14 / induce-01
                        :ARG0 (x12 / protein
                              :name (x13 / name :op1 "EGF")
                              :xref (x25 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x15 / enzyme
                        :name (x16 / name :op1 "Akt")
                        :xref (x26 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                  :location (x20 / protein
                        :mod (x18 / protein
                              :name (x19 / name :op1 "Gab1")
                              :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :ARG2-of (x21 / mutate-01 :mod "-/-")
                        :name (x22 / name :op1 "mef")
                        :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))))


# ::id PMC5341140.257
# ::snt Cell extracts were analyzed for EGFR tyrosine phosphorylation and EGFR expression, and for ErbB3 tyrosine phosphorylation and ErbB3 expression.
# ::tok Cell extracts were analyzed for EGFR tyrosine phosphorylation and EGFR expression , and for ErbB3 tyrosine phosphorylation and ErbB3 expression .
(x3 / analyze-01
      :ARG1 (x2 / extract-01
            :ARG1 (x1 / cell))
      :purpose (x13 / and
            :op1 (x12 / express-03
                  :ARG2 (x9 / and
                        :op1 (x8 / phosphorylate-01
                              :ARG1 (x4 / amino-acid
                                    :part-of (x5 / enzyme
                                          :name (x6 / name :op1 "EGFR")
                                          :xref (x23 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
                                    :name (x7 / name :op1 "tyrosine")
                                    :xref (x26 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                        :op2 (x10 / enzyme
                              :name (x11 / name :op1 "EGFR")
                              :xref (x24 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))))
            :op2 (x22 / express-03
                  :ARG2 (x19 / and
                        :op1 (x18 / phosphorylate-01
                              :ARG1 (x14 / amino-acid
                                    :part-of (x15 / protein
                                          :name (x16 / name :op1 "ErbB3")
                                          :xref (x25 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
                                    :name (x17 / name :op1 "tyrosine")
                                    :xref (x27 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                        :op2 (x20 / protein
                              :name (x21 / name :op1 "ErbB3")
                              :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))))))


# ::id PMC5341140.258
# ::snt Cells were additionally stimulated with 10 ng/ml NRG and cell extracts analyzed for ErbB3 tyrosine phosphorylation.
# ::tok Cells were additionally stimulated with 10 ng @/@ ml NRG and cell extracts analyzed for ErbB3 tyrosine phosphorylation .
(x10 / analyze-01
      :ARG1 (x1 / cell)
      :manner (x2 / and
            :op1 (x3 / stimulate-01
                  :ARG2 (x4 / protein
                        :quant (x5 / concentration-quantity
                              :quant "10"
                              :unit (x6 / nanogram-per-milliliter))
                        :name (x7 / name :op1 "NRG")
                        :xref (x16 / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.263")))
            :op2 (x9 / extract-01
                  :ARG1 (x8 / cell)))
      :purpose (x15 / phosphorylate-01
            :ARG1 (x11 / amino-acid
                  :part-of (x12 / protein
                        :name (x13 / name :op1 "ErbB3")
                        :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
                  :name (x14 / name :op1 "tyrosine")
                  :xref (x17 / xref :value "PUBCHEM:1153" :prob "11.081481"))))


# ::id PMC5341140.259
# ::snt The endogenous EGFR is tyrosine phosphorylated in response to EGF in all cell lines.
# ::tok The endogenous EGFR is tyrosine phosphorylated in response to EGF in all cell lines .
(x6 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :mod (x2 / endogenous)
            :name (x3 / name :op1 "EGFR")
            :xref (x12 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "tyrosine")
            :xref (x13 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
      :ARG2-of (x7 / respond-01
            :ARG1 (x8 / protein
                  :name (x9 / name :op1 "EGF")
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :location (x11 / cell-line
            :mod (x10 / all)))


# ::id PMC5341140.260
# ::snt ErbB3 exhibits weak constitutive tyrosine phosphorylation that is enhanced by NRG treatment, but is not significantly enhanced by treatment with EGF.
# ::tok ErbB3 exhibits weak constitutive tyrosine phosphorylation that is enhanced by NRG treatment , but is not significantly enhanced by treatment with EGF .
(x13 / contrast-01
      :ARG1 (x3 / exhibit-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "ErbB3")
                  :xref (x19 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
            :ARG1 (x8 / phosphorylate-01
                  :ARG1-of (x4 / weak-02)
                  :mod (x5 / constitutive)
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "tyrosine")
                        :xref (x20 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
                  :ARG1-of (x9 / enhance-01
                        :ARG0 (x12 / treat-04
                              :ARG2 (x10 / protein
                                    :name (x11 / name :op1 "NRG")
                                    :xref (x / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.263"))))))
      :ARG2 (x15 / enhance-01
            :polarity "-"
            :ARG1-of (x14 / significant-02)
            :ARG0 (x16 / treat-04
                  :ARG2 (x17 / small-molecule
                        :name (x18 / name :op1 "EGF")
                        :xref (x21 / xref :value "PUBCHEM:56841751" :prob "18.167522")))))


# ::id PMC5341140.261
# ::snt Selected bands were quantitated by densitometry to determine relative increase in growth factor-induced tyrosine phosphorylation.
# ::tok Selected bands were quantitated by densitometry to determine relative increase in growth factor @-@ induced tyrosine phosphorylation .
(x7 / determine-01
      :ARG1 (x2 / band
            :ARG0-of (x1 / select-01))
      :ARG2 (x5 / and
            :op1 (x3 / enzyme
                  :name (x4 / name :op1 "quantitated"))
            :op2 (x6 / densitometry))
      :ARG1 (x9 / increase-01
            :ARG2-of (x8 / relative-05)
            :ARG1 (x14 / phosphorylate-01
                  :ARG2-of (x11 / induce-01
                        :ARG0 (x10 / growth-factor))
                  :ARG1 (x12 / amino-acid
                        :name (x13 / name :op1 "tyrosine")
                        :xref (x / xref :value "PUBCHEM:1153" :prob "11.081481")))))


# ::id PMC5341140.264
# ::snt Cell extracts were analyzed for Gab1 tyrosine phosphorylation and Gab1 expression.
# ::tok Cell extracts were analyzed for Gab1 tyrosine phosphorylation and Gab1 expression .
(x3 / analyze-01
      :ARG1 (x2 / extract-01
            :ARG1 (x1 / cell))
      :purpose (x12 / express-03
            :ARG2 (x9 / and
                  :op1 (x4 / enzyme
                        :name (x5 / name :op1 "Gab1")
                        :ARG2-of (x8 / phosphorylate-01
                              :ARG1 (x6 / enzyme
                                    :name (x7 / name :op1 "tyrosine")
                                    :xref (x13 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352")))
                        :xref (x14 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :op2 (x10 / protein
                        :name (x11 / name :op1 "Gab1")
                        :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))


# ::id PMC5341140.265
# ::snt Cells rescued with wild type Gab1 exhibit Gab1 tyrosine phosphorylation in response to EGF treatment, while Gab1 -/- cells and Gab1-deficient cells expressing ErbB3 do not.
# ::tok Cells rescued with wild type Gab1 exhibit Gab1 tyrosine phosphorylation in response to EGF treatment , while Gab1 -/- cells and Gab1 @-@ deficient cells expressing ErbB3 do not .
(x16 / contrast-01
      :ARG1 (x6 / exhibit-01
            :ARG0 (x1 / cell
                  :ARG1-of (x2 / rescue-01
                        :ARG0 (x3 / enzyme
                              :mod (x4 / wild-type)
                              :name (x5 / name :op1 "Gab1")
                              :xref (x31 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :ARG1 (x11 / phosphorylate-01
                  :ARG2 (x7 / protein
                        :name (x8 / name :op1 "Gab1")
                        :xref (x32 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG1 (x9 / amino-acid
                        :name (x10 / name :op1 "tyrosine")
                        :xref (x35 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2-of (x12 / respond-01
                        :ARG1 (x15 / treat-04
                              :ARG2 (x13 / protein
                                    :name (x14 / name :op1 "EGF")
                                    :xref (x33 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))
      :ARG2 (x29 / do-02
            :ARG1 (x21 / and
                  :op1 (x20 / cell
                        :mod (x17 / protein
                              :name (x18 / name :op1 "Gab1")
                              :ARG2-of (x19 / mutate-01 :mod "-/-")
                              :xref (x34 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :op2 (x24 / lack-01
                        :ARG1 (x22 / protein
                              :name (x23 / name :op1 "Gab1")
                              :xref (x30 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :ARG0 (x25 / cell
                  :ARG3-of (x26 / express-03
                        :ARG2 (x27 / protein
                              :name (x28 / name :op1 "ErbB3")
                              :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))))
            :polarity "-"))


# ::id PMC5341140.270
# ::snt Gab1 deficient MEFs exogenously expressing ErbB3 exhibit PI-3 kinase activity that is largely EGF-independent.
# ::tok Gab1 deficient MEFs exogenously expressing ErbB3 exhibit PI @-@ 3 kinase activity that is largely EGF @-@ independent .
(x8 / exhibit-01
      :ARG0 (x5 / express-03
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "Gab1")
                  :ARG2-of (x3 / mutate-01 :mod "-/-")
                  :xref (x16 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :mod (x4 / exogenous)
            :ARG2 (x6 / protein
                  :name (x7 / name :op1 "ErbB3")
                  :xref (x17 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634")))
      :ARG1 (x11 / activity-06
            :ARG0 (x10 / kinase
                  :name (x9 / name :op1 "PI-3"))
            :mod (x12 / large)
            :ARG0-of (x15 / depend-01
                  :ARG1 (x13 / protein
                        :name (x14 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :polarity "-")))


# ::id PMC5341140.272
# ::snt The indicated cell lines were serum-starved for 24 hours and stimulated with 1 ng/ml EGF for varying periods of time at 37°.
# ::tok The indicated cell lines were serum @-@ starved for 24 hours and stimulated with 1 ng @/@ ml EGF for varying periods of time at 37°.
(x1 / indicate-01
      :ARG0 (x7 / and
            :op1 (x2 / cell-line
                  :ARG1-of (x4 / starve-01
                        :ARG2 (x3 / serum))
                  :duration (x5 / temporal-quantity
                        :quant "24"
                        :unit (x6 / hour)))
            :op2 (x8 / stimulate-01
                  :ARG2 (x9 / protein
                        :quant (x10 / concentration-quantity
                              :quant "1"
                              :unit (x11 / nanogram-per-milliliter))
                        :name (x12 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :duration (x14 / period
                        :ARG1-of (x13 / vary-01)
                        :consist-of (x15 / time))))
      :ARG1 (x16 / enzyme
            :name (x17 / name :op1 "37°.")))


# ::id PMC5341140.277
# ::snt The indicated cell lines were serum-starved for 24 hours and stimulated with 1 ng/ml NRG for varying periods of time at 37°C.
# ::tok The indicated cell lines were serum @-@ starved for 24 hours and stimulated with 1 ng @/@ ml NRG for varying periods of time at 37 °C .
(x4 / starve-01
      :ARG1 (x2 / cell-line
            :ARG1-of (x1 / indicate-01))
      :ARG2 (x3 / serum)
      :duration (x5 / temporal-quantity
            :quant "24"
            :unit (x6 / hour))
      :time (x7 / and
            :op1 (x8 / stimulate-01
                  :ARG2 (x9 / small-molecule
                        :quant (x10 / concentration-quantity
                              :quant "1"
                              :unit (x11 / nanogram-per-milliliter))
                        :name (x12 / name :op1 "NRG")
                        :xref (x / xref :value "PUBCHEM:440005" :prob "18.86067"))))
      :duration (x14 / period
            :ARG1-of (x13 / vary-01)
            :consist-of (x15 / time))
      :mod (x16 / temperature-quantity
            :quant "37"
            :scale (x17 / celsius)))


# ::id PMC5341140.280
# ::snt Treatment of Gab1-deficient cells exogenously expressing ErbB3 with NRG results in a robust and sustained activation of Akt, while cells expressing exogenous Gab1 do not exhibit Akt activation in response to NRG treatment.
# ::tok Treatment of Gab1 @-@ deficient cells exogenously expressing ErbB3 with NRG results in a robust and sustained activation of Akt , while cells expressing exogenous Gab1 do not exhibit Akt activation in response to NRG treatment .
(x12 / result-01
      :ARG1 (x1 / treat-04
            :ARG1 (x5 / cell
                  :ARG0-of (x4 / lack-01
                        :ARG1 (x2 / protein
                              :name (x3 / name :op1 "Gab1")
                              :xref (x35 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :name (x6 / name :op1 "exogenously")
                  :ARG3-of (x7 / express-03
                        :ARG2 (x8 / protein
                              :name (x9 / name :op1 "ErbB3")
                              :xref (x34 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))))
            :ARG2 (x10 / protein
                  :name (x11 / name :op1 "NRG")
                  :xref (x36 / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.263")))
      :ARG2 (x18 / contrast-01
            :ARG1 (x15 / activate-01
                  :mod (x13 / robust)
                  :ARG1-of (x14 / sustain-01)
                  :ARG1 (x16 / enzyme
                        :name (x17 / name :op1 "Akt")
                        :xref (x37 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :ARG2 (x24 / exhibit-01
                  :ARG0 (x19 / cell
                        :ARG3-of (x20 / express-03
                              :ARG2 (x21 / protein
                                    :mod (x22 / exogenous)
                                    :name (x23 / name :op1 "Gab1")
                                    :xref (x33 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
                  :polarity "-"
                  :ARG1 (x27 / activate-01
                        :ARG0 (x25 / enzyme
                              :name (x26 / name :op1 "Akt")
                              :xref (x32 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                        :ARG2-of (x28 / respond-01
                              :ARG1 (x31 / treat-04
                                    :ARG2 (x29 / protein
                                          :name (x30 / name :op1 "NRG")
                                          :xref (x / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.263"))))))))


# ::id PMC2841635.0
# ::snt Ack1 Mediated AKT/PKB Tyrosine 176 Phosphorylation Regulates Its Activation
# ::tok Ack1 Mediated AKT @/@ PKB Tyrosine 176 Phosphorylation Regulates Its Activation
(x3 / mediate-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "Ack1")
            :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
      :ARG1 (x9 / regulate-01
            :ARG0 (x4 / enzyme
                  :name (x5 / name :op1 "AKT/PKB")
                  :ARG1-of (x8 / phosphorylate-01
                        :ARG1 (x6 / amino-acid
                              :mod "176"
                              :name (x7 / name :op1 "tyrosine")
                              :xref (x11 / xref :value "PUBCHEM:1153" :prob "11.081481"))))
            :ARG1 (x10 / activate-01)))


# ::id PMC2841635.2
# ::snt The AKT/PKB kinase is a key signaling component of one of the most frequently activated pathways in cancer and is a major target of cancer drug development.
# ::tok The AKT @/@ PKB kinase is a key signaling component of one of the most frequently activated pathways in cancer and is a major target of cancer drug development .
(x13 / and
      :op1 (x5 / component
            :domain (x2 / kinase
                  :name (x1 / name :op1 "AKT/PKB"))
            :ARG1-of (x3 / key-02)
            :ARG0-of (x4 / signal-07)
            :ARG1-of (x6 / include-91
                  :ARG2 (x9 / activate-01
                        :ARG1-of (x8 / frequent-02
                              :degree (x7 / most))
                        :ARG1 (x10 / pathway)
                        :location (x11 / disease
                              :wiki "cancer"
                              :name (x12 / name :op1 "cancer")))))
      :op2 (x15 / target-01
            :ARG1-of (x14 / major-02)
            :ARG1 (x19 / develop-02
                  :ARG1 (x18 / drug
                        :mod (x16 / disease
                              :wiki "cancer"
                              :name (x17 / name :op1 "cancer"))))))


# ::id PMC2841635.3
# ::snt Most studies have focused on its activation by Receptor Tyrosine Kinase (RTK) mediated Phosphatidylinositol-3-OH kinase (PI3K) activation or loss of Phosphatase and Tensin homolog (PTEN).
# ::tok Most studies have focused on its activation by Receptor Tyrosine Kinase ( RTK ) mediated Phosphatidylinositol @-@ 3 @-@ OH kinase ( PI3K ) activation or loss of Phosphatase and Tensin homolog ( PTEN ) .
(x1 / and
      :op1 (x4 / focus-01
            :ARG0 (x3 / study-01
                  :degree (x2 / most))
            :ARG1 (x5 / activate-01
                  :ARG0 (x6 / enzyme
                        :name (x7 / name
                              :op1 "receptor"
                              :op2 "tyrosine"
                              :op3 "kinase"))
                  :ARG1-of (x10 / mediate-01
                        :ARG0 (x8 / enzyme
                              :name (x9 / name :op1 "RTK")
                              :xref (x25 / xref :value "UNIPROT:DDR1_HUMAN" :prob "0.262"))
                        :ARG1 (x11 / protein
                              :name (x12 / name :op1 "Phosphatidylinositol-3")))))
      :op2 (x14 / kinase
            :mod (x13 / oh :mode "expressive"))
      :ARG1-of (x17 / activate-01
            :ARG0 (x15 / enzyme
                  :name (x16 / name :op1 "PI3K")
                  :xref (x26 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
            :ARG1 (x18 / or
                  :op1 (x19 / lose-02
                        :ARG1 (x20 / protein
                              :name (x21 / name
                                    :op1 "Phosphatase"
                                    :op2 "and"
                                    :op3 "Tensin"
                                    :op4 "homolog")
                              :ARG1-of (x22 / mean-01
                                    :ARG2 (x23 / protein
                                          :name (x24 / name :op1 "PTEN")
                                          :xref (x / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004"))))))))


# ::id PMC2841635.4
# ::snt We have uncovered that growth factors binding to RTKs lead to activation of a non-receptor tyrosine kinase, Ack1 (also known as ACK or TNK2), which directly phosphorylates AKT at an evolutionarily conserved tyrosine 176 in the kinase domain.
# ::tok We have uncovered that growth factors binding to RTKs lead to activation of a non @-@ receptor tyrosine kinase , Ack1 ( also known as ACK or TNK2 ) , which directly phosphorylates AKT at an evolutionarily conserved tyrosine 176 in the kinase domain .
(x2 / uncover-01
      :ARG0 (x1 / we)
      :ARG1 (x7 / lead-03
            :ARG1 (x3 / growth-factor)
            :ARG1-of (x4 / bind-01
                  :ARG2 (x5 / enzyme
                        :name (x6 / name :op1 "rtk")
                        :xref (x33 / xref :value "UNIPROT:DDR1_HUMAN" :prob "0.202")))
            :ARG2 (x8 / activate-01
                  :ARG1 (x18 / or
                        :op1 (x9 / and
                              :polarity "-"
                              :op1 (x10 / enzyme
                                    :name (x11 / name
                                          :op1 "receptor"
                                          :op2 "tyrosine"
                                          :op3 "kinase"))
                              :op2 (x12 / enzyme
                                    :name (x13 / name :op1 "Ack1")
                                    :xref (x34 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                              :ARG1-of (x15 / know-02
                                    :mod (x14 / also)
                                    :ARG2 (x16 / protein
                                          :name (x17 / name :op1 "ACK"))))
                        :op1 (x19 / protein
                              :name (x20 / name :op1 "TNK2"))))
            :ARG0-of (x22 / phosphorylate-01
                  :ARG1-of (x21 / direct-02)
                  :ARG1 (x23 / enzyme
                        :name (x24 / name :op1 "AKT")
                        :xref (x32 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :ARG2 (x27 / conserve-01
                        :ARG1 (x25 / enzyme
                              :name (x26 / name :op1 "evolutionarily")
                              :xref (x / xref :value "UNIPROT:GPTC1_HUMAN" :prob "0.202")))
                  :ARG1 (x28 / amino-acid
                        :mod "176"
                        :name (x29 / name :op1 "tyrosine")
                        :xref (x35 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :part-of (x30 / enzyme
                        :name (x31 / name :op1 "kinase" :op2 "domain")))))


# ::id PMC2841635.5
# ::snt Tyr176-phosphorylated AKT localizes to the plasma membrane and promotes Thr308/Ser473-phosphorylation leading to AKT activation.
# ::tok Tyr176 @-@ phosphorylated AKT localizes to the plasma membrane and promotes Thr308 @/@ Ser473 @-@ phosphorylation leading to AKT activation .
(x6 / localize-01
      :ARG1 (x3 / phosphorylate-01
            :ARG1 (x1 / amino-acid
                  :mod "176"
                  :name (x2 / name :op1 "tyrosine")
                  :xref (x23 / xref :value "PUBCHEM:1153" :prob "11.081481")))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "AKT")
            :xref (x21 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
      :location (x9 / and
            :op1 (x8 / membrane
                  :mod (x7 / plasma)
                  :xref (x22 / xref :value "GO:0016020" :prob "0.8"))
            :op2 (x10 / promote-01
                  :ARG1 (x16 / phosphorylate-01
                        :ARG1 (x11 / and
                              :op1 (x12 / amino-acid
                                    :mod "308"
                                    :name (x13 / name :op1 "threonine")
                                    :xref (x24 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x14 / amino-acid
                                    :mod "473"
                                    :name (x15 / name :op1 "serine")
                                    :xref (x25 / xref :value "PUBCHEM:5951" :prob "11.218784"))))))
      :ARG0-of (x17 / lead-03
            :ARG2 (x20 / activate-01
                  :ARG1 (x18 / enzyme
                        :name (x19 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))


# ::id PMC2841635.6
# ::snt Mice expressing activated Ack1 specifically in the prostate exhibit AKT Tyr176-phosphorylation and develop murine prostatic intraepithelial neoplasia (mPINs).
# ::tok Mice expressing activated Ack1 specifically in the prostate exhibit AKT Tyr176 @-@ phosphorylation and develop murine prostatic intraepithelial neoplasia ( mPINs ) .
(x8 / exhibit-01
      :ARG0 (x6 / specific-02
            :mod (x1 / mouse
                  :ARG3-of (x2 / express-03
                        :ARG2 (x3 / enzyme
                              :ARG1-of (x4 / activate-01)
                              :name (x5 / name :op1 "Ack1")
                              :xref (x22 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))))
            :location (x7 / prostate))
      :ARG1 (x14 / and
            :op1 (x9 / enzyme
                  :name (x10 / name :op1 "AKT")
                  :ARG1-of (x13 / phosphorylate-01
                        :ARG1 (x11 / amino-acid
                              :mod "176"
                              :name (x12 / name :op1 "tyrosine")
                              :xref (x23 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :op2 (x15 / develop-02
                  :ARG1 (x20 / neoplasia
                        :mod (x16 / organism
                              :name (x17 / name :op1 "muridae"))
                        :mod (x18 / enzyme
                              :name (x19 / name :op1 "prostatic" :op2 "intraepithelial"))
                        :name (x21 / name :op1 "mPINs")))))


# ::id PMC2841635.7
# ::snt Further, expression levels of Tyr176-phosphorylated-AKT and Tyr284-phosphorylated-Ack1 were positively correlated with the severity of disease progression, and inversely correlated with the survival of breast cancer patients.
# ::tok Further , expression levels of Tyr176 @-@ phosphorylated @-@ AKT and Tyr284 @-@ phosphorylated @-@ Ack1 were positively correlated with the severity of disease progression , and inversely correlated with the survival of breast cancer patients .
(x16 / correlate-01
      :mod (x1 / further)
      :ARG1 (x9 / and
            :op1 (x2 / level
                  :degree-of (x3 / express-03
                        :ARG2 (x4 / enzyme
                              :ARG3-of (x7 / phosphorylate-01
                                    :ARG1 (x5 / amino-acid
                                          :mod "176"
                                          :name (x6 / name :op1 "tyrosine")
                                          :xref (x28 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                              :name (x8 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
            :op2 (x12 / phosphorylate-01
                  :ARG1 (x10 / amino-acid
                        :mod "284"
                        :name (x11 / name :op1 "tyrosine")
                        :xref (x29 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2 (x13 / enzyme
                        :name (x14 / name :op1 "Ack1")
                        :xref (x27 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))))
      :manner (x15 / positive)
      :ARG2 (x17 / severity
            :ARG1 (x20 / and
                  :op1 (x19 / progress-01
                        :ARG1 (x18 / disease))
                  :op2 (x22 / correlate-01
                        :manner (x21 / inverse)
                        :ARG2 (x23 / survive-01
                              :ARG1 (x24 / disease
                                    :wiki "breast_cancer"
                                    :name (x25 / name :op1 "breast" :op2 "cancer")))))
            :ARG2 (x26 / patient)))


# ::id PMC2841635.8
# ::snt Thus, RTK/Ack1/AKT pathway provides a novel target for drug discovery.
# ::tok Thus , RTK/Ack1/AKT pathway provides a novel target for drug discovery .
(x1 / cause-01
      :ARG1 (x4 / provide-01
            :ARG0 (x2 / pathway
                  :name (x3 / name :op1 "RTK/Ack1/AKT"))
            :ARG1 (x6 / target-01
                  :mod (x5 / novel))
            :ARG2 (x8 / discover-01
                  :ARG1 (x7 / drug))))


# ::id PMC2841635.28
# ::snt Ack1 Phosphorylates AKT at Evolutionary Conserved Tyr176 Resulting in AKT Activation
# ::tok Ack1 Phosphorylates AKT at Evolutionary Conserved Tyr176 Resulting in AKT Activation
(x3 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "Ack1")
            :xref (x15 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "AKT")
            :xref (x16 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
      :time (x8 / conserve-01
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "Evolutionary")))
      :ARG1 (x9 / amino-acid
            :mod "176"
            :name (x10 / name :op1 "tyrosine")
            :xref (x17 / xref :value "PUBCHEM:1153" :prob "11.081481"))
      :ARG1-of (x11 / result-01
            :ARG2 (x14 / activate-01
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))


# ::id PMC2841635.29
# ::snt We observed that EGF treatment of mouse embryonic fibroblasts (MEFs) resulted in rapid Tyr-phosphorylation of Ack1 as well as Akt1 at 5 and 10 mins respectively, suggesting that these two Tyr-phosphorylation events could be linked ( Fig. 1A ).
# ::tok We observed that EGF treatment of mouse embryonic fibroblasts ( MEFs ) resulted in rapid Tyr @-@ phosphorylation of Ack1 as well as Akt1 at 5 and 10 mins respectively , suggesting that these two Tyr @-@ phosphorylation events could be linked ( Fig . 1A ) .
(x2 / observe-01
      :ARG0 (x1 / we)
      :ARG1 (x12 / result-01
            :ARG1 (x5 / treat-04
                  :ARG0 (x3 / protein
                        :name (x4 / name :op1 "EGF")
                        :xref (x36 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :ARG1 (x8 / fibroblast
                        :part-of (x7 / embryo
                              :mod (x6 / mouse)))
                  :ARG1-of (x9 / describe-01
                        :ARG0 (x10 / cell
                              :name (x11 / name :op1 "mef"))))
            :ARG2 (x16 / phosphorylate-01
                  :mod (x13 / rapid)
                  :ARG1 (x14 / amino-acid
                        :name (x15 / name :op1 "tyrosine")
                        :xref (x39 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG1 (x19 / and
                        :op1 (x17 / enzyme
                              :name (x18 / name :op1 "Ack1")
                              :xref (x37 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                        :op2 (x20 / gene
                              :name (x21 / name :op1 "Akt1")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.604")))
                  :location (x22 / temporal-quantity
                        :quant (x23 / and :op1 "5" :op2 "10")
                        :unit (x24 / minute))))
      :mod (x25 / respective)
      :ARG0-of (x26 / suggest-01
            :ARG1 (x27 / possible-01
                  :ARG1 (x33 / link-01
                        :ARG1 (x32 / event
                              :mod (x28 / this)
                              :quant "2"
                              :ARG0-of (x31 / phosphorylate-01
                                    :ARG1 (x29 / amino-acid
                                          :name (x30 / name :op1 "tyrosine")
                                          :xref (x38 / xref :value "PUBCHEM:1153" :prob "11.081481")))))))
      :ARG1-of (x34 / describe-01
            :ARG0 (x35 / figure :mod "1a")))


# ::id PMC2841635.30
# ::snt To test this hypothesis, we examined whether Ack1 could bind and Tyr-phosphorylate AKT following RTK activation.
# ::tok To test this hypothesis , we examined whether Ack1 could bind and Tyr @-@ phosphorylate AKT following RTK activation .
(x6 / examine-01
      :purpose (x1 / test-01
            :ARG1 (x3 / thing
                  :mod (x2 / this)
                  :ARG1-of (x4 / hypothesize-01)))
      :ARG0 (x5 / we)
      :ARG1 (x7 / possible-01
            :mode "interrogative"
            :ARG1 (x10 / bind-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "Ack1")
                        :xref (x22 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                  :ARG2 (x11 / and
                        :op1 (x12 / amino-acid
                              :name (x13 / name :op1 "tyrosine")
                              :xref (x23 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :op2 (x14 / phosphorylate-01
                              :ARG1 (x15 / enzyme
                                    :name (x16 / name :op1 "AKT")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                              :ARG1-of (x17 / follow-01
                                    :ARG2 (x20 / activate-01
                                          :ARG1 (x18 / enzyme
                                                :name (x19 / name :op1 "RTK")
                                                :xref (x21 / xref :value "UNIPROT:DDR1_HUMAN" :prob "0.262")))))))))


# ::id PMC2841635.31
# ::snt Co-immunoprecipitation of lysates derived from Akt1, Akt2, and Akt1& 2 knockout mouse embryo fibroblasts (MEF1KO, MEF2KO, and MEF1&2KO, respectively, Fig. S1A ) that were treated with EGF, either with or without pretreatment with LY294002, a PI3K inhibitor, revealed that endogenous Akt1 (AKT here onwards) and Ack1 formed a stable complex which was not abrogated by LY294002 ( Fig. 1B ).
# ::tok Co @-@ immunoprecipitation of lysates derived from Akt1 , Akt2 , and Akt1& 2 knockout mouse embryo fibroblasts ( MEF1KO , MEF2KO , and MEF1&2KO , respectively , Fig . S1A ) that were treated with EGF , either with or without pretreatment with LY294002 , a PI3K inhibitor , revealed that endogenous Akt1 ( AKT here onwards ) and Ack1 formed a stable complex which was not abrogated by LY294002 ( Fig . 1B ) .
(x1 / multi-sentence
      :snt1 (x16 / fibroblast
            :ARG1 (x2 / cotransfect-01
                  :ARG2 (x3 / immunoprecipitate-01
                        :ARG1 (x4 / lysate
                              :ARG1-of (x5 / derive-01
                                    :ARG2 (x10 / and
                                          :op1 (x6 / gene
                                                :name (x7 / name :op1 "Akt1")
                                                :xref (x63 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.604"))
                                          :op2 (x8 / gene
                                                :name (x9 / name :op1 "Akt2")
                                                :xref (x62 / xref :value "UNIPROT:AKT2_HUMAN" :prob "0.604"))
                                          :op2 (x11 / enzyme
                                                :name (x12 / name :op1 "Akt1&")
                                                :xref (x66 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.593")))))))
            :quant "2"
            :ARG1-of (x13 / knock-out-03)
            :part-of (x15 / embryo
                  :mod (x14 / mouse))
            :ARG1-of (x17 / describe-01
                  :ARG0 (x22 / and
                        :op1 (x18 / enzyme
                              :name (x19 / name :op1 "MEF1KO")
                              :xref (x65 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.212"))
                        :op2 (x20 / protein
                              :name (x21 / name :op1 "MEF2KO")
                              :xref (x60 / xref :value "UNIPROT:MEF2A_HUMAN" :prob "0.282"))
                        :op2 (x23 / enzyme
                              :name (x24 / name :op1 "MEF1&2KO")
                              :xref (x61 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.202"))))
            :ARG1-of (x25 / describe-01
                  :ARG0 (x26 / figure :mod "s1a")))
      :snt2 (x28 / treat-04
            :ARG1 (x27 / that)
            :ARG2 (x31 / or
                  :op1 (x29 / protein
                        :name (x30 / name :op1 "EGF")
                        :xref (x59 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :op2 (x32 / or
                        :op2 (x33 / pretreat-01
                              :ARG3 (x34 / small-molecule
                                    :name (x35 / name :op1 "LY294002")
                                    :ARG0-of (x38 / inhibit-01
                                          :ARG1 (x36 / enzyme
                                                :name (x37 / name :op1 "PI3K")
                                                :xref (x64 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                                    :xref (x68 / xref :value "PUBCHEM:3973" :prob "18.86067")))
                        :ARG0-of (x39 / reveal-01
                              :ARG1 (x40 / enzyme
                                    :mod (x41 / endogenous)
                                    :name (x42 / name :op1 "Akt1")
                                    :xref (x58 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.604"))
                              :ARG1-of (x49 / form-01
                                    :ARG0 (x43 / enzyme
                                          :name (x44 / name :op1 "AKT")
                                          :xref (x57 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                                    :location (x46 / and
                                          :op1 (x45 / onwards)
                                          :op2 (x47 / enzyme
                                                :name (x48 / name :op1 "Ack1")
                                                :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
                                    :ARG1 (x51 / macro-molecular-complex
                                          :ARG1-of (x50 / stable-03)))
                              :ARG1-of (x52 / abrogate-01
                                    :polarity "-"
                                    :ARG2 (x53 / small-molecule
                                          :name (x54 / name :op1 "LY294002")
                                          :xref (x67 / xref :value "PUBCHEM:3973" :prob "18.86067"))))
                        :ARG1-of (x55 / describe-01
                              :ARG0 (x56 / figure :mod "1b"))))))


# ::id PMC2841635.32
# ::snt The bottom panel shows that upon LY294002 addition there was substantial decrease in AKT Ser473-phosphorylation, suggesting that LY294002 is functional.
# ::tok The bottom panel shows that upon LY294002 addition there was substantial decrease in AKT Ser473 @-@ phosphorylation , suggesting that LY294002 is functional .
(x3 / show-01
      :ARG0 (x2 / panel
            :mod (x1 / bottom))
      :ARG1 (x6 / and
            :op1 (x4 / small-molecule
                  :name (x5 / name :op1 "LY294002")
                  :xref (x20 / xref :value "PUBCHEM:3973" :prob "18.86067"))
            :op2 (x8 / decrease-01
                  :degree (x7 / substantial)
                  :ARG1 (x13 / phosphorylate-01
                        :ARG1 (x9 / amino-acid
                              :part-of (x10 / enzyme
                                    :name (x11 / name :op1 "AKT")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                              :mod "473"
                              :name (x12 / name :op1 "serine")
                              :xref (x19 / xref :value "PUBCHEM:5951" :prob "11.218784")))))
      :ARG0-of (x14 / suggest-01
            :ARG1 (x17 / function-01
                  :ARG0 (x15 / small-molecule
                        :name (x16 / name :op1 "LY294002")
                        :xref (x18 / xref :value "PUBCHEM:3973" :prob "18.86067")))))


# ::id PMC2841635.33
# ::snt Akt2 interacted weakly with Ack1, while Akt3 present at low levels in the MEF1&2KO cells was not detectable in the complex.
# ::tok Akt2 interacted weakly with Ack1 , while Akt3 present at low levels in the MEF1&2KO cells was not detectable in the complex .
(x7 / contrast-01
      :ARG1 (x3 / interact-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "Akt2")
                  :xref (x / xref :value "UNIPROT:AKT2_HUMAN" :prob "0.604"))
            :ARG1-of (x4 / weak-02)
            :ARG2 (x5 / enzyme
                  :name (x6 / name :op1 "Ack1")
                  :xref (x17 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
      :ARG2 (x15 / detect-01
            :ARG1 (x10 / present-02
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "Akt3"))
                  :ARG2 (x12 / level
                        :ARG1-of (x11 / low-04))
                  :location (x14 / cell-line
                        :name (x13 / name :op1 "MEF1&2KO")))
            :polarity "-"
            :location (x16 / complex)))


# ::id PMC2841635.34
# ::snt Tyr176 phosphorylation precedes AKT activation.
# ::tok Tyr176 phosphorylation precedes AKT activation .
(x1 / precede-01
      :ARG1 (x7 / activate-01
            :ARG0 (x4 / phosphorylate-01
                  :ARG1 (x2 / amino-acid
                        :mod "176"
                        :name (x3 / name :op1 "tyrosine")
                        :xref (x8 / xref :value "PUBCHEM:1153" :prob "11.081481")))
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))


# ::id PMC2841635.36
# ::snt Remaining panel represents IB with antibodies as shown.
# ::tok Remaining panel represents IB with antibodies as shown .
(x3 / represent-01
      :ARG0 (x2 / panel
            :ARG1-of (x1 / remain-01))
      :ARG1 (x4 / immunoblot-01
            :ARG3 (x5 / antibody
                  :ARG1-of (x6 / show-01))))


# ::id PMC2841635.37
# ::snt The lysates were IP with Ack1 antibodies followed by IB with pan-AKT antibodies (top panel).
# ::tok The lysates were IP with Ack1 antibodies followed by IB with pan @-@ AKT antibodies ( top panel ) .
(x7 / antibody
      :ARG1 (x1 / lysate)
      :ARG2 (x2 / and
            :op1 (x3 / protein
                  :name (x4 / name :op1 "ip-10")
                  :xref (x17 / xref :value "UNIPROT:CXL10_HUMAN" :prob "0.663"))
            :op2 (x5 / enzyme
                  :name (x6 / name :op1 "Ack1")
                  :xref (x18 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
      :ARG2-of (x8 / follow-01
            :ARG1 (x9 / immunoblot-01
                  :ARG3 (x13 / antibody
                        :mod (x10 / pan
                              :op1 (x11 / enzyme
                                    :name (x12 / name :op1 "AKT")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))))
      :ARG1-of (x14 / describe-01
            :ARG0 (x16 / panel
                  :mod (x15 / top))))


# ::id PMC2841635.38
# ::snt The peptide was detected at 13.83 mins in the total ion chromatogram ( C ) with mass-to-charge ratio 647.8132, which represents an error of 0.38 ppm ( D ) .
# ::tok The peptide was detected at 13.83 mins in the total ion chromatogram ( C ) with mass @-@ to @-@ charge ratio 647.8132 , which represents an error of 0.38 ppm ( D ) .
(x2 / detect-01
      :ARG1 (x1 / peptide)
      :time (x3 / after
            :quant (x4 / temporal-quantity
                  :quant "13.83"
                  :unit (x5 / minute)))
      :location (x7 / ion
            :mod (x6 / total)
            :ARG1-of (x8 / chromatogram)
            :ARG1-of (x9 / describe-01
                  :ARG0 (x10 / figure :mod "c"))
            :ARG2 (x12 / charge-01
                  :ARG3 (x11 / mass)
                  :ARG2 (x13 / ratio-of :op1 "647.8132"))
            :ARG0-of (x14 / represent-01
                  :ARG1 (x15 / error
                        :domain (x16 / about :op1 "0.38"))))
      :ARG1-of (x17 / describe-01
            :ARG0 (x18 / figure :mod "3d")))


# ::id PMC2841635.39
# ::snt The lysates were also IP with anti-Ack1 antibodies followed by IB with pTyr antibodies (panel 4).
# ::tok The lysates were also IP with anti @-@ Ack1 antibodies followed by IB with pTyr antibodies ( panel 4 ) .
(x7 / antibody
      :ARG1 (x1 / lysate
            :mod (x2 / also)
            :name (x3 / name :op1 "ip-10")
            :ARG0-of (x4 / counter-01
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "Ack1")
                        :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))))
      :ARG2-of (x8 / follow-01
            :ARG1 (x9 / immunoblot-01
                  :ARG3 (x11 / antibody
                        :name (x10 / name :op1 "pTyr"))))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / panel)))


# ::id PMC2841635.40
# ::snt The same blot was stripped and IB with anti-Ack1 antibodies (Bottom panel).
# ::tok The same blot was stripped and IB with anti @-@ Ack1 antibodies ( Bottom panel ) .
(x3 / strip-01
      :ARG1 (x2 / immunoblot-01
            :ARG1-of (x1 / same-01))
      :ARG1 (x4 / and
            :op1 (x5 / enzyme
                  :name (x6 / name :op1 "IB"))
            :op2 (x10 / antibody
                  :ARG0-of (x7 / counter-01
                        :ARG1 (x8 / enzyme
                              :name (x9 / name :op1 "Ack1")
                              :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))))
      :ARG1-of (x11 / describe-01
            :ARG0 (x13 / panel
                  :mod (x12 / bottom))))


# ::id PMC2841635.41
# ::snt These lysates were also subjected to IP with anti-HA antibodies followed by IB with Ser473, pTyr and AKT antibodies (panels 2, 3 and 5, respectively).
# ::tok These lysates were also subjected to IP with anti @-@ HA antibodies followed by IB with Ser473 , pTyr and AKT antibodies ( panels 2 , 3 and 5 , respectively ) .
(x4 / subject-01
      :ARG1 (x2 / lysate
            :mod (x1 / this))
      :mod (x3 / also)
      :ARG2 (x5 / protein
            :name (x6 / name :op1 "ip-10")
            :xref (x26 / xref :value "UNIPROT:CXL10_HUMAN" :prob "0.663"))
      :ARG2 (x10 / antibody
            :ARG0-of (x7 / counter-01
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "HA")
                        :xref (x / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
            :ARG2-of (x11 / follow-01
                  :ARG1 (x12 / immunoblot-01
                        :ARG1 (x13 / amino-acid
                              :mod "473"
                              :name (x14 / name :op1 "serine")
                              :xref (x28 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
            :ARG0-of (x20 / counter-01
                  :ARG1 (x17 / and
                        :op1 (x15 / enzyme
                              :name (x16 / name :op1 "pTyr"))
                        :op2 (x18 / enzyme
                              :name (x19 / name :op1 "AKT")
                              :xref (x27 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
            :ARG1-of (x21 / describe-01
                  :ARG0 (x22 / panel
                        :ARG1-of (x24 / and
                              :op1 (x23 / and :op1 "2" :op2 "3")
                              :op2 "5"
                              :manner (x25 / respective))))))


# ::id PMC2841635.42
# ::snt Cells were serum starved for 24 h, treated with EGF for 15 mins, fixed and stained with HA-antibodies conjugated to Alexa488 and phosphoSer473-antibodies conjugated to Alexa 647.
# ::tok Cells were serum starved for 24 h , treated with EGF for 15 mins , fixed and stained with HA @-@ antibodies conjugated to Alexa488 and phosphoSer473 @-@ antibodies conjugated to Alexa 647 .
(x12 / and
      :op1 (x3 / starve-01
            :ARG1 (x1 / cell)
            :ARG2 (x2 / serum)
            :duration (x4 / temporal-quantity
                  :quant "24"
                  :unit (x5 / hour)))
      :op2 (x6 / treat-04
            :ARG2 (x7 / protein
                  :name (x8 / name :op1 "EGF")
                  :xref (x27 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :duration (x9 / temporal-quantity
                  :quant "15"
                  :unit (x10 / minute)))
      :op1 (x11 / fix-02)
      :op2 (x13 / stain-01
            :ARG2 (x23 / antibody
                  :ARG0-of (x16 / counter-01
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "HA")
                              :xref (x29 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
                  :ARG1-of (x17 / conjugate-02
                        :ARG2 (x20 / and
                              :op1 (x18 / enzyme
                                    :name (x19 / name :op1 "Alexa488")
                                    :xref (x28 / xref :value "UNIPROT:ALEX_HUMAN" :prob "0.202"))
                              :op2 (x21 / enzyme
                                    :name (x22 / name :op1 "phosphoSer473")
                                    :xref (x / xref :value "UNIPROT:PLD3_HUMAN" :prob "0.222"))))
                  :ARG1-of (x24 / conjugate-02
                        :ARG2 (x25 / enzyme
                              :name (x26 / name :op1 "Alexa" :op2 "647"))))))


# ::id PMC2841635.43
# ::snt Upper right quadrant represents cells which express HA-tagged AKT or Y176F mutant that are also Ser473-phosphorylated.
# ::tok Upper right quadrant represents cells which express HA @-@ tagged AKT or Y176F mutant that are also Ser473 @-@ phosphorylated .
(x4 / represent-01
      :ARG0 (x3 / quadrant
            :ARG1-of (x2 / right-04
                  :mod (x1 / upper)))
      :ARG1 (x5 / cell
            :ARG0-of (x14 / mutate-01
                  :ARG1 (x6 / express-03
                        :ARG2 (x12 / or
                              :op1 (x7 / enzyme
                                    :ARG1-of (x10 / tag-01
                                          :ARG2 (x8 / protein
                                                :name (x9 / name :op1 "HA")
                                                :xref (x / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
                                    :name (x11 / name :op1 "AKT")
                                    :xref (x19 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                              :op2 (x13 / mutate-01 :value "Y176F"))))
            :ARG0-of (x18 / phosphorylate-01
                  :mod (x15 / also)
                  :ARG1 (x16 / amino-acid
                        :mod "473"
                        :name (x17 / name :op1 "serine")
                        :xref (x20 / xref :value "PUBCHEM:5951" :prob "11.218784")))))


# ::id PMC2841635.44
# ::snt To test whether Ack1 directly phosphorylates AKT, in vitro binding assay was performed and AKT Tyr-phosphorylation was assessed.
# ::tok To test whether Ack1 directly phosphorylates AKT , in vitro binding assay was performed and AKT Tyr @-@ phosphorylation was assessed .
(x12 / perform-01
      :purpose (x1 / test-01
            :ARG1 (x2 / possible-01
                  :mode "interrogative"
                  :ARG1 (x6 / phosphorylate-01
                        :ARG0 (x3 / enzyme
                              :name (x4 / name :op1 "Ack1")
                              :xref (x20 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                        :ARG1-of (x5 / direct-02)
                        :ARG1 (x7 / enzyme
                              :name (x8 / name :op1 "AKT")
                              :xref (x21 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))
      :ARG1 (x11 / assay-01
            :manner (x9 / in-vitro)
            :ARG1 (x10 / bind-01))
      :ARG2 (x13 / and
            :op1 (x14 / enzyme
                  :name (x15 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :op2 (x19 / assess-01
                  :ARG1 (x18 / phosphorylate-01
                        :ARG1 (x16 / amino-acid
                              :name (x17 / name :op1 "tyrosine")
                              :xref (x22 / xref :value "PUBCHEM:1153" :prob "11.081481"))))))


# ::id PMC2841635.45
# ::snt Myc-tagged Ack1 and HA-tagged AKT constructs were expressed and purified using respective antibody beads followed by elution, as described in methods section ( Fig. S1B ).
# ::tok Myc @-@ tagged Ack1 and HA @-@ tagged AKT constructs were expressed and purified using respective antibody beads followed by elution , as described in methods section ( Fig . S1B ) .
(x14 / and
      :op1 (x13 / express-03
            :ARG1 (x6 / and
                  :op1 (x1 / enzyme
                        :ARG1-of (x4 / tag-01
                              :ARG2 (x2 / protein
                                    :name (x3 / name :op1 "Myc")
                                    :xref (x / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604")))
                        :name (x5 / name :op1 "Ack1")
                        :xref (x26 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                  :op2 (x12 / construct
                        :ARG1-of (x9 / tag-01
                              :ARG2 (x7 / protein
                                    :name (x8 / name :op1 "HA")
                                    :xref (x27 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
                        :mod (x10 / enzyme
                              :name (x11 / name :op1 "AKT")
                              :xref (x28 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))
      :op2 (x15 / purify-01
            :ARG2 (x18 / bead
                  :ARG0 (x17 / antibody
                        :mod (x16 / respective))
                  :ARG2-of (x19 / follow-01
                        :ARG1 (x20 / elute-00)))
            :ARG1-of (x21 / describe-01
                  :location (x23 / section-01
                        :ARG1 (x22 / method)))
            :ARG1-of (x24 / describe-01
                  :ARG0 (x25 / figure :mod "s1b"))))


# ::id PMC2841635.46
# ::snt In vitro binding assay revealed that purified Ack1 interacted directly with AKT resulting in AKT Tyr176-phosphorylation ( Fig. S1B –D ).
# ::tok In vitro binding assay revealed that purified Ack1 interacted directly with AKT resulting in AKT Tyr176 @-@ phosphorylation ( Fig . S1B –D ) .
(x4 / reveal-01
      :ARG0 (x3 / assay-01
            :manner (x1 / in-vitro)
            :ARG1 (x2 / bind-01))
      :ARG1 (x8 / interact-01
            :ARG1 (x5 / enzyme
                  :ARG1-of (x6 / purify-01)
                  :name (x7 / name :op1 "Ack1")
                  :xref (x22 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :ARG1-of (x9 / direct-02)
            :ARG2 (x10 / enzyme
                  :name (x11 / name :op1 "AKT")
                  :xref (x21 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :ARG1-of (x12 / result-01
            :ARG2 (x13 / enzyme
                  :name (x14 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :ARG0-of (x17 / phosphorylate-01
            :ARG1 (x15 / amino-acid
                  :mod "176"
                  :name (x16 / name :op1 "tyrosine")
                  :xref (x23 / xref :value "PUBCHEM:1153" :prob "11.081481")))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / and
                  :op1 (x20 / figure :mod "s1b")
                  :op2 "47")))


# ::id PMC2841635.47
# ::snt Further, we generated GST-Ack construct that harbors kinase, SH3 and CRIB domain (schematic shown in Fig. S1E ) and expressed it in E.
# ::tok Further , we generated GST @-@ Ack construct that harbors kinase , SH3 and CRIB domain ( schematic shown in Fig . S1E ) and expressed it in E .
(x3 / generate-01
      :mod (x1 / further)
      :ARG0 (x2 / we)
      :ARG1 (x6 / construct-01
            :mod (x4 / protein
                  :name (x5 / name :op1 "GST-Ack"))
            :ARG0-of (x7 / harbor-01
                  :ARG1 (x10 / and
                        :op1 (x8 / kinase
                              :name (x9 / name :op1 "SH3"))
                        :op2 (x11 / enzyme
                              :name (x12 / name :op1 "CRIB" :op2 "domain"))
                        :ARG1-of (x13 / schematic
                              :ARG1-of (x14 / show-01
                                    :medium (x15 / figure :mod "s1e")))
                        :op2 (x16 / express-03
                              :ARG2 (x17 / protein
                                    :name (x18 / name :op1 "e-cadherin")
                                    :xref (x / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703")))))))


# ::id PMC2841635.48
# ::snt coli ( Fig. S1E ) [25] , [31] .
# ::tok coli ( Fig . S1E ) [ 25 ] , [ 31 ] .
(x11 / describe-01
      :ARG2 (x1 / protein
            :name (x2 / name :op1 "coli")
            :ARG1-of (x3 / describe-01
                  :ARG0 (x4 / and
                        :op1 (x5 / figure :mod "s1e")
                        :op2 (x8 / describe-01
                              :ARG0 (x7 / publication
                                    :ARG1-of (x6 / cite-01 :ARG2 "25")))))
            :xref (x / xref :value "UNIPROT:COLI_HUMAN" :prob "0.603"))
      :ARG0 (x9 / publication
            :ARG1-of (x10 / cite-01 :ARG2 "31")))


# ::id PMC2841635.49
# ::snt Androgen-receptor (AR), another Ack1 substrate [26] was expressed as FLAG-tagged construct in HEK293 cells and purified using FLAG-beads ( Fig. S1E , left panel).
# ::tok Androgen @-@ receptor ( AR ) , another Ack1 substrate [ 26 ] was expressed as FLAG @-@ tagged construct in HEK293 cells and purified using FLAG @-@ beads ( Fig . S1E , left panel ) .
(x17 / construct-01
      :ARG1 (x3 / and
            :op1 (x1 / protein
                  :name (x2 / name :op1 "Androgen-receptor"))
            :op1 (x4 / enzyme
                  :name (x5 / name :op1 "AR")
                  :xref (x31 / xref :value "UNIPROT:ANDR_HUMAN" :prob "1.003"))
            :op2 (x6 / person
                  :mod (x7 / another)
                  :ARG0-of (x9 / substrate
                        :name (x8 / name :op1 "Ack1"))
                  :ARG1-of (x10 / describe-01
                        :ARG0 (x11 / publication
                              :ARG1-of (x12 / cite-01 :ARG2 "26")))))
      :ARG2 (x13 / express-03
            :ARG3 (x16 / tag-01
                  :ARG2 (x14 / protein
                        :name (x15 / name :op1 "FLAG")
                        :xref (x32 / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222"))))
      :location (x20 / and
            :op1 (x19 / cell-line
                  :name (x18 / name :op1 "HEK293"))
            :op2 (x21 / purify-01
                  :ARG0-of (x22 / use-01
                        :ARG1 (x25 / bead
                              :ARG2 (x23 / protein
                                    :name (x24 / name :op1 "FLAG")
                                    :xref (x / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222"))))
                  :ARG1-of (x26 / describe-01
                        :ARG0 (x27 / and
                              :op1 (x28 / figure :mod "s1e")
                              :op2 (x30 / panel
                                    :ARG1-of (x29 / left-20)))))))


# ::id PMC2841635.50
# ::snt GST-tagged Ack1 or GST (as control) bound to glutathione beads were incubated with purified AKT or Y176F mutant of AKT or AR (shown in Fig. S1B and E ).
# ::tok GST @-@ tagged Ack1 or GST ( as control ) bound to glutathione beads were incubated with purified AKT or Y176F mutant of AKT or AR ( shown in Fig . S1B and E ) .
(x23 / or
      :op1 (x20 / mutate-01
            :ARG1 (x18 / or
                  :ARG1-of (x3 / tag-01
                        :ARG2 (x1 / enzyme
                              :name (x2 / name :op1 "GST")
                              :xref (x31 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
                  :op1 (x14 / incubate-01
                        :ARG1 (x6 / or
                              :op1 (x4 / enzyme
                                    :name (x5 / name :op1 "Ack1")
                                    :xref (x33 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                              :op2 (x7 / enzyme
                                    :name (x8 / name :op1 "GST")
                                    :xref (x32 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))
                              :ARG1-of (x9 / resemble-01
                                    :ARG2 (x10 / control-01))
                              :ARG1-of (x11 / bind-01
                                    :ARG2 (x12 / enzyme
                                          :name (x13 / name :op1 "glutathione" :op2 "beads"))))
                        :ARG2 (x15 / enzyme
                              :ARG1-of (x16 / purify-01)
                              :name (x17 / name :op1 "AKT")
                              :xref (x34 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                  :op2 (x19 / mutate-01 :value "Y176F"))
            :ARG2 (x21 / enzyme
                  :name (x22 / name :op1 "AKT")
                  :xref (x30 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :op2 (x24 / enzyme
            :name (x25 / name :op1 "AR")
            :xref (x / xref :value "UNIPROT:ANDR_HUMAN" :prob "1.003"))
      :ARG1-of (x26 / show-01
            :ARG0 (x29 / and
                  :op1 (x27 / figure :mod "s1b")
                  :op2 (x28 / figure :mod "3e"))))


# ::id PMC2841635.51
# ::snt GST-Ack1 bound to purified AKT and AR but not the Y176F mutant of AKT suggesting that AKT and AR are direct binding partners of Ack1 ( Fig.
# ::tok GST @-@ Ack1 bound to purified AKT and AR but not the Y176F mutant of AKT suggesting that AKT and AR are direct binding partners of Ack1 ( Fig .
(x10 / contrast-01
      :ARG1 (x7 / and
            :op1 (x3 / bind-01
                  :ARG1 (x1 / protein
                        :name (x2 / name :op1 "GST-Ack1"))
                  :ARG2 (x4 / enzyme
                        :ARG1-of (x5 / purify-01)
                        :name (x6 / name :op1 "AKT")
                        :xref (x29 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :op2 (x8 / enzyme
                  :name (x9 / name :op1 "AR")
                  :xref (x28 / xref :value "UNIPROT:ANDR_HUMAN" :prob "1.003")))
      :ARG2 (x22 / bind-01
            :polarity "-"
            :ARG1 (x12 / mutate-01
                  :ARG1-of (x11 / mutate-01 :value "Y176F")
                  :ARG2 (x13 / enzyme
                        :name (x14 / name :op1 "AKT")
                        :xref (x31 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :ARG0-of (x15 / suggest-01
                        :ARG1 (x18 / and
                              :op1 (x16 / enzyme
                                    :name (x17 / name :op1 "AKT")
                                    :xref (x32 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                              :op2 (x19 / enzyme
                                    :name (x20 / name :op1 "AR")
                                    :xref (x30 / xref :value "UNIPROT:ANDR_HUMAN" :prob "1.003")))))
            :ARG1-of (x21 / direct-02)
            :ARG0-of (x23 / partner-01
                  :ARG1 (x24 / enzyme
                        :name (x25 / name :op1 "Ack1")
                        :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
            :ARG1-of (x26 / describe-01
                  :ARG0 (x27 / figure :mod "2b"))))


# ::id PMC2841635.53
# ::snt Affinity purification of AKT coexpressed with Ack1 ( Fig. S2A ), followed by mass spectrometry analysis revealed that AKT was phosphorylated at Tyrosine 176 ( Fig. 1C–E ).
# ::tok Affinity purification of AKT coexpressed with Ack1 ( Fig . S2A ) , followed by mass spectrometry analysis revealed that AKT was phosphorylated at Tyrosine 176 ( Fig . 1C–E ) .
(x5 / coexpress-01
      :ARG1-of (x2 / purify-01
            :ARG2 (x1 / affinity))
      :ARG2 (x3 / enzyme
            :name (x4 / name :op1 "AKT")
            :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
      :ARG2 (x6 / enzyme
            :name (x7 / name :op1 "Ack1")
            :xref (x23 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
      :ARG1-of (x8 / describe-01
            :ARG0 (x9 / figure :mod "s2a"))
      :ARG2-of (x10 / follow-01
            :ARG1 (x14 / reveal-01
                  :ARG0 (x13 / analyze-01
                        :degree (x11 / mass)
                        :mod (x12 / spectrometry))
                  :ARG1 (x17 / phosphorylate-01
                        :ARG1 (x15 / enzyme
                              :name (x16 / name :op1 "AKT")
                              :xref (x24 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :ARG2 (x18 / amino-acid
                              :mod "176"
                              :name (x19 / name :op1 "tyrosine")
                              :xref (x25 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                  :ARG1-of (x20 / describe-01
                        :ARG0 (x21 / figure
                              :mod "1"
                              :name (x22 / name :op1 "c" :op2 "e"))))))


# ::id PMC2841635.54
# ::snt Tyr176, located in the kinase domain, is evolutionarily conserved from unicellular eukaryotes to mammals and within all the three AKT isoforms ( Fig. 1F ).
# ::tok Tyr176 , located in the kinase domain , is evolutionarily conserved from unicellular eukaryotes to mammals and within all the three AKT isoforms ( Fig . 1F ) .
(x8 / conserve-01
      :ARG1 (x3 / be-located-at-91
            :ARG1 (x1 / amino-acid
                  :mod "176"
                  :name (x2 / name :op1 "tyrosine")
                  :xref (x19 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :ARG2 (x5 / domain
                  :mod (x4 / kinase)))
      :ARG1 (x6 / enzyme
            :name (x7 / name :op1 "evolutionarily")
            :xref (x18 / xref :value "UNIPROT:GPTC1_HUMAN" :prob "0.202"))
      :ARG3 (x9 / eukaryote)
      :ARG2 (x11 / and
            :mod (x10 / mammal)
            :location (x15 / isoform
                  :mod (x12 / all)
                  :quant "3"
                  :mod (x13 / enzyme
                        :name (x14 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / figure :mod "1f")))


# ::id PMC2841635.55
# ::snt Two other phosphorylation events, Ser473 and Thr308 were also identified in the same preparation ( Fig. S2B –G ).
# ::tok Two other phosphorylation events , Ser473 and Thr308 were also identified in the same preparation ( Fig . S2B –G ) .
(x10 / identify-01
      :ARG1 (x3 / event
            :quant "2"
            :mod (x1 / other)
            :mod (x2 / phosphorylate-01))
      :ARG1 (x4 / and
            :op1 (x5 / amino-acid
                  :mod "473"
                  :name (x6 / name :op1 "serine")
                  :xref (x16 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :op2 (x7 / amino-acid
                  :mod "308"
                  :name (x8 / name :op1 "threonine")
                  :xref (x / xref :value "PUBCHEM:205" :prob "11.848252")))
      :mod (x9 / also)
      :ARG2 (x12 / prepare-01
            :ARG1-of (x11 / same-01))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure
                  :mod "s2b"
                  :name (x15 / name :op1 "–G"))))


# ::id PMC2841635.56
# ::snt In-silico analysis revealed that Tyr176 and Ser473 are located in regions with increased conformational flexibility and phosphorylation at Tyr176 is likely to induce substantial conformational change and thus affect the loop harboring Ser473 ( Fig. S3 ).
# ::tok In @-@ silico analysis revealed that Tyr176 and Ser473 are located in regions with increased conformational flexibility and phosphorylation at Tyr176 is likely to induce substantial conformational change and thus affect the loop harboring Ser473 ( Fig . S3 ) .
(x18 / likely-01
      :ARG1 (x14 / and
            :op1 (x13 / flexibility
                  :ARG2 (x9 / locate-01
                        :ARG1 (x3 / reveal-01
                              :ARG0 (x2 / analyze-01
                                    :manner (x1 / in-silico))
                              :ARG1 (x4 / and
                                    :op1 (x5 / amino-acid
                                          :mod "176"
                                          :name (x6 / name :op1 "tyrosine")
                                          :xref (x32 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                                    :op2 (x7 / amino-acid
                                          :mod "473"
                                          :name (x8 / name :op1 "serine")
                                          :xref (x31 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
                        :location (x10 / region
                              :ARG0-of (x11 / increase-01)
                              :ARG1-of (x12 / conformational))))
            :op2 (x15 / phosphorylate-01
                  :ARG1 (x16 / amino-acid
                        :mod "176"
                        :name (x17 / name :op1 "tyrosine")
                        :xref (x33 / xref :value "PUBCHEM:1153" :prob "11.081481"))))
      :ARG1 (x19 / induce-01
            :ARG2 (x22 / change-01
                  :degree (x20 / substantial)
                  :mod (x21 / conformational)))
      :ARG1-of (x23 / cause-01
            :ARG0 (x24 / affect-01
                  :ARG1 (x25 / loop-01
                        :ARG0-of (x26 / harbor-01
                              :ARG1 (x27 / amino-acid
                                    :mod "473"
                                    :name (x28 / name :op1 "serine")
                                    :xref (x / xref :value "PUBCHEM:5951" :prob "11.218784")))
                        :ARG1-of (x29 / describe-01
                              :ARG0 (x30 / figure :mod "s3"))))))


# ::id PMC2841635.57
# ::snt To determine whether AKT Tyr176-phosphorylation is an upstream event that regulates AKT activation (or Ser473 phosphorylation, hereafter), site directed mutagenesis was performed to generate AKT phospho-tyrosine (Y176F) mutant ( Fig. S4A ).
# ::tok To determine whether AKT Tyr176 @-@ phosphorylation is an upstream event that regulates AKT activation ( or Ser473 phosphorylation , hereafter ) , site directed mutagenesis was performed to generate AKT phospho @-@ tyrosine ( Y176F ) mutant ( Fig . S4A ) .
(x21 / perform-01
      :purpose (x1 / determine-01
            :ARG1 (x8 / event
                  :domain (x6 / phosphorylate-01
                        :mode "interrogative"
                        :ARG0 (x2 / enzyme
                              :name (x3 / name :op1 "AKT")
                              :xref (x33 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :ARG1 (x4 / amino-acid
                              :mod "176"
                              :name (x5 / name :op1 "tyrosine")
                              :xref (x35 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                  :mod (x7 / upstream)
                  :ARG0-of (x9 / regulate-01
                        :ARG1 (x13 / or
                              :op1 (x12 / activate-01
                                    :ARG1 (x10 / enzyme
                                          :name (x11 / name :op1 "AKT")
                                          :xref (x34 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                              :op2 (x16 / phosphorylate-01
                                    :ARG1 (x14 / amino-acid
                                          :mod "473"
                                          :name (x15 / name :op1 "serine")
                                          :xref (x36 / xref :value "PUBCHEM:5951" :prob "11.218784")))))
                  :name (x17 / name :op1 "hereafter")))
      :ARG1 (x18 / protein-segment
            :ARG1-of (x19 / direct-01
                  :ARG2 (x20 / mutagenesis)))
      :purpose (x22 / generate-01
            :ARG1 (x29 / mutate-01
                  :ARG1 (x23 / enzyme
                        :name (x24 / name :op1 "AKT")
                        :ARG1-of (x25 / phosphorylate-01
                              :ARG2 (x26 / enzyme
                                    :name (x27 / name :op1 "tyrosine")
                                    :xref (x / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352")))
                        :ARG1-of (x28 / mutate-01 :value "Y176F")
                        :xref (x32 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :ARG1-of (x30 / describe-01
                        :ARG0 (x31 / figure :mod "s4a")))))


# ::id PMC2841635.58
# ::snt The Y176F mutant interacted poorly with Ack1 in the absence of ligand, and in the presence of ligand failed to interact with Ack1 resulting in decreased AKT Tyr/Ser-phosphorylations ( Fig. 1G , lane 6).
# ::tok The Y176F mutant interacted poorly with Ack1 in the absence of ligand , and in the presence of ligand failed to interact with Ack1 resulting in decreased AKT Tyr @/@ Ser @-@ phosphorylations ( Fig . 1G , lane 6 ) .
(x12 / fail-01
      :ARG1 (x9 / and
            :op1 (x3 / interact-01
                  :ARG1-of (x2 / mutate-01
                        :ARG2 (x1 / mutate-01 :value "Y176F"))
                  :manner (x4 / poor)
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "Ack1")
                        :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                  :condition (x7 / absent-01
                        :ARG1 (x8 / ligand)))
            :op2 (x10 / present-02
                  :ARG1 (x11 / ligand)))
      :ARG2 (x13 / interact-01
            :ARG1 (x14 / enzyme
                  :name (x15 / name :op1 "Ack1")
                  :xref (x31 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
      :ARG1-of (x16 / result-01
            :ARG2 (x17 / decrease-01
                  :ARG1 (x18 / enzyme
                        :name (x19 / name :op1 "AKT")
                        :xref (x30 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :ARG0 (x25 / phosphorylate-01
                        :ARG1 (x20 / and
                              :op1 (x21 / amino-acid
                                    :name (x22 / name :op1 "tyrosine")
                                    :xref (x32 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                              :op2 (x23 / amino-acid
                                    :name (x24 / name :op1 "serine")
                                    :xref (x33 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
                  :ARG1-of (x26 / describe-01
                        :ARG0 (x27 / and
                              :op1 (x28 / figure :mod "1g")
                              :op2 (x29 / lane :mod "6"))))))


# ::id PMC2841635.59
# ::snt Flow cytometric analysis of EGF treated cells revealed significant reduction in Ser473-phosphorylation in MEF1&2KO cells expressing Y176F as compared to AKT ( Fig. 1H and Fig. S4B ).
# ::tok Flow cytometric analysis of EGF treated cells revealed significant reduction in Ser473 @-@ phosphorylation in MEF1&2KO cells expressing Y176F as compared to AKT ( Fig . 1H and Fig . S4B ) .
(x8 / reveal-01
      :ARG0 (x3 / analyze-01
            :mod (x2 / cytometry
                  :mod (x1 / flow))
            :ARG1 (x7 / cell
                  :ARG1-of (x6 / treat-04
                        :ARG2 (x4 / protein
                              :name (x5 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :ARG1 (x10 / reduce-01
            :ARG1-of (x9 / significant-02)
            :ARG1 (x13 / phosphorylate-01
                  :ARG1 (x11 / amino-acid
                        :mod "473"
                        :name (x12 / name :op1 "serine")
                        :xref (x26 / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :location (x15 / cell
                  :name (x14 / name :op1 "MEF1&2KO")
                  :ARG3-of (x16 / express-03
                        :ARG2 (x17 / mutate-01 :value "Y176F")))
            :ARG1-of (x18 / compare-01
                  :ARG2 (x19 / enzyme
                        :name (x20 / name :op1 "AKT")
                        :xref (x25 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
      :ARG1-of (x21 / describe-01
            :ARG0 (x23 / and
                  :op1 (x22 / figure :mod "1h")
                  :op2 (x24 / figure :mod "s4b"))))


# ::id PMC2841635.60
# ::snt These results imply that Ack1 mediated AKT Tyr-phosphorylation results in subsequent AKT activation.
# ::tok These results imply that Ack1 mediated AKT Tyr @-@ phosphorylation results in subsequent AKT activation .
(x4 / imply-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x7 / mediate-01
            :ARG0 (x5 / enzyme
                  :name (x6 / name :op1 "Ack1")
                  :xref (x19 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :ARG1 (x13 / result-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "AKT")
                        :ARG0-of (x12 / phosphorylate-01
                              :ARG1 (x10 / amino-acid
                                    :name (x11 / name :op1 "tyrosine")
                                    :xref (x20 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                        :xref (x18 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :ARG2 (x17 / activate-01
                        :mod (x14 / subsequent)
                        :ARG1 (x15 / enzyme
                              :name (x16 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))))


# ::id PMC2841635.61
# ::snt Ack1/AKT Interacting Domains
# ::tok Ack1 @/@ AKT Interacting Domains
(x6 / interact-01
      :ARG0 (x3 / slash
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "Ack1")
                  :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "AKT")
                  :xref (x10 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :ARG1 (x7 / protein
            :name (x8 / name :op1 "domain")
            :xref (x9 / xref :value "UNIPROT:GEPH_HUMAN" :prob "0.322")))


# ::id PMC2841635.62
# ::snt To identify domains involved in Ack1-AKT interaction, various deletions of Ack1 and AKT were generated ( Fig. S4A ).
# ::tok To identify domains involved in Ack1 @-@ AKT interaction , various deletions of Ack1 and AKT were generated ( Fig . S4A ) .
(x17 / generate-01
      :purpose (x1 / identify-01
            :ARG1 (x2 / gene
                  :name (x3 / name :op1 "domain")
                  :ARG1-of (x4 / involve-01
                        :ARG2 (x9 / interact-01
                              :ARG1 (x5 / enzyme
                                    :name (x6 / name :op1 "Ack1")
                                    :xref (x23 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                              :ARG0 (x7 / enzyme
                                    :name (x8 / name :op1 "AKT")
                                    :xref (x22 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
                  :xref (x20 / xref :value "UNIPROT:GEPH_HUMAN" :prob "0.322")))
      :ARG1 (x11 / delete-01
            :mod (x10 / various)
            :ARG1 (x14 / and
                  :op1 (x12 / enzyme
                        :name (x13 / name :op1 "Ack1")
                        :xref (x21 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                  :op2 (x15 / enzyme
                        :name (x16 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / figure :mod "s4a")))


# ::id PMC2841635.63
# ::snt MEF1&2KO cells were co-transfected with HA-tagged AKT deletions and activated Ack1 or caAck.
# ::tok MEF1&2KO cells were co @-@ transfected with HA @-@ tagged AKT deletions and activated Ack1 or caAck .
(x3 / cotransfect-01
      :ARG1 (x2 / cell-line
            :name (x1 / name :op1 "MEF1&2KO"))
      :ARG2 (x15 / or
            :op1 (x4 / transfect-01
                  :ARG2 (x11 / and
                        :ARG1-of (x7 / tag-01
                              :ARG2 (x5 / protein
                                    :name (x6 / name :op1 "HA")
                                    :xref (x19 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
                        :op1 (x10 / delete-01
                              :ARG1 (x8 / enzyme
                                    :name (x9 / name :op1 "AKT")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                        :op2 (x12 / enzyme
                              :ARG1-of (x13 / activate-01)
                              :name (x14 / name :op1 "Ack1")
                              :xref (x18 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))))
            :op2 (x16 / enzyme
                  :name (x17 / name :op1 "caAck"))))


# ::id PMC2841635.64
# ::snt Immunoprecipitation using HA antibodies followed by immunoblotting with pTyr antibodies revealed Tyr-phosphorylation of full-length AKT and AKT lacking carboxy terminus (ΔCT-AKT), however, AKT deletion construct lacking the PH domain (ΔPH-AKT) exhibited significant decrease in Tyr-phosphorylation ( Fig. S4C , top panel).
# ::tok Immunoprecipitation using HA antibodies followed by immunoblotting with pTyr antibodies revealed Tyr @-@ phosphorylation of full @-@ length AKT and AKT lacking carboxy terminus ( ΔCT @-@ AKT ) , however , AKT deletion construct lacking the PH domain ( ΔPH @-@ AKT ) exhibited significant decrease in Tyr @-@ phosphorylation ( Fig . S4C , top panel ) .
(x1 / multi-sentence
      :snt1 (x11 / reveal-01
            :ARG0 (x6 / antibody
                  :ARG0 (x2 / use-01
                        :ARG2 (x3 / immunoprecipitate-01
                              :ARG2 (x4 / protein
                                    :name (x5 / name :op1 "HA")
                                    :xref (x52 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002"))))
                  :ARG2-of (x7 / follow-01
                        :ARG1 (x8 / immunoblot-01
                              :ARG3 (x10 / antibody
                                    :name (x9 / name :op1 "pTyr")))))
            :ARG1 (x29 / contrast-01
                  :ARG1 (x12 / amino-acid
                        :name (x13 / name :op1 "tyrosine")
                        :ARG1-of (x14 / phosphorylate-01
                              :ARG1 (x19 / and
                                    :op1 (x15 / enzyme
                                          :ARG1-of (x17 / long-03
                                                :ARG1-of (x16 / full-09))
                                          :name (x18 / name :op1 "AKT")
                                          :xref (x56 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                                    :op2 (x20 / enzyme
                                          :name (x21 / name :op1 "AKT")
                                          :ARG0-of (x22 / lack-01
                                                :ARG1 (x23 / enzyme
                                                      :name (x24 / name :op1 "carboxy" :op2 "terminus")))
                                          :xref (x51 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
                        :part-of (x25 / enzyme
                              :name (x26 / name :op1 "ΔCT")
                              :mod (x27 / enzyme
                                    :name (x28 / name :op1 "AKT")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                        :xref (x58 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2 (x33 / construct-01
                        :ARG0 (x32 / delete-01
                              :ARG1 (x30 / enzyme
                                    :name (x31 / name :op1 "AKT")
                                    :xref (x53 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))))
      :snt2 (x41 / exhibit-01
            :ARG0 (x34 / lack-01
                  :ARG1 (x36 / domain
                        :name (x35 / name :op1 "PH")
                        :mod (x37 / enzyme
                              :name (x38 / name :op1 "ΔPH")
                              :mod (x39 / enzyme
                                    :name (x40 / name :op1 "AKT")
                                    :xref (x55 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                              :xref (x54 / xref :value "UNIPROT:PAHO_HUMAN" :prob "0.682"))))
            :ARG1 (x43 / decrease-01
                  :ARG2 (x42 / significant-02)
                  :ARG1 (x46 / phosphorylate-01
                        :ARG1 (x44 / amino-acid
                              :name (x45 / name :op1 "tyrosine")
                              :xref (x57 / xref :value "PUBCHEM:1153" :prob "11.081481"))))
            :ARG1-of (x47 / describe-01
                  :ARG0 (x50 / panel
                        :part-of (x48 / figure :mod "s4c")
                        :location (x49 / top)))))


# ::id PMC2841635.65
# ::snt The decreased phosphorylation of AKT deletion construct lacking PH domain could be due to poor binding with activated Ack1.
# ::tok The decreased phosphorylation of AKT deletion construct lacking PH domain could be due to poor binding with activated Ack1 .
(x6 / construct-01
      :ARG0 (x5 / delete-01
            :ARG1 (x1 / decrease-01
                  :ARG1 (x2 / phosphorylate-01
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))
      :ARG1 (x7 / lack-01
            :ARG1 (x8 / protein-segment
                  :name (x9 / name :op1 "PH")
                  :ARG1-of (x11 / cause-01
                        :ARG1-of (x10 / possible-01)
                        :ARG0 (x13 / bind-01
                              :mod (x12 / poor)
                              :ARG2 (x14 / enzyme
                                    :ARG1-of (x15 / activate-01)
                                    :name (x16 / name :op1 "Ack1")
                                    :xref (x17 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))))))


# ::id PMC2841635.67
# ::snt It revealed that in contrast to AKT or ΔCT-AKT, ΔPH-AKT weakly binds Ack1 ( Fig. S4D , top panel).
# ::tok It revealed that in contrast to AKT or ΔCT @-@ AKT , ΔPH @-@ AKT weakly binds Ack1 ( Fig . S4D , top panel ) .
(x2 / reveal-01
      :ARG0 (x1 / it)
      :ARG1 (x3 / contrast-01
            :ARG1 (x6 / or
                  :op1 (x4 / enzyme
                        :name (x5 / name :op1 "AKT")
                        :xref (x23 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :op2 (x7 / enzyme
                        :name (x8 / name :op1 "ΔCT"))
                  :op2 (x9 / enzyme
                        :name (x10 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :ARG2 (x16 / bind-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "ΔPH")
                        :mod (x13 / enzyme
                              :name (x14 / name :op1 "AKT")
                              :xref (x25 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :xref (x24 / xref :value "UNIPROT:PAHO_HUMAN" :prob "0.682"))
                  :ARG1-of (x15 / weak-02)
                  :ARG2 (x17 / enzyme
                        :name (x18 / name :op1 "Ack1")
                        :xref (x26 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))))
      :ARG1-of (x19 / describe-01
            :ARG0 (x22 / panel
                  :part-of (x20 / figure :mod "s4d")
                  :location (x21 / top))))


# ::id PMC2841635.68
# ::snt We have demonstrated that Tyr176 residue in AKT kinase domain is necessary for Ack1/AKT interaction, thus, collectively it indicates that the Ack1 need both the PH domain and tyrosine176 in AKT kinase domain for complex formation.
# ::tok We have demonstrated that Tyr176 residue in AKT kinase domain is necessary for Ack1 @/@ AKT interaction , thus , collectively it indicates that the Ack1 need both the PH domain and tyrosine176 in AKT kinase domain for complex formation .
(x2 / demonstrate-01
      :ARG0 (x1 / we)
      :ARG1 (x10 / need-01
            :ARG1 (x5 / residue
                  :mod (x3 / amino-acid
                        :mod "176"
                        :name (x4 / name :op1 "tyrosine")
                        :xref (x36 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :location (x9 / domain
                        :mod (x6 / enzyme
                              :name (x7 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :mod (x8 / kinase)))
            :ARG0 (x15 / interact-01
                  :ARG0 (x11 / enzyme
                        :name (x12 / name :op1 "Ack1")
                        :xref (x33 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "AKT")
                        :xref (x34 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :ARG0-of (x16 / cause-01
                  :ARG1 (x18 / indicate-01
                        :mod (x17 / collective)
                        :ARG1 (x21 / need-01
                              :ARG0 (x19 / enzyme
                                    :name (x20 / name :op1 "Ack1")
                                    :xref (x32 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                              :ARG1 (x22 / and
                                    :op1 (x23 / and
                                          :op1 (x24 / protein-segment
                                                :name (x25 / name :op1 "PH" :op2 "domain")
                                                :part-of (x26 / enzyme
                                                      :name (x27 / name :op1 "AKT" :op2 "kinase")))
                                          :op2 (x28 / amino-acid
                                                :mod "176"
                                                :name (x29 / name :op1 "tyrosine")
                                                :xref (x35 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                                    :purpose (x31 / form-01
                                          :ARG1 (x30 / macro-molecular-complex))))))))


# ::id PMC2841635.69
# ::snt To identify the region in Ack1 that recognize AKT, MEF1&2KO cells were transfected with Myc-tagged Ack1 deletions (shown in Fig. S4A ) and HA-tagged AKT.
# ::tok To identify the region in Ack1 that recognize AKT , MEF1&2KO cells were transfected with Myc @-@ tagged Ack1 deletions ( shown in Fig . S4A ) and HA @-@ tagged AKT .
(x15 / delete-01
      :purpose (x1 / identify-01
            :ARG1 (x2 / region
                  :part-of (x4 / recognize-02
                        :name (x3 / name :op1 "Ack1")
                        :ARG1 (x5 / enzyme
                              :name (x6 / name :op1 "AKT")
                              :xref (x24 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :ARG0-of (x9 / transfect-01
                              :ARG1 (x7 / cell-line
                                    :name (x8 / name :op1 "MEF1&2KO"))
                              :ARG2 (x10 / enzyme
                                    :ARG1-of (x13 / tag-01
                                          :ARG2 (x11 / protein
                                                :name (x12 / name :op1 "Myc")
                                                :xref (x27 / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604")))
                                    :name (x14 / name :op1 "Ack1")
                                    :xref (x26 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))))))
      :ARG1-of (x16 / show-01
            :ARG0 (x18 / and
                  :op1 (x17 / figure :mod "s4a")
                  :op2 (x19 / enzyme
                        :ARG1-of (x22 / tag-01
                              :ARG2 (x20 / protein
                                    :name (x21 / name :op1 "HA")
                                    :xref (x / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
                        :name (x23 / name :op1 "AKT")
                        :xref (x25 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))


# ::id PMC2841635.71
# ::snt The Ack1 construct expressing SAM and kinase domains (cAck) was able to bind AKT, however, construct lacking a part of kinase domain (dAck) bound poorly to endogeneous AKT ( Fig. S4E , top panel).
# ::tok The Ack1 construct expressing SAM and kinase domains ( cAck ) was able to bind AKT , however , construct lacking a part of kinase domain ( dAck ) bound poorly to endogeneous AKT ( Fig . S4E , top panel ) .
(x7 / and
      :op1 (x3 / construct-01
            :ARG0 (x1 / enzyme
                  :name (x2 / name :op1 "Ack1")
                  :xref (x32 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :ARG1 (x4 / express-03
                  :ARG2 (x5 / enzyme
                        :name (x6 / name :op1 "SAM")
                        :xref (x33 / xref :value "UNIPROT:SAMC_HUMAN" :prob "0.262"))))
      :op2 (x11 / capable-01
            :ARG1 (x8 / enzyme
                  :name (x9 / name :op1 "kinase" :op2 "domain")
                  :name (x10 / name :op1 "cAck")
                  :xref (x31 / xref :value "UNIPROT:CAH2_HUMAN" :prob "0.202"))
            :ARG2 (x12 / bind-01
                  :ARG2 (x13 / enzyme
                        :name (x14 / name :op1 "AKT")
                        :xref (x34 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
      :ARG1-of (x15 / contrast-01
            :ARG2 (x16 / construct-01
                  :ARG1 (x17 / lack-01
                        :ARG1 (x18 / part
                              :part-of (x20 / domain
                                    :mod (x19 / kinase)
                                    :ARG1-of (x23 / bind-01
                                          :ARG2 (x21 / small-molecule
                                                :name (x22 / name :op1 "dAck"))))))
                  :degree (x24 / poor)
                  :ARG2 (x25 / enzyme
                        :name (x26 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :ARG1-of (x27 / describe-01
                  :ARG0 (x30 / panel
                        :part-of (x28 / figure :mod "s4e")
                        :location (x29 / top)))))


# ::id PMC2841635.72
# ::snt GST-Ack1 that possess Kinase-SH3-CRIB domains but lacking SAM domain was able to bind AKT ( Fig. S1F ).
# ::tok GST @-@ Ack1 that possess Kinase @-@ SH3 @-@ CRIB domains but lacking SAM domain was able to bind AKT ( Fig . S1F ) .
(x7 / contrast-01
      :ARG1 (x3 / possess-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "GST-Ack1"))
            :ARG1 (x4 / kinase)
            :ARG1 (x5 / protein-segment
                  :name (x6 / name
                        :op1 "SH3"
                        :op1 "CRIB"
                        :op2 "domain")))
      :ARG2 (x11 / capable-01
            :ARG1 (x8 / lack-01
                  :ARG1 (x9 / protein-segment
                        :name (x10 / name :op1 "SAM" :op2 "domain")))
            :ARG2 (x12 / bind-01
                  :ARG2 (x13 / enzyme
                        :name (x14 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / figure :mod "s1f"))))


# ::id PMC2841635.73
# ::snt Taken together it indicates that the kinase domain in Ack1 and tyrosine176 in the kinase domain along with AKT PH domain appear to be minimal domains required for efficient Ack1/AKT complex formation.
# ::tok Taken together it indicates that the kinase domain in Ack1 and tyrosine176 in the kinase domain along with AKT PH domain appear to be minimal domains required for efficient Ack1 @/@ AKT complex formation .
(x4 / indicate-01
      :ARG0 (x3 / it
            :ARG1-of (x1 / take-01
                  :mod (x2 / together)))
      :ARG1 (x21 / require-01
            :ARG1 (x6 / domain
                  :mod (x5 / kinase)
                  :location (x9 / and
                        :op1 (x7 / enzyme
                              :name (x8 / name :op1 "Ack1")
                              :xref (x30 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                        :op2 (x10 / amino-acid
                              :mod "176"
                              :name (x11 / name :op1 "tyrosine")
                              :xref (x32 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :part-of (x12 / enzyme
                              :name (x13 / name :op1 "kinase" :op2 "domain"))
                        :op2 (x14 / enzyme
                              :name (x15 / name :op1 "AKT")
                              :xref (x31 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                  :mod (x16 / protein-segment
                        :name (x17 / name :op1 "PH")
                        :ARG1-of (x18 / appear-02
                              :ARG1 (x20 / domain
                                    :ARG1-of (x19 / minimal-02)))))
            :ARG0 (x28 / form-01
                  :ARG1-of (x22 / efficient-01)
                  :ARG1 (x27 / macro-molecular-complex
                        :part (x23 / enzyme
                              :name (x24 / name :op1 "Ack1")
                              :xref (x29 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                        :part (x25 / enzyme
                              :name (x26 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))))


# ::id PMC2841635.74
# ::snt Somatic Autoactivating Mutation (E346K) in Ack1 Activates AKT
# ::tok Somatic Autoactivating Mutation ( E346K ) in Ack1 Activates AKT
(x8 / activate-01
      :ARG0 (x4 / mutate-01
            :mod (x1 / somatic)
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "Autoactivating"))
            :ARG1-of (x5 / mutate-01 :value "E346K")
            :location (x6 / enzyme
                  :name (x7 / name :op1 "Ack1")
                  :xref (x11 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
      :ARG1 (x9 / enzyme
            :name (x10 / name :op1 "AKT")
            :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))


# ::id PMC2841635.75
# ::snt While growth factor binding to RTK or amplification of the Ack1 gene causes Ack1 kinase activation [25] , [26] , [30] , somatic autoactivating mutations in Ack1 have not yet been identified.
# ::tok While growth factor binding to RTK or amplification of the Ack1 gene causes Ack1 kinase activation [ 25 ] , [ 26 ] , [ 30 ] , somatic autoactivating mutations in Ack1 have not yet been identified .
(x1 / contrast-01
      :ARG2 (x2 / growth-factor
            :ARG0-of (x3 / bind-01
                  :ARG2 (x6 / or
                        :op1 (x4 / enzyme
                              :name (x5 / name :op1 "RTK")
                              :xref (x33 / xref :value "UNIPROT:DDR1_HUMAN" :prob "0.262"))
                        :op2 (x7 / amplify-01
                              :ARG1 (x9 / gene
                                    :name (x8 / name :op1 "Ack1")
                                    :ARG0-of (x10 / cause-01
                                          :ARG1 (x11 / enzyme
                                                :name (x12 / name :op1 "Ack1")
                                                :ARG0-of (x14 / activate-01
                                                      :ARG1 (x13 / kinase))
                                                :ARG1-of (x15 / describe-01
                                                      :ARG0 (x16 / publication
                                                            :ARG1-of (x17 / cite-01 :ARG2 "25")))
                                                :xref (x34 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
                                    :ARG1-of (x18 / describe-01
                                          :ARG0 (x19 / publication
                                                :ARG1-of (x20 / cite-01 :ARG2 "26")))
                                    :xref (x32 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))))
            :ARG1-of (x21 / describe-01
                  :ARG0 (x22 / publication
                        :ARG1-of (x23 / cite-01 :ARG2 "30"))))
      :ARG1 (x31 / identify-01
            :ARG1 (x27 / mutate-01
                  :mod (x24 / somatic)
                  :ARG1 (x25 / enzyme
                        :name (x26 / name :op1 "autoactivating"))
                  :location (x28 / enzyme
                        :name (x29 / name :op1 "Ack1")
                        :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
            :polarity "-"
            :time (x30 / yet)))


# ::id PMC2841635.76
# ::snt Recently, four point mutations in Ack1, i.e. R34L, R99Q, E346K, M409I have been identified in the COSMIC database.
# ::tok Recently , four point mutations in Ack1 , i.e. R34L , R99Q , E346K , M409I have been identified in the COSMIC database .
(x12 / identify-01
      :time (x1 / recent)
      :ARG0 (x3 / mutate-01
            :quant "4"
            :mod (x2 / point)
            :location (x4 / enzyme
                  :name (x5 / name :op1 "Ack1")
                  :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :ARG1-of (x6 / mean-01
                  :ARG2 (x7 / and
                        :op1 (x8 / mutate-01 :value "R34L")
                        :op2 (x9 / mutate-01 :value "R99Q")
                        :op3 (x10 / mutate-01 :value "E346K"))))
      :ARG1 (x11 / mutate-01 :value "M409I")
      :location (x14 / database
            :name (x13 / name :op1 "COSMIC")))


# ::id PMC2841635.77
# ::snt Using site-directed mutagenesis, we generated HA-tagged point mutants ( Fig. S5A ).
# ::tok Using site @-@ directed mutagenesis , we generated HA @-@ tagged point mutants ( Fig . S5A ) .
(x6 / generate-01
      :ARG2-of (x1 / use-01
            :ARG1 (x2 / protein-segment
                  :ARG1-of (x3 / direct-01
                        :ARG2 (x4 / mutagenesis))))
      :ARG0 (x5 / we)
      :ARG1 (x11 / mutate-01
            :ARG1-of (x9 / tag-01
                  :ARG2 (x7 / protein
                        :name (x8 / name :op1 "HA")
                        :xref (x / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
            :mod (x10 / point))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / figure :mod "s5a")))


# ::id PMC2841635.78
# ::snt We tested these mutants and observed that E346K mutant undergoes autoactivation and causes AKT Tyr/Ser/Thr-phosphorylation in serum starved cells ( Fig. S5B and C ).
# ::tok We tested these mutants and observed that E346K mutant undergoes autoactivation and causes AKT Tyr/Ser/Thr @-@ phosphorylation in serum starved cells ( Fig . S5B and C ) .
(x12 / cause-01
      :ARG0 (x2 / test-01
            :ARG0 (x1 / we)
            :ARG1 (x5 / and
                  :op1 (x4 / mutate-01
                        :mod (x3 / this))
                  :op2 (x6 / observe-01
                        :ARG1 (x10 / undergo-28
                              :ARG1 (x8 / enzyme
                                    :ARG1-of (x7 / mutate-01 :value "E346K")
                                    :ARG2-of (x9 / mutate-01))
                              :ARG2 (x11 / autoactivation)))))
      :ARG1 (x15 / phosphorylate-01
            :ARG0 (x13 / enzyme
                  :name (x14 / name :op1 "AKT" :op2 "Tyr/Ser/Thr"))
            :location (x18 / cell
                  :ARG1-of (x17 / starve-01
                        :ARG2 (x16 / serum))))
      :ARG1-of (x19 / describe-01
            :ARG0 (x22 / and
                  :op1 (x20 / figure :mod "s5b")
                  :op2 (x21 / figure :mod "4c"))))


# ::id PMC2841635.79
# ::snt Earlier we and others have characterized a point mutant (L487F mutation) that leads to constitutive activation of Ack1, also called caAck [26] , [32] .
# ::tok Earlier we and others have characterized a point mutant ( L487F mutation ) that leads to constitutive activation of Ack1 , also called caAck [ 26 ] , [ 32 ] .
(x7 / have-03
      :time (x1 / early
            :degree (x2 / more))
      :ARG0 (x4 / and
            :op1 (x3 / we)
            :op2 (x5 / person
                  :mod (x6 / other)))
      :ARG1 (x8 / characterize-01
            :ARG0 (x10 / mutate-01
                  :mod (x9 / point)
                  :ARG1-of (x13 / mutate-01
                        :ARG2 (x11 / enzyme
                              :name (x12 / name :op1 "L487F"))))
            :ARG0-of (x14 / lead-03
                  :ARG2 (x16 / activate-01
                        :mod (x15 / constitutive)
                        :ARG1 (x17 / enzyme
                              :name (x18 / name :op1 "Ack1")
                              :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
                  :ARG1 (x20 / call-01
                        :mod (x19 / also)
                        :ARG0-of (x21 / caack)
                        :ARG1-of (x22 / describe-01
                              :ARG0 (x23 / publication
                                    :ARG1-of (x24 / cite-01 :ARG2 "26")))))
            :ARG1-of (x25 / describe-01
                  :ARG0 (x26 / publication
                        :ARG1-of (x27 / cite-01 :ARG2 "32")))))


# ::id PMC2841635.80
# ::snt Both caAck(L487F mutant) and E346K autoactivating mutant of Ack1 exhibited Tyr284-phosphorylation in the activation loop ( Fig. S5D ).
# ::tok Both caAck ( L487F mutant ) and E346K autoactivating mutant of Ack1 exhibited Tyr284 @-@ phosphorylation in the activation loop ( Fig . S5D ) .
(x13 / exhibit-01
      :ARG0 (x6 / and
            :op1 (x1 / protein
                  :name (x2 / name :op1 "caAck")
                  :ARG1-of (x5 / mutate-01
                        :ARG2 (x3 / enzyme
                              :name (x4 / name :op1 "L487F"))))
            :op2 (x10 / mutate-01
                  :ARG1 (x7 / enzyme
                        :ARG1-of (x8 / mutate-01 :value "E346K")
                        :name (x9 / name :op1 "autoactivating"))
                  :ARG2 (x11 / enzyme
                        :name (x12 / name :op1 "Ack1")
                        :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))))
      :ARG1 (x16 / phosphorylate-01
            :ARG1 (x14 / amino-acid
                  :mod "284"
                  :name (x15 / name :op1 "tyrosine")
                  :xref (x21 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :location (x18 / loop
                  :ARG0-of (x17 / activate-01)))
      :ARG1-of (x19 / describe-01
            :ARG0 (x20 / figure :mod "s5d")))


# ::id PMC2841635.81
# ::snt We also measured the intrinsic kinase activity of the Y176F mutant and the wildtype AKT in the absence and presence of activated Ack1.
# ::tok We also measured the intrinsic kinase activity of the Y176F mutant and the wildtype AKT in the absence and presence of activated Ack1 .
(x2 / measure-01
      :ARG0 (x1 / we)
      :ARG1 (x6 / activity-06
            :ARG1 (x3 / enzyme
                  :mod (x4 / intrinsic)
                  :name (x5 / name :op1 "kinase")
                  :xref (x21 / xref :value "UNIPROT:ITK_HUMAN" :prob "0.293"))
            :ARG0 (x8 / enzyme
                  :ARG1-of (x7 / mutate-01 :value "Y176F")
                  :ARG2-of (x9 / mutate-01)))
      :ARG1 (x10 / and
            :op1 (x11 / gene
                  :mod (x12 / wild-type)
                  :name (x13 / name :op1 "AKT")
                  :xref (x20 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :ARG2 (x14 / and
            :op2 (x15 / present-02)
            :op1 (x16 / absent-01
                  :ARG1 (x17 / enzyme
                        :ARG1-of (x18 / activate-01)
                        :name (x19 / name :op1 "Ack1")
                        :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))))


# ::id PMC2841635.82
# ::snt The wildtype AKT displays significant increase in the kinase activity as compared to the Y176F mutant when coexpressed with either one of the Ack1 constructs, E346K and caAck ( Fig. S5E and F ).
# ::tok The wildtype AKT displays significant increase in the kinase activity as compared to the Y176F mutant when coexpressed with either one of the Ack1 constructs , E346K and caAck ( Fig . S5E and F ) .
(x6 / increase-01
      :ARG0 (x4 / epidermis
            :mod (x1 / gene
                  :mod (x2 / wild-type)
                  :name (x3 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :ARG2 (x5 / significant-02)
      :ARG1 (x8 / activity-06
            :ARG0 (x7 / kinase))
      :ARG1-of (x10 / mutate-01
            :compared-to (x9 / mutate-01 :value "Y176F")
            :time (x11 / coexpress-01
                  :ARG2 (x17 / and
                        :mod (x12 / either)
                        :op1 (x15 / construct-01
                              :quant "1"
                              :ARG1 (x13 / enzyme
                                    :name (x14 / name :op1 "Ack1")
                                    :xref (x24 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                              :ARG1-of (x16 / mutate-01 :value "E346K"))
                        :op2 (x18 / enzyme
                              :name (x19 / name :op1 "caAck")))))
      :ARG1-of (x20 / describe-01
            :ARG0 (x21 / and
                  :op1 (x22 / figure :mod "s5e")
                  :op1 (x23 / figure :mod "s5f"))))


# ::id PMC2841635.83
# ::snt These results demonstrate that the somatic autoactivating mutations in Ack1 are sufficient to activate AKT.
# ::tok These results demonstrate that the somatic autoactivating mutations in Ack1 are sufficient to activate AKT .
(x4 / demonstrate-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x11 / suffice-01
            :ARG0 (x8 / mutate-01
                  :mod (x5 / somatic)
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "autoactivating"))
                  :location (x9 / enzyme
                        :name (x10 / name :op1 "Ack1")
                        :xref (x15 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
            :ARG1 (x12 / activate-01
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))


# ::id PMC2841635.84
# ::snt Taken together with the earlier evidence indicating direct Ack1-AKT interaction, it opens an intriguing possibility of RTK/PI3K-independent AKT activation in tumors that is mediated by (auto) activated Ack1.
# ::tok Taken together with the earlier evidence indicating direct Ack1 @-@ AKT interaction , it opens an intriguing possibility of RTK @/@ PI3K @-@ independent AKT activation in tumors that is mediated by ( auto ) activated Ack1 .
(x13 / open-01
      :ARG1-of (x1 / take-01
            :mod (x2 / together)
            :ARG2 (x5 / evidence-01
                  :time (x3 / early
                        :degree (x4 / more))
                  :ARG0-of (x6 / indicate-01
                        :ARG1 (x12 / interact-01
                              :ARG1-of (x7 / direct-02)
                              :ARG0 (x8 / enzyme
                                    :name (x9 / name :op1 "Ack1")
                                    :xref (x32 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                              :ARG1 (x10 / enzyme
                                    :name (x11 / name :op1 "AKT")
                                    :xref (x34 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))))
      :ARG1 (x14 / intrigue-01
            :ARG1 (x24 / activate-01
                  :ARG1-of (x15 / possible-01
                        :ARG1 (x21 / depend-01
                              :ARG1 (x18 / slash
                                    :op1 (x16 / enzyme
                                          :name (x17 / name :op1 "RTK")
                                          :xref (x35 / xref :value "UNIPROT:DDR1_HUMAN" :prob "0.262"))
                                    :op2 (x19 / enzyme
                                          :name (x20 / name :op1 "PI3K")
                                          :xref (x33 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                              :polarity "-"))
                  :ARG1 (x22 / enzyme
                        :name (x23 / name :op1 "AKT")
                        :xref (x31 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :location (x25 / tumor)
            :ARG1-of (x26 / mediate-01
                  :ARG0 (x27 / automate-01)
                  :ARG1 (x28 / enzyme
                        :ARG1-of (x29 / activate-01)
                        :name (x30 / name :op1 "Ack1")
                        :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))))


# ::id PMC2841635.85
# ::snt Tyr176-Phosphorylated AKT Translocates to the Plasma Membrane Leading to AKT Activation
# ::tok Tyr176 @-@ Phosphorylated AKT Translocates to the Plasma Membrane Leading to AKT Activation
(x3 / phosphorylate-01
      :ARG1 (x1 / amino-acid
            :mod "176"
            :name (x2 / name :op1 "tyrosine")
            :xref (x15 / xref :value "PUBCHEM:1153" :prob "11.081481"))
      :ARG2 (x4 / enzyme
            :name (x5 / name :op1 "AKT")
            :xref (x13 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
      :ARG1-of (x6 / translocate-00)
      :ARG2 (x8 / membrane
            :mod (x7 / plasma)
            :ARG0-of (x9 / lead-03
                  :ARG2 (x12 / activate-01
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
            :xref (x14 / xref :value "GO:0016020" :prob "0.8")))


# ::id PMC2841635.86
# ::snt Mechanistically, targeting AKT to the plasma membrane is necessary for AKT activation [1] , [6] , [7] , [13] .
# ::tok Mechanistically , targeting AKT to the plasma membrane is necessary for AKT activation [ 1 ] , [ 6 ] , [ 7 ] , [ 13 ] .
(x1 / mechanistic
      :ARG1 (x7 / need-01
            :ARG1 (x2 / target-01
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "AKT")
                        :xref (x21 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :ARG2 (x6 / membrane
                        :mod (x5 / plasma)
                        :xref (x22 / xref :value "GO:0016020" :prob "0.8")))
            :purpose (x10 / activate-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :ARG1-of (x11 / describe-01
                        :ARG0-of (x12 / cite-01
                              :ARG2 (x13 / and
                                    :op1 "6"
                                    :op2 (x17 / describe-01
                                          :ARG1-of (x14 / describe-01
                                                :ARG0 (x15 / publication
                                                      :ARG1-of (x16 / cite-01 :ARG2 "7"))))))
                        :ARG1-of (x18 / describe-01
                              :ARG0 (x19 / publication
                                    :ARG1-of (x20 / cite-01 :ARG2 "13")))))))


# ::id PMC2841635.87
# ::snt Loss of the PH domain resulted in decrease in AKT Tyr-phosphorylation upon co-expression with activated Ack1 ( Fig. S4A , C and D ).
# ::tok Loss of the PH domain resulted in decrease in AKT Tyr @-@ phosphorylation upon co @-@ expression with activated Ack1 ( Fig . S4A , C and D ) .
(x1 / lose-02
      :ARG1 (x2 / protein-segment
            :name (x3 / name :op1 "PH")
            :ARG1-of (x4 / result-01
                  :ARG2 (x5 / decrease-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "AKT")
                              :xref (x20 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                  :manner (x10 / phosphorylate-01
                        :ARG1 (x8 / amino-acid
                              :name (x9 / name :op1 "tyrosine")
                              :xref (x21 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                  :time (x11 / after
                        :op1 (x12 / express-03
                              :ARG2 (x13 / enzyme
                                    :ARG1-of (x14 / activate-01)
                                    :name (x15 / name :op1 "Ack1")
                                    :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))))
                  :ARG1-of (x16 / describe-01
                        :ARG0 (x18 / and
                              :op1 (x17 / figure :mod "s4a")
                              :op2 (x19 / figure :mod "5d"))))))


# ::id PMC2841635.88
# ::snt Further, Ack1 interacts with RTKs which are located in the membrane [25] , [26] , [28] .
# ::tok Further , Ack1 interacts with RTKs which are located in the membrane [ 25 ] , [ 26 ] , [ 28 ] .
(x4 / interact-01
      :mod (x1 / further)
      :ARG0 (x2 / enzyme
            :name (x3 / name :op1 "Ack1")
            :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
      :ARG1 (x5 / enzyme
            :name (x6 / name :op1 "rtk")
            :xref (x21 / xref :value "UNIPROT:DDR1_HUMAN" :prob "0.202"))
      :mod (x7 / be-located-at-91
            :ARG2 (x8 / membrane
                  :xref (x22 / xref :value "GO:0016020" :prob "0.8"))
            :ARG1-of (x9 / describe-01
                  :ARG0 (x10 / publication
                        :ARG1-of (x11 / cite-01 :ARG2 "25")))
            :ARG0-of (x17 / describe-01
                  :ARG1-of (x12 / describe-01
                        :ARG2 (x13 / enzyme
                              :name (x14 / name :op1 "[")))
                  :ARG0 (x15 / publication
                        :ARG1-of (x16 / cite-01 :ARG2 "26")))
            :ARG1-of (x18 / describe-01
                  :ARG0 (x19 / publication
                        :ARG1-of (x20 / cite-01 :ARG2 "28")))))


# ::id PMC2841635.89
# ::snt These attributes suggest that activated Ack1 could engage AKT at the plasma membrane.
# ::tok These attributes suggest that activated Ack1 could engage AKT at the plasma membrane .
(x3 / suggest-01
      :ARG0 (x2 / attribute-01
            :mod (x1 / this))
      :ARG1 (x4 / possible-01
            :ARG1 (x8 / engage-01
                  :ARG0 (x5 / enzyme
                        :ARG1-of (x6 / activate-01)
                        :name (x7 / name :op1 "Ack1")
                        :xref (x13 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                  :ARG1 (x9 / enzyme
                        :name (x10 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :location (x12 / membrane
                        :mod (x11 / plasma)
                        :xref (x14 / xref :value "GO:0016020" :prob "0.8")))))


# ::id PMC2841635.90
# ::snt To investigate the role of AKT Tyr176-phosphorylation on its cellular compartmentalization, we generated phospho-antibodies that specifically recognized Tyr176-phosphorylated AKT or pTyr176-AKT (details in SI methods ).
# ::tok To investigate the role of AKT Tyr176 @-@ phosphorylation on its cellular compartmentalization , we generated phospho @-@ antibodies that specifically recognized Tyr176 @-@ phosphorylated AKT or pTyr176 @-@ AKT ( details in SI methods ) .
(x11 / generate-01
      :purpose (x1 / investigate-01
            :ARG1 (x2 / role
                  :poss (x3 / enzyme
                        :name (x4 / name :op1 "AKT")
                        :xref (x28 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :ARG1-of (x7 / phosphorylate-01
                        :ARG0 (x5 / amino-acid
                              :mod "176"
                              :name (x6 / name :op1 "tyrosine")
                              :xref (x29 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :location (x8 / cell
                              :name (x9 / name :op1 "compartmentalization")))))
      :ARG0 (x10 / we)
      :ARG1 (x20 / or
            :op1 (x12 / phosphorylate-01
                  :ARG2 (x13 / antibody
                        :ARG0-of (x15 / recognize-02
                              :ARG1-of (x14 / specific-02)
                              :ARG1 (x18 / phosphorylate-01
                                    :ARG1 (x16 / amino-acid
                                          :mod "176"
                                          :name (x17 / name :op1 "tyrosine")
                                          :xref (x30 / xref :value "PUBCHEM:1153" :prob "11.081481"))))
                        :name (x19 / name :op1 "AKT")))
            :op2 (x21 / enzyme
                  :name (x22 / name :op1 "pTyr176")
                  :mod (x23 / enzyme
                        :name (x24 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
      :ARG1-of (x25 / detail-01
            :location (x27 / method
                  :mod (x26 / small))))


# ::id PMC2841635.91
# ::snt The antibodies were extensively validated ( Fig. 2A , Fig. S6A , also see top panels of Fig. 2B, C and E , Fig. S6B ).
# ::tok The antibodies were extensively validated ( Fig . 2A , Fig . S6A , also see top panels of Fig . 2B , C and E , Fig . S6B ) .
(x3 / validate-01
      :ARG1 (x1 / antibody)
      :ARG1-of (x2 / extensive-03)
      :ARG1-of (x4 / describe-01
            :ARG0 (x5 / and
                  :op1 (x6 / figure :mod "2a")
                  :op2 (x10 / see-01
                        :ARG1-of (x7 / describe-01
                              :ARG0 (x8 / figure :mod "s6a"))
                        :mod (x9 / also)
                        :location (x11 / panel
                              :consist-of (x13 / and
                                    :op1 (x12 / figure :mod "2b")
                                    :op2 (x14 / figure :mod "3e"))))
                  :op3 (x15 / figure :mod "s6b"))))


# ::id PMC2841635.92
# ::snt Normal prostate epithelial cells, RWPE, exhibited pTyr176-AKT expression upon treatment with EGF and heregulin ligand ( Fig. 2A ).
# ::tok Normal prostate epithelial cells , RWPE , exhibited pTyr176 @-@ AKT expression upon treatment with EGF and heregulin ligand ( Fig . 2A ) .
(x6 / exhibit-01
      :ARG1 (x4 / cell
            :mod (x2 / prostate
                  :ARG1-of (x1 / normal-02))
            :source (x3 / epithelium)
            :name (x5 / name :op1 "rwpe-erg"))
      :ARG1 (x11 / express-03
            :ARG1 (x7 / enzyme
                  :name (x8 / name :op1 "pTyr176"))
            :ARG2 (x9 / enzyme
                  :name (x10 / name :op1 "AKT")
                  :xref (x20 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :condition (x12 / treat-04
            :ARG2 (x15 / and
                  :op1 (x13 / protein
                        :name (x14 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :op2 (x17 / ligand
                        :name (x16 / name :op1 "heregulin"))))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / figure :mod "2a")))


# ::id PMC2841635.93
# ::snt The pTyr176-AKT was detected when activated Ack1 was coexpressed with AKT but not the Y176F mutant.
# ::tok The pTyr176 @-@ AKT was detected when activated Ack1 was coexpressed with AKT but not the Y176F mutant .
(x12 / contrast-01
      :ARG1 (x5 / detect-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "pTyr176")
                  :mod (x3 / enzyme
                        :name (x4 / name :op1 "AKT")
                        :xref (x15 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :time (x9 / coexpress-01
                  :ARG1 (x6 / enzyme
                        :ARG1-of (x7 / activate-01)
                        :name (x8 / name :op1 "Ack1")
                        :xref (x16 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                  :ARG2 (x10 / enzyme
                        :name (x11 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
      :ARG2 (x14 / mutate-01
            :polarity "-"
            :mod (x13 / mutate-01 :value "Y176F")))


# ::id PMC2841635.94
# ::snt Further, incubation of the pTyr176-AKT-antibody with phosphoAKT-Y176-peptide resulted in loss of binding to Tyr176-phosphorylated AKT ( Fig. S6A ).
# ::tok Further , incubation of the pTyr176 @-@ AKT @-@ antibody with phosphoAKT @-@ Y176 @-@ peptide resulted in loss of binding to Tyr176 @-@ phosphorylated AKT ( Fig . S6A ) .
(x13 / result-01
      :ARG1 (x2 / incubate-01
            :mod (x1 / further)
            :ARG1 (x3 / enzyme
                  :name (x4 / name :op1 "pTyr176")
                  :mod (x5 / enzyme
                        :name (x6 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :ARG2 (x7 / and
                  :op1 (x8 / antibody)
                  :op2 (x12 / peptide
                        :name (x9 / name :op1 "phosphoAKT")
                        :ARG1-of (x10 / amino-acid
                              :mod "176"
                              :name (x11 / name :op1 "tyrosine")
                              :xref (x25 / xref :value "PUBCHEM:1153" :prob "11.081481")))))
      :ARG2 (x14 / lose-02
            :ARG1 (x15 / bind-01
                  :ARG2 (x16 / and
                        :op1 (x17 / amino-acid
                              :mod "176"
                              :name (x18 / name :op1 "tyrosine")
                              :xref (x26 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :op2 (x19 / enzyme
                              :ARG3-of (x20 / phosphorylate-01)
                              :name (x21 / name :op1 "AKT")
                              :xref (x24 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :ARG1-of (x22 / describe-01
                              :ARG0 (x23 / figure :mod "s6a"))))))


# ::id PMC2841635.95
# ::snt Cell fractionation studies revealed that heregulin, insulin and EGF treatment resulted in a time-dependent accumulation of pTyr176-AKT at the plasma membrane that lead to AKT activation ( Fig. 2B, C and Fig. S6B , top panels).
# ::tok Cell fractionation studies revealed that heregulin , insulin and EGF treatment resulted in a time @-@ dependent accumulation of pTyr176 @-@ AKT at the plasma membrane that lead to AKT activation ( Fig . 2B , C and Fig . S6B , top panels ) .
(x4 / reveal-01
      :ARG0 (x3 / study-01
            :mod (x1 / cell-line
                  :name (x2 / name :op1 "fractionation")))
      :ARG1 (x9 / and
            :op1 (x5 / cell-line
                  :name (x6 / name :op1 "heregulin")
                  :mod (x7 / protein
                        :name (x8 / name :op1 "insulin")
                        :xref (x34 / xref :value "UNIPROT:INS_HUMAN" :prob "0.703")))
            :op2 (x13 / result-01
                  :ARG1 (x12 / treat-04
                        :ARG2 (x10 / protein
                              :name (x11 / name :op1 "EGF")
                              :xref (x36 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG2 (x16 / accumulate-01
                        :ARG0-of (x15 / depend-01
                              :ARG1 (x14 / time))
                        :ARG1 (x17 / enzyme
                              :name (x18 / name :op1 "pTyr176")
                              :mod (x19 / enzyme
                                    :name (x20 / name :op1 "AKT")
                                    :xref (x35 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                        :location (x22 / membrane
                              :mod (x21 / plasma)
                              :xref (x37 / xref :value "GO:0016020" :prob "0.8"))))
            :ARG0-of (x23 / lead-03
                  :ARG2 (x26 / activate-01
                        :ARG1 (x24 / enzyme
                              :name (x25 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))
      :ARG1-of (x27 / describe-01
            :ARG0 (x28 / and
                  :op1 (x29 / figure :mod "2b")
                  :op2 (x30 / figure :mod "5c")
                  :op3 (x31 / figure
                        :mod "s6b"
                        :location (x33 / panel
                              :mod (x32 / top))))))


# ::id PMC2841635.96
# ::snt Optimal AKT Tyr-176 phosphorylation and plasma membrane accumulation was observed at 10, 30 and 40 mins upon EGF, insulin and heregulin ligand treatments, respectively ( Fig. S6B and Fig. 2B, C ).
# ::tok Optimal AKT Tyr @-@ 176 phosphorylation and plasma membrane accumulation was observed at 10 , 30 and 40 mins upon EGF , insulin and heregulin ligand treatments , respectively ( Fig . S6B and Fig . 2B , C ) .
(x5 / and
      :op1 (x4 / phosphorylate-01
            :mod (x1 / optimal)
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "AKT" :op2 "Tyr-176")))
      :op2 (x9 / observe-01
            :ARG1 (x8 / accumulate-01
                  :ARG0 (x7 / membrane
                        :mod (x6 / plasma)
                        :xref (x27 / xref :value "GO:0016020" :prob "0.8")))
            :location (x10 / and
                  :op1 "10"
                  :op2 "30"
                  :op3 "40")
            :ARG2 (x11 / minute)
            :time (x19 / treat-04
                  :ARG2 (x16 / and
                        :op1 (x12 / protein
                              :name (x13 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                        :op2 (x14 / protein
                              :name (x15 / name :op1 "insulin")
                              :xref (x26 / xref :value "UNIPROT:INS_HUMAN" :prob "0.703"))
                        :op3 (x18 / ligand
                              :name (x17 / name :op1 "heregulin")))))
      :ARG1-of (x20 / describe-01
            :ARG0 (x22 / and
                  :op1 (x21 / figure :mod "s6b")
                  :op2 (x23 / and
                        :op1 (x24 / figure :mod "2b")
                        :op2 (x25 / figure :mod "4c")))))


# ::id PMC2841635.97
# ::snt To assess whether EGF mediated AKT activation is dependent upon Tyr176-phosphorylation, MEF1&2KO cells expressing AKT or Y176F mutant were treated with EGF ligand.
# ::tok To assess whether EGF mediated AKT activation is dependent upon Tyr176 @-@ phosphorylation , MEF1&2KO cells expressing AKT or Y176F mutant were treated with EGF ligand .
(x19 / treat-04
      :purpose (x1 / assess-01
            :ARG1 (x4 / mediate-01
                  :mode "interrogative"
                  :ARG0 (x2 / protein
                        :name (x3 / name :op1 "EGF")
                        :xref (x22 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :ARG1 (x8 / depend-01
                        :ARG0 (x7 / activate-01
                              :ARG1 (x5 / enzyme
                                    :name (x6 / name :op1 "AKT")
                                    :xref (x23 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                        :ARG1 (x11 / phosphorylate-01
                              :ARG1 (x9 / amino-acid
                                    :mod "176"
                                    :name (x10 / name :op1 "tyrosine")
                                    :xref (x24 / xref :value "PUBCHEM:1153" :prob "11.081481"))))))
      :ARG1 (x13 / cell
            :name (x12 / name :op1 "MEF1&2KO")
            :ARG2-of (x14 / express-03
                  :ARG2 (x17 / or
                        :op1 (x15 / enzyme
                              :name (x16 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :op2 (x18 / mutate-01 :value "Y176F"))))
      :ARG2 (x21 / ligand
            :name (x20 / name :op1 "EGF")))


# ::id PMC2841635.98
# ::snt The Y176F mutant failed to translocate to the plasma membrane and become activated by EGF ( Fig. 2D ).
# ::tok The Y176F mutant failed to translocate to the plasma membrane and become activated by EGF ( Fig . 2D ) .
(x4 / fail-01
      :ARG0 (x2 / enzyme
            :ARG1-of (x1 / mutate-01 :value "Y176F")
            :ARG2-of (x3 / mutate-01))
      :ARG2 (x8 / and
            :op1 (x5 / translocate-01
                  :ARG2 (x7 / membrane
                        :mod (x6 / plasma)
                        :xref (x15 / xref :value "GO:0016020" :prob "0.8")))
            :op2 (x9 / become-01
                  :ARG2 (x10 / activate-01
                        :ARG0 (x11 / protein
                              :name (x12 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure :mod "2d")))


# ::id PMC2841635.99
# ::snt The basal levels of pTyr176-AKT seen in cytosolic fraction ( Fig. 2D , panel 2, lanes 4–6) is likely to be Tyr-phosphorylated AKT3.
# ::tok The basal levels of pTyr176 @-@ AKT seen in cytosolic fraction ( Fig . 2D , panel 2 , lanes 4–6 ) is likely to be Tyr @-@ phosphorylated AKT3 .
(x7 / see-01
      :ARG1 (x2 / level
            :mod (x1 / basal)
            :quant-of (x3 / enzyme
                  :name (x4 / name :op1 "pTyr176")
                  :mod (x5 / enzyme
                        :name (x6 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
      :location (x9 / fraction
            :mod (x8 / cytosol
                  :xref (x24 / xref :value "GO:0005829" :prob "0.8"))
            :ARG1-of (x10 / describe-01
                  :ARG0 (x11 / figure :mod "2d")))
      :ARG1-of (x17 / likely-01
            :ARG2 (x12 / and
                  :op1 (x13 / enzyme
                        :name (x14 / name :op1 "erk2")
                        :xref (x23 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.603"))
                  :op2 (x15 / lane
                        :mod (x16 / value-interval :op1 "4" :op2 "6")))
            :ARG1 (x20 / phosphorylate-01
                  :ARG1 (x18 / amino-acid
                        :name (x19 / name :op1 "tyrosine")
                        :xref (x25 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2 (x21 / protein
                        :name (x22 / name :op1 "AKT3")))))


# ::id PMC2841635.100
# ::snt Depletion of Ack1 by siRNA abrogated heregulin mediated AKT Tyr176-phosphorylation, plasma membrane localization and activation in MCF-7 cells ( Fig. 2E ) and MEFs (unpublished data).
# ::tok Depletion of Ack1 by siRNA abrogated heregulin mediated AKT Tyr176 @-@ phosphorylation , plasma membrane localization and activation in MCF @-@ 7 cells ( Fig . 2E ) and MEFs ( unpublished data ) .
(x6 / abrogate-01
      :ARG0 (x1 / deplete-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "Ack1")
                  :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :ARG0 (x4 / nucleic-acid
                  :name (x5 / name :op1 "siRNA")))
      :ARG1 (x9 / mediate-01
            :ARG0 (x7 / enzyme
                  :name (x8 / name :op1 "heregulin")
                  :xref (x30 / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.703"))
            :ARG1 (x19 / activate-01
                  :ARG1 (x18 / and
                        :op1 (x10 / enzyme
                              :name (x11 / name :op1 "AKT")
                              :xref (x31 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :op2 (x14 / phosphorylate-01
                              :ARG1 (x12 / amino-acid
                                    :mod "176"
                                    :name (x13 / name :op1 "tyrosine")
                                    :xref (x33 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                        :ARG0-of (x17 / be-located-at-91
                              :ARG2 (x16 / membrane
                                    :mod (x15 / plasma)
                                    :xref (x32 / xref :value "GO:0016020" :prob "0.8"))))
                  :location (x21 / cell-line
                        :name (x20 / name :op1 "MCF-7")))
            :ARG1-of (x22 / describe-01
                  :ARG0 (x24 / and
                        :op1 (x23 / figure :mod "2e")
                        :op2 (x25 / cell
                              :name (x26 / name :op1 "mef")))))
      :ARG1-of (x27 / describe-01
            :ARG0 (x29 / data
                  :ARG1-of (x28 / publish-01 :polarity "-"))))


# ::id PMC2841635.101
# ::snt Further, GFP-E346K recruited dsRed-AKT but not the dsRed-Y176F mutant to the plasma membrane as assessed by immunofluorescence ( Fig. S6C –J ).
# ::tok Further , GFP @-@ E346K recruited dsRed @-@ AKT but not the dsRed @-@ Y176F mutant to the plasma membrane as assessed by immunofluorescence ( Fig . S6C –J ) .
(x5 / recruit-01
      :mod (x1 / further)
      :ARG0 (x2 / protein
            :name (x3 / name :op1 "GFP")
            :ARG1-of (x4 / mutate-01 :value "E346K")
            :xref (x23 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))
      :ARG1 (x6 / enzyme
            :name (x7 / name :op1 "dsRed")
            :mod (x8 / enzyme
                  :name (x9 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :xref (x24 / xref :value "UNIPROT:Q9BYM5_HUMAN" :prob "0.241"))
      :ARG1-of (x10 / contrast-01
            :ARG2 (x11 / possible-01
                  :polarity "-"
                  :ARG1 (x15 / mutate-01
                        :ARG1 (x12 / enzyme
                              :name (x13 / name :op1 "dsRed")
                              :ARG2-of (x14 / mutate-01 :value "Y176F")
                              :xref (x25 / xref :value "UNIPROT:Q9BYM5_HUMAN" :prob "0.241")))))
      :ARG2 (x17 / membrane
            :mod (x16 / plasma)
            :xref (x26 / xref :value "GO:0016020" :prob "0.8"))
      :ARG1-of (x18 / assess-01
            :ARG0 (x19 / immunofluoresce-01
                  :ARG1-of (x20 / describe-01
                        :ARG0 (x21 / figure :mod "s6c"))
                  :name (x22 / name :op1 "–J"))))


# ::id PMC2841635.102
# ::snt Taken together, these data suggest that Ack1 is a key intermediate signaling entity necessary for RTK mediated AKT Tyr176-phosphorylation.
# ::tok Taken together , these data suggest that Ack1 is a key intermediate signaling entity necessary for RTK mediated AKT Tyr176 @-@ phosphorylation .
(x5 / suggest-01
      :ARG0 (x4 / data
            :ARG1-of (x1 / take-01
                  :mod (x2 / together))
            :mod (x3 / this))
      :ARG1 (x19 / phosphorylate-01
            :ARG0 (x6 / enzyme
                  :name (x7 / name :op1 "Ack1")
                  :xref (x21 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :degree (x8 / intermediate
                  :ARG0-of (x9 / signal-07)
                  :ARG1-of (x10 / key-02
                        :ARG2 (x11 / need-01
                              :ARG0 (x14 / mediate-01
                                    :ARG0 (x12 / enzyme
                                          :name (x13 / name :op1 "RTK")
                                          :xref (x20 / xref :value "UNIPROT:DDR1_HUMAN" :prob "0.262")))
                              :ARG1 (x15 / enzyme
                                    :name (x16 / name :op1 "AKT")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))
            :ARG1 (x17 / amino-acid
                  :mod "176"
                  :name (x18 / name :op1 "tyrosine")
                  :xref (x22 / xref :value "PUBCHEM:1153" :prob "11.081481"))))


# ::id PMC2841635.103
# ::snt Tyr176-phosphorylation regulates AKT plasma membrane localization.
# ::tok Tyr176 @-@ phosphorylation regulates AKT plasma membrane localization .
(x4 / regulate-01
      :ARG0 (x3 / phosphorylate-01
            :ARG1 (x1 / amino-acid
                  :mod "176"
                  :name (x2 / name :op1 "tyrosine")
                  :xref (x11 / xref :value "PUBCHEM:1153" :prob "11.081481")))
      :ARG1 (x9 / be-located-at-91
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :ARG2 (x8 / membrane
                  :mod (x7 / plasma)
                  :xref (x10 / xref :value "GO:0016020" :prob "0.8"))))


# ::id PMC2841635.104
# ::snt Cell lysates were fractionated and IB with the indicated antibodies.
# ::tok Cell lysates were fractionated and IB with the indicated antibodies .
(x4 / and
      :op1 (x3 / fractionate-00
            :ARG1 (x2 / lysate
                  :mod (x1 / cell)))
      :op2 (x5 / immunoblot-01
            :ARG3 (x7 / antibody
                  :ARG1-of (x6 / indicate-01))))


# ::id PMC2841635.105
# ::snt Input panels pAck1(Tyr), pIR(Tyr) and pHER-2(Tyr) represents IP with respective antibodies followed by IB with pTyr antibodies.
# ::tok Input panels pAck1 ( Tyr ) , pIR ( Tyr ) and pHER @-@ 2 ( Tyr ) represents IP with respective antibodies followed by IB with pTyr antibodies .
(x11 / and
      :op1 (x2 / panel
            :mod (x1 / input)
            :name (x3 / name :op1 "pAck1")
            :ARG1-of (x4 / and
                  :op1 (x5 / amino-acid
                        :name (x6 / name :op1 "tyrosine")
                        :xref (x27 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :op2 (x7 / protein
                        :name (x8 / name :op1 "pIR"))
                  :op3 (x9 / enzyme
                        :name (x10 / name :op1 "tyrosine")
                        :xref (x / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))))
      :op2 (x12 / cell-line
            :name (x13 / name :op1 "pHER")
            :ARG0-of (x16 / represent-01
                  :ARG0 (x14 / amino-acid
                        :name (x15 / name :op1 "tyrosine")
                        :xref (x28 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG1 (x17 / and
                        :op1 (x18 / protein
                              :name (x19 / name :op1 "ip-10")
                              :xref (x26 / xref :value "UNIPROT:CXL10_HUMAN" :prob "0.663"))
                        :op2 (x21 / antibody
                              :mod (x20 / respective)
                              :ARG2-of (x22 / follow-01
                                    :ARG1 (x23 / immunoblot-01
                                          :ARG3 (x25 / antibody
                                                :name (x24 / name :op1 "pTyr")))))))))


# ::id PMC2841635.106
# ::snt Cell lysates were fractionated and IB with anti-HA (top panel) and indicated antibodies (bottom panels).
# ::tok Cell lysates were fractionated and IB with anti @-@ HA ( top panel ) and indicated antibodies ( bottom panels ) .
(x4 / and
      :op1 (x3 / fractionate-00
            :ARG1 (x2 / lysate
                  :mod (x1 / cell)))
      :op2 (x5 / immunoblot-01
            :ARG3 (x6 / antibody
                  :ARG0-of (x7 / counter-01
                        :ARG1 (x8 / protein
                              :name (x9 / name :op1 "HA")
                              :xref (x / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))))
      :ARG1-of (x10 / describe-01
            :ARG0 (x13 / and
                  :op1 (x12 / panel
                        :mod (x11 / top))
                  :op2 (x15 / antibody
                        :ARG1-of (x14 / indicate-01)
                        :ARG1-of (x16 / describe-01
                              :ARG0 (x18 / panel
                                    :mod (x17 / bottom)))))))


# ::id PMC2841635.107
# ::snt Cell lysates were fractionated and IB with indicated antibodies.
# ::tok Cell lysates were fractionated and IB with indicated antibodies .
(x4 / and
      :op1 (x3 / fractionate-00
            :ARG1 (x2 / lysate
                  :mod (x1 / cell)))
      :op2 (x5 / immunoblot-01
            :ARG3 (x7 / antibody
                  :ARG1-of (x6 / indicate-01))))


# ::id PMC2841635.108
# ::snt In this experiment we have used half the volumes buffer for extraction of cytosolic proteins.
# ::tok In this experiment we have used half the volumes buffer for extraction of cytosolic proteins .
(x4 / use-01
      :location (x2 / experiment-01
            :mod (x1 / this))
      :ARG0 (x3 / we)
      :ARG1 (x7 / buffer
            :mod (x5 / half)
            :mod (x6 / volume))
      :ARG2 (x8 / extract-01)
      :ARG1 (x10 / protein
            :mod (x9 / cytosolic)))


# ::id PMC2841635.109
# ::snt Thus, the cytosolic extracts are 2X concentrated as compared to Fig.
# ::tok Thus , the cytosolic extracts are 2X concentrated as compared to Fig .
(x1 / cause-01
      :ARG1 (x6 / concentrate-01
            :ARG1 (x3 / extract-01
                  :ARG2 (x2 / cytosol
                        :xref (x / xref :value "GO:0005829" :prob "0.8")))
            :ARG2 (x4 / enzyme
                  :name (x5 / name :op1 "2X"))
            :ARG1-of (x7 / compare-01
                  :ARG2 (x8 / figure :mod "1b"))))


# ::id PMC2841635.110
# ::snt 2B–C , which explains more p176-AKT in cytosol fraction than the plasma membrane fraction.
# ::tok 2B–C , which explains more p176 @-@ AKT in cytosol fraction than the plasma membrane fraction .
(x10 / fraction-01
      :ARG1 (x1 / protein
            :name (x2 / name :op1 "2B–C")
            :ARG0-of (x3 / explain-01))
      :degree (x4 / more)
      :ARG0 (x5 / protein
            :name (x6 / name :op1 "p176")
            :xref (x14 / xref :value "UNIPROT:RLGPB_HUMAN" :prob "0.222"))
      :ARG1 (x7 / enzyme
            :name (x8 / name :op1 "AKT")
            :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
      :location (x9 / cytosol
            :xref (x15 / xref :value "GO:0005829" :prob "0.8"))
      :compared-to (x13 / fraction
            :mod (x12 / membrane
                  :mod (x11 / plasma)
                  :xref (x16 / xref :value "GO:0016020" :prob "0.8"))))


# ::id PMC2841635.111
# ::snt Ack1 Facilitates AKT Plasma Membrane Localization and Activation
# ::tok Ack1 Facilitates AKT Plasma Membrane Localization and Activation
(x3 / facilitate-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "Ack1")
            :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
      :ARG1 (x9 / and
            :op1 (x8 / be-located-at-91
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "AKT")
                        :xref (x11 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :ARG2 (x7 / membrane
                        :mod (x6 / plasma)
                        :xref (x12 / xref :value "GO:0016020" :prob "0.8")))
            :op2 (x10 / activate-01)))


# ::id PMC2841635.112
# ::snt Because Ack1/AKT interaction was unaffected by LY294002 treatment ( Fig. 1B ) we assessed whether AKT Tyr176-phosphorylation could occur upon inhibition of PI3K activity.
# ::tok Because Ack1 @/@ AKT interaction was unaffected by LY294002 treatment ( Fig . 1B ) we assessed whether AKT Tyr176 @-@ phosphorylation could occur upon inhibition of PI3K activity .
(x14 / assess-01
      :ARG1-of (x1 / cause-01
            :ARG0 (x6 / interact-01
                  :ARG0 (x2 / protein
                        :name (x3 / name :op1 "Ack1")
                        :xref (x26 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "AKT")
                        :xref (x27 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :ARG1 (x7 / affect-01
                  :ARG0 (x10 / treat-04
                        :ARG2 (x8 / small-molecule
                              :name (x9 / name :op1 "LY294002")
                              :xref (x29 / xref :value "PUBCHEM:3973" :prob "18.86067"))
                        :ARG1-of (x11 / describe-01
                              :ARG0 (x12 / figure :mod "1b")))))
      :ARG0 (x13 / we)
      :ARG1 (x20 / possible-01
            :mode "interrogative"
            :ARG1 (x19 / phosphorylate-01
                  :ARG0 (x15 / enzyme
                        :name (x16 / name :op1 "AKT")
                        :xref (x28 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :ARG1 (x17 / amino-acid
                        :mod "176"
                        :name (x18 / name :op1 "tyrosine")
                        :xref (x30 / xref :value "PUBCHEM:1153" :prob "11.081481")))
            :ARG1-of (x21 / cause-01
                  :ARG0 (x22 / inhibit-01
                        :ARG1 (x25 / activity-06
                              :ARG0 (x23 / enzyme
                                    :name (x24 / name :op1 "PI3K")
                                    :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))))))


# ::id PMC2841635.113
# ::snt First, LY294002 treatment neither affected endogenous AKT Tyr176-phosphorylation nor its membrane localization ( Fig. 3A ).
# ::tok First , LY294002 treatment neither affected endogenous AKT Tyr176 @-@ phosphorylation nor its membrane localization ( Fig . 3A ) .
(x12 / or
      :mod (x1 / ordinal-entity :value "1")
      :ARG2 (x5 / affect-01
            :ARG0 (x4 / treat-04
                  :ARG2 (x2 / small-molecule
                        :name (x3 / name :op1 "LY294002")
                        :xref (x19 / xref :value "PUBCHEM:3973" :prob "18.86067")))
            :polarity "-"
            :ARG1 (x6 / enzyme
                  :mod (x7 / endogenous)
                  :name (x8 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :ARG1-of (x11 / phosphorylate-01
            :ARG1 (x9 / amino-acid
                  :mod "176"
                  :name (x10 / name :op1 "tyrosine")
                  :xref (x18 / xref :value "PUBCHEM:1153" :prob "11.081481")))
      :op2 (x14 / be-located-at-91
            :ARG2 (x13 / membrane
                  :xref (x17 / xref :value "GO:0016020" :prob "0.8")))
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / figure :mod "3a")))


# ::id PMC2841635.114
# ::snt Second, in contrast to Ack1 knockdown, depletion of PI3K 110α subunit by siRNA did not inhibit pTyr176-AKT levels in MCF7 cells treated with insulin ( Fig. 3B ).
# ::tok Second , in contrast to Ack1 knockdown , depletion of PI3K 110α subunit by siRNA did not inhibit pTyr176 @-@ AKT levels in MCF7 cells treated with insulin ( Fig . 3B ) .
(x20 / treat-04
      :mod (x1 / ordinal-entity :value "2")
      :ARG0 (x17 / level
            :ARG1-of (x2 / contrast-01
                  :ARG2 (x5 / knock-down-02
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "Ack1")
                              :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))))
            :ARG1 (x12 / inhibit-01
                  :ARG0 (x6 / deplete-01
                        :ARG1 (x9 / subunit
                              :mod (x7 / enzyme
                                    :name (x8 / name :op1 "PI3K" :op2 "110α")))
                        :ARG0 (x10 / nucleic-acid
                              :name (x11 / name :op1 "siRNA")))
                  :polarity "-"
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "pTyr176")))
            :quant-of (x15 / enzyme
                  :name (x16 / name :op1 "AKT")
                  :xref (x25 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :location (x19 / cell-line
                  :name (x18 / name :op1 "MCF7")))
      :ARG2 (x21 / small-molecule
            :name (x22 / name :op1 "insulin")
            :xref (x26 / xref :value "PUBCHEM:70678557" :prob "15.003454"))
      :ARG1-of (x23 / describe-01
            :ARG0 (x24 / figure :mod "3b")))


# ::id PMC2841635.115
# ::snt However, Ser473 phosphorylation of AKT was reduced upon knockdown of either Ack1 or PI3K, suggesting existence of two distinct pathways of AKT activation.
# ::tok However , Ser473 phosphorylation of AKT was reduced upon knockdown of either Ack1 or PI3K , suggesting existence of two distinct pathways of AKT activation .
(x1 / contrast-01
      :ARG2 (x7 / reduce-01
            :ARG1 (x2 / phosphorylate-01
                  :ARG1 (x3 / amino-acid
                        :mod "473"
                        :name (x4 / name :op1 "serine")
                        :part-of (x5 / enzyme
                              :name (x6 / name :op1 "AKT")
                              :xref (x23 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :xref (x24 / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :time (x8 / knock-down-02
                  :ARG1 (x9 / or
                        :op1 (x10 / enzyme
                              :name (x11 / name :op1 "Ack1")
                              :xref (x21 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                        :op2 (x12 / enzyme
                              :name (x13 / name :op1 "PI3K")
                              :xref (x22 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                  :ARG0-of (x14 / suggest-01
                        :ARG1 (x15 / exist-01
                              :ARG1 (x17 / pathway
                                    :quant "2"
                                    :mod (x16 / distinct))))
                  :ARG1 (x20 / activate-01
                        :ARG1 (x18 / enzyme
                              :name (x19 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))))


# ::id PMC2841635.116
# ::snt Third, membrane fraction of AKT was phosphorylated at Ser473 even in the presence of LY294002 when coexpressed with activated Ack1 in serum starved MEF1&2KO cells ( Fig. S7A , panel 2).
# ::tok Third , membrane fraction of AKT was phosphorylated at Ser473 even in the presence of LY294002 when coexpressed with activated Ack1 in serum starved MEF1&2KO cells ( Fig . S7A , panel 2 ) .
(x3 / fraction-01
      :mod (x1 / ordinal-entity :value "3")
      :ARG1 (x2 / membrane
            :xref (x25 / xref :value "GO:0016020" :prob "0.8"))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "AKT")
            :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
      :ARG2 (x6 / phosphorylate-01
            :ARG1 (x7 / amino-acid
                  :mod "473"
                  :name (x8 / name :op1 "serine")
                  :xref (x26 / xref :value "PUBCHEM:5951" :prob "11.218784")))
      :concession (x9 / present-02
            :ARG1 (x10 / small-molecule
                  :name (x11 / name :op1 "LY294002")
                  :xref (x27 / xref :value "PUBCHEM:3973" :prob "18.86067")))
      :time (x12 / coexpress-01
            :ARG2 (x13 / enzyme
                  :ARG1-of (x14 / activate-01)
                  :name (x15 / name :op1 "Ack1")
                  :xref (x24 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
      :location (x19 / cell-line
            :ARG1-of (x17 / starve-01
                  :ARG2 (x16 / serum))
            :name (x18 / name :op1 "MEF1&2KO"))
      :ARG1-of (x20 / describe-01
            :ARG0 (x21 / and
                  :op1 (x22 / figure :mod "s7a")
                  :op2 (x23 / panel)
                  :op3 "2")))


# ::id PMC2841635.117
# ::snt To determine whether Tyr-phosphorylated AKT can translocate to the plasma membrane in the absence of PIP3, AKT point mutant R25C that binds PIP3 inefficiently [4] was generated ( Fig. S7B ).
# ::tok To determine whether Tyr @-@ phosphorylated AKT can translocate to the plasma membrane in the absence of PIP3 , AKT point mutant R25C that binds PIP3 inefficiently [ 4 ] was generated ( Fig . S7B ) .
(x27 / generate-01
      :purpose (x1 / determine-01
            :ARG1 (x2 / possible-01
                  :mode "interrogative"
                  :ARG1 (x8 / translocate-01
                        :ARG1 (x5 / phosphorylate-01
                              :ARG1 (x3 / amino-acid
                                    :name (x4 / name :op1 "tyrosine")
                                    :xref (x32 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                        :ARG0 (x6 / enzyme
                              :name (x7 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :ARG2 (x10 / membrane
                              :mod (x9 / plasma)
                              :xref (x31 / xref :value "GO:0016020" :prob "0.8"))))
            :condition (x11 / absent-01
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "PIP3"))))
      :ARG1 (x16 / point
            :mod (x14 / enzyme
                  :name (x15 / name :op1 "AKT")
                  :xref (x30 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :mod (x17 / enzyme
                  :ARG2-of (x18 / mutate-01)
                  :name (x19 / name :op1 "R25C"))
            :ARG0-of (x20 / bind-01
                  :ARG2 (x21 / protein
                        :name (x22 / name :op1 "PIP3"))
                  :ARG1-of (x23 / efficient-01 :polarity "-"))
            :ARG1-of (x24 / describe-01
                  :ARG0 (x25 / publication
                        :ARG1-of (x26 / cite-01 :ARG2 "4"))))
      :ARG1-of (x28 / describe-01
            :ARG0 (x29 / figure :mod "s7b")))


# ::id PMC2841635.118
# ::snt The R25C mutant was Tyr-phosphorylated and recruited to membrane when coexpressed with activated Ack1, in the absence of ligand ( Fig. S7C and D ).
# ::tok The R25C mutant was Tyr @-@ phosphorylated and recruited to membrane when coexpressed with activated Ack1 , in the absence of ligand ( Fig . S7C and D ) .
(x14 / absent-01
      :ARG1 (x3 / mutate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "R25C")))
      :ARG2 (x7 / and
            :op1 (x6 / phosphorylate-01
                  :ARG1 (x4 / amino-acid
                        :name (x5 / name :op1 "tyrosine")
                        :xref (x21 / xref :value "PUBCHEM:1153" :prob "11.081481")))
            :op2 (x8 / recruit-01
                  :ARG2 (x9 / membrane
                        :xref (x20 / xref :value "GO:0016020" :prob "0.8"))
                  :time (x10 / coexpress-01
                        :ARG2 (x11 / enzyme
                              :ARG1-of (x12 / activate-01)
                              :name (x13 / name :op1 "Ack1")
                              :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))))
      :ARG1 (x15 / ligand)
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / and
                  :op1 (x18 / figure :mod "s7c")
                  :op1 (x19 / figure :mod "s7d"))))


# ::id PMC2841635.119
# ::snt Interestingly, in contrast to AKT which bound PIP3, Tyr-phosphorylated AKT bound another membrane phospholipid, phosphatidic acid (PA) ( Fig. S8 ).
# ::tok Interestingly , in contrast to AKT which bound PIP3 , Tyr @-@ phosphorylated AKT bound another membrane phospholipid , phosphatidic acid ( PA ) ( Fig . S8 ) .
(x13 / bind-01
      :ARG2-of (x1 / interest-01)
      :ARG0 (x10 / phosphorylate-01
            :ARG1-of (x2 / contrast-01
                  :ARG2 (x5 / bind-01
                        :ARG0 (x3 / enzyme
                              :name (x4 / name :op1 "AKT")
                              :xref (x22 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :ARG2 (x6 / protein
                              :name (x7 / name :op1 "PIP3"))))
            :ARG1 (x8 / amino-acid
                  :name (x9 / name :op1 "tyrosine")
                  :xref (x24 / xref :value "PUBCHEM:1153" :prob "11.081481")))
      :ARG1 (x11 / enzyme
            :name (x12 / name :op1 "AKT")
            :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
      :ARG2 (x15 / membrane
            :mod (x14 / another)
            :name (x16 / name :op1 "phospholipid")
            :xref (x23 / xref :value "GO:0016020" :prob "0.8"))
      :ARG0 (x17 / small-molecule
            :name (x18 / name :op1 "phosphatidic" :op2 "acid")
            :name (x19 / name :op1 "PA")
            :xref (x25 / xref :value "PUBCHEM:985" :prob "7.888558"))
      :ARG1-of (x20 / describe-01
            :ARG0 (x21 / figure :mod "s8")))


# ::id PMC2841635.120
# ::snt Combined together, our data indicates that RTK/Ack1 pathway could directly facilitate AKT plasma membrane localization and activation and a fraction of AKT that is Tyr176-phosphorylated can translocate to the membrane and undergo Ser473-phosphorylation even when PI3K is inhibited.
# ::tok Combined together , our data indicates that RTK @/@ Ack1 pathway could directly facilitate AKT plasma membrane localization and activation and a fraction of AKT that is Tyr176 @-@ phosphorylated can translocate to the membrane and undergo Ser473 @-@ phosphorylation even when PI3K is inhibited .
(x5 / indicate-01
      :mod (x1 / combine-01
            :mod (x2 / together))
      :ARG0 (x4 / data
            :poss (x3 / we))
      :ARG1 (x6 / possible-01
            :ARG1 (x10 / facilitate-01
                  :ARG0 (x7 / pathway
                        :name (x8 / name :op1 "RTK/Ack1"))
                  :ARG1-of (x9 / direct-02)
                  :ARG1 (x16 / and
                        :op1 (x15 / be-located-at-91
                              :ARG1 (x11 / enzyme
                                    :name (x12 / name :op1 "AKT")
                                    :xref (x37 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                              :ARG2 (x14 / membrane
                                    :mod (x13 / plasma)
                                    :xref (x39 / xref :value "GO:0016020" :prob "0.8")))
                        :op2 (x17 / activate-01
                              :ARG0 (x18 / and
                                    :op1 (x26 / translocate-01
                                          :ARG1 (x19 / fraction
                                                :quant-of (x20 / enzyme
                                                      :name (x21 / name :op1 "AKT")
                                                      :ARG3-of (x24 / phosphorylate-01
                                                            :ARG1 (x22 / amino-acid
                                                                  :mod "176"
                                                                  :name (x23 / name :op1 "tyrosine")
                                                                  :xref (x41 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                                                      :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                                                :ARG1-of (x25 / possible-01))
                                          :ARG2 (x27 / membrane
                                                :xref (x38 / xref :value "GO:0016020" :prob "0.8")))
                                    :op2 (x28 / undergo-28
                                          :ARG2 (x31 / phosphorylate-01
                                                :ARG1 (x29 / amino-acid
                                                      :mod "473"
                                                      :name (x30 / name :op1 "serine")
                                                      :xref (x40 / xref :value "PUBCHEM:5951" :prob "11.218784")))))))
                  :concession (x32 / even-when
                        :op1 (x35 / inhibit-01
                              :ARG1 (x33 / enzyme
                                    :name (x34 / name :op1 "PI3K")
                                    :xref (x36 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))))))


# ::id PMC2841635.121
# ::snt Tyr176-phosphorylation of AKT is PI3K-independent.
# ::tok Tyr176 @-@ phosphorylation of AKT is PI3K @-@ independent .
(x8 / depend-01
      :ARG1 (x3 / phosphorylate-01
            :ARG1 (x1 / amino-acid
                  :mod "176"
                  :name (x2 / name :op1 "tyrosine")
                  :xref (x10 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :ARG2 (x4 / enzyme
                  :name (x5 / name :op1 "AKT")
                  :xref (x9 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :ARG0 (x6 / enzyme
            :name (x7 / name :op1 "PI3K")
            :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
      :polarity "-")


# ::id PMC2841635.122
# ::snt Cell lysates were fractionated and membrane fraction was subjected to IB with indicated antibodies.
# ::tok Cell lysates were fractionated and membrane fraction was subjected to IB with indicated antibodies .
(x7 / subject-01
      :ARG1 (x4 / and
            :op1 (x3 / fractionate-00
                  :ARG1 (x2 / lysate
                        :mod (x1 / cell)))
            :op2 (x6 / fraction-01
                  :ARG1 (x5 / membrane
                        :xref (x / xref :value "GO:0016020" :prob "0.8"))))
      :ARG2 (x8 / immunoblot-01
            :ARG3 (x10 / antibody
                  :ARG1-of (x9 / indicate-01))))


# ::id PMC2841635.123
# ::snt Cell lysates were subjected to IP with pTyr-antibodies, followed by IB with pTyr176-AKT antibodies (top panel).
# ::tok Cell lysates were subjected to IP with pTyr @-@ antibodies , followed by IB with pTyr176 @-@ AKT antibodies ( top panel ) .
(x3 / subject-01
      :ARG1 (x2 / lysate
            :mod (x1 / cell))
      :ARG2 (x4 / and
            :op1 (x5 / protein
                  :name (x6 / name :op1 "ip-10")
                  :xref (x19 / xref :value "UNIPROT:CXL10_HUMAN" :prob "0.663"))
            :op2 (x8 / antibody
                  :name (x7 / name :op1 "pTyr")))
      :ARG2-of (x9 / follow-01
            :ARG1 (x10 / immunoblot-01
                  :ARG3 (x15 / antibody
                        :mod (x11 / enzyme
                              :name (x12 / name :op1 "pTyr176")
                              :mod (x13 / enzyme
                                    :name (x14 / name :op1 "AKT")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))))
      :ARG1-of (x16 / describe-01
            :ARG0 (x18 / panel
                  :mod (x17 / top))))


# ::id PMC2841635.124
# ::snt Lower panels show IB with indicated antibodies.
# ::tok Lower panels show IB with indicated antibodies .
(x4 / show-01
      :ARG0 (x3 / panel
            :ARG1-of (x1 / low-04
                  :degree (x2 / more)))
      :ARG1 (x5 / immunoblot-01
            :ARG3 (x7 / antibody
                  :ARG1-of (x6 / indicate-01))))


# ::id PMC2841635.125
# ::snt The experiment was performed with two different Ack1 siRNAs (Qiagen).
# ::tok The experiment was performed with two different Ack1 siRNAs ( Qiagen ) .
(x2 / perform-01
      :ARG1 (x1 / experiment-01)
      :ARG2 (x3 / person
            :quant "2"
            :ARG1-of (x4 / differ-02
                  :ARG2 (x5 / enzyme
                        :name (x6 / name :op1 "Ack1")
                        :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
            :name (x7 / name :op1 "sirna"))
      :ARG1-of (x8 / qiagen))


# ::id PMC2841635.126
# ::snt AKT Tyr176-Phosphorylation Suppresses Expression of Apoptotic Genes and Promotes Mitotic Progression
# ::tok AKT Tyr176 @-@ Phosphorylation Suppresses Expression of Apoptotic Genes and Promotes Mitotic Progression
(x10 / and
      :op1 (x6 / suppress-01
            :ARG0 (x1 / enzyme
                  :name (x2 / name :op1 "AKT")
                  :ARG1-of (x5 / phosphorylate-01
                        :ARG1 (x3 / amino-acid
                              :mod "176"
                              :name (x4 / name :op1 "tyrosine")
                              :xref (x14 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :ARG1 (x7 / express-03
                  :ARG1 (x9 / gene
                        :mod (x8 / apoptotic))))
      :op2 (x13 / progress-01
            :ARG1 (x11 / promote-01
                  :ARG1 (x12 / mitosis))))


# ::id PMC2841635.127
# ::snt Earlier we have observed that Ack1 translocates to the nucleus upon it's Tyr-phosphorylation [26] .
# ::tok Earlier we have observed that Ack1 translocates to the nucleus upon it 's Tyr @-@ phosphorylation [ 26 ] .
(x4 / observe-01
      :time (x1 / early
            :degree (x2 / more))
      :ARG0 (x3 / we)
      :ARG1 (x5 / enzyme
            :name (x6 / name :op1 "Ack1")
            :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
      :ARG1 (x7 / translocate-00)
      :ARG2 (x8 / nucleus
            :ARG0-of (x9 / cause-01
                  :ARG1 (x12 / phosphorylate-01
                        :ARG1 (x10 / amino-acid
                              :name (x11 / name :op1 "tyrosine")
                              :xref (x17 / xref :value "PUBCHEM:1153" :prob "11.081481"))))
            :ARG1-of (x13 / describe-01
                  :ARG0 (x14 / publication
                        :ARG1-of (x15 / cite-01 :ARG2 "26")))
            :xref (x16 / xref :value "GO:0005634" :prob "0.8")))


# ::id PMC2841635.128
# ::snt We assessed the localization of pTyr176-AKT when Ack1 was activated.
# ::tok We assessed the localization of pTyr176 @-@ AKT when Ack1 was activated .
(x2 / assess-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / be-located-at-91
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "pTyr176")
                  :mod (x6 / enzyme
                        :name (x7 / name :op1 "AKT")
                        :xref (x11 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
      :time (x10 / activate-01
            :ARG1 (x8 / enzyme
                  :name (x9 / name :op1 "Ack1")
                  :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))))


# ::id PMC2841635.129
# ::snt Ligand treatment facilitated nuclear translocation of both endogenous pTyr284-Ack1 and pTyr176-AKT ( Fig. S9A ).
# ::tok Ligand treatment facilitated nuclear translocation of both endogenous pTyr284 @-@ Ack1 and pTyr176 @-@ AKT ( Fig . S9A ) .
(x2 / treat-04
      :ARG0 (x1 / ligand)
      :ARG1 (x12 / and
            :op1 (x3 / facilitate-01
                  :ARG1 (x5 / translocate-01
                        :ARG2 (x4 / nucleus
                              :xref (x20 / xref :value "GO:0005634" :prob "0.8"))
                        :ARG1 (x6 / and
                              :op1 (x7 / enzyme
                                    :mod (x8 / endogenous)
                                    :name (x9 / name :op1 "pTyr284"))
                              :op2 (x10 / enzyme
                                    :name (x11 / name :op1 "Ack1")
                                    :xref (x19 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))))
            :op2 (x13 / enzyme
                  :name (x14 / name :op1 "pTyr176")
                  :mod (x15 / enzyme
                        :name (x16 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
      :ARG1-of (x17 / describe-01
            :ARG0 (x18 / figure :mod "s9a")))


# ::id PMC2841635.130
# ::snt FoxO subgroup of transcription factors are phosphorylated by AKT leading to rapid relocalization of FoxO proteins from nucleus to cytoplasm, thus, preventing transactivation of target genes [1] , [11] , [12] .
# ::tok FoxO subgroup of transcription factors are phosphorylated by AKT leading to rapid relocalization of FoxO proteins from nucleus to cytoplasm , thus , preventing transactivation of target genes [ 1 ] , [ 11 ] , [ 12 ] .
(x3 / subgroup
      :mod (x1 / protein
            :name (x2 / name :op1 "FoxO"))
      :ARG1 (x6 / phosphorylate-01
            :ARG1 (x5 / factor
                  :ARG0-of (x4 / transcribe-01))
            :ARG2 (x7 / enzyme
                  :name (x8 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :ARG0-of (x9 / lead-03
                  :ARG2 (x15 / and
                        :op1 (x11 / protein-segment
                              :mod (x10 / rapid)
                              :name (x12 / name :op1 "relocalization")
                              :part-of (x13 / protein
                                    :name (x14 / name :op1 "FoxO")))
                        :op2 (x16 / protein
                              :source (x18 / and
                                    :op1 (x17 / nucleus
                                          :xref (x35 / xref :value "GO:0005634" :prob "0.8"))
                                    :op2 (x19 / cytoplasm
                                          :xref (x34 / xref :value "GO:0005737" :prob "0.8")))
                              :ARG0-of (x20 / cause-01
                                    :ARG1 (x21 / prevent-01
                                          :ARG1 (x22 / transactivate-01
                                                :ARG1 (x24 / gene
                                                      :ARG0-of (x23 / target-01)
                                                      :ARG1-of (x25 / describe-01
                                                            :ARG0 (x26 / publication
                                                                  :ARG1-of (x27 / cite-01 :ARG2 "1")))))))
                              :ARG1-of (x28 / describe-01
                                    :ARG0 (x29 / publication
                                          :ARG1-of (x30 / cite-01 :ARG2 "11"))))))
            :ARG1-of (x31 / describe-01
                  :ARG0 (x32 / publication
                        :ARG1-of (x33 / cite-01 :ARG2 "12")))))


# ::id PMC2841635.131
# ::snt FoxO proteins regulate genes involved in cell cycle arrest ( e.g. p21 , p27KIP1 ), cell death ( e.g .
# ::tok FoxO proteins regulate genes involved in cell cycle arrest ( e.g. p21 , p27KIP1 ) , cell death ( e.g .
(x3 / regulate-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "FoxO"))
      :ARG1 (x4 / gene
            :ARG1-of (x5 / involve-01
                  :ARG2 (x8 / arrest-02
                        :ARG1 (x7 / cycle-02
                              :ARG1 (x6 / cell))))
            :ARG1-of (x15 / die-01
                  :ARG1 (x9 / thing
                        :example (x10 / protein
                              :name (x11 / name :op1 "p21")
                              :xref (x / xref :value "UNIPROT:CDN1A_HUMAN" :prob "1.002")))
                  :ARG0 (x12 / protein
                        :name (x13 / name :op1 "p27KIP1")
                        :xref (x17 / xref :value "UNIPROT:CDN1B_HUMAN" :prob "0.663"))
                  :ARG1 (x14 / cell)
                  :ARG1-of (x16 / possible-01))))


# ::id PMC2841635.132
# ::snt Bim-1 ) and DNA repair (e.g. GADD45 ) [11] .
# ::tok Bim @-@ 1 ) and DNA repair ( e.g . GADD45 ) [ 11 ] .
(x11 / describe-01
      :ARG1 (x3 / and
            :op1 (x1 / protein
                  :name (x2 / name :op1 "Bim-1"))
            :op2 (x6 / repair-01
                  :ARG1 (x4 / nucleic-acid
                        :wiki "dna"
                        :name (x5 / name :op1 "DNA"))
                  :example (x7 / protein
                        :name (x8 / name :op1 "GADD45")))
            :op2 (x9 / publication
                  :ARG1-of (x10 / cite-01 :ARG2 "11"))))


# ::id PMC2841635.133
# ::snt Real time quantitative RT-PCR analysis revealed that in MEF1&2KO cells co-expressing caAck and AKT, expression of p21, p27, Bim-1 and GADD45 is down regulated as opposed to the activated Ack and Y176F mutant co-expressing cells ( Fig. 4A ).
# ::tok Real time quantitative RT @-@ PCR analysis revealed that in MEF1&2KO cells co @-@ expressing caAck and AKT , expression of p21 , p27 , Bim @-@ 1 and GADD45 is down regulated as opposed to the activated Ack and Y176F mutant co @-@ expressing cells ( Fig . 4A ) .
(x1 / multi-sentence
      :snt1 (x7 / reveal-01
            :ARG0 (x6 / analyze-01
                  :mod (x2 / real-time)
                  :mod (x3 / quantitative)
                  :mod (x4 / thing
                        :name (x5 / name :op1 "RT-PCR")))
            :ARG1 (x9 / cell
                  :name (x8 / name :op1 "MEF1&2KO")))
      :snt2 (x26 / regulate-01
            :ARG0 (x25 / downregulate-01
                  :ARG1 (x13 / and
                        :op1 (x10 / express-03
                              :ARG2 (x11 / enzyme
                                    :name (x12 / name :op1 "caAck")))
                        :op2 (x14 / enzyme
                              :name (x15 / name :op1 "AKT")
                              :xref (x43 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :ARG1-of (x16 / express-03
                              :ARG2 (x17 / enzyme
                                    :name (x18 / name :op1 "p21")
                                    :xref (x44 / xref :value "UNIPROT:CDN1A_HUMAN" :prob "1.002")))
                        :op2 (x19 / protein
                              :name (x20 / name :op1 "p27"))
                        :op3 (x21 / protein
                              :name (x22 / name :op1 "Bim-1"))
                        :op4 (x23 / protein
                              :name (x24 / name :op1 "GADD45"))))
            :ARG1 (x33 / activate-01
                  :ARG1-of (x27 / instead-of-91
                        :ARG2 (x28 / activate-01))
                  :ARG0 (x31 / and
                        :op1 (x29 / protein
                              :name (x30 / name :op1 "Ack"))
                        :op2 (x32 / mutate-01 :value "Y176F"))
                  :ARG1 (x40 / cell
                        :ARG3-of (x34 / express-03
                              :ARG2 (x35 / enzyme
                                    :name (x36 / name :op1 "mek")
                                    :mod (x37 / constitutive)
                                    :ARG2-of (x38 / mutate-01)
                                    :ARG1-of (x39 / activate-01)
                                    :xref (x / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.243")))))
            :ARG1-of (x41 / describe-01
                  :ARG0 (x42 / figure :mod "4a"))))


# ::id PMC2841635.134
# ::snt Consistent with this observation, depletion of Ack1 protein by siRNA resulted in increased FoxO-responsive gene expression ( Fig.
# ::tok Consistent with this observation , depletion of Ack1 protein by siRNA resulted in increased FoxO @-@ responsive gene expression ( Fig .
(x9 / result-01
      :ARG1-of (x1 / consistent-01
            :ARG2 (x3 / observe-01
                  :mod (x2 / this)))
      :ARG1 (x4 / deplete-01
            :ARG1 (x6 / protein
                  :name (x5 / name :op1 "Ack1")
                  :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :ARG2 (x7 / nucleic-acid
                  :name (x8 / name :op1 "siRNA")))
      :ARG2 (x10 / increase-01
            :ARG1 (x15 / express-03
                  :ARG1 (x14 / gene
                        :ARG0-of (x13 / responsive-02
                              :ARG1 (x11 / protein
                                    :name (x12 / name :op1 "FoxO"))))))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / figure :mod "2b")))


# ::id PMC2841635.136
# ::snt Tyr176 phosphorylated AKT suppresses FoxO gene transcription and promotes cell cycle progression.
# ::tok Tyr176 phosphorylated AKT suppresses FoxO gene transcription and promotes cell cycle progression .
(x10 / and
      :op1 (x6 / suppress-01
            :ARG0 (x3 / phosphorylate-01
                  :ARG1 (x1 / amino-acid
                        :mod "176"
                        :name (x2 / name :op1 "tyrosine")
                        :xref (x15 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2 (x4 / enzyme
                        :name (x5 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :ARG1 (x9 / transcribe-01
                  :ARG1 (x7 / protein
                        :name (x8 / name :op1 "FoxO"))))
      :op2 (x11 / promote-01
            :ARG1 (x14 / progress-01
                  :ARG1 (x13 / cycle-02
                        :ARG1 (x12 / cell)))))


# ::id PMC2841635.138
# ::snt Data are representative of three independent experiments.
# ::tok Data are representative of three independent experiments .
(x2 / represent-01
      :ARG0 (x1 / data)
      :ARG1 (x4 / experiment
            :quant "3"
            :ARG0-of (x3 / depend-01 :polarity "-")))


# ::id PMC2841635.139
# ::snt * p≤ 0.05; ** p ≤0.03; *** p ≤0.02; **** p ≤0.02.
# ::tok * p≤ 0.05; ** p ≤0.03; *** p ≤0.02; **** p ≤0.02 .
(x6 / enzyme
      :ARG1-of (x3 / phosphorylate-01
            :ARG2 (x1 / enzyme
                  :name (x2 / name :op1 "**"))
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "≤0.03;")))
      :name (x7 / name :op1 "***")
      :ARG1-of (x11 / phosphorylate-01
            :ARG1 (x8 / enzyme
                  :ARG3-of (x9 / phosphorylate-01)
                  :name (x10 / name :op1 "≤0.02;"))
            :ARG2 (x12 / enzyme
                  :name (x13 / name :op1 "≤0.02"))))


# ::id PMC2841635.141
# ::snt * p ≤0.01; ** p ≤0.05; *** p ≤0.06; **** p≤ 0.05.
# ::tok * p ≤0.01; ** p ≤0.05; *** p ≤0.06; **** p≤ 0.05 .
(x4 / enzyme
      :ARG1-of (x1 / phosphorylate-01
            :ARG2 (x2 / enzyme
                  :name (x3 / name :op1 "≤0.01;" :op2 "**")))
      :ARG3-of (x5 / phosphorylate-01)
      :name (x6 / name :op1 "≤0.05;")
      :ARG1-of (x7 / phosphorylate-01
            :ARG2 (x8 / enzyme
                  :name (x9 / name :op1 "p≤" :op2 "0.05"))))


# ::id PMC2841635.142
# ::snt SDM of myr-AKT was performed to generate the Y176F mutation.
# ::tok SDM of myr @-@ AKT was performed to generate the Y176F mutation .
(x5 / perform-01
      :ARG1 (x1 / protein-segment
            :name (x2 / name :op1 "SDM")
            :part-of (x3 / protein
                  :name (x4 / name :op1 "myr-AKT")))
      :purpose (x6 / generate-01
            :ARG1 (x8 / mutate-01
                  :ARG1 (x7 / mutate-01 :value "Y176F"))))


# ::id PMC2841635.143
# ::snt PH, Pleckstrin homology domain; Kinase, Kinase domain and CT, Carboxy Terminal regulatory region.
# ::tok PH , Pleckstrin homology domain ; Kinase , Kinase domain and CT , Carboxy Terminal regulatory region .
(x3 / and
      :op1 (x1 / protein
            :name (x2 / name :op1 "PH")
            :xref (x / xref :value "UNIPROT:PAHO_HUMAN" :prob "1.002"))
      :op1 (x4 / protein-segment
            :name (x5 / name :op1 "Pleckstrin" :op2 "homology"))
      :op2 (x13 / regulate-01
            :manner (x8 / and
                  :op1 (x6 / kinase
                        :name (x7 / name :op1 "Kinase" :op2 "domain"))
                  :op2 (x9 / enzyme
                        :name (x10 / name :op1 "CT")))
            :ARG0 (x11 / enzyme
                  :name (x12 / name :op1 "Carboxy" :op2 "terminus"))))


# ::id PMC2841635.144
# ::snt Cells were fixed and stained with anti-HA antibodies conjugated with Alexa 488 and anti-pSerine10-Histone3 conjugated with Alexa 647, a marker used to distinguish cells in late G2 and early M phase, and analyzed by flow cytometry.
# ::tok Cells were fixed and stained with anti @-@ HA antibodies conjugated with Alexa 488 and anti @-@ pSerine10 @-@ Histone3 conjugated with Alexa 647 , a marker used to distinguish cells in late G2 and early M phase , and analyzed by flow cytometry .
(x3 / and
      :op1 (x2 / fix-02
            :ARG1 (x1 / cell))
      :op2 (x4 / stain-01
            :ARG2 (x8 / antibody
                  :ARG0-of (x5 / counter-01
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "HA")
                              :xref (x / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
                  :ARG1-of (x9 / conjugate-02
                        :ARG2 (x10 / small-molecule
                              :name (x11 / name :op1 "Alexa" :op2 "488")))
                  :ARG0-of (x12 / counter-01
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "pSerine10")))
                  :name (x15 / name :op1 "Histone3")))
      :ARG1-of (x16 / conjugate-02
            :ARG2 (x18 / marker
                  :name (x17 / name :op1 "Alexa" :op2 "647")
                  :ARG0-of (x19 / use-01
                        :purpose (x20 / distinguish-01
                              :ARG1 (x21 / cell
                                    :mod (x22 / late)
                                    :name (x23 / name :op1 "G2"))))))
      :op2 (x27 / and
            :time (x24 / early)
            :op1 (x25 / event
                  :name (x26 / name :op1 "M" :op2 "phase"))
            :op2 (x28 / analyze-01
                  :manner (x30 / cytometry
                        :mod (x29 / flow)))))


# ::id PMC2841635.145
# ::snt HA-myrAKT expressing cells showed 75% increase in the number of cells undergoing mitosis (upper right quadrant), while, HA-myrY176F-AKT expressing mitotic cells remain unchanged.
# ::tok HA @-@ myrAKT expressing cells showed 75 % increase in the number of cells undergoing mitosis ( upper right quadrant ) , while , HA @-@ myrY176F @-@ AKT expressing mitotic cells remain unchanged .
(x16 / contrast-01
      :ARG1 (x7 / show-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "HA")
                  :xref (x29 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002"))
            :ARG0 (x6 / cell
                  :ARG1-of (x5 / express-03
                        :ARG2 (x3 / protein
                              :name (x4 / name :op1 "myrAKT"))))
            :ARG1 (x9 / increase-01
                  :ARG2 (x8 / percentage-entity :value "75")
                  :ARG1 (x10 / number
                        :quant-of (x11 / cell
                              :ARG1-of (x12 / undergo-28))))
            :ARG1-of (x14 / right-04
                  :mod (x13 / upper))
            :ARG1-of (x15 / quadrant))
      :ARG2 (x27 / remain-01
            :ARG1 (x26 / cell
                  :mod (x17 / macro-molecular-complex
                        :part (x18 / protein
                              :name (x19 / name :op1 "HA")
                              :xref (x30 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002"))
                        :part (x20 / enzyme
                              :name (x21 / name :op1 "myrY176F")
                              :ARG2-of (x24 / express-03
                                    :ARG1 (x22 / enzyme
                                          :name (x23 / name :op1 "AKT")
                                          :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))
                  :mod (x25 / mitosis))
            :ARG3 (x28 / change-01 :polarity "-")))


# ::id PMC2841635.146
# ::snt To further understand the molecular role of Tyr176 in cell growth, we generated a HA-tagged myristoylated Y176F or myr-Y176F ( Fig. 4C ).
# ::tok To further understand the molecular role of Tyr176 in cell growth , we generated a HA @-@ tagged myristoylated Y176F or myr @-@ Y176F ( Fig . 4C ) .
(x10 / generate-01
      :purpose (x2 / understand-01
            :degree (x1 / further)
            :ARG1 (x4 / role
                  :mod (x3 / molecule)
                  :poss (x5 / amino-acid
                        :mod "176"
                        :name (x6 / name :op1 "tyrosine")
                        :xref (x23 / xref :value "PUBCHEM:1153" :prob "11.081481")))
            :ARG1 (x8 / grow-01
                  :ARG1 (x7 / cell)))
      :ARG0 (x9 / we)
      :ARG1 (x16 / or
            :ARG1-of (x13 / tag-01
                  :ARG2 (x11 / protein
                        :name (x12 / name :op1 "HA")
                        :xref (x22 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
            :op1 (x14 / and
                  :op1 (x15 / mutate-01 :value "Y176F"))
            :op2 (x17 / enzyme
                  :name (x18 / name :op1 "myr")
                  :ARG2-of (x19 / mutate-01 :value "Y176F")
                  :xref (x / xref :value "UNIPROT:MYO9B_HUMAN" :prob "0.202")))
      :ARG1-of (x20 / describe-01
            :ARG0 (x21 / figure :mod "4c")))


# ::id PMC2841635.147
# ::snt As the myristoylated version of AKT is constitutively anchored at the membrane, it exhibits high levels of AKT activation, as seen by Thr308-phosphorylation ( Fig. S9B ).
# ::tok As the myristoylated version of AKT is constitutively anchored at the membrane , it exhibits high levels of AKT activation , as seen by Thr308 @-@ phosphorylation ( Fig . S9B ) .
(x8 / exhibit-01
      :ARG1 (x6 / anchor-01
            :ARG1 (x2 / version
                  :ARG1-of (x1 / myristoylate-00)
                  :mod (x3 / enzyme
                        :name (x4 / name :op1 "AKT")
                        :xref (x20 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :mod (x5 / constitutive)
            :location (x7 / membrane
                  :xref (x21 / xref :value "GO:0016020" :prob "0.8")))
      :ARG1 (x13 / activate-01
            :ARG1 (x10 / level
                  :ARG1-of (x9 / high-02)
                  :quant-of (x11 / enzyme
                        :name (x12 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
      :ARG1-of (x14 / see-01)
      :ARG0 (x17 / phosphorylate-01
            :ARG1 (x15 / amino-acid
                  :mod "308"
                  :name (x16 / name :op1 "threonine")
                  :xref (x22 / xref :value "PUBCHEM:205" :prob "11.848252")))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / figure :mod "s9b")))


# ::id PMC2841635.148
# ::snt MEF1&2KO cells expressing myr-Y176F exhibited significant decrease in Thr308-phosphorylation confirming that AKT Tyr176-phosphorylation is an important event for subsequent AKT activation.
# ::tok MEF1&2KO cells expressing myr @-@ Y176F exhibited significant decrease in Thr308 @-@ phosphorylation confirming that AKT Tyr176 @-@ phosphorylation is an important event for subsequent AKT activation .
(x7 / exhibit-01
      :ARG0 (x2 / cell
            :name (x1 / name :op1 "MEF1&2KO")
            :ARG3-of (x3 / express-03
                  :ARG2 (x4 / enzyme
                        :name (x5 / name :op1 "myr")
                        :ARG2-of (x6 / mutate-01 :value "Y176F")
                        :xref (x25 / xref :value "UNIPROT:MYO9B_HUMAN" :prob "0.202"))))
      :ARG1 (x9 / decrease-01
            :ARG2 (x8 / significant-02)
            :ARG1 (x12 / phosphorylate-01
                  :ARG1 (x10 / amino-acid
                        :mod "308"
                        :name (x11 / name :op1 "threonine")
                        :xref (x27 / xref :value "PUBCHEM:205" :prob "11.848252")))
            :ARG1-of (x13 / confirm-01
                  :ARG1 (x20 / event
                        :domain (x14 / enzyme
                              :name (x15 / name :op1 "AKT")
                              :ARG1-of (x18 / phosphorylate-01
                                    :ARG1 (x16 / amino-acid
                                          :mod "176"
                                          :name (x17 / name :op1 "tyrosine")
                                          :xref (x28 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                              :xref (x26 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :mod (x19 / important))))
      :ARG2 (x24 / activate-01
            :mod (x21 / subsequent)
            :ARG1 (x22 / enzyme
                  :name (x23 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))


# ::id PMC2841635.149
# ::snt Further, MEF1&2KO cells expressing myr-AKT grow exponentially as observed by an increase in the number of the double-positive HA and phospho-H3 (Ser10) stained cells, indicative of cells undergoing mitosis ( Fig. 4D ).
# ::tok Further , MEF1&2KO cells expressing myr @-@ AKT grow exponentially as observed by an increase in the number of the double @-@ positive HA and phospho @-@ H3 ( Ser10 ) stained cells , indicative of cells undergoing mitosis ( Fig . 4D ) .
(x11 / observe-01
      :mod (x1 / further)
      :ARG0 (x9 / grow-01
            :ARG1 (x3 / cell
                  :name (x2 / name :op1 "MEF1&2KO")
                  :ARG3-of (x4 / express-03
                        :ARG2 (x5 / enzyme
                              :name (x6 / name :op1 "myr")
                              :mod (x7 / enzyme
                                    :name (x8 / name :op1 "AKT")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                              :xref (x30 / xref :value "UNIPROT:MYO9B_HUMAN" :prob "0.202")))))
      :ARG1-of (x10 / exponential)
      :ARG1 (x12 / increase-01
            :ARG1 (x13 / number
                  :quant-of (x23 / stain-01
                        :mod (x15 / positive
                              :mod (x14 / double))
                        :ARG1-of (x18 / and
                              :op1 (x16 / protein
                                    :name (x17 / name :op1 "HA")
                                    :xref (x32 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002"))
                              :op2 (x19 / enzyme
                                    :ARG3-of (x20 / phosphorylate-01)
                                    :name (x21 / name :op1 "H3")
                                    :name (x22 / name :op1 "serine")
                                    :xref (x31 / xref :value "UNIPROT:SRR_HUMAN" :prob "0.282")))
                        :ARG1 (x24 / cell))))
      :ARG0-of (x25 / indicate-01
            :ARG1 (x26 / cell
                  :ARG1-of (x27 / undergo-28)))
      :ARG1-of (x28 / describe-01
            :ARG0 (x29 / figure :mod "4d")))


# ::id PMC2841635.150
# ::snt In contrast, the number of double-positive myr-Y176F expressing cells remained unchanged after 24 hours ( Fig. 4D ).
# ::tok In contrast , the number of double @-@ positive myr @-@ Y176F expressing cells remained unchanged after 24 hours ( Fig . 4D ) .
(x1 / contrast-01
      :ARG2 (x9 / remain-01
            :ARG1 (x2 / number
                  :quant-of (x8 / cell
                        :mod (x4 / positive
                              :mod (x3 / double))
                        :ARG0-of (x7 / express-03
                              :time (x5 / before
                                    :op1 (x6 / mutate-01 :value "Y176F")))))
            :ARG3 (x10 / change-01 :polarity "-")
            :time (x11 / after
                  :op1 (x12 / temporal-quantity
                        :quant "24"
                        :unit (x13 / hour))))
      :ARG1-of (x14 / describe-01
            :ARG0 (x15 / figure :mod "4d")))


# ::id PMC2841635.151
# ::snt Thus, AKT Tyr176-phosphorylation can both suppress pro-apoptotic gene transcription and promote mitotic progression.
# ::tok Thus , AKT Tyr176 @-@ phosphorylation can both suppress pro @-@ apoptotic gene transcription and promote mitotic progression .
(x1 / infer-01
      :ARG1 (x2 / possible-01
            :ARG1 (x16 / progress-01
                  :ARG0 (x3 / enzyme
                        :name (x4 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :ARG1-of (x7 / phosphorylate-01
                        :ARG1 (x5 / amino-acid
                              :mod "176"
                              :name (x6 / name :op1 "tyrosine")
                              :xref (x17 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                  :ARG1 (x8 / and
                        :op1 (x9 / suppress-01
                              :ARG1 (x13 / transcribe-01
                                    :ARG0-of (x10 / favor-01
                                          :ARG1 (x11 / apoptosis))
                                    :ARG1 (x12 / gene)))
                        :op2 (x14 / promote-01
                              :ARG1 (x15 / mitosis))))))


# ::id PMC2841635.152
# ::snt Probasin-Ack1 Transgenic Mice Display AKT Activation and Develop Prostatic Intraepithelial Neoplasia
# ::tok Probasin @-@ Ack1 Transgenic Mice Display AKT Activation and Develop Prostatic Intraepithelial Neoplasia
(x11 / and
      :op1 (x10 / activate-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "Probasin")
                  :mod (x6 / mouse
                        :mod (x3 / enzyme
                              :name (x4 / name :op1 "Ack1")
                              :xref (x16 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                        :mod (x5 / transgenic)
                        :ARG0-of (x7 / display-01
                              :ARG1 (x8 / enzyme
                                    :name (x9 / name :op1 "AKT")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
                  :xref (x17 / xref :value "UNIPROT:PRSS8_HUMAN" :prob "0.322")))
      :op2 (x12 / develop-01
            :ARG2 (x15 / neoplasia
                  :mod (x13 / enzyme
                        :name (x14 / name :op1 "Prostatic" :op2 "Intraepithelial")))))


# ::id PMC2841635.153
# ::snt We generated a transgenic mouse model in which Myc-tagged activated Ack1 was expressed under the control of modified Probasin (PB) promoter, ARR2PB ( Fig. 5A and B ).
# ::tok We generated a transgenic mouse model in which Myc @-@ tagged activated Ack1 was expressed under the control of modified Probasin ( PB ) promoter , ARR2PB ( Fig . 5A and B ) .
(x2 / generate-01
      :ARG0 (x1 / we)
      :ARG1 (x5 / model
            :mod (x4 / mouse
                  :mod (x3 / transgenic))
            :ARG0-of (x13 / control-01
                  :ARG1 (x8 / tag-01
                        :ARG2 (x6 / protein
                              :name (x7 / name :op1 "Myc")
                              :xref (x26 / xref :value "UNIPROT:MYC_HUMAN" :prob "0.604")))
                  :ARG1 (x12 / express-03
                        :ARG2 (x9 / enzyme
                              :ARG1-of (x10 / activate-01)
                              :name (x11 / name :op1 "Ack1")
                              :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
                  :ARG0 (x14 / modify-01
                        :ARG1 (x15 / enzyme
                              :name (x16 / name :op1 "Probasin")
                              :xref (x27 / xref :value "UNIPROT:PRSS8_HUMAN" :prob "0.322")))
                  :ARG1-of (x20 / molecular-physical-entity
                        :ARG0-of (x19 / promote-01
                              :ARG1 (x17 / small-molecule
                                    :name (x18 / name :op1 "atra")
                                    :xref (x28 / xref :value "PUBCHEM:444795" :prob "17.251232")))))
            :name (x21 / name :op1 "ARR2PB"))
      :ARG1-of (x22 / describe-01
            :ARG0 (x25 / and
                  :op1 (x23 / figure :mod "5a")
                  :op2 (x24 / figure :mod "1b"))))


# ::id PMC2841635.154
# ::snt PB-Ack1 transgenic mice (TG) display significant increase in AKT Tyr176-phosphorylation leading to Ser473/Thr308-phosphorylation ( Fig. 5C , top 3 panels) and AKT substrate FOXO3a Ser318/321-phosphorylation ( Fig. 5B , panel 2) in the prostates.
# ::tok PB @-@ Ack1 transgenic mice ( TG ) display significant increase in AKT Tyr176 @-@ phosphorylation leading to Ser473 @/@ Thr308 @-@ phosphorylation ( Fig . 5C , top 3 panels ) and AKT substrate FOXO3a Ser318 @/@ 321 @-@ phosphorylation ( Fig . 5B , panel 2 ) in the prostates .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op1 (x7 / display-01
                  :ARG1 (x5 / mouse
                        :name (x3 / name :op1 "Ack1")
                        :mod (x4 / transgenic)
                        :mod (x6 / transgenic))
                  :ARG1 (x9 / increase-01
                        :ARG2 (x8 / significant-02)
                        :ARG1 (x14 / phosphorylate-01
                              :ARG1 (x10 / enzyme
                                    :name (x11 / name :op1 "AKT")
                                    :xref (x44 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                              :ARG1 (x12 / amino-acid
                                    :mod "176"
                                    :name (x13 / name :op1 "tyrosine")
                                    :xref (x47 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                              :ARG0-of (x15 / lead-03
                                    :ARG2 (x21 / phosphorylate-01
                                          :ARG1 (x16 / and
                                                :op1 (x17 / amino-acid
                                                      :mod "473"
                                                      :name (x18 / name :op1 "serine")
                                                      :xref (x48 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                                :op2 (x19 / amino-acid
                                                      :mod "308"
                                                      :name (x20 / name :op1 "threonine")
                                                      :xref (x46 / xref :value "PUBCHEM:205" :prob "11.848252")))))))
                  :ARG1-of (x22 / describe-01
                        :ARG0 (x23 / and
                              :op1 (x24 / figure :mod "5c")
                              :op2 (x29 / panel
                                    :mod (x25 / top
                                          :ord (x26 / ordinal-entity :value "1")
                                          :ord (x27 / ordinal-entity :value "2")
                                          :ord (x28 / ordinal-entity :value "3"))))))
            :op2 (x32 / substrate
                  :mod (x30 / enzyme
                        :name (x31 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :name (x33 / name :op1 "FOXO3a")))
      :snt2 (x37 / phosphorylate-01
            :ARG0 (x34 / amino-acid
                  :mod "318"
                  :name (x35 / name :op1 "serine")
                  :xref (x45 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :ARG1 (x36 / slash :op1 "202" :op2 "321")
            :ARG1-of (x38 / describe-01
                  :ARG0 (x39 / and
                        :op1 (x40 / figure :mod "5b")
                        :op2 (x41 / panel
                              :mod (x42 / string-entity :value "2"))))
            :location (x43 / prostate)))


# ::id PMC2841635.155
# ::snt These mice developed intraepithelial hyperplasia by 22 weeks ( Fig. 5E ) and mPINs by 44 weeks ( Fig. 5F, J–L ).
# ::tok These mice developed intraepithelial hyperplasia by 22 weeks ( Fig . 5E ) and mPINs by 44 weeks ( Fig . 5F , J–L ) .
(x19 / have-org-role-91
      :op1 (x3 / develop-01
            :ARG1 (x2 / mouse
                  :mod (x1 / this))
            :ARG2 (x5 / hyperplasia
                  :name (x4 / name :op1 "intraepithelial")
                  :ARG2 (x6 / temporal-quantity
                        :quant "22"
                        :unit (x7 / week))
                  :ARG1-of (x8 / describe-01
                        :ARG0 (x10 / and
                              :op1 (x9 / figure :mod "5e")
                              :op2 (x11 / enzyme
                                    :name (x12 / name :op1 "mPINs"))))
                  :ARG0 (x13 / temporal-quantity
                        :quant "44"
                        :unit (x14 / week))
                  :ARG1-of (x15 / describe-01
                        :ARG0 (x16 / and
                              :op1 (x17 / figure :mod "5f")
                              :op1 (x18 / figure :mod "5j")))))
      :op2 (x20 / cell-line
            :name (x21 / name :op1 "l-540")))


# ::id PMC2841635.156
# ::snt The prostate epithelium of TG mice was crowded with round to polygonal stratified nuclei, forming micropapillary projections and tufts ( Fig. 5E ).
# ::tok The prostate epithelium of TG mice was crowded with round to polygonal stratified nuclei , forming micropapillary projections and tufts ( Fig . 5E ) .
(x6 / round-05
      :ARG1 (x2 / epithelium
            :mod (x1 / prostate)
            :part-of (x4 / mouse
                  :mod (x3 / transgenic)))
      :ARG0-of (x5 / crowd-01)
      :ARG1 (x9 / nucleus
            :mod (x7 / polygon)
            :mod (x8 / stratified)
            :xref (x17 / xref :value "GO:0005634" :prob "0.8"))
      :ARG0-of (x10 / form-01
            :ARG1 (x13 / and
                  :op1 (x11 / enzyme
                        :name (x12 / name :op1 "projections")
                        :xref (x / xref :value "UNIPROT:SPG17_HUMAN" :prob "0.242"))
                  :op2 (x14 / tuft)))
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / figure :mod "5e")))


# ::id PMC2841635.157
# ::snt The acini were lined by a rim of basal cells ( Fig. 5F ).
# ::tok The acini were lined by a rim of basal cells ( Fig . 5F ) .
(x2 / line-01
      :ARG1 (x1 / acini)
      :ARG2 (x3 / rim
            :ARG1 (x5 / cell
                  :mod (x4 / basal)))
      :ARG1-of (x6 / describe-01
            :ARG0 (x7 / figure :mod "5f")))


# ::id PMC2841635.158
# ::snt The areas of mPINs were easily identifiable and were characterized by prostatic acini containing intraluminal papillary structures lined by atypical cells with elongated nuclei exhibiting prominent nucleoli.
# ::tok The areas of mPINs were easily identifiable and were characterized by prostatic acini containing intraluminal papillary structures lined by atypical cells with elongated nuclei exhibiting prominent nucleoli .
(x3 / easy-05
      :ARG1 (x1 / area
            :part-of (x2 / mpins))
      :ARG1 (x5 / and
            :op1 (x4 / identifiable)
            :op2 (x11 / structure
                  :ARG1-of (x6 / characterize-01
                        :ARG2 (x10 / papilla
                              :ARG0-of (x7 / contain-01
                                    :ARG1 (x8 / enzyme
                                          :name (x9 / name :op1 "intraluminal")))))
                  :ARG0-of (x12 / line-01
                        :ARG0 (x14 / cell-line
                              :name (x13 / name :op1 "atypical"))
                        :ARG1 (x16 / nucleus
                              :ARG1-of (x15 / elongate-01)
                              :ARG0-of (x17 / exhibit-01
                                    :ARG1 (x18 / prominent))
                              :xref (x / xref :value "GO:0005634" :prob "0.8")))))
      :ARG1-of (x19 / nucleolus))


# ::id PMC2841635.159
# ::snt Focally, the papillae merged into each other within the acini generating a cribiform pattern of growth ( Fig. 5J–L ).
# ::tok Focally , the papillae merged into each other within the acini generating a cribiform pattern of growth ( Fig . 5J–L ) .
(x8 / generate-01
      :manner (x1 / focus)
      :ARG0 (x4 / penetrate-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "merged"))
            :ARG1 (x6 / other
                  :mod (x5 / each))
            :location (x7 / acini))
      :ARG1 (x11 / pattern-01
            :ARG0 (x9 / protein
                  :name (x10 / name :op1 "cribiform"))
            :ARG1 (x12 / grow-01
                  :ARG1-of (x13 / describe-01
                        :ARG0 (x14 / figure))
                  :name (x15 / name :op1 "5J–L"))))


# ::id PMC2841635.160
# ::snt Dorsal lobe exhibited an increased number of small acini lined by cells containing nuclei exhibiting prominent nucleoli and the neoplastic acini were devoid of myoepithelial cells ( Fig. 5L ).
# ::tok Dorsal lobe exhibited an increased number of small acini lined by cells containing nuclei exhibiting prominent nucleoli and the neoplastic acini were devoid of myoepithelial cells ( Fig . 5L ) .
(x17 / lack-01
      :ARG1 (x3 / exhibit-01
            :mod (x1 / dorsal)
            :mod (x2 / lobe)
            :ARG1 (x5 / number
                  :ARG1-of (x4 / increase-01)
                  :quant-of (x8 / line
                        :mod (x6 / small-molecule
                              :name (x7 / name :op1 "acini"))))
            :ARG0 (x9 / cell
                  :ARG0-of (x10 / contain-01
                        :ARG1 (x11 / nucleus
                              :ARG0-of (x12 / exhibit-01
                                    :ARG1 (x15 / tumor
                                          :mod (x13 / prominent)
                                          :ARG1-of (x14 / nucleolus)))
                              :name (x16 / name :op1 "acini")
                              :xref (x / xref :value "GO:0005634" :prob "0.8")))))
      :ARG1 (x19 / cell-line
            :name (x18 / name :op1 "myoepithelial"))
      :ARG1-of (x20 / describe-01
            :ARG0 (x21 / figure :mod "5l")))


# ::id PMC2841635.161
# ::snt We previously demonstrated that Ack1 regulates phosphorylation of androgen receptor [ 26 ] and tumor suppressor Wwox [25] in human prostate tumors.
# ::tok We previously demonstrated that Ack1 regulates phosphorylation of androgen receptor [ 26 ] and tumor suppressor Wwox [ 25 ] in human prostate tumors .
(x3 / demonstrate-01
      :ARG0 (x1 / we)
      :time (x2 / previous)
      :ARG1 (x6 / regulate-01
            :ARG0 (x4 / enzyme
                  :name (x5 / name :op1 "Ack1")
                  :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :ARG1 (x13 / and
                  :op1 (x7 / phosphorylate-01
                        :ARG1 (x8 / enzyme
                              :name (x9 / name :op1 "androgen" :op2 "receptor"))
                        :ARG1-of (x10 / describe-01
                              :ARG0 (x11 / publication
                                    :ARG1-of (x12 / cite-01 :ARG2 "26"))))
                  :op2 (x15 / suppress-01
                        :ARG1 (x14 / tumor)
                        :ARG0 (x16 / gene
                              :name (x17 / name :op1 "Wwox")
                              :ARG1-of (x18 / describe-01
                                    :ARG0 (x19 / publication
                                          :ARG1-of (x20 / cite-01 :ARG2 "25")))
                              :xref (x25 / xref :value "UNIPROT:WWOX_HUMAN" :prob "0.603")))))
      :ARG1-of (x21 / describe-01
            :ARG0 (x24 / tumor
                  :mod (x22 / human)
                  :mod (x23 / prostate))))


# ::id PMC2841635.162
# ::snt Neoplasia observed in PB-Ack1 mice could be due to the combined effect of Ack1 mediated AKT, AR and Wwox Tyr-phosphorylations.
# ::tok Neoplasia observed in PB @-@ Ack1 mice could be due to the combined effect of Ack1 mediated AKT , AR and Wwox Tyr @-@ phosphorylations .
(x19 / and
      :op1 (x3 / observe-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "Neoplasia"))
            :location (x4 / and
                  :op1 (x5 / possible-01
                        :ARG1 (x9 / cause-01
                              :ARG1 (x8 / mouse
                                    :mod (x6 / enzyme
                                          :name (x7 / name :op1 "Ack1")
                                          :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
                              :ARG0 (x10 / combine-01
                                    :ARG1 (x14 / mediate-01
                                          :ARG1 (x11 / affect-01
                                                :ARG0 (x12 / small-molecule
                                                      :name (x13 / name :op1 "Ack1")))
                                          :ARG0 (x15 / enzyme
                                                :name (x16 / name :op1 "AKT")
                                                :xref (x24 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))))
                  :op2 (x17 / enzyme
                        :name (x18 / name :op1 "AR")
                        :xref (x25 / xref :value "UNIPROT:ANDR_HUMAN" :prob "1.003"))))
      :op2 (x21 / amino-acid
            :name (x20 / name :op1 "Wwox")
            :name (x22 / name :op1 "tyrosine")
            :ARG1-of (x23 / phosphorylate-01)
            :xref (x26 / xref :value "PUBCHEM:1153" :prob "11.081481")))


# ::id PMC2841635.163
# ::snt AR and Wwox Tyr-phosphorylations appear to be involved in late stage progression of prostate cancer to androgen-independence [26] .
# ::tok AR and Wwox Tyr @-@ phosphorylations appear to be involved in late stage progression of prostate cancer to androgen @-@ independence [ 26 ] .
(x3 / and
      :op1 (x1 / enzyme
            :name (x2 / name :op1 "AR")
            :xref (x / xref :value "UNIPROT:ANDR_HUMAN" :prob "1.003"))
      :op2 (x4 / enzyme
            :name (x5 / name :op1 "tyrosine")
            :ARG1-of (x6 / phosphorylate-01)
            :xref (x19 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
      :ARG1-of (x7 / appear-01
            :ARG0-of (x8 / involve-01
                  :ARG2 (x11 / progress-01
                        :mod (x10 / stage
                              :time (x9 / late))
                        :ARG1 (x12 / disease
                              :wiki "prostate_cancer"
                              :name (x13 / name :op1 "prostate" :op2 "cancer"))))
            :ARG0-of (x15 / depend-01
                  :ARG1 (x14 / androgen)
                  :polarity "-")
            :ARG1-of (x16 / describe-01
                  :ARG0 (x17 / publication
                        :ARG1-of (x18 / cite-01 :ARG2 "26")))))


# ::id PMC2841635.164
# ::snt Ack1 mediated AKT Tyr176-phosphorylation and activation may be more proximal stage initiating processes in neoplastic progression that mimic or serve as an alternative to those of PTEN loss which has been prominently emphasized in other mouse models of prostate cancer [33] .
# ::tok Ack1 mediated AKT Tyr176 @-@ phosphorylation and activation may be more proximal stage initiating processes in neoplastic progression that mimic or serve as an alternative to those of PTEN loss which has been prominently emphasized in other mouse models of prostate cancer [ 33 ] .
(x3 / mediate-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "Ack1")
            :xref (x38 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
      :ARG1 (x4 / possible-01
            :ARG1 (x15 / initiate-01
                  :ARG0 (x10 / and
                        :op1 (x5 / enzyme
                              :name (x6 / name :op1 "AKT")
                              :xref (x39 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                        :op2 (x9 / phosphorylate-01
                              :ARG1 (x7 / amino-acid
                                    :mod "176"
                                    :name (x8 / name :op1 "tyrosine")
                                    :xref (x40 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                        :op3 (x11 / activate-01))
                  :time (x14 / stage
                        :mod (x13 / proximal
                              :degree (x12 / more)))
                  :ARG1 (x16 / process-02
                        :location (x18 / progress-01
                              :ARG1 (x17 / tumor)))
                  :ARG1 (x19 / or
                        :op1 (x20 / mimic-01
                              :ARG1 (x23 / lose-02
                                    :ARG1 (x21 / protein
                                          :name (x22 / name :op1 "PTEN")
                                          :xref (x / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004"))))
                        :op2 (x24 / serve-01
                              :ARG1 (x25 / alternative)
                              :ARG2 (x26 / person))))
            :ARG0-of (x27 / have-03
                  :ARG1 (x29 / emphasize-01
                        :mod (x28 / prominent)
                        :location (x32 / model
                              :mod (x30 / other)
                              :mod (x31 / mouse)
                              :mod (x33 / disease
                                    :wiki "prostate_cancer"
                                    :name (x34 / name :op1 "prostate" :op2 "cancer")))))
            :ARG1-of (x35 / describe-01
                  :ARG0 (x36 / publication
                        :ARG1-of (x37 / cite-01 :ARG2 "33")))))


# ::id PMC2841635.165
# ::snt Probasin-Ack1 transgenic mice display pTyr176-AKT and develop mPINs.
# ::tok Probasin @-@ Ack1 transgenic mice display pTyr176 @-@ AKT and develop mPINs .
(x7 / display-01
      :ARG0 (x6 / mouse
            :mod (x1 / enzyme
                  :name (x2 / name :op1 "Probasin")
                  :mod (x3 / enzyme
                        :name (x4 / name :op1 "Ack1")
                        :xref (x15 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                  :xref (x16 / xref :value "UNIPROT:PRSS8_HUMAN" :prob "0.322"))
            :mod (x5 / transgenic))
      :ARG1 (x8 / enzyme
            :name (x9 / name :op1 "pTyr176")
            :mod (x12 / and
                  :op1 (x10 / enzyme
                        :name (x11 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :op2 (x13 / enzyme
                        :name (x14 / name :op1 "mPINs")))))


# ::id PMC2841635.166
# ::snt For bottom panels, lysates were subjected to IB with indicated antibodies.
# ::tok For bottom panels , lysates were subjected to IB with indicated antibodies .
(x4 / subject-01
      :location (x2 / panel
            :mod (x1 / bottom))
      :ARG1 (x3 / lysate)
      :ARG2 (x5 / immunoblot-01
            :ARG3 (x7 / antibody
                  :ARG1-of (x6 / indicate-01))))


# ::id PMC2841635.167
# ::snt The bottom 2 panels represent tail-PCR of these mice.
# ::tok The bottom 2 panels represent tail @-@ PCR of these mice .
(x5 / represent-01
      :ARG0 (x4 / panel
            :mod (x1 / bottom)
            :mod (x2 / enzyme
                  :name (x3 / name :op1 "erk2")
                  :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.603")))
      :ARG1 (x6 / tail
            :ARG2 (x7 / analyze-01
                  :ARG1 (x9 / mouse
                        :mod (x8 / this)))))


# ::id PMC2841635.168
# ::snt IL-2 was an internal control for PCR.
# ::tok IL @-@ 2 was an internal control for PCR .
(x5 / react-01
      :ARG0 (x4 / control-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "IL-2"))
            :ARG1-of (x3 / internal-02))
      :ARG0 (x6 / polymerase)
      :ARG1-of (x7 / chain-01))


# ::id PMC2841635.169
# ::snt Histological appearance of the prostate lateral lobe from a 22 wk old WT mouse ( D ), and corresponding lobe from age-matched TG mice with intraepithelial hyperplasia ( E ).
# ::tok Histological appearance of the prostate lateral lobe from a 22 wk old WT mouse ( D ) , and corresponding lobe from age @-@ matched TG mice with intraepithelial hyperplasia ( E ) .
(x1 / and
      :op1 (x3 / appear-01
            :mod (x2 / histology)
            :ARG1 (x4 / disease
                  :wiki "prostate_cancer"
                  :name (x5 / name :op1 "prostate" :op2 "lateral"))
            :mod (x6 / lobe)
            :source (x10 / mouse
                  :age (x7 / temporal-quantity
                        :quant "22"
                        :unit (x8 / week))
                  :mod (x9 / wild-type)
                  :ARG1-of (x11 / describe-01
                        :ARG0 (x12 / figure :mod "3d"))))
      :op2 (x13 / correspond-02
            :ARG1 (x14 / cell-line
                  :name (x15 / name :op1 "lobe")
                  :source (x19 / mouse
                        :ARG1-of (x17 / match-01
                              :ARG2 (x16 / age))
                        :mod (x18 / transgenic)))
            :ARG2 (x21 / hyperplasia
                  :name (x20 / name :op1 "intraepithelial"))
            :ARG1-of (x22 / describe-01
                  :ARG0 (x23 / figure :mod "1e"))))


# ::id PMC2841635.170
# ::snt The lateral prostate from 49 wk old TG mice exhibiting mPIN ( F ) is shown.
# ::tok The lateral prostate from 49 wk old TG mice exhibiting mPIN ( F ) is shown .
(x12 / show-01
      :ARG1 (x7 / exhibit-01
            :ARG1 (x2 / prostate
                  :mod (x1 / lateral)
                  :source (x6 / mouse
                        :age (x3 / temporal-quantity
                              :quant "49"
                              :unit (x4 / week))
                        :mod (x5 / transgenic)))
            :ARG1 (x8 / enzyme
                  :name (x9 / name :op1 "mPIN")
                  :xref (x / xref :value "UNIPROT:MPI_HUMAN" :prob "0.222"))
            :ARG1-of (x10 / describe-01
                  :ARG0 (x11 / figure :mod "f"))))


# ::id PMC2841635.171
# ::snt Contrasting histological appearance of the lateral, ventral and dorsal lobes of the prostate glands from a WT mouse ( G–I ), and corresponding lobes from TG mice (49 week old) are shown ( J–L ).
# ::tok Contrasting histological appearance of the lateral , ventral and dorsal lobes of the prostate glands from a WT mouse ( G–I ) , and corresponding lobes from TG mice ( 49 week old ) are shown ( J–L ) .
(x3 / appear-01
      :ARG0 (x1 / contrast-01)
      :mod (x2 / histology)
      :ARG1 (x14 / and
            :op1 (x4 / lateral)
            :op2 (x5 / ventral)
            :op3 (x9 / gland
                  :mod (x6 / dorsal)
                  :mod (x8 / prostate
                        :mod (x7 / lobe))
                  :source (x11 / mouse
                        :mod (x10 / wild-type))
                  :ARG1-of (x12 / mean-01
                        :ARG2 (x13 / name :op1 "G–I"))))
      :ARG1-of (x15 / correspond-02
            :ARG1 (x16 / lobe)
            :ARG2 (x18 / mouse
                  :mod (x17 / transgenic))
            :ARG1 (x19 / person
                  :age (x20 / temporal-quantity
                        :quant "49"
                        :unit (x21 / week))))
      :ARG1-of (x22 / show-01
            :ARG2 (x23 / small-molecule
                  :name (x24 / name :op1 "J–L")
                  :xref (x / xref :value "PUBCHEM:3042" :prob "8.006737"))))


# ::id PMC2841635.172
# ::snt pTyr284-Ack1 and pTyr176-AKT Expressions Correlate with Breast Cancer Progression
# ::tok pTyr284 @-@ Ack1 and pTyr176 @-@ AKT Expressions Correlate with Breast Cancer Progression
(x11 / correlate-01
      :ARG1 (x10 / express-03
            :ARG1 (x5 / and
                  :op1 (x1 / enzyme
                        :name (x2 / name :op1 "pTyr284")
                        :mod (x3 / enzyme
                              :name (x4 / name :op1 "Ack1")
                              :xref (x15 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "pTyr176")
                        :mod (x8 / enzyme
                              :name (x9 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))
      :ARG2 (x14 / progress-01
            :ARG1 (x12 / disease
                  :wiki "breast_cancer"
                  :name (x13 / name :op1 "Breast" :op2 "Cancer"))))


# ::id PMC2841635.173
# ::snt To examine the role of pTyr284-Ack1 and pTyr176-AKT in breast tumor progression, we performed an extensive tissue microarray analysis (TMA) of clinically annotated breast (n = 476) tumor samples.
# ::tok To examine the role of pTyr284 @-@ Ack1 and pTyr176 @-@ AKT in breast tumor progression , we performed an extensive tissue microarray analysis ( TMA ) of clinically annotated breast ( n = 476 ) tumor samples .
(x15 / perform-01
      :purpose (x1 / examine-01
            :ARG1 (x2 / role
                  :poss (x3 / enzyme
                        :name (x4 / name :op1 "pTyr284")
                        :ARG1-of (x7 / and
                              :op1 (x5 / enzyme
                                    :name (x6 / name :op1 "Ack1")
                                    :xref (x30 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                              :op2 (x8 / enzyme
                                    :name (x9 / name :op1 "pTyr176")))
                        :name (x10 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :topic (x13 / progress-01
                        :ARG1 (x12 / tumor
                              :mod (x11 / breast)))))
      :ARG0 (x14 / we)
      :ARG1 (x19 / analyze-01
            :ARG1 (x18 / microarray
                  :ARG1-of (x16 / extensive-03)
                  :mod (x17 / tissue)))
      :ARG1-of (x20 / describe-01
            :ARG0 (x21 / protein-segment
                  :name (x22 / name :op1 "TMA")
                  :part-of (x24 / annotate-01
                        :mod (x23 / clinic)
                        :mod (x25 / breast))
                  :mod (x28 / tumor
                        :ARG1-of (x26 / sample-01
                              :ARG2 (x27 / thing :quant "476"))
                        :ARG1-of (x29 / sample-01)))))


# ::id PMC2841635.174
# ::snt Tyr284 is the primary autophosphorylation site in Ack1, hence, phospho-Ack1(Tyr284) antibodies were used to assess Ack1 activation [27] , [29] .
# ::tok Tyr284 is the primary autophosphorylation site in Ack1 , hence , phospho @-@ Ack1 ( Tyr284 ) antibodies were used to assess Ack1 activation [ 27 ] , [ 29 ] .
(x4 / phosphorylate-01
      :ARG0 (x1 / amino-acid
            :mod "284"
            :name (x2 / name :op1 "tyrosine")
            :xref (x29 / xref :value "PUBCHEM:1153" :prob "11.081481"))
      :mod (x3 / primary)
      :ARG1 (x5 / protein-segment
            :location (x6 / enzyme
                  :name (x7 / name :op1 "Ack1")
                  :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :ARG0-of (x8 / cause-01
                  :ARG1 (x9 / and
                        :op1 (x10 / enzyme
                              :ARG3-of (x11 / phosphorylate-01)
                              :name (x12 / name :op1 "Ack1")
                              :xref (x28 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                        :op2 (x13 / amino-acid
                              :mod "284"
                              :name (x14 / name :op1 "tyrosine")
                              :xref (x30 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                  :ARG1-of (x15 / antibody
                        :ARG0-of (x16 / use-01
                              :purpose (x17 / assess-01
                                    :ARG1 (x20 / activate-01
                                          :ARG1 (x18 / enzyme
                                                :name (x19 / name :op1 "Ack1")
                                                :xref (x27 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))))
                        :ARG1-of (x21 / describe-01
                              :ARG0 (x22 / publication
                                    :ARG1-of (x23 / cite-01 :ARG2 "27")))))
            :ARG1-of (x24 / describe-01
                  :ARG0 (x25 / publication
                        :ARG1-of (x26 / cite-01 :ARG2 "29")))))


# ::id PMC2841635.175
# ::snt Immunohistochemical analysis revealed that pTyr284-Ack1 and pTyr176-AKT were expressed in both membrane and nucleus ( Fig. S10A ,B ).
# ::tok Immunohistochemical analysis revealed that pTyr284 @-@ Ack1 and pTyr176 @-@ AKT were expressed in both membrane and nucleus ( Fig . S10A , B ) .
(x3 / reveal-01
      :ARG0 (x2 / analyze-01
            :mod (x1 / immunohistochemical))
      :ARG1 (x8 / and
            :op1 (x4 / enzyme
                  :name (x5 / name :op1 "pTyr284")
                  :mod (x6 / enzyme
                        :name (x7 / name :op1 "Ack1")
                        :xref (x21 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
            :op2 (x13 / express-03
                  :ARG2 (x9 / enzyme
                        :name (x10 / name :op1 "pTyr176")
                        :mod (x11 / enzyme
                              :name (x12 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                  :ARG3 (x14 / and
                        :op1 (x15 / membrane
                              :xref (x22 / xref :value "GO:0016020" :prob "0.8"))
                        :op2 (x16 / nucleus
                              :xref (x23 / xref :value "GO:0005634" :prob "0.8")))))
      :ARG1-of (x17 / describe-01
            :ARG0 (x18 / and
                  :op1 (x19 / figure :mod "s10a")
                  :op1 (x20 / figure :mod "s10b"))))


# ::id PMC2841635.176
# ::snt A significant increase in expression of pTyr284-Ack1 and pTyr176-AKT was seen when breast cancers from progressive stages were examined, i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages ( Fig. 6A–C and Table 1 ).
# ::tok A significant increase in expression of pTyr284 @-@ Ack1 and pTyr176 @-@ AKT was seen when breast cancers from progressive stages were examined , i.e. normal to hyperplasia ( ADH ) , ductal carcinoma in situ ( DCIS ) , invasive ductal carcinoma ( IDC ) and lymph node metastatic ( LNMM ) stages ( Fig . 6A–C and Table 1 ) .
(x1 / multi-sentence
      :snt1 (x19 / examine-01
            :ARG0 (x14 / see-01
                  :ARG1 (x3 / increase-01
                        :ARG2 (x2 / significant-02)
                        :ARG1 (x4 / express-03
                              :ARG2 (x5 / enzyme
                                    :name (x6 / name :op1 "pTyr284"))))
                  :ARG1 (x9 / and
                        :op1 (x7 / enzyme
                              :name (x8 / name :op1 "Ack1")
                              :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                        :op2 (x10 / enzyme
                              :name (x11 / name :op1 "pTyr176"))
                        :op2 (x12 / enzyme
                              :name (x13 / name :op1 "AKT")
                              :xref (x42 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
                  :time (x15 / disease
                        :wiki "breast_cancer"
                        :name (x16 / name :op1 "breast" :op2 "cancer"))
                  :ARG2 (x17 / progress-01))
            :ARG1 (x18 / stage)
            :ARG1-of (x20 / mean-01
                  :ARG2 (x30 / carcinoma
                        :ARG1-of (x21 / normal-02
                              :ARG1 (x24 / duct
                                    :op1 (x22 / protein
                                          :name (x23 / name :op1 "hyperplasia" :op2 "ADH"))
                                    :op2 (x25 / medical-condition
                                          :name (x26 / name :op1 "carcinoma"))))
                        :mod (x27 / in-situ
                              :ARG1-of (x28 / dcis)
                              :ARG0-of (x29 / invade-01))))
            :ARG1-of (x31 / disease
                  :name (x32 / name :op1 "IDC")))
      :snt2 (x33 / and
            :op2 (x36 / metastasize-bab
                  :ARG2 (x35 / node
                        :mod (x34 / lymph)))
            :ARG1-of (x38 / stage-02
                  :name (x37 / name :op1 "LNMM"))
            :ARG1-of (x39 / describe-01
                  :ARG0 (x40 / and
                        :op1 (x41 / table :mod "1")))))


# ::id PMC2841635.177
# ::snt In contrast to pTyr284-Ack1, the total Ack1 levels remained unchanged between normal and tumor samples (compare Fig. S10D and E with F and G ).
# ::tok In contrast to pTyr284 @-@ Ack1 , the total Ack1 levels remained unchanged between normal and tumor samples ( compare Fig . S10D and E with F and G ) .
(x1 / contrast-01
      :ARG2 (x2 / enzyme
            :name (x3 / name :op1 "pTyr284")
            :mod (x4 / enzyme
                  :name (x5 / name :op1 "Ack1")
                  :xref (x20 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
      :ARG1 (x10 / remain-01
            :ARG1 (x9 / level
                  :quant-of (x6 / enzyme
                        :mod (x7 / total)
                        :name (x8 / name :op1 "Ack1")
                        :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
            :ARG3 (x11 / change-01 :polarity "-")
            :ARG1 (x13 / tumor
                  :ARG1-of (x12 / normal-02)
                  :ARG1-of (x14 / sample-01))
            :ARG1-of (x15 / compare-01
                  :ARG1 (x16 / and
                        :op1 (x17 / figure :mod "s10d")
                        :op1 (x18 / figure :mod "s10e"))
                  :ARG2 (x19 / figure :mod "1g"))))


# ::id PMC2841635.178
# ::snt ANOVA results indicated that both pTyr284-Ack1 and pTyr176-AKT expression differed significantly among progression stages ( p <0.0001).
# ::tok ANOVA results indicated that both pTyr284 @-@ Ack1 and pTyr176 @-@ AKT expression differed significantly among progression stages ( p
(x3 / indicate-01
      :ARG0 (x1 / thing
            :ARG2-of (x2 / result-01))
      :ARG1 (x14 / differ-02
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "pTyr284"))
            :ARG0 (x8 / and
                  :op1 (x6 / enzyme
                        :name (x7 / name :op1 "Ack1")
                        :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                  :op2 (x13 / express-03
                        :ARG1 (x9 / enzyme
                              :name (x10 / name :op1 "pTyr176"))
                        :ARG2 (x11 / enzyme
                              :name (x12 / name :op1 "AKT")
                              :xref (x20 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
            :ARG1-of (x15 / significant-02)
            :location (x17 / stage
                  :ARG1-of (x16 / progress-01))
            :ARG1-of (x18 / statistical-test-91
                  :ARG2 (x19 / less-than :op1 "0.05"))))


# ::id PMC2841635.179
# ::snt When using Tukey-Kramer method to examine all pairwise differences between different stages, the expression levels of pTyr284-Ack1 and pTyr176-AKT in LNMM were significantly higher than those of all the earlier tumor stages; the expression levels were significantly lower in the normal samples when compared to those of all the later stages except for hyperplasia ( Tables 2 and 3 ).
# ::tok When using Tukey @-@ Kramer method to examine all pairwise differences between different stages , the expression levels of pTyr284 @-@ Ack1 and pTyr176 @-@ AKT in LNMM were significantly higher than those of all the earlier tumor stages ; the expression levels were significantly lower in the normal samples when compared to those of all the later stages except for hyperplasia ( Tables 2 and 3 ) .
(x1 / multi-sentence
      :snt1 (x29 / high-02
            :condition (x2 / use-01
                  :ARG1 (x6 / method
                        :name (x3 / name :op1 "Tukey")
                        :mod (x4 / person
                              :wiki "-"
                              :name (x5 / name :op1 "Kramer")))
                  :ARG2 (x7 / examine-01
                        :ARG1 (x13 / stage
                              :mod (x8 / all)
                              :ARG1-of (x11 / differ-02
                                    :ARG2 (x9 / enzyme
                                          :name (x10 / name :op1 "pairwise"))
                                    :ARG1 (x12 / differ-02)))))
            :ARG1 (x14 / level
                  :degree-of (x15 / express-03
                        :ARG2 (x20 / and
                              :op1 (x16 / enzyme
                                    :name (x17 / name :op1 "pTyr284")
                                    :mod (x18 / enzyme
                                          :name (x19 / name :op1 "Ack1")
                                          :xref (x56 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
                              :op2 (x21 / enzyme
                                    :name (x22 / name :op1 "pTyr176")))))
            :ARG1 (x25 / and
                  :op1 (x23 / enzyme
                        :name (x24 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
                  :op2 (x26 / enzyme
                        :name (x27 / name :op1 "LNMM")))
            :ARG1-of (x28 / significant-02)
            :degree (x30 / more)
            :compared-to (x35 / stage
                  :mod (x31 / all)
                  :mod (x32 / early
                        :degree (x33 / more))
                  :mod (x34 / tumor)))
      :snt2 (x53 / and
            :op1 (x39 / low-04
                  :ARG1 (x37 / level
                        :mod (x36 / express-03))
                  :ARG1-of (x38 / significant-02)
                  :degree (x40 / more)
                  :location (x42 / sample
                        :ARG1-of (x41 / normal-02))
                  :ARG1-of (x43 / compare-01
                        :ARG2 (x50 / hyperplasia
                              :mod (x44 / that)
                              :mod (x48 / stage
                                    :mod (x45 / all)
                                    :mod (x46 / late
                                          :degree (x47 / more)))
                              :mod (x49 / except-for)
                              :ARG1-of (x51 / describe-01
                                    :ARG0 (x52 / table :mod "2")))))
            :op2 (x54 / publication
                  :ARG1-of (x55 / cite-01 :ARG2 "3"))))


# ::id PMC2841635.180
# ::snt Kaplan-Meir analyses revealed that patients with high expression of pTyr284-Ack1 and pTyr176-AKT are at a higher risk for cancer-related deaths ( Fig. 6D, E and Table 4 ).
# ::tok Kaplan @-@ Meir analyses revealed that patients with high expression of pTyr284 @-@ Ack1 and pTyr176 @-@ AKT are at a higher risk for cancer @-@ related deaths ( Fig . 6D , E and Table 4 ) .
(x6 / reveal-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "kaplan-meier")
            :mod (x5 / analyze-01
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "Meir")
                        :xref (x / xref :value "UNIPROT:SFR1_HUMAN" :prob "0.232"))))
      :ARG1 (x16 / and
            :op1 (x7 / person
                  :ARG0-of (x8 / have-rel-role-91
                        :ARG2 (x9 / patient))
                  :ARG0-of (x10 / have-03
                        :ARG1 (x12 / express-03
                              :ARG1-of (x11 / high-02)
                              :ARG2 (x13 / enzyme
                                    :name (x14 / name :op1 "pTyr284"))))
                  :name (x15 / name :op1 "Ack1"))
            :op2 (x17 / enzyme
                  :name (x18 / name :op1 "pTyr176")
                  :mod (x19 / enzyme
                        :name (x20 / name :op1 "AKT")
                        :xref (x34 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
      :location (x32 / and
            :op1 (x23 / risk-01
                  :ARG1-of (x21 / high-02
                        :degree (x22 / more))
                  :ARG2 (x27 / die-01
                        :ARG1-of (x26 / relate-01
                              :ARG2 (x24 / disease
                                    :wiki "cancer"
                                    :name (x25 / name :op1 "cancer")))
                        :ARG1-of (x28 / describe-01
                              :ARG0 (x29 / and
                                    :op1 (x30 / figure :mod "6d")
                                    :op2 (x31 / figure :mod "3e")))))
            :op2 (x33 / table :mod "4")))


# ::id PMC2841635.181
# ::snt Furthermore, expression of pTyr284-Ack1 was significantly correlated with pTyr176-AKT in situ (Spearman rank correlation coefficient ρ = 0.43, p <0.0001; Fig.
# ::tok Furthermore , expression of pTyr284 @-@ Ack1 was significantly correlated with pTyr176 @-@ AKT in situ ( Spearman rank correlation coefficient ρ = 0.43 , p
(x1 / and
      :op2 (x8 / correlate-01
            :ARG1 (x2 / express-03
                  :ARG2 (x3 / enzyme
                        :name (x4 / name :op1 "pTyr284")
                        :mod (x5 / enzyme
                              :name (x6 / name :op1 "Ack1")
                              :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))))
            :ARG1-of (x7 / significant-02)
            :ARG2 (x9 / enzyme
                  :name (x10 / name :op1 "pTyr176")
                  :ARG1-of (x13 / in-situ
                        :ARG0 (x11 / enzyme
                              :name (x12 / name :op1 "AKT")
                              :xref (x25 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
            :ARG1-of (x18 / coefficient
                  :name (x14 / name :op1 "Spearman")
                  :mod (x17 / correlate-01
                        :ARG2 (x15 / protein
                              :name (x16 / name :op1 "rank")
                              :xref (x26 / xref :value "UNIPROT:TNR11_HUMAN" :prob "0.602")))
                  :mod (x19 / enzyme
                        :name (x20 / name :op1 "ρ")))
            :ARG2 (x21 / enzyme
                  :name (x22 / name :op1 "0.43")
                  :ARG1-of (x23 / statistical-test-91
                        :ARG2 (x24 / less-than :op1 "0.05")))))


# ::id PMC2841635.183
# ::snt pTyr284-Ack1 and pTyr176-AKT expression in breast cancer.
# ::tok pTyr284 @-@ Ack1 and pTyr176 @-@ AKT expression in breast cancer .
(x5 / and
      :op1 (x1 / enzyme
            :name (x2 / name :op1 "pTyr284")
            :mod (x3 / enzyme
                  :name (x4 / name :op1 "Ack1")
                  :xref (x13 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
      :op2 (x10 / express-03
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "pTyr176"))
            :ARG2 (x8 / enzyme
                  :name (x9 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :ARG3 (x11 / disease
                  :wiki "breast_cancer"
                  :name (x12 / name :op1 "breast" :op2 "cancer"))))


# ::id PMC2841635.184
# ::snt A significant increasing trend of intensity across progression stages was detected (Mantel-Haenszel test, p = 0.02).
# ::tok A significant increasing trend of intensity across progression stages was detected ( Mantel @-@ Haenszel test , p = 0.02 ) .
(x8 / detect-01
      :ARG1 (x3 / trend-01
            :ARG1-of (x2 / increase-01
                  :ARG2 (x1 / significant-02))
            :ARG1 (x7 / stage
                  :ARG1-of (x4 / intense-02
                        :ARG1 (x5 / across
                              :op1 (x6 / progress-01)))))
      :ARG1-of (x11 / test-01
            :ARG1 (x9 / mantel)
            :ARG0 (x10 / haenszel))
      :ARG1-of (x12 / statistical-test-91 :ARG2 "0.02"))


# ::id PMC2841635.185
# ::snt The box has lines at the lower quartile (25%), median (50%), and upper quartile values (75%) while the red-cross within the circle marks the mean value.
# ::tok The box has lines at the lower quartile ( 25 % ) , median ( 50 % ) , and upper quartile values ( 75 % ) while the red @-@ cross within the circle marks the mean value .
(x17 / mark-01
      :ARG0 (x2 / line
            :ARG0 (x1 / box)
            :location (x5 / temporal-quantity
                  :ARG1-of (x3 / low-04
                        :degree (x4 / more))
                  :quant "7.01")
            :ARG1-of (x6 / percentage-entity :value "25")
            :ARG0-of (x9 / and
                  :mod (x7 / median)
                  :op1 (x8 / percentage-entity :value "50")
                  :op2 (x11 / value
                        :mod (x10 / temporal-quantity :quant "4.62")))
            :ARG1-of (x13 / contrast-01
                  :ARG2 (x12 / percentage-entity :value "75")
                  :ARG2 (x14 / red-02)
                  :ARG1 (x15 / crosstalk-00
                        :ARG1 (x16 / circle))))
      :ARG1 (x19 / value
            :mod (x18 / mean)))


# ::id PMC2841635.186
# ::snt Whiskers extend from each end of the box to the most extreme values within 1.5 times the interquartile range from the ends of the box.
# ::tok Whiskers extend from each end of the box to the most extreme values within 1.5 times the interquartile range from the ends of the box .
(x2 / extend-01
      :ARG1 (x1 / whisker)
      :ARG3 (x4 / end-01
            :mod (x3 / each)
            :ARG1 (x5 / dna-sequence
                  :name (x6 / name :op1 "e-box")))
      :ARG2 (x13 / range-01
            :ARG1 (x9 / value
                  :mod (x8 / extreme
                        :degree (x7 / most))
                  :ARG1-of (x10 / conform-01
                        :ARG2 (x11 / product-of
                              :op1 "1.5"
                              :op2 (x12 / interquartile))))
            :ARG3 (x14 / end-01
                  :ARG1 (x15 / box))))


# ::id PMC2841635.187
# ::snt The data with values beyond the ends of the whiskers, displayed with black circles, are potential outliers.
# ::tok The data with values beyond the ends of the whiskers , displayed with black circles , are potential outliers .
(x6 / display-01
      :ARG1 (x1 / data
            :ARG2 (x2 / value
                  :mod (x3 / beyond
                        :op1 (x4 / end-01))
                  :ARG1 (x5 / whisker)))
      :ARG2 (x9 / potential
            :domain (x8 / circle
                  :ARG1-of (x7 / black-04))
            :mod (x10 / outlier)))


# ::id PMC2841635.188
# ::snt A significant increasing trend of intensity across progression stages was detected (Mantel-Haenszel test, p <0.0001).
# ::tok A significant increasing trend of intensity across progression stages was detected ( Mantel @-@ Haenszel test , p
(x8 / detect-01
      :ARG1 (x2 / increase-01
            :ARG2 (x1 / significant-02))
      :ARG1 (x3 / trend-01
            :ARG1 (x7 / stage
                  :ARG1-of (x4 / intense-02
                        :ARG1 (x5 / across
                              :op1 (x6 / progress-01)))))
      :ARG1-of (x9 / mantel)
      :ARG1-of (x12 / test-01
            :ARG0 (x10 / enzyme
                  :name (x11 / name :op1 "Haenszel")))
      :ARG1-of (x13 / statistical-test-91
            :ARG2 (x14 / less-than :op1 "0.05")))


# ::id PMC2841635.190
# ::snt The intensities of Tyr284-phosphorylated-Ack1 and Tyr176-phosphorylated-AKT for the trend analysis of breast cancer.
# ::tok The intensities of Tyr284 @-@ phosphorylated @-@ Ack1 and Tyr176 @-@ phosphorylated @-@ AKT for the trend analysis of breast cancer .
(x7 / and
      :op1 (x4 / phosphorylate-01
            :ARG1 (x1 / intense)
            :ARG1 (x2 / amino-acid
                  :mod "284"
                  :name (x3 / name :op1 "tyrosine")
                  :xref (x19 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :ARG2 (x5 / enzyme
                  :name (x6 / name :op1 "Ack1")
                  :xref (x17 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
      :op2 (x13 / trend-01
            :ARG1 (x10 / phosphorylate-01
                  :ARG1 (x8 / amino-acid
                        :mod "176"
                        :name (x9 / name :op1 "tyrosine")
                        :xref (x18 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2 (x11 / enzyme
                        :name (x12 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :ARG2 (x14 / analyze-01
                  :ARG1 (x15 / disease
                        :wiki "breast_cancer"
                        :name (x16 / name :op1 "breast" :op2 "cancer")))))


# ::id PMC2841635.191
# ::snt Protein Statistics Normal ADH DCIS IDC LNMM pTyr284-Ack1 N 52 31 38 126 39 Mean 2 2.9 2.55 1.94 3.87 Median 2 3 2 2 3 Std 0.714 1.3 1.25 1.41 2 SE 0.1 0.23 0.20 0.13 0.32 CI Low 1.8 2.43 2.14 1.7 3.22 CI Upper 2.2 3.38 2.96 2.19 4.52 pTyr176-AKT N 45 39 38 118 37 Mean 2.36 2.9 3.97 3.86 5.32 Median 2 3 4 4 6 Std 0.8 0.79 1.96 2.17 1.93 SE 0.12 0.13 0.32 0.2 0.32 CI Low 2.11 2.64 3.22 3.46 4.68 CI Upper 2.6 3.15 4.51 4.25 5.97 10.1371/journal.pone.0009646.t002
# ::tok Protein Statistics Normal ADH DCIS IDC LNMM pTyr284 @-@ Ack1 N 52 31 38 126 39 Mean 2 2.9 2.55 1.94 3.87 Median 2 3 2 2 3 Std 0.714 1.3 1.25 1.41 2 SE 0.1 0.23 0.20 0.13 0.32 CI Low 1.8 2.43 2.14 1.7 3.22 CI Upper 2.2 3.38 2.96 2.19 4.52 pTyr176 @-@ AKT N 45 39 38 118 37 Mean 2.36 2.9 3.97 3.86 5.32 Median 2 3 4 4 6 Std 0.8 0.79 1.96 2.17 1.93 SE 0.12 0.13 0.32 0.2 0.32 CI Low 2.11 2.64 3.22 3.46 4.68 CI Upper 2.6 3.15 4.51 4.25 5.97 10.1371/journal.pone.0009646.t002
(x1 / multi-sentence
      :snt1 (x3 / statistic
            :mod (x2 / protein)
            :ARG1-of (x7 / cell-line
                  :ARG1-of (x4 / normal-02)
                  :mod (x5 / disease
                        :name (x6 / name :op1 "IDC"))
                  :name (x8 / name :op1 "LNMM")
                  :mod (x9 / enzyme
                        :name (x10 / name :op1 "pTyr284")
                        :mod (x13 / enzyme
                              :mod (x11 / enzyme
                                    :name (x12 / name :op1 "Ack1")
                                    :xref (x72 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                              :name (x14 / name :op1 "n-ras")
                              :name (x15 / name
                                    :op1 "52"
                                    :op2 "31"
                                    :op3 "38")
                              :xref (x73 / xref :value "UNIPROT:Q9UM97_HUMAN" :prob "0.701")))
                  :quant "126")
            :ARG1-of (x16 / describe-01
                  :ARG0 (x17 / publication
                        :ARG1-of (x18 / cite-01 :ARG2 "39"))))
      :snt2 (x35 / ratio
            :ARG1-of (x19 / mean-01
                  :ARG2 (x31 / interval
                        :op1 (x20 / small-molecule
                              :quant (x21 / percentage-entity :value "2.9")
                              :name (x22 / name :op1 "2.55" :op2 "1.94"))
                        :quant "3.87"
                        :mod (x23 / median)
                        :mod (x24 / amino-acid
                              :name (x25 / name :op1 "2")
                              :mod "3"
                              :mod "2"
                              :mod "2"
                              :mod "3"
                              :mod (x26 / std)
                              :quant "0.714"
                              :name (x27 / name :op1 "1.3" :op2 "1.25")
                              :xref (x74 / xref :value "PUBCHEM:72670316" :prob "2.248541"))
                        :quant "1.41"
                        :mod "2"
                        :mod (x28 / per-se :value "0.1")
                        :quant "0.23"
                        :mod (x29 / enzyme
                              :name (x30 / name :op1 "0.20" :op2 "0.13"))
                        :quant "0.32"
                        :mod (x32 / confidence)))
            :ARG1-of (x33 / low-04)
            :quant "1.8"
            :quant "2.43"
            :quant "2.14"
            :quant "1.7"
            :quant "3.22"
            :mod (x34 / upper)
            :quant "2.2"
            :quant "3.38"
            :mod (x36 / enzyme
                  :name (x37 / name :op1 "2.96" :op2 "2.19"))
            :quant "4.52"
            :mod (x38 / enzyme
                  :name (x39 / name :op1 "pTyr176")
                  :mod (x40 / enzyme
                        :name (x41 / name :op1 "AKT")
                        :xref (x71 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :mod (x42 / enzyme
                  :name (x43 / name :op1 "n-ras")
                  :xref (x / xref :value "UNIPROT:Q9UM97_HUMAN" :prob "0.701"))
            :ARG1-of (x44 / describe-01
                  :ARG0 (x45 / publication
                        :ARG1-of (x46 / cite-01 :ARG2 "45")))
            :ARG1-of (x47 / and
                  :op1 "39"
                  :op2 "38"
                  :op3 "118")
            :ARG1-of (x48 / describe-01
                  :ARG0 (x49 / publication
                        :ARG1-of (x50 / cite-01 :ARG2 "37"))))
      :snt3 (x51 / mean-01
            :ARG1 (x52 / monetary-quantity
                  :quant "2.36"
                  :quant "2900000000"
                  :mod (x53 / enzyme
                        :name (x54 / name :op1 "3.97" :op2 "3.86"))
                  :quant "5.32"
                  :mod (x55 / median)
                  :mod "2"
                  :mod "3"
                  :mod "4"
                  :mod "4"
                  :mod "6"
                  :name (x56 / name :op1 "0.8" :op2 "0.79"))
            :ARG2 (x64 / interval
                  :mod (x59 / per-se
                        :mod (x57 / enzyme
                              :name (x58 / name :op1 "1.96" :op2 "2.17"))
                        :quant "1.93"
                        :name (x60 / name :op1 "0.12" :op2 "0.13"))
                  :quant "0.32"
                  :mod (x61 / confidence
                        :value "0.2"
                        :quant "0.32"
                        :ARG1-of (x62 / low-04
                              :name (x63 / name :op1 "2.11" :op2 "2.64")))
                  :quant "3.22"
                  :quant "3.46"
                  :quant "4.68"
                  :mod (x65 / upper)
                  :mod (x66 / percentage-entity :value "2.6")
                  :mod (x67 / enzyme
                        :name (x68 / name :op1 "3.15" :op2 "4.51"))
                  :quant "4.25")
            :ARG1 (x69 / protein
                  :name (x70 / name :op1 "5.97" :op2 "10.1371/journal.pone.0009646.t002"))))


# ::id PMC2841635.192
# ::snt P-values of Tukey-Kramer multiple comparisons (simultaneous inference) of pTyr284-Ack1 intensity levels between all pairs of stages for breast cancer.
# ::tok P @-@ values of Tukey @-@ Kramer multiple comparisons ( simultaneous inference ) of pTyr284 @-@ Ack1 intensity levels between all pairs of stages for breast cancer .
(x9 / compare-01
      :ARG1 (x3 / value
            :ARG1-of (x1 / statistical-test-91
                  :ARG2 (x2 / less-than :op1 "0.05"))
            :poss (x4 / enzyme
                  :name (x5 / name :op1 "Tukey")
                  :mod (x8 / multiple
                        :mod (x6 / person
                              :wiki "-"
                              :name (x7 / name :op1 "Kramer")))))
      :ARG2 (x16 / level
            :ARG1-of (x10 / inference)
            :degree-of (x15 / intensity
                  :part-of (x11 / enzyme
                        :name (x12 / name :op1 "pTyr284")
                        :mod (x13 / enzyme
                              :name (x14 / name :op1 "Ack1")
                              :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))))
            :location (x18 / pair
                  :mod (x17 / all))
            :ARG1-of (x19 / stage-02
                  :ARG1 (x20 / disease
                        :wiki "breast_cancer"
                        :name (x21 / name :op1 "breast" :op2 "cancer")))))


# ::id PMC2841635.193
# ::snt pTyr284-Ack1 Normal ADH DCIS IDC LMM Normal 0.0340 * 0.3324 0.9992 <0.0001 * ADH 0.8313 0.0055 * 0.3324 DCIS 0.1234 0.0004 * IDC <0.0001 * LMM
# ::tok pTyr284 @-@ Ack1 Normal ADH DCIS IDC LMM Normal 0.0340 * 0.3324 0.9992
(x5 / normal-02
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "pTyr284")
            :mod (x3 / enzyme
                  :name (x4 / name :op1 "Ack1")
                  :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603")))
      :op2 (x6 / disease
            :name (x7 / name :op1 "IDC"))
      :ARG1-of (x8 / normal-02
            :quant "0.0340"
            :name (x9 / name :op1 "0.3324" :op2 "0.9992")))


# ::id PMC2841635.196
# ::snt P-values of Tukey-Kramer multiple comparisons (simultaneous inference) of pTyr176-AKT intensity levels between all pairs of stages for breast cancer.
# ::tok P @-@ values of Tukey @-@ Kramer multiple comparisons ( simultaneous inference ) of pTyr176 @-@ AKT intensity levels between all pairs of stages for breast cancer .
(x9 / compare-01
      :ARG1 (x3 / value
            :ARG1-of (x1 / statistical-test-91
                  :ARG2 (x2 / less-than :op1 "0.05"))
            :poss (x4 / enzyme
                  :name (x5 / name :op1 "Tukey")
                  :mod (x8 / multiple
                        :mod (x6 / person
                              :wiki "-"
                              :name (x7 / name :op1 "Kramer")))))
      :ARG2 (x16 / level
            :ARG1-of (x10 / inference)
            :degree-of (x15 / intensity
                  :part-of (x11 / enzyme
                        :name (x12 / name :op1 "pTyr176")
                        :mod (x13 / enzyme
                              :name (x14 / name :op1 "AKT")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
            :location (x18 / pair
                  :mod (x17 / all))
            :ARG1-of (x19 / stage-02
                  :ARG1 (x20 / disease
                        :wiki "breast_cancer"
                        :name (x21 / name :op1 "breast" :op2 "cancer")))))


# ::id PMC2841635.197
# ::snt pTyr176-AKT Normal ADH DCIS IDC LMM Normal 0.6434 0.0016 * <0.0001 * <0.0001 * ADH 0.1276 0.0342 * <0.0001 * DCIS 1.0000 0.0049 * IDC 0.0002 * LMM
# ::tok pTyr176 @-@ AKT Normal ADH DCIS IDC LMM Normal 0.6434 0.0016 *
(x5 / normal-02
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "pTyr176")
            :mod (x3 / enzyme
                  :name (x4 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :op2 (x6 / disease
            :name (x7 / name :op1 "IDC"))
      :ARG1-of (x8 / normal-02
            :quant "0.6434"
            :name (x9 / name :op1 "0.0016" :op2 "*")))


# ::id PMC2841635.200
# ::snt Kaplan–Meier survival estimates by Tyr284-phosphorylated Ack1 and Tyr176-phosphorylated AKT intensities for breast cancer TMA samples.
# ::tok Kaplan–Meier survival estimates by Tyr284 @-@ phosphorylated Ack1 and Tyr176 @-@ phosphorylated AKT intensities for breast cancer TMA samples .
(x4 / estimate-01
      :ARG0 (x3 / survive-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "Kaplan–Meier")))
      :ARG1 (x7 / phosphorylate-01
            :ARG1 (x5 / amino-acid
                  :mod "284"
                  :name (x6 / name :op1 "tyrosine")
                  :xref (x25 / xref :value "PUBCHEM:1153" :prob "11.081481")))
      :ARG1 (x10 / and
            :op1 (x8 / enzyme
                  :name (x9 / name :op1 "Ack1")
                  :xref (x23 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :op2 (x11 / amino-acid
                  :mod "176"
                  :name (x12 / name :op1 "tyrosine")
                  :xref (x24 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :op2 (x13 / enzyme
                  :ARG3-of (x14 / phosphorylate-01)
                  :name (x15 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :degree (x16 / intense)
      :ARG2 (x21 / sample
            :mod (x17 / disease
                  :wiki "breast_cancer"
                  :name (x18 / name :op1 "breast" :op2 "cancer"))
            :mod (x19 / enzyme
                  :name (x20 / name :op1 "TMA")
                  :xref (x22 / xref :value "UNIPROT:TMA7_HUMAN" :prob "0.262"))))


# ::id PMC2841635.201
# ::snt Protein Expression No.
# ::tok Protein Expression No .
(x2 / express-03
      :ARG1 (x1 / protein)
      :polarity "-")


# ::id PMC2841635.202
# ::snt of subjects Event Censored pTyr284-Ack1 < = 4 133 14% (19) 86% (114) pTyr284-Ack1 >4 11 36% (4) 64% (7) pTyr176-AKT < = 4 104 11% (11) 89% (93) pTyr176-AKT >4 36 25% (9) 75% (27)
# ::tok of subjects Event Censored pTyr284 @-@ Ack1 11 36 % ( 4 ) 64 % ( 7 ) pTyr176 @-@ AKT 36 25 % ( 9 ) 75 % ( 27 )
(x3 / censor-01
      :ARG0 (x2 / event
            :part-of (x1 / subject))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "pTyr284"))
      :ARG2 (x6 / small-molecule
            :name (x7 / name :op1 "Ack1" :op2 "11")
            :mod (x8 / percentage-entity :value "36")
            :mod (x9 / percentage-entity :value "4"))
      :mod (x10 / percentage-entity :value "64")
      :ARG1-of (x11 / describe-01
            :ARG0 (x12 / publication
                  :ARG1-of (x13 / cite-01 :ARG2 "7")))
      :ARG0-of (x15 / amino-acid
            :name (x14 / name :op1 "pTyr176")
            :part-of (x16 / enzyme
                  :name (x17 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
            :mod "36"
            :mod (x18 / percentage-entity :value "25"))
      :ARG1-of (x19 / describe-01
            :ARG0 (x20 / publication
                  :ARG1-of (x21 / cite-01 :ARG2 "9")))
      :ARG0-of (x22 / percentage-entity :value "75")
      :ARG1-of (x23 / describe-01
            :ARG0 (x24 / publication
                  :ARG1-of (x25 / cite-01 :ARG2 "27"))))


# ::id PMC2841635.213
# ::snt Tyr176-phosphorylation leads to AKT activation, a model.
# ::tok Tyr176 @-@ phosphorylation leads to AKT activation , a model .
(x3 / phosphorylate-01
      :ARG1 (x1 / amino-acid
            :mod "176"
            :name (x2 / name :op1 "tyrosine")
            :xref (x9 / xref :value "PUBCHEM:1153" :prob "11.081481"))
      :ARG0-of (x4 / lead-03
            :ARG2 (x7 / activate-01
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "AKT")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
            :ARG1 (x8 / model)))


# ::id PMC2841635.214
# ::snt Our data demonstrates an alternate pathway of AKT activation wherein RTKs facilitate Ack1 phosphorylation at Tyr284 leading to its kinase activation.
# ::tok Our data demonstrates an alternate pathway of AKT activation wherein RTKs facilitate Ack1 phosphorylation at Tyr284 leading to its kinase activation .
(x3 / demonstrate-01
      :ARG0 (x2 / data
            :poss (x1 / we))
      :ARG1 (x8 / activate-01
            :ARG0 (x5 / pathway
                  :ARG1-of (x4 / alternate-01))
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "AKT")
                  :xref (x21 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :ARG1 (x11 / facilitate-01
            :ARG0 (x9 / enzyme
                  :name (x10 / name :op1 "rtk")
                  :xref (x / xref :value "UNIPROT:DDR1_HUMAN" :prob "0.202"))
            :ARG1 (x14 / phosphorylate-01
                  :ARG2 (x12 / enzyme
                        :name (x13 / name :op1 "Ack1")
                        :xref (x20 / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
                  :ARG1 (x15 / amino-acid
                        :mod "284"
                        :name (x16 / name :op1 "tyrosine")
                        :xref (x22 / xref :value "PUBCHEM:1153" :prob "11.081481")))
            :ARG1-of (x17 / lead-03
                  :ARG2 (x19 / activate-01
                        :ARG1 (x18 / kinase)))))


# ::id PMC2841635.215
# ::snt Ack1 could also be activated in some tumors by autoactivating somatic mutations, e.g. E346K.
# ::tok Ack1 could also be activated in some tumors by autoactivating somatic mutations , e.g. E346K .
(x1 / possible-01
      :ARG1 (x5 / activate-01
            :ARG0 (x2 / enzyme
                  :name (x3 / name :op1 "Ack1")
                  :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :mod (x4 / also)
            :location (x7 / tumor
                  :quant (x6 / some))
            :manner (x9 / mutate-01
                  :mod (x8 / somatic)
                  :example (x10 / mutate-01 :value "E346K"))))


# ::id PMC2841635.216
# ::snt Activated Ack1 phosphorylates AKT at Tyr176 resulting in its binding to the anionic plasma membrane phospholipid PA.
# ::tok Activated Ack1 phosphorylates AKT at Tyr176 resulting in its binding to the anionic plasma membrane phospholipid PA .
(x4 / phosphorylate-01
      :ARG0 (x1 / enzyme
            :ARG1-of (x2 / activate-01)
            :name (x3 / name :op1 "Ack1")
            :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
      :ARG1 (x5 / enzyme
            :name (x6 / name :op1 "AKT")
            :xref (x14 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))
      :ARG2 (x7 / amino-acid
            :mod "176"
            :name (x8 / name :op1 "tyrosine")
            :xref (x16 / xref :value "PUBCHEM:1153" :prob "11.081481"))
      :ARG1-of (x9 / result-01
            :ARG2 (x10 / bind-01
                  :ARG2 (x12 / membrane
                        :mod (x11 / plasma)
                        :name (x13 / name :op1 "PA")
                        :xref (x15 / xref :value "GO:0016020" :prob "0.8")))))


# ::id PMC2841635.217
# ::snt pTyr176-AKT localizes to the plasma membrane, where it is targeted by PDK1 and PDK2 (mTORC2 complex) for Thr308/Ser473 phosphorylations, respectively, leading to optimal AKT kinase activation.
# ::tok pTyr176 @-@ AKT localizes to the plasma membrane , where it is targeted by PDK1 and PDK2 ( mTORC2 complex ) for Thr308 @/@ Ser473 phosphorylations , respectively , leading to optimal AKT kinase activation .
(x5 / localize-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "pTyr176")
            :mod (x3 / enzyme
                  :name (x4 / name :op1 "AKT")
                  :xref (x28 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :ARG2 (x7 / membrane
            :mod (x6 / plasma)
            :location-of (x8 / target-01
                  :ARG0 (x9 / enzyme
                        :name (x10 / name :op1 "PDK1")
                        :xref (x27 / xref :value "UNIPROT:PDK1_HUMAN" :prob "1.003"))
                  :ARG1 (x11 / and
                        :op1 (x12 / protein
                              :name (x13 / name :op1 "PDK2"))
                        :ARG1-of (x15 / macro-molecular-complex
                              :name (x14 / name :op1 "mTORC2"))
                        :condition (x20 / phosphorylate-01
                              :ARG1 (x16 / amino-acid
                                    :mod "308"
                                    :name (x17 / name :op1 "threonine")
                                    :xref (x31 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :ARG2 (x18 / amino-acid
                                    :mod "473"
                                    :name (x19 / name :op1 "serine")
                                    :xref (x30 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                              :mod (x21 / respective)))
                  :ARG0-of (x22 / lead-03
                        :ARG2 (x26 / activate-01
                              :mod (x23 / optimal)
                              :ARG1 (x24 / enzyme
                                    :name (x25 / name :op1 "AKT")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))
            :xref (x29 / xref :value "GO:0016020" :prob "0.8")))


# ::id PMC2841635.218
# ::snt Activated AKT translocates to the nucleus, phosphorylates FoxO transcription factors to downregulate expression of FoxO target genes.
# ::tok Activated AKT translocates to the nucleus , phosphorylates FoxO transcription factors to downregulate expression of FoxO target genes .
(x1 / activate-01
      :ARG1 (x2 / enzyme
            :name (x3 / name :op1 "AKT" :op2 "translocates"))
      :ARG2 (x4 / nucleus
            :xref (x / xref :value "GO:0005634" :prob "0.8"))
      :ARG0 (x5 / phosphorylate-01
            :ARG1 (x9 / factor
                  :ARG0-of (x8 / transcribe-01
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "FoxO"))))
            :ARG2 (x10 / downregulate-01))
      :ARG1 (x11 / express-03
            :ARG1 (x15 / gene
                  :ARG1-of (x14 / target-01
                        :ARG0 (x12 / protein
                              :name (x13 / name :op1 "FoxO"))))))


# ::id PMC2841635.264
# ::snt AKT Phospho-Site Determination Using Mass Spectrometry
# ::tok AKT Phospho @-@ Site Determination Using Mass Spectrometry
(x1 / and
      :op1 (x4 / phosphorylate-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "AKT")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :op2 (x5 / protein-segment
            :ARG1-of (x6 / determine-01
                  :ARG1 (x7 / use-01
                        :ARG1 (x8 / spectrometry)))))


# ::id PMC2841635.281
# ::snt Generation and Purification of pTyr176-AKT Phospho-Antibody
# ::tok Generation and Purification of pTyr176 @-@ AKT Phospho @-@ Antibody
(x1 / and
      :op2 (x2 / purify-01)
      :op1 (x3 / generate-01
            :ARG1 (x9 / antibody
                  :ARG2 (x4 / enzyme
                        :name (x5 / name :op1 "pTyr176")
                        :ARG2-of (x8 / phosphorylate-01
                              :ARG1 (x6 / enzyme
                                    :name (x7 / name :op1 "AKT")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))))


# ::id PMC2841635.301
# ::snt Purification, In Vitro Binding and Phosphorylation Assay
# ::tok Purification , In Vitro Binding and Phosphorylation Assay
(x4 / and
      :ARG1-of (x1 / purify-01)
      :op1 (x3 / bind-01
            :manner (x2 / in-vitro))
      :op2 (x6 / assay-01
            :ARG1 (x5 / phosphorylate-01)))


# ::id PMC2841635.328
# ::snt Primer sequences for qRT-PCR.
# ::tok Primer sequences for qRT @-@ PCR .
(x2 / sequence
      :ARG0 (x1 / primer)
      :purpose (x3 / thing
            :name (x4 / name :op1 "qRT-PCR")))


# ::id PMC2841635.335
# ::snt Ack1 Transgenic (TG) Mice
# ::tok Ack1 Transgenic ( TG ) Mice
(x5 / mouse
      :mod (x3 / transgenic
            :mod (x1 / enzyme
                  :name (x2 / name :op1 "Ack1")
                  :xref (x / xref :value "UNIPROT:ACK1_HUMAN" :prob "0.603"))
            :ARG1-of (x4 / transgenic)))


# ::id PMC2841635.347
# ::snt Flow Cytometry Analysis
# ::tok Flow Cytometry Analysis
(x3 / analyze-01
      :manner (x2 / cytometry
            :mod (x1 / flow)))


# ::id PMC2841635.358
# ::snt Tissue Microarray (TMA) Analysis
# ::tok Tissue Microarray ( TMA ) Analysis
(x4 / analyze-01
      :ARG1 (x2 / microarray
            :mod (x1 / tissue)
            :name (x3 / name :op1 "TMA")))


# ::id PMC3595493.0
# ::snt ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells
# ::tok ASPP1 and ASPP2 bind active RAS , potentiate RAS signalling and enhance p53 activity in cancer cells
(x6 / bind-01
      :ARG0 (x3 / and
            :op1 (x1 / protein
                  :name (x2 / name :op1 "ASPP1")
                  :xref (x24 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
            :op2 (x4 / protein
                  :name (x5 / name :op1 "ASPP2")
                  :xref (x25 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
      :ARG1 (x14 / and
            :op1 (x7 / activate-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :ARG1-of (x10 / potentiate-01
                        :ARG1 (x13 / signal-07
                              :ARG0 (x11 / enzyme
                                    :name (x12 / name :op1 "RAS")
                                    :xref (x23 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))
            :op2 (x15 / enhance-01
                  :ARG1 (x18 / activity-06
                        :ARG0 (x16 / enzyme
                              :name (x17 / name :op1 "p53")
                              :xref (x22 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))))
      :location (x21 / cell
            :mod (x19 / disease
                  :wiki "cancer"
                  :name (x20 / name :op1 "cancer"))))


# ::id PMC3595493.2
# ::snt RAS mutations occur frequently in human cancer and activated RAS signalling contributes to tumour development and progression.
# ::tok RAS mutations occur frequently in human cancer and activated RAS signalling contributes to tumour development and progression .
(x8 / and
      :op1 (x3 / mutate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "RAS")
                  :xref (x17 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
            :ARG0-of (x4 / frequent-02)
            :location (x5 / disease
                  :wiki "cancer"
                  :mod (x6 / human)
                  :name (x7 / name :op1 "cancer")))
      :op2 (x13 / contribute-01
            :ARG0 (x12 / signal-07
                  :ARG0 (x9 / enzyme
                        :ARG1-of (x10 / activate-01)
                        :name (x11 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
            :ARG2 (x15 / develop-02
                  :ARG1 (x14 / tumor)))
      :op3 (x16 / progress-01))


# ::id PMC3595493.3
# ::snt Apart from its oncogenic effects on cell growth, active RAS has tumour-suppressive functions via its ability to induce cellular senescence and apoptosis.
# ::tok Apart from its oncogenic effects on cell growth , active RAS has tumour @-@ suppressive functions via its ability to induce cellular senescence and apoptosis .
(x1 / have-concession-91
      :ARG2 (x5 / affect-01
            :ARG0-of (x2 / cause-01
                  :ARG1 (x3 / disease
                        :wiki "cancer"
                        :name (x4 / name :op1 "cancer")))
            :ARG1 (x7 / grow-01
                  :ARG1 (x6 / cell)))
      :ARG1 (x8 / activate-01
            :ARG1 (x13 / function-01
                  :ARG0 (x9 / enzyme
                        :name (x10 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :ARG1 (x12 / suppress-01
                        :ARG1 (x11 / tumor)))
            :instrument (x14 / capable-01
                  :ARG2 (x15 / induce-01
                        :ARG2 (x18 / and
                              :op1 (x17 / senescence
                                    :mod (x16 / cell))
                              :op2 (x19 / apoptosis))))))


# ::id PMC3595493.4
# ::snt RAS is known to induce p53-dependent cell cycle arrest, yet its effect on p53-dependent apoptosis remains unclear.
# ::tok RAS is known to induce p53 @-@ dependent cell cycle arrest , yet its effect on p53 @-@ dependent apoptosis remains unclear .
(x4 / induce-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "RAS")
            :xref (x19 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
      :ARG1-of (x3 / know-01)
      :ARG2 (x10 / arrest-02
            :ARG0-of (x7 / depend-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "p53")
                        :xref (x20 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
            :ARG1 (x9 / cycle-02
                  :ARG1 (x8 / cell)))
      :ARG1-of (x11 / contrast-01
            :ARG2 (x12 / affect-01
                  :ARG1 (x17 / remain-01
                        :ARG1 (x16 / apoptosis
                              :ARG0-of (x15 / depend-01
                                    :ARG1 (x13 / protein
                                          :name (x14 / name :op1 "p53")
                                          :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))
                        :ARG3 (x18 / clear-06 :polarity "-")))))


# ::id PMC3595493.5
# ::snt We report here that apoptosis-stimulating protein of p53 (ASPP) 1 and 2, two activators of p53, preferentially bind active RAS via their N-terminal RAS-association domains (RAD).
# ::tok We report here that apoptosis @-@ stimulating protein of p53 ( ASPP ) 1 and 2 , two activators of p53 , preferentially bind active RAS via their N @-@ terminal RAS @-@ association domains ( RAD ) .
(x2 / report-01
      :ARG0 (x1 / we)
      :medium (x3 / here)
      :ARG1 (x5 / stimulate-01
            :ARG1 (x4 / apoptosis)
            :ARG2 (x6 / protein))
      :ARG1-of (x16 / bind-01
            :ARG2 (x7 / protein
                  :name (x8 / name :op1 "p53")
                  :ARG1-of (x12 / activate-01
                        :ARG0 (x11 / and
                              :op1 (x9 / protein
                                    :name (x10 / name :op1 "ASPP")
                                    :xref (x26 / xref :value "UNIPROT:A1CF_HUMAN" :prob "0.342"))
                              :op1 "1"
                              :op2 "2"
                              :op2 "2")
                        :ARG1 (x13 / enzyme
                              :name (x14 / name :op1 "p53")
                              :xref (x28 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))
                        :ARG1-of (x15 / prefer-01))
                  :xref (x27 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))
            :ARG2 (x17 / enzyme
                  :ARG0-of (x18 / activity-06)
                  :name (x19 / name :op1 "RAS")
                  :xref (x29 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
            :ARG3 (x20 / protein-segment
                  :name (x21 / name :op1 "n-terminus")
                  :ARG0-of (x24 / associate-01
                        :ARG1 (x22 / enzyme
                              :name (x23 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
                  :name (x25 / name :op1 "RAD"))))


# ::id PMC3595493.6
# ::snt Additionally, ASPP2 colocalises with and contributes to RAS cellular membrane localisation and potentiates RAS signalling.
# ::tok Additionally , ASPP2 colocalises with and contributes to RAS cellular membrane localisation and potentiates RAS signalling .
(x1 / and
      :op2 (x13 / potentiate-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "ASPP2")
                  :xref (x18 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :ARG1-of (x6 / and
                  :op1 (x4 / small-molecule
                        :name (x5 / name :op1 "colocalises"))
                  :op2 (x7 / contribute-01
                        :ARG2 (x11 / membrane
                              :mod (x8 / enzyme
                                    :name (x9 / name :op1 "RAS")
                                    :xref (x17 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                              :mod (x10 / cell)
                              :ARG0-of (x12 / localize-01)
                              :xref (x19 / xref :value "GO:0016020" :prob "0.8"))))
            :ARG1 (x16 / signal-07
                  :ARG0 (x14 / enzyme
                        :name (x15 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))


# ::id PMC3595493.7
# ::snt In cancer cells, ASPP1 and ASPP2 cooperate with oncogenic RAS to enhance the transcription and apoptotic function of p53.
# ::tok In cancer cells , ASPP1 and ASPP2 cooperate with oncogenic RAS to enhance the transcription and apoptotic function of p53 .
(x9 / cooperate-01
      :location (x3 / cell
            :mod (x1 / disease
                  :wiki "cancer"
                  :name (x2 / name :op1 "cancer")))
      :ARG0 (x6 / and
            :op1 (x4 / protein
                  :name (x5 / name :op1 "ASPP1")
                  :xref (x24 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
            :op2 (x7 / protein
                  :name (x8 / name :op1 "ASPP2")
                  :xref (x23 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
      :ARG1 (x19 / function-01
            :ARG1 (x17 / and
                  :op1 (x15 / enhance-01
                        :ARG0 (x10 / enzyme
                              :ARG0-of (x11 / cause-01
                                    :ARG1 (x12 / disease
                                          :wiki "cancer"
                                          :name (x13 / name :op1 "cancer")))
                              :name (x14 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                        :ARG1 (x16 / transcribe-01))
                  :op2 (x18 / apoptosis))
            :ARG0 (x20 / protein
                  :name (x21 / name :op1 "p53")
                  :xref (x22 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))


# ::id PMC3595493.8
# ::snt Thus, loss of ASPP1 and ASPP2 in human cancer cells may contribute to the full transforming property of RAS oncogene.
# ::tok Thus , loss of ASPP1 and ASPP2 in human cancer cells may contribute to the full transforming property of RAS oncogene .
(x1 / infer-01
      :ARG1 (x2 / possible-01
            :ARG1 (x13 / contribute-01
                  :ARG0 (x3 / lose-02
                        :ARG1 (x6 / and
                              :op1 (x4 / protein
                                    :name (x5 / name :op1 "ASPP1")
                                    :xref (x23 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                              :op2 (x7 / protein
                                    :name (x8 / name :op1 "ASPP2")
                                    :xref (x22 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
                        :location (x12 / cell
                              :mod (x9 / human)
                              :mod (x10 / disease
                                    :wiki "cancer"
                                    :name (x11 / name :op1 "cancer"))))
                  :ARG2 (x16 / property
                        :mod (x15 / transform-01
                              :degree (x14 / full))
                        :poss (x17 / enzyme
                              :name (x18 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                        :ARG0-of (x19 / cause-01
                              :ARG1 (x20 / disease
                                    :wiki "cancer"
                                    :name (x21 / name :op1 "cancer")))))))


# ::id PMC3595493.49
# ::snt ASPP1 and ASPP2 preferentially bind active RAS
# ::tok ASPP1 and ASPP2 preferentially bind active RAS
(x7 / bind-01
      :ARG1-of (x6 / prefer-01
            :ARG2 (x3 / and
                  :op1 (x1 / protein
                        :name (x2 / name :op1 "ASPP1")
                        :xref (x11 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                  :op2 (x4 / protein
                        :name (x5 / name :op1 "ASPP2")
                        :xref (x12 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
      :ARG2 (x8 / enzyme
            :ARG0-of (x9 / activity-06)
            :name (x10 / name :op1 "RAS")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))


# ::id PMC3595493.50
# ::snt The evolutionarily conserved N-terminal 100 amino acids of ASPP1 and ASPP2 share high sequence homology with RAD present in c-Raf, PI3K and RasGDL, 23 suggesting that ASPP1 and ASPP2 may interact with RAS.
# ::tok The evolutionarily conserved N @-@ terminal 100 amino acids of ASPP1 and ASPP2 share high sequence homology with RAD present in c @-@ Raf , PI3K and RasGDL , 23 suggesting that ASPP1 and ASPP2 may interact with RAS .
(x26 / suggest-01
      :ARG0 (x12 / share-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "evolutionarily")
                  :xref (x38 / xref :value "UNIPROT:GPTC1_HUMAN" :prob "0.202"))
            :ARG1-of (x3 / conserve-01
                  :ARG1 (x9 / and
                        :op1 (x4 / protein-segment
                              :name (x5 / name :op1 "n-terminus")
                              :mod (x6 / amino-acid :value "100")
                              :part-of (x7 / protein
                                    :name (x8 / name :op1 "ASPP1")
                                    :xref (x39 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003")))
                        :op2 (x10 / protein
                              :name (x11 / name :op1 "ASPP2")
                              :xref (x43 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
            :ARG1 (x14 / dna-sequence
                  :ARG1-of (x13 / high-02)
                  :name (x15 / name :op1 "homology"))
            :ARG2 (x23 / and
                  :op1 (x18 / present-02
                        :ARG1 (x16 / enzyme
                              :name (x17 / name :op1 "RAD")
                              :xref (x44 / xref :value "UNIPROT:RAD_HUMAN" :prob "1.003"))
                        :ARG2 (x19 / enzyme
                              :name (x20 / name :op1 "c-Raf")
                              :xref (x42 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.673")))
                  :op1 (x21 / enzyme
                        :name (x22 / name :op1 "PI3K")
                        :xref (x37 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                  :op2 (x24 / enzyme
                        :name (x25 / name :op1 "RasGDL")
                        :xref (x36 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.243"))
                  :op2 "23"))
      :ARG1 (x27 / possible-01
            :ARG1 (x33 / interact-01
                  :ARG0 (x30 / and
                        :op1 (x28 / protein
                              :name (x29 / name :op1 "ASPP1")
                              :xref (x / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                        :op2 (x31 / protein
                              :name (x32 / name :op1 "ASPP2")
                              :xref (x40 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
                  :ARG1 (x34 / enzyme
                        :name (x35 / name :op1 "RAS")
                        :xref (x41 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))


# ::id PMC3595493.51
# ::snt Purified N-terminal ASPP1 and purified RAS loaded with [ 3 H]-labelled GTP or GDP were used to investigate whether ASPP1 RAD has a binding preference towards either RAS–GTP or RAS–GDP.
# ::tok Purified N @-@ terminal ASPP1 and purified RAS loaded with [ 3 H ] -labelled GTP or GDP were used to investigate whether ASPP1 RAD has a binding preference towards either RAS–GTP or RAS–GDP .
(x18 / use-01
      :ARG1-of (x6 / load-01
            :ARG0 (x1 / enzyme
                  :ARG1-of (x2 / purify-01)
                  :name (x3 / name :op1 "n-terminus")
                  :xref (x30 / xref :value "UNIPROT:CREB3_HUMAN" :prob "0.262"))
            :ARG2 (x4 / protein
                  :name (x5 / name :op1 "ASPP1")
                  :xref (x31 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
            :accompanier (x7 / and
                  :op1 (x8 / enzyme
                        :ARG1-of (x9 / purify-01)
                        :name (x10 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
      :ARG1-of (x11 / temporal-quantity
            :quant "3"
            :unit (x12 / hour))
      :ARG1 (x15 / or
            :op1 (x13 / small-molecule
                  :name (x14 / name :op1 "GTP")
                  :xref (x32 / xref :value "PUBCHEM:6830" :prob "15.470645"))
            :op2 (x16 / small-molecule
                  :name (x17 / name :op1 "GDP")
                  :xref (x33 / xref :value "PUBCHEM:8977" :prob "14.712257")))
      :ARG2 (x19 / investigate-01
            :ARG1 (x20 / possible-01
                  :mode "interrogative"
                  :ARG1 (x23 / bind-01
                        :ARG0 (x21 / enzyme
                              :name (x22 / name :op1 "ASPP1" :op2 "RAD"))
                        :ARG1-of (x24 / prefer-01
                              :ARG1 (x25 / or
                                    :op1 (x26 / protein
                                          :name (x27 / name :op1 "RAS–GTP"))
                                    :op2 (x28 / protein
                                          :name (x29 / name :op1 "RAS–GDP"))))))))


# ::id PMC3595493.52
# ::snt We observed that purified ASPP1 fragment (1–310), containing the RAD, interacted with purified RAS in vitro .
# ::tok We observed that purified ASPP1 fragment ( 1–310 ) , containing the RAD , interacted with purified RAS in vitro .
(x2 / observe-01
      :ARG0 (x1 / we)
      :ARG1 (x6 / fragment
            :ARG1-of (x3 / purify-01)
            :mod (x4 / protein
                  :name (x5 / name :op1 "ASPP1")
                  :xref (x16 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
            :name (x7 / name :op1 "1–310")
            :ARG0-of (x8 / contain-01
                  :ARG1 (x9 / thing
                        :name (x10 / name :op1 "RAD")))
            :ARG0-of (x11 / interact-01
                  :ARG1 (x12 / enzyme
                        :ARG1-of (x13 / purify-01)
                        :name (x14 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :manner (x15 / in-vitro))))


# ::id PMC3595493.53
# ::snt The ASPP1 N-terminus bound RAS–GTP with a four-fold higher affinity than RAS–GDP ( Figure 1a , compare lanes 4 and 5).
# ::tok The ASPP1 N @-@ terminus bound RAS–GTP with a four @-@ fold higher affinity than RAS–GDP ( Figure 1a , compare lanes 4 and 5 ) .
(x5 / bind-01
      :ARG1 (x1 / protein
            :name (x2 / name :op1 "ASPP1")
            :xref (x / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
      :ARG2 (x3 / protein-segment
            :name (x4 / name :op1 "N-terminus"))
      :ARG2 (x6 / protein
            :name (x7 / name :op1 "RAS–GTP"))
      :manner (x11 / affinity
            :ARG1-of (x9 / high-02
                  :degree (x8 / product-of :op1 "4")
                  :degree (x10 / more))
            :compared-to (x12 / protein
                  :name (x13 / name :op1 "RAS–GDP"))
            :ARG1-of (x14 / describe-01
                  :ARG0 (x15 / figure :mod "1a")))
      :ARG1-of (x16 / compare-01
            :ARG1 (x17 / lane :mod "4")
            :ARG2 (x18 / lane :mod "5")))


# ::id PMC3595493.54
# ::snt To illustrate that only the N-terminal region of ASPP1 binds RAS, various truncated ASPP1 mutants were constructed.
# ::tok To illustrate that only the N @-@ terminal region of ASPP1 binds RAS , various truncated ASPP1 mutants were constructed .
(x15 / construct-01
      :purpose (x1 / illustrate-01
            :ARG1 (x7 / bind-01
                  :mod (x2 / only)
                  :ARG0 (x3 / protein-segment
                        :name (x4 / name :op1 "n-terminus")
                        :part-of (x5 / protein
                              :name (x6 / name :op1 "ASPP1")
                              :xref (x17 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003")))
                  :ARG2 (x8 / enzyme
                        :name (x9 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
      :ARG1 (x11 / truncate-01
            :mod (x10 / various)
            :ARG1 (x12 / protein
                  :name (x13 / name :op1 "ASPP1")
                  :xref (x16 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
            :ARG2-of (x14 / mutate-01)))


# ::id PMC3595493.55
# ::snt All truncated ASPP1 mutants containing RAD complexed with endogenous RAS except ASPP1 (310–1090) lacking RAD ( Supplementary Figures 1a and b ).
# ::tok All truncated ASPP1 mutants containing RAD complexed with endogenous RAS except ASPP1 ( 310–1090 ) lacking RAD ( Supplementary Figures 1a and b ) .
(x23 / and
      :op1 (x6 / contain-01
            :ARG0 (x2 / truncate-01
                  :mod (x1 / all)
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "ASPP1")
                        :xref (x / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                  :ARG2-of (x5 / mutate-01))
            :ARG1 (x9 / and
                  :op1 (x8 / macro-molecular-complex
                        :name (x7 / name :op1 "RAD"))
                  :op2 (x10 / enzyme
                        :name (x11 / name :op1 "RAS")
                        :xref (x26 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :ARG1-of (x12 / except-01
                        :ARG1 (x13 / protein-segment
                              :part-of (x14 / protein
                                    :name (x15 / name :op1 "ASPP1")
                                    :xref (x27 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                              :name (x16 / name :op1 "310–1090")))
                  :ARG0-of (x17 / lack-01
                        :ARG1 (x18 / protein
                              :name (x19 / name :op1 "RAD")
                              :ARG1-of (x20 / describe-01
                                    :ARG0 (x22 / figure
                                          :ARG2-of (x21 / supplement-01)
                                          :mod "1a"))
                              :xref (x25 / xref :value "UNIPROT:RAD_HUMAN" :prob "1.003")))))
      :op2 (x24 / figure :mod "4b"))


# ::id PMC3595493.56
# ::snt Activated RAS has a higher interaction affinity with the RAS-binding domain (RBD) of Raf1.
# ::tok Activated RAS has a higher interaction affinity with the RAS @-@ binding domain ( RBD ) of Raf1 .
(x7 / affinity
      :ARG0 (x1 / enzyme
            :ARG1-of (x2 / activate-01)
            :name (x3 / name :op1 "RAS")
            :xref (x15 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
      :ARG1-of (x4 / high-02
            :degree (x5 / more))
      :ARG0-of (x6 / interact-01)
      :topic (x10 / bind-01
            :ARG1 (x8 / enzyme
                  :name (x9 / name :op1 "RAS")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
      :name (x11 / name :op1 "RBD")
      :part-of (x12 / enzyme
            :name (x13 / name :op1 "Raf1")
            :xref (x14 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.674")))


# ::id PMC3595493.57
# ::snt Agarose beads linked to the Raf1–RBD can be used to pull down proteins associated with RAS–GTP.
# ::tok Agarose beads linked to the Raf1–RBD can be used to pull down proteins associated with RAS–GTP .
(x7 / associate-01
      :ARG1 (x1 / link-01
            :ARG2 (x6 / protein
                  :name (x2 / name :op1 "Raf1–RBD")
                  :ARG1-of (x4 / use-01
                        :ARG1-of (x3 / possible-01)
                        :ARG2 (x5 / pull-down-00))
                  :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.213")))
      :ARG2 (x8 / protein
            :name (x9 / name :op1 "RAS–GTP")))


# ::id PMC3595493.58
# ::snt In this assay, the presence of small but detectable amounts of c-Raf served as a positive control for the assay.
# ::tok In this assay , the presence of small but detectable amounts of c @-@ Raf served as a positive control for the assay .
(x5 / contrast-01
      :location (x2 / assay-01
            :mod (x1 / this))
      :ARG1 (x3 / present-02
            :ARG1 (x4 / small-molecule))
      :ARG2 (x11 / serve-01
            :ARG0 (x8 / amount
                  :ARG1-of (x6 / detect-01
                        :ARG1-of (x7 / possible-01))
                  :quant-of (x9 / enzyme
                        :name (x10 / name :op1 "c-Raf")
                        :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.673")))
            :ARG1 (x13 / control
                  :mod (x12 / positive))
            :purpose (x14 / assay-01)))


# ::id PMC3595493.59
# ::snt We thus used this as an alternative assay to investigate whether ASPP2 also selectively binds RAS–GTP.
# ::tok We thus used this as an alternative assay to investigate whether ASPP2 also selectively binds RAS–GTP .
(x1 / cause-01
      :ARG1 (x3 / use-01
            :ARG0 (x2 / we)
            :ARG1 (x6 / assay-01
                  :mod (x4 / this)
                  :mod (x5 / alternative)
                  :purpose (x7 / investigate-01
                        :ARG1 (x11 / bind-01
                              :mode "interrogative"
                              :ARG0 (x8 / protein
                                    :name (x9 / name :op1 "ASPP2")
                                    :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                              :mod (x10 / selective)
                              :ARG2 (x12 / protein
                                    :name (x13 / name :op1 "RAS–GTP")))))))


# ::id PMC3595493.60
# ::snt Under the same conditions, the percentage of ASPP2 pulled down by Raf1–RBD is clearly higher than that of c-Raf, illustrating that endogenous ASPP2 also complexes with active RAS ( Figure 1b ).
# ::tok Under the same conditions , the percentage of ASPP2 pulled down by Raf1–RBD is clearly higher than that of c @-@ Raf , illustrating that endogenous ASPP2 also complexes with active RAS ( Figure 1b ) .
(x14 / illustrate-01
      :condition (x10 / high-02
            :ARG1 (x2 / condition-01
                  :ARG1-of (x1 / same-01)
                  :ARG1 (x3 / percentage
                        :quant-of (x4 / protein
                              :name (x5 / name :op1 "ASPP2")
                              :xref (x25 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :ARG1-of (x6 / pull-down-00))
                  :ARG0 (x7 / small-molecule
                        :name (x8 / name :op1 "Raf1–RBD")))
            :ARG1-of (x9 / clear-06)
            :degree (x11 / more)
            :compared-to (x12 / enzyme
                  :name (x13 / name :op1 "c-Raf")
                  :xref (x26 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.673")))
      :ARG1 (x19 / macro-molecular-complex
            :mod (x15 / endogenous)
            :mod (x16 / protein
                  :name (x17 / name :op1 "ASPP2")
                  :xref (x27 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :mod (x18 / also)
            :ARG0-of (x20 / activity-06
                  :ARG1 (x21 / enzyme
                        :name (x22 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
      :ARG1-of (x23 / describe-01
            :ARG0 (x24 / figure :mod "1b")))


# ::id PMC3595493.61
# ::snt Raf1–RBD failed to pull down iASPP, which does not contain RAD at its N-terminus.
# ::tok Raf1–RBD failed to pull down iASPP , which does not contain RAD at its N @-@ terminus .
(x3 / fail-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "Raf1–RBD")
            :xref (x12 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.213"))
      :ARG2 (x4 / pull-down-08
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "iASPP")
                  :xref (x13 / xref :value "UNIPROT:IASPP_HUMAN" :prob "0.703"))
            :ARG0-of (x7 / contain-01
                  :polarity "-"
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "RAD")
                        :part (x10 / protein-segment
                              :name (x11 / name :op1 "N" :op2 "terminus"))
                        :xref (x / xref :value "UNIPROT:RAD_HUMAN" :prob "1.003")))))


# ::id PMC3595493.62
# ::snt These results illustrate that ASPP1 and ASPP2 can bind active RAS, and this interaction is likely mediated through their N-termini.
# ::tok These results illustrate that ASPP1 and ASPP2 can bind active RAS , and this interaction is likely mediated through their N @-@ termini .
(x4 / illustrate-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x21 / possible-01
            :ARG1 (x10 / bind-01
                  :ARG1 (x7 / and
                        :op1 (x5 / protein
                              :name (x6 / name :op1 "ASPP1")
                              :xref (x23 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                        :op2 (x8 / protein
                              :name (x9 / name :op1 "ASPP2")
                              :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
                  :ARG2 (x14 / and
                        :op1 (x11 / enzyme
                              :ARG1-of (x12 / activate-01)
                              :name (x13 / name :op1 "RAS")
                              :xref (x22 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                        :op2 (x15 / likely-01
                              :ARG1 (x18 / mediate-01
                                    :ARG0 (x17 / interact-01
                                          :mod (x16 / this))
                                    :ARG1 (x19 / protein-segment
                                          :name (x20 / name :op1 "N" :op2 "termini"))))))))


# ::id PMC3595493.63
# ::snt An ASPP2 inducible U2OS cell line that expresses wild-type p53 was first used to test whether endogenous wild-type RAS binds ASPP2 with different efficiency upon EGF stimulation.
# ::tok An ASPP2 inducible U2OS cell line that expresses wild @-@ type p53 was first used to test whether endogenous wild @-@ type RAS binds ASPP2 with different efficiency upon EGF stimulation .
(x11 / use-01
      :ARG0 (x3 / induce-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "ASPP2")
                  :xref (x25 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
      :ARG1 (x6 / express-01
            :ARG0 (x4 / cell-line
                  :name (x5 / name :op1 "U2OS"))
            :ARG1 (x7 / enzyme
                  :mod (x8 / wild-type)
                  :name (x9 / name :op1 "p53")
                  :xref (x26 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
      :ord (x10 / ordinal-entity :value "1")
      :ARG2 (x12 / test-01
            :ARG1 (x17 / bind-01
                  :mode "interrogative"
                  :ARG1 (x13 / enzyme
                        :mod (x14 / endogenous)
                        :mod (x15 / wild-type)
                        :name (x16 / name :op1 "RAS")
                        :xref (x28 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :ARG2 (x18 / protein
                        :name (x19 / name :op1 "ASPP2")
                        :xref (x27 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
      :ARG2 (x21 / efficient-01
            :ARG1-of (x20 / differ-02)
            :ARG2 (x24 / stimulate-01
                  :ARG0 (x22 / protein
                        :name (x23 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC3595493.65
# ::snt We found that there is very little binding between RAS and ASPP2 in starved cells.
# ::tok We found that there is very little binding between RAS and ASPP2 in starved cells .
(x2 / find-01
      :ARG0 (x1 / we)
      :ARG1 (x4 / little
            :degree (x3 / very))
      :ARG1 (x5 / bind-01
            :ARG1 (x8 / and
                  :op1 (x6 / enzyme
                        :name (x7 / name :op1 "RAS")
                        :xref (x13 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :op2 (x9 / protein
                        :name (x10 / name :op1 "ASPP2")
                        :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
            :location (x12 / cell
                  :ARG1-of (x11 / starve-01))))


# ::id PMC3595493.66
# ::snt The RAS–ASPP2 complex was mainly detected in EGF-treated cells that express active RAS ( Supplementary Figure 1c , compare lanes 7 and 8).
# ::tok The RAS–ASPP2 complex was mainly detected in EGF @-@ treated cells that express active RAS ( Supplementary Figure 1c , compare lanes 7 and 8 ) .
(x5 / detect-01
      :ARG1 (x3 / complex
            :mod (x1 / protein
                  :name (x2 / name :op1 "RAS–ASPP2")))
      :mod (x4 / main)
      :location (x9 / cell-line
            :ARG1-of (x8 / treat-04
                  :ARG2 (x6 / protein
                        :name (x7 / name :op1 "EGF")
                        :xref (x19 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG3-of (x10 / express-03
                  :ARG2 (x11 / enzyme
                        :name (x12 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
      :ARG1-of (x13 / describe-01
            :ARG0 (x15 / figure
                  :ARG2-of (x14 / supplement-01)
                  :mod "1c"))
      :ARG1-of (x16 / compare-01
            :ARG1 (x17 / lane :mod "7")
            :ARG2 (x18 / lane :mod "8")))


# ::id PMC3595493.67
# ::snt It is important to note that the expression levels of RAS and ASPP2 are similar in cells before or after EGF treatment.
# ::tok It is important to note that the expression levels of RAS and ASPP2 are similar in cells before or after EGF treatment .
(x1 / important
      :domain (x2 / note-01
            :ARG1 (x10 / resemble-01
                  :ARG1 (x3 / level
                        :degree-of (x4 / express-03
                              :ARG2 (x7 / and
                                    :op1 (x5 / enzyme
                                          :name (x6 / name :op1 "RAS")
                                          :xref (x19 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                                    :op2 (x8 / protein
                                          :name (x9 / name :op1 "ASPP2")
                                          :xref (x18 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))))
            :location (x11 / cell)
            :time (x12 / before
                  :op1 (x13 / or
                        :op1 (x14 / after
                              :op1 (x17 / treat-04
                                    :ARG2 (x15 / protein
                                          :name (x16 / name :op1 "EGF")
                                          :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))))


# ::id PMC3595493.68
# ::snt Moreover, an interaction was also observed between endogenous ASPP2 and HRASV12 in a human colon cancer cell line HKe3 ER:HRASV12 cells, in which RAS activation is induced upon the addition of 4-hydroxytamoxifen (4-OHT) ( Figure 1c ).
# ::tok Moreover , an interaction was also observed between endogenous ASPP2 and HRASV12 in a human colon cancer cell line HKe3 ER : HRASV12 cells , in which RAS activation is induced upon the addition of 4 @-@ hydroxytamoxifen ( 4 @-@ OHT ) ( Figure 1c ) .
(x1 / and
      :op2 (x4 / observe-01
            :ARG1 (x2 / interact-01)
            :mod (x3 / also)
            :ARG1 (x22 / induce-01
                  :ARG1 (x8 / and
                        :mod (x5 / endogenous
                              :mod (x6 / protein
                                    :name (x7 / name :op1 "ASPP2")
                                    :xref (x30 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
                        :op2 (x9 / enzyme
                              :name (x10 / name :op1 "HRASV12")
                              :xref (x / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312"))
                        :location (x14 / cell-line
                              :mod (x11 / human)
                              :mod (x12 / disease
                                    :wiki "colorectal_cancer"
                                    :name (x13 / name :op1 "colon" :op2 "cancer"))
                              :name (x15 / name :op1 "HKe3"))
                        :mod (x16 / er :mode "expressive")
                        :ARG1-of (x18 / cell-line
                              :name (x17 / name :op1 "HRASV12")
                              :location-of (x21 / activate-01
                                    :ARG1 (x19 / enzyme
                                          :name (x20 / name :op1 "RAS")
                                          :xref (x31 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))
                  :ARG2 (x23 / gene
                        :ARG2-of (x24 / add-02
                              :ARG1 (x25 / small-molecule
                                    :name (x26 / name :op1 "4-hydroxytamoxifen")
                                    :xref (x32 / xref :value "PUBCHEM:449459" :prob "11.717745")))
                        :name (x27 / name :op1 "4-OHT")))
            :ARG1-of (x28 / describe-01
                  :ARG0 (x29 / figure :mod "1c"))))


# ::id PMC3595493.69
# ::snt 24 , 25 The ability of endogenous ASPP2 to bind with endogenous active RAS was further tested in mouse embryonic fibroblasts (MEFs) derived from ASPP2 wild-type and ASPP2 (Δ3/Δ3) embryos.
# ::tok 24 , 25 The ability of endogenous ASPP2 to bind with endogenous active RAS was further tested in mouse embryonic fibroblasts ( MEFs ) derived from ASPP2 wild @-@ type and ASPP2 ( Δ3/Δ3 ) embryos .
(x12 / test-01
      :ARG0 (x1 / and :op1 "24" :op2 "25")
      :ARG1 (x2 / capable-01
            :ARG2 (x6 / bind-01
                  :ARG1 (x3 / enzyme
                        :mod (x4 / endogenous)
                        :name (x5 / name :op1 "ASPP2")
                        :xref (x30 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                  :ARG2 (x8 / enzyme
                        :mod (x7 / endogenous)
                        :ARG0-of (x9 / activity-06)
                        :name (x10 / name :op1 "RAS")
                        :xref (x29 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
      :degree (x11 / further)
      :location (x23 / and
            :op1 (x15 / fibroblast
                  :mod (x14 / embryo
                        :mod (x13 / mouse))
                  :ARG1-of (x16 / describe-01
                        :ARG0 (x17 / cell
                              :name (x18 / name :op1 "mef")))
                  :ARG1-of (x19 / derive-01
                        :ARG2 (x20 / protein
                              :name (x21 / name :op1 "ASPP2")
                              :xref (x28 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
                  :mod (x22 / wild-type))
            :op2 (x24 / protein
                  :name (x25 / name :op1 "ASPP2")
                  :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
      :ARG1-of (x27 / embryo
            :name (x26 / name :op1 "Δ3/Δ3")))


# ::id PMC3595493.70
# ::snt Growth factors such as EGF or insulin were used to stimulate serum-starved ASPP2 (+/+) and ASPP2 (Δ3/Δ3) MEFs to induce RAS activation.
# ::tok Growth factors such as EGF or insulin were used to stimulate serum @-@ starved ASPP2 ( +/+ ) and ASPP2 ( Δ3/Δ3 ) MEFs to induce RAS activation .
(x7 / use-01
      :ARG0 (x4 / or
            :op1 (x1 / growth-factor
                  :example (x2 / protein
                        :name (x3 / name :op1 "EGF")
                        :xref (x23 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :op2 (x5 / protein
                  :name (x6 / name :op1 "insulin")
                  :xref (x24 / xref :value "UNIPROT:INS_HUMAN" :prob "0.703")))
      :ARG2 (x8 / stimulate-01
            :ARG1 (x15 / and
                  :ARG1-of (x10 / starve-01
                        :ARG2 (x9 / serum))
                  :op1 (x11 / protein-segment
                        :part-of (x12 / protein
                              :name (x13 / name :op1 "ASPP2")
                              :xref (x25 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :name (x14 / name :op1 "+/+"))
                  :op2 (x16 / protein
                        :name (x17 / name :op1 "ASPP2" :op2 "Δ3/Δ3")
                        :ARG2-of (x18 / mutate-01 :mod "-/-"))))
      :ARG1 (x19 / induce-01
            :ARG2 (x22 / activate-01
                  :ARG1 (x20 / enzyme
                        :name (x21 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))


# ::id PMC3595493.72
# ::snt However, no co-immunoprecipitation was detected in ASPP2 (Δ3/Δ3) MEFs, which occasionally express reduced amounts of N-terminal-truncated ASPP2 ( Figure 1d ).
# ::tok However , no co @-@ immunoprecipitation was detected in ASPP2 ( Δ3/Δ3 ) MEFs , which occasionally express reduced amounts of N @-@ terminal @-@ truncated ASPP2 ( Figure 1d ) .
(x1 / contrast-01
      :ARG2 (x5 / detect-01
            :polarity "-"
            :ARG1 (x4 / coimmunoprecipitate-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "co")))
            :location (x6 / protein
                  :name (x7 / name :op1 "ASPP2")
                  :xref (x24 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :ARG1-of (x8 / describe-01
                  :ARG0 (x9 / protein
                        :name (x10 / name :op1 "Δ3/Δ3")
                        :ARG2-of (x14 / express-03
                              :ARG3 (x11 / cell
                                    :name (x12 / name :op1 "mef")
                                    :ARG0-of (x13 / occasional))
                              :ARG2 (x16 / amount
                                    :ARG1-of (x15 / reduce-01)
                                    :quant-of (x19 / truncate-01
                                          :ARG2 (x17 / protein-segment
                                                :name (x18 / name :op1 "n-terminus"))
                                          :ARG1 (x20 / protein
                                                :name (x21 / name :op1 "ASPP2")
                                                :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))))))
      :ARG1-of (x22 / describe-01
            :ARG0 (x23 / figure :mod "1d")))


# ::id PMC3595493.73
# ::snt These data demonstrate that ASPP2 preferentially binds RAS when it is activated.
# ::tok These data demonstrate that ASPP2 preferentially binds RAS when it is activated .
(x3 / demonstrate-01
      :ARG0 (x2 / data
            :mod (x1 / this))
      :ARG1 (x7 / bind-01
            :ARG1 (x6 / prefer-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "ASPP2")
                        :xref (x11 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
            :ARG2 (x8 / enzyme
                  :name (x9 / name :op1 "RAS")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
      :time (x10 / activate-01))


# ::id PMC3595493.74
# ::snt To provide further evidence that ASPP1 and ASPP2 preferentially interact with RAS–GTP, a p53-null osteosarcoma cell line Saos2 was starved for 20 h and then stimulated with 20% foetal calf serum (FCS) and EGF.
# ::tok To provide further evidence that ASPP1 and ASPP2 preferentially interact with RAS–GTP , a p53 @-@ null osteosarcoma cell line Saos2 was starved for 20 h and then stimulated with 20 % foetal calf serum ( FCS ) and EGF .
(x19 / starve-01
      :purpose (x1 / provide-01
            :ARG1 (x3 / evidence-01
                  :degree (x2 / further)
                  :ARG1 (x10 / interact-01
                        :ARG1-of (x9 / prefer-01
                              :ARG2 (x6 / and
                                    :op1 (x4 / protein
                                          :name (x5 / name :op1 "ASPP1")
                                          :xref (x32 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                                    :op2 (x7 / protein
                                          :name (x8 / name :op1 "ASPP2")
                                          :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
                        :ARG1 (x11 / protein
                              :name (x12 / name :op1 "RAS–GTP")))))
      :ARG1 (x17 / cell-line
            :mod (x14 / enzyme
                  :name (x13 / name :op1 "p53")
                  :ARG2-of (x15 / mutate-01 :mod "-/-")
                  :xref (x34 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))
            :name (x16 / name :op1 "osteosarcoma")
            :name (x18 / name :op1 "Saos2"))
      :duration (x22 / and
            :op1 (x20 / temporal-quantity
                  :quant "20"
                  :unit (x21 / hour))
            :op2 (x23 / stimulate-01))
      :ARG2 (x29 / and
            :op1 (x27 / serum
                  :mod (x24 / percentage-entity :value "20")
                  :mod (x25 / foetal)
                  :ARG0-of (x26 / calf)
                  :name (x28 / name :op1 "FCS"))
            :op2 (x30 / protein
                  :name (x31 / name :op1 "EGF")
                  :xref (x33 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))


# ::id PMC3595493.75
# ::snt More RAS was detected in the ASPP1 and ASPP2 immunoprecipitates derived from serum- and EGF-stimulated cell lysates than in non-stimulated ones ( Figure 1e , compare lanes 1–2 for ASPP2 and 3–4 for ASPP1).
# ::tok More RAS was detected in the ASPP1 and ASPP2 immunoprecipitates derived from serum @- and EGF @-@ stimulated cell lysates than in non @-@ stimulated ones ( Figure 1e , compare lanes 1–2 for ASPP2 and 3–4 for ASPP1 ) .
(x20 / one
      :ARG0 (x7 / and
            :op1 (x4 / detect-01
                  :degree (x1 / more)
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "RAS")
                        :xref (x35 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :location (x5 / protein
                        :name (x6 / name :op1 "ASPP1")
                        :xref (x36 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003")))
            :op2 (x10 / immunoprecipitate-01
                  :ARG0 (x8 / protein
                        :name (x9 / name :op1 "ASPP2")
                        :xref (x34 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                  :ARG1-of (x11 / derive-01
                        :ARG2 (x13 / and
                              :op1 (x12 / serum)
                              :op2 (x16 / stimulate-01
                                    :ARG0 (x14 / protein
                                          :name (x15 / name :op1 "EGF")
                                          :xref (x39 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
                  :ARG1 (x18 / lysate
                        :mod (x17 / cell)
                        :compared-to (x19 / stimulate-01 :polarity "-"))))
      :ARG1-of (x21 / describe-01
            :ARG0 (x22 / and
                  :op1 (x23 / figure :mod "1e")
                  :op2 (x24 / compare-01
                        :ARG1 (x25 / lane
                              :mod (x26 / value-interval :op1 "1" :op2 "2"))
                        :ARG2 (x29 / and
                              :op1 (x27 / protein
                                    :name (x28 / name :op1 "ASPP2")
                                    :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                              :op2 (x30 / enzyme
                                    :name (x31 / name :op1 "3–4")
                                    :xref (x38 / xref :value "UNIPROT:AMZ1_HUMAN" :prob "0.562")))
                        :ARG1 (x32 / protein
                              :name (x33 / name :op1 "ASPP1")
                              :xref (x37 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))))))


# ::id PMC3595493.76
# ::snt All these suggest that N-termini of ASPP1 and ASPP2 selectively bind active RAS.
# ::tok All these suggest that N @-@ termini of ASPP1 and ASPP2 selectively bind active RAS .
(x3 / suggest-01
      :ARG0 (x2 / this
            :mod (x1 / all))
      :ARG1 (x12 / bind-01
            :ARG0 (x8 / and
                  :op1 (x4 / protein-segment
                        :name (x5 / name :op1 "N" :op2 "termini")
                        :part-of (x6 / protein
                              :name (x7 / name :op1 "ASPP1")
                              :xref (x17 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003")))
                  :op2 (x9 / protein
                        :name (x10 / name :op1 "ASPP2")
                        :xref (x16 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
            :manner (x11 / selective)
            :ARG1 (x13 / enzyme
                  :ARG0-of (x14 / activity-06)
                  :name (x15 / name :op1 "RAS")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))


# ::id PMC3595493.77
# ::snt This new property of ASPP1 and ASPP2 is independent of p53 because p53 binds the C-termini of the ASPPs and Saos2 cells are p53-null.
# ::tok This new property of ASPP1 and ASPP2 is independent of p53 because p53 binds the C @-@ termini of the ASPPs and Saos2 cells are p53 @-@ null .
(x12 / cause-01
      :ARG1 (x3 / property
            :mod (x1 / this)
            :ARG1-of (x2 / new-01)
            :poss (x4 / protein
                  :name (x5 / name :op1 "ASPP1")
                  :xref (x27 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
            :ARG1-of (x9 / depend-01
                  :ARG0 (x6 / and
                        :op1 (x7 / protein
                              :name (x8 / name :op1 "ASPP2")
                              :xref (x26 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
                  :polarity "-"
                  :ARG1 (x10 / protein
                        :name (x11 / name :op1 "p53")
                        :xref (x29 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))
      :ARG0 (x15 / bind-01
            :ARG2 (x13 / protein
                  :name (x14 / name :op1 "p53")
                  :xref (x30 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))
            :ARG2 (x16 / protein
                  :name (x17 / name :op1 "C" :op2 "termini"))
            :ARG1 (x20 / and
                  :op1 (x18 / enzyme
                        :name (x19 / name :op1 "ASPPs")
                        :xref (x28 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "0.282"))
                  :op1 (x22 / cell-line
                        :name (x21 / name :op1 "Saos2"))
                  :op2 (x24 / protein
                        :name (x23 / name :op1 "p53")
                        :ARG2-of (x25 / mutate-01 :mod "-/-")
                        :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))))


# ::id PMC3595493.78
# ::snt ASPP2 colocalises with and contributes to RAS activation at cell membrane
# ::tok ASPP2 colocalises with and contributes to RAS activation at cell membrane
(x3 / and
      :op1 (x1 / small-molecule
            :name (x2 / name :op1 "colocalises"))
      :op2 (x4 / contribute-01
            :ARG2 (x7 / activate-01
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :location (x9 / membrane
                        :part-of (x8 / cell)
                        :xref (x10 / xref :value "GO:0016020" :prob "0.8")))))


# ::id PMC3595493.79
# ::snt Activated RAS is mainly located at cellular membranes.
# ::tok Activated RAS is mainly located at cellular membranes .
(x5 / be-located-at-91
      :ARG1 (x1 / enzyme
            :ARG1-of (x2 / activate-01)
            :name (x3 / name :op1 "RAS")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
      :mod (x4 / main)
      :ARG2 (x7 / membrane
            :mod (x6 / cell)
            :xref (x8 / xref :value "GO:0016020" :prob "0.8")))


# ::id PMC3595493.80
# ::snt To test the biological importance of the observed RAS–ASPP interactions, we first examined the cellular localisation of exogenously coexpressed HRASV12 and ASPP2, and observed that they colocalise to the cell membrane in U2OS cells ( Figure 2a ).
# ::tok To test the biological importance of the observed RAS–ASPP interactions , we first examined the cellular localisation of exogenously coexpressed HRASV12 and ASPP2 , and observed that they colocalise to the cell membrane in U2OS cells ( Figure 2a ) .
(x9 / examine-01
      :purpose (x1 / test-01
            :ARG1 (x3 / importance
                  :mod (x2 / biology)
                  :poss (x4 / observe-01
                        :ARG1 (x7 / interact-01
                              :ARG0 (x5 / protein
                                    :name (x6 / name :op1 "RAS–ASPP"))))))
      :ARG0 (x8 / we)
      :ARG1 (x18 / and
            :op1 (x11 / localize-01
                  :ARG0 (x10 / cell)
                  :ARG1 (x15 / and
                        :op1 (x13 / coexpress-01
                              :mod (x12 / exogenous)
                              :name (x14 / name :op1 "HRASV12"))
                        :op2 (x16 / protein
                              :name (x17 / name :op1 "ASPP2")
                              :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
            :op2 (x19 / observe-01
                  :ARG1 (x20 / they
                        :name (x21 / name :op1 "colocalise"))
                  :ARG2 (x23 / membrane
                        :mod (x22 / cell)
                        :xref (x28 / xref :value "GO:0016020" :prob "0.8"))))
      :location (x25 / cell-line
            :name (x24 / name :op1 "U2OS"))
      :ARG1-of (x26 / describe-01
            :ARG0 (x27 / figure :mod "2a")))


# ::id PMC3595493.81
# ::snt In HK-e3ER:HRASV12 cells, ASPP2 is normally expressed at cell/cell junctions.
# ::tok In HK @-@ e3ER : HRASV12 cells , ASPP2 is normally expressed at cell @/@ cell junctions .
(x1 / cause-01
      :ARG1 (x2 / protein
            :name (x3 / name :op1 "HK" :op2 "e3ER"))
      :ARG0 (x12 / junction
            :mod (x5 / cell
                  :name (x4 / name :op1 "HRASV12")
                  :ARG1-of (x9 / express-03
                        :ARG2 (x6 / protein
                              :name (x7 / name :op1 "ASPP2")
                              :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :ARG1-of (x8 / normal-02))
                  :location (x10 / cell))
            :mod (x11 / cell)))


# ::id PMC3595493.82
# ::snt 22 One hour after RAS induction, endogenous ASPP2 colocalised with induced HRASV12 at the cell membrane in HKe3 cells ( Figure 2b ).
# ::tok 22 One hour after RAS induction , endogenous ASPP2 colocalised with induced HRASV12 at the cell membrane in HKe3 cells ( Figure 2b ) .
(x14 / induce-01
      :ARG0 (x1 / publication
            :ARG1-of (x2 / cite-01 :ARG2 "22"))
      :time (x5 / after
            :quant (x3 / temporal-quantity
                  :quant "1"
                  :unit (x4 / hour))
            :op1 (x8 / induce-01
                  :ARG2 (x6 / enzyme
                        :name (x7 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
      :ARG2 (x9 / enzyme
            :mod (x10 / endogenous
                  :op2 (x11 / protein
                        :name (x12 / name :op1 "ASPP2")
                        :xref (x23 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
            :name (x13 / name :op1 "colocalised"))
      :ARG1 (x15 / enzyme
            :name (x16 / name :op1 "HRASV12")
            :xref (x24 / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312"))
      :location (x18 / membrane
            :mod (x17 / cell)
            :location (x20 / cell
                  :name (x19 / name :op1 "HKe3"))
            :xref (x25 / xref :value "GO:0016020" :prob "0.8"))
      :ARG1-of (x21 / describe-01
            :ARG0 (x22 / figure :mod "2b")))


# ::id PMC3595493.83
# ::snt Importantly, ASPP2 depletion by RNA interference (RNAi) largely abolished the membrane localisation of HRASV12 after RAS induction in these cells ( Supplementary Figure 2 ).
# ::tok Importantly , ASPP2 depletion by RNA interference ( RNAi ) largely abolished the membrane localisation of HRASV12 after RAS induction in these cells ( Supplementary Figure 2 ) .
(x11 / abolish-01
      :mod (x1 / important)
      :ARG0 (x4 / deplete-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "ASPP2")
                  :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :ARG1 (x7 / interfere-01
                  :ARG0 (x5 / nucleic-acid
                        :name (x6 / name :op1 "RNA")))
            :ARG0 (x8 / nucleic-acid
                  :name (x9 / name :op1 "RNA")))
      :degree (x10 / large)
      :ARG1 (x12 / membrane
            :xref (x27 / xref :value "GO:0016020" :prob "0.8"))
      :ARG1 (x13 / localize-01
            :ARG1 (x14 / protein
                  :name (x15 / name :op1 "HRASV12")
                  :xref (x25 / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312")))
      :time (x16 / after
            :op1 (x19 / induce-01
                  :ARG0 (x17 / enzyme
                        :name (x18 / name :op1 "RAS")
                        :xref (x26 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :location (x21 / cell
                        :mod (x20 / this))
                  :ARG1-of (x22 / describe-01
                        :ARG0 (x24 / figure
                              :ARG2-of (x23 / supplement-01)
                              :mod "2")))))


# ::id PMC3595493.84
# ::snt The ability of endogenous ASPP2 to bind and colocalise with endogenous active RAS was tested in a physiological setting.
# ::tok The ability of endogenous ASPP2 to bind and colocalise with endogenous active RAS was tested in a physiological setting .
(x14 / test-01
      :ARG1 (x10 / and
            :op1 (x1 / capable-01
                  :ARG1 (x2 / enzyme
                        :mod (x3 / endogenous)
                        :name (x4 / name :op1 "ASPP2")
                        :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                  :ARG2 (x7 / and
                        :op1 (x5 / enzyme
                              :name (x6 / name :op1 "p50")
                              :xref (x19 / xref :value "UNIPROT:E4F1_HUMAN" :prob "0.212"))
                        :op2 (x8 / enzyme
                              :name (x9 / name :op1 "colocalise")
                              :xref (x17 / xref :value "UNIPROT:COL_HUMAN" :prob "0.232"))))
            :op2 (x11 / enzyme
                  :ARG1-of (x12 / activate-01)
                  :name (x13 / name :op1 "RAS")
                  :xref (x18 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
      :location (x16 / setting
            :mod (x15 / physiology)))


# ::id PMC3595493.85
# ::snt In ASPP2 (+/+) MEFs, insulin-induced active RAS and ASPP2 colocalised at the cell membrane.
# ::tok In ASPP2 ( +/+ ) MEFs , insulin @-@ induced active RAS and ASPP2 colocalised at the cell membrane .
(x6 / induce-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "ASPP2" :op2 "+/+")
            :ARG2-of (x3 / mutate-01 :mod "-/-"))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "insulin")
            :xref (x15 / xref :value "UNIPROT:INS_HUMAN" :prob "0.703"))
      :ARG2 (x7 / activate-01
            :ARG1 (x10 / and
                  :op1 (x8 / enzyme
                        :name (x9 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :op2 (x11 / enzyme
                        :name (x12 / name :op1 "ASPP2" :op2 "colocalised"))))
      :location (x14 / membrane
            :part-of (x13 / cell)
            :xref (x16 / xref :value "GO:0016020" :prob "0.8")))


# ::id PMC3595493.86
# ::snt The majority of the cells expressing membrane-associated ASPP2 also had membrane-localised RAS and vice versa ( Figure 2c , left panel with arrows).
# ::tok The majority of the cells expressing membrane @-@ associated ASPP2 also had membrane @-@ localised RAS and vice versa ( Figure 2c , left panel with arrows ) .
(x9 / have-03
      :ARG1 (x1 / majority
            :part-of (x2 / cell
                  :ARG3-of (x3 / express-03
                        :ARG2 (x5 / associate-01
                              :ARG2 (x4 / membrane
                                    :xref (x22 / xref :value "GO:0016020" :prob "0.8"))))))
      :ARG2 (x6 / protein
            :name (x7 / name :op1 "ASPP2")
            :xref (x21 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
      :mod (x8 / also)
      :ARG1 (x10 / membrane
            :ARG1-of (x11 / local-02
                  :ARG1 (x14 / and
                        :op1 (x12 / enzyme
                              :name (x13 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                        :op2 (x15 / vice-versa)))
            :xref (x23 / xref :value "GO:0016020" :prob "0.8"))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / figure
                  :mod "2c"
                  :location (x19 / panel
                        :ARG1-of (x18 / left-20))))
      :ARG1-of (x20 / arrow))


# ::id PMC3595493.87
# ::snt RAS was not detected at the cell membrane in ASPP2 (Δ3/Δ3) MEFs ( Figure 2c ) under the same conditions, consistent with the results in HKe3 cells ( Supplementary Figure 2 ).
# ::tok RAS was not detected at the cell membrane in ASPP2 ( Δ3/Δ3 ) MEFs ( Figure 2c ) under the same conditions , consistent with the results in HKe3 cells ( Supplementary Figure 2 ) .
(x3 / detect-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "RAS")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
      :polarity "-"
      :location (x5 / membrane
            :mod (x4 / cell)
            :xref (x21 / xref :value "GO:0016020" :prob "0.8"))
      :location (x6 / protein
            :name (x7 / name :op1 "ASPP2" :op2 "Δ3/Δ3")
            :ARG2-of (x8 / mutate-01 :mod "-/-"))
      :ARG1-of (x9 / describe-01
            :ARG0 (x10 / figure :mod "2c"))
      :ARG1-of (x13 / consistent-01
            :condition (x12 / condition
                  :ARG1-of (x11 / same-01))
            :ARG2 (x14 / thing
                  :ARG2-of (x15 / result-01))
            :location (x17 / cell-line
                  :name (x16 / name :op1 "HKe3"))
            :ARG1-of (x18 / describe-01
                  :ARG0 (x20 / figure
                        :ARG2-of (x19 / supplement-01)
                        :mod "2"))))


# ::id PMC3595493.88
# ::snt Similar results were observed in HRASV12-expressing ASPP2 (+/+) and ASPP2 (Δ3/Δ3) MEFs ( Figure 2c , right panel).
# ::tok Similar results were observed in HRASV12 @-@ expressing ASPP2 ( +/+ ) and ASPP2 ( Δ3/Δ3 ) MEFs ( Figure 2c , right panel ) .
(x4 / observe-01
      :ARG1 (x2 / thing
            :ARG1-of (x1 / resemble-01)
            :ARG2-of (x3 / result-01))
      :location (x12 / and
            :ARG1-of (x7 / express-03
                  :ARG2 (x5 / enzyme
                        :name (x6 / name :op1 "HRASV12")
                        :xref (x20 / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312")))
            :op1 (x8 / protein-segment
                  :part-of (x9 / protein
                        :name (x10 / name :op1 "ASPP2")
                        :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                  :name (x11 / name :op1 "+/+"))
            :op2 (x13 / protein
                  :name (x14 / name :op1 "ASPP2" :op2 "Δ3/Δ3")
                  :ARG2-of (x15 / mutate-01 :mod "-/-")))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / figure
                  :mod "2c"
                  :part (x19 / panel
                        :ARG1-of (x18 / right-04)))))


# ::id PMC3595493.89
# ::snt Together, these data suggest that ASPP2 colocalises with RAS and facilitates the membrane localisation of RAS in human cancer cells and MEFs.
# ::tok Together , these data suggest that ASPP2 colocalises with RAS and facilitates the membrane localisation of RAS in human cancer cells and MEFs .
(x4 / suggest-01
      :ARG0 (x3 / data
            :mod (x1 / together)
            :mod (x2 / this))
      :ARG1 (x5 / protein
            :name (x6 / name :op1 "ASPP2")
            :xref (x24 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
      :ARG1 (x7 / enzyme
            :name (x8 / name :op1 "colocalises"))
      :ARG2 (x11 / and
            :op1 (x9 / enzyme
                  :name (x10 / name :op1 "RAS")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
            :op2 (x12 / facilitate-01
                  :ARG1 (x21 / and
                        :op1 (x14 / localize-01
                              :ARG1 (x13 / membrane
                                    :xref (x26 / xref :value "GO:0016020" :prob "0.8"))
                              :ARG1 (x15 / enzyme
                                    :name (x16 / name :op1 "RAS")
                                    :xref (x25 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                              :location (x20 / cell
                                    :mod (x17 / human)
                                    :mod (x18 / disease
                                          :wiki "cancer"
                                          :name (x19 / name :op1 "cancer"))))
                        :op2 (x22 / cell
                              :name (x23 / name :op1 "mef"))))))


# ::id PMC3595493.90
# ::snt ASPP2's N-terminus is required and sufficient to potentiate RAS signalling
# ::tok ASPP2 's N @-@ terminus is required and sufficient to potentiate RAS signalling
(x4 / and
      :op1 (x3 / require-01
            :ARG1 (x1 / protein-segment
                  :name (x2 / name :op1 "N-terminus")))
      :op2 (x7 / suffice-01
            :ARG0 (x5 / protein
                  :name (x6 / name :op1 "ASPP2")
                  :xref (x12 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :ARG1 (x8 / potentiate-01
                  :ARG1 (x11 / signal-07
                        :ARG0 (x9 / enzyme
                              :name (x10 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))))


# ::id PMC3595493.91
# ::snt The biological implications of ASPP2–RAS binding and colocalisation were investigated by examining the RAS signalling cascade in ASPP2 (+/+) and ASPP2 (Δ3/Δ3) MEFs.
# ::tok The biological implications of ASPP2–RAS binding and colocalisation were investigated by examining the RAS signalling cascade in ASPP2 ( +/+ ) and ASPP2 ( Δ3/Δ3 ) MEFs .
(x9 / investigate-01
      :ARG1 (x2 / implicate-01
            :mod (x1 / biology)
            :ARG1 (x6 / and
                  :op1 (x5 / bind-01
                        :ARG1 (x3 / protein
                              :name (x4 / name :op1 "ASPP2–RAS")))
                  :op2 (x7 / enzyme
                        :name (x8 / name :op1 "colocalisation"))))
      :ARG0 (x19 / and
            :op1 (x10 / examine-01
                  :ARG1 (x14 / cascade
                        :ARG0-of (x13 / signal-07
                              :ARG1 (x11 / enzyme
                                    :name (x12 / name :op1 "RAS")
                                    :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
                  :location (x15 / protein-segment
                        :part-of (x16 / protein
                              :name (x17 / name :op1 "ASPP2")
                              :xref (x23 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :name (x18 / name :op1 "+/+")))
            :op2 (x20 / protein
                  :name (x21 / name :op1 "ASPP2" :op2 "Δ3/Δ3")
                  :ARG2-of (x22 / mutate-01 :mod "-/-"))))


# ::id PMC3595493.92
# ::snt The basal phosphorylation level of ERK in ASPP2 (+/+) MEFs was higher than that in ASPP2 (Δ3/Δ3) MEFs ( Figure 3a ; Supplementary Figure 3a ).
# ::tok The basal phosphorylation level of ERK in ASPP2 ( +/+ ) MEFs was higher than that in ASPP2 ( Δ3/Δ3 ) MEFs ( Figure 3a ; Supplementary Figure 3a ) .
(x12 / high-02
      :ARG1 (x2 / phosphorylate-01
            :mod (x1 / basal)
            :ARG1 (x3 / level
                  :quant-of (x4 / enzyme
                        :name (x5 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :location (x6 / cell-line
                  :name (x7 / name :op1 "ASPP2")
                  :mod (x8 / gene
                        :name (x9 / name :op1 "+/+")
                        :mod (x10 / cell
                              :name (x11 / name :op1 "mef")))))
      :degree (x13 / more)
      :compared-to (x14 / protein
            :name (x15 / name :op1 "ASPP2" :op2 "Δ3/Δ3")
            :ARG2-of (x16 / mutate-01 :mod "-/-"))
      :ARG1-of (x17 / describe-01
            :ARG0 (x18 / and
                  :op1 (x19 / figure :mod "3a")
                  :op2 (x21 / figure
                        :ARG2-of (x20 / supplement-01)
                        :mod "3a"))))


# ::id PMC3595493.93
# ::snt This difference was more notable in HRASV12-expressing ASPP2 (+/+) than in ASPP2 (Δ3/Δ3) MEFs ( Figure 3b ; Supplementary Figure 3b ).
# ::tok This difference was more notable in HRASV12 @-@ expressing ASPP2 ( +/+ ) than in ASPP2 ( Δ3/Δ3 ) MEFs ( Figure 3b ; Supplementary Figure 3b ) .
(x4 / notable-04
      :ARG1 (x2 / differ-02
            :mod (x1 / this))
      :degree (x3 / more)
      :location (x5 / and
            :op1 (x8 / express-03
                  :ARG2 (x6 / enzyme
                        :name (x7 / name :op1 "HRASV12")
                        :xref (x21 / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312")))
            :op2 (x9 / protein-segment
                  :part-of (x10 / protein
                        :name (x11 / name :op1 "ASPP2")
                        :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                  :name (x12 / name :op1 "+/+")))
      :compared-to (x13 / protein
            :name (x14 / name :op1 "ASPP2" :op2 "Δ3/Δ3")
            :ARG2-of (x15 / mutate-01 :mod "-/-"))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / and
                  :op1 (x18 / figure :mod "3b")
                  :op2 (x20 / figure
                        :ARG2-of (x19 / supplement-01)
                        :mod "3b"))))


# ::id PMC3595493.94
# ::snt Upon insulin treatment, a stronger response was observed in ASPP2 (+/+) compared with ASPP2 (Δ3/Δ3) MEFs, reflected by the phosphorylation level of both ERK and AKT ( Figures 3a and b ; Supplementary Figures 3a and b ).
# ::tok Upon insulin treatment , a stronger response was observed in ASPP2 ( +/+ ) compared with ASPP2 ( Δ3/Δ3 ) MEFs , reflected by the phosphorylation level of both ERK and AKT ( Figures 3a and b ; Supplementary Figures 3a and b ) .
(x7 / observe-01
      :time (x3 / treat-04
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "insulin")
                  :xref (x37 / xref :value "UNIPROT:INS_HUMAN" :prob "0.703")))
      :ARG1 (x6 / respond-01
            :ARG1-of (x4 / strong-02
                  :degree (x5 / more)))
      :location (x31 / and
            :op1 (x19 / reflect-01
                  :ARG1 (x8 / protein-segment
                        :part-of (x9 / protein
                              :name (x10 / name :op1 "ASPP2")
                              :xref (x36 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :name (x11 / name :op1 "+/+"))
                  :ARG1-of (x12 / compare-01
                        :ARG2 (x13 / protein-segment
                              :part-of (x14 / protein
                                    :name (x15 / name :op1 "ASPP2")
                                    :xref (x38 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                              :name (x16 / name :op1 "Δ3/Δ3")))
                  :ARG1 (x17 / cell
                        :name (x18 / name :op1 "mef"))
                  :ARG2 (x20 / level
                        :degree-of (x21 / phosphorylate-01
                              :ARG1 (x22 / and
                                    :op1 (x23 / enzyme
                                          :name (x24 / name :op1 "ERK")
                                          :xref (x35 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                                    :op2 (x25 / enzyme
                                          :name (x26 / name :op1 "AKT")
                                          :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))
                  :ARG1-of (x27 / describe-01
                        :ARG0 (x30 / and
                              :op1 (x28 / figure :mod "3a")
                              :op2 (x29 / figure :mod "1b"))))
            :op2 (x34 / and
                  :op1 (x32 / figure :mod "3a")
                  :op2 (x33 / figure :mod "1b"))))


# ::id PMC3595493.95
# ::snt These data suggest that by binding to and colocalising with active RAS at the cell membrane, ASPP2 potentiates RAS signalling.
# ::tok These data suggest that by binding to and colocalising with active RAS at the cell membrane , ASPP2 potentiates RAS signalling .
(x3 / suggest-01
      :ARG0 (x2 / data
            :mod (x1 / this))
      :ARG1 (x4 / bind-01
            :ARG2 (x5 / and
                  :op1 (x6 / enzyme
                        :name (x7 / name :op1 "colocalising"))
                  :op2 (x8 / enzyme
                        :ARG1-of (x9 / activate-01)
                        :name (x10 / name :op1 "RAS")
                        :xref (x19 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
            :location (x12 / membrane
                  :part-of (x11 / cell)
                  :xref (x21 / xref :value "GO:0016020" :prob "0.8"))
            :ARG1-of (x15 / potentiate-01
                  :ARG0 (x13 / protein
                        :name (x14 / name :op1 "ASPP2")
                        :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                  :ARG1 (x18 / signal-07
                        :ARG0 (x16 / enzyme
                              :name (x17 / name :op1 "RAS")
                              :xref (x20 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))))


# ::id PMC3595493.96
# ::snt The effects of ASPP2 on RAS signalling were further confirmed with human phospho-MAPK arrays.
# ::tok The effects of ASPP2 on RAS signalling were further confirmed with human phospho @-@ MAPK arrays .
(x8 / confirm-01
      :ARG1 (x1 / affect-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "ASPP2")
                  :xref (x14 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :ARG1 (x6 / signal-07
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "RAS")
                        :xref (x15 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
      :degree (x7 / further)
      :ARG2 (x13 / array-01
            :mod (x9 / human
                  :ARG1-of (x10 / phosphorylate-01
                        :ARG2 (x11 / enzyme
                              :name (x12 / name :op1 "MAPK")
                              :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))))))


# ::id PMC3595493.97
# ::snt As expected, phosphorylation levels of several downstream effectors of RAS were increased to various extents following RAS activation in HKe3 ER:HRASV12 cells.
# ::tok As expected , phosphorylation levels of several downstream effectors of RAS were increased to various extents following RAS activation in HKe3 ER : HRASV12 cells .
(x9 / increase-01
      :ARG1-of (x1 / expect-01)
      :ARG1 (x2 / level
            :degree-of (x3 / phosphorylate-01
                  :ARG1 (x6 / effector
                        :quant (x4 / several)
                        :mod (x5 / downstream)
                        :mod (x7 / enzyme
                              :name (x8 / name :op1 "RAS")
                              :xref (x22 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))
      :ARG2 (x11 / extent
            :mod (x10 / various))
      :ARG1-of (x12 / follow-01
            :ARG2 (x15 / activate-01
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :location (x20 / cell
                        :part-of (x16 / protein
                              :name (x17 / name :op1 "erα")
                              :xref (x21 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
                        :mod (x18 / disease
                              :name (x19 / name :op1 "HRASV12"))))))


# ::id PMC3595493.98
# ::snt ASPP2 knockdown dampened the RAS-induced activation of some effectors such as MSK2, p38s and JNKs ( Supplementary Figure 3d ).
# ::tok ASPP2 knockdown dampened the RAS @-@ induced activation of some effectors such as MSK2 , p38s and JNKs ( Supplementary Figure 3d ) .
(x3 / knock-down-02
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "ASPP2")
            :xref (x22 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
      :ARG1 (x4 / dampen-01)
      :ARG0-of (x8 / activate-01
            :ARG2-of (x7 / induce-01
                  :ARG0 (x5 / enzyme
                        :name (x6 / name :op1 "RAS")
                        :xref (x23 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
            :ARG1 (x10 / effector
                  :quant (x9 / some)
                  :example (x15 / and
                        :op1 (x11 / protein
                              :name (x12 / name :op1 "MSK2"))
                        :op2 (x13 / enzyme
                              :name (x14 / name :op1 "p38s")
                              :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.263"))
                        :op3 (x16 / enzyme
                              :name (x17 / name :op1 "JNKs")
                              :xref (x21 / xref :value "UNIPROT:MK08_HUMAN" :prob "0.223")))))
      :ARG1-of (x18 / describe-01
            :ARG0 (x20 / figure
                  :ARG2-of (x19 / supplement-01)
                  :mod "3d")))


# ::id PMC3595493.99
# ::snt Consistent with this, RAS-induced phosphorylation of ERK and AKT is compromised in these cells upon ASPP2 depletion ( Figure 3c ; Supplementary Figure 3c ).
# ::tok Consistent with this , RAS @-@ induced phosphorylation of ERK and AKT is compromised in these cells upon ASPP2 depletion ( Figure 3c ; Supplementary Figure 3c ) .
(x12 / compromise-02
      :ARG1-of (x1 / consistent-01
            :ARG2 (x2 / this))
      :ARG1 (x9 / and
            :op1 (x6 / phosphorylate-01
                  :ARG2-of (x5 / induce-01
                        :ARG0 (x3 / enzyme
                              :name (x4 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "ERK")
                        :xref (x23 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :op2 (x10 / enzyme
                  :name (x11 / name :op1 "AKT")
                  :xref (x24 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))
      :location (x14 / cell
            :mod (x13 / this))
      :time (x17 / deplete-01
            :ARG1 (x15 / protein
                  :name (x16 / name :op1 "ASPP2")
                  :xref (x25 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / and
                  :op1 (x20 / figure :mod "3c")
                  :op2 (x22 / figure
                        :ARG2-of (x21 / supplement-01)
                        :mod "3c"))))


# ::id PMC3595493.100
# ::snt Finally, to confirm whether the RAD in the N-terminus of ASPP2 is critical for its potentiation of RAS signalling, two ASPP2 mutants were generated: ASPP2 (1–360) and ASPP2 (123–1128), representing a naturally occurring ASPP2 splice variant.
# ::tok Finally , to confirm whether the RAD in the N @-@ terminus of ASPP2 is critical for its potentiation of RAS signalling , two ASPP2 mutants were generated : ASPP2 ( 1–360 ) and ASPP2 ( 123–1128 ) , representing a naturally occurring ASPP2 splice variant .
(x1 / multi-sentence
      :snt1 (x2 / and
            :li "-1"
            :purpose (x3 / confirm-01
                  :ARG1 (x10 / critical-02
                        :ARG1 (x4 / protein
                              :name (x5 / name :op1 "RAD")
                              :location (x6 / protein-segment
                                    :name (x7 / name :op1 "N" :op2 "terminus")
                                    :part-of (x8 / protein
                                          :name (x9 / name :op1 "ASPP2")
                                          :xref (x35 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
                              :xref (x36 / xref :value "UNIPROT:RAD_HUMAN" :prob "1.003"))
                        :ARG2 (x11 / potentiate-01
                              :ARG1 (x14 / signal-07
                                    :ARG0 (x12 / enzyme
                                          :name (x13 / name :op1 "RAS")
                                          :xref (x38 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))))
            :op1 (x18 / generate-01
                  :ARG1 (x17 / mutate-01
                        :quant "2"
                        :mod (x15 / protein
                              :name (x16 / name :op1 "ASPP2")
                              :xref (x39 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))))
      :snt2 (x28 / represent-01
            :ARG0 (x23 / and
                  :op1 (x19 / protein-segment
                        :part-of (x20 / protein
                              :name (x21 / name :op1 "ASPP2")
                              :xref (x34 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :name (x22 / name :op1 "1–360"))
                  :op2 (x24 / protein-segment
                        :part-of (x25 / protein
                              :name (x26 / name :op1 "ASPP2")
                              :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :name (x27 / name :op1 "123–1128")))
            :ARG1 (x33 / variant
                  :ARG1-of (x32 / splice-01
                        :mod (x29 / natural-03)
                        :ARG1 (x30 / protein
                              :name (x31 / name :op1 "ASPP2")
                              :xref (x37 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))))


# ::id PMC3595493.101
# ::snt 26 Retroviruses expressing full-length or truncated ASPP2 were infected into HRASV12-expressing ASPP2 (Δ3/Δ3) MEFs.
# ::tok 26 Retroviruses expressing full @-@ length or truncated ASPP2 were infected into HRASV12 @-@ expressing ASPP2 ( Δ3/Δ3 ) MEFs .
(x9 / infect-01
      :ARG1 (x1 / retrovirus
            :quant "26"
            :ARG0-of (x2 / express-03
                  :ARG2 (x5 / or
                        :op1 (x4 / long-03
                              :ARG1-of (x3 / full-09))
                        :op2 (x6 / truncate-01
                              :ARG1 (x7 / protein
                                    :name (x8 / name :op1 "ASPP2")
                                    :xref (x16 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))))
      :ARG2 (x10 / enzyme
            :name (x11 / name :op1 "HRASV12")
            :ARG2-of (x12 / express-03
                  :ARG2 (x13 / protein
                        :name (x14 / name :op1 "ASPP2" :op2 "Δ3/Δ3")
                        :ARG2-of (x15 / mutate-01 :mod "-/-")))
            :xref (x / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312")))


# ::id PMC3595493.102
# ::snt The impaired RAS–ERK and RAS–AKT signalling in HRASV12-expressing ASPP2 (Δ3/Δ3) MEFs was largely rescued by the expression of full-length ASPP2 ( Figure 3d , lower panel, lanes 7–9).
# ::tok The impaired RAS–ERK and RAS–AKT signalling in HRASV12 @-@ expressing ASPP2 ( Δ3/Δ3 ) MEFs was largely rescued by the expression of full @-@ length ASPP2 ( Figure 3d , lower panel , lanes 7–9 ) .
(x1 / multi-sentence
      :snt1 (x5 / and
            :op1 (x2 / impair-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "RAS–ERK")))
            :op2 (x8 / signal-07
                  :ARG0 (x6 / protein
                        :name (x7 / name :op1 "RAS–AKT"))
                  :ARG1 (x11 / express-03
                        :ARG2 (x9 / enzyme
                              :name (x10 / name :op1 "HRASV12")
                              :xref (x / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312")))))
      :snt2 (x16 / rescue-01
            :ARG1 (x12 / protein
                  :name (x13 / name :op1 "ASPP2" :op2 "Δ3/Δ3")
                  :ARG2-of (x14 / mutate-01 :mod "-/-"))
            :degree (x15 / large)
            :ARG0 (x17 / express-03
                  :ARG2 (x18 / protein
                        :ARG1-of (x20 / long-03
                              :ARG1-of (x19 / full-09))
                        :name (x21 / name :op1 "ASPP2")
                        :xref (x30 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                  :ARG1-of (x22 / describe-01
                        :ARG0 (x23 / and
                              :op1 (x24 / figure :mod "3d")
                              :op2 (x27 / panel
                                    :ARG1-of (x25 / low-04
                                          :degree (x26 / more)))
                              :op3 (x28 / lane
                                    :mod (x29 / value-interval :op1 "7" :op2 "9")))))))


# ::id PMC3595493.103
# ::snt The expression of ASPP2 (1–360) also partially restored the activities of ERK and AKT ( Figure 3d , lower panel, lanes 10–12).
# ::tok The expression of ASPP2 ( 1–360 ) also partially restored the activities of ERK and AKT ( Figure 3d , lower panel , lanes 10–12 ) .
(x8 / restore-01
      :ARG0 (x1 / express-03
            :ARG2 (x2 / protein
                  :name (x3 / name :op1 "ASPP2")
                  :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :ARG1-of (x4 / gene
                  :name (x5 / name :op1 "1–360")
                  :mod (x6 / also)))
      :degree (x7 / part)
      :ARG1 (x9 / activity-06
            :ARG0 (x12 / and
                  :op1 (x10 / enzyme
                        :name (x11 / name :op1 "ERK")
                        :xref (x23 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :op2 (x13 / enzyme
                        :name (x14 / name :op1 "AKT")
                        :xref (x24 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263"))))
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / and
                  :op1 (x17 / figure :mod "3d")
                  :op2 (x20 / panel
                        :ARG1-of (x18 / low-04
                              :degree (x19 / more)))
                  :op3 (x21 / lane
                        :mod (x22 / value-interval :op1 "10" :op2 "12")))))


# ::id PMC3595493.104
# ::snt This may be explained by the reduced expression of ASPP2 (1–360) relative to full-length ASPP2 ( Figure 3e ).
# ::tok This may be explained by the reduced expression of ASPP2 ( 1–360 ) relative to full @-@ length ASPP2 ( Figure 3e ) .
(x1 / possible-01
      :ARG1 (x3 / explain-01
            :ARG1 (x2 / this)
            :ARG0 (x4 / reduce-01
                  :ARG1 (x5 / express-03
                        :ARG2 (x6 / protein
                              :name (x7 / name :op1 "ASPP2")
                              :xref (x16 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :ARG1-of (x9 / relative-05
                              :name (x8 / name :op1 "1–360")))
                  :ARG1-of (x11 / long-03
                        :ARG1-of (x10 / full-09))
                  :ARG2 (x12 / protein
                        :name (x13 / name :op1 "ASPP2")
                        :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
      :ARG1-of (x14 / describe-01
            :ARG0 (x15 / figure :mod "3e")))


# ::id PMC3595493.105
# ::snt The expression of ASPP2 (123–1128) failed to stimulate ERK and AKT pathways, although the amount of protein was similar to that of ASPP2 (1–1128) ( Figure 3d (lower panel, lanes 13–15) and Figure 3e ).
# ::tok The expression of ASPP2 ( 123–1128 ) failed to stimulate ERK and AKT pathways , although the amount of protein was similar to that of ASPP2 ( 1–1128 ) ( Figure 3d ( lower panel , lanes 13–15 ) and Figure 3e ) .
(x1 / multi-sentence
      :snt1 (x14 / have-concession-91
            :ARG1 (x7 / fail-01
                  :ARG1 (x2 / express-03
                        :ARG2 (x3 / protein-segment
                              :part-of (x4 / protein
                                    :name (x5 / name :op1 "ASPP2")
                                    :xref (x33 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                              :name (x6 / name :op1 "123–1128")))
                  :ARG2 (x8 / stimulate-01
                        :ARG1 (x11 / and
                              :op1 (x9 / enzyme
                                    :name (x10 / name :op1 "ERK")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                              :op2 (x12 / pathway
                                    :name (x13 / name :op1 "AKT")))))
            :ARG2 (x17 / resemble-01
                  :ARG1 (x15 / amount
                        :quant-of (x16 / protein))
                  :ARG2 (x18 / amino-acid
                        :part-of (x19 / protein
                              :name (x20 / name :op1 "ASPP2")
                              :xref (x34 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :name (x21 / name :op1 "1–1128"))
                  :ARG1-of (x22 / describe-01
                        :ARG0 (x23 / figure :mod "3d")))
            :ARG1-of (x27 / lane
                  :location (x26 / panel
                        :ARG1-of (x24 / low-04
                              :degree (x25 / more)))))
      :snt2 (x30 / and
            :op2 (x28 / cell-line
                  :name (x29 / name :op1 "13–15"))
            :ARG1-of (x31 / describe-01
                  :ARG0 (x32 / figure :mod "3e"))))


# ::id PMC3595493.106
# ::snt This result illustrates that the N-terminus of ASPP2 (1–123) is sufficient to potentiate RAS signalling.
# ::tok This result illustrates that the N @-@ terminus of ASPP2 ( 1–123 ) is sufficient to potentiate RAS signalling .
(x4 / illustrate-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x10 / suffice-01
            :ARG2 (x5 / protein-segment
                  :name (x6 / name :op1 "N" :op2 "terminus")
                  :part-of (x7 / protein
                        :name (x8 / name :op1 "ASPP2")
                        :xref (x15 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                  :name (x9 / name :op1 "1–123"))
            :ARG1 (x11 / potentiate-01
                  :ARG1 (x14 / signal-07
                        :ARG0 (x12 / enzyme
                              :name (x13 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))))


# ::id PMC3595493.107
# ::snt ASPP1 and ASPP2 cooperate with RAS to enhance the transcriptional activity of p53
# ::tok ASPP1 and ASPP2 cooperate with RAS to enhance the transcriptional activity of p53
(x6 / cooperate-01
      :ARG0 (x3 / and
            :op1 (x1 / protein
                  :name (x2 / name :op1 "ASPP1")
                  :xref (x14 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
            :op2 (x4 / protein
                  :name (x5 / name :op1 "ASPP2")
                  :xref (x16 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
      :ARG1 (x9 / enhance-01
            :ARG0 (x7 / enzyme
                  :name (x8 / name :op1 "RAS")
                  :xref (x15 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
            :ARG1 (x11 / activity-06
                  :ARG1 (x10 / transcribe-01)
                  :ARG0 (x12 / protein
                        :name (x13 / name :op1 "p53")
                        :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))))


# ::id PMC3595493.108
# ::snt We showed previously that the N-termini of ASPP1 and ASPP2 are required for full enhancement of p53 activity.
# ::tok We showed previously that the N @-@ termini of ASPP1 and ASPP2 are required for full enhancement of p53 activity .
(x2 / show-01
      :ARG0 (x1 / we)
      :time (x3 / previous)
      :ARG1 (x11 / require-01
            :ARG1 (x8 / and
                  :op1 (x4 / protein-segment
                        :name (x5 / name :op1 "N" :op2 "termini")
                        :part-of (x6 / protein
                              :name (x7 / name :op1 "ASPP1")
                              :xref (x18 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003")))
                  :op2 (x9 / protein
                        :name (x10 / name :op1 "ASPP2")
                        :xref (x17 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
            :ARG0 (x13 / enhance-01
                  :ARG1-of (x12 / full-09)
                  :ARG1 (x16 / activity-06
                        :ARG0 (x14 / enzyme
                              :name (x15 / name :op1 "p53")
                              :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))))


# ::id PMC3595493.109
# ::snt 16 We thus tested whether ASPP1 and ASPP2 cooperate with RAS to stimulate the apoptotic function of p53.
# ::tok 16 We thus tested whether ASPP1 and ASPP2 cooperate with RAS to stimulate the apoptotic function of p53 .
(x1 / and
      :op1 "16"
      :op2 (x2 / cause-01
            :ARG1 (x4 / test-01
                  :ARG0 (x3 / we)
                  :ARG1 (x10 / cooperate-01
                        :mode "interrogative"
                        :ARG0 (x7 / and
                              :op1 (x5 / protein
                                    :name (x6 / name :op1 "ASPP1")
                                    :xref (x17 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                              :op2 (x8 / protein
                                    :name (x9 / name :op1 "ASPP2")
                                    :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
                        :ARG1 (x11 / enzyme
                              :name (x12 / name :op1 "RAS")
                              :xref (x16 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                        :ARG2 (x13 / stimulate-01
                              :ARG1 (x15 / function-01
                                    :ARG1 (x14 / apoptosis)))))))


# ::id PMC3595493.110
# ::snt HRASV12 or KRASV12 was co-transfected with ASPP1, ASPP2 and p53 into Saos2 cells.
# ::tok HRASV12 or KRASV12 was co @-@ transfected with ASPP1 , ASPP2 and p53 into Saos2 cells .
(x6 / be-located-at-91
      :ARG1 (x3 / or
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "HRASV12")
                  :xref (x19 / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312"))
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "KRASV12")
                  :xref (x20 / xref :value "UNIPROT:RASK_HUMAN" :prob "0.313")))
      :ARG1 (x12 / and
            :ARG1-of (x7 / transfect-01
                  :ARG2 (x8 / protein
                        :name (x9 / name :op1 "ASPP1")
                        :xref (x18 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003")))
            :op1 (x10 / protein
                  :name (x11 / name :op1 "ASPP2")
                  :xref (x17 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :op2 (x13 / protein
                  :name (x14 / name :op1 "p53")
                  :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
      :ARG2 (x16 / cell-line
            :name (x15 / name :op1 "Saos2")))


# ::id PMC3595493.111
# ::snt The results shown in Figure 4a illustrate that HRASV12 or KRASV12 alone had a small stimulatory effect on p53 transactivity.
# ::tok The results shown in Figure 4a illustrate that HRASV12 or KRASV12 alone had a small stimulatory effect on p53 transactivity .
(x5 / illustrate-01
      :ARG0 (x1 / thing
            :ARG2-of (x2 / result-01))
      :ARG1-of (x3 / show-01
            :ARG0 (x4 / figure :mod "4a"))
      :ARG1 (x13 / affect-01
            :ARG0 (x8 / or
                  :op1 (x6 / enzyme
                        :name (x7 / name :op1 "HRASV12")
                        :xref (x16 / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312"))
                  :op2 (x9 / enzyme
                        :name (x10 / name :op1 "KRASV12")
                        :mod (x11 / alone)
                        :xref (x / xref :value "UNIPROT:RASK_HUMAN" :prob "0.313")))
            :ARG2 (x12 / small-molecule)
            :ARG1 (x14 / enzyme
                  :name (x15 / name :op1 "p53" :op2 "transactivity"))))


# ::id PMC3595493.112
# ::snt As expected, coexpression of ASPP1 or ASPP2 with p53 enhanced the transcriptional activity of p53 on the Bax promoter–luciferase reporter by 3 and 10 times, respectively.
# ::tok As expected , coexpression of ASPP1 or ASPP2 with p53 enhanced the transcriptional activity of p53 on the Bax promoter–luciferase reporter by 3 and 10 times , respectively .
(x17 / report-01
      :ARG1-of (x1 / expect-01)
      :ARG1 (x10 / enhance-01
            :ARG0 (x2 / express-03
                  :ARG2 (x5 / or
                        :op1 (x3 / protein
                              :name (x4 / name :op1 "ASPP1")
                              :xref (x22 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                        :op2 (x6 / protein
                              :name (x7 / name :op1 "ASPP2")
                              :xref (x23 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :op2 (x8 / protein
                              :name (x9 / name :op1 "p53")
                              :xref (x21 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))
            :ARG1 (x12 / activity-06
                  :ARG1 (x11 / transcribe-01)
                  :ARG0 (x13 / protein
                        :name (x14 / name :op1 "p53")
                        :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
            :ARG1 (x15 / enzyme
                  :name (x16 / name :op1 "Bax" :op2 "promoter–luciferase")))
      :ARG0 (x18 / and
            :op1 "3"
            :op2 (x19 / product-of :op1 "10")
            :mod (x20 / respective)))


# ::id PMC3595493.113
# ::snt In the presence of ASPP1, expression of HRASV12 or KRASV12 stimulated the transactivation function of p53 by ∼10-fold ( Figure 4a ).
# ::tok In the presence of ASPP1 , expression of HRASV12 or KRASV12 stimulated the transactivation function of p53 by ∼10 @-@ fold ( Figure 4a ) .
(x10 / stimulate-01
      :condition (x1 / present-02
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "ASPP1")
                  :xref (x19 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003")))
      :ARG0 (x4 / express-03
            :ARG2 (x7 / or
                  :op1 (x5 / enzyme
                        :name (x6 / name :op1 "HRASV12")
                        :xref (x20 / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312"))
                  :op2 (x8 / enzyme
                        :name (x9 / name :op1 "KRASV12")
                        :xref (x18 / xref :value "UNIPROT:RASK_HUMAN" :prob "0.313"))))
      :ARG1 (x11 / transactivate-01
            :ARG1 (x12 / function-01
                  :ARG0 (x13 / protein
                        :name (x14 / name :op1 "p53")
                        :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))
      :manner (x15 / product-of :op1 "∼10")
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / figure :mod "4a")))


# ::id PMC3595493.114
# ::snt Similarly, the coexpression of ASPP2 and HRASV12 or KRASV12 stimulated the transcriptional activity of p53 by around 30–35-fold.
# ::tok Similarly , the coexpression of ASPP2 and HRASV12 or KRASV12 stimulated the transcriptional activity of p53 by around 30–35 @-@ fold .
(x11 / stimulate-01
      :ARG1-of (x1 / resemble-01)
      :ARG0 (x8 / or
            :op1 (x2 / express-03
                  :ARG2 (x5 / and
                        :op1 (x3 / protein
                              :name (x4 / name :op1 "ASPP2")
                              :xref (x19 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :op2 (x6 / enzyme
                              :name (x7 / name :op1 "HRASV12")
                              :xref (x20 / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312"))))
            :op2 (x9 / enzyme
                  :name (x10 / name :op1 "KRASV12")
                  :xref (x18 / xref :value "UNIPROT:RASK_HUMAN" :prob "0.313")))
      :ARG1 (x13 / activity-06
            :ARG1 (x12 / transcribe-01)
            :ARG0 (x14 / protein
                  :name (x15 / name :op1 "p53")
                  :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
      :manner (x16 / around
            :op1 (x17 / product-of :op1 "30–35")))


# ::id PMC3595493.115
# ::snt When the transcriptional activities of p53+ASPP1 and p53+ASPP2 were set as 1, we observed that both HRASV12 and KRASV12 were able to further enhance the transcriptional activity of p53 by around three-folds ( Figure 4b ).
# ::tok When the transcriptional activities of p53+ASPP1 and p53+ASPP2 were set as 1 , we observed that both HRASV12 and KRASV12 were able to further enhance the transcriptional activity of p53 by around three @-@ folds ( Figure 4b ) .
(x12 / observe-01
      :time (x8 / set-up-03
            :ARG1 (x2 / activity-06
                  :ARG1 (x1 / transcribe-01)
                  :ARG0 (x5 / and
                        :op1 (x3 / enzyme
                              :name (x4 / name :op1 "p53+ASPP1")
                              :xref (x30 / xref :value "UNIPROT:TPIP1_HUMAN" :prob "0.282"))
                        :op2 (x6 / enzyme
                              :name (x7 / name :op1 "p53+ASPP2")
                              :xref (x31 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "0.262"))))
            :ARG2 (x9 / protein
                  :name (x10 / name :op1 "1")
                  :xref (x29 / xref :value "UNIPROT:NOX1_HUMAN" :prob "0.573")))
      :ARG0 (x11 / we)
      :ARG1 (x18 / capable-01
            :ARG1 (x15 / and
                  :op1 (x13 / enzyme
                        :name (x14 / name :op1 "HRASV12")
                        :xref (x32 / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312"))
                  :op2 (x16 / enzyme
                        :name (x17 / name :op1 "KRASV12")
                        :xref (x33 / xref :value "UNIPROT:RASK_HUMAN" :prob "0.313")))
            :ARG2 (x20 / enhance-01
                  :degree (x19 / further)
                  :ARG1 (x22 / activity-06
                        :ARG1 (x21 / transcribe-01)
                        :ARG0 (x23 / protein
                              :name (x24 / name :op1 "p53")
                              :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
                  :manner (x26 / fold-03
                        :ARG2 (x25 / around :op1 "3"))))
      :ARG1-of (x27 / describe-01
            :ARG0 (x28 / figure :mod "4b")))


# ::id PMC3595493.116
# ::snt To demonstrate further that RAS activation is required to enhance the transcriptional activity of p53 via ASPP1 or ASPP2, a wild-type RAS or a dominant negative form of HRAS–HRASN17 was co-transfected with ASPP2 and p53 into Saos2 cells.
# ::tok To demonstrate further that RAS activation is required to enhance the transcriptional activity of p53 via ASPP1 or ASPP2 , a wild @-@ type RAS or a dominant negative form of HRAS–HRASN17 was co @-@ transfected with ASPP2 and p53 into Saos2 cells .
(x1 / multi-sentence
      :snt1 (x2 / cause-01
            :ARG1 (x3 / demonstrate-01
                  :mod (x4 / further)
                  :ARG1 (x8 / require-01
                        :ARG1 (x7 / activate-01
                              :ARG1 (x5 / enzyme
                                    :name (x6 / name :op1 "RAS")
                                    :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
                        :ARG0 (x16 / or
                              :op1 (x9 / enhance-01
                                    :ARG1 (x11 / activity-06
                                          :ARG1 (x10 / transcribe-01)
                                          :ARG0 (x12 / protein
                                                :name (x13 / name :op1 "p53")
                                                :xref (x40 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
                                    :ARG2 (x14 / protein
                                          :name (x15 / name :op1 "ASPP1")
                                          :xref (x41 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003")))
                              :op2 (x17 / protein
                                    :name (x18 / name :op1 "ASPP2")
                                    :xref (x42 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))))
      :snt2 (x28 / be-located-at-91
            :ARG1 (x22 / or
                  :op1 (x19 / enzyme
                        :mod (x20 / wild-type)
                        :name (x21 / name :op1 "RAS")
                        :xref (x39 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :op2 (x25 / form
                        :ARG0-of (x23 / dominate-01
                              :mod (x24 / negative))
                        :mod (x26 / enzyme
                              :name (x27 / name :op1 "HRAS–HRASN17"))))
            :ARG2 (x29 / transfect-01
                  :ARG2 (x32 / and
                        :op1 (x30 / protein
                              :name (x31 / name :op1 "ASPP2")
                              :xref (x38 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :op2 (x33 / enzyme
                              :name (x34 / name :op1 "p53")
                              :xref (x37 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
                  :ARG1 (x36 / cell-line
                        :name (x35 / name :op1 "Saos2")))))


# ::id PMC3595493.117
# ::snt The results shown in Figure 4c illustrate that HRASV12 alone had a small stimulatory effect on the transactivation function of p53.
# ::tok The results shown in Figure 4c illustrate that HRASV12 alone had a small stimulatory effect on the transactivation function of p53 .
(x5 / illustrate-01
      :ARG0 (x1 / thing
            :ARG2-of (x2 / result-01))
      :ARG1-of (x3 / show-01
            :ARG0 (x4 / figure :mod "4c"))
      :ARG1 (x10 / affect-01
            :ARG0 (x6 / small-molecule
                  :name (x7 / name :op1 "HRASV12")
                  :mod (x8 / alone))
            :ARG2 (x9 / small-molecule)
            :ARG1 (x11 / transactivate-01
                  :ARG1 (x12 / function-01
                        :ARG0 (x13 / protein
                              :name (x14 / name :op1 "p53")
                              :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))))


# ::id PMC3595493.118
# ::snt In the presence of ASPP2, however, HRASV12 stimulated the transactivation function of p53 by approximately 3-fold.
# ::tok In the presence of ASPP2 , however , HRASV12 stimulated the transactivation function of p53 by approximately 3 @-@ fold .
(x4 / contrast-01
      :condition (x1 / present-02
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "ASPP2")
                  :xref (x14 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
      :ARG2 (x7 / stimulate-01
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "HRASV12")
                  :xref (x15 / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312")))
      :ARG1 (x8 / transactivate-01
            :ARG1 (x9 / function-01
                  :ARG0 (x10 / protein
                        :name (x11 / name :op1 "p53")
                        :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))
                  :manner (x12 / approximately
                        :op1 (x13 / product-of :op1 "3")))))


# ::id PMC3595493.119
# ::snt When HRASN17 was co-transfected with ASPP2 and p53, the transactivation activity of p53 was inhibited.
# ::tok When HRASN17 was co @-@ transfected with ASPP2 and p53 , the transactivation activity of p53 was inhibited .
(x10 / transactivate-01
      :time (x7 / and
            :op1 (x3 / be-located-at-91
                  :ARG1 (x1 / enzyme
                        :name (x2 / name :op1 "HRASN17")
                        :xref (x16 / xref :value "UNIPROT:RASH_HUMAN" :prob "0.263"))
                  :ARG2 (x4 / transfect-01
                        :ARG2 (x5 / protein
                              :name (x6 / name :op1 "ASPP2")
                              :xref (x17 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
            :op2 (x8 / protein
                  :name (x9 / name :op1 "p53")
                  :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
      :op2 (x14 / inhibit-01
            :ARG1 (x11 / activity-06
                  :ARG0 (x12 / enzyme
                        :name (x13 / name :op1 "p53")
                        :xref (x15 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))))


# ::id PMC3595493.120
# ::snt This inhibition was via ASPP2, as HRASN17 transfected only with p53 did not have such a strong inhibitory effect: HRASN17 inhibited p53 and ASPP2 activity more than 4-fold, whereas it inhibited p53 via endogenous ASPP about 1.5-fold.
# ::tok This inhibition was via ASPP2 , as HRASN17 transfected only with p53 did not have such a strong inhibitory effect : HRASN17 inhibited p53 and ASPP2 activity more than 4 @-@ fold , whereas it inhibited p53 via endogenous ASPP about 1.5 @-@ fold .
(x27 / contrast-01
      :ARG1 (x2 / inhibit-01
            :mod (x1 / this)
            :ARG2 (x3 / protein
                  :name (x4 / name :op1 "ASPP2")
                  :xref (x37 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :ARG1-of (x7 / transfect-01
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "HRASN17")
                        :xref (x38 / xref :value "UNIPROT:RASH_HUMAN" :prob "0.263"))
                  :mod (x8 / only)
                  :ARG2 (x11 / have-03
                        :ARG0 (x9 / protein
                              :name (x10 / name :op1 "p53")
                              :xref (x36 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))
                        :polarity "-"
                        :ARG1 (x15 / affect-01
                              :ARG1-of (x13 / strong-02
                                    :degree (x12 / such))
                              :ARG0-of (x14 / inhibit-01)))))
      :ARG1 (x18 / inhibit-01
            :ARG1 (x16 / protein
                  :name (x17 / name :op1 "HRASN17")
                  :xref (x41 / xref :value "UNIPROT:RASH_HUMAN" :prob "0.263"))
            :ARG1 (x24 / activity-06
                  :ARG0 (x21 / and
                        :op1 (x19 / protein
                              :name (x20 / name :op1 "p53")
                              :xref (x40 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))
                        :op2 (x22 / protein
                              :name (x23 / name :op1 "ASPP2")
                              :xref (x35 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
            :degree (x25 / more)
            :compared-to (x26 / product-of :op1 "4"))
      :ARG2 (x28 / inhibit-01
            :ARG1 (x29 / protein
                  :name (x30 / name :op1 "p53")
                  :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))
            :instrument (x31 / enzyme
                  :mod (x32 / endogenous)
                  :name (x33 / name :op1 "ASPP")
                  :xref (x39 / xref :value "UNIPROT:A1CF_HUMAN" :prob "0.342")))
      :ARG2 (x34 / product-of :op1 "1.5"))


# ::id PMC3595493.121
# ::snt In contrast, wild-type RAS had very little effect on the transactivation function of p53.
# ::tok In contrast , wild @-@ type RAS had very little effect on the transactivation function of p53 .
(x1 / contrast-01
      :ARG2 (x7 / affect-01
            :ARG0 (x2 / enzyme
                  :mod (x3 / wild-type)
                  :name (x4 / name :op1 "RAS")
                  :xref (x12 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
            :degree (x6 / little
                  :degree (x5 / very))
            :ARG1 (x8 / transactivate-01
                  :ARG1 (x9 / function-01
                        :ARG0 (x10 / protein
                              :name (x11 / name :op1 "p53")
                              :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))))


# ::id PMC3595493.122
# ::snt This may be explained by the fact that increased RAS expression does not necessarily lead to increased levels of RAS–GTP in cells.
# ::tok This may be explained by the fact that increased RAS expression does not necessarily lead to increased levels of RAS–GTP in cells .
(x1 / possible-01
      :ARG1 (x3 / explain-01
            :ARG1 (x2 / this)
            :ARG0 (x4 / fact
                  :mod (x9 / need-01
                        :ARG0 (x8 / express-03
                              :ARG1-of (x5 / increase-01)
                              :ARG2 (x6 / enzyme
                                    :name (x7 / name :op1 "RAS")
                                    :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
                        :polarity "-"
                        :ARG1 (x10 / lead-03
                              :ARG2 (x12 / level
                                    :ARG1-of (x11 / increase-01)
                                    :quant-of (x13 / protein
                                          :name (x14 / name :op1 "RAS–GTP")))
                              :location (x15 / cell))))))


# ::id PMC3595493.123
# ::snt We tested whether the observed ability of RAS oncogene to cooperate with ASPP2 to enhance p53 transcriptional activity is promoter-specific.
# ::tok We tested whether the observed ability of RAS oncogene to cooperate with ASPP2 to enhance p53 transcriptional activity is promoter @-@ specific .
(x2 / test-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / observe-01
            :mode "interrogative"
            :ARG1 (x4 / capable-01
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "RAS")
                        :ARG0-of (x7 / cause-01
                              :ARG1 (x8 / disease
                                    :wiki "cancer"
                                    :name (x9 / name :op1 "cancer")))
                        :xref (x22 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :ARG2 (x10 / cooperate-01
                        :ARG2 (x13 / enhance-01
                              :ARG0 (x11 / protein
                                    :name (x12 / name :op1 "ASPP2")
                                    :xref (x21 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                              :ARG1 (x17 / activity-06
                                    :ARG0 (x16 / transcribe-01
                                          :ARG0 (x14 / protein
                                                :name (x15 / name :op1 "p53")
                                                :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))))))
      :ARG1 (x20 / specific-02
            :ARG2 (x18 / molecular-physical-entity
                  :ARG0-of (x19 / promote-01))))


# ::id PMC3595493.124
# ::snt Three p53 target gene promoter-containing reporters, PIG3-, Bax- and Mdm2-luciferases, were used.
# ::tok Three p53 target gene promoter @-@ containing reporters , PIG3-, Bax @- and Mdm2 @-@ luciferases , were used .
(x16 / use-01
      :ARG1 (x8 / person
            :quant "3"
            :ARG0-of (x7 / contain-01
                  :ARG1 (x6 / molecular-physical-entity
                        :ARG0-of (x5 / promote-01
                              :ARG1 (x4 / gene
                                    :ARG0-of (x3 / target-01
                                          :ARG1 (x1 / protein
                                                :name (x2 / name :op1 "p53")
                                                :xref (x18 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))))))
            :ARG0-of (x9 / report-01)
            :ARG1-of (x12 / and
                  :op1 (x10 / protein
                        :name (x11 / name :op1 "Bax")
                        :xref (x17 / xref :value "UNIPROT:A0A0C4MVT1_HUMAN" :prob "1.001"))
                  :op2 (x13 / protein
                        :name (x14 / name :op1 "Mdm2")
                        :xref (x / xref :value "UNIPROT:A7UKX7_HUMAN" :prob "0.701")))
            :name (x15 / name :op1 "luciferases")))


# ::id PMC3595493.125
# ::snt We observed that HRASV12 had the most profound effect on the transcriptional activity of p53 on PIG3 and BAX promoters.
# ::tok We observed that HRASV12 had the most profound effect on the transcriptional activity of p53 on PIG3 and BAX promoters .
(x2 / observe-01
      :ARG0 (x1 / we)
      :ARG1 (x5 / have-03
            :ARG0 (x3 / enzyme
                  :name (x4 / name :op1 "HRASV12")
                  :xref (x20 / xref :value "UNIPROT:RASE_HUMAN" :prob "0.312"))
            :ARG1 (x19 / molecular-physical-entity
                  :ARG1-of (x8 / affect-01
                        :degree (x7 / profound
                              :degree (x6 / most))
                        :ARG1 (x10 / activity-06
                              :ARG1 (x9 / transcribe-01)
                              :ARG0 (x11 / protein
                                    :name (x12 / name :op1 "p53")
                                    :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "PIG3")))
                  :ARG0-of (x18 / promote-01
                        :ARG1 (x15 / and
                              :op1 (x16 / protein
                                    :name (x17 / name :op1 "BAX")))))))


# ::id PMC3595493.126
# ::snt Under the same conditions, a reduced stimulatory effect was seen on Mdm2 promoter ( Figure 4d ).
# ::tok Under the same conditions , a reduced stimulatory effect was seen on Mdm2 promoter ( Figure 4d ) .
(x6 / see-01
      :ARG1 (x5 / affect-01
            :condition (x2 / condition
                  :ARG1-of (x1 / same-01)
                  :mod (x3 / reduce-01))
            :ARG2 (x4 / stimulate-01))
      :location (x10 / molecular-physical-entity
            :ARG0-of (x9 / promote-01
                  :ARG1 (x7 / protein
                        :name (x8 / name :op1 "Mdm2")
                        :xref (x / xref :value "UNIPROT:A7UKX7_HUMAN" :prob "0.701"))))
      :ARG1-of (x11 / describe-01
            :ARG0 (x12 / figure :mod "4d")))


# ::id PMC3595493.127
# ::snt This agrees with our previous finding that ASPP2 has minimal impact on the transcriptional activity of p53 on the promoters of Mdm2 and p21 waf1 .
# ::tok This agrees with our previous finding that ASPP2 has minimal impact on the transcriptional activity of p53 on the promoters of Mdm2 and p21 waf1 .
(x18 / and
      :op1 (x9 / impact-01
            :ARG0 (x2 / agree-01
                  :mod (x1 / this)
                  :ARG2 (x5 / find-01
                        :ARG0 (x3 / we)
                        :time (x4 / previous)
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "ASPP2")
                              :xref (x22 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
            :degree (x8 / minimal)
            :ARG1 (x11 / activity-06
                  :ARG1 (x10 / transcribe-01)
                  :ARG0 (x12 / protein
                        :name (x13 / name :op1 "p53")
                        :xref (x21 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
            :location (x14 / molecular-physical-entity
                  :ARG0-of (x15 / promote-02))
            :ARG1 (x16 / protein
                  :name (x17 / name :op1 "Mdm2")
                  :xref (x / xref :value "UNIPROT:A7UKX7_HUMAN" :prob "0.701")))
      :op2 (x19 / protein
            :name (x20 / name :op1 "p21" :op2 "waf1/cip1")))


# ::id PMC3595493.128
# ::snt 16 Consistent with this, we also observed that p21 waf1 mRNA expression induced by activated RAS in HKe3 cells is independent of ASPP2 status, as ASPP2 knockdown in these cells did not alter p21 waf1 expression ( Supplementary Figure 4a ).
# ::tok 16 Consistent with this , we also observed that p21 waf1 mRNA expression induced by activated RAS in HKe3 cells is independent of ASPP2 status , as ASPP2 knockdown in these cells did not alter p21 waf1 expression ( Supplementary Figure 4a ) .
(x20 / depend-01
      :ARG0 (x8 / observe-01
            :ARG1-of (x1 / describe-01
                  :ARG0 (x2 / publication
                        :ARG1-of (x3 / cite-01 :ARG2 "16")))
            :ARG1-of (x4 / consistent-01
                  :ARG2 (x5 / this))
            :ARG0 (x6 / we)
            :mod (x7 / also)
            :ARG1 (x9 / protein
                  :name (x10 / name :op1 "p21" :op2 "waf1/cip1"))
            :ARG1 (x13 / express-03
                  :ARG1 (x11 / nucleic-acid
                        :name (x12 / name :op1 "mRNA"))
                  :ARG2-of (x14 / induce-01
                        :ARG0 (x15 / enzyme
                              :ARG1-of (x16 / activate-01)
                              :name (x17 / name :op1 "RAS")
                              :xref (x37 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
            :location (x19 / cell-line
                  :name (x18 / name :op1 "HKe3")))
      :polarity "-"
      :ARG1 (x23 / status
            :mod (x21 / protein
                  :name (x22 / name :op1 "ASPP2")
                  :xref (x36 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :ARG1-of (x29 / alter-01
                  :ARG0 (x26 / knock-down-02
                        :ARG1 (x24 / protein
                              :name (x25 / name :op1 "ASPP2")
                              :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :location (x28 / cell
                              :mod (x27 / this)))
                  :polarity "-"
                  :ARG1 (x32 / express-03
                        :ARG2 (x30 / protein
                              :name (x31 / name :op1 "p21" :op2 "waf1/cip1")))
                  :ARG1-of (x33 / describe-01
                        :ARG0 (x35 / figure
                              :ARG2-of (x34 / supplement-01)
                              :mod "4a")))))


# ::id PMC3595493.129
# ::snt The requirement of endogenous RAS to stimulate the transcriptional activity of p53 via ASPP2 was tested using shRNA against HRAS or KRAS.
# ::tok The requirement of endogenous RAS to stimulate the transcriptional activity of p53 via ASPP2 was tested using shRNA against HRAS or KRAS .
(x12 / test-01
      :ARG1 (x1 / require-01
            :ARG1 (x2 / enzyme
                  :mod (x3 / endogenous)
                  :name (x4 / name :op1 "RAS")
                  :xref (x24 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
            :ARG2 (x5 / stimulate-01
                  :ARG1 (x7 / activity-06
                        :ARG1 (x6 / transcribe-01)
                        :ARG0 (x8 / protein
                              :name (x9 / name :op1 "p53")
                              :xref (x23 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
                  :ARG2 (x10 / protein
                        :name (x11 / name :op1 "ASPP2")
                        :xref (x22 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
      :ARG0-of (x13 / use-01
            :ARG1 (x14 / nucleic-acid
                  :name (x15 / name :op1 "shRNA")
                  :ARG0-of (x16 / counter-01
                        :ARG1 (x19 / or
                              :op1 (x17 / enzyme
                                    :name (x18 / name :op1 "HRAS")
                                    :xref (x25 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
                              :op2 (x20 / enzyme
                                    :name (x21 / name :op1 "KRAS")
                                    :xref (x / xref :value "UNIPROT:RASK_HUMAN" :prob "1.003")))))))


# ::id PMC3595493.130
# ::snt Their ability to specifically reduce the expression level of HRAS or KRAS was confirmed ( Supplementary Figure 4b ).
# ::tok Their ability to specifically reduce the expression level of HRAS or KRAS was confirmed ( Supplementary Figure 4b ) .
(x11 / confirm-01
      :ARG0 (x1 / capable-01
            :ARG2 (x2 / specific-02))
      :ARG1 (x3 / reduce-01
            :ARG1 (x4 / level
                  :degree-of (x5 / express-03
                        :ARG2 (x8 / or
                              :op1 (x6 / enzyme
                                    :name (x7 / name :op1 "HRAS")
                                    :xref (x15 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
                              :op2 (x9 / enzyme
                                    :name (x10 / name :op1 "KRAS")
                                    :xref (x / xref :value "UNIPROT:RASK_HUMAN" :prob "1.003"))))))
      :ARG1-of (x12 / describe-01
            :ARG0 (x14 / figure
                  :ARG2-of (x13 / supplement-01)
                  :mod "4b")))


# ::id PMC3595493.131
# ::snt We found that RNAi against HRAS or KRAS dampened the ability of ASPP2 to stimulate the transactivation function of p53 on the promoters of the pro-apoptotic gene Bax ( Figure 4e ) and PIG3 ( Supplementary Figure 4c ).
# ::tok We found that RNAi against HRAS or KRAS dampened the ability of ASPP2 to stimulate the transactivation function of p53 on the promoters of the pro @-@ apoptotic gene Bax ( Figure 4e ) and PIG3 ( Supplementary Figure 4c ) .
(x2 / find-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / nucleic-acid
            :name (x4 / name :op1 "rna"))
      :ARG2 (x7 / or
            :op1 (x5 / enzyme
                  :name (x6 / name :op1 "HRAS")
                  :xref (x34 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
            :op2 (x8 / gene
                  :name (x9 / name :op1 "KRAS")
                  :ARG2-of (x10 / dampen-01)
                  :xref (x33 / xref :value "UNIPROT:RASK_HUMAN" :prob "1.003")))
      :ARG1 (x11 / capable-01
            :ARG1 (x12 / protein
                  :name (x13 / name :op1 "ASPP2")
                  :xref (x35 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :ARG2 (x14 / stimulate-01
                  :ARG1 (x15 / transactivate-01
                        :ARG1 (x16 / function-01
                              :ARG0 (x17 / protein
                                    :name (x18 / name :op1 "p53")
                                    :xref (x36 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))
                  :ARG2 (x19 / molecular-physical-entity
                        :ARG0-of (x20 / promote-02))
                  :ARG1 (x27 / and
                        :op1 (x23 / gene
                              :ARG0-of (x21 / favor-01
                                    :ARG1 (x22 / apoptosis))
                              :name (x24 / name :op1 "Bax")
                              :ARG1-of (x25 / describe-01
                                    :ARG0 (x26 / figure :mod "4e"))
                              :xref (x / xref :value "UNIPROT:A0A0C4MVT1_HUMAN" :prob "1.001"))
                        :op2 (x28 / protein
                              :name (x29 / name :op1 "PIG3"))
                        :ARG1-of (x30 / describe-01
                              :ARG0 (x32 / figure
                                    :ARG2-of (x31 / supplement-01)
                                    :mod "4c"))))))


# ::id PMC3595493.132
# ::snt All these support the notion that ASPP1 and ASPP2 cooperate with RAS to enhance the transcriptional activity of p53 for apoptotic genes.
# ::tok All these support the notion that ASPP1 and ASPP2 cooperate with RAS to enhance the transcriptional activity of p53 for apoptotic genes .
(x10 / cooperate-01
      :ARG0 (x3 / support-01
            :mod (x1 / all)
            :mod (x2 / this)
            :ARG1 (x4 / notion
                  :topic (x7 / and
                        :op1 (x5 / protein
                              :name (x6 / name :op1 "ASPP1")
                              :xref (x22 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                        :op2 (x8 / protein
                              :name (x9 / name :op1 "ASPP2")
                              :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))))
      :ARG1 (x11 / enzyme
            :name (x12 / name :op1 "RAS")
            :xref (x21 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
      :ARG2 (x19 / gene
            :ARG1-of (x13 / enhance-01
                  :ARG1 (x15 / activity-06
                        :ARG1 (x14 / transcribe-01)
                        :ARG0 (x16 / protein
                              :name (x17 / name :op1 "p53")
                              :xref (x20 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
                  :ARG2 (x18 / apoptosis))))


# ::id PMC3595493.133
# ::snt This cooperation is likely to be mediated by the identified interaction between active RAS and RAD of the ASPPs, which also explains why the RAD of the ASPPs is required for their full potential to enhance the transcriptional activity of p53.
# ::tok This cooperation is likely to be mediated by the identified interaction between active RAS and RAD of the ASPPs , which also explains why the RAD of the ASPPs is required for their full potential to enhance the transcriptional activity of p53 .
(x26 / enhance-01
      :ARG1 (x2 / cooperate-01
            :mod (x1 / this))
      :ARG1-of (x3 / likely-01
            :ARG1 (x4 / mediate-01
                  :ARG0 (x5 / identify-01
                        :ARG1 (x6 / interact-01
                              :ARG0 (x10 / and
                                    :op1 (x7 / enzyme
                                          :ARG1-of (x8 / activate-01)
                                          :name (x9 / name :op1 "RAS")
                                          :xref (x31 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                                    :op2 (x11 / enzyme
                                          :name (x12 / name :op1 "RAD")
                                          :xref (x33 / xref :value "UNIPROT:RAD_HUMAN" :prob "1.003")))))
                  :ARG1 (x13 / protein
                        :name (x14 / name :op1 "ASPPs")
                        :ARG0-of (x16 / explain-01
                              :mod (x15 / also)
                              :ARG1 (x17 / cause-01
                                    :ARG1 (x23 / require-01
                                          :ARG1 (x18 / enzyme
                                                :name (x19 / name :op1 "RAD")
                                                :ARG1-of (x20 / include-91
                                                      :ARG2 (x21 / protein-family
                                                            :name (x22 / name :op1 "ASPPs")))
                                                :xref (x32 / xref :value "UNIPROT:RAD_HUMAN" :prob "1.003"))
                                          :ARG0 (x25 / potential
                                                :ARG1-of (x24 / full-09)))))
                        :xref (x34 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "0.282"))))
      :ARG1 (x28 / activity-06
            :ARG1 (x27 / transcribe-01)
            :ARG0 (x29 / protein
                  :name (x30 / name :op1 "p53")
                  :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))


# ::id PMC3595493.134
# ::snt RAS oncogene enhances the apoptotic function of p53 via ASPP1 and ASPP2
# ::tok RAS oncogene enhances the apoptotic function of p53 via ASPP1 and ASPP2
(x6 / enhance-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "RAS")
            :ARG0-of (x3 / cause-01
                  :ARG1 (x4 / disease
                        :wiki "cancer"
                        :name (x5 / name :op1 "cancer")))
            :xref (x17 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
      :ARG1 (x7 / apoptosis)
      :ARG1 (x8 / function-01
            :ARG0 (x9 / protein
                  :name (x10 / name :op1 "p53")
                  :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
      :instrument (x13 / and
            :op1 (x11 / protein
                  :name (x12 / name :op1 "ASPP1")
                  :xref (x16 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
            :op2 (x14 / protein
                  :name (x15 / name :op1 "ASPP2")
                  :xref (x18 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))


# ::id PMC3595493.135
# ::snt The requirement of RAS activation to potentiate the pro-apoptotic function of ASPP1 and ASPP2 was tested in two human cancer cell lines with wild-type p53: MCF7 and U2OS.
# ::tok The requirement of RAS activation to potentiate the pro @-@ apoptotic function of ASPP1 and ASPP2 was tested in two human cancer cell lines with wild @-@ type p53: MCF7 and U2OS .
(x11 / and
      :op1 (x1 / require-01
            :ARG0 (x4 / activate-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "RAS")
                        :xref (x25 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
            :ARG1 (x5 / potentiate-01
                  :ARG1 (x8 / function-01
                        :ARG0-of (x6 / favor-01
                              :ARG1 (x7 / apoptosis))
                        :ARG0 (x9 / protein
                              :name (x10 / name :op1 "ASPP1")
                              :xref (x / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003")))))
      :op2 (x14 / test-01
            :ARG1 (x12 / protein
                  :name (x13 / name :op1 "ASPP2")
                  :xref (x26 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :location (x18 / cell-line
                  :quant "2"
                  :mod (x15 / human)
                  :mod (x16 / disease
                        :wiki "cancer"
                        :name (x17 / name :op1 "cancer")))
            :ARG2 (x22 / and
                  :op1 (x19 / enzyme
                        :mod (x20 / wild-type)
                        :name (x21 / name :op1 "p53:"))
                  :op2 (x23 / cell
                        :name (x24 / name :op1 "U2OS")))))


# ::id PMC3595493.136
# ::snt As published previously, increased expression of ASPP1 or ASPP2 induces p53-mediated apoptosis in both cell lines.
# ::tok As published previously , increased expression of ASPP1 or ASPP2 induces p53 @-@ mediated apoptosis in both cell lines .
(x10 / induce-01
      :ARG1-of (x1 / publish-01
            :time (x2 / previous))
      :ARG0 (x7 / or
            :op1 (x4 / express-03
                  :ARG1-of (x3 / increase-01)
                  :ARG2 (x5 / protein
                        :name (x6 / name :op1 "ASPP1")
                        :xref (x18 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003")))
            :op2 (x8 / protein
                  :name (x9 / name :op1 "ASPP2")
                  :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
      :ARG2 (x14 / apoptosis
            :ARG1-of (x13 / mediate-01
                  :ARG0 (x11 / protein
                        :name (x12 / name :op1 "p53")
                        :xref (x17 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
            :location (x16 / cell-line
                  :mod (x15 / both))))


# ::id PMC3595493.137
# ::snt 16 Using shRNAs to reduce the expression of endogenous HRAS or KRAS, we observed a reduction in the percentage of apoptosis in cells induced by ASPP1 or ASPP2 overexpression ( Figure 5a ).
# ::tok 16 Using shRNAs to reduce the expression of endogenous HRAS or KRAS , we observed a reduction in the percentage of apoptosis in cells induced by ASPP1 or ASPP2 overexpression ( Figure 5a ) .
(x16 / observe-01
      :time (x4 / use-01
            :ARG1-of (x1 / describe-01
                  :ARG0 (x2 / publication
                        :ARG1-of (x3 / cite-01 :ARG2 "16")))
            :ARG1 (x5 / nucleic-acid
                  :name (x6 / name :op1 "shrna"))
            :ARG2 (x7 / reduce-01
                  :ARG1 (x8 / express-03
                        :ARG2 (x12 / or
                              :op1 (x9 / enzyme
                                    :mod (x10 / endogenous)
                                    :name (x11 / name :op1 "HRAS")
                                    :xref (x31 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
                              :op2 (x13 / enzyme
                                    :name (x14 / name :op1 "KRAS")
                                    :xref (x32 / xref :value "UNIPROT:RASK_HUMAN" :prob "1.003"))))))
      :ARG0 (x15 / we)
      :ARG1 (x17 / reduce-01
            :ARG1 (x18 / percentage
                  :quant-of (x20 / cell
                        :mod (x19 / apoptosis)))
            :ARG2-of (x21 / induce-01
                  :ARG0 (x24 / or
                        :op1 (x22 / protein
                              :name (x23 / name :op1 "ASPP1")
                              :xref (x30 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                        :op2 (x27 / overexpress-01
                              :ARG1 (x25 / protein
                                    :name (x26 / name :op1 "ASPP2")
                                    :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))))
      :ARG1-of (x28 / describe-01
            :ARG0 (x29 / figure :mod "5a")))


# ::id PMC3595493.138
# ::snt These findings suggest that endogenous HRAS and KRAS are required for the full activities of ASPP1 and ASPP2.
# ::tok These findings suggest that endogenous HRAS and KRAS are required for the full activities of ASPP1 and ASPP2 .
(x4 / suggest-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG1-of (x3 / find-01))
      :ARG1 (x11 / require-01
            :ARG1 (x8 / and
                  :op1 (x5 / enzyme
                        :mod (x6 / endogenous)
                        :name (x7 / name :op1 "HRAS")
                        :xref (x21 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))
                  :op2 (x9 / gene
                        :name (x10 / name :op1 "KRAS")
                        :xref (x20 / xref :value "UNIPROT:RASK_HUMAN" :prob "1.003")))
            :ARG0 (x13 / activity-06
                  :ARG1-of (x12 / full-09)
                  :ARG0 (x16 / and
                        :op1 (x14 / protein
                              :name (x15 / name :op1 "ASPP1")
                              :xref (x19 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                        :op2 (x17 / protein
                              :name (x18 / name :op1 "ASPP2")
                              :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))))


# ::id PMC3595493.139
# ::snt To further confirm this, we used HKe3 ER:HRASV12 cells, in which RAS activation is induced upon the addition of 4-OHT.
# ::tok To further confirm this , we used HKe3 ER : HRASV12 cells , in which RAS activation is induced upon the addition of 4 @-@ OHT .
(x5 / use-01
      :purpose (x2 / confirm-01
            :degree (x1 / further)
            :ARG1 (x3 / this))
      :ARG0 (x4 / we)
      :ARG1 (x6 / protein
            :name (x7 / name :op1 "erα")
            :xref (x17 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
      :ARG2 (x13 / induce-01
            :ARG1 (x9 / cell-line
                  :name (x8 / name :op1 "HRASV12")
                  :location-of (x12 / activate-01
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
            :ARG2 (x14 / add-02
                  :ARG1 (x15 / small-molecule
                        :name (x16 / name :op1 "4-OHT")
                        :xref (x18 / xref :value "PUBCHEM:449459" :prob "9.856737")))))


# ::id PMC3595493.140
# ::snt Importantly, oncogenic RAS activation induced apoptosis in these cells indicated by the presence of cleaved-PARP ( Figure 5c ).
# ::tok Importantly , oncogenic RAS activation induced apoptosis in these cells indicated by the presence of cleaved @-@ PARP ( Figure 5c ) .
(x8 / induce-01
      :mod (x1 / important)
      :ARG0 (x7 / activate-01
            :ARG1 (x2 / enzyme
                  :ARG0-of (x3 / cause-01
                        :ARG1 (x4 / disease
                              :wiki "cancer"
                              :name (x5 / name :op1 "cancer")))
                  :name (x6 / name :op1 "RAS")
                  :xref (x19 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
      :ARG2 (x9 / apoptosis
            :location (x11 / cell
                  :mod (x10 / this)))
      :ARG1-of (x12 / indicate-01
            :ARG0 (x13 / present-02
                  :ARG1 (x14 / protein
                        :ARG1-of (x15 / cleave-01)
                        :name (x16 / name :op1 "PARP")
                        :xref (x / xref :value "UNIPROT:PARI_HUMAN" :prob "0.352"))))
      :ARG1-of (x17 / describe-01
            :ARG0 (x18 / figure :mod "5c")))


# ::id PMC3595493.141
# ::snt To test whether p53 has a role in mediating the observed RAS-induced apoptosis in HKe3 cells, RNAi against p53 was used.
# ::tok To test whether p53 has a role in mediating the observed RAS @-@ induced apoptosis in HKe3 cells , RNAi against p53 was used .
(x19 / use-01
      :purpose (x1 / test-01
            :ARG1 (x4 / have-03
                  :mode "interrogative"
                  :ARG0 (x2 / protein
                        :name (x3 / name :op1 "p53")
                        :xref (x21 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))
                  :ARG1 (x5 / role
                        :topic (x6 / mediate-01
                              :ARG1 (x7 / observe-01
                                    :ARG1 (x11 / apoptosis
                                          :ARG2-of (x10 / induce-01
                                                :ARG0 (x8 / enzyme
                                                      :name (x9 / name :op1 "RAS")
                                                      :xref (x20 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))))
                  :location (x13 / cell-line
                        :name (x12 / name :op1 "HKe3"))))
      :ARG0 (x14 / nucleic-acid
            :name (x15 / name :op1 "rna")
            :ARG0-of (x16 / counter-01
                  :ARG1 (x17 / enzyme
                        :name (x18 / name :op1 "p53")
                        :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))))


# ::id PMC3595493.142
# ::snt Depletion of p53 abolished RAS-induced apoptosis in these cells.
# ::tok Depletion of p53 abolished RAS @-@ induced apoptosis in these cells .
(x4 / abolish-01
      :ARG0 (x1 / deplete-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "p53")
                  :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
      :ARG1 (x7 / induce-01
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "RAS")
                  :xref (x11 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
            :ARG2 (x8 / apoptosis
                  :location (x10 / cell
                        :mod (x9 / this)))))


# ::id PMC3595493.143
# ::snt This is evident from a lack of PARP cleavage in these cells ( Figure 5d ).
# ::tok This is evident from a lack of PARP cleavage in these cells ( Figure 5d ) .
(x2 / evidence-01
      :ARG1 (x1 / this)
      :ARG0 (x3 / lack-01
            :ARG1 (x6 / cleave-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "PARP")
                        :xref (x / xref :value "UNIPROT:PARI_HUMAN" :prob "0.352"))
                  :location (x8 / cell
                        :mod (x7 / this))))
      :ARG1-of (x9 / describe-01
            :ARG0 (x10 / figure :mod "5d")))


# ::id PMC3595493.144
# ::snt RAS activation induces ASPP2 translocation and enhances p53 binding in colon cancer cells
# ::tok RAS activation induces ASPP2 translocation and enhances p53 binding in colon cancer cells
(x4 / induce-01
      :ARG0 (x3 / activate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "RAS")
                  :xref (x16 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
      :ARG2 (x8 / and
            :op1 (x7 / translocate-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "ASPP2")
                        :xref (x17 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
            :op2 (x9 / enhance-01
                  :ARG1 (x12 / bind-01
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "p53")
                              :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
                  :location (x15 / cell
                        :mod (x13 / disease
                              :wiki "colorectal_cancer"
                              :name (x14 / name :op1 "colon" :op2 "cancer"))))))


# ::id PMC3595493.145
# ::snt To understand how ASPP2 cooperates with p53 to induce apoptosis in cancer cells, we examined the cellular localisation of ASPP2 in HKe3 ER:HRASV12 cells upon RAS induction.
# ::tok To understand how ASPP2 cooperates with p53 to induce apoptosis in cancer cells , we examined the cellular localisation of ASPP2 in HKe3 ER : HRASV12 cells upon RAS induction .
(x14 / examine-01
      :purpose (x1 / understand-01
            :ARG1 (x2 / thing
                  :manner-of (x5 / cooperate-01
                        :ARG0 (x3 / protein
                              :name (x4 / name :op1 "ASPP2")
                              :xref (x27 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "p53")
                              :xref (x28 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))
            :ARG2 (x8 / induce-01
                  :ARG2 (x9 / apoptosis)
                  :location (x12 / cell
                        :mod (x10 / disease
                              :wiki "cancer"
                              :name (x11 / name :op1 "cancer")))))
      :ARG0 (x13 / we)
      :ARG1 (x16 / localize-01
            :ARG1 (x15 / cell)
            :ARG1 (x17 / protein
                  :name (x18 / name :op1 "ASPP2")
                  :xref (x30 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :location (x23 / cell
                  :part-of (x19 / protein
                        :name (x20 / name :op1 "erα")
                        :xref (x29 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
                  :mod (x21 / disease
                        :name (x22 / name :op1 "HRASV12")))
            :condition (x26 / induce-01
                  :ARG1 (x24 / enzyme
                        :name (x25 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))


# ::id PMC3595493.146
# ::snt We observed that endogenous ASPP2 translocates from cell/cell junctions to the cytosol/nucleus following RAS activation ( Figure 6a ).
# ::tok We observed that endogenous ASPP2 translocates from cell @/@ cell junctions to the cytosol @/@ nucleus following RAS activation ( Figure 6a ) .
(x2 / observe-01
      :ARG0 (x1 / we)
      :ARG1 (x10 / junction
            :mod (x3 / endogenous)
            :mod (x4 / protein
                  :name (x5 / name :op1 "ASPP2")
                  :xref (x19 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :mod (x6 / cell
                  :name (x7 / name :op1 "translocates")
                  :source (x8 / cell))
            :mod (x9 / cell)
            :location (x11 / cytosol
                  :xref (x20 / xref :value "GO:0005829" :prob "0.8"))
            :mod (x12 / nucleus
                  :xref (x21 / xref :value "GO:0005634" :prob "0.8")))
      :ARG1-of (x13 / follow-01
            :ARG2 (x16 / activate-01
                  :ARG1 (x14 / enzyme
                        :name (x15 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :ARG1-of (x17 / describe-01
                        :ARG0 (x18 / figure :mod "6a")))))


# ::id PMC3595493.147
# ::snt This is also confirmed by the detection of an increase in the expression levels of ASPP2 in the nuclear and cytoplasmic fractions in these cells upon RAS activation, with around two–three-folds increase in the level of nuclear and cytoplasmic ASPP2, respectively ( Figure 6b ).
# ::tok This is also confirmed by the detection of an increase in the expression levels of ASPP2 in the nuclear and cytoplasmic fractions in these cells upon RAS activation , with around two–three @-@ folds increase in the level of nuclear and cytoplasmic ASPP2 , respectively ( Figure 6b ) .
(x1 / multi-sentence
      :snt1 (x4 / confirm-01
            :ARG1 (x2 / this)
            :mod (x3 / also)
            :ARG0 (x5 / detect-01
                  :ARG1 (x6 / increase-01
                        :ARG1 (x7 / level
                              :degree-of (x8 / express-03
                                    :ARG2 (x9 / protein
                                          :name (x10 / name :op1 "ASPP2")
                                          :xref (x32 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
                        :location (x12 / and
                              :op1 (x11 / nucleus
                                    :xref (x36 / xref :value "GO:0005634" :prob "0.8"))
                              :op2 (x14 / fraction
                                    :part-of (x13 / cytoplasm
                                          :xref (x37 / xref :value "GO:0005737" :prob "0.8"))))
                        :location (x16 / cell
                              :mod (x15 / this))
                        :time (x19 / activate-01
                              :ARG1 (x17 / enzyme
                                    :name (x18 / name :op1 "RAS")
                                    :xref (x33 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
                  :ARG2 (x20 / around)))
      :snt2 (x24 / increase-01
            :ARG0 (x23 / fold-03
                  :ARG1 (x21 / enzyme
                        :name (x22 / name :op1 "two–three")))
            :ARG1 (x25 / level
                  :quant-of (x26 / enzyme
                        :mod (x27 / nucleus
                              :xref (x35 / xref :value "GO:0005634" :prob "0.8"))
                        :mod (x28 / cytoplasm
                              :xref (x34 / xref :value "GO:0005737" :prob "0.8"))
                        :name (x29 / name :op1 "ASPP2")
                        :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
            :ARG1-of (x30 / describe-01
                  :ARG0 (x31 / figure :mod "6b"))))


# ::id PMC3595493.148
# ::snt Moreover, we also detected an increase in the amount of p53–ASPP2 complex in these cells following RAS activation ( Figure 6c ).
# ::tok Moreover , we also detected an increase in the amount of p53–ASPP2 complex in these cells following RAS activation ( Figure 6c ) .
(x1 / and
      :op2 (x4 / detect-01
            :ARG0 (x2 / we)
            :mod (x3 / also)
            :ARG1 (x5 / increase-01
                  :ARG1 (x6 / amount
                        :quant-of (x8 / macro-molecular-complex
                              :name (x7 / name :op1 "p53–ASPP2"))))
            :location (x10 / cell
                  :mod (x9 / this))
            :ARG1-of (x11 / follow-01
                  :ARG2 (x14 / activate-01
                        :ARG1 (x12 / enzyme
                              :name (x13 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / figure :mod "6c")))


# ::id PMC3595493.149
# ::snt To test whether endogenous ASPP2 mediates the observed RAS-induced apoptosis in HKe3 cells, ASPP2 RNAi was used.
# ::tok To test whether endogenous ASPP2 mediates the observed RAS @-@ induced apoptosis in HKe3 cells , ASPP2 RNAi was used .
(x17 / use-01
      :purpose (x1 / test-01
            :ARG1 (x5 / mediate-01
                  :mode "interrogative"
                  :ARG0 (x2 / enzyme
                        :mod (x3 / endogenous)
                        :name (x4 / name :op1 "ASPP2")
                        :xref (x18 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                  :ARG1 (x6 / observe-01
                        :ARG1 (x10 / apoptosis
                              :ARG2-of (x9 / induce-01
                                    :ARG0 (x7 / enzyme
                                          :name (x8 / name :op1 "RAS")
                                          :xref (x19 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))
                  :location (x12 / cell-line
                        :name (x11 / name :op1 "HKe3"))))
      :ARG0 (x13 / protein
            :name (x14 / name :op1 "ASPP2")
            :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
      :ARG1 (x15 / nucleic-acid
            :name (x16 / name :op1 "rna")))


# ::id PMC3595493.150
# ::snt ASPP2 knockdown abolished RAS-induced apoptosis indicated by a lack of PARP cleavage ( Figure 6d ).
# ::tok ASPP2 knockdown abolished RAS @-@ induced apoptosis indicated by a lack of PARP cleavage ( Figure 6d ) .
(x4 / abolish-01
      :ARG0 (x3 / knock-down-02
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "ASPP2")
                  :xref (x16 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
      :ARG1 (x8 / apoptosis
            :ARG2-of (x7 / induce-01
                  :ARG0 (x5 / enzyme
                        :name (x6 / name :op1 "RAS")
                        :xref (x17 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
      :ARG1-of (x9 / indicate-01
            :ARG0 (x10 / lack-01
                  :ARG1 (x13 / cleave-01
                        :ARG1 (x11 / protein
                              :name (x12 / name :op1 "PARP")
                              :xref (x / xref :value "UNIPROT:PARI_HUMAN" :prob "0.352"))
                        :ARG1-of (x14 / describe-01
                              :ARG0 (x15 / figure :mod "6d"))))))


# ::id PMC3595493.151
# ::snt These data identify ASPP2 as an important mediator of oncogenic RAS-induced apoptosis.
# ::tok These data identify ASPP2 as an important mediator of oncogenic RAS @-@ induced apoptosis .
(x3 / identify-01
      :ARG0 (x2 / data
            :mod (x1 / this))
      :ARG1 (x4 / protein
            :name (x5 / name :op1 "ASPP2")
            :xref (x15 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
      :ARG2 (x7 / mediate-01
            :mod (x6 / important)
            :ARG1 (x14 / apoptosis
                  :ARG2-of (x13 / induce-01
                        :ARG0 (x8 / enzyme
                              :ARG0-of (x9 / cause-01
                                    :ARG1 (x10 / disease
                                          :wiki "cancer"
                                          :name (x11 / name :op1 "cancer")))
                              :name (x12 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))))


# ::id PMC3595493.152
# ::snt This may be achieved via the ability of the active RAS to induce the cellular translocation of ASPP2, and enhance the ability of ASPP2 to bind p53 and to enhance its activity.
# ::tok This may be achieved via the ability of the active RAS to induce the cellular translocation of ASPP2 , and enhance the ability of ASPP2 to bind p53 and to enhance its activity .
(x1 / possible-01
      :ARG1 (x3 / achieve-01
            :ARG1 (x2 / this)
            :manner (x21 / and
                  :op1 (x4 / capable-01
                        :ARG1 (x5 / enzyme
                              :ARG0-of (x6 / activity-06)
                              :name (x7 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                        :ARG2 (x8 / induce-01
                              :ARG2 (x13 / and
                                    :op1 (x10 / translocate-01
                                          :ARG2 (x9 / cell)
                                          :ARG1 (x11 / protein
                                                :name (x12 / name :op1 "ASPP2")
                                                :xref (x25 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
                                    :op2 (x14 / enhance-01
                                          :ARG1 (x15 / capable-01
                                                :ARG1 (x16 / protein
                                                      :name (x17 / name :op1 "ASPP2")
                                                      :xref (x26 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
                                                :ARG2 (x18 / bind-01
                                                      :ARG2 (x19 / protein
                                                            :name (x20 / name :op1 "p53")
                                                            :xref (x24 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))))))
                  :op2 (x22 / enhance-01
                        :ARG1 (x23 / activity-06)))))


# ::id PMC3595493.199
# ::snt RAS GDP/GTP loading
# ::tok RAS GDP @/@ GTP loading
(x1 / enzyme
      :name (x2 / name :op1 "RAS")
      :ARG1-of (x7 / load-01
            :ARG2 (x3 / small-molecule
                  :name (x4 / name :op1 "GDP")
                  :xref (x8 / xref :value "PUBCHEM:8977" :prob "14.712257"))
            :ARG1 (x5 / small-molecule
                  :name (x6 / name :op1 "GTP")
                  :xref (x9 / xref :value "PUBCHEM:6830" :prob "15.470645")))
      :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))


# ::id PMC3595493.208
# ::snt Active RAS pull-down assay
# ::tok Active RAS pull @-@ down assay
(x6 / assay-01
      :ARG1 (x1 / enzyme
            :ARG0-of (x2 / activity-06)
            :name (x3 / name :op1 "RAS")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
      :ARG0 (x4 / enzyme
            :name (x5 / name :op1 "gst")
            :xref (x7 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "0.602")))


# ::id PMC3595493.269
# ::snt ASPP1 and ASPP2 preferentially bind active RAS.
# ::tok ASPP1 and ASPP2 preferentially bind active RAS .
(x7 / bind-01
      :ARG1 (x6 / prefer-01
            :ARG1 (x3 / and
                  :op1 (x1 / protein
                        :name (x2 / name :op1 "ASPP1")
                        :xref (x11 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                  :op2 (x4 / protein
                        :name (x5 / name :op1 "ASPP2")
                        :xref (x12 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
      :ARG2 (x8 / enzyme
            :ARG0-of (x9 / activity-06)
            :name (x10 / name :op1 "RAS")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))


# ::id PMC3595493.273
# ::snt Values are shown as a bar graph.
# ::tok Values are shown as a bar graph .
(x2 / show-01
      :ARG1 (x1 / value)
      :manner (x4 / graph
            :mod (x3 / bar)))


# ::id PMC3595493.274
# ::snt Standard deviation represents the mean of three independent experiments.
# ::tok Standard deviation represents the mean of three independent experiments .
(x2 / deviate-01
      :ARG1-of (x1 / standard-02)
      :ARG1 (x3 / represent-01
            :ARG2 (x4 / mean
                  :poss (x6 / experiment-01
                        :quant "3"
                        :ARG0-of (x5 / depend-01 :polarity "-")))))


# ::id PMC3595493.275
# ::snt HKe3 ER:HRASV12 cells were treated with 100 nM 4-OHT for 2 days and Raf-1–RBD agarose pull-down assays were performed to pull down GTP-bound active RAS.
# ::tok HKe3 ER : HRASV12 cells were treated with 100 nM 4 @-@ OHT for 2 days and Raf @-@ 1–RBD agarose pull @-@ down assays were performed to pull down GTP @-@ bound active RAS .
(x21 / perform-02
      :ARG0 (x13 / and
            :op1 (x6 / treat-04
                  :ARG1 (x5 / cell
                        :part-of (x1 / protein
                              :name (x2 / name :op1 "erα")
                              :xref (x29 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
                        :mod (x3 / disease
                              :name (x4 / name :op1 "HRASV12")))
                  :ARG2 (x7 / small-molecule
                        :quant (x8 / concentration-quantity
                              :quant "100"
                              :unit (x9 / nanomolar))
                        :name (x10 / name :op1 "4-OHT")
                        :xref (x33 / xref :value "PUBCHEM:449459" :prob "9.856737"))
                  :duration (x11 / temporal-quantity
                        :quant "2"
                        :unit (x12 / day)))
            :op2 (x17 / agarose
                  :mod (x14 / enzyme
                        :name (x15 / name :op1 "Raf")
                        :xref (x31 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
                  :name (x16 / name :op1 "1–RBD")))
      :ARG1 (x20 / assay-01
            :ARG1 (x18 / enzyme
                  :name (x19 / name :op1 "gst")
                  :xref (x30 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "0.602")))
      :purpose (x22 / pull-down-08
            :ARG1 (x25 / bind-01
                  :ARG2 (x23 / small-molecule
                        :name (x24 / name :op1 "GTP")
                        :xref (x32 / xref :value "PUBCHEM:6830" :prob "15.470645")))
            :ARG2 (x26 / enzyme
                  :ARG0-of (x27 / activity-06)
                  :name (x28 / name :op1 "RAS")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))


# ::id PMC3595493.279
# ::snt The ASPP proteins were detected with mAbASPP1.54.1, which is known to crossreact with both ASPP1 and ASPP2
# ::tok The ASPP proteins were detected with mAbASPP1.54.1 , which is known to crossreact with both ASPP1 and ASPP2
(x13 / and
      :op1 (x4 / detect-01
            :ARG1 (x3 / protein
                  :mod (x1 / protein
                        :name (x2 / name :op1 "ASPP")
                        :xref (x17 / xref :value "UNIPROT:A1CF_HUMAN" :prob "0.342")))
            :ARG2 (x5 / protein
                  :name (x6 / name :op1 "mAbASPP1.54.1")
                  :ARG1-of (x7 / know-02
                        :ARG2 (x10 / and
                              :op1 (x8 / small-molecule
                                    :name (x9 / name :op1 "crossreact"))
                              :op2 (x11 / protein
                                    :name (x12 / name :op1 "ASPP1")
                                    :xref (x16 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))))))
      :op2 (x14 / protein
            :name (x15 / name :op1 "ASPP2")
            :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))


# ::id PMC3595493.280
# ::snt ASPP2 colocalises with and contributes to RAS activation at the cell membrane.
# ::tok ASPP2 colocalises with and contributes to RAS activation at the cell membrane .
(x6 / and
      :op1 (x5 / treat-04
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "ASPP2")
                  :xref (x13 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :ARG2 (x3 / small-molecule
                  :name (x4 / name :op1 "colocalises")))
      :op2 (x7 / contribute-01
            :ARG2 (x10 / activate-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :location (x12 / membrane
                        :part-of (x11 / cell)
                        :xref (x14 / xref :value "GO:0016020" :prob "0.8")))))


# ::id PMC3595493.281
# ::snt Arrows indicate cell membrane.
# ::tok Arrows indicate cell membrane .
(x2 / indicate-01
      :ARG0 (x1 / arrow)
      :ARG1 (x4 / membrane
            :mod (x3 / cell)
            :xref (x / xref :value "GO:0016020" :prob "0.8")))


# ::id PMC3595493.282
# ::snt Cells were treated with 1 μ g/ml insulin for 15 min.
# ::tok Cells were treated with 1 μ g/ml insulin for 15 min .
(x2 / treat-04
      :ARG1 (x1 / cell)
      :ARG2 (x3 / small-molecule
            :quant (x4 / concentration-quantity
                  :quant "1"
                  :unit (x5 / micromolar
                        :name (x6 / name :op1 "g/ml")))
            :name (x7 / name :op1 "insulin")
            :xref (x / xref :value "PUBCHEM:70678557" :prob "15.003454"))
      :duration (x8 / temporal-quantity
            :quant "15"
            :unit (x9 / minute)))


# ::id PMC3595493.283
# ::snt Arrows indicate cell membrane
# ::tok Arrows indicate cell membrane
(x2 / indicate-01
      :ARG0 (x1 / arrow)
      :ARG1 (x4 / membrane
            :mod (x3 / cell)
            :xref (x / xref :value "GO:0016020" :prob "0.8")))


# ::id PMC3595493.284
# ::snt ASPP2's N-terminus is required and is sufficient to potentiate RAS signalling.
# ::tok ASPP2 's N @-@ terminus is required and is sufficient to potentiate RAS signalling .
(x1 / and
      :op1 (x6 / require-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "ASPP2")
                  :xref (x12 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))
            :ARG1 (x4 / protein-segment
                  :name (x5 / name :op1 "N-terminus")))
      :op2 (x7 / suffice-01
            :ARG1 (x8 / potentiate-01
                  :ARG1 (x11 / signal-07
                        :ARG0 (x9 / enzyme
                              :name (x10 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))))


# ::id PMC3595493.285
# ::snt The activation status of ERK or AKT was determined by western blots.
# ::tok The activation status of ERK or AKT was determined by western blots .
(x8 / determine-01
      :ARG1 (x1 / status
            :mod (x2 / activate-01
                  :ARG1 (x5 / or
                        :op1 (x3 / enzyme
                              :name (x4 / name :op1 "ERK")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                        :op2 (x6 / enzyme
                              :name (x7 / name :op1 "AKT")
                              :xref (x10 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))
      :ARG0 (x9 / immunoblot-01))


# ::id PMC3595493.286
# ::snt GAPDH was used as a loading control.
# ::tok GAPDH was used as a loading control .
(x3 / use-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "GAPDH")
            :xref (x / xref :value "UNIPROT:G3P_HUMAN" :prob "1.002"))
      :ARG2 (x5 / control-01
            :ARG1 (x4 / load-01)))


# ::id PMC3595493.287
# ::snt The activation status of ERK or AKT was determined by western blot analysis.
# ::tok The activation status of ERK or AKT was determined by western blot analysis .
(x8 / determine-01
      :ARG1 (x1 / status
            :mod (x2 / activate-01
                  :ARG1 (x5 / or
                        :op1 (x3 / enzyme
                              :name (x4 / name :op1 "ERK")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                        :op2 (x6 / enzyme
                              :name (x7 / name :op1 "AKT")
                              :xref (x11 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.263")))))
      :manner (x10 / analyze-01
            :manner (x9 / immunoblot-01)))


# ::id PMC3595493.288
# ::snt ASPP1 and ASPP2 cooperates with RAS to enhance the transcriptional activity of p53.
# ::tok ASPP1 and ASPP2 cooperates with RAS to enhance the transcriptional activity of p53 .
(x6 / cooperate-01
      :ARG0 (x3 / and
            :op1 (x1 / protein
                  :name (x2 / name :op1 "ASPP1")
                  :xref (x14 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
            :op2 (x4 / protein
                  :name (x5 / name :op1 "ASPP2")
                  :xref (x16 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
      :ARG1 (x7 / enzyme
            :name (x8 / name :op1 "RAS")
            :xref (x15 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
      :ARG2 (x9 / enhance-01
            :ARG1 (x11 / activity-06
                  :ARG1 (x10 / transcribe-01)
                  :ARG0 (x12 / protein
                        :name (x13 / name :op1 "p53")
                        :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))))


# ::id PMC3595493.289
# ::snt The expression of the proteins was verified by western blot (upper left panel).
# ::tok The expression of the proteins was verified by western blot ( upper left panel ) .
(x3 / verify-01
      :ARG1 (x1 / express-03
            :ARG2 (x2 / protein))
      :manner (x4 / immunoblot-01)
      :ARG1-of (x5 / describe-01
            :ARG0 (x8 / panel
                  :ARG1-of (x7 / left-20
                        :mod (x6 / upper)))))


# ::id PMC3595493.291
# ::snt The value of ASPP2+p53 was taken as 1.0 to reflect the fold increase.
# ::tok The value of ASPP2+p53 was taken as 1.0 to reflect the fold increase .
(x9 / increase-01
      :ARG1 (x1 / value-01
            :ARG1 (x4 / take-04
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "ASPP2+p53")
                        :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "0.282"))
                  :ARG2 (x5 / enzyme
                        :name (x6 / name :op1 "1.0")
                        :ARG1-of (x7 / reflect-01))))
      :ARG2 (x8 / product-of))


# ::id PMC3595493.293
# ::snt RAS oncogene enhances the apoptotic function of p53 via ASPP1 and ASPP2.
# ::tok RAS oncogene enhances the apoptotic function of p53 via ASPP1 and ASPP2 .
(x6 / enhance-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "RAS")
            :ARG0-of (x3 / cause-01
                  :ARG1 (x4 / disease
                        :wiki "cancer"
                        :name (x5 / name :op1 "cancer")))
            :xref (x17 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
      :ARG1 (x7 / apoptosis)
      :ARG1 (x8 / function-01
            :ARG0 (x9 / protein
                  :name (x10 / name :op1 "p53")
                  :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
      :instrument (x13 / and
            :op1 (x11 / protein
                  :name (x12 / name :op1 "ASPP1")
                  :xref (x16 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
            :op2 (x14 / protein
                  :name (x15 / name :op1 "ASPP2")
                  :xref (x18 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))


# ::id PMC3595493.294
# ::snt shRNA against HRAS or KRAS was co-transfected with ASPP1 or ASPP2 in U2OS or MCF7 cells.
# ::tok shRNA against HRAS or KRAS was co @-@ transfected with ASPP1 or ASPP2 in U2OS or MCF7 cells .
(x9 / be-located-at-91
      :ARG1 (x6 / or
            :op1 (x1 / nucleic-acid
                  :name (x2 / name :op1 "shRNA")
                  :ARG0-of (x3 / counter-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "HRAS")
                              :xref (x23 / xref :value "UNIPROT:RASH_HUMAN" :prob "1.003"))))
            :op2 (x7 / enzyme
                  :name (x8 / name :op1 "KRAS")
                  :xref (x22 / xref :value "UNIPROT:RASK_HUMAN" :prob "1.003")))
      :ARG2 (x10 / transfect-01
            :ARG2 (x13 / or
                  :op1 (x11 / protein
                        :name (x12 / name :op1 "ASPP1")
                        :xref (x21 / xref :value "UNIPROT:ASPP1_HUMAN" :prob "1.003"))
                  :op2 (x14 / protein
                        :name (x15 / name :op1 "ASPP2")
                        :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))
      :location (x18 / or
            :op1 (x16 / cell
                  :name (x17 / name :op1 "U2OS"))
            :op2 (x20 / cell-line
                  :name (x19 / name :op1 "MCF7"))))


# ::id PMC3595493.295
# ::snt FACS analysis was used to determine apoptotic cells.
# ::tok FACS analysis was used to determine apoptotic cells .
(x4 / use-01
      :ARG1 (x3 / analyze-01
            :mod (x1 / thing
                  :name (x2 / name :op1 "FACS")))
      :purpose (x5 / determine-01
            :ARG1 (x7 / cell
                  :mod (x6 / apoptotic))))


# ::id PMC3595493.296
# ::snt PCNA was used as a loading control.
# ::tok PCNA was used as a loading control .
(x3 / use-01
      :ARG1 (x1 / protein
            :name (x2 / name :op1 "PCNA"))
      :ARG2 (x5 / control-01
            :ARG1 (x4 / load-01)))


# ::id PMC3595493.297
# ::snt HKe3 ER:HRASV12 cells were treated with 4-OHT (100 nM) for the indicated time.
# ::tok HKe3 ER : HRASV12 cells were treated with 4 @-@ OHT ( 100 nM ) for the indicated time .
(x5 / treat-04
      :ARG2 (x1 / protein
            :name (x2 / name :op1 "erα")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
      :ARG1 (x4 / cell-line
            :name (x3 / name :op1 "HRASV12"))
      :ARG2 (x6 / and
            :op1 (x7 / small-molecule
                  :name (x8 / name :op1 "4-OHT")
                  :xref (x13 / xref :value "PUBCHEM:449459" :prob "9.856737"))
            :ARG1-of (x9 / concentration-quantity
                  :quant "100"
                  :unit (x10 / nanomolar)))
      :duration (x12 / time
            :ARG1-of (x11 / indicate-01)))


# ::id PMC3595493.298
# ::snt Western blot showing expression levels of cleaved PARP and ASPP2.
# ::tok Western blot showing expression levels of cleaved PARP and ASPP2 .
(x2 / show-01
      :ARG0 (x1 / immunoblot-01)
      :ARG1 (x8 / and
            :op1 (x3 / level
                  :degree-of (x4 / express-03
                        :ARG2 (x5 / protein
                              :ARG1-of (x6 / cleave-01)
                              :name (x7 / name :op1 "PARP")
                              :xref (x11 / xref :value "UNIPROT:PARI_HUMAN" :prob "0.352"))))
            :op2 (x9 / protein
                  :name (x10 / name :op1 "ASPP2")
                  :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))


# ::id PMC3595493.299
# ::snt HKe3 ER:HRASV12 cells transfected with control siRNA or siRNA against p53 for 3 days were treated with or without 4-OHT (100 nM) for another day.
# ::tok HKe3 ER : HRASV12 cells transfected with control siRNA or siRNA against p53 for 3 days were treated with or without 4 @-@ OHT ( 100 nM ) for another day .
(x1 / and
      :op1 (x2 / protein
            :name (x3 / name :op1 "erα")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
      :op2 (x17 / treat-04
            :ARG1 (x4 / cell
                  :ARG1-of (x5 / transfect-01
                        :ARG2 (x6 / control-01
                              :ARG1 (x9 / or
                                    :op1 (x7 / enzyme
                                          :name (x8 / name :op1 "siRNA")
                                          :xref (x26 / xref :value "UNIPROT:SHPS1_HUMAN" :prob "0.212"))
                                    :op2 (x10 / nucleic-acid
                                          :name (x11 / name :op1 "siRNA")
                                          :ARG0-of (x12 / counter-01
                                                :ARG1 (x13 / protein
                                                      :name (x14 / name :op1 "p53")
                                                      :xref (x27 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))))
                              :duration (x15 / temporal-quantity
                                    :quant "3"
                                    :unit (x16 / day)))))
            :ARG2 (x18 / or
                  :op2 (x19 / small-molecule
                        :name (x20 / name :op1 "4-OHT")
                        :xref (x28 / xref :value "PUBCHEM:449459" :prob "9.856737"))
                  :ARG1-of (x21 / small-molecule
                        :quant (x22 / concentration-quantity
                              :quant "100"
                              :unit (x23 / nanomolar))
                        :mod (x25 / day
                              :mod (x24 / another))))))


# ::id PMC3595493.300
# ::snt Western blots showing expression levels of cleaved PARP and p53
# ::tok Western blots showing expression levels of cleaved PARP and p53
(x2 / show-01
      :ARG0 (x1 / immunoblot-01)
      :ARG1 (x3 / level
            :degree-of (x4 / express-03
                  :ARG2 (x8 / and
                        :op1 (x5 / protein
                              :ARG1-of (x6 / cleave-01)
                              :name (x7 / name :op1 "PARP")
                              :xref (x11 / xref :value "UNIPROT:PARI_HUMAN" :prob "0.352"))
                        :op2 (x9 / protein
                              :name (x10 / name :op1 "p53")
                              :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001"))))))


# ::id PMC3595493.301
# ::snt RAS activation induces ASPP2 translocation and enhances p53 binding in colon cancer cells.
# ::tok RAS activation induces ASPP2 translocation and enhances p53 binding in colon cancer cells .
(x4 / induce-01
      :ARG0 (x3 / activate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "RAS")
                  :xref (x16 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
      :ARG2 (x8 / and
            :op1 (x7 / translocate-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "ASPP2")
                        :xref (x17 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
            :op2 (x9 / enhance-01
                  :ARG1 (x12 / bind-01
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "p53")
                              :xref (x / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
                  :location (x15 / cell
                        :mod (x13 / disease
                              :wiki "colorectal_cancer"
                              :name (x14 / name :op1 "colon" :op2 "cancer"))))))


# ::id PMC3595493.302
# ::snt Immunofluorescence staining of ASPP2 in HKe3 ER:HRASV12 cells treated without (control) or with 100 nM 4-OHT for 3 days.
# ::tok Immunofluorescence staining of ASPP2 in HKe3 ER : HRASV12 cells treated without ( control ) or with 100 nM 4 @-@ OHT for 3 days .
(x10 / treat-04
      :ARG1 (x2 / stain-01
            :ARG2 (x1 / immunofluoresce-01)
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "ASPP2")
                  :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
      :location (x9 / cell
            :part-of (x5 / protein
                  :name (x6 / name :op1 "erα")
                  :xref (x19 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
            :mod (x7 / disease
                  :name (x8 / name :op1 "HRASV12")))
      :manner (x12 / or
            :op1 (x11 / contrast-01)
            :op2 (x13 / small-molecule
                  :quant (x14 / concentration-quantity
                        :quant "100"
                        :unit (x15 / nanomolar))
                  :name (x16 / name :op1 "4-OHT")
                  :xref (x20 / xref :value "PUBCHEM:449459" :prob "9.856737")))
      :duration (x17 / temporal-quantity
            :quant "3"
            :unit (x18 / day)))


# ::id PMC3595493.303
# ::snt Cytoplasmic and nuclear fractions in HKe3 ER:HRASV12 cells with indicated treatments were isolated.
# ::tok Cytoplasmic and nuclear fractions in HKe3 ER : HRASV12 cells with indicated treatments were isolated .
(x2 / and
      :op1 (x1 / cytoplasm
            :xref (x13 / xref :value "GO:0005737" :prob "0.8"))
      :op2 (x4 / fraction
            :mod (x3 / nucleus
                  :xref (x12 / xref :value "GO:0005634" :prob "0.8"))
            :part-of (x5 / protein
                  :name (x6 / name :op1 "erα")
                  :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593")))
      :op2 (x8 / cell
            :name (x7 / name :op1 "HRASV12")
            :ARG0-of (x9 / indicate-01
                  :ARG1 (x11 / isolate-01
                        :ARG1 (x10 / treat-04)))))


# ::id PMC3595493.304
# ::snt GAPDH was used as a loading control for the cytoplasmic fraction, whereas Lamin B was used as a loading control for the nuclear fraction.
# ::tok GAPDH was used as a loading control for the cytoplasmic fraction , whereas Lamin B was used as a loading control for the nuclear fraction .
(x8 / contrast-01
      :ARG1 (x3 / use-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "GAPDH")
                  :xref (x / xref :value "UNIPROT:G3P_HUMAN" :prob "1.002"))
            :ARG2 (x5 / control-01
                  :ARG1 (x4 / load-01))
            :purpose (x7 / fraction
                  :part-of (x6 / cytoplasm
                        :xref (x17 / xref :value "GO:0005737" :prob "0.8"))))
      :ARG2 (x11 / use-01
            :ARG1 (x9 / protein
                  :name (x10 / name :op1 "Lamin" :op2 "B"))
            :ARG2 (x13 / control-01
                  :ARG1 (x12 / load-01))
            :ARG0 (x15 / fraction
                  :mod (x14 / nucleus
                        :xref (x16 / xref :value "GO:0005634" :prob "0.8")))))


# ::id PMC3595493.305
# ::snt The levels of ASPP2 and p53 were calculated by densitometry.
# ::tok The levels of ASPP2 and p53 were calculated by densitometry .
(x7 / calculate-01
      :ARG1 (x4 / and
            :op1 (x1 / level
                  :quant-of (x2 / protein
                        :name (x3 / name :op1 "ASPP2")
                        :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))
            :op2 (x5 / protein
                  :name (x6 / name :op1 "p53")
                  :xref (x9 / xref :value "UNIPROT:A0A0C4KX50_HUMAN" :prob "1.001")))
      :ARG0 (x8 / densitometry))


# ::id PMC3595493.306
# ::snt Fold increase was calculated by normalising control group.
# ::tok Fold increase was calculated by normalising control group .
(x2 / increase-01
      :ARG2 (x1 / product-of)
      :ARG1 (x7 / group
            :mod (x6 / control-01
                  :ARG1-of (x3 / calculate-01
                        :ARG0 (x4 / small-molecule
                              :name (x5 / name :op1 "normalising"))))))


# ::id PMC3595493.308
# ::snt HKe3 ER:HRASV12 cells transfected with control siRNA or siRNA against ASPP2 for 3 days were treated with or without 4-OHT (100 nM) for another day.
# ::tok HKe3 ER : HRASV12 cells transfected with control siRNA or siRNA against ASPP2 for 3 days were treated with or without 4 @-@ OHT ( 100 nM ) for another day .
(x1 / and
      :op1 (x2 / protein
            :name (x3 / name :op1 "erα")
            :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
      :op2 (x17 / treat-04
            :ARG1 (x4 / cell
                  :ARG1-of (x5 / transfect-01
                        :ARG2 (x6 / control-01
                              :ARG1 (x9 / or
                                    :op1 (x7 / enzyme
                                          :name (x8 / name :op1 "siRNA")
                                          :xref (x26 / xref :value "UNIPROT:SHPS1_HUMAN" :prob "0.212"))
                                    :op2 (x10 / nucleic-acid
                                          :name (x11 / name :op1 "siRNA")
                                          :ARG0-of (x12 / counter-01
                                                :ARG1 (x13 / protein
                                                      :name (x14 / name :op1 "ASPP2")
                                                      :xref (x27 / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003")))))
                              :duration (x15 / temporal-quantity
                                    :quant "3"
                                    :unit (x16 / day)))))
            :ARG2 (x18 / or
                  :op2 (x19 / small-molecule
                        :name (x20 / name :op1 "4-OHT")
                        :xref (x28 / xref :value "PUBCHEM:449459" :prob "9.856737"))
                  :ARG1-of (x21 / small-molecule
                        :quant (x22 / concentration-quantity
                              :quant "100"
                              :unit (x23 / nanomolar))
                        :mod (x25 / day
                              :mod (x24 / another))))))


# ::id PMC3595493.309
# ::snt Western blots showing expression levels of cleaved PARP and ASPP2.
# ::tok Western blots showing expression levels of cleaved PARP and ASPP2 .
(x2 / show-01
      :ARG0 (x1 / immunoblot-01)
      :ARG1 (x8 / and
            :op1 (x3 / level
                  :degree-of (x4 / express-03
                        :ARG2 (x5 / protein
                              :ARG1-of (x6 / cleave-01)
                              :name (x7 / name :op1 "PARP")
                              :xref (x11 / xref :value "UNIPROT:PARI_HUMAN" :prob "0.352"))))
            :op2 (x9 / protein
                  :name (x10 / name :op1 "ASPP2")
                  :xref (x / xref :value "UNIPROT:ASPP2_HUMAN" :prob "1.003"))))


# ::id PMC4052680.0
# ::snt Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells
# ::tok Phosphorylation by Akt within the ST loop of AMPK-α1 down @-@ regulates its activation in tumour cells
(x8 / downregulate-01
      :ARG0 (x1 / phosphorylate-01
            :ARG2 (x2 / enzyme
                  :name (x3 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :location (x5 / loop-01
                  :mod (x4 / st)
                  :mod (x6 / enzyme
                        :name (x7 / name :op1 "AMPK-α1")
                        :xref (x12 / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662"))))
      :ARG1 (x9 / activate-01
            :location (x11 / cell
                  :mod (x10 / tumor))))


# ::id PMC4052680.2
# ::snt The insulin/IGF-1 (insulin-like growth factor 1)-activated protein kinase Akt (also known as protein kinase B) phosphorylates Ser 487 in the ‘ST loop’ (serine/threonine-rich loop) within the C-terminal domain of AMPK-α1 (AMP-activated protein kinase-α1), leading to inhibition of phosphorylation by upstream kinases at the activating site, Thr 172 .
# ::tok The insulin @/@ IGF @-@ 1 ( insulin @-@ like growth factor 1 ) -activated protein kinase Akt ( also known as protein kinase B ) phosphorylates Ser 487 in the ‘ST loop’ ( serine/threonine @-@ rich loop ) within the C @-@ terminal domain of AMPK-α1 ( AMP @-@ activated protein kinase-α1 ) , leading to inhibition of phosphorylation by upstream kinases at the activating site , Thr 172 .
(x1 / multi-sentence
      :snt1 (x4 / slash
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "insulin")
                  :xref (x41 / xref :value "UNIPROT:INS_HUMAN" :prob "0.703"))
            :op2 (x5 / enzyme
                  :name (x6 / name :op1 "IGF-1")
                  :xref (x42 / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))
            :ARG1-of (x17 / phosphorylate-01
                  :ARG0 (x7 / protein
                        :name (x8 / name
                              :op1 "insulin-like"
                              :op2 "growth"
                              :op3 "factor"
                              :op4 "1"))
                  :ARG1 (x9 / enzyme
                        :name (x10 / name :op1 "-activated")
                        :xref (x40 / xref :value "UNIPROT:MUSC_HUMAN" :prob "0.242"))
                  :ARG0 (x11 / enzyme
                        :name (x12 / name
                              :op1 "protein"
                              :op2 "kinase"
                              :op3 "Akt")
                        :ARG1-of (x14 / know-02
                              :mod (x13 / also)
                              :ARG2 (x15 / enzyme
                                    :name (x16 / name
                                          :op1 "protein"
                                          :op2 "kinase"
                                          :op3 "B"))))
                  :ARG1 (x18 / amino-acid
                        :mod "487"
                        :name (x19 / name :op1 "serine")
                        :xref (x44 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :location (x23 / loop-01
                        :mod (x22 / rich
                              :mod (x20 / amino-acid
                                    :name (x21 / name :op1 "loop’" :op2 "serine/threonine"))))))
      :snt2 (x31 / lead-03
            :location (x24 / and
                  :op1 (x25 / protein-segment
                        :name (x26 / name :op1 "c-terminus")
                        :part-of (x27 / protein
                              :name (x28 / name :op1 "AMPK-α1")
                              :xref (x / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662")))
                  :op2 (x29 / enzyme
                        :name (x30 / name
                              :op1 "AMP"
                              :op2 "protein"
                              :op3 "kinase-α1")))
            :ARG2 (x32 / inhibit-01
                  :ARG1 (x33 / phosphorylate-01
                        :ARG2 (x35 / kinase
                              :location (x34 / upstream))))
            :time (x36 / activate-01
                  :ARG1 (x37 / protein-segment
                        :mod (x38 / amino-acid
                              :mod "172"
                              :name (x39 / name :op1 "threonine")
                              :xref (x43 / xref :value "PUBCHEM:205" :prob "11.848252"))))))


# ::id PMC4052680.3
# ::snt Surprisingly, the equivalent site on AMPK-α2, Ser 491 , is not an Akt target and is modified instead by autophosphorylation.
# ::tok Surprisingly , the equivalent site on AMPK-α2 , Ser 491 , is not an Akt target and is modified instead by autophosphorylation .
(x12 / modify-01
      :ARG1-of (x1 / surprise-01)
      :ARG1 (x3 / protein-segment
            :ARG1-of (x2 / equal-01)
            :part-of (x4 / protein
                  :name (x5 / name :op1 "AMPK-α2")
                  :xref (x15 / xref :value "UNIPROT:AAPK2_HUMAN" :prob "0.662")))
      :mod (x6 / amino-acid
            :mod "491"
            :name (x7 / name :op1 "serine")
            :xref (x16 / xref :value "PUBCHEM:5951" :prob "11.218784"))
      :polarity "-"
      :ARG1 (x11 / and
            :ARG0-of (x10 / target-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
      :ARG1-of (x13 / instead-of-91)
      :ARG0 (x14 / phosphorylate-01))


# ::id PMC4052680.4
# ::snt Stimulation of HEK (human embryonic kidney)-293 cells with IGF-1 caused reduced subsequent Thr 172 phosphorylation and activation of AMPK-α1 in response to the activator A769662 and the Ca 2+ ionophore A23187, effects we show to be dependent on Akt activation and Ser 487 phosphorylation.
# ::tok Stimulation of HEK ( human embryonic kidney ) -293 cells with IGF @-@ 1 caused reduced subsequent Thr 172 phosphorylation and activation of AMPK-α1 in response to the activator A769662 and the Ca 2+ ionophore A23187 , effects we show to be dependent on Akt activation and Ser 487 phosphorylation .
(x1 / multi-sentence
      :snt1 (x12 / cause-01
            :ARG0 (x2 / stimulate-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "HEK")
                        :source (x9 / cell
                              :mod (x7 / kidney
                                    :mod (x5 / human)
                                    :ARG1-of (x6 / embryo))
                              :name (x8 / name :op1 "-293"))
                        :xref (x42 / xref :value "UNIPROT:EPHA3_HUMAN" :prob "1.003"))
                  :ARG2 (x10 / protein
                        :name (x11 / name :op1 "IGF-1")
                        :xref (x44 / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673")))
            :ARG1 (x13 / reduce-01
                  :ARG1 (x18 / and
                        :op1 (x17 / phosphorylate-01
                              :mod (x14 / subsequent)
                              :ARG1 (x15 / amino-acid
                                    :mod "172"
                                    :name (x16 / name :op1 "threonine")
                                    :xref (x46 / xref :value "PUBCHEM:205" :prob "11.848252")))
                        :op2 (x19 / activate-01
                              :ARG1 (x20 / enzyme
                                    :name (x21 / name :op1 "AMPK-α1")
                                    :xref (x / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662"))))
                  :ARG2-of (x22 / respond-01
                        :ARG1 (x26 / and
                              :op1 (x23 / activate-01
                                    :ARG1 (x24 / enzyme
                                          :name (x25 / name :op1 "A769662")))
                              :op2 (x27 / assay-01
                                    :mod (x28 / clonogenic))))))
      :snt2 (x31 / affect-01
            :ARG0 (x29 / protein
                  :name (x30 / name
                        :op1 "2+"
                        :op2 "ionophore"
                        :op3 "A23187"))
            :ARG1 (x34 / depend-01
                  :ARG1-of (x33 / show-01
                        :ARG0 (x32 / we))
                  :ARG1 (x38 / and
                        :op1 (x37 / activate-01
                              :ARG1 (x35 / enzyme
                                    :name (x36 / name :op1 "Akt")
                                    :xref (x43 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                        :op2 (x41 / phosphorylate-01
                              :ARG1 (x39 / amino-acid
                                    :mod "487"
                                    :name (x40 / name :op1 "serine")
                                    :xref (x45 / xref :value "PUBCHEM:5951" :prob "11.218784")))))))


# ::id PMC4052680.5
# ::snt Consistent with this, in three PTEN (phosphatase and tensin homologue deleted on chromosome 10)-null tumour cell lines (in which the lipid phosphatase PTEN that normally restrains the Akt pathway is absent and Akt is thus hyperactivated), AMPK was resistant to activation by A769662.
# ::tok Consistent with this , in three PTEN ( phosphatase and tensin homologue deleted on chromosome 10 ) -null tumour cell lines ( in which the lipid phosphatase PTEN that normally restrains the Akt pathway is absent and Akt is thus hyperactivated ) , AMPK was resistant to activation by A769662 .
(x1 / multi-sentence
      :snt1 (x2 / consistent-01
            :ARG2 (x3 / this)
            :location (x4 / cell-line
                  :quant "3"
                  :ARG1-of (x7 / delete-01
                        :ARG2 (x5 / enzyme
                              :name (x6 / name
                                    :op1 "phosphatase"
                                    :op2 "and"
                                    :op3 "tensin"
                                    :op4 "homologue"))
                        :ARG1 (x8 / chromosome
                              :mod "10"
                              :xref (x35 / xref :value "GO:0005694" :prob "0.8"))
                        :ARG1-of (x11 / cell-line
                              :name (x9 / name :op1 "-null")
                              :mod (x10 / tumor))))
            :ARG1-of (x12 / describe-01
                  :ARG0 (x13 / and
                        :ARG1-of (x17 / normal-02
                              :ARG0 (x15 / phosphatase
                                    :mod (x14 / lipid)
                                    :name (x16 / name :op1 "PTEN"))
                              :ARG1 (x18 / restrain-01)))))
      :snt2 (x25 / cause-01
            :ARG0 (x21 / absent-01
                  :ARG1 (x19 / pathway
                        :name (x20 / name :op1 "Akt")))
            :ARG1 (x22 / and
                  :op1 (x23 / enzyme
                        :name (x24 / name :op1 "Akt")
                        :xref (x34 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :ARG1 (x26 / enzyme
                  :name (x27 / name :op1 "hyperactivated"))
            :ARG0-of (x30 / resist-01
                  :ARG1 (x28 / protein
                        :name (x29 / name :op1 "AMPK")
                        :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
                  :ARG1 (x31 / activate-01)
                  :ARG0 (x32 / enzyme
                        :name (x33 / name :op1 "A769662")))))


# ::id PMC4052680.6
# ::snt However, full AMPK activation could be restored by pharmacological inhibition of Akt, or by re-expression of active PTEN.
# ::tok However , full AMPK activation could be restored by pharmacological inhibition of Akt , or by re @-@ expression of active PTEN .
(x1 / contrast-01
      :ARG2 (x2 / possible-01
            :ARG1 (x7 / restore-01
                  :ARG1 (x6 / activate-01
                        :ARG1-of (x3 / full-09)
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "AMPK")
                              :xref (x18 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))
                  :ARG0 (x9 / inhibit-01
                        :mod (x8 / pharmacology)
                        :ARG1 (x12 / or
                              :op1 (x10 / enzyme
                                    :name (x11 / name :op1 "Akt")
                                    :xref (x17 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                              :op2 (x13 / reinject-00
                                    :ARG1 (x14 / enzyme
                                          :ARG0-of (x15 / activity-06)
                                          :name (x16 / name :op1 "PTEN")
                                          :xref (x / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004"))))))))


# ::id PMC4052680.7
# ::snt We also show that inhibition of Thr 172 phosphorylation is due to interaction of the phosphorylated ST loop with basic side chains within the αC-helix of the kinase domain.
# ::tok We also show that inhibition of Thr 172 phosphorylation is due to interaction of the phosphorylated ST loop with basic side chains within the αC @-@ helix of the kinase domain .
(x3 / show-01
      :ARG0 (x1 / we)
      :mod (x2 / also)
      :ARG1 (x8 / cause-01
            :ARG0 (x4 / inhibit-01
                  :ARG1 (x7 / phosphorylate-01
                        :ARG1 (x5 / amino-acid
                              :mod "172"
                              :name (x6 / name :op1 "threonine")
                              :xref (x / xref :value "PUBCHEM:205" :prob "11.848252"))))
            :ARG1 (x9 / interact-01
                  :ARG1 (x10 / phosphorylate-01
                        :location (x11 / loop-01
                              :ARG2 (x14 / chain
                                    :mod (x12 / basic)
                                    :mod (x13 / side)))
                        :time (x15 / after
                              :op1 (x16 / enzyme
                                    :name (x17 / name :op1 "αC")
                                    :ARG1-of (x18 / helix)))
                        :ARG1 (x19 / enzyme
                              :name (x20 / name :op1 "kinase" :op2 "domain"))))))


# ::id PMC4052680.8
# ::snt Our findings reveal that a previously unrecognized effect of hyperactivation of Akt in tumour cells is to restrain activation of the LKB1 (liver kinase B1)–AMPK pathway, which would otherwise inhibit cell growth and proliferation.
# ::tok Our findings reveal that a previously unrecognized effect of hyperactivation of Akt in tumour cells is to restrain activation of the LKB1 ( liver kinase B1 ) –AMPK pathway , which would otherwise inhibit cell growth and proliferation .
(x4 / reveal-01
      :ARG0 (x3 / thing
            :ARG1-of (x2 / find-01
                  :ARG0 (x1 / we)))
      :ARG1 (x7 / affect-01
            :time (x5 / previous)
            :ARG1-of (x6 / unrecognized)
            :ARG0 (x8 / hyper)
            :ARG1 (x9 / enzyme
                  :name (x10 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :location (x12 / cell
                  :mod (x11 / tumor)))
      :ARG1 (x25 / and
            :op1 (x13 / restrain-01
                  :ARG1 (x14 / activate-01
                        :ARG1 (x15 / enzyme
                              :name (x16 / name :op1 "LKB1")
                              :xref (x27 / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002"))
                        :ARG0 (x17 / enzyme
                              :name (x18 / name
                                    :op1 "liver"
                                    :op2 "kinase"
                                    :op3 "B1"))
                        :ARG1 (x20 / pathway
                              :name (x19 / name :op1 "–AMPK")))
                  :ARG0-of (x22 / inhibit-01
                        :mod (x21 / otherwise)
                        :ARG1 (x24 / grow-01
                              :ARG1 (x23 / cell))))
            :op2 (x26 / proliferate-01)))


# ::id PMC4052680.10
# ::snt Akt phosphorylates the α1 subunit of AMPK at Ser 487 , leading to reduced Thr 172 phosphorylation and activation by LKB1.
# ::tok Akt phosphorylates the α1 subunit of AMPK at Ser 487 , leading to reduced Thr 172 phosphorylation and activation by LKB1 .
(x15 / and
      :op1 (x3 / phosphorylate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "Akt")
                  :xref (x19 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :ARG1 (x4 / protein-segment
                  :name (x5 / name :op1 "α1")
                  :part-of (x6 / protein
                        :name (x7 / name :op1 "AMPK")
                        :xref (x20 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))
            :ARG2 (x8 / amino-acid
                  :mod "487"
                  :name (x9 / name :op1 "serine")
                  :xref (x21 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :ARG0-of (x10 / lead-03
                  :ARG2 (x11 / reduce-01
                        :ARG1 (x14 / phosphorylate-01
                              :ARG1 (x12 / amino-acid
                                    :mod "172"
                                    :name (x13 / name :op1 "threonine")
                                    :xref (x22 / xref :value "PUBCHEM:205" :prob "11.848252"))))))
      :op2 (x16 / activate-01
            :ARG0 (x17 / enzyme
                  :name (x18 / name :op1 "LKB1")
                  :xref (x / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002"))))


# ::id PMC4052680.11
# ::snt We establish a molecular mechanism for this effect and show that it causes down-regulation of AMPK in several PTEN-null tumour cell lines.
# ::tok We establish a molecular mechanism for this effect and show that it causes down @-@ regulation of AMPK in several PTEN @-@ null tumour cell lines .
(x7 / and
      :op1 (x2 / establish-01
            :ARG0 (x1 / we)
            :ARG1 (x4 / mechanism
                  :mod (x3 / molecule))
            :ARG1 (x6 / affect-01
                  :mod (x5 / this)))
      :op2 (x8 / show-01
            :ARG1 (x10 / cause-01
                  :ARG0 (x9 / it)
                  :ARG1 (x11 / downregulate-01
                        :ARG1 (x12 / protein
                              :name (x13 / name :op1 "AMPK")
                              :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))))
            :location (x19 / cell-line
                  :quant (x14 / several)
                  :mod (x15 / protein
                        :name (x16 / name :op1 "PTEN")
                        :mod (x17 / null)
                        :xref (x20 / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004"))
                  :mod (x18 / tumor))))


# ::id PMC4052680.42
# ::snt Materials and proteins
# ::tok Materials and proteins
(x2 / and
      :op1 (x1 / material)
      :op2 (x3 / protein))


# ::id PMC4052680.52
# ::snt Expression and purification of AMPK in bacteria
# ::tok Expression and purification of AMPK in bacteria
(x6 / bacterium
      :ARG1 (x1 / and
            :op1 (x2 / express-03
                  :ARG2 (x3 / protein
                        :name (x4 / name :op1 "AMPK")
                        :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))
            :op2 (x5 / purify-01)))


# ::id PMC4052680.58
# ::snt Sources of cells and cell culture conditions
# ::tok Sources of cells and cell culture conditions
(x1 / source-02
      :ARG1 (x6 / condition
            :mod (x3 / and
                  :op1 (x2 / cell)
                  :op2 (x5 / culture
                        :mod (x4 / cell)))))


# ::id PMC4052680.67
# ::snt AMPK assays in cell-free systems and cell lysates
# ::tok AMPK assays in cell @-@ free systems and cell lysates
(x7 / and
      :op1 (x3 / assay-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "AMPK")
                  :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
            :location (x6 / system
                  :ARG1-of (x5 / free-04
                        :ARG2 (x4 / cell))))
      :op2 (x9 / lysate
            :mod (x8 / cell)))


# ::id PMC4052680.72
# ::snt Phosphorylation of GSK3β and AMPK by Akt in cell-free assays
# ::tok Phosphorylation of GSK3β and AMPK by Akt in cell @-@ free assays
(x1 / phosphorylate-01
      :ARG1 (x4 / and
            :op1 (x2 / enzyme
                  :name (x3 / name :op1 "GSK3β")
                  :xref (x / xref :value "UNIPROT:GSK3A_HUMAN" :prob "0.292"))
            :op2 (x5 / protein
                  :name (x6 / name :op1 "AMPK")
                  :xref (x13 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))
      :ARG2 (x7 / enzyme
            :name (x8 / name :op1 "Akt")
            :xref (x12 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
      :location (x11 / assay-01
            :ARG1-of (x10 / free-04
                  :ARG2 (x9 / cell))))


# ::id PMC4052680.75
# ::snt Phosphorylation of AMPK by LKB1 in cell-free assays
# ::tok Phosphorylation of AMPK by LKB1 in cell @-@ free assays
(x1 / phosphorylate-01
      :ARG1 (x2 / protein
            :name (x3 / name :op1 "AMPK")
            :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
      :ARG2 (x4 / enzyme
            :name (x5 / name :op1 "LKB1")
            :xref (x9 / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002"))
      :location (x8 / assay-01
            :ARG1-of (x7 / free-04
                  :ARG2 (x6 / cell))))


# ::id PMC4052680.79
# ::snt Generation of HEK-293 cells stably expressing α1, α2 or specified mutations
# ::tok Generation of HEK @-@ 293 cells stably expressing α1 , α2 or specified mutations
(x1 / generate-01
      :ARG1 (x12 / mutate-01
            :ARG0-of (x5 / express-03
                  :ARG1 (x3 / cell
                        :name (x2 / name :op1 "HEK-293"))
                  :ARG1-of (x4 / stable-03))
            :ARG2 (x10 / or
                  :op1 (x6 / protein
                        :name (x7 / name :op1 "riα" :op2 "1"))
                  :op2 (x8 / protein-segment
                        :name (x9 / name :op1 "riα"))
                  :op3 (x11 / specify-01))))


# ::id PMC4052680.83
# ::snt Incubation of HEK-293 cells with IGF-1 and various activators and inhibitors
# ::tok Incubation of HEK @-@ 293 cells with IGF @-@ 1 and various activators and inhibitors
(x1 / incubate-01
      :ARG1 (x3 / cell
            :name (x2 / name :op1 "HEK-293"))
      :ARG2 (x6 / and
            :op1 (x4 / protein
                  :name (x5 / name :op1 "IGF-1")
                  :xref (x / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))
            :op2 (x9 / molecular-physical-entity
                  :mod (x7 / various)
                  :ARG0-of (x8 / activate-01)
                  :ARG0-of (x10 / inhibit-01))))


# ::id PMC4052680.90
# ::snt Cloning, expression, purification and phosphorylation of the ST loop peptide
# ::tok Cloning , expression , purification and phosphorylation of the ST loop peptide
(x1 / clone-01
      :ARG1 (x2 / express-03
            :ARG2 (x4 / and
                  :op1 (x3 / purify-01)
                  :op2 (x5 / phosphorylate-01
                        :ARG1 (x8 / peptide
                              :ARG1-of (x7 / loop
                                    :ARG0-of (x6 / st)))))))


# ::id PMC4052680.99
# ::snt Western blotting and other analytical procedures
# ::tok Western blotting and other analytical procedures
(x2 / and
      :op1 (x1 / immunoblot-01)
      :op2 (x5 / procedure
            :mod (x3 / other)
            :ARG1-of (x4 / analytical)))


# ::id PMC4052680.108
# ::snt Akt phosphorylates Ser 487 on AMPK-α1, but not the equivalent site on AMPK-α2
# ::tok Akt phosphorylates Ser 487 on AMPK-α1 , but not the equivalent site on AMPK-α2
(x8 / contrast-01
      :ARG1 (x3 / phosphorylate-01
            :mod (x1 / enzyme
                  :name (x2 / name :op1 "Akt")
                  :xref (x13 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :ARG1 (x4 / amino-acid
                  :mod "487"
                  :name (x5 / name :op1 "serine")
                  :xref (x15 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :part-of (x6 / protein
                  :name (x7 / name :op1 "AMPK-α1")
                  :xref (x14 / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662")))
      :ARG2 (x10 / protein-segment
            :polarity "-"
            :ARG1-of (x9 / equal-01)
            :part-of (x11 / protein
                  :name (x12 / name :op1 "AMPK-α2")
                  :xref (x / xref :value "UNIPROT:AAPK2_HUMAN" :prob "0.662"))))


# ::id PMC4052680.109
# ::snt Akt phosphorylates serine or threonine residues within the sequence motif RXRXXS/TΦ, where Φ is a bulky hydrophobic residue [ 39 ].
# ::tok Akt phosphorylates serine or threonine residues within the sequence motif RXRXXS/TΦ, where Φ is a bulky hydrophobic residue [ 39 ] .
(x3 / phosphorylate-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "Akt")
            :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
      :ARG1 (x6 / or
            :op1 (x4 / amino-acid
                  :name (x5 / name :op1 "serine")
                  :xref (x21 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :op2 (x7 / residue
                  :mod (x8 / amino-acid
                        :name (x9 / name :op1 "threonine")
                        :xref (x20 / xref :value "PUBCHEM:205" :prob "11.848252"))))
      :location (x11 / motif
            :mod (x10 / sequence)
            :name (x12 / name :op1 "RXRXXS/TΦ,")
            :location-of (x15 / hydrophobic
                  :name (x13 / name :op1 "Φ")
                  :ARG0-of (x14 / bulky)
                  :ARG0-of (x16 / residue)
                  :ARG1-of (x17 / describe-01
                        :ARG0 (x18 / publication
                              :ARG1-of (x19 / cite-01 :ARG2 "39"))))))


# ::id PMC4052680.110
# ::snt Figure 1 (A) shows an alignment of this consensus with sequences around some established Akt targets, the ST loop sequence containing Ser 487 in human α1, and the equivalent site on α2 (Ser 491 ).
# ::tok Figure 1 ( A ) shows an alignment of this consensus with sequences around some established Akt targets , the ST loop sequence containing Ser 487 in human α1 , and the equivalent site on α2 ( Ser 491 ) .
(x2 / show-01
      :ARG0 (x1 / figure :mod "1")
      :li "a"
      :ARG1 (x21 / and
            :op1 (x3 / align-01
                  :ARG1 (x14 / dna-sequence
                        :mod (x4 / this)
                        :mod (x5 / consensus
                              :ARG2 (x6 / sequence)
                              :ARG1 (x13 / loop-01
                                    :mod (x7 / some)
                                    :ARG1-of (x8 / establish-01
                                          :ARG1 (x11 / target-01
                                                :ARG0 (x9 / enzyme
                                                      :name (x10 / name :op1 "Akt")
                                                      :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                                                :ARG1 (x12 / st)))))
                        :ARG0-of (x15 / contain-01
                              :ARG1 (x16 / amino-acid
                                    :mod "487"
                                    :name (x17 / name :op1 "serine")
                                    :xref (x29 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                        :location (x18 / disease
                              :wiki "cancer"
                              :mod (x19 / human)
                              :name (x20 / name :op1 "α1"))))
            :op2 (x23 / protein-segment
                  :ARG1-of (x22 / equal-01)
                  :part-of (x24 / protein-segment
                        :name (x25 / name :op1 "riα"))
                  :mod "2")
            :ARG1-of (x26 / amino-acid
                  :mod "491"
                  :name (x27 / name :op1 "serine")
                  :xref (x28 / xref :value "PUBCHEM:5951" :prob "11.218784"))))


# ::id PMC4052680.111
# ::snt Both of the latter have a serine residue at P-2, with Akt having a preference for the serine or threonine residue at this position [ 39 ].
# ::tok Both of the latter have a serine residue at P @-@ 2 , with Akt having a preference for the serine or threonine residue at this position [ 39 ] .
(x3 / have-03
      :ARG0 (x1 / and
            :op1 (x2 / latter))
      :ARG1 (x6 / residue
            :mod (x4 / amino-acid
                  :name (x5 / name :op1 "serine")
                  :xref (x26 / xref :value "PUBCHEM:5951" :prob "11.218784")))
      :location (x7 / and
            :op1 (x8 / enzyme
                  :ARG3-of (x9 / phosphorylate-01)
                  :name (x10 / name :op1 "erk1/2"))
            :op2 (x11 / enzyme
                  :name (x12 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :ARG0-of (x13 / have-03
                  :ARG1 (x17 / or
                        :op1 (x14 / prefer-01
                              :ARG2 (x15 / amino-acid
                                    :name (x16 / name :op1 "serine")
                                    :xref (x28 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                        :op2 (x20 / residue
                              :mod (x18 / amino-acid
                                    :name (x19 / name :op1 "threonine")
                                    :xref (x27 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :location (x22 / position
                                    :mod (x21 / this)))))
            :ARG1-of (x23 / describe-01
                  :ARG0 (x24 / publication
                        :ARG1-of (x25 / cite-01 :ARG2 "39")))))


# ::id PMC4052680.112
# ::snt However, both also have a proline residue rather than arginine at the P-5 position, and Ser 491 also has an alanine residue rather than a bulky hydrophobic residue at P+1.
# ::tok However , both also have a proline residue rather than arginine at the P @-@ 5 position , and Ser 491 also has an alanine residue rather than a bulky hydrophobic residue at P+1 .
(x1 / contrast-01
      :ARG2 (x17 / have-03
            :ARG0 (x13 / and
                  :op1 (x3 / have-03
                        :mod (x2 / also)
                        :ARG1 (x4 / residue
                              :mod (x5 / amino-acid
                                    :name (x6 / name :op1 "proline")
                                    :xref (x26 / xref :value "PUBCHEM:614" :prob "10.45396")))
                        :ARG1-of (x7 / instead-of-91
                              :ARG2 (x8 / amino-acid
                                    :name (x9 / name :op1 "arginine")
                                    :xref (x / xref :value "PUBCHEM:232" :prob "11.348415")))
                        :ARG2 (x10 / protein
                              :name (x11 / name :op1 "P-5")))
                  :op2 (x12 / position-02)
                  :op3 (x14 / amino-acid
                        :mod "491"
                        :name (x15 / name :op1 "serine")
                        :xref (x28 / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :mod (x16 / also)
            :ARG1 (x24 / residue
                  :mod (x18 / residue
                        :mod (x19 / amino-acid
                              :name (x20 / name :op1 "alanine")
                              :xref (x27 / xref :value "PUBCHEM:602" :prob "10.089661")))
                  :mod (x23 / hydrophobic
                        :ARG1-of (x21 / instead-of-91
                              :ARG2 (x22 / bulky)))
                  :name (x25 / name :op1 "P+1"))))


# ::id PMC4052680.113
# ::snt Neither is therefore a perfect fit to the Akt consensus; Scansite 2.0 [ 40 ] identifies Ser 487 as a potential Akt site only at medium stringency, and Ser 491 only at low stringency.
# ::tok Neither is therefore a perfect fit to the Akt consensus ; Scansite 2.0 [ 40 ] identifies Ser 487 as a potential Akt site only at medium stringency , and Ser 491 only at low stringency .
(x2 / cause-01
      :ARG1 (x1 / neither)
      :ARG1 (x4 / fit-06
            :ARG1-of (x3 / perfect-02)
            :ARG2 (x7 / and
                  :op1 (x5 / enzyme
                        :name (x6 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                  :op1 (x8 / consensus)
                  :op2 (x9 / amino-acid
                        :name (x10 / name :op1 "Scansite")
                        :mod "2.0"))
            :ARG1-of (x11 / describe-01
                  :ARG0 (x12 / publication
                        :ARG1-of (x13 / cite-01 :ARG2 "40")))
            :ARG1-of (x14 / identify-01
                  :ARG1 (x15 / amino-acid
                        :mod "487"
                        :name (x16 / name :op1 "serine")
                        :xref (x33 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :ARG2 (x20 / site
                        :mod (x17 / potential)
                        :mod (x18 / enzyme
                              :name (x19 / name :op1 "Akt")
                              :xref (x31 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                  :mod (x21 / only)))
      :location (x22 / medium
            :ARG1-of (x29 / low-04
                  :ARG1 (x25 / and
                        :op1 (x23 / enzyme
                              :name (x24 / name :op1 "stringency"))
                        :op2 (x26 / amino-acid
                              :mod "491"
                              :name (x27 / name :op1 "serine")
                              :xref (x32 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                  :mod (x28 / only)))
      :mod (x30 / stringent))


# ::id PMC4052680.114
# ::snt Phosphorylation by Akt of inactive α1 at Ser 487 , but not α2 at Ser 491 , inhibits Thr 172 phosphorylation by LKB1
# ::tok Phosphorylation by Akt of inactive α1 at Ser 487 , but not α2 at Ser 491 , inhibits Thr 172 phosphorylation by LKB1
(x9 / contrast-01
      :ARG1 (x4 / activate-01
            :ARG0 (x1 / phosphorylate-01
                  :ARG2 (x2 / enzyme
                        :name (x3 / name :op1 "Akt")
                        :xref (x21 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "α1")
                  :part (x7 / amino-acid
                        :mod "487"
                        :name (x8 / name :op1 "serine")
                        :xref (x23 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :xref (x22 / xref :value "UNIPROT:AK1C3_HUMAN" :prob "0.553")))
      :ARG2 (x14 / inhibit-01
            :polarity "-"
            :ARG0 (x10 / protein
                  :name (x11 / name :op1 "α2")
                  :part (x12 / amino-acid
                        :mod "491"
                        :name (x13 / name :op1 "serine")
                        :xref (x24 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :xref (x20 / xref :value "UNIPROT:FKRP_HUMAN" :prob "0.552"))
            :ARG1 (x17 / phosphorylate-01
                  :ARG1 (x15 / amino-acid
                        :mod "172"
                        :name (x16 / name :op1 "threonine")
                        :xref (x25 / xref :value "PUBCHEM:205" :prob "11.848252"))
                  :ARG2 (x18 / enzyme
                        :name (x19 / name :op1 "LKB1")
                        :xref (x / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002")))))


# ::id PMC4052680.115
# ::snt The right-hand column shows the percentile score for the sequence as a potential Akt target computed using Scansite ( http://scansite.mit.edu/ ).
# ::tok The right @-@ hand column shows the percentile score for the sequence as a potential Akt target computed using Scansite ( http : //scansite.mit.edu/ ) .
(x4 / show-01
      :ARG0 (x3 / column
            :mod (x2 / hand
                  :ARG1-of (x1 / right-04)))
      :ARG1 (x6 / score-01
            :ARG1-of (x5 / percentile)
            :ARG2 (x7 / sequence
                  :ARG0-of (x11 / target-01
                        :mod (x8 / potential)
                        :ARG0 (x9 / enzyme
                              :name (x10 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                        :ARG1 (x12 / enzyme
                              :name (x13 / name :op1 "computed")
                              :xref (x19 / xref :value "UNIPROT:COMP_HUMAN" :prob "0.202"))
                        :instrument (x14 / small-molecule
                              :name (x15 / name :op1 "Scansite")
                              :ARG1-of (x16 / hyperlink-91))
                        :ARG1 (x17 / enzyme
                              :name (x18 / name :op1 "//scansite.mit.edu/"))))))


# ::id PMC4052680.116
# ::snt Incubations were analysed by Western blotting with the indicated antibodies, or by autoradiography to detect 32 P radioactivity.
# ::tok Incubations were analysed by Western blotting with the indicated antibodies , or by autoradiography to detect 32 P radioactivity .
(x2 / analyze-01
      :ARG1 (x1 / incubate-01)
      :manner (x6 / or
            :op1 (x3 / immunoblot-01
                  :ARG3 (x5 / antibody
                        :ARG1-of (x4 / indicate-01)))
            :op2 (x7 / autoradiography
                  :purpose (x8 / detect-01
                        :ARG1 (x10 / radioactivity
                              :quant "32"
                              :ARG1-of (x9 / statistical-test-91))))))


# ::id PMC4052680.119
# ::snt To avoid complications caused by autophosphorylation, we initially used inactive mutants of human AMPK complexes (α1-D159A/β2/γ1 and α2-D157A/β2/γ1), with or without α1-S487A or α2-S491A mutations, as substrates for phosphorylation by human Akt.
# ::tok To avoid complications caused by autophosphorylation , we initially used inactive mutants of human AMPK complexes ( α1 @-@ D159A/β2/γ1 and α2 @-@ D157A/β2/γ1 ) , with or without α1 @-@ S487A or α2 @-@ S491A mutations , as substrates for phosphorylation by human Akt .
(x1 / multi-sentence
      :snt1 (x8 / use-01
            :purpose (x2 / avoid-01
                  :ARG1 (x3 / complicate-01
                        :ARG1-of (x4 / cause-01
                              :ARG0 (x5 / phosphorylate-01))))
            :ARG0 (x6 / we)
            :time (x7 / initial)
            :ARG1 (x10 / mutate-01
                  :ARG0-of (x9 / activate-01 :polarity "-")
                  :ARG1 (x17 / and
                        :op1 (x14 / macro-molecular-complex
                              :mod (x11 / human)
                              :mod (x12 / protein
                                    :name (x13 / name :op1 "AMPK")
                                    :xref (x39 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
                              :name (x15 / name :op1 "α1")
                              :name (x16 / name :op1 "D159A/β2/γ1"))
                        :op2 (x18 / protein-segment
                              :name (x19 / name :op1 "riα")))))
      :snt2 (x20 / and
            :op1 (x21 / protein
                  :name (x22 / name :op1 "2" :op2 "D157A/β2/γ1"))
            :op2 (x23 / or
                  :op2 (x31 / mutate-01
                        :polarity "-"
                        :ARG2 (x27 / or
                              :op1 (x24 / enzyme
                                    :name (x25 / name :op1 "α1")
                                    :ARG2-of (x26 / mutate-01 :value "S487A")
                                    :xref (x37 / xref :value "UNIPROT:AK1C3_HUMAN" :prob "0.553"))
                              :op2 (x28 / enzyme
                                    :name (x29 / name :op1 "α2")
                                    :ARG2-of (x30 / mutate-01 :value "S491A")
                                    :xref (x / xref :value "UNIPROT:FKRP_HUMAN" :prob "0.552")))
                        :ARG1-of (x32 / substrate
                              :beneficiary (x33 / enzyme
                                    :ARG3-of (x34 / phosphorylate-01
                                          :ARG0 (x35 / human))
                                    :name (x36 / name :op1 "Akt")
                                    :xref (x38 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))))


# ::id PMC4052680.120
# ::snt For comparison, we used an inactive (D200A) mutant of the known Akt substrate GSK3β, with or without mutation of the Akt site (Ser 9 ).
# ::tok For comparison , we used an inactive ( D200A ) mutant of the known Akt substrate GSK3β, with or without mutation of the Akt site ( Ser 9 ) .
(x3 / use-01
      :purpose (x1 / compare-01)
      :ARG0 (x2 / we)
      :ARG1 (x6 / mutate-01
            :ARG0-of (x4 / activity-06 :polarity "-")
            :ARG1-of (x5 / mutate-01 :value "D200A")
            :ARG1 (x10 / substrate
                  :ARG1-of (x7 / know-01)
                  :mod (x8 / enzyme
                        :name (x9 / name :op1 "Akt")
                        :xref (x18 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                  :name (x11 / name :op1 "GSK3β,")))
      :ARG2 (x12 / or
            :op2 (x13 / mutate-01
                  :polarity "-"
                  :ARG1 (x14 / enzyme
                        :name (x15 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :op1 (x16 / protein-segment
                  :name (x17 / name :op1 "serine")
                  :mod "9")))


# ::id PMC4052680.121
# ::snt Interestingly, AMPK-α1 was a reasonable substrate for Akt although not as good as GSK3, whereas AMPK-α2 was a very poor substrate.
# ::tok Interestingly , AMPK-α1 was a reasonable substrate for Akt although not as good as GSK3 , whereas AMPK-α2 was a very poor substrate .
(x7 / have-concession-91
      :ARG2-of (x1 / interest-01)
      :ARG1 (x3 / reasonable-02
            :name (x2 / name :op1 "AMPK-α1")
            :mod (x4 / substrate
                  :beneficiary (x5 / enzyme
                        :name (x6 / name :op1 "Akt")
                        :xref (x16 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
      :ARG2 (x9 / good-02
            :degree (x8 / equal :polarity "-")
            :compared-to (x10 / enzyme
                  :name (x11 / name :op1 "GSK3")
                  :xref (x / xref :value "UNIPROT:GSK3A_HUMAN" :prob "0.312")))
      :ARG1-of (x15 / substrate
            :name (x12 / name :op1 "AMPK-α2")
            :mod (x14 / poor
                  :degree (x13 / very))))


# ::id PMC4052680.122
# ::snt Using either an anti-pS9 antibody or by 32 P-labelling, phosphorylation of GSK3β was saturated at 0.5 unit/ml Akt, when the phosphorylation stoichiometry by 32 P-labelling was 1.03 mol/mol ( Figure 1 B).
# ::tok Using either an anti @-@ pS9 antibody or by 32 P @-@ labelling , phosphorylation of GSK3β was saturated at 0.5 unit @/@ ml Akt , when the phosphorylation stoichiometry by 32 P @-@ labelling was 1.03 mol @/@ mol ( Figure 1 B ) .
(x12 / phosphorylate-01
      :ARG0 (x1 / use-01
            :ARG1 (x2 / or
                  :op1 (x7 / or
                        :op1 (x6 / antibody
                              :ARG0-of (x3 / counter-01
                                    :ARG1 (x4 / protein
                                          :name (x5 / name :op1 "pS9"))))
                        :op2 (x8 / publication
                              :ARG1-of (x9 / cite-01 :ARG2 "32")))
                  :op2 (x10 / enzyme
                        :name (x11 / name :op1 "labelling"))))
      :ARG1 (x13 / enzyme
            :name (x14 / name :op1 "GSK3β")
            :xref (x33 / xref :value "UNIPROT:GSK3A_HUMAN" :prob "0.292"))
      :ARG2 (x15 / small-molecule
            :name (x16 / name :op1 "saturated")
            :quant (x18 / concentration-quantity
                  :quant "0.5"
                  :unit (x17 / unit)
                  :name (x19 / name :op1 "Akt"))
            :xref (x35 / xref :value "PUBCHEM:71581110" :prob "10.43824"))
      :ARG0-of (x26 / label-01
            :time (x20 / stoichiometry
                  :mod (x21 / phosphorylate-01
                        :ARG1 (x22 / enzyme
                              :name (x23 / name :op1 "32")
                              :ARG1-of (x24 / statistical-test-91
                                    :ARG2 (x25 / less-than :op1 "0.05"))
                              :xref (x / xref :value "UNIPROT:ARHL1_HUMAN" :prob "0.572"))))
            :ARG0 (x27 / small-molecule
                  :quant (x28 / concentration-quantity
                        :quant "1.03"
                        :unit (x29 / mol))
                  :name (x30 / name :op1 "mol")
                  :xref (x34 / xref :value "PUBCHEM:5287789" :prob "16.24571")))
      :ARG1-of (x31 / describe-01
            :ARG0 (x32 / figure :mod "1")))


# ::id PMC4052680.123
# ::snt The phosphorylation of AMPK-α1 within the α1β2γ1 complex was only saturated at 5 units/ml, when the stoichiometry was 0.96 mol/mol ( Figure 1 C).
# ::tok The phosphorylation of AMPK-α1 within the α1β2γ1 complex was only saturated at 5 units/ml , when the stoichiometry was 0.96 mol @/@ mol ( Figure 1 C ) .
(x1 / phosphorylate-01
      :ARG1 (x2 / enzyme
            :name (x3 / name :op1 "AMPK-α1")
            :xref (x / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662"))
      :ARG2 (x5 / macro-molecular-complex
            :name (x4 / name :op1 "α1β2γ1"))
      :mod (x6 / only)
      :ARG1-of (x7 / saturate-01)
      :ARG1 (x8 / amino-acid
            :part-of (x9 / protein
                  :name (x10 / name :op1 "5"))
            :name (x11 / name :op1 "units/ml"))
      :time (x12 / stoichiometry
            :quant "0.96"
            :op1 (x13 / mol)
            :op2 (x14 / mol))
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / figure :mod "1c")))


# ::id PMC4052680.124
# ::snt For both GSK3β and AMPK-α1, the signals obtained using phospho-specific antibodies (pS9/pS487) or 32 P-labelling were abolished by mutation of the respective sites to alanine (S9A/S487A).
# ::tok For both GSK3β and AMPK-α1 , the signals obtained using phospho @-@ specific antibodies ( pS9/pS487 ) or 32 P @-@ labelling were abolished by mutation of the respective sites to alanine ( S9A/S487A ) .
(x7 / obtain-01
      :purpose (x1 / and
            :op1 (x2 / enzyme
                  :name (x3 / name :op1 "GSK3β")
                  :xref (x / xref :value "UNIPROT:GSK3A_HUMAN" :prob "0.292"))
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "AMPK-α1")
                  :xref (x28 / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662")))
      :ARG1 (x6 / signal-07)
      :manner (x8 / use-01
            :ARG1 (x14 / or
                  :op1 (x11 / antibody
                        :ARG1-of (x10 / specific-02
                              :ARG2 (x9 / phosphorylate-01))
                        :ARG1-of (x12 / describe-01
                              :ARG2 (x13 / name :op1 "pS9/pS487")))
                  :op2 (x21 / abolish-01
                        :ARG1-of (x15 / describe-01
                              :ARG0 (x16 / publication
                                    :ARG1-of (x17 / cite-01 :ARG2 "32")))
                        :ARG1 (x18 / enzyme
                              :ARG3-of (x19 / phosphorylate-01)
                              :name (x20 / name :op1 "labelling"))
                        :ARG0 (x22 / mutate-01
                              :ARG1 (x24 / protein-segment
                                    :mod (x23 / respective))))))
      :ARG2 (x25 / amino-acid
            :name (x26 / name :op1 "alanine")
            :name (x27 / name :op1 "S9A/S487A")
            :xref (x29 / xref :value "PUBCHEM:602" :prob "10.089661")))


# ::id PMC4052680.125
# ::snt By contrast, there was much less phosphorylation of Ser 491 within the α2β2γ1 complex ( Figure 1 D).
# ::tok By contrast , there was much less phosphorylation of Ser 491 within the α2β2γ1 complex ( Figure 1 D ) .
(x1 / contrast-01
      :ARG2 (x4 / phosphorylate-01
            :degree (x3 / less
                  :degree (x2 / much))
            :ARG1 (x5 / amino-acid
                  :mod "491"
                  :name (x6 / name :op1 "serine")
                  :xref (x / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :location (x8 / macro-molecular-complex
                  :name (x7 / name :op1 "α2β2γ1")))
      :ARG1-of (x9 / describe-01
            :ARG0 (x10 / figure :mod "1")))


# ::id PMC4052680.126
# ::snt By 32 P-labelling, the stoichiometry of α2 phosphorylation was only 0.18 mol/mol, even with Akt at 30- and 300-fold higher concentrations than those required to obtain stoichiometric phosphorylation of α1 and GSK3β respectively.
# ::tok By 32 P @-@ labelling , the stoichiometry of α2 phosphorylation was only 0.18 mol/mol , even with Akt at 30 @- and 300 @-@ fold higher concentrations than those required to obtain stoichiometric phosphorylation of α1 and GSK3β respectively .
(x12 / even-02
      :ARG1-of (x4 / label-01
            :ARG0 (x3 / phosphorylate-01
                  :ARG1 (x1 / enzyme
                        :name (x2 / name :op1 "32")
                        :xref (x30 / xref :value "UNIPROT:ARHL1_HUMAN" :prob "0.572"))))
      :ARG1 (x5 / stoichiometry
            :ARG1 (x8 / phosphorylate-01
                  :ARG1 (x6 / protein-segment
                        :name (x7 / name :op1 "riα"))))
      :mod (x9 / only)
      :ARG0 (x10 / enzyme
            :name (x11 / name :op1 "0.18" :op2 "mol/mol"))
      :ARG2 (x13 / enzyme
            :name (x14 / name :op1 "Akt")
            :xref (x31 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
      :degree (x15 / product-of :op1 "30" :op2 "300")
      :ARG1 (x18 / concentrate-02
            :ARG1-of (x16 / high-02
                  :degree (x17 / more)))
      :compared-to (x20 / require-01
            :mod (x19 / that)
            :purpose (x21 / obtain-01
                  :ARG1 (x25 / and
                        :op1 (x22 / phosphorylate-01
                              :ARG1 (x23 / enzyme
                                    :name (x24 / name :op1 "α1")
                                    :xref (x29 / xref :value "UNIPROT:AK1C3_HUMAN" :prob "0.553")))
                        :op2 (x26 / enzyme
                              :name (x27 / name :op1 "GSK3β")
                              :xref (x / xref :value "UNIPROT:GSK3A_HUMAN" :prob "0.292"))
                        :mod (x28 / respective)))))


# ::id PMC4052680.127
# ::snt Although we did detect some phosphorylation of Ser 491 using a phospho-specific antibody and this was abolished in a S491A mutant, 32 P-labelling was not affected by the S491A mutation, suggesting that the low level of α2 phosphorylation by Akt was mainly accounted for by modification at other site(s).
# ::tok Although we did detect some phosphorylation of Ser 491 using a phospho @-@ specific antibody and this was abolished in a S491A mutant , 32 P @-@ labelling was not affected by the S491A mutation , suggesting that the low level of α2 phosphorylation by Akt was mainly accounted for by modification at other site ( s ) .
(x1 / multi-sentence
      :snt1 (x2 / have-concession-91
            :ARG2 (x4 / detect-01
                  :ARG0 (x3 / we)
                  :ARG1 (x5 / phosphorylate-01
                        :ARG1 (x6 / amino-acid
                              :mod "491"
                              :name (x7 / name :op1 "serine")
                              :xref (x41 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
            :ARG1 (x12 / and
                  :op1 (x8 / use-01
                        :ARG1 (x11 / antibody
                              :ARG1-of (x10 / specific-02
                                    :ARG2 (x9 / phosphorylate-01))))
                  :op2 (x14 / abolish-01
                        :ARG1 (x13 / this)
                        :location (x16 / mutate-01
                              :ARG1-of (x15 / mutate-01 :value "S491A")
                              :ARG2 (x17 / enzyme
                                    :name (x18 / name :op1 "32")
                                    :xref (x40 / xref :value "UNIPROT:ARHL1_HUMAN" :prob "0.572"))
                              :ARG0-of (x22 / affect-01
                                    :ARG1 (x19 / enzyme
                                          :ARG3-of (x20 / phosphorylate-01)
                                          :name (x21 / name :op1 "labelling"))
                                    :polarity "-"
                                    :ARG0 (x24 / mutate-01
                                          :ARG1 (x23 / mutate-01 :value "S491A"))))
                        :ARG0-of (x25 / suggest-01
                              :ARG1 (x27 / level
                                    :ARG1-of (x26 / low-04)
                                    :quant-of (x28 / enzyme
                                          :name (x29 / name :op1 "α2")
                                          :xref (x / xref :value "UNIPROT:FKRP_HUMAN" :prob "0.552")))))))
      :snt2 (x34 / account-01
            :ARG1 (x30 / phosphorylate-01
                  :ARG2 (x31 / enzyme
                        :name (x32 / name :op1 "Akt")
                        :xref (x39 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :mod (x33 / main)
            :ARG1 (x35 / modify-01
                  :ARG1 (x37 / protein-segment
                        :mod (x36 / other)
                        :name (x38 / name :op1 "s")))))


# ::id PMC4052680.128
# ::snt Ser 487 phosphorylation reduces Thr 172 phosphorylation: studies with inactive AMPK
# ::tok Ser 487 phosphorylation reduces Thr 172 phosphorylation : studies with inactive AMPK
(x4 / reduce-01
      :ARG1 (x3 / phosphorylate-01
            :ARG1 (x1 / amino-acid
                  :mod "487"
                  :name (x2 / name :op1 "serine")
                  :xref (x12 / xref :value "PUBCHEM:5951" :prob "11.218784")))
      :ARG1 (x7 / phosphorylate-01
            :ARG1 (x5 / amino-acid
                  :mod "172"
                  :name (x6 / name :op1 "threonine")
                  :xref (x13 / xref :value "PUBCHEM:205" :prob "11.848252")))
      :ARG2 (x8 / study-01
            :ARG2 (x9 / activate-01 :polarity "-"))
      :ARG0 (x10 / protein
            :name (x11 / name :op1 "AMPK")
            :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))


# ::id PMC4052680.129
# ::snt We next tested the ability of the human LKB1–STRADα–MO25α complex to phosphorylate Thr 172 in an inactive (α1-D157A) human α1β2γ1 complex.
# ::tok We next tested the ability of the human LKB1–STRADα–MO25α complex to phosphorylate Thr 172 in an inactive ( α1 @-@ D157A ) human α1β2γ1 complex .
(x3 / test-01
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x4 / capable-01
            :ARG1 (x8 / complex
                  :mod (x5 / disease
                        :wiki "cancer"
                        :mod (x6 / human)
                        :name (x7 / name :op1 "LKB1–STRADα–MO25α")))
            :ARG2 (x9 / phosphorylate-01
                  :ARG1 (x10 / amino-acid
                        :mod "172"
                        :name (x11 / name :op1 "threonine")
                        :xref (x20 / xref :value "PUBCHEM:205" :prob "11.848252"))
                  :ARG2 (x12 / activate-01 :polarity "-")
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "α1")
                        :ARG2-of (x15 / mutate-01 :value "D157A")
                        :xref (x / xref :value "UNIPROT:AK1C3_HUMAN" :prob "0.553")))
            :ARG1 (x19 / complex
                  :mod (x16 / disease
                        :wiki "cancer"
                        :mod (x17 / human)
                        :name (x18 / name :op1 "α1β2γ1")))))


# ::id PMC4052680.130
# ::snt Before phosphorylation by Akt, the rate of phosphorylation of Thr 172 by the LKB1 complex was unaffected by an S487A mutation, although an S487D mutation reduced the rate of Thr 172 phosphorylation by approximately 30% ( Figure 1 E).
# ::tok Before phosphorylation by Akt , the rate of phosphorylation of Thr 172 by the LKB1 complex was unaffected by an S487A mutation , although an S487D mutation reduced the rate of Thr 172 phosphorylation by approximately 30 % ( Figure 1 E ) .
(x14 / have-concession-91
      :ARG1 (x11 / affect-01
            :time (x1 / before
                  :op1 (x2 / phosphorylate-01
                        :ARG2 (x3 / enzyme
                              :name (x4 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
            :ARG1 (x5 / rate
                  :degree-of (x6 / phosphorylate-01
                        :ARG1 (x7 / amino-acid
                              :mod "172"
                              :name (x8 / name :op1 "threonine")
                              :xref (x28 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :ARG2 (x10 / macro-molecular-complex
                              :name (x9 / name :op1 "LKB1"))))
            :polarity "-"
            :ARG0 (x13 / mutate-01
                  :ARG1 (x12 / mutate-01 :value "S487A")))
      :ARG2 (x18 / reduce-01
            :ARG0 (x17 / mutate-01
                  :ARG1 (x15 / gene
                        :name (x16 / name :op1 "S487D")))
            :ARG1 (x19 / rate
                  :degree-of (x22 / phosphorylate-01
                        :ARG1 (x20 / amino-acid
                              :mod "172"
                              :name (x21 / name :op1 "threonine")
                              :xref (x27 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :ARG2 (x23 / approximately
                              :op1 (x24 / percentage-entity :value "30")))))
      :ARG1-of (x25 / describe-01
            :ARG0 (x26 / figure :mod "3e")))


# ::id PMC4052680.131
# ::snt When the inactive (D157A) mutant complex was first phosphorylated by Akt under conditions that yielded stoichiometric Ser 487 phosphorylation, subsequent phosphorylation of Thr 172 was reduced by approximately 40%, an effect abolished by an S487A mutation ( Figure 1 F).
# ::tok When the inactive ( D157A ) mutant complex was first phosphorylated by Akt under conditions that yielded stoichiometric Ser 487 phosphorylation , subsequent phosphorylation of Thr 172 was reduced by approximately 40 % , an effect abolished by an S487A mutation ( Figure 1 F ) .
(x18 / reduce-01
      :condition (x6 / phosphorylate-01
            :ARG1 (x4 / complex
                  :ARG0-of (x1 / activity-06 :polarity "-")
                  :ARG1-of (x2 / mutate-01 :value "D157A")
                  :mod (x3 / mutate-01))
            :ord (x5 / ordinal-entity :value "1")
            :ARG2 (x7 / enzyme
                  :name (x8 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :condition (x9 / condition
                  :ARG1-of (x10 / yield-01
                        :ARG1 (x13 / phosphorylate-01
                              :ARG1 (x11 / amino-acid
                                    :mod "487"
                                    :name (x12 / name :op1 "serine")
                                    :xref (x27 / xref :value "PUBCHEM:5951" :prob "11.218784"))))))
      :time (x14 / subsequent)
      :ARG1 (x15 / phosphorylate-01
            :ARG1 (x16 / amino-acid
                  :mod "172"
                  :name (x17 / name :op1 "threonine")
                  :xref (x28 / xref :value "PUBCHEM:205" :prob "11.848252")))
      :ARG2 (x19 / approximately
            :op1 (x20 / percentage-entity :value "40"))
      :ARG1-of (x21 / affect-01
            :ARG1 (x24 / mutate-01
                  :ARG1 (x22 / abolish-01
                        :ARG0 (x23 / mutate-01 :value "S487A"))))
      :ARG1-of (x25 / describe-01
            :ARG0 (x26 / figure :mod "4f")))


# ::id PMC4052680.132
# ::snt Phosphorylation of Ser 491 on AMPK-α2 is due to autophosphorylation
# ::tok Phosphorylation of Ser 491 on AMPK-α2 is due to autophosphorylation
(x1 / phosphorylate-01
      :ARG1 (x2 / amino-acid
            :mod "491"
            :name (x3 / name :op1 "serine")
            :xref (x8 / xref :value "PUBCHEM:5951" :prob "11.218784"))
      :ARG2 (x6 / cause-01
            :ARG1 (x4 / protein
                  :name (x5 / name :op1 "AMPK-α2")
                  :xref (x / xref :value "UNIPROT:AAPK2_HUMAN" :prob "0.662"))
            :ARG0 (x7 / phosphorylate-01)))


# ::id PMC4052680.133
# ::snt We next tested the effects of Akt on either WT, S487A or S491A mutants of active α1β2γ1 and α2β2γ1 complexes.
# ::tok We next tested the effects of Akt on either WT , S487A or S491A mutants of active α1β2γ1 and α2β2γ1 complexes .
(x3 / test-01
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x4 / affect-01
            :ARG0 (x5 / enzyme
                  :name (x6 / name :op1 "Akt")
                  :xref (x19 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :ARG1 (x16 / and
                  :op1 (x12 / mutate-01
                        :ARG1 (x7 / or
                              :op1 (x8 / enzyme
                                    :mod (x9 / wild-type)
                                    :ARG1-of (x10 / mutate-01 :value "S487A"))
                              :op2 (x11 / mutate-01 :value "S491A"))
                        :ARG2 (x13 / enzyme
                              :ARG0-of (x14 / activity-06)
                              :name (x15 / name :op1 "α1β2γ1")
                              :xref (x / xref :value "UNIPROT:AL8A1_HUMAN" :prob "0.562")))
                  :op2 (x18 / macro-molecular-complex
                        :name (x17 / name :op1 "α2β2γ1")))))


# ::id PMC4052680.134
# ::snt Figure 2 (A) shows that with the α1β2γ1 complex there was slight phosphorylation of Ser 487 even in the absence of Akt, although phosphorylation of this site increased markedly with increasing Akt.
# ::tok Figure 2 ( A ) shows that with the α1β2γ1 complex there was slight phosphorylation of Ser 487 even in the absence of Akt , although phosphorylation of this site increased markedly with increasing Akt .
(x2 / show-01
      :ARG0 (x1 / figure :mod "2")
      :li "a"
      :ARG1 (x17 / increase-01
            :ARG0 (x6 / phosphorylate-01
                  :location (x4 / macro-molecular-complex
                        :name (x3 / name :op1 "α1β2γ1"))
                  :mod (x5 / slight)
                  :ARG1 (x7 / amino-acid
                        :mod "487"
                        :name (x8 / name :op1 "serine")
                        :xref (x21 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :concession (x9 / absent-01
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "Akt")
                              :xref (x20 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                  :concession (x15 / increase-01
                        :ARG1 (x12 / phosphorylate-01
                              :ARG1 (x14 / protein-segment
                                    :mod (x13 / this)))))
            :ARG2 (x16 / marked)
            :ARG1 (x18 / enzyme
                  :name (x19 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))


# ::id PMC4052680.135
# ::snt By contrast, Ser 491 in an α2β2γ1 complex appeared to be fully phosphorylated in the absence of Akt, and addition of Akt had no further effect.
# ::tok By contrast , Ser 491 in an α2β2γ1 complex appeared to be fully phosphorylated in the absence of Akt , and addition of Akt had no further effect .
(x1 / contrast-01
      :ARG2 (x4 / appear-02
            :ARG0 (x2 / amino-acid
                  :mod "491"
                  :name (x3 / name :op1 "serine")
                  :xref (x19 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :ARG1 (x8 / phosphorylate-01
                  :ARG1 (x6 / complex
                        :name (x5 / name :op1 "α2β2γ1"))
                  :degree (x7 / full)
                  :location (x12 / and
                        :op1 (x9 / absent-01
                              :ARG1 (x10 / enzyme
                                    :name (x11 / name :op1 "Akt")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                        :op2 (x17 / affect-01
                              :ARG0 (x13 / add-02
                                    :ARG1 (x14 / small-molecule
                                          :name (x15 / name :op1 "Akt")
                                          :xref (x18 / xref :value "PUBCHEM:5287662" :prob "16.868237")))
                              :polarity "-"
                              :degree (x16 / further))))))


# ::id PMC4052680.136
# ::snt These results suggested that Ser 491 was modified by autophosphorylation, whereas Ser 487 is phosphorylated by Akt, with a small degree of autophosphorylation.
# ::tok These results suggested that Ser 491 was modified by autophosphorylation , whereas Ser 487 is phosphorylated by Akt , with a small degree of autophosphorylation .
(x4 / suggest-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x11 / phosphorylate-01
            :ARG1 (x7 / modify-01
                  :ARG1 (x5 / amino-acid
                        :mod "491"
                        :name (x6 / name :op1 "serine")
                        :xref (x18 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :ARG0 (x8 / phosphorylate-01
                        :ARG1 (x9 / amino-acid
                              :mod "487"
                              :name (x10 / name :op1 "serine")
                              :xref (x17 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
            :ARG2 (x12 / enzyme
                  :name (x13 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
      :accompanier (x15 / degree
            :mod (x14 / small)
            :degree-of (x16 / phosphorylate-01)))


# ::id PMC4052680.137
# ::snt Consistent with this, there was substantial phosphorylation of Ser 491 in a human α2β2γ1 complex, and slight phosphorylation of Ser 487 in a human α1β2γ1 complex, when they were incubated with MgATP alone; these effects were completely abolished by D157A mutations that rendered the complexes inactive, although Ser 487 could still be phosphorylated by Akt in the inactive complex ( Figure 2 B).
# ::tok Consistent with this , there was substantial phosphorylation of Ser 491 in a human α2β2γ1 complex , and slight phosphorylation of Ser 487 in a human α1β2γ1 complex , when they were incubated with MgATP alone ; these effects were completely abolished by D157A mutations that rendered the complexes inactive , although Ser 487 could still be phosphorylated by Akt in the inactive complex ( Figure 2 B ) .
(x1 / multi-sentence
      :snt1 (x5 / phosphorylate-01
            :time (x2 / consistent-01
                  :ARG2 (x3 / this))
            :degree (x4 / substantial)
            :ARG1 (x6 / amino-acid
                  :mod "491"
                  :name (x7 / name :op1 "serine")
                  :xref (x45 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :location (x11 / and
                  :op1 (x10 / macro-molecular-complex
                        :mod (x8 / human)
                        :name (x9 / name :op1 "α2β2γ1"))
                  :op2 (x13 / phosphorylate-01
                        :degree (x12 / slight)
                        :ARG1 (x14 / amino-acid
                              :mod "487"
                              :name (x15 / name :op1 "serine")
                              :xref (x47 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :location (x18 / macro-molecular-complex
                              :mod (x16 / human)
                              :name (x17 / name :op1 "α1β2γ1"))))
            :time (x20 / incubate-01
                  :ARG1 (x19 / they)
                  :ARG2 (x21 / small-molecule
                        :name (x22 / name :op1 "MgATP")
                        :mod (x23 / alone)
                        :xref (x44 / xref :value "PUBCHEM:15126" :prob "18.86067"))))
      :snt2 (x31 / render-01
            :ARG1 (x25 / affect-01
                  :mod (x24 / this))
            :ARG0 (x27 / abolish-01
                  :ARG1-of (x26 / complete-02)
                  :ARG0 (x30 / mutate-01
                        :ARG1 (x28 / enzyme
                              :name (x29 / name :op1 "D157A"))))
            :ARG1 (x32 / macro-molecular-complex
                  :ARG0-of (x33 / activity-06 :polarity "-"))
            :concession (x34 / possible-01
                  :ARG1 (x38 / phosphorylate-01
                        :ARG1 (x35 / amino-acid
                              :mod "487"
                              :name (x36 / name :op1 "serine")
                              :xref (x46 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :mod (x37 / still)
                        :ARG2 (x39 / enzyme
                              :name (x40 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
            :ARG2 (x41 / activate-01 :polarity "-")
            :ARG1-of (x42 / describe-01
                  :ARG0 (x43 / figure :mod "2b"))))


# ::id PMC4052680.138
# ::snt Unlike the equivalent α1β2γ1 complexes, where the S487D mutant was phosphorylated at a lower rate ( Figure 1 E), the WT, S491A and S491D mutant α2β2γ1 complexes were phosphorylated on Thr 172 at equal rates by LKB1 ( Figure 2 C).
# ::tok Unlike the equivalent α1β2γ1 complexes , where the S487D mutant was phosphorylated at a lower rate ( Figure 1 E ) , the WT , S491A and S491D mutant α2β2γ1 complexes were phosphorylated on Thr 172 at equal rates by LKB1 ( Figure 2 C ) .
(x1 / multi-sentence
      :snt1 (x9 / phosphorylate-01
            :ARG1-of (x2 / resemble-01
                  :polarity "-"
                  :ARG2 (x3 / equal-01))
            :ARG1 (x5 / complex
                  :name (x4 / name :op1 "α1β2γ1")
                  :location-of (x8 / mutate-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "S487D"))))
            :location (x12 / rate
                  :ARG1-of (x10 / low-04
                        :degree (x11 / more))
                  :ARG1-of (x13 / describe-01
                        :ARG0 (x14 / figure :mod "e")))
            :ARG2 (x18 / enzyme
                  :mod (x15 / wild-type
                        :op1 (x16 / mutate-01 :value "S491A")
                        :op2 (x17 / mutate-01 :value "S491D"))
                  :ARG2-of (x19 / mutate-01)
                  :name (x20 / name :op1 "α2β2γ1")
                  :xref (x31 / xref :value "UNIPROT:ILVBL_HUMAN" :prob "0.562")))
      :snt2 (x22 / phosphorylate-01
            :ARG1 (x21 / macro-molecular-complex)
            :ARG1 (x23 / amino-acid
                  :mod "172"
                  :name (x24 / name :op1 "threonine")
                  :xref (x32 / xref :value "PUBCHEM:205" :prob "11.848252"))
            :location (x26 / rate
                  :ARG1-of (x25 / equal-01))
            :ARG2 (x27 / enzyme
                  :name (x28 / name :op1 "LKB1")
                  :xref (x / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002"))
            :ARG1-of (x29 / describe-01
                  :ARG0 (x30 / figure :mod "4c"))))


# ::id PMC4052680.139
# ::snt Ser 491 (AMPK-α2), and to a lesser extent Ser 487 (AMPK-α1), are caused by autophosphorylation
# ::tok Ser 491 ( AMPK-α2 ) , and to a lesser extent Ser 487 ( AMPK-α1 ) , are caused by autophosphorylation
(x12 / be-located-at-91
      :ARG1 (x5 / and
            :op1 (x1 / protein-segment
                  :part-of (x2 / amino-acid
                        :mod "491"
                        :name (x3 / name :op1 "serine")
                        :xref (x15 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :name (x4 / name :op1 "AMPK-α2"))
            :op2 (x7 / extent
                  :degree (x6 / less))
            :op3 (x8 / amino-acid
                  :mod "487"
                  :name (x9 / name :op1 "serine")
                  :xref (x / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :op2 (x10 / small-molecule
                  :name (x11 / name :op1 "AMPK-α1")))
      :ARG2 (x13 / cause-01
            :ARG0 (x14 / phosphorylate-01)))


# ::id PMC4052680.140
# ::snt AMPK (0.1 unit, either α1β2γ1, α2β2γ1 complexes or purified from rat liver [ 2 ]) was incubated with 5 nmol of the SAMS, S485 or S491 peptides in the presence of 5 mM MgCl 2 and 200 μM [γ- 32 P]ATP in a final volume of 25 μl for 30 min at 30°C, before SDS/PAGE and autoradiography.
# ::tok AMPK ( 0.1 unit , either α1β2γ1 , α2β2γ1 complexes or purified from rat liver [ 2 ] ) was incubated with 5 nmol of the SAMS , S485 or S491 peptides in the presence of 5 mM MgCl 2 and 200 μM [ γ- 32 P ] ATP in a final volume of 25 μl for 30 min at 30 °C , before SDS @/@ PAGE and autoradiography .
(x1 / multi-sentence
      :snt1 (x18 / incubate-01
            :ARG1 (x10 / macro-molecular-complex
                  :ARG0 (x2 / small-molecule
                        :name (x3 / name :op1 "AMPK")
                        :quant (x4 / concentration-quantity
                              :quant "0.1"
                              :unit (x5 / or
                                    :op1 (x6 / enzyme
                                          :name (x7 / name :op1 "α1β2γ1")
                                          :xref (x60 / xref :value "UNIPROT:AL8A1_HUMAN" :prob "0.562"))
                                    :op2 (x8 / enzyme
                                          :name (x9 / name :op1 "α2β2γ1")
                                          :xref (x59 / xref :value "UNIPROT:ILVBL_HUMAN" :prob "0.562"))))
                        :xref (x64 / xref :value "PUBCHEM:11524144" :prob "11.258356"))
                  :ARG1-of (x12 / purify-01
                        :ARG0-of (x11 / or)
                        :ARG2 (x14 / liver
                              :part-of (x13 / rat))
                        :ARG1-of (x15 / describe-01
                              :ARG0 (x16 / publication
                                    :ARG1-of (x17 / cite-01 :ARG2 "2")))))
            :ARG2 (x19 / small-molecule
                  :name (x20 / name :op1 "5" :op2 "nmol"))
            :ARG1 (x25 / or
                  :op1 (x21 / enzyme
                        :name (x22 / name :op1 "SAMS")
                        :xref (x / xref :value "UNIPROT:SAMN1_HUMAN" :prob "0.282"))
                  :op2 (x23 / amino-acid
                        :mod "485"
                        :name (x24 / name :op1 "serine")
                        :xref (x63 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :op3 (x26 / amino-acid
                        :mod "491"
                        :name (x27 / name :op1 "serine")
                        :xref (x62 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :op2 (x28 / peptide))
            :condition (x29 / present-02
                  :ARG1 (x30 / small-molecule
                        :quant (x31 / concentration-quantity
                              :quant "5"
                              :unit (x32 / millimolar))
                        :name (x33 / name :op1 "MgCl")
                        :xref (x65 / xref :value "PUBCHEM:123352" :prob "9.286493"))))
      :snt2 (x57 / and
            :op1 (x46 / volume
                  :ARG0 (x34 / and
                        :quant "2"
                        :op2 (x35 / concentration-quantity
                              :quant "200"
                              :unit (x36 / micromolar))
                        :ARG1-of (x37 / describe-01
                              :ARG0 (x38 / publication
                                    :ARG1-of (x39 / cite-01 :ARG2 "32")))
                        :ARG1-of (x40 / statistical-test-91
                              :ARG2 (x41 / less-than :op1 "0.05")))
                  :ARG1-of (x42 / describe-01
                        :ARG0 (x43 / small-molecule
                              :name (x44 / name :op1 "ATP")
                              :xref (x61 / xref :value "PUBCHEM:5957" :prob "14.368295"))
                        :time (x45 / final))
                  :quant-of (x47 / enzyme
                        :name (x48 / name :op1 "25" :op2 "μl"))
                  :duration (x49 / temporal-quantity
                        :quant "30"
                        :unit (x50 / minute))
                  :mod (x51 / temperature-quantity
                        :quant "30"
                        :scale (x52 / celsius))
                  :mod (x53 / before
                        :op1 (x56 / analyze-01
                              :ARG1 (x54 / thing
                                    :name (x55 / name :op1 "sds-page")))))
            :op2 (x58 / autoradiography)))


# ::id PMC4052680.141
# ::snt We also synthesized peptides corresponding to the sequences around Ser 485 on rat α1 (S485, TPQRSGSISNYRS) or Ser 491 on rat/human α2 (S491, TPQRSCSAAGLHR), and compared them as AMPK substrates with the classical SAMS peptide [ 36 ].
# ::tok We also synthesized peptides corresponding to the sequences around Ser 485 on rat α1 ( S485 , TPQRSGSISNYRS ) or Ser 491 on rat @/@ human α2 ( S491 , TPQRSCSAAGLHR ) , and compared them as AMPK substrates with the classical SAMS peptide [ 36 ] .
(x26 / and
      :op1 (x3 / synthesize-01
            :ARG0 (x1 / we)
            :mod (x2 / also)
            :ARG1 (x4 / peptide
                  :ARG1-of (x5 / correspond-02
                        :ARG2 (x6 / sequence
                              :ARG1-of (x7 / around
                                    :op1 (x8 / amino-acid
                                          :mod "485"
                                          :name (x9 / name :op1 "serine")
                                          :xref (x38 / xref :value "PUBCHEM:5951" :prob "11.218784"))))))
            :ARG2 (x16 / or
                  :op1 (x10 / cell
                        :mod (x11 / rat)
                        :name (x12 / name :op1 "α1")
                        :ARG1-of (x13 / amino-acid
                              :mod "485"
                              :name (x14 / name :op1 "serine")
                              :xref (x39 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :name (x15 / name :op1 "TPQRSGSISNYRS"))
                  :op2 (x17 / amino-acid
                        :mod "491"
                        :name (x18 / name :op1 "serine")
                        :xref (x40 / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :location (x20 / disease
                  :mod (x19 / rat)
                  :mod (x21 / human)
                  :name (x22 / name :op1 "α2")
                  :ARG1-of (x23 / amino-acid
                        :mod "491"
                        :name (x24 / name :op1 "serine")
                        :xref (x37 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :name (x25 / name :op1 "TPQRSCSAAGLHR")))
      :op2 (x27 / compare-01
            :ARG2 (x30 / substrate
                  :mod (x28 / protein
                        :name (x29 / name :op1 "AMPK")
                        :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))
            :ARG1 (x33 / peptide
                  :ARG0-of (x31 / classical
                        :name (x32 / name :op1 "SAMS"))
                  :ARG1-of (x34 / describe-01
                        :ARG0 (x35 / publication
                              :ARG1-of (x36 / cite-01 :ARG2 "36"))))))


# ::id PMC4052680.142
# ::snt Although the SAMS peptide was by far the best substrate, the S491 peptide was also phosphorylated, whereas the S485 peptide was not phosphorylated at all.
# ::tok Although the SAMS peptide was by far the best substrate , the S491 peptide was also phosphorylated , whereas the S485 peptide was not phosphorylated at all .
(x1 / have-concession-91
      :ARG2 (x7 / substrate
            :ARG0 (x3 / peptide
                  :name (x2 / name :op1 "SAMS"))
            :degree (x4 / by-far
                  :ARG1 (x5 / good-02
                        :degree (x6 / most))))
      :ARG1 (x13 / contrast-01
            :ARG1 (x12 / phosphorylate-01
                  :ARG1 (x10 / peptide
                        :mod (x8 / amino-acid
                              :mod "491"
                              :name (x9 / name :op1 "serine")
                              :xref (x19 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                  :mod (x11 / also))
            :ARG2 (x17 / phosphorylate-01
                  :ARG1 (x16 / peptide
                        :mod (x14 / amino-acid
                              :mod "485"
                              :name (x15 / name :op1 "serine")
                              :xref (x / xref :value "PUBCHEM:5951" :prob "11.218784")))
                  :polarity "-"
                  :degree (x18 / at-all))))


# ::id PMC4052680.143
# ::snt The results were identical with rat liver AMPK (a mixture of α1β1γ1 and α2β1γ1 complexes) or with recombinant human α1β2γ1 and α2β2γ1 complexes ( Figure 2 D).
# ::tok The results were identical with rat liver AMPK ( a mixture of α1β1γ1 and α2β1γ1 complexes ) or with recombinant human α1β2γ1 and α2β2γ1 complexes ( Figure 2 D ) .
(x1 / multi-sentence
      :snt1 (x15 / or
            :op1 (x4 / identical-01
                  :ARG1 (x2 / thing
                        :ARG2-of (x3 / result-01))
                  :ARG2 (x6 / liver
                        :mod (x5 / rat)
                        :ARG1-of (x14 / macro-molecular-complex
                              :name (x7 / name :op1 "AMPK")
                              :ARG0-of (x8 / mixture
                                    :consist-of (x11 / and
                                          :op1 (x9 / enzyme
                                                :name (x10 / name :op1 "α1β1γ1")
                                                :xref (x / xref :value "UNIPROT:3BHS7_HUMAN" :prob "0.562"))
                                          :op2 (x12 / enzyme
                                                :name (x13 / name :op1 "α2β1γ1")
                                                :xref (x25 / xref :value "UNIPROT:ANM1_HUMAN" :prob "0.562")))))))
            :op2 (x16 / protein
                  :ARG3-of (x17 / recombine-01)
                  :mod (x18 / human)
                  :name (x19 / name :op1 "α1β2γ1")
                  :xref (x26 / xref :value "UNIPROT:AL8A1_HUMAN" :prob "0.562")))
      :snt2 (x20 / and
            :op2 (x22 / macro-molecular-complex
                  :name (x21 / name :op1 "α2β2γ1"))
            :ARG1-of (x23 / describe-01
                  :ARG0 (x24 / figure :mod "2"))))


# ::id PMC4052680.144
# ::snt Ser 487 phosphorylation reduces Thr 172 phosphorylation: studies with active AMPK
# ::tok Ser 487 phosphorylation reduces Thr 172 phosphorylation : studies with active AMPK
(x4 / reduce-01
      :ARG1 (x3 / phosphorylate-01
            :ARG1 (x1 / amino-acid
                  :mod "487"
                  :name (x2 / name :op1 "serine")
                  :xref (x12 / xref :value "PUBCHEM:5951" :prob "11.218784")))
      :ARG1 (x7 / phosphorylate-01
            :ARG1 (x5 / amino-acid
                  :mod "172"
                  :name (x6 / name :op1 "threonine")
                  :xref (x13 / xref :value "PUBCHEM:205" :prob "11.848252")))
      :ARG2 (x8 / study-01
            :ARG1 (x9 / activity-06))
      :ARG0 (x10 / protein
            :name (x11 / name :op1 "AMPK")
            :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))


# ::id PMC4052680.145
# ::snt We next incubated the active α1β2γ1 complex with Akt under conditions where we obtained stoichiometric phosphorylation of Ser 487 , and subsequently treated with the LKB1 complex under conditions where we could measure the initial rate of Thr 172 phosphorylation and consequent activation.
# ::tok We next incubated the active α1β2γ1 complex with Akt under conditions where we obtained stoichiometric phosphorylation of Ser 487 , and subsequently treated with the LKB1 complex under conditions where we could measure the initial rate of Thr 172 phosphorylation and consequent activation .
(x3 / incubate-01
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x6 / macro-molecular-complex
            :ARG0-of (x4 / activity-06
                  :name (x5 / name :op1 "α1β2γ1"))
            :part (x7 / enzyme
                  :name (x8 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
      :condition (x10 / obtain-01
            :ARG0 (x9 / we)
            :ARG1 (x16 / and
                  :op1 (x13 / phosphorylate-01
                        :ARG2 (x11 / enzyme
                              :name (x12 / name :op1 "stoichiometric"))
                        :ARG1 (x14 / amino-acid
                              :mod "487"
                              :name (x15 / name :op1 "serine")
                              :xref (x36 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                  :op2 (x18 / treat-04
                        :time (x17 / subsequent)
                        :ARG2 (x30 / and
                              :op1 (x21 / macro-molecular-complex
                                    :mod (x19 / enzyme
                                          :name (x20 / name :op1 "LKB1")
                                          :xref (x34 / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002"))
                                    :condition (x22 / possible-01
                                          :ARG1 (x24 / measure-01
                                                :ARG0 (x23 / we)
                                                :ARG1 (x26 / rate
                                                      :mod (x25 / initial)
                                                      :degree-of (x29 / phosphorylate-01
                                                            :ARG1 (x27 / amino-acid
                                                                  :mod "172"
                                                                  :name (x28 / name :op1 "threonine")
                                                                  :xref (x35 / xref :value "PUBCHEM:205" :prob "11.848252")))))))
                              :op2 (x33 / activate-01
                                    :ARG1 (x31 / enzyme
                                          :name (x32 / name :op1 "consequent"))))))))


# ::id PMC4052680.146
# ::snt As with the inactive complex ( Figure 1 F), prior Akt phosphorylation reduced the rate of subsequent Thr 172 phosphorylation ( Figure 3 A), but using the active complex this could also be seen to be associated with a reduction in activation by LKB1 of approximately 40% ( Figure 3 B); both effects were abolished by an S487A mutation within the ST loop.
# ::tok As with the inactive complex ( Figure 1 F ) , prior Akt phosphorylation reduced the rate of subsequent Thr 172 phosphorylation ( Figure 3 A ) , but using the active complex this could also be seen to be associated with a reduction in activation by LKB1 of approximately 40 % ( Figure 3 B ) ; both effects were abolished by an S487A mutation within the ST loop .
(x1 / multi-sentence
      :snt1 (x10 / reduce-01
            :time (x3 / macro-molecular-complex
                  :ARG0-of (x2 / activity-06 :polarity "-")
                  :ARG1-of (x4 / describe-01
                        :ARG0 (x5 / figure :mod "f")))
            :ARG0 (x6 / prior
                  :op1 (x9 / phosphorylate-01
                        :ARG1 (x7 / enzyme
                              :name (x8 / name :op1 "Akt")
                              :xref (x42 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
            :ARG1 (x11 / rate
                  :degree-of (x15 / phosphorylate-01
                        :mod (x12 / subsequent)
                        :ARG1 (x13 / amino-acid
                              :mod "172"
                              :name (x14 / name :op1 "threonine")
                              :xref (x43 / xref :value "PUBCHEM:205" :prob "11.848252"))))
            :ARG1-of (x16 / describe-01
                  :ARG0 (x17 / figure :mod "a"))
            :ARG1 (x18 / use-01
                  :ARG1 (x20 / complex
                        :ARG1-of (x19 / activate-01))))
      :snt2 (x21 / and
            :op1 (x37 / abolish-01
                  :ARG1-of (x25 / see-01
                        :ARG1-of (x23 / possible-01
                              :mod (x22 / this)
                              :mod (x24 / also)))
                  :ARG1 (x35 / and
                        :op1 (x26 / associate-01
                              :ARG2 (x27 / reduce-01
                                    :ARG1 (x28 / activate-01
                                          :ARG0 (x29 / enzyme
                                                :name (x30 / name :op1 "LKB1")
                                                :xref (x / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002")))
                                    :ARG2 (x31 / approximately
                                          :op1 (x32 / percentage-entity :value "40")))
                              :ARG1-of (x33 / describe-01
                                    :ARG0 (x34 / figure :mod "3b")))
                        :op2 (x36 / affect-01))
                  :ARG0 (x38 / mutate-01 :value "S487A"))
            :op2 (x39 / mutate-01
                  :ARG1 (x41 / loop
                        :ARG0-of (x40 / st)))))


# ::id PMC4052680.147
# ::snt Figure 3 (C) shows that the inhibitory effect of prior Ser 487 phosphorylation on Thr 172 phosphorylation and AMPK activation was identical using either LKB1 or CaMKKβ, showing that the effect is independent of the upstream kinase utilized.
# ::tok Figure 3 ( C ) shows that the inhibitory effect of prior Ser 487 phosphorylation on Thr 172 phosphorylation and AMPK activation was identical using either LKB1 or CaMKKβ, showing that the effect is independent of the upstream kinase utilized .
(x4 / show-01
      :ARG0 (x1 / figure
            :mod "3"
            :ARG1-of (x2 / describe-01
                  :ARG0 (x3 / figure :mod "5c")))
      :ARG1 (x30 / utilize-01
            :ARG0 (x25 / show-01
                  :ARG1 (x6 / affect-01
                        :ARG2 (x5 / inhibit-01)
                        :ARG0 (x10 / phosphorylate-01
                              :time (x7 / prior)
                              :ARG1 (x8 / amino-acid
                                    :mod "487"
                                    :name (x9 / name :op1 "serine")
                                    :xref (x33 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                        :ARG1 (x14 / and
                              :op1 (x13 / phosphorylate-01
                                    :ARG1 (x11 / amino-acid
                                          :mod "172"
                                          :name (x12 / name :op1 "threonine")
                                          :xref (x34 / xref :value "PUBCHEM:205" :prob "11.848252")))
                              :op2 (x17 / activate-01
                                    :ARG1 (x15 / protein
                                          :name (x16 / name :op1 "AMPK")
                                          :xref (x32 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))))
                  :ARG0 (x19 / use-01
                        :ARG1-of (x18 / identical-01)
                        :ARG1 (x22 / or
                              :op1 (x20 / enzyme
                                    :name (x21 / name :op1 "LKB1")
                                    :xref (x / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002"))
                              :op2 (x23 / enzyme
                                    :name (x24 / name :op1 "CaMKKβ,")
                                    :xref (x31 / xref :value "UNIPROT:KKCC1_HUMAN" :prob "0.302"))))
                  :ARG1 (x26 / affect-01))
            :ARG1 (x27 / depend-01
                  :polarity "-"
                  :ARG1 (x29 / kinase
                        :location (x28 / upstream)))))


# ::id PMC4052680.148
# ::snt Prior phosphorylation of AMPK-α1 by Akt at Ser 487 reduces subsequent phosphorylation and activation of Thr 172 by LKB1 or CaMKKβ
# ::tok Prior phosphorylation of AMPK-α1 by Akt at Ser 487 reduces subsequent phosphorylation and activation of Thr 172 by LKB1 or CaMKKβ
(x2 / phosphorylate-01
      :time (x1 / prior)
      :ARG1 (x3 / enzyme
            :name (x4 / name :op1 "AMPK-α1")
            :xref (x22 / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662"))
      :ARG0 (x5 / enzyme
            :name (x6 / name :op1 "Akt")
            :xref (x23 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
      :location (x7 / amino-acid
            :mod "487"
            :name (x8 / name :op1 "serine")
            :xref (x24 / xref :value "PUBCHEM:5951" :prob "11.218784"))
      :ARG1-of (x9 / reduce-01
            :ARG1 (x11 / and
                  :op1 (x10 / subsequent)
                  :op1 (x12 / phosphorylate-01
                        :ARG1 (x13 / amino-acid
                              :mod "172"
                              :name (x14 / name :op1 "threonine")
                              :xref (x25 / xref :value "PUBCHEM:205" :prob "11.848252")))
                  :op2 (x15 / activate-01))
            :ARG0 (x18 / or
                  :op1 (x16 / enzyme
                        :name (x17 / name :op1 "LKB1")
                        :xref (x21 / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002"))
                  :op2 (x19 / enzyme
                        :name (x20 / name :op1 "CaMKKβ")
                        :xref (x / xref :value "UNIPROT:KKCC1_HUMAN" :prob "0.312")))))


# ::id PMC4052680.149
# ::snt AMPK (α1β2γ1 complex, WT or S487A mutant) was pre-incubated with MgATP and Akt for 30 min, and then with LKB1 (50 ng) or CaMKKβ (23 ng) for 10 min at 30°C in a final volume of 40 μl.
# ::tok AMPK ( α1β2γ1 complex , WT or S487A mutant ) was pre @-@ incubated with MgATP and Akt for 30 min , and then with LKB1 ( 50 ng ) or CaMKKβ ( 23 ng ) for 10 min at 30 °C in a final volume of 40 μl .
(x1 / multi-sentence
      :snt1 (x7 / or
            :mod (x2 / protein
                  :name (x3 / name :op1 "AMPK")
                  :xref (x38 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
            :op1 (x5 / macro-molecular-complex
                  :name (x4 / name :op1 "α1β2γ1"))
            :op2 (x6 / wild-type)
            :op3 (x8 / mutate-01 :value "S487A"))
      :snt2 (x35 / volume
            :ARG1 (x9 / mutate-01)
            :ARG1-of (x11 / incubate-01
                  :time (x10 / before)
                  :ARG2 (x14 / and
                        :op1 (x12 / enzyme
                              :name (x13 / name :op1 "MgATP")
                              :xref (x39 / xref :value "UNIPROT:MGAP_HUMAN" :prob "0.232"))
                        :op2 (x15 / enzyme
                              :name (x16 / name :op1 "Akt")
                              :xref (x40 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                  :duration (x19 / and
                        :op1 (x17 / temporal-quantity
                              :quant "30"
                              :unit (x18 / minute))
                        :op2 (x20 / then))
                  :ARG2 (x25 / or
                        :op1 (x21 / enzyme
                              :name (x22 / name :op1 "LKB1")
                              :quant (x23 / mass-quantity
                                    :quant "50"
                                    :unit (x24 / nanogram-per-milliliter))
                              :xref (x / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002"))
                        :op2 (x26 / small-molecule
                              :name (x27 / name :op1 "CaMKKβ")
                              :quant (x28 / concentration-quantity
                                    :quant "23"
                                    :unit (x29 / nanogram-per-milliliter))))
                  :duration (x30 / temporal-quantity
                        :quant "10"
                        :unit (x31 / minute))
                  :mod (x32 / temperature-quantity
                        :quant "30"
                        :scale (x33 / celsius))
                  :ARG2 (x34 / final))
            :quant-of (x36 / enzyme
                  :name (x37 / name :op1 "40" :op2 "μl"))))


# ::id PMC4052680.150
# ::snt Phosphorylation ( A and C ) was assessed in duplicate samples by Western blotting, and AMPK activity ( B and C ) by kinase assays.
# ::tok Phosphorylation ( A and C ) was assessed in duplicate samples by Western blotting , and AMPK activity ( B and C ) by kinase assays .
(x6 / assess-01
      :ARG1 (x1 / phosphorylate-01
            :ARG1-of (x2 / describe-01
                  :ARG0 (x4 / and
                        :op1 (x3 / figure :mod "a")
                        :op2 (x5 / figure :mod "5c"))))
      :ARG2 (x15 / and
            :op1 (x14 / activity-06
                  :ARG1-of (x7 / duplicate-01)
                  :ARG0 (x8 / thing
                        :ARG1-of (x9 / sample-01)
                        :manner (x11 / and
                              :op1 (x10 / immunoblot-01)
                              :op2 (x12 / protein
                                    :name (x13 / name :op1 "AMPK")
                                    :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))))
            :op2 (x16 / figure :mod "4c"))
      :ARG0 (x18 / assay-01
            :ARG1 (x17 / kinase)))


# ::id PMC4052680.151
# ::snt Results in ( B ) and ( C ) are means±S.E.M.
# ::tok Results in ( B ) and ( C ) are means±S.E.M .
(x4 / and
      :op1 (x1 / result-01
            :ARG1-of (x2 / describe-01
                  :ARG0 (x3 / figure :mod "b")))
      :op2 (x7 / be-located-at-91
            :ARG1-of (x5 / describe-01
                  :ARG0 (x6 / figure :mod "c"))
            :ARG1 (x8 / enzyme
                  :name (x9 / name :op1 "means±S.E.M"))))


# ::id PMC4052680.152
# ::snt Phosphorylation of Ser 487 in intact cells reduces LKB1-dependent AMPK activation
# ::tok Phosphorylation of Ser 487 in intact cells reduces LKB1 @-@ dependent AMPK activation
(x6 / reduce-01
      :ARG0 (x1 / phosphorylate-01
            :ARG1 (x2 / amino-acid
                  :mod "487"
                  :name (x3 / name :op1 "serine")
                  :xref (x14 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :location (x5 / cell
                  :mod (x4 / intact)))
      :ARG1 (x12 / activate-01
            :ARG0-of (x9 / depend-01
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "LKB1")
                        :xref (x13 / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002")))
            :ARG1 (x10 / protein
                  :name (x11 / name :op1 "AMPK")
                  :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))))


# ::id PMC4052680.153
# ::snt To test the effects of Ser 487 phosphorylation in intact cells, we generated isogenic HEK-293 cells stably expressing FLAG-tagged WT AMPK-α1 or AMPK-α2, or a non-phosphorylatable (S487A) α1 mutant.
# ::tok To test the effects of Ser 487 phosphorylation in intact cells , we generated isogenic HEK @-@ 293 cells stably expressing FLAG @-@ tagged WT AMPK-α1 or AMPK-α2 , or a non @-@ phosphorylatable ( S487A ) α1 mutant .
(x1 / multi-sentence
      :snt1 (x10 / generate-01
            :purpose (x2 / test-01
                  :ARG1 (x3 / affect-01
                        :ARG0 (x6 / phosphorylate-01
                              :ARG1 (x4 / amino-acid
                                    :mod "487"
                                    :name (x5 / name :op1 "serine")
                                    :xref (x36 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                        :ARG1 (x8 / cell
                              :mod (x7 / intact))))
            :ARG0 (x9 / we)
            :ARG1-of (x14 / stable-03
                  :mod (x11 / isogenic)
                  :mod (x13 / cell
                        :name (x12 / name :op1 "HEK-293"))
                  :ARG1 (x15 / express-03
                        :ARG2 (x16 / enzyme
                              :ARG1-of (x19 / tag-01
                                    :ARG2 (x17 / protein
                                          :name (x18 / name :op1 "FLAG")
                                          :xref (x35 / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                              :mod (x20 / wild-type)
                              :name (x21 / name :op1 "AMPK-α1")
                              :xref (x34 / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662")))))
      :snt2 (x22 / or
            :op1 (x25 / or
                  :op1 (x23 / enzyme
                        :name (x24 / name :op1 "AMPK-α2")
                        :xref (x33 / xref :value "UNIPROT:AAPK2_HUMAN" :prob "0.662"))
                  :op2 (x26 / protein
                        :polarity "-"
                        :name (x27 / name :op1 "phosphorylatable")
                        :ARG1-of (x28 / mutate-01 :value "S487A")
                        :xref (x32 / xref :value "UNIPROT:Q59GM9_HUMAN" :prob "0.331")))
            :op2 (x31 / mutate-01
                  :ARG2 (x29 / enzyme
                        :name (x30 / name :op1 "α1")
                        :xref (x / xref :value "UNIPROT:AK1C3_HUMAN" :prob "0.553")))))


# ::id PMC4052680.154
# ::snt We have shown previously that when AMPK-β [ 16 ] or AMPK-γ [ 19 ] subunits are expressed using this system, they largely replace the endogenous subunit because they compete for the available α/γ or α/β partners, with free subunits being unstable.
# ::tok We have shown previously that when AMPK-β [ 16 ] or AMPK-γ [ 19 ] subunits are expressed using this system , they largely replace the endogenous subunit because they compete for the available α/γ or α/β partners , with free subunits being unstable .
(x1 / multi-sentence
      :snt1 (x3 / show-01
            :ARG0 (x2 / we)
            :time (x4 / previous)
            :ARG1 (x5 / and
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "AMPK-β")
                        :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "0.662"))
                  :ARG1-of (x8 / describe-01
                        :ARG0 (x9 / publication
                              :ARG1-of (x10 / cite-01
                                    :ARG2 (x11 / or
                                          :op1 "16"
                                          :op2 (x12 / enzyme
                                                :name (x13 / name :op1 "AMPK-γ")
                                                :xref (x39 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "0.662"))))))
                  :ARG1-of (x14 / describe-01
                        :ARG0 (x15 / publication
                              :ARG1-of (x16 / cite-01 :ARG2 "19")))
                  :ARG1-of (x18 / express-01
                        :ARG1 (x17 / subunit)))
            :ARG1 (x19 / use-01
                  :ARG1 (x21 / system
                        :mod (x20 / this))))
      :snt2 (x24 / replace-01
            :ARG0 (x22 / they)
            :degree (x23 / large)
            :ARG1 (x26 / subunit
                  :mod (x25 / endogenous))
            :ARG1-of (x27 / cause-01
                  :ARG0 (x28 / compete-01
                        :ARG0 (x29 / available-02)
                        :ARG1 (x35 / partner-01
                              :ARG1 (x32 / or
                                    :op1 (x30 / enzyme
                                          :name (x31 / name :op1 "α/γ"))
                                    :op2 (x33 / enzyme
                                          :name (x34 / name :op1 "α/β"))))))
            :ARG2 (x36 / free-04)
            :ARG1 (x37 / subunit
                  :ARG1-of (x38 / stable-03 :polarity "-"))))


# ::id PMC4052680.156
# ::snt The presence of a small amount of endogenous α subunits does not affect interpretation of the kinase assays shown in Figure 4 , which were conducted in anti-FLAG antibody immunoprecipitates, but a small proportion of AMPK-α subunits detected in the Western blots (e.g.
# ::tok The presence of a small amount of endogenous α subunits does not affect interpretation of the kinase assays shown in Figure 4 , which were conducted in anti @-@ FLAG antibody immunoprecipitates , but a small proportion of AMPK-α subunits detected in the Western blots ( e.g .
(x1 / multi-sentence
      :snt1 (x9 / affect-01
            :ARG0 (x8 / subunit
                  :ARG1-of (x2 / present-02
                        :ARG1 (x4 / amount
                              :mod (x3 / small)
                              :quant-of (x5 / enzyme
                                    :mod (x6 / endogenous)
                                    :name (x7 / name :op1 "riα")))))
            :polarity "-"
            :ARG1 (x10 / interpret-01
                  :ARG1 (x12 / assay-01
                        :ARG1 (x11 / kinase)
                        :ARG1-of (x13 / show-01
                              :ARG0 (x14 / figure :mod "4")))
                  :ARG1-of (x15 / conduct-01)
                  :location (x19 / antibody
                        :ARG0-of (x16 / counter-01
                              :ARG1 (x17 / protein
                                    :name (x18 / name :op1 "FLAG")
                                    :xref (x / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222"))))))
      :snt2 (x21 / contrast-01
            :ARG1 (x20 / immunoprecipitate-01)
            :ARG2 (x26 / detect-01
                  :ARG0 (x23 / proportion
                        :mod (x22 / small)
                        :quant-of (x25 / subunit
                              :name (x24 / name :op1 "AMPK-α")))
                  :location (x27 / immunoblot-01)
                  :ARG1-of (x28 / possible-01))))


# ::id PMC4052680.157
# ::snt the faint signal obtained using the anti-pS487 antibody in the cells expressing the S487A mutant) may be due to these endogenous subunits.
# ::tok the faint signal obtained using the anti @-@ pS487 antibody in the cells expressing the S487A mutant ) may be due to these endogenous subunits .
(x18 / subunit
      :ARG0 (x3 / signal-07
            :ARG0 (x1 / enzyme
                  :name (x2 / name :op1 "faint"))
            :ARG1-of (x4 / obtain-01
                  :ARG2 (x8 / antibody
                        :ARG0-of (x5 / counter-01
                              :ARG1 (x6 / protein
                                    :name (x7 / name :op1 "pS487")))))
            :location (x9 / cell
                  :ARG3-of (x10 / express-03
                        :ARG2 (x12 / enzyme
                              :ARG1-of (x11 / mutate-01 :value "S487A")
                              :ARG2-of (x13 / mutate-01)))))
      :ARG0-of (x15 / cause-01
            :ARG1-of (x14 / possible-01)
            :ARG0 (x16 / this))
      :mod (x17 / endogenous))


# ::id PMC4052680.158
# ::snt Phosphorylation of Ser 487 on AMPK-α1 by Akt in HEK-293 cells inhibits subsequent phosphorylation of Thr 172 and AMPK activation, Ser 491 on AMPK-α2 is modified by autophosphorylation, and Ser 487 phosphorylation is rapamycin-insensitive
# ::tok Phosphorylation of Ser 487 on AMPK-α1 by Akt in HEK @-@ 293 cells inhibits subsequent phosphorylation of Thr 172 and AMPK activation , Ser 491 on AMPK-α2 is modified by autophosphorylation , and Ser 487 phosphorylation is rapamycin @-@ insensitive
(x1 / multi-sentence
      :snt1 (x2 / phosphorylate-01
            :ARG1 (x3 / amino-acid
                  :mod "487"
                  :name (x4 / name :op1 "serine")
                  :xref (x39 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :ARG2 (x7 / activate-01
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "AMPK-α1")
                        :xref (x35 / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662"))
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "Akt")
                        :xref (x34 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                  :location (x11 / cell
                        :name (x10 / name :op1 "HEK-293"))))
      :snt2 (x33 / sensitive-03
            :ARG1 (x12 / inhibit-01
                  :ARG1 (x14 / phosphorylate-01
                        :time (x13 / subsequent)
                        :ARG1 (x17 / and
                              :op1 (x15 / amino-acid
                                    :mod "172"
                                    :name (x16 / name :op1 "threonine")
                                    :xref (x41 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x20 / activate-01
                                    :ARG1 (x18 / protein
                                          :name (x19 / name :op1 "AMPK")
                                          :xref (x36 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))))
                        :ARG1 (x21 / amino-acid
                              :mod "491"
                              :name (x22 / name :op1 "serine")
                              :xref (x38 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :ARG2 (x27 / and
                              :op1 (x25 / modify-01
                                    :ARG1 (x23 / protein
                                          :name (x24 / name :op1 "AMPK-α2")
                                          :xref (x / xref :value "UNIPROT:AAPK2_HUMAN" :prob "0.662"))
                                    :ARG0 (x26 / phosphorylate-01))
                              :op2 (x30 / phosphorylate-01
                                    :ARG1 (x28 / amino-acid
                                          :mod "487"
                                          :name (x29 / name :op1 "serine")
                                          :xref (x37 / xref :value "PUBCHEM:5951" :prob "11.218784"))))))
            :ARG0 (x31 / small-molecule
                  :name (x32 / name :op1 "rapamycin")
                  :xref (x40 / xref :value "PUBCHEM:5040" :prob "15.003454"))
            :polarity "-"))


# ::id PMC4052680.159
# ::snt HEK-293 cells stably expressing WT AMPK ( A ) or an S487A mutant ( B ) were serum-starved overnight and then incubated with IGF-1 in the presence or absence of MK2206 as described in the Experimental section.
# ::tok HEK @-@ 293 cells stably expressing WT AMPK ( A ) or an S487A mutant ( B ) were serum @-@ starved overnight and then incubated with IGF @-@ 1 in the presence or absence of MK2206 as described in the Experimental section .
(x16 / and
      :op1 (x14 / starve-01
            :ARG0 (x4 / express-03
                  :ARG1 (x2 / cell
                        :name (x1 / name :op1 "HEK-293"))
                  :ARG1-of (x3 / stable-03)
                  :ARG2 (x5 / enzyme
                        :mod (x6 / wild-type)
                        :name (x7 / name :op1 "AMPK")
                        :xref (x29 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))
            :li "a"
            :ARG1 (x8 / or
                  :op2 (x9 / mutate-01 :value "S487A")
                  :op2 (x10 / mutate-01)
                  :ARG1-of (x11 / describe-01
                        :ARG0 (x12 / figure :mod "1b")))
            :ARG2 (x13 / serum)
            :time (x15 / overnight))
      :op2 (x18 / incubate-01
            :time (x17 / then)
            :ARG2 (x19 / protein
                  :name (x20 / name :op1 "IGF-1")
                  :xref (x30 / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))
            :ARG2 (x21 / or
                  :op2 (x22 / absent-01)
                  :op1 (x23 / present-02
                        :ARG1 (x24 / enzyme
                              :name (x25 / name :op1 "MK2206")
                              :ARG0-of (x26 / describe-01)
                              :xref (x / xref :value "UNIPROT:MAPK2_HUMAN" :prob "0.212"))))
            :location (x28 / section-01
                  :ARG1 (x27 / experiment-01))))


# ::id PMC4052680.161
# ::snt Blots are samples from separate dishes ( n =2), whereas activity data are means±S.E.M.
# ::tok Blots are samples from separate dishes ( n =2 ) , whereas activity data are means±S.E.M .
(x2 / sample-01
      :ARG1 (x1 / immunoblot-01)
      :ARG2 (x4 / dish-01
            :ARG1-of (x3 / separate-02)
            :ARG1-of (x5 / mean-01
                  :ARG2 (x6 / enzyme
                        :name (x7 / name :op1 "n-ras")
                        :xref (x / xref :value "UNIPROT:Q9UM97_HUMAN" :prob "0.701")))
            :name (x8 / name :op1 "=2"))
      :ARG2 (x9 / activity-06
            :domain (x10 / data)
            :name (x11 / name :op1 "means±S.E.M")))


# ::id PMC4052680.164
# ::snt The cells expressing AMPK-α1 were serum-starved, and some were then treated with IGF-1 to activate Akt.
# ::tok The cells expressing AMPK-α1 were serum @-@ starved , and some were then treated with IGF @-@ 1 to activate Akt .
(x10 / treat-04
      :ARG1 (x1 / cell
            :ARG3-of (x2 / express-03
                  :ARG2 (x3 / enzyme
                        :name (x4 / name :op1 "AMPK-α1")
                        :xref (x17 / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662"))))
      :ARG1 (x7 / and
            :ARG1-of (x6 / starve-01
                  :ARG2 (x5 / serum))
            :op2 (x8 / some))
      :time (x9 / then)
      :ARG2 (x11 / protein
            :name (x12 / name :op1 "IGF-1")
            :xref (x16 / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))
      :ARG2 (x13 / activate-01
            :ARG1 (x14 / enzyme
                  :name (x15 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))


# ::id PMC4052680.165
# ::snt As expected, IGF-1 resulted in marked increases in phosphorylation of the activating sites on Akt (Thr 308 and Ser 473 ), which were blocked by the Akt inhibitor MK2206 [ 41 ], as was the phosphorylation of Ser 9 /Ser 21 on GSK3-α/β (markers of Akt activation) and Ser 487 on AMPK-α1 ( Figure 4 A).
# ::tok As expected , IGF @-@ 1 resulted in marked increases in phosphorylation of the activating sites on Akt ( Thr 308 and Ser 473 ) , which were blocked by the Akt inhibitor MK2206 [ 41 ] , as was the phosphorylation of Ser 9 /Ser 21 on GSK3-α/β ( markers of Akt activation ) and Ser 487 on AMPK-α1 ( Figure 4 A ) .
(x1 / multi-sentence
      :snt1 (x5 / result-01
            :ARG1-of (x2 / expect-01)
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "IGF-1")
                  :xref (x / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))
            :ARG2 (x7 / increase-01
                  :ARG1-of (x6 / mark-01)
                  :ARG1 (x8 / phosphorylate-01
                        :ARG1 (x13 / and
                              :op1 (x9 / activate-01
                                    :ARG1 (x10 / protein-segment
                                          :location (x11 / enzyme
                                                :name (x12 / name :op1 "Akt")
                                                :xref (x46 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
                              :op1 (x14 / amino-acid
                                    :mod "308"
                                    :name (x15 / name :op1 "threonine")
                                    :xref (x49 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x16 / amino-acid
                                    :mod "473"
                                    :name (x17 / name :op1 "serine")
                                    :xref (x50 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
                  :ARG1-of (x18 / block-01
                        :ARG0 (x21 / inhibit-01
                              :ARG1 (x19 / enzyme
                                    :name (x20 / name :op1 "Akt")
                                    :xref (x45 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                        :ARG0-of (x22 / mk2206)
                        :ARG1-of (x23 / describe-01
                              :ARG0 (x24 / publication
                                    :ARG1-of (x25 / cite-01 :ARG2 "41"))))))
      :snt2 (x26 / cause-01
            :ARG1 (x27 / phosphorylate-01
                  :ARG1 (x28 / amino-acid
                        :name (x29 / name :op1 "serine")
                        :mod "9"
                        :name (x30 / name :op1 "/Ser" :op2 "21")
                        :xref (x47 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :ARG2 (x36 / and
                        :op1 (x32 / marker
                              :name (x31 / name :op1 "GSK3-α/β")
                              :ARG0-of (x35 / activate-01
                                    :ARG1 (x33 / enzyme
                                          :name (x34 / name :op1 "Akt")
                                          :xref (x43 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
                        :op2 (x37 / amino-acid
                              :mod "487"
                              :name (x38 / name :op1 "serine")
                              :xref (x48 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :op2 (x39 / enzyme
                              :name (x40 / name :op1 "AMPK-α1")
                              :xref (x44 / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662"))))
            :ARG1-of (x41 / describe-01
                  :ARG0 (x42 / figure :mod "4"))))


# ::id PMC4052680.166
# ::snt When cells expressing WT α1 were treated with A769662, the activation of AMPK, and Thr 172 phosphorylation, was markedly blunted if the cells had been exposed previously to IGF-1, an effect abolished by MK2206.
# ::tok When cells expressing WT α1 were treated with A769662 , the activation of AMPK , and Thr 172 phosphorylation , was markedly blunted if the cells had been exposed previously to IGF @-@ 1 , an effect abolished by MK2206 .
(x24 / abolish-01
      :time (x6 / treat-04
            :ARG1 (x1 / cell
                  :ARG3-of (x2 / express-03
                        :ARG2 (x3 / enzyme
                              :mod (x4 / wild-type)
                              :name (x5 / name :op1 "α1")
                              :xref (x27 / xref :value "UNIPROT:AK1C3_HUMAN" :prob "0.553"))))
            :ARG2 (x7 / enzyme
                  :name (x8 / name :op1 "A769662")
                  :ARG1-of (x9 / activate-01
                        :ARG1 (x12 / and
                              :op1 (x10 / protein
                                    :name (x11 / name :op1 "AMPK")
                                    :xref (x28 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
                              :op2 (x17 / blunt-01
                                    :ARG1 (x15 / phosphorylate-01
                                          :ARG1 (x13 / amino-acid
                                                :mod "172"
                                                :name (x14 / name :op1 "threonine")
                                                :xref (x30 / xref :value "PUBCHEM:205" :prob "11.848252")))
                                    :mod (x16 / marked)))
                        :condition (x19 / expose-01
                              :ARG1 (x18 / cell)
                              :time (x20 / previous)
                              :ARG2 (x21 / protein
                                    :name (x22 / name :op1 "IGF-1")
                                    :ARG1-of (x23 / affect-01)
                                    :xref (x / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))))))
      :ARG0 (x25 / small-molecule
            :name (x26 / name :op1 "MK2206")
            :xref (x29 / xref :value "PUBCHEM:46930998" :prob "18.572987")))


# ::id PMC4052680.167
# ::snt The effect of IGF-1 to reduce AMPK activation and phosphorylation of Thr 172 correlated with increased Ser 487 phosphorylation, and was absent in cells expressing the S487A mutant ( Figure 4 B).
# ::tok The effect of IGF @-@ 1 to reduce AMPK activation and phosphorylation of Thr 172 correlated with increased Ser 487 phosphorylation , and was absent in cells expressing the S487A mutant ( Figure 4 B ) .
(x12 / correlate-01
      :ARG1 (x1 / affect-01
            :ARG0 (x2 / small-molecule
                  :name (x3 / name :op1 "IGF-1")
                  :xref (x26 / xref :value "PUBCHEM:5748425" :prob "10.189081"))
            :ARG2 (x4 / reduce-01
                  :ARG1 (x8 / and
                        :op1 (x7 / activate-01
                              :ARG1 (x5 / protein
                                    :name (x6 / name :op1 "AMPK")
                                    :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))
                        :op2 (x9 / phosphorylate-01
                              :ARG1 (x10 / amino-acid
                                    :mod "172"
                                    :name (x11 / name :op1 "threonine")
                                    :xref (x27 / xref :value "PUBCHEM:205" :prob "11.848252"))))))
      :ARG2 (x17 / and
            :op1 (x13 / increase-01
                  :ARG1 (x16 / phosphorylate-01
                        :ARG1 (x14 / amino-acid
                              :mod "487"
                              :name (x15 / name :op1 "serine")
                              :xref (x28 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
            :op2 (x18 / absent-01
                  :ARG2 (x19 / cell
                        :ARG3-of (x20 / express-03
                              :ARG2 (x21 / and
                                    :op1 (x22 / mutate-01 :value "S487A")
                                    :op2 (x23 / mutate-01)
                                    :ARG1-of (x24 / describe-01
                                          :ARG0 (x25 / figure :mod "4b"))))))))


# ::id PMC4052680.168
# ::snt Ser 491 on AMPK-α2 is not phosphorylated by Akt, but by autophosphorylation
# ::tok Ser 491 on AMPK-α2 is not phosphorylated by Akt , but by autophosphorylation
(x5 / phosphorylate-01
      :ARG1 (x1 / amino-acid
            :mod "491"
            :name (x2 / name :op1 "serine")
            :xref (x11 / xref :value "PUBCHEM:5951" :prob "11.218784"))
      :ARG2 (x3 / protein
            :name (x4 / name :op1 "AMPK-α2")
            :xref (x / xref :value "UNIPROT:AAPK2_HUMAN" :prob "0.662"))
      :polarity "-"
      :ARG2 (x6 / enzyme
            :name (x7 / name :op1 "Akt")
            :xref (x10 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
      :ARG1-of (x8 / contrast-01
            :ARG2 (x9 / phosphorylate-01)))


# ::id PMC4052680.169
# ::snt Figure 4 (C) shows results obtained when serum-starved cells expressing WT AMPK-α1 or AMPK-α2 were treated either with IGF-1 or with berberine, which activates AMPK by inhibiting mitochondrial ATP synthesis [ 19 ].
# ::tok Figure 4 ( C ) shows results obtained when serum @-@ starved cells expressing WT AMPK-α1 or AMPK-α2 were treated either with IGF @-@ 1 or with berberine , which activates AMPK by inhibiting mitochondrial ATP synthesis [ 19 ] .
(x1 / multi-sentence
      :snt1 (x5 / show-01
            :ARG0 (x2 / and
                  :op1 (x3 / figure :mod "4")
                  :op2 (x4 / figure :mod "5c")))
      :snt2 (x8 / obtain-01
            :ARG1 (x6 / thing
                  :ARG2-of (x7 / result-01))
            :time (x19 / treat-04
                  :ARG1 (x11 / cell
                        :ARG1-of (x10 / starve-01
                              :ARG2 (x9 / serum))
                        :ARG3-of (x12 / express-03
                              :ARG2 (x16 / or
                                    :op1 (x13 / enzyme
                                          :mod (x14 / wild-type)
                                          :name (x15 / name :op1 "AMPK-α1")
                                          :xref (x38 / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662"))
                                    :op2 (x17 / enzyme
                                          :name (x18 / name :op1 "AMPK-α2")
                                          :xref (x39 / xref :value "UNIPROT:AAPK2_HUMAN" :prob "0.662")))))
                  :mod (x20 / either)
                  :ARG2 (x23 / or
                        :op1 (x21 / protein
                              :name (x22 / name :op1 "IGF-1")
                              :xref (x37 / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))
                        :op2 (x24 / protein
                              :name (x25 / name :op1 "berberine")
                              :ARG0-of (x26 / activate-01
                                    :ARG1 (x27 / protein
                                          :name (x28 / name :op1 "AMPK")
                                          :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
                                    :ARG0 (x29 / inhibit-01
                                          :ARG1 (x33 / synthesize-01
                                                :ARG1 (x30 / mitochondrium)
                                                :ARG0 (x31 / small-molecule
                                                      :name (x32 / name :op1 "ATP")
                                                      :xref (x40 / xref :value "PUBCHEM:5957" :prob "14.368295")))))
                              :ARG1-of (x34 / describe-01
                                    :ARG0 (x35 / publication
                                          :ARG1-of (x36 / cite-01 :ARG2 "19"))))))))


# ::id PMC4052680.170
# ::snt As expected, treatment of α1-expressing cells with IGF-1 caused increased phosphorylation of Ser 487 , but not Thr 172 , whereas treatment with berberine caused increased phosphorylation of Thr 172 , accompanied by AMPK activation, but not Ser 487 .
# ::tok As expected , treatment of α1 @-@ expressing cells with IGF @-@ 1 caused increased phosphorylation of Ser 487 , but not Thr 172 , whereas treatment with berberine caused increased phosphorylation of Thr 172 , accompanied by AMPK activation , but not Ser 487 .
(x9 / cause-01
      :ARG1-of (x1 / expect-01)
      :ARG0 (x2 / treat-04
            :ARG1 (x6 / cell
                  :ARG1-of (x5 / express-03
                        :ARG2 (x3 / enzyme
                              :name (x4 / name :op1 "α1")
                              :xref (x33 / xref :value "UNIPROT:AK1C3_HUMAN" :prob "0.553"))))
            :ARG2 (x7 / protein
                  :name (x8 / name :op1 "IGF-1")
                  :xref (x34 / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673")))
      :ARG1 (x10 / increase-01
            :ARG1 (x11 / phosphorylate-01
                  :ARG1 (x12 / amino-acid
                        :mod "487"
                        :name (x13 / name :op1 "serine")
                        :xref (x38 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :ARG1-of (x14 / contrast-01
                        :ARG2 (x15 / amino-acid
                              :mod "172"
                              :name (x16 / name :op1 "threonine")
                              :xref (x39 / xref :value "PUBCHEM:205" :prob "11.848252"))))
            :ARG1-of (x17 / contrast-01
                  :ARG2 (x21 / cause-01
                        :ARG0 (x18 / treat-04
                              :ARG2 (x19 / small-molecule
                                    :name (x20 / name :op1 "berberine")
                                    :xref (x37 / xref :value "PUBCHEM:2353" :prob "15.481944")))
                        :ARG1 (x22 / increase-01
                              :ARG1 (x23 / phosphorylate-01
                                    :ARG1 (x24 / amino-acid
                                          :mod "172"
                                          :name (x25 / name :op1 "threonine")
                                          :xref (x35 / xref :value "PUBCHEM:205" :prob "11.848252"))))))
            :ARG1-of (x26 / accompany-01
                  :ARG0 (x29 / activate-01
                        :ARG1 (x27 / protein
                              :name (x28 / name :op1 "AMPK")
                              :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
                        :ARG1-of (x30 / contrast-01
                              :ARG2 (x31 / amino-acid
                                    :mod "487"
                                    :name (x32 / name :op1 "serine")
                                    :xref (x36 / xref :value "PUBCHEM:5951" :prob "11.218784")))))))


# ::id PMC4052680.171
# ::snt This contrasted markedly with results in α2-expressing cells, where treatment with IGF-1 did not increase phosphorylation of Ser 491 , whereas treatment with berberine caused increased phosphorylation of both Ser 491 and Thr 172 , together with AMPK activation.
# ::tok This contrasted markedly with results in α2 @-@ expressing cells , where treatment with IGF @-@ 1 did not increase phosphorylation of Ser 491 , whereas treatment with berberine caused increased phosphorylation of both Ser 491 and Thr 172 , together with AMPK activation .
(x17 / contrast-01
      :ARG1 (x9 / cell-line
            :mod (x1 / this)
            :mod (x3 / marked
                  :ARG1-of (x2 / contrast-01)
                  :ARG2 (x4 / thing
                        :ARG2-of (x5 / result-01
                              :ARG1 (x8 / express-03
                                    :ARG2 (x6 / enzyme
                                          :name (x7 / name :op1 "α2")
                                          :xref (x / xref :value "UNIPROT:FKRP_HUMAN" :prob "0.552"))))))
            :location-of (x13 / increase-01
                  :ARG0 (x10 / treat-04
                        :ARG2 (x11 / small-molecule
                              :name (x12 / name :op1 "IGF-1")
                              :xref (x37 / xref :value "PUBCHEM:5748425" :prob "10.189081")))
                  :polarity "-"
                  :ARG1 (x14 / phosphorylate-01
                        :ARG1 (x15 / amino-acid
                              :mod "491"
                              :name (x16 / name :op1 "serine")
                              :xref (x38 / xref :value "PUBCHEM:5951" :prob "11.218784")))))
      :ARG2 (x18 / and
            :op1 (x22 / cause-01
                  :ARG0 (x19 / treat-04
                        :ARG2 (x20 / small-molecule
                              :name (x21 / name :op1 "berberine")
                              :xref (x36 / xref :value "PUBCHEM:2353" :prob "15.481944")))
                  :ARG1 (x23 / increase-01
                        :ARG1 (x24 / phosphorylate-01
                              :ARG1 (x25 / and
                                    :op1 (x26 / amino-acid
                                          :mod "491"
                                          :name (x27 / name :op1 "serine")
                                          :xref (x35 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x28 / amino-acid
                                          :mod "172"
                                          :name (x29 / name :op1 "threonine")
                                          :xref (x34 / xref :value "PUBCHEM:205" :prob "11.848252"))))))
            :op2 (x32 / activate-01
                  :ARG1 (x30 / protein
                        :name (x31 / name :op1 "AMPK")
                        :xref (x33 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))))


# ::id PMC4052680.172
# ::snt The results for phosphorylation of Ser 487 and Ser 491 were very similar whether we used in-house phospho-specific antibodies that are isoform-specific, or a commercial antibody that recognizes the equivalent sites on both α1 and α2.
# ::tok The results for phosphorylation of Ser 487 and Ser 491 were very similar whether we used in @-@ house phospho @-@ specific antibodies that are isoform @-@ specific , or a commercial antibody that recognizes the equivalent sites on both α1 and α2 .
(x29 / and
      :op1 (x23 / recognize-02
            :ARG1 (x1 / thing
                  :ARG2-of (x2 / result-01
                        :ARG1 (x3 / phosphorylate-01
                              :ARG1 (x6 / and
                                    :op1 (x4 / amino-acid
                                          :mod "487"
                                          :name (x5 / name :op1 "serine")
                                          :xref (x33 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x7 / amino-acid
                                          :mod "491"
                                          :name (x8 / name :op1 "serine")
                                          :xref (x32 / xref :value "PUBCHEM:5951" :prob "11.218784"))))))
            :ARG1-of (x10 / resemble-01
                  :degree (x9 / very)
                  :ARG2 (x12 / use-01
                        :mode "interrogative"
                        :ARG0 (x11 / we)
                        :ARG1 (x13 / and
                              :op1 (x14 / house))))
            :ARG0 (x22 / antibody
                  :ARG1-of (x16 / specific-02
                        :ARG2 (x15 / phosphorylate-01))
                  :ARG0 (x20 / or
                        :op1 (x17 / antibody
                              :ARG1-of (x19 / specific-02
                                    :ARG2 (x18 / isoform)))
                        :op2 (x21 / commerce)))
            :ARG1 (x25 / protein-segment
                  :ARG1-of (x24 / equal-01)
                  :location (x26 / and
                        :op1 (x27 / cell-line
                              :name (x28 / name :op1 "riα"))
                        :op2 "1")))
      :op2 (x30 / enzyme
            :name (x31 / name :op1 "α2")
            :xref (x / xref :value "UNIPROT:FKRP_HUMAN" :prob "0.552")))


# ::id PMC4052680.173
# ::snt These results are consistent with the results in Figures 2 and 3 , showing that Ser 491 on α2 is modified by autophosphorylation, and not by Akt as for Ser 487 on α1.
# ::tok These results are consistent with the results in Figures 2 and 3 , showing that Ser 491 on α2 is modified by autophosphorylation , and not by Akt as for Ser 487 on α1 .
(x4 / consistent-01
      :ARG1 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG2 (x5 / thing
            :ARG2-of (x6 / result-01
                  :ARG1 (x11 / show-01
                        :ARG1-of (x7 / describe-01
                              :ARG0 (x8 / and
                                    :op1 (x9 / figure :mod "2")
                                    :op2 (x10 / figure :mod "3")))
                        :ARG1 (x12 / amino-acid
                              :mod "491"
                              :name (x13 / name :op1 "serine")
                              :xref (x27 / xref :value "PUBCHEM:5951" :prob "11.218784")))))
      :ARG1 (x16 / modify-01
            :ARG1 (x14 / protein
                  :name (x15 / name :op1 "α2")
                  :xref (x25 / xref :value "UNIPROT:FKRP_HUMAN" :prob "0.552"))
            :ARG0 (x17 / phosphorylate-01
                  :ARG2 (x18 / and :polarity "-")
                  :ARG0 (x19 / enzyme
                        :name (x20 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :ARG2 (x21 / amino-acid
                  :mod "487"
                  :name (x22 / name :op1 "serine")
                  :xref (x26 / xref :value "PUBCHEM:5951" :prob "11.218784")))
      :ARG2 (x23 / enzyme
            :name (x24 / name :op1 "riα" :op2 "1")))


# ::id PMC4052680.174
# ::snt As expected, increased phosphorylation of the downstream AMPK target ACC correlated with Thr 172 phosphorylation and AMPK activation in both cell lines.
# ::tok As expected , increased phosphorylation of the downstream AMPK target ACC correlated with Thr 172 phosphorylation and AMPK activation in both cell lines .
(x10 / correlate-01
      :ARG1-of (x1 / expect-01)
      :ARG0 (x3 / phosphorylate-01
            :ARG1-of (x2 / increase-01)
            :ARG1 (x7 / target-01
                  :mod (x4 / downstream)
                  :mod (x5 / protein
                        :name (x6 / name :op1 "AMPK")
                        :xref (x21 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))))
      :ARG1 (x8 / enzyme
            :name (x9 / name :op1 "ACC")
            :xref (x20 / xref :value "UNIPROT:ACACA_HUMAN" :prob "0.262"))
      :ARG2 (x14 / and
            :op1 (x13 / phosphorylate-01
                  :ARG1 (x11 / amino-acid
                        :mod "172"
                        :name (x12 / name :op1 "threonine")
                        :xref (x22 / xref :value "PUBCHEM:205" :prob "11.848252")))
            :op2 (x17 / activate-01
                  :ARG1 (x15 / protein
                        :name (x16 / name :op1 "AMPK")
                        :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
                  :location (x19 / cell-line
                        :mod (x18 / both)))))


# ::id PMC4052680.175
# ::snt Ser 487 is phosphorylated by Akt and not by a kinase downstream of mTORC1 [mammalian (or mechanistic) target of rapamycin complex 1]
# ::tok Ser 487 is phosphorylated by Akt and not by a kinase downstream of mTORC1 [ mammalian ( or mechanistic ) target of rapamycin complex 1 ]
(x6 / and
      :op1 (x3 / phosphorylate-01
            :ARG1 (x1 / amino-acid
                  :mod "487"
                  :name (x2 / name :op1 "serine")
                  :xref (x21 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :ARG2 (x4 / enzyme
                  :name (x5 / name :op1 "Akt")
                  :xref (x19 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
      :op2 (x11 / mammal
            :ARG1-of (x8 / downstream
                  :polarity "-"
                  :mod (x7 / kinase)
                  :mod (x9 / enzyme
                        :name (x10 / name :op1 "mTORC1")
                        :xref (x / xref :value "UNIPROT:MTOR_HUMAN" :prob "0.283")))
            :ARG1-of (x18 / cite-01
                  :ARG2 (x12 / or
                        :op2 (x14 / target-01
                              :mod (x13 / mechanistic)
                              :ARG0 (x15 / small-molecule
                                    :name (x16 / name :op1 "rapamycin")
                                    :xref (x20 / xref :value "PUBCHEM:5040" :prob "15.003454")))
                        :op1 (x17 / macro-molecular-complex :mod "1")))))


# ::id PMC4052680.176
# ::snt To confirm that Ser 487 was phosphorylated directly by Akt in the cells, and not by a downstream kinase such as p70 S6K1, we tested the effects of rapamycin, an inhibitor of mTORC1.
# ::tok To confirm that Ser 487 was phosphorylated directly by Akt in the cells , and not by a downstream kinase such as p70 S6K1 , we tested the effects of rapamycin , an inhibitor of mTORC1 .
(x15 / test-01
      :purpose (x1 / confirm-01
            :ARG1 (x4 / phosphorylate-01
                  :ARG1 (x2 / amino-acid
                        :mod "487"
                        :name (x3 / name :op1 "serine")
                        :xref (x23 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :ARG1-of (x5 / direct-02)
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "Akt")
                        :xref (x22 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                  :location (x8 / cell)
                  :ARG1 (x9 / and :polarity "-")
                  :ARG0 (x11 / kinase
                        :mod (x10 / downstream)
                        :example (x12 / protein
                              :name (x13 / name :op1 "p70" :op2 "S6K1")))))
      :ARG0 (x14 / we)
      :ARG1 (x16 / affect-01
            :ARG0 (x17 / small-molecule
                  :name (x18 / name :op1 "rapamycin")
                  :ARG0-of (x19 / inhibit-01
                        :ARG1 (x20 / enzyme
                              :name (x21 / name :op1 "mTORC1")
                              :xref (x / xref :value "UNIPROT:MTOR_HUMAN" :prob "0.283")))
                  :xref (x24 / xref :value "PUBCHEM:5040" :prob "15.003454"))))


# ::id PMC4052680.177
# ::snt Rapamycin did not block the IGF-1-stimulated phosphorylation of Ser 487 on α1 or Ser 473 on Akt although, as expected, it blocked phosphorylation of an established mTORC1 substrate, Thr 389 on the p70/p85 isoforms of S6K1 ( Figure 4 D).
# ::tok Rapamycin did not block the IGF @-@ 1 @-@ stimulated phosphorylation of Ser 487 on α1 or Ser 473 on Akt although , as expected , it blocked phosphorylation of an established mTORC1 substrate , Thr 389 on the p70 @/@ p85 isoforms of S6K1 ( Figure 4 D ) .
(x1 / multi-sentence
      :snt1 (x4 / block-01
            :ARG0 (x2 / small-molecule
                  :name (x3 / name :op1 "Rapamycin")
                  :xref (x40 / xref :value "PUBCHEM:5040" :prob "15.003454"))
            :polarity "-"
            :ARG1 (x7 / stimulate-01
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "IGF-1")
                        :xref (x / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673")))
            :ARG1 (x8 / phosphorylate-01
                  :ARG1 (x9 / amino-acid
                        :mod "487"
                        :name (x10 / name :op1 "serine")
                        :xref (x39 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :ARG2 (x13 / or
                        :op1 (x11 / enzyme
                              :name (x12 / name :op1 "α1")
                              :xref (x36 / xref :value "UNIPROT:AK1C3_HUMAN" :prob "0.553"))
                        :op2 (x14 / amino-acid
                              :mod "473"
                              :name (x15 / name :op1 "serine")
                              :xref (x41 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
            :ARG2 (x16 / enzyme
                  :name (x17 / name :op1 "Akt")
                  :xref (x37 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
      :snt2 (x18 / have-concession-91
            :ARG1 (x20 / block-01
                  :ARG1-of (x19 / expect-01)
                  :ARG1 (x21 / phosphorylate-01
                        :ARG1 (x25 / substrate
                              :ARG1-of (x22 / establish-01)
                              :mod (x23 / macro-molecular-complex
                                    :name (x24 / name :op1 "mTORC1"))
                              :mod (x26 / amino-acid
                                    :mod "389"
                                    :name (x27 / name :op1 "threonine")
                                    :xref (x38 / xref :value "PUBCHEM:205" :prob "11.848252")))
                        :ARG2 (x30 / isoform
                              :mod (x28 / protein
                                    :name (x29 / name :op1 "p70/p85"))
                              :mod (x31 / enzyme
                                    :name (x32 / name :op1 "S6K1")
                                    :xref (x35 / xref :value "UNIPROT:KS6B1_HUMAN" :prob "1.003"))))
                  :ARG1-of (x33 / describe-01
                        :ARG0 (x34 / figure :mod "4d")))))


# ::id PMC4052680.178
# ::snt Phosphorylation of Ser 487 in intact cells reduces CaMKKβ-dependent AMPK activation
# ::tok Phosphorylation of Ser 487 in intact cells reduces CaMKKβ-dependent AMPK activation
(x6 / reduce-01
      :ARG0 (x1 / phosphorylate-01
            :ARG1 (x2 / amino-acid
                  :mod "487"
                  :name (x3 / name :op1 "serine")
                  :xref (x10 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :location (x5 / cell
                  :mod (x4 / intact)))
      :ARG1 (x9 / activate-01
            :ARG1 (x7 / enzyme
                  :name (x8 / name :op1 "AMPK")
                  :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))))


# ::id PMC4052680.179
# ::snt To show that phosphorylation of Ser 487 on AMPK-α1 by Akt could also reduce subsequent activation by CaMKKβ, we used the LKB1-null G361 melanoma cell line.
# ::tok To show that phosphorylation of Ser 487 on AMPK-α1 by Akt could also reduce subsequent activation by CaMKKβ, we used the LKB1 @-@ null G361 melanoma cell line .
(x18 / use-01
      :purpose (x1 / show-01
            :ARG1 (x2 / possible-01
                  :ARG1 (x12 / reduce-01
                        :ARG0 (x3 / phosphorylate-01
                              :ARG1 (x4 / amino-acid
                                    :mod "487"
                                    :name (x5 / name :op1 "serine")
                                    :xref (x30 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                              :ARG2 (x8 / and
                                    :op1 (x6 / enzyme
                                          :name (x7 / name :op1 "AMPK-α1")
                                          :xref (x27 / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662"))
                                    :op2 (x9 / enzyme
                                          :name (x10 / name :op1 "Akt")
                                          :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
                        :mod (x11 / also)
                        :ARG1 (x14 / activate-01
                              :time (x13 / subsequent))))
            :ARG0 (x15 / enzyme
                  :name (x16 / name :op1 "CaMKKβ,")
                  :xref (x29 / xref :value "UNIPROT:KKCC1_HUMAN" :prob "0.302")))
      :ARG0 (x17 / we)
      :ARG1 (x19 / enzyme
            :name (x20 / name :op1 "LKB1")
            :xref (x28 / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002"))
      :ARG2 (x26 / cell-line
            :mod (x21 / null)
            :mod (x22 / amino-acid
                  :mod "361"
                  :name (x23 / name :op1 "glycine"))
            :source (x24 / medical-condition
                  :name (x25 / name :op1 "melanoma"))))


# ::id PMC4052680.180
# ::snt The cells were serum-starved, and some were then treated with IGF-1 to activate Akt.
# ::tok The cells were serum @-@ starved , and some were then treated with IGF @-@ 1 to activate Akt .
(x7 / treat-04
      :ARG1 (x1 / cell)
      :ARG1 (x4 / and
            :ARG1-of (x3 / starve-01
                  :ARG2 (x2 / serum))
            :op2 (x5 / some))
      :time (x6 / then)
      :ARG2 (x8 / protein
            :name (x9 / name :op1 "IGF-1")
            :xref (x / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))
      :ARG2 (x10 / activate-01
            :ARG1 (x11 / enzyme
                  :name (x12 / name :op1 "Akt")
                  :xref (x13 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))


# ::id PMC4052680.181
# ::snt As expected, IGF-1 resulted in marked increases in phosphorylation of Thr 308 and Ser 473 on Akt, Ser 9 /Ser 21 on GSK3α/β and Ser 487 on AMPK-α1, all of which were blocked or reduced by MK2206 ( Figure 5 ).
# ::tok As expected , IGF @-@ 1 resulted in marked increases in phosphorylation of Thr 308 and Ser 473 on Akt , Ser 9 /Ser 21 on GSK3α/β and Ser 487 on AMPK-α1 , all of which were blocked or reduced by MK2206 ( Figure 5 ) .
(x1 / multi-sentence
      :snt1 (x5 / result-01
            :ARG1-of (x2 / expect-01)
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "IGF-1")
                  :xref (x / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))
            :ARG2 (x7 / increase-01
                  :ARG1-of (x6 / mark-01)
                  :ARG1 (x8 / phosphorylate-01
                        :ARG1 (x9 / and
                              :op1 (x10 / amino-acid
                                    :mod "308"
                                    :name (x11 / name :op1 "threonine")
                                    :xref (x38 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x12 / amino-acid
                                    :mod "473"
                                    :name (x13 / name :op1 "serine")
                                    :xref (x39 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                        :ARG2 (x14 / enzyme
                              :name (x15 / name :op1 "Akt")
                              :xref (x36 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))
      :snt2 (x28 / block-01
            :ARG1 (x21 / and
                  :op1 (x16 / amino-acid
                        :name (x17 / name :op1 "serine")
                        :mod "9"
                        :name (x18 / name :op1 "/Ser")
                        :mod "21"
                        :part-of (x19 / protein
                              :name (x20 / name :op1 "GSK3α/β"))
                        :xref (x40 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :op2 (x22 / amino-acid
                        :mod "487"
                        :name (x23 / name :op1 "serine")
                        :xref (x37 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :location (x24 / cell-line
                        :name (x25 / name :op1 "AMPK-α1")
                        :mod (x27 / amr-unknown
                              :mod (x26 / all))))
            :ARG1 (x29 / or
                  :op2 (x30 / reduce-01))
            :ARG0 (x31 / enzyme
                  :name (x32 / name :op1 "MK2206")
                  :xref (x35 / xref :value "UNIPROT:MAPK2_HUMAN" :prob "0.212"))
            :ARG1-of (x33 / describe-01
                  :ARG0 (x34 / figure :mod "5"))))


# ::id PMC4052680.182
# ::snt When the cells were treated with the Ca 2+ ionophore A23187 to activate CaMKKβ, the activation of AMPK and Thr 172 phosphorylation, was significantly blunted if the cells had been exposed previously to IGF-1, an effect completely abolished by MK2206 ( Figure 5 ).
# ::tok When the cells were treated with the Ca 2+ ionophore A23187 to activate CaMKKβ, the activation of AMPK and Thr 172 phosphorylation , was significantly blunted if the cells had been exposed previously to IGF @-@ 1 , an effect completely abolished by MK2206 ( Figure 5 ) .
(x1 / multi-sentence
      :snt1 (x11 / activate-01
            :time (x3 / treat-04
                  :ARG1 (x2 / cell)
                  :ARG2 (x8 / activate-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "Ca"))
                        :ARG0 (x6 / enzyme
                              :name (x7 / name
                                    :op1 "2+"
                                    :op2 "ionophore"
                                    :op3 "A23187"))
                        :ARG1 (x9 / enzyme
                              :name (x10 / name :op1 "CaMKKβ,")
                              :xref (x32 / xref :value "UNIPROT:KKCC1_HUMAN" :prob "0.302"))))
            :ARG1 (x12 / protein
                  :name (x13 / name :op1 "AMPK")
                  :xref (x33 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))
      :snt2 (x14 / and
            :op2 (x19 / blunt-01
                  :ARG1 (x17 / phosphorylate-01
                        :ARG1 (x15 / amino-acid
                              :mod "172"
                              :name (x16 / name :op1 "threonine")
                              :xref (x35 / xref :value "PUBCHEM:205" :prob "11.848252")))
                  :ARG1-of (x18 / significant-02)
                  :condition (x21 / expose-01
                        :ARG1 (x20 / cell)
                        :time (x22 / previous)
                        :ARG2 (x23 / protein
                              :name (x24 / name :op1 "IGF-1")
                              :ARG1-of (x25 / affect-01
                                    :ARG1 (x27 / abolish-01
                                          :ARG1-of (x26 / complete-02)
                                          :ARG0 (x28 / small-molecule
                                                :name (x29 / name :op1 "MK2206")
                                                :xref (x34 / xref :value "PUBCHEM:46930998" :prob "18.572987"))))
                              :xref (x / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673")))
                  :ARG1-of (x30 / describe-01
                        :ARG0 (x31 / figure :mod "5")))))


# ::id PMC4052680.183
# ::snt Phosphorylation of Ser 487 on AMPK-α1 by Akt in G361 cells inhibits subsequent phosphorylation of Thr 172 and AMPK activation by CaMKKβ
# ::tok Phosphorylation of Ser 487 on AMPK-α1 by Akt in G361 cells inhibits subsequent phosphorylation of Thr 172 and AMPK activation by CaMKKβ
(x12 / inhibit-01
      :ARG1 (x1 / phosphorylate-01
            :ARG1 (x2 / amino-acid
                  :mod "487"
                  :name (x3 / name :op1 "serine")
                  :xref (x26 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :ARG2 (x6 / activate-01
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "AMPK-α1")
                        :xref (x24 / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662"))
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "Akt")
                        :xref (x23 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                  :location (x11 / cell
                        :mod (x9 / amino-acid
                              :mod "361"
                              :name (x10 / name :op1 "glycine")))))
      :ARG1 (x20 / activate-01
            :mod (x13 / subsequent)
            :ARG1 (x14 / phosphorylate-01
                  :ARG1 (x17 / and
                        :op1 (x15 / amino-acid
                              :mod "172"
                              :name (x16 / name :op1 "threonine")
                              :xref (x27 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :op2 (x18 / protein
                              :name (x19 / name :op1 "AMPK")
                              :xref (x25 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))))
      :ARG0 (x21 / enzyme
            :name (x22 / name :op1 "CaMKKβ")
            :xref (x / xref :value "UNIPROT:KKCC1_HUMAN" :prob "0.312")))


# ::id PMC4052680.184
# ::snt G361 cells were serum-starved overnight and then incubated with IGF-1 in the presence or absence of MK2206 as described in the Experimental section.
# ::tok G361 cells were serum @-@ starved overnight and then incubated with IGF @-@ 1 in the presence or absence of MK2206 as described in the Experimental section .
(x7 / and
      :op1 (x5 / starve-01
            :ARG1 (x3 / cell
                  :mod (x1 / amino-acid
                        :mod "361"
                        :name (x2 / name :op1 "glycine")))
            :ARG2 (x4 / serum)
            :time (x6 / overnight))
      :op2 (x9 / incubate-01
            :time (x8 / then)
            :ARG2 (x10 / protein
                  :name (x11 / name :op1 "IGF-1")
                  :xref (x / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))
            :ARG2 (x12 / or
                  :op2 (x13 / absent-01)
                  :op1 (x14 / present-02
                        :ARG1 (x15 / enzyme
                              :name (x16 / name :op1 "MK2206")
                              :ARG0-of (x17 / describe-01)
                              :xref (x20 / xref :value "UNIPROT:MAPK2_HUMAN" :prob "0.212"))))
            :ARG1 (x19 / section-01
                  :ARG1 (x18 / experiment-01))))


# ::id PMC4052680.186
# ::snt Blots are samples from separate dishes, whereas activity data are means±S.E.M.
# ::tok Blots are samples from separate dishes , whereas activity data are means±S.E.M .
(x2 / sample-01
      :ARG1 (x1 / immunoblot-01)
      :ARG2 (x4 / dish-01
            :ARG1-of (x3 / separate-02)
            :ARG1-of (x5 / contrast-01
                  :ARG2 (x6 / activity-06)
                  :ARG1 (x7 / data))
            :name (x8 / name :op1 "means±S.E.M")))


# ::id PMC4052680.187
# ::snt AMPK activation is reduced in PTEN-null tumour cells in an Akt-dependent manner
# ::tok AMPK activation is reduced in PTEN @-@ null tumour cells in an Akt @-@ dependent manner
(x4 / reduce-01
      :ARG1 (x3 / activate-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "AMPK")
                  :xref (x13 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))
      :location (x9 / cell
            :mod (x5 / protein
                  :name (x6 / name :op1 "PTEN")
                  :mod (x7 / null)
                  :xref (x14 / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004"))
            :mod (x8 / tumor))
      :manner (x12 / depend-01
            :ARG1 (x10 / enzyme
                  :name (x11 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))


# ::id PMC4052680.188
# ::snt To examine whether hyperactivation of Akt in tumour cells due to PTEN loss might also inhibit AMPK activation, we initially examined the PTEN-null glioblastoma cell line DBTRG-05MG.
# ::tok To examine whether hyperactivation of Akt in tumour cells due to PTEN loss might also inhibit AMPK activation , we initially examined the PTEN @-@ null glioblastoma cell line DBTRG @-@ 05MG .
(x19 / examine-01
      :purpose (x1 / examine-01
            :ARG1 (x2 / possible-01
                  :mode "interrogative"
                  :ARG1 (x13 / inhibit-01
                        :ARG1 (x3 / hyperactivate-00
                              :ARG1 (x4 / enzyme
                                    :name (x5 / name :op1 "Akt")
                                    :xref (x29 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                              :location (x7 / cell
                                    :mod (x6 / tumor)
                                    :ARG1-of (x8 / cause-01
                                          :ARG0 (x11 / lose-02
                                                :ARG1 (x9 / protein
                                                      :name (x10 / name :op1 "PTEN")
                                                      :xref (x28 / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004"))))))
                        :mod (x12 / also)
                        :ARG1 (x16 / activate-01
                              :ARG1 (x14 / protein
                                    :name (x15 / name :op1 "AMPK")
                                    :xref (x30 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))))))
      :ARG0 (x17 / we)
      :time (x18 / initial)
      :ARG1 (x25 / cell-line
            :mod (x20 / medical-condition
                  :mod (x22 / enzyme
                        :name (x21 / name :op1 "PTEN")
                        :ARG2-of (x23 / mutate-01 :mod "-/-")
                        :xref (x / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004"))
                  :name (x24 / name :op1 "glioblastoma"))
            :name (x26 / name :op1 "DBTRG")
            :name (x27 / name :op1 "05MG")))


# ::id PMC4052680.189
# ::snt We first tested a range of AMPK activators to see whether any interfered with Akt activation.
# ::tok We first tested a range of AMPK activators to see whether any interfered with Akt activation .
(x2 / test-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / range-01
            :ARG1 (x6 / activate-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "AMPK")
                        :xref (x13 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))))
      :purpose (x7 / see-01
            :ARG1 (x9 / interfere-01
                  :mode "interrogative"
                  :mod (x8 / any)
                  :ARG1 (x12 / activate-01
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))))


# ::id PMC4052680.190
# ::snt Surprisingly, phenformin and quercetin blocked phosphorylation of Akt at Ser 473 , although berberine, A769662 and A23187 did not (Supplementary Figure S2A at http://www.biochemj.org/bj/459/bj4590275add.htm ).
# ::tok Surprisingly , phenformin and quercetin blocked phosphorylation of Akt at Ser 473 , although berberine , A769662 and A23187 did not ( Supplementary Figure S2A at http : //www.biochemj.org/bj/459/bj4590275add.htm ) .
(x7 / block-01
      :ARG1-of (x1 / surprise-01)
      :ARG0 (x4 / and
            :op1 (x2 / enzyme
                  :name (x3 / name :op1 "phenformin"))
            :op2 (x5 / enzyme
                  :name (x6 / name :op1 "quercetin")))
      :ARG1 (x8 / phosphorylate-01
            :ARG1 (x9 / enzyme
                  :name (x10 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :ARG2 (x11 / amino-acid
                  :mod "473"
                  :name (x12 / name :op1 "serine")
                  :xref (x27 / xref :value "PUBCHEM:5951" :prob "11.218784")))
      :concession (x20 / do-02
            :ARG0 (x17 / and
                  :op1 (x13 / enzyme
                        :name (x14 / name :op1 "berberine"))
                  :op2 (x15 / enzyme
                        :name (x16 / name :op1 "A769662"))
                  :op3 (x18 / enzyme
                        :name (x19 / name :op1 "A23187")))
            :polarity "-"
            :ARG1-of (x21 / describe-01
                  :ARG0 (x23 / figure
                        :ARG2-of (x22 / supplement-01)
                        :mod "s2a"))
            :location (x24 / url-entity :value "http://webdefence.global.blackspider.com/urlwrap/?q=axicy2rn8frcwhb9aqnduu6lixmkxnfrmv5uymzocn5esvf-jl5yfi5diagjuaehsy6bgam5mrfduljismjryqldcqpepqokpmbkxz8osdg5fagrmucvvyidaqia65qdsa&z"))
      :ARG1 (x25 / enzyme
            :name (x26 / name :op1 "//www.biochemj.org/bj/459/bj4590275add.htm")))


# ::id PMC4052680.191
# ::snt As expected, all agents also increased the phosphorylation of ACC1 at Ser 79 and AMPK at Thr 172 in MEFs (mouse embryonic fibroblasts), although the effect of A769662 on Thr 172 phosphorylation was small, indicating that it was mainly acting through an allosteric mechanism (Supplementary Figure S2B).
# ::tok As expected , all agents also increased the phosphorylation of ACC1 at Ser 79 and AMPK at Thr 172 in MEFs ( mouse embryonic fibroblasts ) , although the effect of A769662 on Thr 172 phosphorylation was small , indicating that it was mainly acting through an allosteric mechanism ( Supplementary Figure S2B ) .
(x1 / multi-sentence
      :snt1 (x6 / increase-01
            :ARG1-of (x2 / expect-01)
            :ARG0 (x4 / agent
                  :mod (x3 / all))
            :mod (x5 / also)
            :ARG1 (x7 / phosphorylate-01
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "ACC1"))
                  :location (x10 / amino-acid
                        :mod "79"
                        :name (x11 / name :op1 "serine")
                        :xref (x40 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
      :snt2 (x22 / have-concession-91
            :ARG1 (x12 / and
                  :op2 (x13 / protein
                        :name (x14 / name :op1 "AMPK")
                        :part (x15 / amino-acid
                              :mod "172"
                              :name (x16 / name :op1 "threonine")
                              :xref (x41 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
                  :location (x17 / cell
                        :name (x18 / name :op1 "mef"))
                  :ARG1-of (x21 / fibroblast
                        :source (x20 / embryo
                              :mod (x19 / mouse))))
            :ARG1 (x23 / affect-01
                  :ARG0 (x24 / small-molecule
                        :name (x25 / name :op1 "A769662")
                        :xref (x38 / xref :value "PUBCHEM:54708532" :prob "18.86067"))
                  :ARG1 (x28 / phosphorylate-01
                        :ARG1 (x26 / amino-acid
                              :mod "172"
                              :name (x27 / name :op1 "threonine")
                              :xref (x39 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :ARG2 (x29 / small-molecule)))
            :ARG0-of (x30 / indicate-01
                  :ARG1 (x32 / act-01
                        :mod (x31 / main)
                        :manner (x34 / mechanism
                              :mod (x33 / allosteric))))
            :ARG1-of (x35 / describe-01
                  :ARG0 (x37 / figure
                        :ARG2-of (x36 / supplement-01)
                        :mod "s2b"))))


# ::id PMC4052680.192
# ::snt The inhibitory effects of phenformin and quercetin on Akt Ser 473 phosphorylation were observed in WT MEFs, but were ‘off-target’ AMPK-independent effects, because they were also observed in double-knockout (α1 −/− α2 −/− ) MEFs (Supplementary Figure S2B and S2C).
# ::tok The inhibitory effects of phenformin and quercetin on Akt Ser 473 phosphorylation were observed in WT MEFs , but were ‘off @-@ target’ AMPK @-@ independent effects , because they were also observed in double @-@ knockout ( α1 −/− α2 −/− ) MEFs ( Supplementary Figure S2B and S2C ) .
(x1 / multi-sentence
      :snt1 (x18 / contrast-01
            :ARG1 (x3 / affect-01
                  :ARG2 (x2 / inhibit-01)
                  :ARG0 (x6 / and
                        :op1 (x4 / enzyme
                              :name (x5 / name :op1 "phenformin"))
                        :op2 (x7 / enzyme
                              :name (x8 / name :op1 "quercetin")))
                  :ARG1 (x9 / enzyme
                        :name (x10 / name :op1 "Akt")
                        :xref (x47 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :ARG1 (x14 / observe-01
                  :ARG1 (x13 / phosphorylate-01
                        :ARG1 (x11 / amino-acid
                              :mod "473"
                              :name (x12 / name :op1 "serine")
                              :xref (x49 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                  :location (x15 / cell
                        :mod (x16 / wild-type)
                        :name (x17 / name :op1 "mef")))
            :ARG2 (x26 / affect-01
                  :ARG1 (x19 / enzyme
                        :name (x20 / name :op1 "‘off"))
                  :ARG0 (x21 / enzyme
                        :name (x22 / name :op1 "target’")
                        :xref (x / xref :value "UNIPROT:TARSH_HUMAN" :prob "0.222"))
                  :ARG0-of (x25 / depend-01
                        :ARG1 (x23 / protein
                              :name (x24 / name :op1 "AMPK")
                              :xref (x46 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
                        :polarity "-"))
            :ARG1-of (x27 / cause-01
                  :ARG0 (x29 / observe-01
                        :mod (x28 / also)
                        :location (x31 / knock-out-03
                              :mod (x30 / double))
                        :ARG1-of (x32 / describe-01
                              :ARG0 (x33 / protein
                                    :name (x34 / name :op1 "riα" :op2 "1"))))))
      :snt2 (x35 / and
            :op1 (x40 / cell
                  :mod (x36 / enzyme
                        :ARG2-of (x37 / mutate-01 :mod "−/−")
                        :name (x38 / name :op1 "α2")
                        :ARG2-of (x39 / mutate-01 :mod "−/−")
                        :xref (x48 / xref :value "UNIPROT:FKRP_HUMAN" :prob "0.552"))
                  :name (x41 / name :op1 "mef")
                  :ARG1-of (x42 / describe-01
                        :ARG0 (x44 / figure
                              :ARG2-of (x43 / supplement-01)
                              :mod "s2b")))
            :op2 (x45 / figure :mod "s2c")))


# ::id PMC4052680.193
# ::snt To avoid this complication, in subsequent studies we focused on the effects of A769662, which activates AMPK by direct binding to the β subunit [ 16 , 17 ] and does not inhibit ATP synthesis [ 19 ] or Akt Ser 473 phosphorylation (Supplementary Figure S2).
# ::tok To avoid this complication , in subsequent studies we focused on the effects of A769662 , which activates AMPK by direct binding to the β subunit [ 16 , 17 ] and does not inhibit ATP synthesis [ 19 ] or Akt Ser 473 phosphorylation ( Supplementary Figure S2 ) .
(x1 / multi-sentence
      :snt1 (x8 / focus-01
            :purpose (x2 / avoid-01
                  :ARG1 (x3 / this))
            :ARG1-of (x4 / complicate-01)
            :ARG1-of (x6 / study-01
                  :time (x5 / subsequent))
            :ARG0 (x7 / we)
            :ARG2 (x9 / affect-01
                  :ARG0 (x10 / small-molecule
                        :name (x11 / name :op1 "A769662")
                        :xref (x43 / xref :value "PUBCHEM:54708532" :prob "18.86067")))
            :ARG0-of (x12 / activate-01
                  :ARG1 (x13 / protein
                        :name (x14 / name :op1 "AMPK")
                        :xref (x40 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
                  :manner (x23 / and
                        :op1 (x16 / bind-01
                              :ARG1-of (x15 / direct-02)
                              :ARG2 (x18 / subunit
                                    :name (x17 / name :op1 "β"))
                              :ARG1-of (x19 / describe-01
                                    :ARG0 (x20 / publication
                                          :ARG1-of (x21 / cite-01
                                                :ARG2 (x22 / and :op1 "16" :op2 "17")))))
                        :op2 (x24 / inhibit-01
                              :polarity "-"
                              :ARG1 (x27 / synthesize-01
                                    :ARG1 (x25 / small-molecule
                                          :name (x26 / name :op1 "ATP")
                                          :xref (x41 / xref :value "PUBCHEM:5957" :prob "14.368295"))))))
            :ARG1-of (x28 / describe-01
                  :ARG0 (x29 / publication
                        :ARG1-of (x30 / cite-01
                              :ARG2 (x31 / or
                                    :op1 "19"
                                    :op2 (x32 / enzyme
                                          :name (x33 / name :op1 "Akt")
                                          :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))))
      :snt2 (x36 / phosphorylate-01
            :ARG1 (x34 / amino-acid
                  :mod "473"
                  :name (x35 / name :op1 "serine")
                  :xref (x42 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :ARG1-of (x37 / describe-01
                  :ARG0 (x39 / figure
                        :ARG2-of (x38 / supplement-01)
                        :mod "s2"))))


# ::id PMC4052680.194
# ::snt AMPK in DBTRG-05MG cells was activated by A769662, but activation ( Figure 6 A) and Thr 172 phosphorylation ( Figure 6 B) were greatly enhanced when the selective Akt inhibitor MK2206 was added before A769662.
# ::tok AMPK in DBTRG @-@ 05MG cells was activated by A769662 , but activation ( Figure 6 A ) and Thr 172 phosphorylation ( Figure 6 B ) were greatly enhanced when the selective Akt inhibitor MK2206 was added before A769662 .
(x12 / and
      :op1 (x8 / contrast-01
            :ARG1 (x5 / activate-01
                  :ARG1 (x1 / enzyme
                        :name (x2 / name :op1 "AMPK")
                        :location (x3 / cell-line
                              :name (x4 / name :op1 "DBTRG-05MG"))
                        :xref (x29 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "A769662")))
            :ARG2 (x9 / activate-01)
            :ARG1-of (x10 / describe-01
                  :ARG0 (x11 / figure :mod "a")))
      :op2 (x19 / enhance-01
            :ARG1 (x15 / phosphorylate-01
                  :ARG1 (x13 / amino-acid
                        :mod "172"
                        :name (x14 / name :op1 "threonine")
                        :xref (x31 / xref :value "PUBCHEM:205" :prob "11.848252"))
                  :ARG1-of (x16 / describe-01
                        :ARG0 (x17 / figure :mod "6b")))
            :degree (x18 / great)
            :time (x26 / add-02
                  :ARG1 (x20 / small-molecule
                        :ARG0-of (x21 / select-01)
                        :ARG0-of (x24 / inhibit-01
                              :ARG1 (x22 / enzyme
                                    :name (x23 / name :op1 "Akt")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                        :name (x25 / name :op1 "MK2206")
                        :xref (x30 / xref :value "PUBCHEM:46930998" :prob "18.572987"))
                  :time (x27 / before
                        :op1 (x28 / a769662)))))


# ::id PMC4052680.195
# ::snt Thus reduced activation of AMPK in these cells was Akt-dependent.
# ::tok Thus reduced activation of AMPK in these cells was Akt @-@ dependent .
(x1 / cause-01
      :ARG0 (x3 / activate-01
            :ARG1-of (x2 / reduce-01)
            :ARG1 (x4 / protein
                  :name (x5 / name :op1 "AMPK")
                  :xref (x11 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
            :location (x7 / cell
                  :mod (x6 / this))
            :ARG0-of (x10 / depend-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))


# ::id PMC4052680.196
# ::snt As expected, inhibition of Akt by MK2206 was associated with greatly reduced phosphorylation of Ser 487 , and of the Akt site on GSK3β, Ser 9 ( Figure 6 B).
# ::tok As expected , inhibition of Akt by MK2206 was associated with greatly reduced phosphorylation of Ser 487 , and of the Akt site on GSK3β, Ser 9 ( Figure 6 B ) .
(x16 / protein-segment
      :ARG1-of (x1 / expect-01)
      :ARG0 (x13 / and
            :op1 (x2 / inhibit-01
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "Akt")
                        :xref (x22 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                  :ARG0 (x7 / associate-01
                        :ARG1 (x5 / enzyme
                              :name (x6 / name :op1 "MK2206")
                              :xref (x23 / xref :value "UNIPROT:MAPK2_HUMAN" :prob "0.212"))
                        :ARG2 (x9 / reduce-01
                              :degree (x8 / great)))
                  :ARG1 (x10 / phosphorylate-01
                        :ARG1 (x11 / amino-acid
                              :mod "487"
                              :name (x12 / name :op1 "serine")
                              :xref (x24 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
            :op2 (x14 / enzyme
                  :name (x15 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
      :location (x18 / amino-acid
            :name (x17 / name :op1 "GSK3β,")
            :name (x19 / name :op1 "serine")
            :mod "9"
            :xref (x26 / xref :value "PUBCHEM:5951" :prob "11.218784"))
      :ARG1-of (x20 / describe-01
            :ARG0 (x21 / figure :mod "6b")))


# ::id PMC4052680.197
# ::snt As reported previously [ 41 ], MK2206 also blocked the phosphorylation of Akt at the activating sites, Thr 308 and Ser 473 .
# ::tok As reported previously [ 41 ] , MK2206 also blocked the phosphorylation of Akt at the activating sites , Thr 308 and Ser 473 .
(x10 / block-01
      :ARG0 (x1 / report-01
            :time (x2 / previous)
            :ARG1-of (x3 / describe-01
                  :ARG0 (x4 / publication
                        :ARG1-of (x5 / cite-01 :ARG2 "41"))))
      :ARG1-of (x6 / describe-01
            :ARG2 (x7 / enzyme
                  :name (x8 / name :op1 "MK2206")
                  :xref (x22 / xref :value "UNIPROT:MAPK2_HUMAN" :prob "0.212")))
      :mod (x9 / also)
      :ARG1 (x11 / phosphorylate-01
            :ARG1 (x12 / enzyme
                  :name (x13 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
      :location (x15 / site
            :ARG0-of (x14 / activate-01)
            :ARG1-of (x16 / mean-01
                  :ARG2 (x17 / and
                        :op1 (x18 / amino-acid
                              :mod "308"
                              :name (x19 / name :op1 "threonine")
                              :xref (x24 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :op2 (x20 / amino-acid
                              :mod "473"
                              :name (x21 / name :op1 "serine")
                              :xref (x23 / xref :value "PUBCHEM:5951" :prob "11.218784"))))))


# ::id PMC4052680.198
# ::snt Prior IGF-1 treatment down-regulates AMPK activation by A769662 in PTEN-null tumour cell lines
# ::tok Prior IGF @-@ 1 treatment down @-@ regulates AMPK activation by A769662 in PTEN @-@ null tumour cell lines
(x5 / downregulate-01
      :time (x1 / prior
            :op1 (x4 / treat-04
                  :ARG2 (x2 / protein
                        :name (x3 / name :op1 "IGF-1")
                        :xref (x16 / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))))
      :ARG1 (x8 / activate-01
            :ARG1 (x6 / protein
                  :name (x7 / name :op1 "AMPK")
                  :xref (x17 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))
      :ARG0 (x9 / enzyme
            :name (x10 / name :op1 "A769662"))
      :location (x15 / cell-line
            :mod (x11 / protein
                  :name (x12 / name :op1 "PTEN")
                  :mod (x13 / null)
                  :xref (x / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004"))
            :mod (x14 / tumor)))


# ::id PMC4052680.199
# ::snt Lysates were then analysed for AMPK activity.
# ::tok Lysates were then analysed for AMPK activity .
(x3 / analyze-01
      :ARG1 (x1 / lysate)
      :time (x2 / then)
      :purpose (x6 / activity-06
            :ARG0 (x4 / protein
                  :name (x5 / name :op1 "AMPK")
                  :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))))


# ::id PMC4052680.202
# ::snt For ( E ) and ( G ), results are means±S.E.M.
# ::tok For ( E ) and ( G ) , results are means±S.E.M .
(x1 / cause-01
      :ARG0 (x9 / be-located-at-91
            :ARG1-of (x2 / describe-01
                  :ARG0 (x3 / figure :mod "e"))
            :ARG2 (x4 / and
                  :ARG1-of (x5 / describe-01
                        :ARG0 (x6 / figure :mod "g")))
            :ARG0 (x7 / thing
                  :ARG2-of (x8 / result-01))
            :ARG1 (x10 / enzyme
                  :name (x11 / name :op1 "means±S.E.M"))))


# ::id PMC4052680.203
# ::snt We also examined the effect of re-expressing PTEN in DBTRG-05MG cells, using a lentiviral vector that gives levels of expression similar to normal cells.
# ::tok We also examined the effect of re @-@ expressing PTEN in DBTRG @-@ 05MG cells , using a lentiviral vector that gives levels of expression similar to normal cells .
(x2 / examine-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / affect-01
            :ARG1 (x5 / express-03
                  :mod (x4 / again)
                  :ARG2 (x6 / protein
                        :name (x7 / name :op1 "PTEN")
                        :xref (x / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004"))
                  :ARG3 (x8 / cell-line
                        :name (x9 / name :op1 "DBTRG-05MG"))))
      :manner (x10 / use-01
            :ARG1 (x12 / vector
                  :mod (x11 / lentiviral)
                  :ARG0-of (x13 / give-01
                        :ARG1 (x14 / level
                              :quant-of (x15 / express-03)
                              :ARG1-of (x16 / resemble-01
                                    :ARG2 (x18 / cell
                                          :ARG1-of (x17 / normal-02))))))))


# ::id PMC4052680.204
# ::snt As a control, we expressed a C124S mutant that has no lipid phosphatase activity.
# ::tok As a control , we expressed a C124S mutant that has no lipid phosphatase activity .
(x3 / express-03
      :ARG2-of (x1 / control-01)
      :ARG0 (x2 / we)
      :ARG2 (x4 / enzyme
            :name (x5 / name :op1 "C124S")
            :ARG2-of (x6 / mutate-01
                  :ARG0-of (x7 / have-03
                        :polarity "-"
                        :ARG1 (x8 / lipid))
                  :ARG1-of (x11 / activity-06
                        :ARG0 (x9 / enzyme
                              :name (x10 / name :op1 "phosphatase")
                              :xref (x / xref :value "UNIPROT:Q59GM9_HUMAN" :prob "0.291"))))
            :xref (x12 / xref :value "UNIPROT:RPC2_HUMAN" :prob "0.202")))


# ::id PMC4052680.205
# ::snt Prior expression of WT PTEN enhanced the activation ( Figure 6 C) and Thr 172 phosphorylation ( Figure 6 D) of AMPK in response to A769662.
# ::tok Prior expression of WT PTEN enhanced the activation ( Figure 6 C ) and Thr 172 phosphorylation ( Figure 6 D ) of AMPK in response to A769662 .
(x1 / and
      :op2 (x4 / phosphorylate-01
            :ARG1 (x2 / amino-acid
                  :mod "172"
                  :name (x3 / name :op1 "threonine")
                  :xref (x22 / xref :value "PUBCHEM:205" :prob "11.848252"))
            :ARG1-of (x5 / describe-01
                  :ARG0 (x6 / figure :mod "5d")))
      :op1 (x12 / enhance-01
            :time (x7 / prior
                  :op1 (x8 / express-03
                        :ARG2 (x9 / enzyme
                              :mod (x10 / wild-type)
                              :name (x11 / name :op1 "PTEN")
                              :xref (x / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004"))))
            :ARG1 (x13 / activate-01)
            :ARG1-of (x14 / describe-01
                  :ARG0 (x15 / figure :mod "6c"))
            :ARG1 (x18 / respond-01
                  :ARG0 (x16 / protein
                        :name (x17 / name :op1 "AMPK")
                        :xref (x21 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
                  :ARG1 (x19 / small-molecule
                        :name (x20 / name :op1 "A769662")
                        :xref (x23 / xref :value "PUBCHEM:54708532" :prob "18.86067")))))


# ::id PMC4052680.206
# ::snt When compared with the C124S mutant, expression of WT PTEN was associated with decreased phosphorylation of Ser 487 on AMPK-α1 and Ser 9 on GSK3β, and markedly decreased phosphorylation of Thr 308 and Ser 473 on Akt ( Figure 6 D).
# ::tok When compared with the C124S mutant , expression of WT PTEN was associated with decreased phosphorylation of Ser 487 on AMPK-α1 and Ser 9 on GSK3β, and markedly decreased phosphorylation of Thr 308 and Ser 473 on Akt ( Figure 6 D ) .
(x1 / multi-sentence
      :snt1 (x10 / associate-01
            :time (x2 / compare-01
                  :ARG2 (x5 / mutate-01
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "C124S")
                              :xref (x / xref :value "UNIPROT:RPC2_HUMAN" :prob "0.202"))))
            :ARG1 (x6 / express-03
                  :ARG2 (x7 / enzyme
                        :mod (x8 / wild-type)
                        :name (x9 / name :op1 "PTEN")
                        :xref (x34 / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004")))
            :ARG2 (x11 / decrease-01
                  :ARG1 (x12 / phosphorylate-01
                        :ARG1 (x13 / amino-acid
                              :mod "487"
                              :name (x14 / name :op1 "serine")
                              :xref (x40 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :ARG2 (x17 / and
                              :op1 (x15 / enzyme
                                    :name (x16 / name :op1 "AMPK-α1")
                                    :xref (x36 / xref :value "UNIPROT:AAPK1_HUMAN" :prob "0.662"))
                              :op2 (x18 / amino-acid
                                    :name (x19 / name :op1 "serine")
                                    :mod "9"
                                    :xref (x39 / xref :value "PUBCHEM:5951" :prob "11.218784")))))
            :location (x21 / and
                  :name (x20 / name :op1 "GSK3β,")))
      :snt2 (x23 / decrease-01
            :ARG2 (x22 / marked)
            :ARG1 (x24 / phosphorylate-01
                  :ARG1 (x25 / and
                        :op1 (x26 / amino-acid
                              :mod "308"
                              :name (x27 / name :op1 "threonine")
                              :xref (x38 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :op2 (x28 / amino-acid
                              :mod "473"
                              :name (x29 / name :op1 "serine")
                              :xref (x37 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                  :ARG2 (x30 / enzyme
                        :name (x31 / name :op1 "Akt")
                        :xref (x35 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :ARG1-of (x32 / describe-01
                  :ARG0 (x33 / figure :mod "5d"))))


# ::id PMC4052680.207
# ::snt We also studied two other PTEN-null human cell lines, i.e. U373-MG (another glioblastoma line) and MDA-MB-468 (a breast cancer line).
# ::tok We also studied two other PTEN @-@ null human cell lines , i.e. U373 @-@ MG ( another glioblastoma line ) and MDA @-@ MB @-@ 468 ( a breast cancer line ) .
(x2 / study-01
      :ARG0 (x1 / we)
      :ARG1 (x8 / cell-line
            :quant "2"
            :mod (x3 / other)
            :mod (x4 / protein
                  :name (x5 / name :op1 "PTEN")
                  :mod (x6 / null)
                  :xref (x / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004"))
            :mod (x7 / human))
      :ARG1-of (x9 / mean-01
            :ARG2 (x12 / milligram
                  :op1 (x10 / amino-acid
                        :mod "373"
                        :name (x11 / name :op1 "selenocysteine"))))
      :ARG1-of (x16 / and
            :op1 (x15 / cell-line
                  :mod (x13 / another)
                  :name (x14 / name :op1 "glioblastoma"))
            :op2 (x21 / cell-line
                  :name (x17 / name :op1 "MDA-MB-468")
                  :ARG1-of (x18 / mean-01)
                  :mod (x19 / disease
                        :wiki "breast_cancer"
                        :name (x20 / name :op1 "breast" :op2 "cancer")))))


# ::id PMC4052680.208
# ::snt Similar to the DBTRG-05MG cells, there was a modest activation ( Figures 6 E and 6 G) and Thr 172 phosphorylation ( Figures 6 F and 6 H) of AMPK in response to A769662, but both were enhanced when Akt was inhibited using MK2206.
# ::tok Similar to the DBTRG @-@ 05MG cells , there was a modest activation ( Figures 6 E and 6 G ) and Thr 172 phosphorylation ( Figures 6 F and 6 H ) of AMPK in response to A769662 , but both were enhanced when Akt was inhibited using MK2206 .
(x1 / multi-sentence
      :snt1 (x2 / multi-sentence
            :snt1 (x7 / activate-01
                  :ARG1-of (x3 / resemble-01
                        :ARG2 (x4 / cell-line
                              :name (x5 / name :op1 "DBTRG-05MG")))
                  :mod (x6 / modest)
                  :ARG1-of (x8 / describe-01
                        :ARG0 (x9 / and
                              :op1 (x10 / figure :mod "6")
                              :op2 (x11 / figure :mod "6"))))
            :snt2 (x14 / and
                  :op1 (x12 / protein
                        :name (x13 / name :op1 "G")
                        :xref (x41 / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "0.601"))
                  :op2 (x17 / phosphorylate-01
                        :ARG1 (x15 / amino-acid
                              :mod "172"
                              :name (x16 / name :op1 "threonine")
                              :xref (x43 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :ARG1-of (x18 / describe-01
                              :ARG0 (x19 / figure :mod "6")))
                  :op2 (x20 / figure :mod "6")))
      :snt2 (x29 / contrast-01
            :ARG1 (x26 / respond-01
                  :ARG2 (x23 / and
                        :op1 (x21 / enzyme
                              :name (x22 / name :op1 "h-ras")
                              :xref (x38 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601"))
                        :op2 (x24 / protein
                              :name (x25 / name :op1 "AMPK")
                              :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))
                  :ARG1 (x27 / small-molecule
                        :name (x28 / name :op1 "A769662")
                        :xref (x42 / xref :value "PUBCHEM:54708532" :prob "18.86067")))
            :ARG2 (x31 / enhance-01
                  :ARG1 (x30 / and)
                  :time (x34 / inhibit-01
                        :ARG1 (x32 / enzyme
                              :name (x33 / name :op1 "Akt")
                              :xref (x39 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                        :ARG0-of (x35 / use-01
                              :ARG1 (x36 / protein
                                    :name (x37 / name :op1 "MK2206")
                                    :xref (x40 / xref :value "UNIPROT:MAPK2_HUMAN" :prob "0.212")))))))


# ::id PMC4052680.209
# ::snt The phosphorylated ST loop interacts with the kinase domain, hindering access to Thr 172
# ::tok The phosphorylated ST loop interacts with the kinase domain , hindering access to Thr 172
(x1 / phosphorylate-01
      :location (x2 / loop-01
            :ARG2 (x3 / interact-01
                  :ARG1 (x5 / domain
                        :mod (x4 / kinase))
                  :ARG0-of (x6 / hinder-01))
            :ARG1 (x7 / access-01
                  :ARG1 (x8 / amino-acid
                        :mod "172"
                        :name (x9 / name :op1 "threonine")
                        :xref (x / xref :value "PUBCHEM:205" :prob "11.848252")))))


# ::id PMC4052680.210
# ::snt We next addressed the mechanism by which Ser 487 phosphorylation inhibits subsequent Thr 172 phosphorylation.
# ::tok We next addressed the mechanism by which Ser 487 phosphorylation inhibits subsequent Thr 172 phosphorylation .
(x3 / address-02
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x4 / mechanism
            :instrument-of (x8 / inhibit-01
                  :ARG0 (x7 / phosphorylate-01
                        :ARG1 (x5 / amino-acid
                              :mod "487"
                              :name (x6 / name :op1 "serine")
                              :xref (x13 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                  :ARG1 (x12 / phosphorylate-01
                        :mod (x9 / subsequent)
                        :ARG1 (x10 / amino-acid
                              :mod "172"
                              :name (x11 / name :op1 "threonine")
                              :xref (x / xref :value "PUBCHEM:205" :prob "11.848252"))))))


# ::id PMC4052680.211
# ::snt In the structure of a partial mammalian α1β2γ1 complex, the ST loop from Ile 470 to Asp 523 (rat numbering) was disordered [ 11 ]; the complex had been expressed in bacteria, so the ST loop was likely to be unphosphorylated.
# ::tok In the structure of a partial mammalian α1β2γ1 complex , the ST loop from Ile 470 to Asp 523 ( rat numbering ) was disordered [ 11 ] ; the complex had been expressed in bacteria , so the ST loop was likely to be unphosphorylated .
(x1 / multi-sentence
      :snt1 (x6 / macro-molecular-complex
            :location (x2 / structure
                  :mod (x3 / part
                        :mod (x4 / mammal)
                        :name (x5 / name :op1 "α1β2γ1")))
            :ARG0-of (x8 / loop-01
                  :ARG1 (x7 / st)
                  :ARG2 (x9 / amino-acid
                        :mod "470"
                        :name (x10 / name :op1 "isoleucine"))
                  :ARG1 (x11 / and
                        :op1 (x12 / amino-acid
                              :mod "523"
                              :name (x13 / name :op1 "aspartic" :op2 "acid"))
                        :op2 (x14 / rat
                              :ARG1-of (x15 / number-01)))
                  :ARG2 (x16 / disorder-00))
            :ARG1-of (x17 / describe-01
                  :ARG0 (x18 / publication
                        :ARG1-of (x19 / cite-01 :ARG2 "11"))))
      :snt2 (x21 / express-01
            :ARG1 (x20 / complex)
            :ARG0 (x23 / cause-01
                  :ARG0 (x22 / bacteria)
                  :ARG1 (x25 / loop
                        :ARG0-of (x24 / st)))
            :ARG1-of (x26 / likely-01
                  :ARG1 (x27 / unphosphorylated))))


# ::id PMC4052680.212
# ::snt In a subsequent structure [ 10 ], the ST loop was deleted as it was thought that it might hinder crystallization.
# ::tok In a subsequent structure [ 10 ] , the ST loop was deleted as it was thought that it might hinder crystallization .
(x8 / delete-01
      :ARG1 (x7 / loop
            :location (x2 / structure
                  :ARG0-of (x1 / subsequent)
                  :ARG1-of (x3 / describe-01
                        :ARG0 (x4 / publication
                              :ARG1-of (x5 / cite-01 :ARG2 "10"))))
            :ARG1 (x6 / st))
      :ARG1-of (x9 / think-01
            :ARG1 (x10 / possible-01
                  :ARG1 (x11 / hinder-01
                        :ARG1 (x12 / crystallize-01)))))


# ::id PMC4052680.213
# ::snt However, the location of the residues at the ends of the loop (Glu 469 and Val 524 ) in this structure show that they lie close to the kinase domain, being approximately 20 and 40 Å (1 Å=0.1 nm) from Thr 172 respectively ( Figure 7 A).
# ::tok However , the location of the residues at the ends of the loop ( Glu 469 and Val 524 ) in this structure show that they lie close to the kinase domain , being approximately 20 and 40 Å ( 1 Å=0.1 nm ) from Thr 172 respectively ( Figure 7 A ) .
(x1 / multi-sentence
      :snt1 (x2 / have-concession-91
            :ARG2 (x3 / be-located-at-91
                  :ARG1 (x4 / residue)
                  :time (x5 / end-01
                        :ARG1 (x6 / loop)))
            :ARG1-of (x7 / describe-01
                  :ARG0 (x10 / and
                        :op1 (x8 / amino-acid
                              :mod "469"
                              :name (x9 / name :op1 "glutamic" :op2 "acid"))
                        :op2 (x11 / amino-acid
                              :mod "524"
                              :name (x12 / name :op1 "valine"))))
            :location (x13 / this))
      :snt2 (x15 / show-01
            :ARG0 (x14 / structure-01)
            :ARG1 (x17 / lie-08
                  :ARG0 (x16 / they)
                  :ARG1-of (x18 / close-10
                        :ARG2 (x20 / domain
                              :mod (x19 / kinase)))
                  :ARG2 (x21 / approximately
                        :op1 (x22 / and :op1 "20" :op2 "40"))
                  :ARG1 (x23 / small-molecule
                        :name (x24 / name :op1 "Å")
                        :quant (x25 / concentration-quantity
                              :quant "1"
                              :unit (x26 / nanomolar)))
                  :ARG2 (x27 / amino-acid
                        :mod "172"
                        :name (x28 / name :op1 "threonine")
                        :xref (x / xref :value "PUBCHEM:205" :prob "11.848252"))
                  :mod (x29 / respective))
            :ARG1-of (x30 / describe-01
                  :ARG0 (x31 / figure :mod "7"))))


# ::id PMC4052680.214
# ::snt We hypothesized that the ST loop might interact with the kinase domain when phosphorylated on Ser 487 .
# ::tok We hypothesized that the ST loop might interact with the kinase domain when phosphorylated on Ser 487 .
(x2 / hypothesize-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / possible-01
            :ARG1 (x6 / interact-01
                  :ARG0 (x5 / loop
                        :mod (x4 / st))
                  :ARG2 (x8 / domain
                        :mod (x7 / kinase))
                  :time (x9 / phosphorylate-01
                        :ARG1 (x10 / amino-acid
                              :mod "487"
                              :name (x11 / name :op1 "serine")
                              :xref (x / xref :value "PUBCHEM:5951" :prob "11.218784"))))))


# ::id PMC4052680.215
# ::snt We also noticed three basic residues, Arg 62 , Lys 69 and Arg 72 (rat α1 numbering), which are located within the ‘αC helix’ of the small lobe of the kinase domain.
# ::tok We also noticed three basic residues , Arg 62 , Lys 69 and Arg 72 ( rat α1 numbering ) , which are located within the ‘αC helix’ of the small lobe of the kinase domain .
(x3 / notice-01
      :ARG0 (x1 / we)
      :mod (x2 / also)
      :ARG1 (x5 / residue
            :quant "3"
            :mod (x4 / basic)
            :mod (x6 / amino-acid
                  :mod "62"
                  :name (x7 / name :op1 "arginine")
                  :xref (x / xref :value "PUBCHEM:232" :prob "11.348415"))
            :ARG1-of (x8 / mean-01
                  :ARG2 (x11 / and
                        :op1 (x9 / amino-acid
                              :mod "69"
                              :name (x10 / name :op1 "lysine"))
                        :op2 (x12 / amino-acid
                              :mod "72"
                              :name (x13 / name :op1 "arginine")
                              :xref (x23 / xref :value "PUBCHEM:232" :prob "11.348415")))))
      :ARG1-of (x14 / rat
            :ARG1-of (x15 / number-01))
      :ARG0-of (x16 / be-located-at-91
            :ARG1 (x17 / enzyme
                  :name (x18 / name :op1 "‘αC" :op2 "helix’"))
            :ARG2 (x19 / small-molecule
                  :name (x20 / name :op1 "lobe")))
      :ARG1 (x22 / domain
            :mod (x21 / kinase)))


# ::id PMC4052680.216
# ::snt An extension of our hypothesis was that phosphate groups on the ST loop interact with these basic side chains, triggering a stable interaction between the ST loop and the kinase domain that physically blocks access of Thr 172 to upstream kinases.
# ::tok An extension of our hypothesis was that phosphate groups on the ST loop interact with these basic side chains , triggering a stable interaction between the ST loop and the kinase domain that physically blocks access of Thr 172 to upstream kinases .
(x18 / and
      :op1 (x1 / extend-01
            :ARG1 (x4 / thing
                  :ARG1-of (x3 / hypothesize-01
                        :ARG0 (x2 / we)))
            :ARG0 (x6 / group
                  :mod (x5 / phosphate)
                  :ARG2 (x13 / trigger-01
                        :location (x8 / interact-01
                              :ARG1-of (x7 / loop-01)
                              :ARG1 (x12 / chain
                                    :mod (x9 / this)
                                    :mod (x10 / basic)
                                    :mod (x11 / side)))
                        :ARG1 (x15 / interact-01
                              :ARG1-of (x14 / stable-03)
                              :ARG0 (x17 / loop
                                    :ARG0-of (x16 / st))))))
      :op2 (x22 / block-01
            :ARG1 (x20 / domain
                  :mod (x19 / kinase))
            :mod (x21 / physical)
            :ARG1 (x23 / access-01
                  :ARG1 (x24 / amino-acid
                        :mod "172"
                        :name (x25 / name :op1 "threonine")
                        :xref (x / xref :value "PUBCHEM:205" :prob "11.848252")))
            :ARG2 (x27 / kinase
                  :location (x26 / upstream))))


# ::id PMC4052680.217
# ::snt Evidence that the phosphorylated ST loop inhibits LKB1 phosphorylation by direct interaction with the kinase domain
# ::tok Evidence that the phosphorylated ST loop inhibits LKB1 phosphorylation by direct interaction with the kinase domain
(x1 / evidence-01
      :ARG1 (x2 / phosphorylate-01
            :location (x3 / loop)
            :ARG1-of (x4 / inhibit-01
                  :ARG1 (x7 / phosphorylate-01
                        :ARG1 (x5 / enzyme
                              :name (x6 / name :op1 "LKB1")
                              :xref (x / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002")))
                  :manner (x9 / interact-01
                        :ARG1-of (x8 / direct-02)
                        :ARG2 (x11 / domain
                              :mod (x10 / kinase))))))


# ::id PMC4052680.219
# ::snt Results for kinase activity are expressed as a percentage of activities obtained without either peptide, and are means±S.E.M.
# ::tok Results for kinase activity are expressed as a percentage of activities obtained without either peptide , and are means±S.E.M .
(x5 / express-01
      :ARG1 (x1 / thing
            :ARG2-of (x2 / result-01
                  :ARG1 (x4 / activity-06
                        :ARG0 (x3 / kinase))))
      :manner (x6 / percentage
            :quant-of (x7 / activity-06)
            :ARG1-of (x8 / obtain-01
                  :manner (x9 / or
                        :op1 (x10 / peptide)
                        :op2 (x11 / person
                              :wiki "-"
                              :name (x12 / name :op1 "means±S.E.M"))))))


# ::id PMC4052680.220
# ::snt Results of Western blots are from duplicate incubations.
# ::tok Results of Western blots are from duplicate incubations .
(x4 / be-from-91
      :ARG1 (x1 / thing
            :ARG2-of (x2 / result-01
                  :ARG1 (x3 / immunoblot-01)))
      :ARG2 (x5 / duplicate-01
            :op1 (x6 / incubate-01)))


# ::id PMC4052680.221
# ::snt AMPK activation (top panel) and phosphorylation of Thr 172 and Ser 487 (bottom panel) was monitored.
# ::tok AMPK activation ( top panel ) and phosphorylation of Thr 172 and Ser 487 ( bottom panel ) was monitored .
(x7 / and
      :op1 (x3 / activate-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "AMPK")
                  :xref (x / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))
            :ARG1-of (x4 / describe-01
                  :ARG0 (x6 / panel
                        :mod (x5 / top))))
      :op2 (x16 / monitor-01
            :ARG1 (x8 / phosphorylate-01
                  :ARG1 (x11 / and
                        :op1 (x9 / amino-acid
                              :mod "172"
                              :name (x10 / name :op1 "threonine")
                              :xref (x17 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :op2 (x12 / amino-acid
                              :mod "487"
                              :name (x13 / name :op1 "serine")
                              :xref (x18 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                  :location (x15 / panel
                        :mod (x14 / bottom)))))


# ::id PMC4052680.222
# ::snt To test the first hypothesis, we made a construct expressing the peptide from Arg 466 to Asp 525 on human α1 as a GST fusion.
# ::tok To test the first hypothesis , we made a construct expressing the peptide from Arg 466 to Asp 525 on human α1 as a GST fusion .
(x6 / make-02
      :purpose (x1 / test-01
            :ARG1 (x3 / thing
                  :ord (x2 / ordinal-entity :value "1")
                  :ARG1-of (x4 / hypothesize-01)))
      :ARG0 (x5 / we)
      :ARG1 (x7 / construct-01
            :ARG1 (x8 / express-03
                  :ARG2 (x9 / peptide))
            :ARG2 (x10 / amino-acid
                  :mod "466"
                  :name (x11 / name :op1 "arginine")
                  :xref (x / xref :value "PUBCHEM:232" :prob "11.348415"))
            :ARG3 (x12 / amino-acid
                  :mod "525"
                  :name (x13 / name :op1 "aspartic" :op2 "acid"))
            :ARG1 (x14 / disease
                  :wiki "cancer"
                  :mod (x15 / human)
                  :name (x16 / name :op1 "α1"))
            :ARG2 (x17 / protein
                  :name (x18 / name :op1 "GST" :op2 "fusion"))))


# ::id PMC4052680.223
# ::snt The protein was expressed in and purified from bacteria, the GST domain removed, and the remaining peptide (Arg 466 –Asp 525 ) either thiophosphorylated using ATPγS (adenosine 5′-[γ-thio]triphosphate) and Akt (thiophosphate being resistant to protein phosphatases), or left unphosphorylated.
# ::tok The protein was expressed in and purified from bacteria , the GST domain removed , and the remaining peptide ( Arg 466 –Asp 525 ) either thiophosphorylated using ATPγS ( adenosine 5′- [ γ-thio ] triphosphate ) and Akt ( thiophosphate being resistant to protein phosphatases ) , or left unphosphorylated .
(x1 / multi-sentence
      :snt1 (x3 / express-03
            :ARG1 (x2 / protein)
            :ARG3 (x4 / and
                  :op1 (x5 / purify-01))
            :ARG2 (x10 / and
                  :mod (x6 / bacteria)
                  :op1 (x9 / remove-01
                        :ARG1 (x7 / enzyme
                              :name (x8 / name :op1 "GST" :op2 "domain")))
                  :op2 (x11 / remain-01
                        :ARG1 (x12 / peptide)))
            :ARG1-of (x13 / amino-acid
                  :mod "466"
                  :name (x14 / name :op1 "arginine")
                  :xref (x37 / xref :value "PUBCHEM:232" :prob "11.348415")))
      :snt2 (x20 / use-01
            :ARG0 (x17 / or
                  :op1 (x15 / enzyme
                        :name (x16 / name :op1 "–Asp" :op2 "525"))
                  :op2 (x18 / enzyme
                        :name (x19 / name :op1 "thiophosphorylated")))
            :ARG1 (x21 / protein
                  :name (x22 / name
                        :op1 "ATPγS"
                        :op2 "adenosine"
                        :op3 "5′-"))
            :ARG1-of (x23 / describe-01
                  :ARG0 (x26 / and
                        :op1 (x24 / protein
                              :name (x25 / name :op1 "γ-thio" :op2 "triphosphate"))
                        :op2 (x30 / resist-01
                              :ARG1-of (x27 / mean-01
                                    :ARG2 (x28 / small-molecule
                                          :name (x29 / name :op1 "thiophosphate")
                                          :xref (x / xref :value "PUBCHEM:167253" :prob "13.888543")))
                              :ARG1 (x33 / or
                                    :op1 (x31 / enzyme
                                          :name (x32 / name :op1 "protein" :op2 "phosphatase"))
                                    :op2 (x34 / left-20)
                                    :op2 (x35 / enzyme
                                          :name (x36 / name :op1 "unphosphorylated"))))))))


# ::id PMC4052680.224
# ::snt Consistent with our hypothesis, the phosphopeptide caused a concentration-dependent inhibition of activation and Thr 172 phosphorylation of the bacterially expressed α1β2γ1 complex by LKB1, although we were unable to generate the peptide at high enough concentrations to fully saturate inhibition.
# ::tok Consistent with our hypothesis , the phosphopeptide caused a concentration @-@ dependent inhibition of activation and Thr 172 phosphorylation of the bacterially expressed α1β2γ1 complex by LKB1 , although we were unable to generate the peptide at high enough concentrations to fully saturate inhibition .
(x22 / have-concession-91
      :ARG1-of (x1 / consistent-01
            :ARG2 (x4 / thing
                  :ARG1-of (x3 / hypothesize-01
                        :ARG0 (x2 / we))))
      :ARG1 (x15 / phosphorylate-01
            :ARG1-of (x7 / cause-01
                  :ARG0 (x5 / enzyme
                        :name (x6 / name :op1 "phosphopeptide")
                        :xref (x34 / xref :value "UNIPROT:PGM2_HUMAN" :prob "0.262"))
                  :ARG1 (x10 / inhibit-01
                        :ARG0-of (x9 / depend-01
                              :ARG1 (x8 / concentrate-02))
                        :ARG1 (x11 / activate-01
                              :ARG1 (x12 / and
                                    :op1 (x13 / amino-acid
                                          :mod "172"
                                          :name (x14 / name :op1 "threonine")
                                          :xref (x35 / xref :value "PUBCHEM:205" :prob "11.848252"))))))
            :ARG1 (x19 / macro-molecular-complex
                  :ARG1-of (x17 / express-03
                        :manner (x16 / bacterial))
                  :name (x18 / name :op1 "α1β2γ1"))
            :ARG0 (x20 / enzyme
                  :name (x21 / name :op1 "LKB1")
                  :xref (x / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002")))
      :ARG2 (x23 / possible-01
            :ARG1 (x25 / generate-01
                  :ARG0 (x24 / we)
                  :ARG1 (x26 / peptide))
            :time (x29 / concentrate-02
                  :ARG1-of (x27 / high-02
                        :degree (x28 / enough))
                  :ARG1 (x33 / inhibit-01
                        :degree (x30 / full)
                        :ARG1 (x31 / enzyme
                              :name (x32 / name :op1 "saturate"))))))


# ::id PMC4052680.225
# ::snt By contrast, the unphosphorylated peptide had no effect ( Figure 7 B).
# ::tok By contrast , the unphosphorylated peptide had no effect ( Figure 7 B ) .
(x1 / contrast-01
      :ARG2 (x4 / affect-01
            :ARG0 (x3 / peptide
                  :name (x2 / name :op1 "unphosphorylated"))
            :polarity "-")
      :ARG1-of (x5 / describe-01
            :ARG0 (x6 / figure :mod "1b")))


# ::id PMC4052680.226
# ::snt To confirm that the inhibition of activation loop phosphorylation was specific to AMPK, we showed that neither the phospho- nor the dephospho-peptide inhibited activation and phosphorylation of the AMPK-related kinase BRSK2 by LKB1 ( Figure 7 C).
# ::tok To confirm that the inhibition of activation loop phosphorylation was specific to AMPK , we showed that neither the phospho @- nor the dephospho @-@ peptide inhibited activation and phosphorylation of the AMPK @-@ related kinase BRSK2 by LKB1 ( Figure 7 C ) .
(x10 / show-01
      :purpose (x1 / confirm-01
            :ARG1 (x6 / specific-02
                  :ARG1 (x2 / inhibit-01
                        :ARG1 (x5 / phosphorylate-01
                              :ARG1 (x4 / loop
                                    :ARG0-of (x3 / activate-01))))
                  :ARG2 (x7 / protein
                        :name (x8 / name :op1 "AMPK")
                        :xref (x30 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002"))))
      :ARG0 (x9 / we)
      :ARG1 (x16 / inhibit-01
            :ARG0 (x11 / have-03
                  :polarity "-"
                  :ARG1 (x13 / or
                        :op1 (x12 / phosphorylate-01)
                        :op2 (x15 / peptide
                              :mod (x14 / dephospho))))
            :ARG1 (x18 / and
                  :op1 (x17 / activate-01)
                  :op2 (x19 / phosphorylate-01
                        :ARG1 (x23 / kinase
                              :ARG1-of (x22 / relate-01
                                    :ARG2 (x20 / protein
                                          :name (x21 / name :op1 "AMPK")
                                          :xref (x29 / xref :value "UNIPROT:AAKB1_HUMAN" :prob "1.002")))
                              :name (x24 / name :op1 "BRSK2"))
                        :ARG0 (x25 / enzyme
                              :name (x26 / name :op1 "LKB1")
                              :xref (x / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002")))))
      :ARG1-of (x27 / describe-01
            :ARG0 (x28 / figure :mod "7c")))


# ::id PMC4052680.227
# ::snt To test the extended hypothesis, we made a triple mutation (R64A/K71A/R74A, human α1 numbering, ‘AAA mutant’), in the context of the recombinant human α1β2γ1 complex used in Figure 3 , of the three basic residues in the kinase domain that we propose to interact with phosphate groups on the ST loop.
# ::tok To test the extended hypothesis , we made a triple mutation ( R64A/K71A/R74A , human α1 numbering , ‘AAA mutant’ ) , in the context of the recombinant human α1β2γ1 complex used in Figure 3 , of the three basic residues in the kinase domain that we propose to interact with phosphate groups on the ST loop .
(x1 / multi-sentence
      :snt1 (x7 / make-02
            :purpose (x2 / test-01
                  :ARG1 (x3 / extend-01
                        :ARG1 (x4 / thing
                              :ARG1-of (x5 / hypothesize-01))))
            :ARG0 (x6 / we)
            :ARG1 (x8 / mutate-01 :quant "3")
            :ARG1-of (x10 / disease
                  :name (x9 / name :op1 "R64A/K71A/R74A")
                  :mod (x11 / human)
                  :name (x12 / name :op1 "α1")
                  :ARG1-of (x13 / number-01)
                  :mod (x14 / enzyme
                        :name (x15 / name :op1 "‘AAA" :op2 "mutant’")))
            :ARG1 (x16 / context
                  :poss (x21 / complex
                        :mod (x17 / protein
                              :ARG3-of (x18 / recombine-01)
                              :mod (x19 / human)
                              :name (x20 / name :op1 "α1β2γ1")
                              :xref (x / xref :value "UNIPROT:AL8A1_HUMAN" :prob "0.562")))))
      :snt2 (x22 / use-01
            :ARG2 (x23 / figure :mod "3")
            :ARG1 (x25 / residue
                  :quant "3"
                  :mod (x24 / basic)
                  :location (x27 / domain
                        :mod (x26 / kinase)))
            :ARG1-of (x29 / propose-01
                  :ARG0 (x28 / we)
                  :ARG1 (x30 / interact-01
                        :ARG2 (x32 / group
                              :mod (x31 / phosphate))
                        :ARG1 (x34 / loop
                              :ARG0-of (x33 / st))))))


# ::id PMC4052680.228
# ::snt Consistent with our hypothesis, prior phosphorylation of the WT complex by Akt reduced subsequent activation and Thr 172 phosphorylation by LKB1, but this effect was completely abolished by either an S487A mutant or an AAA mutant, even though the latter was still phosphorylated on Ser 487 by Akt ( Figure 7 D).
# ::tok Consistent with our hypothesis , prior phosphorylation of the WT complex by Akt reduced subsequent activation and Thr 172 phosphorylation by LKB1 , but this effect was completely abolished by either an S487A mutant or an AAA mutant , even though the latter was still phosphorylated on Ser 487 by Akt ( Figure 7 D ) .
(x1 / multi-sentence
      :snt1 (x7 / phosphorylate-01
            :ARG1-of (x2 / consistent-01
                  :ARG2 (x5 / thing
                        :ARG1-of (x4 / hypothesize-01
                              :ARG0 (x3 / we))))
            :time (x6 / prior)
            :ARG1 (x9 / complex
                  :mod (x8 / wild-type))
            :ARG0 (x10 / enzyme
                  :name (x11 / name :op1 "Akt")
                  :xref (x42 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
      :snt2 (x21 / contrast-01
            :ARG2 (x12 / reduce-01
                  :ARG1 (x14 / activate-01
                        :time (x13 / subsequent)
                        :ARG1 (x15 / and
                              :op1 (x18 / phosphorylate-01
                                    :ARG1 (x16 / amino-acid
                                          :mod "172"
                                          :name (x17 / name :op1 "threonine")
                                          :xref (x44 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                    :ARG2 (x19 / enzyme
                                          :name (x20 / name :op1 "LKB1")
                                          :xref (x41 / xref :value "UNIPROT:STK11_HUMAN" :prob "1.002"))))))
            :ARG1 (x25 / abolish-01
                  :ARG1 (x23 / affect-01
                        :mod (x22 / this))
                  :ARG1-of (x24 / complete-02)
                  :ARG0 (x26 / or
                        :op1 (x27 / mutate-01 :value "S487A")
                        :op2 (x28 / mutate-01
                              :ARG1 (x29 / or
                                    :op1 (x30 / protein
                                          :name (x31 / name :op1 "AAA")))))
                  :concession (x34 / phosphorylate-01
                        :ARG1 (x32 / latter)
                        :mod (x33 / still)
                        :ARG1 (x35 / amino-acid
                              :mod "487"
                              :name (x36 / name :op1 "serine")
                              :xref (x43 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :ARG2 (x37 / enzyme
                              :name (x38 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                        :ARG1-of (x39 / describe-01
                              :ARG0 (x40 / figure :mod "7d"))))))


# ::id PMC4329006.0
# ::snt Induction of Ras by SAF-1/MAZ through a feed-forward loop promotes angiogenesis in breast cancer
# ::tok Induction of Ras by SAF @-@ 1/MAZ through a feed @-@ forward loop promotes angiogenesis in breast cancer
(x9 / promote-02
      :ARG1 (x1 / induce-01
            :ARG2 (x2 / enzyme
                  :name (x3 / name :op1 "Ras")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
            :ARG0 (x4 / enzyme
                  :name (x5 / name :op1 "1/MAZ")))
      :instrument (x6 / feed-01
            :ARG1 (x8 / loop
                  :ARG0-of (x7 / forward-01)))
      :ARG1 (x10 / angiogenesis)
      :location (x11 / disease
            :wiki "breast_cancer"
            :name (x12 / name :op1 "breast" :op2 "cancer")))


# ::id PMC4329006.2
# ::snt In the majority of breast cancers, overexpression and hyperactivation of Ras in the tumor microenvironment play significant role in promoting cancer cell growth, angiogenesis, and metastasis.
# ::tok In the majority of breast cancers , overexpression and hyperactivation of Ras in the tumor microenvironment play significant role in promoting cancer cell growth , angiogenesis , and metastasis .
(x20 / and
      :op1 (x11 / play-02
            :time (x1 / majority
                  :ARG1 (x2 / disease
                        :wiki "breast_cancer"
                        :name (x3 / name :op1 "breast" :op2 "cancer")))
            :ARG0 (x4 / overexpress-01
                  :ARG1 (x5 / and)
                  :degree (x6 / hyper)
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :location (x10 / microenvironment
                        :mod (x9 / tumor)))
            :ARG1 (x13 / role
                  :mod (x12 / significant-02)
                  :topic (x14 / promote-01
                        :ARG1 (x18 / grow-01
                              :ARG1 (x17 / cell
                                    :mod (x15 / disease
                                          :wiki "cancer"
                                          :name (x16 / name :op1 "cancer")))))))
      :op2 (x19 / angiogenesis)
      :op3 (x21 / metastasis))


# ::id PMC4329006.3
# ::snt We have previously shown that vascular endothelial growth factor (VEGF) expression in triple negative breast cancer cells is regulated, at least in part, by SAF-1 (serum amyloid A activating factor 1) transcription factor.
# ::tok We have previously shown that vascular endothelial growth factor ( VEGF ) expression in triple negative breast cancer cells is regulated , at least in part , by SAF @-@ 1 ( serum amyloid A activating factor 1 ) transcription factor .
(x3 / show-01
      :ARG0 (x1 / we)
      :time (x2 / previous)
      :ARG1 (x14 / regulate-01
            :ARG1 (x4 / protein
                  :name (x5 / name
                        :op1 "vascular"
                        :op2 "endothelial"
                        :op3 "growth"
                        :op4 "factor")
                  :ARG1-of (x8 / express-03
                        :ARG2 (x6 / protein
                              :name (x7 / name :op1 "VEGF")
                              :xref (x / xref :value "UNIPROT:VEGFA_HUMAN" :prob "1.003"))
                        :ARG3 (x13 / cell
                              :ARG1-of (x10 / negative-01
                                    :ARG1-of (x9 / triple-01))
                              :mod (x11 / disease
                                    :wiki "breast_cancer"
                                    :name (x12 / name :op1 "breast" :op2 "cancer")))))
            :ARG1 (x16 / part
                  :mod (x15 / at-least))
            :ARG0 (x17 / protein
                  :name (x18 / name :op1 "SAF-1")
                  :xref (x26 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
            :ARG1-of (x21 / activate-01
                  :ARG0 (x19 / enzyme
                        :name (x20 / name
                              :op1 "serum"
                              :op2 "amyloid"
                              :op3 "A"))
                  :ARG1 (x25 / factor
                        :mod (x22 / protein
                              :name (x23 / name :op1 "factor" :op2 "1"))
                        :ARG0-of (x24 / transcribe-01)))))


# ::id PMC4329006.4
# ::snt In this study we show that transformation of normal MCF-10A breast epithelial cells by constitutively active, oncogenic Ras, induces the DNA-binding activity and transcription function of SAF-1.
# ::tok In this study we show that transformation of normal MCF @-@ 10A breast epithelial cells by constitutively active , oncogenic Ras , induces the DNA @-@ binding activity and transcription function of SAF @-@ 1 .
(x4 / show-01
      :location (x2 / study-01
            :mod (x1 / this))
      :ARG0 (x3 / we)
      :ARG1 (x19 / induce-01
            :ARG1 (x11 / cell
                  :ARG1-of (x5 / transform-01
                        :ARG1 (x6 / cell
                              :ARG1-of (x7 / normal-02)
                              :name (x8 / name :op1 "MCF-10A")))
                  :mod (x9 / breast)
                  :mod (x10 / epithelium)
                  :ARG0-of (x13 / activity-06
                        :manner (x12 / constitutive))
                  :ARG0-of (x14 / enzyme
                        :ARG0-of (x15 / cause-01
                              :ARG1 (x16 / disease
                                    :wiki "cancer"
                                    :name (x17 / name :op1 "cancer")))
                        :name (x18 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG2 (x24 / and
                  :op1 (x23 / activity-06
                        :ARG1-of (x22 / bind-01
                              :ARG2 (x20 / nucleic-acid
                                    :wiki "dna"
                                    :name (x21 / name :op1 "DNA"))))
                  :op2 (x26 / function-01
                        :ARG1 (x25 / transcribe-01)))))


# ::id PMC4329006.5
# ::snt Furthermore, we show that inhibition of MEK/MAPK-signaling pathway prevents Ras-mediated activation of SAF-1.
# ::tok Furthermore , we show that inhibition of MEK @/@ MAPK @-@ signaling pathway prevents Ras @-@ mediated activation of SAF @-@ 1 .
(x1 / and
      :op2 (x3 / show-01
            :ARG0 (x2 / we)
            :ARG1 (x11 / prevent-01
                  :ARG0 (x4 / inhibit-01
                        :ARG1 (x10 / pathway
                              :mod (x5 / enzyme
                                    :name (x6 / name :op1 "MEK")
                                    :xref (x20 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343"))
                              :ARG0-of (x9 / signal-07
                                    :ARG1 (x7 / enzyme
                                          :name (x8 / name :op1 "MAPK")
                                          :xref (x19 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313")))))
                  :ARG1 (x15 / activate-01
                        :ARG1-of (x14 / mediate-01
                              :ARG0 (x12 / enzyme
                                    :name (x13 / name :op1 "Ras")
                                    :xref (x18 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                        :ARG1 (x16 / protein
                              :name (x17 / name :op1 "SAF-1")
                              :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))))))


# ::id PMC4329006.6
# ::snt Interestingly, silencing of SAF-1 expression in breast cancer cells by SAF-1-specific short hairpin RNAs (shRNAs) significantly reduced H-Ras and K-Ras mRNA level.
# ::tok Interestingly , silencing of SAF @-@ 1 expression in breast cancer cells by SAF @-@ 1 @-@ specific short hairpin RNAs ( shRNAs ) significantly reduced H @-@ Ras and K @-@ Ras mRNA level .
(x17 / reduce-01
      :ARG2-of (x1 / interest-01)
      :ARG0 (x2 / silence-01
            :ARG1 (x5 / express-03
                  :ARG2 (x3 / protein
                        :name (x4 / name :op1 "SAF-1")
                        :xref (x26 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
            :location (x8 / cell
                  :mod (x6 / disease
                        :wiki "breast_cancer"
                        :name (x7 / name :op1 "breast" :op2 "cancer")))
            :ARG0 (x9 / enzyme
                  :ARG1-of (x12 / specific-02
                        :ARG2 (x10 / protein
                              :name (x11 / name :op1 "SAF-1")
                              :xref (x28 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
                  :name (x13 / name
                        :op1 "short"
                        :op2 "hairpin"
                        :op3 "rna")
                  :ARG1-of (x14 / nucleic-acid
                        :name (x15 / name :op1 "shrna"))))
      :ARG2 (x16 / significant-02)
      :ARG1 (x20 / and
            :op1 (x18 / enzyme
                  :name (x19 / name :op1 "H-Ras")
                  :xref (x27 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))
            :op2 (x21 / enzyme
                  :name (x22 / name :op1 "K-Ras")
                  :xref (x / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661")))
      :ARG1 (x25 / level
            :mod (x23 / nucleic-acid
                  :name (x24 / name :op1 "mRNA"))))


# ::id PMC4329006.7
# ::snt We show that SAF-1 is a direct transcriptional regulator of H-Ras and K-Ras and overexpression of SAF-1 increases H-Ras and K-Ras gene expression.
# ::tok We show that SAF @-@ 1 is a direct transcriptional regulator of H @-@ Ras and K @-@ Ras and overexpression of SAF @-@ 1 increases H @-@ Ras and K @-@ Ras gene expression .
(x2 / show-01
      :ARG0 (x1 / we)
      :ARG1 (x13 / and
            :op1 (x7 / regulate-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "SAF-1")
                        :xref (x25 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                  :mod (x6 / transcribe-01
                        :ARG1-of (x5 / direct-02))
                  :ARG1 (x10 / and
                        :op1 (x8 / enzyme
                              :name (x9 / name :op1 "H-Ras")
                              :xref (x24 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))
                        :op2 (x11 / enzyme
                              :name (x12 / name :op1 "K-Ras")
                              :xref (x27 / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661"))))
            :op2 (x17 / increase-01
                  :ARG0 (x14 / overexpress-01
                        :ARG1 (x15 / protein
                              :name (x16 / name :op1 "SAF-1")
                              :xref (x28 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
                  :ARG1 (x23 / express-03
                        :ARG1 (x20 / and
                              :op1 (x18 / enzyme
                                    :name (x19 / name :op1 "H-Ras")
                                    :xref (x26 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))
                              :op2 (x21 / enzyme
                                    :name (x22 / name :op1 "K-Ras")
                                    :xref (x / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661")))))))


# ::id PMC4329006.8
# ::snt Chromatin immunoprecipitation (ChIP) analyses demonstrated in vivo interaction of SAF-1 at highly purine-rich sequences present at the proximal promoter region, upstream of the transcription start site, in H-Ras and K-Ras genes.
# ::tok Chromatin immunoprecipitation ( ChIP ) analyses demonstrated in vivo interaction of SAF @-@ 1 at highly purine @-@ rich sequences present at the proximal promoter region , upstream of the transcription start site , in H @-@ Ras and K @-@ Ras genes .
(x8 / demonstrate-01
      :ARG0 (x7 / analyze-01
            :manner (x3 / immunoprecipitate-01
                  :ARG1 (x1 / macro-molecular-complex
                        :name (x2 / name :op1 "Chromatin"))
                  :ARG1-of (x4 / describe-01
                        :ARG0 (x5 / protein
                              :name (x6 / name :op1 "ChIP")
                              :xref (x32 / xref :value "UNIPROT:CHIP_HUMAN" :prob "0.653")))))
      :ARG1 (x10 / interact-01
            :manner (x9 / in-vivo)
            :ARG0 (x11 / protein
                  :name (x12 / name :op1 "SAF-1")
                  :xref (x34 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
            :location (x29 / and
                  :op1 (x18 / present-02
                        :ARG1-of (x13 / high-02
                              :ARG1 (x17 / sequence
                                    :mod (x16 / rich
                                          :mod (x14 / amino-acid
                                                :name (x15 / name :op1 "purine")
                                                :xref (x35 / xref :value "PUBCHEM:1044" :prob "8.760163")))))
                        :ARG2 (x21 / region
                              :mod (x19 / proximal)
                              :ARG0-of (x20 / promote-01)
                              :location (x22 / relative-position
                                    :direction (x23 / upstream)
                                    :op1 (x26 / protein-segment
                                          :location-of (x25 / start-01
                                                :ARG1 (x24 / transcribe-01)))))
                        :location (x27 / enzyme
                              :name (x28 / name :op1 "H-Ras")
                              :xref (x / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631")))
                  :op2 (x31 / gene
                        :name (x30 / name :op1 "K-Ras")
                        :xref (x33 / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661")))))


# ::id PMC4329006.9
# ::snt Previous studies have shown that these sequences are nuclease hypersensitive and capable of forming G4 quadruplex structure.
# ::tok Previous studies have shown that these sequences are nuclease hypersensitive and capable of forming G4 quadruplex structure .
(x3 / show-01
      :ARG0 (x2 / study-01
            :time (x1 / previous))
      :ARG1 (x5 / sequence
            :mod (x4 / this))
      :ARG1 (x10 / and
            :op1 (x8 / sensitive-03
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "nuclease")
                        :xref (x / xref :value "UNIPROT:DHX9_HUMAN" :prob "0.222"))
                  :degree (x9 / hyper))
            :op2 (x11 / capable-01
                  :ARG1 (x12 / form-01
                        :ARG1 (x15 / structure
                              :mod (x13 / enzyme
                                    :name (x14 / name :op1 "G4" :op2 "quadruplex")))))))


# ::id PMC4329006.10
# ::snt Together, our results show the presence of a novel transactivating loop, in which, Ras and SAF-1 are interconnected.
# ::tok Together , our results show the presence of a novel transactivating loop , in which , Ras and SAF @-@ 1 are interconnected .
(x5 / show-01
      :mod (x1 / together)
      :ARG0 (x3 / thing
            :poss (x2 / we)
            :ARG2-of (x4 / result-01))
      :ARG1 (x6 / present-02
            :ARG1 (x9 / loop
                  :mod (x7 / novel)
                  :ARG0-of (x8 / transactivate-00)
                  :location (x10 / amr-unknown)
                  :ARG0-of (x16 / interconnect-01
                        :ARG1 (x13 / and
                              :op1 (x11 / enzyme
                                    :name (x12 / name :op1 "Ras")
                                    :xref (x17 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                              :op2 (x14 / protein
                                    :name (x15 / name :op1 "SAF-1")
                                    :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))))))


# ::id PMC4329006.11
# ::snt These findings will help defining molecular mechanisms of abnormal overexpression of Ras in breast tumors, which seldom show genetic Ras mutations.
# ::tok These findings will help defining molecular mechanisms of abnormal overexpression of Ras in breast tumors , which seldom show genetic Ras mutations .
(x4 / help-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG1-of (x3 / find-01))
      :ARG1 (x5 / define-01
            :ARG1 (x7 / mechanism
                  :mod (x6 / molecule)
                  :poss (x18 / mutate-01
                        :ARG1-of (x8 / normal-02 :polarity "-")
                        :ARG0 (x9 / overexpress-01
                              :ARG1 (x10 / enzyme
                                    :name (x11 / name :op1 "Ras")
                                    :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                              :location (x13 / tumor
                                    :mod (x12 / breast)
                                    :ARG0-of (x15 / show-01
                                          :ARG1-of (x14 / seldom)
                                          :ARG1 (x16 / gene
                                                :name (x17 / name :op1 "Ras")
                                                :xref (x19 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))))))))


# ::id PMC4329006.40
# ::snt Material and Methods
# ::tok Material and Methods
(x2 / and
      :op1 (x1 / material)
      :op2 (x3 / method))


# ::id PMC4329006.44
# ::snt Establishment of cell lines and transfection assay
# ::tok Establishment of cell lines and transfection assay
(x1 / establish-01
      :ARG1 (x3 / and
            :op1 (x2 / cell-line)
            :op2 (x5 / assay-01
                  :ARG1 (x4 / transfect-01))))


# ::id PMC4329006.51
# ::snt Reporter gene and expression plasmids
# ::tok Reporter gene and expression plasmids
(x4 / plasmid
      :ARG1 (x3 / express-03
            :ARG1 (x2 / gene
                  :ARG0-of (x1 / report-01))))


# ::id PMC4329006.62
# ::snt Preparation of nuclear extract and DNA-binding assay
# ::tok Preparation of nuclear extract and DNA @-@ binding assay
(x4 / and
      :op1 (x1 / prepare-01
            :ARG1 (x3 / extract-01
                  :mod (x2 / nucleus
                        :xref (x / xref :value "GO:0005634" :prob "0.8"))))
      :op2 (x8 / assay-01
            :ARG1 (x7 / bind-01
                  :ARG1 (x5 / nucleic-acid
                        :wiki "dna"
                        :name (x6 / name :op1 "DNA")))))


# ::id PMC4329006.68
# ::snt RNA isolation and qRT-PCR
# ::tok RNA isolation and qRT @-@ PCR
(x4 / and
      :op1 (x3 / isolate-01
            :ARG1 (x1 / nucleic-acid
                  :name (x2 / name :op1 "RNA")))
      :op2 (x5 / thing
            :name (x6 / name :op1 "qRT-PCR")))


# ::id PMC4329006.87
# ::snt SAF-1/MAZ DNA-binding and transcriptional activities are induced in oncogenic rasV12 transformed MCF-10A cells
# ::tok SAF @-@ 1/MAZ DNA @-@ binding and transcriptional activities are induced in oncogenic rasV12 transformed MCF @-@ 10A cells
(x9 / induce-01
      :ARG2 (x1 / enzyme
            :name (x2 / name :op1 "1/MAZ"))
      :ARG0 (x6 / and
            :op1 (x5 / bind-01
                  :ARG2 (x3 / nucleic-acid
                        :wiki "dna"
                        :name (x4 / name :op1 "DNA")))
            :op2 (x8 / activity-06
                  :ARG1 (x7 / transcribe-01)))
      :location (x22 / cell-line
            :ARG0-of (x10 / cause-01
                  :ARG1 (x11 / disease
                        :wiki "cancer"
                        :name (x12 / name :op1 "cancer")))
            :ARG1-of (x20 / transform-01
                  :ARG0 (x13 / and
                        :op1 (x14 / enzyme
                              :name (x15 / name :op1 "ras")
                              :ARG2-of (x16 / mutate-01 :value "v12")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                        :op2 (x17 / enzyme
                              :name (x18 / name :op1 "ras")
                              :ARG2-of (x19 / mutate-01 :value "v12s35")
                              :xref (x23 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))))
            :name (x21 / name :op1 "MCF-10A")))


# ::id PMC4329006.88
# ::snt To understand whether in the TME, SAF-1/MAZ activity is increased by oncogenic signaling, we stably transduced MCF-10A cells, which has a low basal SAF-1/MAZ activity 34 , with a constitutively active oncogenic pCMV ras V12 expression vector or a control empty vector DNA.
# ::tok To understand whether in the TME , SAF @-@ 1/MAZ activity is increased by oncogenic signaling , we stably transduced MCF @-@ 10A cells , which has a low basal SAF @-@ 1/MAZ activity 34 , with a constitutively active oncogenic pCMV ras V12 expression vector or a control empty vector DNA .
(x1 / multi-sentence
      :snt1 (x14 / transduce-01
            :purpose (x2 / understand-01
                  :ARG1 (x7 / increase-01
                        :mode "interrogative"
                        :ARG1 (x6 / activity-06
                              :location (x3 / tme)
                              :ARG0 (x4 / enzyme
                                    :name (x5 / name :op1 "1/MAZ")))
                        :ARG0 (x11 / signal-07
                              :ARG0-of (x8 / cause-01
                                    :ARG1 (x9 / disease
                                          :wiki "cancer"
                                          :name (x10 / name :op1 "cancer")))))
                  :ARG0 (x12 / we))
            :ARG1-of (x13 / stable-03)
            :ARG1 (x16 / cell-line
                  :name (x15 / name :op1 "MCF-10A")
                  :ARG0-of (x17 / have-03
                        :ARG1 (x22 / activity-06
                              :ARG1-of (x18 / low-04)
                              :mod (x19 / basal)
                              :mod (x20 / enzyme
                                    :name (x21 / name :op1 "1/MAZ")))
                        :ARG1-of (x23 / describe-01
                              :ARG0 (x24 / publication
                                    :ARG1-of (x25 / cite-01 :ARG2 "34")))))
            :ARG2 (x26 / enzyme
                  :ARG0-of (x28 / activity-06
                        :mod (x27 / constitutive))
                  :ARG0-of (x29 / cause-01
                        :ARG1 (x30 / disease
                              :wiki "cancer"
                              :name (x31 / name :op1 "cancer")))
                  :name (x32 / name :op1 "pCMV")))
      :snt2 (x38 / or
            :op1 (x37 / vector
                  :ARG1-of (x36 / express-03
                        :ARG2 (x33 / enzyme
                              :name (x34 / name :op1 "ras")
                              :ARG2-of (x35 / mutate-01 :value "V12")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))))
            :op2 (x41 / vector
                  :ARG2-of (x39 / control-01)
                  :ARG1-of (x40 / empty-02))
            :op2 (x42 / nucleic-acid
                  :wiki "dna"
                  :name (x43 / name :op1 "DNA"))))


# ::id PMC4329006.89
# ::snt MCF-10A is a spontaneously immortalized cell line originated from nonmalignant breast epithelial cells and these cells have many characteristics of normal breast epithelium, including inability to form colonies in soft agar and tumors in nude mice 35 .
# ::tok MCF @-@ 10A is a spontaneously immortalized cell line originated from nonmalignant breast epithelial cells and these cells have many characteristics of normal breast epithelium , including inability to form colonies in soft agar and tumors in nude mice 35 .
(x10 / and
      :ARG0 (x6 / and
            :op1 (x1 / cell-line
                  :name (x2 / name :op1 "MCF-10A")
                  :ARG1-of (x4 / immortalize-03
                        :mod (x3 / spontaneous)
                        :mod (x5 / cell-line)))
            :op2 (x9 / cell
                  :source (x8 / epithelium
                        :mod (x7 / breast))))
      :op2 (x14 / characteristic-02
            :ARG1 (x12 / cell
                  :mod (x11 / this))
            :ARG2 (x13 / many)
            :ARG1 (x17 / epithelium
                  :ARG1-of (x15 / normal-02)
                  :mod (x16 / breast)))
      :ARG2-of (x18 / include-91
            :ARG1 (x24 / and
                  :op1 (x19 / possible-01
                        :polarity "-"
                        :ARG1 (x20 / form-01
                              :ARG1 (x21 / colony)
                              :location (x23 / agar
                                    :ARG1-of (x22 / soft-02))))
                  :op2 (x25 / tumor
                        :location (x27 / mouse
                              :mod (x26 / nude)))
                  :ARG1-of (x28 / describe-01
                        :ARG0 (x29 / publication
                              :ARG1-of (x30 / cite-01 :ARG2 "35"))))))


# ::id PMC4329006.90
# ::snt Previous studies have shown that upon the introduction of Ras oncogene, MCF-10A cells undergo transformation and these transformed cells exhibit hall marks of transformation and epithelial-mesenchymal transition (EMT), including anchorage-independent growth, loss of requirement of hormones, invasiveness, and tumorigenicity in nude mice 36 , 37 .
# ::tok Previous studies have shown that upon the introduction of Ras oncogene , MCF @-@ 10A cells undergo transformation and these transformed cells exhibit hall marks of transformation and epithelial @-@ mesenchymal transition ( EMT ) , including anchorage @-@ independent growth , loss of requirement of hormones , invasiveness , and tumorigenicity in nude mice 36 , 37 .
(x1 / multi-sentence
      :snt1 (x4 / show-01
            :ARG0 (x3 / study-01
                  :time (x2 / previous))
            :ARG1 (x5 / and
                  :op1 (x6 / introduce-02
                        :ARG1 (x7 / enzyme
                              :name (x8 / name :op1 "Ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                        :ARG0-of (x9 / cause-01
                              :ARG1 (x10 / disease
                                    :wiki "cancer"
                                    :name (x11 / name :op1 "cancer"))))))
      :snt2 (x16 / and
            :op1 (x14 / undergo-28
                  :ARG1 (x12 / cell-line
                        :name (x13 / name :op1 "MCF-10A"))
                  :ARG2 (x15 / transform-01))
            :op2 (x20 / exhibit-01
                  :ARG0 (x19 / cell
                        :mod (x17 / this)
                        :ARG1-of (x18 / transform-01))
                  :ARG1 (x25 / and
                        :op1 (x23 / mark-01
                              :ARG0 (x21 / person
                                    :name (x22 / name :op1 "hall"))
                              :ARG1 (x24 / transform-01))
                        :op2 (x28 / transition-01
                              :ARG3 (x26 / epithelium)
                              :ARG2 (x27 / mesenchyme)))
                  :ARG1 (x29 / include-91
                        :ARG1 (x37 / and
                              :op1 (x32 / grow-01
                                    :ARG0-of (x31 / depend-01
                                          :ARG1 (x30 / anchorage)
                                          :polarity "-"))
                              :op2 (x33 / lose-02
                                    :ARG1 (x34 / require-01
                                          :ARG1 (x35 / hormone
                                                :ARG1-of (x36 / invade-01))))
                              :op2 (x38 / create-01
                                    :ARG1 (x39 / tumor)
                                    :location (x41 / mouse
                                          :mod (x40 / nude))
                                    :ARG1-of (x42 / describe-01
                                          :ARG0 (x43 / publication
                                                :ARG1-of (x44 / cite-01 :ARG2 "36"))))
                              :op3 (x45 / publication
                                    :ARG1-of (x46 / cite-01 :ARG2 "37")))))))


# ::id PMC4329006.91
# ::snt As shown in Figure 1 , DNA-binding activity of SAF-1 was low in untransfected or empty vector transfected MCF-10A cells, but in oncogenic pCMV ras V12 transfected MCF-10A cells, the DNA-binding activity became markedly higher (Fig. 1 , lanes 2–4).
# ::tok As shown in Figure 1 , DNA @-@ binding activity of SAF @-@ 1 was low in untransfected or empty vector transfected MCF @-@ 10A cells , but in oncogenic pCMV ras V12 transfected MCF @-@ 10A cells , the DNA @-@ binding activity became markedly higher ( Fig . 1 , lanes 2–4 ) .
(x1 / multi-sentence
      :snt1 (x10 / low-04
            :ARG1-of (x2 / show-01
                  :ARG0 (x3 / figure :mod "1"))
            :ARG1 (x7 / activity-06
                  :ARG1 (x6 / bind-01
                        :ARG1 (x4 / nucleic-acid
                              :wiki "dna"
                              :name (x5 / name :op1 "DNA")))
                  :ARG0 (x8 / protein
                        :name (x9 / name :op1 "SAF-1")
                        :xref (x44 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
            :location (x16 / transfect-01
                  :ARG2 (x13 / or
                        :op1 (x11 / enzyme
                              :name (x12 / name :op1 "untransfected"))
                        :op2 (x15 / vector
                              :ARG1-of (x14 / empty-02)))
                  :ARG1 (x17 / cell-line
                        :name (x18 / name :op1 "MCF-10A"))))
      :snt2 (x19 / contrast-01
            :ARG2 (x35 / become-01
                  :location (x30 / cell-line
                        :mod (x20 / enzyme
                              :ARG0-of (x21 / cause-01
                                    :ARG1 (x22 / disease
                                          :wiki "cancer"
                                          :name (x23 / name :op1 "cancer")))
                              :name (x24 / name :op1 "pCMV"))
                        :ARG1-of (x28 / transfect-01
                              :ARG2 (x25 / enzyme
                                    :name (x26 / name :op1 "ras")
                                    :ARG2-of (x27 / mutate-01 :value "V12")
                                    :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203")))
                        :name (x29 / name :op1 "MCF-10A"))
                  :ARG1 (x34 / activity-06
                        :ARG1-of (x33 / bind-01
                              :ARG2 (x31 / nucleic-acid
                                    :wiki "dna"
                                    :name (x32 / name :op1 "DNA"))))
                  :ARG2 (x38 / high-02
                        :degree (x37 / more
                              :degree (x36 / marked))))
            :ARG1-of (x39 / describe-01
                  :ARG0 (x40 / and
                        :op1 (x41 / figure :mod "1")
                        :op2 (x42 / lane
                              :mod (x43 / value-interval :op1 "2" :op2 "4"))))))


# ::id PMC4329006.92
# ::snt Presence of SAF-1 in this DNA-protein complex was verified by using molar excess of competitor SAF-1-binding oligonucleotide and an anti-SAF-1 antibody, both of which inhibited the DNA-protein complex formation (Fig. 1 , lanes 7 and 9).
# ::tok Presence of SAF @-@ 1 in this DNA @-@ protein complex was verified by using molar excess of competitor SAF @-@ 1 @-@ binding oligonucleotide and an anti @-@ SAF @-@ 1 antibody , both of which inhibited the DNA @-@ protein complex formation ( Fig . 1 , lanes 7 and 9 ) .
(x1 / multi-sentence
      :snt1 (x9 / verify-01
            :ARG1 (x2 / present-02
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "SAF-1")
                        :xref (x35 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                  :ARG2 (x8 / complex
                        :mod (x5 / this)
                        :mod (x7 / protein
                              :name (x6 / name :op1 "DNA")
                              :xref (x36 / xref :value "UNIPROT:DNS2A_HUMAN" :prob "0.272"))))
            :manner (x10 / use-01
                  :ARG1 (x11 / molar)))
      :snt2 (x18 / and
            :op1 (x17 / oligonucleotide
                  :ARG0-of (x12 / exceed-01
                        :ARG1 (x13 / compete-01))
                  :ARG0-of (x16 / bind-01
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "SAF-1")
                              :xref (x37 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))))
            :op2 (x22 / antibody
                  :ARG0-of (x19 / counter-01
                        :ARG1 (x20 / protein
                              :name (x21 / name :op1 "SAF-1")
                              :xref (x34 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))))
            :ARG1-of (x23 / and
                  :ARG0-of (x24 / inhibit-01
                        :ARG1 (x28 / form-01
                              :ARG0 (x26 / protein
                                    :name (x25 / name :op1 "DNA")
                                    :xref (x / xref :value "UNIPROT:DNS2A_HUMAN" :prob "0.272"))
                              :ARG1 (x27 / macro-molecular-complex)
                              :ARG1-of (x29 / describe-01
                                    :ARG0 (x30 / figure
                                          :mod "1a"
                                          :ARG0-of (x31 / compare-01
                                                :ARG1 (x32 / lane :mod "7")
                                                :ARG2 (x33 / lane :mod "9")))))))))


# ::id PMC4329006.93
# ::snt Involvement of Sp1 transcription factor in this DNA-protein complex was evident by the appearance of a super-shifted complex (ss) when anti-Sp1 antibody was used (Fig. 1 , lanes 10 and 11).
# ::tok Involvement of Sp1 transcription factor in this DNA @-@ protein complex was evident by the appearance of a super @-@ shifted complex ( ss ) when anti @-@ Sp1 antibody was used ( Fig . 1 , lanes 10 and 11 ) .
(x10 / evidence-01
      :ARG1 (x1 / involve-01
            :ARG1 (x5 / factor
                  :ARG0-of (x4 / transcribe-01
                        :ARG1 (x2 / protein
                              :name (x3 / name :op1 "Sp1")
                              :xref (x26 / xref :value "UNIPROT:C4PGM0_HUMAN" :prob "1.001"))))
            :ARG2 (x9 / complex
                  :mod (x6 / this)
                  :mod (x8 / protein
                        :name (x7 / name :op1 "DNA")
                        :xref (x / xref :value "UNIPROT:DNS2A_HUMAN" :prob "0.272"))))
      :ARG0 (x11 / appear-01
            :ARG1 (x13 / shift-01
                  :degree (x12 / super)
                  :ARG2 (x14 / macro-molecular-complex)))
      :ARG1-of (x15 / s)
      :time (x20 / use-01
            :ARG1 (x19 / antibody
                  :ARG0-of (x16 / counter-01
                        :ARG1 (x17 / protein
                              :name (x18 / name :op1 "Sp1")
                              :xref (x27 / xref :value "UNIPROT:C4PGM0_HUMAN" :prob "1.001")))))
      :ARG1-of (x21 / describe-01
            :ARG0 (x23 / lane
                  :part-of (x22 / figure :mod "1a")
                  :ARG1-of (x24 / label-01
                        :ARG2 (x25 / and :op1 "10" :op2 "11")))))


# ::id PMC4329006.94
# ::snt It is likely that SAF-1 and Sp1 together bind to the VEGF promoter.
# ::tok It is likely that SAF @-@ 1 and Sp1 together bind to the VEGF promoter .
(x1 / likely-01
      :ARG1 (x8 / bind-01
            :ARG1 (x4 / and
                  :op1 (x2 / protein
                        :name (x3 / name :op1 "SAF-1")
                        :xref (x13 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                  :op2 (x5 / protein
                        :name (x6 / name :op1 "Sp1")
                        :xref (x14 / xref :value "UNIPROT:C4PGM0_HUMAN" :prob "1.001")))
            :mod (x7 / together)
            :ARG2 (x12 / molecular-physical-entity
                  :ARG0-of (x11 / promote-01
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "VEGF")
                              :xref (x / xref :value "UNIPROT:VEGFA_HUMAN" :prob "1.003"))))))


# ::id PMC4329006.95
# ::snt Indeed, such interaction of SAF-1 and Sp1 may have a synergistic effect on the VEGF expression as these two transcription factors have earlier been shown to synergize in the transcriptional induction process 38 .
# ::tok Indeed , such interaction of SAF @-@ 1 and Sp1 may have a synergistic effect on the VEGF expression as these two transcription factors have earlier been shown to synergize in the transcriptional induction process 38 .
(x2 / possible-01
      :mod (x1 / indeed)
      :ARG1 (x8 / affect-01
            :ARG0 (x3 / and
                  :op1 (x4 / interact-01
                        :ARG1 (x5 / protein
                              :name (x6 / name :op1 "Sp1")
                              :xref (x26 / xref :value "UNIPROT:C4PGM0_HUMAN" :prob "1.001"))))
            :ARG2 (x7 / synergize-01)
            :ARG1 (x17 / show-01
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "VEGF")
                        :xref (x / xref :value "UNIPROT:VEGFA_HUMAN" :prob "1.003"))
                  :ARG0 (x11 / express-03
                        :ARG2 (x14 / factor
                              :mod (x12 / this)
                              :quant "2"
                              :ARG0-of (x13 / transcribe-01)))
                  :time (x15 / early
                        :degree (x16 / more))
                  :ARG1 (x18 / small-molecule
                        :name (x19 / name :op1 "synergize"))
                  :location (x22 / process-02
                        :ARG1-of (x21 / induce-01
                              :ARG2 (x20 / transcribe-01))
                        :ARG1-of (x23 / describe-01
                              :ARG0 (x24 / publication
                                    :ARG1-of (x25 / cite-01 :ARG2 "38")))))))


# ::id PMC4329006.96
# ::snt A minor DNA-protein complex, complex A, was not affected by either SAF-1 or Sp1-specific antibodies and is composed of KLF-4 as described earlier 34 .
# ::tok A minor DNA @-@ protein complex , complex A , was not affected by either SAF @-@ 1 or Sp1 @-@ specific antibodies and is composed of KLF @-@ 4 as described earlier 34 .
(x15 / and
      :op1 (x4 / macro-molecular-complex
            :ARG1-of (x1 / minor-01)
            :ARG1-of (x3 / protein
                  :name (x2 / name :op1 "DNA")
                  :xref (x25 / xref :value "UNIPROT:DNS2A_HUMAN" :prob "0.272"))
            :part (x5 / protein
                  :name (x6 / name :op1 "A")
                  :ARG1-of (x7 / affect-01
                        :polarity "-"
                        :ARG0 (x8 / or
                              :op1 (x9 / protein
                                    :name (x10 / name :op1 "SAF-1")
                                    :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                              :op2 (x14 / antibody
                                    :ARG1-of (x13 / specific-02
                                          :ARG2 (x11 / protein
                                                :name (x12 / name :op1 "Sp1")
                                                :xref (x26 / xref :value "UNIPROT:C4PGM0_HUMAN" :prob "1.001"))))))))
      :op2 (x16 / compose-01
            :ARG2 (x17 / protein
                  :name (x18 / name :op1 "KLF-4"))
            :ARG1-of (x19 / describe-01
                  :time (x20 / early
                        :degree (x21 / more)))
            :ARG1-of (x22 / describe-01
                  :ARG0 (x23 / publication
                        :ARG1-of (x24 / cite-01 :ARG2 "34")))))


# ::id PMC4329006.97
# ::snt Ras expression seems to have little effect in this complex formation.
# ::tok Ras expression seems to have little effect in this complex formation .
(x1 / and
      :op1 (x4 / express-03
            :ARG2 (x2 / enzyme
                  :name (x3 / name :op1 "Ras")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
      :op2 (x5 / seem-01
            :ARG1 (x7 / affect-01
                  :degree (x6 / little)
                  :ARG1 (x10 / form-01
                        :ARG1 (x9 / complex
                              :mod (x8 / this))))))


# ::id PMC4329006.98
# ::snt Increase of SAF-1 DNA-binding activity in oncogenic ras -transformed MCF-10A cells.
# ::tok Increase of SAF @-@ 1 DNA @-@ binding activity in oncogenic ras -@ transformed MCF @-@ 10A cells .
(x1 / increase-01
      :ARG1 (x7 / activity-06
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "SAF-1")
                  :xref (x17 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
            :ARG1 (x6 / bind-01
                  :ARG2 (x4 / nucleic-acid
                        :wiki "dna"
                        :name (x5 / name :op1 "DNA")))
            :location (x16 / cell
                  :mod (x8 / enzyme
                        :ARG0-of (x9 / cause-01
                              :ARG1 (x10 / disease
                                    :wiki "cancer"
                                    :name (x11 / name :op1 "cancer")))
                        :name (x12 / name :op1 "ras")
                        :mod (x13 / transform-01
                              :ARG1 (x14 / cell-line
                                    :name (x15 / name :op1 "MCF-10A")))
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203")))))


# ::id PMC4329006.99
# ::snt Nuclear extracts (10 μ g of protein) prepared from untreated (lane 2), empty vector transformed (lane 3) or pCMV- ras V12 transformed (lanes 4–11) MCF-10A cells, as indicated, were incubated with 32 P-labeled VEGF DNA (−135 to +29) containing SAF-1-binding element.
# ::tok Nuclear extracts ( 10 μ g of protein ) prepared from untreated ( lane 2 ) , empty vector transformed ( lane 3 ) or pCMV @- ras V12 transformed ( lanes 4–11 ) MCF @-@ 10A cells , as indicated , were incubated with 32 P @-@ labeled VEGF DNA ( −135 to +29 ) containing SAF @-@ 1 @-@ binding element .
(x1 / multi-sentence
      :snt1 (x32 / incubate-01
            :ARG1 (x2 / and
                  :op1 (x4 / extract
                        :mod (x3 / nucleus
                              :xref (x51 / xref :value "GO:0005634" :prob "0.8"))
                        :ARG1-of (x5 / mean-01
                              :ARG2 (x6 / protein
                                    :quant (x7 / concentration-quantity
                                          :quant "10"
                                          :unit (x8 / micromolar))
                                    :name (x9 / name
                                          :op1 "g"
                                          :op2 "of"
                                          :op3 "protein")))
                        :ARG1-of (x10 / prepare-01
                              :ARG2 (x11 / treat-04 :polarity "-"))
                        :ARG1-of (x12 / describe-01
                              :ARG0 (x13 / lane :mod "2"))
                        :ARG0-of (x25 / transform-01
                              :ARG0 (x19 / or
                                    :op1 (x15 / vector
                                          :ARG1-of (x14 / empty-02)
                                          :ARG1-of (x16 / transform-01)
                                          :ARG1-of (x17 / describe-01
                                                :ARG0 (x18 / lane :mod "3")))
                                    :op2 (x20 / enzyme
                                          :name (x21 / name :op1 "pCMV"))
                                    :op2 (x22 / enzyme
                                          :name (x23 / name :op1 "ras")
                                          :ARG2-of (x24 / mutate-01 :value "V12")
                                          :xref (x49 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))))
                        :ARG1-of (x26 / describe-01
                              :ARG0 (x27 / lane
                                    :name (x28 / name :op1 "4–11"))))
                  :op2 (x29 / cell-line
                        :name (x30 / name :op1 "MCF-10A"))
                  :ARG1-of (x31 / indicate-01))
            :ARG2 (x33 / publication
                  :ARG1-of (x34 / cite-01 :ARG2 "32")))
      :snt2 (x44 / contain-01
            :ARG0 (x43 / molecular-physical-entity
                  :ARG1-of (x35 / statistical-test-91
                        :ARG2 (x36 / less-than :op1 "0.05"))
                  :ARG1-of (x37 / label-01
                        :ARG2 (x38 / protein
                              :name (x39 / name :op1 "VEGF")
                              :xref (x50 / xref :value "UNIPROT:VEGFA_HUMAN" :prob "1.003")))
                  :mod (x40 / nucleic-acid
                        :wiki "dna"
                        :name (x41 / name :op1 "DNA")
                        :name (x42 / name :op1 "−135"))
                  :quant "29")
            :ARG1 (x48 / element
                  :ARG0-of (x47 / bind-01
                        :ARG1 (x45 / protein
                              :name (x46 / name :op1 "saf-1")
                              :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "0.632"))))))


# ::id PMC4329006.100
# ::snt Lane 1 contains no nuclear extract.
# ::tok Lane 1 contains no nuclear extract .
(x2 / contain-01
      :ARG0 (x1 / lane :mod "1")
      :ARG1 (x4 / extract-01
            :polarity "-"
            :mod (x3 / nucleus
                  :xref (x / xref :value "GO:0005634" :prob "0.8"))))


# ::id PMC4329006.102
# ::snt In some assays, 50-fold molar excess of either nonspecific oligonucleotide (lane 6) or SAF-1-binding competitor oligonucleotide (lane 7) or normal IgG (lane 8) or antibody to SAF-1 (lanes 9 and 11) or antibody to Sp1 (lanes 10 and 11) were included during a preincubation reaction.
# ::tok In some assays , 50 @-@ fold molar excess of either nonspecific oligonucleotide ( lane 6 ) or SAF @-@ 1 @-@ binding competitor oligonucleotide ( lane 7 ) or normal IgG ( lane 8 ) or antibody to SAF @-@ 1 ( lanes 9 and 11 ) or antibody to Sp1 ( lanes 10 and 11 ) were included during a preincubation reaction .
(x1 / multi-sentence
      :snt1 (x11 / or
            :op1 (x6 / exceed-01
                  :location (x3 / assay-01
                        :quant (x2 / some))
                  :degree (x4 / product-of
                        :op1 "50"
                        :op2 (x5 / molar))
                  :ARG1 (x8 / oligonucleotide
                        :ARG1-of (x7 / specific-02 :polarity "-"))
                  :ARG1-of (x9 / describe-01
                        :ARG0 (x10 / lane :mod "6")))
            :op2 (x14 / bind-01
                  :ARG2 (x12 / protein
                        :name (x13 / name :op1 "SAF-1")
                        :xref (x43 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))))
      :snt2 (x39 / include-01
            :ARG0 (x15 / compete-01)
            :ARG1 (x31 / or
                  :op1 (x16 / oligonucleotide
                        :ARG0-of (x23 / or
                              :op1 (x18 / or
                                    :op1 (x17 / lane :mod "7")
                                    :op2 (x22 / lane
                                          :mod (x19 / cell
                                                :ARG1-of (x20 / normal-02)
                                                :name (x21 / name :op1 "IgG"))
                                          :mod "8"))
                              :op2 (x24 / antibody
                                    :ARG0-of (x25 / counter-01
                                          :ARG1 (x26 / protein
                                                :name (x27 / name :op1 "SAF-1")
                                                :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))))
                        :ARG1-of (x28 / compare-01
                              :ARG1 (x29 / lane :mod "9")
                              :ARG2 (x30 / lane :mod "11")))
                  :op2 (x36 / lane
                        :mod (x32 / antibody
                              :ARG0-of (x33 / counter-01
                                    :ARG1 (x34 / protein
                                          :name (x35 / name :op1 "Sp1")
                                          :xref (x42 / xref :value "UNIPROT:C4PGM0_HUMAN" :prob "1.001"))))
                        :ARG1-of (x37 / label-01
                              :ARG2 (x38 / and :op1 "10" :op2 "11"))))
            :time (x40 / preincubate-01
                  :ARG2 (x41 / react-01))))


# ::id PMC4329006.103
# ::snt Migration positions of SAF-1-specific complex are indicated.
# ::tok Migration positions of SAF @-@ 1 @-@ specific complex are indicated .
(x7 / indicate-01
      :ARG0 (x1 / migrate-01)
      :ARG1 (x2 / position-01
            :ARG1 (x6 / macro-molecular-complex
                  :ARG1-of (x5 / specific-02
                        :ARG2 (x3 / protein
                              :name (x4 / name :op1 "saf-1")
                              :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "0.632"))))))


# ::id PMC4329006.104
# ::snt Super-shift (ss) of Sp1-specific DNA-protein complex is indicated.
# ::tok Super @-@ shift ( ss ) of Sp1 @-@ specific DNA @-@ protein complex is indicated .
(x11 / indicate-01
      :ARG1 (x2 / shift-01
            :degree (x1 / super)
            :ARG1-of (x3 / s)
            :ARG1 (x10 / macro-molecular-complex
                  :ARG1-of (x6 / specific-02
                        :ARG2 (x4 / protein
                              :name (x5 / name :op1 "Sp1")
                              :xref (x / xref :value "UNIPROT:C4PGM0_HUMAN" :prob "1.001")))
                  :part (x7 / nucleic-acid
                        :wiki "dna"
                        :name (x8 / name :op1 "DNA"))
                  :part (x9 / protein))))


# ::id PMC4329006.105
# ::snt Complex A represents a DNA-protein complex present in normal MCF-10A cell nuclear extract is not affected by either SAF-1 competitor oligonucleotide, or the antibodies.
# ::tok Complex A represents a DNA @-@ protein complex present in normal MCF @-@ 10A cell nuclear extract is not affected by either SAF @-@ 1 competitor oligonucleotide , or the antibodies .
(x12 / affect-01
      :ARG1 (x6 / present-02
            :ARG1 (x1 / macro-molecular-complex
                  :ARG0-of (x2 / represent-01
                        :ARG1 (x5 / complex
                              :mod (x4 / protein
                                    :name (x3 / name :op1 "DNA")
                                    :xref (x19 / xref :value "UNIPROT:DNS2A_HUMAN" :prob "0.272")))))
            :ARG2 (x11 / extract-01
                  :ARG1-of (x7 / normal-02)
                  :mod (x8 / cell-line
                        :name (x9 / name :op1 "MCF-10A"))
                  :mod (x10 / nucleus
                        :xref (x20 / xref :value "GO:0005634" :prob "0.8"))))
      :polarity "-"
      :ARG0 (x17 / or
            :op1 (x16 / oligonucleotide
                  :ARG0-of (x15 / compete-01
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "SAF-1")
                              :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))))
            :op2 (x18 / antibody)))


# ::id PMC4329006.107
# ::snt To assess whether increased DNA-binding activity of SAF-1 in Ras-transformed MCF-10A- ras cells leads to an alteration in its transcriptional function, we evaluated SAF-1-driven promoter activity using a CAT reporter gene that contains three tandem copies of a bona fide SAF-1-binding element 31 .
# ::tok To assess whether increased DNA @-@ binding activity of SAF @-@ 1 in Ras @-@ transformed MCF @-@ 10A @- ras cells leads to an alteration in its transcriptional function , we evaluated SAF @-@ 1 @-@ driven promoter activity using a CAT reporter gene that contains three tandem copies of a bona fide SAF @-@ 1 @-@ binding element 31 .
(x1 / multi-sentence
      :snt1 (x23 / evaluate-01
            :purpose (x2 / assess-01
                  :ARG1 (x7 / activity-06
                        :mode "interrogative"
                        :ARG0 (x3 / increase-01
                              :ARG1 (x6 / bind-01
                                    :ARG1 (x4 / nucleic-acid
                                          :wiki "dna"
                                          :name (x5 / name :op1 "DNA"))))
                        :ARG0 (x8 / protein
                              :name (x9 / name :op1 "SAF-1")
                              :xref (x46 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                        :location (x13 / cell
                              :ARG1-of (x12 / transform-01
                                    :ARG0 (x10 / enzyme
                                          :name (x11 / name :op1 "Ras")
                                          :xref (x49 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                              :ARG0-of (x14 / and
                                    :op1 (x15 / cell-line
                                          :name (x16 / name :op1 "MCF-10A"))
                                    :op2 (x17 / enzyme
                                          :name (x18 / name :op1 "Ras")
                                          :xref (x50 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))))
                  :ARG2 (x19 / alter-01)
                  :ARG1 (x21 / function-01
                        :ARG1 (x20 / transcribe-01)))
            :ARG0 (x22 / we)
            :ARG1 (x29 / activity-06
                  :ARG1-of (x26 / drive-02
                        :ARG0 (x24 / protein
                              :name (x25 / name :op1 "SAF-1")
                              :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
                  :ARG0 (x27 / molecular-physical-entity
                        :ARG0-of (x28 / promote-01))))
      :snt2 (x30 / use-01
            :ARG1 (x33 / gene
                  :name (x31 / name :op1 "CAT")
                  :ARG0-of (x32 / report-01)
                  :ARG0-of (x34 / contain-01
                        :ARG1 (x42 / element
                              :mod (x35 / tandem
                                    :quant "3"
                                    :mod (x36 / copy-01
                                          :ARG1 (x37 / bona))
                                    :name (x38 / name :op1 "fide"))
                              :ARG1-of (x41 / bind-01
                                    :ARG2 (x39 / protein
                                          :name (x40 / name :op1 "SAF-1")
                                          :xref (x48 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))))
                        :ARG1-of (x43 / describe-01
                              :ARG0 (x44 / publication
                                    :ARG1-of (x45 / cite-01 :ARG2 "31"))))
                  :xref (x47 / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002"))))


# ::id PMC4329006.108
# ::snt Transcription from this promoter was evaluated by transfection of this reporter plasmid in MCF-10A, MCF-10A- ras , or empty vector transformed MCF-10A cells (Fig. 2A ).
# ::tok Transcription from this promoter was evaluated by transfection of this reporter plasmid in MCF @-@ 10A , MCF @-@ 10A @- ras , or empty vector transformed MCF @-@ 10A cells ( Fig . 2A ) .
(x5 / evaluate-01
      :ARG1 (x4 / molecular-physical-entity
            :ARG0-of (x3 / promote-01
                  :ARG1 (x1 / transcribe-01
                        :ARG2 (x2 / this))))
      :manner (x6 / transfect-01
            :ARG1 (x9 / plasmid
                  :mod (x7 / this)
                  :ARG0-of (x8 / report-01)))
      :location (x10 / cell-line
            :name (x11 / name :op1 "MCF-10A"))
      :ARG1-of (x19 / transform-01
            :ARG0 (x16 / or
                  :op1 (x12 / cell-line
                        :name (x13 / name :op1 "MCF-10A"))
                  :op1 (x14 / enzyme
                        :name (x15 / name :op1 "ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                  :op2 (x18 / vector
                        :ARG1-of (x17 / empty-02)))
            :ARG1 (x20 / cell-line
                  :name (x21 / name :op1 "MCF-10A"))
            :ARG1-of (x22 / describe-01
                  :ARG0 (x23 / figure :mod "2a"))))


# ::id PMC4329006.109
# ::snt The CAT expression was significantly higher in Ras-transformed MCF-10A cells as compared to untransformed or empty vector transformed cells (Fig. 2A ).
# ::tok The CAT expression was significantly higher in Ras @-@ transformed MCF @-@ 10A cells as compared to untransformed or empty vector transformed cells ( Fig . 2A ) .
(x5 / high-02
      :ARG1 (x3 / express-03
            :ARG2 (x1 / enzyme
                  :name (x2 / name :op1 "CAT")
                  :xref (x / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002")))
      :ARG1-of (x4 / significant-02)
      :degree (x6 / more)
      :location (x11 / cell-line
            :ARG1-of (x9 / transform-01
                  :ARG0 (x7 / enzyme
                        :name (x8 / name :op1 "Ras")
                        :xref (x20 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :name (x10 / name :op1 "MCF-10A"))
      :compared-to (x17 / cell
            :ARG1-of (x16 / transform-01
                  :ARG0 (x13 / or
                        :op1 (x12 / transform-01 :polarity "-")
                        :op2 (x15 / vector
                              :ARG1-of (x14 / empty-02)))))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / figure :mod "2a")))


# ::id PMC4329006.110
# ::snt The reporter gene containing mutated SAF-binding element, mt SAF-CAT, showed no response to oncogenic ras , indicating that Ras-activated SAF-1 that binds to a bona fide SAF-1-binding element can drive CAT expression.
# ::tok The reporter gene containing mutated SAF @-@ binding element , mt SAF @-@ CAT , showed no response to oncogenic ras , indicating that Ras @-@ activated SAF @-@ 1 that binds to a bona fide SAF @-@ 1 @-@ binding element can drive CAT expression .
(x10 / show-01
      :ARG1 (x2 / gene
            :ARG0-of (x1 / report-01))
      :ARG0-of (x3 / contain-01
            :ARG1 (x4 / mutate-01
                  :ARG1 (x6 / element
                        :ARG1-of (x5 / bind-01)
                        :mod (x7 / protein
                              :name (x8 / name :op1 "mt")
                              :xref (x35 / xref :value "UNIPROT:FABD_HUMAN" :prob "0.602"))
                        :name (x9 / name :op1 "CAT"))))
      :ARG1 (x11 / respond-01
            :polarity "-"
            :ARG1 (x12 / enzyme
                  :ARG0-of (x13 / cause-01
                        :ARG1 (x14 / disease
                              :wiki "cancer"
                              :name (x15 / name :op1 "cancer")))
                  :name (x16 / name :op1 "Ras")
                  :xref (x38 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
      :ARG0-of (x17 / indicate-01
            :ARG1 (x18 / possible-01
                  :ARG1 (x30 / drive-02
                        :ARG0 (x24 / bind-01
                              :ARG1 (x19 / enzyme
                                    :name (x20 / name :op1 "Ras")
                                    :ARG1-of (x21 / activate-01
                                          :ARG1 (x22 / protein
                                                :name (x23 / name :op1 "SAF-1")
                                                :xref (x34 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
                                    :xref (x37 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                              :ARG2 (x29 / element
                                    :mod (x25 / fide)
                                    :ARG1-of (x28 / bind-01
                                          :ARG2 (x26 / protein
                                                :name (x27 / name :op1 "SAF-1")
                                                :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))))
                        :ARG1 (x33 / express-03
                              :ARG2 (x31 / enzyme
                                    :name (x32 / name :op1 "CAT")
                                    :xref (x36 / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002")))))))


# ::id PMC4329006.111
# ::snt To assess whether Ras-activated SAF-1 can promote angiogenesis-associated gene promoter activity, we used VEGF promoter-driven CAT reporter system (Fig. 2B ).
# ::tok To assess whether Ras @-@ activated SAF @-@ 1 can promote angiogenesis @-@ associated gene promoter activity , we used VEGF promoter @-@ driven CAT reporter system ( Fig . 2B ) .
(x16 / use-01
      :purpose (x1 / assess-01
            :ARG1 (x2 / possible-01
                  :mode "interrogative"
                  :ARG1 (x8 / promote-01
                        :ARG0 (x5 / activate-01
                              :ARG1 (x3 / enzyme
                                    :name (x4 / name :op1 "Ras")
                                    :xref (x28 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                              :ARG0 (x6 / protein
                                    :name (x7 / name :op1 "SAF-1")
                                    :xref (x29 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
                        :ARG1 (x14 / activity-06
                              :ARG0 (x13 / molecular-physical-entity
                                    :ARG0-of (x12 / promote-01
                                          :ARG1 (x11 / gene
                                                :ARG1-of (x10 / associate-01
                                                      :ARG2 (x9 / angiogenesis)))))))))
      :ARG0 (x15 / we)
      :ARG1 (x25 / system
            :ARG1-of (x21 / drive-02
                  :ARG2 (x20 / molecular-physical-entity
                        :ARG0-of (x19 / promote-01
                              :ARG1 (x17 / protein
                                    :name (x18 / name :op1 "VEGF")
                                    :xref (x30 / xref :value "UNIPROT:VEGFA_HUMAN" :prob "1.003")))))
            :mod (x24 / report-01
                  :ARG1 (x22 / enzyme
                        :name (x23 / name :op1 "CAT")
                        :xref (x / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002"))))
      :ARG1-of (x26 / describe-01
            :ARG0 (x27 / figure :mod "2b")))


# ::id PMC4329006.112
# ::snt This assay revealed that CAT activity is highly increased in ras -transformed MCF-10A- ras cells that are transfected with the 1.2 VEGF-CAT plasmid.
# ::tok This assay revealed that CAT activity is highly increased in ras -@ transformed MCF @-@ 10A @- ras cells that are transfected with the 1.2 VEGF @-@ CAT plasmid .
(x3 / reveal-01
      :ARG0 (x2 / assay-01
            :mod (x1 / this))
      :ARG1 (x8 / increase-01
            :ARG1 (x6 / activity-06
                  :ARG0 (x4 / enzyme
                        :name (x5 / name :op1 "CAT")
                        :xref (x25 / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002")))
            :ARG1-of (x7 / high-02)
            :location (x9 / and
                  :op2 (x10 / enzyme
                        :name (x11 / name :op1 "ras")
                        :xref (x26 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                  :op1 (x17 / cell
                        :mod (x12 / gene
                              :name (x13 / name :op1 "ras")
                              :ARG2-of (x14 / transform-01
                                    :ARG1 (x15 / cell-line
                                          :name (x16 / name :op1 "MCF-10A")))
                              :xref (x27 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                        :ARG1-of (x18 / transfect-01
                              :ARG2 (x24 / plasmid
                                    :mod (x19 / protein
                                          :name (x20 / name :op1 "1.2")
                                          :mod (x21 / protein
                                                :name (x22 / name :op1 "VEGF")
                                                :xref (x / xref :value "UNIPROT:VEGFA_HUMAN" :prob "1.003")))
                                    :name (x23 / name :op1 "CAT")))))))


# ::id PMC4329006.113
# ::snt This region of VEGF promoter contains a SAF-1-binding site with two tandem SAF-binding elements located between nucleotide position −130 and −30 14 .
# ::tok This region of VEGF promoter contains a SAF @-@ 1 @-@ binding site with two tandem SAF @-@ binding elements located between nucleotide position −130 and −30 14 .
(x19 / and
      :op1 (x7 / contain-01
            :ARG0 (x6 / molecular-physical-entity
                  :ARG0-of (x5 / promote-01
                        :ARG1 (x2 / region
                              :mod (x1 / this)
                              :part-of (x3 / protein
                                    :name (x4 / name :op1 "VEGF")
                                    :xref (x25 / xref :value "UNIPROT:VEGFA_HUMAN" :prob "1.003")))))
            :ARG1 (x14 / element
                  :mod (x11 / protein-segment
                        :ARG1-of (x10 / bind-01
                              :ARG2 (x8 / protein
                                    :name (x9 / name :op1 "saf-1")
                                    :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "0.632")))
                        :ARG0-of (x12 / tandem :quant "2"))
                  :mod (x13 / bind-01)
                  :ARG1-of (x15 / locate-01
                        :location (x17 / position
                              :mod (x16 / nucleotide)
                              :name (x18 / name :op1 "−130")))))
      :op2 (x20 / enzyme
            :name (x21 / name :op1 "−30")
            :ARG1-of (x22 / describe-01
                  :ARG0 (x23 / publication
                        :ARG1-of (x24 / cite-01 :ARG2 "14")))))


# ::id PMC4329006.114
# ::snt Involvement of Ras-activated SAF-1 in the promoter activation was further verified when the VEGF promoter with a deletion in the SAF-1-binding site, failed to show a significant induction in the ras-transformed cells (Fig. 2B ).
# ::tok Involvement of Ras @-@ activated SAF @-@ 1 in the promoter activation was further verified when the VEGF promoter with a deletion in the SAF @-@ 1 @-@ binding site , failed to show a significant induction in the ras @-@ transformed cells ( Fig . 2B ) .
(x11 / verify-01
      :ARG1 (x1 / involve-01
            :ARG1 (x4 / activate-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "Ras")
                        :xref (x31 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "SAF-1")
                        :xref (x32 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
            :ARG2 (x9 / activate-01
                  :ARG1 (x7 / molecular-physical-entity
                        :ARG0-of (x8 / promote-01))))
      :degree (x10 / further)
      :time (x15 / molecular-physical-entity
            :ARG0-of (x14 / promote-01
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "VEGF")
                        :xref (x33 / xref :value "UNIPROT:VEGFA_HUMAN" :prob "1.003"))))
      :ARG0-of (x16 / delete-01
            :ARG1 (x20 / protein-segment
                  :ARG1-of (x19 / bind-01
                        :ARG2 (x17 / protein
                              :name (x18 / name :op1 "SAF-1")
                              :xref (x34 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))))
      :ARG1-of (x21 / fail-01
            :ARG2 (x22 / show-01
                  :ARG1 (x24 / induce-01
                        :ARG1-of (x23 / significant-02)
                        :location (x28 / cell
                              :ARG1-of (x27 / transform-01
                                    :ARG0 (x25 / enzyme
                                          :name (x26 / name :op1 "Ras")
                                          :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))))
            :ARG1-of (x29 / describe-01
                  :ARG0 (x30 / figure :mod "2b"))))


# ::id PMC4329006.115
# ::snt Together, these results suggested that Ras increases both the DNA-binding activity and transcription function of SAF-1.
# ::tok Together , these results suggested that Ras increases both the DNA @-@ binding activity and transcription function of SAF @-@ 1 .
(x5 / suggest-01
      :ARG0 (x3 / thing
            :mod (x1 / together)
            :mod (x2 / this)
            :ARG2-of (x4 / result-01))
      :ARG1 (x14 / and
            :op1 (x8 / increase-01
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :ARG1 (x13 / activity-06
                        :ARG0 (x9 / and
                              :op1 (x12 / bind-01
                                    :ARG2 (x10 / nucleic-acid
                                          :wiki "dna"
                                          :name (x11 / name :op1 "DNA"))))))
            :op2 (x16 / function-01
                  :ARG1 (x15 / transcribe-01))))


# ::id PMC4329006.116
# ::snt Induction of SAF-1 promoter function in oncogenic ras -transformed MCF-10A cells.
# ::tok Induction of SAF @-@ 1 promoter function in oncogenic ras -@ transformed MCF @-@ 10A cells .
(x1 / induce-01
      :ARG1 (x6 / function-01
            :ARG0 (x5 / molecular-physical-entity
                  :ARG0-of (x4 / promote-01
                        :ARG1 (x2 / protein
                              :name (x3 / name :op1 "SAF-1")
                              :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))))
            :location (x7 / enzyme
                  :ARG0-of (x8 / cause-01
                        :ARG1 (x9 / disease
                              :wiki "cancer"
                              :name (x10 / name :op1 "cancer")))
                  :name (x11 / name :op1 "ras")
                  :xref (x15 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203")))
      :ARG2 (x12 / transform-01
            :ARG1 (x13 / cell-line
                  :name (x14 / name :op1 "MCF-10A"))))


# ::id PMC4329006.117
# ::snt The wild-type SAF-CAT reporter contains three tandem repeats of SAF-1-binding elements ligated in pBLCAT2 vector.
# ::tok The wild @-@ type SAF @-@ CAT reporter contains three tandem repeats of SAF @-@ 1 @-@ binding elements ligated in pBLCAT2 vector .
(x13 / ligate-01
      :ARG1 (x6 / contain-01
            :ARG0 (x4 / gene
                  :mod (x1 / wild-type)
                  :mod (x2 / enzyme
                        :name (x3 / name :op1 "CAT")
                        :xref (x16 / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002"))
                  :ARG0-of (x5 / report-01))
            :ARG1 (x8 / repeat-01
                  :mod (x7 / tandem :quant "3")
                  :ARG1 (x12 / element
                        :ARG1-of (x11 / bind-01
                              :ARG2 (x9 / protein
                                    :name (x10 / name :op1 "saf-1")
                                    :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "0.632"))))))
      :ARG2 (x15 / vector
            :name (x14 / name :op1 "pBLCAT2")))


# ::id PMC4329006.118
# ::snt The mutant SAF-CAT contains three tandem copies of mutant SAF-1-binding elements ligated to pBLCAT2.
# ::tok The mutant SAF @-@ CAT contains three tandem copies of mutant SAF @-@ 1 @-@ binding elements ligated to pBLCAT2 .
(x12 / ligate-01
      :ARG1 (x4 / contain-01
            :ARG0 (x1 / enzyme
                  :ARG2-of (x2 / mutate-01)
                  :name (x3 / name :op1 "CAT")
                  :xref (x / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002"))
            :ARG1 (x11 / element
                  :mod (x5 / tandem :quant "3")
                  :mod (x6 / copy-01
                        :ARG1 (x10 / bind-01
                              :ARG2 (x7 / enzyme
                                    :ARG2-of (x8 / mutate-01)
                                    :name (x9 / name :op1 "saf-1")
                                    :xref (x15 / xref :value "UNIPROT:MAZ_HUMAN" :prob "0.632"))))))
      :ARG2 (x13 / enzyme
            :name (x14 / name :op1 "pBLCAT2")))


# ::id PMC4329006.124
# ::snt ** P < 0.02.
# ::tok ** P
(x3 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "**")))


# ::id PMC4329006.125
# ::snt SAF-1, serum amyloid A activating factor 1; CAT, chroramphenicol acetyl transferase; VEGF, vascular endothelial growth factor.
# ::tok SAF @-@ 1 , serum amyloid A activating factor 1; CAT , chroramphenicol acetyl transferase ; VEGF , vascular endothelial growth factor .
(x1 / and
      :op1 (x2 / protein
            :name (x3 / name :op1 "SAF-1")
            :xref (x19 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
      :op2 (x7 / factor
            :ARG1-of (x6 / activate-01
                  :ARG1 (x4 / enzyme
                        :name (x5 / name
                              :op1 "serum"
                              :op2 "amyloid"
                              :op3 "A")))
            :ARG1-of (x8 / mean-01
                  :ARG2 (x11 / and
                        :op1 (x9 / enzyme
                              :name (x10 / name :op1 "CAT" :op2 "chroramphenicol"))
                        :op1 (x12 / enzyme
                              :name (x13 / name :op1 "acetyltransferase")
                              :mod (x14 / transferase)
                              :xref (x20 / xref :value "UNIPROT:NAT8B_HUMAN" :prob "0.392"))
                        :op2 (x15 / protein
                              :name (x16 / name :op1 "VEGF")
                              :xref (x / xref :value "UNIPROT:VEGFA_HUMAN" :prob "1.003")))))
      :op3 (x17 / protein
            :name (x18 / name
                  :op1 "vascular"
                  :op2 "endothelial"
                  :op3 "growth"
                  :op4 "factor")))


# ::id PMC4329006.126
# ::snt Ras activates SAF-1/MAZ activity through ERK/MAPK-signaling
# ::tok Ras activates SAF @-@ 1/MAZ activity through ERK @/@ MAPK @-@ signaling
(x12 / signal-07
      :ARG1 (x6 / activity-06
            :ARG1-of (x3 / activate-01
                  :ARG0 (x1 / enzyme
                        :name (x2 / name :op1 "Ras")
                        :xref (x14 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "1/MAZ")))
            :ARG0 (x7 / and
                  :op1 (x8 / enzyme
                        :name (x9 / name :op1 "ERK")
                        :xref (x13 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :op2 (x10 / enzyme
                        :name (x11 / name :op1 "MAPK")
                        :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313")))))


# ::id PMC4329006.127
# ::snt The Ras oncogenes utilize various signaling pathways to modify downstream effectors that drive tumorigenesis.
# ::tok The Ras oncogenes utilize various signaling pathways to modify downstream effectors that drive tumorigenesis .
(x6 / utilize-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "Ras")
            :ARG0-of (x3 / cause-01
                  :ARG1 (x4 / disease
                        :wiki "cancer"
                        :name (x5 / name :op1 "cancer")))
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
      :ARG1 (x9 / pathway
            :mod (x7 / various)
            :ARG0-of (x8 / signal-07))
      :purpose (x10 / modify-01
            :ARG1 (x12 / effector
                  :mod (x11 / downstream)
                  :ARG0-of (x13 / drive-02
                        :ARG1 (x14 / create-01
                              :ARG1 (x15 / tumor))))))


# ::id PMC4329006.128
# ::snt Among these pathways, the Raf-MEK-ERK-MAPK cascade is a major one.
# ::tok Among these pathways , the Raf @-@ MEK @-@ ERK @-@ MAPK cascade is a major one .
(x1 / include-91
      :ARG2 (x3 / pathway
            :mod (x2 / this))
      :ARG1 (x4 / and
            :op1 (x5 / enzyme
                  :name (x6 / name :op1 "Raf")
                  :xref (x17 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
            :op2 (x7 / enzyme
                  :name (x8 / name :op1 "MEK")
                  :xref (x16 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343"))
            :op3 (x9 / enzyme
                  :name (x10 / name :op1 "ERK")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
      :ARG2 (x15 / one
            :domain (x13 / cascade-01
                  :ARG1 (x11 / pathway
                        :name (x12 / name :op1 "ras/mapk")))
            :ARG1-of (x14 / major-02)))


# ::id PMC4329006.129
# ::snt Raf serine/threonine kinases (c-Raf-1, A-Raf, and B-Raf) phosphorylate and activate MEK1/2 dual specificity kinases, which then phosphorylate and activate the ERK1 and ERK2 MAPKs.
# ::tok Raf serine @/@ threonine kinases ( c @-@ Raf @-@ 1 , A @-@ Raf , and B @-@ Raf ) phosphorylate and activate MEK1 @/@ 2 dual specificity kinases , which then phosphorylate and activate the ERK1 and ERK2 MAPKs .
(x17 / and
      :op1 (x16 / phosphorylate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "raf-1")
                  :xref (x34 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.703"))
            :ARG2 (x3 / or
                  :op1 (x4 / enzyme
                        :name (x5 / name :op1 "serine" :op2 "kinase"))
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "threonine" :op2 "kinase"))
                  :ARG1-of (x8 / mean-01
                        :ARG2 (x13 / and
                              :op1 (x9 / protein
                                    :name (x10 / name :op1 "c-Raf-1"))
                              :op2 (x11 / enzyme
                                    :name (x12 / name :op1 "raf-1")
                                    :xref (x37 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.703"))
                              :op2 (x14 / enzyme
                                    :name (x15 / name :op1 "B-Raf")
                                    :xref (x38 / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.661"))))))
      :op2 (x23 / kinase
            :ARG0-of (x18 / activate-01
                  :ARG1 (x19 / enzyme
                        :name (x20 / name :op1 "MEK1/2")))
            :mod (x22 / specificity
                  :mod (x21 / dual))
            :ARG0-of (x25 / phosphorylate-01
                  :time (x24 / then))
            :ARG0-of (x26 / activate-01
                  :ARG1 (x29 / and
                        :op1 (x27 / enzyme
                              :name (x28 / name :op1 "ERK1")
                              :xref (x / xref :value "UNIPROT:MK03_HUMAN" :prob "1.003"))
                        :op2 (x30 / enzyme
                              :name (x31 / name :op1 "ERK2")
                              :xref (x36 / xref :value "UNIPROT:MK01_HUMAN" :prob "1.003"))
                        :op2 (x32 / enzyme
                              :name (x33 / name :op1 "mapk")
                              :xref (x35 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.233"))))))


# ::id PMC4329006.130
# ::snt Activated ERKs translocate to the nucleus where they phosphorylate and regulate various transcription factors.
# ::tok Activated ERKs translocate to the nucleus where they phosphorylate and regulate various transcription factors .
(x7 / and
      :op1 (x4 / translocate-01
            :ARG1 (x1 / enzyme
                  :ARG1-of (x2 / activate-01)
                  :name (x3 / name :op1 "erk")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
            :ARG2 (x5 / nucleus
                  :location-of (x6 / phosphorylate-01)
                  :xref (x12 / xref :value "GO:0005634" :prob "0.8")))
      :op2 (x8 / regulate-01
            :ARG1 (x11 / factor
                  :mod (x9 / various)
                  :ARG0-of (x10 / transcribe-01))))


# ::id PMC4329006.131
# ::snt To determine if Ras-mediated activation of SAF-1 proceeds through Raf-MEK-ERK-MAPK cascade, MCF-10A- ras cells were grown with or without PD98059, which is a specific inhibitor of mammalian MEK-1/2 and ERK (P42/44 MAP kinase).
# ::tok To determine if Ras @-@ mediated activation of SAF @-@ 1 proceeds through Raf @-@ MEK @-@ ERK @-@ MAPK cascade , MCF @-@ 10A @- ras cells were grown with or without PD98059 , which is a specific inhibitor of mammalian MEK @-@ 1 @/@ 2 and ERK ( P42 @/@ 44 MAP kinase ) .
(x1 / multi-sentence
      :snt1 (x2 / and
            :purpose (x3 / determine-01
                  :ARG1 (x4 / possible-01
                        :ARG1 (x11 / proceed-01
                              :ARG0 (x8 / activate-01
                                    :ARG1-of (x7 / mediate-01
                                          :ARG0 (x5 / enzyme
                                                :name (x6 / name :op1 "Ras")
                                                :xref (x48 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                                    :ARG1 (x9 / protein
                                          :name (x10 / name :op1 "SAF-1")
                                          :xref (x47 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
                              :ARG1 (x12 / and
                                    :op1 (x13 / enzyme
                                          :name (x14 / name :op1 "Raf")
                                          :xref (x51 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
                                    :op2 (x15 / enzyme
                                          :name (x16 / name :op1 "MEK")
                                          :xref (x52 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343"))
                                    :op3 (x17 / enzyme
                                          :name (x18 / name :op1 "ERK")
                                          :xref (x53 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                              :ARG2 (x21 / cascade-01
                                    :ARG1 (x19 / pathway
                                          :name (x20 / name :op1 "ras/mapk"))))))
            :op1 (x22 / cell-line
                  :name (x23 / name :op1 "MCF-10A"))
            :op2 (x26 / grow-01
                  :ARG1 (x24 / enzyme
                        :name (x25 / name :op1 "Ras")
                        :xref (x46 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :ARG2 (x27 / or
                        :op2 (x28 / small-molecule
                              :name (x29 / name :op1 "PD98059")
                              :xref (x54 / xref :value "PUBCHEM:4713" :prob "18.349844"))
                        :mod (x31 / small-molecule
                              :ARG1-of (x30 / specific-02)
                              :ARG0-of (x32 / inhibit-01
                                    :ARG1 (x33 / enzyme
                                          :name (x34 / name :op1 "mammalia")
                                          :xref (x49 / xref :value "UNIPROT:GRHL1_HUMAN" :prob "0.252")))))))
      :snt2 (x37 / and
            :op1 (x35 / protein
                  :name (x36 / name :op1 "MEK-1/2"))
            :op2 (x38 / enzyme
                  :name (x39 / name :op1 "ERK")
                  :xref (x50 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :ARG1-of (x40 / describe-01
                  :ARG0 (x43 / slash
                        :op1 (x41 / enzyme
                              :name (x42 / name :op1 "P42")
                              :xref (x / xref :value "UNIPROT:NUP43_HUMAN" :prob "0.672"))
                        :op2 (x44 / enzyme
                              :name (x45 / name
                                    :op1 "44"
                                    :op2 "MAP"
                                    :op3 "kinase"))))))


# ::id PMC4329006.132
# ::snt PD98059 markedly inhibited DNA-binding activity of SAF-1/MAZ in MCF-10A- ras cells (Fig. 3A ).
# ::tok PD98059 markedly inhibited DNA @-@ binding activity of SAF @-@ 1/MAZ in MCF @-@ 10A @- ras cells ( Fig . 3A ) .
(x4 / inhibit-01
      :ARG0 (x1 / small-molecule
            :name (x2 / name :op1 "PD98059")
            :xref (x18 / xref :value "PUBCHEM:4713" :prob "18.349844"))
      :degree (x3 / marked)
      :ARG1 (x8 / activity-06
            :ARG1 (x7 / bind-01
                  :ARG1 (x5 / nucleic-acid
                        :wiki "dna"
                        :name (x6 / name :op1 "DNA")))
            :ARG0 (x9 / enzyme
                  :name (x10 / name :op1 "1/MAZ")))
      :location (x15 / cell
            :mod (x11 / protein
                  :name (x12 / name :op1 "MCF-10A"))
            :mod (x13 / enzyme
                  :name (x14 / name :op1 "ras")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203")))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / figure :mod "3a")))


# ::id PMC4329006.133
# ::snt U0126, a specific inhibitor of MEK1/2 and SB203580 which inhibits both p42/44 and p38 MAP kinases also inhibited the binding activity.
# ::tok U0126 , a specific inhibitor of MEK1 @/@ 2 and SB203580 which inhibits both p42 @/@ 44 and p38 MAP kinases also inhibited the binding activity .
(x17 / inhibit-01
      :ARG0 (x3 / small-molecule
            :name (x1 / name :op1 "U0126")
            :ARG1-of (x2 / specific-02)
            :ARG0-of (x4 / inhibit-01
                  :ARG1 (x7 / and
                        :op1 (x5 / enzyme
                              :name (x6 / name :op1 "MEK1")
                              :xref (x / xref :value "UNIPROT:MP2K1_HUMAN" :prob "1.003"))
                        :op2 (x8 / enzyme
                              :name (x9 / name :op1 "SB203580"))))
            :ARG0-of (x10 / inhibit-01
                  :ARG1 (x11 / and
                        :op1 (x12 / enzyme
                              :name (x13 / name :op1 "p42" :op2 "44"))
                        :op2 (x14 / enzyme
                              :name (x15 / name
                                    :op1 "p38"
                                    :op2 "MAP"
                                    :op3 "kinase"))))
            :xref (x20 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
      :mod (x16 / also)
      :ARG1 (x19 / activity-06
            :ARG1 (x18 / bind-01)))


# ::id PMC4329006.134
# ::snt Identity of the protein in the DNA-protein complex was verified as SAF-1 by the ablation of the complex by anti SAF-1 antibody (Fig.
# ::tok Identity of the protein in the DNA @-@ protein complex was verified as SAF @-@ 1 by the ablation of the complex by anti SAF @-@ 1 antibody ( Fig .
(x6 / verify-01
      :ARG1 (x1 / identity
            :mod (x2 / protein
                  :location (x5 / complex
                        :mod (x4 / protein
                              :name (x3 / name :op1 "DNA")
                              :xref (x18 / xref :value "UNIPROT:DNS2A_HUMAN" :prob "0.272")))))
      :ARG1 (x7 / protein
            :name (x8 / name :op1 "SAF-1")
            :xref (x17 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
      :ARG0 (x9 / ablate-01
            :ARG1 (x10 / complex)
            :ARG0 (x14 / antibody
                  :ARG0-of (x11 / counter-01
                        :ARG1 (x12 / protein
                              :name (x13 / name :op1 "SAF-1")
                              :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))))
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / figure :mod "4b")))


# ::id PMC4329006.135
# ::snt 3A , lane 8).
# ::tok 3A , lane 8 ) .
(x1 / and
      :op2 (x2 / and
            :op1 (x3 / figure :mod "3a")
            :op2 (x4 / lane :mod "8")))


# ::id PMC4329006.136
# ::snt Oncogenic ras -mediated activation of SAF-1 is regulated via MEK/MAPK pathway.
# ::tok Oncogenic ras -@ mediated activation of SAF @-@ 1 is regulated via MEK @/@ MAPK pathway .
(x10 / regulate-01
      :ARG1 (x1 / enzyme
            :ARG0-of (x2 / cause-01
                  :ARG1 (x3 / disease
                        :wiki "cancer"
                        :name (x4 / name :op1 "cancer")))
            :name (x5 / name :op1 "ras")
            :ARG2-of (x7 / activate-01
                  :ARG1-of (x6 / mediate-01)
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "SAF-1")
                        :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
            :xref (x13 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
      :ARG0 (x11 / pathway
            :name (x12 / name :op1 "MEK/MAPK")))


# ::id PMC4329006.137
# ::snt Nuclear extracts (10 μ g of protein) prepared from these cells, as indicated, were incubated with 32 P-labeled DNA containing SAF-1-binding element of the SAA promoter.
# ::tok Nuclear extracts ( 10 μ g of protein ) prepared from these cells , as indicated , were incubated with 32 P @-@ labeled DNA containing SAF @-@ 1 @-@ binding element of the SAA promoter .
(x18 / contain-01
      :ARG0 (x2 / extract
            :mod (x1 / nucleus
                  :xref (x28 / xref :value "GO:0005634" :prob "0.8"))
            :ARG1-of (x3 / mean-01
                  :ARG2 (x4 / protein
                        :quant (x5 / concentration-quantity
                              :quant "10"
                              :unit (x6 / micromolar))
                        :name (x7 / name
                              :op1 "g"
                              :op2 "of"
                              :op3 "protein")))
            :ARG1-of (x8 / prepare-01
                  :ARG2 (x10 / cell
                        :mod (x9 / this)
                        :ARG1-of (x12 / incubate-01
                              :ARG1 (x11 / indicate-01)
                              :ARG2 (x13 / small-molecule
                                    :name (x14 / name :op1 "32")
                                    :ARG1-of (x16 / label-01
                                          :ARG2 (x15 / phosphorylate-01))
                                    :xref (x29 / xref :value "PUBCHEM:85846376" :prob "6.15278")))
                        :name (x17 / name :op1 "DNA"))))
      :ARG1 (x22 / element
            :ARG1-of (x21 / bind-01
                  :ARG2 (x19 / protein
                        :name (x20 / name :op1 "saf-1")
                        :xref (x27 / xref :value "UNIPROT:MAZ_HUMAN" :prob "0.632")))
            :part-of (x26 / molecular-physical-entity
                  :ARG0-of (x25 / promote-01
                        :ARG1 (x23 / gene
                              :name (x24 / name :op1 "SAA")
                              :xref (x / xref :value "UNIPROT:SAA1_HUMAN" :prob "1.002"))))))


# ::id PMC4329006.139
# ::snt Cells were grown for an additional 24 h in absence or presence of 20 μ mol/L each of U0126, PD98059, SB203580, or SB202474, as indicated.
# ::tok Cells were grown for an additional 24 h in absence or presence of 20 μ mol/L each of U0126 , PD98059 , SB203580 , or SB202474 , as indicated .
(x2 / grow-01
      :ARG1 (x1 / cell)
      :ARG2 (x20 / or
            :op1 (x3 / add-02
                  :ARG2 (x4 / temporal-quantity
                        :quant "24"
                        :unit (x5 / hour))
                  :ARG1 (x6 / or
                        :op2 (x7 / present-02
                              :ARG1 (x8 / small-molecule
                                    :quant (x9 / concentration-quantity
                                          :quant "20"
                                          :unit (x10 / micromolar))
                                    :name (x11 / name :op1 "mol/L")
                                    :mod (x12 / each)))
                        :op1 (x13 / absent-01
                              :ARG1 (x14 / small-molecule
                                    :name (x15 / name :op1 "U0126")
                                    :xref (x24 / xref :value "PUBCHEM:3006531" :prob "17.656696")))))
            :op2 (x16 / small-molecule
                  :name (x17 / name :op1 "PD98059")
                  :xref (x25 / xref :value "PUBCHEM:4713" :prob "18.349844"))
            :op3 (x18 / small-molecule
                  :name (x19 / name :op1 "SB203580")
                  :xref (x / xref :value "PUBCHEM:176155" :prob "18.572987"))
            :op4 (x21 / small-molecule
                  :name (x22 / name :op1 "SB202474")))
      :ARG1-of (x23 / indicate-01))


# ::id PMC4329006.140
# ::snt Relative CAT activity in ras-transformed cells was determined by comparing it to that in normal MCF-10A cells.
# ::tok Relative CAT activity in ras @-@ transformed cells was determined by comparing it to that in normal MCF @-@ 10A cells .
(x9 / determine-01
      :ARG1 (x4 / activity-06
            :ARG2-of (x1 / relative-05)
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "CAT")
                  :xref (x / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002"))
            :location (x8 / cell
                  :ARG1-of (x7 / transform-01
                        :ARG0 (x5 / enzyme
                              :name (x6 / name :op1 "ras")
                              :xref (x15 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203")))))
      :instrument (x10 / compare-01
            :ARG2 (x11 / that))
      :location (x14 / cell-line
            :ARG1-of (x12 / normal-02)
            :name (x13 / name :op1 "MCF-10A")))


# ::id PMC4329006.143
# ::snt In addition, some cells were cotransfected with either a wild-type SAF-1 expression plasmid, wt pcD-SAF-1 (0.5 μ g) or a mutant SAF-1 expression plasmid, mut pcD-SAF-1(V71) (0.5 μ g).
# ::tok In addition , some cells were cotransfected with either a wild @-@ type SAF @-@ 1 expression plasmid , wt pcD @-@ SAF @-@ 1 ( 0.5 μ g ) or a mutant SAF @-@ 1 expression plasmid , mut pcD @-@ SAF @-@ 1 ( V71 ) ( 0.5 μ g ) .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op2 (x5 / cotransfect-01
                  :ARG1 (x4 / cell
                        :quant (x3 / some))
                  :ARG2 (x10 / plasmid
                        :ARG1-of (x9 / express-03
                              :ARG2 (x6 / enzyme
                                    :mod (x7 / wild-type)
                                    :name (x8 / name :op1 "SAF-1")
                                    :xref (x36 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
                        :ARG0-of (x19 / or
                              :mod (x11 / enzyme
                                    :mod (x12 / wild-type)
                                    :name (x13 / name :op1 "pcD")
                                    :xref (x37 / xref :value "UNIPROT:PHS_HUMAN" :prob "0.622"))
                              :op1 (x14 / protein
                                    :name (x15 / name :op1 "SAF-1")
                                    :quant (x16 / concentration-quantity
                                          :quant "0.5"
                                          :unit (x17 / micromolar))
                                    :name (x18 / name :op1 "g")
                                    :xref (x39 / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "1.001"))
                              :op2 (x24 / plasmid
                                    :ARG1-of (x23 / express-03
                                          :ARG2 (x20 / enzyme
                                                :ARG2-of (x21 / mutate-01)
                                                :name (x22 / name :op1 "SAF-1")
                                                :xref (x35 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))))
                        :ARG0-of (x25 / mut))))
      :snt2 (x26 / and
            :op2 (x27 / enzyme
                  :name (x28 / name :op1 "pcD")
                  :ARG1-of (x29 / amino-acid
                        :mod "71"
                        :name (x30 / name :op1 "valine"))
                  :quant (x31 / concentration-quantity
                        :quant "0.5"
                        :unit (x32 / micromolar))
                  :name (x33 / name :op1 "g")
                  :xref (x34 / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "1.001"))))


# ::id PMC4329006.144
# ::snt Also, some cells were transfected with Ras expression plasmid, pCMV ras V12 (0.5 μ g), as indicated.
# ::tok Also , some cells were transfected with Ras expression plasmid , pCMV ras V12 ( 0.5 μ g ) , as indicated .
(x4 / transfect-01
      :ARG1 (x3 / cell
            :mod (x1 / also)
            :mod (x2 / some))
      :ARG2 (x8 / plasmid
            :mod (x7 / express-03
                  :ARG2 (x5 / enzyme
                        :name (x6 / name :op1 "Ras")
                        :xref (x18 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG0-of (x9 / and
                  :op1 (x10 / enzyme
                        :name (x11 / name :op1 "Ras")
                        :ARG2-of (x12 / mutate-01 :value "V12")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :op2 (x13 / small-molecule
                        :quant (x14 / concentration-quantity
                              :quant "0.5"
                              :unit (x15 / micromolar))
                        :name (x16 / name :op1 "g")
                        :xref (x19 / xref :value "PUBCHEM:132841" :prob "7.947479")))
            :ARG1-of (x17 / indicate-01)))


# ::id PMC4329006.145
# ::snt Relative CAT activity was determined by measuring CAT activity of cotransfected MCF-10A cells compared to that of SAF-CAT transfected MCF-10A cells.
# ::tok Relative CAT activity was determined by measuring CAT activity of cotransfected MCF @-@ 10A cells compared to that of SAF @-@ CAT transfected MCF @-@ 10A cells .
(x4 / determine-01
      :ARG1 (x3 / activity-06
            :ARG0 (x1 / enzyme
                  :name (x2 / name :op1 "CAT")
                  :xref (x / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002")))
      :manner (x5 / measure-01
            :ARG1 (x8 / activity-06
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "CAT")
                        :xref (x18 / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002")))
            :ARG0 (x9 / cotransfect-01
                  :ARG1 (x10 / cell-line
                        :name (x11 / name :op1 "MCF-10A"))))
      :ARG1-of (x12 / relative-05
            :compared-to (x13 / cell-line
                  :name (x14 / name :op1 "CAT")))
      :ARG1 (x17 / cell-line
            :ARG1-of (x15 / transfect-01)
            :name (x16 / name :op1 "MCF-10A")))


# ::id PMC4329006.148
# ::snt SAF-1, serum amyloid A activating factor 1; CAT, chroramphenicol acetyl transferase.
# ::tok SAF @-@ 1 , serum amyloid A activating factor 1; CAT , chroramphenicol acetyl transferase .
(x1 / and
      :op1 (x2 / protein
            :name (x3 / name :op1 "SAF-1")
            :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
      :op2 (x7 / factor
            :ARG1-of (x6 / activate-01
                  :ARG1 (x4 / enzyme
                        :name (x5 / name
                              :op1 "serum"
                              :op2 "amyloid"
                              :op3 "A")))
            :ARG1-of (x9 / cell-line
                  :name (x8 / name :op1 "CAT" :op2 "chroramphenicol")
                  :name (x10 / name :op1 "acetyltransferase")
                  :mod (x11 / transferase))))


# ::id PMC4329006.149
# ::snt To test whether changes in the DNA-binding activity of SAF-1 in response to the MEK and MAPK inhibitors also affects its transcriptional function, we used CAT reporter assay using wt SAF-CAT, where CAT expression is driven by the SAF-binding promoter element (Fig. 3B ).
# ::tok To test whether changes in the DNA @-@ binding activity of SAF @-@ 1 in response to the MEK and MAPK inhibitors also affects its transcriptional function , we used CAT reporter assay using wt SAF @-@ CAT , where CAT expression is driven by the SAF @-@ binding promoter element ( Fig . 3B ) .
(x1 / multi-sentence
      :snt1 (x23 / use-01
            :purpose (x2 / test-01
                  :ARG1 (x19 / affect-01
                        :mode "interrogative"
                        :ARG0 (x3 / change-01
                              :ARG1 (x7 / activity-06
                                    :ARG1-of (x6 / bind-01
                                          :ARG2 (x4 / nucleic-acid
                                                :wiki "dna"
                                                :name (x5 / name :op1 "DNA")))
                                    :ARG1 (x8 / protein
                                          :name (x9 / name :op1 "SAF-1")
                                          :xref (x42 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                                    :ARG2-of (x10 / respond-01
                                          :ARG1 (x17 / molecular-physical-entity
                                                :ARG0-of (x16 / inhibit-01
                                                      :ARG1 (x13 / and
                                                            :op1 (x11 / enzyme
                                                                  :name (x12 / name :op1 "MEK")
                                                                  :xref (x44 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343"))
                                                            :op2 (x14 / enzyme
                                                                  :name (x15 / name :op1 "MAPK")
                                                                  :xref (x45 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))))))))
                        :mod (x18 / also)
                        :ARG1 (x21 / function-01
                              :ARG1 (x20 / transcribe-01))))
            :ARG0 (x22 / we)
            :ARG1 (x27 / assay-01
                  :ARG0-of (x26 / report-01
                        :ARG1 (x24 / enzyme
                              :name (x25 / name :op1 "CAT")
                              :xref (x41 / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002")))))
      :snt2 (x28 / use-01
            :ARG1 (x29 / enzyme
                  :mod (x30 / wild-type)
                  :name (x31 / name :op1 "CAT")
                  :location-of (x35 / drive-02
                        :ARG1 (x34 / express-03
                              :ARG2 (x32 / enzyme
                                    :name (x33 / name :op1 "CAT")
                                    :xref (x43 / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002")))
                        :ARG0 (x38 / element
                              :ARG1-of (x36 / bind-01)
                              :ARG0-of (x37 / promote-01))
                        :ARG1-of (x39 / describe-01
                              :ARG0 (x40 / figure :mod "3b")))
                  :xref (x / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002"))))


# ::id PMC4329006.150
# ::snt Treatment of the CAT vector-transfected cells with U0126, PD98059, and SB203580 but not by SB202474, which is an inactive analog of SB203580, significantly reduced the ras-mediated induction of SAF-1/MAZ function, suggesting involvement of MEK-ERK-MAPK cascade in the activation of SAF-1/MAZ by Ras.
# ::tok Treatment of the CAT vector @-@ transfected cells with U0126 , PD98059 , and SB203580 but not by SB202474 , which is an inactive analog of SB203580 , significantly reduced the ras @-@ mediated induction of SAF @-@ 1/MAZ function , suggesting involvement of MEK @-@ ERK @-@ MAPK cascade in the activation of SAF @-@ 1/MAZ by Ras .
(x1 / multi-sentence
      :snt1 (x11 / and
            :op1 (x2 / treat-04
                  :ARG1 (x6 / cell
                        :ARG1-of (x5 / transfect-01
                              :ARG2 (x4 / vector
                                    :name (x3 / name :op1 "CAT"))))
                  :ARG2 (x7 / small-molecule
                        :name (x8 / name :op1 "U0126")
                        :xref (x49 / xref :value "PUBCHEM:3006531" :prob "17.656696")))
            :op2 (x9 / small-molecule
                  :name (x10 / name :op1 "PD98059")
                  :xref (x48 / xref :value "PUBCHEM:4713" :prob "18.349844"))
            :op2 (x12 / small-molecule
                  :name (x13 / name :op1 "SB203580")
                  :xref (x51 / xref :value "PUBCHEM:176155" :prob "18.572987")))
      :snt2 (x14 / contrast-01
            :ARG2 (x15 / protein
                  :name (x16 / name :op1 "SB202474")
                  :ARG1-of (x22 / reduce-01
                        :ARG0 (x17 / activate-01 :polarity "-")
                        :ARG1 (x18 / small-molecule
                              :mod (x19 / analog)
                              :name (x20 / name :op1 "SB203580")
                              :xref (x50 / xref :value "PUBCHEM:176155" :prob "18.572987"))
                        :ARG2 (x21 / significant-02)
                        :ARG1 (x29 / function-01
                              :ARG0 (x26 / induce-01
                                    :ARG1-of (x25 / mediate-01
                                          :ARG0 (x23 / enzyme
                                                :name (x24 / name :op1 "Ras")
                                                :xref (x44 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                                    :ARG2 (x27 / enzyme
                                          :name (x28 / name :op1 "1/MAZ"))))
                        :ARG0-of (x30 / suggest-01
                              :ARG1 (x31 / involve-01
                                    :ARG1 (x38 / cascade
                                          :mod (x32 / enzyme
                                                :name (x33 / name :op1 "MEK")
                                                :xref (x45 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343"))
                                          :mod (x34 / enzyme
                                                :name (x35 / name :op1 "ERK")
                                                :xref (x47 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                                          :mod (x36 / enzyme
                                                :name (x37 / name :op1 "MAPK")
                                                :xref (x46 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313")))
                                    :ARG2 (x39 / activate-01
                                          :ARG1 (x40 / enzyme
                                                :name (x41 / name :op1 "1/MAZ"))
                                          :ARG0 (x42 / enzyme
                                                :name (x43 / name :op1 "Ras")
                                                :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))))))))


# ::id PMC4329006.151
# ::snt To examine whether SAF-1/MAZ is directly targeted by Ras, we used a mutant SAF-1 construct, SAF-1(V71), that contains a defective MAP-kinase phosphorylation site 21 .
# ::tok To examine whether SAF @-@ 1/MAZ is directly targeted by Ras , we used a mutant SAF @-@ 1 construct , SAF @-@ 1 ( V71 ) , that contains a defective MAP @-@ kinase phosphorylation site 21 .
(x9 / use-01
      :purpose (x1 / examine-01
            :ARG1 (x5 / target-01
                  :mode "interrogative"
                  :ARG2 (x2 / enzyme
                        :name (x3 / name :op1 "1/MAZ"))
                  :ARG1-of (x4 / direct-02)
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))
      :ARG0 (x8 / we)
      :ARG1 (x18 / contain-01
            :ARG1-of (x13 / construct-01
                  :ARG0 (x10 / enzyme
                        :ARG2-of (x11 / mutate-01)
                        :name (x12 / name :op1 "SAF-1")
                        :xref (x24 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                  :ARG2 (x14 / protein
                        :name (x15 / name :op1 "SAF-1")
                        :xref (x25 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                  :ARG1-of (x16 / amino-acid
                        :mod "71"
                        :name (x17 / name :op1 "valine")))
            :ARG1 (x23 / protein-segment
                  :mod (x19 / defective)
                  :part-of (x20 / protein
                        :name (x21 / name :op1 "MAP-kinase"))
                  :ARG1-of (x22 / phosphorylate-01)
                  :mod "21")))


# ::id PMC4329006.152
# ::snt The DNA-binding activity and transactivation potential of this mutated SAF-1 protein has earlier been shown to be markedly less than that of wt SAF-1 21 .
# ::tok The DNA @-@ binding activity and transactivation potential of this mutated SAF @-@ 1 protein has earlier been shown to be markedly less than that of wt SAF @-@ 1 21 .
(x14 / show-01
      :ARG0 (x5 / and
            :op1 (x4 / activity-06
                  :ARG1-of (x3 / bind-01
                        :ARG2 (x1 / nucleic-acid
                              :wiki "dna"
                              :name (x2 / name :op1 "DNA"))))
            :op2 (x6 / transactivate-01
                  :ARG1 (x7 / potential
                        :mod (x8 / this))))
      :ARG0 (x9 / mutate-01
            :ARG1 (x11 / protein
                  :name (x10 / name :op1 "SAF-1")
                  :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
      :time (x12 / early
            :degree (x13 / more))
      :ARG1 (x15 / marked)
      :degree (x16 / less)
      :compared-to (x17 / enzyme
            :mod (x18 / wild-type)
            :name (x19 / name :op1 "SAF-1")
            :ARG1-of (x20 / describe-01
                  :ARG0 (x21 / publication
                        :ARG1-of (x22 / cite-01 :ARG2 "21")))
            :xref (x23 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))


# ::id PMC4329006.153
# ::snt We cotrasnfected MCF-10A cells with the reporter plasmid wt SAF-CAT along with oncogenic pCMV ras V12 and wild-type pcD-SAF-1 or mutant pcD-SAF-1(V71) plasmid DNAs (Fig. 3C ).
# ::tok We cotrasnfected MCF @-@ 10A cells with the reporter plasmid wt SAF @-@ CAT along with oncogenic pCMV ras V12 and wild @-@ type pcD @-@ SAF @-@ 1 or mutant pcD @-@ SAF @-@ 1 ( V71 ) plasmid DNAs ( Fig . 3C ) .
(x4 / have-03
      :ARG0 (x1 / we)
      :ARG0 (x2 / cell-line
            :name (x3 / name :op1 "MCF-10A"))
      :ARG1 (x5 / and
            :op1 (x7 / plasmid
                  :ARG0-of (x6 / report-01)
                  :mod (x8 / wild-type)
                  :name (x9 / name :op1 "CAT"))
            :op2 (x10 / enzyme
                  :ARG0-of (x11 / cause-01
                        :ARG1 (x12 / disease
                              :wiki "cancer"
                              :name (x13 / name :op1 "cancer")))
                  :name (x14 / name :op1 "pCMV")))
      :ARG1 (x18 / and
            :op1 (x15 / enzyme
                  :name (x16 / name :op1 "ras")
                  :ARG2-of (x17 / mutate-01 :value "V12")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
            :op2 (x22 / or
                  :mod (x19 / wild-type)
                  :op1 (x20 / protein
                        :name (x21 / name :op1 "pcD-SAF-1"))
                  :op2 (x23 / mutate-01
                        :ARG2 (x24 / protein
                              :name (x25 / name :op1 "pcD-SAF-1")))))
      :ARG1-of (x28 / plasmid
            :op1 (x26 / amino-acid
                  :mod "71"
                  :name (x27 / name :op1 "valine"))
            :op2 (x29 / nucleic-acid
                  :wiki "dna"
                  :name (x30 / name :op1 "dna")
                  :ARG1-of (x31 / describe-01
                        :ARG0 (x32 / figure :mod "3c")))))


# ::id PMC4329006.154
# ::snt There was marked increase in the reporter gene expression in the cells cotransfected with wild-type pcD-SAF-1 and oncogenic pCMV ras V12 as compared to the cells cotransfected with mutant pcD-SAF-1(V71) and oncogenic pCMV ras V12 plasmid DNAs (Fig. 3C ).
# ::tok There was marked increase in the reporter gene expression in the cells cotransfected with wild @-@ type pcD @-@ SAF @-@ 1 and oncogenic pCMV ras V12 as compared to the cells cotransfected with mutant pcD @-@ SAF @-@ 1 ( V71 ) and oncogenic pCMV ras V12 plasmid DNAs ( Fig . 3C ) .
(x1 / multi-sentence
      :snt1 (x2 / cause-01
            :ARG0 (x30 / and
                  :op1 (x4 / increase-01
                        :ARG1-of (x3 / mark-01)
                        :ARG1 (x7 / express-03
                              :ARG1 (x6 / gene
                                    :ARG0-of (x5 / report-01))
                              :ARG3 (x8 / cell
                                    :ARG1-of (x9 / cotransfect-01
                                          :ARG2 (x13 / and
                                                :mod (x10 / wild-type)
                                                :op1 (x11 / protein
                                                      :name (x12 / name :op1 "pcD-SAF-1"))
                                                :op2 (x14 / enzyme
                                                      :ARG0-of (x15 / cause-01
                                                            :ARG1 (x16 / disease
                                                                  :wiki "cancer"
                                                                  :name (x17 / name :op1 "cancer")))
                                                      :name (x18 / name :op1 "pCMV")))))
                              :ARG2 (x19 / enzyme
                                    :name (x20 / name :op1 "ras")
                                    :ARG2-of (x21 / mutate-01 :value "V12")
                                    :xref (x45 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203")))
                        :ARG1-of (x22 / compare-01
                              :ARG2 (x23 / cell
                                    :ARG1-of (x24 / cotransfect-01
                                          :ARG2 (x25 / mutate-01
                                                :ARG2 (x26 / protein
                                                      :name (x27 / name :op1 "pcD-SAF-1"))))))
                        :ARG1-of (x28 / amino-acid
                              :mod "71"
                              :name (x29 / name :op1 "valine")))
                  :op2 (x31 / enzyme
                        :ARG0-of (x32 / cause-01
                              :ARG1 (x33 / disease
                                    :wiki "cancer"
                                    :name (x34 / name :op1 "cancer")))
                        :name (x35 / name :op1 "pCMV"))))
      :snt2 (x39 / plasmid
            :ARG0 (x36 / enzyme
                  :name (x37 / name :op1 "ras")
                  :ARG2-of (x38 / mutate-01 :value "V12")
                  :xref (x44 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
            :op2 (x40 / enzyme
                  :name (x41 / name :op1 "dna")
                  :xref (x / xref :value "UNIPROT:DNA2_HUMAN" :prob "0.202"))
            :ARG1-of (x42 / describe-01
                  :ARG0 (x43 / figure :mod "3c"))))


# ::id PMC4329006.155
# ::snt The level of induction in cells transfected with mutant pcD-SAF-1(V71) + pCMV ras V12 was same as that with pCMV ras V12 alone.
# ::tok The level of induction in cells transfected with mutant pcD @-@ SAF @-@ 1 ( V71 ) + pCMV ras V12 was same as that with pCMV ras V12 alone .
(x15 / capable-01
      :ARG1 (x1 / level
            :quant-of (x10 / and
                  :op1 (x2 / induce-01
                        :location (x3 / cell
                              :ARG1-of (x4 / transfect-01
                                    :ARG2 (x5 / mutate-01
                                          :ARG2 (x6 / protein
                                                :name (x7 / name :op1 "pcD-SAF-1")))))
                        :ARG1-of (x8 / amino-acid
                              :mod "71"
                              :name (x9 / name :op1 "valine")))
                  :op2 (x11 / enzyme
                        :name (x12 / name :op1 "ras")
                        :ARG2-of (x13 / mutate-01 :value "V12")
                        :xref (x20 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))))
      :ARG1-of (x14 / same-01)
      :ARG2 (x16 / enzyme
            :name (x17 / name :op1 "ras")
            :ARG2-of (x18 / mutate-01 :value "V12")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
      :mod (x19 / alone))


# ::id PMC4329006.156
# ::snt This level of induction is the result of Ras-mediated activation of endogenous SAF-1 in the MCF-10A cells.
# ::tok This level of induction is the result of Ras @-@ mediated activation of endogenous SAF @-@ 1 in the MCF @-@ 10A cells .
(x5 / result-01
      :ARG1 (x2 / level
            :mod (x1 / this)
            :quant-of (x3 / enzyme
                  :name (x4 / name :op1 "induction")
                  :xref (x15 / xref :value "UNIPROT:NOS2_HUMAN" :prob "0.202")))
      :ARG2 (x9 / activate-01
            :ARG1-of (x8 / mediate-01
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "Ras")
                        :xref (x16 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG1 (x10 / enzyme
                  :mod (x11 / endogenous)
                  :name (x12 / name :op1 "SAF-1")
                  :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
            :location (x13 / cell-line
                  :name (x14 / name :op1 "MCF-10A"))))


# ::id PMC4329006.157
# ::snt These data suggested that MAPK site of SAF-1 is necessary for Ras-mediated activation of SAF-1 and confirmed the involvement of MEK-ERK-MAPK-signaling in Ras -mediated activation of SAF-1/MAZ.
# ::tok These data suggested that MAPK site of SAF @-@ 1 is necessary for Ras @-@ mediated activation of SAF @-@ 1 and confirmed the involvement of MEK @-@ ERK @-@ MAPK @-@ signaling in Ras -@ mediated activation of SAF @-@ 1/MAZ .
(x3 / suggest-01
      :ARG0 (x2 / data
            :mod (x1 / this))
      :ARG1 (x8 / need-01
            :ARG1 (x5 / protein-segment
                  :name (x4 / name :op1 "MAPK")
                  :part-of (x6 / protein
                        :name (x7 / name :op1 "SAF-1")
                        :xref (x35 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
            :purpose (x15 / and
                  :op1 (x12 / activate-01
                        :ARG1-of (x11 / mediate-01
                              :ARG0 (x9 / enzyme
                                    :name (x10 / name :op1 "Ras")
                                    :xref (x34 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "SAF-1")
                              :xref (x37 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
                  :op2 (x16 / confirm-01
                        :ARG1 (x17 / involve-01
                              :ARG1 (x18 / and
                                    :op1 (x19 / enzyme
                                          :name (x20 / name :op1 "MEK")
                                          :xref (x36 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343"))
                                    :op2 (x21 / enzyme
                                          :name (x22 / name :op1 "ERK")
                                          :xref (x32 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                                    :op3 (x25 / signal-07
                                          :ARG1 (x23 / enzyme
                                                :name (x24 / name :op1 "MAPK")
                                                :xref (x33 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))))
                              :ARG2 (x26 / enzyme
                                    :name (x27 / name :op1 "Ras")
                                    :ARG2-of (x29 / activate-01
                                          :ARG1-of (x28 / mediate-01)
                                          :ARG1 (x30 / enzyme
                                                :name (x31 / name :op1 "1/MAZ")))
                                    :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))))))


# ::id PMC4329006.158
# ::snt Knockdown of SAF-1/MAZ in breast cancer cells represses Ras gene expression
# ::tok Knockdown of SAF @-@ 1/MAZ in breast cancer cells represses Ras gene expression
(x7 / repress-01
      :ARG0 (x1 / knock-down-02
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "1/MAZ"))
            :location (x6 / cell
                  :mod (x4 / disease
                        :wiki "breast_cancer"
                        :name (x5 / name :op1 "breast" :op2 "cancer"))))
      :ARG1 (x10 / express-03
            :ARG1 (x9 / gene
                  :name (x8 / name :op1 "Ras")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))


# ::id PMC4329006.159
# ::snt To further validate the role of Ras in SAF-1 activation, we knocked-down SAF-1 in the breast cancer cells.
# ::tok To further validate the role of Ras in SAF @-@ 1 activation , we knocked @-@ down SAF @-@ 1 in the breast cancer cells .
(x10 / knock-down-02
      :purpose (x2 / validate-01
            :degree (x1 / further)
            :ARG1 (x3 / role
                  :poss (x4 / enzyme
                        :name (x5 / name :op1 "Ras")
                        :xref (x17 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :topic (x8 / activate-01
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "SAF-1")
                              :xref (x16 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))))
      :ARG0 (x9 / we)
      :ARG1 (x11 / protein
            :name (x12 / name :op1 "SAF-1")
            :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
      :location (x15 / cell
            :mod (x13 / disease
                  :wiki "breast_cancer"
                  :name (x14 / name :op1 "breast" :op2 "cancer"))))


# ::id PMC4329006.160
# ::snt The evidences that overexpression of SAF-1/MAZ occurs in many human cancers and SAF-1/MAZ transcription factor is a target of activated Ras proteins, raised the questions, what downstream pathways are affected during aberrant activation of SAF-1 in cancer.
# ::tok The evidences that overexpression of SAF @-@ 1/MAZ occurs in many human cancers and SAF @-@ 1/MAZ transcription factor is a target of activated Ras proteins , raised the questions , what downstream pathways are affected during aberrant activation of SAF @-@ 1 in cancer .
(x20 / raise-01
      :ARG1 (x1 / evidence-01
            :ARG1 (x5 / be-located-at-91
                  :ARG0 (x2 / overexpress-01
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "1/MAZ")))
                  :ARG2 (x10 / and
                        :op1 (x6 / person
                              :quant (x7 / many)
                              :mod (x8 / human)
                              :name (x9 / name :op1 "cancer"))
                        :op2 (x14 / factor
                              :ARG0-of (x13 / transcribe-01
                                    :ARG1 (x11 / enzyme
                                          :name (x12 / name :op1 "1/MAZ")))))
                  :ARG1 (x15 / target-01
                        :ARG1 (x16 / enzyme
                              :ARG1-of (x17 / activate-01)
                              :name (x18 / name :op1 "Ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                        :ARG0 (x19 / protein))))
      :ARG1 (x21 / question-01)
      :ARG2 (x22 / thing
            :ARG1-of (x25 / affect-01
                  :ARG0 (x24 / pathway
                        :mod (x23 / downstream))))
      :time (x27 / activate-01
            :manner (x26 / aberrant))
      :location (x28 / disease
            :wiki "cancer"
            :name (x29 / name :op1 "cancer")))


# ::id PMC4329006.161
# ::snt MDA-MB-468 breast cancer cells are triple negative and contain no mutation in Ras genes 39 .
# ::tok MDA @-@ MB @-@ 468 breast cancer cells are triple negative and contain no mutation in Ras genes 39 .
(x7 / and
      :op1 (x6 / negative-01
            :ARG1 (x4 / cell
                  :name (x1 / name :op1 "MDA-MB-468")
                  :mod (x2 / disease
                        :wiki "breast_cancer"
                        :name (x3 / name :op1 "breast" :op2 "cancer")))
            :ARG1-of (x5 / triple-01))
      :op2 (x8 / contain-01
            :ARG1 (x12 / gene
                  :ARG1-of (x9 / mutate-01
                        :polarity "-"
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "Ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                  :ARG1-of (x13 / describe-01
                        :ARG0 (x14 / publication
                              :ARG1-of (x15 / cite-01 :ARG2 "39"))))))


# ::id PMC4329006.162
# ::snt Also, presence of high level of SAF-1/MAZ in MDA-MB-468 cells 14 renders it suitable to assess the effect of silencing SAF-1/MAZ.
# ::tok Also , presence of high level of SAF @-@ 1/MAZ in MDA @-@ MB @-@ 468 cells 14 renders it suitable to assess the effect of silencing SAF @-@ 1/MAZ .
(x12 / render-02
      :mod (x1 / also)
      :ARG0 (x2 / present-02
            :ARG1 (x4 / level
                  :ARG1-of (x3 / high-02)
                  :quant-of (x5 / enzyme
                        :name (x6 / name :op1 "1/MAZ")))
            :location (x8 / cell-line
                  :name (x7 / name :op1 "MDA-MB-468")))
      :ARG1-of (x9 / describe-01
            :ARG0 (x10 / publication
                  :ARG1-of (x11 / cite-01 :ARG2 "14")))
      :ARG2 (x13 / suitable)
      :purpose (x14 / assess-01
            :ARG1 (x15 / affect-01
                  :ARG0 (x16 / silence-01)
                  :ARG1 (x17 / enzyme
                        :name (x18 / name :op1 "1/MAZ")))))


# ::id PMC4329006.163
# ::snt To examine, SAF-1/MAZ expression was silenced in MDA-MB-468 cells by transfection of SAF-1/MAZ shRNA and global gene expression profile was examined.
# ::tok To examine , SAF @-@ 1/MAZ expression was silenced in MDA @-@ MB @-@ 468 cells by transfection of SAF @-@ 1/MAZ shRNA and global gene expression profile was examined .
(x13 / and
      :purpose (x1 / examine-01)
      :op1 (x5 / silence-01
            :ARG1 (x4 / express-03
                  :ARG2 (x2 / enzyme
                        :name (x3 / name :op1 "1/MAZ")))
            :location (x7 / cell-line
                  :name (x6 / name :op1 "MDA-MB-468"))
            :ARG0 (x11 / nucleic-acid
                  :ARG1-of (x8 / transfect-01
                        :ARG2 (x9 / enzyme
                              :name (x10 / name :op1 "1/MAZ")))
                  :name (x12 / name :op1 "shRNA")))
      :op2 (x18 / examine-01
            :ARG1 (x17 / profile-01
                  :mod (x14 / globe)
                  :ARG1 (x16 / express-03
                        :ARG1 (x15 / gene)))))


# ::id PMC4329006.164
# ::snt These data revealed down-regulation of several prominent cancer-linked genes that included MMP-1, MMP-9, MMP-14, p21 WAF1/CIP1 , hTERT, PPARg1, Prox-1 and VEGF (data not shown), and surprisingly, it showed downregulation of Ras mRNA expression.
# ::tok These data revealed down @-@ regulation of several prominent cancer @-@ linked genes that included MMP @-@ 1 , MMP @-@ 9 , MMP @-@ 14 , p21 WAF1 @/@ CIP1 , hTERT , PPARg1 , Prox @-@ 1 and VEGF ( data not shown ) , and surprisingly , it showed downregulation of Ras mRNA expression .
(x1 / multi-sentence
      :snt1 (x12 / include-01
            :ARG0 (x3 / data
                  :mod (x2 / this)
                  :ARG0-of (x4 / reveal-01
                        :ARG1 (x5 / downregulate-01
                              :ARG1 (x11 / gene
                                    :quant (x6 / several)
                                    :mod (x7 / prominent)
                                    :ARG1-of (x10 / link-01
                                          :ARG2 (x8 / disease
                                                :wiki "cancer"
                                                :name (x9 / name :op1 "cancer")))))))
            :ARG1 (x33 / and
                  :op1 (x13 / enzyme
                        :name (x14 / name :op1 "MMP-1")
                        :xref (x43 / xref :value "UNIPROT:MMP1_HUMAN" :prob "1.002"))
                  :op2 (x15 / enzyme
                        :name (x16 / name :op1 "MMP-9")
                        :xref (x44 / xref :value "UNIPROT:MMP9_HUMAN" :prob "1.002"))
                  :op2 (x27 / and
                        :op1 (x21 / and
                              :op1 (x17 / protein
                                    :name (x18 / name :op1 "MMP-14"))
                              :op2 (x19 / protein
                                    :name (x20 / name :op1 "p21" :op2 "WAF1/CIP1"))
                              :op1 (x22 / htert)
                              :op2 (x23 / protein
                                    :name (x24 / name :op1 "PPARg1"))
                              :op3 (x25 / protein
                                    :name (x26 / name :op1 "Prox-1")))
                        :op2 (x28 / protein
                              :name (x29 / name :op1 "VEGF")
                              :xref (x / xref :value "UNIPROT:VEGFA_HUMAN" :prob "1.003"))
                        :ARG1-of (x30 / describe-01
                              :ARG0 (x31 / data
                                    :ARG1-of (x32 / show-01 :polarity "-"))))))
      :snt2 (x35 / show-01
            :ARG0-of (x34 / surprise-01)
            :ARG1 (x36 / downregulate-01
                  :ARG1 (x37 / enzyme
                        :name (x38 / name :op1 "Ras")
                        :xref (x42 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :ARG1-of (x41 / express-03
                        :ARG2 (x39 / nucleic-acid
                              :name (x40 / name :op1 "mRNA"))))))


# ::id PMC4329006.165
# ::snt Quantitative RT-PCR analysis revealed downregulation of both H-Ras and K-Ras mRNAs by about 50% in SAF-1 knockdown MDA-MB-468 cells (Fig. 4A ).
# ::tok Quantitative RT @-@ PCR analysis revealed downregulation of both H @-@ Ras and K @-@ Ras mRNAs by about 50 % in SAF @-@ 1 knockdown MDA @-@ MB @-@ 468 cells ( Fig . 4A ) .
(x5 / reveal-01
      :ARG0 (x4 / analyze-01
            :mod (x1 / quantitative)
            :mod (x2 / thing
                  :name (x3 / name :op1 "RT-PCR")))
      :ARG1 (x6 / downregulate-01
            :ARG1 (x7 / and
                  :op1 (x8 / enzyme
                        :name (x9 / name :op1 "H-Ras")
                        :xref (x / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))
                  :op2 (x10 / enzyme
                        :name (x11 / name :op1 "K-Ras")
                        :xref (x23 / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661")))
            :ARG2 (x12 / nucleic-acid
                  :name (x13 / name :op1 "mrna")))
      :quant (x14 / about
            :op1 (x15 / percentage-entity :value "50"))
      :location (x20 / cell-line
            :ARG0-of (x18 / knock-down-02
                  :ARG1 (x16 / protein
                        :name (x17 / name :op1 "SAF-1")
                        :xref (x24 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))
            :name (x19 / name :op1 "MDA-MB-468"))
      :ARG1-of (x21 / describe-01
            :ARG0 (x22 / figure :mod "4a")))


# ::id PMC4329006.166
# ::snt Reciprocally, overexpression of SAF-1 in MCF-10A cells that normally contain low level of SAF-1 34 and therefore suitable to examine the effect of overexpression of SAF-1, showed increased H-Ras and K-Ras mRNA levels by more than threefold compared to empty vector transfected cells (Fig.
# ::tok Reciprocally , overexpression of SAF @-@ 1 in MCF @-@ 10A cells that normally contain low level of SAF @-@ 1 34 and therefore suitable to examine the effect of overexpression of SAF @-@ 1 , showed increased H @-@ Ras and K @-@ Ras mRNA levels by more than threefold compared to empty vector transfected cells ( Fig .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op2 (x9 / contain-01
                  :ARG1 (x3 / overexpress-01
                        :ARG1 (x4 / protein
                              :name (x5 / name :op1 "SAF-1")
                              :xref (x44 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                        :location (x6 / cell-line
                              :name (x7 / name :op1 "MCF-10A")))
                  :ARG1-of (x8 / normal-02)
                  :ARG1 (x11 / level
                        :ARG1-of (x10 / low-04)
                        :quant-of (x12 / protein
                              :name (x13 / name :op1 "SAF-1")
                              :xref (x45 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))))
      :snt2 (x24 / show-01
            :ARG0 (x17 / and
                  :ARG1-of (x14 / describe-01
                        :ARG0 (x15 / publication
                              :ARG1-of (x16 / cite-01 :ARG2 "34"))))
            :ARG1-of (x18 / suitable-04
                  :ARG2 (x19 / examine-01
                        :ARG1 (x20 / affect-01
                              :ARG0 (x21 / overexpress-01
                                    :ARG1 (x22 / protein
                                          :name (x23 / name :op1 "SAF-1")
                                          :xref (x43 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))))))
            :ARG1 (x33 / level
                  :ARG1-of (x25 / increase-01
                        :ARG1 (x28 / and
                              :op1 (x26 / enzyme
                                    :name (x27 / name :op1 "H-Ras")
                                    :xref (x42 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))
                              :op2 (x29 / enzyme
                                    :name (x30 / name :op1 "K-Ras")
                                    :xref (x / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661"))))
                  :quant-of (x31 / nucleic-acid
                        :name (x32 / name :op1 "mRNA")))
            :ARG2 (x34 / more-than
                  :op1 (x35 / threefold))
            :compared-to (x39 / cell
                  :ARG1-of (x38 / transfect-01
                        :ARG2 (x37 / vector
                              :ARG1-of (x36 / empty-02))))
            :ARG1-of (x40 / describe-01
                  :ARG0 (x41 / figure :mod "3b"))))


# ::id PMC4329006.168
# ::snt Silencing of SAF-1/MAZ reduces mRNA level of K-Ras and H-Ras.
# ::tok Silencing of SAF @-@ 1/MAZ reduces mRNA level of K @-@ Ras and H @-@ Ras .
(x4 / reduce-01
      :ARG0 (x1 / silence-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "1/MAZ")))
      :ARG1 (x10 / and
            :op1 (x7 / level
                  :mod (x5 / nucleic-acid
                        :name (x6 / name :op1 "mRNA"))
                  :quant-of (x8 / enzyme
                        :name (x9 / name :op1 "K-Ras")
                        :xref (x / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661")))
            :op2 (x11 / enzyme
                  :name (x12 / name :op1 "H-Ras")
                  :xref (x13 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))))


# ::id PMC4329006.169
# ::snt Total RNA isolated from these cells was subjected to qRT-PCR analysis with primers specific for SAF-1/MAZ, K-Ras and H-Ras.
# ::tok Total RNA isolated from these cells was subjected to qRT @-@ PCR analysis with primers specific for SAF @-@ 1/MAZ , K @-@ Ras and H @-@ Ras .
(x4 / isolate-01
      :ARG2 (x1 / enzyme
            :mod (x2 / total)
            :name (x3 / name :op1 "RNA")
            :xref (x22 / xref :value "UNIPROT:RCL1_HUMAN" :prob "0.262"))
      :ARG2 (x6 / cell
            :mod (x5 / this))
      :ARG1-of (x7 / subject-01
            :ARG2 (x10 / analyze-01
                  :mod (x8 / thing
                        :name (x9 / name :op1 "qRT-PCR"))
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "primer")
                        :ARG1-of (x13 / specific-02)
                        :name (x14 / name :op1 "1/MAZ")
                        :xref (x21 / xref :value "UNIPROT:PRI1_HUMAN" :prob "0.202")))
            :ARG1 (x17 / and
                  :op1 (x15 / enzyme
                        :name (x16 / name :op1 "K-Ras")
                        :xref (x / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661"))
                  :op2 (x18 / enzyme
                        :name (x19 / name :op1 "H-Ras")
                        :xref (x20 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631")))))


# ::id PMC4329006.172
# ::snt Total RNA isolated from these cells was subjected to qRT-PCR analysis with primers specific for SAF-1/MAZ, K-Ras, and H-Ras, as described in (A).
# ::tok Total RNA isolated from these cells was subjected to qRT @-@ PCR analysis with primers specific for SAF @-@ 1/MAZ , K @-@ Ras , and H @-@ Ras , as described in ( A ) .
(x4 / isolate-01
      :ARG0 (x1 / enzyme
            :mod (x2 / total)
            :name (x3 / name :op1 "RNA")
            :xref (x / xref :value "UNIPROT:RCL1_HUMAN" :prob "0.262"))
      :ARG2 (x6 / cell
            :mod (x5 / this))
      :ARG1-of (x7 / subject-01
            :ARG2 (x10 / analyze-01
                  :mod (x8 / thing
                        :name (x9 / name :op1 "qRT-PCR"))))
      :ARG2 (x17 / and
            :op1 (x11 / enzyme
                  :name (x12 / name :op1 "primer")
                  :ARG1-of (x13 / specific-02)
                  :name (x14 / name :op1 "1/MAZ")
                  :xref (x24 / xref :value "UNIPROT:PRI1_HUMAN" :prob "0.202"))
            :op2 (x15 / enzyme
                  :name (x16 / name :op1 "K-Ras")
                  :xref (x25 / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661"))
            :op2 (x18 / enzyme
                  :name (x19 / name :op1 "H-Ras")
                  :xref (x23 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631")))
      :ARG1-of (x20 / describe-01
            :location (x21 / statistical-test-91
                  :ARG2 (x22 / less-than :op1 "0.02"))))


# ::id PMC4329006.174
# ::snt ** P < 0.03.
# ::tok ** P
(x3 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "**")))


# ::id PMC4329006.175
# ::snt SAF-1, serum amyloid A activating factor 1; qRT-PCR, quantitative reverse transcription-polymerase chain reaction.
# ::tok SAF @-@ 1 , serum amyloid A activating factor 1; qRT @-@ PCR , quantitative reverse transcription @-@ polymerase chain reaction .
(x1 / and
      :op1 (x2 / protein
            :name (x3 / name :op1 "SAF-1")
            :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
      :op2 (x7 / factor
            :ARG1-of (x6 / activate-01
                  :ARG1 (x4 / enzyme
                        :name (x5 / name
                              :op1 "serum"
                              :op2 "amyloid"
                              :op3 "A")))
            :ARG1-of (x8 / thing
                  :name (x9 / name :op1 "qRT-PCR")))
      :op3 (x10 / thing
            :name (x11 / name
                  :op1 "quantitative"
                  :op2 "reverse"
                  :op3 "transcription"
                  :op4 "polymerase"
                  :op5 "chain"
                  :op6 "reaction")))


# ::id PMC4329006.176
# ::snt SAF-1 acts as a transcriptional regulator of Ras
# ::tok SAF @-@ 1 acts as a transcriptional regulator of Ras
(x3 / act-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "SAF-1")
            :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
      :ARG1 (x5 / regulate-01
            :mod (x4 / transcribe-01)
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "Ras")
                  :xref (x8 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))


# ::id PMC4329006.177
# ::snt A strong correlation between SAF-1 and Ras, in vivo, suggested that SAF-1 could be involved in regulating Ras gene expression.
# ::tok A strong correlation between SAF @-@ 1 and Ras , in vivo , suggested that SAF @-@ 1 could be involved in regulating Ras gene expression .
(x5 / in-vivo
      :ARG1 (x2 / correlate-01
            :ARG1-of (x1 / strong-02)
            :ARG2 (x3 / enzyme
                  :name (x4 / name :op1 "Ras")
                  :xref (x16 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
      :ARG0-of (x6 / suggest-01
            :ARG1 (x7 / possible-01
                  :ARG1 (x10 / involve-01
                        :ARG1 (x8 / protein
                              :name (x9 / name :op1 "SAF-1")
                              :xref (x15 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                        :ARG2 (x11 / regulate-01
                              :ARG1 (x14 / express-03
                                    :ARG1 (x13 / gene
                                          :name (x12 / name :op1 "Ras")
                                          :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))))))


# ::id PMC4329006.178
# ::snt It has long been known that human breast tumors have low percentage of activating Ras mutations 27 , 28 but that does not necessarily mean that Ras plays no role in breast cancer.
# ::tok It has long been known that human breast tumors have low percentage of activating Ras mutations 27 , 28 but that does not necessarily mean that Ras plays no role in breast cancer .
(x14 / contrast-01
      :ARG1 (x2 / know-01
            :ARG1-of (x1 / long-03)
            :ARG1 (x13 / and
                  :op1 (x5 / tumor
                        :mod (x4 / breast
                              :part-of (x3 / human))
                        :ARG0-of (x6 / have-03
                              :ARG1 (x12 / mutate-01
                                    :ARG1 (x8 / percentage
                                          :ARG1-of (x7 / low-04)
                                          :quant-of (x9 / enzyme
                                                :ARG1-of (x10 / activate-01)
                                                :name (x11 / name :op1 "Ras")
                                                :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))))
                  :op1 "27"
                  :op2 "28"))
      :ARG2 (x15 / need-01
            :ARG1 (x16 / mean-01
                  :polarity "-"
                  :ARG2 (x19 / play-02
                        :ARG0 (x17 / enzyme
                              :name (x18 / name :op1 "Ras")
                              :xref (x23 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                        :polarity "-"
                        :ARG1 (x20 / role
                              :topic (x21 / disease
                                    :wiki "breast_cancer"
                                    :name (x22 / name :op1 "breast" :op2 "cancer")))))))


# ::id PMC4329006.179
# ::snt In fact there is extensive experimental evidence demonstrating overexpression of wild-type Ras proteins and high level of activated Ras proteins in human breast tumor tissues 29 , 30 , suggesting activation of upstream mechanisms regulating Ras in breast cancer.
# ::tok In fact there is extensive experimental evidence demonstrating overexpression of wild @-@ type Ras proteins and high level of activated Ras proteins in human breast tumor tissues 29 , 30 , suggesting activation of upstream mechanisms regulating Ras in breast cancer .
(x21 / suggest-01
      :mod (x1 / in-fact)
      :ARG0 (x4 / evidence-01
            :ARG1-of (x2 / extensive-03)
            :mod (x3 / experiment-01)
            :ARG0-of (x5 / demonstrate-01
                  :ARG1 (x10 / and
                        :op1 (x6 / overexpress-01
                              :ARG1 (x7 / enzyme
                                    :mod (x8 / wild-type)
                                    :name (x9 / name :op1 "Ras")
                                    :xref (x32 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                        :op2 (x12 / level
                              :ARG1-of (x11 / high-02)
                              :quant-of (x13 / enzyme
                                    :ARG1-of (x14 / activate-01)
                                    :name (x15 / name :op1 "Ras")
                                    :xref (x33 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))
                  :location (x19 / tissue
                        :mod (x18 / tumor
                              :mod (x17 / breast
                                    :part-of (x16 / human))))
                  :ARG1-of (x20 / and :op1 "29" :op2 "30")))
      :ARG1 (x25 / mechanism
            :ARG0-of (x22 / activate-01
                  :ARG1 (x23 / enzyme
                        :name (x24 / name :op1 "upstream")
                        :xref (x31 / xref :value "UNIPROT:UBF1_HUMAN" :prob "0.232")))
            :ARG0-of (x26 / regulate-01
                  :ARG1 (x27 / enzyme
                        :name (x28 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :location (x29 / disease
                        :wiki "breast_cancer"
                        :name (x30 / name :op1 "breast" :op2 "cancer")))))


# ::id PMC4329006.180
# ::snt Overexpression of Ras proteins is also very common in other human cancers that harbor genetic Ras mutations.
# ::tok Overexpression of Ras proteins is also very common in other human cancers that harbor genetic Ras mutations .
(x6 / common
      :domain (x1 / overexpress-01
            :ARG1 (x3 / protein-family
                  :name (x2 / name :op1 "Ras")))
      :mod (x4 / also)
      :degree (x5 / very)
      :location (x8 / human
            :mod (x7 / other)
            :name (x9 / name :op1 "cancer"))
      :ARG0-of (x10 / harbor-01
            :ARG1 (x13 / mutate-01
                  :ARG1 (x11 / gene
                        :name (x12 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))))


# ::id PMC4329006.181
# ::snt Thus, upregulation of Ras may be one mechanism leading to carcinogenic transformation in many types of human cancer.
# ::tok Thus , upregulation of Ras may be one mechanism leading to carcinogenic transformation in many types of human cancer .
(x1 / cause-01
      :ARG1 (x9 / transform-01
            :ARG0 (x2 / upregulate-01
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG1-of (x5 / possible-01
                  :ARG1 (x6 / mechanism
                        :quant "1"
                        :ARG0-of (x7 / lead-03
                              :ARG2 (x8 / carcinoma))))
            :ARG1 (x11 / type-03
                  :mod (x10 / many)
                  :ARG1 (x12 / disease
                        :wiki "cancer"
                        :mod (x13 / human)
                        :name (x14 / name :op1 "cancer")))))


# ::id PMC4329006.182
# ::snt To determine, if SAF-1 is a direct transcriptional regulator of Ras , we examined the promoter function of human H-Ras and K-Ras genes in SAF-1 overexpressing cells.
# ::tok To determine , if SAF @-@ 1 is a direct transcriptional regulator of Ras , we examined the promoter function of human H @-@ Ras and K @-@ Ras genes in SAF @-@ 1 overexpressing cells .
(x11 / examine-01
      :purpose (x1 / determine-01
            :ARG1 (x2 / possible-01
                  :ARG1 (x7 / regulate-01
                        :ARG0 (x3 / protein
                              :name (x4 / name :op1 "SAF-1")
                              :xref (x25 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                        :mod (x6 / transcribe-01
                              :ARG1-of (x5 / direct-02))
                        :ARG1 (x8 / enzyme
                              :name (x9 / name :op1 "Ras")
                              :xref (x24 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))))
      :ARG0 (x10 / we)
      :ARG1 (x12 / promote-01
            :ARG1 (x13 / function-01
                  :ARG0 (x14 / human)
                  :ARG1 (x17 / and
                        :op1 (x15 / enzyme
                              :name (x16 / name :op1 "H-Ras")
                              :xref (x27 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))
                        :op2 (x18 / enzyme
                              :name (x19 / name :op1 "K-Ras")
                              :xref (x26 / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661"))))
            :location (x23 / cell
                  :ARG0-of (x22 / overexpress-01
                        :ARG1 (x20 / protein
                              :name (x21 / name :op1 "SAF-1")
                              :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))))))


# ::id PMC4329006.183
# ::snt It is worthy of mention that like the protein coding regions, the proximal promoter region of human Ras genes are highly similar.
# ::tok It is worthy of mention that like the protein coding regions , the proximal promoter region of human Ras genes are highly similar .
(x1 / deserve-01
      :ARG1 (x2 / mention-01
            :ARG1 (x6 / region
                  :ARG1-of (x3 / resemble-01
                        :ARG2 (x4 / protein))
                  :ARG0-of (x5 / code-01)
                  :ARG0-of (x14 / resemble-01
                        :ARG1 (x9 / region
                              :mod (x7 / proximal)
                              :ARG0-of (x8 / promote-01)
                              :part-of (x12 / gene
                                    :mod (x10 / human)
                                    :name (x11 / name :op1 "Ras")
                                    :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                        :ARG1-of (x13 / high-02)))))


# ::id PMC4329006.184
# ::snt The expression 0.6HRas-CAT and 0.68KRas-CAT reporter genes was consistently increased, in a dose-dependent manner, in pcD-SAF-1 expression plasmid transfected cells (Fig. 5A and B).
# ::tok The expression 0.6HRas @-@ CAT and 0.68KRas @-@ CAT reporter genes was consistently increased , in a dose @-@ dependent manner , in pcD @-@ SAF @-@ 1 expression plasmid transfected cells ( Fig . 5A and B ) .
(x14 / increase-01
      :ARG1 (x1 / express-03
            :ARG2 (x2 / and
                  :op1 (x3 / protein
                        :name (x4 / name :op1 "0.6HRas"))
                  :op2 (x7 / and
                        :op1 (x5 / enzyme
                              :name (x6 / name :op1 "CAT")
                              :xref (x / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002"))
                        :op2 (x8 / protein
                              :name (x9 / name :op1 "0.68KRas")))
                  :op3 (x12 / gene
                        :name (x10 / name :op1 "CAT")
                        :ARG0-of (x11 / report-01)
                        :xref (x26 / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002"))))
      :ARG1-of (x13 / consistent-02)
      :manner (x16 / depend-01
            :ARG1 (x15 / dose))
      :ARG0-of (x21 / transfect-01
            :location (x20 / plasmid
                  :ARG1-of (x19 / express-03
                        :ARG2 (x17 / protein
                              :name (x18 / name :op1 "pcD-SAF-1")))))
      :ARG1-of (x22 / describe-01
            :ARG0 (x25 / and
                  :op1 (x23 / figure :mod "5a")
                  :op2 (x24 / figure :mod "1b"))))


# ::id PMC4329006.185
# ::snt These data suggested that SAF-1 is a transcriptional regulator of human H-Ras and K-Ras genes.
# ::tok These data suggested that SAF @-@ 1 is a transcriptional regulator of human H @-@ Ras and K @-@ Ras genes .
(x3 / suggest-01
      :ARG0 (x2 / data
            :mod (x1 / this))
      :ARG1 (x7 / regulate-01
            :ARG0 (x4 / protein
                  :name (x5 / name :op1 "SAF-1")
                  :xref (x16 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
            :mod (x6 / transcribe-01)
            :ARG1 (x14 / gene
                  :mod (x8 / human)
                  :mod (x11 / and
                        :op1 (x9 / enzyme
                              :name (x10 / name :op1 "H-Ras")
                              :xref (x / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))
                        :op2 (x12 / enzyme
                              :name (x13 / name :op1 "K-Ras")
                              :xref (x15 / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661"))))))


# ::id PMC4329006.186
# ::snt SAF-1 increases H-Ras and K-Ras promoter function by binding to the G-box promoter elements.
# ::tok SAF @-@ 1 increases H @-@ Ras and K @-@ Ras promoter function by binding to the G @-@ box promoter elements .
(x3 / increase-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "SAF-1")
            :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
      :ARG1 (x16 / element
            :ARG1 (x6 / and
                  :op1 (x4 / enzyme
                        :name (x5 / name :op1 "H-Ras")
                        :xref (x18 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631"))
                  :op2 (x7 / enzyme
                        :name (x8 / name :op1 "K-Ras")
                        :xref (x17 / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661")))
            :ARG0-of (x9 / promote-01)
            :mod (x10 / function-01
                  :ARG0 (x15 / molecular-physical-entity
                        :ARG0-of (x14 / promote-01
                              :ARG1 (x11 / bind-01
                                    :ARG2 (x12 / protein
                                          :name (x13 / name :op1 "G" :op2 "box"))))))))


# ::id PMC4329006.187
# ::snt MDA-MB-468 cells were cotransfected with equal amount (1.0 μ g) of pBLCAT3 or 0.6HRas-CAT reporter plasmid DNA (A) or 0.68KRas-CAT reporter plasmid DNA (B), as indicated, and increasing concentration (0.5 and 1.0 μ g) of pcD-SAF-1 plasmid DNA.
# ::tok MDA @-@ MB @-@ 468 cells were cotransfected with equal amount ( 1.0 μ g ) of pBLCAT3 or 0.6HRas @-@ CAT reporter plasmid DNA ( A ) or 0.68KRas @-@ CAT reporter plasmid DNA ( B ) , as indicated , and increasing concentration ( 0.5 and 1.0 μ g ) of pcD @-@ SAF @-@ 1 plasmid DNA .
(x1 / multi-sentence
      :snt1 (x4 / cotransfect-01
            :ARG1 (x3 / cell-line
                  :name (x2 / name :op1 "MDA-MB-468"))
            :ARG2 (x13 / or
                  :op1 (x6 / amount
                        :ARG1-of (x5 / equal-01)
                        :quant (x7 / concentration-quantity
                              :quant "1.0"
                              :unit (x8 / micromolar))
                        :ARG1-of (x9 / describe-01
                              :ARG0 (x10 / figure :mod "g"))
                        :ARG1 (x11 / protein
                              :name (x12 / name :op1 "pBLCAT3")))
                  :op2 (x16 / cat
                        :mod (x14 / protein
                              :name (x15 / name :op1 "0.6HRas")))))
      :snt2 (x22 / or
            :op1 (x18 / plasmid
                  :ARG0-of (x17 / report-01)
                  :name (x19 / name :op1 "DNA")
                  :ARG1-of (x20 / describe-01
                        :ARG0 (x21 / figure :mod "a")))
            :op2 (x28 / plasmid
                  :mod (x23 / protein
                        :name (x24 / name :op1 "0.68KRas"))
                  :ARG0-of (x27 / report-01
                        :ARG1 (x25 / enzyme
                              :name (x26 / name :op1 "CAT")
                              :xref (x / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002")))
                  :ARG0-of (x29 / nucleic-acid
                        :wiki "dna"
                        :name (x30 / name :op1 "DNA"))
                  :ARG1-of (x31 / describe-01
                        :ARG0 (x32 / figure :mod "1b"))
                  :ARG0-of (x45 / plasmid
                        :ARG1-of (x33 / indicate-01)
                        :ARG0 (x34 / and
                              :op1 (x36 / concentrate-02
                                    :ARG1-of (x35 / increase-01)
                                    :quant (x37 / concentration-quantity :quant "0.5"))
                              :op2 (x38 / small-molecule
                                    :quant (x39 / concentration-quantity
                                          :quant "1.0"
                                          :unit (x40 / micromolar))
                                    :name (x41 / name :op1 "g")
                                    :xref (x48 / xref :value "PUBCHEM:132841" :prob "7.947479")))
                        :ARG1-of (x42 / include-91
                              :ARG2 (x43 / protein
                                    :name (x44 / name :op1 "pcD-SAF-1")))
                        :ARG0-of (x46 / nucleic-acid
                              :wiki "dna"
                              :name (x47 / name :op1 "DNA"))))))


# ::id PMC4329006.188
# ::snt Relative CAT activity was determined by comparing the CAT activities of transfected plasmids with that of pBLCAT3 alone.
# ::tok Relative CAT activity was determined by comparing the CAT activities of transfected plasmids with that of pBLCAT3 alone .
(x5 / determine-01
      :ARG1 (x4 / activity-06
            :ARG2-of (x1 / relative-05)
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "CAT")
                  :xref (x / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002")))
      :ARG2 (x6 / compare-01
            :ARG1 (x9 / activity-06
                  :ARG0 (x7 / enzyme
                        :name (x8 / name :op1 "CAT")
                        :xref (x15 / xref :value "UNIPROT:CACP_HUMAN" :prob "1.002"))
                  :ARG1 (x10 / transfect-01
                        :ARG1 (x11 / plasmid
                              :ARG3 (x12 / protein
                                    :name (x13 / name :op1 "pBLCAT3")))))
            :mod (x14 / alone)))


# ::id PMC4329006.190
# ::snt The precipitated chromatin DNA or input DNA was used for PCR amplification using H-Ras (C) and K-Ras (D) gene-specific primers.
# ::tok The precipitated chromatin DNA or input DNA was used for PCR amplification using H @-@ Ras ( C ) and K @-@ Ras ( D ) gene @-@ specific primers .
(x14 / amplify-01
      :ARG0 (x6 / or
            :ARG1-of (x1 / precipitate-01
                  :ARG1 (x2 / macro-molecular-complex
                        :name (x3 / name :op1 "chromatin")))
            :op1 (x4 / nucleic-acid
                  :wiki "dna"
                  :name (x5 / name :op1 "DNA"))
            :op2 (x7 / input
                  :ARG1-of (x10 / use-01
                        :ARG1 (x8 / nucleic-acid
                              :wiki "dna"
                              :name (x9 / name :op1 "DNA"))
                        :ARG2 (x11 / react-01
                              :ARG0 (x12 / polymerase)
                              :ARG1-of (x13 / chain-01)))))
      :ARG0-of (x15 / use-01
            :ARG1 (x16 / enzyme
                  :name (x17 / name :op1 "H-Ras")
                  :xref (x28 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631")))
      :ARG1-of (x18 / describe-01
            :ARG0 (x20 / and
                  :op1 (x19 / figure :mod "5c")
                  :op2 (x21 / enzyme
                        :name (x22 / name :op1 "K-Ras")
                        :xref (x / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661"))))
      :ARG1-of (x23 / describe-01
            :ARG0 (x24 / figure :mod "3d"))
      :ARG0-of (x27 / primer
            :mod (x25 / gene
                  :ARG1-of (x26 / specific-02))))


# ::id PMC4329006.191
# ::snt An unrelated upstream region was amplified to serve as negative control.
# ::tok An unrelated upstream region was amplified to serve as negative control .
(x5 / serve-01
      :ARG1 (x3 / region
            :mod (x2 / upstream
                  :name (x1 / name :op1 "unrelated")))
      :ARG2 (x4 / amplify-01)
      :ARG1 (x7 / control-01
            :ARG2-of (x6 / negative-01)))


# ::id PMC4329006.193
# ::snt SAF-1 interacts at a purine-rich region in the proximal promoters of H-Ras and K-Ras
# ::tok SAF @-@ 1 interacts at a purine @-@ rich region in the proximal promoters of H @-@ Ras and K @-@ Ras
(x13 / and
      :op1 (x3 / interact-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "SAF-1")
                  :xref (x17 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
            :ARG2 (x7 / region
                  :mod (x6 / rich
                        :mod (x4 / amino-acid
                              :name (x5 / name :op1 "purine")
                              :xref (x18 / xref :value "PUBCHEM:1044" :prob "8.760163")))
                  :location (x8 / proximal
                        :mod (x9 / molecular-physical-entity
                              :ARG0-of (x10 / promote-02))))
            :ARG1 (x11 / enzyme
                  :name (x12 / name :op1 "H-Ras")
                  :xref (x16 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.631")))
      :op2 (x14 / enzyme
            :name (x15 / name :op1 "K-Ras")
            :xref (x / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.661")))


# ::id PMC4329006.194
# ::snt The proximal promoter regions of the three functional Ras -genes are highly similar and contain many copies of the GGGC/A/TGGG element (G-boxes) or its inverted complement, which have been shown to be essential for the promoter transcriptional activity 40 .
# ::tok The proximal promoter regions of the three functional Ras -@ genes are highly similar and contain many copies of the GGGC/A/TGGG element ( G @-@ boxes ) or its inverted complement , which have been shown to be essential for the promoter transcriptional activity 40 .
(x10 / resemble-01
      :ARG1 (x4 / region
            :mod (x1 / proximal)
            :mod (x2 / molecular-physical-entity
                  :ARG0-of (x3 / promote-01))
            :part-of (x8 / gene
                  :ARG2 (x5 / enzyme
                        :quant "3"
                        :ARG0-of (x6 / function-01)
                        :name (x7 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))
      :ARG1-of (x9 / high-02)
      :ARG0-of (x11 / contain-01
            :ARG1 (x16 / element
                  :quant (x12 / many)
                  :ARG0-of (x13 / copy-01
                        :ARG1 (x14 / enzyme
                              :name (x15 / name :op1 "GGGC/A/TGGG")))))
      :ARG1-of (x21 / complement-01
            :ARG2 (x19 / or
                  :op1 (x17 / protein
                        :name (x18 / name :op1 "G" :op2 "box"))
                  :op2 (x20 / invert-01))
            :ARG0-of (x22 / have-03
                  :ARG1 (x24 / essential
                        :ARG1-of (x23 / show-01)
                        :purpose (x28 / activity-06
                              :ARG0 (x25 / molecular-physical-entity
                                    :ARG0-of (x26 / promote-01))
                              :ARG1 (x27 / transcribe-01)
                              :ARG1-of (x29 / describe-01
                                    :ARG0 (x30 / publication
                                          :ARG1-of (x31 / cite-01 :ARG2 "40"))))))))


# ::id PMC4329006.195
# ::snt SAF-1/MAZ also binds to highly purine-rich sequences and the G-boxes in Ras promoters appeared to bear considerable similarity with the consensus SAF-1/MAZ -binding element, RGGGRAGGRR, in which R is a purine 31 .
# ::tok SAF @-@ 1/MAZ also binds to highly purine @-@ rich sequences and the G @-@ boxes in Ras promoters appeared to bear considerable similarity with the consensus SAF @-@ 1/MAZ -@ binding element , RGGGRAGGRR , in which R is a purine 31 .
(x3 / appear-02
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "1/MAZ"))
      :ARG1 (x18 / bear-01
            :ARG1 (x5 / bind-01
                  :mod (x4 / also)
                  :ARG2 (x17 / molecular-physical-entity
                        :ARG1-of (x6 / high-02)
                        :ARG0-of (x16 / promote-01
                              :ARG1 (x11 / and
                                    :op1 (x10 / sequence
                                          :mod (x9 / rich
                                                :mod (x7 / amino-acid
                                                      :name (x8 / name :op1 "purine")
                                                      :xref (x34 / xref :value "PUBCHEM:1044" :prob "8.760163"))))
                                    :op2 (x12 / protein
                                          :name (x13 / name :op1 "G" :op2 "box"))
                                    :part-of (x14 / enzyme
                                          :name (x15 / name :op1 "Ras")
                                          :xref (x33 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))))
            :ARG1 (x20 / resemble-01
                  :degree (x19 / considerable))
            :ARG2 (x25 / element
                  :mod (x21 / consensus)
                  :ARG0-of (x24 / bind-01
                        :ARG1 (x22 / enzyme
                              :name (x23 / name :op1 "1/MAZ")))
                  :ARG0-of (x26 / cell-line
                        :name (x27 / name :op1 "RGGGRAGGRR")
                        :location-of (x28 / enzyme
                              :name (x29 / name :op1 "egf-r")
                              :xref (x / xref :value "UNIPROT:EGFR_HUMAN" :prob "0.593")))
                  :ARG1-of (x30 / describe-01
                        :ARG0 (x31 / publication
                              :ARG1-of (x32 / cite-01 :ARG2 "31"))))))


# ::id PMC4329006.196
# ::snt We employed ChIP analysis, which readily detects in vivo interaction of a transcription factor with the DNA in the chromosomal context.
# ::tok We employed ChIP analysis , which readily detects in vivo interaction of a transcription factor with the DNA in the chromosomal context .
(x2 / employ-02
      :ARG0 (x1 / we)
      :ARG1 (x5 / analyze-01
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "ChIP")
                  :xref (x / xref :value "UNIPROT:CHIP_HUMAN" :prob "0.653")))
      :ARG0-of (x7 / detect-01
            :manner (x6 / ready)
            :location (x9 / interact-01
                  :manner (x8 / in-vivo)
                  :ARG1 (x11 / factor
                        :ARG0-of (x10 / transcribe-01)))
            :ARG1 (x12 / nucleic-acid
                  :wiki "dna"
                  :name (x13 / name :op1 "DNA"))
            :ARG2 (x15 / context
                  :ARG1 (x14 / chromosome
                        :xref (x16 / xref :value "GO:0005694" :prob "0.8")))))


# ::id PMC4329006.197
# ::snt Formalin-fixed and SAF-1 antibody immunoprecipitated chromatin from MDA-MB-468 breast cancer cells showed specific enrichment of the purine-rich promoter regions of H- ras and K- ras (Fig. 5C and D).
# ::tok Formalin @-@ fixed and SAF @-@ 1 antibody immunoprecipitated chromatin from MDA @-@ MB @-@ 468 breast cancer cells showed specific enrichment of the purine @-@ rich promoter regions of H @- ras and K @- ras ( Fig . 5C and D ) .
(x14 / show-01
      :ARG0 (x3 / and
            :op1 (x2 / fix-01
                  :ARG1 (x1 / formalin))
            :op2 (x6 / antibody
                  :mod (x4 / protein
                        :name (x5 / name :op1 "SAF-1")
                        :xref (x36 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                  :ARG1-of (x7 / immunoprecipitate-01
                        :ARG1 (x8 / macro-molecular-complex
                              :name (x9 / name :op1 "chromatin"))))
            :source (x13 / cell
                  :name (x10 / name :op1 "MDA-MB-468")
                  :mod (x11 / disease
                        :wiki "breast_cancer"
                        :name (x12 / name :op1 "breast" :op2 "cancer"))))
      :ARG1 (x16 / enrich-01
            :ARG1-of (x15 / specific-02)
            :ARG1 (x25 / and
                  :op1 (x22 / region
                        :mod (x19 / rich
                              :mod (x17 / amino-acid
                                    :name (x18 / name :op1 "purine")
                                    :xref (x37 / xref :value "PUBCHEM:1044" :prob "8.760163")))
                        :mod (x20 / molecular-physical-entity
                              :ARG0-of (x21 / promote-01))
                        :part-of (x23 / gene
                              :name (x24 / name :op1 "h-ras")
                              :xref (x35 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601")))
                  :op2 (x26 / enzyme
                        :name (x27 / name :op1 "k-ras")
                        :xref (x34 / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.701"))
                  :op2 (x28 / enzyme
                        :name (x29 / name :op1 "ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))))
      :ARG1-of (x30 / describe-01
            :ARG0 (x33 / and
                  :op1 (x31 / figure :mod "5c")
                  :op2 (x32 / figure :mod "5d"))))


# ::id PMC4329006.198
# ::snt There was no enrichment of these sequences when a nonspecific antibody was used, indicating specificity of SAF-1 interaction.
# ::tok There was no enrichment of these sequences when a nonspecific antibody was used , indicating specificity of SAF @-@ 1 interaction .
(x1 / enrich-01
      :polarity "-"
      :ARG1 (x3 / dna-sequence
            :mod (x2 / this)
            :time (x6 / use-01
                  :ARG1 (x5 / antibody
                        :ARG1-of (x4 / specific-02 :polarity "-")))
            :ARG0-of (x7 / indicate-01
                  :ARG1 (x11 / interact-01
                        :ARG1-of (x8 / specific-02
                              :ARG1 (x9 / protein
                                    :name (x10 / name :op1 "SAF-1")
                                    :xref (x / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002")))))))


# ::id PMC4329006.199
# ::snt Together these results demonstrated that SAF-1 interacts with Ras genes in vivo and is capable of inducing expression of H- Ras and K- Ras genes.
# ::tok Together these results demonstrated that SAF @-@ 1 interacts with Ras genes in vivo and is capable of inducing expression of H @- Ras and K @- Ras genes .
(x5 / demonstrate-01
      :ARG0 (x3 / thing
            :mod (x1 / together)
            :mod (x2 / this)
            :ARG2-of (x4 / result-01))
      :ARG1 (x12 / and
            :op1 (x8 / interact-01
                  :ARG0 (x6 / protein
                        :name (x7 / name :op1 "SAF-1")
                        :xref (x23 / xref :value "UNIPROT:MAZ_HUMAN" :prob "1.002"))
                  :ARG1 (x10 / gene
                        :name (x9 / name :op1 "Ras")
                        :xref (x25 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :manner (x11 / in-vivo))
            :op2 (x13 / capable-01
                  :ARG2 (x14 / induce-01
                        :ARG2 (x15 / express-03
                              :ARG2 (x18 / and
                                    :op1 (x16 / enzyme
                                          :name (x17 / name :op1 "h-ras")
                                          :xref (x26 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601"))
                                    :op2 (x19 / enzyme
                                          :name (x20 / name :op1 "k-ras")
                                          :xref (x24 / xref :value "UNIPROT:Q92668_HUMAN" :prob "0.701"))
                                    :op2 (x22 / gene
                                          :name (x21 / name :op1 "Ras")
                                          :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))))))


# ::id PMC4329006.207
# ::snt Model illustrating the Ras→SAF-1/MAZ→VEGF signaling network axis.
# ::tok Model illustrating the Ras→SAF @-@ 1/MAZ→VEGF signaling network axis .
(x7 / network
      :ARG0 (x1 / model
            :ARG0-of (x2 / illustrate-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "Ras→SAF")))
            :name (x5 / name :op1 "1/MAZ→VEGF"))
      :ARG0-of (x6 / signal-07)
      :mod (x8 / axis))


# ::id PMC4329006.208
# ::snt Ras activates SAF-1/MAZ by Raf-MEK-ERK-MAPK pathway of phosphorylation.
# ::tok Ras activates SAF @-@ 1/MAZ by Raf @-@ MEK @-@ ERK @-@ MAPK pathway of phosphorylation .
(x3 / activate-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "Ras")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "1/MAZ"))
      :instrument (x8 / phosphorylate-01
            :ARG2 (x6 / pathway
                  :name (x7 / name :op1 "Raf-MEK-ERK-MAPK"))))


# ::id PMC4329006.209
# ::snt Activated SAF-1/MAZ promotes Ras expression by transcriptional induction of ras gene.
# ::tok Activated SAF @-@ 1/MAZ promotes Ras expression by transcriptional induction of ras gene .
(x4 / promote-01
      :ARG0 (x1 / activate-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "1/MAZ")))
      :ARG1 (x7 / express-03
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "Ras")
                  :xref (x13 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
            :ARG2 (x12 / gene
                  :ARG0-of (x8 / transcribe-01
                        :ARG1 (x9 / induce-01
                              :ARG2 (x10 / enzyme
                                    :name (x11 / name :op1 "Ras")
                                    :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))))))


# ::id PMC4329006.210
# ::snt The cyclical feed-forward regulation of SAF-1/MAZ and Ras promotes angiogenesis by promoting VEGF expression 14 , 27 .
# ::tok The cyclical feed @-@ forward regulation of SAF @-@ 1/MAZ and Ras promotes angiogenesis by promoting VEGF expression 14 , 27 .
(x10 / promote-01
      :ARG0 (x4 / regulate-01
            :ARG0-of (x3 / forward-01
                  :ARG1 (x2 / feed-01
                        :ARG1 (x1 / cyclical)))
            :ARG1 (x7 / and
                  :op1 (x5 / enzyme
                        :name (x6 / name :op1 "1/MAZ"))
                  :op2 (x8 / enzyme
                        :name (x9 / name :op1 "Ras")
                        :xref (x17 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))
      :ARG1 (x11 / angiogenesis)
      :manner (x12 / promote-01
            :ARG1 (x16 / and
                  :op1 (x15 / express-03
                        :ARG2 (x13 / protein
                              :name (x14 / name :op1 "VEGF")
                              :xref (x / xref :value "UNIPROT:VEGFA_HUMAN" :prob "1.003")))
                  :op1 "14"
                  :op2 "27")))


# ::id PMC4329006.239
# ::snt Conflict of Interest
# ::tok Conflict of Interest
(x1 / conflict-01
      :ARG2 (x2 / interest))


# ::id PMC4729484.0
# ::snt Phosphorylation and Activation of RhoA by ERK in Response to Epidermal Growth Factor Stimulation
# ::tok Phosphorylation and Activation of RhoA by ERK in Response to Epidermal Growth Factor Stimulation
(x1 / phosphorylate-01
      :ARG1 (x2 / and
            :op2 (x3 / activate-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "RhoA")
                        :xref (x12 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :ARG2-of (x8 / respond-01
                  :ARG1 (x11 / stimulate-01
                        :ARG0 (x9 / protein
                              :name (x10 / name
                                    :op1 "Epidermal"
                                    :op2 "growth"
                                    :op3 "factor"))))))


# ::id PMC4729484.2
# ::snt The small GTPase RhoA has been implicated in various cellular activities, including the formation of stress fibers, cell motility, and cytokinesis.
# ::tok The small GTPase RhoA has been implicated in various cellular activities , including the formation of stress fibers , cell motility , and cytokinesis .
(x5 / implicate-01
      :ARG0 (x1 / small-molecule
            :name (x2 / name :op1 "GTPase")
            :xref (x17 / xref :value "PUBCHEM:71464389" :prob "9.633067"))
      :ARG1 (x3 / protein
            :name (x4 / name :op1 "RhoA")
            :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :ARG2 (x8 / activity-06
            :mod (x7 / cell
                  :mod (x6 / various))
            :ARG2-of (x9 / include-01
                  :ARG1 (x15 / and
                        :op1 (x14 / motility
                              :ARG1 (x10 / form-01
                                    :ARG1 (x12 / fiber
                                          :mod (x11 / stress)))
                              :mod (x13 / cell))
                        :op2 (x16 / cytokinesis)))))


# ::id PMC4729484.3
# ::snt In addition to the canonical GTPase cycle, recent findings have suggested that phosphorylation further contributes to the tight regulation of Rho GTPases.
# ::tok In addition to the canonical GTPase cycle , recent findings have suggested that phosphorylation further contributes to the tight regulation of Rho GTPases .
(x1 / add-02
      :ARG2 (x4 / cycle-02
            :mod (x2 / canonical
                  :name (x3 / name :op1 "GTPase")))
      :ARG1 (x8 / suggest-01
            :ARG0 (x6 / thing
                  :time (x5 / recent)
                  :ARG1-of (x7 / find-01))
            :ARG1 (x11 / contribute-01
                  :ARG0 (x9 / phosphorylate-01)
                  :degree (x10 / further)
                  :ARG2 (x13 / regulate-01
                        :ARG1-of (x12 / tight-05)
                        :ARG1 (x14 / pathway
                              :name (x15 / name :op1 "Rho" :op2 "GTPase"))))))


# ::id PMC4729484.4
# ::snt Indeed, RhoA is phosphorylated on serine 188 ( 188 S) by a number of protein kinases.
# ::tok Indeed , RhoA is phosphorylated on serine 188 ( 188 S ) by a number of protein kinases .
(x4 / phosphorylate-01
      :mod (x1 / indeed)
      :ARG1 (x2 / protein
            :name (x3 / name :op1 "RhoA")
            :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :ARG1 (x5 / and
            :op1 (x6 / amino-acid
                  :mod "188"
                  :name (x7 / name :op1 "serine")
                  :xref (x13 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :op2 (x8 / small-molecule
                  :name (x9 / name :op1 "188" :op2 "S")))
      :ARG2 (x10 / number
            :quant-of (x11 / enzyme
                  :name (x12 / name :op1 "protein" :op2 "kinase"))))


# ::id PMC4729484.5
# ::snt We have recently reported that Rac1 is phosphorylated on threonine 108 ( 108 T) by extracellular signal-regulated kinases (ERK) in response to epidermal growth factor (EGF) stimulation.
# ::tok We have recently reported that Rac1 is phosphorylated on threonine 108 ( 108 T ) by extracellular signal @-@ regulated kinases ( ERK ) in response to epidermal growth factor ( EGF ) stimulation .
(x3 / report-01
      :ARG0 (x1 / we)
      :time (x2 / recent)
      :ARG1 (x6 / phosphorylate-01
            :ARG1 (x4 / protein
                  :name (x5 / name :op1 "Rac1")
                  :xref (x20 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
            :ARG1 (x7 / amino-acid
                  :mod "108"
                  :name (x8 / name :op1 "threonine")
                  :xref (x21 / xref :value "PUBCHEM:205" :prob "11.848252"))
            :ARG1-of (x9 / describe-01
                  :ARG0 (x10 / protein
                        :name (x11 / name :op1 "108" :op2 "T")))
            :ARG2 (x12 / and
                  :op1 (x13 / enzyme
                        :name (x14 / name
                              :op1 "extracellular"
                              :op2 "signal-regulated"
                              :op3 "kinase"))
                  :op2 (x15 / enzyme
                        :name (x16 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :ARG2-of (x17 / respond-01
                  :ARG1 (x18 / protein
                        :name (x19 / name
                              :op1 "epidermal"
                              :op2 "growth"
                              :op3 "factor"
                              :op4 "receptor")))))


# ::id PMC4729484.6
# ::snt Here, we provide evidence that RhoA is phosphorylated by ERK on 88 S and 100 T in response to EGF stimulation.
# ::tok Here , we provide evidence that RhoA is phosphorylated by ERK on 88 S and 100 T in response to EGF stimulation .
(x3 / provide-01
      :medium (x1 / here)
      :ARG0 (x2 / we)
      :ARG1 (x4 / evidence
            :topic (x13 / and
                  :op1 (x7 / phosphorylate-01
                        :ARG1 (x5 / protein
                              :name (x6 / name :op1 "RhoA")
                              :xref (x21 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                        :ARG2 (x8 / enzyme
                              :name (x9 / name :op1 "ERK")
                              :xref (x20 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                        :ARG1-of (x10 / describe-01
                              :ARG0 (x11 / publication
                                    :ARG1-of (x12 / cite-01 :ARG2 "88"))))
                  :op2 (x14 / protein
                        :name (x15 / name
                              :op1 "100"
                              :op2 "T"
                              :ARG2-of (x16 / respond-01
                                    :ARG1 (x19 / stimulate-01
                                          :ARG0 (x17 / protein
                                                :name (x18 / name :op1 "EGF")
                                                :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))))))


# ::id PMC4729484.7
# ::snt We show that ERK interacts with RhoA and that this interaction is dependent on the ERK docking site (D-site) at the C-terminus of RhoA.
# ::tok We show that ERK interacts with RhoA and that this interaction is dependent on the ERK docking site ( D @-@ site ) at the C @-@ terminus of RhoA .
(x2 / show-01
      :ARG0 (x1 / we)
      :ARG1 (x8 / and
            :op1 (x5 / interact-01
                  :ARG0 (x3 / enzyme
                        :name (x4 / name :op1 "ERK")
                        :xref (x22 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "RhoA")
                        :xref (x24 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :op2 (x11 / depend-01
                  :ARG0 (x10 / interact-01
                        :mod (x9 / this))
                  :ARG1 (x15 / site
                        :ARG0-of (x14 / dock-01
                              :ARG1 (x12 / enzyme
                                    :name (x13 / name :op1 "ERK")
                                    :xref (x23 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
                  :ARG1-of (x17 / protein-segment
                        :name (x16 / name :op1 "D"))))
      :location (x18 / protein-segment
            :name (x19 / name :op1 "C-terminus")
            :part-of (x20 / protein
                  :name (x21 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))


# ::id PMC4729484.8
# ::snt EGF stimulation enhanced the activation of the endogenous RhoA.
# ::tok EGF stimulation enhanced the activation of the endogenous RhoA .
(x4 / enhance-01
      :ARG0 (x3 / stimulate-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "EGF")
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :ARG1 (x5 / activate-01
            :ARG1 (x6 / enzyme
                  :mod (x7 / endogenous)
                  :name (x8 / name :op1 "RhoA")
                  :xref (x9 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))


# ::id PMC4729484.9
# ::snt The phosphomimetic mutant, GFP-RhoA S88E/T100E, when transiently expressed in COS-7 cells, displayed higher GTP-binding than wild type RhoA.
# ::tok The phosphomimetic mutant , GFP @-@ RhoA S88E/T100E , when transiently expressed in COS @-@ 7 cells , displayed higher GTP @-@ binding than wild type RhoA .
(x12 / display-01
      :ARG1 (x1 / enzyme
            :ARG2-of (x4 / mutate-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "phosphomimetic")
                        :xref (x21 / xref :value "UNIPROT:PHOP1_HUMAN" :prob "0.202"))
                  :ARG2 (x5 / protein
                        :name (x6 / name :op1 "GFP-RhoA")))
            :name (x7 / name :op1 "S88E/T100E"))
      :time (x9 / express-03
            :ARG1-of (x8 / transient-02)
            :ARG3 (x11 / cell-line
                  :name (x10 / name :op1 "COS-7")))
      :ARG1 (x13 / high-02
            :degree (x14 / more)
            :ARG1 (x17 / bind-01
                  :ARG2 (x15 / small-molecule
                        :name (x16 / name :op1 "GTP")
                        :xref (x22 / xref :value "PUBCHEM:6830" :prob "15.470645")))
            :compared-to (x18 / enzyme
                  :mod (x19 / wild-type)
                  :name (x20 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))


# ::id PMC4729484.10
# ::snt Moreover, the expression of GFP-RhoA S88E/T100E increased actin stress fiber formation in COS-7 cells, which is consistent with its higher activity.
# ::tok Moreover , the expression of GFP @-@ RhoA S88E @/@ T100E increased actin stress fiber formation in COS @-@ 7 cells , which is consistent with its higher activity .
(x1 / and
      :op2 (x10 / increase-01
            :ARG1 (x2 / express-03
                  :ARG2 (x3 / protein
                        :name (x4 / name :op1 "GFP-RhoA")))
            :ARG2 (x7 / slash
                  :op1 (x5 / enzyme
                        :name (x6 / name :op1 "S88E"))
                  :op2 (x8 / enzyme
                        :name (x9 / name :op1 "T100E")
                        :xref (x / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232")))
            :ARG1 (x15 / form-01
                  :ARG1 (x14 / fiber
                        :mod (x11 / protein
                              :name (x12 / name :op1 "actin")
                              :xref (x22 / xref :value "UNIPROT:KLH17_HUMAN" :prob "0.302"))
                        :mod (x13 / stress))
                  :location (x17 / cell-line
                        :name (x16 / name :op1 "COS-7")))
            :ARG1-of (x18 / consistent-01
                  :ARG2 (x21 / activity-06
                        :ARG1-of (x19 / high-02
                              :degree (x20 / more))))))


# ::id PMC4729484.11
# ::snt In contrast to Rac1, phosphorylation of RhoA by ERK does not target RhoA to the nucleus.
# ::tok In contrast to Rac1 , phosphorylation of RhoA by ERK does not target RhoA to the nucleus .
(x1 / contrast-01
      :ARG2 (x2 / protein
            :name (x3 / name :op1 "Rac1")
            :xref (x13 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
      :ARG1 (x9 / target-01
            :ARG0 (x4 / phosphorylate-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "RhoA")
                        :xref (x15 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :ARG2 (x7 / enzyme
                        :name (x8 / name :op1 "ERK")
                        :xref (x14 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :polarity "-"
            :ARG1 (x10 / protein
                  :name (x11 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG2 (x12 / nucleus
                  :xref (x16 / xref :value "GO:0005634" :prob "0.8"))))


# ::id PMC4729484.12
# ::snt Finally, we show that regardless of the phosphorylation status of RhoA and Rac1, substitution of the RhoA PBR with the Rac1 PBR targets RhoA to the nucleus and substitution of Rac1 PBR with RhoA PBR significantly reduces the nuclear localization of Rac1.
# ::tok Finally , we show that regardless of the phosphorylation status of RhoA and Rac1 , substitution of the RhoA PBR with the Rac1 PBR targets RhoA to the nucleus and substitution of Rac1 PBR with RhoA PBR significantly reduces the nuclear localization of Rac1 .
(x2 / show-01
      :li "-1"
      :ARG0 (x1 / we)
      :ARG1 (x29 / reduce-01
            :ARG1-of (x3 / regardless-91
                  :ARG2 (x22 / and
                        :op1 (x11 / substitute-01
                              :ARG1 (x4 / status
                                    :mod (x5 / phosphorylate-01
                                          :ARG1 (x8 / and
                                                :op1 (x6 / protein
                                                      :name (x7 / name :op1 "RhoA")
                                                      :xref (x34 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                                                :op2 (x9 / protein
                                                      :name (x10 / name :op1 "Rac1")
                                                      :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604")))))
                              :ARG1 (x12 / amino-acid
                                    :part-of (x13 / protein
                                          :name (x14 / name :op1 "RhoA")
                                          :xref (x37 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                                    :name (x15 / name :op1 "PBR")
                                    :xref (x40 / xref :value "PUBCHEM:11852" :prob "17.474375"))
                              :ARG3 (x18 / target-01
                                    :ARG0 (x16 / protein
                                          :name (x17 / name :op1 "Rac1" :op2 "PBR"))
                                    :ARG1 (x19 / protein
                                          :name (x20 / name :op1 "RhoA")
                                          :xref (x36 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
                              :ARG2 (x21 / nucleus
                                    :xref (x38 / xref :value "GO:0005634" :prob "0.8")))
                        :op2 (x23 / substitute-01
                              :ARG1 (x24 / protein
                                    :name (x25 / name :op1 "Rac1" :op2 "PBR"))
                              :ARG2 (x26 / protein
                                    :name (x27 / name :op1 "RhoA" :op2 "PBR")))))
            :ARG2 (x28 / significant-02)
            :ARG1 (x31 / localize-01
                  :ARG1 (x30 / nucleus
                        :xref (x39 / xref :value "GO:0005634" :prob "0.8")))
            :ARG1 (x32 / protein
                  :name (x33 / name :op1 "Rac1")
                  :xref (x35 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))))


# ::id PMC4729484.13
# ::snt In conclusion, ERK phosphorylates RhoA on 88 S and 100 T in response to EGF, which upregulates RhoA activity.
# ::tok In conclusion , ERK phosphorylates RhoA on 88 S and 100 T in response to EGF , which upregulates RhoA activity .
(x1 / conclude-02
      :ARG1 (x4 / phosphorylate-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "ERK")
                  :xref (x19 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "RhoA")
                  :xref (x21 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG2 (x9 / and
                  :op1 (x7 / temporal-quantity
                        :quant "88"
                        :unit (x8 / year))
                  :op2 (x10 / enzyme
                        :name (x11 / name :op1 "100" :op2 "T")))
            :ARG2-of (x12 / respond-01
                  :ARG1 (x13 / protein
                        :name (x14 / name :op1 "EGF")
                        :ARG0-of (x15 / upregulate-01
                              :ARG1 (x18 / activity-06
                                    :ARG0 (x16 / protein
                                          :name (x17 / name :op1 "RhoA")
                                          :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
                        :xref (x20 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC4729484.44
# ::snt Cell culture and treatment
# ::tok Cell culture and treatment
(x3 / and
      :op1 (x2 / culture
            :mod (x1 / cell))
      :op2 (x4 / treat-04))


# ::id PMC4729484.55
# ::snt Antibodies and chemicals
# ::tok Antibodies and chemicals
(x2 / and
      :op1 (x1 / antibody)
      :op2 (x3 / chemical))


# ::id PMC4729484.74
# ::snt Expression and purification of GST-fusion proteins
# ::tok Expression and purification of GST @-@ fusion proteins
(x1 / and
      :op1 (x2 / express-03
            :ARG2 (x5 / protein
                  :mod (x3 / protein
                        :name (x4 / name :op1 "GST-fusion"))))
      :op2 (x6 / purify-01))


# ::id PMC4729484.79
# ::snt GST pull-down assay
# ::tok GST pull @-@ down assay
(x3 / assay-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "GST")
            :xref (x / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))


# ::id PMC4729484.86
# ::snt RhoA activation assay
# ::tok RhoA activation assay
(x4 / assay-01
      :ARG1 (x3 / activate-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))


# ::id PMC4729484.95
# ::snt In vitro ERK kinase assay
# ::tok In vitro ERK kinase assay
(x4 / assay-01
      :manner (x1 / in-vitro)
      :ARG1 (x2 / enzyme
            :name (x3 / name :op1 "ERK" :op2 "kinase")))


# ::id PMC4729484.128
# ::snt Subcellular localization of proteins by fluorescence microscopy
# ::tok Subcellular localization of proteins by fluorescence microscopy
(x2 / localize-01
      :mod (x1 / subcellular)
      :ARG1 (x3 / protein)
      :ARG0 (x5 / microscopy
            :mod (x4 / fluoresce-01)))


# ::id PMC4729484.138
# ::snt Immunofluorescence staining for stress fibers
# ::tok Immunofluorescence staining for stress fibers
(x2 / stain-01
      :ARG2 (x1 / immunofluoresce-01)
      :ARG1 (x4 / fiber
            :mod (x3 / stress)))


# ::id PMC4729484.152
# ::snt The direct interaction between RhoA and ERK is mediated by the ERK docking site in the C-terminus of RhoA
# ::tok The direct interaction between RhoA and ERK is mediated by the ERK docking site in the C @-@ terminus of RhoA
(x8 / mediate-01
      :ARG1 (x5 / and
            :op1 (x2 / interact-01
                  :ARG1-of (x1 / direct-02)
                  :ARG0 (x3 / protein
                        :name (x4 / name :op1 "RhoA")
                        :xref (x18 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :op2 (x6 / enzyme
                  :name (x7 / name :op1 "ERK")
                  :xref (x19 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
      :ARG0 (x9 / enzyme
            :name (x10 / name :op1 "ERK")
            :xref (x17 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
      :ARG1 (x12 / site
            :ARG0-of (x11 / dock-01))
      :location (x13 / protein-segment
            :name (x14 / name :op1 "C-terminus")
            :part-of (x15 / protein
                  :name (x16 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))


# ::id PMC4729484.153
# ::snt We have shown previously that Rac1 is directly associated with ERK, but in an EGF-independent manner [ 21 ].
# ::tok We have shown previously that Rac1 is directly associated with ERK , but in an EGF @-@ independent manner [ 21 ] .
(x10 / contrast-01
      :ARG1 (x2 / show-01
            :ARG0 (x1 / we)
            :time (x3 / previous)
            :ARG1 (x7 / associate-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "Rac1")
                        :xref (x19 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
                  :ARG1-of (x6 / direct-02)
                  :ARG2 (x8 / enzyme
                        :name (x9 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
      :ARG2 (x14 / manner
            :ARG0-of (x13 / depend-01
                  :ARG1 (x11 / protein
                        :name (x12 / name :op1 "EGF")
                        :xref (x18 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :polarity "-")
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / publication
                        :ARG1-of (x17 / cite-01 :ARG2 "21")))))


# ::id PMC4729484.154
# ::snt In this study, we first examined whether RhoA also interacts with ERK.
# ::tok In this study , we first examined whether RhoA also interacts with ERK .
(x4 / examine-01
      :medium (x2 / study-01
            :mod (x1 / this))
      :ARG0 (x3 / we)
      :ARG1 (x7 / interact-01
            :mode "interrogative"
            :ARG0 (x5 / protein
                  :name (x6 / name :op1 "RhoA")
                  :xref (x10 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG1 (x8 / enzyme
                  :name (x9 / name :op1 "ERK")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))


# ::id PMC4729484.155
# ::snt We expressed GFP-RhoA in COS-7 cells by transient transfection.
# ::tok We expressed GFP @-@ RhoA in COS @-@ 7 cells by transient transfection .
(x2 / express-03
      :ARG0 (x1 / we)
      :ARG2 (x3 / protein
            :name (x4 / name :op1 "GFP-RhoA"))
      :location (x6 / cell-line
            :name (x5 / name :op1 "COS-7"))
      :manner (x8 / transfect-01
            :ARG1-of (x7 / transient-02)))


# ::id PMC4729484.157
# ::snt As shown in Fig 1 , ERK was co-IPed with GFP-RhoA with or without EGF stimulation.
# ::tok As shown in Fig 1 , ERK was co @-@ IPed with GFP @-@ RhoA with or without EGF stimulation .
(x5 / be-located-at-91
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "1"))
      :ARG0 (x3 / enzyme
            :name (x4 / name :op1 "ERK")
            :xref (x19 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
      :ARG2 (x8 / and
            :op1 (x6 / enzyme
                  :name (x7 / name :op1 "IPed"))
            :op2 (x9 / protein
                  :name (x10 / name :op1 "GFP")
                  :xref (x17 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
      :ARG1 (x11 / protein
            :name (x12 / name :op1 "RhoA")
            :xref (x18 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :ARG2 (x13 / or
            :op1 (x16 / stimulate-01
                  :polarity "-"
                  :ARG1 (x14 / protein
                        :name (x15 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC4729484.158
# ::snt However, the association of RhoA with p-ERK was much stronger following EGF stimulation, which could be due to the increase of p-ERK in response to EGF ( Fig 1A ).
# ::tok However , the association of RhoA with p @-@ ERK was much stronger following EGF stimulation , which could be due to the increase of p @-@ ERK in response to EGF ( Fig 1A ) .
(x1 / contrast-01
      :ARG2 (x10 / strong-02
            :ARG1 (x2 / associate-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "RhoA")
                        :xref (x26 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :ARG2 (x5 / enzyme
                        :ARG3-of (x6 / phosphorylate-01)
                        :name (x7 / name :op1 "ERK")
                        :xref (x27 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :degree (x8 / more
                  :degree (x9 / much)))
      :ARG1-of (x11 / follow-01
            :ARG2 (x14 / stimulate-01
                  :ARG2 (x12 / protein
                        :name (x13 / name :op1 "EGF")
                        :xref (x29 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
      :ARG1-of (x16 / cause-01
            :ARG1-of (x15 / possible-01)
            :ARG0 (x17 / increase-01
                  :ARG1 (x18 / enzyme
                        :ARG3-of (x19 / phosphorylate-01)
                        :name (x20 / name :op1 "ERK")
                        :xref (x28 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG2-of (x21 / respond-01
                        :ARG1 (x22 / protein
                              :name (x23 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :ARG1-of (x24 / describe-01
            :ARG0 (x25 / figure :mod "1a")))


# ::id PMC4729484.159
# ::snt We further examined the interaction between RhoA and ERK by GST pull-down assay ( Fig 1B ).
# ::tok We further examined the interaction between RhoA and ERK by GST pull @-@ down assay ( Fig 1B ) .
(x3 / examine-01
      :ARG0 (x1 / we)
      :degree (x2 / further)
      :ARG1 (x4 / interact-01
            :ARG0 (x5 / protein
                  :name (x6 / name :op1 "RhoA")
                  :xref (x15 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG1 (x7 / enzyme
                  :name (x8 / name :op1 "ERK")
                  :xref (x14 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
      :ARG0 (x11 / assay-01
            :ARG1 (x9 / enzyme
                  :name (x10 / name :op1 "GST")
                  :xref (x / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / figure :mod "1b")))


# ::id PMC4729484.160
# ::snt Total cell lysates from COS-7 cells, either treated with EGF or not treated, were incubated with GST-RhoA.
# ::tok Total cell lysates from COS @-@ 7 cells , either treated with EGF or not treated , were incubated with GST @-@ RhoA .
(x12 / incubate-01
      :ARG1 (x6 / or
            :op1 (x3 / lysate
                  :mod (x1 / total)
                  :mod (x2 / cell)
                  :source (x5 / cell-line
                        :name (x4 / name :op1 "COS-7")))
            :op2 (x7 / treat-04
                  :ARG2 (x10 / or
                        :op1 (x8 / protein
                              :name (x9 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                        :op2 (x11 / treat-04 :polarity "-"))))
      :ARG2 (x13 / protein
            :name (x14 / name :op1 "GST-RhoA")))


# ::id PMC4729484.161
# ::snt ERK was associated with GST-RhoA with or without EGF stimulation; however, the association between p-ERK and GST-RhoA was only observed following EGF stimulation ( Fig 1B ).
# ::tok ERK was associated with GST @-@ RhoA with or without EGF stimulation ; however , the association between p @-@ ERK and GST @-@ RhoA was only observed following EGF stimulation ( Fig 1B ) .
(x10 / contrast-01
      :ARG1 (x3 / associate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "ERK")
                  :xref (x25 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :ARG2 (x4 / protein
                  :name (x5 / name :op1 "GST-RhoA"))
            :ARG2 (x6 / or
                  :op2 (x9 / stimulate-01
                        :polarity "-"
                        :ARG1 (x7 / protein
                              :name (x8 / name :op1 "EGF")
                              :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :ARG2 (x18 / observe-01
            :ARG1 (x11 / associate-01
                  :ARG1 (x12 / enzyme
                        :ARG3-of (x13 / phosphorylate-01)
                        :name (x14 / name :op1 "ERK")
                        :xref (x27 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG2 (x15 / protein
                        :name (x16 / name :op1 "GST-RhoA")))
            :mod (x17 / only)
            :ARG1-of (x19 / follow-01
                  :ARG2 (x22 / stimulate-01
                        :ARG1 (x20 / protein
                              :name (x21 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
            :ARG1-of (x23 / describe-01
                  :ARG0 (x24 / figure :mod "1b"))))


# ::id PMC4729484.162
# ::snt As a control, we showed that there is no association between ERK or p-ERK and GST ( Fig 1B ).
# ::tok As a control , we showed that there is no association between ERK or p @-@ ERK and GST ( Fig 1B ) .
(x3 / show-01
      :ARG1-of (x1 / control-01)
      :ARG0 (x2 / we)
      :ARG1 (x4 / exist-01
            :polarity "-"
            :ARG1 (x5 / associate-01
                  :ARG1 (x8 / or
                        :op1 (x6 / enzyme
                              :name (x7 / name :op1 "ERK")
                              :xref (x17 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                        :op2 (x9 / enzyme
                              :ARG3-of (x10 / phosphorylate-01)
                              :name (x11 / name :op1 "ERK")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                  :ARG2 (x12 / enzyme
                        :name (x13 / name :op1 "GST")
                        :xref (x16 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))))
      :ARG1-of (x14 / describe-01
            :ARG0 (x15 / figure :mod "1b")))


# ::id PMC4729484.163
# ::snt Interaction between RhoA and ERK is mediated by the RhoA D-site.
# ::tok Interaction between RhoA and ERK is mediated by the RhoA D @-@ site .
(x6 / mediate-01
      :ARG1 (x1 / interact-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "ERK")
                  :xref (x9 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
      :ARG0 (x8 / protein-segment
            :name (x7 / name :op1 "RhoA" :op2 "D")))


# ::id PMC4729484.164
# ::snt COS-7 cells expressing GFP-RhoA were stimulated with EGF as indicated.
# ::tok COS @-@ 7 cells expressing GFP @-@ RhoA were stimulated with EGF as indicated .
(x6 / stimulate-01
      :ARG1 (x2 / cell-line
            :name (x1 / name :op1 "COS-7")
            :ARG3-of (x3 / express-03
                  :ARG2 (x4 / protein
                        :name (x5 / name :op1 "GFP-RhoA"))))
      :ARG2 (x7 / protein
            :name (x8 / name :op1 "EGF")
            :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :ARG1-of (x9 / indicate-01))


# ::id PMC4729484.165
# ::snt GFP-RhoA was IPed from cell lysates with antibodies to GFP, and the co-IPed ERK and phosphor ERK (p-ERK) were analyzed by immunoblotting with antibodies to ERK and p-ERK.
# ::tok GFP @-@ RhoA was IPed from cell lysates with antibodies to GFP , and the co @-@ IPed ERK and phosphor ERK ( p @-@ ERK ) were analyzed by immunoblotting with antibodies to ERK and p @-@ ERK .
(x23 / analyze-01
      :ARG1 (x6 / lysate
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "GFP-RhoA"))
            :mod (x3 / cell
                  :name (x4 / name :op1 "IPed")
                  :source (x5 / cell))
            :ARG2 (x7 / antibody
                  :ARG0-of (x8 / counter-01
                        :ARG1 (x11 / and
                              :op1 (x9 / protein
                                    :name (x10 / name :op1 "GFP")
                                    :xref (x34 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))
                              :op2 (x12 / cotransfect-01
                                    :ARG2 (x15 / and
                                          :op1 (x13 / enzyme
                                                :name (x14 / name :op1 "ERK")
                                                :xref (x36 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                                          :op2 (x16 / enzyme
                                                :ARG3-of (x17 / phosphorylate-01)
                                                :name (x18 / name :op1 "ERK")
                                                :xref (x37 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))))
                  :ARG1-of (x19 / mean-01
                        :ARG2 (x20 / enzyme
                              :ARG3-of (x21 / phosphorylate-01)
                              :name (x22 / name :op1 "ERK")
                              :xref (x33 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))
      :manner (x24 / immunoblot-01
            :ARG3 (x25 / antibody
                  :ARG0-of (x26 / counter-01
                        :ARG1 (x29 / and
                              :op1 (x27 / enzyme
                                    :name (x28 / name :op1 "ERK")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                              :op2 (x30 / enzyme
                                    :ARG3-of (x31 / phosphorylate-01)
                                    :name (x32 / name :op1 "ERK")
                                    :xref (x35 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))))


# ::id PMC4729484.166
# ::snt Lysates of COS-7 cells, with or without EGF stimulation, were incubated with GST-RhoA or GST bound to glutathione sepharose beads.
# ::tok Lysates of COS @-@ 7 cells , with or without EGF stimulation , were incubated with GST @-@ RhoA or GST bound to glutathione sepharose beads .
(x1 / and
      :op1 (x2 / lysate
            :mod (x4 / cell-line
                  :name (x3 / name :op1 "COS-7")))
      :op2 (x9 / incubate-01
            :ARG1 (x5 / or
                  :op1 (x8 / stimulate-01
                        :polarity "-"
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "EGF")
                              :xref (x20 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
            :ARG2 (x14 / or
                  :op1 (x10 / protein
                        :name (x11 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :op2 (x12 / enzyme
                        :name (x13 / name :op1 "GST")
                        :xref (x19 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))
                  :mod (x15 / bind-01
                        :ARG2 (x18 / bead
                              :mod (x16 / enzyme
                                    :name (x17 / name :op1 "glutathione" :op2 "sepharose")))))))


# ::id PMC4729484.167
# ::snt The sepharose beads were collected, washed and analyzed by immunoblotting with antibodies against p-ERK and ERK.
# ::tok The sepharose beads were collected , washed and analyzed by immunoblotting with antibodies against p @-@ ERK and ERK .
(x5 / and
      :op1 (x3 / collect-01
            :ARG1 (x2 / bead
                  :name (x1 / name :op1 "sepharose"))
            :ARG1-of (x4 / complete-02))
      :op2 (x6 / analyze-01
            :manner (x7 / immunoblot-01
                  :ARG3 (x8 / antibody
                        :ARG0-of (x9 / counter-01
                              :ARG1 (x13 / and
                                    :op1 (x10 / enzyme
                                          :ARG3-of (x11 / phosphorylate-01)
                                          :name (x12 / name :op1 "ERK")
                                          :xref (x16 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                                    :op2 (x14 / enzyme
                                          :name (x15 / name :op1 "ERK")
                                          :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))))))


# ::id PMC4729484.168
# ::snt GST/GST-RhoA fusion protein loading was verified by Amido Black staining of the nitrocellulose membrane.
# ::tok GST @/@ GST @-@ RhoA fusion protein loading was verified by Amido Black staining of the nitrocellulose membrane .
(x9 / stain-01
      :ARG0 (x4 / protein
            :ARG1-of (x3 / fuse-01
                  :ARG2 (x1 / protein
                        :name (x2 / name :op1 "GST/GST-RhoA"))))
      :ARG1-of (x6 / verify-01
            :ARG1 (x5 / load-01)
            :manner (x8 / black-04
                  :name (x7 / name :op1 "Amido")))
      :ARG2 (x11 / membrane
            :mod (x10 / nitrocellulose)
            :xref (x / xref :value "GO:0016020" :prob "0.8")))


# ::id PMC4729484.169
# ::snt Cells were lysed and the expression levels of RhoA were determined by immunoblotting with anti-RhoA antibody.
# ::tok Cells were lysed and the expression levels of RhoA were determined by immunoblotting with anti @-@ RhoA antibody .
(x7 / determine-01
      :ARG0 (x1 / cell)
      :ARG1 (x2 / and
            :op1 (x3 / level
                  :degree-of (x4 / express-03
                        :ARG2 (x5 / protein
                              :name (x6 / name :op1 "RhoA")
                              :xref (x13 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))))
      :ARG2 (x8 / immunoblot-01
            :ARG3 (x12 / antibody
                  :ARG0-of (x9 / counter-01
                        :ARG1 (x10 / protein
                              :name (x11 / name :op1 "RhoA")
                              :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))))


# ::id PMC4729484.171
# ::snt Endogenous RhoA was IPed from lysates of COS-7 and SKBR3 cells by anti-RhoA antibody, and the co-IP of endogenous ERK was determined by immunoblotting with antibodies to ERK.
# ::tok Endogenous RhoA was IPed from lysates of COS @-@ 7 and SKBR3 cells by anti @-@ RhoA antibody , and the co @-@ IP of endogenous ERK was determined by immunoblotting with antibodies to ERK .
(x20 / determine-01
      :ARG1 (x1 / enzyme
            :mod (x2 / endogenous)
            :name (x3 / name :op1 "IPed")
            :source (x4 / lysate
                  :ARG2 (x7 / and
                        :op1 (x5 / cell-line
                              :name (x6 / name :op1 "COS")
                              :mod "7")
                        :op2 (x9 / cell-line
                              :name (x8 / name :op1 "SKBR3")))
                  :ARG0 (x14 / and
                        :op1 (x13 / antibody
                              :ARG0-of (x10 / counter-01
                                    :ARG1 (x11 / protein
                                          :name (x12 / name :op1 "RhoA")
                                          :xref (x26 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
                        :op2 (x15 / enzyme
                              :name (x16 / name :op1 "IP")
                              :xref (x27 / xref :value "UNIPROT:SDHB_HUMAN" :prob "0.602"))
                        :quant-of (x17 / enzyme
                              :mod (x18 / endogenous)
                              :name (x19 / name :op1 "ERK")
                              :xref (x28 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))
      :ARG2 (x21 / immunoblot-01
            :ARG3 (x22 / antibody
                  :ARG0-of (x23 / oppose-01
                        :ARG1 (x24 / enzyme
                              :name (x25 / name :op1 "ERK")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))))


# ::id PMC4729484.173
# ::snt Lysates of COS-7 cells (with or without EGF stimulation) were incubated with GST-RhoA or mutant GST-RhoA with its D-site deleted (GST-RhoAΔD) bound to glutathione agarose beads.
# ::tok Lysates of COS @-@ 7 cells ( with or without EGF stimulation ) were incubated with GST @-@ RhoA or mutant GST @-@ RhoA with its D @-@ site deleted ( GST @-@ RhoAΔD ) bound to glutathione agarose beads .
(x1 / and
      :op1 (x9 / incubate-01
            :ARG1 (x2 / lysate
                  :mod (x4 / cell-line
                        :name (x3 / name :op1 "COS-7")
                        :ARG1-of (x5 / or
                              :op2 (x8 / stimulate-01
                                    :polarity "-"
                                    :ARG1 (x6 / protein
                                          :name (x7 / name :op1 "EGF")
                                          :xref (x24 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))
            :ARG2 (x12 / or
                  :op1 (x10 / protein
                        :name (x11 / name :op1 "GST-RhoA"))
                  :op2 (x13 / mutate-01
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "GST-RhoA"))
                        :ARG2 (x16 / enzyme
                              :name (x17 / name :op1 "D")
                              :ARG1-of (x21 / bind-01
                                    :ARG0 (x18 / delete-01
                                          :ARG1 (x19 / protein-segment
                                                :name (x20 / name :op1 "GST" :op2 "RhoAΔD")))
                                    :ARG2 (x22 / protein
                                          :name (x23 / name :op1 "glutathione")
                                          :xref (x / xref :value "UNIPROT:GSHB_HUMAN" :prob "0.333"))))))))


# ::id PMC4729484.174
# ::snt The sepharose beads were then collected, washed and analyzed by immunoblotting with antibodies against p-ERK and ERK.
# ::tok The sepharose beads were then collected , washed and analyzed by immunoblotting with antibodies against p @-@ ERK and ERK .
(x6 / and
      :op1 (x4 / collect-01
            :ARG1 (x2 / bead
                  :name (x1 / name :op1 "sepharose"))
            :time (x3 / then)
            :ARG1-of (x5 / complete-02))
      :op2 (x7 / analyze-01
            :manner (x8 / immunoblot-01
                  :ARG3 (x9 / antibody
                        :ARG0-of (x10 / counter-01
                              :ARG1 (x14 / and
                                    :op1 (x11 / enzyme
                                          :ARG3-of (x12 / phosphorylate-01)
                                          :name (x13 / name :op1 "ERK")
                                          :xref (x17 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                                    :op2 (x15 / enzyme
                                          :name (x16 / name :op1 "ERK")
                                          :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))))))


# ::id PMC4729484.175
# ::snt GST/GST fusion protein loading was verified by Amido Black stain of the nitrocellulose membrane.
# ::tok GST @/@ GST fusion protein loading was verified by Amido Black stain of the nitrocellulose membrane .
(x10 / stain-01
      :ARG1 (x7 / verify-01
            :ARG1 (x6 / load-01
                  :ARG2 (x1 / and
                        :op1 (x2 / enzyme
                              :name (x3 / name :op1 "GST")
                              :xref (x / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))
                        :op2 (x5 / protein
                              :name (x4 / name :op1 "GST" :op2 "fusion"))))
            :manner (x9 / black-04
                  :name (x8 / name :op1 "Amido")))
      :ARG2 (x12 / membrane
            :mod (x11 / nitrocellulose)
            :xref (x13 / xref :value "GO:0016020" :prob "0.8")))


# ::id PMC4729484.176
# ::snt We next examined whether endogenous RhoA and ERK interact with each other and whether this association also exists in breast cancer cell lines.
# ::tok We next examined whether endogenous RhoA and ERK interact with each other and whether this association also exists in breast cancer cell lines .
(x3 / examine-01
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x10 / interact-01
            :mode "interrogative"
            :ARG0 (x7 / and
                  :op1 (x4 / enzyme
                        :mod (x5 / endogenous)
                        :name (x6 / name :op1 "RhoA")
                        :xref (x21 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :op2 (x8 / enzyme
                        :name (x9 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :ARG1 (x13 / and
                  :op1 (x12 / other
                        :mod (x11 / each))
                  :op2 (x17 / exist-01
                        :mode "interrogative"
                        :ARG0 (x15 / associate-01
                              :mod (x14 / this))
                        :mod (x16 / also))))
      :location (x20 / cell-line
            :mod (x18 / disease
                  :wiki "breast_cancer"
                  :name (x19 / name :op1 "breast" :op2 "cancer"))))


# ::id PMC4729484.177
# ::snt We examined the expression level of RhoA in COS-7 cells and various breast cancer cells including BT-20, MCF-7, MDA-MB-453, and SKBR-3 cells.
# ::tok We examined the expression level of RhoA in COS @-@ 7 cells and various breast cancer cells including BT @-@ 20 , MCF @-@ 7 , MDA @-@ MB @-@ 453 , and SKBR @-@ 3 cells .
(x20 / and
      :op1 (x2 / examine-01
            :ARG0 (x1 / we)
            :ARG1 (x3 / level
                  :degree-of (x4 / express-03
                        :ARG2 (x5 / protein
                              :name (x6 / name :op1 "RhoA")
                              :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
                  :location (x8 / cell-line
                        :name (x7 / name :op1 "COS-7")))
            :ARG1 (x9 / and
                  :op2 (x13 / cell
                        :mod (x10 / various)
                        :mod (x11 / disease
                              :wiki "breast_cancer"
                              :name (x12 / name :op1 "breast" :op2 "cancer"))
                        :ARG2-of (x14 / include-01
                              :ARG1 (x15 / amino-acid
                                    :name (x16 / name :op1 "BT")
                                    :mod "20"
                                    :name (x17 / name :op1 "MCF-7")
                                    :xref (x23 / xref :value "PUBCHEM:7222" :prob "14.996436"))))
                  :op3 (x18 / cell-line
                        :name (x19 / name :op1 "MDA-MB-453"))))
      :op2 (x22 / cell-line
            :name (x21 / name :op1 "SKBR")
            :mod "3"))


# ::id PMC4729484.178
# ::snt As shown in Fig 1C , RhoA was well expressed in all of these cells.
# ::tok As shown in Fig 1C , RhoA was well expressed in all of these cells .
(x6 / express-03
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "1c"))
      :ARG1 (x3 / protein
            :name (x4 / name :op1 "RhoA")
            :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :degree (x5 / well)
      :location (x9 / cell
            :mod (x7 / all)
            :mod (x8 / this)))


# ::id PMC4729484.179
# ::snt Except for MCF-7 cells, the expression level of RhoA was notably higher in the rest of the breast cancer cells than in COS-7 cells, with highest expression level in SKBR-3 cells ( Fig 1C ).
# ::tok Except for MCF @-@ 7 cells , the expression level of RhoA was notably higher in the rest of the breast cancer cells than in COS @-@ 7 cells , with highest expression level in SKBR @-@ 3 cells ( Fig 1C ) .
(x1 / except-01
      :ARG1 (x3 / cell-line
            :name (x2 / name :op1 "MCF-7"))
      :ARG2 (x9 / high-02
            :ARG1 (x4 / level
                  :degree-of (x5 / express-03
                        :ARG2 (x6 / protein
                              :name (x7 / name :op1 "RhoA")
                              :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
            :ARG1-of (x8 / notable-04)
            :degree (x10 / more)
            :location (x11 / rest
                  :part-of (x14 / cell
                        :mod (x12 / disease
                              :wiki "breast_cancer"
                              :name (x13 / name :op1 "breast" :op2 "cancer"))))
            :compared-to (x16 / cell-line
                  :name (x15 / name :op1 "COS-7"))
            :ARG2 (x19 / level
                  :ARG1-of (x17 / high-02
                        :degree (x18 / most))
                  :degree-of (x20 / express-03
                        :ARG2 (x21 / amino-acid
                              :name (x22 / name :op1 "SKBR")
                              :mod "3"))))
      :ARG1-of (x23 / describe-01
            :ARG0 (x24 / figure :mod "1c")))


# ::id PMC4729484.180
# ::snt The interaction between endogenous RhoA and ERK was examined by co-IP experiments in COS-7 and SKBR-3 cells ( Fig 1D ).
# ::tok The interaction between endogenous RhoA and ERK was examined by co @-@ IP experiments in COS @-@ 7 and SKBR @-@ 3 cells ( Fig 1D ) .
(x7 / examine-01
      :ARG1 (x1 / interact-01
            :ARG0 (x2 / enzyme
                  :mod (x3 / endogenous)
                  :name (x4 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "ERK")
                  :xref (x18 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
      :ARG0 (x10 / experiment-01
            :ARG0 (x8 / person
                  :name (x9 / name :op1 "IP"))
            :ARG2 (x11 / and
                  :op1 (x13 / cell-line
                        :name (x12 / name :op1 "COS-7"))
                  :op2 (x14 / amino-acid
                        :name (x15 / name :op1 "SKBR")
                        :mod "3"))
            :ARG1-of (x16 / describe-01
                  :ARG0 (x17 / figure :mod "1d"))))


# ::id PMC4729484.182
# ::snt We showed that ERK co-IPed with endogenous RhoA with or without EGF stimulation in both COS-7 and SKBR-3 cells ( Fig 1D ).
# ::tok We showed that ERK co @-@ IPed with endogenous RhoA with or without EGF stimulation in both COS @-@ 7 and SKBR @-@ 3 cells ( Fig 1D ) .
(x2 / show-01
      :ARG0 (x1 / we)
      :ARG1 (x7 / treat-04
            :ARG0 (x3 / enzyme
                  :name (x4 / name :op1 "ERK")
                  :xref (x22 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "IPed"))
            :ARG1 (x8 / enzyme
                  :mod (x9 / endogenous)
                  :name (x10 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG2 (x11 / or
                  :op2 (x14 / stimulate-01
                        :ARG0 (x12 / protein
                              :name (x13 / name :op1 "EGF")
                              :xref (x23 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                        :location (x15 / and
                              :op1 (x16 / cell-line
                                    :name (x17 / name :op1 "COS")
                                    :mod "7")
                              :op2 (x19 / cell-line
                                    :name (x18 / name :op1 "SKBR")
                                    :mod "3")))
                  :ARG1-of (x20 / describe-01
                        :ARG0 (x21 / figure :mod "1d")))))


# ::id PMC4729484.183
# ::snt It has been well established that the substrate selectivity of ERK is dependent on ERK-docking sites (D-sites) [ 22 , 23 ].
# ::tok It has been well established that the substrate selectivity of ERK is dependent on ERK @-@ docking sites ( D @-@ sites ) [ 22 , 23 ] .
(x3 / establish-01
      :ARG1 (x1 / it)
      :mod (x2 / well)
      :ARG1 (x4 / substrate
            :ARG0-of (x5 / select-01
                  :ARG1 (x8 / depend-01
                        :ARG0 (x6 / enzyme
                              :name (x7 / name :op1 "ERK")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                        :ARG1 (x9 / and
                              :op1 (x12 / protein-segment
                                    :name (x10 / name :op1 "ERK")
                                    :ARG2-of (x11 / dock-01))
                              :op2 (x14 / protein-segment
                                    :name (x13 / name :op1 "D")))))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / publication
                        :ARG1-of (x17 / cite-01
                              :ARG2 (x18 / and :op1 "22" :op2 "23"))))))


# ::id PMC4729484.184
# ::snt The amino acid sequence analysis indicates that RhoA contains a putative ERK D-site 185 KKKSGCLLL 193 in its C-terminus.
# ::tok The amino acid sequence analysis indicates that RhoA contains a putative ERK D @-@ site 185 KKKSGCLLL 193 in its C @-@ terminus .
(x4 / indicate-01
      :ARG0 (x3 / analyze-01
            :mod (x2 / dna-sequence
                  :mod (x1 / amino-acid)))
      :ARG1 (x7 / contain-01
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG1 (x8 / amino-acid
                  :part-of (x10 / protein-segment
                        :name (x9 / name :op1 "ERK" :op2 "D"))
                  :mod "185"
                  :name (x11 / name :op1 "KKKSGCLLL")
                  :mod "193")
            :location (x12 / protein-segment
                  :name (x13 / name :op1 "C-terminus"))))


# ::id PMC4729484.185
# ::snt We examined whether the interaction between RhoA and ERK is mediated by this putative RhoA D-site.
# ::tok We examined whether the interaction between RhoA and ERK is mediated by this putative RhoA D @-@ site .
(x2 / examine-01
      :ARG0 (x1 / we)
      :ARG1 (x8 / mediate-01
            :mode "interrogative"
            :ARG1 (x3 / interact-01
                  :ARG0 (x4 / protein
                        :name (x5 / name :op1 "RhoA")
                        :xref (x13 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :ARG0 (x10 / think-01
                  :ARG0 (x9 / this)
                  :ARG1 (x12 / protein-segment
                        :name (x11 / name :op1 "RhoA" :op2 "D")))))


# ::id PMC4729484.186
# ::snt We constructed a GST fusion RhoA mutant with the deletion of its putative D-site (GST-RhoAΔD) and examined its interaction with ERK by GST pull-down assay ( Fig 1E ).
# ::tok We constructed a GST fusion RhoA mutant with the deletion of its putative D @-@ site ( GST @-@ RhoAΔD ) and examined its interaction with ERK by GST pull @-@ down assay ( Fig 1E ) .
(x16 / examine-01
      :ARG0 (x1 / we)
      :mod (x2 / construct-01
            :ARG1 (x3 / enzyme
                  :name (x4 / name :op1 "GST")
                  :ARG1-of (x5 / fuse-01)
                  :name (x6 / name :op1 "RhoA")
                  :ARG2-of (x7 / mutate-01)
                  :xref (x26 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG2 (x15 / and
                  :op1 (x8 / delete-01
                        :ARG1 (x9 / amino-acid
                              :part-of (x11 / protein-segment
                                    :name (x10 / name :op1 "D"))
                              :name (x12 / name :op1 "GST")
                              :xref (x25 / xref :value "PUBCHEM:5288476" :prob "18.572987")))
                  :op2 (x13 / cell-line
                        :name (x14 / name :op1 "RhoAΔD"))))
      :ARG1 (x17 / interact-01
            :ARG1 (x18 / enzyme
                  :name (x19 / name :op1 "ERK")
                  :xref (x27 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :manner (x22 / assay-01
                  :ARG1 (x20 / enzyme
                        :name (x21 / name :op1 "GST")
                        :xref (x / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))))
      :ARG1-of (x23 / describe-01
            :ARG0 (x24 / figure :mod "1e")))


# ::id PMC4729484.187
# ::snt Our results showed that GST-RhoAΔD pulled down substantially less p-ERK and total ERK compared with wild type GST-RhoA, indicating that the D-site is required for the interaction between RhoA and ERK.
# ::tok Our results showed that GST @-@ RhoAΔD pulled down substantially less p @-@ ERK and total ERK compared with wild type GST @-@ RhoA , indicating that the D @-@ site is required for the interaction between RhoA and ERK .
(x4 / show-01
      :ARG0 (x2 / thing
            :poss (x1 / we)
            :ARG2-of (x3 / result-01))
      :ARG1 (x13 / and
            :op1 (x5 / enzyme
                  :name (x6 / name :op1 "GST")
                  :ARG1-of (x7 / pull-down-00)
                  :xref (x33 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))
            :degree (x9 / less
                  :degree (x8 / substantial))
            :op1 (x10 / enzyme
                  :ARG3-of (x11 / phosphorylate-01)
                  :name (x12 / name :op1 "ERK")
                  :xref (x36 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :op2 (x14 / enzyme
                  :mod (x15 / total)
                  :name (x16 / name :op1 "ERK")
                  :xref (x37 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :ARG1-of (x17 / compare-01
                  :ARG2 (x18 / enzyme
                        :mod (x19 / wild-type)
                        :name (x20 / name :op1 "GST")
                        :xref (x35 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
            :op2 (x21 / protein
                  :name (x22 / name :op1 "RhoA")
                  :xref (x32 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG0-of (x23 / indicate-01
                  :ARG1 (x26 / require-01
                        :ARG1 (x25 / protein-segment
                              :name (x24 / name :op1 "D"))
                        :ARG0 (x27 / interact-01
                              :ARG0 (x28 / protein
                                    :name (x29 / name :op1 "RhoA")
                                    :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                              :ARG1 (x30 / enzyme
                                    :name (x31 / name :op1 "ERK")
                                    :xref (x34 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))))


# ::id PMC4729484.188
# ::snt Phosphorylation of RhoA by ERK in response to EGF treatment
# ::tok Phosphorylation of RhoA by ERK in response to EGF treatment
(x1 / phosphorylate-01
      :ARG1 (x2 / protein
            :name (x3 / name :op1 "RhoA")
            :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :ARG2 (x4 / enzyme
            :name (x5 / name :op1 "ERK")
            :xref (x11 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
      :ARG2-of (x6 / respond-01
            :ARG1 (x9 / treat-04
                  :ARG2 (x7 / protein
                        :name (x8 / name :op1 "EGF")
                        :xref (x10 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC4729484.189
# ::snt We have shown previously that the interaction between Rac1 and ERK resulted in Rac1 phosphorylation on T108 [ 21 ].
# ::tok We have shown previously that the interaction between Rac1 and ERK resulted in Rac1 phosphorylation on T108 [ 21 ] .
(x2 / show-01
      :ARG0 (x1 / we)
      :time (x3 / previous)
      :ARG1 (x9 / result-01
            :ARG1 (x4 / interact-01
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "Rac1")
                        :xref (x19 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "ERK")
                        :xref (x18 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :ARG2 (x10 / protein
                  :name (x11 / name :op1 "Rac1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
            :ARG0-of (x12 / phosphorylate-01
                  :ARG1 (x13 / amino-acid
                        :mod "108"
                        :name (x14 / name :op1 "threonine")
                        :xref (x20 / xref :value "PUBCHEM:205" :prob "11.848252")))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / publication
                        :ARG1-of (x17 / cite-01 :ARG2 "21")))))


# ::id PMC4729484.190
# ::snt In the present study, we examined whether ERK also phosphorylates RhoA and Cdc42.
# ::tok In the present study , we examined whether ERK also phosphorylates RhoA and Cdc42 .
(x4 / examine-01
      :medium (x2 / study-01
            :time (x1 / present))
      :ARG0 (x3 / we)
      :ARG1 (x8 / phosphorylate-01
            :mode "interrogative"
            :ARG0 (x5 / enzyme
                  :name (x6 / name :op1 "ERK")
                  :xref (x14 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :mod (x7 / also)
            :ARG1 (x9 / protein
                  :name (x10 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG2 (x11 / protein
                  :name (x12 / name :op1 "Cdc42")
                  :xref (x13 / xref :value "UNIPROT:CDC42_HUMAN" :prob "0.634"))))


# ::id PMC4729484.191
# ::snt Using affinity-purified recombinant His-tagged fusion proteins, we showed by in vitro ERK kinase assay that RhoA, Rac1, and Cdc42 were all phosphorylated by the activated ERK1.
# ::tok Using affinity @-@ purified recombinant His @-@ tagged fusion proteins , we showed by in vitro ERK kinase assay that RhoA , Rac1 , and Cdc42 were all phosphorylated by the activated ERK1 .
(x1 / use-01
      :ARG1 (x9 / protein
            :ARG1-of (x3 / purify-01
                  :ARG2 (x2 / affinity))
            :ARG1-of (x4 / recombine-01)
            :ARG1-of (x7 / tag-01
                  :ARG2 (x5 / amino-acid
                        :name (x6 / name :op1 "histidine")))
            :ARG1-of (x8 / fuse-01)
            :ARG1-of (x24 / phosphorylate-01
                  :ARG0 (x10 / we)
                  :ARG1-of (x11 / show-01
                        :ARG0 (x15 / assay-01
                              :manner (x12 / in-vitro)
                              :ARG1 (x13 / enzyme
                                    :name (x14 / name :op1 "ERK" :op2 "kinase")))
                        :ARG1 (x16 / and
                              :op1 (x17 / protein
                                    :name (x18 / name :op1 "RhoA")
                                    :xref (x30 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                              :op2 (x19 / protein
                                    :name (x20 / name :op1 "Rac1")
                                    :xref (x29 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
                              :op3 (x21 / protein
                                    :name (x22 / name :op1 "Cdc42")
                                    :xref (x28 / xref :value "UNIPROT:CDC42_HUMAN" :prob "0.634"))
                              :mod (x23 / all)))
                  :ARG2 (x25 / enzyme
                        :ARG1-of (x26 / activate-01)
                        :name (x27 / name :op1 "ERK1")
                        :xref (x / xref :value "UNIPROT:MK03_HUMAN" :prob "1.003")))))


# ::id PMC4729484.192
# ::snt Interestingly, RhoA phosphorylation was much stronger than Rac1, and Cdc42 phosphorylation was very weak ( Fig 2A & 2B ).
# ::tok Interestingly , RhoA phosphorylation was much stronger than Rac1 , and Cdc42 phosphorylation was very weak ( Fig 2A & 2B ) .
(x4 / phosphorylate-01
      :ARG2-of (x1 / interest-01)
      :ARG0 (x2 / protein
            :name (x3 / name :op1 "RhoA")
            :xref (x21 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :ARG1-of (x7 / strong-02
            :degree (x5 / more
                  :degree (x6 / much))
            :degree (x8 / more)
            :compared-to (x16 / weak-02
                  :ARG1 (x14 / phosphorylate-01
                        :ARG1 (x11 / and
                              :op1 (x9 / protein
                                    :name (x10 / name :op1 "Rac1")
                                    :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
                              :op2 (x12 / protein
                                    :name (x13 / name :op1 "Cdc42")
                                    :xref (x22 / xref :value "UNIPROT:CDC42_HUMAN" :prob "0.634"))))
                  :degree (x15 / very)))
      :ARG1-of (x17 / describe-01
            :ARG0 (x19 / and
                  :op1 (x18 / figure :mod "2a")
                  :op2 (x20 / figure :mod "2b"))))


# ::id PMC4729484.193
# ::snt Phosphorylation of RhoA on 88 S and 100 T by active ERK1 in vitro .
# ::tok Phosphorylation of RhoA on 88 S and 100 T by active ERK1 in vitro .
(x7 / express-03
      :ARG0 (x1 / phosphorylate-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "RhoA")
                  :xref (x12 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG2 (x6 / and
                  :op1 (x4 / publication
                        :ARG1-of (x5 / cite-01 :ARG2 "88"))
                  :op2 "100"))
      :ARG2 (x8 / enzyme
            :ARG1-of (x9 / activate-01)
            :name (x10 / name :op1 "ERK1")
            :xref (x / xref :value "UNIPROT:MK03_HUMAN" :prob "1.003"))
      :manner (x11 / in-vitro))


# ::id PMC4729484.194
# ::snt The phosphorylation of purified His-tagged Rho proteins by purified active ERK1 was performed with an in vitro ERK kinase assay kit in the presence of [γ- 32 P]ATP as described in the Materials and Methods.
# ::tok The phosphorylation of purified His @-@ tagged Rho proteins by purified active ERK1 was performed with an in vitro ERK kinase assay kit in the presence of [ γ- 32 P ] ATP as described in the Materials and Methods .
(x11 / perform-01
      :ARG1 (x1 / phosphorylate-01
            :ARG1 (x3 / enzyme
                  :ARG1-of (x2 / purify-01)
                  :ARG1-of (x6 / tag-01
                        :ARG2 (x4 / amino-acid
                              :name (x5 / name :op1 "histidine")))
                  :name (x7 / name :op1 "Rho")
                  :xref (x30 / xref :value "UNIPROT:OPSD_HUMAN" :prob "0.602"))
            :ARG2 (x8 / enzyme
                  :ARG1-of (x9 / purify-01)
                  :name (x10 / name :op1 "ERK1")
                  :xref (x / xref :value "UNIPROT:MK03_HUMAN" :prob "1.003")))
      :ARG2 (x18 / and
            :op1 (x15 / assay-01
                  :manner (x12 / in-vitro)
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "ERK" :op2 "kinase")))
            :mod (x16 / enzyme
                  :name (x17 / name :op1 "c-kit")
                  :xref (x31 / xref :value "UNIPROT:CHKA_HUMAN" :prob "0.202"))
            :op2 (x19 / enzyme
                  :name (x20 / name :op1 "γ-" :op2 "32"))
            :ARG1-of (x21 / statistical-test-91
                  :ARG2 (x22 / less-than :op1 "0.05"))
            :ARG1-of (x23 / describe-01
                  :ARG2 (x24 / small-molecule
                        :name (x25 / name :op1 "ATP")
                        :xref (x32 / xref :value "PUBCHEM:5957" :prob "14.368295")))
            :ARG1-of (x26 / describe-01))
      :location (x28 / and
            :op1 (x27 / material)
            :op2 (x29 / method)))


# ::id PMC4729484.195
# ::snt 32 P was detected by autoradiography.
# ::tok 32 P was detected by autoradiography .
(x4 / detect-01
      :ARG1 (x3 / phosphorylate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "32")
                  :xref (x / xref :value "UNIPROT:ARHL1_HUMAN" :prob "0.572")))
      :ARG0 (x5 / autoradiography))


# ::id PMC4729484.196
# ::snt The intensity of the bands of 32 P was normalized against the intensity of the His-tagged protein loading.
# ::tok The intensity of the bands of 32 P was normalized against the intensity of the His @-@ tagged protein loading .
(x8 / normalize-01
      :ARG1 (x1 / intensity
            :poss (x2 / band
                  :ARG1-of (x3 / describe-01
                        :ARG0 (x4 / publication
                              :ARG1-of (x5 / cite-01 :ARG2 "32")))
                  :ARG1-of (x6 / statistical-test-91
                        :ARG2 (x7 / less-than :op1 "0.05"))))
      :ARG1 (x9 / intensity
            :poss (x13 / protein
                  :ARG1-of (x12 / tag-01
                        :ARG2 (x10 / amino-acid
                              :name (x11 / name :op1 "histidine")))))
      :ARG0-of (x14 / load-01))


# ::id PMC4729484.199
# ::snt The phosphorylation of GST-RhoA (5 μg) and various mutant GST-RhoA (5 μg) by purified active ERK1 was performed as described in (A).
# ::tok The phosphorylation of GST @-@ RhoA ( 5 μg ) and various mutant GST @-@ RhoA ( 5 μg ) by purified active ERK1 was performed as described in ( A ) .
(x18 / perform-02
      :ARG0 (x1 / phosphorylate-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "GST-RhoA"))
            :ARG1-of (x4 / describe-01
                  :ARG0 (x7 / and
                        :op1 (x5 / temporal-quantity
                              :quant "5"
                              :unit (x6 / microgram))
                        :op2 (x9 / mutate-01
                              :mod (x8 / various)
                              :ARG1 (x10 / protein
                                    :name (x11 / name :op1 "GST-RhoA")))
                        :op2 (x12 / mass-quantity
                              :quant "5"
                              :unit (x13 / microgram))))
            :manner (x15 / activity-06
                  :ARG1-of (x14 / purify-01)))
      :ARG1 (x16 / enzyme
            :name (x17 / name :op1 "ERK1")
            :xref (x / xref :value "UNIPROT:MK03_HUMAN" :prob "1.003"))
      :ARG1-of (x19 / describe-01)
      :ARG1-of (x20 / describe-01
            :ARG0 (x21 / figure :mod "a")))


# ::id PMC4729484.200
# ::snt GST was used as a negative control.
# ::tok GST was used as a negative control .
(x3 / use-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "GST")
            :xref (x / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))
      :ARG2 (x5 / control-01
            :ARG2-of (x4 / negative-01)))


# ::id PMC4729484.201
# ::snt GST fusion protein loading was verified by Amido Black stain of the PVDF membrane.
# ::tok GST fusion protein loading was verified by Amido Black stain of the PVDF membrane .
(x7 / stain-01
      :ARG1 (x4 / verify-01
            :ARG1 (x3 / load-01
                  :ARG2 (x2 / protein
                        :name (x1 / name :op1 "GST" :op2 "fusion")))
            :manner (x6 / black-04
                  :name (x5 / name :op1 "Amido")))
      :ARG2 (x9 / membrane
            :name (x8 / name :op1 "PVDF")
            :xref (x / xref :value "GO:0016020" :prob "0.8")))


# ::id PMC4729484.202
# ::snt The intensity of the bands of 32 P was normalized against the intensity of the GST fusion protein loading.
# ::tok The intensity of the bands of 32 P was normalized against the intensity of the GST fusion protein loading .
(x8 / normalize-01
      :ARG1 (x1 / intensity
            :poss (x2 / band
                  :ARG1-of (x3 / describe-01
                        :ARG0 (x4 / publication
                              :ARG1-of (x5 / cite-01 :ARG2 "32")))
                  :ARG1-of (x6 / statistical-test-91
                        :ARG2 (x7 / less-than :op1 "0.05"))))
      :ARG1 (x9 / intensity
            :poss (x11 / protein
                  :name (x10 / name :op1 "GST" :op2 "fusion")))
      :ARG0-of (x12 / load-01))


# ::id PMC4729484.204
# ::snt * indicates p<0.05 and ** indicates p<0.01.
# ::tok * indicates
(x3 / indicate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "*")))


# ::id PMC4729484.205
# ::snt As a proline directed serine/threonine protein kinase, ERK phosphorylates the serine or threonine in the dipeptide motif S/T-P [ 27 ].
# ::tok As a proline directed serine @/@ threonine protein kinase , ERK phosphorylates the serine or threonine in the dipeptide motif S/T @-@ P [ 27 ] .
(x1 / or
      :op1 (x4 / direct-01
            :ARG2 (x2 / amino-acid
                  :name (x3 / name :op1 "proline")
                  :xref (x29 / xref :value "PUBCHEM:614" :prob "10.45396"))
            :ARG1 (x5 / slash
                  :op1 (x6 / amino-acid
                        :name (x7 / name :op1 "serine")
                        :xref (x30 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :op2 (x8 / amino-acid
                        :name (x9 / name :op1 "threonine")
                        :xref (x28 / xref :value "PUBCHEM:205" :prob "11.848252"))))
      :op2 (x10 / enzyme
            :name (x11 / name :op1 "protein" :op2 "kinase")
            :ARG0-of (x14 / phosphorylate-01
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG1 (x17 / or
                        :op1 (x15 / amino-acid
                              :name (x16 / name :op1 "serine")
                              :xref (x32 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :op2 (x18 / amino-acid
                              :name (x19 / name :op1 "threonine")
                              :xref (x31 / xref :value "PUBCHEM:205" :prob "11.848252")))
                  :location (x21 / motif
                        :name (x20 / name :op1 "dipeptide")
                        :ARG0-of (x24 / phosphorylate-01
                              :ARG1 (x22 / enzyme
                                    :name (x23 / name :op1 "S/T")))))
            :ARG1-of (x25 / describe-01
                  :ARG0 (x26 / publication
                        :ARG1-of (x27 / cite-01 :ARG2 "27")))))


# ::id PMC4729484.206
# ::snt Analysis of the RhoA protein sequence showed 88 SP and 100 TP could be two potential ERK phosphorylation sites.
# ::tok Analysis of the RhoA protein sequence showed 88 SP and 100 TP could be two potential ERK phosphorylation sites .
(x5 / show-01
      :ARG0 (x1 / analyze-01
            :ARG1 (x4 / sequence
                  :mod (x3 / protein
                        :name (x2 / name :op1 "RhoA")
                        :xref (x15 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
      :ARG1 (x7 / and
            :op1 (x6 / event :value "88")
            :op2 (x14 / protein-segment
                  :value "100"
                  :ARG1-of (x9 / possible-01
                        :name (x8 / name :op1 "TP"))
                  :quant "2"
                  :ARG1-of (x13 / phosphorylate-01
                        :mod (x10 / potential)
                        :ARG1 (x11 / enzyme
                              :name (x12 / name :op1 "ERK")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))))


# ::id PMC4729484.207
# ::snt To determine which site is phosphorylated by ERK, we generated several RhoA mutants with the substitution of 88 S and/or 100 T with alanine (A) or glutamic acid (E).
# ::tok To determine which site is phosphorylated by ERK , we generated several RhoA mutants with the substitution of 88 S and @/@ or 100 T with alanine ( A ) or glutamic acid ( E ) .
(x7 / generate-01
      :purpose (x1 / determine-01
            :ARG1 (x3 / phosphorylate-01
                  :ARG1 (x2 / protein-segment)
                  :ARG2 (x4 / enzyme
                        :name (x5 / name :op1 "ERK")
                        :xref (x27 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
      :ARG0 (x6 / we)
      :ARG1 (x8 / protein
            :quant (x9 / several)
            :name (x10 / name :op1 "RhoA")
            :ARG2-of (x11 / mutate-01)
            :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :ARG2 (x22 / or
            :op1 (x12 / substitute-01
                  :ARG1 (x15 / and
                        :op1 (x13 / publication
                              :ARG1-of (x14 / cite-01 :ARG2 "88"))
                        :op2 (x16 / or
                              :op2 (x17 / enzyme
                                    :name (x18 / name :op1 "100" :op2 "T"))))
                  :ARG2 (x19 / amino-acid
                        :name (x20 / name :op1 "alanine")
                        :name (x21 / name :op1 "A")
                        :xref (x29 / xref :value "PUBCHEM:16186443" :prob "5.50734")))
            :op2 (x23 / amino-acid
                  :name (x24 / name :op1 "glutamic" :op2 "acid")))
      :ARG1-of (x25 / describe-01
            :ARG0 (x26 / figure :mod "1e")))


# ::id PMC4729484.208
# ::snt These mutants include: GST-RhoA S88A, GST-RhoA T100A, GST-RhoA S88A/T100A, GST-RhoA S88E, GST-RhoA T100E, and GST-RhoA S88E/T100E.
# ::tok These mutants include : GST @-@ RhoA S88A , GST @-@ RhoA T100A , GST @-@ RhoA S88A/T100A , GST @-@ RhoA S88E , GST @-@ RhoA T100E , and GST @-@ RhoA S88E/T100E .
(x3 / include-01
      :ARG0 (x2 / mutate-01
            :mod (x1 / this))
      :ARG2 (x4 / protein
            :name (x5 / name :op1 "GST-RhoA"))
      :ARG1 (x20 / and
            :op1 (x6 / mutate-01 :value "S88A")
            :op2 (x7 / protein
                  :name (x8 / name :op1 "GST-RhoA"))
            :ARG0-of (x9 / mutate-01 :value "T100A")
            :op1 (x10 / protein
                  :name (x11 / name :op1 "GST-RhoA"))
            :op2 (x12 / protein
                  :name (x13 / name :op1 "S88A/T100A")
                  :mod (x14 / protein
                        :name (x15 / name :op1 "GST-RhoA"))
                  :name (x16 / name :op1 "S88E"))
            :op3 (x17 / protein
                  :name (x18 / name :op1 "GST-RhoA"))
            :op3 (x19 / mutate-01 :value "T100E")
            :op2 (x21 / protein
                  :name (x22 / name :op1 "GST-RhoA"))
            :op4 "s88e/t100e"))


# ::id PMC4729484.209
# ::snt The S or T to E mutants are phosphomimetic mutants.
# ::tok The S or T to E mutants are phosphomimetic mutants .
(x11 / mutate-01
      :ARG1 (x3 / or
            :op1 (x1 / protein
                  :name (x2 / name :op1 "S")
                  :xref (x12 / xref :value "UNIPROT:Q0EFA5_HUMAN" :prob "1.001"))
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "T")
                  :xref (x14 / xref :value "UNIPROT:BRAC_HUMAN" :prob "1.002"))
            :op2 (x6 / protein
                  :name (x7 / name :op1 "e-cadherin")
                  :ARG2-of (x8 / mutate-01)
                  :xref (x13 / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703")))
      :ARG2 (x9 / enzyme
            :name (x10 / name :op1 "phosphomimetic")
            :xref (x / xref :value "UNIPROT:PHOP1_HUMAN" :prob "0.202")))


# ::id PMC4729484.210
# ::snt We then examined whether these mutants were phosphorylated by using the in vitro ERK kinase assay as described in Materials and Methods.
# ::tok We then examined whether these mutants were phosphorylated by using the in vitro ERK kinase assay as described in Materials and Methods .
(x3 / examine-01
      :ARG0 (x1 / we)
      :time (x2 / then)
      :ARG1 (x7 / phosphorylate-01
            :mode "interrogative"
            :ARG1 (x5 / enzyme
                  :mod (x4 / this)
                  :ARG2-of (x6 / mutate-01)))
      :manner (x8 / use-01
            :ARG1 (x13 / assay-01
                  :manner (x9 / in-vitro)
                  :ARG1 (x10 / enzyme
                        :name (x11 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG1 (x12 / kinase)
                  :ARG1-of (x14 / describe-01
                        :location (x16 / and
                              :op1 (x15 / material)
                              :op2 (x17 / method))))))


# ::id PMC4729484.211
# ::snt As shown in Fig 2C & 2D , the results were complicated.
# ::tok As shown in Fig 2C & 2D , the results were complicated .
(x7 / complicate-01
      :ARG1-of (x1 / show-01
            :ARG0 (x3 / and
                  :op1 (x2 / figure :mod "2c")
                  :op2 (x4 / figure :mod "2d")))
      :ARG1 (x5 / thing
            :ARG2-of (x6 / result-01)))


# ::id PMC4729484.212
# ::snt In general, mutation of either 88 S or 100 T to E significantly reduced RhoA phosphorylation by ERK.
# ::tok In general , mutation of either 88 S or 100 T to E significantly reduced RhoA phosphorylation by ERK .
(x9 / reduce-01
      :ARG1-of (x1 / general-02)
      :ARG0 (x5 / express-03
            :ARG1 (x4 / or
                  :op1 (x2 / mutate-01
                        :ARG1 (x3 / or :op1 "88"))
                  :op2 "100")
            :ARG2 (x6 / protein
                  :name (x7 / name :op1 "e-cadherin")
                  :xref (x16 / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703")))
      :ARG1-of (x8 / significant-02)
      :ARG1 (x12 / phosphorylate-01
            :ARG1 (x10 / protein
                  :name (x11 / name :op1 "RhoA")
                  :xref (x15 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG2 (x13 / enzyme
                  :name (x14 / name :op1 "ERK")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))


# ::id PMC4729484.213
# ::snt Simultaneous mutation of both 88 S and 100 T inhibited RhoA phosphorylation more strongly than the single mutation of either 88 S or 100 T, except for the mutation of 100 T to 100 E that inhibited RhoA phosphorylation to the same degree as the double mutation of both 88 S and 100 T to E.
# ::tok Simultaneous mutation of both 88 S and 100 T inhibited RhoA phosphorylation more strongly than the single mutation of either 88 S or 100 T , except for the mutation of 100 T to 100 E that inhibited RhoA phosphorylation to the same degree as the double mutation of both 88 S and 100 T to E .
(x1 / multi-sentence
      :snt1 (x12 / inhibit-01
            :ARG0 (x3 / mutate-01
                  :mod (x2 / simultaneous)
                  :ARG1 (x4 / and
                        :op1 (x5 / enzyme
                              :ARG1-of (x6 / describe-01
                                    :ARG0 (x7 / publication
                                          :ARG1-of (x8 / cite-01 :ARG2 "88")))
                              :name (x9 / name :op1 "S")
                              :xref (x / xref :value "UNIPROT:Q0EFA5_HUMAN" :prob "1.001"))
                        :op2 (x10 / protein
                              :name (x11 / name :op1 "100" :op2 "T"))))
            :ARG1 (x15 / phosphorylate-01
                  :ARG1 (x13 / protein
                        :name (x14 / name :op1 "RhoA")
                        :xref (x56 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG1-of (x17 / strong-02
                  :degree (x16 / more)
                  :compared-to (x19 / mutate-01
                        :ARG1-of (x18 / single-02)
                        :ARG1 (x20 / or
                              :op1 (x21 / small-molecule
                                    :name (x22 / name :op1 "88" :op2 "S"))
                              :op2 (x23 / publication
                                    :ARG1-of (x24 / cite-01 :ARG2 "100"))))
                  :ARG1 (x25 / small-molecule
                        :name (x26 / name :op1 "T")
                        :ARG2-of (x27 / except-01
                              :ARG1 (x28 / mutate-01
                                    :ARG1 (x29 / gene
                                          :name (x30 / name :op1 "100"))))
                        :name (x31 / name :op1 "T" :op2 "100")
                        :xref (x57 / xref :value "PUBCHEM:5460632" :prob "10.509924"))))
      :snt2 (x34 / inhibit-01
            :ARG0 (x32 / protein
                  :name (x33 / name :op1 "e-cadherin")
                  :xref (x53 / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703"))
            :ARG1 (x37 / phosphorylate-01
                  :ARG1 (x35 / protein
                        :name (x36 / name :op1 "RhoA")
                        :xref (x54 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :ARG2 (x46 / and
                        :op1 (x38 / degree
                              :ARG2-of (x40 / mutate-01
                                    :mod (x39 / double))
                              :ARG1-of (x41 / same-01
                                    :ARG2 (x42 / and
                                          :ARG1-of (x43 / describe-01
                                                :ARG0 (x44 / publication
                                                      :ARG1-of (x45 / cite-01 :ARG2 "88"))))))
                        :op2 (x50 / express-03
                              :ARG1-of (x47 / describe-01
                                    :ARG0 (x48 / publication
                                          :ARG1-of (x49 / cite-01 :ARG2 "100")))
                              :ARG2 (x51 / protein
                                    :name (x52 / name :op1 "e-cadherin")
                                    :xref (x55 / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703")))))))


# ::id PMC4729484.214
# ::snt These results suggest that both 88 SP and 100 TP are phosphorylated by ERK in response to EGF.
# ::tok These results suggest that both 88 SP and 100 TP are phosphorylated by ERK in response to EGF .
(x4 / suggest-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x9 / phosphorylate-01
            :ARG1 (x5 / and
                  :op1 (x6 / event :value "88")
                  :op2 (x7 / person
                        :quant "100"
                        :name (x8 / name :op1 "TP")))
            :ARG2 (x10 / enzyme
                  :name (x11 / name :op1 "ERK")
                  :xref (x15 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :ARG2-of (x12 / respond-01
                  :ARG1 (x13 / protein
                        :name (x14 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC4729484.215
# ::snt We further examined whether 88 SP and 100 TP are ERK phosphorylation sites by immunoblotting.
# ::tok We further examined whether 88 SP and 100 TP are ERK phosphorylation sites by immunoblotting .
(x3 / examine-01
      :ARG0 (x1 / we)
      :degree (x2 / further)
      :ARG1 (x8 / be-located-at-91
            :mode "interrogative"
            :ARG1 (x5 / and
                  :op1 (x4 / event :value "88")
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "100" :op2 "TP"))))
      :ARG1 (x12 / site
            :ARG0-of (x11 / phosphorylate-01
                  :ARG1 (x9 / enzyme
                        :name (x10 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
      :ARG0 (x13 / immunoblot-01))


# ::id PMC4729484.216
# ::snt We constructed a series of GFP-tagged RhoA mutants including GFP-RhoA S88A, GFP-RhoA T100A, GFP-RhoA S88A/T100A, GFP-RhoA S88E, GFP-RhoA T100E, and GFP-RhoA S88E/T100E.
# ::tok We constructed a series of GFP @-@ tagged RhoA mutants including GFP @-@ RhoA S88A , GFP @-@ RhoA T100A , GFP @-@ RhoA S88A/T100A , GFP @-@ RhoA S88E , GFP @-@ RhoA T100E , and GFP @-@ RhoA S88E/T100E .
(x2 / construct-01
      :ARG0 (x1 / we)
      :ARG1 (x28 / and
            :op1 (x3 / series
                  :consist-of (x9 / enzyme
                        :mod (x4 / enzyme
                              :ARG1-of (x7 / tag-01
                                    :ARG2 (x5 / protein
                                          :name (x6 / name :op1 "GFP")
                                          :xref (x31 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
                              :name (x8 / name :op1 "RhoA")
                              :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                        :ARG2-of (x10 / mutate-01)
                        :ARG2-of (x11 / include-01
                              :ARG1 (x12 / protein
                                    :name (x13 / name :op1 "GFP-RhoA")))
                        :name (x14 / name :op1 "S88A")))
            :op2 (x15 / protein
                  :name (x16 / name :op1 "GFP-RhoA"))
            :ARG0-of (x17 / mutate-01 :value "T100A")
            :op1 (x18 / protein
                  :name (x19 / name :op1 "GFP-RhoA"))
            :op2 (x20 / protein
                  :name (x21 / name :op1 "S88A/T100A")
                  :mod (x22 / protein
                        :name (x23 / name :op1 "GFP-RhoA"))
                  :name (x24 / name :op1 "S88E"))
            :op3 (x25 / protein
                  :name (x26 / name :op1 "GFP-RhoA"))
            :op3 (x27 / mutate-01 :value "T100E")
            :op2 (x29 / protein
                  :name (x30 / name :op1 "GFP-RhoA"))
            :op4 "s88e/t100e"))


# ::id PMC4729484.217
# ::snt These mutants were expressed in COS-7 cells by transient transfection.
# ::tok These mutants were expressed in COS @-@ 7 cells by transient transfection .
(x4 / express-03
      :ARG1 (x2 / gene
            :mod (x1 / this)
            :ARG2-of (x3 / mutate-01))
      :ARG3 (x6 / cell-line
            :name (x5 / name :op1 "COS-7"))
      :manner (x8 / transfect-01
            :ARG1-of (x7 / transient-02)))


# ::id PMC4729484.218
# ::snt Following EGF stimulation for 15 min, these RhoA mutants were IPed by anti-GFP antibody and the phosphorylation status of these mutants was examined with anti-phosphoserine (p-Ser) or anti-phosphothreonine (p-Thr) antibodies.
# ::tok Following EGF stimulation for 15 min , these RhoA mutants were IPed by anti @-@ GFP antibody and the phosphorylation status of these mutants was examined with anti @-@ phosphoserine ( p @-@ Ser ) or anti @-@ phosphothreonine ( p @-@ Thr ) antibodies .
(x16 / and
      :ARG1-of (x1 / follow-01
            :ARG2 (x4 / stimulate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "EGF")
                        :xref (x36 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :duration (x5 / temporal-quantity
                        :quant "15"
                        :unit (x6 / minute))))
      :op1 (x10 / mutate-01
            :mod (x7 / this)
            :ARG1 (x8 / enzyme
                  :name (x9 / name :op1 "RhoA")
                  :xref (x35 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :mod (x11 / iped)
            :ARG0 (x15 / antibody
                  :ARG0-of (x12 / counter-01
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "GFP")
                              :xref (x38 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))))
      :op2 (x22 / examine-01
            :ARG1 (x17 / status
                  :mod (x18 / phosphorylate-01
                        :ARG1 (x20 / enzyme
                              :mod (x19 / this)
                              :ARG2-of (x21 / mutate-01))))
            :ARG2 (x28 / or
                  :op1 (x23 / antibody
                        :ARG0-of (x24 / counter-01
                              :ARG1 (x25 / enzyme
                                    :name (x26 / name :op1 "phosphoserine")
                                    :xref (x / xref :value "UNIPROT:SERB_HUMAN" :prob "0.292")))
                        :name (x27 / name :op1 "serine"))
                  :op2 (x34 / antibody
                        :ARG0-of (x29 / counter-01
                              :ARG1 (x30 / protein
                                    :name (x31 / name :op1 "phosphothreonine")
                                    :xref (x37 / xref :value "UNIPROT:SERC_HUMAN" :prob "0.262")))
                        :mod (x32 / protein
                              :name (x33 / name :op1 "p-Thr"))))))


# ::id PMC4729484.219
# ::snt As shown in Fig 3A , EGF treatment induced RhoA phosphorylation that can be detected by both p-Ser and p-Thr antibodies.
# ::tok As shown in Fig 3A , EGF treatment induced RhoA phosphorylation that can be detected by both p @-@ Ser and p @-@ Thr antibodies .
(x6 / induce-01
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "3a"))
      :ARG0 (x5 / treat-04
            :ARG2 (x3 / protein
                  :name (x4 / name :op1 "EGF")
                  :xref (x19 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :ARG2 (x9 / phosphorylate-01
            :ARG1 (x7 / protein
                  :name (x8 / name :op1 "RhoA")
                  :xref (x20 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
      :ARG1 (x18 / antibody
            :ARG0-of (x11 / detect-01
                  :ARG1-of (x10 / possible-01)
                  :ARG0 (x12 / and
                        :op1 (x13 / enzyme
                              :ARG3-of (x14 / phosphorylate-01)
                              :name (x15 / name :op1 "serine")
                              :xref (x / xref :value "UNIPROT:SRR_HUMAN" :prob "0.282"))
                        :op2 (x16 / protein
                              :name (x17 / name :op1 "p-Thr"))))))


# ::id PMC4729484.220
# ::snt Mutation of 88 S substantially reduced the phosphorylation level of RhoA serine phosphorylation, but had no effect on the threonine phosphorylation of RhoA.
# ::tok Mutation of 88 S substantially reduced the phosphorylation level of RhoA serine phosphorylation , but had no effect on the threonine phosphorylation of RhoA .
(x13 / contrast-01
      :ARG1 (x5 / reduce-01
            :ARG0 (x1 / mutate-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "88" :op2 "S")))
            :ARG2 (x4 / substantial)
            :ARG1 (x6 / phosphorylate-01
                  :ARG1 (x7 / level
                        :quant-of (x8 / protein
                              :name (x9 / name :op1 "RhoA")
                              :xref (x20 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                        :ARG1-of (x12 / phosphorylate-01
                              :ARG1 (x10 / amino-acid
                                    :name (x11 / name :op1 "serine")
                                    :xref (x21 / xref :value "PUBCHEM:5951" :prob "11.218784"))))))
      :ARG2 (x14 / affect-01
            :polarity "-"
            :ARG1 (x15 / phosphorylate-01
                  :ARG1 (x16 / amino-acid
                        :name (x17 / name :op1 "threonine")
                        :part-of (x18 / enzyme
                              :name (x19 / name :op1 "RhoA")
                              :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                        :xref (x22 / xref :value "PUBCHEM:205" :prob "11.848252")))))


# ::id PMC4729484.221
# ::snt Similarly, mutation of 100 T strongly inhibited RhoA threonine phosphorylation, but had no effect on RhoA serine phosphorylation.
# ::tok Similarly , mutation of 100 T strongly inhibited RhoA threonine phosphorylation , but had no effect on RhoA serine phosphorylation .
(x14 / contrast-01
      :ARG1 (x8 / inhibit-01
            :ARG1-of (x1 / resemble-01)
            :ARG0 (x2 / mutate-01
                  :ARG1 (x3 / gene
                        :name (x4 / name :op1 "100")))
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "T")
                  :xref (x22 / xref :value "UNIPROT:BRAC_HUMAN" :prob "1.002"))
            :ARG1-of (x7 / strong-02)
            :ARG1 (x9 / protein
                  :name (x10 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG1 (x13 / phosphorylate-01
                  :ARG1 (x11 / amino-acid
                        :name (x12 / name :op1 "threonine")
                        :xref (x24 / xref :value "PUBCHEM:205" :prob "11.848252"))))
      :ARG2 (x15 / affect-01
            :polarity "-"
            :ARG1 (x16 / protein
                  :name (x17 / name :op1 "RhoA")
                  :xref (x21 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG1 (x20 / phosphorylate-01
                  :ARG1 (x18 / amino-acid
                        :name (x19 / name :op1 "serine")
                        :xref (x23 / xref :value "PUBCHEM:5951" :prob "11.218784")))))


# ::id PMC4729484.222
# ::snt Mutation of both 88 S and 100 T simultaneously inhibits EGF-induced serine and threonine phosphorylation of RhoA.
# ::tok Mutation of both 88 S and 100 T simultaneously inhibits EGF @-@ induced serine and threonine phosphorylation of RhoA .
(x11 / inhibit-01
      :ARG0 (x1 / mutate-01
            :ARG1 (x2 / and
                  :op1 (x3 / enzyme
                        :ARG1-of (x4 / describe-01
                              :ARG0 (x5 / publication
                                    :ARG1-of (x6 / cite-01 :ARG2 "88")))
                        :name (x7 / name :op1 "S")
                        :xref (x21 / xref :value "UNIPROT:Q0EFA5_HUMAN" :prob "1.001"))
                  :op2 (x8 / protein
                        :name (x9 / name :op1 "100" :op2 "T"))))
      :manner (x10 / simultaneous)
      :ARG1 (x15 / phosphorylate-01
            :ARG2-of (x14 / induce-01
                  :ARG0 (x12 / protein
                        :name (x13 / name :op1 "EGF")
                        :xref (x22 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x16 / amino-acid
                  :name (x17 / name :op1 "serine")
                  :mod "386"
                  :name (x18 / name :op1 "threonine")
                  :part-of (x19 / protein
                        :name (x20 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :xref (x24 / xref :value "PUBCHEM:205" :prob "11.848252"))))


# ::id PMC4729484.223
# ::snt These results confirmed that both RhoA 88 S and 100 T are phosphorylated in response to EGF.
# ::tok These results confirmed that both RhoA 88 S and 100 T are phosphorylated in response to EGF .
(x4 / confirm-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x14 / phosphorylate-01
            :ARG1 (x5 / and
                  :op1 (x6 / protein
                        :name (x7 / name :op1 "RhoA")
                        :ARG1-of (x8 / describe-01
                              :ARG0 (x9 / publication
                                    :ARG1-of (x10 / cite-01 :ARG2 "88")))
                        :name (x11 / name :op1 "S")
                        :xref (x18 / xref :value "UNIPROT:Q0EFA5_HUMAN" :prob "1.001"))
                  :op2 (x12 / protein
                        :name (x13 / name :op1 "100" :op2 "T")))
            :ARG2-of (x15 / respond-01
                  :ARG1 (x16 / protein
                        :name (x17 / name :op1 "EGF")
                        :xref (x19 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC4729484.224
# ::snt Phosphorylation of RhoA on 88 S and 100 T by ERK in response to EGF in vivo .
# ::tok Phosphorylation of RhoA on 88 S and 100 T by ERK in response to EGF in vivo .
(x1 / phosphorylate-01
      :ARG1 (x2 / protein
            :name (x3 / name :op1 "RhoA")
            :xref (x16 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :ARG2 (x6 / and
            :op1 (x4 / publication
                  :ARG1-of (x5 / cite-01 :ARG2 "88"))
            :op2 (x9 / express-03
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "100"))
                  :ARG2 (x10 / enzyme
                        :name (x11 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG2-of (x12 / respond-01
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "EGF")
                              :xref (x17 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :manner (x15 / in-vivo))))


# ::id PMC4729484.225
# ::snt COS-7 cells were transfected with expression constructs encoding GFP-RhoA and various GFP-RhoA mutants.
# ::tok COS @-@ 7 cells were transfected with expression constructs encoding GFP @-@ RhoA and various GFP @-@ RhoA mutants .
(x10 / and
      :op1 (x3 / transfect-01
            :ARG1 (x2 / cell-line
                  :name (x1 / name :op1 "COS-7"))
            :ARG2 (x4 / express-03
                  :ARG1 (x6 / gene
                        :ARG1-of (x5 / construct-01)
                        :ARG0-of (x7 / encode-01
                              :ARG1 (x8 / protein
                                    :name (x9 / name :op1 "GFP-RhoA"))))))
      :op2 (x14 / mutate-01
            :mod (x11 / various)
            :ARG2 (x12 / protein
                  :name (x13 / name :op1 "GFP-RhoA"))))


# ::id PMC4729484.226
# ::snt The cells were stimulated with EGF (50 ng/ml).
# ::tok The cells were stimulated with EGF ( 50 ng/ml ) .
(x2 / stimulate-01
      :ARG1 (x1 / cell)
      :ARG2 (x3 / protein
            :name (x4 / name :op1 "EGF")
            :quant (x5 / concentration-quantity
                  :quant "50"
                  :unit (x6 / nanogram-per-milliliter))
            :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))


# ::id PMC4729484.228
# ::snt To confirm the GFP antibody captured protein is GFP-RhoA, the membranes with p-Ser (shown in the panel) and p-Thr blots were reprobed with anti-RhoA antibody.
# ::tok To confirm the GFP antibody captured protein is GFP @-@ RhoA , the membranes with p @-@ Ser ( shown in the panel ) and p @-@ Thr blots were reprobed with anti @-@ RhoA antibody .
(x5 / capture-01
      :purpose (x1 / confirm-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "GFP")
                  :xref (x24 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
      :ARG0 (x4 / antibody)
      :ARG0 (x6 / protein)
      :ARG2 (x7 / protein
            :name (x8 / name :op1 "GFP-RhoA"))
      :ARG1 (x9 / membrane
            :xref (x26 / xref :value "GO:0016020" :prob "0.8"))
      :ARG2 (x15 / and
            :op1 (x10 / enzyme
                  :ARG3-of (x11 / phosphorylate-01)
                  :name (x12 / name :op1 "serine")
                  :ARG1-of (x13 / show-01
                        :location (x14 / panel))
                  :xref (x25 / xref :value "UNIPROT:SRR_HUMAN" :prob "0.282"))
            :op2 (x18 / immunoblot-01
                  :ARG1 (x16 / protein
                        :name (x17 / name :op1 "p-Thr"))
                  :ARG1 (x19 / reprobed)
                  :ARG2 (x23 / antibody
                        :ARG0-of (x20 / counter-01
                              :ARG1 (x21 / protein
                                    :name (x22 / name :op1 "RhoA")
                                    :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))))))


# ::id PMC4729484.229
# ::snt The expression level of GFP-tagged RhoA proteins was determined by immunoblotting of the total lysates with antibody to GFP (bottom panel).
# ::tok The expression level of GFP @-@ tagged RhoA proteins was determined by immunoblotting of the total lysates with antibody to GFP ( bottom panel ) .
(x8 / determine-01
      :ARG1 (x1 / level
            :degree-of (x2 / express-03
                  :ARG2 (x7 / protein
                        :ARG1-of (x5 / tag-01
                              :ARG2 (x3 / protein
                                    :name (x4 / name :op1 "GFP")
                                    :xref (x19 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
                        :name (x6 / name :op1 "RhoA")
                        :xref (x20 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
      :ARG2 (x9 / immunoblot-01
            :ARG1 (x11 / lysate
                  :mod (x10 / total))
            :ARG3 (x12 / antibody
                  :ARG0-of (x13 / counter-01
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "GFP")
                              :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))))
      :ARG1-of (x16 / describe-01
            :ARG0 (x18 / panel
                  :mod (x17 / bottom))))


# ::id PMC4729484.230
# ::snt The COS-7 cells were treated similar to the method described in (A), but with the addition of U0126.
# ::tok The COS @-@ 7 cells were treated similar to the method described in ( A ) , but with the addition of U0126 .
(x3 / treat-04
      :ARG1 (x2 / cell-line
            :name (x1 / name :op1 "COS-7"))
      :ARG1-of (x4 / resemble-01
            :ARG2 (x5 / method
                  :ARG1-of (x6 / describe-01))
            :ARG1-of (x7 / describe-01
                  :ARG0 (x8 / figure :mod "a"))
            :ARG1-of (x9 / contrast-01
                  :ARG2 (x10 / add-02
                        :ARG1 (x11 / small-molecule
                              :name (x12 / name :op1 "U0126")
                              :xref (x / xref :value "PUBCHEM:3006531" :prob "17.656696"))))))


# ::id PMC4729484.231
# ::snt Following IP of cell lysates with anti-GFP antibodies, the phosphorylation of GFP-RhoA and its various mutants was determined by immunoblotting with antibodies to p-Ser and p-Thr.
# ::tok Following IP of cell lysates with anti @-@ GFP antibodies , the phosphorylation of GFP @-@ RhoA and its various mutants was determined by immunoblotting with antibodies to p @-@ Ser and p @-@ Thr .
(x21 / and
      :time (x1 / after
            :op1 (x3 / lysate
                  :part-of (x2 / cell))
            :op2 (x7 / antibody
                  :ARG0-of (x4 / counter-01
                        :ARG1 (x5 / protein
                              :name (x6 / name :op1 "GFP")
                              :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))))
      :op1 (x14 / determine-01
            :ARG1 (x8 / phosphorylate-01
                  :ARG1 (x11 / and
                        :op1 (x9 / protein
                              :name (x10 / name :op1 "GFP-RhoA"))
                        :op2 (x13 / mutate-01
                              :mod (x12 / various))))
            :ARG2 (x15 / immunoblot-01
                  :ARG3 (x16 / antibody
                        :ARG0-of (x17 / oppose-01
                              :ARG1 (x18 / enzyme
                                    :ARG3-of (x19 / phosphorylate-01)
                                    :name (x20 / name :op1 "serine")
                                    :xref (x24 / xref :value "UNIPROT:SRR_HUMAN" :prob "0.282"))))))
      :op2 (x22 / protein
            :name (x23 / name :op1 "p-Thr")))


# ::id PMC4729484.232
# ::snt We next examined whether EGF-induced RhoA phosphorylation is mediated by ERK in vivo .
# ::tok We next examined whether EGF @-@ induced RhoA phosphorylation is mediated by ERK in vivo .
(x3 / examine-01
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x10 / mediate-01
            :mode "interrogative"
            :ARG1 (x9 / phosphorylate-01
                  :ARG2-of (x6 / induce-01
                        :ARG0 (x4 / protein
                              :name (x5 / name :op1 "EGF")
                              :xref (x15 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x7 / protein
                        :name (x8 / name :op1 "RhoA")
                        :xref (x14 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG0 (x11 / enzyme
                  :name (x12 / name :op1 "ERK")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
      :manner (x13 / in-vivo))


# ::id PMC4729484.233
# ::snt As a positive control, we verified that U0126, a MEK inhibitor, blocked EGF-induced ERK phosphorylation in COS-7 cells ( Fig 3B ).
# ::tok As a positive control , we verified that U0126 , a MEK inhibitor , blocked EGF @-@ induced ERK phosphorylation in COS @-@ 7 cells ( Fig 3B ) .
(x4 / verify-01
      :ARG1-of (x2 / control-01
            :mod (x1 / positive))
      :ARG0 (x3 / we)
      :ARG1 (x10 / block-01
            :ARG0 (x5 / small-molecule
                  :name (x6 / name :op1 "U0126")
                  :ARG0-of (x9 / inhibit-01
                        :ARG1 (x7 / protein-family
                              :name (x8 / name :op1 "MEK")))
                  :xref (x22 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
            :ARG1 (x16 / phosphorylate-01
                  :ARG2-of (x13 / induce-01
                        :ARG0 (x11 / protein
                              :name (x12 / name :op1 "EGF")
                              :xref (x21 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x14 / enzyme
                        :name (x15 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :location (x18 / cell-line
                        :name (x17 / name :op1 "COS-7"))))
      :ARG1-of (x19 / describe-01
            :ARG0 (x20 / figure :mod "3b")))


# ::id PMC4729484.234
# ::snt We then expressed GFP-RhoA and various mutants in COS-7 and stimulated the cells with EGF in the presence of U0126.
# ::tok We then expressed GFP @-@ RhoA and various mutants in COS @-@ 7 and stimulated the cells with EGF in the presence of U0126 .
(x11 / stimulate-01
      :ARG0 (x1 / we)
      :time (x2 / then)
      :ARG0 (x3 / express-03
            :ARG2 (x6 / and
                  :op1 (x4 / protein
                        :name (x5 / name :op1 "GFP-RhoA"))
                  :op2 (x8 / mutate-01
                        :mod (x7 / various)
                        :location (x9 / cell-line
                              :name (x10 / name :op1 "COS-7")))))
      :ARG1 (x12 / cell)
      :ARG2 (x13 / protein
            :name (x14 / name :op1 "EGF")
            :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :condition (x15 / present-02
            :ARG1 (x16 / small-molecule
                  :name (x17 / name :op1 "U0126")
                  :xref (x18 / xref :value "PUBCHEM:3006531" :prob "17.656696"))))


# ::id PMC4729484.235
# ::snt Following IP of these expressed GFP-tagged proteins, the phosphorylation of these proteins was examined by immunoblotting with antibodies to p-Ser and p-Thr.
# ::tok Following IP of these expressed GFP @-@ tagged proteins , the phosphorylation of these proteins was examined by immunoblotting with antibodies to p @-@ Ser and p @-@ Thr .
(x19 / and
      :op1 (x12 / examine-01
            :ARG1 (x4 / express-03
                  :ARG1-of (x1 / follow-01
                        :ARG2 (x2 / figure
                              :mod (x3 / this)))
                  :ARG2 (x8 / protein
                        :ARG1-of (x7 / tag-01
                              :ARG2 (x5 / protein
                                    :name (x6 / name :op1 "GFP")
                                    :xref (x22 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
                        :ARG1-of (x9 / phosphorylate-01
                              :ARG1 (x11 / protein
                                    :mod (x10 / this)))))
            :manner (x13 / immunoblot-01
                  :ARG3 (x14 / antibody
                        :ARG0-of (x15 / oppose-01
                              :ARG1 (x16 / enzyme
                                    :ARG3-of (x17 / phosphorylate-01)
                                    :name (x18 / name :op1 "serine")
                                    :xref (x / xref :value "UNIPROT:SRR_HUMAN" :prob "0.282"))))))
      :op2 (x20 / protein
            :name (x21 / name :op1 "p-Thr")))


# ::id PMC4729484.236
# ::snt As shown in Fig 3C , inhibition of ERK by U0126 blocked EGF-induced phosphorylation of wild type and mutant RhoA, which suggested that EGF-induced RhoA phosphorylation of both 88 S and 100 T is most likely mediated by ERK.
# ::tok As shown in Fig 3C , inhibition of ERK by U0126 blocked EGF @-@ induced phosphorylation of wild type and mutant RhoA , which suggested that EGF @-@ induced RhoA phosphorylation of both 88 S and 100 T is most likely mediated by ERK .
(x8 / block-01
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "3c"))
      :ARG0 (x3 / inhibit-01
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "ERK")
                  :xref (x42 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :ARG0 (x6 / small-molecule
                  :name (x7 / name :op1 "U0126")
                  :xref (x47 / xref :value "PUBCHEM:3006531" :prob "17.656696")))
      :ARG1 (x12 / phosphorylate-01
            :ARG2-of (x11 / induce-01
                  :ARG0 (x9 / protein
                        :name (x10 / name :op1 "EGF")
                        :xref (x41 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x16 / and
                  :op1 (x13 / enzyme
                        :mod (x14 / wild-type)
                        :name (x15 / name :op1 "braf")
                        :xref (x45 / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.671"))
                  :op2 (x17 / enzyme
                        :ARG2-of (x18 / mutate-01)
                        :name (x19 / name :op1 "RhoA")
                        :xref (x46 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
      :ARG0-of (x20 / suggest-01
            :ARG1 (x23 / induce-01
                  :ARG0 (x21 / protein
                        :name (x22 / name :op1 "EGF")
                        :xref (x40 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :ARG1 (x24 / protein
                        :name (x25 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG1-of (x27 / likely-01
                  :degree (x26 / most)
                  :ARG1 (x37 / mediate-01
                        :ARG1 (x28 / phosphorylate-01
                              :ARG1 (x29 / and
                                    :op1 (x30 / enzyme
                                          :ARG1-of (x31 / describe-01
                                                :ARG0 (x32 / publication
                                                      :ARG1-of (x33 / cite-01 :ARG2 "88")))
                                          :name (x34 / name :op1 "S")
                                          :xref (x43 / xref :value "UNIPROT:Q0EFA5_HUMAN" :prob "1.001"))
                                    :op2 (x35 / protein
                                          :name (x36 / name :op1 "100" :op2 "T"))))
                        :ARG0 (x38 / enzyme
                              :name (x39 / name :op1 "ERK")
                              :xref (x44 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))))


# ::id PMC4729484.237
# ::snt The effects of RhoA phosphorylation on its interaction with ERK
# ::tok The effects of RhoA phosphorylation on its interaction with ERK
(x1 / affect-01
      :ARG0 (x2 / small-molecule
            :name (x3 / name :op1 "RhoA"))
      :ARG1 (x4 / phosphorylate-01
            :ARG1 (x5 / interact-01
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))


# ::id PMC4729484.238
# ::snt We showed above that the interaction between RhoA and ERK is mediated by RhoA D-site ( Fig 1E ).
# ::tok We showed above that the interaction between RhoA and ERK is mediated by RhoA D @-@ site ( Fig 1E ) .
(x2 / show-01
      :ARG0 (x1 / we)
      :medium (x3 / above)
      :ARG1 (x9 / mediate-01
            :ARG1 (x4 / interact-01
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "RhoA")
                        :xref (x14 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :ARG0 (x11 / protein-segment
                  :name (x10 / name :op1 "RhoA" :op2 "D")))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / figure :mod "1e")))


# ::id PMC4729484.239
# ::snt We next examined whether the phosphorylation status of RhoA affects its interaction with ERK.
# ::tok We next examined whether the phosphorylation status of RhoA affects its interaction with ERK .
(x3 / examine-01
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x8 / affect-01
            :mode "interrogative"
            :ARG0 (x4 / status
                  :mod (x5 / phosphorylate-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "RhoA")
                              :xref (x12 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
            :ARG1 (x9 / interact-01
                  :ARG1 (x10 / enzyme
                        :name (x11 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))


# ::id PMC4729484.240
# ::snt By using GST pull down assays, we showed that all of the RhoA single mutants including GST-RhoA S88A, S88E, T100A, and T100E bind to ERK similarly as wild type RhoA ( Fig 4A ).
# ::tok By using GST pull down assays , we showed that all of the RhoA single mutants including GST @-@ RhoA S88A , S88E , T100A , and T100E bind to ERK similarly as wild type RhoA ( Fig 4A ) .
(x7 / show-01
      :manner (x1 / use-01
            :ARG1 (x5 / assay-01
                  :ARG1 (x4 / pull-down-08
                        :ARG1 (x2 / enzyme
                              :name (x3 / name :op1 "GST")
                              :xref (x35 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))))
      :ARG0 (x6 / we)
      :ARG1 (x23 / bind-01
            :ARG0 (x20 / and
                  :op1 (x12 / mutate-01
                        :mod (x8 / all)
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "RhoA")
                              :xref (x34 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                        :ARG1-of (x11 / single-02)
                        :ARG1-of (x13 / include-91
                              :ARG1 (x16 / and
                                    :op1 (x14 / protein
                                          :name (x15 / name :op1 "GST-RhoA"))
                                    :op1 (x17 / mutate-01 :value "S88A")
                                    :op2 (x18 / mutate-01 :value "S88E"))))
                  :op2 (x19 / mutate-01 :value "T100A")
                  :op2 (x21 / enzyme
                        :name (x22 / name :op1 "T100E")
                        :xref (x33 / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232")))
            :ARG2 (x24 / enzyme
                  :name (x25 / name :op1 "ERK")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
      :ARG1-of (x26 / resemble-01
            :ARG2 (x27 / enzyme
                  :mod (x28 / wild-type)
                  :name (x29 / name :op1 "RhoA")
                  :xref (x32 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
      :ARG1-of (x30 / describe-01
            :ARG0 (x31 / figure :mod "4a")))


# ::id PMC4729484.241
# ::snt However, the double RhoA mutants, including both the alanine mutant that are unable to be phosphorylated by ERK (GST-RhoA S88A/T100A) and phosphomimetic RhoA mutant (GST-RhoA S88E/T100E), bind to ERK at a much lower level than the wild type RhoA ( Fig 4A ).
# ::tok However , the double RhoA mutants , including both the alanine mutant that are unable to be phosphorylated by ERK ( GST @-@ RhoA S88A/T100A ) and phosphomimetic RhoA mutant ( GST @-@ RhoA S88E/T100E ) , bind to ERK at a much lower level than the wild type RhoA ( Fig 4A ) .
(x1 / multi-sentence
      :snt1 (x2 / contrast-01
            :ARG2 (x21 / and
                  :op1 (x6 / mutate-01
                        :mod (x3 / double)
                        :ARG1 (x4 / protein
                              :name (x5 / name :op1 "RhoA")
                              :xref (x42 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                        :ARG2-of (x7 / include-91
                              :ARG1 (x8 / and
                                    :op1 (x9 / amino-acid
                                          :name (x10 / name :op1 "alanine")
                                          :xref (x46 / xref :value "PUBCHEM:602" :prob "10.089661"))
                                    :op2 (x11 / enzyme
                                          :ARG2-of (x12 / mutate-01)
                                          :ARG1-of (x14 / phosphorylate-01
                                                :ARG1-of (x13 / possible-01 :polarity "-")
                                                :ARG2 (x15 / enzyme
                                                      :name (x16 / name :op1 "ERK")
                                                      :xref (x45 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                                                :ARG1-of (x17 / describe-01
                                                      :ARG0 (x18 / protein
                                                            :name (x19 / name :op1 "GST-RhoA"))))
                                          :name (x20 / name :op1 "S88A/T100A")))))
                  :op2 (x22 / protein
                        :name (x23 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
      :snt2 (x30 / bind-01
            :ARG0 (x24 / enzyme
                  :ARG2-of (x25 / mutate-01)
                  :ARG1-of (x26 / describe-01
                        :ARG0 (x27 / protein
                              :name (x28 / name :op1 "GST-RhoA")))
                  :name (x29 / name :op1 "S88E/T100E"))
            :ARG2 (x31 / enzyme
                  :name (x32 / name :op1 "ERK")
                  :xref (x43 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :time (x36 / level
                  :degree (x33 / much)
                  :ARG1-of (x34 / low-04
                        :degree (x35 / more))
                  :compared-to (x37 / enzyme
                        :mod (x38 / wild-type)
                        :name (x39 / name :op1 "RhoA")
                        :xref (x44 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG1-of (x40 / describe-01
                  :ARG0 (x41 / figure :mod "4a"))))


# ::id PMC4729484.242
# ::snt These data indicated that RhoA and ERK interaction is mediated mostly by RhoA D-site, but is also affected by the ERK phosphorylation sites S88 and T100.
# ::tok These data indicated that RhoA and ERK interaction is mediated mostly by RhoA D @-@ site , but is also affected by the ERK phosphorylation sites S88 and T100 .
(x3 / indicate-01
      :ARG0 (x2 / data
            :mod (x1 / this))
      :ARG1 (x14 / contrast-01
            :ARG1 (x10 / mediate-01
                  :ARG0 (x6 / and
                        :op1 (x4 / protein
                              :name (x5 / name :op1 "RhoA")
                              :xref (x26 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                        :op2 (x7 / enzyme
                              :name (x8 / name :op1 "ERK")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                  :ARG1 (x9 / interact-01)
                  :degree (x11 / most)
                  :ARG2 (x13 / protein-segment
                        :name (x12 / name :op1 "RhoA" :op2 "D")))
            :ARG2 (x16 / affect-01
                  :mod (x15 / also)
                  :ARG0 (x23 / and
                        :op1 (x20 / site
                              :mod (x19 / phosphorylate-01
                                    :ARG1 (x17 / enzyme
                                          :name (x18 / name :op1 "ERK")
                                          :xref (x27 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                              :mod (x21 / amino-acid
                                    :mod "88"
                                    :name (x22 / name :op1 "serine")
                                    :xref (x29 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                        :op2 (x24 / amino-acid
                              :mod "100"
                              :name (x25 / name :op1 "threonine")
                              :xref (x28 / xref :value "PUBCHEM:205" :prob "11.848252"))))))


# ::id PMC4729484.243
# ::snt The effects of RhoA phosphorylation ( 88 S and 100 T) on RhoA interaction with ERK and on EGF-induced ERK phosphorylation.
# ::tok The effects of RhoA phosphorylation ( 88 S and 100 T ) on RhoA interaction with ERK and on EGF @-@ induced ERK phosphorylation .
(x8 / and
      :op1 (x1 / affect-01
            :ARG0 (x4 / phosphorylate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "RhoA")
                        :xref (x24 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG1-of (x5 / describe-01
                  :ARG0 (x6 / publication
                        :ARG1-of (x7 / cite-01 :ARG2 "88"))))
      :op2 (x10 / protein-segment
            :name (x9 / name :op1 "100")
            :name (x11 / name :op1 "T")
            :part-of (x12 / protein
                  :name (x13 / name :op1 "RhoA")
                  :xref (x26 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG0-of (x14 / interact-01
                  :ARG1 (x17 / and
                        :op1 (x15 / enzyme
                              :name (x16 / name :op1 "ERK")
                              :xref (x27 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                        :op2 (x23 / phosphorylate-01
                              :ARG2-of (x20 / induce-01
                                    :ARG0 (x18 / protein
                                          :name (x19 / name :op1 "EGF")
                                          :xref (x25 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                              :ARG1 (x21 / enzyme
                                    :name (x22 / name :op1 "ERK")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))))


# ::id PMC4729484.244
# ::snt COS-7 cells were serum starved and treated with EGF (50 ng/ml) for 15 min.
# ::tok COS @-@ 7 cells were serum starved and treated with EGF ( 50 ng/ml ) for 15 min .
(x6 / treat-04
      :ARG1 (x2 / cell-line
            :name (x1 / name :op1 "COS-7"))
      :ARG2 (x5 / and
            :ARG1-of (x4 / starve-01
                  :ARG2 (x3 / serum)))
      :ARG2 (x7 / protein
            :name (x8 / name :op1 "EGF")
            :quant (x9 / concentration-quantity
                  :quant "50"
                  :unit (x10 / nanogram-per-milliliter))
            :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :duration (x11 / temporal-quantity
            :quant "15"
            :unit (x12 / minute)))


# ::id PMC4729484.245
# ::snt The cell lysates were incubated with GST-fused wild type and mutant RhoA proteins bound to glutathione-sepharose beads.
# ::tok The cell lysates were incubated with GST @-@ fused wild type and mutant RhoA proteins bound to glutathione @-@ sepharose beads .
(x3 / incubate-01
      :ARG1 (x2 / lysate
            :mod (x1 / cell))
      :ARG2 (x9 / and
            :op1 (x7 / enzyme
                  :ARG1-of (x6 / fuse-01
                        :ARG2 (x4 / enzyme
                              :name (x5 / name :op1 "GST")
                              :xref (x17 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
                  :mod (x8 / wild-type))
            :op2 (x10 / mutate-01
                  :ARG1 (x12 / protein
                        :name (x11 / name :op1 "RhoA")
                        :ARG1-of (x13 / bind-01
                              :ARG2 (x14 / small-molecule
                                    :name (x15 / name :op1 "glutathione-sepharose")))
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
      :time (x16 / bead))


# ::id PMC4729484.246
# ::snt ERK pulldowns were analyzed by immunoblotting with antibodies to ERK.
# ::tok ERK pulldowns were analyzed by immunoblotting with antibodies to ERK .
(x3 / analyze-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "ERK" :op2 "pulldowns"))
      :manner (x4 / immunoblot-01
            :ARG3 (x5 / antibody
                  :ARG0-of (x6 / oppose-01
                        :ARG1 (x7 / enzyme
                              :name (x8 / name :op1 "ERK")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))))


# ::id PMC4729484.247
# ::snt GST fusion protein loading was verified by Amido Black staining of the nitrocellulose membrane.
# ::tok GST fusion protein loading was verified by Amido Black staining of the nitrocellulose membrane .
(x7 / stain-01
      :ARG1 (x4 / verify-01
            :ARG1 (x3 / load-01
                  :ARG2 (x2 / protein
                        :name (x1 / name :op1 "GST" :op2 "fusion")))
            :manner (x6 / black-04
                  :name (x5 / name :op1 "Amido")))
      :ARG2 (x9 / membrane
            :mod (x8 / nitrocellulose)
            :xref (x / xref :value "GO:0016020" :prob "0.8")))


# ::id PMC4729484.248
# ::snt COS-7 cells were transfected with expression constructs encoding GFP-tagged wild type and mutant RhoA proteins and these proteins were overexpressed.
# ::tok COS @-@ 7 cells were transfected with expression constructs encoding GFP @-@ tagged wild type and mutant RhoA proteins and these proteins were overexpressed .
(x17 / and
      :op1 (x3 / transfect-01
            :ARG1 (x2 / cell-line
                  :name (x1 / name :op1 "COS-7"))
            :ARG2 (x13 / and
                  :op1 (x4 / express-03
                        :ARG1 (x6 / gene
                              :ARG1-of (x5 / construct-01)
                              :ARG0-of (x7 / encode-01
                                    :ARG1 (x8 / enzyme
                                          :ARG1-of (x11 / tag-01
                                                :ARG2 (x9 / protein
                                                      :name (x10 / name :op1 "GFP")
                                                      :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
                                          :mod (x12 / wild-type)))))
                  :op2 (x14 / mutate-01
                        :ARG1 (x16 / protein
                              :name (x15 / name :op1 "RhoA")
                              :xref (x21 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))))
      :op2 (x20 / overexpress-01
            :ARG1 (x19 / protein
                  :mod (x18 / this))))


# ::id PMC4729484.250
# ::snt ERK phosphorylation and activation was determined by immunoblotting cell lysates with antibodies to p-ERK and p-ELK1, respectively.
# ::tok ERK phosphorylation and activation was determined by immunoblotting cell lysates with antibodies to p @-@ ERK and p @-@ ELK1 , respectively .
(x4 / and
      :op1 (x3 / phosphorylate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "ERK")
                  :xref (x19 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
      :op2 (x6 / determine-01
            :ARG1 (x5 / activate-01)
            :ARG2 (x7 / immunoblot-01
                  :ARG1 (x9 / lysate
                        :mod (x8 / cell)))
            :ARG2 (x15 / and
                  :op1 (x10 / antibody
                        :ARG0-of (x11 / counter-01
                              :ARG1 (x12 / enzyme
                                    :ARG3-of (x13 / phosphorylate-01)
                                    :name (x14 / name :op1 "ERK")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
                  :op2 (x16 / protein
                        :name (x17 / name :op1 "p-ELK1"))
                  :manner (x18 / respective))))


# ::id PMC4729484.251
# ::snt The expression of GFP-RhoA wild type and mutant proteins was determined by immunoblotting with antibodies to GFP.
# ::tok The expression of GFP @-@ RhoA wild type and mutant proteins was determined by immunoblotting with antibodies to GFP .
(x8 / determine-01
      :ARG1 (x1 / express-03
            :ARG2 (x5 / and
                  :op1 (x4 / wild-type
                        :ARG1 (x2 / protein
                              :name (x3 / name :op1 "GFP-RhoA")))
                  :op2 (x7 / protein
                        :ARG2-of (x6 / mutate-01))))
      :ARG2 (x9 / immunoblot-01
            :ARG3 (x10 / antibody
                  :ARG0-of (x11 / counter-01
                        :ARG1 (x12 / protein
                              :name (x13 / name :op1 "GFP")
                              :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))))))


# ::id PMC4729484.252
# ::snt It has been reported that RhoA activation regulates ERK activity, although the data are controversial with regard to the net effects of this regulation [ 28 , 29 ].
# ::tok It has been reported that RhoA activation regulates ERK activity , although the data are controversial with regard to the net effects of this regulation [ 28 , 29 ] .
(x1 / report-01
      :ARG1 (x5 / regulate-01
            :ARG0 (x4 / activate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG1 (x8 / activity-06
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "ERK")
                        :xref (x20 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :concession (x10 / controversial
                        :domain (x9 / data)
                        :ARG1-of (x11 / with-regard-to)
                        :ARG0-of (x13 / affect-01
                              :mod (x12 / net)
                              :ARG0 (x15 / regulate-01
                                    :mod (x14 / this)))
                        :ARG1-of (x16 / describe-01
                              :ARG0 (x17 / publication
                                    :ARG1-of (x18 / cite-01
                                          :ARG2 (x19 / and :op1 "28" :op2 "29"))))))))


# ::id PMC4729484.253
# ::snt We examined the effects of RhoA phosphorylation on the activation of ERK.
# ::tok We examined the effects of RhoA phosphorylation on the activation of ERK .
(x2 / examine-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / affect-01
            :ARG0 (x6 / phosphorylate-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "RhoA")
                        :xref (x10 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG1 (x7 / activate-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))


# ::id PMC4729484.254
# ::snt We examined whether overexpression of GFP-RhoA-S88A/T100A or GFP-RhoA-S88E/T100E in COS-7 cells affects ERK activation.
# ::tok We examined whether overexpression of GFP @-@ RhoA @-@ S88A @/@ T100A or GFP @-@ RhoA @-@ S88E @/@ T100E in COS @-@ 7 cells affects ERK activation .
(x2 / examine-01
      :ARG0 (x1 / we)
      :ARG1 (x21 / affect-01
            :mode "interrogative"
            :ARG0 (x3 / overexpress-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "GFP")
                        :ARG1-of (x10 / or
                              :op1 (x6 / protein
                                    :name (x7 / name :op1 "RhoA")
                                    :ARG1-of (x8 / mutate-01 :value "S88A")
                                    :xref (x25 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                              :op2 (x9 / mutate-01 :value "T100A")
                              :op3 (x11 / protein
                                    :name (x12 / name :op1 "GFP")
                                    :xref (x28 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
                        :name (x13 / name :op1 "RhoA")
                        :xref (x27 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :ARG2 (x16 / slash
                        :op1 (x14 / enzyme
                              :name (x15 / name :op1 "S88E"))
                        :op2 (x17 / enzyme
                              :name (x18 / name :op1 "T100E")
                              :xref (x29 / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232")))
                  :location (x20 / cell-line
                        :name (x19 / name :op1 "COS-7")))
            :ARG1 (x24 / activate-01
                  :ARG1 (x22 / enzyme
                        :name (x23 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))


# ::id PMC4729484.255
# ::snt We showed that overexpression of GFP-RhoA S88A/T100A or GFP-RhoA S88E/T100E did not have any detectable effects on EGF-induced ERK phosphorylation ( Fig 4B ).
# ::tok We showed that overexpression of GFP @-@ RhoA S88A @/@ T100A or GFP @-@ RhoA S88E @/@ T100E did not have any detectable effects on EGF @-@ induced ERK phosphorylation ( Fig 4B ) .
(x2 / show-01
      :ARG0 (x1 / we)
      :ARG1 (x17 / have-03
            :ARG0 (x3 / overexpress-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "GFP-RhoA")))
            :ARG1-of (x6 / cell-line
                  :name (x7 / name :op1 "S88A")
                  :mod (x9 / or
                        :op1 (x8 / mutate-01 :value "T100A")
                        :op2 (x10 / protein
                              :name (x11 / name :op1 "GFP-RhoA"))))
            :ARG0 (x14 / slash
                  :op1 (x12 / enzyme
                        :name (x13 / name :op1 "S88E"))
                  :op2 (x15 / enzyme
                        :name (x16 / name :op1 "T100E")
                        :xref (x31 / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232")))
            :polarity "-"
            :ARG1 (x21 / affect-01
                  :mod (x18 / any)
                  :ARG1-of (x19 / detect-01
                        :ARG1-of (x20 / possible-01))
                  :ARG1 (x27 / phosphorylate-01
                        :ARG2-of (x24 / induce-01
                              :ARG0 (x22 / protein
                                    :name (x23 / name :op1 "EGF")
                                    :xref (x30 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                        :ARG1 (x25 / enzyme
                              :name (x26 / name :op1 "ERK")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
            :ARG1-of (x28 / describe-01
                  :ARG0 (x29 / figure :mod "4b"))))


# ::id PMC4729484.256
# ::snt Moreover, the EGF-induced activation of Elk1, an ERK substrate, was also not affected by RhoA phosphorylation on S88 and T100 ( Fig 4B ).
# ::tok Moreover , the EGF @-@ induced activation of Elk1 , an ERK substrate , was also not affected by RhoA phosphorylation on S88 and T100 ( Fig 4B ) .
(x1 / and
      :op2 (x12 / affect-01
            :ARG1 (x5 / activate-01
                  :ARG2-of (x4 / induce-01
                        :ARG0 (x2 / protein
                              :name (x3 / name :op1 "EGF")
                              :xref (x23 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "Elk1")
                        :mod (x10 / substrate
                              :mod (x8 / enzyme
                                    :name (x9 / name :op1 "ERK")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                        :xref (x24 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.603")))
            :mod (x11 / also)
            :polarity "-"
            :ARG0 (x15 / phosphorylate-01
                  :ARG1 (x13 / protein
                        :name (x14 / name :op1 "RhoA")
                        :xref (x25 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG1 (x16 / and
                  :op1 (x17 / amino-acid
                        :mod "88"
                        :name (x18 / name :op1 "serine")
                        :xref (x27 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :op2 (x19 / amino-acid
                        :mod "100"
                        :name (x20 / name :op1 "threonine")
                        :xref (x26 / xref :value "PUBCHEM:205" :prob "11.848252")))
            :ARG1-of (x21 / describe-01
                  :ARG0 (x22 / figure :mod "4b"))))


# ::id PMC4729484.257
# ::snt The effects of RhoA phosphorylation on RhoA activity
# ::tok The effects of RhoA phosphorylation on RhoA activity
(x7 / activity-06
      :ARG1-of (x1 / affect-01
            :ARG0 (x4 / phosphorylate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "RhoA")
                  :xref (x8 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))


# ::id PMC4729484.258
# ::snt We next examined whether phosphorylation by ERK regulates RhoA activity.
# ::tok We next examined whether phosphorylation by ERK regulates RhoA activity .
(x3 / examine-01
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x4 / possible-01
            :mode "interrogative"
            :ARG1 (x8 / regulate-01
                  :ARG0 (x5 / phosphorylate-01
                        :ARG2 (x6 / enzyme
                              :name (x7 / name :op1 "ERK")
                              :xref (x12 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                  :ARG1 (x11 / activity-06
                        :ARG0 (x9 / protein
                              :name (x10 / name :op1 "RhoA")
                              :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))))


# ::id PMC4729484.259
# ::snt Since only the activated RhoA is able to bind the Rho-binding domain (RBD; amino acids 7–89) of Rhotekin, the activation of RhoA was assessed by its binding to the GST fusion RBD of Rhotekin (GST-RBD).
# ::tok Since only the activated RhoA is able to bind the Rho @-@ binding domain ( RBD ; amino acids 7–89 ) of Rhotekin , the activation of RhoA was assessed by its binding to the GST fusion RBD of Rhotekin ( GST @-@ RBD ) .
(x1 / cause-01
      :ARG0 (x22 / bind-01
            :mod (x2 / only)
            :ARG1-of (x3 / capable-01
                  :ARG2 (x7 / bind-01
                        :ARG0 (x4 / enzyme
                              :ARG1-of (x5 / activate-01)
                              :name (x6 / name :op1 "RhoA")
                              :xref (x30 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                        :ARG1 (x8 / protein
                              :name (x9 / name :op1 "Rho" :op2 "domain")))
                  :ARG1-of (x10 / describe-01
                        :ARG0 (x11 / and
                              :op1 (x12 / protein-segment
                                    :name (x13 / name :op1 "RBD"))
                              :op2 (x14 / amino-acid
                                    :name (x15 / name :op1 "7–89"))))
                  :ARG1 (x21 / assess-01
                        :ARG1 (x16 / enzyme
                              :name (x17 / name :op1 "Rhotekin")
                              :ARG1-of (x18 / activate-01
                                    :ARG1 (x19 / protein
                                          :name (x20 / name :op1 "RhoA")
                                          :xref (x31 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
                              :xref (x32 / xref :value "UNIPROT:RTKN_HUMAN" :prob "1.002"))))
            :ARG2 (x23 / protein
                  :name (x24 / name :op1 "GST" :op2 "fusion")))
      :ARG1 (x25 / protein-segment
            :name (x26 / name :op1 "RBD")
            :part-of (x27 / protein
                  :name (x28 / name :op1 "Rhotekin")
                  :xref (x / xref :value "UNIPROT:RTKN_HUMAN" :prob "1.002"))
            :name (x29 / name :op1 "GST-RBD")))


# ::id PMC4729484.260
# ::snt We expressed GFP-RhoA S88E/T100E and GFP-RhoA S88A/T100A in COS-7 cells by transient transfection.
# ::tok We expressed GFP @-@ RhoA S88E @/@ T100E and GFP @-@ RhoA S88A @/@ T100A in COS @-@ 7 cells by transient transfection .
(x2 / express-03
      :ARG0 (x1 / we)
      :ARG2 (x10 / and
            :mod (x3 / protein
                  :name (x4 / name :op1 "GFP-RhoA"))
            :op1 (x7 / slash
                  :op1 (x5 / enzyme
                        :name (x6 / name :op1 "S88E"))
                  :op2 (x8 / enzyme
                        :name (x9 / name :op1 "T100E")
                        :xref (x / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232")))
            :op2 (x11 / protein
                  :name (x12 / name :op1 "GFP-RhoA"))
            :op1 (x13 / mutate-01 :value "S88A")
            :op2 (x14 / mutate-01 :value "T100A"))
      :location (x16 / cell-line
            :name (x15 / name :op1 "COS-7"))
      :manner (x18 / transfect-01
            :ARG1-of (x17 / transient-02)))


# ::id PMC4729484.261
# ::snt The cells were either not treated or stimulated with EGF for 15 min and the cell lysates were incubated with GST-RBD.
# ::tok The cells were either not treated or stimulated with EGF for 15 min and the cell lysates were incubated with GST @-@ RBD .
(x10 / and
      :op1 (x3 / treat-04
            :ARG1 (x1 / cell)
            :ARG2 (x2 / or :polarity "-")
            :ARG2 (x4 / or
                  :op2 (x5 / stimulate-01
                        :ARG2 (x6 / protein
                              :name (x7 / name :op1 "EGF")
                              :xref (x16 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
            :duration (x8 / temporal-quantity
                  :quant "15"
                  :unit (x9 / minute)))
      :op2 (x13 / incubate-01
            :ARG1 (x12 / lysate
                  :mod (x11 / cell))
            :ARG2 (x14 / protein
                  :name (x15 / name :op1 "GST-RBD")
                  :xref (x / xref :value "UNIPROT:GSTCD_HUMAN" :prob "0.252"))))


# ::id PMC4729484.262
# ::snt The pulled-down GFP-tagged RhoA and mutants were examined by immunoblotting with antibody to GFP.
# ::tok The pulled @-@ down GFP @-@ tagged RhoA and mutants were examined by immunoblotting with antibody to GFP .
(x1 / and
      :op1 (x2 / pull-out-02
            :ARG1 (x3 / enzyme
                  :ARG1-of (x6 / tag-01
                        :ARG2 (x4 / protein
                              :name (x5 / name :op1 "GFP")
                              :xref (x16 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
                  :name (x7 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
      :op2 (x9 / examine-01
            :ARG1 (x8 / mutate-01)
            :manner (x10 / immunoblot-01
                  :ARG3 (x11 / antibody
                        :ARG0-of (x12 / counter-01
                              :ARG1 (x13 / protein
                                    :name (x14 / name :op1 "GFP")
                                    :xref (x15 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))))))


# ::id PMC4729484.263
# ::snt As shown in Fig 5A & 5B , GST-RBD was able to pull down a larger amount of phosphomimetic GFP-RhoA S88E/T100E than wild type GFP-RhoA and the mutant GFP-RhoA S88A/T100A with or without EGF stimulation.
# ::tok As shown in Fig 5A & 5B , GST @-@ RBD was able to pull down a larger amount of phosphomimetic GFP @-@ RhoA S88E @/@ T100E than wild type GFP @-@ RhoA and the mutant GFP @-@ RhoA S88A @/@ T100A with or without EGF stimulation .
(x32 / stimulate-01
      :ARG1-of (x1 / show-01
            :ARG0 (x3 / and
                  :op1 (x2 / figure :mod "5a")
                  :op2 (x4 / figure :mod "5b")))
      :ARG0 (x7 / capable-01
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "GST-RBD")
                  :xref (x / xref :value "UNIPROT:GSTCD_HUMAN" :prob "0.252"))
            :ARG2 (x8 / pull-down-08
                  :ARG1 (x11 / amount
                        :mod (x9 / large
                              :degree (x10 / more))
                        :quant-of (x12 / protein
                              :name (x13 / name :op1 "GFP-RhoA")))
                  :ARG2 (x16 / slash
                        :op1 (x14 / enzyme
                              :name (x15 / name :op1 "S88E"))
                        :op2 (x17 / enzyme
                              :name (x18 / name :op1 "T100E")
                              :xref (x34 / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232")))
                  :compared-to (x22 / and
                        :mod (x19 / wild-type)
                        :op1 (x20 / protein
                              :name (x21 / name :op1 "GFP-RhoA"))
                        :op2 (x23 / mutate-01
                              :ARG2 (x24 / protein
                                    :name (x25 / name :op1 "GFP-RhoA")))
                        :op1 (x26 / mutate-01 :value "S88A")
                        :op2 (x28 / or
                              :op1 (x27 / mutate-01 :value "T100A")
                              :op2 (x29 / accompany-01 :polarity "-")))))
      :ARG1 (x30 / protein
            :name (x31 / name :op1 "EGF")
            :xref (x33 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))


# ::id PMC4729484.264
# ::snt Although the increase in active, wild type GFP-RhoA after EGF treatment is marginal, the significantly higher levels of active GFP-RhoA S88E/T100E (regardless of EGF stimulation) suggest that the phosphorylation of these two sites is important in RhoA activation.
# ::tok Although the increase in active , wild type GFP @-@ RhoA after EGF treatment is marginal , the significantly higher levels of active GFP @-@ RhoA S88E @/@ T100E ( regardless of EGF stimulation ) suggest that the phosphorylation of these two sites is important in RhoA activation .
(x27 / suggest-01
      :concession (x1 / increase-01
            :ARG1 (x2 / activity-06))
      :ARG0 (x10 / marginal-02
            :ARG0 (x6 / after
                  :mod (x3 / wild-type
                        :mod (x4 / protein
                              :name (x5 / name :op1 "GFP-RhoA")))
                  :op1 (x9 / treat-04
                        :ARG2 (x7 / protein
                              :name (x8 / name :op1 "EGF")
                              :xref (x36 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
            :ARG1 (x14 / level
                  :ARG1-of (x12 / high-02
                        :ARG1-of (x11 / significant-02)
                        :degree (x13 / more))
                  :quant-of (x20 / slash
                        :op1 (x15 / enzyme
                              :ARG1-of (x16 / activate-01
                                    :ARG1 (x17 / protein
                                          :name (x18 / name :op1 "GFP-RhoA")))
                              :name (x19 / name :op1 "S88E"))
                        :op2 (x21 / enzyme
                              :name (x22 / name :op1 "T100E")
                              :xref (x35 / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232"))))
            :ARG1-of (x23 / regardless-91
                  :ARG2 (x26 / stimulate-01
                        :ARG0 (x24 / protein
                              :name (x25 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :ARG1 (x31 / important
            :domain (x28 / phosphorylate-01
                  :ARG1 (x30 / protein-segment
                        :mod (x29 / this)
                        :quant "2"))
            :purpose (x34 / activate-01
                  :ARG1 (x32 / protein
                        :name (x33 / name :op1 "RhoA")
                        :xref (x37 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))))


# ::id PMC4729484.265
# ::snt The effects of RhoA phosphorylation on the activation of RhoA.
# ::tok The effects of RhoA phosphorylation on the activation of RhoA .
(x1 / affect-01
      :ARG0 (x4 / phosphorylate-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
      :ARG1 (x5 / activate-01)
      :ARG0 (x6 / protein
            :name (x7 / name :op1 "RhoA")
            :xref (x8 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))


# ::id PMC4729484.266
# ::snt COS-7 cells were transfected with expression constructs encoding wild type and mutant GFP-tagged RhoA proteins.
# ::tok COS @-@ 7 cells were transfected with expression constructs encoding wild type and mutant GFP @-@ tagged RhoA proteins .
(x11 / and
      :op1 (x3 / transfect-01
            :ARG1 (x2 / cell-line
                  :name (x1 / name :op1 "COS-7"))
            :ARG2 (x4 / express-03
                  :ARG1 (x6 / gene
                        :ARG1-of (x5 / construct-01)
                        :ARG0-of (x7 / encode-01
                              :ARG1 (x8 / enzyme
                                    :mod (x9 / wild-type)
                                    :name (x10 / name :op1 "braf")
                                    :xref (x18 / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.671"))))))
      :op2 (x17 / protein
            :ARG2-of (x12 / mutate-01)
            :ARG1-of (x15 / tag-01
                  :ARG2 (x13 / protein
                        :name (x14 / name :op1 "GFP")
                        :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
            :name (x16 / name :op1 "RhoA")
            :xref (x19 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))


# ::id PMC4729484.268
# ::snt Cell lysates were incubated with a GST fusion Rhotekin Rho-binding domain (GST-RBD).
# ::tok Cell lysates were incubated with a GST fusion Rhotekin Rho @-@ binding domain ( GST @-@ RBD ) .
(x6 / protein-segment
      :ARG1 (x2 / lysate
            :mod (x1 / cell))
      :ARG1-of (x3 / incubate-01
            :ARG2 (x4 / protein
                  :name (x5 / name :op1 "GST" :op2 "fusion")))
      :ARG0-of (x9 / bind-01
            :ARG1 (x7 / protein
                  :name (x8 / name :op1 "Rho")
                  :xref (x / xref :value "UNIPROT:OPSD_HUMAN" :prob "0.602")))
      :name (x10 / name :op1 "GST-RBD"))


# ::id PMC4729484.269
# ::snt The active RhoA proteins that bound to GST-RBD were determined by immunoblotting with antibodies to GFP.
# ::tok The active RhoA proteins that bound to GST @-@ RBD were determined by immunoblotting with antibodies to GFP .
(x7 / determine-01
      :ARG1 (x3 / protein
            :ARG0-of (x1 / activity-06)
            :name (x2 / name :op1 "RhoA")
            :ARG1-of (x4 / bind-01
                  :ARG2 (x5 / protein
                        :name (x6 / name :op1 "GST-RBD")
                        :xref (x14 / xref :value "UNIPROT:GSTCD_HUMAN" :prob "0.252")))
            :xref (x13 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :ARG2 (x8 / immunoblot-01
            :ARG3 (x9 / antibody
                  :ARG0-of (x10 / counter-01
                        :ARG1 (x11 / protein
                              :name (x12 / name :op1 "GFP")
                              :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))))))


# ::id PMC4729484.270
# ::snt The GTP-GFP-RhoA protein intensity was normalized to the intensity of the expressed GFP proteins (input) as detected by anti-GFP antibodies.
# ::tok The GTP @-@ GFP @-@ RhoA protein intensity was normalized to the intensity of the expressed GFP proteins ( input ) as detected by anti @-@ GFP antibodies .
(x7 / normalize-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "ras")
            :ARG1-of (x6 / intensity
                  :ARG0 (x5 / protein
                        :mod (x3 / protein
                              :name (x4 / name :op1 "GFP-RhoA"))))
            :xref (x18 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
      :ARG1 (x8 / intensity
            :poss (x9 / express-03
                  :ARG2 (x11 / protein
                        :name (x10 / name :op1 "GFP")
                        :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))
                  :ARG1 (x12 / input)))
      :ARG1-of (x13 / detect-01
            :ARG2 (x17 / antibody
                  :ARG0-of (x14 / counter-01
                        :ARG1 (x15 / protein
                              :name (x16 / name :op1 "GFP")
                              :xref (x19 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))))))


# ::id PMC4729484.271
# ::snt COS-7 cells were stimulated with EGF for the indicated time with or without U0126.
# ::tok COS @-@ 7 cells were stimulated with EGF for the indicated time with or without U0126 .
(x3 / stimulate-01
      :ARG1 (x2 / cell-line
            :name (x1 / name :op1 "COS-7"))
      :ARG2 (x4 / protein
            :name (x5 / name :op1 "EGF")
            :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :duration (x7 / time
            :ARG1-of (x6 / indicate-01))
      :ARG2 (x8 / or
            :manner (x9 / small-molecule
                  :name (x10 / name :op1 "U0126")
                  :xref (x11 / xref :value "PUBCHEM:3006531" :prob "17.656696"))))


# ::id PMC4729484.272
# ::snt The amount of active RhoA was determined by GST-RBD pull down assay as described in (A), except that antibodies to RhoA were used to detect the endogenous RhoA.
# ::tok The amount of active RhoA was determined by GST @-@ RBD pull down assay as described in ( A ) , except that antibodies to RhoA were used to detect the endogenous RhoA .
(x17 / use-01
      :ARG1 (x5 / determine-01
            :ARG1 (x1 / amount
                  :quant-of (x2 / enzyme
                        :ARG0-of (x3 / activity-06)
                        :name (x4 / name :op1 "RhoA")
                        :xref (x23 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG2 (x9 / assay-01
                  :ARG1 (x8 / pull-down-08
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "GST-RBD")
                              :xref (x24 / xref :value "UNIPROT:GSTCD_HUMAN" :prob "0.252"))))
            :ARG1-of (x10 / describe-01
                  :ARG0 (x11 / have-li-91 :ARG2 "a"))
            :ARG2-of (x12 / except-01
                  :ARG1 (x13 / antibody
                        :ARG0-of (x14 / counter-01
                              :ARG1 (x15 / protein
                                    :name (x16 / name :op1 "RhoA")
                                    :xref (x22 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))))
      :ARG2 (x18 / detect-01
            :ARG1 (x19 / enzyme
                  :mod (x20 / endogenous)
                  :name (x21 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))


# ::id PMC4729484.273
# ::snt The GTP-RhoA protein intensity was normalized to the intensity of the total endogenous RhoA protein (input) as detected by anti-RhoA antibodies.
# ::tok The GTP @-@ RhoA protein intensity was normalized to the intensity of the total endogenous RhoA protein ( input ) as detected by anti @-@ RhoA antibodies .
(x6 / normalize-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "ras")
            :ARG1-of (x5 / intensity
                  :ARG0 (x4 / protein
                        :name (x3 / name :op1 "RhoA")
                        :xref (x21 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :xref (x20 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
      :ARG1 (x7 / intensity
            :poss (x11 / protein
                  :mod (x8 / total)
                  :mod (x9 / endogenous)
                  :name (x10 / name :op1 "RhoA")
                  :ARG1-of (x12 / describe-01
                        :ARG0 (x13 / input))
                  :xref (x19 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
      :ARG1-of (x14 / detect-01
            :ARG2 (x18 / antibody
                  :ARG0-of (x15 / counter-01
                        :ARG1 (x16 / protein
                              :name (x17 / name :op1 "RhoA")
                              :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))))


# ::id PMC4729484.274
# ::snt Each value is the average of at least three experiments and the error bar is standard error.
# ::tok Each value is the average of at least three experiments and the error bar is standard error .
(x6 / and
      :op1 (x3 / average-01
            :ARG1 (x2 / value
                  :mod (x1 / each))
            :ARG0 (x5 / experiment-01
                  :mod (x4 / at-least :op1 "3")))
      :op2 (x10 / error
            :domain (x8 / bar
                  :mod (x7 / error))
            :ARG1-of (x9 / standard-02)))


# ::id PMC4729484.276
# ::snt We also examined whether ERK activation is required for EGF-induced activation of endogenous RhoA.
# ::tok We also examined whether ERK activation is required for EGF @-@ induced activation of endogenous RhoA .
(x3 / examine-01
      :ARG0 (x1 / we)
      :mod (x2 / also)
      :ARG1 (x7 / require-01
            :mode "interrogative"
            :ARG1 (x6 / activate-01
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "ERK")
                        :xref (x16 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :ARG0 (x11 / activate-01
                  :ARG2-of (x10 / induce-01
                        :ARG0 (x8 / protein
                              :name (x9 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x12 / enzyme
                        :mod (x13 / endogenous)
                        :name (x14 / name :op1 "RhoA")
                        :xref (x15 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))))


# ::id PMC4729484.277
# ::snt We stimulated the cells with EGF with or without U0126.
# ::tok We stimulated the cells with EGF with or without U0126 .
(x2 / stimulate-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / cell)
      :ARG2 (x6 / or
            :op1 (x4 / protein
                  :name (x5 / name :op1 "EGF")
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :op2 (x7 / small-molecule
                  :name (x8 / name :op1 "U0126")
                  :xref (x9 / xref :value "PUBCHEM:3006531" :prob "17.656696"))))


# ::id PMC4729484.278
# ::snt The activated GTP-bound RhoA was pulled down with GST-RBD of Rhotekin.
# ::tok The activated GTP @-@ bound RhoA was pulled down with GST @-@ RBD of Rhotekin .
(x1 / and
      :op1 (x2 / enzyme
            :ARG1-of (x3 / activate-01)
            :ARG1-of (x6 / bind-01
                  :ARG2 (x4 / small-molecule
                        :name (x5 / name :op1 "GTP")
                        :xref (x14 / xref :value "PUBCHEM:6830" :prob "15.470645")))
            :name (x7 / name :op1 "RhoA")
            :ARG1-of (x8 / pull-down-00)
            :xref (x13 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :op2 (x9 / protein-segment
            :name (x10 / name :op1 "GST-RBD")
            :part-of (x11 / enzyme
                  :name (x12 / name :op1 "Rhotekin")
                  :xref (x / xref :value "UNIPROT:RTKN_HUMAN" :prob "1.002"))))


# ::id PMC4729484.279
# ::snt We showed that EGF stimulated RhoA activation and this activation was inhibited by U0126 ( Fig 5C & 5D ).
# ::tok We showed that EGF stimulated RhoA activation and this activation was inhibited by U0126 ( Fig 5C & 5D ) .
(x2 / show-01
      :ARG0 (x1 / we)
      :ARG1 (x5 / stimulate-01
            :ARG0 (x3 / protein
                  :name (x4 / name :op1 "EGF")
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :ARG1 (x9 / and
                  :op1 (x8 / activate-01
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "RhoA")
                              :xref (x19 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
                  :op2 (x12 / inhibit-01
                        :ARG1 (x11 / activate-01
                              :mod (x10 / this))
                        :ARG0 (x13 / small-molecule
                              :name (x14 / name :op1 "U0126")
                              :xref (x20 / xref :value "PUBCHEM:3006531" :prob "17.656696")))))
      :ARG1-of (x15 / describe-01
            :ARG0 (x17 / and
                  :op1 (x16 / figure :mod "5c")
                  :op2 (x18 / figure :mod "5d"))))


# ::id PMC4729484.280
# ::snt As controls, we showed that EGF stimulated ERK activation and this ERK activation is abolished in the presence of U0126 ( Fig 5C ).
# ::tok As controls , we showed that EGF stimulated ERK activation and this ERK activation is abolished in the presence of U0126 ( Fig 5C ) .
(x3 / show-01
      :ARG1-of (x1 / control-01)
      :ARG0 (x2 / we)
      :ARG1 (x6 / stimulate-01
            :ARG0 (x4 / protein
                  :name (x5 / name :op1 "EGF")
                  :xref (x21 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :ARG1 (x10 / and
                  :op1 (x9 / activate-01
                        :ARG1 (x7 / enzyme
                              :name (x8 / name :op1 "ERK")
                              :xref (x20 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                  :op2 (x14 / abolish-01
                        :ARG1 (x13 / activate-01
                              :ARG1 (x11 / enzyme
                                    :name (x12 / name :op1 "ERK")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                        :location (x15 / present-02
                              :ARG1 (x16 / small-molecule
                                    :name (x17 / name :op1 "U0126")
                                    :xref (x22 / xref :value "PUBCHEM:3006531" :prob "17.656696"))))))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / figure :mod "5c")))


# ::id PMC4729484.281
# ::snt Together our results indicate that phosphorylation of RhoA 88 S and 100 T by ERK in response to EGF enhances RhoA activity.
# ::tok Together our results indicate that phosphorylation of RhoA 88 S and 100 T by ERK in response to EGF enhances RhoA activity .
(x5 / indicate-01
      :mod (x1 / together)
      :ARG0 (x3 / thing
            :poss (x2 / we)
            :ARG2-of (x4 / result-01))
      :ARG1 (x21 / enhance-01
            :ARG0 (x6 / phosphorylate-01
                  :ARG1 (x13 / and
                        :op1 (x7 / protein
                              :name (x8 / name :op1 "RhoA")
                              :ARG1-of (x9 / describe-01
                                    :ARG0 (x10 / publication
                                          :ARG1-of (x11 / cite-01 :ARG2 "88")))
                              :name (x12 / name :op1 "S")
                              :xref (x26 / xref :value "UNIPROT:Q0EFA5_HUMAN" :prob "1.001"))
                        :op2 (x14 / enzyme
                              :name (x15 / name :op1 "100" :op2 "T")))
                  :ARG2 (x16 / enzyme
                        :name (x17 / name :op1 "ERK")
                        :xref (x28 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG2-of (x18 / respond-01
                        :ARG1 (x19 / protein
                              :name (x20 / name :op1 "EGF")
                              :xref (x27 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
            :ARG1 (x24 / activity-06
                  :ARG0 (x22 / protein
                        :name (x23 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))))


# ::id PMC4729484.282
# ::snt The effects of RhoA phosphorylation on cell stress fiber formation
# ::tok The effects of RhoA phosphorylation on cell stress fiber formation
(x1 / affect-01
      :ARG0 (x4 / phosphorylate-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :location (x5 / cell))
      :ARG1 (x8 / form-01
            :ARG1 (x7 / fiber
                  :mod (x6 / stress))))


# ::id PMC4729484.283
# ::snt The most well-studied function of RhoA is its capacity to regulate the formation of actin stress fibers, which consist of long bundles of filaments traversing the cell [ 30 ].
# ::tok The most well @-@ studied function of RhoA is its capacity to regulate the formation of actin stress fibers , which consist of long bundles of filaments traversing the cell [ 30 ] .
(x4 / function-01
      :mod (x1 / most
            :ARG1-of (x3 / study-01
                  :ARG1-of (x2 / well-09)))
      :ARG0 (x5 / protein
            :name (x6 / name :op1 "RhoA")
            :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :ARG1 (x7 / capable-01
            :ARG2 (x8 / regulate-01
                  :ARG1 (x9 / form-01
                        :ARG1 (x11 / fiber
                              :mod (x10 / stress))
                        :ARG0-of (x12 / consist-01
                              :ARG2 (x14 / bundle-01
                                    :ARG1-of (x13 / long-03)
                                    :ARG1 (x15 / filament
                                          :ARG1-of (x16 / traverse-01)))
                              :ARG1 (x17 / cell))
                        :ARG1-of (x18 / describe-01
                              :ARG0 (x19 / publication
                                    :ARG1-of (x20 / cite-01 :ARG2 "30")))))))


# ::id PMC4729484.284
# ::snt EGF has also been shown to stimulate the formation of actin stress fibers [ 30 – 32 ], and this stimulation is mediated by RhoA [ 30 ].
# ::tok EGF has also been shown to stimulate the formation of actin stress fibers [ 30 – 32 ] , and this stimulation is mediated by RhoA [ 30 ] .
(x4 / show-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "EGF")
            :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :mod (x3 / also)
      :ARG1 (x5 / stimulate-01
            :ARG1 (x10 / fiber
                  :ARG0-of (x6 / form-01
                        :ARG1 (x7 / protein
                              :name (x8 / name :op1 "actin")
                              :xref (x24 / xref :value "UNIPROT:KLH17_HUMAN" :prob "0.302")))
                  :mod (x9 / stress)
                  :ARG1-of (x11 / describe-01
                        :ARG0 (x12 / publication
                              :ARG1-of (x13 / cite-01
                                    :ARG2 (x14 / value-interval :op1 "30" :op2 "32")))))
            :ARG0-of (x18 / mediate-01
                  :ARG1 (x15 / and
                        :op1 (x17 / stimulate-01
                              :ARG0 (x16 / this)))
                  :ARG0 (x19 / protein
                        :name (x20 / name :op1 "RhoA")
                        :xref (x25 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG1-of (x21 / describe-01
                  :ARG0 (x22 / publication
                        :ARG1-of (x23 / cite-01 :ARG2 "30")))))


# ::id PMC4729484.285
# ::snt To determine the role of RhoA 88 S and 100 T phosphorylation in EGF-induced formation of actin stress fibers, we overexpressed GFP-RhoA, GFP-RhoA S88A/T100A and GFP-RhoA S88E/T100E in COS-7 cells by transient transfection.
# ::tok To determine the role of RhoA 88 S and 100 T phosphorylation in EGF @-@ induced formation of actin stress fibers , we overexpressed GFP @-@ RhoA , GFP @-@ RhoA S88A @/@ T100A and GFP @-@ RhoA S88E @/@ T100E in COS @-@ 7 cells by transient transfection .
(x20 / overexpress-01
      :purpose (x1 / determine-01
            :ARG1 (x2 / role
                  :poss (x12 / phosphorylate-01
                        :ARG1 (x9 / and
                              :op1 (x3 / enzyme
                                    :name (x4 / name :op1 "RhoA")
                                    :ARG1-of (x5 / describe-01
                                          :ARG0 (x6 / publication
                                                :ARG1-of (x7 / cite-01 :ARG2 "88")))
                                    :name (x8 / name :op1 "S")
                                    :xref (x39 / xref :value "UNIPROT:Q0EFA5_HUMAN" :prob "1.001"))
                              :op2 (x10 / enzyme
                                    :name (x11 / name :op1 "100" :op2 "T"))))
                  :topic (x16 / form-01
                        :ARG2-of (x15 / induce-01
                              :ARG0 (x13 / protein
                                    :name (x14 / name :op1 "EGF")
                                    :xref (x41 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                        :ARG1 (x18 / fiber
                              :mod (x17 / stress)))))
      :ARG0 (x19 / we)
      :ARG1 (x21 / protein
            :name (x22 / name :op1 "GFP-RhoA"))
      :ARG2 (x23 / protein
            :name (x24 / name :op1 "GFP-RhoA"))
      :ARG1 (x27 / and
            :op1 (x25 / mutate-01 :value "S88A")
            :op2 (x26 / mutate-01 :value "T100A")
            :op3 (x28 / protein
                  :name (x29 / name :op1 "GFP-RhoA")))
      :ARG2 (x32 / slash
            :op1 (x30 / enzyme
                  :name (x31 / name :op1 "S88E"))
            :op2 (x33 / enzyme
                  :name (x34 / name :op1 "T100E")
                  :xref (x40 / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232")))
      :location (x36 / cell-line
            :name (x35 / name :op1 "COS-7"))
      :manner (x38 / transfect-01
            :ARG1-of (x37 / transient-02)))


# ::id PMC4729484.286
# ::snt The organization of stress fibers was observed using phalloidin staining.
# ::tok The organization of stress fibers was observed using phalloidin staining .
(x4 / observe-01
      :ARG1 (x1 / organize-01
            :ARG1 (x3 / fiber
                  :mod (x2 / stress)))
      :instrument (x7 / stain-01
            :ARG2 (x5 / small-molecule
                  :name (x6 / name :op1 "phalloidin")
                  :xref (x / xref :value "PUBCHEM:4752" :prob "16.525295"))))


# ::id PMC4729484.287
# ::snt Our results showed that cells with the overexpression of either GFP-RhoA or GFP-RhoA S88E/T100E had enhanced stress fiber formation when compared with non-transfected cells ( Fig 6A ).
# ::tok Our results showed that cells with the overexpression of either GFP @-@ RhoA or GFP @-@ RhoA S88E @/@ T100E had enhanced stress fiber formation when compared with non @-@ transfected cells ( Fig 6A ) .
(x4 / show-01
      :ARG0 (x2 / thing
            :poss (x1 / we)
            :ARG2-of (x3 / result-01))
      :ARG1 (x5 / cell)
      :ARG2 (x17 / enhance-01
            :ARG0 (x6 / overexpress-01
                  :ARG1 (x7 / or
                        :op1 (x8 / protein
                              :name (x9 / name :op1 "GFP-RhoA"))
                        :op2 (x10 / protein
                              :name (x11 / name :op1 "GFP-RhoA"))
                        :op1 (x14 / slash
                              :op1 (x12 / enzyme
                                    :name (x13 / name :op1 "S88E"))
                              :op2 (x15 / enzyme
                                    :name (x16 / name :op1 "T100E")
                                    :xref (x / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232")))))
            :ARG1 (x20 / form-01
                  :ARG1 (x19 / fiber
                        :mod (x18 / stress)))
            :time (x21 / compare-01
                  :ARG2 (x23 / cell
                        :ARG1-of (x22 / transfect-01 :polarity "-"))))
      :ARG1-of (x24 / describe-01
            :ARG0 (x25 / figure :mod "6a")))


# ::id PMC4729484.288
# ::snt Cells with overexpression of GFP-RhoA S88E/T100E showed the strongest phalloidin staining with or without EGF stimulation ( Fig 6A & 6B ).
# ::tok Cells with overexpression of GFP @-@ RhoA S88E @/@ T100E showed the strongest phalloidin staining with or without EGF stimulation ( Fig 6A & 6B ) .
(x6 / show-01
      :ARG0 (x1 / cell-line
            :ARG0-of (x2 / overexpress-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "GFP-RhoA")))
            :name (x5 / name :op1 "S88E" :op2 "T100E"))
      :ARG1 (x11 / stain-01
            :ARG1-of (x7 / strong-02
                  :degree (x8 / most))
            :ARG2 (x9 / small-molecule
                  :name (x10 / name :op1 "phalloidin")
                  :xref (x20 / xref :value "PUBCHEM:4752" :prob "16.525295"))
            :ARG1 (x12 / or
                  :op1 (x15 / stimulate-01
                        :polarity "-"
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :ARG1-of (x16 / describe-01
            :ARG0 (x18 / and
                  :op1 (x17 / figure :mod "6a")
                  :op2 (x19 / figure :mod "6b"))))


# ::id PMC4729484.289
# ::snt Treatment with EGF for 15 min increased the intensity of the stress fibers in cells transfected with wild type GFP-RhoA ( Fig 6A & 6B ).
# ::tok Treatment with EGF for 15 min increased the intensity of the stress fibers in cells transfected with wild type GFP @-@ RhoA ( Fig 6A & 6B ) .
(x6 / increase-01
      :ARG0 (x1 / treat-04
            :ARG2 (x2 / protein
                  :name (x3 / name :op1 "EGF")
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :duration (x4 / temporal-quantity
                  :quant "15"
                  :unit (x5 / minute)))
      :ARG1 (x7 / intensity
            :poss (x9 / fiber
                  :mod (x8 / stress)))
      :location (x10 / cell
            :ARG1-of (x11 / transfect-01
                  :ARG2 (x12 / enzyme
                        :mod (x13 / wild-type)
                        :name (x14 / name :op1 "GFP")
                        :xref (x20 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
            :name (x15 / name :op1 "RhoA"))
      :ARG1-of (x16 / describe-01
            :ARG0 (x18 / and
                  :op1 (x17 / figure :mod "6a")
                  :op2 (x19 / figure :mod "6b"))))


# ::id PMC4729484.290
# ::snt However, overexpression of GFP-RhoA S88A/T100A had little effect on the formation of stress fibers ( Fig 6A & 6B ).
# ::tok However , overexpression of GFP @-@ RhoA S88A @/@ T100A had little effect on the formation of stress fibers ( Fig 6A & 6B ) .
(x1 / contrast-01
      :ARG2 (x10 / affect-01
            :ARG0 (x2 / overexpress-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "GFP-RhoA"))
                  :ARG2 (x7 / slash
                        :op1 (x5 / enzyme
                              :name (x6 / name :op1 "S88A"))
                        :op2 (x8 / mutate-01 :value "T100A")))
            :degree (x9 / little)
            :ARG1 (x11 / form-01
                  :ARG1 (x13 / fiber
                        :mod (x12 / stress))))
      :ARG1-of (x14 / describe-01
            :ARG0 (x16 / and
                  :op1 (x15 / figure :mod "6a")
                  :op2 (x17 / figure :mod "6b"))))


# ::id PMC4729484.291
# ::snt These results indicated that RhoA phosphorylation by ERK enhanced its function in regulating the formation of stress fibers, possible through increasing RhoA activity.
# ::tok These results indicated that RhoA phosphorylation by ERK enhanced its function in regulating the formation of stress fibers , possible through increasing RhoA activity .
(x4 / indicate-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x10 / enhance-01
            :ARG0 (x7 / phosphorylate-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "RhoA")
                        :xref (x22 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :ARG2 (x8 / enzyme
                        :name (x9 / name :op1 "ERK")
                        :xref (x21 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :ARG1 (x11 / function-01
                  :ARG1 (x12 / regulate-01
                        :ARG1 (x16 / possible-01
                              :ARG1 (x13 / form-01
                                    :ARG1 (x15 / fiber
                                          :mod (x14 / stress)))))
                  :manner (x17 / increase-01
                        :ARG1 (x20 / activity-06
                              :ARG0 (x18 / protein
                                    :name (x19 / name :op1 "RhoA")
                                    :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))))))


# ::id PMC4729484.292
# ::snt The effects of EGF and RhoA phosphorylation on actin stress fiber formation in COS-7 cells.
# ::tok The effects of EGF and RhoA phosphorylation on actin stress fiber formation in COS @-@ 7 cells .
(x12 / form-01
      :ARG1 (x11 / fiber
            :ARG1 (x1 / affect-01
                  :ARG0 (x7 / phosphorylate-01
                        :ARG1 (x4 / and
                              :op1 (x2 / protein
                                    :name (x3 / name :op1 "EGF")
                                    :xref (x15 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                              :op2 (x5 / protein
                                    :name (x6 / name :op1 "RhoA")
                                    :xref (x16 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "actin")
                        :xref (x / xref :value "UNIPROT:KLH17_HUMAN" :prob "0.302")))
            :mod (x10 / stress))
      :location (x14 / cell-line
            :name (x13 / name :op1 "COS-7")))


# ::id PMC4729484.293
# ::snt COS-7 cells were transfected with expression constructs encoding GFP-tagged wild type, 88A/100A (S88A/T100A) or 88E/100E (S88E/T100E) RhoA.
# ::tok COS @-@ 7 cells were transfected with expression constructs encoding GFP @-@ tagged wild type , 88A @/@ 100A ( S88A/T100A ) or 88E @/@ 100E ( S88E/T100E ) RhoA .
(x3 / transfect-01
      :ARG1 (x2 / cell-line
            :name (x1 / name :op1 "COS-7"))
      :ARG2 (x15 / or
            :op1 (x4 / express-03
                  :ARG1 (x5 / construct-01
                        :ARG1 (x6 / gene
                              :ARG0-of (x7 / encode-01
                                    :ARG1 (x8 / enzyme
                                          :ARG1-of (x11 / tag-01
                                                :ARG2 (x9 / protein
                                                      :name (x10 / name :op1 "GFP")
                                                      :xref (x23 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
                                          :mod (x12 / wild-type)))
                              :name (x13 / name :op1 "88A" :op2 "100A")
                              :name (x14 / name :op1 "S88A/T100A"))))
            :op2 (x18 / slash
                  :op1 (x16 / enzyme
                        :name (x17 / name :op1 "88E"))
                  :op2 (x19 / enzyme
                        :name (x20 / name :op1 "100E" :op2 "S88E/T100E"))))
      :ARG0 (x21 / protein
            :name (x22 / name :op1 "RhoA")
            :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))


# ::id PMC4729484.294
# ::snt The formation of actin stress fibers was viewed by fluorescence microscopy following staining with 70 nM rhodamine-conjugated phalloidin as described in the Materials and Methods.
# ::tok The formation of actin stress fibers was viewed by fluorescence microscopy following staining with 70 nM rhodamine @-@ conjugated phalloidin as described in the Materials and Methods .
(x6 / view-02
      :ARG1 (x1 / form-01
            :ARG1 (x5 / fiber
                  :consist-of (x2 / protein
                        :wiki "actin"
                        :name (x3 / name :op1 "actin")
                        :xref (x / xref :value "UNIPROT:KLH17_HUMAN" :prob "0.302"))
                  :mod (x4 / stress)))
      :ARG0 (x8 / microscopy
            :mod (x7 / fluoresce-01))
      :ARG2-of (x9 / follow-01
            :ARG1 (x10 / stain-01
                  :ARG2 (x11 / small-molecule
                        :quant (x12 / mass-quantity
                              :quant "70"
                              :unit (x13 / nanomolar))
                        :ARG1-of (x16 / conjugate-02
                              :ARG2 (x14 / small-molecule
                                    :name (x15 / name :op1 "rhodamine")
                                    :xref (x23 / xref :value "PUBCHEM:6694" :prob "14.36086")))
                        :name (x17 / name :op1 "phalloidin")
                        :ARG1-of (x18 / describe-01
                              :location (x20 / and
                                    :op1 (x19 / material)
                                    :op2 (x21 / method)))
                        :xref (x22 / xref :value "PUBCHEM:4752" :prob "16.525295")))))


# ::id PMC4729484.295
# ::snt Boxed areas are shown at higher magnification.
# ::tok Boxed areas are shown at higher magnification .
(x3 / show-01
      :ARG1 (x2 / area
            :ARG1-of (x1 / box-02))
      :location (x6 / magnify-01
            :ARG1-of (x4 / high-02
                  :degree (x5 / more))))


# ::id PMC4729484.297
# ::snt Each value is the mean of at least three experiments with more than 20 cells analyzed for each experiment.
# ::tok Each value is the mean of at least three experiments with more than 20 cells analyzed for each experiment .
(x3 / mean
      :domain (x2 / value
            :mod (x1 / each))
      :mod (x5 / experiment-01
            :ARG2 (x4 / at-least :op1 "3")
            :ARG1 (x7 / cell-line
                  :quant (x6 / more-than :op1 "20")
                  :ARG1-of (x8 / analyze-01
                        :purpose (x10 / experiment-01
                              :mod (x9 / each))))))


# ::id PMC4729484.300
# ::snt To understand the mechanism by which RhoA phosphorylation increases stress fiber formation, we examined whether RhoA phosphorylation increases its interaction with its effectors, ROCK1 and mDia.
# ::tok To understand the mechanism by which RhoA phosphorylation increases stress fiber formation , we examined whether RhoA phosphorylation increases its interaction with its effectors , ROCK1 and mDia .
(x11 / examine-01
      :purpose (x1 / understand-01
            :ARG1 (x2 / mechanism
                  :instrument-of (x6 / increase-01
                        :ARG0 (x5 / phosphorylate-01
                              :ARG1 (x3 / protein
                                    :name (x4 / name :op1 "RhoA")
                                    :xref (x23 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
                        :ARG1 (x9 / form-01
                              :ARG1 (x8 / fiber
                                    :mod (x7 / stress))))))
      :ARG0 (x10 / we)
      :ARG1 (x15 / increase-01
            :mode "interrogative"
            :ARG0 (x14 / phosphorylate-01
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "RhoA")
                        :xref (x25 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG1 (x16 / interact-01
                  :ARG1 (x20 / and
                        :op1 (x17 / effector)
                        :op2 (x18 / protein
                              :name (x19 / name :op1 "ROCK1")
                              :xref (x24 / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004"))
                        :op3 (x21 / enzyme
                              :name (x22 / name :op1 "mDia")
                              :xref (x / xref :value "UNIPROT:DIAP3_HUMAN" :prob "0.272"))))))


# ::id PMC4729484.301
# ::snt Several RhoA substrates including ROCK1 and mDia have been implicated in mediating RhoA regulation of actin remodeling [ 33 – 35 ].
# ::tok Several RhoA substrates including ROCK1 and mDia have been implicated in mediating RhoA regulation of actin remodeling [ 33 – 35 ] .
(x11 / implicate-01
      :ARG1 (x4 / substrate
            :quant (x1 / several)
            :mod (x2 / protein
                  :name (x3 / name :op1 "RhoA")
                  :xref (x23 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG2-of (x5 / include-01
                  :ARG1 (x8 / and
                        :op1 (x6 / protein
                              :name (x7 / name :op1 "ROCK1")
                              :xref (x24 / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004"))
                        :op2 (x9 / enzyme
                              :name (x10 / name :op1 "mDia")
                              :xref (x22 / xref :value "UNIPROT:DIAP3_HUMAN" :prob "0.272")))))
      :ARG2 (x12 / mediate-01
            :ARG1 (x13 / protein
                  :name (x14 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG0-of (x15 / regulate-01
                  :ARG1 (x17 / remodel-01
                        :ARG1 (x16 / actin)))
            :ARG1-of (x18 / describe-01
                  :ARG0 (x19 / publication
                        :ARG1-of (x20 / cite-01
                              :ARG2 (x21 / value-interval :op1 "33" :op2 "35"))))))


# ::id PMC4729484.302
# ::snt We expressed GFP-RhoA, GFP-RhoA S88A/T100A and GFP-RhoA S88E/T100E in COS-7 cells by transient transfection.
# ::tok We expressed GFP @-@ RhoA , GFP @-@ RhoA S88A @/@ T100A and GFP @-@ RhoA S88E @/@ T100E in COS @-@ 7 cells by transient transfection .
(x2 / express-03
      :ARG0 (x1 / we)
      :ARG2 (x13 / slash
            :op1 (x3 / protein
                  :name (x4 / name :op1 "GFP-RhoA"))
            :op2 (x5 / protein
                  :name (x6 / name :op1 "GFP-RhoA"))
            :ARG0-of (x9 / and
                  :op1 (x7 / mutate-01 :value "S88A")
                  :op2 (x8 / mutate-01 :value "T100A")
                  :op3 (x10 / protein
                        :name (x11 / name :op1 "GFP-RhoA")))
            :ARG0-of (x12 / mutate-01 :value "S88E")
            :op2 (x14 / enzyme
                  :name (x15 / name :op1 "T100E")
                  :xref (x / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232")))
      :location (x17 / cell-line
            :name (x16 / name :op1 "COS-7"))
      :manner (x19 / transfect-01
            :ARG1-of (x18 / transient-02)))


# ::id PMC4729484.303
# ::snt The cells were either not treated or treated with EGF for 15 min.
# ::tok The cells were either not treated or treated with EGF for 15 min .
(x3 / treat-04
      :ARG1 (x1 / cell)
      :ARG2 (x2 / or :polarity "-")
      :ARG2 (x4 / or
            :op1 (x5 / treat-04
                  :ARG2 (x6 / protein
                        :name (x7 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
      :duration (x8 / temporal-quantity
            :quant "15"
            :unit (x9 / minute)))


# ::id PMC4729484.304
# ::snt GFP-tagged RhoA and the mutants were IPed with antibody to GFP.
# ::tok GFP @-@ tagged RhoA and the mutants were IPed with antibody to GFP .
(x1 / and
      :op1 (x2 / enzyme
            :ARG1-of (x5 / tag-01
                  :ARG2 (x3 / protein
                        :name (x4 / name :op1 "GFP")
                        :xref (x14 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
            :name (x6 / name :op1 "RhoA")
            :xref (x13 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :op2 (x7 / mutate-01
            :mod (x8 / iped)
            :ARG2 (x9 / antibody
                  :ARG0-of (x10 / counter-01
                        :ARG1 (x11 / protein
                              :name (x12 / name :op1 "GFP")
                              :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))))))


# ::id PMC4729484.305
# ::snt The co-IP of ROCK1 and mDia was determined by immunoblotting.
# ::tok The co @-@ IP of ROCK1 and mDia was determined by immunoblotting .
(x7 / determine-01
      :ARG1 (x1 / cotransfect-01
            :ARG2 (x4 / and
                  :op1 (x2 / protein
                        :name (x3 / name :op1 "ROCK1")
                        :xref (x / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004"))
                  :op2 (x5 / enzyme
                        :name (x6 / name :op1 "mDia")
                        :xref (x9 / xref :value "UNIPROT:DIAP3_HUMAN" :prob "0.272"))))
      :ARG0 (x8 / immunoblot-01))


# ::id PMC4729484.306
# ::snt As shown in Fig 7A–7C , EGF stimulates the interaction between ROCK1 and wild type RhoA.
# ::tok As shown in Fig 7A–7C , EGF stimulates the interaction between ROCK1 and wild type RhoA .
(x5 / stimulate-01
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :op1 "7a–7c"))
      :ARG0 (x3 / protein
            :name (x4 / name :op1 "EGF")
            :xref (x12 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :ARG1 (x6 / interact-01
            :ARG0 (x7 / protein
                  :name (x8 / name :op1 "ROCK1")
                  :xref (x13 / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004"))
            :ARG1 (x9 / enzyme
                  :mod (x10 / wild-type)
                  :name (x11 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))


# ::id PMC4729484.307
# ::snt The phosphomimetic GFP-RhoA S88E/T100E strongly interacts with ROCK1 with or without EGF stimulation.
# ::tok The phosphomimetic GFP @-@ RhoA S88E @/@ T100E strongly interacts with ROCK1 with or without EGF stimulation .
(x1 / and
      :op1 (x10 / interact-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "GFP-RhoA"))
            :degree (x9 / strong-02
                  :ARG1 (x6 / slash
                        :op1 (x4 / enzyme
                              :name (x5 / name :op1 "S88E"))
                        :op2 (x7 / enzyme
                              :name (x8 / name :op1 "T100E")
                              :xref (x18 / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232"))))
            :ARG1 (x11 / protein
                  :name (x12 / name :op1 "ROCK1")
                  :xref (x17 / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004")))
      :op2 (x13 / or
            :op2 (x16 / stimulate-01
                  :polarity "-"
                  :ARG1 (x14 / protein
                        :name (x15 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC4729484.308
# ::snt The interaction between GFP-RhoA S88A/T100A and ROCK1 is weaker ( Fig 7A & 7B ).
# ::tok The interaction between GFP @-@ RhoA S88A @/@ T100A and ROCK1 is weaker ( Fig 7A & 7B ) .
(x10 / weak-02
      :ARG1 (x1 / interact-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "GFP-RhoA"))
            :ARG1 (x7 / and
                  :op1 (x4 / cell-line
                        :name (x5 / name :op1 "S88A")
                        :mod (x6 / mutate-01 :value "T100A"))
                  :op2 (x8 / protein
                        :name (x9 / name :op1 "ROCK1")
                        :xref (x / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004"))))
      :degree (x11 / more)
      :ARG1-of (x12 / describe-01
            :ARG0 (x14 / and
                  :op1 (x13 / figure :mod "7a")
                  :op2 (x15 / figure :mod "7b"))))


# ::id PMC4729484.309
# ::snt These results suggest that the phosphorylation of RhoA 88 S and 100 T increases the interaction between RhoA and ROCK1.
# ::tok These results suggest that the phosphorylation of RhoA 88 S and 100 T increases the interaction between RhoA and ROCK1 .
(x4 / suggest-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x11 / and
            :op1 (x5 / phosphorylate-01
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "RhoA")
                        :xref (x20 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :ARG1-of (x8 / describe-01
                        :ARG0 (x9 / publication
                              :ARG1-of (x10 / cite-01 :ARG2 "88"))))
            :op2 (x14 / increase-01
                  :ARG0 (x12 / protein
                        :name (x13 / name :op1 "100" :op2 "T"))
                  :ARG1 (x15 / interact-01
                        :ARG0 (x16 / protein
                              :name (x17 / name :op1 "RhoA")
                              :xref (x21 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                        :ARG2 (x18 / protein
                              :name (x19 / name :op1 "ROCK1")
                              :xref (x / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004"))))))


# ::id PMC4729484.310
# ::snt It has been reported that ROCK1 is activated when it binds to RhoA, and ROCK1 promotes the formation of actin stress fibers and adhesion complexes [ 36 – 38 ].
# ::tok It has been reported that ROCK1 is activated when it binds to RhoA , and ROCK1 promotes the formation of actin stress fibers and adhesion complexes [ 36 – 38 ] .
(x1 / report-01
      :ARG1 (x17 / and
            :op1 (x11 / promote-01
                  :ARG0 (x4 / activate-01
                        :ARG1 (x2 / protein
                              :name (x3 / name :op1 "ROCK1")
                              :xref (x24 / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004"))
                        :time (x5 / bind-01
                              :ARG2 (x8 / and
                                    :op1 (x6 / protein
                                          :name (x7 / name :op1 "RhoA")
                                          :xref (x25 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                                    :op2 (x9 / protein
                                          :name (x10 / name :op1 "ROCK1")
                                          :xref (x / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004")))))
                  :ARG1 (x12 / form-01
                        :ARG1 (x16 / fiber
                              :consist-of (x13 / protein
                                    :wiki "actin"
                                    :name (x14 / name :op1 "actin")
                                    :xref (x26 / xref :value "UNIPROT:KLH17_HUMAN" :prob "0.302"))
                              :mod (x15 / stress))))
            :op2 (x19 / macro-molecular-complex
                  :ARG0-of (x18 / adhere-01)
                  :ARG1-of (x20 / describe-01
                        :ARG0 (x21 / publication
                              :ARG1-of (x22 / cite-01
                                    :ARG2 (x23 / value-interval :op1 "36" :op2 "38")))))))


# ::id PMC4729484.311
# ::snt In contrast, the interaction between mDia and RhoA is not affected by EGF stimulation and the phosphorylation status of RhoA ( Fig 7A & 7C ).
# ::tok In contrast , the interaction between mDia and RhoA is not affected by EGF stimulation and the phosphorylation status of RhoA ( Fig 7A & 7C ) .
(x1 / contrast-01
      :ARG2 (x2 / interact-01
            :ARG0 (x8 / affect-01
                  :ARG1 (x5 / and
                        :op1 (x3 / enzyme
                              :name (x4 / name :op1 "mDia")
                              :xref (x21 / xref :value "UNIPROT:DIAP3_HUMAN" :prob "0.272"))
                        :op2 (x6 / protein
                              :name (x7 / name :op1 "RhoA")
                              :xref (x22 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
                  :polarity "-"
                  :ARG0 (x11 / stimulate-01
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "EGF")
                              :xref (x20 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
            :ARG1 (x12 / status
                  :mod (x13 / phosphorylate-01
                        :ARG1 (x14 / enzyme
                              :name (x15 / name :op1 "RhoA")
                              :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))))
      :ARG1-of (x16 / describe-01
            :ARG0 (x18 / and
                  :op1 (x17 / figure :mod "7a")
                  :op2 (x19 / figure :mod "7c"))))


# ::id PMC4729484.312
# ::snt The effects of RhoA phosphorylation on its interaction with ROCK1 and mDia.
# ::tok The effects of RhoA phosphorylation on its interaction with ROCK1 and mDia .
(x8 / and
      :op1 (x1 / affect-01
            :ARG0 (x4 / phosphorylate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "RhoA")
                        :xref (x11 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG1 (x5 / interact-01
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "ROCK1")
                        :xref (x12 / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004"))))
      :op2 (x9 / enzyme
            :name (x10 / name :op1 "mDia")
            :xref (x / xref :value "UNIPROT:DIAP3_HUMAN" :prob "0.272")))


# ::id PMC4729484.313
# ::snt COS-7 cells were transfected with constructs encoding wild type or mutant GFP-tagged RhoA and stimulated with EGF (50 ng/ml).
# ::tok COS @-@ 7 cells were transfected with constructs encoding wild type or mutant GFP @-@ tagged RhoA and stimulated with EGF ( 50 ng/ml ) .
(x3 / transfect-01
      :ARG1 (x2 / cell-line
            :name (x1 / name :op1 "COS-7"))
      :ARG2 (x14 / and
            :op1 (x4 / construct-01
                  :ARG1 (x5 / encode-01
                        :ARG1 (x6 / enzyme
                              :mod (x7 / wild-type)
                              :ARG1-of (x12 / tag-01
                                    :ARG2 (x8 / or
                                          :op1 (x9 / enzyme
                                                :ARG2-of (x10 / mutate-01)
                                                :name (x11 / name :op1 "GFP")
                                                :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))))
                              :name (x13 / name :op1 "RhoA")
                              :xref (x21 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
            :op2 (x15 / stimulate-01
                  :ARG0 (x16 / protein
                        :name (x17 / name :op1 "EGF")
                        :quant (x18 / concentration-quantity
                              :quant "50"
                              :unit (x19 / nanogram-per-milliliter))
                        :xref (x20 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC4729484.315
# ::snt The input GFP was determined by immunoblotting the whole lysate with anti-GFP antibodies (bottom panel).
# ::tok The input GFP was determined by immunoblotting the whole lysate with anti @-@ GFP antibodies ( bottom panel ) .
(x4 / determine-01
      :ARG1 (x1 / nucleic-acid
            :wiki "dna"
            :mod (x2 / input)
            :name (x3 / name :op1 "GFP"))
      :ARG2 (x5 / immunoblot-01
            :ARG1 (x7 / lysate
                  :mod (x6 / whole))
            :ARG3 (x11 / antibody
                  :ARG0-of (x8 / counter-01
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "GFP")
                              :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))))
      :ARG1-of (x12 / describe-01
            :ARG0 (x14 / panel
                  :mod (x13 / bottom))))


# ::id PMC4729484.316
# ::snt The binding between ROCK1/mDia and the RhoA proteins was measured as the ratio of the ROCK1/mDia band intensity relative to the RhoA band intensity.
# ::tok The binding between ROCK1 @/@ mDia and the RhoA proteins was measured as the ratio of the ROCK1 @/@ mDia band intensity relative to the RhoA band intensity .
(x13 / band
      :ARG1 (x1 / bind-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "ROCK1" :op2 "mDia"))
            :ARG2 (x4 / and
                  :op1 (x6 / protein
                        :name (x5 / name :op1 "RhoA")
                        :xref (x22 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
      :ARG1-of (x7 / measure-01
            :ARG2 (x8 / ratio-of
                  :op1 (x9 / protein
                        :name (x10 / name :op1 "ROCK1")
                        :xref (x / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004"))
                  :op2 (x11 / enzyme
                        :name (x12 / name :op1 "mDia")
                        :xref (x21 / xref :value "UNIPROT:DIAP3_HUMAN" :prob "0.272"))))
      :ARG1-of (x14 / intensity
            :ARG1-of (x15 / relative-05
                  :ARG2 (x18 / band
                        :mod (x16 / protein
                              :name (x17 / name :op1 "RhoA")
                              :xref (x20 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                        :ARG1-of (x19 / intense-02)))))


# ::id PMC4729484.320
# ::snt COS-7 cells were transfected with wild type or mutant GFP tagged RhoA.
# ::tok COS @-@ 7 cells were transfected with wild type or mutant GFP tagged RhoA .
(x3 / transfect-01
      :ARG1 (x2 / cell-line
            :name (x1 / name :op1 "COS-7"))
      :ARG2 (x7 / or
            :op1 (x4 / enzyme
                  :mod (x5 / wild-type)
                  :name (x6 / name :op1 "braf")
                  :xref (x15 / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.671"))
            :op2 (x8 / enzyme
                  :ARG2-of (x9 / mutate-01)
                  :name (x10 / name :op1 "GFP")
                  :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))
            :ARG1-of (x11 / tag-01
                  :ARG2 (x12 / protein
                        :name (x13 / name :op1 "RhoA")
                        :xref (x14 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))))


# ::id PMC4729484.321
# ::snt After pretreatment with Y-27632 (5uM) for 60 min, cells were stimulated with EGF (50 ng/ml) for 15min.
# ::tok After pretreatment with Y @-@ 27632 ( 5 uM ) for 60 min , cells were stimulated with EGF ( 50 ng/ml ) for 15 min .
(x10 / stimulate-01
      :time (x1 / after
            :op1 (x2 / pretreat-01
                  :ARG3 (x3 / small-molecule
                        :name (x4 / name :op1 "Y-27632")
                        :ARG0-of (x5 / do-02
                              :mod "5"
                              :mod (x6 / um :mode "expressive")
                              :ARG2 (x7 / temporal-quantity
                                    :quant "60"
                                    :unit (x8 / minute)))
                        :xref (x17 / xref :value "PUBCHEM:448042" :prob "16.518612"))))
      :ARG1 (x9 / cell)
      :ARG2 (x11 / protein
            :name (x12 / name :op1 "EGF")
            :quant (x13 / concentration-quantity
                  :quant "50"
                  :unit (x14 / nanogram-per-milliliter))
            :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :duration (x15 / temporal-quantity
            :quant "15"
            :unit (x16 / minute)))


# ::id PMC4729484.325
# ::snt To determine if ROCK1 activity has changed, we investigated the phosphorylation level of MYPT1, a substrate of ROCK1 [ 39 ].
# ::tok To determine if ROCK1 activity has changed , we investigated the phosphorylation level of MYPT1 , a substrate of ROCK1 [ 39 ] .
(x7 / investigate-01
      :purpose (x1 / determine-01
            :ARG1 (x5 / change-01
                  :ARG1 (x4 / activity-06
                        :ARG0 (x2 / protein
                              :name (x3 / name :op1 "ROCK1")
                              :xref (x18 / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004")))))
      :ARG0 (x6 / we)
      :ARG1 (x8 / phosphorylate-01
            :ARG1 (x9 / level
                  :quant-of (x10 / protein
                        :name (x11 / name :op1 "MYPT1")))
            :ARG0-of (x12 / substrate
                  :ARG1 (x13 / protein
                        :name (x14 / name :op1 "ROCK1")
                        :xref (x / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004")))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / publication
                        :ARG1-of (x17 / cite-01 :ARG2 "39")))))


# ::id PMC4729484.326
# ::snt As shown in Fig 7D–7F , EGF treatment did not affect ROCK1 protein expression level; however, it increased MYPT1 phosphorylation on site 853, which was blocked by pretreatment with ROCK1 inhibitor Y-27632.
# ::tok As shown in Fig 7D–7F , EGF treatment did not affect ROCK1 protein expression level ; however , it increased MYPT1 phosphorylation on site 853 , which was blocked by pretreatment with ROCK1 inhibitor Y @-@ 27632 .
(x6 / affect-01
      :ARG1-of (x1 / show-01
            :medium (x2 / figure :op1 "7d–7f"))
      :ARG0 (x5 / treat-04
            :ARG2 (x3 / protein
                  :name (x4 / name :op1 "EGF")
                  :xref (x27 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :polarity "-"
      :ARG1 (x7 / and
            :op1 (x11 / level
                  :ARG1-of (x10 / express-03
                        :ARG2 (x9 / protein
                              :name (x8 / name :op1 "ROCK1")
                              :xref (x26 / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004"))))
            :op2 (x12 / have-concession-91
                  :ARG1 (x13 / increase-01
                        :ARG1 (x16 / phosphorylate-01
                              :ARG2 (x14 / protein
                                    :name (x15 / name :op1 "MYPT1"))
                              :ARG1 (x17 / protein-segment
                                    :name (x18 / name :op1 "853"))))
                  :ARG1-of (x19 / block-01
                        :ARG0 (x20 / pretreat-01
                              :ARG3 (x21 / small-molecule
                                    :ARG0-of (x24 / inhibit-01
                                          :ARG1 (x22 / protein
                                                :name (x23 / name :op1 "ROCK1")
                                                :xref (x / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004")))
                                    :name (x25 / name :op1 "Y-27632")
                                    :xref (x28 / xref :value "PUBCHEM:448042" :prob "16.518612")))))))


# ::id PMC4729484.327
# ::snt COS-7 cells transfected with RhoA 88E/100E increased MYPT1 phosphorylation level compared to wild type RhoA and RhoA 88A/100A, suggesting the increased interaction of RhoA and ROCK1 enhanced ROCK1 activity ( Fig 7D–7F ).
# ::tok COS @-@ 7 cells transfected with RhoA 88E @/@ 100E increased MYPT1 phosphorylation level compared to wild type RhoA and RhoA 88A/100A , suggesting the increased interaction of RhoA and ROCK1 enhanced ROCK1 activity ( Fig 7D–7F ) .
(x20 / suggest-01
      :ARG0 (x17 / and
            :op1 (x2 / cell-line
                  :name (x1 / name :op1 "COS-7")
                  :ARG1-of (x3 / transfect-01
                        :ARG2 (x4 / protein
                              :name (x5 / name :op1 "RhoA" :op2 "88E"))))
            :op2 (x8 / increase-01
                  :ARG0 (x6 / protein
                        :name (x7 / name :op1 "100E"))
                  :ARG1 (x11 / phosphorylate-01
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "MYPT1")))
                  :ARG1 (x12 / level
                        :ARG1-of (x13 / compare-01
                              :ARG2 (x14 / enzyme
                                    :mod (x15 / wild-type)
                                    :name (x16 / name :op1 "RhoA")
                                    :xref (x35 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))))
            :op3 (x18 / protein
                  :name (x19 / name :op1 "RhoA" :op2 "88A/100A")))
      :ARG1 (x27 / enhance-01
            :ARG0 (x21 / increase-01
                  :ARG1 (x22 / interact-01
                        :ARG0 (x23 / protein
                              :name (x24 / name :op1 "RhoA")
                              :xref (x34 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                        :ARG2 (x25 / protein
                              :name (x26 / name :op1 "ROCK1")
                              :xref (x33 / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004"))))
            :ARG1 (x30 / activity-06
                  :ARG0 (x28 / protein
                        :name (x29 / name :op1 "ROCK1")
                        :xref (x / xref :value "UNIPROT:ROCK1_HUMAN" :prob "1.004")))
            :ARG1-of (x31 / describe-01
                  :ARG0 (x32 / figure :op1 "7d–7f"))))


# ::id PMC4729484.328
# ::snt The effects of RhoA phosphorylation on its subcellular translocation
# ::tok The effects of RhoA phosphorylation on its subcellular translocation
(x6 / translocate-01
      :ARG1 (x1 / affect-01
            :ARG0 (x4 / phosphorylate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
      :ARG2 (x5 / subcellular))


# ::id PMC4729484.329
# ::snt Evidence is increasing that the subcellular localization of the Rho proteins plays a major role in their activation, and interaction with downstream effectors [ 7 , 40 ].
# ::tok Evidence is increasing that the subcellular localization of the Rho proteins plays a major role in their activation , and interaction with downstream effectors [ 7 , 40 ] .
(x1 / evidence-01
      :ARG0 (x2 / increase-01)
      :ARG1 (x4 / localize-01
            :mod (x3 / subcellular)
            :ARG1 (x6 / protein
                  :name (x5 / name :op1 "Rho")
                  :ARG0-of (x7 / play-08
                        :ARG1-of (x8 / major-02)
                        :ARG1 (x10 / and
                              :op1 (x9 / activate-01)
                              :op2 (x11 / interact-01
                                    :ARG1 (x13 / effector
                                          :mod (x12 / downstream)))))
                  :ARG1-of (x14 / describe-01
                        :ARG0 (x15 / publication
                              :ARG1-of (x16 / cite-01
                                    :ARG2 (x17 / and :op1 "7" :op2 "40"))))
                  :xref (x / xref :value "UNIPROT:OPSD_HUMAN" :prob "0.602"))))


# ::id PMC4729484.330
# ::snt Although the majority of RhoA protein is localized in the cytosol and at the plasma membrane of cells, there have been reports that a fraction of the total RhoA pool is translocated to the nucleus and regulates downstream signaling [ 41 – 45 ].
# ::tok Although the majority of RhoA protein is localized in the cytosol and at the plasma membrane of cells , there have been reports that a fraction of the total RhoA pool is translocated to the nucleus and regulates downstream signaling [ 41 – 45 ] .
(x1 / have-concession-91
      :ARG2 (x5 / localize-01
            :ARG1 (x2 / majority
                  :consist-of (x4 / protein
                        :name (x3 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :location (x7 / and
                  :mod (x6 / cytosol
                        :xref (x29 / xref :value "GO:0005829" :prob "0.8")))
            :location (x9 / membrane
                  :mod (x8 / plasma)
                  :part-of (x10 / cell)
                  :xref (x28 / xref :value "GO:0016020" :prob "0.8")))
      :ARG1 (x19 / and
            :op1 (x11 / report-01
                  :ARG1 (x17 / translocate-01
                        :ARG1 (x12 / fraction
                              :part-of (x13 / enzyme
                                    :mod (x14 / total)
                                    :name (x15 / name :op1 "RhoA")
                                    :xref (x27 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                              :name (x16 / name :op1 "pool"))
                        :ARG2 (x18 / nucleus
                              :xref (x30 / xref :value "GO:0005634" :prob "0.8"))))
            :op2 (x22 / signal-07
                  :ARG0-of (x20 / regulate-01)
                  :mod (x21 / downstream)
                  :ARG1-of (x23 / describe-01
                        :ARG0 (x24 / publication
                              :ARG1-of (x25 / cite-01
                                    :ARG2 (x26 / value-interval :op1 "41" :op2 "45")))))))


# ::id PMC4729484.331
# ::snt We have shown previously that treatment of cells with EGF induced a significant amount of Rac1 to translocate from the cytosol into the nucleus [ 21 ].
# ::tok We have shown previously that treatment of cells with EGF induced a significant amount of Rac1 to translocate from the cytosol into the nucleus [ 21 ] .
(x2 / show-01
      :ARG0 (x1 / we)
      :time (x3 / previous)
      :ARG1 (x4 / treat-04
            :ARG1 (x5 / cell)
            :ARG2 (x6 / protein
                  :name (x7 / name :op1 "EGF")
                  :xref (x19 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :ARG0-of (x8 / induce-01
                  :ARG2 (x10 / amount
                        :ARG1-of (x9 / significant-02)
                        :quant-of (x11 / protein
                              :name (x12 / name :op1 "Rac1")
                              :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604")))
                  :ARG1 (x13 / translocate-01
                        :ARG2 (x14 / cytosol
                              :xref (x20 / xref :value "GO:0005829" :prob "0.8"))
                        :ARG3 (x15 / nucleus
                              :xref (x21 / xref :value "GO:0005634" :prob "0.8"))))
            :ARG1-of (x16 / describe-01
                  :ARG0 (x17 / publication
                        :ARG1-of (x18 / cite-01 :ARG2 "21")))))


# ::id PMC4729484.332
# ::snt In the present study, we examined whether the phosphorylation of RhoA would also induce its translocation into the nucleus.
# ::tok In the present study , we examined whether the phosphorylation of RhoA would also induce its translocation into the nucleus .
(x4 / examine-01
      :medium (x2 / study-01
            :time (x1 / present))
      :ARG0 (x3 / we)
      :ARG1 (x9 / induce-01
            :mode "interrogative"
            :ARG0 (x5 / phosphorylate-01
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :mod (x8 / also)
            :ARG2 (x10 / translocate-01
                  :ARG2 (x11 / nucleus
                        :xref (x12 / xref :value "GO:0005634" :prob "0.8")))))


# ::id PMC4729484.333
# ::snt We first examined the subcellular localization of transiently-expressed GFP-tagged RhoA by fluorescence microscopy.
# ::tok We first examined the subcellular localization of transiently @-@ expressed GFP @-@ tagged RhoA by fluorescence microscopy .
(x2 / examine-01
      :ARG0 (x1 / we)
      :ARG1 (x4 / localize-01
            :mod (x3 / subcellular)
            :ARG1 (x6 / express-03
                  :ARG1-of (x5 / transient-02)))
      :ARG2 (x7 / protein
            :ARG1-of (x10 / tag-01
                  :ARG2 (x8 / protein
                        :name (x9 / name :op1 "GFP")
                        :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
            :name (x11 / name :op1 "RhoA")
            :xref (x14 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :manner (x13 / microscopy
            :mod (x12 / fluoresce-01)))


# ::id PMC4729484.334
# ::snt As shown in Fig 8A , wild type RhoA or mutant RhoA S88A/T100A were mainly localized in the cytoplasm of untreated cells.
# ::tok As shown in Fig 8A , wild type RhoA or mutant RhoA S88A @/@ T100A were mainly localized in the cytoplasm of untreated cells .
(x13 / be-located-at-91
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "8a"))
      :ARG1 (x6 / or
            :op1 (x3 / enzyme
                  :mod (x4 / wild-type)
                  :name (x5 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :op2 (x7 / enzyme
                  :ARG2-of (x8 / mutate-01)
                  :name (x9 / name :op1 "RhoA")
                  :xref (x17 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG1-of (x10 / mutate-01 :value "S88A")
            :op2 (x11 / mutate-01 :value "T100A"))
      :mod (x12 / main)
      :ARG2 (x14 / cytoplasm
            :part-of (x16 / cell
                  :ARG1-of (x15 / treat-04 :polarity "-"))
            :xref (x18 / xref :value "GO:0005737" :prob "0.8")))


# ::id PMC4729484.335
# ::snt EGF treatment failed to induce GFP-RhoA or GFP-RhoA S88A/T100A to translocate into the nucleus.
# ::tok EGF treatment failed to induce GFP @-@ RhoA or GFP @-@ RhoA S88A @/@ T100A to translocate into the nucleus .
(x4 / fail-01
      :ARG1 (x3 / treat-04
            :ARG2 (x1 / protein
                  :name (x2 / name :op1 "EGF")
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :ARG2 (x5 / induce-01
            :ARG0 (x8 / or
                  :op1 (x6 / protein
                        :name (x7 / name :op1 "GFP-RhoA"))
                  :op2 (x9 / protein
                        :name (x10 / name :op1 "GFP-RhoA")))
            :ARG1 (x14 / translocate-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "S88A"))
                  :ARG2 (x13 / mutate-01 :value "T100A")
                  :ARG2 (x15 / nucleus
                        :xref (x16 / xref :value "GO:0005634" :prob "0.8")))))


# ::id PMC4729484.336
# ::snt Moreover, in contrast to the phosphomimetic GFP-Rac1 T108E that is mainly accumulated in the nucleus [ 21 ], phosphomimetic GFP-RhoA S88E/T100E was almost exclusively distributed in the cytoplasm with or without EGF stimulation ( Fig 8A ).
# ::tok Moreover , in contrast to the phosphomimetic GFP @-@ Rac1 T108E that is mainly accumulated in the nucleus [ 21 ] , phosphomimetic GFP @-@ RhoA S88E @/@ T100E was almost exclusively distributed in the cytoplasm with or without EGF stimulation ( Fig 8A ) .
(x1 / and
      :op2 (x2 / contrast-01
            :ARG2 (x24 / or
                  :op1 (x7 / accumulate-01
                        :ARG1 (x3 / protein
                              :name (x4 / name :op1 "GFP-Rac1"))
                        :ARG2-of (x5 / mutate-01 :value "T108E")
                        :mod (x6 / main)
                        :location (x8 / nucleus
                              :xref (x32 / xref :value "GO:0005634" :prob "0.8"))
                        :ARG1-of (x9 / describe-01
                              :ARG0 (x10 / publication
                                    :ARG1-of (x11 / cite-01 :ARG2 "21")))
                        :ARG1-of (x12 / describe-01
                              :ARG2 (x13 / protein
                                    :name (x14 / name :op1 "GFP-RhoA")))
                        :ARG1-of (x22 / distribute-01
                              :ARG1 (x17 / slash
                                    :op1 (x15 / enzyme
                                          :name (x16 / name :op1 "S88E"))
                                    :op2 (x18 / enzyme
                                          :name (x19 / name :op1 "T100E")
                                          :xref (x30 / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232")))
                              :degree (x21 / exclusive-02
                                    :degree (x20 / almost))
                              :location (x23 / cytoplasm
                                    :xref (x31 / xref :value "GO:0005737" :prob "0.8"))))
                  :op2 (x27 / stimulate-01
                        :polarity "-"
                        :ARG1 (x25 / protein
                              :name (x26 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
            :ARG1-of (x28 / describe-01
                  :ARG0 (x29 / figure :mod "8a"))))


# ::id PMC4729484.337
# ::snt These observations were confirmed by subcellular fractionation experiments ( Fig 8B & 8C ).
# ::tok These observations were confirmed by subcellular fractionation experiments ( Fig 8B & 8C ) .
(x3 / confirm-01
      :ARG1 (x2 / observe-01
            :mod (x1 / this))
      :ARG0 (x6 / experiment-01
            :mod (x4 / subcellular)
            :ARG1 (x5 / fraction-01))
      :ARG1-of (x7 / describe-01
            :ARG0 (x9 / and
                  :op1 (x8 / figure :mod "8b")
                  :op2 (x10 / figure :mod "8c"))))


# ::id PMC4729484.338
# ::snt COS-7 cells expressing GFP-RhoA and the mutants were either treated with EGF or not treated with EGF.
# ::tok COS @-@ 7 cells expressing GFP @-@ RhoA and the mutants were either treated with EGF or not treated with EGF .
(x9 / treat-04
      :ARG1 (x2 / cell-line
            :name (x1 / name :op1 "COS-7")
            :ARG3-of (x3 / express-03
                  :ARG2 (x6 / and
                        :op1 (x4 / protein
                              :name (x5 / name :op1 "GFP-RhoA"))
                        :op2 (x7 / mutate-01))))
      :mod (x8 / either)
      :ARG2 (x12 / or
            :op1 (x10 / protein
                  :name (x11 / name :op1 "EGF")
                  :xref (x16 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :op2 (x13 / treat-04
                  :polarity "-"
                  :ARG2 (x14 / protein
                        :name (x15 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC4729484.339
# ::snt Homogenates of these cells were fractionated into nuclear and non-nuclear fractions.
# ::tok Homogenates of these cells were fractionated into nuclear and non @-@ nuclear fractions .
(x6 / and
      :op1 (x4 / fractionate-00
            :ARG1 (x3 / cell
                  :mod (x1 / homogenate)
                  :mod (x2 / this))
            :ARG2 (x5 / nucleus
                  :xref (x9 / xref :value "GO:0005634" :prob "0.8")))
      :op2 (x8 / fraction
            :mod (x7 / nucleus
                  :polarity "-"
                  :xref (x / xref :value "GO:0005634" :prob "0.8"))))


# ::id PMC4729484.340
# ::snt As shown in Fig 8B & 8C , GFP-RhoA and the various mutants were mainly distributed in the non-nuclear fraction with or without EGF stimulation.
# ::tok As shown in Fig 8B & 8C , GFP @-@ RhoA and the various mutants were mainly distributed in the non @-@ nuclear fraction with or without EGF stimulation .
(x11 / distribute-01
      :ARG1-of (x1 / show-01
            :ARG0 (x3 / and
                  :op1 (x2 / figure :mod "8b")
                  :op2 (x4 / figure :mod "8c")))
      :ARG1 (x7 / and
            :op1 (x5 / protein
                  :name (x6 / name :op1 "GFP-RhoA"))
            :op2 (x9 / mutate-01
                  :mod (x8 / various)))
      :mod (x10 / main)
      :location (x13 / fraction
            :mod (x12 / nucleus
                  :polarity "-"
                  :xref (x18 / xref :value "GO:0005634" :prob "0.8")))
      :ARG1 (x14 / or
            :op1 (x17 / stimulate-01
                  :polarity "-"
                  :ARG1 (x15 / protein
                        :name (x16 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC4729484.341
# ::snt The effects of RhoA phosphorylation on its subcellular localization.
# ::tok The effects of RhoA phosphorylation on its subcellular localization .
(x6 / localize-01
      :ARG0 (x1 / affect-01
            :ARG0 (x4 / phosphorylate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
      :mod (x5 / subcellular))


# ::id PMC4729484.343
# ::snt Cells were either untreated or treated with EGF for 15 min.
# ::tok Cells were either untreated or treated with EGF for 15 min .
(x5 / treat-04
      :ARG1 (x1 / cell)
      :ARG2 (x2 / or
            :op1 (x4 / or
                  :ARG1-of (x3 / treat-04 :polarity "-")))
      :ARG2 (x6 / protein
            :name (x7 / name :op1 "EGF")
            :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :duration (x8 / temporal-quantity
            :quant "15"
            :unit (x9 / minute)))


# ::id PMC4729484.344
# ::snt The localization of various RhoA proteins was observed by fluorescence microscopy.
# ::tok The localization of various RhoA proteins was observed by fluorescence microscopy .
(x5 / observe-01
      :ARG1 (x1 / be-located-at-91
            :ARG1 (x4 / protein
                  :mod (x2 / various)
                  :name (x3 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
      :manner (x7 / microscopy
            :mod (x6 / fluoresce-01)))


# ::id PMC4729484.347
# ::snt The transfected COS-7 cells expressing GFP-proteins were homogenized, and the cell homogenates were separated into nuclear and non-nuclear fractions as described in Materials and Methods.
# ::tok The transfected COS @-@ 7 cells expressing GFP @-@ proteins were homogenized , and the cell homogenates were separated into nuclear and non @-@ nuclear fractions as described in Materials and Methods .
(x11 / separate-01
      :ARG1 (x8 / and
            :op1 (x1 / transfect-01
                  :ARG1 (x3 / cell-line
                        :name (x2 / name :op1 "COS-7")
                        :ARG3-of (x4 / express-03
                              :ARG2 (x6 / protein
                                    :name (x5 / name :op1 "GFP")
                                    :ARG2-of (x7 / homogenize-00)
                                    :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))))
            :op2 (x9 / cell-line
                  :name (x10 / name :op1 "homogenates")))
      :ARG2 (x13 / and
            :op1 (x12 / nucleus
                  :xref (x21 / xref :value "GO:0005634" :prob "0.8"))
            :op2 (x15 / fraction
                  :mod (x14 / nucleus
                        :polarity "-"
                        :xref (x20 / xref :value "GO:0005634" :prob "0.8"))))
      :ARG1-of (x16 / describe-01
            :medium (x18 / and
                  :op1 (x17 / material)
                  :op2 (x19 / method))))


# ::id PMC4729484.348
# ::snt The loading volumes of the nuclear fraction and non-nuclear fraction were about 25% and 3% of total sample volume, respectively, and were analyzed by SDS-PAGE and immunoblotting.
# ::tok The loading volumes of the nuclear fraction and non @-@ nuclear fraction were about 25 % and 3 % of total sample volume , respectively , and were analyzed by SDS @-@ PAGE and immunoblotting .
(x17 / and
      :op1 (x12 / volume
            :ARG1 (x2 / volume
                  :ARG2-of (x1 / load-01)
                  :quant-of (x6 / fraction
                        :mod (x4 / fraction
                              :mod (x3 / nucleus
                                    :xref (x / xref :value "GO:0005634" :prob "0.8")))
                        :mod (x5 / nucleus
                              :polarity "-"
                              :xref (x19 / xref :value "GO:0005634" :prob "0.8"))))
            :quant (x7 / about
                  :op1 (x8 / percentage-entity :value "25")
                  :op2 (x9 / percentage-entity :value "3"))
            :mod (x11 / sample
                  :mod (x10 / total))
            :ARG1-of (x13 / and
                  :op2 (x14 / analyze-01
                        :manner (x15 / thing
                              :name (x16 / name :op1 "SDS-PAGE")))))
      :op2 (x18 / immunoblot-01))


# ::id PMC4729484.349
# ::snt Nu, nuclear fraction; Non, non-nuclear fraction.
# ::tok Nu , nuclear fraction ; Non , non @-@ nuclear fraction .
(x2 / and
      :op1 (x1 / nu)
      :op1 (x4 / fraction
            :mod (x3 / nucleus
                  :xref (x / xref :value "GO:0005634" :prob "0.8")))
      :op2 (x7 / fraction
            :ARG1-of (x5 / possible-01 :polarity "-")
            :mod (x6 / nucleus
                  :polarity "-"
                  :xref (x8 / xref :value "GO:0005634" :prob "0.8"))))


# ::id PMC4729484.350
# ::snt After EGF stimulation for 15 and 60 min, lysates of COS-7 cells were separated into nuclear, total membrane, and cytosolic fractions as described in Materials and Methods.
# ::tok After EGF stimulation for 15 and 60 min , lysates of COS @-@ 7 cells were separated into nuclear , total membrane , and cytosolic fractions as described in Materials and Methods .
(x11 / separate-01
      :time (x1 / after
            :op1 (x4 / stimulate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :duration (x5 / temporal-quantity
                        :quant (x6 / and :op1 "15" :op2 "60")
                        :unit (x7 / minute))))
      :ARG0 (x8 / lysate
            :mod (x10 / cell-line
                  :name (x9 / name :op1 "COS-7")))
      :ARG2 (x15 / and
            :op1 (x14 / membrane
                  :mod (x12 / nucleus
                        :xref (x22 / xref :value "GO:0005634" :prob "0.8"))
                  :mod (x13 / total)
                  :xref (x23 / xref :value "GO:0016020" :prob "0.8"))
            :op2 (x17 / fraction-01
                  :location (x16 / cytosol
                        :xref (x24 / xref :value "GO:0005829" :prob "0.8"))))
      :ARG1-of (x18 / describe-01
            :medium (x20 / and
                  :op1 (x19 / material)
                  :op2 (x21 / method))))


# ::id PMC4729484.351
# ::snt One-third of the nuclear fraction, one-half of the membrane fraction, and 3% of the cytosolic fraction were analyzed by immunoblotting.
# ::tok One @-@ third of the nuclear fraction , one @-@ half of the membrane fraction , and 3 % of the cytosolic fraction were analyzed by immunoblotting .
(x9 / analyze-01
      :ARG1 (x8 / fraction
            :quant "1/3"
            :ARG1-of (x2 / fraction-01
                  :ARG1 (x1 / nucleus
                        :xref (x / xref :value "GO:0005634" :prob "0.8")))
            :ARG1-of (x3 / include-91
                  :ARG3 "1/2"
                  :ARG2 (x5 / fraction-01
                        :ARG1 (x4 / membrane
                              :xref (x12 / xref :value "GO:0016020" :prob "0.8"))))
            :mod (x6 / percentage-entity
                  :value "3"
                  :part-of (x7 / cytosol
                        :xref (x11 / xref :value "GO:0005829" :prob "0.8"))))
      :manner (x10 / immunoblot-01))


# ::id PMC4729484.355
# ::snt We also examined the effects of EGF stimulation on the subcellular localization of endogenous RhoA.
# ::tok We also examined the effects of EGF stimulation on the subcellular localization of endogenous RhoA .
(x3 / examine-01
      :ARG0 (x1 / we)
      :mod (x2 / also)
      :ARG1 (x4 / affect-01
            :ARG0 (x7 / stimulate-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "EGF")
                        :xref (x13 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x9 / localize-01
                  :mod (x8 / subcellular)
                  :ARG1 (x10 / protein
                        :mod (x11 / endogenous)
                        :name (x12 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))))


# ::id PMC4729484.356
# ::snt As shown in Fig 8D & 8E , RhoA was mostly distributed in the cytoplasm without EGF stimulation.
# ::tok As shown in Fig 8D & 8E , RhoA was mostly distributed in the cytoplasm without EGF stimulation .
(x9 / distribute-01
      :ARG1-of (x1 / show-01
            :ARG0 (x3 / and
                  :op1 (x2 / figure :mod "8d")
                  :op2 (x4 / person
                        :name (x5 / name :op1 "8E"))))
      :ARG1 (x6 / protein
            :name (x7 / name :op1 "RhoA")
            :xref (x14 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :degree (x8 / most)
      :location (x10 / cytoplasm
            :ARG1-of (x13 / stimulate-01
                  :polarity "-"
                  :ARG1 (x11 / protein
                        :name (x12 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :xref (x15 / xref :value "GO:0005737" :prob "0.8")))


# ::id PMC4729484.357
# ::snt Following EGF stimulation for 15 min, a significant amount of RhoA was translocated to the plasma membrane, but not to the nucleus.
# ::tok Following EGF stimulation for 15 min , a significant amount of RhoA was translocated to the plasma membrane , but not to the nucleus .
(x14 / contrast-01
      :ARG1 (x11 / translocate-01
            :time (x1 / after
                  :op1 (x4 / stimulate-01
                        :ARG1 (x2 / protein
                              :name (x3 / name :op1 "EGF")
                              :xref (x17 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                        :duration (x5 / temporal-quantity
                              :quant "15"
                              :unit (x6 / minute))))
            :ARG1 (x8 / amount
                  :ARG1-of (x7 / significant-02)
                  :quant-of (x9 / protein
                        :name (x10 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
            :ARG2 (x13 / membrane
                  :mod (x12 / plasma)
                  :xref (x18 / xref :value "GO:0016020" :prob "0.8")))
      :ARG2 (x15 / bind-01
            :polarity "-"
            :ARG2 (x16 / nucleus
                  :xref (x19 / xref :value "GO:0005634" :prob "0.8"))))


# ::id PMC4729484.358
# ::snt It has been shown previously that Rac1 PBR (PVKKRKRK), containing a nuclear localization signal (NLS), promotes the accumulation of Rac1 in the nucleus, whereas RhoA PBR (RRGKKKSG), without an NLS, sequesters RhoA in the cytosol [ 42 ].
# ::tok It has been shown previously that Rac1 PBR ( PVKKRKRK ) , containing a nuclear localization signal ( NLS ) , promotes the accumulation of Rac1 in the nucleus , whereas RhoA PBR ( RRGKKKSG ) , without an NLS , sequesters RhoA in the cytosol [ 42 ] .
(x1 / have-concession-91
      :ARG2 (x2 / show-01
            :time (x3 / previous)
            :ARG1 (x4 / protein
                  :name (x5 / name :op1 "Rac1" :op2 "PBR"))
            :ARG1-of (x6 / pvkkrkrk)
            :ARG0-of (x7 / contain-01
                  :ARG1 (x9 / localize-01
                        :ARG1 (x8 / nucleus
                              :xref (x32 / xref :value "GO:0005634" :prob "0.8")))))
      :ARG1 (x10 / signal-07
            :ARG1-of (x11 / protein-segment
                  :name (x12 / name :op1 "NLS"))
            :ARG0-of (x13 / promote-01
                  :ARG1 (x14 / accumulate-01
                        :ARG1 (x15 / protein
                              :name (x16 / name :op1 "Rac1")
                              :xref (x30 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
                        :location (x17 / nucleus
                              :xref (x33 / xref :value "GO:0005634" :prob "0.8")))
                  :ARG2 (x20 / have-03
                        :ARG0 (x18 / protein
                              :name (x19 / name
                                    :op1 "RhoA"
                                    :op2 "PBR"
                                    :op3 "RRGKKKSG"))
                        :polarity "-"
                        :ARG1 (x21 / protein-segment
                              :name (x22 / name :op1 "NLS"))
                        :ARG1-of (x23 / sequester)
                        :ARG1 (x24 / protein
                              :name (x25 / name :op1 "RhoA")
                              :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
                  :location (x26 / cytosol
                        :xref (x31 / xref :value "GO:0005829" :prob "0.8")))
            :ARG1-of (x27 / describe-01
                  :ARG0 (x28 / publication
                        :ARG1-of (x29 / cite-01 :ARG2 "42")))))


# ::id PMC4729484.359
# ::snt We have shown previously that the phosphorylation of Rac1 by ERK enhanced its nuclear translocation [ 21 ].
# ::tok We have shown previously that the phosphorylation of Rac1 by ERK enhanced its nuclear translocation [ 21 ] .
(x2 / show-01
      :ARG0 (x1 / we)
      :time (x3 / previous)
      :ARG1 (x4 / phosphorylate-01
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "Rac1")
                  :xref (x15 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
            :ARG2 (x7 / enzyme
                  :name (x8 / name :op1 "ERK")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :ARG0-of (x9 / enhance-01
                  :ARG1 (x11 / translocate-01
                        :ARG2 (x10 / nucleus
                              :xref (x16 / xref :value "GO:0005634" :prob "0.8"))))
            :ARG1-of (x12 / describe-01
                  :ARG0 (x13 / publication
                        :ARG1-of (x14 / cite-01 :ARG2 "21")))))


# ::id PMC4729484.360
# ::snt Here, we examined the roles of both the PBR and phosphorylation on the nuclear localization of RhoA and Rac1.
# ::tok Here , we examined the roles of both the PBR and phosphorylation on the nuclear localization of RhoA and Rac1 .
(x3 / examine-01
      :medium (x1 / here)
      :ARG0 (x2 / we)
      :ARG1 (x4 / role
            :poss (x5 / and
                  :op1 (x6 / and
                        :op1 (x7 / phosphorylate-01
                              :ARG2 (x9 / localize-01
                                    :ARG1 (x8 / nucleus
                                          :xref (x15 / xref :value "GO:0005634" :prob "0.8")))
                              :ARG1 (x10 / protein
                                    :name (x11 / name :op1 "RhoA")
                                    :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
                  :op2 (x12 / protein
                        :name (x13 / name :op1 "Rac1")
                        :xref (x14 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604")))))


# ::id PMC4729484.361
# ::snt We replaced the PBR of GFP-Rac1 T108E with RhoA PBR to generate the mutant GFP-Rac1 T108E RhoA-PBR .
# ::tok We replaced the PBR of GFP @-@ Rac1 T108E with RhoA PBR to generate the mutant GFP @-@ Rac1 T108E RhoA @-@ PBR .
(x2 / replace-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / protein-segment
            :name (x4 / name :op1 "PBR")
            :part-of (x5 / protein
                  :name (x6 / name :op1 "GFP")
                  :xref (x22 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))
            :name (x7 / name :op1 "T108E"))
      :ARG2 (x8 / protein
            :name (x9 / name :op1 "RhoA" :op2 "PBR"))
      :purpose (x10 / generate-01
            :ARG0 (x11 / enzyme
                  :ARG2-of (x12 / mutate-01)
                  :name (x13 / name :op1 "GFP")
                  :xref (x21 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342"))
            :ARG1 (x14 / protein
                  :name (x15 / name :op1 "Rac1")
                  :mod (x16 / protein
                        :name (x17 / name :op1 "RhoA")
                        :xref (x20 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :name (x18 / name :op1 "PBR")
                  :xref (x19 / xref :value "UNIPROT:TSPOA_HUMAN" :prob "1.002"))))


# ::id PMC4729484.362
# ::snt We also replaced the PBR of GFP-RhoA S88E/T100E with Rac1 PBR to generate GFP-RhoA S88E/T100E Rac1-PBR .
# ::tok We also replaced the PBR of GFP @-@ RhoA S88E @/@ T100E with Rac1 PBR to generate GFP @-@ RhoA S88E @/@ T100E Rac1 @-@ PBR .
(x3 / replace-01
      :ARG0 (x1 / we)
      :mod (x2 / also)
      :ARG1 (x4 / protein-segment
            :name (x5 / name :op1 "PBR")
            :part-of (x6 / protein
                  :name (x7 / name :op1 "GFP-RhoA"))
            :name (x8 / name :op1 "S88E" :op2 "T100E"))
      :ARG2 (x9 / protein
            :name (x10 / name :op1 "Rac1" :op2 "PBR"))
      :purpose (x11 / generate-01
            :ARG1 (x12 / protein
                  :name (x13 / name :op1 "GFP-RhoA")))
      :ARG1 (x16 / slash
            :op1 (x14 / enzyme
                  :name (x15 / name :op1 "S88E"))
            :op2 (x17 / enzyme
                  :name (x18 / name :op1 "T100E")
                  :xref (x / xref :value "UNIPROT:CD38_HUMAN" :prob "0.232")))
      :ARG2 (x19 / protein
            :name (x20 / name :op1 "Rac1" :op2 "PBR")))


# ::id PMC4729484.363
# ::snt These two mutants and two previously generated mutants (GFP-RhoA Rac1-PBR and GFP-Rac1 RhoA-PBR ) were expressed in COS-7 cells by transient transfection.
# ::tok These two mutants and two previously generated mutants ( GFP @-@ RhoA Rac1 @-@ PBR and GFP @-@ Rac1 RhoA @-@ PBR ) were expressed in COS @-@ 7 cells by transient transfection .
(x5 / generate-01
      :ARG0 (x2 / mutate-01
            :mod (x1 / this)
            :quant "2"
            :ARG0-of (x3 / and :op1 "2" :op2 "10"))
      :time (x4 / previous)
      :ARG1 (x6 / mutate-01)
      :ARG1-of (x7 / describe-01
            :ARG0 (x8 / protein
                  :name (x9 / name :op1 "GFP")
                  :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
      :ARG1 (x10 / protein
            :name (x11 / name :op1 "RhoA")
            :xref (x28 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
      :ARG2 (x14 / and
            :op1 (x12 / protein
                  :name (x13 / name :op1 "Rac1" :op2 "PBR"))
            :op2 (x15 / protein
                  :name (x16 / name :op1 "GFP")
                  :xref (x29 / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
      :ARG1 (x22 / express-03
            :ARG1 (x17 / protein
                  :name (x18 / name :op1 "Rac1")
                  :mod (x19 / protein
                        :name (x20 / name :op1 "RhoA")
                        :xref (x27 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :name (x21 / name :op1 "PBR")
                  :xref (x31 / xref :value "UNIPROT:TSPOA_HUMAN" :prob "1.002"))
            :ARG3 (x24 / cell-line
                  :name (x23 / name :op1 "COS-7"))
            :manner (x26 / transfect-01
                  :ARG1-of (x25 / transient-02))))


# ::id PMC4729484.364
# ::snt The localization of these four mutants was examined by fluorescence microscopy.
# ::tok The localization of these four mutants was examined by fluorescence microscopy .
(x5 / examine-01
      :ARG1 (x1 / be-located-at-91
            :ARG1 (x3 / gene
                  :mod (x2 / this)
                  :quant "4"
                  :ARG2-of (x4 / mutate-01)))
      :manner (x7 / microscopy
            :mod (x6 / fluoresce-01)))


# ::id PMC4729484.365
# ::snt As shown in Fig 9 , Rac1 PBR targets RhoA to the nucleus with or without EGF stimulation and RhoA PBR targets Rac1 to the cytoplasm, which is consistent with a previous report [ 42 ].
# ::tok As shown in Fig 9 , Rac1 PBR targets RhoA to the nucleus with or without EGF stimulation and RhoA PBR targets Rac1 to the cytoplasm , which is consistent with a previous report [ 42 ] .
(x1 / show-01
      :ARG0 (x2 / figure :mod "9")
      :ARG1 (x5 / target-01
            :ARG0 (x3 / protein
                  :name (x4 / name :op1 "Rac1" :op2 "PBR"))
            :ARG1 (x6 / protein
                  :name (x7 / name :op1 "RhoA")
                  :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG2 (x8 / nucleus
                  :ARG0-of (x13 / and
                        :op1 (x9 / or
                              :op2 (x12 / stimulate-01
                                    :polarity "-"
                                    :ARG1 (x10 / protein
                                          :name (x11 / name :op1 "EGF")
                                          :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
                        :op2 (x16 / target-01
                              :ARG0 (x14 / protein
                                    :name (x15 / name :op1 "RhoA" :op2 "PBR"))
                              :ARG1 (x17 / protein
                                    :name (x18 / name :op1 "Rac1")
                                    :xref (x27 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
                              :ARG2 (x19 / cytoplasm
                                    :xref (x29 / xref :value "GO:0005737" :prob "0.8")))
                        :ARG1-of (x20 / consistent-01
                              :ARG2 (x22 / report-01
                                    :time (x21 / previous))))
                  :ARG1-of (x23 / describe-01
                        :ARG0 (x24 / publication
                              :ARG1-of (x25 / cite-01 :ARG2 "42")))
                  :xref (x28 / xref :value "GO:0005634" :prob "0.8"))))


# ::id PMC4729484.366
# ::snt Interestingly, RhoA PBR was able to target the phosphomimetic mutant Rac1 T108E to cytoplasm and Rac1 PBR was able to target the phosphomimetic mutants RhoA S88E/100E to the nucleus.
# ::tok Interestingly , RhoA PBR was able to target the phosphomimetic mutant Rac1 T108E to cytoplasm and Rac1 PBR was able to target the phosphomimetic mutants RhoA S88E @/@ 100E to the nucleus .
(x13 / and
      :ARG2-of (x1 / interest-01)
      :op1 (x12 / cytoplasm
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "RhoA")
                  :xref (x30 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
            :ARG1-of (x4 / possible-01
                  :ARG1 (x7 / target-01
                        :ARG0 (x5 / protein
                              :name (x6 / name :op1 "PBR")
                              :xref (x31 / xref :value "UNIPROT:TSPOA_HUMAN" :prob "1.002"))
                        :ARG1 (x8 / enzyme
                              :ARG1-of (x9 / mutate-01)
                              :name (x10 / name :op1 "Rac1")
                              :xref (x29 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
                        :ARG1-of (x11 / mutate-01 :value "T108E")))
            :xref (x35 / xref :value "GO:0005737" :prob "0.8"))
      :op2 (x14 / protein
            :name (x15 / name :op1 "Rac1")
            :xref (x32 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
      :op2 (x16 / possible-01
            :ARG1 (x19 / target-01
                  :ARG0 (x17 / protein
                        :name (x18 / name :op1 "PBR")
                        :xref (x33 / xref :value "UNIPROT:TSPOA_HUMAN" :prob "1.002"))
                  :ARG1 (x20 / enzyme
                        :ARG2-of (x21 / mutate-01)
                        :name (x22 / name :op1 "RhoA")
                        :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                  :ARG0-of (x25 / slash
                        :op1 (x23 / enzyme
                              :name (x24 / name :op1 "S88E"))
                        :op2 (x26 / enzyme
                              :name (x27 / name :op1 "100E"))))
            :ARG2 (x28 / nucleus
                  :xref (x34 / xref :value "GO:0005634" :prob "0.8"))))


# ::id PMC4729484.367
# ::snt These data suggest that PBR is the determining factor for the subcellular localization of RhoA and Rac1.
# ::tok These data suggest that PBR is the determining factor for the subcellular localization of RhoA and Rac1 .
(x3 / suggest-01
      :ARG0 (x2 / data
            :mod (x1 / this))
      :ARG1 (x5 / factor
            :domain (x4 / pbr)
            :ARG1-of (x6 / determine-01
                  :ARG3 (x11 / and
                        :op1 (x8 / localize-01
                              :mod (x7 / subcellular)
                              :ARG1 (x9 / protein
                                    :name (x10 / name :op1 "RhoA")
                                    :xref (x / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
                        :op2 (x12 / protein
                              :name (x13 / name :op1 "Rac1")
                              :xref (x14 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))))))


# ::id PMC4729484.368
# ::snt The effects of the polybasic region (PBR) and ERK-induced S/T phosphorylation on the nuclear localization of RhoA and Rac1.
# ::tok The effects of the polybasic region ( PBR ) and ERK @-@ induced S/T phosphorylation on the nuclear localization of RhoA and Rac1 .
(x1 / and
      :op1 (x2 / affect-01
            :ARG0 (x6 / and
                  :op1 (x4 / region
                        :name (x3 / name :op1 "polybasic")
                        :ARG1-of (x5 / pbr))
                  :op2 (x12 / phosphorylate-01
                        :ARG2-of (x9 / induce-01
                              :ARG0 (x7 / enzyme
                                    :name (x8 / name :op1 "ERK")
                                    :xref (x20 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "S/T"))))
            :ARG1 (x14 / localize-01
                  :mod (x13 / nucleus
                        :xref (x21 / xref :value "GO:0005634" :prob "0.8"))
                  :ARG1 (x15 / protein
                        :name (x16 / name :op1 "RhoA")
                        :xref (x19 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))))
      :op2 (x17 / protein
            :name (x18 / name :op1 "Rac1")
            :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604")))


# ::id PMC4729484.369
# ::snt Cells were either not treated or treated with EGF for 15 min.
# ::tok Cells were either not treated or treated with EGF for 15 min .
(x3 / treat-04
      :ARG1 (x1 / cell)
      :ARG1-of (x2 / possible-01 :polarity "-")
      :ARG2 (x4 / or
            :op1 (x5 / treat-04
                  :ARG2 (x6 / protein
                        :name (x7 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
      :duration (x8 / temporal-quantity
            :quant "15"
            :unit (x9 / minute)))


# ::id PMC4729484.370
# ::snt The localization of these wold type and mutant RhoA and Rac1 proteins was examined by fluorescence microscopy.
# ::tok The localization of these wold type and mutant RhoA and Rac1 proteins was examined by fluorescence microscopy .
(x11 / examine-01
      :ARG1 (x1 / be-located-at-91
            :ARG1 (x8 / and
                  :op1 (x4 / type
                        :mod (x2 / this)
                        :mod (x3 / wold)
                        :mod (x5 / enzyme
                              :ARG2-of (x6 / mutate-01)
                              :name (x7 / name :op1 "RhoA")
                              :xref (x14 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604")))
                  :op2 (x10 / protein
                        :name (x9 / name :op1 "Rac1")
                        :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))))
      :manner (x13 / microscopy
            :mod (x12 / fluoresce-01)))


# ::id PMC4729484.372
# ::snt Each value is the mean of at least three experiments with at least 20 transfected cells counted for each experiment.
# ::tok Each value is the mean of at least three experiments with at least 20 transfected cells counted for each experiment .
(x3 / mean
      :domain (x2 / value
            :mod (x1 / each))
      :mod (x5 / experiment-01
            :ARG2 (x4 / at-least :op1 "3")
            :ARG1 (x9 / count-01
                  :quant (x6 / at-least :op1 "20")
                  :mod (x8 / cell
                        :ARG1-of (x7 / transfect-01))
                  :ARG1 (x11 / experiment-01
                        :mod (x10 / each)))))


# ::id PMC4729484.373
# ::snt The error bar is the standard error.
# ::tok The error bar is the standard error .
(x4 / error
      :domain (x2 / bar
            :mod (x1 / error))
      :ARG1-of (x3 / standard-02))


# ::id PMC4729484.374
# ::snt *, p < 0.05 and **, p<0.01.
# ::tok *, p
(x3 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "*,")))


# ::id PMC3412844.0
# ::snt TGF-Beta Induced Erk Phosphorylation of Smad Linker Region Regulates Smad Signaling
# ::tok TGF @-@ Beta Induced Erk Phosphorylation of Smad Linker Region Regulates Smad Signaling
(x3 / induce-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "TGF-Beta")
            :xref (x15 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.333"))
      :ARG2 (x10 / region
            :ARG1-of (x6 / phosphorylate-01
                  :ARG2 (x4 / enzyme
                        :name (x5 / name :op1 "Erk")
                        :xref (x16 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                  :ARG1 (x7 / protein-segment
                        :name (x8 / name :op1 "Smad")
                        :ARG0-of (x9 / link-01)))
            :ARG0-of (x11 / regulate-01
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "Smad")
                        :xref (x / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.312")))
            :ARG0-of (x14 / signal-07)))


# ::id PMC3412844.2
# ::snt The Transforming Growth Factor-Beta (TGF-β) family is involved in regulating a variety of cellular processes such as apoptosis, differentiation, and proliferation.
# ::tok The Transforming Growth Factor @-@ Beta ( TGF-β ) family is involved in regulating a variety of cellular processes such as apoptosis , differentiation , and proliferation .
(x8 / involve-01
      :ARG1 (x1 / and
            :op1 (x2 / protein
                  :name (x3 / name
                        :op1 "Transforming"
                        :op2 "growth"
                        :op3 "factor"))
            :op2 (x4 / protein
                  :name (x5 / name :op1 "beta-catenin")
                  :ARG1-of (x7 / protein-family
                        :name (x6 / name :op1 "TGF-β"))
                  :xref (x / xref :value "UNIPROT:CTNB1_HUMAN" :prob "0.703")))
      :ARG2 (x9 / regulate-01
            :ARG1 (x12 / process-02
                  :mod (x10 / variety)
                  :mod (x11 / cell)
                  :example (x15 / and
                        :op1 (x13 / apoptosis)
                        :op2 (x14 / differentiate-01)
                        :op2 (x16 / proliferate-01)))))


# ::id PMC3412844.3
# ::snt TGF-β binding to a Serine/Threonine kinase receptor complex causes the recruitment and subsequent activation of transcription factors known as smad2 and smad3.
# ::tok TGF-β binding to a Serine @/@ Threonine kinase receptor complex causes the recruitment and subsequent activation of transcription factors known as smad2 and smad3 .
(x17 / and
      :op1 (x8 / macro-molecular-complex
            :name (x1 / name :op1 "TGF-β")
            :ARG0-of (x2 / bind-01
                  :ARG2 (x5 / slash
                        :op1 (x3 / amino-acid
                              :name (x4 / name :op1 "serine")
                              :xref (x20 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :op2 (x6 / enzyme
                              :name (x7 / name
                                    :op1 "threonine"
                                    :op2 "kinase"
                                    :op3 "receptor"))))
            :ARG0-of (x9 / cause-01
                  :ARG1 (x11 / and
                        :op1 (x10 / recruit-01)
                        :op2 (x13 / activate-01
                              :time (x12 / subsequent)
                              :ARG1 (x15 / factor
                                    :ARG0-of (x14 / transcribe-01)))))
            :name (x16 / name :op1 "smad2"))
      :op2 (x18 / protein
            :name (x19 / name :op1 "smad3")
            :xref (x / xref :value "UNIPROT:SMAD3_HUMAN" :prob "0.703")))


# ::id PMC3412844.4
# ::snt These proteins subsequently translocate into the nucleus to negatively or positively regulate gene expression.
# ::tok These proteins subsequently translocate into the nucleus to negatively or positively regulate gene expression .
(x7 / or
      :op1 (x4 / translocate-01
            :ARG1 (x2 / protein
                  :mod (x1 / this))
            :time (x3 / subsequent)
            :ARG2 (x5 / nucleus
                  :xref (x / xref :value "GO:0005634" :prob "0.8"))
            :ARG2 (x6 / negative-01))
      :op2 (x9 / regulate-01
            :mod (x8 / positive)
            :ARG1 (x11 / express-03
                  :ARG1 (x10 / gene))))


# ::id PMC3412844.5
# ::snt In this study, we define a second signaling pathway leading to TGF-β receptor activation of Extracellular Signal Regulated Kinase (Erk) in a cell-type dependent manner.
# ::tok In this study , we define a second signaling pathway leading to TGF-β receptor activation of Extracellular Signal Regulated Kinase ( Erk ) in a cell @-@ type dependent manner .
(x4 / define-01
      :medium (x2 / study-01
            :mod (x1 / this))
      :ARG0 (x3 / we)
      :ARG1 (x7 / pathway
            :ord (x5 / ordinal-entity :value "2")
            :ARG0-of (x6 / signal-07))
      :ARG0-of (x8 / lead-03
            :ARG2 (x11 / activate-01
                  :ARG0 (x10 / receptor
                        :name (x9 / name :op1 "TGF-β"))
                  :ARG1 (x12 / and
                        :op1 (x15 / regulate-01
                              :ARG0 (x14 / signal-07
                                    :mod (x13 / extracellular))
                              :ARG1 (x16 / enzyme
                                    :name (x17 / name :op1 "Kinase")
                                    :xref (x23 / xref :value "UNIPROT:ITK_HUMAN" :prob "0.313")))
                        :op2 (x18 / enzyme
                              :name (x19 / name :op1 "Erk")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
                  :manner (x22 / depend-01
                        :ARG1 (x21 / type
                              :mod (x20 / cell))))))


# ::id PMC3412844.6
# ::snt TGF-β induced Erk activation was found in phenotypically normal mesenchymal cells, but not normal epithelial cells.
# ::tok TGF-β induced Erk activation was found in phenotypically normal mesenchymal cells , but not normal epithelial cells .
(x11 / contrast-01
      :ARG1 (x7 / find-01
            :ARG1 (x6 / activate-01
                  :ARG2-of (x3 / induce-01
                        :ARG0 (x1 / protein
                              :name (x2 / name :op1 "TGF-β")
                              :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233")))
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "Erk")
                        :xref (x15 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
            :location (x10 / cell
                  :ARG1-of (x8 / normal-02)
                  :mod (x9 / mesenchyme)))
      :ARG2 (x14 / cell
            :polarity "-"
            :ARG1-of (x12 / normal-02)
            :mod (x13 / epithelium)))


# ::id PMC3412844.7
# ::snt By activating phosphotidylinositol 3-kinase (PI3K), TGF-β stimulates p21-activated kinase2 (Pak2) to phosphorylate c-Raf, ultimately resulting in Erk activation.
# ::tok By activating phosphotidylinositol 3 @-@ kinase ( PI3K ) , TGF-β stimulates p21 @-@ activated kinase2 ( Pak2 ) to phosphorylate c @-@ Raf , ultimately resulting in Erk activation .
(x16 / result-01
      :ARG1 (x12 / phosphorylate-01
            :ARG0 (x1 / activate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "phosphotidylinositol" :op2 "3-kinase"))
                  :ARG1-of (x9 / stimulate-01
                        :ARG0 (x4 / and
                              :op1 (x5 / enzyme
                                    :name (x6 / name :op1 "PI3K")
                                    :xref (x22 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                              :op2 (x7 / protein
                                    :name (x8 / name :op1 "TGF-β")
                                    :xref (x21 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233")))
                        :ARG1 (x10 / enzyme
                              :name (x11 / name
                                    :op1 "p21"
                                    :op2 "kinase2"
                                    :op1 "Pak2"))))
            :ARG1 (x13 / enzyme
                  :name (x14 / name :op1 "c-Raf")
                  :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.673")))
      :mod (x15 / ultimate)
      :ARG2 (x19 / activate-01
            :ARG1 (x17 / enzyme
                  :name (x18 / name :op1 "Erk")
                  :xref (x20 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))


# ::id PMC3412844.8
# ::snt Activation of Erk was necessary for TGF-β induced fibroblast replication.
# ::tok Activation of Erk was necessary for TGF-β induced fibroblast replication .
(x4 / need-01
      :ARG1 (x1 / activate-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "Erk")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
      :ARG0 (x9 / replicate-01
            :ARG1 (x8 / fibroblast
                  :ARG2-of (x7 / induce-01
                        :ARG0 (x5 / protein
                              :name (x6 / name :op1 "TGF-β")
                              :xref (x10 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))))))


# ::id PMC3412844.9
# ::snt In addition, Erk phosphorylated the linker region of nuclear localized smads, resulting in increased half-life of C-terminal phospho-smad 2 and 3 and increased duration of smad target gene transcription.
# ::tok In addition , Erk phosphorylated the linker region of nuclear localized smads , resulting in increased half @-@ life of C @-@ terminal phospho @-@ smad 2 and 3 and increased duration of smad target gene transcription .
(x1 / and
      :op2 (x4 / phosphorylate-01
            :ARG0 (x2 / enzyme
                  :name (x3 / name :op1 "Erk")
                  :xref (x30 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
            :ARG1 (x21 / and
                  :op1 (x5 / link-01
                        :ARG2 (x6 / region
                              :part-of (x8 / localize-01
                                    :ARG1 (x7 / nucleus
                                          :xref (x32 / xref :value "GO:0005634" :prob "0.8"))
                                    :ARG1 (x9 / protein
                                          :name (x10 / name :op1 "smads")
                                          :xref (x29 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.252"))
                                    :ARG1-of (x11 / result-01
                                          :ARG2 (x12 / increase-01)))
                              :ARG0-of (x14 / live-01
                                    :degree (x13 / half)))
                        :ARG1 (x15 / protein-segment
                              :name (x16 / name :op1 "c-terminus")
                              :ARG1-of (x17 / phosphorylate-01
                                    :ARG2 (x18 / enzyme
                                          :name (x19 / name :op1 "smad")
                                          :xref (x31 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.272"))))
                        :ARG2 (x20 / and :op1 "2" :op2 "3"))
                  :op2 (x22 / increase-01
                        :ARG1 (x28 / transcribe-01
                              :ARG0-of (x23 / duration
                                    :duration-of (x26 / target-01
                                          :ARG0 (x24 / protein
                                                :name (x25 / name :op1 "smad")
                                                :xref (x / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.272"))))
                              :ARG1 (x27 / gene))))))


# ::id PMC3412844.10
# ::snt Together, these data show that in mesenchymal cell types the TGF-β/PI3K/Pak2/Raf/MEK/Erk pathway regulates smad signaling, is critical for TGF-β-induced growth and is part of an integrated signaling web containing multiple interacting pathways rather than discrete smad/non-smad pathways.
# ::tok Together , these data show that in mesenchymal cell types the TGF-β/PI3K/Pak2/Raf/MEK/Erk pathway regulates smad signaling , is critical for TGF-β-induced growth and is part of an integrated signaling web containing multiple interacting pathways rather than discrete smad @/@ non @-@ smad pathways .
(x1 / multi-sentence
      :snt1 (x5 / show-01
            :ARG0 (x4 / data
                  :mod (x2 / together)
                  :mod (x3 / this))
            :ARG1 (x8 / type-03
                  :ARG1 (x7 / cell
                        :location (x6 / mesenchyme)))
            :ARG1 (x9 / pathway
                  :name (x10 / name :op1 "TGF-β/PI3K/Pak2/Raf/MEK/Erk")))
      :snt2 (x19 / and
            :op1 (x15 / critical-02
                  :ARG1 (x11 / regulate-01
                        :ARG1 (x14 / signal-07
                              :ARG0 (x12 / protein
                                    :name (x13 / name :op1 "smad")
                                    :xref (x33 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.272"))))
                  :ARG2 (x18 / grow-01
                        :ARG1 (x16 / enzyme
                              :name (x17 / name :op1 "TGF-β-induced")
                              :xref (x34 / xref :value "UNIPROT:TGIF2_HUMAN" :prob "0.262"))))
            :op2 (x20 / have-part-91
                  :ARG1 (x21 / integrate-01)
                  :ARG2 (x23 / web
                        :ARG0-of (x22 / signal-07)
                        :ARG0-of (x24 / contain-01
                              :ARG1 (x25 / interact-01
                                    :ARG1 (x26 / pathway
                                          :ARG1-of (x27 / instead-of-91
                                                :ARG2 (x28 / discrete))
                                          :name (x29 / name :op1 "smad"))))
                        :ARG1-of (x32 / pathway
                              :polarity "-"
                              :mod (x30 / protein
                                    :name (x31 / name :op1 "smad")
                                    :xref (x / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.272")))))))


# ::id PMC3412844.80
# ::snt TGF-β Activates Erk in a Cell Type Specific Manner
# ::tok TGF-β Activates Erk in a Cell Type Specific Manner
(x3 / activate-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "TGF-β")
            :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "Erk")
            :xref (x9 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
      :manner (x8 / specific-02
            :ARG2 (x7 / type
                  :mod (x6 / cell))))


# ::id PMC3412844.81
# ::snt Since TGF-β has been known to stimulate fibroblast replication and had been shown to activate PI3K [10] , [12] we wished to further define activation of the Erk pathway in normal (untransformed) cell lines.
# ::tok Since TGF-β has been known to stimulate fibroblast replication and had been shown to activate PI3K [ 10 ] , [ 12 ] we wished to further define activation of the Erk pathway in normal ( untransformed ) cell lines .
(x20 / wish-01
      :ARG1-of (x1 / cause-01
            :ARG0 (x2 / know-01
                  :ARG1 (x5 / stimulate-01
                        :ARG0 (x3 / protein
                              :name (x4 / name :op1 "TGF-β")
                              :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
                        :ARG1 (x6 / fibroblast
                              :ARG1-of (x7 / replicate-01))))
            :ARG1 (x8 / and
                  :op2 (x9 / show-01)
                  :ARG0-of (x10 / activate-01
                        :ARG1 (x11 / enzyme
                              :name (x12 / name :op1 "PI3K")
                              :xref (x29 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                  :ARG1-of (x13 / describe-01
                        :ARG0 (x14 / publication
                              :ARG1-of (x15 / cite-01 :ARG2 "10")))))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / publication
                  :ARG1-of (x18 / cite-01 :ARG2 "12")))
      :ARG0 (x19 / we)
      :ARG1 (x22 / define-01
            :degree (x21 / further)
            :ARG1 (x23 / activate-01
                  :ARG1 (x25 / pathway
                        :name (x24 / name :op1 "Erk"))
                  :location (x28 / cell-line
                        :ARG1-of (x26 / normal-02
                              :ARG1-of (x27 / transform-01 :polarity "-"))))))


# ::id PMC3412844.82
# ::snt Temporal changes in Erk phosphorylation as the result of fibroblast cell lines treated with TGF-β over the course of 4 h were determined ( Figure 1 ).
# ::tok Temporal changes in Erk phosphorylation as the result of fibroblast cell lines treated with TGF-β over the course of 4 h were determined ( Figure 1 ) .
(x15 / determine-01
      :ARG1 (x2 / change-01
            :mod (x1 / time)
            :ARG1 (x5 / phosphorylate-01
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "Erk")
                        :xref (x18 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
            :ARG1-of (x6 / result-01
                  :ARG2 (x8 / cell-line
                        :mod (x7 / fibroblast)
                        :ARG1-of (x9 / treat-04
                              :ARG2 (x10 / protein
                                    :name (x11 / name :op1 "TGF-β")
                                    :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))))
                  :duration (x12 / course
                        :consist-of (x13 / temporal-quantity
                              :quant "4"
                              :unit (x14 / hour)))))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / figure :mod "1")))


# ::id PMC3412844.83
# ::snt Taking into account protein loading (total Erk) between lanes, we found Erk phosphorylation increased significantly above background between 60–90 minutes after TGF-β addition ( Figure 1B ).
# ::tok Taking into account protein loading ( total Erk ) between lanes , we found Erk phosphorylation increased significantly above background between 60–90 minutes after TGF-β addition ( Figure 1B ) .
(x4 / load-01
      :time (x1 / take-01
            :ARG2 (x2 / account-01
                  :ARG1 (x3 / protein)))
      :ARG2 (x5 / enzyme
            :mod (x6 / total)
            :name (x7 / name :op1 "Erk")
            :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
      :ARG2 (x8 / lane
            :op2 (x10 / find-01
                  :ARG0 (x9 / we)
                  :ARG1 (x14 / increase-01
                        :ARG0 (x13 / phosphorylate-01
                              :ARG1 (x11 / enzyme
                                    :name (x12 / name :op1 "Erk")
                                    :xref (x25 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
                        :ARG2 (x15 / significant-02))
                  :location (x16 / background)
                  :ARG1 (x17 / minute)))
      :time (x18 / after
            :op1 (x21 / add-02
                  :ARG1 (x19 / protein
                        :name (x20 / name :op1 "TGF-β")
                        :xref (x24 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))))
      :ARG1-of (x22 / describe-01
            :ARG0 (x23 / figure :mod "1b")))


# ::id PMC3412844.84
# ::snt Previous reports have shown Erk activation at earlier time points [7] , [13] .
# ::tok Previous reports have shown Erk activation at earlier time points [ 7 ] , [ 13 ] .
(x4 / show-01
      :ARG0 (x2 / thing
            :time (x1 / previous)
            :ARG1-of (x3 / report-01))
      :ARG1 (x5 / enzyme
            :name (x6 / name :op1 "Erk")
            :ARG0-of (x7 / activate-01
                  :ARG1 (x11 / point
                        :ARG0-of (x10 / time
                              :time (x8 / early
                                    :degree (x9 / more)))
                        :ARG1-of (x12 / describe-01
                              :ARG0 (x13 / publication
                                    :ARG1-of (x14 / cite-01 :ARG2 "7")))))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / publication
                        :ARG1-of (x17 / cite-01 :ARG2 "13")))
            :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))


# ::id PMC3412844.85
# ::snt We likewise saw an increase in phospho-Erk earlier, but only when cells were allowed to cool when taken from the incubator during addition of TGF-β.
# ::tok We likewise saw an increase in phospho @-@ Erk earlier , but only when cells were allowed to cool when taken from the incubator during addition of TGF-β.
(x3 / see-01
      :ARG0 (x1 / we)
      :mod (x2 / likewise)
      :ARG1 (x4 / increase-01
            :ARG1 (x5 / enzyme
                  :ARG3-of (x6 / phosphorylate-01)
                  :name (x7 / name :op1 "Erk")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
      :time (x8 / early
            :degree (x9 / more))
      :ARG1-of (x10 / contrast-01
            :ARG2 (x13 / allow-01
                  :mod (x11 / only)
                  :ARG0 (x12 / cell)
                  :ARG1 (x14 / cool-04)
                  :time (x15 / take-01
                        :ARG1 (x16 / incubator)
                        :time (x17 / add-02
                              :ARG1 (x18 / small-molecule
                                    :name (x19 / name :op1 "TGF-β.")
                                    :xref (x20 / xref :value "PUBCHEM:446991" :prob "17.394333")))))))


# ::id PMC3412844.86
# ::snt Cells maintained near 37°C, demonstrated no significant activation of Erk prior to the 60–90 minute window.
# ::tok Cells maintained near 37 °C , demonstrated no significant activation of Erk prior to the 60–90 minute window .
(x6 / demonstrate-01
      :ARG0 (x1 / cell
            :ARG1-of (x2 / maintain-01
                  :ARG1 (x3 / near-02
                        :ARG2 (x4 / temperature-quantity
                              :quant "37"
                              :scale (x5 / celsius)))))
      :ARG1 (x8 / activate-01
            :polarity "-"
            :ARG1-of (x7 / significant-02)
            :ARG1 (x9 / enzyme
                  :name (x10 / name :op1 "Erk")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
      :time (x11 / prior
            :op1 (x14 / window
                  :name (x12 / name :op1 "60–90")
                  :mod (x13 / minute))))


# ::id PMC3412844.87
# ::snt Earlier activation was consistent with Erk signaling being indicative of an induced stress response [32] , [33] .
# ::tok Earlier activation was consistent with Erk signaling being indicative of an induced stress response [ 32 ] , [ 33 ] .
(x4 / consistent-01
      :ARG1 (x3 / activate-01
            :time (x1 / early
                  :degree (x2 / more)))
      :ARG2 (x5 / enzyme
            :name (x6 / name :op1 "Erk")
            :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
      :ARG0-of (x7 / signal-07
            :ARG0-of (x8 / indicate-01
                  :ARG1 (x9 / induce-01
                        :ARG2 (x11 / respond-01
                              :ARG0-of (x10 / stress-02)
                              :ARG1-of (x12 / describe-01
                                    :ARG0 (x13 / publication
                                          :ARG1-of (x14 / cite-01 :ARG2 "32"))))))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / publication
                        :ARG1-of (x17 / cite-01 :ARG2 "33")))))


# ::id PMC3412844.88
# ::snt Since TGF-β activation of PI3K has been shown to be cell type dependent [10] , [12] the previous experiment was repeated using Mv1Lu and NMuMG epithelial cells.
# ::tok Since TGF-β activation of PI3K has been shown to be cell type dependent [ 10 ] , [ 12 ] the previous experiment was repeated using Mv1Lu and NMuMG epithelial cells .
(x1 / cause-01
      :ARG0 (x7 / show-01
            :ARG1 (x4 / activate-01
                  :ARG0 (x2 / protein
                        :name (x3 / name :op1 "TGF-β")
                        :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "PI3K")
                        :xref (x28 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))
      :ARG1 (x8 / cell
            :ARG1-of (x9 / type-03
                  :ARG1 (x10 / protein
                        :ARG0-of (x11 / depend-01)
                        :ARG1-of (x12 / describe-01
                              :ARG0 (x13 / publication
                                    :ARG1-of (x14 / cite-01 :ARG2 "10")))))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / publication
                        :ARG1-of (x17 / cite-01 :ARG2 "12")))
            :ARG1-of (x24 / and
                  :op1 (x20 / repeat-01
                        :ARG1 (x19 / experiment-01
                              :time (x18 / previous))
                        :manner (x21 / use-01
                              :ARG1 (x22 / protein
                                    :name (x23 / name :op1 "Mv1Lu"))))
                  :op2 (x27 / cell
                        :name (x25 / name :op1 "NMuMG")
                        :source (x26 / epithelium)))))


# ::id PMC3412844.89
# ::snt No increase in Erk phosphorylation was identified at any time point ( Figure 1C ) following TGF-β treatment.
# ::tok No increase in Erk phosphorylation was identified at any time point ( Figure 1C ) following TGF-β treatment .
(x5 / identify-01
      :ARG1 (x1 / increase-01
            :polarity "-"
            :ARG1 (x4 / phosphorylate-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "Erk")
                        :xref (x14 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))
      :time (x7 / point
            :mod (x6 / any))
      :ARG1-of (x8 / describe-01
            :ARG0 (x9 / figure :mod "1c"))
      :ARG1-of (x10 / follow-01
            :ARG2 (x13 / treat-04
                  :ARG2 (x11 / protein
                        :name (x12 / name :op1 "TGF-β")
                        :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233")))))


# ::id PMC3412844.90
# ::snt Together these results confirm that activation of Erk upon TGF-β treatment occurs in phenotypically normal cells of mesenchymal origin, but not epithelial cells.
# ::tok Together these results confirm that activation of Erk upon TGF-β treatment occurs in phenotypically normal cells of mesenchymal origin , but not epithelial cells .
(x16 / originate-01
      :ARG1 (x5 / confirm-01
            :mod (x1 / together)
            :ARG0 (x3 / thing
                  :mod (x2 / this)
                  :ARG2-of (x4 / result-01))
            :ARG1 (x6 / activate-01
                  :ARG1 (x7 / enzyme
                        :name (x8 / name :op1 "Erk")
                        :xref (x20 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
            :time (x11 / treat-04
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "TGF-β")
                        :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233")))
            :location (x12 / phenotypically))
      :ARG2 (x14 / cell
            :ARG1-of (x13 / normal-02)
            :part-of (x15 / mesenchyme))
      :ARG1-of (x17 / contrast-01
            :ARG2 (x19 / cell
                  :polarity "-"
                  :mod (x18 / epithelium))))


# ::id PMC3412844.91
# ::snt Cell type specific activation of Erk.
# ::tok Cell type specific activation of Erk .
(x3 / specific-02
      :ARG2 (x2 / type
            :mod (x1 / cell))
      :ARG1 (x4 / activate-01
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "Erk")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))


# ::id PMC3412844.94
# ::snt Typical results are shown representing four independent time course experiments.
# ::tok Typical results are shown representing four independent time course experiments .
(x5 / represent-01
      :ARG0 (x4 / show-01
            :ARG1-of (x1 / typical-02)
            :ARG0 (x2 / thing
                  :ARG2-of (x3 / result-01)))
      :ARG1 (x9 / experiment
            :quant "4"
            :ARG0-of (x6 / depend-01
                  :polarity "-"
                  :ARG1 (x8 / course
                        :mod (x7 / time)))))


# ::id PMC3412844.95
# ::snt Shown is the mean fold increase of Phospho-Erk relative to total Erk for each time point with the 0 time set as 1.
# ::tok Shown is the mean fold increase of Phospho @-@ Erk relative to total Erk for each time point with the 0 time set as 1 .
(x1 / show-01
      :ARG1 (x4 / increase-01
            :ARG1-of (x2 / mean-01)
            :ARG2 (x3 / product-of)
            :ARG1 (x5 / enzyme
                  :ARG3-of (x6 / phosphorylate-01)
                  :name (x7 / name :op1 "Erk")
                  :xref (x20 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
            :ARG1-of (x8 / relative-05
                  :ARG2 (x9 / enzyme
                        :mod (x10 / total)
                        :name (x11 / name :op1 "Erk")
                        :xref (x19 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))
      :purpose (x14 / point
            :mod (x12 / each)
            :mod (x13 / time))
      :ARG2 (x15 / temporal-quantity :quant "0")
      :ARG1 (x16 / set
            :consist-of (x17 / protein
                  :name (x18 / name :op1 "sos-1")
                  :xref (x / xref :value "UNIPROT:SOS1_HUMAN" :prob "0.633"))))


# ::id PMC3412844.96
# ::snt Statistically significant change from 0 time is noted as, (*) P<0.05 and (**) P<0.01.
# ::tok Statistically significant change from 0 time is noted as , ( * )
(x5 / note-01
      :ARG0 (x3 / change-01
            :ARG1 (x2 / significant-02
                  :mod (x1 / statistics))
            :ARG2 (x4 / temporal-quantity :quant "0"))
      :ARG1 (x6 / protein-segment
            :part-of (x7 / molecular-physical-entity)
            :name (x8 / name :op1 "*")))


# ::id PMC3412844.99
# ::snt Triplicate blots were performed on three independent time course experiments with typical results shown.
# ::tok Triplicate blots were performed on three independent time course experiments with typical results shown .
(x2 / perform-01
      :ARG1 (x1 / immunoblot-01 :quant "3")
      :ARG2 (x6 / experiment-01
            :quant "3"
            :ARG0-of (x3 / depend-01 :polarity "-")
            :mod (x5 / course
                  :mod (x4 / time))
            :ARG2 (x10 / show-01
                  :ARG1-of (x7 / typical-02)
                  :ARG0 (x8 / thing
                        :ARG2-of (x9 / result-01)))))


# ::id PMC3412844.100
# ::snt TGF-β Mechanism of Erk Activation
# ::tok TGF-β Mechanism of Erk Activation
(x2 / mechanism
      :name (x1 / name :op1 "TGF-β")
      :ARG0-of (x5 / activate-01
            :ARG1 (x3 / enzyme
                  :name (x4 / name :op1 "Erk")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))


# ::id PMC3412844.101
# ::snt Having shown Erk activation, via TGF-β, as a cell type specific response, we next wanted to confirm the mechanism through which the TGF-β signal was propagated.
# ::tok Having shown Erk activation , via TGF-β, as a cell type specific response , we next wanted to confirm the mechanism through which the TGF-β signal was propagated .
(x14 / want-01
      :ARG1-of (x1 / cause-01
            :ARG0 (x2 / show-01
                  :ARG1 (x5 / activate-01
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "Erk")
                              :xref (x21 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                        :instrument (x6 / small-molecule
                              :name (x7 / name :op1 "TGF-β,")
                              :mod (x11 / respond-01
                                    :ARG1-of (x10 / specific-02
                                          :ARG2 (x9 / type
                                                :mod (x8 / cell))))
                              :xref (x22 / xref :value "PUBCHEM:446991" :prob "17.394333")))))
      :ARG0 (x12 / we)
      :time (x13 / next)
      :ARG1 (x16 / mechanism
            :mod (x15 / confirm-01)
            :manner-of (x19 / signal-07
                  :ARG0 (x17 / protein
                        :name (x18 / name :op1 "TGF-β")
                        :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
                  :ARG1 (x20 / propagate-01))))


# ::id PMC3412844.102
# ::snt Previous studies have shown that TGF-β induced activation of Pak2 and/or Ras [10] , [12] , [13] , we sought to identify the pathway resulting in Erk activation.
# ::tok Previous studies have shown that TGF-β induced activation of Pak2 and @/@ or Ras [ 10 ] , [ 12 ] , [ 13 ] , we sought to identify the pathway resulting in Erk activation .
(x3 / show-01
      :ARG0 (x2 / study-01
            :time (x1 / previous))
      :ARG1 (x6 / induce-01
            :ARG0 (x4 / protein
                  :name (x5 / name :op1 "TGF-β")
                  :xref (x32 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
            :ARG2 (x7 / activate-01
                  :ARG1 (x10 / and-or
                        :ARG0 (x8 / protein
                              :name (x9 / name :op1 "Pak2")
                              :xref (x31 / xref :value "UNIPROT:PAK2_HUMAN" :prob "0.604"))
                        :op2 (x11 / enzyme
                              :name (x12 / name :op1 "Ras")
                              :xref (x33 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                        :ARG1-of (x13 / describe-01
                              :ARG0 (x15 / publication
                                    :ARG1-of (x14 / cite-01 :ARG2 "10")))))
            :ARG1-of (x16 / describe-01
                  :ARG0 (x18 / publication
                        :ARG1-of (x17 / cite-01 :ARG2 "12"))))
      :ARG1-of (x22 / describe-01
            :ARG1-of (x19 / describe-01
                  :ARG0 (x20 / publication
                        :ARG1-of (x21 / cite-01 :ARG2 "13"))))
      :ARG1 (x24 / seek-01
            :ARG0 (x23 / we)
            :ARG1 (x25 / identify-01
                  :ARG1 (x26 / pathway)
                  :ARG2-of (x27 / result-01
                        :ARG1 (x30 / activate-01
                              :ARG1 (x28 / enzyme
                                    :name (x29 / name :op1 "Erk")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))))


# ::id PMC3412844.103
# ::snt Using LY294002, a specific inhibitor of PI3K, Erk phosphorylation was inhibited ( Figure 2 ).
# ::tok Using LY294002 , a specific inhibitor of PI3K , Erk phosphorylation was inhibited ( Figure 2 ) .
(x1 / use-01
      :ARG1 (x4 / small-molecule
            :name (x2 / name :op1 "LY294002")
            :ARG1-of (x3 / specific-02)
            :ARG0-of (x5 / inhibit-01
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "PI3K")
                        :xref (x14 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
            :ARG0-of (x11 / inhibit-01
                  :ARG1 (x10 / phosphorylate-01
                        :ARG1 (x8 / enzyme
                              :name (x9 / name :op1 "Erk")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
                  :ARG1-of (x12 / describe-01
                        :ARG0 (x13 / figure :mod "2")))
            :xref (x15 / xref :value "PUBCHEM:3973" :prob "18.86067")))


# ::id PMC3412844.104
# ::snt Additionally, the MEK1/2 inhibitor U0126, blocked Erk phosphorylation, demonstrating that not only is PI3K necessary but also the MAPKK, MEK is involved in TGF-β activation of Erk.
# ::tok Additionally , the MEK1 @/@ 2 inhibitor U0126 , blocked Erk phosphorylation , demonstrating that not only is PI3K necessary but also the MAPKK , MEK is involved in TGF-β activation of Erk .
(x1 / and
      :op2 (x23 / involve-01
            :ARG1 (x2 / and
                  :op1 (x6 / small-molecule
                        :ARG0-of (x5 / inhibit-01
                              :ARG1 (x3 / enzyme
                                    :name (x4 / name :op1 "MEK1/2")))
                        :name (x7 / name :op1 "U0126")
                        :xref (x34 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
                  :op2 (x8 / block-01
                        :ARG1 (x11 / phosphorylate-01
                              :ARG1 (x9 / enzyme
                                    :name (x10 / name :op1 "Erk")
                                    :xref (x31 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
                        :ARG0-of (x12 / demonstrate-01
                              :ARG1 (x16 / need-01
                                    :ARG0 (x13 / only :polarity "-")
                                    :ARG1 (x14 / enzyme
                                          :name (x15 / name :op1 "PI3K")
                                          :xref (x33 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))
                        :ARG1-of (x17 / contrast-01
                              :mod (x18 / also)
                              :ARG2 (x19 / enzyme
                                    :name (x20 / name :op1 "mapk")
                                    :xref (x32 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.233"))))
                  :op3 (x21 / enzyme
                        :name (x22 / name :op1 "MEK")
                        :xref (x30 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343")))
            :ARG2 (x26 / activate-01
                  :ARG2 (x24 / protein
                        :name (x25 / name :op1 "TGF-β")
                        :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
                  :ARG1 (x27 / enzyme
                        :name (x28 / name :op1 "Erk")
                        :xref (x29 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))


# ::id PMC3412844.105
# ::snt There was also a temporal increase in c-Raf phosphorylation ( Figure 2B ) dependent on TGF-β stimulation and subsequent to PI3K activation as shown by the phosphorylation of S338, a known Pak activation site [34] , [35] and its inhibition by the PI3K inhibitor LY294002.
# ::tok There was also a temporal increase in c @-@ Raf phosphorylation ( Figure 2B ) dependent on TGF-β stimulation and subsequent to PI3K activation as shown by the phosphorylation of S338 , a known Pak activation site [ 34 ] , [ 35 ] and its inhibition by the PI3K inhibitor LY294002 .
(x1 / multi-sentence
      :snt1 (x2 / be-located-at-91
            :ARG1 (x4 / time
                  :mod (x3 / also))
            :ARG2 (x5 / increase-01
                  :ARG1 (x8 / phosphorylate-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "c-Raf")
                              :xref (x42 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.673")))
                  :ARG1-of (x9 / describe-01
                        :ARG0 (x10 / figure :mod "2b"))))
      :snt2 (x35 / and
            :op1 (x11 / depend-01
                  :ARG1 (x15 / and
                        :op1 (x14 / stimulate-01
                              :ARG0 (x12 / protein
                                    :name (x13 / name :op1 "TGF-β")
                                    :xref (x43 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233")))
                        :op2 (x16 / subsequent
                              :op1 (x19 / activate-01
                                    :ARG1 (x17 / enzyme
                                          :name (x18 / name :op1 "PI3K")
                                          :xref (x44 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                                    :ARG1-of (x20 / show-01
                                          :ARG0 (x21 / phosphorylate-01
                                                :ARG1 (x22 / amino-acid
                                                      :mod "338"
                                                      :name (x23 / name :op1 "serine")
                                                      :xref (x46 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                                          :ARG0-of (x28 / protein-segment
                                                :ARG1-of (x24 / know-01
                                                      :ARG1 (x27 / activate-01
                                                            :ARG1 (x25 / enzyme
                                                                  :name (x26 / name :op1 "Pak")
                                                                  :xref (x / xref :value "UNIPROT:PAK1_HUMAN" :prob "0.203")))))
                                          :ARG1-of (x29 / describe-01
                                                :ARG0 (x30 / publication
                                                      :ARG1-of (x31 / cite-01 :ARG2 "34")))))))
                  :ARG1-of (x32 / describe-01
                        :ARG0 (x33 / publication
                              :ARG1-of (x34 / cite-01 :ARG2 "35"))))
            :op2 (x36 / inhibit-01
                  :ARG0 (x40 / small-molecule
                        :ARG0-of (x39 / inhibit-01
                              :ARG1 (x37 / protein-family
                                    :name (x38 / name :op1 "PI3K")))
                        :name (x41 / name :op1 "LY294002")
                        :xref (x45 / xref :value "PUBCHEM:3973" :prob "18.86067")))))


# ::id PMC3412844.106
# ::snt In the canonical Erk pathway, activated Ras initiates a cascade resulting in Erk activation.
# ::tok In the canonical Erk pathway , activated Ras initiates a cascade resulting in Erk activation .
(x9 / result-01
      :location (x3 / pathway
            :mod (x1 / canonical)
            :name (x2 / name :op1 "Erk"))
      :ARG1 (x7 / initiate-01
            :ARG0 (x4 / enzyme
                  :ARG1-of (x5 / activate-01)
                  :name (x6 / name :op1 "Ras")
                  :xref (x13 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
            :ARG1 (x8 / cascade))
      :ARG2 (x12 / activate-01
            :ARG1 (x10 / enzyme
                  :name (x11 / name :op1 "Erk")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))


# ::id PMC3412844.107
# ::snt Using small molecular weight inhibitors, we evaluated the activation of two different PI3K activated pathways, Erk and Akt ( Figure 2C ).
# ::tok Using small molecular weight inhibitors , we evaluated the activation of two different PI3K activated pathways , Erk and Akt ( Figure 2C ) .
(x6 / evaluate-01
      :purpose (x3 / weight-01
            :mod (x2 / molecule
                  :mod (x1 / small))
            :ARG0-of (x4 / inhibit-01))
      :ARG0 (x5 / we)
      :ARG1 (x7 / activate-01
            :ARG1 (x12 / pathway
                  :quant "2"
                  :ARG1-of (x8 / differ-02)
                  :ARG0-of (x11 / activate-01
                        :ARG1 (x9 / enzyme
                              :name (x10 / name :op1 "PI3K")
                              :xref (x21 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                  :ARG1-of (x13 / mean-01
                        :ARG2 (x16 / and
                              :op1 (x14 / enzyme
                                    :name (x15 / name :op1 "Erk")
                                    :xref (x22 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                              :op2 (x17 / enzyme
                                    :name (x18 / name :op1 "Akt")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))))
      :ARG1-of (x19 / describe-01
            :ARG0 (x20 / figure :mod "2c")))


# ::id PMC3412844.108
# ::snt Although both pathways were activated by TGF-β through PI3K, only Erk phosphorylation was sensitive to U0126 and neither pathway was inhibited by the Ras farnysylation inhibitor, FPT II [36] .
# ::tok Although both pathways were activated by TGF-β through PI3K , only Erk phosphorylation was sensitive to U0126 and neither pathway was inhibited by the Ras farnysylation inhibitor , FPT II [ 36 ] .
(x1 / have-concession-91
      :ARG2 (x4 / activate-01
            :ARG1 (x3 / pathway
                  :mod (x2 / both))
            :ARG0 (x5 / protein
                  :name (x6 / name :op1 "TGF-β")
                  :xref (x26 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
            :path (x7 / enzyme
                  :name (x8 / name :op1 "PI3K")
                  :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
      :ARG1 (x12 / phosphorylate-01
            :mod (x9 / only)
            :ARG1 (x10 / enzyme
                  :name (x11 / name :op1 "Erk")
                  :xref (x27 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
            :ARG1-of (x13 / sensitive-03
                  :ARG1 (x14 / small-molecule
                        :name (x15 / name :op1 "U0126")
                        :xref (x28 / xref :value "PUBCHEM:3006531" :prob "17.656696")))
            :ARG0-of (x17 / inhibit-01
                  :polarity "-"
                  :ARG1 (x16 / pathway)
                  :ARG0 (x18 / small-molecule
                        :ARG0-of (x19 / inhibit-01
                              :ARG1 (x20 / enzyme
                                    :name (x21 / name :op1 "Ras" :op2 "farnysylation")))
                        :name (x22 / name :op1 "FPT" :op2 "II")))
            :ARG1-of (x23 / describe-01
                  :ARG0 (x24 / publication
                        :ARG1-of (x25 / cite-01 :ARG2 "36")))))


# ::id PMC3412844.109
# ::snt TGF-β induced Erk phosphorylation was significantly increased, above control levels (untreated and FTPII), with no significant difference found between the two TGF-β treated groups (TGF-β alone and TGF- β+FTPII).
# ::tok TGF-β induced Erk phosphorylation was significantly increased , above control levels ( untreated and FTPII ) , with no significant difference found between the two TGF-β treated groups ( TGF-β alone and TGF @- β+FTPII ) .
(x1 / multi-sentence
      :snt1 (x9 / increase-01
            :ARG1 (x7 / phosphorylate-01
                  :ARG2-of (x4 / induce-01
                        :ARG0 (x2 / protein
                              :name (x3 / name :op1 "TGF-β")
                              :xref (x32 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233")))
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "Erk")
                        :xref (x33 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
            :ARG1-of (x8 / significant-02)
            :ARG2 (x10 / above
                  :op1 (x12 / level
                        :mod (x11 / control)))
            :ARG1-of (x13 / treat-04 :polarity "-"))
      :snt2 (x19 / find-01
            :ARG0 (x14 / and
                  :op1 (x15 / enzyme
                        :name (x16 / name :op1 "FTPII")
                        :xref (x34 / xref :value "UNIPROT:HNRH2_HUMAN" :prob "0.202"))
                  :op2 (x18 / differ-02
                        :polarity "-"
                        :ARG1-of (x17 / significant-02)))
            :ARG1 (x23 / group
                  :quant "2"
                  :mod (x22 / treat-04
                        :ARG2 (x20 / protein
                              :name (x21 / name :op1 "TGF-β")
                              :xref (x31 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))))
            :ARG1-of (x24 / describe-01
                  :ARG0 (x28 / and
                        :op1 (x25 / protein
                              :name (x26 / name :op1 "TGF-β")
                              :mod (x27 / alone)
                              :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
                        :op2 (x29 / protein
                              :name (x30 / name :op1 "TGF" :op2 "β+FTPII"))))))


# ::id PMC3412844.110
# ::snt Erk is activated in fibroblasts via the PI3K/c-Raf/MEK pathway.
# ::tok Erk is activated in fibroblasts via the PI3K/c @-@ Raf @/@ MEK pathway .
(x3 / activate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "Erk")
            :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
      :location (x4 / fibroblast
            :ARG3 (x5 / pathway
                  :name (x6 / name :op1 "PI3K/c-Raf/MEK"))))


# ::id PMC3412844.111
# ::snt Cell lysates were probed with an antibody specific to phospho-Erk, blots were then stripped and reprobed for total Erk as a loading control.
# ::tok Cell lysates were probed with an antibody specific to phospho @-@ Erk , blots were then stripped and reprobed for total Erk as a loading control .
(x3 / probe-01
      :ARG1 (x2 / lysate
            :mod (x1 / cell))
      :ARG2 (x12 / and
            :op1 (x11 / strip-01
                  :ARG1 (x4 / antibody
                        :ARG1-of (x5 / specific-02
                              :ARG2 (x6 / enzyme
                                    :ARG3-of (x7 / phosphorylate-01)
                                    :name (x8 / name :op1 "Erk")
                                    :xref (x21 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                              :ARG1 (x9 / immunoblot-01)))
                  :time (x10 / then))
            :op2 (x13 / enzyme
                  :name (x14 / name :op1 "reprobed")
                  :xref (x / xref :value "UNIPROT:SPAG6_HUMAN" :prob "0.212"))
            :purpose (x15 / enzyme
                  :mod (x16 / total)
                  :name (x17 / name :op1 "Erk")
                  :ARG0-of (x19 / control-01
                        :ARG0-of (x18 / load-01))
                  :xref (x20 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))


# ::id PMC3412844.112
# ::snt Cells were also treated with LY294002 (10 µM) 30 minutes before TGF-β was added for 2 h.
# ::tok Cells were also treated with LY294002 ( 10 µM ) 30 minutes before TGF-β was added for 2 h .
(x3 / treat-04
      :ARG1 (x1 / cell)
      :mod (x2 / also)
      :ARG2 (x4 / small-molecule
            :name (x5 / name :op1 "LY294002")
            :quant "10"
            :name (x6 / name :op1 "µM")
            :xref (x17 / xref :value "PUBCHEM:71464640" :prob "8.13809"))
      :time (x7 / after
            :op1 (x8 / temporal-quantity
                  :quant "30"
                  :unit (x9 / minute)))
      :time (x10 / before
            :op1 (x13 / add-02
                  :ARG1 (x11 / protein
                        :name (x12 / name :op1 "TGF-β")
                        :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))))
      :duration (x14 / temporal-quantity
            :quant "2"
            :unit (x15 / hour)))


# ::id PMC3412844.113
# ::snt Blots were probed using an antibody specific to phospho-c-Raf (Ser338), and total Erk as a loading control.
# ::tok Blots were probed using an antibody specific to phospho @-@ c @-@ Raf ( Ser338 ) , and total Erk as a loading control .
(x2 / probe-01
      :ARG1 (x1 / immunoblot-01)
      :manner (x3 / use-01
            :ARG1 (x4 / antibody
                  :ARG1-of (x5 / specific-02))
            :ARG2 (x11 / and
                  :op1 (x6 / enzyme
                        :ARG3-of (x7 / phosphorylate-01)
                        :name (x8 / name :op1 "c-Raf")
                        :part (x9 / amino-acid
                              :mod "338"
                              :name (x10 / name :op1 "serine")
                              :xref (x18 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :xref (x17 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.673"))
                  :op2 (x12 / enzyme
                        :mod (x13 / total)
                        :name (x14 / name :op1 "Erk")
                        :ARG0-of (x16 / control-01
                              :ARG0-of (x15 / load-01))
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))


# ::id PMC3412844.114
# ::snt The loading control blot was obtained using the lower molecular mass portion of the same blot.
# ::tok The loading control blot was obtained using the lower molecular mass portion of the same blot .
(x4 / obtain-01
      :ARG0 (x2 / control-01
            :ARG1 (x1 / load-01))
      :ARG1 (x3 / immunoblot-01)
      :ARG2 (x9 / portion
            :ARG1-of (x5 / low-04
                  :degree (x6 / more))
            :mod (x7 / molecule)
            :mod (x8 / mass)
            :part-of (x11 / immunoblot-01
                  :ARG1-of (x10 / same-01))))


# ::id PMC3412844.115
# ::snt Cell lysates were probed with antibodies specific to phospho-Erk or phospho-Akt (S473) with the blots stripped and reprobed for the corresponding total protein as a loading control.
# ::tok Cell lysates were probed with antibodies specific to phospho @-@ Erk or phospho @-@ Akt ( S473 ) with the blots stripped and reprobed for the corresponding total protein as a loading control .
(x3 / probe-01
      :ARG1 (x2 / lysate
            :mod (x1 / cell))
      :ARG2 (x4 / antibody
            :ARG1-of (x5 / specific-02
                  :ARG2 (x9 / or
                        :op1 (x6 / enzyme
                              :ARG3-of (x7 / phosphorylate-01)
                              :name (x8 / name :op1 "Erk")
                              :xref (x26 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                        :op2 (x10 / enzyme
                              :ARG3-of (x11 / phosphorylate-01)
                              :name (x12 / name :op1 "Akt")
                              :xref (x28 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))
      :ARG1-of (x13 / amino-acid
            :mod "473"
            :name (x14 / name :op1 "serine")
            :xref (x29 / xref :value "PUBCHEM:5951" :prob "11.218784"))
      :ARG2 (x15 / immunoblot-01)
      :ARG1 (x17 / and
            :op1 (x16 / strip-01)
            :op2 (x18 / enzyme
                  :name (x19 / name :op1 "reprobed")
                  :xref (x27 / xref :value "UNIPROT:SPAG6_HUMAN" :prob "0.212")))
      :ARG1-of (x20 / correspond-02
            :ARG2 (x21 / enzyme
                  :mod (x22 / total)
                  :name (x23 / name :op1 "protein")
                  :ARG0-of (x25 / control-01
                        :ARG0-of (x24 / load-01))
                  :xref (x / xref :value "UNIPROT:S45A3_HUMAN" :prob "0.342"))))


# ::id PMC3412844.116
# ::snt Comparisons of the relative intensity of bands of Phopho-Erk relative to total Erk loading control was expressed as fold increase relative to untreated control (set at 1).
# ::tok Comparisons of the relative intensity of bands of Phopho @-@ Erk relative to total Erk loading control was expressed as fold increase relative to untreated control ( set at 1 ) .
(x1 / compare-01
      :ARG2 (x3 / intensity
            :ARG1-of (x2 / relative-05)
            :degree-of (x14 / express-03
                  :ARG1 (x4 / band
                        :consist-of (x6 / enzyme
                              :name (x5 / name :op1 "Phopho")
                              :name (x7 / name :op1 "Erk")
                              :ARG1-of (x8 / relative-05
                                    :ARG2 (x9 / enzyme
                                          :mod (x10 / total)
                                          :name (x11 / name :op1 "Erk")
                                          :xref (x23 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
                              :xref (x25 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                        :ARG1-of (x13 / control-01
                              :ARG1 (x12 / load-01)))
                  :ARG1-of (x16 / increase-01
                        :ARG2 (x15 / product-of)
                        :ARG1-of (x17 / relative-05
                              :ARG3 (x19 / control
                                    :ARG1-of (x18 / treat-04 :polarity "-"))))))
      :ARG1-of (x20 / set
            :ARG1 (x21 / protein
                  :name (x22 / name :op1 "sos-1")
                  :xref (x / xref :value "UNIPROT:SOS1_HUMAN" :prob "0.633"))))


# ::id PMC3412844.117
# ::snt Statistical analysis was used to determine if treatments were not significant (NS), or significant at P<0.05 (*) or P<0.01 (**).
# ::tok Statistical analysis was used to determine if treatments were not significant ( NS ) , or significant at
(x8 / or
      :op1 (x3 / use-01
            :ARG1 (x2 / analyze-01
                  :mod (x1 / statistics))
            :purpose (x4 / determine-01
                  :ARG1 (x6 / significant-02
                        :mode "interrogative"
                        :ARG1 (x5 / treat-04)
                        :polarity "-"
                        :ARG1-of (x7 / ns))))
      :op2 (x10 / after
            :ARG1-of (x9 / significant-02)))


# ::id PMC3412844.118
# ::snt Analysis was performed on four independent blots and the mean values (±SEM) shown.
# ::tok Analysis was performed on four independent blots and the mean values ( ±SEM ) shown .
(x2 / perform-02
      :ARG1 (x1 / analyze-01)
      :location (x5 / and
            :quant "4"
            :ARG0-of (x3 / depend-01 :polarity "-")
            :mod (x4 / immunoblot-01)
            :op2 (x7 / value
                  :mod (x6 / mean))
            :source (x8 / company
                  :name (x9 / name :op1 "±SEM")))
      :ARG0 (x10 / show-01))


# ::id PMC3412844.119
# ::snt Since inhibition of Ras farnysylation did not appear to effect TGF-β induced Erk activation, and previous data had shown Pak to be downstream of PI3K and phosphorylate Raf [34] , [35] , we wanted to determine where Pak2 acted within this signaling pathway.
# ::tok Since inhibition of Ras farnysylation did not appear to effect TGF-β induced Erk activation , and previous data had shown Pak to be downstream of PI3K and phosphorylate Raf [ 34 ] , [ 35 ] , we wanted to determine where Pak2 acted within this signaling pathway .
(x1 / multi-sentence
      :snt1 (x2 / cause-01
            :ARG0 (x8 / appear-02
                  :ARG0 (x3 / small-molecule
                        :ARG0-of (x4 / inhibit-01
                              :ARG1 (x5 / enzyme
                                    :name (x6 / name :op1 "Ras")
                                    :xref (x50 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                        :name (x7 / name :op1 "farnysylation"))
                  :polarity "-"))
      :snt2 (x38 / want-01
            :purpose (x9 / affect-01
                  :ARG0-of (x12 / induce-01
                        :ARG1 (x10 / protein
                              :name (x11 / name :op1 "TGF-β")
                              :xref (x51 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
                        :ARG2 (x16 / and
                              :op1 (x15 / activate-01
                                    :ARG1 (x13 / enzyme
                                          :name (x14 / name :op1 "Erk")
                                          :xref (x52 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
                              :op2 (x18 / data
                                    :time (x17 / previous)
                                    :ARG0-of (x19 / show-01
                                          :ARG0 (x20 / enzyme
                                                :name (x21 / name :op1 "Pak")
                                                :xref (x49 / xref :value "UNIPROT:PAK1_HUMAN" :prob "0.203"))
                                          :ARG1 (x26 / and
                                                :op1 (x22 / relative-position
                                                      :direction (x23 / downstream)
                                                      :op1 (x24 / enzyme
                                                            :name (x25 / name :op1 "PI3K")
                                                            :xref (x48 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                                                :op2 (x27 / phosphorylate-01
                                                      :ARG1 (x28 / enzyme
                                                            :name (x29 / name :op1 "Raf")
                                                            :xref (x47 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))))
                                          :ARG1-of (x33 / describe-01
                                                :ARG1-of (x30 / describe-01
                                                      :ARG0 (x31 / publication
                                                            :ARG1-of (x32 / cite-01 :ARG2 "34"))))))))
                  :ARG1-of (x34 / describe-01
                        :ARG0 (x35 / publication
                              :ARG1-of (x36 / cite-01 :ARG2 "35"))))
            :ARG0 (x37 / we)
            :ARG1 (x39 / determine-01
                  :ARG1 (x42 / act-01
                        :ARG0 (x40 / protein
                              :name (x41 / name :op1 "Pak2")
                              :xref (x / xref :value "UNIPROT:PAK2_HUMAN" :prob "0.604"))
                        :ARG1 (x43 / up-to
                              :op1 (x46 / pathway
                                    :mod (x44 / this)
                                    :ARG0-of (x45 / signal-07)))))))


# ::id PMC3412844.120
# ::snt Initially we assessed S338 phosphorylation of c-Raf in fibroblasts expressing a dn-Pak2.
# ::tok Initially we assessed S338 phosphorylation of c @-@ Raf in fibroblasts expressing a dn @-@ Pak2 .
(x3 / assess-01
      :time (x1 / initial)
      :ARG0 (x2 / we)
      :ARG1 (x6 / phosphorylate-01
            :ARG1 (x4 / amino-acid
                  :mod "338"
                  :name (x5 / name :op1 "serine")
                  :xref (x16 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :ARG2 (x7 / enzyme
                  :name (x8 / name :op1 "c-Raf")
                  :xref (x15 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.673")))
      :location (x9 / fibroblast
            :ARG1-of (x10 / express-03
                  :ARG2 (x11 / protein
                        :name (x12 / name :op1 "dn")
                        :mod (x13 / protein
                              :name (x14 / name :op1 "Pak2")
                              :xref (x / xref :value "UNIPROT:PAK2_HUMAN" :prob "0.604"))))))


# ::id PMC3412844.121
# ::snt When fibroblasts were treated with TGF-β, both c-Raf and Erk phosphorylation was dramatically reduced ( Figure 3A ).
# ::tok When fibroblasts were treated with TGF-β, both c @-@ Raf and Erk phosphorylation was dramatically reduced ( Figure 3A ) .
(x12 / reduce-01
      :time (x2 / treat-04
            :ARG1 (x1 / fibroblast)
            :ARG2 (x3 / small-molecule
                  :name (x4 / name :op1 "TGF-β,")
                  :xref (x16 / xref :value "PUBCHEM:446991" :prob "17.394333")))
      :ARG1 (x5 / and
            :op1 (x6 / enzyme
                  :name (x7 / name :op1 "c-Raf")
                  :xref (x15 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.673"))
            :op2 (x10 / phosphorylate-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "Erk")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))
      :degree (x11 / dramatic)
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure :mod "3a")))


# ::id PMC3412844.122
# ::snt Additionally, a dramatic reduction in phosphorylation of Erk ( Figure 3B ) was seen when Pak2 was knocked out in MEFs.
# ::tok Additionally , a dramatic reduction in phosphorylation of Erk ( Figure 3B ) was seen when Pak2 was knocked out in MEFs .
(x1 / and
      :op2 (x9 / see-01
            :ARG1 (x3 / reduce-01
                  :degree (x2 / dramatic)
                  :ARG1 (x4 / phosphorylate-01
                        :ARG1 (x5 / enzyme
                              :name (x6 / name :op1 "Erk")
                              :xref (x15 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                        :ARG1-of (x7 / describe-01
                              :ARG0 (x8 / figure :mod "3b"))))
            :time (x12 / knock-out-03
                  :ARG1 (x10 / protein
                        :name (x11 / name :op1 "Pak2")
                        :xref (x / xref :value "UNIPROT:PAK2_HUMAN" :prob "0.604")))
            :location (x13 / cell
                  :name (x14 / name :op1 "mef"))))


# ::id PMC3412844.123
# ::snt The low levels of Erk activation in both dnPak2 expressing fibroblasts and Pak2 KO-MEFs, suggests Erk activation can occur via Ras, albeit at a greatly reduced amount.
# ::tok The low levels of Erk activation in both dnPak2 expressing fibroblasts and Pak2 KO @-@ MEFs , suggests Erk activation can occur via Ras , albeit at a greatly reduced amount .
(x5 / activate-01
      :ARG0 (x2 / level
            :ARG1-of (x1 / low-04)
            :quant-of (x3 / enzyme
                  :name (x4 / name :op1 "Erk")
                  :xref (x29 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
      :location (x6 / and
            :op1 (x9 / express-03
                  :ARG2 (x7 / enzyme
                        :name (x8 / name :op1 "dnPak2"))
                  :ARG2 (x11 / and
                        :op1 (x10 / fibroblast)
                        :op2 (x12 / protein
                              :name (x13 / name :op1 "Pak2")
                              :xref (x31 / xref :value "UNIPROT:PAK2_HUMAN" :prob "0.604")))
                  :mod (x14 / also))
            :op2 (x15 / cell
                  :name (x16 / name :op1 "mef")))
      :ARG0-of (x17 / suggest-01
            :ARG1 (x18 / possible-01
                  :ARG1 (x22 / be-temporally-at-91
                        :ARG0 (x21 / activate-01
                              :ARG1 (x19 / enzyme
                                    :name (x20 / name :op1 "Erk")
                                    :xref (x30 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
                        :ARG2 (x23 / enzyme
                              :name (x24 / name :op1 "Ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                        :ARG1 (x25 / albeit)
                        :location (x28 / amount
                              :ARG1-of (x27 / reduce-01
                                    :degree (x26 / great)))))))


# ::id PMC3412844.124
# ::snt This data is consistent with the hypothesis that TGF-β induced phosphorylation of Erk primarily follows the pathway of PI3K/Pak2/c-Raf/MEK/Erk, with a secondary contribution of Ras, similarly to that described for PDGF [21] .
# ::tok This data is consistent with the hypothesis that TGF-β induced phosphorylation of Erk primarily follows the pathway of PI3K/Pak2/c @-@ Raf/MEK/Erk , with a secondary contribution of Ras , similarly to that described for PDGF [ 21 ] .
(x12 / follow-02
      :ARG0 (x2 / data
            :mod (x1 / this)
            :ARG1-of (x3 / consistent-01
                  :ARG2 (x4 / hypothesize-01
                        :ARG1 (x7 / induce-01
                              :ARG0 (x5 / protein
                                    :name (x6 / name :op1 "TGF-β")
                                    :xref (x32 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
                              :ARG2 (x8 / phosphorylate-01
                                    :ARG1 (x9 / enzyme
                                          :name (x10 / name :op1 "Erk")
                                          :xref (x31 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))))
            :mod (x11 / primary))
      :ARG1 (x13 / pathway
            :ARG1-of (x14 / include-91
                  :ARG2 (x15 / protein-family
                        :name (x16 / name :op1 "PI3K/Pak2/c")))
            :name (x17 / name :op1 "b-raf/mek/erk"))
      :accompanier (x19 / contribute-01
            :mod (x18 / secondary)
            :ARG2 (x20 / enzyme
                  :name (x21 / name :op1 "Ras")
                  :xref (x30 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
            :ARG1-of (x22 / resemble-01
                  :ARG2 (x23 / that))
            :ARG0-of (x24 / describe-01
                  :ARG1 (x25 / protein
                        :name (x26 / name :op1 "PDGF")
                        :xref (x / xref :value "UNIPROT:PDGFA_HUMAN" :prob "0.313")))
            :ARG1-of (x27 / describe-01
                  :ARG0 (x28 / publication
                        :ARG1-of (x29 / cite-01 :ARG2 "21")))))


# ::id PMC3412844.125
# ::snt Erk activation requires activation of Pak2 and c-Raf.
# ::tok Erk activation requires activation of Pak2 and c @-@ Raf .
(x4 / require-01
      :ARG0 (x3 / activate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "Erk")
                  :xref (x11 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
      :ARG1 (x5 / activate-01
            :ARG1 (x8 / and
                  :op1 (x6 / protein
                        :name (x7 / name :op1 "Pak2")
                        :xref (x12 / xref :value "UNIPROT:PAK2_HUMAN" :prob "0.604"))
                  :op2 (x9 / enzyme
                        :name (x10 / name :op1 "c-Raf")
                        :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.673")))))


# ::id PMC3412844.126
# ::snt Cells were treated with TGF-β (2 ng/ml) for 2 h prior to lysis.
# ::tok Cells were treated with TGF-β ( 2 ng/ml ) for 2 h prior to lysis .
(x2 / treat-04
      :ARG1 (x1 / cell)
      :ARG2 (x3 / small-molecule
            :name (x4 / name :op1 "TGF-β")
            :quant (x5 / concentration-quantity
                  :quant "2"
                  :unit (x6 / nanogram-per-milliliter))
            :xref (x / xref :value "PUBCHEM:446991" :prob "17.394333"))
      :duration (x7 / temporal-quantity
            :quant "2"
            :unit (x8 / hour))
      :time (x9 / prior
            :op1 (x10 / lysis)))


# ::id PMC3412844.127
# ::snt Cell lysates were then probed for phospho-Erk, and phospho-c-Raf (Ser338).
# ::tok Cell lysates were then probed for phospho @-@ Erk , and phospho @-@ c @-@ Raf ( Ser338 ) .
(x4 / probe-01
      :ARG1 (x2 / lysate
            :mod (x1 / cell))
      :time (x3 / then)
      :ARG2 (x8 / and
            :op1 (x5 / enzyme
                  :ARG3-of (x6 / phosphorylate-01)
                  :name (x7 / name :op1 "Erk")
                  :xref (x14 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
            :op2 (x9 / enzyme
                  :ARG3-of (x10 / phosphorylate-01)
                  :name (x11 / name :op1 "c-Raf")
                  :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.673")))
      :ARG1-of (x12 / amino-acid
            :mod "338"
            :name (x13 / name :op1 "serine")
            :xref (x15 / xref :value "PUBCHEM:5951" :prob "11.218784")))


# ::id PMC3412844.128
# ::snt The phospho-Erk1/2, and the stripped/reprobed total Erk loading control blot was obtained using the lower molecular mass portion of the same blot as that for P-cRaf.
# ::tok The phospho @-@ Erk1 @/@ 2 , and the stripped @/@ reprobed total Erk loading control blot was obtained using the lower molecular mass portion of the same blot as that for P @-@ cRaf .
(x12 / obtain-01
      :ARG1 (x4 / and
            :op1 (x1 / enzyme
                  :ARG3-of (x2 / phosphorylate-01)
                  :name (x3 / name :op1 "Erk1/2"))
            :op2 (x11 / immunoblot-01
                  :op1 (x5 / strip-01
                        :ARG1 (x6 / enzyme
                              :mod (x7 / total)
                              :name (x8 / name :op1 "Erk")
                              :xref (x25 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
                  :ARG0-of (x10 / control-01
                        :ARG1 (x9 / load-01))))
      :ARG2-of (x13 / use-01
            :ARG1 (x18 / portion
                  :ARG1-of (x14 / low-04
                        :degree (x15 / more))
                  :mod (x16 / molecule)
                  :mod (x17 / mass)
                  :part-of (x20 / immunoblot-01
                        :ARG1-of (x19 / same-01))
                  :ARG1 (x21 / that))
            :ARG2 (x22 / enzyme
                  :ARG3-of (x23 / phosphorylate-01)
                  :name (x24 / name :op1 "c-raf")
                  :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.633"))))


# ::id PMC3412844.129
# ::snt The same cell lysates were analyzed on a separate blot for PAK2 to confirm expression.
# ::tok The same cell lysates were analyzed on a separate blot for PAK2 to confirm expression .
(x4 / analyze-01
      :ARG1 (x3 / lysate
            :ARG1-of (x1 / same-01)
            :mod (x2 / cell))
      :ARG1 (x6 / immunoblot-01
            :ARG1-of (x5 / separate-02)
            :ARG1 (x7 / protein
                  :name (x8 / name :op1 "PAK2")))
      :purpose (x9 / confirm-01
            :ARG1 (x10 / express-03)))


# ::id PMC3412844.130
# ::snt Smad2 Linker Region is Phosphorylated by Erk
# ::tok Smad2 Linker Region is Phosphorylated by Erk
(x4 / phosphorylate-01
      :ARG1 (x3 / link-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "Smad2")
                  :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003")))
      :ARG2 (x5 / enzyme
            :name (x6 / name :op1 "Erk")
            :xref (x7 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))


# ::id PMC3412844.131
# ::snt Having shown a direct TGF-β/Erk signaling pathway, our next goal was to show an association existed between Erk and smad signaling, both under the direct control of TGF-β.
# ::tok Having shown a direct TGF-β/Erk signaling pathway , our next goal was to show an association existed between Erk and smad signaling , both under the direct control of TGF-β.
(x10 / have-purpose-91
      :ARG1-of (x1 / cause-01
            :ARG0 (x2 / show-01
                  :ARG1 (x7 / pathway
                        :ARG0-of (x6 / signal-07
                              :ARG1-of (x3 / direct-02)
                              :ARG0 (x4 / enzyme
                                    :name (x5 / name :op1 "TGF-β/Erk"))))))
      :ARG0 (x8 / we)
      :time (x9 / next)
      :ARG2 (x11 / show-01
            :ARG1 (x12 / associate-01))
      :ARG1 (x13 / exist-01
            :ARG1 (x19 / signal-07
                  :ARG0 (x16 / and
                        :op1 (x14 / enzyme
                              :name (x15 / name :op1 "Erk")
                              :xref (x25 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                        :op2 (x17 / protein
                              :name (x18 / name :op1 "smad")
                              :xref (x26 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.272"))))
            :ARG2 (x20 / and
                  :condition (x22 / control-01
                        :ARG1-of (x21 / direct-02)
                        :ARG0 (x23 / protein
                              :name (x24 / name :op1 "TGF-β.")
                              :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))))))


# ::id PMC3412844.132
# ::snt AKR-2B fibroblasts were treated with TGF-β and probed for phosphorylation of smad2 at the Erk phosphorylation sites ( Figure 4A ; Ser 245, 250, and 255).
# ::tok AKR @-@ 2B fibroblasts were treated with TGF-β and probed for phosphorylation of smad2 at the Erk phosphorylation sites ( Figure 4A ; Ser 245 , 250 , and 255 ) .
(x7 / and
      :op1 (x4 / treat-04
            :ARG1 (x3 / fibroblast
                  :mod (x1 / protein
                        :name (x2 / name :op1 "AKR-2B")))
            :ARG2 (x5 / protein
                  :name (x6 / name :op1 "TGF-β")
                  :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233")))
      :op2 (x8 / probe-01
            :ARG1 (x21 / and
                  :op1 (x9 / phosphorylate-01
                        :ARG1 (x10 / protein
                              :name (x11 / name :op1 "smad2")
                              :xref (x25 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))
                        :location (x15 / site
                              :ARG0-of (x14 / phosphorylate-01
                                    :ARG1 (x12 / enzyme
                                          :name (x13 / name :op1 "Erk")
                                          :xref (x26 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))
                        :ARG1-of (x16 / describe-01
                              :ARG0 (x17 / and
                                    :op1 (x18 / figure :mod "4a")
                                    :op2 (x19 / amino-acid
                                          :mod "245"
                                          :name (x20 / name :op1 "serine")
                                          :xref (x27 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 "250")))
                  :ARG1-of (x22 / describe-01
                        :ARG0 (x23 / publication
                              :ARG1-of (x24 / cite-01 :ARG2 "255"))))))


# ::id PMC3412844.133
# ::snt We observed a temporal increase in smad2 linker region phosphorylation that was dependant on MEK activitivation of Erk, as treatment with U0216 abolished linker region phosphorylation ( Figure 4A,C ).
# ::tok We observed a temporal increase in smad2 linker region phosphorylation that was dependant on MEK activitivation of Erk , as treatment with U0216 abolished linker region phosphorylation ( Figure 4A , C ) .
(x2 / observe-01
      :ARG0 (x1 / we)
      :ARG1 (x4 / increase-01
            :time (x3 / temporal)
            :ARG1 (x7 / link-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "smad2")
                        :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))))
      :ARG1 (x9 / phosphorylate-01
            :mod (x8 / region)
            :ARG0-of (x10 / depend-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "MEK" :op2 "activitivation")))
            :part-of (x13 / enzyme
                  :name (x14 / name :op1 "Erk")
                  :xref (x25 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
      :ARG1-of (x18 / abolish-01
            :ARG0 (x15 / treat-04
                  :ARG2 (x16 / small-molecule
                        :name (x17 / name :op1 "U0216")))
            :ARG1 (x19 / link-01
                  :ARG1 (x20 / phosphorylate-01))
            :ARG1-of (x21 / describe-01
                  :ARG0 (x22 / and
                        :op1 (x23 / figure :mod "4a")
                        :op2 (x24 / figure :mod "5c")))))


# ::id PMC3412844.134
# ::snt Similarly, inhibition of TGF-β receptor kinase activity (LY364947) blocked smad2 linker phosphorylation ( Figure 4C ).
# ::tok Similarly , inhibition of TGF-β receptor kinase activity ( LY364947 ) blocked smad2 linker phosphorylation ( Figure 4C ) .
(x8 / block-01
      :ARG1-of (x1 / resemble-01)
      :ARG0 (x2 / inhibit-01
            :ARG1 (x5 / activity-06
                  :ARG0 (x3 / enzyme
                        :name (x4 / name
                              :op1 "TGF-β"
                              :op2 "receptor"
                              :op3 "kinase"))
                  :ARG1-of (x6 / describe-01
                        :ARG2 (x7 / name :op1 "LY364947"))))
      :ARG1 (x11 / link-01
            :ARG1 (x9 / protein
                  :name (x10 / name :op1 "smad2")
                  :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))
            :ARG1-of (x12 / phosphorylate-01))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure :mod "4c")))


# ::id PMC3412844.135
# ::snt Smad2 phosphorylation showed prominent C-terminal phosphorylation (Ser465/467) at all times tested, independent of MEK activity ( Figure 4B ; TGF-β+U0126).
# ::tok Smad2 phosphorylation showed prominent C @-@ terminal phosphorylation ( Ser465 @/@ 467 ) at all times tested , independent of MEK activity ( Figure 4B ; TGF-β+U0126 ) .
(x15 / test-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "Smad2")
            :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003"))
      :ARG1-of (x3 / phosphorylate-01)
      :ARG1-of (x4 / show-01
            :ARG1 (x8 / phosphorylate-01
                  :mod (x5 / prominent)
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "c-terminus")
                        :xref (x25 / xref :value "UNIPROT:7B2_HUMAN" :prob "0.242"))
                  :ARG0 (x9 / amino-acid
                        :mod "465"
                        :name (x10 / name :op1 "serine")
                        :xref (x27 / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :ARG2 (x11 / enzyme
                  :name (x12 / name :op1 "467")))
      :time (x14 / time
            :mod (x13 / all))
      :ARG0 (x16 / and
            :op1 (x17 / depend-01
                  :polarity "-"
                  :ARG1 (x20 / activity-06
                        :ARG0 (x18 / enzyme
                              :name (x19 / name :op1 "MEK")
                              :xref (x26 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343")))
                  :ARG1-of (x21 / describe-01
                        :ARG0 (x22 / figure :mod "4b"))))
      :ARG1 (x23 / enzyme
            :name (x24 / name :op1 "TGF-β+U0126")))


# ::id PMC3412844.136
# ::snt The linker phosphorylation seen at the 30 min. time point ( Figure 4A ) was not significantly above background levels (0 min.).
# ::tok The linker phosphorylation seen at the 30 min . time point ( Figure 4A ) was not significantly above background levels ( 0 min. ) .
(x12 / above
      :ARG1 (x4 / see-01
            :ARG1 (x3 / phosphorylate-01
                  :ARG1 (x1 / enzyme
                        :name (x2 / name :op1 "linker")
                        :xref (x / xref :value "UNIPROT:NEUL3_HUMAN" :prob "0.202")))
            :time (x8 / point
                  :mod (x5 / temporal-quantity
                        :quant "30"
                        :unit (x6 / minute))
                  :mod (x7 / time))
            :ARG1-of (x9 / describe-01
                  :ARG0 (x10 / figure :mod "4a")))
      :ARG1-of (x11 / significant-02 :polarity "-")
      :op1 (x14 / level
            :mod (x13 / background))
      :ARG1-of (x15 / mass-quantity
            :quant "0"
            :name (x16 / name :op1 "min.")))


# ::id PMC3412844.137
# ::snt However, rapid activation of Erk by EGF did result in significant smad2 linker phosphorylation ( Figure 4D ).
# ::tok However , rapid activation of Erk by EGF did result in significant smad2 linker phosphorylation ( Figure 4D ) .
(x1 / contrast-01
      :ARG2 (x8 / result-01
            :ARG1 (x3 / activate-01
                  :mod (x2 / rapid)
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "Erk")
                        :xref (x19 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                  :ARG0 (x6 / protein
                        :name (x7 / name :op1 "EGF")
                        :xref (x18 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG2 (x14 / phosphorylate-01
                  :ARG1-of (x9 / significant-02
                        :ARG1 (x10 / protein
                              :name (x11 / name :op1 "smad2")
                              :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703")))
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "linker")
                        :xref (x17 / xref :value "UNIPROT:NEUL3_HUMAN" :prob "0.202"))))
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / figure :mod "4d")))


# ::id PMC3412844.138
# ::snt Together this data indicates TGF-β stimulation causes phosphorylation of smad 2 via two distinct mechanisms, within the linker region, through Erk, and at the C-terminus, by TGF-β receptors.
# ::tok Together this data indicates TGF-β stimulation causes phosphorylation of smad 2 via two distinct mechanisms , within the linker region , through Erk , and at the C @-@ terminus , by TGF-β receptors .
(x4 / indicate-01
      :ARG0 (x3 / data
            :mod (x1 / together)
            :mod (x2 / this))
      :ARG1 (x18 / and
            :op1 (x8 / cause-01
                  :ARG0 (x7 / stimulate-01
                        :ARG0 (x5 / protein
                              :name (x6 / name :op1 "TGF-β")
                              :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233")))
                  :ARG1 (x9 / phosphorylate-01
                        :ARG1 (x10 / protein
                              :name (x11 / name :op1 "smad" :op2 "2"))
                        :ARG2 (x14 / after
                              :op1 (x13 / mechanism
                                    :quant "2"
                                    :mod (x12 / distinct)))))
            :op1 (x15 / link-01
                  :ARG2 (x16 / enzyme
                        :name (x17 / name :op1 "Erk")
                        :xref (x23 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
            :op2 (x19 / protein-segment
                  :name (x20 / name :op1 "C-terminus"))
            :op2 (x21 / protein
                  :name (x22 / name :op1 "TGF-β" :op2 "receptor"))))


# ::id PMC3412844.139
# ::snt TGF-β directs Erk phosphorylation of Smad2 linker region.
# ::tok TGF-β directs Erk phosphorylation of Smad2 linker region .
(x3 / direct-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "TGF-β")
            :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
      :ARG2 (x6 / phosphorylate-01
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "Erk")
                  :xref (x11 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
      :ARG1 (x9 / link-01
            :ARG1 (x7 / protein
                  :name (x8 / name :op1 "Smad2")
                  :xref (x10 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003"))))


# ::id PMC3412844.140
# ::snt Blots were probed for smad2 phosphorylated within the linker region at S245, 250 and 255, striped and reprobed for total smad2 to demonstrate each loading.
# ::tok Blots were probed for smad2 phosphorylated within the linker region at S245 , 250 and 255 , striped and reprobed for total smad2 to demonstrate each loading .
(x17 / demonstrate-01
      :ARG0 (x2 / probe-01
            :ARG1 (x1 / immunoblot-01)
            :ARG0 (x3 / protein
                  :name (x4 / name :op1 "smad2")
                  :xref (x20 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))
            :ARG1-of (x5 / phosphorylate-01
                  :ARG1 (x11 / and
                        :op1 (x6 / link-01
                              :ARG2 (x7 / amino-acid
                                    :mod "245"
                                    :name (x8 / name :op1 "serine")
                                    :xref (x22 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                        :op2 (x9 / and :op1 "250" :op2 "255")
                        :ARG0-of (x10 / stripe-00)
                        :op2 (x12 / enzyme
                              :name (x13 / name :op1 "reprobed")
                              :xref (x21 / xref :value "UNIPROT:SPAG6_HUMAN" :prob "0.212")))
                  :ARG2 (x14 / enzyme
                        :mod (x15 / total)
                        :name (x16 / name :op1 "smad2")
                        :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))))
      :ARG1 (x19 / load-01
            :mod (x18 / each)))


# ::id PMC3412844.141
# ::snt The blots were stripped and reprobed for total smad2 to demonstrate similar loading of all samples.
# ::tok The blots were stripped and reprobed for total smad2 to demonstrate similar loading of all samples .
(x9 / demonstrate-01
      :ARG1 (x1 / immunoblot-01)
      :ARG0 (x2 / and
            :op2 (x3 / enzyme
                  :name (x4 / name :op1 "reprobed")
                  :xref (x / xref :value "UNIPROT:SPAG6_HUMAN" :prob "0.212"))
            :op1 (x5 / strip-01
                  :ARG1 (x6 / enzyme
                        :mod (x7 / total)
                        :name (x8 / name :op1 "smad2")
                        :xref (x15 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))))
      :ARG1 (x11 / load-01
            :ARG1-of (x10 / resemble-01)
            :ARG2 (x13 / thing
                  :mod (x12 / all)
                  :ARG1-of (x14 / sample-01))))


# ::id PMC3412844.142
# ::snt Representative western-blots are shown with each time course performed in triplicate with consistent results.
# ::tok Representative western @-@ blots are shown with each time course performed in triplicate with consistent results .
(x4 / show-01
      :ARG0 (x3 / blot
            :ARG0-of (x1 / represent-01)
            :mod (x2 / western))
      :ARG2 (x7 / course
            :mod (x5 / each)
            :mod (x6 / time)
            :ARG1-of (x8 / perform-02
                  :location (x9 / triplicate)
                  :ARG1-of (x10 / consistent-01
                        :ARG2 (x11 / thing
                              :ARG2-of (x12 / result-01))))))


# ::id PMC3412844.143
# ::snt P-Erk blots are also shown to indicate Erk activation.
# ::tok P @-@ Erk blots are also shown to indicate Erk activation .
(x6 / show-01
      :ARG0 (x4 / immunoblot-01
            :ARG1 (x1 / enzyme
                  :ARG3-of (x2 / phosphorylate-01)
                  :name (x3 / name :op1 "Erk")
                  :xref (x11 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
      :mod (x5 / also)
      :ARG1 (x7 / indicate-01
            :ARG1 (x10 / activate-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "Erk")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))


# ::id PMC3412844.144
# ::snt Intensity of P-smad2 linker region band was determined and expressed graphically as fold increase (using total Erk band intensity as the loading control) relative to untreated control values for each experiment.
# ::tok Intensity of P @-@ smad2 linker region band was determined and expressed graphically as fold increase ( using total Erk band intensity as the loading control ) relative to untreated control values for each experiment .
(x8 / determine-01
      :ARG1 (x7 / band
            :mod (x1 / intensity
                  :degree-of (x2 / enzyme
                        :ARG3-of (x3 / phosphorylate-01)
                        :name (x4 / name :op1 "smad2")
                        :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703")))
            :ARG1-of (x5 / link-01
                  :ARG2 (x6 / region)))
      :ARG2 (x9 / express-03
            :ARG2 (x10 / enzyme
                  :name (x11 / name :op1 "graphically")))
      :ARG1-of (x12 / increase-01
            :ARG2 (x13 / product-of
                  :ARG1-of (x14 / use-01
                        :ARG1 (x18 / band
                              :mod (x15 / enzyme
                                    :mod (x16 / total)
                                    :name (x17 / name :op1 "Erk")
                                    :xref (x27 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                              :ARG1-of (x19 / intensity
                                    :ARG1-of (x21 / control-01
                                          :ARG1 (x20 / load-01)))
                              :ARG1-of (x22 / relative-05))
                        :ARG2 (x24 / control
                              :ARG1-of (x23 / treat-04 :polarity "-"))))
            :ARG3 (x26 / experiment-01
                  :mod (x25 / each))))


# ::id PMC3412844.145
# ::snt The mean values of three independent experiments are shown (±SEM).
# ::tok The mean values of three independent experiments are shown ( ±SEM ) .
(x5 / be-located-at-91
      :ARG1 (x2 / value
            :mod (x1 / mean)
            :poss (x4 / experiment
                  :quant "3"
                  :ARG0-of (x3 / depend-01 :polarity "-")))
      :ARG2 (x6 / show-01
            :ARG2 (x7 / small-molecule
                  :name (x8 / name :op1 "±SEM")
                  :xref (x / xref :value "PUBCHEM:2724271" :prob "10.871458"))))


# ::id PMC3412844.146
# ::snt Letters above each column indicate the different statistically significant (P>0.05) groupings.
# ::tok Letters above each column indicate the different statistically significant ( P>0.05 ) groupings .
(x4 / indicate-01
      :ARG0 (x3 / column
            :mod (x1 / above
                  :op1 (x2 / each)))
      :ARG1 (x7 / significant-02
            :ARG1-of (x5 / differ-02)
            :mod (x6 / statistics)
            :ARG1-of (x8 / gene
                  :name (x9 / name :op1 "P>0.05")
                  :mod (x10 / grouping))))


# ::id PMC3412844.147
# ::snt Blots were stripped and reprobed for total smad 2 as a loading control.
# ::tok Blots were stripped and reprobed for total smad 2 as a loading control .
(x2 / strip-01
      :ARG1 (x1 / immunoblot-01)
      :ARG1 (x3 / and
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "reprobed")
                  :xref (x / xref :value "UNIPROT:SPAG6_HUMAN" :prob "0.212"))
            :beneficiary (x6 / enzyme
                  :mod (x7 / total)
                  :name (x8 / name :op1 "smad" :op2 "2")))
      :ARG2 (x10 / control-01
            :ARG1 (x9 / load-01)))


# ::id PMC3412844.148
# ::snt Although these results indicate a direct cross-talk between smad2 and Erk, in light of the controversy between the Erk and smad linker region phosphorylation, we wished to examine their spatial relationship.
# ::tok Although these results indicate a direct cross @-@ talk between smad2 and Erk , in light of the controversy between the Erk and smad linker region phosphorylation , we wished to examine their spatial relationship .
(x1 / have-concession-91
      :ARG2 (x5 / indicate-01
            :ARG0 (x3 / thing
                  :mod (x2 / this)
                  :ARG2-of (x4 / result-01))
            :ARG1 (x8 / talk-01
                  :ARG1-of (x6 / direct-02)
                  :ARG1-of (x7 / cross-01)
                  :ARG0 (x11 / and
                        :op1 (x9 / protein
                              :name (x10 / name :op1 "smad2")
                              :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))
                        :op2 (x12 / enzyme
                              :name (x13 / name :op1 "Erk")
                              :xref (x29 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))
      :ARG1 (x24 / wish-01
            :ARG1-of (x14 / cause-01
                  :ARG0 (x15 / controversy)
                  :ARG1 (x21 / link-01
                        :ARG0 (x18 / and
                              :op1 (x16 / enzyme
                                    :name (x17 / name :op1 "Erk")
                                    :xref (x30 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                              :op2 (x19 / protein
                                    :name (x20 / name :op1 "smad")
                                    :xref (x28 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.272")))
                        :ARG1 (x22 / phosphorylate-01)))
            :ARG0 (x23 / we)
            :ARG1 (x25 / examine-01
                  :ARG1 (x27 / relation-03
                        :mod (x26 / space)))))


# ::id PMC3412844.149
# ::snt Since smad2 is a transcription factor that translocates quickly into the nucleus following receptor mediated phosphorylation, we fractionated TGF-β treated fibroblasts into cytoplasmic and nuclear fractions and examined smad2 phosphorylation.
# ::tok Since smad2 is a transcription factor that translocates quickly into the nucleus following receptor mediated phosphorylation , we fractionated TGF-β treated fibroblasts into cytoplasmic and nuclear fractions and examined smad2 phosphorylation .
(x1 / cause-01
      :ARG0 (x7 / quick-02
            :ARG1 (x5 / factor
                  :domain (x2 / protein
                        :name (x3 / name :op1 "smad2")
                        :xref (x30 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))
                  :ARG0-of (x4 / transcribe-01)
                  :ARG0-of (x6 / translocate-00))
            :ARG2 (x8 / nucleus
                  :xref (x35 / xref :value "GO:0005634" :prob "0.8"))
            :ARG1-of (x9 / follow-01
                  :ARG2 (x13 / phosphorylate-01
                        :ARG1-of (x12 / mediate-01
                              :ARG0 (x10 / enzyme
                                    :name (x11 / name :op1 "receptor")
                                    :xref (x31 / xref :value "UNIPROT:CIR1_HUMAN" :prob "0.243"))))))
      :ARG1 (x15 / fractionate-00
            :ARG0 (x14 / we)
            :ARG1 (x25 / and
                  :op1 (x18 / treat-04
                        :ARG1 (x16 / protein
                              :name (x17 / name :op1 "TGF-β")
                              :xref (x32 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
                        :ARG1 (x19 / fibroblast)
                        :ARG2 (x20 / and
                              :op1 (x22 / fraction
                                    :part-of (x21 / cytoplasm
                                          :xref (x33 / xref :value "GO:0005737" :prob "0.8")))
                              :op2 (x24 / fraction
                                    :mod (x23 / nucleus
                                          :xref (x34 / xref :value "GO:0005634" :prob "0.8")))))
                  :op2 (x26 / examine-01
                        :ARG1 (x29 / phosphorylate-01
                              :ARG1 (x27 / protein
                                    :name (x28 / name :op1 "smad2")
                                    :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703")))))))


# ::id PMC3412844.150
# ::snt Linker phosphorylation was seen primarily in the nuclear fraction ( Figure 5A ).
# ::tok Linker phosphorylation was seen primarily in the nuclear fraction ( Figure 5A ) .
(x4 / see-01
      :ARG1 (x3 / phosphorylate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "Linker")
                  :xref (x / xref :value "UNIPROT:RPGFL_HUMAN" :prob "0.212")))
      :location (x7 / fraction
            :mod (x5 / primary)
            :part-of (x6 / nucleus
                  :xref (x10 / xref :value "GO:0005634" :prob "0.8")))
      :ARG1-of (x8 / describe-01
            :ARG0 (x9 / figure :mod "5a")))


# ::id PMC3412844.151
# ::snt Similarly, receptor phosphorylated smad2 was primarily in the nucleus, with small amounts in the cytoplasmic fraction, following TGF-β treatment.
# ::tok Similarly , receptor phosphorylated smad2 was primarily in the nucleus , with small amounts in the cytoplasmic fraction , following TGF-β treatment .
(x1 / and
      :op1 (x8 / primary
            :ARG0 (x5 / phosphorylate-01
                  :ARG1-of (x2 / resemble-01)
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "receptor")
                        :xref (x18 / xref :value "UNIPROT:CIR1_HUMAN" :prob "0.243")))
            :ARG1 (x6 / protein
                  :name (x7 / name :op1 "smad2")
                  :xref (x19 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))
            :location (x9 / nucleus
                  :xref (x20 / xref :value "GO:0005634" :prob "0.8")))
      :op2 (x11 / amount
            :mod (x10 / small)
            :location (x13 / fraction
                  :part-of (x12 / cytoplasm
                        :xref (x21 / xref :value "GO:0005737" :prob "0.8")))
            :ARG1-of (x14 / follow-01
                  :ARG2 (x17 / treat-04
                        :ARG2 (x15 / protein
                              :name (x16 / name :op1 "TGF-β")
                              :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))))))


# ::id PMC3412844.152
# ::snt Total smad2 was present in both the cytoplasm and the nucleus.
# ::tok Total smad2 was present in both the cytoplasm and the nucleus .
(x4 / present-02
      :ARG1 (x1 / enzyme
            :mod (x2 / total)
            :name (x3 / name :op1 "smad2")
            :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))
      :ARG2 (x7 / and
            :mod (x5 / both)
            :op1 (x6 / cytoplasm
                  :xref (x10 / xref :value "GO:0005737" :prob "0.8"))
            :op2 (x8 / nucleus
                  :xref (x9 / xref :value "GO:0005634" :prob "0.8"))))


# ::id PMC3412844.153
# ::snt Since our concern was cytoplasmic protein contamination of the nuclear fractions, both cytoplasmic and nuclear fractions were probed for GAPDH to demonstrate purity of nuclear fractions relative to cytoplasmic protein contamination ( Figure 5A ).
# ::tok Since our concern was cytoplasmic protein contamination of the nuclear fractions , both cytoplasmic and nuclear fractions were probed for GAPDH to demonstrate purity of nuclear fractions relative to cytoplasmic protein contamination ( Figure 5A ) .
(x1 / cause-01
      :ARG0 (x13 / probe-01
            :ARG1 (x2 / concern-01
                  :ARG0 (x5 / contaminate-01
                        :ARG2 (x4 / protein
                              :mod (x3 / cytoplasm
                                    :xref (x28 / xref :value "GO:0005737" :prob "0.8"))))
                  :ARG1 (x8 / and
                        :op1 (x7 / fraction
                              :mod (x6 / nucleus
                                    :xref (x29 / xref :value "GO:0005634" :prob "0.8")))
                        :op1 (x10 / fraction
                              :part-of (x9 / cytoplasm
                                    :xref (x26 / xref :value "GO:0005737" :prob "0.8")))
                        :op2 (x12 / fraction
                              :part-of (x11 / nucleus
                                    :xref (x27 / xref :value "GO:0005634" :prob "0.8")))))
            :ARG1 (x14 / enzyme
                  :name (x15 / name :op1 "GAPDH")
                  :xref (x / xref :value "UNIPROT:G3P_HUMAN" :prob "1.002"))
            :ARG2 (x16 / demonstrate-01
                  :ARG1 (x18 / fraction
                        :part-of (x17 / nucleus
                              :xref (x30 / xref :value "GO:0005634" :prob "0.8"))))
            :ARG1-of (x19 / relative-05
                  :ARG2 (x21 / protein
                        :mod (x20 / cytoplasm
                              :xref (x25 / xref :value "GO:0005737" :prob "0.8"))
                        :name (x22 / name :op1 "contamination")))
            :ARG1-of (x23 / describe-01
                  :ARG0 (x24 / figure :mod "5a"))))


# ::id PMC3412844.154
# ::snt Nuclear Smad levels are controlled by the proteasome and activated Erk.
# ::tok Nuclear Smad levels are controlled by the proteasome and activated Erk .
(x5 / control-01
      :ARG1 (x4 / level
            :quant-of (x1 / enzyme
                  :mod (x2 / nucleus
                        :xref (x14 / xref :value "GO:0005634" :prob "0.8"))
                  :name (x3 / name :op1 "Smad")
                  :xref (x12 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.312")))
      :ARG0 (x8 / and
            :op1 (x6 / enzyme
                  :name (x7 / name :op1 "proteasome")
                  :xref (x13 / xref :value "UNIPROT:VP113_HUMAN" :prob "0.352"))
            :op2 (x9 / enzyme
                  :ARG1-of (x10 / activate-01)
                  :name (x11 / name :op1 "Erk")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))


# ::id PMC3412844.155
# ::snt Nuclear and cytoplasmic fractions were isolated and probed for smad2 linker region phosphorylation (245/250/255), or receptor phosphorylation (465/467).
# ::tok Nuclear and cytoplasmic fractions were isolated and probed for smad2 linker region phosphorylation ( 245 @/@ 250 @/@ 255 ) , or receptor phosphorylation ( 465 @/@ 467 ) .
(x6 / and
      :op1 (x5 / isolate-01
            :ARG1 (x2 / and
                  :op1 (x1 / nucleus
                        :xref (x24 / xref :value "GO:0005634" :prob "0.8"))
                  :op2 (x4 / fraction
                        :part-of (x3 / cytoplasm
                              :xref (x23 / xref :value "GO:0005737" :prob "0.8")))))
      :op2 (x7 / probe-01
            :ARG1 (x16 / or
                  :op1 (x10 / region
                        :mod (x8 / protein
                              :name (x9 / name :op1 "smad2")
                              :xref (x22 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))
                        :mod (x11 / phosphorylate-01
                              :ARG2 (x12 / enzyme
                                    :name (x13 / name :op1 "245" :op2 "250"))))
                  :op2 (x14 / publication
                        :ARG1-of (x15 / cite-01 :ARG2 "255"))
                  :op3 (x19 / phosphorylate-01
                        :ARG1 (x17 / enzyme
                              :name (x18 / name :op1 "receptor")
                              :xref (x / xref :value "UNIPROT:CIR1_HUMAN" :prob "0.243"))
                        :ARG2 (x20 / enzyme
                              :name (x21 / name :op1 "465" :op2 "467"))))))


# ::id PMC3412844.156
# ::snt Linker phosphorylation blots were stripped and reprobed for total smad2 as a loading control, while receptor phosphorylated blots were stripped and reprobed for GAPDH to monitor the presence of cytoplasmic protein in the nuclear fraction.
# ::tok Linker phosphorylation blots were stripped and reprobed for total smad2 as a loading control , while receptor phosphorylated blots were stripped and reprobed for GAPDH to monitor the presence of cytoplasmic protein in the nuclear fraction .
(x13 / contrast-01
      :ARG1 (x1 / link-01
            :ARG1 (x2 / phosphorylate-01
                  :ARG1 (x3 / immunoblot-01)
                  :ARG2 (x4 / and
                        :op2 (x5 / enzyme
                              :name (x6 / name :op1 "reprobed")
                              :xref (x32 / xref :value "UNIPROT:SPAG6_HUMAN" :prob "0.212"))
                        :op1 (x7 / strip-01
                              :ARG1 (x8 / enzyme
                                    :mod (x9 / total)
                                    :name (x10 / name :op1 "smad2")
                                    :xref (x31 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703")))))
            :ARG2 (x12 / control-01
                  :ARG1 (x11 / load-01)))
      :ARG2 (x24 / monitor-01
            :ARG0 (x16 / phosphorylate-01
                  :ARG1 (x14 / enzyme
                        :name (x15 / name :op1 "receptor")
                        :xref (x33 / xref :value "UNIPROT:CIR1_HUMAN" :prob "0.243"))
                  :manner (x17 / immunoblot-01
                        :ARG1 (x19 / and
                              :op1 (x18 / strip-01)
                              :op2 (x20 / enzyme
                                    :name (x21 / name :op1 "reprobed")
                                    :xref (x / xref :value "UNIPROT:SPAG6_HUMAN" :prob "0.212"))))
                  :ARG2 (x22 / enzyme
                        :name (x23 / name :op1 "GAPDH")
                        :xref (x30 / xref :value "UNIPROT:G3P_HUMAN" :prob "1.002")))
            :ARG1 (x25 / present-02
                  :ARG1 (x27 / protein
                        :mod (x26 / cytoplasm
                              :xref (x35 / xref :value "GO:0005737" :prob "0.8")))
                  :ARG2 (x29 / fraction
                        :mod (x28 / nucleus
                              :xref (x34 / xref :value "GO:0005634" :prob "0.8"))))))


# ::id PMC3412844.157
# ::snt Cells were incubated with phospho-smad2 (S245/250/255) linker antibody and specific immune complexes detected using Rhodamine X conjugated secondary antibody.
# ::tok Cells were incubated with phospho @-@ smad2 ( S245 @/@ 250 @/@ 255 ) linker antibody and specific immune complexes detected using Rhodamine X conjugated secondary antibody .
(x14 / and
      :op1 (x2 / incubate-01
            :ARG1 (x1 / cell)
            :ARG2 (x13 / antibody
                  :ARG0-of (x12 / link-01
                        :ARG1 (x3 / enzyme
                              :ARG3-of (x4 / phosphorylate-01)
                              :name (x5 / name :op1 "smad2")
                              :ARG1-of (x6 / mean-01
                                    :ARG2 (x7 / and
                                          :op1 (x8 / amino-acid
                                                :mod "245"
                                                :name (x9 / name :op1 "serine")
                                                :xref (x24 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                          :op2 (x10 / small-molecule
                                                :name (x11 / name :op1 "250" :op2 "255"))))
                              :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703")))))
      :op2 (x18 / detect-01
            :ARG1 (x17 / macro-molecular-complex
                  :ARG1-of (x15 / specific-02)
                  :ARG1-of (x16 / immune-02))
            :ARG2 (x23 / antibody
                  :mod (x19 / small-molecule
                        :name (x20 / name :op1 "Rhodamine")
                        :xref (x25 / xref :value "PUBCHEM:6694" :prob "14.36086"))
                  :ARG1-of (x21 / conjugate-02)
                  :mod (x22 / secondary))))


# ::id PMC3412844.158
# ::snt Blots were stripped and reprobed for β-actin as a loading control.
# ::tok Blots were stripped and reprobed for β-actin as a loading control .
(x2 / strip-01
      :ARG0 (x1 / immunoblot-01)
      :ARG1 (x3 / reprobed)
      :ARG2 (x4 / protein
            :name (x5 / name :op1 "β-actin")
            :ARG0-of (x7 / control-01
                  :ARG0-of (x6 / load-01))
            :xref (x / xref :value "UNIPROT:KLH17_HUMAN" :prob "0.282")))


# ::id PMC3412844.159
# ::snt The mean values for each time point (n = 3 for smad 2, n = 4 for smad 3) are displayed with the solid line representing the curve for TGF-β+U0126 and the dotted line representing TGF-β treatment.
# ::tok The mean values for each time point ( n = 3 for smad 2 , n = 4 for smad 3 ) are displayed with the solid line representing the curve for TGF-β+U0126 and the dotted line representing TGF-β treatment .
(x1 / multi-sentence
      :snt1 (x17 / represent-01
            :ARG1 (x3 / value
                  :mod (x2 / mean)
                  :ARG2 (x6 / point
                        :mod (x4 / each)
                        :mod (x5 / time))
                  :ARG1-of (x7 / sample-01
                        :quant "3"
                        :ARG1 (x8 / and
                              :op1 (x9 / protein
                                    :name (x10 / name :op1 "smad" :op2 "2"))
                              :op2 (x11 / sample-01 :quant "4"))
                        :ARG2 (x12 / protein
                              :name (x13 / name :op1 "smad" :op2 "3"))))
            :ARG1-of (x14 / display-01
                  :ARG2 (x16 / cell-line
                        :ARG1-of (x15 / solid-02)))
            :ARG1 (x18 / curve
                  :mod (x19 / protein
                        :name (x20 / name :op1 "TGF-β+U0126"))))
      :snt2 (x24 / represent-01
            :ARG1 (x21 / and
                  :op1 (x23 / line
                        :ARG1-of (x22 / dot-01)))
            :ARG0 (x27 / treat-04
                  :ARG2 (x25 / small-molecule
                        :name (x26 / name :op1 "TGF-β")
                        :xref (x / xref :value "PUBCHEM:446991" :prob "17.394333")))))


# ::id PMC3412844.160
# ::snt In order to substantiate our findings, immunofluorescent localization of phospho-smad2 linker region was determined.
# ::tok In order to substantiate our findings , immunofluorescent localization of phospho @-@ smad2 linker region was determined .
(x13 / determine-01
      :purpose (x1 / substantiate-01
            :ARG1 (x4 / thing
                  :ARG1-of (x3 / find-01
                        :ARG0 (x2 / we))))
      :ARG0 (x7 / be-located-at-91
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "immunofluorescent"))
            :ARG1 (x8 / enzyme
                  :ARG3-of (x9 / phosphorylate-01)
                  :name (x10 / name :op1 "smad2")
                  :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))
            :ARG1-of (x11 / link-01))
      :ARG1 (x12 / region))


# ::id PMC3412844.161
# ::snt Nuclear localization of phospho-smad2 linker region was observed, in agreement with previous biochemical data that phosphorylated smad2 linker region localizes primarily in the nucleus of fibroblasts ( Figure 5B ).
# ::tok Nuclear localization of phospho @-@ smad2 linker region was observed , in agreement with previous biochemical data that phosphorylated smad2 linker region localizes primarily in the nucleus of fibroblasts ( Figure 5B ) .
(x18 / localize-01
      :ARG1 (x8 / observe-01
            :ARG1 (x2 / be-located-at-91
                  :ARG2 (x1 / nucleus
                        :xref (x26 / xref :value "GO:0005634" :prob "0.8"))
                  :ARG1 (x7 / region
                        :ARG1-of (x6 / link-01
                              :ARG2 (x3 / enzyme
                                    :ARG3-of (x4 / phosphorylate-01)
                                    :name (x5 / name :op1 "smad2")
                                    :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))))))
      :location (x17 / region
            :mod (x9 / agree-01
                  :ARG2 (x12 / data
                        :time (x10 / previous)
                        :mod (x11 / biochemistry)
                        :ARG0-of (x13 / phosphorylate-01
                              :ARG1 (x14 / protein
                                    :name (x15 / name :op1 "smad2")
                                    :xref (x24 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))))
                  :ARG1-of (x16 / link-01)))
      :mod (x19 / primary)
      :location (x20 / nucleus
            :part-of (x21 / fibroblast)
            :xref (x25 / xref :value "GO:0005634" :prob "0.8"))
      :ARG1-of (x22 / describe-01
            :ARG0 (x23 / figure :mod "5b")))


# ::id PMC3412844.162
# ::snt These data suggests Erk phosphorylation of the smad2 linker region is likely limited to a specific subcellular location via TGF-β induction of both smad C-terminal phosphorylation/translocation and activation of the PI3K/Pak2/Erk pathway.
# ::tok These data suggests Erk phosphorylation of the smad2 linker region is likely limited to a specific subcellular location via TGF-β induction of both smad C @-@ terminal phosphorylation @/@ translocation and activation of the PI3K/Pak2/Erk pathway .
(x3 / suggest-01
      :ARG0 (x2 / data
            :mod (x1 / this))
      :ARG1 (x4 / likely-01
            :ARG1 (x12 / limit-01
                  :ARG0 (x11 / region
                        :mod (x7 / phosphorylate-01
                              :ARG2 (x5 / enzyme
                                    :name (x6 / name :op1 "Erk")
                                    :xref (x30 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                              :ARG1 (x8 / protein
                                    :name (x9 / name :op1 "smad2")
                                    :xref (x29 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703")))
                        :ARG1-of (x10 / link-01))
                  :ARG2 (x18 / induce-01
                        :ARG1-of (x13 / specific-02
                              :ARG1 (x15 / be-located-at-91
                                    :mod (x14 / subcellular)
                                    :ARG2 (x16 / protein
                                          :name (x17 / name :op1 "TGF-β")
                                          :xref (x32 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))))
                        :ARG1 (x19 / protein
                              :name (x20 / name :op1 "smad")
                              :xref (x31 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.272")))
                  :ARG1 (x23 / phosphorylate-01
                        :ARG1 (x21 / enzyme
                              :name (x22 / name :op1 "c-terminus")
                              :xref (x / xref :value "UNIPROT:7B2_HUMAN" :prob "0.242"))
                        :ARG2 (x25 / and
                              :op1 (x24 / translocate-01)
                              :op2 (x26 / activate-01
                                    :ARG1 (x27 / pathway
                                          :name (x28 / name :op1 "PI3K/Pak2/Erk"))))))))


# ::id PMC3412844.163
# ::snt Smad linker region function
# ::tok Smad linker region function
(x5 / function-01
      :ARG0 (x4 / region
            :mod (x1 / protein-segment
                  :name (x2 / name :op1 "Smad")
                  :ARG0-of (x3 / link-01))))


# ::id PMC3412844.164
# ::snt To ascertain the function of linker region phosphorylation of smads, initially we treated fibroblasts with the proteosomal inhibitor MG132 with and without TGF-β ( Figure 5A,B ).
# ::tok To ascertain the function of linker region phosphorylation of smads , initially we treated fibroblasts with the proteosomal inhibitor MG132 with and without TGF-β ( Figure 5A , B ) .
(x12 / treat-04
      :ARG1-of (x1 / cause-01
            :ARG0 (x2 / enzyme
                  :name (x3 / name :op1 "ascertain"))
            :ARG1 (x4 / function-01
                  :ARG0 (x6 / region
                        :ARG1-of (x5 / link-01))
                  :ARG1 (x7 / phosphorylate-01
                        :ARG1 (x8 / enzyme
                              :name (x9 / name :op1 "smads")
                              :xref (x24 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.252")))))
      :time (x10 / initial)
      :ARG0 (x11 / we)
      :ARG1 (x13 / fibroblast)
      :ARG2 (x14 / protein
            :name (x15 / name :op1 "proteosome")
            :xref (x25 / xref :value "UNIPROT:VP113_HUMAN" :prob "0.262"))
      :ARG2 (x16 / small-molecule
            :ARG0-of (x17 / inhibit-01)
            :name (x18 / name :op1 "MG132")
            :xref (x26 / xref :value "PUBCHEM:462382" :prob "18.349844"))
      :ARG1 (x19 / and
            :op2 (x20 / protein
                  :name (x21 / name :op1 "TGF-β")
                  :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
            :ARG1-of (x22 / describe-01
                  :ARG0 (x23 / figure :mod "5a"))))


# ::id PMC3412844.165
# ::snt Nuclear levels of both receptor and linker region phosphorylated smad 2 increased with inhibition of proteosomal degradation, consistent with previous data showing nuclear proteosomal degradation of smads [37] , but suggested that linker region phosphorylation may be associated with directing smads to proteosomal degradation [28] .
# ::tok Nuclear levels of both receptor and linker region phosphorylated smad 2 increased with inhibition of proteosomal degradation , consistent with previous data showing nuclear proteosomal degradation of smads [ 37 ] , but suggested that linker region phosphorylation may be associated with directing smads to proteosomal degradation [ 28 ] .
(x1 / multi-sentence
      :snt1 (x2 / nucleus
            :xref (x47 / xref :value "GO:0005634" :prob "0.8"))
      :snt2 (x11 / increase-01
            :ARG1 (x3 / level
                  :quant-of (x4 / and
                        :op1 (x5 / enzyme
                              :name (x6 / name :op1 "receptor")
                              :xref (x43 / xref :value "UNIPROT:CIR1_HUMAN" :prob "0.243"))
                        :op2 (x7 / link-01
                              :ARG2 (x8 / enzyme
                                    :ARG3-of (x9 / phosphorylate-01)
                                    :name (x10 / name :op1 "smad" :op2 "2")))))
            :ARG2 (x12 / inhibit-01
                  :ARG1 (x15 / degrade-01
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "proteosome")
                              :xref (x45 / xref :value "UNIPROT:VP113_HUMAN" :prob "0.262"))))
            :ARG1-of (x16 / consistent-01
                  :ARG2 (x18 / data
                        :time (x17 / previous)
                        :ARG0-of (x19 / show-01
                              :ARG0-of (x29 / suggest-01
                                    :ARG2 (x20 / nucleus
                                          :ARG0-of (x23 / degrade-01
                                                :ARG2 (x21 / protein
                                                      :name (x22 / name :op1 "proteosome")
                                                      :xref (x42 / xref :value "UNIPROT:VP113_HUMAN" :prob "0.262"))
                                                :ARG1 (x24 / protein
                                                      :name (x25 / name :op1 "smads")
                                                      :xref (x / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.252")))
                                          :ARG1-of (x26 / describe-01
                                                :ARG0 (x27 / publication
                                                      :ARG1-of (x28 / cite-01 :ARG2 "37")))
                                          :xref (x46 / xref :value "GO:0005634" :prob "0.8"))
                                    :ARG1 (x30 / possible-01
                                          :ARG1 (x38 / degrade-01
                                                :ARG1 (x31 / link-01
                                                      :ARG1 (x32 / phosphorylate-01))
                                                :ARG0 (x33 / associate-01
                                                      :ARG2 (x34 / enzyme
                                                            :name (x35 / name :op1 "directing" :op2 "smads")))
                                                :ARG2 (x36 / protein
                                                      :name (x37 / name :op1 "proteosome")
                                                      :xref (x44 / xref :value "UNIPROT:VP113_HUMAN" :prob "0.262")))))
                              :ARG1-of (x39 / describe-01
                                    :ARG0 (x40 / publication
                                          :ARG1-of (x41 / cite-01 :ARG2 "28"))))))))


# ::id PMC3412844.166
# ::snt However, TGF-β stimulated fibroblasts treated with U0126 alone or with MG132 did not show an increase in C-terminal phospho-smad2 or 3, even after 3 h, as would be expected if Erk mediated linker phosphorylation targeted smads for proteosomal degradation (data not shown).
# ::tok However , TGF-β stimulated fibroblasts treated with U0126 alone or with MG132 did not show an increase in C @-@ terminal phospho @-@ smad2 or 3 , even after 3 h , as would be expected if Erk mediated linker phosphorylation targeted smads for proteosomal degradation ( data not shown ) .
(x1 / multi-sentence
      :snt1 (x2 / have-concession-91
            :ARG1 (x5 / stimulate-01
                  :ARG0 (x3 / protein
                        :name (x4 / name :op1 "TGF-β")
                        :xref (x42 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
                  :ARG1 (x6 / fibroblast)))
      :snt2 (x14 / show-01
            :ARG0 (x7 / treat-04
                  :ARG2 (x11 / or
                        :op1 (x8 / small-molecule
                              :name (x9 / name :op1 "U0126")
                              :mod (x10 / alone)
                              :xref (x46 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
                        :op2 (x12 / small-molecule
                              :name (x13 / name :op1 "MG132")
                              :xref (x47 / xref :value "PUBCHEM:462382" :prob "18.349844"))))
            :polarity "-"
            :ARG1 (x15 / increase-01
                  :ARG1 (x21 / or
                        :op1 (x16 / protein-segment
                              :name (x17 / name :op1 "c-terminus")
                              :part-of (x18 / enzyme
                                    :ARG3-of (x19 / phosphorylate-01)
                                    :name (x20 / name :op1 "smad2")
                                    :xref (x45 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703")))
                        :op2 "3"
                        :time (x23 / after
                              :mod (x22 / even)
                              :quant (x24 / temporal-quantity
                                    :quant "3"
                                    :unit (x25 / hour)))))
            :ARG0-of (x26 / cause-01
                  :ARG0 (x27 / expect-01
                        :ARG1 (x32 / phosphorylate-01
                              :ARG1-of (x30 / mediate-01
                                    :ARG0 (x28 / enzyme
                                          :name (x29 / name :op1 "Erk")
                                          :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
                              :ARG1 (x31 / link-01)
                              :ARG1 (x33 / target-01
                                    :ARG1 (x34 / enzyme
                                          :name (x35 / name :op1 "smads")
                                          :xref (x44 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.252"))
                                    :purpose (x38 / degrade-01
                                          :ARG1 (x36 / protein
                                                :name (x37 / name :op1 "proteosome")
                                                :xref (x43 / xref :value "UNIPROT:VP113_HUMAN" :prob "0.262")))))))
            :ARG1-of (x39 / describe-01
                  :ARG0 (x40 / data
                        :ARG1-of (x41 / show-01 :polarity "-")))))


# ::id PMC3412844.167
# ::snt To the contrary, treatment of fibroblast with TGF-β, in the absence or presence of active Erk ( Figure 5C ), demonstrated that linker region phosphorylation (TGF-β alone) resulted in sustained levels of smad 2 and 3 (C-terminal phosphorylated), suggesting that linker phosphorylation is associated with an increased stability of C-terminal phospho-smads 2 and 3.
# ::tok To the contrary , treatment of fibroblast with TGF-β, in the absence or presence of active Erk ( Figure 5C ) , demonstrated that linker region phosphorylation ( TGF-β alone ) resulted in sustained levels of smad 2 and 3 ( C @-@ terminal phosphorylated ) , suggesting that linker phosphorylation is associated with an increased stability of C @-@ terminal phospho @-@ smads 2 and 3 .
(x1 / multi-sentence
      :snt1 (x2 / cause-01
            :ARG1 (x3 / contrast-01
                  :ARG2 (x4 / treat-04
                        :ARG1 (x5 / fibroblast)
                        :ARG2 (x6 / small-molecule
                              :name (x7 / name :op1 "TGF-β,")
                              :xref (x46 / xref :value "PUBCHEM:446991" :prob "17.394333")))
                  :condition (x8 / or
                        :op2 (x9 / present-02)
                        :op1 (x10 / absent-01
                              :ARG1 (x11 / enzyme
                                    :ARG0-of (x12 / activity-06)
                                    :name (x13 / name :op1 "Erk")
                                    :xref (x45 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))
                  :ARG1-of (x14 / describe-01
                        :ARG0 (x15 / figure :mod "5c"))
                  :ARG0-of (x16 / demonstrate-01
                        :ARG1 (x17 / link-01))))
      :snt2 (x27 / and
            :op1 (x18 / phosphorylate-01
                  :ARG1-of (x22 / result-01
                        :ARG0 (x19 / small-molecule
                              :name (x20 / name :op1 "TGF-β")
                              :mod (x21 / alone)
                              :xref (x47 / xref :value "PUBCHEM:446991" :prob "17.394333"))
                        :ARG2 (x24 / level
                              :ARG1-of (x23 / sustain-01)
                              :quant-of (x25 / protein
                                    :name (x26 / name :op1 "smad" :op2 "2")))))
            :op2 (x28 / protein-segment
                  :quant "3"
                  :name (x29 / name :op1 "c-terminus")
                  :ARG1-of (x30 / phosphorylate-01)
                  :ARG0-of (x31 / suggest-01
                        :ARG1 (x35 / associate-01
                              :ARG1 (x34 / phosphorylate-01
                                    :ARG1 (x32 / enzyme
                                          :name (x33 / name :op1 "linker")
                                          :xref (x44 / xref :value "UNIPROT:NEUL3_HUMAN" :prob "0.202")))
                              :ARG2 (x36 / increase-01
                                    :ARG1 (x37 / stable-03
                                          :ARG1 (x38 / protein-segment
                                                :name (x39 / name :op1 "c-terminus")
                                                :ARG1-of (x40 / phosphorylate-01
                                                      :ARG2 (x41 / enzyme
                                                            :name (x42 / name :op1 "smads")
                                                            :xref (x / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.252")))))
                                    :ARG2 (x43 / and :op1 "2" :op2 "3")))))))


# ::id PMC3412844.168
# ::snt Using the band densities of multiple experiments, we calculated decay rates for the C-terminal phospho-smad proteins ( Figure 5D ).
# ::tok Using the band densities of multiple experiments , we calculated decay rates for the C @-@ terminal phospho @-@ smad proteins ( Figure 5D ) .
(x7 / calculate-01
      :manner (x1 / use-01
            :ARG1 (x3 / density
                  :mod (x2 / band))
            :ARG2 (x5 / experiment-01
                  :mod (x4 / multiple)))
      :ARG0 (x6 / we)
      :ARG1 (x9 / rate
            :ARG1-of (x8 / decay))
      :ARG2 (x14 / protein
            :name (x10 / name :op1 "c-terminus")
            :ARG1-of (x11 / phosphorylate-01
                  :ARG2 (x12 / enzyme
                        :name (x13 / name :op1 "smad")
                        :xref (x17 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.272")))
            :xref (x / xref :value "UNIPROT:7B2_HUMAN" :prob "0.242"))
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / figure :mod "5d")))


# ::id PMC3412844.169
# ::snt The time to decrease the signal intensity by 50% differed between treatment groups for both smad 2 and 3 (116 vs. 135 min. for smad2, and 100 vs 127 min. for smad3; P<0.05, for TGF-β+U0126 vs.
# ::tok The time to decrease the signal intensity by 50 % differed between treatment groups for both smad 2 and 3 ( 116 vs . 135 min . for smad2 , and 100 vs 127 min . for smad3;
(x23 / and
      :op1 (x1 / time
            :ARG1 (x2 / decrease-01
                  :ARG1 (x4 / intensity
                        :ARG1 (x3 / signal-07))
                  :ARG2 (x5 / percentage-entity :value "50")
                  :ARG1-of (x6 / differ-02
                        :degree (x7 / between
                              :op1 (x9 / group
                                    :mod (x8 / treat-04)))
                        :ARG1 (x10 / and
                              :op1 (x11 / protein
                                    :name (x12 / name :op1 "smad" :op2 "2"))
                              :op2 (x13 / protein
                                    :name (x14 / name :op1 "3" :op2 "116")))
                        :ARG2 (x15 / mass-quantity
                              :quant "135"
                              :unit (x16 / minute))))
            :ARG2 (x19 / and
                  :op1 (x17 / protein
                        :name (x18 / name :op1 "smad2")
                        :xref (x26 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))
                  :op2 (x20 / temporal-quantity
                        :quant "100"
                        :compared-to (x21 / temporal-quantity
                              :quant "127"
                              :unit (x22 / minute)))))
      :op2 (x24 / enzyme
            :name (x25 / name :op1 "smad3;")
            :xref (x / xref :value "UNIPROT:SMAD3_HUMAN" :prob "0.652")))


# ::id PMC3412844.170
# ::snt TGF-β alone, respectively).
# ::tok TGF-β alone , respectively ) .
(x4 / and
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "TGF-β")
            :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
      :mod (x3 / alone)
      :mod (x5 / respective))


# ::id PMC3412844.171
# ::snt Although only linker region phosphorylation of smad2 is shown in previous figures ( Figures 4 and 5 ), there are equivalent putative Erk phosphorylation sites found on smad 3 [24] but the equivalent phospho-linker region antibody for smad 3 is not commercially available.
# ::tok Although only linker region phosphorylation of smad2 is shown in previous figures ( Figures 4 and 5 ) , there are equivalent putative Erk phosphorylation sites found on smad 3 [ 24 ] but the equivalent phospho @-@ linker region antibody for smad 3 is not commercially available .
(x1 / have-concession-91
      :ARG2 (x26 / contrast-01
            :ARG1 (x3 / region
                  :mod (x2 / only)
                  :mod (x4 / phosphorylate-01
                        :ARG1 (x5 / protein
                              :name (x6 / name :op1 "smad2")
                              :xref (x38 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "0.703"))))
            :ARG1-of (x7 / show-01
                  :ARG0 (x9 / describe-01
                        :time (x8 / previous))
                  :ARG1-of (x10 / describe-01
                        :ARG0 (x13 / and
                              :op1 (x11 / figure :mod "4")
                              :op2 (x12 / figure :mod "5")))
                  :ARG0-of (x20 / find-01
                        :time (x19 / protein-segment
                              :ARG1-of (x14 / equal-01)
                              :ARG1-of (x15 / think-01
                                    :ARG2 (x18 / phosphorylate-01
                                          :ARG1 (x16 / enzyme
                                                :name (x17 / name :op1 "Erk")
                                                :xref (x39 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))
                        :ARG1 (x21 / protein
                              :name (x22 / name :op1 "smad" :op2 "3")))
                  :ARG1-of (x23 / describe-01
                        :ARG0 (x24 / publication
                              :ARG1-of (x25 / cite-01 :ARG2 "24"))))
            :ARG2 (x35 / possible-01
                  :ARG1 (x31 / region
                        :ARG1-of (x27 / equal-01
                              :ARG2 (x28 / enzyme
                                    :ARG3-of (x29 / phosphorylate-01)
                                    :name (x30 / name :op1 "linker")
                                    :xref (x / xref :value "UNIPROT:NEUL3_HUMAN" :prob "0.202")))
                        :ARG0-of (x32 / counter-01
                              :ARG1 (x33 / protein
                                    :name (x34 / name :op1 "smad" :op2 "3"))))
                  :polarity "-"))
      :ARG1 (x37 / available-02
            :manner (x36 / commercial)))


# ::id PMC3412844.172
# ::snt Based on the data shown in figure 5C , smad 3 linker region is similarly phosphorylated by Erk, in that U0126 has the same effect on inhibiting the decay of C-terminal phosphorylated smads 2 and 3.
# ::tok Based on the data shown in figure 5C , smad 3 linker region is similarly phosphorylated by Erk , in that U0126 has the same effect on inhibiting the decay of C @-@ terminal phosphorylated smads 2 and 3 .
(x9 / resemble-01
      :ARG1-of (x1 / base-02
            :ARG2 (x2 / data
                  :ARG1-of (x3 / show-01
                        :ARG0 (x4 / figure :mod "5c"))))
      :ARG1 (x8 / region
            :mod (x5 / protein-segment
                  :name (x6 / name :op1 "smad" :op2 "3")
                  :ARG0-of (x7 / link-01)))
      :ARG1 (x10 / phosphorylate-01
            :ARG2 (x11 / enzyme
                  :name (x12 / name :op1 "Erk")
                  :xref (x25 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
      :ARG0-of (x16 / affect-01
            :ARG0 (x13 / small-molecule
                  :name (x14 / name :op1 "U0126")
                  :xref (x26 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
            :ARG1-of (x15 / same-01)
            :ARG1 (x17 / inhibit-01
                  :ARG1 (x18 / decay-01
                        :ARG0 (x19 / protein-segment
                              :name (x20 / name :op1 "c-terminus")
                              :ARG1-of (x21 / phosphorylate-01
                                    :ARG1 (x22 / enzyme
                                          :name (x23 / name :op1 "smads")
                                          :xref (x / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.252"))
                                    :ARG2 (x24 / and :op1 "2" :op2 "3")))))))


# ::id PMC3412844.173
# ::snt Since nuclear localized, C-terminal phospho-smads bind DNA and regulate gene expression [38] , this implies that increased stability would likely increase duration of function.
# ::tok Since nuclear localized , C @-@ terminal phospho @-@ smads bind DNA and regulate gene expression [ 38 ] , this implies that increased stability would likely increase duration of function .
(x18 / likely-01
      :ARG1-of (x1 / cause-01
            :ARG0 (x3 / localize-01
                  :ARG1 (x2 / nucleus
                        :xref (x26 / xref :value "GO:0005634" :prob "0.8")))
            :ARG1 (x9 / bind-01
                  :ARG1 (x4 / protein-segment
                        :name (x5 / name :op1 "c-terminus")
                        :ARG1-of (x6 / phosphorylate-01
                              :ARG2 (x7 / enzyme
                                    :name (x8 / name :op1 "smads")
                                    :xref (x / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.252"))))
                  :ARG2 (x10 / nucleic-acid
                        :wiki "dna"
                        :name (x11 / name :op1 "DNA")))
            :ARG0-of (x12 / regulate-01
                  :ARG1 (x14 / express-03
                        :ARG1 (x13 / gene)))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / publication
                        :ARG1-of (x17 / cite-01 :ARG2 "38"))))
      :ARG1 (x23 / increase-01
            :ARG0 (x20 / imply-01
                  :mod (x19 / this)
                  :ARG1 (x21 / increase-01
                        :ARG1 (x22 / stability)))
            :ARG2 (x24 / duration
                  :duration-of (x25 / function-01))))


# ::id PMC3412844.174
# ::snt By transiently treating fibroblasts with TGF-β (10 min.), we wished to assess the stability of smad mediated transcription.
# ::tok By transiently treating fibroblasts with TGF-β ( 10 min. ) , we wished to assess the stability of smad mediated transcription .
(x7 / wish-01
      :ARG0 (x2 / treat-04
            :manner (x1 / transient-02)
            :ARG1 (x3 / fibroblast)
            :ARG2 (x4 / small-molecule
                  :name (x5 / name :op1 "TGF-β")
                  :quant "10"
                  :name (x6 / name :op1 "min.")
                  :xref (x16 / xref :value "PUBCHEM:448763" :prob "15.205691")))
      :ARG1 (x9 / assess-01
            :ARG0 (x8 / we)
            :ARG1 (x10 / stable-03
                  :ARG1 (x14 / transcribe-01
                        :ARG1-of (x13 / mediate-01
                              :ARG0 (x11 / protein
                                    :name (x12 / name :op1 "smad")
                                    :xref (x / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.272")))))))


# ::id PMC3412844.175
# ::snt The 3 h time point chosen to assess mRNA stability was based on the differences in western blot phospho-smad densities in figure 5C .
# ::tok The 3 h time point chosen to assess mRNA stability was based on the differences in western blot phospho @-@ smad densities in figure 5C .
(x5 / choose-01
      :ARG0 (x4 / point
            :mod (x1 / temporal-quantity
                  :quant "3"
                  :unit (x2 / hour))
            :mod (x3 / time))
      :purpose (x6 / assess-01
            :ARG1 (x16 / density
                  :ARG1 (x9 / stability
                        :mod (x7 / nucleic-acid
                              :name (x8 / name :op1 "mRNA")))
                  :ARG1-of (x10 / base-02
                        :ARG2 (x11 / differ-02
                              :ARG1 (x12 / immunoblot-01
                                    :ARG1 (x13 / enzyme
                                          :ARG3-of (x14 / phosphorylate-01)
                                          :name (x15 / name :op1 "smad")
                                          :xref (x / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.272")))))
                  :location (x17 / figure :mod "5c"))))


# ::id PMC3412844.176
# ::snt As shown in figure 5C/D , smads remained phosphorylated longer when Erk was active.
# ::tok As shown in figure 5C/D , smads remained phosphorylated longer when Erk was active .
(x7 / long-03
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :op1 "5c/d"))
      :ARG1 (x5 / remain-01
            :ARG1 (x3 / enzyme
                  :name (x4 / name :op1 "smads")
                  :xref (x12 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.252")))
      :ARG1-of (x6 / phosphorylate-01)
      :degree (x8 / more)
      :time (x11 / activate-01
            :ARG1 (x9 / enzyme
                  :name (x10 / name :op1 "Erk")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))


# ::id PMC3412844.177
# ::snt Likewise, smad mediated gene transcription of both PAI-1 and Smad7 remained elevated greater than 2 fold (P>0.001; Figure 6A ) in the presence of active Erk, three hours after removal of TGF-β treatment.
# ::tok Likewise , smad mediated gene transcription of both PAI @-@ 1 and Smad7 remained elevated greater than 2 fold ( P>0.001; Figure 6A ) in the presence of active Erk , three hours after removal of TGF-β treatment .
(x12 / remain-01
      :mod (x1 / likewise)
      :ARG0 (x6 / transcribe-01
            :ARG1-of (x4 / mediate-01
                  :ARG0 (x2 / protein
                        :name (x3 / name :op1 "smad")
                        :xref (x32 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.272")))
            :ARG1 (x5 / gene)
            :ARG0 (x7 / and
                  :op1 (x8 / protein
                        :name (x9 / name :op1 "PAI-1")
                        :xref (x31 / xref :value "UNIPROT:PAI1_HUMAN" :prob "1.002"))
                  :op2 (x10 / protein
                        :name (x11 / name :op1 "Smad7")
                        :xref (x33 / xref :value "UNIPROT:SMAD7_HUMAN" :prob "1.003"))))
      :ARG3 (x13 / elevate-01
            :mod (x14 / great
                  :degree (x15 / more)
                  :compared-to (x16 / product-of :op1 "2"))
            :ARG1-of (x17 / describe-01
                  :ARG0 (x18 / figure :mod "6a")))
      :condition (x19 / present-02
            :ARG1 (x20 / enzyme
                  :ARG0-of (x21 / activity-06)
                  :name (x22 / name :op1 "Erk")
                  :xref (x30 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
      :time (x25 / after
            :quant (x23 / temporal-quantity
                  :quant "3"
                  :unit (x24 / hour))
            :op1 (x26 / remove-01
                  :ARG1 (x29 / treat-04
                        :ARG2 (x27 / protein
                              :name (x28 / name :op1 "TGF-β")
                              :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))))))


# ::id PMC3412844.178
# ::snt Erk activity is integral for TGF-β signaling and inducing growth in fibroblasts.
# ::tok Erk activity is integral for TGF-β signaling and inducing growth in fibroblasts .
(x4 / integral
      :domain (x3 / activity-06
            :ARG0 (x1 / enzyme
                  :name (x2 / name :op1 "Erk")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
      :purpose (x8 / and
            :op1 (x7 / signal-07
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "TGF-β")
                        :xref (x12 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233")))
            :op2 (x9 / induce-01
                  :ARG2 (x10 / grow-01
                        :location (x11 / fibroblast)))))


# ::id PMC3412844.179
# ::snt The mean values (±SEM) of six independent experiments are shown with statistical evaluation indicating differences between groups as (NS) not significant, (*) P<0.05, (***) P<0.001.
# ::tok The mean values ( ±SEM ) of six independent experiments are shown with statistical evaluation indicating differences between groups as ( NS ) not significant , ( * )
(x5 / and
      :op1 (x2 / value
            :mod (x1 / mean))
      :op2 (x3 / cell-line
            :name (x4 / name :op1 "±SEM"))
      :op2 (x8 / show-01
            :ARG1 (x7 / experiment-01
                  :quant "6"
                  :ARG0-of (x6 / depend-01 :polarity "-"))
            :ARG0 (x9 / statistics
                  :ARG0-of (x10 / evaluate-01
                        :ARG1 (x12 / differ-02
                              :ARG1-of (x11 / indicate-01)
                              :ARG1 (x13 / group)
                              :ARG1-of (x14 / resemble-01
                                    :ARG2 (x15 / enzyme
                                          :name (x16 / name :op1 "NS")
                                          :xref (x / xref :value "UNIPROT:GNL3_HUMAN" :prob "1.002")))
                              :ARG1-of (x17 / significant-02 :polarity "-")))
                  :mod (x18 / protein
                        :name (x19 / name :op1 "*")))))


# ::id PMC3412844.180
# ::snt The effect of treatment is expressed as a fold change in thymidine incorporation relative to untreated cells (control = 1).
# ::tok The effect of treatment is expressed as a fold change in thymidine incorporation relative to untreated cells ( control = 1 ) .
(x1 / affect-01
      :ARG0 (x2 / treat-04)
      :ARG1 (x3 / express-03)
      :ARG2 (x5 / change-01
            :mod (x4 / fold)
            :ARG1 (x8 / incorporate-02
                  :ARG1 (x6 / small-molecule
                        :name (x7 / name :op1 "thymidine")
                        :xref (x / xref :value "PUBCHEM:5789" :prob "12.207807"))
                  :ARG1-of (x9 / relative-05
                        :ARG3 (x10 / treat-04 :polarity "-")))
            :ARG1-of (x11 / control-01))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / publication
                  :ARG1-of (x14 / cite-01 :ARG2 "1"))))


# ::id PMC3412844.181
# ::snt The mean (±SEM) of triplicate assays is shown with statistical evaluation indicating differences between groups as previously describe.
# ::tok The mean ( ±SEM ) of triplicate assays is shown with statistical evaluation indicating differences between groups as previously describe .
(x9 / indicate-01
      :ARG0 (x4 / and
            :op1 (x1 / mean-01
                  :ARG2 (x2 / small-molecule
                        :name (x3 / name :op1 "±SEM")
                        :xref (x / xref :value "PUBCHEM:2724271" :prob "10.871458")))
            :op2 (x6 / show-01
                  :ARG0 (x5 / assay-01 :quant "3")
                  :ARG1 (x8 / evaluate-01
                        :mod (x7 / statistics))))
      :ARG1 (x10 / differ-02
            :ARG1 (x11 / group)
            :ARG1-of (x13 / describe-01
                  :time (x12 / previous))))


# ::id PMC3412844.182
# ::snt Arrows represent a functional link between the subsequent proteins, not necessarily a direct interaction.
# ::tok Arrows represent a functional link between the subsequent proteins , not necessarily a direct interaction .
(x1 / arrow
      :ARG0-of (x2 / represent-01
            :ARG1 (x4 / link-01
                  :ARG0-of (x3 / function-01)
                  :ARG1 (x6 / protein
                        :mod (x5 / subsequent))
                  :ARG0-of (x7 / need-01
                        :polarity "-"
                        :ARG1 (x9 / interact-01
                              :ARG1-of (x8 / direct-02))))))


# ::id PMC3412844.183
# ::snt In addition to the described phosphorylation of nuclear translocated smads, Erk functions by phosphorylating a variety of cytoplasmic and nuclear targets, many of which are critical in cell cycle progression [39] – [42] .
# ::tok In addition to the described phosphorylation of nuclear translocated smads , Erk functions by phosphorylating a variety of cytoplasmic and nuclear targets , many of which are critical in cell cycle progression [ 39 ] – [ 42 ] .
(x1 / and
      :op1 (x11 / phosphorylate-01
            :ARG0 (x10 / function-01
                  :ARG1-of (x2 / describe-01)
                  :ARG0 (x3 / phosphorylate-01
                        :ARG1 (x5 / translocate-01
                              :ARG2 (x4 / nucleus
                                    :xref (x29 / xref :value "GO:0005634" :prob "0.8"))
                              :ARG1 (x6 / protein
                                    :name (x7 / name :op1 "smads")
                                    :xref (x28 / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.252")))
                        :ARG2 (x8 / enzyme
                              :name (x9 / name :op1 "Erk")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))
            :ARG1 (x14 / and
                  :mod (x12 / variety)
                  :mod (x13 / cytoplasm
                        :xref (x30 / xref :value "GO:0005737" :prob "0.8"))))
      :op2 (x15 / nucleus
            :ARG0-of (x16 / target-01
                  :ARG1 (x18 / and
                        :quant (x17 / many)
                        :op2 (x19 / critical-02
                              :ARG2 (x22 / progress-01
                                    :ARG1 (x21 / cycle-02
                                          :ARG1 (x20 / cell))))
                        :ARG1-of (x23 / describe-01
                              :ARG0 (x24 / and :op1 "39" :op2 "47"))))
            :ARG1-of (x25 / describe-01
                  :ARG0 (x26 / publication
                        :ARG1-of (x27 / cite-01 :ARG2 "42")))
            :xref (x31 / xref :value "GO:0005634" :prob "0.8")))


# ::id PMC3412844.184
# ::snt Having established a functional connection between Erk and the Smad signaling pathway, we sought to determine if Erk also plays a role in the proliferative effects of TGF-β in fibroblasts.
# ::tok Having established a functional connection between Erk and the Smad signaling pathway , we sought to determine if Erk also plays a role in the proliferative effects of TGF-β in fibroblasts .
(x12 / seek-01
      :ARG1-of (x1 / cause-01
            :ARG0 (x7 / and
                  :op1 (x2 / establish-01
                        :ARG1 (x4 / connect-01
                              :ARG0-of (x3 / function-01)
                              :ARG1 (x5 / enzyme
                                    :name (x6 / name :op1 "Erk")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))))
                  :op2 (x10 / pathway
                        :name (x8 / name :op1 "Smad")
                        :ARG0-of (x9 / signal-07))))
      :ARG0 (x11 / we)
      :ARG1 (x13 / determine-01
            :ARG1 (x17 / play-02
                  :ARG0 (x14 / enzyme
                        :name (x15 / name :op1 "Erk")
                        :xref (x24 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                  :mod (x16 / also)
                  :ARG1 (x18 / role)
                  :topic (x20 / affect-01
                        :ARG1 (x19 / proliferate-01)
                        :ARG0 (x21 / small-molecule
                              :name (x22 / name :op1 "TGF-β")
                              :xref (x25 / xref :value "PUBCHEM:446991" :prob "17.394333"))
                        :location (x23 / fibroblast)))))


# ::id PMC3412844.185
# ::snt The biological consequences of TGF-β induced Erk activation were addressed using a thymidine incorporation assay ( Fig. 6B ).
# ::tok The biological consequences of TGF-β induced Erk activation were addressed using a thymidine incorporation assay ( Fig . 6B ) .
(x10 / address-02
      :ARG1 (x2 / consequence
            :mod (x1 / biology)
            :ARG1-of (x3 / cause-01
                  :ARG0 (x9 / activate-01
                        :ARG2-of (x6 / induce-01
                              :ARG0 (x4 / protein
                                    :name (x5 / name :op1 "TGF-β")
                                    :xref (x18 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233")))
                        :ARG1 (x7 / enzyme
                              :name (x8 / name :op1 "Erk")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))
      :ARG2-of (x11 / use-01
            :ARG1 (x15 / assay-01
                  :ARG1 (x14 / incorporate-02
                        :ARG1 (x12 / small-molecule
                              :name (x13 / name :op1 "thymidine")
                              :xref (x19 / xref :value "PUBCHEM:5789" :prob "12.207807")))))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / figure :mod "6b")))


# ::id PMC3412844.186
# ::snt Treatment with TGF-β yielded a 6 fold increase in DNA synthesis as compared to untreated fibroblasts.
# ::tok Treatment with TGF-β yielded a 6 fold increase in DNA synthesis as compared to untreated fibroblasts .
(x4 / yield-01
      :ARG0 (x1 / treat-04
            :ARG2 (x2 / small-molecule
                  :name (x3 / name :op1 "TGF-β")
                  :xref (x / xref :value "PUBCHEM:446991" :prob "17.394333")))
      :ARG1 (x6 / increase-01
            :ARG2 (x5 / product-of :op1 "6")
            :ARG1 (x9 / synthesize-01
                  :ARG0 (x7 / nucleic-acid
                        :wiki "dna"
                        :name (x8 / name :op1 "DNA")))
            :compared-to (x11 / fibroblast
                  :ARG1-of (x10 / treat-04 :polarity "-"))))


# ::id PMC3412844.187
# ::snt When cells were treated with U0126 to inhibit Erk activation prior to TGF-β addition, this growth stimulation was attenuated (P<0.001).
# ::tok When cells were treated with U0126 to inhibit Erk activation prior to TGF-β addition , this growth stimulation was attenuated (
(x16 / attenuate-01
      :time (x2 / treat-04
            :ARG1 (x1 / cell)
            :ARG2 (x3 / small-molecule
                  :name (x4 / name :op1 "U0126")
                  :xref (x20 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
            :ARG2 (x5 / inhibit-01
                  :ARG1 (x8 / activate-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "Erk")
                              :xref (x19 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                        :time (x9 / prior
                              :op1 (x12 / add-02
                                    :ARG1 (x10 / protein
                                          :name (x11 / name :op1 "TGF-β")
                                          :xref (x / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233")))))))
      :ARG1 (x15 / stimulate-01
            :mod (x13 / this)
            :ARG1 (x14 / grow-01))
      :ARG1-of (x17 / statistical-test-91
            :ARG2 (x18 / less-than :op1 "0.02")))


# ::id PMC3412844.188
# ::snt Consistent with our previous data showing Pak2's role in Erk activation, expression of dnPak2 dramatically decreased TGF-β induced growth stimulation (Ad-EGFP+TGF-β vs Ad-dnPAK2+TGF-β; P<0.001).
# ::tok Consistent with our previous data showing Pak2 's role in Erk activation , expression of dnPak2 dramatically decreased TGF-β induced growth stimulation ( Ad @-@ EGFP+TGF-β vs Ad @-@ dnPAK2+TGF-β;
(x1 / multi-sentence
      :snt1 (x17 / decrease-01
            :ARG1-of (x2 / consistent-01
                  :ARG2 (x5 / data
                        :poss (x3 / we)
                        :time (x4 / previous)
                        :ARG0-of (x6 / show-01
                              :ARG1 (x9 / role
                                    :poss (x7 / protein
                                          :name (x8 / name :op1 "Pak2")
                                          :xref (x / xref :value "UNIPROT:PAK2_HUMAN" :prob "0.604"))
                                    :topic (x12 / activate-01
                                          :ARG1 (x10 / enzyme
                                                :name (x11 / name :op1 "Erk")
                                                :xref (x30 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))))
            :ARG0 (x13 / express-03
                  :ARG2 (x14 / protein
                        :name (x15 / name :op1 "dnPak2")))
            :degree (x16 / dramatic)
            :ARG1 (x20 / induce-01
                  :ARG0 (x18 / protein
                        :name (x19 / name :op1 "TGF-β")
                        :xref (x29 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
                  :ARG2 (x22 / stimulate-01
                        :ARG1 (x21 / grow-01)))
            :ARG1-of (x26 / versus
                  :mod (x23 / disease
                        :wiki "alzheimer's_disease"
                        :name (x24 / name :op1 "alzheimer's"))
                  :name (x25 / name :op1 "EGFP+TGF-β")))
      :snt2 (x27 / disease
            :wiki "alzheimer's_disease"
            :name (x28 / name :op1 "dnPAK2+TGF-β;")))


# ::id PMC3412844.189
# ::snt This reduction, rather than a complete block, may be due to the high endogenous Pak2 levels in these cells and dnPak2 being a competitive inhibitor over 20 h, in addition to the previously described minor contribution of Ras.
# ::tok This reduction , rather than a complete block , may be due to the high endogenous Pak2 levels in these cells and dnPak2 being a competitive inhibitor over 20 h , in addition to the previously described minor contribution of Ras .
(x2 / reduce-01
      :ARG0 (x1 / this)
      :ARG1-of (x3 / instead-of-91
            :ARG2 (x5 / block-01
                  :ARG1-of (x4 / complete-02)))
      :ARG1 (x22 / and
            :op1 (x6 / possible-01
                  :ARG1 (x7 / cause-01
                        :ARG0 (x15 / and
                              :op1 (x12 / level
                                    :ARG1-of (x8 / high-02)
                                    :quant-of (x9 / enzyme
                                          :mod (x10 / endogenous)
                                          :name (x11 / name :op1 "Pak2")
                                          :xref (x29 / xref :value "UNIPROT:PAK2_HUMAN" :prob "0.604"))
                                    :location (x14 / cell
                                          :mod (x13 / this)))
                              :op2 (x16 / enzyme
                                    :name (x17 / name :op1 "dnPak2"))))
                  :ARG2 (x19 / inhibit-01
                        :ARG0-of (x18 / compete-01))
                  :duration (x20 / temporal-quantity
                        :quant "20"
                        :unit (x21 / hour)))
            :op2 (x26 / contribute-01
                  :ARG1-of (x24 / describe-01
                        :time (x23 / previous))
                  :ARG1-of (x25 / minor-01)
                  :ARG0 (x27 / enzyme
                        :name (x28 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))))


# ::id PMC3412844.190
# ::snt Thus, the ability of TGF-β to induce replication in fibroblasts appears to depend primarily on the function of Pak2 acting through Erk.
# ::tok Thus , the ability of TGF-β to induce replication in fibroblasts appears to depend primarily on the function of Pak2 acting through Erk .
(x1 / cause-01
      :ARG1 (x8 / appear-02
            :ARG1 (x2 / capable-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "TGF-β")
                        :xref (x17 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233"))
                  :ARG2 (x5 / induce-01
                        :ARG2 (x6 / replicate-01)
                        :location (x7 / fibroblast)))
            :ARG2 (x14 / act-02
                  :ARG0 (x9 / depend-01
                        :degree (x10 / primary)
                        :ARG1 (x11 / function-01
                              :ARG0 (x12 / protein
                                    :name (x13 / name :op1 "Pak2")
                                    :xref (x18 / xref :value "UNIPROT:PAK2_HUMAN" :prob "0.604"))))
                  :path (x15 / enzyme
                        :name (x16 / name :op1 "Erk")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))


# ::id PMC3905876.0
# ::snt ERK phosphorylation of MED14 in promoter complexes during mitogen-induced gene activation by Elk-1
# ::tok ERK phosphorylation of MED14 in promoter complexes during mitogen @-@ induced gene activation by Elk @-@ 1
(x3 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "ERK")
            :xref (x16 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "MED14")
            :xref (x17 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
      :location (x7 / macro-molecular-complex
            :ARG0-of (x6 / promote-01))
      :time (x12 / activate-01
            :ARG2-of (x10 / induce-01
                  :ARG0 (x8 / enzyme
                        :name (x9 / name :op1 "mitogen-activated")
                        :xref (x15 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313")))
            :ARG1 (x11 / gene)
            :ARG0 (x13 / protein
                  :name (x14 / name :op1 "Elk-1")
                  :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))))


# ::id PMC3905876.2
# ::snt The ETS domain transcription factor Elk-1 stimulates expression of immediate early genes (IEGs) in response to mitogens.
# ::tok The ETS domain transcription factor Elk @-@ 1 stimulates expression of immediate early genes ( IEGs ) in response to mitogens .
(x6 / stimulate-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "ETS" :op2 "domain")
            :mod (x4 / factor
                  :ARG0-of (x3 / transcribe-01)
                  :name (x5 / name :op1 "Elk-1")))
      :ARG1 (x7 / express-03
            :ARG2 (x10 / gene
                  :mod (x9 / early
                        :mod (x8 / immediate))
                  :name (x11 / name :op1 "IEGs")
                  :xref (x / xref :value "UNIPROT:PDGFD_HUMAN" :prob "0.223"))
            :ARG3 (x12 / respond-01
                  :ARG1 (x13 / small-molecule
                        :name (x14 / name :op1 "mitogens")))))


# ::id PMC3905876.3
# ::snt These events require phosphorylation of Elk-1 by extracellular signal-regulated kinase (ERK) and phosphorylation-dependent interaction of Elk-1 with co-activators, including histone acetyltransferases and the Mediator complex.
# ::tok These events require phosphorylation of Elk @-@ 1 by extracellular signal @-@ regulated kinase ( ERK ) and phosphorylation @-@ dependent interaction of Elk @-@ 1 with co @-@ activators , including histone acetyltransferases and the Mediator complex .
(x3 / require-01
      :ARG0 (x2 / event
            :mod (x1 / this))
      :ARG1 (x4 / phosphorylate-01
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "Elk-1")
                  :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
            :ARG2 (x7 / enzyme
                  :name (x8 / name
                        :op1 "extracellular"
                        :op2 "signal-regulated"
                        :op3 "kinase"))
            :ARG1-of (x9 / describe-01
                  :ARG0 (x12 / and
                        :op1 (x10 / enzyme
                              :name (x11 / name :op1 "ERK")
                              :xref (x26 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                        :op2 (x15 / interact-01
                              :ARG0-of (x14 / depend-01
                                    :ARG1 (x13 / phosphorylate-01))
                              :ARG0 (x16 / protein
                                    :name (x17 / name :op1 "Elk-1")
                                    :xref (x27 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))
                        :op2 (x19 / activate-01
                              :ARG1 (x18 / co-culture))))
            :ARG2-of (x20 / include-91
                  :ARG1 (x23 / and
                        :op1 (x21 / protein
                              :name (x22 / name :op1 "histone" :op2 "acetyltransferases"))
                        :op2 (x25 / complex
                              :mod (x24 / mediator))))))


# ::id PMC3905876.4
# ::snt Elk-1 also recruits ERK to the promoters of its target genes, suggesting that ERK phosphorylates additional substrates in transcription complexes at mitogen-responsive promoters.
# ::tok Elk @-@ 1 also recruits ERK to the promoters of its target genes , suggesting that ERK phosphorylates additional substrates in transcription complexes at mitogen @-@ responsive promoters .
(x3 / recruit-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "Elk-1")
            :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "ERK")
            :xref (x23 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
      :ARG2 (x6 / molecular-physical-entity
            :ARG0-of (x7 / promote-02))
      :ARG1 (x9 / gene
            :ARG1-of (x8 / target-01))
      :ARG0-of (x10 / suggest-01
            :ARG1 (x22 / molecular-physical-entity
                  :ARG1-of (x13 / phosphorylate-01
                        :ARG2 (x11 / enzyme
                              :name (x12 / name :op1 "ERK")
                              :xref (x25 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                  :ARG0-of (x21 / promote-01
                        :ARG1 (x15 / substrate
                              :mod (x14 / additional)
                              :location (x17 / macro-molecular-complex
                                    :ARG0-of (x16 / transcribe-01))
                              :time (x20 / responsive-02
                                    :ARG1 (x18 / enzyme
                                          :name (x19 / name :op1 "mitogen-activated")
                                          :xref (x24 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))))))))


# ::id PMC3905876.5
# ::snt Here we report that MED14, a core subunit of the Mediator, is a bona fide ERK substrate and identify serine 986 (S986) within a serine-proline rich region of MED14 as the major ERK phosphorylation site.
# ::tok Here we report that MED14 , a core subunit of the Mediator , is a bona fide ERK substrate and identify serine 986 ( S986 ) within a serine @-@ proline rich region of MED14 as the major ERK phosphorylation site .
(x3 / report-01
      :location (x1 / here)
      :ARG0 (x2 / we)
      :ARG1 (x7 / subunit
            :mod (x4 / protein
                  :name (x5 / name :op1 "MED14")
                  :xref (x34 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
            :mod (x6 / core)
            :part-of (x8 / mediate-01))
      :ARG0 (x14 / and
            :op1 (x13 / substrate
                  :mod (x9 / bona)
                  :mod (x10 / fide)
                  :mod (x11 / enzyme
                        :name (x12 / name :op1 "ERK")
                        :xref (x36 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :op2 (x15 / identify-01
                  :ARG1 (x16 / and
                        :op1 (x17 / amino-acid
                              :mod "986"
                              :name (x18 / name :op1 "serine")
                              :xref (x40 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :op2 (x19 / amino-acid
                              :mod "986"
                              :name (x20 / name :op1 "serine")
                              :xref (x39 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                  :ARG2 (x26 / region
                        :mod (x25 / rich
                              :mod (x21 / amino-acid
                                    :name (x22 / name :op1 "serine")
                                    :xref (x37 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                              :mod (x23 / amino-acid
                                    :name (x24 / name :op1 "proline")
                                    :xref (x38 / xref :value "PUBCHEM:614" :prob "10.45396")))
                        :part-of (x27 / protein
                              :name (x28 / name :op1 "MED14")
                              :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))))
      :ARG1 (x33 / site
            :ARG1-of (x29 / major-02)
            :ARG0-of (x32 / phosphorylate-01
                  :ARG1 (x30 / enzyme
                        :name (x31 / name :op1 "ERK")
                        :xref (x35 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))


# ::id PMC3905876.6
# ::snt Mitogens induced phosphorylation of MED14 on S986 at IEG promoters; RNAi knockdown of MED14 reduced CDK8 and RNA polymerase II (RNAPII) recruitment, RNAPII C-terminal domain phosphorylation and impaired activation of IEG transcription.
# ::tok Mitogens induced phosphorylation of MED14 on S986 at IEG promoters ; RNAi knockdown of MED14 reduced CDK8 and RNA polymerase II ( RNAPII ) recruitment , RNAPII C @-@ terminal domain phosphorylation and impaired activation of IEG transcription .
(x30 / and
      :op1 (x3 / induce-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "Mitogens")
                  :xref (x / xref :value "UNIPROT:NOX1_HUMAN" :prob "0.243"))
            :ARG2 (x4 / phosphorylate-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "MED14")
                        :xref (x36 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :ARG2 (x7 / amino-acid
                        :mod "986"
                        :name (x8 / name :op1 "serine")
                        :xref (x40 / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :location (x9 / molecular-physical-entity
                  :ARG0-of (x10 / promote-02))
            :ARG1-of (x16 / reduce-01
                  :ARG0 (x13 / knock-down-02
                        :ARG0 (x11 / nucleic-acid
                              :name (x12 / name :op1 "RNA"))
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "MED14")
                              :xref (x38 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                  :ARG1 (x29 / phosphorylate-01
                        :ARG1 (x19 / and
                              :op1 (x17 / enzyme
                                    :name (x18 / name :op1 "CDK8")
                                    :xref (x39 / xref :value "UNIPROT:CDK8_HUMAN" :prob "1.003"))
                              :op2 (x20 / nucleic-acid
                                    :name (x21 / name :op1 "RNA")
                                    :ARG0-of (x22 / encode-01
                                          :ARG1 (x23 / enzyme
                                                :name (x24 / name :op1 "polymerase" :op2 "II"))))
                              :ARG1-of (x26 / recruit-01
                                    :ARG0 (x25 / rnapii)
                                    :ARG2 (x27 / protein-segment
                                          :name (x28 / name :op1 "c-terminus")))))))
      :op2 (x31 / impair-01
            :ARG1 (x35 / transcribe-01
                  :ARG0-of (x32 / activate-01
                        :ARG1 (x33 / enzyme
                              :name (x34 / name :op1 "IEG")
                              :xref (x37 / xref :value "UNIPROT:PDGFD_HUMAN" :prob "0.263"))))))


# ::id PMC3905876.7
# ::snt A single alanine substitution at S986 reduced activation of an E26 (ETS)-responsive reporter by oncogenic Ras and mitogen-induced, Elk-1-dependent transcription, whereas activities of other transcriptional activators were unaffected.
# ::tok A single alanine substitution at S986 reduced activation of an E26 ( ETS ) -responsive reporter by oncogenic Ras and mitogen @-@ induced , Elk @-@ 1 @-@ dependent transcription , whereas activities of other transcriptional activators were unaffected .
(x29 / contrast-01
      :ARG1 (x7 / reduce-01
            :ARG1-of (x1 / single-02)
            :ARG2 (x4 / substitute-01
                  :ARG1 (x2 / amino-acid
                        :name (x3 / name :op1 "alanine")
                        :xref (x39 / xref :value "PUBCHEM:602" :prob "10.089661"))
                  :ARG2 (x5 / amino-acid
                        :mod "986"
                        :name (x6 / name :op1 "serine")
                        :xref (x40 / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :ARG1 (x8 / activate-01
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "E26")))
            :ARG1-of (x28 / transcribe-01
                  :ARG0 (x11 / protein
                        :name (x12 / name :op1 "ETS")
                        :xref (x37 / xref :value "UNIPROT:ETS1_HUMAN" :prob "0.262"))
                  :ARG0-of (x15 / report-01
                        :ARG1 (x13 / enzyme
                              :name (x14 / name :op1 "-responsive"))
                        :ARG0 (x21 / and
                              :op1 (x16 / enzyme
                                    :ARG0-of (x17 / cause-01
                                          :ARG1 (x18 / disease
                                                :wiki "cancer"
                                                :name (x19 / name :op1 "cancer")))
                                    :name (x20 / name :op1 "Ras")
                                    :xref (x38 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                              :op2 (x24 / induce-01
                                    :ARG0 (x22 / enzyme
                                          :name (x23 / name :op1 "mitogen-activated")
                                          :xref (x36 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313")))))
                  :ARG0-of (x27 / depend-01
                        :ARG1 (x25 / protein
                              :name (x26 / name :op1 "Elk-1")
                              :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))))
      :ARG2 (x35 / affect-01
            :ARG1 (x30 / activity-06
                  :ARG0 (x34 / molecular-physical-entity
                        :mod (x31 / other)
                        :ARG0-of (x33 / activate-01
                              :ARG1 (x32 / transcribe-01))))
            :polarity "-"))


# ::id PMC3905876.8
# ::snt We also demonstrate that Elk-1 can associate with MED14 independently of MED23, which may facilitate phosphorylation of MED14 by ERK to impart a positive and selective impact on mitogen-responsive gene expression.
# ::tok We also demonstrate that Elk @-@ 1 can associate with MED14 independently of MED23 , which may facilitate phosphorylation of MED14 by ERK to impart a positive and selective impact on mitogen @-@ responsive gene expression .
(x3 / demonstrate-01
      :ARG0 (x1 / we)
      :mod (x2 / also)
      :ARG1 (x4 / possible-01
            :ARG1 (x7 / associate-01
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "Elk-1")
                        :xref (x30 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
                  :ARG2 (x8 / protein
                        :name (x9 / name :op1 "MED14")
                        :xref (x29 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))))
      :ARG0-of (x10 / depend-01
            :polarity "-"
            :ARG1 (x11 / protein
                  :name (x12 / name :op1 "MED23")
                  :xref (x32 / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003")))
      :ARG0-of (x20 / impart-01
            :ARG1-of (x13 / possible-01
                  :ARG1 (x14 / facilitate-01
                        :ARG1 (x15 / phosphorylate-01
                              :ARG1 (x16 / protein
                                    :name (x17 / name :op1 "MED14")
                                    :xref (x33 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                              :ARG2 (x18 / enzyme
                                    :name (x19 / name :op1 "ERK")
                                    :xref (x31 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))
            :ARG1 (x23 / impact-01
                  :mod (x21 / positive)
                  :mod (x22 / selective)
                  :ARG1 (x28 / express-03
                        :ARG1 (x27 / gene
                              :ARG0-of (x26 / responsive-02
                                    :ARG1 (x24 / enzyme
                                          :name (x25 / name :op1 "mitogen-activated")
                                          :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))))))))


# ::id PMC3905876.26
# ::snt Cell culture, transfections and extract preparation
# ::tok Cell culture , transfections and extract preparation
(x6 / prepare-01
      :ARG0 (x2 / culture
            :mod (x1 / cell))
      :ARG1-of (x3 / transfect-01)
      :ARG1 (x4 / and
            :op1 (x5 / extract-01)))


# ::id PMC3905876.42
# ::snt In vitro kinase assays
# ::tok In vitro kinase assays
(x3 / assay-01
      :manner (x1 / in-vitro)
      :ARG1 (x2 / kinase))


# ::id PMC3905876.46
# ::snt Quantitative reverse transcriptase PCR
# ::tok Quantitative reverse transcriptase PCR
(x4 / react-01
      :mod (x1 / quantitative)
      :mod (x3 / transcriptase
            :ARG1-of (x2 / reverse-01))
      :ARG0 (x5 / polymerase
            :ARG1-of (x6 / chain-01)))


# ::id PMC3905876.54
# ::snt Identification of potential ERK targets in mediator
# ::tok Identification of potential ERK targets in mediator
(x1 / identify-01
      :ARG1 (x5 / target-01
            :mod (x2 / potential)
            :ARG0 (x3 / enzyme
                  :name (x4 / name :op1 "ERK")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :location (x6 / mediator)))


# ::id PMC3905876.55
# ::snt Our earlier report on the recruitment of kinases to IEG promoters described the presence of ERK in immobilized PICs assembled in vitro on SRE promoters ( 19 ).
# ::tok Our earlier report on the recruitment of kinases to IEG promoters described the presence of ERK in immobilized PICs assembled in vitro on SRE promoters ( 19 ) .
(x14 / assemble-02
      :ARG0 (x4 / report-01
            :ARG0 (x1 / we)
            :time (x2 / early
                  :degree (x3 / more))
            :ARG1 (x5 / recruit-01
                  :ARG1 (x6 / kinase)
                  :ARG2 (x8 / heterochromatin
                        :name (x7 / name :op1 "IEG")
                        :ARG1-of (x9 / present-02
                              :ARG1 (x10 / enzyme
                                    :name (x11 / name :op1 "ERK")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                        :location (x13 / picture
                              :ARG1-of (x12 / immobilize-01)))))
      :manner (x15 / in-vitro)
      :ARG2 (x16 / molecular-physical-entity
            :ARG0-of (x17 / promote-02))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / publication
                  :ARG1-of (x20 / cite-01 :ARG2 "19"))))


# ::id PMC3905876.56
# ::snt In subsequent kinase assays, we reproducibly detected phosphorylation of multiple proteins in PICs assembled on SRE promoters in nuclear extracts from mitogen stimulated cells ( Figure 1 a, lane 4) but not on basal promoters or in nuclear extracts from mitogen starved cells (lanes 1–3).
# ::tok In subsequent kinase assays , we reproducibly detected phosphorylation of multiple proteins in PICs assembled on SRE promoters in nuclear extracts from mitogen stimulated cells ( Figure 1 a , lane 4 ) but not on basal promoters or in nuclear extracts from mitogen starved cells ( lanes 1–3 ) .
(x1 / multi-sentence
      :snt1 (x4 / assay-01
            :time (x2 / subsequent)
            :ARG1 (x3 / kinase)
            :ARG0 (x5 / we))
      :snt2 (x7 / detect-01
            :ARG0 (x6 / reproducibly)
            :ARG1 (x8 / phosphorylate-01
                  :ARG1 (x10 / protein
                        :name (x9 / name :op1 "multiple")))
            :location (x15 / molecular-physical-entity
                  :mod (x11 / picture)
                  :ARG0-of (x14 / promote-01
                        :ARG1 (x12 / assemble-01
                              :ARG1 (x13 / sre))))
            :location (x17 / extract-01
                  :mod (x16 / nucleus
                        :xref (x39 / xref :value "GO:0005634" :prob "0.8"))
                  :ARG2 (x20 / stimulate-01
                        :ARG1 (x18 / enzyme
                              :name (x19 / name :op1 "mitogen-activated")
                              :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))))
            :ARG1-of (x21 / describe-01
                  :ARG0 (x22 / and
                        :op1 (x23 / figure :mod "1")
                        :op2 (x24 / lane :mod "4")))
            :ARG1-of (x25 / contrast-01
                  :ARG2 (x34 / cell
                        :mod (x26 / basal)
                        :ARG1-of (x33 / starve-01
                              :ARG2 (x29 / or
                                    :op1 (x27 / molecular-physical-entity
                                          :ARG0-of (x28 / promote-02))
                                    :op2 (x31 / extract-01
                                          :mod (x30 / nucleus
                                                :xref (x38 / xref :value "GO:0005634" :prob "0.8"))
                                          :ARG2 (x32 / mitogen))))))
            :ARG1-of (x35 / describe-01
                  :ARG0 (x36 / lane
                        :mod (x37 / value-interval :op1 "1" :op2 "3")))))


# ::id PMC3905876.57
# ::snt Unfortunately, we were unable to ascribe any of these phosphorylation events unambiguously to ERK (unpublished data).
# ::tok Unfortunately , we were unable to ascribe any of these phosphorylation events unambiguously to ERK ( unpublished data ) .
(x1 / fortunate-01
      :polarity "-"
      :ARG2 (x3 / possible-01
            :ARG0 (x2 / we)
            :polarity "-"
            :ARG1 (x4 / ascribe-01
                  :ARG1 (x9 / event
                        :mod (x5 / any
                              :ARG1-of (x6 / include-91
                                    :ARG2 (x8 / phosphorylate-01
                                          :mod (x7 / this))))
                        :name (x10 / name :op1 "unambiguously"))
                  :ARG2 (x11 / enzyme
                        :name (x12 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG1-of (x13 / describe-01
                        :ARG0 (x15 / data
                              :ARG1-of (x14 / publish-01 :polarity "-"))))))


# ::id PMC3905876.58
# ::snt However, an alternative candidate approach did allow us to identify ERK substrates at IEG promoters.
# ::tok However , an alternative candidate approach did allow us to identify ERK substrates at IEG promoters .
(x1 / have-concession-91
      :ARG1 (x5 / allow-01
            :mod (x2 / alternative)
            :ARG0 (x4 / approach-02
                  :mod (x3 / candidate))
            :ARG1 (x7 / identify-01
                  :ARG0 (x6 / we)
                  :ARG1 (x10 / substrate
                        :mod (x8 / enzyme
                              :name (x9 / name :op1 "ERK")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
            :location (x11 / molecular-physical-entity
                  :ARG0-of (x12 / promote-02))))


# ::id PMC3905876.59
# ::snt Phosphorylation of PIC components and Mediator subunits in vitro ( a ) Nuclear extracts from unstimulated (lanes 1 and 3) or serum-stimulated (lanes 2 and 4) HeLa cells were used for PIC assembly on TATA (lanes 1 and 2) or SRE (lanes 3 and 4) templates as described earlier ( 19 ).
# ::tok Phosphorylation of PIC components and Mediator subunits in vitro ( a ) Nuclear extracts from unstimulated ( lanes 1 and 3 ) or serum @-@ stimulated ( lanes 2 and 4 ) HeLa cells were used for PIC assembly on TATA ( lanes 1 and 2 ) or SRE ( lanes 3 and 4 ) templates as described earlier ( 19 ) .
(x1 / multi-sentence
      :snt1 (x10 / extract-01
            :ARG0 (x2 / phosphorylate-01
                  :ARG1 (x5 / and
                        :op1 (x4 / component
                              :name (x3 / name :op1 "PIC"))
                        :op2 (x6 / mediate-01
                              :ARG1 (x7 / subunit)))
                  :manner (x8 / in-vitro))
            :li "a"
            :ARG1 (x9 / nucleus
                  :xref (x47 / xref :value "GO:0005634" :prob "0.8"))
            :ARG2 (x11 / stimulate-01 :polarity "-")
            :ARG1-of (x12 / describe-01
                  :ARG0 (x13 / publication
                        :ARG1-of (x14 / cite-01
                              :ARG2 (x17 / and
                                    :op1 (x15 / lane :mod "1")
                                    :op2 (x16 / lane :mod "3")
                                    :op2 (x19 / stimulate-01
                                          :ARG0 (x18 / serum)))
                              :ARG1 (x22 / and
                                    :op1 (x20 / lane :mod "2")
                                    :op2 (x21 / lane :mod "4"))))))
      :snt2 (x25 / use-01
            :ARG1 (x24 / cell-line
                  :name (x23 / name :op1 "HeLa"))
            :ARG2 (x28 / assemble-01
                  :ARG2 (x26 / protein
                        :name (x27 / name :op1 "PIC")
                        :xref (x / xref :value "UNIPROT:CDN1A_HUMAN" :prob "0.262")))
            :ARG1 (x34 / or
                  :op1 (x29 / small-molecule
                        :name (x30 / name :op1 "TATA")
                        :ARG1-of (x31 / compare-01
                              :ARG1 (x32 / lane :mod "1")
                              :ARG2 (x33 / lane :mod "2"))
                        :xref (x48 / xref :value "PUBCHEM:129469" :prob "12.041334"))
                  :op2 (x35 / small-molecule
                        :name (x36 / name :op1 "SRE")
                        :ARG1-of (x37 / compare-01
                              :ARG1 (x38 / lane :mod "3")
                              :ARG2 (x39 / lane :mod "4"))
                        :xref (x49 / xref :value "PUBCHEM:68617" :prob "19.266134")))
            :ARG2 (x40 / template)
            :ARG1-of (x41 / describe-01
                  :time (x42 / early
                        :degree (x43 / more)))
            :ARG1-of (x44 / describe-01
                  :ARG0 (x45 / publication
                        :ARG1-of (x46 / cite-01 :ARG2 "19")))))


# ::id PMC3905876.60
# ::snt Complexes were washed, incubated in transcription buffer containing 32 P-γ-ATP and resolved by SDS-PAGE.
# ::tok Complexes were washed , incubated in transcription buffer containing 32 P-γ-ATP and resolved by SDS @-@ PAGE .
(x9 / resolve-03
      :ARG1 (x3 / incubate-01
            :ARG1 (x2 / wash-01
                  :ARG1 (x1 / macro-molecular-complex))
            :ARG2 (x5 / buffer
                  :name (x4 / name :op1 "transcription")
                  :ARG0-of (x6 / contain-01
                        :ARG1 (x7 / enzyme
                              :name (x8 / name :op1 "32" :op2 "P-γ-ATP")))))
      :ARG3 (x10 / thing
            :name (x11 / name :op1 "SDS-PAGE")))


# ::id PMC3905876.61
# ::snt Gels were dried and visualized by phosphor-imaging (Fujifilm).
# ::tok Gels were dried and visualized by phosphor @-@ imaging ( Fujifilm ) .
(x3 / and
      :op1 (x2 / dry-08
            :ARG1 (x1 / gel))
      :op2 (x4 / visualize-01
            :instrument (x5 / enzyme
                  :ARG3-of (x6 / phosphorylate-01)
                  :name (x7 / name :op1 "imaging")))
      :ARG1-of (x8 / fujifilm))


# ::id PMC3905876.62
# ::snt Arrowheads indicate discrete radiolabeled species observed in multiple independent experiments.
# ::tok Arrowheads indicate discrete radiolabeled species observed in multiple independent experiments .
(x2 / indicate-01
      :ARG0 (x1 / arrowhead)
      :ARG1 (x7 / observe-01
            :ARG1 (x6 / species
                  :mod (x3 / discrete)
                  :mod (x4 / enzyme
                        :name (x5 / name :op1 "radiolabeled")))
            :location (x10 / experiment
                  :quant (x8 / multiple)
                  :ARG0-of (x9 / depend-01 :polarity "-"))))


# ::id PMC3905876.63
# ::snt Reactions were separated by SDS-PAGE and visualized by phosphor-imaging (lower panels).
# ::tok Reactions were separated by SDS @-@ PAGE and visualized by phosphor @-@ imaging ( lower panels ) .
(x5 / and
      :op1 (x2 / separate-01
            :ARG1 (x1 / react-01)
            :ARG0 (x3 / thing
                  :name (x4 / name :op1 "SDS-PAGE")))
      :op2 (x6 / visualize-01
            :instrument (x7 / enzyme
                  :ARG3-of (x8 / phosphorylate-01)
                  :name (x9 / name :op1 "imaging")))
      :ARG1-of (x10 / describe-01
            :ARG0 (x13 / panel
                  :ARG1-of (x11 / low-04
                        :degree (x12 / more)))))


# ::id PMC3905876.64
# ::snt Bands corresponding to auto-phosphorylated rERK2* are indicated by asterisks.
# ::tok Bands corresponding to auto @-@ phosphorylated rERK2* are indicated by asterisks .
(x7 / indicate-01
      :ARG1 (x1 / band
            :ARG1-of (x2 / correspond-02
                  :ARG2 (x5 / phosphorylate-01
                        :ARG2 (x3 / enzyme
                              :name (x4 / name :op1 "auto")
                              :xref (x / xref :value "UNIPROT:ENPP2_HUMAN" :prob "0.202"))))
            :name (x6 / name :op1 "rERK2*"))
      :ARG0 (x8 / asterisk))


# ::id PMC3905876.65
# ::snt Several Mediator components had been identified in SRE PICs and some appeared to be good candidate ERK substrates, based on the presence of consensus ERK phosphorylation sites and docking motifs (see Table 1 ).
# ::tok Several Mediator components had been identified in SRE PICs and some appeared to be good candidate ERK substrates , based on the presence of consensus ERK phosphorylation sites and docking motifs ( see Table 1 ) .
(x1 / appear-02
      :ARG1 (x9 / good-02
            :ARG1 (x5 / identify-01
                  :ARG1 (x4 / component
                        :quant (x2 / several)
                        :mod (x3 / mediator))
                  :location (x7 / and
                        :op1 (x6 / picture)
                        :op2 (x8 / some)))
            :ARG2 (x12 / substrate
                  :mod (x10 / enzyme
                        :name (x11 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
      :ARG1-of (x13 / base-02
            :ARG2 (x14 / present-02
                  :ARG1 (x19 / site
                        :mod (x15 / consensus)
                        :ARG0-of (x18 / phosphorylate-01
                              :ARG1 (x16 / enzyme
                                    :name (x17 / name :op1 "ERK")
                                    :xref (x24 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                        :ARG0-of (x20 / dock-01
                              :ARG1 (x21 / protein-segment)
                              :ARG1-of (x22 / see-01
                                    :location (x23 / table :mod "1")))))))


# ::id PMC3905876.67
# ::snt Of the seven proteins expressed successfully in HEK293 cells, only MED14 was phosphorylated in an ERK-dependent manner ( Figure 1 b, lower panels, lane 4).
# ::tok Of the seven proteins expressed successfully in HEK293 cells , only MED14 was phosphorylated in an ERK @-@ dependent manner ( Figure 1 b , lower panels , lane 4 ) .
(x9 / phosphorylate-01
      :ARG2 (x2 / express-03
            :ARG1 (x1 / protein :quant "7")
            :ARG1-of (x3 / succeed-01
                  :location (x5 / cell-line
                        :name (x4 / name :op1 "HEK293")))
            :mod (x6 / only))
      :ARG1 (x7 / protein
            :name (x8 / name :op1 "MED14")
            :xref (x20 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
      :manner (x12 / depend-01
            :ARG1 (x10 / enzyme
                  :name (x11 / name :op1 "ERK")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / and
                  :op1 (x15 / figure :mod "1b")
                  :op2 (x18 / panel
                        :ARG1-of (x16 / low-04
                              :degree (x17 / more)))
                  :op3 (x19 / lane :mod "4"))))


# ::id PMC3905876.68
# ::snt In further experiments, we confirmed this result and, in addition, demonstrated phosphorylation of MED1 and, weakly, MED15 ( Supplementary Figure S1a lanes 6, 2 and 8).
# ::tok In further experiments , we confirmed this result and , in addition , demonstrated phosphorylation of MED1 and , weakly , MED15 ( Supplementary Figure S1a lanes 6 , 2 and 8 ) .
(x22 / and
      :location (x2 / experiment-01
            :degree (x1 / further))
      :ARG1-of (x4 / confirm-01
            :ARG0 (x3 / we)
            :ARG1 (x6 / thing
                  :mod (x5 / this)
                  :ARG2-of (x7 / result-01))
            :ARG2 (x8 / and))
      :op1 (x9 / and
            :op1 (x10 / demonstrate-01
                  :ARG1 (x14 / and
                        :op1 (x11 / phosphorylate-01
                              :ARG1 (x12 / protein
                                    :name (x13 / name :op1 "MED1")))
                        :op1 (x15 / weak-02)
                        :op2 (x16 / protein
                              :name (x17 / name :op1 "MED15"))
                        :ARG1-of (x18 / describe-01
                              :ARG0 (x20 / figure
                                    :ARG2-of (x19 / supplement-01)
                                    :mod "s1a"))))
            :op2 (x21 / lane :mod "6" :mod "2"))
      :op2 (x23 / protein
            :name (x24 / name :op1 "il-8")
            :xref (x / xref :value "UNIPROT:IL8_HUMAN" :prob "0.653")))


# ::id PMC3905876.69
# ::snt The lack of a suitable expression vector precluded MED13 from these analyses.
# ::tok The lack of a suitable expression vector precluded MED13 from these analyses .
(x5 / preclude-01
      :ARG0 (x1 / lack-01
            :ARG1 (x4 / vector
                  :ARG1-of (x3 / express-03
                        :ARG2 (x2 / suitable))))
      :ARG1 (x6 / enzyme
            :name (x7 / name :op1 "MED13")
            :xref (x / xref :value "UNIPROT:MED13_HUMAN" :prob "1.003"))
      :ARG2 (x9 / analyze-01
            :mod (x8 / this)))


# ::id PMC3905876.70
# ::snt Human mediator subunits with consensus ERK motifs
# ::tok Human mediator subunits with consensus ERK motifs
(x5 / protein-segment
      :ARG1 (x3 / subunit
            :mod (x1 / human)
            :mod (x2 / mediator))
      :mod (x4 / consensus))


# ::id PMC3905876.71
# ::snt Rank Subunit MW SP/ TP PX 1/2 (S/T)P DEF Phosphorylation Module a 1 MED13 250 38 13 2 Yes b cdk 2 MED1 220 41 7 0 Yes c body 3 MED14 150 24 7 0 Yes tail 4 MED15 105 16 6 0 ND tail 5 MED26 70 17 5 0 Not ERK unassigned 6 MED12 240 15 3 0 Yes cdk 7 MED16 95 10 2 0
# ::tok Rank Subunit MW SP/ TP PX 1 @/@ 2 ( S/T ) P DEF Phosphorylation Module a 1 MED13 250 38 13 2 Yes b cdk 2 MED1 220 41 7 0 Yes c body 3 MED14 150 24 7 0 Yes tail 4 MED15 105 16 6 0 ND tail 5 MED26 70 17 5 0 Not ERK unassigned 6 MED12 240 15 3 0 Yes cdk 7 MED16 95 10 2 0
(x1 / multi-sentence
      :snt1 (x8 / phosphorylate-01
            :ARG0 (x4 / amino-acid
                  :mod (x2 / protein
                        :name (x3 / name :op1 "Rank")
                        :xref (x42 / xref :value "UNIPROT:TNR11_HUMAN" :prob "0.602"))
                  :part-of (x5 / enzyme
                        :name (x6 / name :op1 "PX" :op2 "1/2"))
                  :name (x7 / name :op1 "S/T"))
            :ARG1 (x12 / module
                  :ARG0-of (x11 / phosphorylate-01
                        :ARG1 (x9 / enzyme
                              :name (x10 / name :op1 "DEF")
                              :xref (x / xref :value "UNIPROT:DIEXF_HUMAN" :prob "1.002")))
                  :ARG1-of (x13 / describe-01
                        :ARG0 (x14 / publication-91
                              :ARG0 (x17 / and
                                    :op1 (x15 / person
                                          :name (x16 / name
                                                :op1 "MED13"
                                                :op2 "250"
                                                :op3 "38"
                                                :op4 "13"
                                                :op5 "2"))
                                    :op2 (x18 / figure :mod "4b"))))))
      :snt2 (x38 / yes
            :ARG0 (x30 / tail
                  :ARG1 (x24 / body
                        :mod (x23 / yes
                              :mod (x19 / amino-acid
                                    :name (x20 / name :op1 "cdk")
                                    :mod "2"
                                    :name (x21 / name :op1 "MED1")
                                    :xref (x46 / xref :value "PUBCHEM:11339532" :prob "16.823788"))
                              :quant "220"
                              :mod (x22 / and
                                    :op1 "41"
                                    :op1 "7"
                                    :op2 "0"))
                        :mod "c"
                        :mod "3"
                        :name (x25 / name :op1 "MED14" :op2 "150")
                        :mod "24"
                        :mod "7")
                  :mod (x27 / tail
                        :quant "0"
                        :mod (x26 / yes)
                        :mod "4"
                        :name (x28 / name :op1 "MED15"))
                  :quant "105"
                  :mod "16"
                  :mod "6"
                  :mod (x29 / ordinal-entity :value "0"))
            :ARG1-of (x31 / amino-acid
                  :mod "5"
                  :name (x32 / name :op1 "MED26")
                  :mod "70"
                  :mod "17"
                  :mod "5"
                  :name (x33 / name :op1 "0")
                  :xref (x45 / xref :value "PUBCHEM:74297" :prob "5.584968"))
            :polarity "-"
            :mod (x34 / enzyme
                  :name (x35 / name :op1 "ERK" :op2 "unassigned")
                  :mod "6"
                  :name (x36 / name :op1 "MED12")
                  :xref (x43 / xref :value "UNIPROT:MED12_HUMAN" :prob "1.003"))
            :quant "240"
            :mod "15"
            :mod (x37 / value-interval :op1 "3" :op2 "0")
            :mod (x39 / enzyme
                  :name (x40 / name :op1 "cdk")
                  :xref (x44 / xref :value "UNIPROT:CDK4_HUMAN_DNA" :prob "0.26"))
            :mod "7"
            :name (x41 / name
                  :op1 "MED16"
                  :op2 "95"
                  :op3 "10")
            :mod "2"
            :quant "0"))


# ::id PMC3905876.72
# ::snt ND tail 8 MED9 25 4 2 0 ND body 9 MED25 82 5 1 0 ND unassigned 10 MED17 78 3 1 0 ND head
# ::tok ND tail 8 MED9 25 4 2 0 ND body 9 MED25 82 5 1 0 ND unassigned 10 MED17 78 3 1 0 ND head
(x12 / head
      :ARG0 (x5 / body
            :mod (x2 / tail
                  :mod (x1 / nd)
                  :mod "8"
                  :name (x3 / name :op1 "MED9"))
            :mod "25"
            :mod "4"
            :mod "2"
            :mod (x4 / ordinal-entity :value "0")
            :mod "9"
            :name (x6 / name :op1 "MED25" :op2 "82")
            :mod "5"
            :mod "1")
      :mod (x7 / ordinal-entity :value "0")
      :mod (x8 / amino-acid
            :name (x9 / name :op1 "unassigned")
            :mod "10"
            :name (x10 / name :op1 "MED17"))
      :quant "78"
      :mod "3"
      :mod "1"
      :mod (x11 / ordinal-entity :value "0"))


# ::id PMC3905876.73
# ::snt a based on ( 21 ), b MDG and PES, unpublished, c ( 22 ) and this work.
# ::tok a based on ( 21 ) , b MDG and PES , unpublished , c ( 22 ) and this work .
(x15 / and
      :op1 (x1 / base-02
            :ARG2 (x2 / and
                  :op1 "21"
                  :op2 (x3 / enzyme
                        :name (x4 / name :op1 "b-raf")
                        :xref (x / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.701"))
                  :op2 (x9 / publish-01
                        :ARG0 (x7 / and
                              :op1 (x5 / protein
                                    :name (x6 / name :op1 "MDG"))
                              :op2 (x8 / pe))
                        :polarity "-"
                        :ARG1-of (x10 / describe-01
                              :ARG0 (x11 / figure :mod "c")))
                  :ARG1-of (x12 / describe-01
                        :ARG0 (x13 / publication
                              :ARG1-of (x14 / cite-01 :ARG2 "22")))))
      :op2 (x17 / work
            :mod (x16 / this)))


# ::id PMC3905876.74
# ::snt MED1 is a known ERK target ( 22 ) implicated together with MED14 in differential gene regulation by the glucocorticoid receptor ( 23 ).
# ::tok MED1 is a known ERK target ( 22 ) implicated together with MED14 in differential gene regulation by the glucocorticoid receptor ( 23 ) .
(x10 / implicate-01
      :ARG0 (x3 / know-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "MED1"))
            :ARG1 (x6 / target-01
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG1-of (x7 / describe-01
                        :ARG0 (x8 / publication
                              :ARG1-of (x9 / cite-01 :ARG2 "22")))))
      :mod (x11 / together)
      :ARG2 (x16 / receptor
            :ARG1-of (x12 / differ-02
                  :ARG1 (x13 / gene
                        :ARG1-of (x14 / regulate-01
                              :ARG0 (x15 / glucocorticoid))))
            :ARG1-of (x17 / describe-01
                  :ARG0 (x18 / publication
                        :ARG1-of (x19 / cite-01 :ARG2 "23")))))


# ::id PMC3905876.76
# ::snt MED14 has a similar migration (see lane 6) and has been shown to co-purify with the CDK8 complex, of which MED12 is a subunit ( 14 ).
# ::tok MED14 has a similar migration ( see lane 6 ) and has been shown to co @-@ purify with the CDK8 complex , of which MED12 is a subunit ( 14 ) .
(x8 / and
      :op1 (x3 / resemble-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "MED14")
                  :xref (x21 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
            :ARG2 (x4 / migrate-01)
            :ARG1-of (x5 / see-01
                  :mode "imperative"
                  :ARG0 (x6 / you)
                  :ARG1 (x7 / lane :mod "6")))
      :op2 (x9 / show-01
            :ARG1 (x10 / co-culture
                  :ARG1-of (x11 / purify-01))
            :ARG2 (x12 / and
                  :op1 (x14 / macro-molecular-complex
                        :name (x13 / name :op1 "CDK8"))
                  :op2 (x17 / subunit
                        :ARG0 (x15 / protein
                              :name (x16 / name :op1 "MED12")
                              :xref (x / xref :value "UNIPROT:MED12_HUMAN" :prob "1.003")))))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / publication
                  :ARG1-of (x20 / cite-01 :ARG2 "14"))))


# ::id PMC3905876.78
# ::snt We therefore focussed on the unreported relationship between ERK and MED14.
# ::tok We therefore focussed on the unreported relationship between ERK and MED14 .
(x1 / cause-01
      :ARG1 (x3 / focus-01
            :ARG0 (x2 / we)
            :ARG1 (x6 / relation-03
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "unreported"))
                  :ARG0 (x9 / and
                        :op1 (x7 / enzyme
                              :name (x8 / name :op1 "ERK")
                              :xref (x12 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                        :op2 (x10 / protein
                              :name (x11 / name :op1 "MED14")
                              :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))))))


# ::id PMC3905876.79
# ::snt Phosphorylation of MED14 by ERK in vitro
# ::tok Phosphorylation of MED14 by ERK in vitro
(x1 / phosphorylate-01
      :ARG1 (x2 / protein
            :name (x3 / name :op1 "MED14")
            :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
      :ARG2 (x4 / enzyme
            :name (x5 / name :op1 "ERK")
            :xref (x7 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
      :manner (x6 / in-vitro))


# ::id PMC3905876.80
# ::snt The carboxy-terminal half of MED14 includes an ∼200 residue region (aas 949–1147), with no obvious structural clues but a series of serine-proline (SP) motifs including several ERK consensus phosphorylation sites, that is conserved among vertebrates and flies ( Figure 2 a and b).
# ::tok The carboxy @-@ terminal half of MED14 includes an ∼200 residue region ( aas 949–1147 ) , with no obvious structural clues but a series of serine @-@ proline ( SP ) motifs including several ERK consensus phosphorylation sites , that is conserved among vertebrates and flies ( Figure 2 a and b ) .
(x1 / multi-sentence
      :snt1 (x17 / clue
            :ARG0 (x2 / enzyme
                  :name (x3 / name :op1 "carboxy" :op2 "1/2"))
            :ARG1-of (x4 / include-91
                  :ARG2 (x10 / region
                        :ARG1-of (x7 / include-01
                              :ARG2 (x5 / protein
                                    :name (x6 / name :op1 "MED14")
                                    :xref (x42 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                              :ARG1 (x9 / residue
                                    :name (x8 / name :op1 "∼200")))
                        :ARG1-of (x11 / describe-01
                              :ARG0 (x12 / and
                                    :op1 (x13 / enzyme
                                          :name (x14 / name :op1 "aas" :op2 "949–1147"))
                                    :op2 (x16 / structure
                                          :ARG1-of (x15 / obvious-01 :polarity "-")))))))
      :snt2 (x18 / contrast-01
            :ARG2 (x26 / protein-segment
                  :ARG0 (x25 / event
                        :mod (x19 / series
                              :consist-of (x20 / and
                                    :op1 (x21 / amino-acid
                                          :name (x22 / name :op1 "serine")
                                          :xref (x43 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x23 / amino-acid
                                          :name (x24 / name :op1 "proline")
                                          :xref (x44 / xref :value "PUBCHEM:614" :prob "10.45396")))))
                  :ARG2-of (x27 / include-01
                        :ARG1 (x32 / phosphorylate-01
                              :ARG0 (x31 / consensus
                                    :quant (x28 / several)
                                    :mod (x29 / enzyme
                                          :name (x30 / name :op1 "ERK")
                                          :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                              :ARG1 (x33 / protein-segment)))
                  :ARG1-of (x34 / conserve-01
                        :location (x36 / and
                              :op1 (x35 / vertebrate)
                              :op2 (x37 / fly-01)))
                  :ARG1-of (x38 / describe-01
                        :ARG0 (x40 / and
                              :op1 (x39 / figure :mod "2a")
                              :op2 (x41 / figure :mod "4b"))))))


# ::id PMC3905876.81
# ::snt Proteomic studies have identified several MED14 phospho-peptides derived from this region ( 24–26 ).
# ::tok Proteomic studies have identified several MED14 phospho @-@ peptides derived from this region ( 24–26 ) .
(x4 / identify-01
      :ARG0 (x3 / study-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "Proteomic")
                  :xref (x / xref :value "UNIPROT:CIP4_HUMAN" :prob "0.272")))
      :ARG1 (x5 / protein
            :quant (x6 / several)
            :name (x7 / name :op1 "MED14")
            :ARG0-of (x8 / phosphorylate-01
                  :ARG2 (x9 / peptide
                        :ARG1-of (x10 / derive-01
                              :ARG2 (x12 / region
                                    :mod (x11 / this)))))
            :name (x13 / name :op1 "24–26")
            :xref (x14 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))


# ::id PMC3905876.82
# ::snt To map potential ERK phosphorylation sites in MED14, this SP-rich region (SPR domain) was first expressed as a recombinant GST fusion and tested as an ERK substrate, then mutated to remove individual or multiple sites.
# ::tok To map potential ERK phosphorylation sites in MED14 , this SP @-@ rich region ( SPR domain ) was first expressed as a recombinant GST fusion and tested as an ERK substrate , then mutated to remove individual or multiple sites .
(x21 / fuse-01
      :purpose (x6 / protein-segment
            :name (x1 / name :op1 "map")
            :ARG1-of (x5 / phosphorylate-01
                  :mod (x2 / potential)
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "ERK")
                        :xref (x33 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :part-of (x7 / protein
                  :name (x8 / name :op1 "MED14")
                  :xref (x34 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
      :ARG0 (x17 / express-03
            :ARG1 (x13 / region
                  :mod (x9 / this)
                  :mod (x12 / rich
                        :mod (x10 / amino-acid
                              :name (x11 / name :op1 "SP")
                              :xref (x36 / xref :value "PUBCHEM:1982" :prob "7.719627")))
                  :ARG1-of (x14 / protein-segment
                        :name (x15 / name :op1 "SPR" :op2 "domain")))
            :ord (x16 / ordinal-entity :value "1")
            :ARG2 (x18 / enzyme
                  :ARG0-of (x19 / recombine-01)
                  :name (x20 / name :op1 "GST")
                  :xref (x35 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
      :ARG1 (x22 / and
            :op2 (x23 / test-01
                  :ARG2 (x26 / substrate
                        :mod (x24 / enzyme
                              :name (x25 / name :op1 "ERK")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                  :ARG1-of (x27 / mutate-01)))
      :ARG2 (x28 / remove-01
            :ARG1 (x30 / or
                  :op1 (x29 / individual)
                  :op2 (x32 / protein-segment
                        :mod (x31 / multiple)))))


# ::id PMC3905876.83
# ::snt ERK phosphorylated the SPR domain efficiently ( Supplementary Figure S2a and Figure 2 c, lanes 1 and 7).
# ::tok ERK phosphorylated the SPR domain efficiently ( Supplementary Figure S2a and Figure 2 c , lanes 1 and 7 ) .
(x3 / phosphorylate-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "ERK")
            :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
      :ARG1 (x4 / protein-segment
            :name (x5 / name :op1 "SPR" :op2 "domain"))
      :ARG1-of (x6 / efficient-01
            :ARG1-of (x7 / describe-01
                  :ARG0 (x9 / figure
                        :ARG2-of (x8 / supplement-01)
                        :mod "s2a"))
            :ARG1-of (x10 / describe-01
                  :ARG0 (x11 / and
                        :part-of (x12 / figure :mod "2")
                        :op1 (x13 / figure :mod "c")
                        :op2 (x16 / and
                              :op1 (x14 / lane :mod "1")
                              :op2 (x15 / lane :mod "7"))))))


# ::id PMC3905876.84
# ::snt A single alanine substitution at S986 reduced phosphate incorporation by 90% ( Figure 2 c, compare lanes 1 and 2, 7 and 8), whereas mutations S1023A, S1128A, S1095A and S1112A (lanes 3, 5, 9 and 11) had little effect.
# ::tok A single alanine substitution at S986 reduced phosphate incorporation by 90 % ( Figure 2 c , compare lanes 1 and 2 , 7 and 8 ) , whereas mutations S1023A , S1128A , S1095A and S1112A ( lanes 3 , 5, 9 and 11 ) had little effect .
(x19 / contrast-01
      :ARG1 (x7 / reduce-01
            :ARG1-of (x1 / single-02)
            :ARG0-of (x4 / substitute-01
                  :ARG1 (x2 / amino-acid
                        :name (x3 / name :op1 "alanine")
                        :xref (x35 / xref :value "PUBCHEM:602" :prob "10.089661"))
                  :ARG2 (x5 / amino-acid
                        :mod "986"
                        :name (x6 / name :op1 "serine")
                        :xref (x36 / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :ARG1 (x9 / incorporate-02
                  :ARG2 (x8 / phosphate)
                  :ARG2 (x10 / percentage-entity :value "90")
                  :ARG1-of (x11 / describe-01
                        :ARG0 (x12 / figure :mod "4c")))
            :ARG0-of (x13 / compare-01
                  :ARG1 (x16 / and
                        :op1 (x14 / lane :mod "1")
                        :op2 (x15 / lane :mod "2")
                        :op2 "7")
                  :ARG2 (x17 / protein
                        :name (x18 / name :op1 "il-8")
                        :xref (x34 / xref :value "UNIPROT:IL8_HUMAN" :prob "0.653"))))
      :ARG2 (x33 / affect-01
            :ARG0 (x20 / and
                  :op1 (x21 / mutate-01
                        :ARG1 (x26 / and
                              :op1 (x22 / gene
                                    :name (x23 / name :op1 "S1023A")
                                    :ARG2-of (x24 / mutate-01 :value "S1128A")
                                    :xref (x / xref :value "UNIPROT:S10A1_HUMAN" :prob "0.262"))
                              :op2 (x25 / mutate-01 :value "S1095A")
                              :op2 (x27 / enzyme
                                    :name (x28 / name :op1 "S1112A"))
                              :ARG1-of (x29 / describe-01
                                    :ARG0 (x30 / lane :mod "3"))))
                  :op2 (x31 / and :op1 "9" :op2 "11"))
            :mod (x32 / little)))


# ::id PMC3905876.85
# ::snt Moreover, in combination with S986A only S1095A caused any further decrease in phosphorylation (compare lanes 8 and 10), suggesting that S986 is the predominant site for ERK phosphorylation within this region of MED14.
# ::tok Moreover , in combination with S986A only S1095A caused any further decrease in phosphorylation ( compare lanes 8 and 10 ) , suggesting that S986 is the predominant site for ERK phosphorylation within this region of MED14 .
(x1 / and
      :op2 (x2 / combine-01
            :ARG2 (x17 / site
                  :ARG1-of (x3 / mutate-01 :value "S986A")
                  :mod (x4 / only)
                  :domain (x6 / cause-01
                        :ARG0 (x5 / mutate-01 :value "S1095A")
                        :ARG1 (x9 / decrease-01
                              :mod (x7 / any)
                              :degree (x8 / further)
                              :ARG1 (x10 / phosphorylate-01)
                              :ARG1-of (x11 / compare-01
                                    :ARG1 (x12 / lane :mod "8")
                                    :ARG2 (x13 / lane :mod "10"))
                              :ARG0-of (x14 / suggest-01
                                    :ARG1 (x15 / amino-acid
                                          :mod "986"
                                          :name (x16 / name :op1 "serine")
                                          :xref (x26 / xref :value "PUBCHEM:5951" :prob "11.218784")))))
                  :mod (x20 / phosphorylate-01
                        :ARG1 (x18 / enzyme
                              :name (x19 / name :op1 "ERK")
                              :xref (x25 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                        :location (x22 / region
                              :mod (x21 / this)
                              :part-of (x23 / protein
                                    :name (x24 / name :op1 "MED14")
                                    :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))))))


# ::id PMC3905876.86
# ::snt Mapping ERK phosphorylation sites in MED14.
# ::tok Mapping ERK phosphorylation sites in MED14 .
(x1 / map-01
      :ARG1 (x5 / site
            :mod (x4 / phosphorylate-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :location (x6 / protein
                  :name (x7 / name :op1 "MED14")
                  :xref (x8 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))))


# ::id PMC3905876.87
# ::snt Black bars indicate ERK consensus sites screened by mutagenesis; gray bars indicate other non-consensus S/TP motifs.
# ::tok Black bars indicate ERK consensus sites screened by mutagenesis ; gray bars indicate other non @-@ consensus S/TP motifs .
(x3 / indicate-01
      :ARG0 (x2 / bar
            :ARG1-of (x1 / black-04))
      :ARG1 (x4 / and
            :op1 (x9 / screen-01
                  :ARG0 (x8 / protein-segment
                        :mod (x5 / enzyme
                              :name (x6 / name :op1 "ERK")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                        :mod (x7 / consensus))
                  :manner (x10 / thing
                        :name (x11 / name :op1 "mutagenesis")))
            :op2 (x13 / bar
                  :ARG1-of (x12 / gray-02)
                  :ARG1-of (x14 / indicate-01
                        :ARG0 (x18 / protein-segment
                              :mod (x15 / other)
                              :mod (x16 / consensus :polarity "-")
                              :name (x17 / name :op1 "S/TP"))))))


# ::id PMC3905876.88
# ::snt MAPK consensus sites are highlighted in black with phosphorylated SP motifs identified by phospho-proteomics marked with asterisks.
# ::tok MAPK consensus sites are highlighted in black with phosphorylated SP motifs identified by phospho @-@ proteomics marked with asterisks .
(x4 / highlight-01
      :ARG1 (x3 / protein-segment
            :name (x1 / name :op1 "MAPK")
            :mod (x2 / consensus))
      :ARG0 (x9 / motif
            :ARG1-of (x5 / black-04
                  :ARG0 (x6 / enzyme
                        :ARG3-of (x7 / phosphorylate-01)
                        :name (x8 / name :op1 "SP")
                        :xref (x16 / xref :value "UNIPROT:TFF2_HUMAN" :prob "1.002")))
            :ARG0-of (x10 / identify-01
                  :ARG0 (x14 / marked
                        :ARG1-of (x11 / phosphorylate-01
                              :ARG2 (x12 / enzyme
                                    :name (x13 / name :op1 "proteomics")
                                    :xref (x / xref :value "UNIPROT:DOS_HUMAN" :prob "0.242"))))
                  :ARG2 (x15 / asterisk))))


# ::id PMC3905876.89
# ::snt NCBI accession numbers for the MED14 proteins compared are: NP_004_220.2, Homo sapiens ; XP_538_001.2, Canis familiaris ; NP_001_041673.1 Mus musculus ; XP_228_713.3, Rattus norvegicus ; XP_416_776.2, Gallus gallus ; NP_612_041.2, Drosophila melanogaster .
# ::tok NCBI accession numbers for the MED14 proteins compared are : NP_004_220.2 , Homo sapiens ; XP_538_001.2 , Canis familiaris ; NP_001_041673.1 Mus musculus ; XP_228_713.3 , Rattus norvegicus ; XP_416_776.2 , Gallus gallus ; NP_612_041.2 , Drosophila melanogaster .
(x3 / number-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "accession"))
      :ARG2 (x6 / compare-01
            :ARG0 (x4 / protein
                  :name (x5 / name :op1 "MED14")
                  :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
      :ARG1 (x13 / and
            :op1 (x7 / enzyme
                  :name (x8 / name :op1 "NP_004_220.2"))
            :op2 (x9 / homo-sapiens)
            :op3 (x10 / cell-line
                  :name (x11 / name :op1 "XP_538_001.2")
                  :mod (x12 / canis-familiaris))
            :op1 (x14 / mus-musculus)
            :op2 (x15 / cell-line
                  :name (x16 / name :op1 "XP_228_713.3")
                  :mod (x17 / rattus-norvegicus))
            :op3 (x18 / cell-line
                  :name (x19 / name :op1 "XP_416_776.2")
                  :mod (x20 / gallus-gallus))
            :op4 (x21 / cell-line
                  :name (x22 / name :op1 "NP_612_041.2")
                  :mod (x23 / organism
                        :name (x24 / name :op1 "Drosophila" :op2 "melanogaster")))))


# ::id PMC3905876.90
# ::snt Reactions were separated by SDS-PAGE and visualized by phosphor-imaging (upper panels) and Coomassie blue staining (lower panels).
# ::tok Reactions were separated by SDS @-@ PAGE and visualized by phosphor @-@ imaging ( upper panels ) and Coomassie blue staining ( lower panels ) .
(x5 / and
      :op1 (x2 / separate-01
            :ARG1 (x1 / react-01)
            :ARG0 (x3 / thing
                  :name (x4 / name :op1 "SDS-PAGE")))
      :op2 (x6 / visualize-01
            :instrument (x13 / and
                  :op1 (x7 / enzyme
                        :ARG3-of (x8 / phosphorylate-01)
                        :name (x9 / name :op1 "imaging")
                        :ARG1-of (x10 / describe-01
                              :ARG0 (x12 / panel
                                    :mod (x11 / upper))))
                  :op2 (x16 / stain-01
                        :ARG2 (x14 / small-molecule
                              :name (x15 / name :op1 "Coomassie" :op2 "blue")))))
      :ARG1-of (x17 / describe-01
            :ARG0 (x20 / panel
                  :ARG1-of (x18 / low-04
                        :degree (x19 / more)))))


# ::id PMC3905876.91
# ::snt Values indicate phosphate incorporation relative to wild-type ( WT ) fusion protein.
# ::tok Values indicate phosphate incorporation relative to wild @-@ type ( WT ) fusion protein .
(x2 / indicate-01
      :ARG0 (x1 / value)
      :ARG1 (x4 / incorporate-02
            :ARG2 (x3 / phosphate)
            :ARG1-of (x5 / relative-05
                  :ARG3 (x8 / protein
                        :mod (x6 / wild-type)
                        :ARG1-of (x7 / fuse-01)))))


# ::id PMC3905876.92
# ::snt Reactions were separated by SDS-PAGE and visualized by phosphor-imaging (upper panel, 80% of IP).
# ::tok Reactions were separated by SDS @-@ PAGE and visualized by phosphor @-@ imaging ( upper panel , 80 % of IP ) .
(x5 / and
      :op1 (x2 / separate-01
            :ARG1 (x1 / react-01)
            :ARG0 (x3 / thing
                  :name (x4 / name :op1 "SDS-PAGE")))
      :op2 (x6 / visualize-01
            :instrument (x7 / enzyme
                  :ARG3-of (x8 / phosphorylate-01)
                  :name (x9 / name :op1 "imaging")))
      :ARG1-of (x13 / include-91
            :ARG1 (x11 / panel
                  :mod (x10 / upper))
            :ARG3 (x12 / percentage-entity :value "80")))


# ::id PMC3905876.93
# ::snt Relative recoveries were assessed by immunoblotting for HA (lower panel, 20% of IP).
# ::tok Relative recoveries were assessed by immunoblotting for HA ( lower panel , 20 % of IP ) .
(x3 / assess-01
      :ARG1 (x2 / recover-01
            :ARG1-of (x1 / relative-05))
      :ARG0 (x4 / immunoblot-01
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "HA")
                  :xref (x14 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
      :ARG1-of (x7 / describe-01
            :ARG0 (x10 / panel
                  :ARG1-of (x8 / low-04
                        :degree (x9 / more))
                  :mod (x11 / percentage-entity
                        :value "20"
                        :quant-of (x12 / protein
                              :name (x13 / name :op1 "ip-10")
                              :xref (x / xref :value "UNIPROT:CXL10_HUMAN" :prob "0.663"))))))


# ::id PMC3905876.94
# ::snt In kinase assays with MED14 proteins immunoprecipitated from HEK293T cells, full-length MED14 was phosphorylated efficiently by ERK but MED14 lacking the SPR (MED14Δ) was not ( Supplementary Figure S2b ), confirming that ERK phosphorylation was confined to the SPR domain.
# ::tok In kinase assays with MED14 proteins immunoprecipitated from HEK293T cells , full @-@ length MED14 was phosphorylated efficiently by ERK but MED14 lacking the SPR ( MED14Δ ) was not ( Supplementary Figure S2b ) , confirming that ERK phosphorylation was confined to the SPR domain .
(x1 / multi-sentence
      :snt1 (x4 / and
            :op1 (x3 / assay-01
                  :ARG1 (x2 / kinase))
            :op1 (x7 / immunoprecipitate-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "MED14")
                        :xref (x36 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :ARG2 (x8 / cell-line
                        :name (x9 / name :op1 "HEK293T")))
            :op2 (x11 / long-03
                  :ARG1-of (x10 / full-09)))
      :snt2 (x18 / contrast-01
            :ARG1 (x14 / phosphorylate-01
                  :ARG2 (x12 / protein
                        :name (x13 / name :op1 "MED14")
                        :xref (x40 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :ARG1-of (x15 / efficient-01)
                  :ARG0 (x16 / enzyme
                        :name (x17 / name :op1 "ERK")
                        :xref (x41 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :ARG2 (x25 / be-located-at-91
                  :ARG0 (x19 / enzyme
                        :name (x20 / name :op1 "MED14")
                        :ARG0-of (x21 / lack-01
                              :ARG1 (x22 / protein
                                    :name (x23 / name :op1 "SPR")
                                    :xref (x / xref :value "UNIPROT:NK1R_HUMAN" :prob "1.002")))
                        :name (x24 / name :op1 "MED14Δ")
                        :xref (x39 / xref :value "UNIPROT:MED14_HUMAN" :prob "0.682"))
                  :polarity "-"
                  :ARG1-of (x26 / describe-01
                        :ARG0 (x28 / figure
                              :ARG2-of (x27 / supplement-01)
                              :mod "s2b"))
                  :ARG0-of (x29 / confirm-01
                        :ARG1 (x33 / confine-01
                              :ARG1 (x32 / phosphorylate-01
                                    :ARG1 (x30 / enzyme
                                          :name (x31 / name :op1 "ERK")
                                          :xref (x37 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                              :ARG2 (x34 / protein-segment
                                    :name (x35 / name :op1 "SPR" :op2 "domain")))))))


# ::id PMC3905876.95
# ::snt Single point mutations were introduced into full-length MED14 at the same five sites and, as seen with the recombinant SPR domain, S986A had the most significant effect, reducing ERK phosphorylation of MED14 by 60% ( Figure 2 d, lane 2 and e).
# ::tok Single point mutations were introduced into full @-@ length MED14 at the same five sites and , as seen with the recombinant SPR domain , S986A had the most significant effect , reducing ERK phosphorylation of MED14 by 60 % ( Figure 2 d , lane 2 and e ) .
(x1 / multi-sentence
      :snt1 (x5 / introduce-02
            :ARG1 (x4 / mutate-01
                  :ARG1-of (x2 / single-02)
                  :mod (x3 / point))
            :ARG2 (x7 / length
                  :ARG1-of (x6 / full-09)
                  :poss (x8 / protein
                        :name (x9 / name :op1 "MED14")
                        :xref (x35 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
            :time (x11 / protein-segment
                  :ARG1-of (x10 / same-01)
                  :quant "5"))
      :snt2 (x12 / and
            :op2 (x21 / reduce-01
                  :ARG1-of (x13 / see-01
                        :ARG1 (x20 / affect-01
                              :ARG0 (x14 / protein
                                    :ARG1-of (x15 / recombine-01)
                                    :name (x16 / name :op1 "SPR" :op2 "domain")
                                    :ARG1-of (x17 / mutate-01 :value "S986A"))
                              :ARG1-of (x19 / significant-02
                                    :degree (x18 / most))))
                  :ARG1 (x31 / and
                        :op1 (x24 / phosphorylate-01
                              :ARG1 (x22 / enzyme
                                    :name (x23 / name :op1 "ERK")
                                    :xref (x34 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                              :ARG1 (x25 / protein
                                    :name (x26 / name :op1 "MED14")
                                    :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                              :ARG2 (x27 / percentage-entity :value "60")
                              :ARG1-of (x28 / describe-01
                                    :ARG0 (x29 / figure :mod "2d")))
                        :op2 (x30 / lane :mod "2")
                        :op3 (x32 / protein
                              :name (x33 / name :op1 "e-cadherin")
                              :xref (x36 / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703"))))))


# ::id PMC3905876.96
# ::snt Substitutions at other sites in combination with S986A did not further reduce MED14 phosphorylation (data not shown).
# ::tok Substitutions at other sites in combination with S986A did not further reduce MED14 phosphorylation ( data not shown ) .
(x8 / reduce-01
      :ARG0 (x1 / substitute-01
            :ARG2 (x3 / site
                  :mod (x2 / other))
            :location (x4 / combine-01
                  :ARG2 (x5 / small-molecule
                        :name (x6 / name :op1 "S986A"))))
      :polarity "-"
      :degree (x7 / further)
      :ARG1 (x11 / phosphorylate-01
            :ARG1 (x9 / enzyme
                  :name (x10 / name :op1 "MED14")
                  :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / data
                  :ARG1-of (x14 / show-01 :polarity "-"))))


# ::id PMC3905876.97
# ::snt Taken together, the data with the recombinant SPR domain and the entire protein indicate that S986 is the primary, but not the sole, ERK phosphorylation site in MED14.
# ::tok Taken together , the data with the recombinant SPR domain and the entire protein indicate that S986 is the primary , but not the sole , ERK phosphorylation site in MED14 .
(x10 / indicate-01
      :condition (x1 / take-01
            :mod (x2 / together))
      :ARG0 (x3 / data
            :ARG2 (x7 / and
                  :ARG3-of (x4 / recombine-01)
                  :op1 (x5 / protein-segment
                        :name (x6 / name :op1 "SPR" :op2 "domain"))
                  :op2 (x9 / protein
                        :mod (x8 / entire))))
      :ARG1 (x14 / contrast-01
            :ARG1 (x11 / amino-acid
                  :mod "986"
                  :name (x12 / name :op1 "serine")
                  :xref (x23 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :mod (x13 / primary)
            :ARG2 (x18 / phosphorylate-01
                  :polarity "-"
                  :ARG0 (x15 / sole)
                  :ARG1 (x16 / enzyme
                        :name (x17 / name :op1 "ERK")
                        :xref (x22 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :ARG2 (x19 / protein-segment
                  :part-of (x20 / protein
                        :name (x21 / name :op1 "MED14")
                        :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))))


# ::id PMC3905876.98
# ::snt The identification of additional MED14 SPR domain phospho-peptides besides those encompassing S986 suggests that the domain is a substrate for multiple kinases.
# ::tok The identification of additional MED14 SPR domain phospho @-@ peptides besides those encompassing S986 suggests that the domain is a substrate for multiple kinases .
(x14 / suggest-01
      :ARG0 (x1 / identify-01
            :ARG1 (x8 / peptide
                  :mod (x2 / additional)
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "MED14")
                        :xref (x20 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :ARG1-of (x7 / phosphorylate-01
                        :ARG1 (x5 / protein-segment
                              :name (x6 / name :op1 "SPR" :op2 "domain")))
                  :ARG2-of (x9 / except-01
                        :ARG1 (x10 / that))
                  :ARG0-of (x11 / encompass-01
                        :ARG1 (x12 / amino-acid
                              :mod "986"
                              :name (x13 / name :op1 "serine")
                              :xref (x21 / xref :value "PUBCHEM:5951" :prob "11.218784")))))
      :ARG1 (x17 / substrate
            :ARG0 (x15 / protein
                  :name (x16 / name :op1 "domain")
                  :xref (x / xref :value "UNIPROT:GEPH_HUMAN" :prob "0.322"))
            :mod (x18 / disease
                  :name (x19 / name :op1 "multiple" :op2 "kinase"))))


# ::id PMC3905876.99
# ::snt As such motifs are often CDK targets and Mediator reversibly associates with the CDK8 complex, we considered that CDK8 might also phosphorylate the MED14 SPR domain.
# ::tok As such motifs are often CDK targets and Mediator reversibly associates with the CDK8 complex , we considered that CDK8 might also phosphorylate the MED14 SPR domain .
(x15 / consider-01
      :ARG1-of (x2 / protein-segment
            :mod (x1 / such)
            :ARG0-of (x6 / target-01
                  :frequency (x3 / often)
                  :ARG0 (x4 / enzyme
                        :name (x5 / name :op1 "CDK")
                        :xref (x / xref :value "UNIPROT:CDK1_HUMAN" :prob "0.262")))
            :ARG0-of (x7 / mediate-01
                  :ARG1 (x10 / associate-01
                        :ARG1 (x8 / enzyme
                              :name (x9 / name :op1 "reversibly"))
                        :ARG2 (x13 / macro-molecular-complex
                              :mod (x11 / protein
                                    :name (x12 / name :op1 "CDK8")
                                    :xref (x23 / xref :value "UNIPROT:CDK8_HUMAN" :prob "1.003"))))))
      :ARG0 (x14 / we)
      :ARG1 (x16 / possible-01
            :ARG1 (x20 / phosphorylate-01
                  :ARG0 (x17 / protein
                        :name (x18 / name :op1 "CDK8")
                        :xref (x24 / xref :value "UNIPROT:CDK8_HUMAN" :prob "1.003"))
                  :mod (x19 / also)
                  :ARG1 (x21 / protein-segment
                        :name (x22 / name :op1 "SPR" :op2 "domain")))))


# ::id PMC3905876.100
# ::snt Co-immunoprecipitations with endogenous and ectopically expressed proteins confirmed that CDK8 and MED14 interact ( Supplementary Figure S2c and d ).
# ::tok Co @-@ immunoprecipitations with endogenous and ectopically expressed proteins confirmed that CDK8 and MED14 interact ( Supplementary Figure S2c and d ) .
(x6 / confirm-01
      :ARG0 (x1 / immunoprecipitate-01
            :ARG2 (x4 / express-03
                  :mod (x2 / endogenous)
                  :mod (x3 / ectopic)
                  :ARG2 (x5 / protein)))
      :ARG1 (x12 / interact-01
            :ARG0 (x9 / and
                  :op1 (x7 / protein
                        :name (x8 / name :op1 "CDK8")
                        :xref (x18 / xref :value "UNIPROT:CDK8_HUMAN" :prob "1.003"))
                  :op2 (x10 / protein
                        :name (x11 / name :op1 "MED14")
                        :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))))
      :ARG1-of (x13 / describe-01
            :ARG0 (x16 / and
                  :op1 (x15 / figure
                        :ARG2-of (x14 / supplement-01)
                        :mod "s2c")
                  :op2 (x17 / figure :mod "5d"))))


# ::id PMC3905876.101
# ::snt We also detected MED12 ( Supplementary Figure S1b ) and MED23 ( Supplementary Figure S2c ) in CDK8 co-immunoprecipitates, which could conceivably influence kinase activity.
# ::tok We also detected MED12 ( Supplementary Figure S1b ) and MED23 ( Supplementary Figure S2c ) in CDK8 co @-@ immunoprecipitates , which could conceivably influence kinase activity .
(x3 / detect-01
      :ARG0 (x1 / we)
      :mod (x2 / also)
      :ARG1 (x9 / and
            :op1 (x4 / protein
                  :name (x5 / name :op1 "MED12")
                  :ARG1-of (x6 / describe-01
                        :ARG0 (x8 / figure
                              :ARG2-of (x7 / supplement-01)
                              :mod "s1b"))
                  :xref (x21 / xref :value "UNIPROT:MED12_HUMAN" :prob "1.003"))
            :op2 (x10 / protein
                  :name (x11 / name :op1 "MED23")
                  :xref (x / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003"))
            :ARG1-of (x12 / describe-01
                  :ARG0 (x14 / figure
                        :ARG2-of (x13 / supplement-01)
                        :mod "s2c")))
      :location (x16 / immunoprecipitate-01
            :ARG0 (x15 / cdk8)
            :ARG1-of (x17 / possible-01
                  :ARG1 (x18 / influence-01)
                  :ARG1-of (x20 / activity-06
                        :ARG0 (x19 / kinase)))))


# ::id PMC3905876.102
# ::snt However, CDK8 immunoprecipitated either directly or indirectly with overexpressed MED12 or MED14, failed to phosphorylate the recombinant SPR domain of MED14, with or without parallel phosphorylation by rERK2* ( Supplementary Figure S2e ).
# ::tok However , CDK8 immunoprecipitated either directly or indirectly with overexpressed MED12 or MED14 , failed to phosphorylate the recombinant SPR domain of MED14 , with or without parallel phosphorylation by rERK2* ( Supplementary Figure S2e ) .
(x1 / have-concession-91
      :ARG1 (x4 / immunoprecipitate-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "CDK8")
                  :xref (x29 / xref :value "UNIPROT:CDK8_HUMAN" :prob "1.003"))
            :ARG1 (x5 / or
                  :op1 (x6 / direct-02)
                  :op2 (x7 / direct-02 :polarity "-"))
            :ARG2 (x14 / fail-01
                  :ARG1 (x8 / overexpress-01
                        :ARG1 (x11 / or
                              :op1 (x9 / enzyme
                                    :name (x10 / name :op1 "MED12")
                                    :xref (x / xref :value "UNIPROT:MED12_HUMAN" :prob "1.003"))
                              :op2 (x12 / protein
                                    :name (x13 / name :op1 "MED14")
                                    :xref (x31 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))))
                  :ARG2 (x15 / phosphorylate-01
                        :ARG1 (x16 / protein
                              :ARG3-of (x17 / recombine-01)
                              :name (x18 / name :op1 "SPR")
                              :part-of (x19 / protein
                                    :name (x20 / name :op1 "MED14")
                                    :xref (x30 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                              :xref (x32 / xref :value "UNIPROT:NK1R_HUMAN" :prob "1.002"))
                        :ARG2 (x21 / or
                              :op2 (x22 / parallel-01 :polarity "-")
                              :ARG1-of (x23 / phosphorylate-01
                                    :ARG2 (x24 / enzyme
                                          :name (x25 / name :op1 "rERK2*")))))
                  :ARG1-of (x26 / describe-01
                        :ARG0 (x27 / and
                              :op1 (x28 / figure :mod "s2e"))))))


# ::id PMC3905876.103
# ::snt We therefore concluded that the SPR domain of MED14 is unlikely to be a substrate for CDK8.
# ::tok We therefore concluded that the SPR domain of MED14 is unlikely to be a substrate for CDK8 .
(x2 / conclude-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / likely-01
            :ARG1 (x8 / substrate
                  :ARG1 (x4 / protein-segment
                        :name (x5 / name :op1 "SPR")
                        :part-of (x6 / protein
                              :name (x7 / name :op1 "MED14")
                              :xref (x11 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                  :mod (x9 / protein
                        :name (x10 / name :op1 "CDK8")
                        :xref (x / xref :value "UNIPROT:CDK8_HUMAN" :prob "1.003")))))


# ::id PMC3905876.104
# ::snt Phosphorylation of MED14 by ERK in vivo
# ::tok Phosphorylation of MED14 by ERK in vivo
(x1 / phosphorylate-01
      :ARG1 (x2 / protein
            :name (x3 / name :op1 "MED14")
            :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
      :ARG2 (x4 / enzyme
            :name (x5 / name :op1 "ERK")
            :xref (x7 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
      :manner (x6 / in-vivo))


# ::id PMC3905876.105
# ::snt To determine if S986 in MED14 is phosphorylated by ERK in vivo , a phospho-specific antibody was developed.
# ::tok To determine if S986 in MED14 is phosphorylated by ERK in vivo , a phospho @-@ specific antibody was developed .
(x13 / develop-02
      :purpose (x1 / determine-01
            :ARG1 (x6 / phosphorylate-01
                  :mode "interrogative"
                  :ARG1 (x2 / amino-acid
                        :mod "986"
                        :name (x3 / name :op1 "serine")
                        :xref (x15 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "MED14")
                        :xref (x14 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :ARG2 (x7 / enzyme
                        :name (x8 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :manner (x9 / in-vivo)))
      :ARG1 (x12 / antibody
            :ARG1-of (x11 / specific-02
                  :ARG2 (x10 / phosphorylate-01))))


# ::id PMC3905876.106
# ::snt In MED14, immunoprecipitates from HeLa cells, the anti- p S986 antibody detected increased phosphorylation of MED14 in response to serum stimulation that was abolished by prior treatment of cells with the MAPK/ERK Kinase (MEK) inhibitor U0126 ( Figure 3 a).
# ::tok In MED14 , immunoprecipitates from HeLa cells , the anti @- p S986 antibody detected increased phosphorylation of MED14 in response to serum stimulation that was abolished by prior treatment of cells with the MAPK @/@ ERK Kinase ( MEK ) inhibitor U0126 ( Figure 3 a ) .
(x3 / immunoprecipitate-01
      :ARG1 (x1 / protein
            :name (x2 / name :op1 "MED14")
            :xref (x33 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
      :ARG2 (x5 / cell-line
            :name (x4 / name :op1 "HeLa"))
      :ARG1 (x10 / antibody
            :ARG0-of (x6 / oppose-01
                  :ARG1 (x7 / phosphorylate-01
                        :ARG1 (x8 / amino-acid
                              :mod "986"
                              :name (x9 / name :op1 "serine")
                              :xref (x36 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
            :ARG0-of (x11 / detect-01
                  :ARG1 (x12 / increase-01
                        :ARG1 (x13 / phosphorylate-01
                              :ARG1 (x14 / protein
                                    :name (x15 / name :op1 "MED14")
                                    :xref (x34 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                              :ARG2-of (x16 / respond-01
                                    :ARG1 (x18 / stimulate-01
                                          :ARG0 (x17 / serum))))))
            :ARG1-of (x19 / abolish-01
                  :ARG0 (x21 / treat-04
                        :mod (x20 / prior)
                        :ARG1 (x22 / cell)
                        :ARG2 (x29 / small-molecule
                              :ARG0-of (x28 / inhibit-01
                                    :ARG1 (x23 / and
                                          :op1 (x24 / enzyme
                                                :name (x25 / name :op1 "MAPK/ERK" :op2 "Kinase"))
                                          :op2 (x26 / enzyme
                                                :name (x27 / name :op1 "MEK")
                                                :xref (x / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343"))))
                              :name (x30 / name :op1 "U0126")
                              :xref (x35 / xref :value "PUBCHEM:3006531" :prob "17.656696")))
                  :ARG1-of (x31 / describe-01
                        :ARG0 (x32 / figure :mod "3a")))))


# ::id PMC3905876.107
# ::snt To confirm that ERK was responsible for MED14 phosphorylation, we used mutants of the Ras/ERK cascade.
# ::tok To confirm that ERK was responsible for MED14 phosphorylation , we used mutants of the Ras @/@ ERK cascade .
(x9 / use-01
      :purpose (x1 / confirm-01
            :ARG1 (x4 / responsible-01
                  :ARG0 (x2 / enzyme
                        :name (x3 / name :op1 "ERK")
                        :xref (x17 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG1 (x7 / phosphorylate-01
                        :ARG1 (x5 / enzyme
                              :name (x6 / name :op1 "MED14")
                              :xref (x18 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))))
      :ARG0 (x8 / we)
      :ARG1 (x15 / cascade
            :mod (x10 / mutate-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "Ras")
                        :xref (x16 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :ARG2 (x13 / enzyme
                        :name (x14 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))


# ::id PMC3905876.108
# ::snt Activated versions of Ras, Raf and MEK all stimulated phosphorylation of MED14 and ERK, which could be substantially blocked by U0126 but not by the p38 inhibitor SB290190 ( Figure 3 b).
# ::tok Activated versions of Ras , Raf and MEK all stimulated phosphorylation of MED14 and ERK , which could be substantially blocked by U0126 but not by the p38 inhibitor SB290190 ( Figure 3 b ) .
(x11 / stimulate-01
      :ARG0 (x7 / and
            :op1 (x2 / version
                  :ARG1-of (x1 / activate-01)
                  :mod (x3 / enzyme
                        :name (x4 / name :op1 "Ras")
                        :xref (x32 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :op2 (x5 / enzyme
                  :name (x6 / name :op1 "Raf")
                  :xref (x33 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
            :op3 (x8 / enzyme
                  :name (x9 / name :op1 "MEK")
                  :xref (x31 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343")))
      :mod (x10 / all)
      :ARG1 (x12 / phosphorylate-01
            :ARG1 (x15 / and
                  :op1 (x13 / protein
                        :name (x14 / name :op1 "MED14")
                        :xref (x34 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :op2 (x16 / enzyme
                        :name (x17 / name :op1 "ERK")
                        :xref (x35 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
      :ARG0-of (x20 / block-01
            :ARG1-of (x18 / possible-01)
            :degree (x19 / substantial)
            :ARG0 (x21 / small-molecule
                  :name (x22 / name :op1 "U0126")
                  :xref (x36 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
            :ARG1-of (x23 / contrast-01)
            :polarity "-"
            :ARG0 (x24 / enzyme
                  :name (x25 / name :op1 "p38")
                  :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "1.003"))
            :ARG1 (x26 / small-molecule
                  :ARG0-of (x27 / inhibit-01)
                  :name (x28 / name :op1 "SB290190")))
      :ARG1-of (x29 / describe-01
            :ARG0 (x30 / figure :mod "3")))


# ::id PMC3905876.109
# ::snt In contrast, active versions of Phosphotidylinositol-3OH-kinase (PI3K), Akt/PKB, the small G proteins RhoA, Rac1 and cdc42 and their downstream kinases SEK and PAK activated ERK weakly at best and did not stimulate MED14 phosphorylation ( Supplementary Figure S3 ).
# ::tok In contrast , active versions of Phosphotidylinositol @-@ 3OH @-@ kinase ( PI3K ) , Akt/PKB , the small G proteins RhoA , Rac1 and cdc42 and their downstream kinases SEK and PAK activated ERK weakly at best and did not stimulate MED14 phosphorylation ( Supplementary Figure S3 ) .
(x1 / contrast-01
      :ARG2 (x26 / activate-01
            :ARG1 (x20 / and
                  :op1 (x3 / version
                        :ARG1-of (x2 / activate-01)
                        :mod (x4 / enzyme
                              :name (x5 / name :op1 "Phosphotidylinositol" :op2 "3OH")
                              :ARG1-of (x6 / mean-01
                                    :ARG2 (x7 / enzyme
                                          :name (x8 / name :op1 "PI3K")
                                          :xref (x41 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))))
                  :op2 (x17 / and
                        :op1 (x9 / enzyme
                              :name (x10 / name :op1 "Akt/PKB"))
                        :op2 (x11 / protein
                              :name (x12 / name
                                    :op1 "small"
                                    :op2 "G"
                                    :op3 "protein"))
                        :op3 (x13 / protein
                              :name (x14 / name :op1 "RhoA")
                              :xref (x44 / xref :value "UNIPROT:RHOA_HUMAN" :prob "0.604"))
                        :op2 (x15 / protein
                              :name (x16 / name :op1 "Rac1")
                              :xref (x45 / xref :value "UNIPROT:RAC1_HUMAN" :prob "0.604"))
                        :op3 (x18 / protein
                              :name (x19 / name :op1 "cdc42")
                              :xref (x43 / xref :value "UNIPROT:CDC42_HUMAN" :prob "0.634")))
                  :op2 (x22 / kinase
                        :mod (x21 / downstream)
                        :name (x23 / name :op1 "SEK"))
                  :op3 (x24 / enzyme
                        :name (x25 / name :op1 "PAK")
                        :xref (x / xref :value "UNIPROT:PAK1_HUMAN" :prob "0.263")))
            :ARG1 (x27 / enzyme
                  :name (x28 / name :op1 "ERK")
                  :xref (x40 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :ARG1-of (x29 / weak-02)
            :condition (x33 / stimulate-01
                  :ARG0 (x32 / and
                        :ARG1-of (x30 / good-02
                              :degree (x31 / most)))
                  :polarity "-"
                  :ARG1 (x36 / phosphorylate-01
                        :ARG1 (x34 / protein
                              :name (x35 / name :op1 "MED14")
                              :xref (x42 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))))
      :ARG1-of (x37 / describe-01
            :ARG0 (x39 / figure
                  :ARG2-of (x38 / supplement-01)
                  :mod "s3")))


# ::id PMC3905876.110
# ::snt Expression of a truncated active version of MEKK1 ( 27 ) efficiently induced MEK-dependent phosphorylation of S986 and also ERK ( Supplementary Figure S3 , lane 3).
# ::tok Expression of a truncated active version of MEKK1 ( 27 ) efficiently induced MEK @-@ dependent phosphorylation of S986 and also ERK ( Supplementary Figure S3 , lane 3 ) .
(x11 / induce-01
      :ARG0 (x1 / express-03
            :ARG2 (x4 / version
                  :mod (x2 / truncate-01)
                  :ARG1-of (x3 / activate-01)
                  :mod (x5 / enzyme
                        :name (x6 / name :op1 "MEKK1")
                        :xref (x26 / xref :value "UNIPROT:M3K1_HUMAN" :prob "1.003")))
            :ARG1-of (x7 / describe-01
                  :ARG0 (x8 / publication
                        :ARG1-of (x9 / cite-01 :ARG2 "27"))))
      :ARG1-of (x10 / efficient-01)
      :ARG2 (x18 / and
            :op1 (x15 / phosphorylate-01
                  :ARG0-of (x14 / depend-01
                        :ARG1 (x12 / enzyme
                              :name (x13 / name :op1 "MEK")
                              :xref (x27 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343")))
                  :ARG1 (x16 / amino-acid
                        :mod "986"
                        :name (x17 / name :op1 "serine")
                        :xref (x28 / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :op2 (x25 / lane
                  :mod (x19 / also)
                  :mod (x20 / enzyme
                        :name (x21 / name :op1 "ERK")
                        :ARG1-of (x22 / describe-01
                              :ARG0 (x24 / figure
                                    :ARG2-of (x23 / supplement-01)
                                    :mod "s3"))
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :mod "3")))


# ::id PMC3905876.111
# ::snt Given the correlation between ERK activation and MED14 phosphorylation in these experiments, we conclude that S986 in MED14 is a bona fide target for ERK and mitogen signaling.
# ::tok Given the correlation between ERK activation and MED14 phosphorylation in these experiments , we conclude that S986 in MED14 is a bona fide target for ERK and mitogen signaling .
(x1 / cause-01
      :ARG0 (x2 / correlate-01
            :ARG1 (x6 / and
                  :op1 (x5 / activate-01
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "ERK")
                              :xref (x28 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                  :op2 (x9 / phosphorylate-01
                        :ARG1 (x7 / protein
                              :name (x8 / name :op1 "MED14")
                              :xref (x29 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))))
            :location (x11 / experiment-01
                  :mod (x10 / this)))
      :ARG1 (x13 / conclude-01
            :ARG0 (x12 / we)
            :ARG1 (x14 / amino-acid
                  :mod "986"
                  :name (x15 / name :op1 "serine")
                  :xref (x31 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :ARG2 (x23 / and
                  :op1 (x20 / target-01
                        :ARG0 (x16 / protein
                              :name (x17 / name :op1 "MED14")
                              :xref (x30 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                        :mod (x18 / bona)
                        :ARG0-of (x19 / fide)
                        :ARG0 (x21 / enzyme
                              :name (x22 / name :op1 "ERK")
                              :xref (x27 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                  :op2 (x26 / signal-07
                        :ARG0 (x24 / enzyme
                              :name (x25 / name :op1 "mitogen-activated")
                              :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))))))


# ::id PMC3905876.112
# ::snt Importantly, the experiments do not rule out other sites in the SPR domain as targets for alternative proline-directed kinases activated by these pathways.
# ::tok Importantly , the experiments do not rule out other sites in the SPR domain as targets for alternative proline @-@ directed kinases activated by these pathways .
(x3 / rule-out-02
      :mod (x1 / important)
      :ARG0 (x2 / experiment-01)
      :polarity "-"
      :ARG1 (x5 / site
            :mod (x4 / other))
      :location (x6 / protein-segment
            :name (x7 / name :op1 "SPR" :op2 "domain"))
      :ARG1-of (x8 / target-01
            :ARG0 (x9 / alternative)
            :ARG1 (x13 / kinase
                  :ARG1-of (x12 / direct-01
                        :ARG2 (x10 / amino-acid
                              :name (x11 / name :op1 "proline")
                              :xref (x / xref :value "PUBCHEM:614" :prob "10.45396")))
                  :ARG1-of (x14 / activate-01
                        :ARG0 (x16 / pathway
                              :mod (x15 / this))))))


# ::id PMC3905876.113
# ::snt ERK phosphorylates MED14 S986 in response to mitogenic signals.
# ::tok ERK phosphorylates MED14 S986 in response to mitogenic signals .
(x3 / phosphorylate-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "ERK")
            :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
      :ARG1 (x4 / protein
            :name (x5 / name :op1 "MED14")
            :xref (x11 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
      :ARG2 (x6 / amino-acid
            :mod "986"
            :name (x7 / name :op1 "serine")
            :xref (x12 / xref :value "PUBCHEM:5951" :prob "11.218784"))
      :ARG2-of (x8 / respond-01
            :ARG1 (x10 / signal-07
                  :mod (x9 / mitogenic))))


# ::id PMC3905876.115
# ::snt MED14 expression levels and ERK activation levels were confirmed by immunoblotting cell lysates (10%, lower panel).
# ::tok MED14 expression levels and ERK activation levels were confirmed by immunoblotting cell lysates ( 10 % , lower panel ) .
(x10 / confirm-01
      :ARG1 (x9 / level
            :ARG1 (x5 / and
                  :op1 (x4 / level
                        :degree-of (x3 / express-03
                              :ARG2 (x1 / protein
                                    :name (x2 / name :op1 "MED14")
                                    :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))))
                  :op2 (x8 / activate-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "ERK")
                              :xref (x19 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))
      :ARG0 (x11 / immunoblot-01
            :ARG1 (x13 / lysate
                  :mod (x12 / cell)
                  :quant (x14 / percentage-entity :value "10")
                  :ARG1-of (x15 / describe-01
                        :ARG0 (x18 / panel
                              :ARG1-of (x16 / low-04
                                    :degree (x17 / more)))))))


# ::id PMC3905876.116
# ::snt MED14 expression, S986 phosphorylation and ERK activation were monitored by immunoblotting cell lysates.
# ::tok MED14 expression , S986 phosphorylation and ERK activation were monitored by immunoblotting cell lysates .
(x11 / monitor-01
      :ARG1 (x7 / and
            :op1 (x3 / express-03
                  :ARG2 (x1 / protein
                        :name (x2 / name :op1 "MED14")
                        :xref (x15 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
            :op2 (x6 / phosphorylate-01
                  :ARG1 (x4 / amino-acid
                        :mod "986"
                        :name (x5 / name :op1 "serine")
                        :xref (x16 / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :op3 (x10 / activate-01
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
      :ARG0 (x12 / immunoblot-01
            :ARG1 (x14 / lysate
                  :mod (x13 / cell))))


# ::id PMC3905876.117
# ::snt MED14 is required for efficient IEG transcription
# ::tok MED14 is required for efficient IEG transcription
(x3 / require-01
      :ARG1 (x1 / protein
            :name (x2 / name :op1 "MED14")
            :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
      :ARG0 (x4 / efficient-01
            :ARG1 (x7 / transcribe-01
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "IEG")
                        :xref (x8 / xref :value "UNIPROT:PDGFD_HUMAN" :prob "0.263")))))


# ::id PMC3905876.118
# ::snt As phosphorylation of S986 in MED14 occurs in response to mitogen or oncogene stimulation of ERK, we next determined the contribution of MED14 to the regulation of mitogen-responsive genes.
# ::tok As phosphorylation of S986 in MED14 occurs in response to mitogen or oncogene stimulation of ERK , we next determined the contribution of MED14 to the regulation of mitogen @-@ responsive genes .
(x20 / determine-01
      :ARG1-of (x1 / cause-01
            :ARG0 (x7 / be-located-at-91
                  :ARG1 (x2 / phosphorylate-01
                        :ARG1 (x3 / amino-acid
                              :mod "986"
                              :name (x4 / name :op1 "serine")
                              :xref (x31 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :ARG2 (x5 / protein
                              :name (x6 / name :op1 "MED14")
                              :xref (x29 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                  :ARG2-of (x8 / respond-01
                        :ARG1 (x15 / stimulate-01
                              :ARG2 (x11 / or
                                    :op1 (x9 / enzyme
                                          :name (x10 / name :op1 "mitogen-activated")
                                          :xref (x28 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))
                                    :op2 (x12 / cause-01
                                          :ARG1 (x13 / disease
                                                :wiki "cancer"
                                                :name (x14 / name :op1 "cancer"))))
                              :ARG1 (x16 / enzyme
                                    :name (x17 / name :op1 "ERK")
                                    :xref (x30 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))))
      :ARG0 (x18 / we)
      :time (x19 / next)
      :ARG1 (x21 / contribute-01
            :ARG0 (x22 / protein
                  :name (x23 / name :op1 "MED14")
                  :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
            :ARG2 (x24 / regulate-01
                  :ARG1 (x27 / gene
                        :mod (x25 / protein
                              :name (x26 / name :op1 "mitogen-responsive"))))))


# ::id PMC3905876.119
# ::snt First we tested the effect of siRNA-mediated knockdown of MED14 in HeLa cells on serum induction of several IEGs.
# ::tok First we tested the effect of siRNA @-@ mediated knockdown of MED14 in HeLa cells on serum induction of several IEGs .
(x3 / test-01
      :ord (x1 / ordinal-entity :value "1")
      :ARG0 (x2 / we)
      :ARG1 (x4 / affect-01
            :ARG0 (x8 / knock-down-02
                  :ARG1-of (x7 / mediate-01
                        :ARG0 (x5 / nucleic-acid
                              :name (x6 / name :op1 "siRNA")))
                  :ARG1 (x9 / enzyme
                        :name (x10 / name :op1 "MED14")
                        :xref (x18 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :location (x12 / cell-line
                        :name (x11 / name :op1 "HeLa")))
            :ARG1 (x14 / induce-01
                  :ARG0 (x13 / serum)
                  :ARG2 (x15 / protein
                        :quant (x16 / several)
                        :name (x17 / name :op1 "IEGs")
                        :xref (x / xref :value "UNIPROT:PDGFD_HUMAN" :prob "0.223")))))


# ::id PMC3905876.120
# ::snt Endogenous MED14 knockdown was achieved with a combination of two MED14 siRNAs ( Figure 4 a, upper panel), with concomitant loss of signal detected by the p S986 antibody (second panel), which followed the activation of ERK induced by serum (third panel).
# ::tok Endogenous MED14 knockdown was achieved with a combination of two MED14 siRNAs ( Figure 4 a , upper panel ) , with concomitant loss of signal detected by the p S986 antibody ( second panel ) , which followed the activation of ERK induced by serum ( third panel ) .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op1 (x7 / achieve-01
                  :ARG1 (x6 / knock-down-02
                        :ARG1 (x3 / enzyme
                              :mod (x4 / endogenous)
                              :name (x5 / name :op1 "MED14")
                              :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                  :ARG2 (x8 / combine-01
                        :ARG1 (x9 / person
                              :quant "2"
                              :mod (x10 / protein
                                    :name (x11 / name :op1 "MED14")
                                    :xref (x39 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                              :name (x12 / name :op1 "sirna")))
                  :ARG1-of (x13 / describe-01
                        :ARG0 (x14 / and
                              :op1 (x15 / figure :mod "4")
                              :op2 (x17 / panel
                                    :mod (x16 / upper)))))
            :op2 (x18 / concomitance))
      :snt2 (x25 / antibody
            :ARG1 (x19 / lose-02
                  :ARG1 (x20 / signal-07
                        :ARG1-of (x21 / detect-01
                              :ARG0 (x22 / phosphorylate-01)
                              :ARG1 (x23 / amino-acid
                                    :mod "986"
                                    :name (x24 / name :op1 "serine")
                                    :xref (x40 / xref :value "PUBCHEM:5951" :prob "11.218784")))))
            :ARG1-of (x26 / describe-01
                  :ARG0 (x28 / panel
                        :mod (x27 / ordinal-entity :value "2")))
            :ARG0-of (x33 / induce-01
                  :ARG1-of (x29 / follow-01
                        :ARG2 (x30 / activate-01
                              :ARG1 (x31 / enzyme
                                    :name (x32 / name :op1 "ERK")
                                    :xref (x38 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
                  :ARG0 (x34 / serum))
            :ARG1-of (x35 / describe-01
                  :ARG0 (x37 / panel
                        :mod (x36 / ordinal-entity :value "3")))))


# ::id PMC3905876.121
# ::snt Parallel analysis of gene expression by quantitative reverse transcriptase PCR revealed that MED14 knockdown reduced the induction of c- fos RNA by 50% at 15 min ( Figure 4 b) and had a similar effect on Egr1 induction ( Figure 4 c).
# ::tok Parallel analysis of gene expression by quantitative reverse transcriptase PCR revealed that MED14 knockdown reduced the induction of c @- fos RNA by 50 % at 15 min ( Figure 4 b ) and had a similar effect on Egr1 induction ( Figure 4 c ) .
(x11 / reveal-01
      :ARG0 (x2 / analyze-01
            :manner (x1 / parallel)
            :ARG1 (x4 / express-03
                  :ARG1 (x3 / gene)
                  :manner (x8 / react-01
                        :mod (x5 / quantitative)
                        :mod (x7 / transcriptase
                              :ARG1-of (x6 / reverse-01))
                        :ARG0 (x9 / polymerase
                              :ARG1-of (x10 / chain-01)))))
      :ARG1 (x15 / reduce-01
            :ARG0 (x14 / knock-down-02
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "MED14")
                        :xref (x33 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
            :ARG1 (x16 / induce-01
                  :ARG2 (x17 / protein
                        :name (x18 / name :op1 "c-fos" :op2 "RNA"))
                  :ARG0 (x20 / after
                        :op1 (x19 / percentage-entity :value "50")
                        :quant (x21 / temporal-quantity
                              :quant "15"
                              :unit (x22 / minute))))
            :ARG1-of (x23 / describe-01
                  :ARG0 (x24 / figure :mod "4b"))
            :ARG0-of (x27 / affect-01
                  :ARG0 (x25 / and)
                  :ARG1-of (x26 / resemble-01)
                  :ARG1 (x30 / induce-01
                        :ARG2 (x28 / protein
                              :name (x29 / name :op1 "Egr1")
                              :xref (x / xref :value "UNIPROT:A0A089VKS7_HUMAN" :prob "0.671"))))
            :ARG1-of (x31 / describe-01
                  :ARG0 (x32 / figure :mod "4"))))


# ::id PMC3905876.122
# ::snt MED14 knockdown did not affect the expression of Mcl1 , which in these cells was relatively high and unresponsive to serum stimulation ( Supplementary Figure S4 ), indicating that MED14 depletion does not inactivate Mediator per se .
# ::tok MED14 knockdown did not affect the expression of Mcl1 , which in these cells was relatively high and unresponsive to serum stimulation ( Supplementary Figure S4 ) , indicating that MED14 depletion does not inactivate Mediator per se .
(x4 / affect-01
      :ARG0 (x3 / knock-down-02
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "MED14")
                  :xref (x28 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
      :polarity "-"
      :ARG1 (x5 / express-03
            :ARG2 (x6 / protein
                  :name (x7 / name :op1 "Mcl1")))
      :manner (x12 / and
            :ARG1 (x9 / cell
                  :mod (x8 / this))
            :ARG1-of (x11 / high-02
                  :ARG2-of (x10 / relative-05))
            :op2 (x13 / respond-01
                  :polarity "-"
                  :ARG1 (x15 / stimulate-01
                        :ARG0 (x14 / serum)))
            :ARG1-of (x16 / describe-01
                  :ARG0 (x18 / figure
                        :ARG2-of (x17 / supplement-01)
                        :mod "s4"))
            :ARG0-of (x19 / indicate-01
                  :ARG1 (x23 / activate-01
                        :ARG0 (x22 / deplete-01
                              :ARG2 (x20 / protein
                                    :name (x21 / name :op1 "MED14")
                                    :xref (x27 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                        :polarity "-"
                        :ARG1 (x24 / enzyme
                              :name (x25 / name :op1 "Mediator")
                              :xref (x / xref :value "UNIPROT:MED10_HUMAN" :prob "0.232")))))
      :ARG0-of (x26 / per-se))


# ::id PMC3905876.123
# ::snt MED14 knockdown impairs IEG induction.
# ::tok MED14 knockdown impairs IEG induction .
(x4 / impair-01
      :ARG0 (x3 / knock-down-02
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "MED14")
                  :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
      :ARG1 (x7 / induce-01
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "IEG")
                  :xref (x8 / xref :value "UNIPROT:PDGFD_HUMAN" :prob "0.263"))))


# ::id PMC3905876.124
# ::snt Hela cells were mock transfected (−) or transfected twice with two MED14-targetting siRNAs (+).
# ::tok Hela cells were mock transfected ( − ) or transfected twice with two MED14 @-@ targetting siRNAs ( + ) .
(x7 / or
      :op1 (x4 / transfect-01
            :ARG1 (x2 / cell-line
                  :name (x1 / name :op1 "Hela"))
            :ARG2 (x3 / mock)
            :ARG1 (x5 / cell-line
                  :name (x6 / name :op1 "−")))
      :op2 (x8 / transfect-01
            :ARG1 (x9 / cell-line
                  :name (x10 / name :op1 "2"))
            :ARG2 (x11 / enzyme
                  :name (x12 / name :op1 "MED14")
                  :ARG1-of (x13 / target-01)
                  :name (x14 / name :op1 "sirna")
                  :xref (x16 / xref :value "UNIPROT:SHPS1_HUMAN" :prob "0.212")))
      :ARG1-of (x15 / and))


# ::id PMC3905876.125
# ::snt After recovery for 24 h, serum was withdrawn for 16 h, cells were then stimulated for 0, 5, 15 or 30 min with FCS and harvested for protein and RNA extraction.
# ::tok After recovery for 24 h , serum was withdrawn for 16 h , cells were then stimulated for 0 , 5, 15 or 30 min with FCS and harvested for protein and RNA extraction .
(x22 / and
      :time (x1 / after
            :op1 (x6 / withdraw-01
                  :ARG1 (x2 / recover-02
                        :ARG0 (x3 / temporal-quantity
                              :quant "24"
                              :unit (x4 / hour))
                        :ARG2 (x5 / serum))
                  :duration (x7 / temporal-quantity
                        :quant "16"
                        :unit (x8 / hour))))
      :op1 (x11 / stimulate-01
            :ARG1 (x9 / cell)
            :time (x10 / then)
            :ARG2 (x17 / or
                  :op1 (x12 / protein
                        :name (x13 / name :op1 "0")
                        :ARG1-of (x14 / describe-01
                              :ARG0 (x15 / publication
                                    :ARG1-of (x16 / cite-01 :ARG2 "15"))))
                  :op2 (x18 / temporal-quantity
                        :quant "30"
                        :unit (x19 / minute)))
            :ARG2 (x20 / small-molecule
                  :name (x21 / name :op1 "FCS")
                  :xref (x / xref :value "PUBCHEM:3040269" :prob "11.608116")))
      :op2 (x23 / harvest-01
            :ARG1 (x25 / and
                  :op1 (x24 / protein)
                  :op2 (x28 / extract-01
                        :ARG1 (x26 / nucleic-acid
                              :name (x27 / name :op1 "RNA"))))))


# ::id PMC3905876.127
# ::snt Multiple two-tailed t-tests (assuming equal SDs, with Holm-Sidak correction using GraphPad Prism 6) were carried out to compare means (control versus MED14 KD) at each time point ( n = 3, P < 0.001 at 15 min and 30 min for both c- fos and Egr1 ).
# ::tok Multiple two @-@ tailed t @-@ tests ( assuming equal SDs , with Holm @-@ Sidak correction using GraphPad Prism 6 ) were carried out to compare means ( control versus MED14 KD ) at each time point ( n = 3 , P
(x17 / carry-out-03
      :ARG0 (x1 / protein-segment
            :name (x2 / name :op1 "Multiple" :op2 "2")
            :ARG1-of (x3 / tail-01)
            :name (x4 / name :op1 "t")
            :ARG1-of (x5 / test-01
                  :ARG2 (x6 / assume-02)))
      :ARG1 (x12 / correct-01
            :ARG1-of (x7 / equal-01
                  :ARG1 (x8 / thing
                        :name (x9 / name :op1 "sds-page"))
                  :ARG2 (x10 / protein
                        :name (x11 / name :op1 "Holm" :op2 "Sidak")))
            :ARG1 (x13 / use-01
                  :ARG1 (x14 / protein
                        :name (x15 / name :op1 "GraphPad")
                        :xref (x / xref :value "UNIPROT:GRAP_HUMAN" :prob "0.203")))
            :mod (x16 / prism)
            :mod "6")
      :ARG1 (x18 / compare-01
            :ARG1 (x23 / dissociate-01
                  :ARG1-of (x19 / mean-01
                        :ARG2 (x20 / control-01
                              :ARG2 (x21 / person
                                    :name (x22 / name :op1 "MED14"))))))
      :ARG2 (x26 / point
            :mod (x24 / each)
            :mod (x25 / time))
      :ARG1-of (x27 / sample-01
            :quant "3"
            :ARG1-of (x28 / statistical-test-91
                  :ARG2 (x29 / less-than :op1 "0.05"))))


# ::id PMC3905876.129
# ::snt Lower panels of lysates indicate extent of Elk-1 knockdown (∼70%) and of ERK activation ( p ERK).
# ::tok Lower panels of lysates indicate extent of Elk @-@ 1 knockdown ( ∼70 % ) and of ERK activation ( p ERK ) .
(x12 / and
      :op1 (x3 / panel
            :ARG1-of (x1 / low-04
                  :degree (x2 / more))
            :consist-of (x4 / lysate)
            :ARG0-of (x5 / indicate-01
                  :ARG1 (x6 / extent
                        :degree-of (x9 / knock-down-02
                              :ARG1 (x7 / protein
                                    :name (x8 / name :op1 "Elk-1")
                                    :xref (x20 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))))
            :ARG1-of (x11 / percentage-entity
                  :name (x10 / name :op1 "∼70")))
      :op2 (x15 / activate-01
            :ARG1 (x13 / enzyme
                  :name (x14 / name :op1 "ERK")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :ARG1-of (x16 / phosphorylate-01
                  :ARG2 (x17 / enzyme
                        :name (x18 / name :op1 "ERK")
                        :xref (x19 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))


# ::id PMC3905876.130
# ::snt If Elk-1 is required to recruit ERK for mitogen-induced p S986 phosphorylation, loss of Elk-1 might abrogate this modification to MED14.
# ::tok If Elk @-@ 1 is required to recruit ERK for mitogen @-@ induced p S986 phosphorylation , loss of Elk @-@ 1 might abrogate this modification to MED14 .
(x22 / possible-01
      :ARG1 (x17 / abrogate-01
            :condition (x3 / require-01
                  :ARG1 (x1 / protein
                        :name (x2 / name :op1 "Elk-1")
                        :xref (x23 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
                  :ARG0 (x4 / recruit-01
                        :ARG1 (x5 / enzyme
                              :name (x6 / name :op1 "ERK")
                              :xref (x25 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                        :ARG2 (x13 / phosphorylate-01
                              :ARG2-of (x9 / induce-01
                                    :ARG0 (x7 / enzyme
                                          :name (x8 / name :op1 "mitogen-activated")
                                          :xref (x24 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313")))
                              :ARG1 (x10 / phosphorylate-01
                                    :ARG1 (x11 / amino-acid
                                          :mod "986"
                                          :name (x12 / name :op1 "serine")
                                          :xref (x27 / xref :value "PUBCHEM:5951" :prob "11.218784"))))))
            :ARG0 (x14 / lose-02
                  :ARG1 (x15 / protein
                        :name (x16 / name :op1 "Elk-1")
                        :xref (x26 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))
            :ARG1 (x19 / modify-01
                  :ARG0 (x18 / this)
                  :ARG1 (x20 / protein
                        :name (x21 / name :op1 "MED14")
                        :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))))


# ::id PMC3905876.132
# ::snt Phosphorylation of MED14 in CDK8-Mediator complexes was apparent in unstimulated cells (upper panel, Figure 4 d, lane 5) and increased upon mitogen stimulation (lane 6 and Figure 4 e).
# ::tok Phosphorylation of MED14 in CDK8 @-@ Mediator complexes was apparent in unstimulated cells ( upper panel , Figure 4 d , lane 5 ) and increased upon mitogen stimulation ( lane 6 and Figure 4 e ) .
(x18 / and
      :op1 (x8 / appear-01
            :ARG1 (x1 / phosphorylate-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "MED14")
                        :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :location (x7 / macro-molecular-complex
                        :ARG1-of (x6 / mediate-01
                              :ARG0 (x4 / protein
                                    :name (x5 / name :op1 "CDK8")
                                    :xref (x26 / xref :value "UNIPROT:CDK8_HUMAN" :prob "1.003")))))
            :location (x10 / cell
                  :ARG1-of (x9 / stimulate-01 :polarity "-"))
            :ARG1-of (x11 / describe-01
                  :ARG0 (x13 / panel
                        :mod (x12 / upper)))
            :ARG1-of (x14 / describe-01
                  :ARG0 (x15 / and
                        :op1 (x16 / figure :mod "5d")
                        :op2 (x17 / lane :mod "5"))))
      :op2 (x19 / increase-01
            :time (x21 / stimulate-01
                  :ARG0 (x20 / mitogen))
            :ARG1-of (x22 / describe-01
                  :ARG0 (x23 / lane
                        :mod "6"
                        :ARG1-of (x24 / describe-01
                              :ARG0 (x25 / figure :mod "4e"))))))


# ::id PMC3905876.133
# ::snt Elk-1 knockdown (∼70%) reduced basal phosphorylation only slightly, but prevented mitogen-induced phosphorylation of MED14 (compare lanes 7 and 8).
# ::tok Elk @-@ 1 knockdown ( ∼70 % ) reduced basal phosphorylation only slightly , but prevented mitogen @-@ induced phosphorylation of MED14 ( compare lanes 7 and 8 ) .
(x6 / reduce-01
      :ARG0 (x3 / knock-down-02
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "Elk-1")
                  :xref (x23 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
            :ARG1-of (x5 / percentage-entity
                  :name (x4 / name :op1 "∼70")))
      :ARG1 (x8 / phosphorylate-01
            :mod (x7 / basal))
      :ARG2 (x10 / slight
            :mod (x9 / only))
      :ARG1-of (x11 / contrast-01
            :ARG2 (x12 / prevent-01
                  :ARG1 (x16 / phosphorylate-01
                        :ARG2-of (x15 / induce-01
                              :ARG0 (x13 / enzyme
                                    :name (x14 / name :op1 "mitogen-activated")
                                    :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313")))
                        :ARG1 (x17 / protein
                              :name (x18 / name :op1 "MED14")
                              :xref (x22 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))))
      :ARG1-of (x19 / compare-01
            :ARG1 (x20 / lane :mod "7")
            :ARG2 (x21 / lane :mod "8")))


# ::id PMC3905876.134
# ::snt Thus, Elk-1 participates in ERK phosphorylation of MED14 in CDK8-Mediator complexes.
# ::tok Thus , Elk @-@ 1 participates in ERK phosphorylation of MED14 in CDK8 @-@ Mediator complexes .
(x1 / infer-01
      :ARG1 (x4 / participate-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "Elk-1")
                  :xref (x15 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
            :ARG1 (x7 / phosphorylate-01
                  :ARG2 (x5 / enzyme
                        :name (x6 / name :op1 "ERK")
                        :xref (x16 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG1 (x8 / enzyme
                        :name (x9 / name :op1 "MED14")
                        :xref (x14 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :location (x13 / macro-molecular-complex
                        :ARG1-of (x12 / mediate-01
                              :ARG0 (x10 / protein
                                    :name (x11 / name :op1 "CDK8")
                                    :xref (x / xref :value "UNIPROT:CDK8_HUMAN" :prob "1.003")))))))


# ::id PMC3905876.135
# ::snt To assess the contribution of MED14 phosphorylation by ERK towards IEG induction, we attempted to rescue the effect of MED14 knockdown with native and mutant versions of siRNA-resistant MED14 expressed transiently in HeLa cells from plasmids or in HCT116 cells from lentiviral vectors ( 15 ).
# ::tok To assess the contribution of MED14 phosphorylation by ERK towards IEG induction , we attempted to rescue the effect of MED14 knockdown with native and mutant versions of siRNA @-@ resistant MED14 expressed transiently in HeLa cells from plasmids or in HCT116 cells from lentiviral vectors ( 15 ) .
(x12 / attempt-01
      :purpose (x1 / assess-01
            :ARG1 (x2 / contribute-01
                  :ARG0 (x5 / phosphorylate-01
                        :ARG1 (x3 / protein
                              :name (x4 / name :op1 "MED14")
                              :xref (x41 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                        :ARG2 (x6 / enzyme
                              :name (x7 / name :op1 "ERK")
                              :xref (x42 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                  :ARG2 (x10 / induce-01
                        :ARG2 (x8 / protein
                              :name (x9 / name :op1 "IEG")
                              :xref (x40 / xref :value "UNIPROT:PDGFD_HUMAN" :prob "0.263")))))
      :ARG0 (x11 / we)
      :ARG1 (x13 / rescue-01
            :ARG1 (x14 / affect-01
                  :ARG0 (x17 / knock-down-02
                        :ARG1 (x15 / protein
                              :name (x16 / name :op1 "MED14")
                              :xref (x43 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                  :ARG1 (x19 / and
                        :op1 (x18 / native)
                        :op2 (x21 / version
                              :ARG2-of (x20 / mutate-01)
                              :mod (x24 / resist-01
                                    :ARG1 (x22 / nucleic-acid
                                          :name (x23 / name :op1 "siRNA"))))))
            :ARG0 (x27 / express-03
                  :ARG1 (x25 / protein
                        :name (x26 / name :op1 "MED14")
                        :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :ARG1-of (x28 / transient-02)
                  :ARG3 (x30 / cell-line
                        :name (x29 / name :op1 "HeLa"))
                  :ARG2 (x32 / or
                        :op1 (x31 / plasmid)
                        :op2 (x33 / cell-line
                              :name (x34 / name :op1 "HCT116")
                              :source (x36 / vector
                                    :mod (x35 / lentiviral)))))
            :ARG1-of (x37 / describe-01
                  :ARG0 (x38 / publication
                        :ARG1-of (x39 / cite-01 :ARG2 "15")))))


# ::id PMC3905876.136
# ::snt However, responses of HeLa cells transfected with both siRNA and MED14 expression vectors to mitogens were erratic and rescue attempts in cells transduced with lentivirus were unsuccessful.
# ::tok However , responses of HeLa cells transfected with both siRNA and MED14 expression vectors to mitogens were erratic and rescue attempts in cells transduced with lentivirus were unsuccessful .
(x1 / have-concession-91
      :ARG1 (x2 / thing
            :ARG2-of (x3 / respond-01
                  :ARG1 (x16 / and
                        :op1 (x15 / erratic
                              :domain (x5 / cell-line
                                    :name (x4 / name :op1 "HeLa")
                                    :ARG1-of (x6 / transfect-01
                                          :ARG2 (x7 / and
                                                :op1 (x8 / nucleic-acid
                                                      :name (x9 / name :op1 "siRNA"))
                                                :op2 (x13 / vector
                                                      :ARG1-of (x12 / express-03
                                                            :ARG2 (x10 / protein
                                                                  :name (x11 / name :op1 "MED14")
                                                                  :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                                                      :name (x14 / name :op1 "mitogens"))))))
                        :op2 (x17 / rescue-01
                              :ARG1 (x18 / attempt-01
                                    :ARG1 (x22 / succeed-01
                                          :ARG1 (x19 / cell
                                                :ARG1-of (x20 / transduce-01
                                                      :ARG2 (x21 / lentivirus)))
                                          :polarity "-")))))))


# ::id PMC3905876.137
# ::snt Nonetheless, the knockdown experiments confirm a role for MED14 in mitogen induction of IEGs, albeit with the caveat that MED14 depletion may have pleiotropic effects on Mediator structure and composition.
# ::tok Nonetheless , the knockdown experiments confirm a role for MED14 in mitogen induction of IEGs , albeit with the caveat that MED14 depletion may have pleiotropic effects on Mediator structure and composition .
(x1 / have-concession-91
      :ARG2 (x4 / confirm-01
            :ARG0 (x3 / experiment-01
                  :ARG1 (x2 / knock-down-02))
            :ARG1 (x5 / role
                  :poss (x6 / enzyme
                        :name (x7 / name :op1 "MED14")
                        :xref (x28 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :topic (x10 / induce-01
                        :ARG1 (x8 / enzyme
                              :name (x9 / name :op1 "mitogen-activated")
                              :xref (x27 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))
                        :ARG2 (x11 / protein
                              :name (x12 / name :op1 "IEGs")
                              :xref (x29 / xref :value "UNIPROT:PDGFD_HUMAN" :prob "0.223"))))
            :concession (x13 / possible-01
                  :ARG1 (x22 / affect-01
                        :ARG0 (x14 / and
                              :op1 (x15 / protein
                                    :name (x16 / name :op1 "caveat")
                                    :xref (x30 / xref :value "UNIPROT:Q712N7_HUMAN" :prob "0.201"))
                              :ARG0-of (x19 / deplete-01
                                    :ARG1 (x17 / enzyme
                                          :name (x18 / name :op1 "MED14")
                                          :xref (x31 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))))
                        :ARG1 (x20 / protein
                              :name (x21 / name :op1 "pleiotropic")
                              :xref (x / xref :value "UNIPROT:PTN_HUMAN" :prob "0.322"))))
            :ARG1 (x25 / and
                  :op1 (x24 / structure
                        :mod (x23 / mediator))
                  :op2 (x26 / compose-01))))


# ::id PMC3905876.138
# ::snt Mutation of S986 impairs oncogene and mitogen-induced transcription
# ::tok Mutation of S986 impairs oncogene and mitogen @-@ induced transcription
(x4 / impair-01
      :ARG0 (x1 / mutate-01
            :ARG1 (x2 / amino-acid
                  :mod "986"
                  :name (x3 / name :op1 "serine")
                  :xref (x13 / xref :value "PUBCHEM:5951" :prob "11.218784")))
      :ARG1 (x11 / induce-01
            :ARG1 (x8 / and
                  :ARG0-of (x5 / cause-01
                        :ARG1 (x6 / disease
                              :wiki "cancer"
                              :name (x7 / name :op1 "cancer")))
                  :op2 (x9 / enzyme
                        :name (x10 / name :op1 "mitogen-activated")
                        :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313")))
            :ARG2 (x12 / transcribe-01)))


# ::id PMC3905876.139
# ::snt Given the inconclusive outcome from RNAi knockdown and rescue experiments in assessing the contribution of MED14 phosphorylation to IEG activation we turned to gene reporter assays.
# ::tok Given the inconclusive outcome from RNAi knockdown and rescue experiments in assessing the contribution of MED14 phosphorylation to IEG activation we turned to gene reporter assays .
(x21 / assay-01
      :ARG1-of (x1 / cause-01
            :ARG0 (x3 / and
                  :op1 (x2 / conclusive :polarity "-")
                  :op2 (x8 / rescue-01
                        :ARG0 (x4 / outcome
                              :source (x7 / knock-down-02
                                    :ARG0 (x5 / nucleic-acid
                                          :name (x6 / name :op1 "rna"))))
                        :ARG1 (x9 / experiment-01
                              :ARG1-of (x10 / assess-01)
                              :ARG1 (x11 / contribute-01
                                    :ARG0 (x14 / phosphorylate-01
                                          :ARG1 (x12 / protein
                                                :name (x13 / name :op1 "MED14")
                                                :xref (x22 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                                    :ARG2 (x17 / activate-01
                                          :ARG1 (x15 / enzyme
                                                :name (x16 / name :op1 "IEG")
                                                :xref (x / xref :value "UNIPROT:PDGFD_HUMAN" :prob "0.263"))))))))
      :ARG0 (x18 / we)
      :ARG1 (x19 / gene)
      :ARG0-of (x20 / report-01))


# ::id PMC3905876.140
# ::snt First we transfected a Ras-responsive reporter gene carrying multimerized ETS binding sites, to which Elk-1 and other ETS factors bind ( 28 ), into HEK293 cells.
# ::tok First we transfected a Ras @-@ responsive reporter gene carrying multimerized ETS binding sites , to which Elk @-@ 1 and other ETS factors bind ( 28 ) , into HEK293 cells .
(x3 / transfect-01
      :ARG0 (x2 / we
            :ord (x1 / ordinal-entity :value "1"))
      :ARG1 (x12 / protein-segment
            :ARG0-of (x6 / responsive-02
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "Ras")
                        :xref (x27 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG0-of (x11 / bind-01
                  :ARG1 (x7 / gene
                        :ARG0-of (x8 / carry-01
                              :ARG1 (x9 / multimerize-00))
                        :name (x10 / name :op1 "ETS")
                        :xref (x / xref :value "UNIPROT:ETS1_HUMAN" :prob "0.262")))
            :ARG0-of (x13 / cause-01
                  :ARG1 (x21 / bind-01
                        :ARG1 (x16 / and
                              :op1 (x14 / protein
                                    :name (x15 / name :op1 "Elk-1")
                                    :xref (x28 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
                              :op2 (x20 / factor
                                    :mod (x17 / other)
                                    :mod (x18 / protein-family
                                          :name (x19 / name :op1 "ETS"))))))
            :ARG1-of (x22 / describe-01
                  :ARG0 (x23 / publication
                        :ARG1-of (x24 / cite-01 :ARG2 "28"))))
      :ARG2 (x26 / cell-line
            :name (x25 / name :op1 "HEK293")))


# ::id PMC3905876.141
# ::snt Expression of MED14 doubled the transcriptional response to active Ras and this effect was significantly impaired by the S986A substitution ( Figure 5 a).
# ::tok Expression of MED14 doubled the transcriptional response to active Ras and this effect was significantly impaired by the S986A substitution ( Figure 5 a ) .
(x4 / double-01
      :ARG0 (x1 / express-03
            :ARG2 (x2 / enzyme
                  :name (x3 / name :op1 "MED14")
                  :xref (x19 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
      :ARG1 (x5 / transcribe-01
            :ARG1 (x6 / respond-01
                  :ARG1 (x16 / substitute-01
                        :ARG2 (x7 / activate-01
                              :ARG1 (x10 / and
                                    :op1 (x8 / enzyme
                                          :name (x9 / name :op1 "Ras")
                                          :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                                    :op2 (x14 / impair-01
                                          :ARG1 (x12 / affect-01
                                                :mod (x11 / this))
                                          :ARG1-of (x13 / significant-02)
                                          :ARG0 (x15 / mutate-01 :value "S986A")))))))
      :ARG1-of (x17 / describe-01
            :ARG0 (x18 / figure :mod "5")))


# ::id PMC3905876.142
# ::snt S986 mutation impairs Ras- and mitogen-induced reporter expression.
# ::tok S986 mutation impairs Ras @- and mitogen @-@ induced reporter expression .
(x4 / impair-01
      :ARG0 (x3 / mutate-01
            :ARG1 (x1 / gene
                  :name (x2 / name :op1 "S986")))
      :ARG1 (x13 / express-03
            :ARG2-of (x10 / induce-01
                  :ARG0 (x7 / and
                        :op1 (x5 / enzyme
                              :name (x6 / name :op1 "Ras")
                              :xref (x14 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                        :op2 (x8 / enzyme
                              :name (x9 / name :op1 "mitogen-activated")
                              :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))))
            :ARG2 (x11 / gene
                  :ARG0-of (x12 / report-01))))


# ::id PMC3905876.143
# ::snt After 36 h cell gene expression was analyzed by fluorescence assay.
# ::tok After 36 h cell gene expression was analyzed by fluorescence assay .
(x7 / analyze-01
      :time (x1 / after
            :op1 (x2 / temporal-quantity
                  :quant "36"
                  :unit (x3 / hour)))
      :ARG0 (x4 / cell)
      :ARG1 (x6 / express-03
            :ARG2 (x5 / gene))
      :manner (x9 / assay-01
            :mod (x8 / fluoresce-01)))


# ::id PMC3905876.144
# ::snt Data represent mean values from three independent experiments each performed in triplicate ( P < 0.001).
# ::tok Data represent mean values from three independent experiments each performed in triplicate ( P
(x8 / perform-02
      :ARG1 (x2 / represent-01
            :ARG0 (x1 / data)
            :ARG1 (x4 / value
                  :mod (x3 / mean)
                  :poss (x6 / experiment
                        :quant "3"
                        :ARG0-of (x5 / depend-01 :polarity "-"))
                  :mod (x7 / each)))
      :location (x9 / triplicate)
      :ARG1-of (x10 / statistical-test-91
            :ARG2 (x11 / less-than :op1 "0.05")))


# ::id PMC3905876.146
# ::snt Data in (b) represent mean values from four experiments, in (c) and (d) from three experiments, all performed in triplicate.
# ::tok Data in ( b ) represent mean values from four experiments , in ( c ) and ( d ) from three experiments , all performed in triplicate .
(x1 / data
      :ARG1-of (x2 / describe-01
            :ARG0 (x3 / figure :mod "1b"))
      :ARG0-of (x4 / represent-01
            :ARG1 (x6 / value
                  :mod (x5 / mean)))
      :source (x7 / experiment-01
            :quant "4"
            :ARG1 (x10 / and
                  :ARG1-of (x8 / describe-01
                        :ARG0 (x9 / figure :mod "c"))
                  :ARG1-of (x11 / describe-01
                        :ARG0 (x12 / figure :mod "3d"))
                  :ARG2 (x13 / experiment-01
                        :quant "3"
                        :ARG1-of (x15 / perform-02
                              :mod (x14 / all)
                              :quant "3")))))


# ::id PMC3905876.147
# ::snt After serum-starvation for 24 h, cells were left untreated (−) or stimulated with TGFβ for 6 h (+).
# ::tok After serum @-@ starvation for 24 h , cells were left untreated ( − ) or stimulated with TGFβ for 6 h ( + ) .
(x17 / and
      :time (x1 / after
            :op1 (x2 / cell-line
                  :ARG1-of (x4 / starve-01
                        :ARG2 (x3 / serum))
                  :duration (x5 / temporal-quantity
                        :quant "24"
                        :unit (x6 / hour))))
      :op1 (x9 / increase-01
            :ARG1 (x7 / cell)
            :ARG1-of (x8 / left-20)
            :ARG1-of (x11 / or
                  :name (x10 / name :op1 "−")))
      :op2 (x12 / stimulate-01
            :ARG2 (x13 / small-molecule
                  :name (x14 / name :op1 "TGFβ")
                  :xref (x / xref :value "PUBCHEM:446991" :prob "17.394333"))
            :duration (x15 / temporal-quantity
                  :quant "6"
                  :unit (x16 / hour))))


# ::id PMC3905876.149
# ::snt To focus specifically on Elk-1-dependent gene expression in response to mitogens we turned to a Gal4 reporter and the well-documented Elk-1 fusion protein consisting of the Gal4 DNA binding domain in place of the ETS domain (Gal-Elk) ( 18 , 29 ).
# ::tok To focus specifically on Elk @-@ 1 @-@ dependent gene expression in response to mitogens we turned to a Gal4 reporter and the well @-@ documented Elk @-@ 1 fusion protein consisting of the Gal4 DNA binding domain in place of the ETS domain ( Gal @-@ Elk ) ( 18 , 29 ) .
(x1 / multi-sentence
      :snt1 (x13 / turn-02
            :ARG2 (x2 / focus-01
                  :ARG1-of (x3 / specific-02)
                  :ARG2 (x8 / express-03
                        :ARG1 (x7 / gene
                              :ARG0-of (x6 / depend-01
                                    :ARG1 (x4 / protein
                                          :name (x5 / name :op1 "Elk-1")
                                          :xref (x41 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))))
                  :ARG2-of (x9 / respond-01
                        :ARG1 (x10 / small-molecule
                              :name (x11 / name :op1 "mitogens"))))
            :ARG0 (x12 / we)
            :ARG2 (x17 / and
                  :op1 (x16 / report-01
                        :ARG1 (x14 / enzyme
                              :name (x15 / name :op1 "Gal4")
                              :xref (x43 / xref :value "UNIPROT:LEG4_HUMAN" :prob "0.672")))
                  :op2 (x19 / document-01
                        :ARG1-of (x18 / well-09))))
      :snt2 (x24 / consist-01
            :ARG0 (x23 / protein
                  :ARG1-of (x22 / fuse-01
                        :ARG2 (x20 / protein
                              :name (x21 / name :op1 "Elk-1")
                              :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))))
            :ARG2 (x30 / domain
                  :mod (x25 / protein
                        :name (x26 / name :op1 "gal4-elk1")
                        :ARG1-of (x29 / bind-01
                              :ARG1 (x27 / nucleic-acid
                                    :wiki "dna"
                                    :name (x28 / name :op1 "DNA"))))
                  :ARG1-of (x31 / instead-of-91
                        :ARG2 (x32 / protein-segment
                              :name (x33 / name :op1 "ETS" :op2 "domain"))))
            :ARG1-of (x34 / describe-01
                  :ARG0 (x35 / protein
                        :name (x36 / name :op1 "Gal-Elk")
                        :xref (x42 / xref :value "UNIPROT:LEG1_HUMAN" :prob "0.213")))
            :ARG1-of (x37 / describe-01
                  :ARG0 (x38 / publication
                        :ARG1-of (x39 / cite-01
                              :ARG2 (x40 / and :op1 "18" :op2 "29"))))))


# ::id PMC3905876.150
# ::snt Initial experiments were inconclusive because MED14 expression influenced both reporter and control genes.
# ::tok Initial experiments were inconclusive because MED14 expression influenced both reporter and control genes .
(x7 / influence-01
      :ARG0 (x2 / experiment-01
            :mod (x1 / initial)
            :polarity "-"
            :ARG0-of (x3 / cause-01
                  :ARG1 (x6 / express-03
                        :ARG2 (x4 / protein
                              :name (x5 / name :op1 "MED14")
                              :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))))
      :ARG1 (x9 / and
            :op1 (x8 / report-01)
            :op2 (x11 / gene
                  :mod (x10 / control))))


# ::id PMC3905876.151
# ::snt However, in NIH3T3 cells we were able to achieve comparatively stable control gene expression by switching promoters (see Supplementary Figure S5a ), whereupon MED14-S986A significantly reduced mitogen-induced reporter expression when compared with native MED14 ( Figure 5 b).
# ::tok However , in NIH3T3 cells we were able to achieve comparatively stable control gene expression by switching promoters ( see Supplementary Figure S5a ) , whereupon MED14 @-@ S986A significantly reduced mitogen @-@ induced reporter expression when compared with native MED14 ( Figure 5 b ) .
(x1 / contrast-01
      :ARG2 (x4 / possible-01
            :location (x3 / cell-line
                  :name (x2 / name :op1 "NIH3T3"))
            :ARG1 (x6 / achieve-01
                  :ARG0 (x5 / we)
                  :ARG1 (x14 / molecular-physical-entity
                        :ARG1-of (x7 / comparable-03)
                        :ARG0-of (x13 / promote-01
                              :ARG1 (x9 / control-01
                                    :ARG1-of (x8 / stable-03)
                                    :ARG1 (x11 / express-03
                                          :ARG1 (x10 / gene))
                                    :instrument (x12 / switch-01))))))
      :ARG1-of (x15 / see-01
            :mode "imperative"
            :ARG0 (x16 / you)
            :ARG1 (x25 / reduce-01
                  :ARG0 (x18 / and
                        :ARG2-of (x17 / supplement-01)
                        :op1 (x19 / figure :mod "s5a")
                        :op2 (x20 / whereupon))
                  :ARG1 (x21 / enzyme
                        :name (x22 / name :op1 "MED14")
                        :ARG2-of (x23 / mutate-01 :value "S986A")
                        :xref (x38 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :ARG2 (x24 / significant-02)
                  :ARG1 (x31 / express-03
                        :ARG2-of (x28 / induce-01
                              :ARG0 (x26 / enzyme
                                    :name (x27 / name :op1 "mitogen-activated")
                                    :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313")))
                        :ARG1 (x29 / gene
                              :ARG0-of (x30 / report-01)))
                  :time (x32 / compare-01
                        :ARG2 (x33 / enzyme
                              :mod (x34 / native)
                              :name (x35 / name :op1 "MED14")
                              :xref (x39 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                  :ARG1-of (x36 / describe-01
                        :ARG0 (x37 / figure :mod "5b")))))


# ::id PMC3905876.152
# ::snt This effect is apparent even though endogenous MED14 is present in the cells.
# ::tok This effect is apparent even though endogenous MED14 is present in the cells .
(x3 / appear-02
      :ARG1 (x2 / affect-01
            :mod (x1 / this))
      :concession (x7 / present-02
            :ARG1 (x4 / enzyme
                  :mod (x5 / endogenous)
                  :name (x6 / name :op1 "MED14")
                  :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
            :ARG2 (x8 / cell)))


# ::id PMC3905876.153
# ::snt Western blots confirmed that expression levels of MED14 and MED14-S986A were indistinguishable in both HEK293 and NIH3T3 cells ( Supplementary Figure S5b ).
# ::tok Western blots confirmed that expression levels of MED14 and MED14 @-@ S986A were indistinguishable in both HEK293 and NIH3T3 cells ( Supplementary Figure S5b ) .
(x2 / confirm-01
      :ARG0 (x1 / immunoblot-01)
      :ARG1 (x7 / and
            :op1 (x3 / level
                  :degree-of (x4 / express-03
                        :ARG2 (x5 / protein
                              :name (x6 / name :op1 "MED14")
                              :xref (x18 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))))
            :op2 (x8 / protein
                  :name (x9 / name :op1 "MED14-S986A")))
      :polarity "-"
      :ARG1 (x10 / and
            :op1 (x11 / enzyme
                  :name (x12 / name :op1 "HEK293")
                  :xref (x / xref :value "UNIPROT:EPHB3_HUMAN" :prob "0.283"))
            :op2 (x14 / cell-line
                  :name (x13 / name :op1 "NIH3T3")))
      :ARG1-of (x15 / describe-01
            :ARG0 (x17 / figure
                  :ARG2-of (x16 / supplement-01)
                  :mod "s5b")))


# ::id PMC3905876.154
# ::snt The observation that ectopic expression of a core component of Mediator was able to influence a control gene led us to explore whether MED14 expression and its phosphorylation on S986 had a generic influence on multiple transcriptional activators.
# ::tok The observation that ectopic expression of a core component of Mediator was able to influence a control gene led us to explore whether MED14 expression and its phosphorylation on S986 had a generic influence on multiple transcriptional activators .
(x11 / lead-03
      :ARG0 (x1 / observe-01
            :ARG1 (x2 / possible-01
                  :ARG1 (x8 / influence-01
                        :ARG0 (x4 / express-03
                              :mod (x3 / ectopic)
                              :ARG2 (x6 / component
                                    :mod (x5 / core)
                                    :part-of (x7 / mediator)))
                        :ARG1 (x9 / control-01)
                        :ARG1-of (x10 / gene))))
      :ARG1 (x12 / we)
      :ARG2 (x13 / explore-01
            :ARG1 (x22 / influence-01
                  :mode "interrogative"
                  :ARG0 (x17 / and
                        :op1 (x16 / express-03
                              :ARG2 (x14 / protein
                                    :name (x15 / name :op1 "MED14")
                                    :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                        :op2 (x18 / phosphorylate-01
                              :ARG1 (x19 / amino-acid
                                    :mod "986"
                                    :name (x20 / name :op1 "serine")
                                    :xref (x26 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
                  :mod (x21 / generic)
                  :ARG1 (x25 / activate-01
                        :ARG1 (x24 / transcribe-01
                              :quant (x23 / multiple))))))


# ::id PMC3905876.155
# ::snt Elk-1 is one of three TCFs, the others being Net (Elk-3) and Sap1 (Elk-4) ( 3 , 4 ).
# ::tok Elk @-@ 1 is one of three TCFs , the others being Net ( Elk @-@ 3 ) and Sap1 ( Elk @-@ 4 ) ( 3 , 4 ) .
(x7 / net
      :ARG1 (x1 / protein
            :name (x2 / name :op1 "Elk-1")
            :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
      :ARG1-of (x3 / include-91
            :ARG2 (x4 / person
                  :quant "3"
                  :name (x5 / name :op1 "TCFs")
                  :mod (x6 / other)))
      :ARG1 (x10 / and
            :op1 (x8 / protein
                  :name (x9 / name :op1 "Elk-3"))
            :op2 (x11 / protein
                  :name (x12 / name :op1 "Sap1")))
      :ARG0 (x13 / protein
            :name (x14 / name :op1 "Elk-4"))
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / publication
                  :ARG1-of (x17 / cite-01
                        :ARG2 (x18 / and :op1 "3" :op2 "4")))))


# ::id PMC3905876.156
# ::snt Like Elk-1, when Sap1 is fused to Gal4 (Gal-Sap) it also mediates induction of Gal4 reporter expression in response to mitogens.
# ::tok Like Elk @-@ 1 , when Sap1 is fused to Gal4 ( Gal @-@ Sap ) it also mediates induction of Gal4 reporter expression in response to mitogens .
(x1 / resemble-01
      :ARG2 (x2 / protein
            :name (x3 / name :op1 "Elk-1")
            :xref (x21 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
      :time (x6 / fuse-01
            :ARG1 (x4 / protein
                  :name (x5 / name :op1 "Sap1"))
            :ARG2 (x7 / protein
                  :name (x8 / name :op1 "gal4-elk1")))
      :ARG1-of (x12 / mediate-01
            :ARG0 (x9 / protein
                  :name (x10 / name :op1 "Gal-Sap"))
            :mod (x11 / also)
            :ARG1 (x13 / induce-01
                  :ARG2 (x17 / express-03
                        :ARG1 (x15 / gene
                              :name (x14 / name :op1 "Gal4")
                              :ARG0-of (x16 / report-01)
                              :xref (x / xref :value "UNIPROT:LEG4_HUMAN" :prob "0.672")))
                  :ARG2-of (x18 / respond-01
                        :ARG1 (x19 / small-molecule
                              :name (x20 / name :op1 "mitogens"))))))


# ::id PMC3905876.157
# ::snt In this case, however, expression of MED14-S986A did not impair reporter expression ( Figure 5 c).
# ::tok In this case , however , expression of MED14 @-@ S986A did not impair reporter expression ( Figure 5 c ) .
(x3 / contrast-01
      :location (x2 / case-04
            :ARG1 (x1 / this))
      :ARG2 (x7 / impair-01
            :ARG0 (x4 / express-03
                  :ARG2 (x5 / protein
                        :name (x6 / name :op1 "MED14-S986A")))
            :polarity "-"
            :ARG1 (x10 / express-03
                  :ARG1 (x8 / gene
                        :ARG0-of (x9 / report-01))))
      :ARG1-of (x11 / describe-01
            :ARG0 (x12 / figure :mod "5c")))


# ::id PMC3905876.158
# ::snt At some promoters, Elk-1 forms ternary complexes with SRF in competition with Myocardin-like factors.
# ::tok At some promoters , Elk @-@ 1 forms ternary complexes with SRF in competition with Myocardin @-@ like factors .
(x11 / compete-01
      :time (x1 / some
            :op1 (x2 / molecular-physical-entity
                  :ARG0-of (x3 / promote-02)))
      :ARG1 (x4 / protein
            :name (x5 / name :op1 "Elk-1")
            :xref (x14 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
      :ARG1-of (x6 / form-01
            :ARG1 (x8 / complex
                  :mod (x7 / ternary))
            :accompanier (x9 / protein
                  :name (x10 / name :op1 "SRF")
                  :xref (x / xref :value "UNIPROT:SRF_HUMAN" :prob "1.003")))
      :ARG2 (x12 / protein
            :name (x13 / name :op1 "Myocardin-like" :op2 "factors")))


# ::id PMC3905876.159
# ::snt A Gal4 fusion containing the activation domain of MKL1 (507–931) ( 30 ) was also active, but only weakly responsive to 12-O-tetradecanoylphorbol-13-Acetate (TPA), and although MED14 expression reduced basal expression, there was no difference between native MED14 and MED14-S986A ( Figure 5 d).
# ::tok A Gal4 fusion containing the activation domain of MKL1 ( 507–931 ) ( 30 ) was also active , but only weakly responsive to 12 @-@ O @-@ tetradecanoylphorbol @-@ 13 @-@ Acetate ( TPA ) , and although MED14 expression reduced basal expression , there was no difference between native MED14 and MED14 @-@ S986A ( Figure 5 d ) .
(x1 / multi-sentence
      :snt1 (x16 / contrast-01
            :ARG1 (x15 / activity-06
                  :ARG1 (x5 / contain-01
                        :ARG0 (x4 / fuse-01
                              :ARG1 (x2 / gene
                                    :name (x3 / name :op1 "Gal4")
                                    :xref (x42 / xref :value "UNIPROT:LEG4_HUMAN" :prob "0.672")))
                        :ARG1 (x7 / domain
                              :ARG1-of (x6 / activate-01)
                              :part-of (x8 / protein
                                    :name (x9 / name :op1 "MKL1"))
                              :name (x10 / name :op1 "507–931"))
                        :ARG1-of (x11 / describe-01
                              :ARG0 (x12 / publication
                                    :ARG1-of (x13 / cite-01 :ARG2 "30"))))
                  :mod (x14 / also))
            :ARG2 (x19 / responsive-02
                  :ARG0 (x18 / weak-02
                        :mod (x17 / only))
                  :ARG1 (x26 / and
                        :op1 "12"
                        :op2 (x21 / cell-line
                              :name (x20 / name :op1 "O" :op2 "tetradecanoylphorbol")
                              :name (x22 / name :op1 "13-acetate")
                              :ARG1-of (x23 / treat-04
                                    :ARG2 (x24 / small-molecule
                                          :name (x25 / name :op1 "TPA")
                                          :xref (x44 / xref :value "PUBCHEM:27924" :prob "16.198082")))))))
      :snt2 (x27 / have-concession-91
            :ARG2 (x31 / reduce-01
                  :ARG0 (x30 / express-03
                        :ARG2 (x28 / protein
                              :name (x29 / name :op1 "MED14")
                              :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                  :ARG1 (x33 / express-03
                        :mod (x32 / basal)))
            :ARG1 (x34 / differ-02
                  :polarity "-"
                  :ARG1 (x35 / enzyme
                        :mod (x36 / native)
                        :name (x37 / name :op1 "MED14")
                        :xref (x43 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :ARG2 (x38 / protein
                        :name (x39 / name :op1 "MED14-S986A"))
                  :ARG1-of (x40 / describe-01
                        :ARG0 (x41 / figure :mod "5d")))))


# ::id PMC3905876.160
# ::snt Other studies describe crosstalk between ERK and transforming growth factor beta (TGFβ) signaling ( 31 , 32 ).
# ::tok Other studies describe crosstalk between ERK and transforming growth factor beta ( TGFβ ) signaling ( 31 , 32 ) .
(x4 / crosstalk-00
      :ARG0 (x2 / study-01
            :mod (x1 / other))
      :ARG1-of (x3 / describe-01)
      :ARG1 (x7 / and
            :op1 (x5 / enzyme
                  :name (x6 / name :op1 "ERK")
                  :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
            :op2 (x8 / protein
                  :name (x9 / name
                        :op1 "transforming"
                        :op2 "growth"
                        :op3 "factor"
                        :op4 "beta"))
            :ARG0-of (x11 / signal-07
                  :name (x10 / name :op1 "TGFβ")))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / publication
                  :ARG1-of (x14 / cite-01
                        :ARG2 (x15 / and :op1 "31" :op2 "32")))))


# ::id PMC3905876.161
# ::snt We therefore also tested SMAD2-dependent gene expression using a Gal4 fusion with the CTD of XfoxH1b, which carries Fast/FoxH1 and SMAD interacting motifs ( 33 ).
# ::tok We therefore also tested SMAD2 @-@ dependent gene expression using a Gal4 fusion with the CTD of XfoxH1b , which carries Fast @/@ FoxH1 and SMAD interacting motifs ( 33 ) .
(x3 / test-01
      :ARG0 (x1 / we)
      :mod (x2 / also)
      :ARG1 (x8 / express-03
            :ARG1 (x7 / gene
                  :ARG0-of (x6 / depend-01
                        :ARG1 (x4 / protein
                              :name (x5 / name :op1 "SMAD2")
                              :xref (x29 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003")))))
      :manner (x9 / use-01
            :ARG1 (x12 / fuse-01
                  :ARG1 (x10 / gene
                        :name (x11 / name :op1 "Gal4")
                        :xref (x30 / xref :value "UNIPROT:LEG4_HUMAN" :prob "0.672"))))
      :ARG2 (x24 / interact-01
            :ARG0 (x21 / and
                  :op1 (x13 / protein-segment
                        :name (x14 / name :op1 "c-terminus")
                        :part-of (x15 / protein
                              :name (x16 / name :op1 "XfoxH1b")
                              :ARG0-of (x17 / carry-01))
                        :ARG1-of (x18 / fast-02))
                  :op2 (x19 / protein
                        :name (x20 / name :op1 "FoxH1"))
                  :op3 (x22 / protein
                        :name (x23 / name :op1 "SMAD")
                        :xref (x / xref :value "UNIPROT:SMAD1_HUMAN" :prob "0.312")))
            :ARG1 (x25 / protein-segment)
            :ARG1-of (x26 / describe-01
                  :ARG0 (x27 / publication
                        :ARG1-of (x28 / cite-01 :ARG2 "33")))))


# ::id PMC3905876.162
# ::snt Again, ectopic expression of either MED14 or the S986A mutant had no significant effect on TGFβ-induced reporter expression ( Figure 5 e).
# ::tok Again , ectopic expression of either MED14 or the S986A mutant had no significant effect on TGFβ-induced reporter expression ( Figure 5 e ) .
(x9 / have-03
      :mod (x1 / again)
      :ARG0 (x3 / express-03
            :mod (x2 / ectopic)
            :ARG2 (x6 / or
                  :op1 (x4 / enzyme
                        :name (x5 / name :op1 "MED14")
                        :xref (x18 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :op1 (x7 / mutate-01 :value "S986A")
                  :op2 (x8 / mutate-01)))
      :ARG1 (x11 / affect-01
            :polarity "-"
            :ARG1-of (x10 / significant-02)
            :ARG1 (x15 / express-03
                  :ARG2 (x14 / report-01
                        :ARG1 (x12 / enzyme
                              :name (x13 / name :op1 "TGFβ-induced")
                              :xref (x / xref :value "UNIPROT:TGIF2_HUMAN" :prob "0.272")))))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / figure :mod "5e")))


# ::id PMC3905876.163
# ::snt Taken together, these data indicate that ERK phosphorylation of MED14 contributes positively to mitogen-induced gene expression mediated by Elk-1 and possibly by other ETS factors.
# ::tok Taken together , these data indicate that ERK phosphorylation of MED14 contributes positively to mitogen @-@ induced gene expression mediated by Elk @-@ 1 and possibly by other ETS factors .
(x5 / indicate-01
      :ARG0 (x4 / data
            :ARG1-of (x1 / take-01
                  :mod (x2 / together))
            :mod (x3 / this))
      :ARG1 (x11 / contribute-01
            :ARG0 (x8 / phosphorylate-01
                  :ARG2 (x6 / enzyme
                        :name (x7 / name :op1 "ERK")
                        :xref (x27 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "MED14")
                        :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
            :mod (x12 / positive)
            :ARG2 (x15 / induce-01
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "mitogen-activated")
                        :xref (x29 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))
                  :ARG2 (x21 / and
                        :op1 (x17 / express-03
                              :ARG1 (x16 / gene)
                              :ARG1-of (x18 / mediate-01
                                    :ARG0 (x19 / protein
                                          :name (x20 / name :op1 "Elk-1")
                                          :xref (x28 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))))
                        :op2 (x22 / possible-01))
                  :ARG0 (x26 / factor
                        :mod (x23 / other)
                        :mod (x24 / protein-family
                              :name (x25 / name :op1 "ETS"))))))


# ::id PMC3905876.164
# ::snt Moreover, this effect is selective, as the activity of several other transcriptional activators is unimpaired by the S986A substitution in MED14.
# ::tok Moreover , this effect is selective , as the activity of several other transcriptional activators is unimpaired by the S986A substitution in MED14 .
(x1 / and
      :op2 (x4 / select-01
            :ARG1 (x3 / affect-01
                  :mod (x2 / this)))
      :ARG1-of (x14 / substitute-01
            :ARG1 (x5 / activity-06
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "mmp")
                        :quant (x8 / several)
                        :mod (x9 / other)
                        :xref (x17 / xref :value "UNIPROT:O43923_HUMAN" :prob "0.231"))
                  :ARG1 (x11 / activate-01
                        :ARG1 (x10 / transcribe-01)
                        :ARG1-of (x12 / impaired :polarity "-")
                        :ARG0 (x13 / mutate-01 :value "S986A")))
            :ARG2 (x15 / protein
                  :name (x16 / name :op1 "MED14")
                  :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))))


# ::id PMC3905876.165
# ::snt MED14 phosphorylation induced at IEG promoters
# ::tok MED14 phosphorylation induced at IEG promoters
(x8 / molecular-physical-entity
      :ARG1 (x3 / phosphorylate-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "MED14")
                  :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
      :ARG0-of (x7 / promote-01
            :ARG1 (x4 / induce-01
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "IEG")
                        :xref (x9 / xref :value "UNIPROT:PDGFD_HUMAN" :prob "0.263")))))


# ::id PMC3905876.166
# ::snt The recruitment of active ERK by Elk-1 to mitogen-responsive gene promoters implicates them as locations at which phosphorylation of MED14 may occur.
# ::tok The recruitment of active ERK by Elk @-@ 1 to mitogen @-@ responsive gene promoters implicates them as locations at which phosphorylation of MED14 may occur .
(x19 / possible-01
      :ARG0 (x1 / recruit-01
            :ARG1 (x2 / activate-01
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "ERK")
                        :xref (x20 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "Elk-1")
                        :xref (x22 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))
            :ARG2 (x12 / molecular-physical-entity
                  :ARG0-of (x11 / promote-01
                        :ARG1 (x10 / gene
                              :ARG0-of (x9 / responsive-02
                                    :ARG1 (x7 / enzyme
                                          :name (x8 / name :op1 "mitogen-activated")
                                          :xref (x21 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313")))))
                  :ARG1-of (x13 / implicate-01
                        :ARG2 (x14 / locate-01)
                        :location (x15 / amr-unknown))))
      :ARG1 (x16 / phosphorylate-01
            :ARG1 (x17 / protein
                  :name (x18 / name :op1 "MED14")
                  :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))))


# ::id PMC3905876.167
# ::snt In chromatin immunoprecipitation (ChIP) experiments with HCT116 cells, mitogens stimulated the recruitment of MED14 to the c- fos promoter region ( Figure 6 a), in line with observations for other Mediator components ( 19 , 34 ).
# ::tok In chromatin immunoprecipitation ( ChIP ) experiments with HCT116 cells , mitogens stimulated the recruitment of MED14 to the c @- fos promoter region ( Figure 6 a ) , in line with observations for other Mediator components ( 19 , 34 ) .
(x7 / experiment-01
      :ARG1 (x3 / immunoprecipitate-01
            :ARG1 (x1 / macro-molecular-complex
                  :name (x2 / name :op1 "chromatin"))
            :ARG1-of (x4 / describe-01
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "ChIP")
                        :xref (x / xref :value "UNIPROT:CHIP_HUMAN" :prob "0.653"))))
      :ARG2 (x8 / and
            :op1 (x10 / cell-line
                  :name (x9 / name :op1 "HCT116"))
            :op2 (x13 / stimulate-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "mitogens")
                        :xref (x33 / xref :value "UNIPROT:NOX1_HUMAN" :prob "0.233"))
                  :ARG1 (x14 / recruit-01
                        :ARG1 (x15 / enzyme
                              :name (x16 / name :op1 "MED14")
                              :xref (x34 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                  :ARG2 (x20 / region
                        :mod (x17 / protein
                              :name (x18 / name :op1 "c-fos"))
                        :ARG0-of (x19 / promote-01)
                        :ARG1-of (x21 / describe-01
                              :ARG0 (x22 / figure :mod "a")))
                  :location (x23 / cell-line
                        :ARG2 (x24 / observe-01
                              :location (x27 / component
                                    :mod (x25 / other)
                                    :mod (x26 / mediator)))
                        :ARG1-of (x28 / describe-01
                              :ARG0 (x29 / publication
                                    :ARG1-of (x30 / cite-01 :ARG2 "19")))))
            :op3 (x31 / publication
                  :ARG1-of (x32 / cite-01 :ARG2 "34"))))


# ::id PMC3905876.168
# ::snt Mediator recruitment was accompanied by a substantial increase in MED14 phosphorylation on S986.
# ::tok Mediator recruitment was accompanied by a substantial increase in MED14 phosphorylation on S986 .
(x3 / accompany-01
      :ARG1 (x2 / recruit-01
            :ARG1 (x1 / mediator))
      :ARG0 (x5 / increase-01
            :degree (x4 / substantial)
            :ARG1 (x8 / phosphorylate-01
                  :ARG0 (x6 / protein
                        :name (x7 / name :op1 "MED14")
                        :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :ARG1 (x9 / amino-acid
                        :mod "986"
                        :name (x10 / name :op1 "serine")
                        :xref (x11 / xref :value "PUBCHEM:5951" :prob "11.218784")))))


# ::id PMC3905876.169
# ::snt Little change in promoter occupancy by RNAPII was observed, in agreement with previous reports ( 15 ), but whereas RNAPII was restricted to the TATA box region in unstimulated cells, its presence on the gene was apparent after stimulation.
# ::tok Little change in promoter occupancy by RNAPII was observed , in agreement with previous reports ( 15 ) , but whereas RNAPII was restricted to the TATA box region in unstimulated cells , its presence on the gene was apparent after stimulation .
(x14 / contrast-01
      :ARG1 (x7 / observe-01
            :ARG1 (x2 / change-01
                  :mod (x1 / little)
                  :ARG1 (x3 / promote-01
                        :ARG1 (x4 / occupancy)
                        :ARG0 (x5 / small-molecule
                              :name (x6 / name :op1 "RNAPII"))))
            :location (x8 / agree-01
                  :ARG2 (x10 / report
                        :time (x9 / previous))
                  :ARG1-of (x11 / describe-01
                        :ARG0 (x12 / publication
                              :ARG1-of (x13 / cite-01 :ARG2 "15")))))
      :ARG2 (x15 / contrast-01
            :ARG2 (x18 / restrict-01
                  :ARG1 (x16 / enzyme
                        :name (x17 / name :op1 "RNAPII")
                        :xref (x / xref :value "UNIPROT:RNC_HUMAN" :prob "0.232"))
                  :ARG2 (x20 / region
                        :name (x19 / name :op1 "TATA" :op2 "box"))
                  :location (x22 / cell
                        :ARG1-of (x21 / stimulate-01 :polarity "-"))
                  :ARG1-of (x23 / present-02
                        :ARG2 (x25 / appear-02
                              :ARG1 (x24 / gene)
                              :time (x26 / after
                                    :op1 (x27 / stimulate-01)))))))


# ::id PMC3905876.170
# ::snt As anticipated, similar patterns of occupation and phosphorylation were observed at the Egr1 promoter ( Figure 6 b).
# ::tok As anticipated , similar patterns of occupation and phosphorylation were observed at the Egr1 promoter ( Figure 6 b ) .
(x3 / pattern-01
      :ARG1-of (x1 / anticipate-01)
      :ARG0 (x2 / resemble-01)
      :ARG1 (x5 / and
            :op1 (x4 / occupy-01)
            :op2 (x7 / observe-01
                  :ARG1 (x6 / phosphorylate-01)
                  :location (x11 / molecular-physical-entity
                        :ARG0-of (x10 / promote-01
                              :ARG1 (x8 / protein
                                    :name (x9 / name :op1 "Egr1")
                                    :xref (x / xref :value "UNIPROT:A0A089VKS7_HUMAN" :prob "0.671"))))))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / figure :mod "6b")))


# ::id PMC3905876.171
# ::snt Thus, phosphorylation of MED14 on S986 at the promoters of these two IEGs accompanies their transcriptional activation by mitogens.
# ::tok Thus , phosphorylation of MED14 on S986 at the promoters of these two IEGs accompanies their transcriptional activation by mitogens .
(x1 / cause-01
      :ARG1 (x14 / activate-01
            :ARG0 (x2 / phosphorylate-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "MED14")
                        :xref (x17 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :ARG2 (x5 / amino-acid
                        :mod "986"
                        :name (x6 / name :op1 "serine")
                        :xref (x18 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :ARG1 (x7 / molecular-physical-entity
                        :ARG0-of (x8 / promote-02))
                  :ARG2 (x9 / enzyme
                        :name (x10 / name :op1 "2" :op2 "IEGs")))
            :ARG1-of (x11 / accompany-01)
            :ARG1 (x12 / they)
            :mod (x13 / transcribe-01)
            :ARG0 (x15 / enzyme
                  :name (x16 / name :op1 "mitogens")
                  :xref (x / xref :value "UNIPROT:NOX1_HUMAN" :prob "0.233"))))


# ::id PMC3905876.172
# ::snt MED14 phosphorylation at IEG promoters.
# ::tok MED14 phosphorylation at IEG promoters .
(x7 / molecular-physical-entity
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "MED14")
            :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
      :ARG0-of (x6 / promote-01
            :ARG1 (x3 / phosphorylate-01
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "IEG")
                        :xref (x8 / xref :value "UNIPROT:PDGFD_HUMAN" :prob "0.263")))))


# ::id PMC3905876.174
# ::snt Data represent mean values from four experiments as mean percentage of maximal signal at each locus (in ng of input DNA).
# ::tok Data represent mean values from four experiments as mean percentage of maximal signal at each locus ( in ng of input DNA ) .
(x2 / represent-01
      :ARG0 (x1 / data)
      :ARG1 (x4 / value
            :mod (x3 / mean))
      :ARG2 (x5 / experiment-01
            :quant "4"
            :ARG1-of (x6 / mean-01
                  :ARG1 (x7 / percentage
                        :quant-of (x9 / signal-07
                              :mod (x8 / maximal)
                              :location (x11 / locus
                                    :mod (x10 / each))))
                  :ARG1-of (x12 / nanogram-per-milliliter
                        :mod (x13 / input)
                        :name (x14 / name :op1 "DNA")))))


# ::id PMC3905876.175
# ::snt RNAPII occupation and CDK8 recruitment (upper graphs), MED14 recruitment and S986 phosphorylation (middle), pS5-CTD and pS2-CTD modifications (bottom) at the Egr1 gene were determined by ChIP assay.
# ::tok RNAPII occupation and CDK8 recruitment ( upper graphs ) , MED14 recruitment and S986 phosphorylation ( middle ) , pS5 @-@ CTD and pS2 @-@ CTD modifications ( bottom ) at the Egr1 gene were determined by ChIP assay .
(x33 / determine-01
      :ARG1 (x7 / recruit-01
            :ARG0 (x4 / and
                  :op1 (x3 / occupy-01
                        :ARG1 (x1 / enzyme
                              :name (x2 / name :op1 "RNAPII")
                              :xref (x37 / xref :value "UNIPROT:RNC_HUMAN" :prob "0.232")))
                  :op2 (x5 / protein
                        :name (x6 / name :op1 "CDK8")
                        :xref (x38 / xref :value "UNIPROT:CDK8_HUMAN" :prob "1.003")))
            :ARG1-of (x9 / graph
                  :mod (x8 / upper))
            :ARG0-of (x16 / phosphorylate-01
                  :ARG1 (x13 / and
                        :op1 (x12 / recruit-01
                              :ARG1 (x10 / protein
                                    :name (x11 / name :op1 "MED14")
                                    :xref (x41 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                        :op2 (x14 / amino-acid
                              :mod "986"
                              :name (x15 / name :op1 "serine")
                              :xref (x42 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
            :ARG1-of (x17 / describe-01
                  :location (x18 / middle))
            :ARG0-of (x28 / modify-01
                  :ARG1 (x19 / protein
                        :name (x20 / name :op1 "pS5"))
                  :ARG2 (x23 / and
                        :op1 (x21 / protein-segment
                              :name (x22 / name :op1 "c-terminus"))
                        :op2 (x24 / protein
                              :name (x25 / name :op1 "pS2")
                              :mod (x26 / protein-segment
                                    :name (x27 / name :op1 "c-terminus"))
                              :xref (x / xref :value "UNIPROT:PSN2_HUMAN" :prob "0.672"))))
            :ARG1-of (x29 / describe-01
                  :location (x30 / bottom)))
      :location (x32 / gene
            :name (x31 / name :op1 "Egr1")
            :xref (x39 / xref :value "UNIPROT:A0A089VKS7_HUMAN" :prob "0.671"))
      :ARG2 (x36 / assay-01
            :ARG1 (x34 / protein
                  :name (x35 / name :op1 "ChIP")
                  :xref (x40 / xref :value "UNIPROT:CHIP_HUMAN" :prob "0.653"))))


# ::id PMC3905876.177
# ::snt Using lentiviral-mediated knockdown we were able to reduce MED14 levels at the Egr1 and c- fos promoters by ∼50% in serum-stimulated cells ( Figure 6 c and Supplementary Figure S6 ) with concomitant decreases in S986 phosphorylation.
# ::tok Using lentiviral @-@ mediated knockdown we were able to reduce MED14 levels at the Egr1 and c @- fos promoters by ∼50 % in serum @-@ stimulated cells ( Figure 6 c and Supplementary Figure S6 ) with concomitant decreases in S986 phosphorylation .
(x29 / decrease-01
      :ARG0 (x4 / knock-down-02
            :ARG1-of (x3 / mediate-01
                  :ARG0 (x1 / use-01
                        :ARG1 (x2 / lentiviral)))
            :ARG1 (x25 / and
                  :op1 (x6 / capable-01
                        :ARG1 (x5 / we)
                        :ARG2 (x7 / reduce-01
                              :ARG1 (x10 / level
                                    :quant-of (x8 / protein
                                          :name (x9 / name :op1 "MED14")
                                          :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                                    :location (x17 / molecular-physical-entity
                                          :mod (x11 / protein
                                                :name (x12 / name :op1 "Egr1")
                                                :xref (x33 / xref :value "UNIPROT:A0A089VKS7_HUMAN" :prob "0.671"))
                                          :ARG0-of (x16 / promote-01
                                                :ARG1 (x13 / and
                                                      :op1 (x14 / protein
                                                            :name (x15 / name :op1 "c-fos"))))))
                              :ARG2 (x19 / percentage-entity
                                    :name (x18 / name :op1 "∼50"))
                              :location (x22 / cell
                                    :ARG1-of (x21 / stimulate-01
                                          :ARG2 (x20 / serum))))
                        :ARG1-of (x23 / describe-01
                              :ARG0 (x24 / figure :mod "6c")))
                  :op2 (x27 / figure
                        :ARG2-of (x26 / supplement-01)
                        :mod "s6"))
            :ARG2 (x28 / concomitant))
      :ARG1 (x32 / phosphorylate-01
            :ARG1 (x30 / amino-acid
                  :mod "986"
                  :name (x31 / name :op1 "serine")
                  :xref (x34 / xref :value "PUBCHEM:5951" :prob "11.218784"))))


# ::id PMC3905876.178
# ::snt MED14 knockdown was associated with reductions in RNAPII occupation and CDK8 recruitment within the timeframe of mitogen stimulation.
# ::tok MED14 knockdown was associated with reductions in RNAPII occupation and CDK8 recruitment within the timeframe of mitogen stimulation .
(x4 / associate-01
      :ARG1 (x3 / knock-down-02
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "MED14")
                  :xref (x18 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
      :ARG2 (x5 / reduce-01
            :ARG1 (x9 / and
                  :op1 (x8 / occupy-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "RNAPII")
                              :xref (x19 / xref :value "UNIPROT:RNC_HUMAN" :prob "0.232")))
                  :op2 (x12 / recruit-01
                        :ARG1 (x10 / protein
                              :name (x11 / name :op1 "CDK8")
                              :xref (x17 / xref :value "UNIPROT:CDK8_HUMAN" :prob "1.003")))))
      :location (x13 / timeframe
            :ARG1 (x16 / stimulate-01
                  :ARG1 (x14 / enzyme
                        :name (x15 / name :op1 "mitogen-activated")
                        :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313")))))


# ::id PMC3905876.179
# ::snt In addition, we observed decreased phosphorylation of the CTD, in the case of phospho-serine 5 at the promoter and for phospho-serine 2 also along the genes ( Figure 6 c and Supplementary Figure S6 ).
# ::tok In addition , we observed decreased phosphorylation of the CTD , in the case of phospho @-@ serine 5 at the promoter and for phospho @-@ serine 2 also along the genes ( Figure 6 c and Supplementary Figure S6 ) .
(x1 / and
      :op2 (x3 / observe-01
            :ARG0 (x2 / we)
            :ARG1 (x4 / decrease-01
                  :ARG1 (x5 / phosphorylate-01
                        :ARG1 (x6 / protein-segment
                              :name (x7 / name :op1 "c-terminus"))
                        :ARG2 (x8 / case-04
                              :ARG1 (x9 / enzyme
                                    :ARG3-of (x10 / phosphorylate-01)
                                    :name (x11 / name :op1 "serine")
                                    :mod "5"
                                    :xref (x / xref :value "UNIPROT:SRR_HUMAN" :prob "0.282"))))
                  :time (x14 / and
                        :op1 (x12 / molecular-physical-entity
                              :ARG0-of (x13 / promote-01))
                        :op2 (x15 / enzyme
                              :ARG3-of (x16 / phosphorylate-01)
                              :name (x17 / name :op1 "serine")
                              :mod "2"
                              :xref (x25 / xref :value "UNIPROT:SRR_HUMAN" :prob "0.282")))
                  :mod (x18 / also)
                  :ARG2 (x19 / gene))
            :ARG1-of (x20 / describe-01
                  :ARG0 (x21 / figure :mod "c"))
            :ARG1-of (x22 / describe-01
                  :ARG0 (x24 / figure
                        :ARG2-of (x23 / supplement-01)
                        :mod "s6"))))


# ::id PMC3905876.180
# ::snt These reductions are consistent with the impairment of c- fos and Egr1 transcription seen with MED14 siRNA ( Figure 4 b and c).
# ::tok These reductions are consistent with the impairment of c @- fos and Egr1 transcription seen with MED14 siRNA ( Figure 4 b and c ) .
(x11 / see-01
      :ARG1 (x2 / reduce-01
            :mod (x1 / this))
      :ARG1-of (x3 / consistent-01
            :ARG2 (x4 / impair-01
                  :ARG1 (x10 / transcribe-01
                        :ARG1 (x7 / and
                              :op1 (x5 / protein
                                    :name (x6 / name :op1 "c-fos"))
                              :op2 (x8 / protein
                                    :name (x9 / name :op1 "Egr1")
                                    :xref (x / xref :value "UNIPROT:A0A089VKS7_HUMAN" :prob "0.671"))))))
      :ARG2 (x12 / nucleic-acid
            :name (x13 / name :op1 "siRNA"))
      :ARG1-of (x14 / describe-01
            :ARG0 (x15 / and
                  :op1 (x16 / figure :mod "4b")
                  :op1 (x17 / figure :mod "4c"))))


# ::id PMC3905876.181
# ::snt Taken together, these data confirm the participation of MED14 and its phosphorylation on S986 in the transcriptional activation of the c- fos and Egr1 genes in response to mitogens.
# ::tok Taken together , these data confirm the participation of MED14 and its phosphorylation on S986 in the transcriptional activation of the c @- fos and Egr1 genes in response to mitogens .
(x5 / confirm-01
      :ARG0 (x4 / data
            :ARG1-of (x1 / take-01
                  :mod (x2 / together))
            :mod (x3 / this))
      :ARG1 (x14 / activate-01
            :ARG1-of (x6 / participate-01
                  :ARG0 (x9 / and
                        :op1 (x7 / protein
                              :name (x8 / name :op1 "MED14")
                              :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                        :op2 (x10 / phosphorylate-01
                              :ARG1 (x11 / amino-acid
                                    :mod "986"
                                    :name (x12 / name :op1 "serine")
                                    :xref (x25 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
                  :ARG1 (x13 / transcribe-01))
            :ARG1 (x17 / and
                  :op1 (x15 / protein
                        :name (x16 / name :op1 "c-fos"))
                  :op2 (x20 / gene
                        :mod (x18 / gene
                              :name (x19 / name :op1 "Egr1")
                              :xref (x24 / xref :value "UNIPROT:A0A089VKS7_HUMAN" :prob "0.671"))))
            :ARG2-of (x21 / respond-01
                  :ARG1 (x22 / small-molecule
                        :name (x23 / name :op1 "mitogens")))))


# ::id PMC3905876.182
# ::snt Elk-1 interactions with MED14
# ::tok Elk @-@ 1 interactions with MED14
(x3 / interact-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "Elk-1")
            :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
      :ARG1 (x4 / protein
            :name (x5 / name :op1 "MED14")
            :xref (x6 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))


# ::id PMC3905876.183
# ::snt Elk-1 is thought to contact Mediator through phosphorylation-dependent interactions with MED23 ( 17 ).
# ::tok Elk @-@ 1 is thought to contact Mediator through phosphorylation @-@ dependent interactions with MED23 ( 17 ) .
(x1 / think-01
      :ARG1 (x4 / contact-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "Elk-1")
                  :xref (x14 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
            :ARG1 (x5 / mediate-01
                  :ARG1 (x8 / interact-01
                        :ARG0-of (x7 / depend-01
                              :ARG1 (x6 / phosphorylate-01))
                        :ARG1 (x9 / protein
                              :name (x10 / name :op1 "MED23")
                              :xref (x / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003")))))
      :ARG1-of (x11 / describe-01
            :ARG0 (x12 / publication
                  :ARG1-of (x13 / cite-01 :ARG2 "17"))))


# ::id PMC3905876.184
# ::snt As MED23 co-immunoprecipitates efficiently with MED14 and CDK8 (see e.g. Supplementary Figure S2c ), we reasoned that an indirect interaction between Elk-1 and MED14 might also be detectable.
# ::tok As MED23 co @-@ immunoprecipitates efficiently with MED14 and CDK8 ( see e.g. Supplementary Figure S2c ) , we reasoned that an indirect interaction between Elk @-@ 1 and MED14 might also be detectable .
(x15 / reason-01
      :ARG1-of (x2 / immunoprecipitate-01
            :ARG0 (x1 / med23)
            :ARG1 (x3 / efficient-01
                  :ARG2 (x6 / and
                        :op1 (x4 / protein
                              :name (x5 / name :op1 "MED14")
                              :xref (x28 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                        :op2 (x7 / protein
                              :name (x8 / name :op1 "CDK8")
                              :xref (x27 / xref :value "UNIPROT:CDK8_HUMAN" :prob "1.003"))))
            :ARG1-of (x9 / see-01
                  :mode "imperative"
                  :ARG0 (x10 / you)
                  :ARG1 (x11 / thing
                        :example (x13 / figure
                              :ARG2-of (x12 / supplement-01)
                              :mod "s2c"))))
      :ARG0 (x14 / we)
      :ARG1 (x16 / possible-01
            :ARG1 (x25 / detect-01
                  :ARG0 (x21 / and
                        :op1 (x18 / interact-01
                              :ARG1-of (x17 / direct-02)
                              :ARG0 (x19 / protein
                                    :name (x20 / name :op1 "Elk-1")
                                    :xref (x29 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))
                        :op2 (x22 / protein
                              :name (x23 / name :op1 "MED14")
                              :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                  :mod (x24 / also)
                  :ARG1-of (x26 / possible-01))))


# ::id PMC3905876.186
# ::snt In co-immunoprecipitates from mitogen-stimulated cells, we also detected phospho-Elk-1 (lane 6).
# ::tok In co @-@ immunoprecipitates from mitogen @-@ stimulated cells , we also detected phospho @-@ Elk @-@ 1 ( lane 6 ) .
(x8 / detect-01
      :ARG1-of (x1 / co-culture
            :ARG1-of (x2 / immunoprecipitate-01
                  :ARG2 (x6 / cell
                        :ARG1-of (x5 / stimulate-01
                              :ARG0 (x3 / protein
                                    :name (x4 / name :op1 "mitogen-activated")
                                    :xref (x14 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))))))
      :ARG0 (x7 / we)
      :ARG1 (x9 / phosphorylate-01
            :ARG2 (x10 / enzyme
                  :name (x11 / name :op1 "Elk-1")
                  :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / lane :mod "6")))


# ::id PMC3905876.187
# ::snt These findings could be recapitulated in HEK293T cells expressing tagged versions of MED14 and Elk-1 ( Figure 7 b and Supplementary Figure S7a ), phosphorylated Elk-1 only being present after mitogen stimulation and more apparent when ERK signaling was enhanced with the p38 inhibitor SB290190 ( Figure 7 b, lane 5).
# ::tok These findings could be recapitulated in HEK293T cells expressing tagged versions of MED14 and Elk @-@ 1 ( Figure 7 b and Supplementary Figure S7a ) , phosphorylated Elk @-@ 1 only being present after mitogen stimulation and more apparent when ERK signaling was enhanced with the p38 inhibitor SB290190 ( Figure 7 b , lane 5 ) .
(x1 / multi-sentence
      :snt1 (x2 / possible-01
            :ARG1 (x6 / recapitulate-01
                  :ARG1 (x4 / thing
                        :mod (x3 / this)
                        :ARG1-of (x5 / find-01))
                  :location (x7 / cell-line
                        :name (x8 / name :op1 "HEK293T"))
                  :ARG1-of (x9 / express-03
                        :ARG2 (x14 / and
                              :op1 (x11 / version
                                    :ARG1-of (x10 / tag-01)
                                    :mod (x12 / protein
                                          :name (x13 / name :op1 "MED14")
                                          :xref (x51 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
                              :op2 (x15 / protein
                                    :name (x16 / name :op1 "Elk-1")
                                    :xref (x52 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))))
                  :ARG1-of (x17 / describe-01
                        :ARG0 (x18 / figure :mod "1b"))))
      :snt2 (x22 / phosphorylate-01
            :ARG1 (x19 / and
                  :op1 (x20 / supplement-01)
                  :op2 (x21 / figure :mod "s7a"))
            :ARG2 (x31 / and
                  :op1 (x26 / present-02
                        :ARG1 (x23 / protein
                              :name (x24 / name :op1 "Elk-1")
                              :xref (x48 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
                        :mod (x25 / only)
                        :time (x27 / after
                              :op1 (x30 / stimulate-01
                                    :ARG1 (x28 / enzyme
                                          :name (x29 / name :op1 "mitogen-activated")
                                          :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313")))))
                  :op2 (x33 / appear-02
                        :degree (x32 / more)
                        :time (x40 / inhibit-01
                              :ARG1 (x36 / signal-07
                                    :ARG0 (x34 / enzyme
                                          :name (x35 / name :op1 "ERK")
                                          :xref (x49 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                              :ARG1-of (x37 / enhance-01
                                    :ARG2 (x38 / enzyme
                                          :name (x39 / name :op1 "p38")
                                          :xref (x50 / xref :value "UNIPROT:CRK_HUMAN" :prob "1.003")))
                              :ARG0 (x41 / protein
                                    :name (x42 / name :op1 "SB290190")))
                        :ARG1-of (x43 / describe-01
                              :ARG0 (x44 / and
                                    :part-of (x45 / figure :mod "7")
                                    :op1 (x46 / figure :mod "1b")
                                    :op2 (x47 / lane :mod "5")))))))


# ::id PMC3905876.188
# ::snt Nonetheless, the amount of Elk-1 was similar under all conditions.
# ::tok Nonetheless , the amount of Elk @-@ 1 was similar under all conditions .
(x1 / have-concession-91
      :ARG2 (x5 / resemble-01
            :ARG1 (x2 / amount
                  :quant-of (x3 / protein
                        :name (x4 / name :op1 "Elk-1")
                        :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))
            :condition (x6 / all)))


# ::id PMC3905876.189
# ::snt These results indicate that a fraction of Elk-1 contacts Mediator regardless of gene activation state, which is consistent with the detection of Elk-1 and several Mediator subunits at IEG promoters in unstimulated cells ( 19 ).
# ::tok These results indicate that a fraction of Elk @-@ 1 contacts Mediator regardless of gene activation state , which is consistent with the detection of Elk @-@ 1 and several Mediator subunits at IEG promoters in unstimulated cells ( 19 ) .
(x4 / indicate-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x8 / contact-01
            :ARG1 (x5 / fraction
                  :quant-of (x6 / protein
                        :name (x7 / name :op1 "Elk-1")
                        :xref (x31 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))
            :ARG1 (x9 / mediate-01
                  :ARG1-of (x10 / regardless-91
                        :ARG2 (x13 / state
                              :mod (x12 / activate-01
                                    :ARG1 (x11 / gene)))))
            :ARG1-of (x14 / consistent-01
                  :ARG2 (x15 / detect-01
                        :ARG1 (x18 / and
                              :op1 (x16 / protein
                                    :name (x17 / name :op1 "Elk-1")
                                    :xref (x32 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
                              :op2 (x25 / molecular-physical-entity
                                    :quant (x19 / several)
                                    :ARG0-of (x24 / promote-01
                                          :ARG1 (x21 / subunit
                                                :mod (x20 / mediator)
                                                :part-of (x22 / enzyme
                                                      :name (x23 / name :op1 "IEG")
                                                      :xref (x / xref :value "UNIPROT:PDGFD_HUMAN" :prob "0.263"))))))
                        :location (x27 / cell
                              :ARG1-of (x26 / stimulate-01 :polarity "-")))))
      :ARG1-of (x28 / describe-01
            :ARG0 (x29 / publication
                  :ARG1-of (x30 / cite-01 :ARG2 "19"))))


# ::id PMC3905876.190
# ::snt Elk-1 interacts with MED14 independently of MED23.
# ::tok Elk @-@ 1 interacts with MED14 independently of MED23 .
(x3 / interact-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "Elk-1")
            :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
      :ARG1 (x4 / protein
            :name (x5 / name :op1 "MED14")
            :xref (x10 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
      :ARG0-of (x6 / depend-01
            :polarity "-"
            :ARG1 (x7 / protein
                  :name (x8 / name :op1 "MED23")
                  :xref (x9 / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003"))))


# ::id PMC3905876.192
# ::snt Cells were serum-starved (lanes 1–3), treated with EGF alone (lane 4) or with EGF after prior addition of the p38 mapk inhibitor SB290190 (lane 5).
# ::tok Cells were serum @-@ starved ( lanes 1–3 ) , treated with EGF alone ( lane 4 ) or with EGF after prior addition of the p38 mapk inhibitor SB290190 ( lane 5 ) .
(x7 / treat-04
      :ARG0 (x1 / cell-line
            :ARG1-of (x3 / starve-01
                  :ARG2 (x2 / serum))
            :ARG1-of (x4 / describe-01
                  :ARG0 (x5 / lane
                        :mod (x6 / value-interval :op1 "1" :op2 "3"))))
      :ARG2 (x13 / or
            :op1 (x8 / protein
                  :name (x9 / name :op1 "EGF")
                  :mod (x10 / alone)
                  :ARG1-of (x11 / describe-01
                        :ARG0 (x12 / lane :mod "4"))
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :op2 (x14 / protein
                  :name (x15 / name :op1 "EGF")
                  :xref (x25 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :time (x16 / prior
            :op1 (x17 / add-02
                  :ARG1 (x21 / small-molecule
                        :ARG0-of (x20 / inhibit-01
                              :ARG1 (x18 / protein-family
                                    :name (x19 / name :op1 "p38" :op2 "mapk")))
                        :name (x22 / name :op1 "SB290190"))))
      :ARG1-of (x23 / describe-01
            :ARG0 (x24 / lane :mod "5")))


# ::id PMC3905876.195
# ::snt Lysates were prepared from serum-starved cells (lanes 1, 3, 5 and 7) or cells treated with EGF (lanes 2, 4, 6 and 8).
# ::tok Lysates were prepared from serum @-@ starved cells ( lanes 1 , 3, 5 and 7 ) or cells treated with EGF ( lanes 2 , 4, 6 and 8 ) .
(x2 / prepare-01
      :ARG1 (x1 / lysate)
      :ARG2 (x5 / cell
            :ARG1-of (x4 / starve-01
                  :ARG2 (x3 / serum)))
      :ARG1-of (x6 / describe-01
            :ARG0 (x7 / lane :mod "1"))
      :ARG2 (x9 / or
            :op1 (x8 / and :op1 "5" :op2 "7")
            :op2 (x14 / lane
                  :mod (x10 / cell
                        :ARG1-of (x11 / treat-04
                              :ARG2 (x12 / protein
                                    :name (x13 / name :op1 "EGF")
                                    :xref (x19 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
                  :ARG1-of (x15 / label-01
                        :ARG2 (x18 / and
                              :op1 "2"
                              :op2 (x16 / protein
                                    :name (x17 / name :op1 "il-6")
                                    :xref (x / xref :value "UNIPROT:IL6_HUMAN" :prob "0.653"))
                              :op3 "8")))))


# ::id PMC3905876.197
# ::snt Samples were analyzed by SDS-PAGE and immunoblotting for the presence of phospho-Elk (upper), Elk-1, MED23 and MED14 (lower panel) with the antibodies indicated left.
# ::tok Samples were analyzed by SDS @-@ PAGE and immunoblotting for the presence of phospho @-@ Elk ( upper ) , Elk @-@ 1 , MED23 and MED14 ( lower panel ) with the antibodies indicated left .
(x6 / and
      :op1 (x3 / analyze-01
            :ARG1 (x1 / thing
                  :ARG1-of (x2 / sample-01))
            :manner (x4 / thing
                  :name (x5 / name :op1 "SDS-PAGE")))
      :op2 (x7 / immunoblot-01
            :ARG3 (x12 / and
                  :op1 (x8 / present-02
                        :ARG1 (x9 / enzyme
                              :ARG3-of (x10 / phosphorylate-01)
                              :name (x11 / name :op1 "Elk-1")
                              :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))
                  :op1 (x13 / upper)
                  :op2 (x18 / and
                        :op1 (x14 / protein
                              :name (x15 / name :op1 "Elk-1")
                              :xref (x29 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
                        :op2 (x16 / protein
                              :name (x17 / name :op1 "MED23")
                              :xref (x30 / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003"))
                        :op2 (x19 / protein
                              :name (x20 / name :op1 "MED14")
                              :xref (x28 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                        :ARG1-of (x21 / describe-01
                              :ARG0 (x24 / panel
                                    :ARG1-of (x22 / low-04
                                          :degree (x23 / more))))))
            :ARG2 (x25 / antibody
                  :ARG1-of (x26 / indicate-01)))
      :ARG1-of (x27 / left-20))


# ::id PMC3905876.198
# ::snt Upper bands in lanes 3, 4, 7 and 8 of MED23 panel are from previous exposure to MED14 antibody.
# ::tok Upper bands in lanes 3 , 4, 7 and 8 of MED23 panel are from previous exposure to MED14 antibody .
(x10 / be-from-91
      :ARG1 (x5 / and
            :op1 (x2 / band
                  :mod (x1 / upper)
                  :location (x3 / lane
                        :mod "3"
                        :name (x4 / name :op1 "4,")
                        :mod "7"))
            :op2 (x6 / protein
                  :name (x7 / name :op1 "il-8")
                  :xref (x16 / xref :value "UNIPROT:IL8_HUMAN" :prob "0.653"))
            :location (x9 / panel
                  :name (x8 / name :op1 "MED23")))
      :ARG2 (x15 / antibody
            :ARG1-of (x12 / expose-01
                  :time (x11 / previous)
                  :ARG2 (x13 / protein
                        :name (x14 / name :op1 "MED14")
                        :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))))


# ::id PMC3905876.206
# ::snt The data above suggest that Elk-1-Mediator interactions involving MED23 may not be contingent on Elk-1 phosphorylation.
# ::tok The data above suggest that Elk @-@ 1 @-@ Mediator interactions involving MED23 may not be contingent on Elk @-@ 1 phosphorylation .
(x3 / suggest-01
      :ARG0 (x1 / data
            :location (x2 / above))
      :ARG1 (x4 / possible-01
            :polarity "-"
            :ARG1 (x12 / contingent
                  :ARG1 (x8 / interact-01
                        :ARG1-of (x7 / mediate-01
                              :ARG0 (x5 / protein
                                    :name (x6 / name :op1 "Elk-1")
                                    :xref (x17 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))
                        :ARG0-of (x9 / involve-01
                              :ARG1 (x10 / protein
                                    :name (x11 / name :op1 "MED23")
                                    :xref (x16 / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003"))))
                  :time (x15 / phosphorylate-01
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "Elk-1")
                              :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))))))


# ::id PMC3905876.210
# ::snt To explain this result, we surmised that the MED23 antibody preferentially recognizes a Mediator-independent population of MED23.
# ::tok To explain this result , we surmised that the MED23 antibody preferentially recognizes a Mediator @-@ independent population of MED23 .
(x12 / recognize-02
      :purpose (x1 / explain-01
            :ARG1 (x3 / thing
                  :mod (x2 / this)
                  :ARG2-of (x4 / result-01)))
      :ARG0 (x5 / we)
      :time (x11 / prefer-01
            :ARG1 (x6 / surmise-01)
            :degree (x10 / antibody
                  :ARG0-of (x7 / counter-01
                        :ARG1 (x8 / protein
                              :name (x9 / name :op1 "MED23")
                              :xref (x / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003")))))
      :ARG1 (x13 / mediate-01
            :ARG1 (x14 / depend-01
                  :polarity "-"
                  :ARG1 (x15 / population
                        :consist-of (x16 / protein
                              :name (x17 / name :op1 "MED23")
                              :xref (x18 / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003"))))))


# ::id PMC3905876.212
# ::snt This result indicates that phospho-Elk-1 only interacts with MED23 in a complex with MED14.
# ::tok This result indicates that phospho @-@ Elk @-@ 1 only interacts with MED23 in a complex with MED14 .
(x4 / indicate-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x9 / interact-01
            :ARG0 (x5 / enzyme
                  :ARG3-of (x6 / phosphorylate-01)
                  :name (x7 / name :op1 "Elk-1")
                  :xref (x16 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
            :mod (x8 / only)
            :ARG1 (x10 / protein
                  :name (x11 / name :op1 "MED23")
                  :xref (x15 / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003"))
            :location (x12 / complex)
            :ARG2 (x13 / protein
                  :name (x14 / name :op1 "MED14")
                  :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))))


# ::id PMC3905876.214
# ::snt To test this we performed experiments with MED23 wt and MED23−/− MEFs.
# ::tok To test this we performed experiments with MED23 wt and MED23−/− MEFs .
(x4 / perform-02
      :purpose (x1 / test-01
            :ARG1 (x2 / this))
      :ARG0 (x3 / we)
      :ARG1 (x5 / experiment-01)
      :ARG2 (x9 / and
            :op1 (x6 / enzyme
                  :name (x7 / name :op1 "MED23")
                  :mod (x8 / wild-type)
                  :xref (x / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003"))
            :op2 (x10 / cell
                  :name (x11 / name :op1 "mef"))))


# ::id PMC3905876.215
# ::snt In fact the association of MED14 and Elk-1 was equally apparent in MED23 wt and MED23−/− MEFs, even though expression of Elk-1 was somewhat lower in MED23−/− MEFs ( Figure 7 d, compare lanes 3 and 5).
# ::tok In fact the association of MED14 and Elk @-@ 1 was equally apparent in MED23 wt and MED23−/− MEFs , even though expression of Elk @-@ 1 was somewhat lower in MED23−/− MEFs ( Figure 7 d , compare lanes 3 and 5 ) .
(x1 / multi-sentence
      :snt1 (x12 / and
            :op1 (x9 / appear-01
                  :mod (x2 / in-fact)
                  :ARG1 (x3 / associate-01
                        :ARG1 (x4 / protein
                              :name (x5 / name :op1 "MED14")
                              :xref (x33 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                        :ARG2 (x6 / protein
                              :name (x7 / name :op1 "Elk-1")
                              :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))
                  :ARG1-of (x8 / equal-01)
                  :location (x11 / wild-type
                        :name (x10 / name :op1 "MED23")))
            :op2 (x13 / enzyme
                  :name (x14 / name :op1 "MED23−/−")))
      :snt2 (x17 / have-concession-91
            :ARG1 (x15 / cell
                  :name (x16 / name :op1 "mef"))
            :ARG2 (x22 / low-04
                  :ARG1 (x18 / express-03
                        :ARG2 (x19 / protein
                              :name (x20 / name :op1 "Elk-1")
                              :xref (x34 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592")))
                  :degree (x21 / somewhat)
                  :degree (x23 / more)
                  :location (x24 / cell
                        :name (x25 / name :op1 "mef")))
            :ARG1-of (x26 / describe-01
                  :ARG0 (x27 / and
                        :part-of (x28 / figure :mod "7")
                        :op1 (x29 / figure :mod "5d")
                        :op2 (x30 / compare-01
                              :ARG1 (x31 / lane :mod "3")
                              :ARG2 (x32 / lane :mod "5"))))))


# ::id PMC3905876.216
# ::snt This result was confirmed with an Elk-GFP fusion protein ( Figure 7 e).
# ::tok This result was confirmed with an Elk @-@ GFP fusion protein ( Figure 7 e ) .
(x4 / confirm-01
      :ARG1 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG2 (x8 / protein
            :ARG1-of (x7 / fuse-01
                  :ARG2 (x5 / protein
                        :name (x6 / name :op1 "Elk-GFP"))))
      :ARG1-of (x9 / describe-01
            :ARG0 (x10 / figure :mod "3e")))


# ::id PMC3905876.217
# ::snt Thus without MED14, MED23 does not contact phospho-Elk, whereas Elk-1 is able to contact Mediator independently of MED23.
# ::tok Thus without MED14 , MED23 does not contact phospho @-@ Elk , whereas Elk @-@ 1 is able to contact Mediator independently of MED23 .
(x10 / contrast-01
      :ARG1-of (x1 / cause-01
            :ARG0 (x6 / contact-01
                  :polarity "-"
                  :ARG0 (x2 / protein
                        :name (x3 / name :op1 "MED14")
                        :xref (x20 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003"))
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "MED23")
                        :xref (x22 / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003"))
                  :polarity "-"
                  :ARG1 (x7 / enzyme
                        :ARG3-of (x8 / phosphorylate-01)
                        :name (x9 / name :op1 "Elk-1")
                        :xref (x21 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))))
      :ARG2 (x13 / capable-01
            :ARG1 (x11 / protein
                  :name (x12 / name :op1 "Elk-1")
                  :xref (x19 / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
            :ARG2 (x15 / mediate-01
                  :ARG0 (x14 / contact-01)
                  :ARG1 (x16 / depend-01
                        :polarity "-"
                        :ARG1 (x17 / protein
                              :name (x18 / name :op1 "MED23")
                              :xref (x / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003"))))))


# ::id PMC3905876.218
# ::snt Moreover, MED14 phosphorylation increases following mitogen stimulation in both MED23 wt and MED23−/− MEFs ( Supplementary Figure S7b ).
# ::tok Moreover , MED14 phosphorylation increases following mitogen stimulation in both MED23 wt and MED23−/− MEFs ( Supplementary Figure S7b ) .
(x1 / and
      :op2 (x5 / increase-01
            :ARG0 (x4 / phosphorylate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "MED14")
                        :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
            :ARG1-of (x6 / follow-01
                  :ARG2 (x9 / stimulate-01
                        :ARG1 (x7 / enzyme
                              :name (x8 / name :op1 "mitogen-activated")
                              :xref (x18 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))))
            :location (x10 / and
                  :op1 (x12 / wild-type
                        :name (x11 / name :op1 "MED23"))
                  :op2 (x13 / cell
                        :name (x14 / name :op1 "mef")))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / and
                        :op1 (x17 / figure :mod "s7b")))))


# ::id PMC3905876.219
# ::snt Nonetheless, Gal-Elk fails to activate reporter expression in response to mitogens in MED23−/− cells ( Figure 7 f), consistent with MED23 acting in a post-recruitment step ( 34 ).
# ::tok Nonetheless , Gal @-@ Elk fails to activate reporter expression in response to mitogens in MED23−/− cells ( Figure 7 f ) , consistent with MED23 acting in a post @-@ recruitment step ( 34 ) .
(x1 / have-concession-91
      :ARG1 (x4 / fail-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "Gal-Elk")
                  :xref (x / xref :value "UNIPROT:LEG1_HUMAN" :prob "0.213"))
            :ARG2 (x5 / activate-01
                  :ARG1 (x8 / express-03
                        :ARG2 (x6 / gene
                              :ARG0-of (x7 / report-01))
                        :ARG3 (x9 / respond-01
                              :ARG1 (x10 / small-molecule
                                    :name (x11 / name :op1 "mitogens"))))
                  :location (x13 / cell-line
                        :name (x12 / name :op1 "MED23−/−"))))
      :ARG1-of (x14 / describe-01
            :ARG0 (x15 / figure :mod "4f"))
      :ARG1-of (x16 / consistent-01
            :ARG2 (x19 / act-01
                  :ARG0 (x17 / protein
                        :name (x18 / name :op1 "MED23")
                        :xref (x26 / xref :value "UNIPROT:MED23_HUMAN" :prob "1.003"))
                  :time (x20 / after
                        :op1 (x21 / recruit-01
                              :ARG1 (x22 / step-01)))
                  :ARG1-of (x23 / describe-01
                        :ARG0 (x24 / publication
                              :ARG1-of (x25 / cite-01 :ARG2 "34"))))))


# ::id PMC3905876.225
# ::snt MED14 phosphorylation and structure
# ::tok MED14 phosphorylation and structure
(x4 / and
      :op1 (x3 / phosphorylate-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "MED14")
                  :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
      :op2 (x5 / structure))


# ::id PMC3905876.244
# ::snt MED14 phosphorylation and IEG transcriptional activation
# ::tok MED14 phosphorylation and IEG transcriptional activation
(x4 / and
      :op1 (x3 / phosphorylate-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "MED14")
                  :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
      :op2 (x8 / activate-01
            :ARG1 (x7 / transcribe-01
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "IEG")
                        :xref (x9 / xref :value "UNIPROT:PDGFD_HUMAN" :prob "0.263")))))


# ::id PMC3905876.258
# ::snt Elk-1 interactions with MED14 and Mediator
# ::tok Elk @-@ 1 interactions with MED14 and Mediator
(x6 / and
      :op1 (x3 / interact-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "Elk-1")
                  :xref (x / xref :value "UNIPROT:ELK1_HUMAN" :prob "0.592"))
            :ARG1 (x4 / protein
                  :name (x5 / name :op1 "MED14")
                  :xref (x8 / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
      :op2 (x7 / mediate-01))


# ::id PMC3905876.277
# ::snt MED14 phosphorylation and Mediator function
# ::tok MED14 phosphorylation and Mediator function
(x6 / function-01
      :ARG0 (x4 / and
            :op1 (x3 / phosphorylate-01
                  :ARG1 (x1 / protein
                        :name (x2 / name :op1 "MED14")
                        :xref (x / xref :value "UNIPROT:MED14_HUMAN" :prob "1.003")))
            :op2 (x5 / mediator)))


# ::id PMC4302068.0
# ::snt Phosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity
# ::tok Phosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity
(x10 / activity-06
      :ARG0 (x6 / inhibit-01
            :ARG0 (x1 / phosphorylate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "Dok1")
                        :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                  :ARG2 (x4 / protein-family
                        :name (x5 / name :op1 "Abl" :op2 "kinase")))
            :ARG1 (x7 / enzyme
                  :name (x8 / name :op1 "CrkI")
                  :xref (x11 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
      :ARG1 (x9 / transform-01))


# ::id PMC4302068.2
# ::snt The Crk SH2/SH3 adaptor and the Abl nonreceptor tyrosine kinase were first identified as oncoproteins, and both can induce tumorigenesis when overexpressed or mutationally activated.
# ::tok The Crk SH2 @/@ SH3 adaptor and the Abl nonreceptor tyrosine kinase were first identified as oncoproteins , and both can induce tumorigenesis when overexpressed or mutationally activated .
(x15 / identify-01
      :ARG0 (x9 / and
            :op1 (x8 / adaptor
                  :mod (x1 / protein
                        :name (x2 / name :op1 "Crk")
                        :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604"))
                  :mod (x3 / and
                        :op1 (x4 / protein-segment
                              :name (x5 / name :op1 "SH2"))
                        :op2 (x6 / protein-segment
                              :name (x7 / name :op1 "SH3"))))
            :op2 (x10 / protein
                  :name (x11 / name :op1 "Abl")
                  :xref (x29 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603")))
      :ARG1 (x12 / enzyme
            :name (x13 / name
                  :op1 "nonreceptor"
                  :op2 "tyrosine"
                  :op3 "kinase"))
      :ord (x14 / ordinal-entity :value "1")
      :ARG2 (x20 / and
            :op1 (x19 / and
                  :ARG0-of (x16 / cause-01
                        :ARG1 (x17 / disease
                              :wiki "cancer"
                              :name (x18 / name :op1 "cancer"))))
            :op2 (x21 / possible-01
                  :ARG1 (x22 / induce-01
                        :ARG2 (x23 / tumor))))
      :time (x25 / or
            :op1 (x24 / overexpress-01)
            :op2 (x28 / activate-01
                  :ARG1 (x26 / enzyme
                        :name (x27 / name :op1 "mutationally")))))


# ::id PMC4302068.3
# ::snt We previously reported the surprising finding that inhibition or knockdown of Abl family kinases enhanced transformation of mouse fibroblasts by CrkI.
# ::tok We previously reported the surprising finding that inhibition or knockdown of Abl family kinases enhanced transformation of mouse fibroblasts by CrkI .
(x3 / report-01
      :ARG0 (x1 / we)
      :time (x2 / previous)
      :ARG1 (x4 / surprise-01
            :ARG1-of (x5 / find-01
                  :ARG1 (x6 / or
                        :op1 (x7 / inhibit-01
                              :ARG1 (x8 / protein-family
                                    :name (x9 / name :op1 "Abl" :op2 "kinase")))
                        :op2 (x10 / knock-down-02)))
            :ARG1 (x12 / transform-01
                  :ARG1-of (x11 / enhance-01)
                  :ARG1 (x14 / fibroblast
                        :mod (x13 / mouse))
                  :ARG0 (x15 / enzyme
                        :name (x16 / name :op1 "CrkI")
                        :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))))


# ::id PMC4302068.4
# ::snt Abl family inhibitors are currently used or are being tested for treatment of human malignancies, and our finding raised concerns that such inhibitors might actually promote the growth of tumors overexpressing CrkI.
# ::tok Abl family inhibitors are currently used or are being tested for treatment of human malignancies , and our finding raised concerns that such inhibitors might actually promote the growth of tumors overexpressing CrkI .
(x12 / and
      :op1 (x6 / use-01
            :ARG1 (x4 / molecular-physical-entity
                  :ARG0-of (x3 / inhibit-01
                        :ARG1 (x2 / protein-family
                              :name (x1 / name :op1 "Abl"))))
            :time (x5 / current)
            :ARG2 (x8 / test-01
                  :ARG1 (x7 / or)
                  :ARG0 (x9 / treat-04
                        :ARG1 (x11 / malignancy
                              :mod (x10 / human)))))
      :op2 (x15 / raise-01
            :ARG0 (x14 / find-01
                  :ARG0 (x13 / we))
            :ARG1 (x16 / concern-01
                  :ARG0 (x18 / molecular-physical-entity
                        :mod (x17 / such)
                        :ARG0-of (x19 / inhibit-01)
                        :ARG0-of (x22 / promote-01
                              :ARG1-of (x20 / possible-01)
                              :ARG1-of (x21 / actual-02)
                              :ARG1 (x23 / grow-01
                                    :ARG1 (x24 / tumor)))))
            :ARG1-of (x25 / overexpress-01
                  :ARG1 (x26 / protein
                        :name (x27 / name :op1 "CrkI")
                        :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))))


# ::id PMC4302068.5
# ::snt Here, we identify the Dok1 adaptor as the key effector for the enhancement of CrkI transformation by Abl inhibition.
# ::tok Here , we identify the Dok1 adaptor as the key effector for the enhancement of CrkI transformation by Abl inhibition .
(x3 / identify-01
      :medium (x1 / here)
      :ARG0 (x2 / we)
      :ARG1 (x6 / adapt-01
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "Dok1")
                  :xref (x17 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
            :ARG2 (x8 / effector
                  :ARG1-of (x7 / key-02))
            :ARG3 (x15 / inhibit-01
                  :ARG1-of (x9 / enhance-01
                        :ARG1 (x12 / transform-01
                              :ARG1 (x10 / enzyme
                                    :name (x11 / name :op1 "CrkI")
                                    :xref (x16 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))
                              :ARG0 (x13 / protein
                                    :name (x14 / name :op1 "Abl")
                                    :xref (x / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603")))))))


# ::id PMC4302068.6
# ::snt We show that phosphorylation of tyrosines 295 and 361 of Dok1 by Abl family kinases suppresses CrkI transforming activity, and that upon phosphorylation these tyrosines bind the SH2 domains of the Ras inhibitor p120 RasGAP.
# ::tok We show that phosphorylation of tyrosines 295 and 361 of Dok1 by Abl family kinases suppresses CrkI transforming activity , and that upon phosphorylation these tyrosines bind the SH2 domains of the Ras inhibitor p120 RasGAP .
(x2 / show-01
      :ARG0 (x1 / we)
      :ARG1 (x11 / suppress-01
            :ARG0 (x3 / phosphorylate-01
                  :ARG1 (x4 / amino-acid
                        :name (x5 / name :op1 "tyrosine")
                        :mod (x6 / value-interval :op1 "295" :op2 "361")
                        :part-of (x7 / protein
                              :name (x8 / name :op1 "Dok1")
                              :xref (x28 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                        :xref (x30 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2 (x9 / protein-family
                        :name (x10 / name :op1 "Abl" :op2 "kinase")))
            :ARG1 (x15 / activity-06
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "CrkI")
                        :xref (x29 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))
                  :ARG1 (x14 / transform-01)
                  :ARG1-of (x20 / bind-01
                        :condition (x16 / phosphorylate-01
                              :mod (x17 / this)
                              :ARG1 (x18 / amino-acid
                                    :name (x19 / name :op1 "tyrosine")
                                    :xref (x31 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                        :ARG2 (x21 / protein-segment
                              :name (x22 / name :op1 "SH2" :op2 "domain"))
                        :ARG1 (x26 / small-molecule
                              :ARG0-of (x25 / inhibit-01
                                    :ARG1 (x23 / enzyme
                                          :name (x24 / name :op1 "Ras")
                                          :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                              :name (x27 / name :op1 "p120" :op2 "RasGAP"))))))


# ::id PMC4302068.7
# ::snt Knockdown of RasGAP resulted in a similar enhancement of CrkI transformation, consistent with a critical role for Ras activity.
# ::tok Knockdown of RasGAP resulted in a similar enhancement of CrkI transformation , consistent with a critical role for Ras activity .
(x4 / result-01
      :ARG1 (x1 / knock-down-02
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "RasGAP")
                  :xref (x16 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003")))
      :ARG2 (x6 / enhance-01
            :ARG1-of (x5 / resemble-01)
            :ARG1 (x9 / transform-01
                  :ARG0 (x7 / enzyme
                        :name (x8 / name :op1 "CrkI")
                        :xref (x17 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))
                  :ARG1-of (x10 / consistent-01
                        :ARG2 (x12 / role
                              :ARG1-of (x11 / critical-02)
                              :topic (x15 / activity-06
                                    :ARG0 (x13 / enzyme
                                          :name (x14 / name :op1 "Ras")
                                          :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))))))


# ::id PMC4302068.8
# ::snt Imaging studies using a FRET sensor of Ras activation revealed alterations in the localization of activated Ras in CrkI-transformed cells.
# ::tok Imaging studies using a FRET sensor of Ras activation revealed alterations in the localization of activated Ras in CrkI @-@ transformed cells .
(x10 / reveal-01
      :ARG0 (x1 / image-bab
            :ARG1 (x2 / study-01
                  :ARG0-of (x3 / use-01
                        :ARG1 (x6 / sensor
                              :mod (x4 / thing
                                    :name (x5 / name :op1 "FRET")))
                        :ARG2 (x9 / activate-01
                              :ARG1 (x7 / enzyme
                                    :name (x8 / name :op1 "Ras")
                                    :xref (x21 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))))
      :ARG1 (x11 / alter-01
            :ARG1 (x12 / be-located-at-91
                  :ARG1 (x13 / enzyme
                        :ARG1-of (x14 / activate-01)
                        :name (x15 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :location (x19 / cell
                        :ARG1-of (x18 / transform-01
                              :ARG0 (x16 / enzyme
                                    :name (x17 / name :op1 "CrkI")
                                    :xref (x20 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))))))


# ::id PMC4302068.9
# ::snt Our results support a model in which Dok1 phosphorylation normally suppresses localized Ras pathway activity in Crk-transformed cells via recruitment and/or activation of RasGAP, and that preventing this negative feedback mechanism by inhibiting Abl family kinases leads to enhanced transformation by Crk.
# ::tok Our results support a model in which Dok1 phosphorylation normally suppresses localized Ras pathway activity in Crk @-@ transformed cells via recruitment and @/@ or activation of RasGAP , and that preventing this negative feedback mechanism by inhibiting Abl family kinases leads to enhanced transformation by Crk .
(x4 / support-01
      :ARG0 (x2 / thing
            :poss (x1 / we)
            :ARG2-of (x3 / result-01))
      :ARG1 (x5 / model
            :ARG0-of (x8 / phosphorylate-01
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "Dok1")
                        :xref (x39 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
            :ARG1-of (x10 / suppress-01
                  :ARG1-of (x9 / normal-02)
                  :ARG1 (x11 / be-located-at-91
                        :ARG1 (x14 / activity-06
                              :ARG0 (x12 / pathway
                                    :name (x13 / name :op1 "Ras"))))
                  :location (x18 / cell
                        :ARG1-of (x17 / transform-01
                              :ARG0 (x15 / protein
                                    :name (x16 / name :op1 "Crk")
                                    :xref (x41 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604"))))))
      :manner (x34 / lead-03
            :ARG0 (x20 / and
                  :op1 (x19 / recruit-01)
                  :op2 (x21 / or
                        :op2 (x22 / activate-01
                              :ARG1 (x25 / and
                                    :op1 (x23 / protein
                                          :name (x24 / name :op1 "RasGAP")
                                          :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
                                    :op2 (x26 / prevent-01
                                          :ARG1 (x30 / mechanism
                                                :mod (x27 / this)
                                                :mod (x29 / feedback
                                                      :ARG0-of (x28 / negative-03)))))
                              :ARG0 (x31 / inhibit-01
                                    :ARG1 (x32 / protein-family
                                          :name (x33 / name :op1 "Abl" :op2 "kinase"))))))
            :ARG2 (x36 / transform-01
                  :ARG1-of (x35 / enhance-01)
                  :ARG0 (x37 / protein
                        :name (x38 / name :op1 "Crk")
                        :xref (x40 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604")))))


# ::id PMC4302068.38
# ::snt Dok1 is the major Abl-dependent phosphoprotein in Crk-transformed cells
# ::tok Dok1 is the major Abl @-@ dependent phosphoprotein in Crk @-@ transformed cells
(x6 / depend-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "Dok1")
            :xref (x12 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
      :ARG1-of (x3 / major-02)
      :ARG1 (x4 / protein
            :name (x5 / name :op1 "Abl")
            :xref (x13 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603"))
      :ARG1 (x7 / phosphoprotein)
      :location (x11 / cell
            :ARG1-of (x10 / transform-01
                  :ARG0 (x8 / protein
                        :name (x9 / name :op1 "Crk")
                        :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604")))))


# ::id PMC4302068.39
# ::snt We first examined more closely how Abl inhibition affected the ability of CrkI-transformed NIH3T3 cells to grow in suspension, a hallmark of malignant transformation.
# ::tok We first examined more closely how Abl inhibition affected the ability of CrkI @-@ transformed NIH3T3 cells to grow in suspension , a hallmark of malignant transformation .
(x2 / examine-01
      :ARG0 (x1 / we)
      :ARG1 (x4 / close-10
            :degree (x3 / more))
      :ARG1 (x5 / thing
            :manner-of (x9 / affect-01
                  :ARG0 (x8 / inhibit-01
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "Abl")
                              :xref (x21 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603")))
                  :ARG1 (x10 / capable-01
                        :ARG1 (x15 / cell-line
                              :ARG1-of (x13 / transform-01
                                    :ARG0 (x11 / enzyme
                                          :name (x12 / name :op1 "CrkI")
                                          :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
                              :name (x14 / name :op1 "NIH3T3"))
                        :ARG2 (x16 / grow-01
                              :location (x18 / and
                                    :name (x17 / name :op1 "suspension")
                                    :ARG0-of (x20 / transform-01
                                          :ARG2-of (x19 / malignant-02))))))))


# ::id PMC4302068.40
# ::snt Consistent with previous results ( 11 ), we found a significant increase (up to 10-fold) in the number of colonies in the soft agar growth assay when cells were treated with the Abl inhibitor imatinib ( Fig. 1a ).
# ::tok Consistent with previous results ( 11 ) , we found a significant increase ( up to 10 @-@ fold ) in the number of colonies in the soft agar growth assay when cells were treated with the Abl inhibitor imatinib ( Fig . 1a ) .
(x9 / find-01
      :ARG1-of (x1 / consistent-01
            :ARG2 (x4 / thing
                  :ARG2-of (x3 / result-01
                        :time (x2 / previous)))
            :ARG1-of (x5 / describe-01
                  :ARG0 (x6 / publication
                        :ARG1-of (x7 / cite-01 :ARG2 "11"))))
      :ARG0 (x8 / we)
      :ARG1 (x11 / increase-01
            :ARG1-of (x10 / significant-02)
            :ARG2 (x12 / up-to
                  :op1 (x13 / product-of :op1 "10")))
      :ARG2 (x19 / assay-01
            :ARG1 (x14 / number
                  :quant-of (x18 / grow-01
                        :ARG1 (x15 / colony
                              :location (x17 / agar
                                    :ARG1-of (x16 / soft-02))))))
      :time (x21 / treat-04
            :ARG1 (x20 / cell)
            :ARG2 (x24 / small-molecule
                  :mod (x22 / protein
                        :name (x23 / name :op1 "Abl")
                        :xref (x / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603"))
                  :ARG0-of (x25 / inhibit-01)
                  :name (x26 / name :op1 "imatinib")
                  :xref (x29 / xref :value "PUBCHEM:5291" :prob "16.088081")))
      :ARG1-of (x27 / describe-01
            :ARG0 (x28 / figure :mod "1a")))


# ::id PMC4302068.41
# ::snt The stimulatory effect of imatinib increased proportionately with concentration up to 10μM then decreased slightly, presumably due to increased toxicity (the reported IC 50 for imatinib falls within the range of 0.4 -1.5μM ( 40 )).
# ::tok The stimulatory effect of imatinib increased proportionately with concentration up to 10μM then decreased slightly , presumably due to increased toxicity ( the reported IC 50 for imatinib falls within the range of 0.4 -@ 1.5μM ( 40 ) ) .
(x5 / increase-01
      :ARG0 (x1 / stimulate-01
            :ARG1 (x2 / affect-01
                  :ARG0 (x3 / small-molecule
                        :name (x4 / name :op1 "imatinib")
                        :xref (x30 / xref :value "PUBCHEM:5291" :prob "16.088081"))))
      :ARG1 (x6 / proportionate)
      :ARG2 (x7 / concentration-quantity
            :quant (x8 / up-to
                  :op1 (x12 / decrease-01
                        :ARG1 (x9 / enzyme
                              :name (x10 / name :op1 "10μM"))
                        :time (x11 / then)
                        :ARG2 (x13 / slight)))
            :ARG1-of (x14 / presume-01))
      :ARG1-of (x15 / cause-01
            :ARG0 (x17 / toxicity
                  :ARG1-of (x16 / increase-01)
                  :ARG1-of (x22 / fall-01
                        :ARG1 (x18 / report-01)
                        :ARG1 (x19 / have-percentage-maximal-inhibitory-concentration-01
                              :ARG2 "50"
                              :ARG1 (x20 / small-molecule
                                    :name (x21 / name :op1 "imatinib")
                                    :xref (x / xref :value "PUBCHEM:5291" :prob "16.088081")))
                        :location (x23 / range-01
                              :ARG1 (x24 / concentration-quantity
                                    :quant "0.4"
                                    :mod (x25 / person
                                          :wiki "-"
                                          :name (x26 / name :op1 "1.5μM"))))
                        :ARG1-of (x27 / describe-01
                              :ARG0 (x28 / publication
                                    :ARG1-of (x29 / cite-01 :ARG2 "40")))))))


# ::id PMC4302068.42
# ::snt We reasoned that Abl inhibition exerted its effects on Crk transformation by altering tyrosine phosphorylation.
# ::tok We reasoned that Abl inhibition exerted its effects on Crk transformation by altering tyrosine phosphorylation .
(x2 / reason-01
      :ARG0 (x1 / we)
      :ARG1 (x6 / exert-01
            :ARG0 (x5 / inhibit-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "Abl")
                        :xref (x15 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603")))
            :ARG1 (x7 / affect-01
                  :ARG1 (x10 / transform-01
                        :ARG0 (x8 / protein
                              :name (x9 / name :op1 "Crk")
                              :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604")))))
      :ARG2 (x11 / alter-01
            :ARG1 (x14 / phosphorylate-01
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "tyrosine")
                        :xref (x16 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352")))))


# ::id PMC4302068.43
# ::snt To identify Abl-dependent phosphoproteins, lysates of control and CrkI-transformed cells (with and without imatinib treatment) were immunoblotted with anti-phosphotyrosine (anti-pTyr) antibody.
# ::tok To identify Abl @-@ dependent phosphoproteins , lysates of control and CrkI @-@ transformed cells ( with and without imatinib treatment ) were immunoblotted with anti @-@ phosphotyrosine ( anti @-@ pTyr ) antibody .
(x19 / immunoblot-01
      :purpose (x1 / identify-01
            :ARG1 (x5 / protein
                  :ARG0-of (x4 / depend-01
                        :ARG1 (x2 / protein
                              :name (x3 / name :op1 "Abl")
                              :xref (x / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603")))
                  :ARG1-of (x6 / phosphorylate-01)))
      :ARG1 (x9 / and
            :op1 (x7 / lysate
                  :mod (x8 / control))
            :op2 (x13 / cell
                  :ARG1-of (x12 / transform-01
                        :ARG0 (x10 / enzyme
                              :name (x11 / name :op1 "CrkI")
                              :xref (x28 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))
            :ARG0-of (x14 / have-03
                  :ARG1 (x15 / and
                        :op1 (x18 / treat-04
                              :polarity "-"
                              :ARG1 (x16 / enzyme
                                    :name (x17 / name :op1 "imatinib"))))))
      :ARG2 (x20 / antibody
            :ARG0-of (x24 / counter-01
                  :ARG1 (x21 / amino-acid
                        :name (x22 / name :op1 "threonine")
                        :ARG3-of (x23 / phosphorylate-01)
                        :xref (x29 / xref :value "PUBCHEM:205" :prob "11.848252")))
            :ARG1-of (x25 / counter-01
                  :ARG1 (x26 / protein
                        :name (x27 / name :op1 "pTyr")))))


# ::id PMC4302068.44
# ::snt A prominent tyrosine-phosphorylated band of ∼64 kDa was seen in CrkI-overexpressing cells when compared to the controls, the phosphorylation of which was strongly reduced upon imatinib treatment ( Fig. 1b ).
# ::tok A prominent tyrosine @-@ phosphorylated band of ∼64 kDa was seen in CrkI @-@ overexpressing cells when compared to the controls , the phosphorylation of which was strongly reduced upon imatinib treatment ( Fig . 1b ) .
(x8 / see-01
      :ARG1 (x5 / band
            :mod (x1 / prominent)
            :mod (x4 / phosphorylate-01
                  :ARG1 (x2 / amino-acid
                        :name (x3 / name :op1 "tyrosine")
                        :xref (x23 / xref :value "PUBCHEM:1153" :prob "11.081481")))
            :consist-of (x7 / kilodalton
                  :name (x6 / name :op1 "∼64")))
      :location (x12 / cell
            :mod (x11 / overexpress-01
                  :ARG1 (x9 / enzyme
                        :name (x10 / name :op1 "CrkI")
                        :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))
      :time (x15 / phosphorylate-01
            :ARG1-of (x13 / compare-01
                  :ARG2 (x14 / control-01))
            :ARG1 (x17 / reduce-01
                  :ARG1-of (x16 / strong-02)
                  :ARG0 (x20 / treat-04
                        :ARG2 (x18 / small-molecule
                              :name (x19 / name :op1 "imatinib")
                              :xref (x24 / xref :value "PUBCHEM:5291" :prob "16.088081")))))
      :ARG1-of (x21 / describe-01
            :ARG0 (x22 / figure :mod "1b")))


# ::id PMC4302068.45
# ::snt Based on known substrates of Abl and the apparent molecular weight, we surmised this phosphoprotein might be Dok1 ( 31 ).
# ::tok Based on known substrates of Abl and the apparent molecular weight , we surmised this phosphoprotein might be Dok1 ( 31 ) .
(x13 / possible-01
      :ARG1-of (x1 / base-02
            :ARG2 (x3 / substrate
                  :ARG1-of (x2 / know-01)
                  :poss (x6 / and
                        :op1 (x4 / protein
                              :name (x5 / name :op1 "Abl")
                              :xref (x19 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603"))
                        :op2 (x9 / weight-01
                              :ARG1-of (x7 / appear-01)
                              :mod (x8 / molecule)
                              :ARG0 (x10 / we)
                              :ARG1 (x11 / this)))))
      :ARG1-of (x12 / phosphoprotein)
      :ARG1 (x14 / protein
            :name (x15 / name :op1 "Dok1")
            :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / publication
                  :ARG1-of (x18 / cite-01 :ARG2 "31"))))


# ::id PMC4302068.47
# ::snt This treatment depleted the 64 kDa tyrosine-phosphorylated protein from the lysates, verifying its identity as Dok1 ( Fig. 1c ).
# ::tok This treatment depleted the 64 kDa tyrosine @-@ phosphorylated protein from the lysates , verifying its identity as Dok1 ( Fig . 1c ) .
(x11 / verify-01
      :ARG1 (x3 / deplete-01
            :ARG0 (x2 / treat-04
                  :mod (x1 / this))
            :ARG1 (x9 / protein
                  :mod (x4 / mass-quantity
                        :quant "64"
                        :unit (x5 / kilodalton))
                  :ARG0-of (x8 / phosphorylate-01
                        :ARG1 (x6 / amino-acid
                              :name (x7 / name :op1 "tyrosine")
                              :xref (x17 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                  :source (x10 / lysate)))
      :ARG1 (x12 / and
            :op1 (x13 / protein
                  :name (x14 / name :op1 "Dok1")
                  :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
      :ARG1-of (x15 / describe-01
            :ARG0 (x16 / figure :mod "1c")))


# ::id PMC4302068.48
# ::snt Immunoblotting with a phosphospecific antibody recognizing pY362 of human Dok1 (pY361 in mouse Dok1) further confirmed the dependence of Dok1 phosphorylation on Abl activity ( Fig. 1d ).
# ::tok Immunoblotting with a phosphospecific antibody recognizing pY362 of human Dok1 ( pY361 in mouse Dok1 ) further confirmed the dependence of Dok1 phosphorylation on Abl activity ( Fig . 1d ) .
(x14 / confirm-01
      :ARG0 (x1 / immunoblot-01
            :ARG3 (x2 / antibody
                  :ARG0-of (x3 / recognize-02
                        :ARG1 (x4 / protein-segment
                              :name (x5 / name :op1 "pY362")
                              :part-of (x6 / human
                                    :mod (x7 / protein
                                          :name (x8 / name :op1 "Dok1")
                                          :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
                              :name (x9 / name :op1 "pY361"))
                        :location (x10 / mouse
                              :mod (x11 / protein
                                    :name (x12 / name :op1 "Dok1")
                                    :xref (x25 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))))
      :degree (x13 / further)
      :ARG1 (x15 / depend-01
            :ARG0 (x18 / phosphorylate-01
                  :ARG1 (x16 / protein
                        :name (x17 / name :op1 "Dok1")
                        :xref (x26 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
            :ARG1 (x21 / activity-06
                  :ARG0 (x19 / protein
                        :name (x20 / name :op1 "Abl")
                        :xref (x24 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603"))))
      :ARG1-of (x22 / describe-01
            :ARG0 (x23 / figure :mod "1d")))


# ::id PMC4302068.49
# ::snt Dok1 corresponded to the only prominent tyrosine-phosphorylated band in CrkI-transformed cells that was Abl-dependent.
# ::tok Dok1 corresponded to the only prominent tyrosine @-@ phosphorylated band in CrkI @-@ transformed cells that was Abl @-@ dependent .
(x3 / correspond-02
      :ARG1 (x1 / protein
            :name (x2 / name :op1 "Dok1")
            :xref (x18 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
      :ARG2 (x9 / band
            :mod (x4 / only)
            :mod (x5 / prominent)
            :mod (x8 / phosphorylate-01
                  :ARG1 (x6 / amino-acid
                        :name (x7 / name :op1 "tyrosine")
                        :xref (x19 / xref :value "PUBCHEM:1153" :prob "11.081481"))))
      :location (x13 / cell-line
            :ARG1-of (x12 / transform-01
                  :ARG0 (x10 / enzyme
                        :name (x11 / name :op1 "CrkI")
                        :xref (x17 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
            :ARG0-of (x16 / depend-01
                  :ARG1 (x14 / protein
                        :name (x15 / name :op1 "Abl")
                        :xref (x / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603")))))


# ::id PMC4302068.50
# ::snt Somewhat paradoxically, Dok1 phosphorylation was increased in CrkI-transformed cells compared to normal control cells ( Fig. 1b ).
# ::tok Somewhat paradoxically , Dok1 phosphorylation was increased in CrkI @-@ transformed cells compared to normal control cells ( Fig . 1b ) .
(x6 / increase-01
      :ARG1 (x5 / phosphorylate-01
            :degree (x1 / somewhat)
            :ARG2 (x2 / paradoxical)
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "Dok1")
                  :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
      :location (x10 / cell
            :ARG1-of (x9 / transform-01
                  :ARG0 (x7 / enzyme
                        :name (x8 / name :op1 "CrkI")
                        :xref (x16 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))
      :compared-to (x13 / cell
            :mod (x12 / control-01
                  :ARG1-of (x11 / normal-02)))
      :ARG1-of (x14 / describe-01
            :ARG0 (x15 / figure :mod "1b")))


# ::id PMC4302068.51
# ::snt Together, these data suggest that tyrosine phosphorylation of Dok1 by Abl is induced by CrkI overexpression, and may act to partially suppress Crk-mediated transformation.
# ::tok Together , these data suggest that tyrosine phosphorylation of Dok1 by Abl is induced by CrkI overexpression , and may act to partially suppress Crk @-@ mediated transformation .
(x4 / suggest-01
      :ARG0 (x3 / data
            :mod (x1 / together)
            :mod (x2 / this))
      :ARG1 (x24 / transform-01
            :ARG0 (x5 / phosphorylate-01
                  :ARG1 (x6 / amino-acid
                        :name (x7 / name :op1 "tyrosine")
                        :part-of (x8 / protein
                              :name (x9 / name :op1 "Dok1")
                              :xref (x25 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                        :xref (x28 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :manner (x16 / and
                        :op1 (x12 / induce-01
                              :ARG2 (x10 / protein
                                    :name (x11 / name :op1 "Abl")
                                    :xref (x26 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603"))
                              :ARG0 (x15 / overexpress-01
                                    :ARG1 (x13 / enzyme
                                          :name (x14 / name :op1 "CrkI")
                                          :xref (x27 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))
                        :op2 (x17 / possible-01
                              :ARG1 (x18 / act-01
                                    :purpose (x20 / suppress-01
                                          :degree (x19 / part))))))
            :ARG1-of (x23 / mediate-01
                  :ARG0 (x21 / protein
                        :name (x22 / name :op1 "Crk")
                        :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604")))))


# ::id PMC4302068.52
# ::snt Phosphorylation of Dok1 regulates CrkI transformation
# ::tok Phosphorylation of Dok1 regulates CrkI transformation
(x4 / regulate-01
      :ARG0 (x1 / phosphorylate-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "Dok1")
                  :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
      :ARG1 (x7 / transform-01
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "CrkI")
                  :xref (x8 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))


# ::id PMC4302068.53
# ::snt To test whether Dok1 is acting as a tumor suppressor protein in this system, we knocked down Dok1 expression in CrkI overexpressing cells using shRNA ( Fig. 2b ).
# ::tok To test whether Dok1 is acting as a tumor suppressor protein in this system , we knocked down Dok1 expression in CrkI overexpressing cells using shRNA ( Fig . 2b ) .
(x10 / knock-down-02
      :purpose (x1 / test-01
            :ARG1 (x4 / act-01
                  :mode "interrogative"
                  :ARG2 (x2 / protein
                        :name (x3 / name :op1 "Dok1")
                        :xref (x20 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                  :ARG1 (x6 / suppress-01
                        :ARG1 (x5 / tumor)
                        :location (x8 / system
                              :mod (x7 / this)))))
      :ARG0 (x9 / we)
      :ARG1 (x13 / express-03
            :ARG2 (x11 / protein
                  :name (x12 / name :op1 "Dok1")
                  :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
      :location (x14 / cell
            :ARG0-of (x16 / overexpress-01
                  :name (x15 / name :op1 "CrkI"))
            :name (x17 / name :op1 "shRNA"))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / figure :mod "2b")))


# ::id PMC4302068.54
# ::snt We observed an enhancement of soft agar colony formation upon Dok1 knockdown, comparable to the effect of Abl knockdown or imatinib treatment ( Fig. 2c ), implicating Dok1 as a crucial regulator of CrkI transformation.
# ::tok We observed an enhancement of soft agar colony formation upon Dok1 knockdown , comparable to the effect of Abl knockdown or imatinib treatment ( Fig . 2c ) , implicating Dok1 as a crucial regulator of CrkI transformation .
(x2 / observe-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / enhance-01
            :ARG1 (x7 / form-01
                  :ARG1 (x6 / colony
                        :mod (x5 / agar
                              :ARG1-of (x4 / soft-02)))))
      :time (x10 / knock-down-02
            :ARG1 (x8 / protein
                  :name (x9 / name :op1 "Dok1")
                  :xref (x31 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
      :ARG1-of (x11 / comparable-03
            :ARG2 (x12 / affect-01
                  :ARG0 (x15 / knock-down-02
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "Abl")
                              :xref (x32 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603")))
                  :ARG1 (x16 / or
                        :op1 (x19 / treat-04
                              :ARG2 (x17 / small-molecule
                                    :name (x18 / name :op1 "imatinib")
                                    :xref (x33 / xref :value "PUBCHEM:5291" :prob "16.088081"))))))
      :ARG1-of (x20 / describe-01
            :ARG0 (x21 / figure :mod "2c"))
      :ARG0-of (x22 / implicate-01
            :ARG2 (x26 / regulate-01
                  :ARG1 (x23 / protein
                        :name (x24 / name :op1 "Dok1")
                        :xref (x30 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                  :mod (x25 / crucial)
                  :ARG1 (x29 / transform-01
                        :ARG1 (x27 / enzyme
                              :name (x28 / name :op1 "CrkI")
                              :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))))


# ::id PMC4302068.55
# ::snt To further probe the significance of Dok1 in suppressing CrkI-mediated transformation, the human homolog of Dok1 (hDok1) was used for rescue experiments.
# ::tok To further probe the significance of Dok1 in suppressing CrkI @-@ mediated transformation , the human homolog of Dok1 ( hDok1 ) was used for rescue experiments .
(x16 / use-01
      :purpose (x2 / probe-01
            :degree (x1 / further)
            :ARG1 (x3 / signify-01
                  :ARG0 (x4 / protein
                        :name (x5 / name :op1 "Dok1")
                        :xref (x20 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                  :manner (x6 / suppress-01
                        :ARG1 (x10 / transform-01
                              :ARG1-of (x9 / mediate-01
                                    :ARG0 (x7 / enzyme
                                          :name (x8 / name :op1 "CrkI")
                                          :xref (x19 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))))))
      :ARG1 (x12 / homolog
            :mod (x11 / human)
            :part-of (x13 / protein
                  :name (x14 / name :op1 "Dok1")
                  :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
            :name (x15 / name :op1 "hDok1"))
      :ARG2 (x17 / rescue-01
            :ARG1 (x18 / experiment-01)))


# ::id PMC4302068.56
# ::snt We used human instead of mouse Dok1 to avoid its being targeted for shRNA-mediated knockdown.
# ::tok We used human instead of mouse Dok1 to avoid its being targeted for shRNA @-@ mediated knockdown .
(x2 / use-01
      :ARG0 (x1 / we)
      :ARG1 (x4 / instead-of-91
            :mod (x3 / human))
      :ARG1 (x5 / mouse
            :mod (x6 / protein
                  :name (x7 / name :op1 "Dok1")
                  :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
      :purpose (x8 / avoid-01
            :ARG1 (x9 / target-01
                  :ARG0 (x13 / knock-down-02
                        :ARG1-of (x12 / mediate-01
                              :ARG0 (x10 / nucleic-acid
                                    :name (x11 / name :op1 "shRNA")))))))


# ::id PMC4302068.57
# ::snt The human homolog of Dok1 has an insertion at position 271, which shifts the amino acid numbering C-terminal to the insertion by +1 compared to mouse.
# ::tok The human homolog of Dok1 has an insertion at position 271 , which shifts the amino acid numbering C @-@ terminal to the insertion by +1 compared to mouse .
(x5 / have-03
      :ARG0 (x1 / human
            :ARG1-of (x2 / homolog
                  :poss (x3 / protein
                        :name (x4 / name :op1 "Dok1")
                        :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))
      :ARG1 (x7 / position-02
            :mod (x6 / insert-01)
            :quant "271")
      :ARG0-of (x8 / shift-01
            :ARG1 (x11 / protein-segment
                  :mod (x9 / amino-acid
                        :name (x10 / name :op1 "numbering"))
                  :name (x12 / name :op1 "c-terminus"))
            :ARG2 (x13 / insert-01
                  :ARG0 (x14 / person
                        :quant "1"
                        :ARG0-of (x15 / compare-01
                              :ARG2 (x16 / mouse))))))


# ::id PMC4302068.58
# ::snt For simplicity, henceforth the mouse amino acid numbering will be used unless stated otherwise.
# ::tok For simplicity , henceforth the mouse amino acid numbering will be used unless stated otherwise .
(x8 / state-01
      :purpose (x1 / simplicity)
      :ARG0 (x2 / henceforth
            :op1 (x6 / use-01
                  :ARG1 (x3 / mouse
                        :mod (x4 / amino-acid
                              :name (x5 / name :op1 "numbering")))
                  :time (x7 / unless)))
      :ARG1 (x9 / otherwise))


# ::id PMC4302068.59
# ::snt In addition to the wild-type (WT) hDok1, we also generated mutant constructs to test the importance of several potential tyrosine phosphorylation sites.
# ::tok In addition to the wild @-@ type ( WT ) hDok1 , we also generated mutant constructs to test the importance of several potential tyrosine phosphorylation sites .
(x1 / add-02
      :ARG2 (x2 / enzyme
            :mod (x3 / wild-type)
            :name (x4 / name :op1 "hDok1"))
      :ARG1 (x6 / generate-01
            :ARG0 (x5 / we)
            :ARG1 (x7 / mutate-01)
            :ARG1 (x8 / construct-01)
            :purpose (x9 / test-01
                  :ARG1 (x10 / important
                        :domain (x16 / site
                              :quant (x11 / several)
                              :mod (x15 / phosphorylate-01
                                    :mod (x12 / potential)
                                    :ARG1 (x13 / amino-acid
                                          :name (x14 / name :op1 "tyrosine")
                                          :xref (x / xref :value "PUBCHEM:1153" :prob "11.081481"))))))))


# ::id PMC4302068.60
# ::snt Shinohara et al.
# ::tok Shinohara et al.
(x3 / and
      :op1 (x1 / enzyme
            :name (x2 / name :op1 "Shinohara"))
      :op2 (x4 / person
            :mod (x5 / other)))


# ::id PMC4302068.61
# ::snt Both Ras and its activator Sos1 were previously shown to play essential roles in Crk transformation ( 11 , 42 ), and the MEK/ERK pathway downstream of Ras is well known to promote cell proliferation ( 43 ).
# ::tok Both Ras and its activator Sos1 were previously shown to play essential roles in Crk transformation ( 11 , 42 ) , and the MEK @/@ ERK pathway downstream of Ras is well known to promote cell proliferation ( 43 ) .
(x8 / show-01
      :ARG1 (x1 / and
            :op1 (x2 / enzyme
                  :name (x3 / name :op1 "Ras")
                  :xref (x34 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
            :op2 (x4 / activate-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "Sos1")
                        :xref (x35 / xref :value "UNIPROT:SOS1_HUMAN" :prob "0.604"))))
      :time (x7 / previous)
      :ARG1 (x9 / play-02
            :ARG1 (x11 / role
                  :mod (x10 / essential)
                  :topic (x19 / and
                        :op1 (x14 / transform-01
                              :ARG1 (x12 / protein
                                    :name (x13 / name :op1 "Crk")
                                    :xref (x36 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604"))
                              :ARG1-of (x15 / describe-01
                                    :ARG0 (x16 / publication
                                          :ARG1-of (x17 / cite-01
                                                :ARG2 (x18 / and :op1 "11" :op2 "42")))))
                        :op2 (x20 / pathway
                              :name (x21 / name :op1 "MEK/ERK"))))
            :ARG1-of (x27 / know-02
                  :domain (x22 / relative-position
                        :direction (x23 / downstream)
                        :op1 (x24 / enzyme
                              :name (x25 / name :op1 "Ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                  :degree (x26 / well))
            :ARG2 (x28 / promote-01
                  :ARG1 (x30 / proliferate-01
                        :ARG0 (x29 / cell))))
      :ARG1-of (x31 / describe-01
            :ARG0 (x32 / publication
                  :ARG1-of (x33 / cite-01 :ARG2 "43"))))


# ::id PMC4302068.62
# ::snt Using site-directed mutagenesis, putative tyrosine phosphorylation sites were changed to phenylalanine.
# ::tok Using site @-@ directed mutagenesis , putative tyrosine phosphorylation sites were changed to phenylalanine .
(x10 / change-01
      :ARG0 (x1 / use-01
            :ARG1 (x2 / protein-segment
                  :ARG1-of (x3 / direct-01
                        :ARG2 (x9 / protein-segment
                              :name (x4 / name :op1 "mutagenesis")
                              :ARG1-of (x5 / think-01
                                    :ARG2 (x8 / phosphorylate-01
                                          :ARG1 (x6 / enzyme
                                                :name (x7 / name :op1 "tyrosine")
                                                :xref (x / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))))))))
      :ARG1 (x11 / amino-acid
            :name (x12 / name :op1 "phenylalanine")))


# ::id PMC4302068.63
# ::snt The resulting constructs were named according to the tyrosines mutated ( Fig. 2a ): M14 for mutation of sites 1 and 4 (Y295 and Y361), M23 for mutation of sites 2 and 3 (Y336 and Y340), M-all for mutation of all four sites, M1 for mutation of Y295, and M4 for mutation of Y361.
# ::tok The resulting constructs were named according to the tyrosines mutated ( Fig . 2a ) : M14 for mutation of sites 1 and 4 ( Y295 and Y361 ) , M23 for mutation of sites 2 and 3 ( Y336 and Y340 ) , M @-@ all for mutation of all four sites , M1 for mutation of Y295 , and M4 for mutation of Y361 .
(x1 / multi-sentence
      :snt1 (x4 / name-01
            :ARG0 (x2 / result-01
                  :ARG2 (x3 / construct-01))
            :ARG1-of (x5 / conform-01
                  :ARG2 (x8 / mutate-01
                        :ARG1 (x6 / amino-acid
                              :name (x7 / name :op1 "tyrosine")
                              :xref (x53 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :ARG1-of (x9 / describe-01
                              :ARG0 (x10 / figure :mod "2a"))))
            :ARG1 (x11 / amino-acid
                  :mod "14"
                  :name (x12 / name :op1 "methionine"))
            :ARG2 (x15 / and
                  :op1 (x13 / mutate-01
                        :ARG1 (x14 / protein-segment :mod "1"))
                  :op2 (x16 / protein
                        :name (x17 / name :op1 "il-4")
                        :xref (x / xref :value "UNIPROT:IL4_HUMAN" :prob "0.653")))
            :ARG1-of (x20 / and
                  :op1 (x18 / amino-acid
                        :mod "295"
                        :name (x19 / name :op1 "tyrosine")
                        :xref (x56 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :op1 (x21 / amino-acid
                        :mod "361"
                        :name (x22 / name :op1 "tyrosine")
                        :xref (x52 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :op2 (x23 / amino-acid
                        :mod "23"
                        :name (x24 / name :op1 "methionine")))
            :ARG0 (x25 / mutate-01
                  :ARG1 (x26 / protein-segment :mod "2")))
      :snt2 (x27 / and
            :op2 "3"
            :ARG1-of (x28 / describe-01
                  :ARG0 (x29 / and
                        :op1 (x30 / amino-acid
                              :mod "336"
                              :name (x31 / name :op1 "tyrosine")
                              :xref (x55 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :op2 (x32 / amino-acid
                              :mod "340"
                              :name (x33 / name :op1 "tyrosine")
                              :xref (x54 / xref :value "PUBCHEM:1153" :prob "11.081481"))))
            :ARG0-of (x37 / mutate-01
                  :ARG1 (x34 / enzyme
                        :name (x35 / name :op1 "M")
                        :mod (x36 / all))
                  :ARG1 (x39 / protein-segment
                        :mod (x38 / all)
                        :quant "4"
                        :name (x40 / name :op1 "M1"))
                  :ARG3 (x44 / and
                        :op1 (x41 / mutate-01
                              :ARG1 (x42 / amino-acid
                                    :mod "295"
                                    :name (x43 / name :op1 "tyrosine")
                                    :xref (x50 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                        :op2 (x45 / enzyme
                              :name (x46 / name :op1 "M4")))
                  :ARG2 (x47 / mutate-01
                        :ARG1 (x48 / amino-acid
                              :mod "361"
                              :name (x49 / name :op1 "tyrosine")
                              :xref (x51 / xref :value "PUBCHEM:1153" :prob "11.081481"))))))


# ::id PMC4302068.64
# ::snt These constructs were re-expressed in the CrkI-transformed Dok1 knockdown cells ( Fig. 2b ) and cells assayed for anchorage-independent growth in soft agar ( Fig. 2c ).
# ::tok These constructs were re @-@ expressed in the CrkI @-@ transformed Dok1 knockdown cells ( Fig . 2b ) and cells assayed for anchorage @-@ independent growth in soft agar ( Fig . 2c ) .
(x4 / express-03
      :ARG1 (x2 / construct
            :mod (x1 / this))
      :mod (x3 / again)
      :location (x11 / cell
            :ARG1-of (x7 / transform-01
                  :ARG0 (x5 / enzyme
                        :name (x6 / name :op1 "CrkI")
                        :xref (x24 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
            :mod (x10 / knock-down-02
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "Dok1")
                        :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))
      :ARG1-of (x12 / describe-01
            :ARG0 (x14 / and
                  :op1 (x13 / figure :mod "2b")
                  :op2 (x16 / assay-01
                        :ARG1 (x15 / cell)
                        :ARG1 (x19 / grow-01
                              :ARG0-of (x18 / depend-01
                                    :ARG1 (x17 / anchorage)
                                    :polarity "-")
                              :location (x21 / agar
                                    :ARG1-of (x20 / soft-02)))
                        :ARG1-of (x22 / describe-01
                              :ARG0 (x23 / figure :mod "2c"))))))


# ::id PMC4302068.65
# ::snt Expression of the WT Dok1 or the M23 mutant rescued the phenotype (enhanced CrkI transformation) caused by Dok1 knockdown; in fact, transforming activity of rescued cells was even lower than cells expressing endogenous amounts of Dok1.
# ::tok Expression of the WT Dok1 or the M23 mutant rescued the phenotype ( enhanced CrkI transformation ) caused by Dok1 knockdown ; in fact , transforming activity of rescued cells was even lower than cells expressing endogenous amounts of Dok1 .
(x9 / rescue-01
      :ARG0 (x1 / express-03
            :ARG2 (x5 / or
                  :op1 (x2 / enzyme
                        :mod (x3 / wild-type)
                        :name (x4 / name :op1 "Dok1")
                        :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                  :op2 (x8 / mutate-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "M23")))))
      :ARG1 (x10 / phenotype
            :ARG1-of (x14 / transform-01
                  :ARG1-of (x11 / enhance-01)
                  :ARG1 (x12 / enzyme
                        :name (x13 / name :op1 "CrkI")
                        :xref (x34 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
            :ARG1-of (x15 / cause-01
                  :ARG0 (x18 / knock-down-02
                        :ARG1 (x16 / protein
                              :name (x17 / name :op1 "Dok1")
                              :xref (x35 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
                  :ARG1 (x21 / activity-06
                        :mod (x19 / in-fact)
                        :ARG1 (x20 / transform-01)))
            :ARG1 (x22 / rescue-01
                  :ARG1 (x23 / cell)
                  :mod (x24 / even)
                  :ARG1-of (x25 / low-04
                        :degree (x26 / more)
                        :compared-to (x27 / cell
                              :ARG3-of (x28 / express-03
                                    :ARG2 (x30 / amount
                                          :mod (x29 / endogenous)
                                          :quant-of (x31 / protein
                                                :name (x32 / name :op1 "Dok1")
                                                :xref (x33 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))))))))


# ::id PMC4302068.66
# ::snt On the other hand, knockdown cells expressing the M14 and M-all mutants showed an even greater increase in colony formation than seen with Dok1 knockdown alone.
# ::tok On the other hand , knockdown cells expressing the M14 and M @-@ all mutants showed an even greater increase in colony formation than seen with Dok1 knockdown alone .
(x12 / show-01
      :ARG1-of (x1 / on-the-other-hand)
      :ARG0 (x2 / knock-down-02
            :ARG1 (x7 / and
                  :op1 (x3 / cell
                        :ARG3-of (x4 / express-03
                              :ARG2 (x5 / protein
                                    :name (x6 / name :op1 "M14"))))
                  :op2 (x8 / enzyme
                        :name (x9 / name :op1 "M")
                        :ARG1-of (x11 / mutate-01
                              :mod (x10 / all)))))
      :ARG1 (x16 / increase-01
            :degree (x14 / great
                  :mod (x13 / even)
                  :degree (x15 / more))
            :ARG1 (x18 / form-01
                  :ARG1 (x17 / colony))
            :compared-to (x19 / see-01
                  :ARG2 (x22 / knock-down-02
                        :ARG1 (x20 / protein
                              :name (x21 / name :op1 "Dok1")
                              :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))))


# ::id PMC4302068.67
# ::snt Expression of single mutants (M1 and M4) partially rescued the Dok1 knockdown phenotype.
# ::tok Expression of single mutants ( M1 and M4 ) partially rescued the Dok1 knockdown phenotype .
(x12 / rescue-01
      :ARG0 (x1 / express-03
            :ARG2 (x3 / mutate-01
                  :ARG1-of (x2 / single-02))
            :ARG1-of (x4 / describe-01
                  :ARG0 (x5 / publication-91
                        :ARG0 (x8 / and
                              :op1 (x6 / person
                                    :name (x7 / name :op1 "M1"))
                              :op2 (x9 / enzyme
                                    :name (x10 / name :op1 "M4"))))))
      :degree (x11 / part)
      :ARG1 (x15 / knock-down-02
            :ARG1 (x13 / protein
                  :name (x14 / name :op1 "Dok1")
                  :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
      :ARG1 (x16 / phenotype))


# ::id PMC4302068.68
# ::snt These results suggested that Y295 and Y361 work together to suppress CrkI tumorigenesis when phosphorylated.
# ::tok These results suggested that Y295 and Y361 work together to suppress CrkI tumorigenesis when phosphorylated .
(x4 / suggest-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x10 / work-01
            :ARG1 (x5 / and
                  :op1 (x6 / amino-acid
                        :mod "295"
                        :name (x7 / name :op1 "tyrosine")
                        :xref (x17 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :op2 (x8 / amino-acid
                        :mod "361"
                        :name (x9 / name :op1 "tyrosine")
                        :xref (x16 / xref :value "PUBCHEM:1153" :prob "11.081481")))
            :ARG1 (x11 / suppress-01
                  :ARG1 (x14 / tumor
                        :mod (x12 / protein
                              :name (x13 / name :op1 "CrkI")
                              :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))
            :time (x15 / phosphorylate-01)))


# ::id PMC4302068.69
# ::snt Dok1 knockdown followed by re-expression of WT or mutant Dok1 in control NIH3T3 cells yielded no colonies (data not shown), consistent with the effect of Dok1 tumor suppression being specific to cells transformed by Crk.
# ::tok Dok1 knockdown followed by re @-@ expression of WT or mutant Dok1 in control NIH3T3 cells yielded no colonies ( data not shown ) , consistent with the effect of Dok1 tumor suppression being specific to cells transformed by Crk .
(x14 / yield-01
      :ARG0 (x3 / knock-down-02
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "Dok1")
                  :xref (x32 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
      :ARG0 (x4 / follow-01
            :ARG1 (x6 / express-03
                  :mod (x5 / again)
                  :ARG2 (x7 / or
                        :op2 (x8 / mutate-01
                              :ARG2 (x9 / protein
                                    :name (x10 / name :op1 "Dok1")
                                    :xref (x31 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))
                  :ARG3 (x13 / cell-line
                        :ARG0-of (x11 / control-01)
                        :name (x12 / name :op1 "NIH3T3"))))
      :ARG1 (x15 / colony :polarity "-")
      :ARG1-of (x16 / describe-01
            :ARG0 (x17 / data
                  :ARG1-of (x18 / show-01 :polarity "-")))
      :ARG1-of (x19 / consistent-01
            :ARG2 (x20 / affect-01
                  :ARG1 (x24 / suppress-01
                        :ARG1 (x23 / tumor
                              :mod (x21 / protein
                                    :name (x22 / name :op1 "Dok1")
                                    :xref (x30 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))
                  :ARG1-of (x25 / specific-02
                        :ARG2 (x26 / cell
                              :ARG1-of (x27 / transform-01
                                    :ARG0 (x28 / protein
                                          :name (x29 / name :op1 "Crk")
                                          :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604"))))))))


# ::id PMC4302068.70
# ::snt We also tested the effect of simple Dok1 overexpression in CrkI-transformed NIH3T3 cells ( Fig. 2d ).
# ::tok We also tested the effect of simple Dok1 overexpression in CrkI @-@ transformed NIH3T3 cells ( Fig . 2d ) .
(x2 / test-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / affect-01
            :ARG0 (x7 / overexpress-01
                  :ARG1-of (x4 / simple-02)
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "Dok1")
                        :xref (x15 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                  :location (x12 / cell-line
                        :ARG1-of (x10 / transform-01
                              :ARG0 (x8 / enzyme
                                    :name (x9 / name :op1 "CrkI")
                                    :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
                        :name (x11 / name :op1 "NIH3T3"))))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure :mod "2d")))


# ::id PMC4302068.71
# ::snt Consistent with its role as a putative tumor suppressor, over-expression of WT Dok1 and the M23 Dok1 mutant both suppressed CrkI transformation in the soft agar assay; by contrast, the M14 and M-all mutants enhanced CrkI transformation ( Fig. 2e ).
# ::tok Consistent with its role as a putative tumor suppressor , over @-@ expression of WT Dok1 and the M23 Dok1 mutant both suppressed CrkI transformation in the soft agar assay ; by contrast , the M14 and M @-@ all mutants enhanced CrkI transformation ( Fig . 2e ) .
(x17 / suppress-01
      :ARG1-of (x1 / consistent-01
            :ARG2 (x2 / role)
            :ARG1-of (x3 / think-01
                  :ARG1 (x5 / suppress-01
                        :ARG1 (x4 / tumor))))
      :ARG0 (x6 / overexpress-01
            :ARG1 (x10 / and
                  :op1 (x7 / enzyme
                        :mod (x8 / wild-type)
                        :name (x9 / name :op1 "Dok1")
                        :xref (x38 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                  :op2 (x11 / amino-acid
                        :mod "23"
                        :name (x12 / name :op1 "methionine"))))
      :time (x16 / and
            :ARG0-of (x15 / mutate-01
                  :ARG2 (x13 / protein
                        :name (x14 / name :op1 "Dok1")
                        :xref (x40 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))
      :ARG1 (x20 / transform-01
            :ARG0 (x18 / enzyme
                  :name (x19 / name :op1 "CrkI")
                  :xref (x39 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))
            :ARG1 (x21 / and
                  :op1 (x24 / assay-01
                        :ARG1 (x23 / agar
                              :ARG1-of (x22 / soft-02)))
                  :op2 (x25 / contrast-01
                        :ARG2 (x28 / and
                              :op1 (x26 / amino-acid
                                    :mod "14"
                                    :name (x27 / name :op1 "methionine"))
                              :op2 (x35 / transform-01
                                    :ARG1 (x29 / enzyme
                                          :name (x30 / name :op1 "M")
                                          :ARG1-of (x32 / mutate-01
                                                :mod (x31 / all)
                                                :ARG1-of (x33 / enhance-01))
                                          :name (x34 / name :op1 "CrkI")
                                          :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))
                        :ARG1-of (x36 / describe-01
                              :ARG0 (x37 / figure :mod "2e"))))))


# ::id PMC4302068.72
# ::snt This demonstrates that expression of Dok1 mutants that cannot be phosphorylated at sites 295 and 361 exerts a dominant-negative (pro-oncogenic) effect over endogenous Dok1.
# ::tok This demonstrates that expression of Dok1 mutants that cannot be phosphorylated at sites 295 and 361 exerts a dominant @-@ negative ( pro @-@ oncogenic ) effect over endogenous Dok1 .
(x2 / demonstrate-01
      :ARG0 (x1 / this)
      :ARG1 (x12 / exert-01
            :ARG0-of (x6 / mutate-01
                  :ARG1 (x3 / express-03
                        :ARG2 (x4 / protein
                              :name (x5 / name :op1 "Dok1")
                              :xref (x24 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))
            :ARG0 (x11 / and
                  :ARG1-of (x7 / possible-01
                        :polarity "-"
                        :ARG1 (x8 / phosphorylate-01
                              :ARG1 (x9 / protein-segment
                                    :name (x10 / name :op1 "295"))))
                  :quant "361")
            :ARG1 (x20 / affect-01
                  :ARG0 (x13 / enzyme
                        :ARG0-of (x14 / dominate-01)
                        :ARG2-of (x15 / mutate-01 :mod "-/-")
                        :ARG1-of (x16 / favor-01
                              :ARG1 (x17 / cause-01
                                    :ARG1 (x18 / disease
                                          :wiki "cancer"
                                          :name (x19 / name :op1 "cancer")))))
                  :ARG1 (x21 / enzyme
                        :mod (x22 / endogenous)
                        :name (x23 / name :op1 "Dok1")
                        :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))))


# ::id PMC4302068.73
# ::snt Surprisingly, overexpression of the M1 and M4 single mutants showed a greater suppression of transformation than seen for WT Dok1.
# ::tok Surprisingly , overexpression of the M1 and M4 single mutants showed a greater suppression of transformation than seen for WT Dok1 .
(x10 / show-01
      :ARG0-of (x1 / surprise-01)
      :ARG0 (x2 / overexpress-01
            :ARG1 (x5 / and
                  :op1 (x3 / enzyme
                        :name (x4 / name :op1 "M1"))
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "M4"))
                  :op2 (x9 / mutate-01
                        :ARG1-of (x8 / single-02))))
      :ARG1 (x13 / suppress-01
            :degree (x11 / great
                  :degree (x12 / more))
            :ARG1 (x14 / transform-01)
            :compared-to (x15 / see-01)
            :ARG1 (x16 / enzyme
                  :mod (x17 / wild-type)
                  :name (x18 / name :op1 "Dok1")
                  :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))


# ::id PMC4302068.74
# ::snt Once again, these results were CrkI-dependent, as no colonies were seen in control 3T3 cells overexpressing Dok1 mutants (data not shown).
# ::tok Once again , these results were CrkI @-@ dependent , as no colonies were seen in control 3T3 cells overexpressing Dok1 mutants ( data not shown ) .
(x8 / depend-01
      :mod (x2 / again
            :mod (x1 / once))
      :ARG0 (x4 / thing
            :mod (x3 / this)
            :ARG2-of (x5 / result-01))
      :ARG1 (x6 / small-molecule
            :name (x7 / name :op1 "CrkI"))
      :ARG1-of (x10 / see-01
            :polarity "-"
            :ARG1 (x9 / colony)
            :location (x13 / cell-line
                  :ARG0-of (x11 / control-01)
                  :name (x12 / name :op1 "3T3")
                  :ARG0-of (x14 / overexpress-01
                        :ARG1 (x15 / protein
                              :name (x16 / name :op1 "Dok1")
                              :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
                  :ARG2-of (x17 / mutate-01))
            :ARG1-of (x18 / describe-01
                  :ARG0 (x19 / data
                        :ARG1-of (x20 / show-01 :polarity "-")))))


# ::id PMC4302068.75
# ::snt SH2 domain binding partners of tyrosine-phosphorylated Dok1
# ::tok SH2 domain binding partners of tyrosine @-@ phosphorylated Dok1
(x3 / bind-01
      :ARG1 (x1 / protein-segment
            :name (x2 / name :op1 "SH2" :op2 "domain"))
      :ARG1-of (x4 / partner-01
            :ARG2 (x7 / phosphorylate-01
                  :ARG1 (x5 / amino-acid
                        :name (x6 / name :op1 "tyrosine")
                        :xref (x10 / xref :value "PUBCHEM:1153" :prob "11.081481")))
            :ARG1 (x8 / protein
                  :name (x9 / name :op1 "Dok1")
                  :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))


# ::id PMC4302068.76
# ::snt Most tyrosine-phosphorylated sites function in signaling by binding to the SH2 or PTB domains of effector proteins ( 44 ).
# ::tok Most tyrosine @-@ phosphorylated sites function in signaling by binding to the SH2 or PTB domains of effector proteins ( 44 ) .
(x6 / function-01
      :ARG0 (x5 / site
            :mod (x1 / most)
            :ARG1-of (x4 / phosphorylate-01
                  :ARG1 (x2 / amino-acid
                        :name (x3 / name :op1 "tyrosine")
                        :xref (x / xref :value "PUBCHEM:1153" :prob "11.081481"))))
      :location (x15 / protein
            :ARG0-of (x7 / signal-07
                  :ARG0 (x11 / or
                        :op1 (x8 / bind-01
                              :ARG2 (x9 / protein-segment
                                    :name (x10 / name :op1 "SH2")))
                        :op2 (x12 / protein-segment
                              :name (x13 / name :op1 "PTB" :op2 "domain"))))
            :mod (x14 / effector)
            :ARG1-of (x16 / describe-01
                  :ARG0 (x17 / publication
                        :ARG1-of (x18 / cite-01 :ARG2 "44")))))


# ::id PMC4302068.77
# ::snt To assess what SH2 domains bind to the Dok1 sites implicated in suppressing CrkI transformation, we carried out a dot-blot SH2 profiling assay ( 45 ) using purified glutathione S-transferase (GST)-SH2 or GST-PTB domain fusion proteins to probe synthetic tyrosine-phosphorylated peptides corresponding the four sites of interest in Dok1 ( Fig. 3a ).
# ::tok To assess what SH2 domains bind to the Dok1 sites implicated in suppressing CrkI transformation , we carried out a dot @-@ blot SH2 profiling assay ( 45 ) using purified glutathione S @-@ transferase ( GST ) -SH2 or GST @-@ PTB domain fusion proteins to probe synthetic tyrosine @-@ phosphorylated peptides corresponding the four sites of interest in Dok1 ( Fig . 3a ) .
(x1 / multi-sentence
      :snt1 (x16 / carry-out-03
            :purpose (x2 / assess-01
                  :ARG1 (x3 / thing
                        :ARG1-of (x10 / implicate-01
                              :ARG0 (x9 / protein-segment
                                    :ARG0-of (x6 / bind-01
                                          :ARG1 (x4 / protein-segment
                                                :name (x5 / name :op1 "SH2" :op2 "domain"))
                                          :ARG2 (x7 / protein
                                                :name (x8 / name :op1 "Dok1")
                                                :xref (x53 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))
                              :ARG2 (x11 / suppress-01
                                    :ARG1 (x14 / transform-01
                                          :ARG1 (x12 / enzyme
                                                :name (x13 / name :op1 "CrkI")
                                                :xref (x57 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))))))
            :ARG0 (x15 / we)
            :ARG1 (x22 / assay-01
                  :ARG1-of (x19 / immunoblot-01
                        :ARG2 (x17 / protein
                              :name (x18 / name :op1 "dot")))
                  :ARG1 (x20 / protein-segment
                        :name (x21 / name :op1 "SH2" :op2 "profiling")))
            :ARG1-of (x23 / describe-01
                  :ARG0 (x24 / publication
                        :ARG1-of (x25 / cite-01 :ARG2 "45")))
            :ARG0-of (x26 / use-01
                  :ARG1 (x27 / enzyme
                        :ARG1-of (x28 / purify-01)
                        :name (x29 / name :op1 "glutathione" :op2 "S-transferase")))
            :ARG1-of (x40 / probe-01
                  :ARG0 (x34 / or
                        :op1 (x30 / enzyme
                              :name (x31 / name :op1 "GST")
                              :xref (x55 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))
                        :op2 (x32 / enzyme
                              :name (x33 / name :op1 "-SH2")
                              :xref (x54 / xref :value "UNIPROT:SH2B2_HUMAN" :prob "0.293"))
                        :op3 (x35 / enzyme
                              :name (x36 / name :op1 "GST")
                              :xref (x56 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))
                        :op2 (x39 / protein
                              :name (x37 / name :op1 "PTB" :op2 "domain")
                              :ARG1-of (x38 / fuse-01)))
                  :ARG1 (x41 / synthetic)))
      :snt2 (x45 / peptide
            :ARG0 (x44 / phosphorylate-01
                  :ARG1 (x42 / amino-acid
                        :name (x43 / name :op1 "tyrosine")
                        :xref (x58 / xref :value "PUBCHEM:1153" :prob "11.081481")))
            :ARG1-of (x46 / correspond-02
                  :ARG2 (x47 / protein-segment
                        :quant "4"
                        :ARG2-of (x48 / interest-01
                              :ARG2 (x49 / protein
                                    :name (x50 / name :op1 "Dok1")
                                    :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))))
            :ARG1-of (x51 / describe-01
                  :ARG0 (x52 / figure :mod "3a"))))


# ::id PMC4302068.78
# ::snt Of the 123 SH2 or PTB probes tested ( supplemental figure S1 ), a few showed strong binding to Dok1-derived phosphopeptides.
# ::tok Of the 123 SH2 or PTB probes tested ( supplemental figure S1 ) , a few showed strong binding to Dok1 @-@ derived phosphopeptides .
(x7 / test-01
      :ARG0 (x6 / probe-01
            :ARG1 (x3 / or
                  :op1 (x1 / amino-acid
                        :mod "123"
                        :name (x2 / name :op1 "SH2")
                        :xref (x22 / xref :value "PUBCHEM:402" :prob "17.186693"))
                  :op2 (x4 / protein
                        :name (x5 / name :op1 "PTB")
                        :xref (x21 / xref :value "UNIPROT:PTBP1_HUMAN" :prob "1.002"))))
      :ARG1-of (x8 / describe-01
            :ARG0 (x10 / figure
                  :ARG2-of (x9 / supplement-01)
                  :mod "s1"))
      :ARG0-of (x12 / show-01
            :ARG0 (x11 / few)
            :ARG1 (x14 / bind-01
                  :ARG1-of (x13 / strong-02)
                  :ARG2 (x15 / enzyme
                        :ARG1-of (x18 / derive-01
                              :ARG2 (x16 / protein
                                    :name (x17 / name :op1 "Dok1")
                                    :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
                        :name (x19 / name :op1 "phosphopeptides")
                        :xref (x20 / xref :value "UNIPROT:PGM2_HUMAN" :prob "0.232")))))


# ::id PMC4302068.79
# ::snt Abl and Arg (Abl2) SH2 domains strongly bound to all four phosphorylated sites, but not the unphosphorylated control peptides ( Fig. 3c ).
# ::tok Abl and Arg ( Abl2 ) SH2 domains strongly bound to all four phosphorylated sites , but not the unphosphorylated control peptides ( Fig . 3c ) .
(x9 / bind-01
      :ARG0 (x3 / and
            :op1 (x1 / protein
                  :name (x2 / name :op1 "Abl")
                  :xref (x / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603"))
            :op2 (x4 / amino-acid
                  :name (x5 / name :op1 "arginine")
                  :ARG1-of (x6 / abl2)
                  :name (x7 / name :op1 "SH2" :op2 "domain")
                  :xref (x20 / xref :value "PUBCHEM:232" :prob "11.348415")))
      :ARG1-of (x8 / strong-02)
      :ARG2 (x12 / protein-segment
            :mod (x10 / all)
            :quant "4"
            :ARG1-of (x11 / phosphorylate-01))
      :ARG1-of (x13 / contrast-01
            :ARG2 (x17 / peptide
                  :polarity "-"
                  :ARG0 (x14 / enzyme
                        :name (x15 / name :op1 "unphosphorylated"))
                  :ARG0-of (x16 / control-01))
            :ARG1-of (x18 / describe-01
                  :ARG0 (x19 / figure :mod "3c"))))


# ::id PMC4302068.80
# ::snt As expected, the SH2 domains of RasGAP bound strongly to pTyr 295 and 361.
# ::tok As expected , the SH2 domains of RasGAP bound strongly to pTyr 295 and 361 .
(x6 / bind-01
      :ARG1-of (x1 / expect-01)
      :ARG0 (x2 / protein-segment
            :name (x3 / name :op1 "SH2" :op2 "domain")
            :part-of (x4 / protein
                  :name (x5 / name :op1 "RasGAP")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003")))
      :ARG1-of (x7 / strong-02)
      :ARG2 (x8 / enzyme
            :name (x9 / name :op1 "pTyr"))
      :ARG1 (x10 / and :op1 "295" :op2 "361"))


# ::id PMC4302068.81
# ::snt The C-terminal RasGAP SH2 domain bound specifically to pTyr 295, while the N-terminal domain was less specific and bound to phosphopeptides corresponding to tyrosines 295, 340 and 361.
# ::tok The C @-@ terminal RasGAP SH2 domain bound specifically to pTyr 295 , while the N @-@ terminal domain was less specific and bound to phosphopeptides corresponding to tyrosines 295 , 340 and 361 .
(x7 / bind-01
      :ARG1 (x1 / protein-segment
            :name (x2 / name :op1 "c-terminus")
            :part-of (x3 / protein
                  :name (x4 / name :op1 "RasGAP")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003")))
      :ARG0 (x5 / protein-segment
            :name (x6 / name :op1 "SH2" :op2 "domain"))
      :ARG1-of (x8 / specific-02)
      :ARG2 (x9 / protein
            :name (x10 / name :op1 "pTyr" :op2 "295"))
      :ARG1-of (x11 / contrast-01
            :ARG2 (x16 / bind-01
                  :ARG1 (x12 / protein-segment
                        :name (x13 / name :op1 "n-terminus"))
                  :degree (x14 / less)
                  :ARG1-of (x15 / specific-02)
                  :ARG2 (x17 / protein
                        :name (x18 / name :op1 "phosphopeptides")
                        :xref (x23 / xref :value "UNIPROT:PGM2_HUMAN" :prob "0.232"))
                  :ARG1-of (x19 / correspond-02
                        :ARG2 (x20 / amino-acid
                              :name (x21 / name :op1 "tyrosine")
                              :xref (x24 / xref :value "PUBCHEM:1153" :prob "11.081481")))))
      :ARG2 (x22 / and
            :op1 "295"
            :op2 "340"
            :op3 "361"))


# ::id PMC4302068.82
# ::snt SH2 domains of p85α, a subunit of phosphatidylinositol 3-kinase, also bound to phosphorylated sites in Dok1.
# ::tok SH2 domains of p85α, a subunit of phosphatidylinositol 3 @-@ kinase , also bound to phosphorylated sites in Dok1 .
(x5 / subunit
      :ARG1 (x1 / protein-segment
            :name (x2 / name :op1 "SH2" :op2 "domain")
            :part-of (x3 / protein
                  :name (x4 / name :op1 "p85α,")
                  :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "0.643")))
      :part-of (x6 / enzyme
            :name (x7 / name :op1 "phosphatidylinositol" :op2 "3-kinase"))
      :ARG1-of (x9 / bind-01
            :mod (x8 / also)
            :ARG2 (x11 / site
                  :mod (x10 / phosphorylate-01)
                  :location (x12 / protein
                        :name (x13 / name :op1 "Dok1")
                        :xref (x14 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))))


# ::id PMC4302068.83
# ::snt The N-terminal SH2 domain of p85α bound pTyr 336, while a construct encompassing both SH2 domains bound pTyr 295, 336, and 361.
# ::tok The N @-@ terminal SH2 domain of p85α bound pTyr 336 , while a construct encompassing both SH2 domains bound pTyr 295 , 336 , and 361 .
(x18 / and
      :op1 (x6 / bind-01
            :ARG0 (x2 / protein-segment
                  :name (x1 / name :op1 "n-terminus")
                  :name (x3 / name :op1 "SH2" :op2 "domain")
                  :part-of (x4 / protein
                        :name (x5 / name :op1 "p85α")
                        :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "0.653")))
            :ARG1 (x7 / enzyme
                  :name (x8 / name :op1 "pTyr" :op2 "336"))
            :time (x9 / construct-01
                  :ARG1 (x14 / bind-01
                        :ARG0-of (x10 / encompass-01
                              :ARG1 (x11 / and
                                    :op1 (x12 / protein-segment
                                          :name (x13 / name :op1 "SH2" :op2 "domain"))))
                        :ARG2 (x17 / and
                              :op1 (x15 / enzyme
                                    :name (x16 / name :op1 "pTyr"))
                              :op1 "295"
                              :op2 "336"))))
      :op2 "361")


# ::id PMC4302068.84
# ::snt Notably, none of the phosphopeptides tested bound strongly to the Crk SH2 domain ( Fig. 3c ).
# ::tok Notably , none of the phosphopeptides tested bound strongly to the Crk SH2 domain ( Fig . 3c ) .
(x6 / test-01
      :ARG1-of (x1 / notable-04)
      :ARG0 (x2 / none
            :ARG1-of (x3 / include-91
                  :ARG2 (x4 / protein-family
                        :name (x5 / name :op1 "phosphopeptides"))))
      :ARG1 (x7 / bind-01
            :ARG1-of (x8 / strong-02)
            :ARG2 (x9 / protein
                  :name (x10 / name :op1 "Crk")
                  :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604"))
            :ARG1 (x11 / protein-segment
                  :name (x12 / name :op1 "SH2" :op2 "domain")))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure :mod "3c")))


# ::id PMC4302068.85
# ::snt The unphosphorylated peptides did not bind appreciably to any of the SH2 domain probes, highlighting the specificity of our SH2 probes for tyrosine-phosphorylated peptides.
# ::tok The unphosphorylated peptides did not bind appreciably to any of the SH2 domain probes , highlighting the specificity of our SH2 probes for tyrosine @-@ phosphorylated peptides .
(x3 / bind-01
      :ARG1 (x2 / peptide
            :name (x1 / name :op1 "unphosphorylated"))
      :polarity "-"
      :ARG1-of (x4 / appreciate-03
            :ARG1-of (x5 / possible-01))
      :ARG2 (x19 / peptide
            :mod (x6 / any)
            :ARG0-of (x9 / probe-01
                  :ARG1 (x7 / protein-segment
                        :name (x8 / name :op1 "SH2" :op2 "domain")))
            :ARG0-of (x10 / highlight-01
                  :ARG1 (x11 / specific-02
                        :ARG1 (x15 / probe-01
                              :ARG0 (x12 / we)
                              :ARG1 (x13 / protein
                                    :name (x14 / name :op1 "SH2")
                                    :xref (x / xref :value "UNIPROT:SH2B2_HUMAN" :prob "0.333")))))
            :ARG1-of (x18 / phosphorylate-01
                  :ARG1 (x16 / amino-acid
                        :name (x17 / name :op1 "tyrosine")
                        :xref (x20 / xref :value "PUBCHEM:1153" :prob "11.081481")))))


# ::id PMC4302068.86
# ::snt We also performed far-Western blotting to probe imatinib-treated cell lysates with RasGAP SH2 domains.
# ::tok We also performed far @-@ Western blotting to probe imatinib @-@ treated cell lysates with RasGAP SH2 domains .
(x3 / perform-01
      :ARG0 (x1 / we)
      :mod (x2 / also)
      :ARG1 (x5 / immunoblot-01
            :degree (x4 / far)
            :ARG2 (x11 / lysate
                  :ARG1-of (x6 / probe-01
                        :ARG1 (x9 / treat-04
                              :ARG2 (x7 / small-molecule
                                    :name (x8 / name :op1 "imatinib")
                                    :xref (x16 / xref :value "PUBCHEM:5291" :prob "16.088081"))))
                  :mod (x10 / cell)))
      :ARG2 (x12 / protein
            :name (x13 / name :op1 "RasGAP")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
      :ARG1 (x14 / protein-segment
            :name (x15 / name :op1 "SH2" :op2 "domain")))


# ::id PMC4302068.87
# ::snt The RasGAP SH2 probes bound to a band in Crk-transformed cells corresponding to phosphorylated Dok1; binding was abolished when Abl-mediated phosphorylation was inhibited with imatinib ( Fig. 3d ).
# ::tok The RasGAP SH2 probes bound to a band in Crk @-@ transformed cells corresponding to phosphorylated Dok1; binding was abolished when Abl @-@ mediated phosphorylation was inhibited with imatinib ( Fig . 3d ) .
(x16 / abolish-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "RasGAP")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
      :ARG1 (x5 / bind-01
            :ARG1 (x3 / protein-segment
                  :name (x4 / name :op1 "SH2" :op2 "probes"))
            :ARG2 (x6 / band
                  :location (x10 / cell
                        :ARG1-of (x9 / transform-01
                              :ARG0 (x7 / protein
                                    :name (x8 / name :op1 "Crk")
                                    :xref (x26 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604"))))
                  :ARG1-of (x11 / correspond-02
                        :ARG2 (x15 / bind-01
                              :ARG1 (x12 / enzyme
                                    :ARG3-of (x13 / phosphorylate-01)
                                    :name (x14 / name :op1 "Dok1;")
                                    :xref (x27 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.593"))))))
      :time (x21 / inhibit-01
            :ARG1 (x20 / phosphorylate-01
                  :ARG1-of (x19 / mediate-01
                        :ARG0 (x17 / protein
                              :name (x18 / name :op1 "Abl")
                              :xref (x28 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603"))))
            :ARG0 (x22 / small-molecule
                  :name (x23 / name :op1 "imatinib")
                  :xref (x29 / xref :value "PUBCHEM:5291" :prob "16.088081")))
      :ARG1-of (x24 / describe-01
            :ARG0 (x25 / figure :mod "3d")))


# ::id PMC4302068.88
# ::snt The relatively less specific RasGAP N-terminal SH2 domain showed the strongest difference in binding to Dok1 when cells were treated with imatinib.
# ::tok The relatively less specific RasGAP N @-@ terminal SH2 domain showed the strongest difference in binding to Dok1 when cells were treated with imatinib .
(x10 / show-01
      :ARG1 (x6 / protein-segment
            :ARG1-of (x3 / specific-02
                  :ARG2-of (x1 / relative-05)
                  :degree (x2 / less))
            :mod (x4 / protein
                  :name (x5 / name :op1 "RasGAP")
                  :xref (x21 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
            :name (x7 / name :op1 "n-terminus")
            :part-of (x8 / protein-segment
                  :name (x9 / name :op1 "SH2" :op2 "domain")))
      :ARG1 (x13 / differ-02
            :ARG1-of (x11 / strong-02
                  :degree (x12 / most))
            :ARG1 (x14 / bind-01
                  :ARG2 (x15 / protein
                        :name (x16 / name :op1 "Dok1")
                        :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))
      :time (x18 / treat-04
            :ARG1 (x17 / cell)
            :ARG2 (x19 / small-molecule
                  :name (x20 / name :op1 "imatinib")
                  :xref (x22 / xref :value "PUBCHEM:5291" :prob "16.088081"))))


# ::id PMC4302068.89
# ::snt This suggests that in vivo , Abl preferentially phosphorylates site 4 (Y361) relative to site 1 (Y295), since little binding was seen with the RasGAP C-terminal SH2 probe which is highly specific to site 1.
# ::tok This suggests that in vivo , Abl preferentially phosphorylates site 4 ( Y361 ) relative to site 1 ( Y295 ) , since little binding was seen with the RasGAP C @-@ terminal SH2 probe which is highly specific to site 1 .
(x2 / suggest-01
      :ARG0 (x1 / this)
      :ARG1 (x6 / prefer-01
            :manner (x3 / in-vivo)
            :ARG0 (x4 / protein
                  :name (x5 / name :op1 "Abl")
                  :xref (x29 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603"))
            :ARG1 (x7 / phosphorylate-01
                  :ARG1 (x8 / protein-segment :mod "4"))
            :ARG1-of (x9 / amino-acid
                  :mod "361"
                  :name (x10 / name :op1 "tyrosine")
                  :xref (x31 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :ARG1-of (x11 / relative-05
                  :ARG3 (x12 / protein-segment :mod "1"))
            :ARG1-of (x13 / amino-acid
                  :mod "295"
                  :name (x14 / name :op1 "tyrosine")
                  :xref (x32 / xref :value "PUBCHEM:1153" :prob "11.081481")))
      :ARG1-of (x15 / cause-01
            :ARG0 (x25 / probe-01
                  :mod (x18 / see-01
                        :degree (x16 / little)
                        :ARG1 (x17 / bind-01)
                        :ARG2 (x19 / protein
                              :name (x20 / name :op1 "RasGAP")
                              :xref (x30 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003")))
                  :ARG0 (x21 / protein-segment
                        :name (x22 / name :op1 "c-terminus"))
                  :ARG1 (x23 / enzyme
                        :name (x24 / name :op1 "SH2")
                        :xref (x / xref :value "UNIPROT:SH2B2_HUMAN" :prob "0.333"))
                  :ARG1-of (x27 / specific-02
                        :ARG1-of (x26 / high-02))
                  :ARG1 (x28 / protein-segment :mod "1"))))


# ::id PMC4302068.90
# ::snt A similar pattern of binding was also observed in the control 3T3 cell lysates, albeit at a much lower intensity.
# ::tok A similar pattern of binding was also observed in the control 3T3 cell lysates , albeit at a much lower intensity .
(x5 / observe-01
      :ARG1 (x2 / pattern-01
            :ARG1-of (x1 / resemble-01)
            :ARG1 (x3 / bind-01))
      :mod (x4 / also)
      :location (x9 / lysate
            :mod (x6 / control)
            :mod (x7 / cell-line
                  :name (x8 / name :op1 "3T3")))
      :ARG1-of (x10 / albeit)
      :location (x14 / intense-02
            :degree (x13 / low-04
                  :degree (x12 / more
                        :quant (x11 / much)))))


# ::id PMC4302068.91
# ::snt Role of RasGAP in regulating Crk transformation
# ::tok Role of RasGAP in regulating Crk transformation
(x1 / role
      :poss (x2 / protein
            :name (x3 / name :op1 "RasGAP")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
      :topic (x4 / regulate-01
            :ARG1 (x7 / transform-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "Crk")
                        :xref (x8 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604")))))


# ::id PMC4302068.92
# ::snt We next sought to confirm that RasGAP binds to phosphorylated Dok1 in our cell system by expressing HA-tagged hDok1 and immunoprecipitating with anti-HA antibody.
# ::tok We next sought to confirm that RasGAP binds to phosphorylated Dok1 in our cell system by expressing HA @-@ tagged hDok1 and immunoprecipitating with anti @-@ HA antibody .
(x3 / seek-01
      :ARG0 (x1 / we)
      :time (x2 / next)
      :ARG1 (x4 / confirm-01
            :ARG1 (x7 / bind-01
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "RasGAP")
                        :xref (x27 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
                  :ARG2 (x20 / and
                        :op1 (x8 / phosphorylate-01
                              :ARG1 (x9 / protein
                                    :name (x10 / name :op1 "Dok1")
                                    :xref (x26 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                              :location (x13 / system
                                    :poss (x11 / we)
                                    :mod (x12 / cell))
                              :ARG0 (x14 / express-03
                                    :ARG2 (x15 / protein
                                          :ARG1-of (x18 / tag-01
                                                :ARG2 (x16 / protein
                                                      :name (x17 / name :op1 "HA")
                                                      :xref (x28 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
                                          :name (x19 / name :op1 "hDok1"))))
                        :op2 (x21 / immunoprecipitate-01
                              :ARG3 (x25 / antibody
                                    :ARG0-of (x22 / counter-01
                                          :ARG1 (x23 / protein
                                                :name (x24 / name :op1 "HA")
                                                :xref (x / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))))))))


# ::id PMC4302068.93
# ::snt To maximize the detection of phosphotyrosine-dependent interactions, cells were treated briefly with pervanadate (POV) before lysis to inhibit endogenous tyrosine phosphatases.
# ::tok To maximize the detection of phosphotyrosine @-@ dependent interactions , cells were treated briefly with pervanadate ( POV ) before lysis to inhibit endogenous tyrosine phosphatases .
(x9 / treat-04
      :purpose (x1 / maximize-01
            :ARG1 (x2 / detect-01
                  :ARG1 (x7 / interact-01
                        :ARG0 (x6 / depend-01
                              :ARG1 (x3 / amino-acid
                                    :name (x4 / name :op1 "tyrosine")
                                    :ARG3-of (x5 / phosphorylate-01)
                                    :xref (x22 / xref :value "PUBCHEM:1153" :prob "11.081481"))))))
      :ARG1 (x8 / cell)
      :ARG1-of (x10 / briefly)
      :ARG2 (x11 / small-molecule
            :name (x12 / name :op1 "pervanadate")
            :ARG1-of (x13 / pov)
            :xref (x21 / xref :value "PUBCHEM:61671" :prob "12.041334"))
      :time (x14 / before
            :op1 (x15 / lyse-01))
      :purpose (x16 / inhibit-01
            :ARG1 (x20 / phosphorylate-01
                  :ARG1 (x17 / enzyme
                        :mod (x18 / endogenous)
                        :name (x19 / name :op1 "tyrosine")
                        :xref (x / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352")))))


# ::id PMC4302068.94
# ::snt Immunoblotting of anti-HA immunoprecipitates with anti-RasGAP antibody demonstrated association between RasGAP and WT Dok1; this binding was decreased, however, when tyrosines 295 and 361 were mutated (mutants M14 and M-all) ( Fig. 4a ).
# ::tok Immunoblotting of anti @-@ HA immunoprecipitates with anti @-@ RasGAP antibody demonstrated association between RasGAP and WT Dok1; this binding was decreased , however , when tyrosines 295 and 361 were mutated ( mutants M14 and M @-@ all ) ( Fig . 4a ) .
(x21 / have-concession-91
      :ARG1 (x10 / demonstrate-01
            :ARG0 (x1 / immunoblot-01
                  :ARG1 (x5 / immunoprecipitate-01
                        :ARG0-of (x2 / counter-01
                              :ARG1 (x3 / protein
                                    :name (x4 / name :op1 "HA")
                                    :xref (x / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002"))))
                  :ARG3 (x9 / antibody
                        :ARG0-of (x6 / counter-01
                              :ARG1 (x7 / protein
                                    :name (x8 / name :op1 "RasGAP")
                                    :xref (x34 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003")))))
            :ARG1 (x11 / associate-01
                  :ARG1 (x14 / and
                        :op1 (x12 / protein
                              :name (x13 / name :op1 "RasGAP")
                              :xref (x35 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
                        :op2 (x15 / enzyme
                              :mod (x16 / wild-type)
                              :name (x17 / name :op1 "Dok1;")
                              :xref (x36 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.593")))
                  :ARG2 (x20 / decrease-01
                        :mod (x18 / this)
                        :ARG1 (x19 / bind-01))))
      :time (x25 / mutate-01
            :ARG2 (x22 / amino-acid
                  :name (x23 / name :op1 "tyrosine")
                  :xref (x37 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :ARG1 (x24 / and :op1 "295" :op2 "361"))
      :ARG1-of (x26 / mutate-01
            :ARG1 (x27 / amino-acid
                  :mod "14"
                  :name (x28 / name :op1 "methionine"))
            :ARG2 (x29 / enzyme
                  :name (x30 / name :op1 "M")
                  :mod (x31 / all)))
      :ARG1-of (x32 / describe-01
            :ARG0 (x33 / figure :mod "4a")))


# ::id PMC4302068.95
# ::snt These results are consistent with the results of phosphopeptide binding experiments ( Fig. 3 ).
# ::tok These results are consistent with the results of phosphopeptide binding experiments ( Fig . 3 ) .
(x4 / consistent-01
      :ARG1 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG2 (x5 / thing
            :ARG2-of (x6 / result-01
                  :ARG1 (x10 / experiment-01
                        :mod (x9 / bind-01
                              :ARG1 (x7 / enzyme
                                    :name (x8 / name :op1 "phosphopeptide")
                                    :xref (x / xref :value "UNIPROT:PGM2_HUMAN" :prob "0.262"))))))
      :ARG1-of (x11 / describe-01
            :ARG0 (x12 / figure :mod "3")))


# ::id PMC4302068.96
# ::snt The M1 and M4 mutants of Dok1 both associated with RasGAP to a similar extent as WT Dok1, demonstrating that, under these conditions, phosphorylation of either Y295 or Y361 alone is sufficient to mediate RasGAP binding.
# ::tok The M1 and M4 mutants of Dok1 both associated with RasGAP to a similar extent as WT Dok1 , demonstrating that , under these conditions , phosphorylation of either Y295 or Y361 alone is sufficient to mediate RasGAP binding .
(x18 / demonstrate-01
      :ARG0 (x3 / and
            :op1 (x1 / person
                  :name (x2 / name :op1 "M1"))
            :op2 (x6 / mutate-01
                  :ARG2 (x4 / enzyme
                        :name (x5 / name :op1 "M4"))
                  :ARG1 (x9 / and
                        :op1 (x7 / enzyme
                              :name (x8 / name :op1 "Dok1")
                              :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                        :op2 (x10 / associate-01
                              :ARG2 (x11 / protein
                                    :name (x12 / name :op1 "RasGAP")
                                    :xref (x34 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))))
                  :degree (x13 / extent
                        :ARG1-of (x14 / resemble-01
                              :ARG2 (x15 / enzyme
                                    :mod (x16 / wild-type)
                                    :name (x17 / name :op1 "Dok1")
                                    :xref (x35 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))))
      :ARG1 (x28 / suffice-01
            :condition (x20 / condition
                  :mod (x19 / this))
            :ARG0 (x21 / phosphorylate-01
                  :ARG1 (x22 / or
                        :op1 (x23 / amino-acid
                              :mod "295"
                              :name (x24 / name :op1 "tyrosine")
                              :xref (x37 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :op2 (x25 / amino-acid
                              :mod "361"
                              :name (x26 / name :op1 "tyrosine")
                              :xref (x36 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                        :mod (x27 / alone)))
            :ARG1 (x29 / mediate-01
                  :ARG1 (x32 / bind-01
                        :ARG1 (x30 / protein
                              :name (x31 / name :op1 "RasGAP")
                              :xref (x33 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))))))


# ::id PMC4302068.97
# ::snt Next we knocked down RasGAP in both the control and CrkI overexpressing cells ( Fig. 4b ).
# ::tok Next we knocked down RasGAP in both the control and CrkI overexpressing cells ( Fig . 4b ) .
(x3 / knock-down-02
      :time (x1 / next)
      :ARG0 (x2 / we)
      :ARG1 (x4 / protein
            :name (x5 / name :op1 "RasGAP")
            :xref (x14 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
      :location (x6 / and
            :op1 (x7 / control-01)
            :op2 (x11 / cell
                  :mod (x10 / overexpress-01
                        :ARG1 (x8 / enzyme
                              :name (x9 / name :op1 "CrkI")
                              :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / figure :mod "4b")))


# ::id PMC4302068.98
# ::snt Loss of endogenous RasGAP in CrkI-transformed NIH3T3 increased the number of colonies ( Fig. 4c ), similar to what was observed in Abl and Dok1 knockdowns ( Fig. 2c ).
# ::tok Loss of endogenous RasGAP in CrkI @-@ transformed NIH3T3 increased the number of colonies ( Fig . 4c ) , similar to what was observed in Abl and Dok1 knockdowns ( Fig . 2c ) .
(x10 / increase-01
      :ARG1 (x1 / lose-02
            :ARG1 (x2 / enzyme
                  :mod (x3 / endogenous)
                  :name (x4 / name :op1 "RasGAP")
                  :xref (x26 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003")))
      :location (x5 / cell-line
            :ARG1-of (x8 / transform-01
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "CrkI")
                        :xref (x27 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
            :name (x9 / name :op1 "NIH3T3"))
      :ARG1 (x11 / number
            :quant-of (x12 / colony))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure :mod "4c"))
      :ARG1-of (x15 / resemble-01
            :ARG2 (x16 / thing
                  :ARG1-of (x17 / observe-01
                        :location (x20 / and
                              :op1 (x18 / protein
                                    :name (x19 / name :op1 "Abl")
                                    :xref (x28 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603"))
                              :op2 (x21 / protein
                                    :name (x22 / name :op1 "Dok1")
                                    :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))))
      :ARG0-of (x23 / knockdown)
      :ARG1-of (x24 / describe-01
            :ARG0 (x25 / figure :mod "2c")))


# ::id PMC4302068.99
# ::snt This observation is consistent with a model in which Abl works through Dok1 and RasGAP to regulate CrkI transformation.
# ::tok This observation is consistent with a model in which Abl works through Dok1 and RasGAP to regulate CrkI transformation .
(x8 / work-09
      :ARG1 (x2 / thing
            :mod (x1 / this)
            :ARG1-of (x3 / observe-01))
      :ARG1-of (x4 / consistent-01
            :ARG2 (x5 / model
                  :mod (x6 / protein
                        :name (x7 / name :op1 "Abl")
                        :xref (x20 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603"))))
      :ARG2 (x11 / and
            :op1 (x9 / protein
                  :name (x10 / name :op1 "Dok1")
                  :xref (x18 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
            :op2 (x12 / protein
                  :name (x13 / name :op1 "RasGAP")
                  :xref (x19 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003")))
      :purpose (x14 / regulate-01
            :ARG1 (x17 / transform-01
                  :ARG1 (x15 / enzyme
                        :name (x16 / name :op1 "CrkI")
                        :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))))


# ::id PMC4302068.100
# ::snt Ras activation in CrkI-transformed cells
# ::tok Ras activation in CrkI @-@ transformed cells
(x3 / activate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "Ras")
            :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
      :location (x7 / cell
            :ARG1-of (x6 / transform-01
                  :ARG0 (x4 / enzyme
                        :name (x5 / name :op1 "CrkI")
                        :xref (x8 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))))


# ::id PMC4302068.101
# ::snt While the previous results all suggest a role for elevated Ras activity in Crk transformation, over many experiments we did not detect significant differences in total Ras or Erk activity in CrkI-transformed cells relative to control, or under conditions where Abl or Dok1 activity was manipulated (see supplemental figure S2 ).
# ::tok While the previous results all suggest a role for elevated Ras activity in Crk transformation , over many experiments we did not detect significant differences in total Ras or Erk activity in CrkI @-@ transformed cells relative to control , or under conditions where Abl or Dok1 activity was manipulated ( see supplemental figure S2 ) .
(x1 / multi-sentence
      :snt1 (x2 / contrast-01
            :ARG2 (x5 / thing
                  :ARG2-of (x4 / result-01
                        :time (x3 / previous)))
            :ARG1 (x18 / experiment-01
                  :mod (x6 / all)
                  :ARG0-of (x7 / suggest-01
                        :ARG1 (x8 / role
                              :topic (x15 / transform-01
                                    :ARG0 (x9 / elevate-01
                                          :ARG1 (x12 / activity-06
                                                :ARG0 (x10 / enzyme
                                                      :name (x11 / name :op1 "Ras")
                                                      :xref (x53 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))
                                    :ARG1 (x13 / protein
                                          :name (x14 / name :op1 "Crk")
                                          :xref (x54 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604")))))
                  :ARG1 (x17 / many
                        :degree (x16 / over))))
      :snt2 (x20 / detect-01
            :ARG0 (x19 / we)
            :polarity "-"
            :ARG1 (x22 / differ-02
                  :ARG1-of (x21 / significant-02)
                  :ARG1 (x29 / activity-06
                        :ARG1-of (x23 / total-01)
                        :ARG1 (x26 / or
                              :op1 (x24 / enzyme
                                    :name (x25 / name :op1 "Ras")
                                    :xref (x49 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                              :op2 (x27 / enzyme
                                    :name (x28 / name :op1 "Erk")
                                    :xref (x50 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
                        :location (x33 / cell
                              :ARG1-of (x32 / transform-01
                                    :ARG0 (x30 / enzyme
                                          :name (x31 / name :op1 "CrkI")
                                          :xref (x51 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))
                        :ARG1-of (x34 / relative-05
                              :ARG3 (x36 / or
                                    :ARG0-of (x35 / control-01))))
                  :condition (x43 / manipulate-02
                        :ARG1 (x42 / activity-06
                              :ARG0 (x39 / or
                                    :op1 (x37 / protein
                                          :name (x38 / name :op1 "Abl")
                                          :xref (x52 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603"))
                                    :op2 (x40 / protein
                                          :name (x41 / name :op1 "Dok1")
                                          :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))))
            :ARG1-of (x44 / see-01
                  :mode "imperative"
                  :ARG0 (x45 / you)
                  :ARG1-of (x46 / describe-01
                        :ARG0 (x48 / figure
                              :ARG2-of (x47 / supplement-01)
                              :mod "s2")))))


# ::id PMC4302068.102
# ::snt We therefore considered whether CrkI overexpression might induce localized differences in Ras activity that were not evident in total cell lysates.
# ::tok We therefore considered whether CrkI overexpression might induce localized differences in Ras activity that were not evident in total cell lysates .
(x1 / cause-01
      :ARG1 (x3 / consider-01
            :ARG0 (x2 / we)
            :ARG1 (x4 / possible-01
                  :mode "interrogative"
                  :ARG1 (x5 / possible-01
                        :ARG1 (x9 / induce-01
                              :ARG0 (x8 / overexpress-01
                                    :ARG1 (x6 / enzyme
                                          :name (x7 / name :op1 "CrkI")
                                          :xref (x19 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
                              :ARG2 (x10 / be-located-at-91
                                    :ARG1 (x11 / differ-02
                                          :location (x14 / activity-06
                                                :ARG0 (x12 / enzyme
                                                      :name (x13 / name :op1 "Ras")
                                                      :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                                          :ARG1-of (x15 / evidence-01 :polarity "-")))
                              :location (x18 / lysate
                                    :mod (x16 / total)
                                    :mod (x17 / cell)))))))


# ::id PMC4302068.103
# ::snt To study the spatiotemporal aspects of Ras activation, we employed a newly developed FRET sensor for activated Ras (Dora-Ras) and conducted live cell imaging of Ras activation during cell spreading on fibronectin.
# ::tok To study the spatiotemporal aspects of Ras activation , we employed a newly developed FRET sensor for activated Ras ( Dora @-@ Ras ) and conducted live cell imaging of Ras activation during cell spreading on fibronectin .
(x8 / employ-02
      :purpose (x1 / study-01
            :ARG1 (x3 / aspect
                  :mod (x2 / space-time)
                  :topic (x6 / activate-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "Ras")
                              :xref (x32 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))))
      :ARG0 (x7 / we)
      :ARG1 (x10 / develop-01
            :ARG1-of (x9 / new-01)
            :ARG2 (x12 / sensor
                  :name (x11 / name :op1 "FRET")))
      :ARG2 (x13 / enzyme
            :ARG1-of (x14 / activate-01)
            :name (x15 / name :op1 "Ras")
            :xref (x35 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
      :ARG1-of (x21 / conduct-01
            :ARG0 (x20 / and
                  :op1 (x16 / protein
                        :name (x17 / name :op1 "Dora")
                        :xref (x36 / xref :value "UNIPROT:IGSF6_HUMAN" :prob "0.602"))
                  :op2 (x18 / enzyme
                        :name (x19 / name :op1 "Ras")
                        :xref (x34 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG1 (x24 / image-bab
                  :ARG0 (x23 / cell
                        :ARG0-of (x22 / live-01))
                  :ARG1 (x27 / activate-01
                        :ARG1 (x25 / enzyme
                              :name (x26 / name :op1 "Ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                  :time (x29 / spread-03
                        :ARG1 (x28 / cell)))
            :ARG1 (x30 / protein
                  :name (x31 / name :op1 "fibronectin")
                  :xref (x33 / xref :value "UNIPROT:FINC_HUMAN" :prob "0.703"))))


# ::id PMC4302068.104
# ::snt Since Ras is activated on the plasma membrane, we used total internal reflection fluorescence (TIRF) excitation in our imaging studies to reduce imaging artifacts typically associated with wide-field imaging.
# ::tok Since Ras is activated on the plasma membrane , we used total internal reflection fluorescence ( TIRF ) excitation in our imaging studies to reduce imaging artifacts typically associated with wide @-@ field imaging .
(x8 / use-01
      :ARG1-of (x1 / cause-01
            :ARG0 (x4 / activate-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
                  :location (x6 / membrane
                        :mod (x5 / plasma)
                        :xref (x26 / xref :value "GO:0016020" :prob "0.8"))))
      :ARG0 (x7 / we)
      :ARG1 (x11 / reflect-01
            :mod (x9 / total)
            :ARG1-of (x10 / internal-02)
            :ARG1 (x12 / fluorescence)
            :ARG1-of (x13 / tirf)
            :ARG0-of (x14 / excite-01)
            :location (x17 / study-01
                  :ARG0 (x15 / we)
                  :ARG1 (x16 / imaging))
            :ARG2 (x18 / reduce-01
                  :ARG1 (x19 / image-bab
                        :ARG1 (x20 / artifact)))
            :ARG1-of (x22 / associate-01
                  :ARG1-of (x21 / typical-02)
                  :ARG2 (x24 / field
                        :ARG1-of (x23 / wide-02)
                        :ARG1-of (x25 / imaging)))))


# ::id PMC4302068.105
# ::snt Fifteen minutes after plating, cells transiently transfected with Dora-Ras sensor showed elevated ratio (FRET/CFP) values, indicative of Ras activation, in lamellipodial protrusions ( Fig. 5a ).
# ::tok Fifteen minutes after plating , cells transiently transfected with Dora @-@ Ras sensor showed elevated ratio ( FRET/CFP ) values , indicative of Ras activation , in lamellipodial protrusions ( Fig . 5a ) .
(x11 / show-01
      :time (x3 / after
            :quant (x1 / temporal-quantity
                  :quant "15"
                  :unit (x2 / minute))
            :op1 (x4 / plate-00))
      :ARG0 (x5 / cell
            :ARG1-of (x7 / transfect-01
                  :ARG1-of (x6 / transient-02)
                  :ARG2 (x10 / sensor
                        :mod (x8 / protein
                              :name (x9 / name :op1 "Dora-Ras")))))
      :ARG1 (x13 / ratio-of
            :ARG1-of (x12 / elevate-01))
      :ARG1-of (x16 / indicate-01
            :ARG1-of (x15 / value-02
                  :name (x14 / name :op1 "FRET/CFP"))
            :ARG0 (x19 / activate-01
                  :ARG1 (x17 / enzyme
                        :name (x18 / name :op1 "Ras")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))
      :location (x21 / protrusion
            :name (x20 / name :op1 "lamellipodial"))
      :ARG1-of (x22 / describe-01
            :ARG0 (x23 / figure :mod "5a")))


# ::id PMC4302068.106
# ::snt In contrast, cells transfected with a control construct (with a point mutation in the Ras binding domain that abolishes sensor response), showed no polarized distribution of ratio values ( Fig. 5b ).
# ::tok In contrast , cells transfected with a control construct ( with a point mutation in the Ras binding domain that abolishes sensor response ) , showed no polarized distribution of ratio values ( Fig . 5b ) .
(x1 / contrast-01
      :ARG2 (x13 / abolish-01
            :ARG0 (x2 / cell
                  :ARG1-of (x3 / transfect-01
                        :ARG2 (x6 / or
                              :op1 (x5 / construct
                                    :ARG1-of (x4 / control-01))
                              :op2 (x8 / mutate-01
                                    :mod (x7 / point)
                                    :location (x12 / domain
                                          :ARG0-of (x11 / bind-01
                                                :ARG1 (x9 / enzyme
                                                      :name (x10 / name :op1 "Ras")
                                                      :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))))))
            :ARG1 (x16 / show-01
                  :ARG0 (x15 / respond-01
                        :mod (x14 / sensor))
                  :ARG1 (x18 / distribute-01
                        :ARG1-of (x17 / polarize-01 :polarity "-")
                        :ARG1 (x19 / ratio-of
                              :op1 (x20 / value)))))
      :ARG1-of (x21 / describe-01
            :ARG0 (x22 / figure :mod "5b")))


# ::id PMC4302068.107
# ::snt Crk is known to localize to adhesions by binding to phosphorylated paxillin and p130Cas( 46 - 49 ), and we showed that CrkI was enriched at paxillin-containing adhesions in CrkI-overexpressing cells ( supplemental movie S3 ).
# ::tok Crk is known to localize to adhesions by binding to phosphorylated paxillin and p130Cas ( 46 - 49 ) , and we showed that CrkI was enriched at paxillin @-@ containing adhesions in CrkI @-@ overexpressing cells ( supplemental movie S3 ) .
(x1 / and
      :op1 (x4 / know-02
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "Crk")
                  :xref (x35 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604"))
            :ARG2 (x5 / localize-01)
            :ARG1 (x6 / adhere-01
                  :ARG0 (x11 / and
                        :op1 (x7 / bind-01
                              :ARG2 (x8 / enzyme
                                    :ARG3-of (x9 / phosphorylate-01)
                                    :name (x10 / name :op1 "paxillin")
                                    :xref (x34 / xref :value "UNIPROT:PAXI_HUMAN" :prob "0.703")))
                        :op2 (x12 / protein
                              :name (x13 / name :op1 "p130Cas")))
                  :ARG1-of (x14 / describe-01
                        :ARG0 (x15 / publication
                              :ARG1-of (x16 / cite-01
                                    :ARG2 (x17 / value-interval :op1 "46" :op2 "49"))))))
      :op2 (x19 / show-01
            :ARG0 (x18 / we)
            :ARG1 (x22 / enrich-01
                  :ARG1 (x20 / enzyme
                        :name (x21 / name :op1 "CrkI")
                        :xref (x32 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))
                  :time (x25 / contain-01
                        :ARG1 (x23 / protein
                              :name (x24 / name :op1 "paxillin")
                              :xref (x33 / xref :value "UNIPROT:PAXI_HUMAN" :prob "0.703")))
                  :ARG1 (x26 / adhere-01
                        :ARG2 (x29 / overexpress-01
                              :ARG1 (x27 / enzyme
                                    :name (x28 / name :op1 "CrkI")
                                    :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))
                  :ARG1-of (x31 / move-01
                        :ARG2-of (x30 / supplement-01)
                        :mod "s3"))))


# ::id PMC4302068.108
# ::snt In order to relate sites of Ras activation to the location of adhesions, we co-expressed mCherry-tagged paxillin with the Dora-Ras sensor.
# ::tok In order to relate sites of Ras activation to the location of adhesions , we co @-@ expressed mCherry @-@ tagged paxillin with the Dora @-@ Ras sensor .
(x9 / express-03
      :purpose (x1 / relate-01
            :ARG1 (x2 / site
                  :location-of (x5 / activate-01
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "Ras")
                              :xref (x19 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))
            :ARG2 (x6 / be-located-at-91
                  :ARG1 (x7 / adhere-01)))
      :ARG0 (x8 / we)
      :ARG2 (x10 / protein
            :ARG1-of (x13 / tag-01
                  :ARG2 (x11 / protein
                        :name (x12 / name :op1 "mCherry")))
            :name (x14 / name :op1 "paxillin")
            :xref (x18 / xref :value "UNIPROT:PAXI_HUMAN" :prob "0.703"))
      :ARG1 (x15 / gene
            :name (x16 / name :op1 "Dora")
            :mod (x17 / sensor)
            :xref (x / xref :value "UNIPROT:IGSF6_HUMAN" :prob "0.602")))


# ::id PMC4302068.109
# ::snt In control NIH3T3 cells, Ras activity co-localized with nascent adhesions at the leading front, but diminished in the vicinity of mature focal adhesions as the cells spread ( Fig. 5c and supplemental movie S4 ).
# ::tok In control NIH3T3 cells , Ras activity co @-@ localized with nascent adhesions at the leading front , but diminished in the vicinity of mature focal adhesions as the cells spread ( Fig . 5c and supplemental movie S4 ) .
(x12 / contrast-01
      :location (x3 / cell-line
            :ARG0-of (x1 / control-01)
            :name (x2 / name :op1 "NIH3T3"))
      :ARG0 (x6 / activity-06
            :ARG0 (x4 / enzyme
                  :name (x5 / name :op1 "Ras")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
      :ARG1 (x7 / be-located-at-91
            :ARG2 (x9 / adhere-01
                  :mod (x8 / nascent))
            :ARG1 (x10 / lead-03
                  :ARG2 (x11 / front)))
      :ARG2 (x13 / diminish-01
            :location (x14 / about
                  :op1 (x17 / adhere-01
                        :ARG1-of (x15 / mature-02)
                        :mod (x16 / focal)
                        :ARG2 (x19 / spread-03
                              :ARG1 (x18 / cell))
                        :ARG1-of (x20 / describe-01
                              :ARG0 (x22 / and
                                    :op1 (x21 / figure :mod "5c")
                                    :op2 (x24 / movie
                                          :ARG2-of (x23 / supplement-01))))
                        :mod "s4"))))


# ::id PMC4302068.110
# ::snt In contrast, CrkI-transformed cells maintained elevated Ras activation while adhesions matured ( Fig. 5d and supplemental movie S5 ).
# ::tok In contrast , CrkI @-@ transformed cells maintained elevated Ras activation while adhesions matured ( Fig . 5d and supplemental movie S5 ) .
(x1 / contrast-01
      :ARG2 (x11 / contrast-01
            :ARG0 (x5 / cell
                  :ARG1-of (x4 / transform-01
                        :ARG0 (x2 / enzyme
                              :name (x3 / name :op1 "CrkI")
                              :xref (x19 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
                  :ARG1-of (x6 / maintain-01
                        :ARG1 (x10 / activate-01
                              :ARG1-of (x7 / elevate-01)
                              :ARG1 (x8 / enzyme
                                    :name (x9 / name :op1 "Ras")
                                    :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))))
            :ARG2 (x12 / adhere-01
                  :ARG1-of (x13 / mature-01))
            :ARG1-of (x14 / describe-01
                  :ARG0 (x16 / and
                        :op1 (x15 / figure :mod "5d")
                        :op2 (x18 / move-01
                              :ARG2-of (x17 / supplement-01)
                              :mod "s5")))))


# ::id PMC4302068.111
# ::snt Strikingly, the spatial distribution of Ras activation often appeared bipolar or multipolar, and the cells developed multiple protrusions at an early stage of cell spreading.
# ::tok Strikingly , the spatial distribution of Ras activation often appeared bipolar or multipolar , and the cells developed multiple protrusions at an early stage of cell spreading .
(x1 / contrast-01
      :ARG2 (x13 / and
            :op1 (x3 / distribute-01
                  :mod (x2 / space)
                  :ARG1 (x10 / or
                        :op1 (x8 / appear-02
                              :ARG0 (x6 / activate-01
                                    :ARG1 (x4 / enzyme
                                          :name (x5 / name :op1 "Ras")
                                          :xref (x22 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                              :frequency (x7 / often)
                              :ARG1 (x9 / bipolar))
                        :op2 (x11 / enzyme
                              :name (x12 / name :op1 "multipolar")
                              :xref (x / xref :value "UNIPROT:MCIN_HUMAN" :prob "0.202"))))
            :op2 (x14 / cell
                  :ARG1-of (x15 / develop-01
                        :ARG2 (x16 / disease
                              :name (x17 / name :op1 "multiple" :op2 "protrusions"))
                        :time (x19 / stage
                              :mod (x18 / early)
                              :subevent-of (x21 / spread-03
                                    :ARG1 (x20 / cell)))))))


# ::id PMC4302068.112
# ::snt Thus we conclude that the localized distribution of activated Ras is dramatically different in CrkI-transformed cells compared to their normal controls.
# ::tok Thus we conclude that the localized distribution of activated Ras is dramatically different in CrkI @-@ transformed cells compared to their normal controls .
(x1 / cause-01
      :ARG1 (x3 / conclude-01
            :ARG0 (x2 / we)
            :ARG1 (x10 / differ-02
                  :domain (x4 / be-located-at-91
                        :ARG1 (x5 / distribute-01
                              :ARG1 (x6 / enzyme
                                    :ARG1-of (x7 / activate-01)
                                    :name (x8 / name :op1 "Ras")
                                    :xref (x17 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))
                  :degree (x9 / dramatic)
                  :location (x14 / cell
                        :ARG1-of (x13 / transform-01
                              :ARG0 (x11 / enzyme
                                    :name (x12 / name :op1 "CrkI")
                                    :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))
                  :compared-to (x16 / control
                        :ARG1-of (x15 / normal-02)))))


# ::id PMC4302068.163
# ::snt Methods and Materials
# ::tok Methods and Materials
(x2 / and
      :op1 (x1 / method)
      :op2 (x3 / material))


# ::id PMC4302068.164
# ::snt Cell culture, transfection, and viral infection
# ::tok Cell culture , transfection , and viral infection
(x4 / and
      :op1 (x2 / culture-01
            :ARG1 (x1 / cell))
      :op2 (x3 / transfect-01)
      :op2 (x6 / infect-01
            :ARG2 (x5 / virus)))


# ::id PMC4302068.174
# ::snt Construction of Dora-Ras
# ::tok Construction of Dora @-@ Ras
(x1 / construct-01
      :ARG1 (x2 / protein
            :name (x3 / name :op1 "Dora-Ras")))


# ::id PMC4302068.186
# ::snt Anchorage independent growth assay
# ::tok Anchorage independent growth assay
(x4 / assay-01
      :ARG1 (x3 / grow-01
            :ARG0-of (x2 / depend-01
                  :ARG1 (x1 / anchorage)
                  :polarity "-")))


# ::id PMC4302068.192
# ::snt SH2-phosphopeptide binding assay and far-western blotting
# ::tok SH2 @-@ phosphopeptide binding assay and far @-@ western blotting
(x5 / and
      :op1 (x4 / assay-01
            :ARG1 (x3 / bind-01
                  :ARG1 (x1 / protein
                        :name (x2 / name :op1 "SH2" :op2 "phosphopeptide"))))
      :op2 (x7 / immunoblot-01
            :mod (x6 / far)))


# ::id PMC4302068.201
# ::snt Live cell imaging and sensor data processing
# ::tok Live cell imaging and sensor data processing
(x4 / and
      :op1 (x3 / image-bab
            :ARG1 (x2 / cell
                  :ARG0-of (x1 / live-01)))
      :op2 (x7 / process-01
            :ARG1 (x6 / data
                  :mod (x5 / sensor))))


# ::id PMC4302068.209
# ::snt Decreased phosphorylation of Dok1 in CrkI-transformed cells treated with imatinib
# ::tok Decreased phosphorylation of Dok1 in CrkI @-@ transformed cells treated with imatinib
(x1 / decrease-01
      :ARG1 (x2 / phosphorylate-01
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "Dok1")
                  :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
            :location (x8 / cell
                  :ARG1-of (x7 / transform-01
                        :ARG0 (x5 / enzyme
                              :name (x6 / name :op1 "CrkI")
                              :xref (x12 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
                  :ARG1-of (x9 / treat-04
                        :ARG2 (x10 / small-molecule
                              :name (x11 / name :op1 "imatinib")
                              :xref (x13 / xref :value "PUBCHEM:5291" :prob "16.088081"))))))


# ::id PMC4302068.210
# ::snt a) Soft agar colonies formed by Crk1-tranformed NIH3T3 cells treated continuously with the indicated concentrations of imatinib.
# ::tok a ) Soft agar colonies formed by Crk1 @-@ tranformed NIH3T3 cells treated continuously with the indicated concentrations of imatinib .
(x1 / and
      :li "a"
      :op1 (x5 / form-01
            :ARG1 (x4 / colony
                  :mod (x3 / agar
                        :ARG1-of (x2 / soft-02)))
            :ARG0 (x6 / protein
                  :name (x7 / name :op1 "Crk1")))
      :op2 (x10 / treat-04
            :ARG1 (x9 / cell-line
                  :name (x8 / name :op1 "NIH3T3"))
            :ARG2 (x12 / concentrate-02
                  :ARG0-of (x11 / indicate-01)
                  :ARG1 (x13 / small-molecule
                        :name (x14 / name :op1 "imatinib")
                        :xref (x / xref :value "PUBCHEM:5291" :prob "16.088081")))))


# ::id PMC4302068.211
# ::snt b) Serum-starved CrkI-transformed NIH3T3 cells treated with 20 μM imatinib for indicated times were lysed and blotted with anti-pTyr.
# ::tok b ) Serum @-@ starved CrkI @-@ transformed NIH3T3 cells treated with 20 μM imatinib for indicated times were lysed and blotted with anti @-@ pTyr .
(x8 / treat-04
      :li "b"
      :ARG0 (x2 / starve-01
            :ARG2 (x1 / serum))
      :ARG2 (x7 / cell-line
            :ARG1-of (x5 / transform-01
                  :ARG0 (x3 / enzyme
                        :name (x4 / name :op1 "CrkI")
                        :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
            :name (x6 / name :op1 "NIH3T3"))
      :ARG2 (x9 / small-molecule
            :quant (x10 / concentration-quantity
                  :quant "20"
                  :unit (x11 / micromolar))
            :name (x12 / name :op1 "imatinib")
            :xref (x22 / xref :value "PUBCHEM:5291" :prob "16.088081"))
      :duration (x14 / time
            :ARG1-of (x13 / indicate-01))
      :ARG1 (x17 / and
            :op1 (x15 / enzyme
                  :name (x16 / name :op1 "lysed"))
            :op2 (x18 / immunoblot-01
                  :ARG0-of (x19 / counter-01
                        :ARG1 (x20 / protein
                              :name (x21 / name :op1 "pTyr"))))))


# ::id PMC4302068.212
# ::snt Phosphorylation of ∼64 kDa band is decreased upon imatinib treatment of CrkI-transformed cells (indicated by arrow).
# ::tok Phosphorylation of ∼64 kDa band is decreased upon imatinib treatment of CrkI @-@ transformed cells ( indicated by arrow ) .
(x5 / decrease-01
      :ARG1 (x1 / phosphorylate-01
            :ARG1 (x4 / band
                  :mod (x3 / kilodalton
                        :name (x2 / name :op1 "∼64"))))
      :ARG0 (x6 / treat-04
            :ARG1 (x10 / cell
                  :ARG1-of (x9 / transform-01
                        :ARG0 (x7 / enzyme
                              :name (x8 / name :op1 "CrkI")
                              :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))))
      :ARG1-of (x11 / indicate-01
            :ARG0 (x12 / arrow)))


# ::id PMC4302068.213
# ::snt IB, immuno-blot; pTyr, anti-phosphotyrosine.
# ::tok IB , immuno @-@ blot ; pTyr , anti @-@ phosphotyrosine .
(x1 / and
      :op2 (x2 / cause-01
            :ARG0 (x3 / immune-02
                  :ARG1-of (x4 / immunoblot-01))
            :ARG1 (x6 / antibody
                  :name (x5 / name :op1 "pTyr")
                  :ARG0-of (x7 / counter-01
                        :ARG1 (x8 / amino-acid
                              :name (x9 / name :op1 "threonine")
                              :ARG3-of (x10 / phosphorylate-01)
                              :xref (x / xref :value "PUBCHEM:205" :prob "11.848252"))))))


# ::id PMC4302068.217
# ::snt d) CrkI-expressing or control NIH3T3 cells treated with indicated concentrations of imatinib were lysed and immunoblotted with phosphospecific Dok1 antibody (α-p362 Dok1).
# ::tok d ) CrkI @-@ expressing or control NIH3T3 cells treated with indicated concentrations of imatinib were lysed and immunoblotted with phosphospecific Dok1 antibody ( α-p362 Dok1 ) .
(x4 / or
      :li "d"
      :op1 (x3 / express-03
            :ARG2 (x1 / enzyme
                  :name (x2 / name :op1 "CrkI")
                  :xref (x22 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
      :op2 (x7 / cell-line
            :ARG0-of (x5 / control-01)
            :name (x6 / name :op1 "NIH3T3")
            :ARG1-of (x8 / treat-04
                  :ARG2 (x18 / antibody
                        :ARG0-of (x9 / indicate-01
                              :ARG1 (x10 / concentrate-02
                                    :ARG1 (x11 / small-molecule
                                          :name (x12 / name :op1 "imatinib")
                                          :xref (x24 / xref :value "PUBCHEM:5291" :prob "16.088081"))
                                    :ARG2 (x15 / and
                                          :op1 (x13 / enzyme
                                                :name (x14 / name :op1 "lysed"))
                                          :op2 (x16 / protein
                                                :name (x17 / name :op1 "Dok1")
                                                :xref (x23 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))))
                        :ARG1-of (x19 / mean-01
                              :ARG2 (x20 / protein
                                    :name (x21 / name :op1 "Dok1")
                                    :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))))))


# ::id PMC4302068.218
# ::snt Immunoblotting with anti-Crk and anti-actin shown as controls.
# ::tok Immunoblotting with anti @-@ Crk and anti @-@ actin shown as controls .
(x9 / show-01
      :ARG0 (x1 / immunoblot-01
            :ARG3 (x2 / antibody
                  :ARG0-of (x3 / counter-01
                        :ARG1 (x4 / protein
                              :name (x5 / name :op1 "Crk")
                              :xref (x11 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604")))
                  :ARG0-of (x6 / counter-01
                        :ARG1 (x7 / protein
                              :name (x8 / name :op1 "actin")
                              :xref (x / xref :value "UNIPROT:KLH17_HUMAN" :prob "0.302")))))
      :ARG1 (x10 / control-01))


# ::id PMC4302068.219
# ::snt Phosphorylation of tyrosine 295 and 361 of Dok1 correlates with suppression of CrkI transformation
# ::tok Phosphorylation of tyrosine 295 and 361 of Dok1 correlates with suppression of CrkI transformation
(x7 / correlate-01
      :ARG1 (x1 / phosphorylate-01
            :ARG1 (x4 / and
                  :op1 (x2 / amino-acid
                        :mod "295"
                        :name (x3 / name :op1 "tyrosine")
                        :xref (x13 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :op2 "361")
            :ARG2 (x5 / protein
                  :name (x6 / name :op1 "Dok1")
                  :xref (x12 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
      :ARG2 (x8 / suppress-01
            :ARG1 (x11 / transform-01
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "CrkI")
                        :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))))


# ::id PMC4302068.220
# ::snt a) Diagram of the human Dok1 cDNA constructs used, indicating positions of tyrosine phosphorylation sites mutated.
# ::tok a ) Diagram of the human Dok1 cDNA constructs used , indicating positions of tyrosine phosphorylation sites mutated .
(x1 / and
      :li "a"
      :op1 (x2 / diagram-01
            :part-of (x3 / human)
            :ARG1-of (x8 / construct-01
                  :ARG0 (x4 / protein
                        :name (x5 / name :op1 "Dok1")
                        :xref (x16 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                  :ARG1 (x6 / nucleic-acid
                        :name (x7 / name :op1 "cDNA"))))
      :op2 (x9 / use-01
            :ARG1 (x11 / position
                  :ARG1-of (x10 / indicate-01)
                  :mod (x12 / enzyme
                        :name (x13 / name :op1 "tyrosine")
                        :ARG2-of (x14 / phosphorylate-01
                              :ARG1 (x15 / protein-segment))
                        :xref (x / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352")))))


# ::id PMC4302068.221
# ::snt PH: Pleckstrin homology domain; PTB: phospho-tyrosine binding domain; Y: tyrosine; F: phenylalanine; HA: HA epitope tag.
# ::tok PH : Pleckstrin homology domain ; PTB : phospho @-@ tyrosine binding domain ; Y: tyrosine ; F: phenylalanine ; HA : HA epitope tag .
(x1 / ph
      :mod (x2 / and
            :op1 (x3 / protein-segment
                  :name (x4 / name :op1 "Pleckstrin" :op2 "homology"))
            :op2 (x5 / protein
                  :name (x6 / name :op1 "PTB")
                  :xref (x25 / xref :value "UNIPROT:PTBP1_HUMAN" :prob "1.002")))
      :ARG1-of (x7 / mean-01
            :ARG2 (x8 / and
                  :op1 (x13 / domain
                        :ARG1-of (x12 / bind-01
                              :ARG2 (x9 / enzyme
                                    :ARG3-of (x10 / phosphorylate-01)
                                    :name (x11 / name :op1 "tyrosine")
                                    :xref (x24 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))))
                  :op2 (x14 / amino-acid
                        :name (x15 / name :op1 "tyrosine")
                        :xref (x27 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :op2 (x16 / amino-acid
                        :name (x17 / name :op1 "phenylalanine"))
                  :op4 (x18 / protein
                        :name (x19 / name :op1 "HA")
                        :xref (x26 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002"))))
      :ARG1-of (x23 / tag-01
            :ARG2 (x22 / epitope
                  :mod (x20 / protein
                        :name (x21 / name :op1 "HA")
                        :xref (x / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))))


# ::id PMC4302068.222
# ::snt b) Dok1 knockdown and rescue with HA-tagged Dok1 constructs.
# ::tok b ) Dok1 knockdown and rescue with HA @-@ tagged Dok1 constructs .
(x4 / and
      :li "b"
      :op1 (x3 / knock-down-02
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "Dok1")
                  :xref (x12 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
      :op2 (x5 / rescue-01
            :ARG1 (x11 / construct
                  :ARG1-of (x8 / tag-01
                        :ARG2 (x6 / protein
                              :name (x7 / name :op1 "HA")
                              :xref (x13 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
                  :mod (x9 / protein
                        :name (x10 / name :op1 "Dok1")
                        :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))))


# ::id PMC4302068.223
# ::snt NIH3T3 cell lysates were immunoblotted with antibodies indicated (αpDok1 = phosphospecific Dok1 antibody).
# ::tok NIH3T3 cell lysates were immunoblotted with antibodies indicated ( αpDok1 = phosphospecific Dok1 antibody ) .
(x4 / immunoblot-01
      :ARG1 (x3 / lysate
            :mod (x1 / cell-line
                  :name (x2 / name :op1 "NIH3T3")))
      :ARG2 (x5 / antibody
            :ARG1-of (x6 / indicate-01))
      :ARG1-of (x10 / antibody
            :ARG0-of (x7 / counter-01
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "Dok1")
                        :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))))


# ::id PMC4302068.224
# ::snt E: empty vector control; C: CrkI transformed; CAi: CrkI-transformed, Abl knockdown; CDi: CrkI-transformed, Dok1 knockdown; WT: wild-type Dok1; M14: Y295F and Y361F mutant Dok1; M23: Y336F and Y340F mutant Dok1; M-all: Y295F, Y336F, Y340F and Y361F mutant Dok1; M1: Y295F mutant Dok1; M4: Y361F mutant Dok1.
# ::tok E : empty vector control ; C: CrkI transformed ; CAi : CrkI @-@ transformed , Abl knockdown ; CDi : CrkI @-@ transformed , Dok1 knockdown ; WT : wild @-@ type Dok1; M14: Y295F and Y361F mutant Dok1; M23: Y336F and Y340F mutant Dok1; M @-@ all : Y295F , Y336F , Y340F and Y361F mutant Dok1; M1: Y295F mutant Dok1; M4: Y361F mutant Dok1 .
(x1 / multi-sentence
      :snt1 (x16 / and
            :location (x4 / and
                  :mod (x2 / protein
                        :name (x3 / name :op1 "e-cadherin")
                        :xref (x65 / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703"))
                  :op1 (x7 / control-01
                        :ARG0 (x6 / vector
                              :ARG1-of (x5 / empty-02)))
                  :op2 (x10 / transform-01
                        :ARG0 (x8 / enzyme
                              :name (x9 / name :op1 "C:" :op2 "CrkI")))
                  :op2 (x11 / protein
                        :name (x12 / name :op1 "CAi")))
            :op1 (x15 / transform-01
                  :ARG0 (x13 / enzyme
                        :name (x14 / name :op1 "CrkI")
                        :xref (x68 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
            :op1 (x19 / knock-down-02
                  :ARG1 (x17 / protein
                        :name (x18 / name :op1 "Abl")
                        :xref (x69 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603")))
            :op2 (x20 / person
                  :wiki "-"
                  :name (x21 / name :op1 "CDi"))
            :ARG1-of (x24 / transform-01
                  :ARG0 (x22 / enzyme
                        :name (x23 / name :op1 "CrkI")
                        :xref (x64 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
            :op2 (x27 / knock-down-02
                  :ARG1 (x25 / protein
                        :name (x26 / name :op1 "Dok1")
                        :xref (x63 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))
      :snt2 (x36 / and
            :op1 (x28 / fibroblast
                  :mod (x29 / wild-type)
                  :mod (x30 / enzyme
                        :mod (x31 / wild-type)
                        :name (x32 / name :op1 "Dok1;")
                        :xref (x66 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.593"))
                  :mod (x33 / enzyme
                        :name (x34 / name :op1 "M14:")
                        :ARG2-of (x35 / mutate-01 :value "Y295F")))
            :op2 (x44 / protein
                  :ARG1-of (x37 / mutate-01 :value "Y361F")
                  :ARG0-of (x38 / mutate-01
                        :ARG1 (x42 / and
                              :op1 (x39 / enzyme
                                    :name (x40 / name :op1 "M23:")
                                    :ARG2-of (x41 / mutate-01 :value "Y336F"))
                              :op2 (x43 / mutate-01 :value "Y340F")))
                  :name (x45 / name :op1 "Dok1;" :op2 "M")
                  :mod (x46 / all)
                  :ARG1-of (x47 / mutate-01 :value "Y295F"))
            :ARG2-of (x48 / mutate-01 :value "Y336F")
            :op2 (x51 / enzyme
                  :ARG2-of (x49 / mutate-01 :value "Y340F")
                  :ARG1-of (x50 / mutate-01 :value "Y361F")
                  :ARG2-of (x52 / mutate-01)
                  :name (x53 / name :op1 "Dok1;")
                  :xref (x67 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.593"))
            :op3 (x60 / mutate-01
                  :ARG1 (x54 / gene
                        :name (x55 / name :op1 "M1:")
                        :ARG2-of (x56 / mutate-01 :value "Y295F"))
                  :ARG0 (x57 / enzyme
                        :name (x58 / name :op1 "M4:")
                        :ARG2-of (x59 / mutate-01 :value "Y361F"))
                  :ARG2 (x61 / protein
                        :name (x62 / name :op1 "Dok1")
                        :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))))


# ::id PMC4302068.225
# ::snt c) Soft agar colony formation results for cells in panel b.
# ::tok c ) Soft agar colony formation results for cells in panel b .
(x5 / result-01
      :li "c"
      :ARG1 (x4 / form-01
            :ARG1 (x3 / colony
                  :mod (x2 / agar
                        :ARG1-of (x1 / soft-02))))
      :ARG2 (x6 / cell-line
            :location (x7 / panel)
            :name (x8 / name :op1 "b")))


# ::id PMC4302068.226
# ::snt d) Over-expression of Dok1 in CrkI-transformed NIH3T3 cells; abbreviations as in panel b.
# ::tok d ) Over @-@ expression of Dok1 in CrkI @-@ transformed NIH3T3 cells ; abbreviations as in panel b .
(x1 / and
      :li "d"
      :op1 (x2 / overexpress-01
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "Dok1")
                  :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
            :location (x9 / cell-line
                  :ARG1-of (x7 / transform-01
                        :ARG0 (x5 / enzyme
                              :name (x6 / name :op1 "CrkI")
                              :xref (x15 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
                  :name (x8 / name :op1 "NIH3T3")))
      :op2 (x10 / thing
            :ARG1-of (x11 / abbreviate-01)
            :ARG1-of (x12 / resemble-01
                  :ARG2 (x13 / panel))
            :name (x14 / name :op1 "b")))


# ::id PMC4302068.227
# ::snt e) Soft agar colony formation results for cells in panel d.
# ::tok e ) Soft agar colony formation results for cells in panel d .
(x7 / result-01
      :ARG1 (x6 / form-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "e-cadherin")
                  :xref (x / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703"))
            :ARG1 (x5 / colony
                  :mod (x4 / agar
                        :ARG1-of (x3 / soft-02))))
      :ARG2 (x8 / cell-line
            :location (x9 / panel
                  :mod (x10 / string-entity :value "d"))))


# ::id PMC4302068.228
# ::snt Binding of SH2 domains to Dok1 phosphorylation sites
# ::tok Binding of SH2 domains to Dok1 phosphorylation sites
(x1 / bind-01
      :ARG1 (x2 / protein-segment
            :name (x3 / name :op1 "SH2" :op2 "domain"))
      :ARG2 (x7 / protein-segment
            :ARG0-of (x6 / phosphorylate-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "Dok1")
                        :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))))


# ::id PMC4302068.229
# ::snt a) Phosphorylation sites on Dok1 are indicated; each site is numbered from 1 to 4.
# ::tok a ) Phosphorylation sites on Dok1 are indicated ; each site is numbered from 1 to 4 .
(x1 / and
      :li "a"
      :op1 (x6 / indicate-01
            :ARG1 (x2 / protein-segment
                  :mod (x3 / phosphorylate-01
                        :ARG1 (x4 / protein
                              :name (x5 / name :op1 "Dok1")
                              :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))))
      :op2 (x9 / number-01
            :ARG1 (x8 / site
                  :mod (x7 / each))
            :ARG2 (x10 / value-interval :op1 "1" :op2 "4")))


# ::id PMC4302068.230
# ::snt Sequences of corresponding synthetic peptides are indicated below.
# ::tok Sequences of corresponding synthetic peptides are indicated below .
(x5 / indicate-01
      :ARG1 (x1 / sequence
            :consist-of (x4 / peptide
                  :ARG1-of (x2 / correspond-02)
                  :mod (x3 / synthetic)))
      :ARG2 (x6 / below))


# ::id PMC4302068.231
# ::snt b) Synthetic peptides were spotted to filters in the pattern shown.
# ::tok b ) Synthetic peptides were spotted to filters in the pattern shown .
(x5 / spot-01
      :ARG1 (x4 / peptide
            :ARG1-of (x1 / describe-01
                  :ARG0 (x2 / figure :mod "b"))
            :mod (x3 / synthetic))
      :ARG1 (x6 / product
            :ARG0-of (x7 / filter-02))
      :location (x8 / pattern
            :ARG1-of (x9 / show-01)))


# ::id PMC4302068.232
# ::snt Grey circles and “p” indicate tyrosine phosphorylation of corresponding site (for example, “p1” denotes peptide in which site 1 is phosphorylated); c: control (whole cell lysates) c) Peptide-spotted filters were probed with purified SH2 and PTB domains.
# ::tok Grey circles and “ p ” indicate tyrosine phosphorylation of corresponding site ( for example , “ p1 ” denotes peptide in which site 1 is phosphorylated ) ; c : control ( whole cell lysates ) c ) Peptide @-@ spotted filters were probed with purified SH2 and PTB domains .
(x1 / multi-sentence
      :snt1 (x7 / indicate-01
            :ARG0 (x6 / drug-01
                  :ARG1-of (x4 / and
                        :mod (x3 / circle
                              :ARG1-of (x2 / gray-02)))
                  :ARG1-of (x5 / statistical-test-91))
            :ARG1 (x8 / phosphorylate-01
                  :ARG1 (x9 / amino-acid
                        :name (x10 / name :op1 "tyrosine")
                        :part-of (x12 / protein-segment
                              :ARG1-of (x11 / correspond-02))
                        :xref (x39 / xref :value "PUBCHEM:1153" :prob "11.081481")))
            :ARG1-of (x13 / exemplify-01
                  :ARG0 (x17 / peptide
                        :mod (x14 / string-entity
                              :name (x15 / name :op1 "p1"))
                        :ARG1-of (x16 / denote-01))
                  :ARG2-of (x19 / phosphorylate-01
                        :ARG1 (x18 / protein-segment :mod "1"))))
      :snt2 (x36 / and
            :ARG1-of (x20 / describe-01
                  :ARG0 (x21 / figure :mod "5c"))
            :op1 (x32 / probe-01
                  :ARG1 (x30 / product
                        :ARG0-of (x22 / control-01)
                        :ARG1-of (x25 / lysate
                              :mod (x23 / whole)
                              :mod (x24 / cell))
                        :mod (x28 / peptide
                              :ARG1-of (x26 / describe-01
                                    :ARG0 (x27 / figure :mod "c"))
                              :name (x29 / name :op1 "spotted"))
                        :ARG0-of (x31 / filter-02))
                  :ARG2 (x33 / enzyme
                        :ARG1-of (x34 / purify-01)
                        :name (x35 / name :op1 "SH2")
                        :xref (x / xref :value "UNIPROT:SH2B2_HUMAN" :prob "0.333")))
            :op2 (x37 / protein-segment
                  :name (x38 / name :op1 "PTB" :op2 "domain"))))


# ::id PMC4302068.233
# ::snt Binding results for selected domains are shown (for data for all domains, see Supplementary Figure 1 ).
# ::tok Binding results for selected domains are shown ( for data for all domains , see Supplementary Figure 1 ) .
(x6 / show-01
      :ARG0 (x1 / bind-01)
      :ARG1 (x2 / thing
            :ARG2-of (x3 / result-01
                  :ARG1 (x5 / domain
                        :ARG1-of (x4 / select-01))))
      :ARG1-of (x7 / data
            :topic (x9 / domain
                  :mod (x8 / all)
                  :ARG1-of (x10 / see-01
                        :mode "imperative"
                        :ARG0 (x11 / you)
                        :ARG1-of (x12 / describe-01
                              :ARG0 (x14 / figure
                                    :ARG2-of (x13 / supplement-01)
                                    :mod "1"))))))


# ::id PMC4302068.234
# ::snt GAP(N): RasGAP N-terminal SH2 domain; GAP(C): RasGAP C-terminal SH2 domain; GAP(NC): Both SH2 domains and SH3 domain of RasGAP; p85a(N): PI3K regulatory subunit 1 (α) N-terminal SH2 domain; p85a(NC): PI3Kα N- and C-terminal SH2 domains; GST: negative control; pY: anti-pTyr antibody.
# ::tok GAP ( N ) : RasGAP N @-@ terminal SH2 domain ; GAP ( C ) : RasGAP C @-@ terminal SH2 domain ; GAP ( NC ) : Both SH2 domains and SH3 domain of RasGAP ; p85a ( N ) : PI3K regulatory subunit 1 ( α ) N @-@ terminal SH2 domain ; p85a ( NC ) : PI3Kα N @- and C @-@ terminal SH2 domains ; GST : negative control ; pY : anti @-@ pTyr antibody .
(x1 / multi-sentence
      :snt1 (x2 / say-01
            :ARG0 (x3 / say-01
                  :ARG0 (x4 / and
                        :op1 (x5 / protein
                              :name (x6 / name :op1 "GAP")
                              :xref (x80 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
                        :op2 (x7 / enzyme
                              :name (x8 / name :op1 "n-ras")
                              :xref (x79 / xref :value "UNIPROT:Q9UM97_HUMAN" :prob "0.701")))
                  :ARG1 (x11 / and
                        :op1 (x9 / protein
                              :name (x10 / name :op1 "RasGAP")
                              :xref (x78 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
                        :op1 (x12 / protein-segment
                              :name (x13 / name :op1 "n-terminus")
                              :part-of (x14 / protein-segment
                                    :name (x15 / name :op1 "SH2" :op2 "domain")))
                        :op2 (x16 / protein
                              :name (x17 / name :op1 "GAP" :op2 "C"))))
            :ARG1 (x20 / and
                  :op1 (x18 / protein
                        :name (x19 / name :op1 "RasGAP")
                        :xref (x84 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
                  :op1 (x21 / protein-segment
                        :name (x22 / name :op1 "c-terminus")
                        :part-of (x23 / protein-segment
                              :name (x24 / name :op1 "SH2" :op2 "domain")))
                  :op2 (x25 / and
                        :op1 (x26 / protein
                              :name (x27 / name :op1 "GAP")
                              :xref (x76 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
                        :op2 (x28 / state
                              :wiki "north_carolina"
                              :name (x29 / name :op1 "NC")))
                  :op2 (x30 / and
                        :op1 (x31 / protein-segment
                              :name (x32 / name :op1 "SH2" :op2 "domain"))
                        :op2 (x33 / protein-segment
                              :name (x34 / name :op1 "SH3" :op2 "domain")
                              :part-of (x35 / protein
                                    :name (x36 / name :op1 "RasGAP")
                                    :xref (x81 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))))
                  :op4 (x37 / cell-line
                        :name (x38 / name :op1 "p85a")
                        :mod (x39 / enzyme
                              :name (x40 / name :op1 "n-ras")
                              :xref (x82 / xref :value "UNIPROT:Q9UM97_HUMAN" :prob "0.701")))))
      :snt2 (x57 / and
            :op1 (x44 / subunit
                  :ARG0 (x41 / enzyme
                        :name (x42 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                  :ARG0-of (x43 / regulate-01)
                  :mod "1"
                  :ARG1-of (x45 / describe-01
                        :ARG0 (x48 / and
                              :op1 (x46 / protein-segment
                                    :name (x47 / name :op1 "riα"))
                              :op1 (x49 / protein-segment
                                    :name (x50 / name :op1 "n-terminus")
                                    :part-of (x51 / protein-segment
                                          :name (x52 / name :op1 "SH2" :op2 "domain")))
                              :op2 (x53 / protein
                                    :name (x54 / name :op1 "p85a" :op2 "NC")))))
            :op1 (x55 / enzyme
                  :name (x56 / name :op1 "PI3Kα")
                  :xref (x77 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.252"))
            :op1 (x60 / and
                  :op1 (x58 / enzyme
                        :name (x59 / name :op1 "n-ras")
                        :xref (x83 / xref :value "UNIPROT:Q9UM97_HUMAN" :prob "0.701"))
                  :op2 (x61 / protein-segment
                        :name (x62 / name :op1 "c-terminus")
                        :part-of (x63 / protein-segment
                              :name (x64 / name :op1 "SH2" :op2 "domain"))))
            :op2 (x65 / enzyme
                  :name (x66 / name :op1 "GST")
                  :xref (x75 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))
            :op2 (x68 / control-01
                  :ARG2-of (x67 / negative-01))
            :op2 (x69 / person
                  :wiki "-"
                  :name (x70 / name :op1 "pY"))
            :op2 (x74 / antibody
                  :ARG0-of (x71 / counter-01
                        :ARG1 (x72 / protein
                              :name (x73 / name :op1 "pTyr"))))))


# ::id PMC4302068.235
# ::snt d) Far-Western and immunoblotting of lysates from imatinib-treated control and CrkI-transformed NIH3T3 cells.
# ::tok d ) Far @-@ Western and immunoblotting of lysates from imatinib @-@ treated control and CrkI @-@ transformed NIH3T3 cells .
(x10 / and
      :li "d"
      :op1 (x1 / so-far
            :op1 (x2 / world-region
                  :wiki "western_world"
                  :name (x3 / name :op1 "west"))
            :op2 (x4 / immunoblot-01
                  :ARG1 (x5 / lysate
                        :source (x8 / treat-04
                              :ARG2 (x6 / small-molecule
                                    :name (x7 / name :op1 "imatinib")
                                    :xref (x16 / xref :value "PUBCHEM:5291" :prob "16.088081")))
                        :mod (x9 / control))))
      :op2 (x15 / cell-line
            :ARG1-of (x13 / transform-01
                  :ARG0 (x11 / enzyme
                        :name (x12 / name :op1 "CrkI")
                        :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
            :name (x14 / name :op1 "NIH3T3")))


# ::id PMC4302068.236
# ::snt Top, lysates were probed with GST-RasGAP SH2 domain fusions; bottom, same lysates were probed with phosphospecific Dok1 antibody.
# ::tok Top , lysates were probed with GST @-@ RasGAP SH2 domain fusions ; bottom , same lysates were probed with phosphospecific Dok1 antibody .
(x13 / probe-01
      :ARG1 (x2 / and
            :op1 (x1 / top)
            :op1 (x4 / probe-01
                  :ARG1 (x3 / lysate)
                  :ARG2 (x9 / fuse-01
                        :ARG1 (x5 / protein
                              :name (x6 / name :op1 "GST-RasGAP"))
                        :ARG0 (x7 / protein-segment
                              :name (x8 / name :op1 "SH2" :op2 "domain"))))
            :op2 (x10 / bottom
                  :ARG1-of (x12 / lysate
                        :ARG1-of (x11 / same-01))))
      :ARG2 (x17 / antibody
            :ARG0-of (x14 / counter-01
                  :ARG1 (x15 / protein
                        :name (x16 / name :op1 "Dok1")
                        :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))))


# ::id PMC4302068.237
# ::snt C: untreated control lysates.
# ::tok C : untreated control lysates .
(x1 / and
      :op1 (x2 / figure :mod "5c")
      :op2 (x5 / lysate
            :mod (x4 / control
                  :ARG1-of (x3 / treat-04 :polarity "-"))))


# ::id PMC4302068.238
# ::snt e) RasGAP domain structure.
# ::tok e ) RasGAP domain structure .
(x5 / structure-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "e-cadherin")
            :xref (x / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703"))
      :ARG1 (x3 / protein-segment
            :name (x4 / name :op1 "RasGAP" :op2 "domain")))


# ::id PMC4302068.239
# ::snt C2: C2 domain.
# ::tok C2: C2 domain .
(x1 / and
      :op2 (x2 / protein-segment
            :name (x3 / name :op1 "C2" :op2 "domain")))


# ::id PMC4302068.240
# ::snt RasGAP binds to phosphorylated Dok1 and is involved in suppressing Crk transformation
# ::tok RasGAP binds to phosphorylated Dok1 and is involved in suppressing Crk transformation
(x12 / transform-01
      :ARG1 (x3 / bind-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "RasGAP")
                  :xref (x13 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
            :ARG2 (x7 / and
                  :op1 (x4 / phosphorylate-01
                        :ARG1 (x5 / protein
                              :name (x6 / name :op1 "Dok1")
                              :xref (x14 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
                  :op2 (x8 / involve-01
                        :ARG2 (x9 / suppress-01
                              :ARG1 (x10 / protein
                                    :name (x11 / name :op1 "Crk")
                                    :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.604")))))))


# ::id PMC4302068.242
# ::snt RasGAP binding to Dok1 was decreased when tyrosines 295 and 361 were both mutated (M14 and M-all).
# ::tok RasGAP binding to Dok1 was decreased when tyrosines 295 and 361 were both mutated ( M14 and M @-@ all ) .
(x6 / decrease-01
      :ARG1 (x3 / bind-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "RasGAP")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
            :ARG2 (x4 / protein
                  :name (x5 / name :op1 "Dok1")
                  :xref (x19 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
      :time (x11 / mutate-01
            :ARG2 (x7 / amino-acid
                  :name (x8 / name :op1 "tyrosine")
                  :xref (x20 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :ARG1 (x9 / and :op1 "295" :op2 "361")
            :mod (x10 / both)
            :ARG1-of (x12 / mean-01
                  :ARG2 (x15 / and
                        :op1 (x13 / amino-acid
                              :mod "14"
                              :name (x14 / name :op1 "methionine"))
                        :op2 (x16 / enzyme
                              :name (x17 / name :op1 "M")
                              :mod (x18 / all))))))


# ::id PMC4302068.243
# ::snt Cells were treated with pervanadate prior to lysis to increase total pTyr levels.
# ::tok Cells were treated with pervanadate prior to lysis to increase total pTyr levels .
(x5 / prior
      :op1 (x2 / treat-04
            :ARG1 (x1 / cell)
            :ARG2 (x3 / small-molecule
                  :name (x4 / name :op1 "pervanadate")
                  :xref (x / xref :value "PUBCHEM:61671" :prob "12.041334")))
      :op1 (x6 / lyse-01
            :ARG1 (x11 / level
                  :ARG1-of (x7 / increase-01)
                  :quant-of (x8 / enzyme
                        :mod (x9 / total)
                        :name (x10 / name :op1 "pTyr")))))


# ::id PMC4302068.244
# ::snt Bottom: bands from two independent experiments were quantified; average RasGAP/HA ratio was normalized to WT Dok1.
# ::tok Bottom : bands from two independent experiments were quantified ; average RasGAP @/@ HA ratio was normalized to WT Dok1 .
(x3 / band
      :ARG1-of (x1 / describe-01
            :location (x2 / bottom))
      :source (x6 / quantify-01
            :ARG1 (x5 / experiment
                  :quant "2"
                  :ARG0-of (x4 / depend-01 :polarity "-"))
            :ARG1-of (x7 / average-01
                  :ARG2 (x12 / ratio-of
                        :part (x8 / protein
                              :name (x9 / name :op1 "RasGAP")
                              :xref (x19 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
                        :part (x10 / protein
                              :name (x11 / name :op1 "HA")
                              :xref (x18 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002"))))
            :ARG1-of (x13 / normalize-01
                  :ARG1-of (x14 / conform-01
                        :ARG2 (x15 / enzyme
                              :mod (x16 / wild-type)
                              :name (x17 / name :op1 "Dok1")
                              :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))))))


# ::id PMC4302068.245
# ::snt b) Western blotting demonstrating knockdown of RasGAP.
# ::tok b ) Western blotting demonstrating knockdown of RasGAP .
(x2 / demonstrate-01
      :li "b"
      :ARG0 (x1 / immunoblot-01)
      :ARG1 (x3 / knock-down-02
            :ARG1 (x4 / protein
                  :name (x5 / name :op1 "RasGAP")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))))


# ::id PMC4302068.246
# ::snt E: empty vector control NIH3T3 cells; EGi: RasGAP knockdown control cells; C: CrkI-transformed cells; CGi: CrkI-transformed, RasGAP knockdown cells.
# ::tok E : empty vector control NIH3T3 cells ; EGi : RasGAP knockdown control cells ; C: CrkI @-@ transformed cells ; CGi : CrkI @-@ transformed , RasGAP knockdown cells .
(x11 / say-01
      :ARG0 (x1 / and
            :op1 (x2 / protein
                  :name (x3 / name :op1 "e-cadherin")
                  :xref (x31 / xref :value "UNIPROT:CADH1_HUMAN" :prob "0.703"))
            :op2 (x8 / cell-line
                  :ARG1-of (x6 / control-01
                        :ARG0 (x5 / vector
                              :ARG1-of (x4 / empty-02)))
                  :name (x7 / name :op1 "NIH3T3"))
            :op2 (x9 / person
                  :wiki "-"
                  :name (x10 / name :op1 "EGi")))
      :ARG0 (x14 / knock-down-02
            :ARG0 (x12 / protein
                  :name (x13 / name :op1 "RasGAP")
                  :xref (x32 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))
            :ARG1 (x15 / and
                  :op1 (x17 / cell
                        :ARG0-of (x16 / control-01))
                  :op2 (x21 / cell
                        :ARG1-of (x20 / transform-01
                              :ARG0 (x18 / enzyme
                                    :name (x19 / name :op1 "C:" :op2 "CrkI"))))
                  :op3 (x22 / protein
                        :name (x23 / name :op1 "CGi"))))
      :ARG2 (x26 / transform-01
            :ARG0 (x24 / enzyme
                  :name (x25 / name :op1 "CrkI")
                  :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))
      :ARG1 (x29 / knock-down-02
            :ARG1 (x27 / protein
                  :name (x28 / name :op1 "RasGAP")
                  :xref (x30 / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))))


# ::id PMC4302068.247
# ::snt c) Soft agar colony formation results for cells shown in panel b.
# ::tok c ) Soft agar colony formation results for cells shown in panel b .
(x5 / result-01
      :li "c"
      :ARG1 (x4 / form-01
            :ARG1 (x3 / colony
                  :mod (x2 / agar
                        :ARG1-of (x1 / soft-02))))
      :ARG2 (x6 / cell-line
            :ARG0-of (x7 / show-01
                  :location (x8 / panel))
            :name (x9 / name :op1 "b")))


# ::id PMC4302068.248
# ::snt RasGAP knockdown increases the number of colonies in CrkI-transformed cells but has no effect on the empty vector control cells.
# ::tok RasGAP knockdown increases the number of colonies in CrkI @-@ transformed cells but has no effect on the empty vector control cells .
(x11 / contrast-01
      :ARG1 (x4 / increase-01
            :ARG0 (x3 / knock-down-02
                  :ARG1 (x1 / protein
                        :name (x2 / name :op1 "RasGAP")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003")))
            :ARG1 (x5 / number
                  :quant-of (x6 / colony))
            :location (x10 / cell
                  :ARG1-of (x9 / transform-01
                        :ARG0 (x7 / enzyme
                              :name (x8 / name :op1 "CrkI")
                              :xref (x17 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))))
      :ARG2 (x12 / affect-01
            :polarity "-"
            :ARG1 (x16 / cell
                  :ARG2-of (x15 / control-01
                        :ARG0 (x14 / vector
                              :ARG1-of (x13 / empty-02))))))


# ::id PMC4302068.249
# ::snt Ras activation is partially uncoupled from the turnover of adhesions in CrkI-transformed cells
# ::tok Ras activation is partially uncoupled from the turnover of adhesions in CrkI @-@ transformed cells
(x7 / turn-over-12
      :ARG1 (x3 / activate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "Ras")
                  :xref (x13 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
      :degree (x4 / part)
      :ARG0 (x6 / molecular-physical-entity
            :mod (x5 / uncouple-00))
      :ARG1 (x8 / adhere-01
            :ARG2 (x12 / cell
                  :ARG1-of (x11 / transform-01
                        :ARG0 (x9 / enzyme
                              :name (x10 / name :op1 "CrkI")
                              :xref (x / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))))


# ::id PMC4302068.250
# ::snt NIH3T3-vector (a-c, n = 18 cells) or -CrkI (d, n = 18 cells) cells were co-transfected with the Dora-Ras FRET sensor (a, c and d) or sensor control (b, n = 9 cells) and mCherry-tagged paxillin.
# ::tok NIH3T3 @-@ vector ( a @-@ c , n = 18 cells ) or -@ CrkI ( d , n = 18 cells ) cells were co @-@ transfected with the Dora @-@ Ras FRET sensor ( a , c and d ) or sensor control ( b , n = 9 cells ) and mCherry @-@ tagged paxillin .
(x1 / multi-sentence
      :snt1 (x9 / or
            :op1 (x3 / vector
                  :name (x2 / name :op1 "NIH3T3")
                  :ARG1-of (x4 / mean-01
                        :ARG2 (x8 / cell
                              :ARG1-of (x7 / sample-01
                                    :ARG1-of (x5 / describe-01
                                          :ARG0 (x6 / figure :mod "c"))
                                    :quant "18"))))
            :op2 (x10 / person
                  :wiki "-"
                  :name (x11 / name :op1 "CrkI")))
      :snt2 (x21 / be-located-at-91
            :ARG1-of (x12 / describe-01
                  :ARG0 (x13 / and
                        :op1 (x14 / figure :mod "5d")
                        :op2 (x15 / sample-01
                              :ARG2 (x19 / cell
                                    :ARG1-of (x16 / describe-01
                                          :ARG0 (x17 / publication
                                                :ARG1-of (x18 / cite-01 :ARG2 "18")))))))
            :ARG1 (x20 / cell)
            :ARG2 (x39 / and
                  :op1 (x38 / cell
                        :ARG1-of (x22 / transfect-01
                              :ARG2 (x32 / or
                                    :op1 (x27 / sensor
                                          :ARG0 (x23 / protein
                                                :name (x24 / name :op1 "Dora-Ras"))
                                          :mod (x25 / thing
                                                :name (x26 / name :op1 "FRET"))
                                          :ARG1-of (x28 / describe-01
                                                :ARG0 (x30 / and
                                                      :op1 (x29 / figure :mod "a")
                                                      :op2 (x31 / figure :mod "5d"))))
                                    :op2 (x34 / control
                                          :mod (x33 / sensor)
                                          :ARG1-of (x35 / describe-01
                                                :ARG0 (x36 / figure :mod "1b")))))
                        :ARG1-of (x37 / sample-01 :quant "9"))
                  :op2 (x40 / enzyme
                        :ARG1-of (x43 / tag-01
                              :ARG2 (x41 / protein
                                    :name (x42 / name :op1 "mCherry")))
                        :name (x44 / name :op1 "paxillin")
                        :xref (x / xref :value "UNIPROT:PAXI_HUMAN" :prob "0.703")))))


# ::id PMC4302068.251
# ::snt The cells were seeded onto fibronectin-coated coverslips and imaged with TIRF excitation 15 minutes after plating.
# ::tok The cells were seeded onto fibronectin @-@ coated coverslips and imaged with TIRF excitation 15 minutes after plating .
(x3 / be-located-at-91
      :ARG1 (x2 / seed-02
            :ARG2 (x1 / cell))
      :ARG2 (x6 / coat-01
            :ARG2 (x4 / protein
                  :name (x5 / name :op1 "fibronectin")
                  :xref (x / xref :value "UNIPROT:FINC_HUMAN" :prob "0.703")))
      :ARG1 (x9 / and
            :op1 (x7 / enzyme
                  :name (x8 / name :op1 "coverslips"))
            :op2 (x10 / enzyme
                  :name (x11 / name :op1 "imaged")))
      :ARG2 (x12 / small-molecule
            :name (x13 / name :op1 "TIRF"))
      :time (x16 / after
            :quant (x14 / temporal-quantity
                  :quant "15"
                  :unit (x15 / minute))
            :op1 (x17 / plate-00)))


# ::id PMC4302068.252
# ::snt The ratio (FRET/CFP) images were calculated and presented in pseudocolor based on the lookup table provided (a and b, right; c and d, bottom).
# ::tok The ratio ( FRET/CFP ) images were calculated and presented in pseudocolor based on the lookup table provided ( a and b , right ; c and d , bottom ) .
(x11 / provide-01
      :ARG0 (x4 / calculate-01
            :ARG1 (x1 / ratio-of
                  :ARG1-of (x3 / images
                        :name (x2 / name :op1 "FRET/CFP")))
            :ARG1-of (x8 / base-02
                  :ARG1 (x5 / and
                        :ARG1-of (x6 / present-01
                              :location (x7 / pseudocolor)))
                  :ARG2 (x10 / table
                        :mod (x9 / lookup))))
      :ARG1-of (x15 / and
            :ARG0 (x12 / and
                  :op2 (x13 / figure
                        :mod "1b"
                        :ARG1-of (x14 / right-04)))
            :op2 (x16 / figure :mod "d")
            :ARG1-of (x17 / describe-01
                  :location (x18 / bottom))))


# ::id PMC4302068.253
# ::snt CFP and mCherry intensities were illustrated in grayscale and inverted grayscale images, respectively.
# ::tok CFP and mCherry intensities were illustrated in grayscale and inverted grayscale images , respectively .
(x7 / illustrate-01
      :ARG0 (x3 / and
            :op1 (x1 / protein
                  :name (x2 / name :op1 "CFP"))
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "mCherry")))
      :ARG1 (x6 / intense)
      :ARG1 (x12 / image
            :location (x9 / and
                  :op1 (x8 / grayscale)
                  :op2 (x10 / invert-01))
            :mod (x11 / grayscale))
      :mod (x13 / respective))


# ::id PMC4302068.254
# ::snt The arrows (a and b) indicate directions of cell movement and the arrowheads (c and d), clusters of focal adhesions.
# ::tok The arrows ( a and b ) indicate directions of cell movement and the arrowheads ( c and d ) , clusters of focal adhesions .
(x7 / indicate-01
      :ARG0 (x1 / arrow
            :ARG1-of (x2 / describe-01
                  :ARG0 (x4 / and
                        :op1 (x3 / figure :mod "a")
                        :op2 (x5 / enzyme
                              :name (x6 / name :op1 "b-raf")
                              :xref (x / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.701")))))
      :ARG1 (x11 / and
            :op1 (x10 / movement-07
                  :quant "5"
                  :ARG1-of (x8 / include-91
                        :ARG2 (x9 / cell)))
            :op2 (x13 / and
                  :op1 (x12 / arrowhead)
                  :op2 (x14 / figure :mod "d"))
            :ARG1-of (x15 / cluster
                  :consist-of (x17 / adhere-01
                        :mod (x16 / focal)))))


# ::id PMC4302068.255
# ::snt Scale bar, 10 μm.
# ::tok Scale bar , 10 μm .
(x1 / bar
      :mod (x2 / distance-quantity
            :quant "10"
            :unit (x3 / micrometer)))


# ::id PMC4302068.256
# ::snt Phosphorylated Dok1 regulates CrkI-transformation
# ::tok Phosphorylated Dok1 regulates CrkI @-@ transformation
(x4 / regulate-01
      :ARG0 (x1 / phosphorylate-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "Dok1")
                  :xref (x / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
      :ARG1 (x7 / transform-01
            :ARG0 (x5 / enzyme
                  :name (x6 / name :op1 "CrkI")
                  :xref (x8 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203"))))


# ::id PMC4302068.257
# ::snt A) CrkI (blue) overexpression nucleates formation of localized protein complexes, including those directly bound (Sos and Abl shown here) and indirectly bound (Dok1 and RasGAP).
# ::tok A ) CrkI ( blue ) overexpression nucleates formation of localized protein complexes , including those directly bound ( Sos and Abl shown here ) and indirectly bound ( Dok1 and RasGAP ) .
(x1 / and
      :li "a"
      :op1 (x4 / overexpress-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "CrkI" :op2 "blue")))
      :ARG1-of (x6 / form-01
            :ARG0 (x5 / nucleate-00)
            :ARG1 (x9 / macro-molecular-complex
                  :mod (x7 / localize-01
                        :ARG1 (x8 / protein))
                  :ARG2-of (x10 / include-01
                        :ARG1 (x21 / and
                              :op1 (x13 / bind-01
                                    :mod (x11 / that)
                                    :ARG1-of (x12 / direct-02)
                                    :ARG1-of (x19 / show-01
                                          :ARG0 (x16 / and
                                                :op1 (x14 / protein
                                                      :name (x15 / name :op1 "sos-1")
                                                      :xref (x31 / xref :value "UNIPROT:SOS1_HUMAN" :prob "0.633"))
                                                :op2 (x17 / protein
                                                      :name (x18 / name :op1 "Abl")
                                                      :xref (x32 / xref :value "UNIPROT:ABL1_HUMAN" :prob "0.603")))
                                          :location (x20 / here)))
                              :op2 (x23 / bind-01
                                    :ARG1-of (x22 / direct-02 :polarity "-")))))
            :ARG1-of (x24 / describe-01
                  :ARG0 (x27 / and
                        :op1 (x25 / protein
                              :name (x26 / name :op1 "Dok1")
                              :xref (x30 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
                        :op2 (x28 / protein
                              :name (x29 / name :op1 "RasGAP")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003"))))))


# ::id PMC4302068.258
# ::snt While Sos serves as a crucial positive effector for CrkI-transformation, phosphorylated Dok1 acts as a negative regulator, likely by inhibiting the Ras pathway by recruiting RasGAP.
# ::tok While Sos serves as a crucial positive effector for CrkI @-@ transformation , phosphorylated Dok1 acts as a negative regulator , likely by inhibiting the Ras pathway by recruiting RasGAP .
(x1 / contrast-01
      :ARG2 (x4 / serve-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "sos-1")
                  :xref (x24 / xref :value "UNIPROT:SOS1_HUMAN" :prob "0.633"))
            :ARG1 (x7 / effector
                  :mod (x5 / crucial)
                  :mod (x6 / positive)
                  :ARG0-of (x10 / transform-01
                        :ARG1 (x8 / enzyme
                              :name (x9 / name :op1 "CrkI")
                              :xref (x23 / xref :value "UNIPROT:CRK_HUMAN" :prob "0.203")))))
      :ARG1 (x14 / act-01
            :ARG0 (x11 / phosphorylate-01
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "Dok1")
                        :xref (x26 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604")))
            :ARG1 (x15 / downregulate-01
                  :ARG1-of (x16 / likely-01)
                  :ARG0 (x17 / inhibit-01)
                  :ARG1 (x18 / enzyme
                        :name (x19 / name :op1 "Ras")
                        :xref (x25 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :manner (x20 / recruit-01
                  :ARG1 (x21 / protein
                        :name (x22 / name :op1 "RasGAP")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "1.003")))))


# ::id PMC4302068.259
# ::snt The net output of the complex is relatively weak transformation.
# ::tok The net output of the complex is relatively weak transformation .
(x5 / weak-02
      :ARG1 (x3 / complex
            :mod (x2 / output
                  :mod (x1 / net)))
      :ARG2-of (x4 / relative-05)
      :ARG0-of (x6 / transform-01))


# ::id PMC4302068.260
# ::snt B) When Abl family kinase activity is inhibited (by knockdown or inhibition), Dok1 is no longer highly phosphorylated and thus loses its ability to repress cell transformation, shifting the balance further toward strong transformation.
# ::tok B ) When Abl family kinase activity is inhibited ( by knockdown or inhibition ) , Dok1 is no longer highly phosphorylated and thus loses its ability to repress cell transformation , shifting the balance further toward strong transformation .
(x7 / inhibit-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "b-raf")
            :xref (x / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.701"))
      :time (x4 / protein-family
            :name (x3 / name :op1 "Abl"))
      :ARG1 (x6 / activity-06
            :ARG0 (x5 / kinase))
      :ARG0 (x9 / or
            :op1 (x8 / knock-down-02)
            :op2 (x10 / inhibit-01))
      :ARG1 (x16 / phosphorylate-01
            :ARG1 (x11 / protein
                  :name (x12 / name :op1 "Dok1")
                  :xref (x28 / xref :value "UNIPROT:DOK1_HUMAN" :prob "0.604"))
            :polarity "-"
            :ARG1-of (x13 / long-03
                  :degree (x14 / more))
            :ARG1-of (x15 / high-02))
      :ARG1-of (x17 / cause-01
            :ARG0 (x18 / lose-02
                  :ARG1 (x19 / capable-01
                        :ARG2 (x20 / repress-01
                              :ARG1 (x22 / transform-01
                                    :ARG1 (x21 / cell)
                                    :ARG2 (x23 / shift-01
                                          :ARG1 (x24 / balance-01)
                                          :degree (x25 / further)))))
                  :ARG2 (x27 / transform-01
                        :ARG1-of (x26 / strong-02)))))


# ::id PMC4331489.0
# ::snt Phosphorylation of ERK5 on Thr732 Is Associated with ERK5 Nuclear Localization and ERK5-Dependent Transcription
# ::tok Phosphorylation of ERK5 on Thr732 Is Associated with ERK5 Nuclear Localization and ERK5 @-@ Dependent Transcription
(x6 / associate-01
      :ARG1 (x1 / phosphorylate-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "ERK5")
                  :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :ARG2 (x4 / amino-acid
                  :mod "732"
                  :name (x5 / name :op1 "threonine")
                  :xref (x19 / xref :value "PUBCHEM:205" :prob "11.848252")))
      :ARG2 (x11 / and
            :op1 (x10 / be-located-at-91
                  :ARG1 (x7 / protein
                        :name (x8 / name :op1 "ERK5")
                        :xref (x17 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :ARG2 (x9 / nucleus
                        :xref (x18 / xref :value "GO:0005634" :prob "0.8")))
            :op2 (x15 / transcribe-01
                  :ARG0-of (x14 / depend-01
                        :ARG1 (x12 / protein
                              :name (x13 / name :op1 "ERK5")
                              :xref (x16 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))))))


# ::id PMC4331489.2
# ::snt Extracellular signal-regulated kinases (ERKs) play critical roles in numerous cellular processes, including proliferation and differentiation.
# ::tok Extracellular signal @-@ regulated kinases ( ERKs ) play critical roles in numerous cellular processes , including proliferation and differentiation .
(x6 / play-02
      :ARG0 (x1 / and
            :op1 (x2 / enzyme
                  :name (x3 / name
                        :op1 "Extracellular"
                        :op2 "signal-regulated"
                        :op3 "kinase"))
            :op2 (x4 / protein-family
                  :name (x5 / name :op1 "erk")))
      :ARG1 (x8 / role
            :ARG1-of (x7 / critical-02)
            :topic (x11 / process-02
                  :quant (x9 / numerous)
                  :location (x10 / cell)))
      :ARG2-of (x12 / include-91
            :ARG1 (x14 / and
                  :op1 (x13 / proliferate-01)
                  :op2 (x15 / differentiate-01))))


# ::id PMC4331489.3
# ::snt ERK5 contains a kinase domain at the N-terminal, and the unique extended C-terminal includes multiple autophosphorylation sites that enhance ERK5-dependent transcription.
# ::tok ERK5 contains a kinase domain at the N @-@ terminal , and the unique extended C @-@ terminal includes multiple autophosphorylation sites that enhance ERK5 @-@ dependent transcription .
(x1 / and
      :op1 (x4 / contain-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "ERK5")
                  :xref (x22 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :ARG1 (x6 / domain
                  :mod (x5 / kinase))
            :location (x7 / protein-segment
                  :name (x8 / name :op1 "n-terminus")))
      :op2 (x10 / extend-01
            :mod (x9 / unique)
            :ARG1 (x11 / protein-segment
                  :name (x12 / name :op1 "c-terminus")
                  :ARG1-of (x13 / include-91
                        :ARG2 (x16 / site
                              :quant (x14 / multiple)
                              :ARG1-of (x15 / phosphorylate-01)
                              :ARG0-of (x17 / enhance-01
                                    :ARG1 (x21 / transcribe-01
                                          :ARG0-of (x20 / depend-01
                                                :ARG1 (x18 / protein
                                                      :name (x19 / name :op1 "ERK5")
                                                      :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))))))))))


# ::id PMC4331489.4
# ::snt However, the impact of phosphorylation at the various sites remain unclear.
# ::tok However , the impact of phosphorylation at the various sites remain unclear .
(x1 / contrast-01
      :ARG2 (x6 / remain-01
            :ARG1 (x2 / impact-01
                  :ARG0 (x3 / phosphorylate-01
                        :ARG1 (x5 / protein-segment
                              :mod (x4 / various))))
            :ARG3 (x7 / clear-06 :polarity "-")))


# ::id PMC4331489.5
# ::snt In this study, we examined the role of phosphorylation at the ERK5 C-terminal.
# ::tok In this study , we examined the role of phosphorylation at the ERK5 C @-@ terminal .
(x4 / examine-01
      :medium (x2 / study-01
            :mod (x1 / this))
      :ARG0 (x3 / we)
      :ARG1 (x5 / role
            :poss (x6 / enzyme
                  :ARG1-of (x7 / phosphorylate-01
                        :ARG1 (x8 / protein
                              :name (x9 / name :op1 "ERK5")
                              :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
                  :name (x10 / name :op1 "c-terminus")
                  :xref (x11 / xref :value "UNIPROT:7B2_HUMAN" :prob "0.242"))))


# ::id PMC4331489.6
# ::snt We found that a constitutively active MEK5 mutant phosphorylated ERK5 at the TEY motif, resulting in the sequential autophosphorylation of multiple C-terminal residues, including Thr732 and Ser769/773/775.
# ::tok We found that a constitutively active MEK5 mutant phosphorylated ERK5 at the TEY motif , resulting in the sequential autophosphorylation of multiple C @-@ terminal residues , including Thr732 and Ser769 @/@ 773 @/@ 775 .
(x2 / find-01
      :ARG0 (x1 / we)
      :ARG1 (x8 / phosphorylate-01
            :ARG1 (x3 / enzyme
                  :ARG0-of (x5 / activity-06
                        :mod (x4 / constitutive))
                  :name (x6 / name :op1 "MEK5")
                  :ARG2-of (x7 / mutate-01)
                  :xref (x29 / xref :value "UNIPROT:MP2K5_HUMAN" :prob "1.002"))
            :ARG1 (x9 / protein
                  :name (x10 / name :op1 "ERK5")
                  :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :location (x12 / protein-segment
                  :name (x11 / name :op1 "TEY"))
            :ARG1-of (x13 / result-01
                  :ARG2 (x26 / slash
                        :op1 (x15 / phosphorylate-01
                              :mod (x14 / sequential)
                              :ARG1 (x19 / residue
                                    :quant (x16 / multiple)
                                    :mod (x17 / protein-segment
                                          :name (x18 / name :op1 "c-terminus"))
                                    :ARG2-of (x20 / include-91
                                          :ARG1 (x21 / and
                                                :op1 (x22 / amino-acid
                                                      :mod "732"
                                                      :name (x23 / name :op1 "threonine")
                                                      :xref (x31 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                                :op2 (x24 / amino-acid
                                                      :mod "769"
                                                      :name (x25 / name :op1 "serine")
                                                      :xref (x30 / xref :value "PUBCHEM:5951" :prob "11.218784"))))))
                        :op2 (x27 / enzyme
                              :name (x28 / name :op1 "773" :op2 "775"))))))


# ::id PMC4331489.7
# ::snt However, when ERK1/2 was selectively activated by an oncogenic RAS mutant, ERK5 phosphorylation at Thr732 was induced without affecting the phosphorylation status at TEY or Ser769/773/775.
# ::tok However , when ERK1 @/@ 2 was selectively activated by an oncogenic RAS mutant , ERK5 phosphorylation at Thr732 was induced without affecting the phosphorylation status at TEY or Ser769 @/@ 773 @/@ 775 .
(x1 / have-concession-91
      :ARG1 (x17 / induce-01
            :time (x11 / mutate-01
                  :ARG1 (x5 / activate-01
                        :ARG1 (x2 / enzyme
                              :name (x3 / name :op1 "ERK1/2"))
                        :manner (x4 / selective)
                        :ARG0 (x6 / enzyme
                              :ARG0-of (x7 / cause-01
                                    :ARG1 (x8 / disease
                                          :wiki "cancer"
                                          :name (x9 / name :op1 "cancer")))
                              :name (x10 / name :op1 "RAS")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
                  :ARG2 (x12 / enzyme
                        :name (x13 / name :op1 "ERK5")
                        :xref (x28 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
            :ARG1 (x14 / phosphorylate-01
                  :ARG1 (x15 / amino-acid
                        :mod "732"
                        :name (x16 / name :op1 "threonine")
                        :xref (x30 / xref :value "PUBCHEM:205" :prob "11.848252")))
            :ARG2 (x18 / affect-01
                  :polarity "-"
                  :ARG1 (x19 / status
                        :mod (x20 / phosphorylate-01
                              :ARG1 (x23 / or
                                    :op1 (x21 / enzyme
                                          :name (x22 / name :op1 "TEY"))
                                    :op2 (x24 / amino-acid
                                          :mod "769"
                                          :name (x25 / name :op1 "serine")
                                          :xref (x29 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x26 / enzyme
                                          :name (x27 / name :op1 "773" :op2 "775"))))))))


# ::id PMC4331489.8
# ::snt The Thr732 phosphorylation was U0126-sensitive and was observed in a kinase-dead mutant of ERK5 as well, suggesting that ERK1/2 can phosphorylate ERK5 at Thr732.
# ::tok The Thr732 phosphorylation was U0126 @-@ sensitive and was observed in a kinase @-@ dead mutant of ERK5 as well , suggesting that ERK1 @/@ 2 can phosphorylate ERK5 at Thr732 .
(x8 / observe-01
      :ARG1 (x3 / phosphorylate-01
            :ARG1 (x1 / amino-acid
                  :mod "732"
                  :name (x2 / name :op1 "threonine")
                  :xref (x28 / xref :value "PUBCHEM:205" :prob "11.848252")))
      :ARG1 (x7 / and
            :ARG0-of (x6 / sensitive-03
                  :ARG1 (x4 / small-molecule
                        :name (x5 / name :op1 "U0126")
                        :xref (x29 / xref :value "PUBCHEM:3006531" :prob "17.656696"))))
      :manner (x12 / mutate-01
            :ARG1 (x9 / enzyme
                  :name (x10 / name :op1 "kinase")
                  :ARG1-of (x11 / die-01)
                  :xref (x25 / xref :value "UNIPROT:ITK_HUMAN" :prob "0.293"))
            :ARG2 (x13 / enzyme
                  :name (x14 / name :op1 "ERK5")
                  :xref (x26 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
      :mod (x15 / as-well)
      :ARG0-of (x16 / suggest-01
            :ARG1 (x17 / possible-01
                  :ARG1 (x20 / phosphorylate-01
                        :ARG0 (x18 / enzyme
                              :name (x19 / name :op1 "ERK1/2"))
                        :ARG1 (x21 / protein
                              :name (x22 / name :op1 "ERK5")
                              :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                        :location (x23 / amino-acid
                              :mod "732"
                              :name (x24 / name :op1 "threonine")
                              :xref (x27 / xref :value "PUBCHEM:205" :prob "11.848252"))))))


# ::id PMC4331489.9
# ::snt This phosphorylation was also promoted by epidermal growth factor and nerve growth factor in HEK293 and PC12 cells, respectively.
# ::tok This phosphorylation was also promoted by epidermal growth factor and nerve growth factor in HEK293 and PC12 cells , respectively .
(x4 / promote-01
      :ARG1 (x2 / phosphorylate-01
            :mod (x1 / this))
      :mod (x3 / also)
      :ARG0 (x7 / and
            :op1 (x5 / enzyme
                  :name (x6 / name
                        :op1 "epidermal"
                        :op2 "growth"
                        :op3 "factor"))
            :op2 (x9 / growth-factor
                  :mod (x8 / nerve)))
      :location (x10 / and
            :op2 (x12 / cell-line
                  :name (x11 / name :op1 "PC12"))
            :mod (x13 / respective)))


# ::id PMC4331489.10
# ::snt The ERK5–T732A mutant was localized in the cytosol under basal conditions.
# ::tok The ERK5–T732A mutant was localized in the cytosol under basal conditions .
(x4 / be-located-at-91
      :ARG1 (x3 / mutate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "ERK5–T732A")
                  :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "0.222")))
      :ARG2 (x5 / cytosol
            :xref (x8 / xref :value "GO:0005829" :prob "0.8"))
      :condition (x7 / condition
            :mod (x6 / basal)))


# ::id PMC4331489.11
# ::snt In contrast, ERK5 phosphorylated at Thr732 via the RAS-ERK1/2 pathway and ERK5–T732E, which mimics the phosphorylated form, were localized in both the nucleus and cytosol.
# ::tok In contrast , ERK5 phosphorylated at Thr732 via the RAS @-@ ERK1 @/@ 2 pathway and ERK5–T732E , which mimics the phosphorylated form , were localized in both the nucleus and cytosol .
(x1 / contrast-01
      :ARG2 (x17 / localize-01
            :ARG1 (x11 / and
                  :op1 (x10 / pathway
                        :ARG1-of (x4 / phosphorylate-01
                              :ARG2 (x2 / protein
                                    :name (x3 / name :op1 "ERK5")
                                    :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                              :ARG1 (x5 / amino-acid
                                    :mod "732"
                                    :name (x6 / name :op1 "threonine")
                                    :xref (x26 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :ARG3 (x7 / enzyme
                                    :name (x8 / name :op1 "RAS")
                                    :xref (x23 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
                        :name (x9 / name :op1 "erk1/2"))
                  :op2 (x12 / enzyme
                        :name (x13 / name :op1 "ERK5–T732E")
                        :xref (x22 / xref :value "UNIPROT:MK07_HUMAN" :prob "0.222"))
                  :ARG0-of (x14 / mimic-01
                        :ARG1 (x15 / phosphorylate-01)
                        :ARG2 (x16 / form)))
            :location (x20 / and
                  :mod (x18 / both)
                  :op1 (x19 / nucleus
                        :xref (x25 / xref :value "GO:0005634" :prob "0.8"))
                  :op2 (x21 / cytosol
                        :xref (x24 / xref :value "GO:0005829" :prob "0.8")))))


# ::id PMC4331489.12
# ::snt Finally, ER–32A and U0126 blocked ERK5-dependent MEF2C transcriptional activity.
# ::tok Finally , ER–32A and U0126 blocked ERK5 @-@ dependent MEF2C transcriptional activity .
(x7 / block-01
      :time (x1 / final)
      :ARG0 (x4 / and
            :op1 (x2 / enzyme
                  :name (x3 / name :op1 "ER–32A"))
            :op2 (x5 / small-molecule
                  :name (x6 / name :op1 "U0126")
                  :xref (x16 / xref :value "PUBCHEM:3006531" :prob "17.656696")))
      :ARG1 (x14 / activity-06
            :ARG0-of (x10 / depend-01
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "ERK5")
                        :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
            :ARG1 (x13 / transcribe-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "MEF2C")
                        :xref (x15 / xref :value "UNIPROT:MEF2C_HUMAN" :prob "1.003")))))


# ::id PMC4331489.13
# ::snt Based on these findings, we propose a novel cross-talk mechanism in which ERK1/2, following activation by growth factor stimulation, phosphorylates ERK5 at Thr732.
# ::tok Based on these findings , we propose a novel cross @-@ talk mechanism in which ERK1 @/@ 2 , following activation by growth factor stimulation , phosphorylates ERK5 at Thr732 .
(x6 / propose-01
      :ARG1-of (x1 / base-02
            :ARG2 (x3 / thing
                  :mod (x2 / this)
                  :ARG1-of (x4 / find-01)))
      :ARG0 (x5 / we)
      :ARG1 (x17 / phosphorylate-01
            :mod (x7 / novel)
            :ARG0-of (x8 / crosstalk-00
                  :ARG0 (x9 / mechanism
                        :ARG2-of (x10 / enzyme
                              :name (x11 / name :op1 "ERK1/2"))))
            :ARG1-of (x12 / follow-01
                  :ARG2 (x13 / activate-01
                        :ARG0 (x16 / stimulate-01
                              :ARG0 (x14 / protein
                                    :name (x15 / name :op1 "growth-factor")
                                    :xref (x22 / xref :value "UNIPROT:MT3_HUMAN" :prob "0.282")))))
            :ARG1 (x18 / protein
                  :name (x19 / name :op1 "ERK5")
                  :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :location (x20 / amino-acid
                  :mod "732"
                  :name (x21 / name :op1 "threonine")
                  :xref (x23 / xref :value "PUBCHEM:205" :prob "11.848252"))))


# ::id PMC4331489.14
# ::snt This phosphorylation event is responsible for ERK5 nuclear localization and ERK5-dependent transcription.
# ::tok This phosphorylation event is responsible for ERK5 nuclear localization and ERK5 @-@ dependent transcription .
(x4 / responsible-01
      :ARG1 (x2 / phosphorylate-01
            :mod (x1 / this))
      :ARG0 (x3 / event)
      :ARG1 (x9 / and
            :op1 (x8 / be-located-at-91
                  :ARG1 (x5 / protein
                        :name (x6 / name :op1 "ERK5")
                        :xref (x14 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :ARG2 (x7 / nucleus
                        :xref (x15 / xref :value "GO:0005634" :prob "0.8")))
            :op2 (x13 / transcribe-01
                  :ARG0-of (x12 / depend-01
                        :ARG1 (x10 / protein
                              :name (x11 / name :op1 "ERK5")
                              :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))))))


# ::id PMC4331489.53
# ::snt SDS-polyacrylamide gel electrophoresis and Western blotting
# ::tok SDS @-@ polyacrylamide gel electrophoresis and Western blotting
(x4 / and
      :op1 (x3 / electrophoresis
            :ARG1 (x2 / gel
                  :name (x1 / name :op1 "SDS" :op2 "polyacrylamide")))
      :op2 (x5 / immunoblot-01))


# ::id PMC4331489.63
# ::snt ERK5 Thr732 and Ser769/773/775 are autophosphorylated in HEK293 cells.
# ::tok ERK5 Thr732 and Ser769 @/@ 773 @/@ 775 are autophosphorylated in HEK293 cells .
(x10 / phosphorylate-01
      :ARG1 (x5 / and
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "ERK5")
                  :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :op1 (x3 / amino-acid
                  :mod "732"
                  :name (x4 / name :op1 "threonine")
                  :xref (x13 / xref :value "PUBCHEM:205" :prob "11.848252"))
            :op2 (x6 / amino-acid
                  :mod "769"
                  :name (x7 / name :op1 "serine")
                  :xref (x14 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :op2 (x8 / enzyme
                  :name (x9 / name :op1 "773"))
            :op2 "775")
      :location (x12 / cell-line
            :name (x11 / name :op1 "HEK293")))


# ::id PMC4331489.64
# ::snt Empty vector (Vec) was used as a control.
# ::tok Empty vector ( Vec ) was used as a control .
(x6 / use-01
      :ARG1 (x1 / and
            :op1 (x3 / vector
                  :ARG1-of (x2 / empty-02))
            :op2 (x4 / cell-line
                  :name (x5 / name :op1 "as2/vec-11")))
      :ARG2 (x7 / control-01))


# ::id PMC4331489.65
# ::snt Cells were lysed, and ERK5 phosphorylation status at the TEY site, Thr732 and Ser769/Ser773/Ser775, as well as mycERK5, ERK1/2 phosphorylation at TEY, and ERK2 were examined by Western blotting.
# ::tok Cells were lysed , and ERK5 phosphorylation status at the TEY site , Thr732 and Ser769/Ser773/Ser775 , as well as mycERK5 , ERK1 @/@ 2 phosphorylation at TEY , and ERK2 were examined by Western blotting .
(x16 / and
      :op1 (x8 / status
            :ARG1 (x1 / cell)
            :mod (x7 / phosphorylate-01
                  :ARG1 (x4 / and
                        :op1 (x2 / enzyme
                              :name (x3 / name :op1 "lysed"))
                        :op2 (x5 / protein
                              :name (x6 / name :op1 "ERK5")
                              :xref (x29 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))))
            :location (x10 / protein-segment
                  :name (x9 / name :op1 "TEY")))
      :op2 (x13 / and
            :op1 (x11 / amino-acid
                  :mod "732"
                  :name (x12 / name :op1 "threonine")
                  :xref (x30 / xref :value "PUBCHEM:205" :prob "11.848252"))
            :op2 (x14 / enzyme
                  :name (x15 / name :op1 "Ser769/Ser773/Ser775")))
      :op2 (x27 / examine-01
            :ARG1 (x24 / and
                  :op1 (x17 / protein
                        :name (x18 / name :op1 "mycERK5"))
                  :op2 (x21 / phosphorylate-01
                        :ARG1 (x19 / enzyme
                              :name (x20 / name :op1 "ERK1/2"))
                        :location (x22 / cell-line
                              :name (x23 / name :op1 "TEY")))
                  :op2 (x25 / enzyme
                        :name (x26 / name :op1 "ERK2")
                        :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "1.003")))
            :manner (x28 / immunoblot-01)))


# ::id PMC4331489.66
# ::snt ERK5 phosphorylation status at the TEY site and Thr732, and mycERK5 were examined by Western blotting.
# ::tok ERK5 phosphorylation status at the TEY site and Thr732 , and mycERK5 were examined by Western blotting .
(x13 / examine-01
      :ARG1 (x10 / and
            :op1 (x4 / status
                  :mod (x3 / phosphorylate-01
                        :ARG1 (x1 / enzyme
                              :name (x2 / name :op1 "ERK5")
                              :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
                  :location (x7 / and
                        :op1 (x6 / protein-segment
                              :name (x5 / name :op1 "TEY"))
                        :op2 (x8 / amino-acid
                              :mod "732"
                              :name (x9 / name :op1 "threonine")
                              :xref (x15 / xref :value "PUBCHEM:205" :prob "11.848252"))))
            :op2 (x11 / enzyme
                  :name (x12 / name :op1 "mycERK5")))
      :manner (x14 / immunoblot-01))


# ::id PMC4331489.67
# ::snt U0126 (30 μM) was added, and the phosphorylation status of ERK5 and ERK2 at their TEY sites and mycERK5 or mycERK2 were examined by Western blotting.
# ::tok U0126 ( 30 μM ) was added , and the phosphorylation status of ERK5 and ERK2 at their TEY sites and mycERK5 or mycERK2 were examined by Western blotting .
(x20 / examine-01
      :ARG1 (x17 / or
            :op1 (x5 / add-02
                  :ARG1 (x1 / small-molecule
                        :name (x2 / name :op1 "U0126")
                        :quant (x3 / concentration-quantity
                              :quant "30"
                              :unit (x4 / micromolar))
                        :xref (x23 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
                  :ARG1 (x6 / and
                        :op1 (x7 / phosphorylate-01
                              :ARG1 (x8 / enzyme
                                    :name (x9 / name :op1 "ERK5")
                                    :xref (x22 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
                        :op2 (x10 / enzyme
                              :name (x11 / name :op1 "ERK2")
                              :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "1.003")))
                  :location (x14 / and
                        :op1 (x13 / protein-segment
                              :name (x12 / name :op1 "TEY"))
                        :op2 (x15 / protein
                              :name (x16 / name :op1 "mycERK5"))))
            :op2 (x18 / enzyme
                  :name (x19 / name :op1 "mycERK2")))
      :ARG0 (x21 / immunoblot-01))


# ::id PMC4331489.82
# ::snt Reporter gene assay
# ::tok Reporter gene assay
(x3 / assay-01
      :ARG1 (x2 / gene
            :ARG0-of (x1 / report-01)))


# ::id PMC4331489.94
# ::snt Upon phosphorylation of the ERK5 TEY activation motif by MEK5, multiple serine and threonine residues in the ERK5 C-terminal are autophosphorylated.
# ::tok Upon phosphorylation of the ERK5 TEY activation motif by MEK5 , multiple serine and threonine residues in the ERK5 C @-@ terminal are autophosphorylated .
(x13 / and
      :condition (x6 / activate-01
            :ARG0 (x1 / phosphorylate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "ERK5")
                        :xref (x24 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "TEY"))
            :ARG1 (x7 / protein-segment)
            :ARG0 (x8 / protein
                  :name (x9 / name :op1 "MEK5")
                  :xref (x23 / xref :value "UNIPROT:MP2K5_HUMAN" :prob "1.002")))
      :op1 (x10 / enzyme
            :mod (x11 / multiple)
            :name (x12 / name :op1 "serine")
            :xref (x22 / xref :value "UNIPROT:SRR_HUMAN" :prob "0.282"))
      :op2 (x21 / phosphorylate-01
            :ARG1 (x16 / residue
                  :mod (x14 / amino-acid
                        :name (x15 / name :op1 "threonine")
                        :xref (x25 / xref :value "PUBCHEM:205" :prob "11.848252"))
                  :location (x19 / protein-segment
                        :mod (x17 / protein
                              :name (x18 / name :op1 "ERK5")
                              :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                        :name (x20 / name :op1 "c-terminus")))))


# ::id PMC4331489.95
# ::snt It is thought that the C-terminal can, by itself, promote gene transcription when phosphorylated at Ser769/773/775 and Thr732 [ 4 ].
# ::tok It is thought that the C @-@ terminal can , by itself , promote gene transcription when phosphorylated at Ser769 @/@ 773 @/@ 775 and Thr732 [ 4 ] .
(x1 / think-01
      :ARG1 (x2 / protein-segment
            :name (x3 / name :op1 "c-terminus")
            :ARG1-of (x4 / possible-01
                  :mod (x5 / by-oneself
                        :ARG0-of (x6 / promote-01
                              :ARG1 (x15 / and
                                    :op1 (x8 / transcribe-01
                                          :ARG1 (x7 / gene)
                                          :time (x12 / slash
                                                :op1 (x9 / phosphorylate-01
                                                      :ARG1 (x10 / amino-acid
                                                            :mod "769"
                                                            :name (x11 / name :op1 "serine")
                                                            :xref (x / xref :value "PUBCHEM:5951" :prob "11.218784")))
                                                :op2 (x13 / enzyme
                                                      :name (x14 / name :op1 "773" :op2 "775"))))
                                    :op2 (x16 / amino-acid
                                          :mod "732"
                                          :name (x17 / name :op1 "threonine")
                                          :xref (x21 / xref :value "PUBCHEM:205" :prob "11.848252"))))
                        :ARG1-of (x18 / describe-01
                              :ARG0 (x19 / publication
                                    :ARG1-of (x20 / cite-01 :ARG2 "4")))))))


# ::id PMC4331489.96
# ::snt Thus, we hypothesized that ERK2 interacts with ERK5 and influences the phosphorylation status of the ERK5 C-terminal.
# ::tok Thus , we hypothesized that ERK2 interacts with ERK5 and influences the phosphorylation status of the ERK5 C @-@ terminal .
(x1 / cause-01
      :ARG1 (x3 / hypothesize-01
            :ARG0 (x2 / we)
            :ARG1 (x6 / interact-01
                  :ARG0 (x4 / enzyme
                        :name (x5 / name :op1 "ERK2")
                        :xref (x18 / xref :value "UNIPROT:MK01_HUMAN" :prob "1.003"))
                  :ARG1 (x9 / and
                        :op1 (x7 / protein
                              :name (x8 / name :op1 "ERK5")
                              :xref (x17 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                        :op2 (x10 / influence-01
                              :ARG1 (x12 / status
                                    :mod (x11 / phosphorylate-01)
                                    :poss (x13 / protein
                                          :name (x14 / name :op1 "ERK5")
                                          :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))))))
            :ARG1 (x15 / protein-segment
                  :name (x16 / name :op1 "c-terminus"))))


# ::id PMC4331489.97
# ::snt To address this possibility, we created antibodies that recognize phospho-Ser769/773/775 or phospho-Thr732.
# ::tok To address this possibility , we created antibodies that recognize phospho @-@ Ser769 @/@ 773 @/@ 775 or phospho @-@ Thr732 .
(x5 / create-01
      :purpose (x1 / address-02
            :ARG1 (x3 / possible-01
                  :mod (x2 / this)))
      :ARG0 (x4 / we)
      :ARG1 (x13 / or
            :op1 (x6 / antibody
                  :ARG0-of (x7 / recognize-02
                        :ARG1 (x8 / phosphorylate-01
                              :ARG2 (x9 / amino-acid
                                    :mod "769"
                                    :name (x10 / name :op1 "serine")
                                    :xref (x17 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                        :ARG2 (x11 / enzyme
                              :name (x12 / name :op1 "773" :op2 "775"))))
            :op2 (x14 / phosphorylate-01
                  :ARG2 (x15 / amino-acid
                        :mod "732"
                        :name (x16 / name :op1 "threonine")
                        :xref (x / xref :value "PUBCHEM:205" :prob "11.848252")))))


# ::id PMC4331489.98
# ::snt In preliminary experiments, we showed that the phospho-Ser769/773/775 antibody displays the strongest preference for triple phospho-Ser peptides (data not shown).
# ::tok In preliminary experiments , we showed that the phospho @-@ Ser769 @/@ 773 @/@ 775 antibody displays the strongest preference for triple phospho @-@ Ser peptides ( data not shown ) .
(x4 / show-01
      :location (x2 / experiment-01
            :mod (x1 / preliminary))
      :ARG0 (x3 / we)
      :ARG1 (x9 / antibody
            :ARG1-of (x5 / phosphorylate-01
                  :ARG2 (x6 / amino-acid
                        :mod "769"
                        :name (x7 / name :op1 "serine")
                        :xref (x22 / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :mod (x8 / slash :op1 "202" :op2 "773")
            :quant "775"
            :ARG0-of (x10 / display-01))
      :ARG1 (x13 / prefer-01
            :ARG1-of (x11 / strong-02
                  :degree (x12 / most))
            :ARG1 (x18 / peptide
                  :ARG1-of (x14 / triple-01
                        :ARG1 (x15 / enzyme
                              :ARG3-of (x16 / phosphorylate-01)
                              :name (x17 / name :op1 "serine")
                              :xref (x / xref :value "UNIPROT:SRR_HUMAN" :prob "0.282")))))
      :ARG1-of (x19 / describe-01
            :ARG0 (x20 / data
                  :ARG1-of (x21 / show-01 :polarity "-"))))


# ::id PMC4331489.99
# ::snt In HEK293 cells, constitutively active mutants of MEK5 (MEK5D) promoted ERK5 phosphorylation at its TEY site, resulting in sequential autophosphorylation at Thr732 and Ser769/773/775.
# ::tok In HEK293 cells , constitutively active mutants of MEK5 ( MEK5D ) promoted ERK5 phosphorylation at its TEY site , resulting in sequential autophosphorylation at Thr732 and Ser769 @/@ 773 @/@ 775 .
(x8 / promote-01
      :location (x1 / cell
            :name (x2 / name :op1 "HEK293"))
      :ARG0 (x5 / mutate-01
            :mod (x3 / constitutive)
            :ARG0-of (x4 / activity-06)
            :ARG2 (x6 / enzyme
                  :name (x7 / name :op1 "MEK5" :op2 "MEK5D")))
      :ARG1 (x20 / and
            :op1 (x11 / phosphorylate-01
                  :ARG1 (x9 / enzyme
                        :name (x10 / name :op1 "ERK5")
                        :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :location (x14 / site
                        :mod (x12 / protein-segment
                              :name (x13 / name :op1 "TEY")))
                  :ARG1-of (x15 / result-01
                        :ARG2 (x17 / phosphorylate-01
                              :mod (x16 / sequence)))
                  :ARG1 (x18 / amino-acid
                        :mod "732"
                        :name (x19 / name :op1 "threonine")
                        :xref (x27 / xref :value "PUBCHEM:205" :prob "11.848252")))
            :op2 (x21 / and
                  :op1 (x22 / amino-acid
                        :mod "769"
                        :name (x23 / name :op1 "serine")
                        :xref (x26 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                  :op2 (x24 / small-molecule
                        :name (x25 / name :op1 "773" :op2 "775")))))


# ::id PMC4331489.100
# ::snt A band shift of phospho-ERK5 was induced by the autophosphorylation, as often observed in other studies [ 11 ] ( Fig. 1A ).
# ::tok A band shift of phospho @-@ ERK5 was induced by the autophosphorylation , as often observed in other studies [ 11 ] ( Fig . 1A ) .
(x6 / induce-01
      :ARG1 (x2 / shift-01
            :ARG0 (x1 / band)
            :ARG1 (x3 / phosphorylate-01
                  :ARG2 (x4 / enzyme
                        :name (x5 / name :op1 "ERK5")
                        :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))))
      :ARG2 (x7 / phosphorylate-01)
      :ARG1-of (x9 / observe-01
            :mod (x8 / often)
            :location (x11 / study-01
                  :mod (x10 / other))
            :ARG1-of (x12 / describe-01
                  :ARG0 (x13 / publication
                        :ARG1-of (x14 / cite-01 :ARG2 "11")))
            :ARG1-of (x15 / describe-01
                  :ARG0 (x16 / figure :mod "1a"))))


# ::id PMC4331489.101
# ::snt However, while MEK5D phosphorylated a kinase-dead mutant of ERK5 (ERK5-KD) at its TEY site, autophosphorylation at Thr732 and Ser769/773/775 and the associated band shift were no longer observed because of the absence of kinase activity ( Fig. 1A ).
# ::tok However , while MEK5D phosphorylated a kinase @-@ dead mutant of ERK5 ( ERK5 @-@ KD ) at its TEY site , autophosphorylation at Thr732 and Ser769 @/@ 773 @/@ 775 and the associated band shift were no longer observed because of the absence of kinase activity ( Fig . 1A ) .
(x1 / multi-sentence
      :snt1 (x2 / have-concession-91
            :ARG1 (x3 / contrast-01
                  :ARG2 (x6 / phosphorylate-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "MEK5D")
                              :xref (x38 / xref :value "UNIPROT:MP2K5_HUMAN" :prob "0.312"))
                        :ARG2 (x7 / enzyme
                              :name (x8 / name :op1 "kinase")
                              :ARG1-of (x9 / die-01
                                    :ARG1-of (x10 / mutate-01
                                          :ARG2 (x11 / enzyme
                                                :name (x12 / name :op1 "ERK5")
                                                :xref (x39 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                                          :ARG1 (x15 / dissociate-01
                                                :ARG1 (x13 / protein
                                                      :name (x14 / name :op1 "ERK5")
                                                      :xref (x40 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))))
                              :xref (x / xref :value "UNIPROT:ITK_HUMAN" :prob "0.293")))
                  :ARG1 (x26 / and
                        :op1 (x17 / protein-segment
                              :name (x16 / name :op1 "TEY"))
                        :op2 (x18 / phosphorylate-01
                              :ARG1 (x19 / and
                                    :op1 (x20 / amino-acid
                                          :mod "732"
                                          :name (x21 / name :op1 "threonine")
                                          :xref (x41 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                    :op2 (x22 / amino-acid
                                          :mod "769"
                                          :name (x23 / name :op1 "serine")
                                          :xref (x42 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                              :ARG2 (x24 / enzyme
                                    :name (x25 / name :op1 "773" :op2 "775"))))))
      :snt2 (x31 / observe-01
            :ARG1 (x27 / associate-01
                  :ARG1 (x28 / band
                        :ARG1-of (x29 / shift-01)))
            :time (x30 / no-longer)
            :ARG1-of (x32 / cause-01
                  :ARG0 (x33 / absent-01
                        :ARG1 (x35 / activity-06
                              :ARG0 (x34 / kinase))))
            :ARG1-of (x36 / describe-01
                  :ARG0 (x37 / figure :mod "1a"))))


# ::id PMC4331489.102
# ::snt ERK1/2 phosphorylation was not induced by MEK5D.
# ::tok ERK1 @/@ 2 phosphorylation was not induced by MEK5D .
(x4 / induce-01
      :ARG1 (x3 / phosphorylate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "ERK1/2")))
      :polarity "-"
      :ARG0 (x5 / protein
            :name (x6 / name :op1 "MEK5D")
            :xref (x / xref :value "UNIPROT:MP2K5_HUMAN" :prob "0.312")))


# ::id PMC4331489.103
# ::snt To evaluate the specificity of the antibody against phospho-ERK5 at Thr732, ERK5-WT, ER–32A and ERK5-KD were expressed in HEK293 cells, and the phosphorylation status of these ERK5 mutants was examined.
# ::tok To evaluate the specificity of the antibody against phospho @-@ ERK5 at Thr732 , ERK5 @-@ WT , ER–32A and ERK5 @-@ KD were expressed in HEK293 cells , and the phosphorylation status of these ERK5 mutants was examined .
(x24 / and
      :purpose (x1 / evaluate-01
            :ARG1 (x2 / specific-02
                  :ARG1 (x3 / antibody
                        :ARG0-of (x4 / counter-01
                              :ARG1 (x5 / enzyme
                                    :ARG3-of (x6 / phosphorylate-01)
                                    :name (x7 / name :op1 "ERK5")
                                    :xref (x32 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))))
                  :ARG2 (x8 / and
                        :op1 (x9 / amino-acid
                              :mod "732"
                              :name (x10 / name :op1 "threonine")
                              :xref (x35 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :op2 (x11 / enzyme
                              :name (x12 / name :op1 "ERK5")
                              :mod (x13 / wild-type)
                              :xref (x33 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                        :op3 (x21 / express-03
                              :ARG2 (x16 / and
                                    :op1 (x14 / enzyme
                                          :name (x15 / name :op1 "ER–32A"))
                                    :op2 (x17 / protein
                                          :name (x18 / name :op1 "ERK5")
                                          :xref (x34 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                                    :op2 (x19 / enzyme
                                          :name (x20 / name :op1 "nik(kd)")))
                              :ARG3 (x23 / cell-line
                                    :name (x22 / name :op1 "HEK293"))))))
      :op2 (x31 / examine-01
            :ARG1 (x25 / status
                  :mod (x26 / phosphorylate-01
                        :ARG1 (x30 / mutate-01
                              :mod (x27 / this)
                              :ARG2 (x28 / enzyme
                                    :name (x29 / name :op1 "ERK5")
                                    :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))))))


# ::id PMC4331489.104
# ::snt As expected, phosphorylation of ERK5 at Thr732 was diminished in ER–32A- and ERK5-KD-expressing cells ( Fig. 1B ), confirming the specificity of the antibody.
# ::tok As expected , phosphorylation of ERK5 at Thr732 was diminished in ER–32A @- and ERK5 @-@ KD @-@ expressing cells ( Fig . 1B ) , confirming the specificity of the antibody .
(x18 / confirm-01
      :ARG1-of (x1 / expect-01)
      :ARG0 (x7 / diminish-01
            :ARG1 (x2 / phosphorylate-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "ERK5")
                        :xref (x21 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :location (x5 / amino-acid
                        :mod "732"
                        :name (x6 / name :op1 "threonine")
                        :xref (x22 / xref :value "PUBCHEM:205" :prob "11.848252")))
            :location (x15 / cell
                  :ARG3-of (x14 / express-03
                        :ARG2 (x10 / and
                              :op1 (x8 / enzyme
                                    :name (x9 / name :op1 "ER–32A"))
                              :op2 (x13 / dissociate-01
                                    :ARG1 (x11 / protein
                                          :name (x12 / name :op1 "ERK5")
                                          :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))))))
            :ARG1-of (x16 / describe-01
                  :ARG0 (x17 / figure :mod "1b")))
      :ARG1-of (x19 / specific-02
            :ARG1 (x20 / antibody)))


# ::id PMC4331489.105
# ::snt The band shift of ERK5 was partially blocked in ER–32A-transfected cells.
# ::tok The band shift of ERK5 was partially blocked in ER–32A @-@ transfected cells .
(x6 / block-01
      :ARG1 (x2 / shift-01
            :ARG0 (x1 / band)
            :ARG1 (x3 / protein
                  :name (x4 / name :op1 "ERK5")
                  :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
      :degree (x5 / part)
      :location (x10 / cell
            :ARG1-of (x9 / transfect-01
                  :ARG2 (x7 / enzyme
                        :name (x8 / name :op1 "ER–32A")))))


# ::id PMC4331489.106
# ::snt We also assessed the specificity of U0126, an inhibitor of ERK1/2 signaling, because the effects of U0126 on MEK5 activity have been controversial [ 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ].
# ::tok We also assessed the specificity of U0126 , an inhibitor of ERK1 @/@ 2 signaling , because the effects of U0126 on MEK5 activity have been controversial [ 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ] .
(x3 / assess-01
      :ARG0 (x1 / we)
      :mod (x2 / also)
      :ARG1 (x4 / specific-02
            :ARG1 (x5 / small-molecule
                  :name (x6 / name :op1 "U0126")
                  :ARG0-of (x7 / inhibit-01
                        :ARG1 (x10 / signal-07
                              :ARG0 (x8 / enzyme
                                    :name (x9 / name :op1 "ERK1/2"))))
                  :xref (x25 / xref :value "PUBCHEM:3006531" :prob "17.656696")))
      :ARG1-of (x11 / cause-01
            :ARG0 (x12 / affect-01
                  :ARG0 (x13 / small-molecule
                        :name (x14 / name :op1 "U0126")
                        :xref (x26 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
                  :ARG1 (x17 / activity-06
                        :ARG0 (x15 / protein
                              :name (x16 / name :op1 "MEK5")
                              :xref (x / xref :value "UNIPROT:MP2K5_HUMAN" :prob "1.002")))
                  :ARG0-of (x18 / have-03
                        :ARG1 (x19 / controversy))
                  :ARG1-of (x20 / describe-01
                        :ARG0 (x24 / and
                              :op1 (x21 / publication
                                    :ARG1-of (x22 / cite-01
                                          :ARG2 (x23 / and
                                                :op1 "23"
                                                :op2 "24"
                                                :op3 "25")))
                              :op1 "26"
                              :op2 "27"
                              :op3 "28"
                              :op4 "29"
                              :op5 "30")))))


# ::id PMC4331489.107
# ::snt Although ERK5 phosphorylation at the TEY site by MEK5D was not affected by U0126 in HEK293 cells, ERK1/2 phosphorylation by oncogenic RAS signaling was abolished by U0126 ( Fig. 1C ).
# ::tok Although ERK5 phosphorylation at the TEY site by MEK5D was not affected by U0126 in HEK293 cells , ERK1 @/@ 2 phosphorylation by oncogenic RAS signaling was abolished by U0126 ( Fig . 1C ) .
(x1 / have-concession-91
      :ARG2 (x9 / affect-01
            :ARG1 (x4 / phosphorylate-01
                  :ARG1 (x2 / protein
                        :name (x3 / name :op1 "ERK5")
                        :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :ARG1 (x6 / protein-segment
                        :name (x5 / name :op1 "TEY"))
                  :ARG0 (x7 / enzyme
                        :name (x8 / name :op1 "MEK5D")
                        :xref (x28 / xref :value "UNIPROT:MP2K5_HUMAN" :prob "0.312")))
            :polarity "-"
            :ARG0 (x10 / small-molecule
                  :name (x11 / name :op1 "U0126")
                  :xref (x31 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
            :location (x13 / cell-line
                  :name (x12 / name :op1 "HEK293")))
      :ARG1 (x23 / abolish-01
            :ARG1 (x16 / phosphorylate-01
                  :ARG1 (x14 / enzyme
                        :name (x15 / name :op1 "ERK1/2"))
                  :ARG2 (x22 / signal-07
                        :ARG0 (x17 / enzyme
                              :ARG0-of (x18 / cause-01
                                    :ARG1 (x19 / disease
                                          :wiki "cancer"
                                          :name (x20 / name :op1 "cancer")))
                              :name (x21 / name :op1 "RAS")
                              :xref (x29 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))))
            :ARG0 (x24 / small-molecule
                  :name (x25 / name :op1 "U0126")
                  :xref (x30 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
            :ARG1-of (x26 / describe-01
                  :ARG0 (x27 / figure :mod "1c"))))


# ::id PMC4331489.108
# ::snt This result is consistent with our previous report [ 11 ] and the result in the present study showing that EGF and NGF-induced ERK5 phosphorylation at the TEY site is not blocked by U0126, whereas ERK1/2 phosphorylation is completely inhibited.
# ::tok This result is consistent with our previous report [ 11 ] and the result in the present study showing that EGF and NGF @-@ induced ERK5 phosphorylation at the TEY site is not blocked by U0126 , whereas ERK1 @/@ 2 phosphorylation is completely inhibited .
(x11 / and
      :op1 (x4 / consistent-01
            :ARG1 (x2 / thing
                  :mod (x1 / this)
                  :ARG2-of (x3 / result-01))
            :ARG2 (x7 / report-01
                  :ARG0 (x5 / we)
                  :time (x6 / previous))
            :ARG1-of (x8 / describe-01
                  :ARG0 (x9 / publication
                        :ARG1-of (x10 / cite-01 :ARG2 "11"))))
      :op2 (x16 / show-01
            :ARG0 (x12 / thing
                  :ARG2-of (x13 / result-01)
                  :ARG1-of (x15 / study-01
                        :time (x14 / present)))
            :ARG1 (x31 / contrast-01
                  :ARG1 (x28 / block-01
                        :ARG1 (x19 / and
                              :op1 (x17 / protein
                                    :name (x18 / name :op1 "EGF")
                                    :xref (x38 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                              :op2 (x25 / phosphorylate-01
                                    :ARG2-of (x22 / induce-01
                                          :ARG0 (x20 / protein
                                                :name (x21 / name :op1 "NGF")
                                                :xref (x / xref :value "UNIPROT:NGF_HUMAN" :prob "1.004")))
                                    :ARG1 (x23 / protein
                                          :name (x24 / name :op1 "ERK5")
                                          :xref (x37 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
                              :location (x27 / protein-segment
                                    :name (x26 / name :op1 "TEY")))
                        :polarity "-"
                        :ARG0 (x29 / small-molecule
                              :name (x30 / name :op1 "U0126")
                              :xref (x39 / xref :value "PUBCHEM:3006531" :prob "17.656696")))
                  :ARG2 (x36 / inhibit-01
                        :ARG1 (x34 / phosphorylate-01
                              :ARG1 (x32 / enzyme
                                    :name (x33 / name :op1 "ERK1/2")))
                        :degree (x35 / complete)))))


# ::id PMC4331489.109
# ::snt It has been shown that ERK1/2 forms homodimers upon phosphorylation by the upstream kinase MEK1/2 [ 31 ].
# ::tok It has been shown that ERK1 @/@ 2 forms homodimers upon phosphorylation by the upstream kinase MEK1 @/@ 2 [ 31 ] .
(x1 / show-01
      :ARG1 (x4 / form-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "ERK1/2"))
            :ARG1 (x5 / homodimer)
            :condition (x6 / phosphorylate-01
                  :ARG0 (x8 / kinase
                        :ARG0-of (x7 / upstream)
                        :name (x9 / name :op1 "MEK1/2")
                        :ARG1-of (x10 / describe-01
                              :ARG0 (x11 / publication
                                    :ARG1-of (x12 / cite-01 :ARG2 "31")))))))


# ::id PMC4331489.110
# ::snt In addition, the ERK5 N-terminal domain is important for oligomerization, and ERK5 oligomerizes under both stimulated and unstimulated conditions, although the role of oligomerization remains unclear [ 5 , 32 ].
# ::tok In addition , the ERK5 N @-@ terminal domain is important for oligomerization , and ERK5 oligomerizes under both stimulated and unstimulated conditions , although the role of oligomerization remains unclear [ 5 , 32 ] .
(x1 / and
      :op2 (x15 / have-concession-91
            :ARG1 (x8 / and
                  :op1 (x2 / protein
                        :name (x3 / name :op1 "ERK5")
                        :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :op2 (x6 / important
                        :domain (x4 / protein-segment
                              :name (x5 / name :op1 "n-terminus"))
                        :purpose (x7 / oligomerization))
                  :op3 (x9 / enzyme
                        :name (x10 / name :op1 "ERK5" :op2 "oligomerizes")))
            :condition (x11 / and
                  :op1 (x12 / stimulate-01)
                  :op2 (x14 / condition
                        :ARG1-of (x13 / stimulate-01 :polarity "-")))
            :ARG2 (x19 / remain-01
                  :ARG1 (x16 / role
                        :poss (x17 / enzyme
                              :name (x18 / name :op1 "oligomerization")))
                  :ARG3 (x20 / clear-06 :polarity "-"))
            :ARG1-of (x22 / describe-01
                  :ARG0 (x21 / and :op1 "5" :op2 "32"))))


# ::id PMC4331489.111
# ::snt Because we sought to better understand the interaction between ERK5 and ERK1/2 and determine whether ERK1/2 affects ERK5 phosphorylation at the C-terminal, we examined if these ERKs also form heterodimers/oligomers.
# ::tok Because we sought to better understand the interaction between ERK5 and ERK1 @/@ 2 and determine whether ERK1 @/@ 2 affects ERK5 phosphorylation at the C @-@ terminal , we examined if these ERKs also form heterodimers/oligomers .
(x1 / cause-01
      :ARG0 (x3 / seek-01
            :ARG0 (x2 / we)
            :ARG1 (x4 / good-02
                  :degree (x5 / more)
                  :ARG1 (x6 / understand-01
                        :ARG1 (x7 / interact-01
                              :ARG0 (x8 / protein
                                    :name (x9 / name :op1 "ERK5")
                                    :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                              :ARG1 (x12 / and
                                    :op1 (x10 / enzyme
                                          :name (x11 / name :op1 "ERK1/2"))
                                    :op2 (x13 / determine-01
                                          :ARG1 (x16 / affect-01
                                                :mode "interrogative"
                                                :ARG0 (x14 / enzyme
                                                      :name (x15 / name :op1 "ERK1/2"))
                                                :ARG1 (x19 / phosphorylate-01
                                                      :ARG1 (x17 / protein
                                                            :name (x18 / name :op1 "ERK5")
                                                            :xref (x30 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))))))))
                  :location (x20 / protein-segment
                        :name (x21 / name :op1 "c-terminus"))))
      :ARG1 (x23 / examine-01
            :ARG0 (x22 / we)
            :ARG1 (x27 / form-01
                  :condition (x25 / mutate-01
                        :mod (x24 / this))
                  :mod (x26 / also)
                  :ARG1 (x28 / enzyme
                        :name (x29 / name :op1 "heterodimers/oligomers")))))


# ::id PMC4331489.112
# ::snt As expected, endogenous ERK5 co-immunoprecipitated with ERK2, indicating that endogenous ERK2 (possibly ERK1 as well) also complexes with ERK5 in PC12 cells ( Fig. 2A ).
# ::tok As expected , endogenous ERK5 co @-@ immunoprecipitated with ERK2 , indicating that endogenous ERK2 ( possibly ERK1 as well ) also complexes with ERK5 in PC12 cells ( Fig . 2A ) .
(x17 / complex
      :ARG1-of (x1 / expect-01)
      :ARG0 (x5 / immunoprecipitate-01
            :mod (x2 / endogenous)
            :ARG0 (x3 / protein
                  :name (x4 / name :op1 "ERK5")
                  :xref (x24 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :ARG2 (x6 / enzyme
                  :name (x7 / name :op1 "ERK2")
                  :xref (x25 / xref :value "UNIPROT:MK01_HUMAN" :prob "1.003"))
            :ARG0-of (x8 / indicate-01
                  :ARG1 (x9 / enzyme
                        :mod (x10 / endogenous)
                        :name (x11 / name :op1 "ERK2")
                        :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "1.003")))
            :ARG1-of (x12 / possible-01
                  :ARG1 (x15 / and
                        :mod (x13 / enzyme
                              :name (x14 / name :op1 "ERK1")
                              :xref (x27 / xref :value "UNIPROT:MK03_HUMAN" :prob "1.003")))))
      :mod (x16 / also)
      :mod (x18 / protein
            :name (x19 / name :op1 "ERK5")
            :xref (x26 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
      :location (x21 / cell-line
            :name (x20 / name :op1 "PC12"))
      :ARG1-of (x22 / describe-01
            :ARG0 (x23 / figure :mod "2a")))


# ::id PMC4331489.113
# ::snt This complex did not change after NGF stimulation (100 ng/ml, 5 min) ( Fig. 2B ).
# ::tok This complex did not change after NGF stimulation ( 100 ng/ml , 5 min ) ( Fig . 2B ) .
(x3 / change-01
      :ARG0 (x2 / macro-molecular-complex
            :mod (x1 / this))
      :polarity "-"
      :time (x4 / after
            :op1 (x7 / stimulate-01
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "NGF")
                        :xref (x / xref :value "UNIPROT:NGF_HUMAN" :prob "1.004"))
                  :ARG1-of (x8 / describe-01
                        :ARG0 (x9 / and
                              :op1 (x10 / concentration-quantity
                                    :quant "100"
                                    :unit (x11 / nanogram-per-milliliter))
                              :op2 (x12 / temporal-quantity
                                    :quant "5"
                                    :unit (x13 / minute))))))
      :ARG1-of (x14 / describe-01
            :ARG0 (x15 / figure :mod "2b")))


# ::id PMC4331489.114
# ::snt To investigate whether this interaction between ERK5 and ERK2 is direct or indirect, we performed in vitro ERK5-ERK2 protein binding experiments using recombinant proteins.
# ::tok To investigate whether this interaction between ERK5 and ERK2 is direct or indirect , we performed in vitro ERK5 @-@ ERK2 protein binding experiments using recombinant proteins .
(x13 / perform-01
      :purpose (x1 / investigate-01
            :ARG1 (x10 / or
                  :mode "interrogative"
                  :op1 (x3 / interact-01
                        :mod (x2 / this)
                        :ARG0 (x6 / and
                              :op1 (x4 / protein
                                    :name (x5 / name :op1 "ERK5")
                                    :xref (x24 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                              :op2 (x7 / enzyme
                                    :name (x8 / name :op1 "ERK2")
                                    :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "1.003")))
                        :ARG1-of (x9 / direct-02))
                  :op2 (x11 / direct-02 :polarity "-")))
      :ARG0 (x12 / we)
      :ARG1 (x20 / experiment-01
            :manner (x14 / in-vitro)
            :ARG1 (x19 / bind-01
                  :ARG1 (x15 / protein
                        :name (x16 / name :op1 "ERK5")
                        :xref (x26 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :ARG2 (x18 / protein
                        :name (x17 / name :op1 "ERK2")
                        :xref (x25 / xref :value "UNIPROT:MK01_HUMAN" :prob "1.003")))
            :ARG0-of (x21 / use-01
                  :ARG1 (x23 / protein
                        :ARG3-of (x22 / recombine-01)))))


# ::id PMC4331489.116
# ::snt ERK5 was absent in the immunoprecipitates under our experimental conditions, suggesting that ERK5 binds to ERK2 indirectly (data not shown).
# ::tok ERK5 was absent in the immunoprecipitates under our experimental conditions , suggesting that ERK5 binds to ERK2 indirectly ( data not shown ) .
(x7 / suggest-01
      :ARG0 (x3 / absent-01
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "ERK5")
                  :xref (x18 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :location (x4 / immunoprecipitate-01)
            :condition (x6 / experiment-01
                  :ARG0 (x5 / we)))
      :ARG1 (x10 / bind-01
            :ARG0 (x8 / protein
                  :name (x9 / name :op1 "ERK5")
                  :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :ARG2 (x11 / enzyme
                  :name (x12 / name :op1 "ERK2")
                  :xref (x17 / xref :value "UNIPROT:MK01_HUMAN" :prob "1.003"))
            :ARG1-of (x13 / direct-02 :polarity "-"))
      :ARG1-of (x14 / describe-01
            :ARG0 (x15 / data
                  :ARG1-of (x16 / show-01 :polarity "-"))))


# ::id PMC4331489.117
# ::snt Endogenous ERK5 forms a complex with ERK1/2 in PC12 cells.
# ::tok Endogenous ERK5 forms a complex with ERK1 @/@ 2 in PC12 cells .
(x4 / form-01
      :ARG0 (x1 / enzyme
            :mod (x2 / endogenous)
            :name (x3 / name :op1 "erk5/bmk1"))
      :ARG1 (x5 / macro-molecular-complex
            :ARG2 (x6 / enzyme
                  :name (x7 / name :op1 "ERK1/2")))
      :location (x9 / cell-line
            :name (x8 / name :op1 "PC12")))


# ::id PMC4331489.120
# ::snt We previously demonstrated that a constitutively active mutant of RAS (RASV12) promotes phosphorylation of the TEY site in ERK1/2, but not the TEY site of ERK5 in PC12 cells [ 11 ].
# ::tok We previously demonstrated that a constitutively active mutant of RAS ( RASV12 ) promotes phosphorylation of the TEY site in ERK1 @/@ 2 , but not the TEY site of ERK5 in PC12 cells [ 11 ] .
(x3 / demonstrate-01
      :ARG0 (x1 / we)
      :time (x2 / previous)
      :ARG1 (x6 / mutate-01
            :mod (x4 / constitutive)
            :ARG0-of (x5 / activity-06)
            :ARG2 (x7 / enzyme
                  :name (x8 / name :op1 "RAS")
                  :xref (x34 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
      :ARG1-of (x16 / promote-02
            :ARG0 (x9 / and
                  :op1 (x10 / enzyme
                        :name (x11 / name :op1 "RAS")
                        :ARG2-of (x12 / mutate-01 :value "v12")
                        :xref (x35 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :op2 (x13 / enzyme
                        :name (x14 / name :op1 "RAS")
                        :ARG2-of (x15 / mutate-01 :value "v12s35")
                        :xref (x36 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))
            :ARG1 (x17 / phosphorylate-01
                  :ARG1 (x19 / protein-segment
                        :name (x18 / name :op1 "TEY")
                        :location (x20 / enzyme
                              :name (x21 / name :op1 "ERK1/2"))
                        :ARG1-of (x22 / contrast-01
                              :ARG2 (x25 / protein-segment
                                    :polarity "-"
                                    :ARG0 (x23 / protein
                                          :name (x24 / name :op1 "TEY"))
                                    :part-of (x26 / protein
                                          :name (x27 / name :op1 "ERK5")
                                          :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                                    :location (x29 / cell-line
                                          :name (x28 / name :op1 "PC12")))
                              :ARG1-of (x33 / describe-01
                                    :ARG1-of (x30 / describe-01
                                          :ARG0 (x31 / publication
                                                :ARG1-of (x32 / cite-01 :ARG2 "11")))))))))


# ::id PMC4331489.121
# ::snt Furthermore, we showed that RASV12 caused phosphorylation of ERK1/2 at its TEY site, but not at the ERK5 TEY site in HEK293 cells.
# ::tok Furthermore , we showed that RASV12 caused phosphorylation of ERK1 @/@ 2 at its TEY site , but not at the ERK5 TEY site in HEK293 cells .
(x1 / and
      :op2 (x3 / show-01
            :ARG0 (x2 / we)
            :ARG1 (x11 / cause-01
                  :ARG0 (x4 / and
                        :op1 (x5 / enzyme
                              :name (x6 / name :op1 "ras")
                              :ARG2-of (x7 / mutate-01 :value "v12")
                              :xref (x24 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                        :op2 (x8 / enzyme
                              :name (x9 / name :op1 "ras")
                              :ARG2-of (x10 / mutate-01 :value "v12s35")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203")))
                  :ARG1 (x12 / phosphorylate-01
                        :ARG1 (x13 / enzyme
                              :name (x14 / name :op1 "ERK1/2")))
                  :location (x21 / site
                        :ARG1-of (x16 / protein-segment
                              :name (x15 / name :op1 "TEY")
                              :ARG1-of (x17 / contrast-01
                                    :ARG2 (x18 / be-located-at-91
                                          :polarity "-"
                                          :ARG2 (x19 / enzyme
                                                :name (x20 / name :op1 "ERK5" :op2 "TEY")))))
                        :location (x23 / cell-line
                              :name (x22 / name :op1 "HEK293"))))))


# ::id PMC4331489.122
# ::snt Nevertheless, phosphorylation of ERK5 at Thr732 was enhanced 2.7-fold, and was completely blocked by U0126 ( Fig. 3A ).
# ::tok Nevertheless , phosphorylation of ERK5 at Thr732 was enhanced 2.7 @-@ fold , and was completely blocked by U0126 ( Fig . 3A ) .
(x1 / have-concession-91
      :ARG1 (x11 / block-01
            :ARG0 (x2 / phosphorylate-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "ERK5")
                        :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :location (x5 / amino-acid
                        :mod "732"
                        :name (x6 / name :op1 "threonine")
                        :xref (x17 / xref :value "PUBCHEM:205" :prob "11.848252"))
                  :ARG1-of (x7 / enhance-01))
            :ARG1 (x9 / and
                  :op1 (x8 / product-of :op1 "2.7"))
            :ARG1-of (x10 / complete-02)
            :ARG0 (x12 / small-molecule
                  :name (x13 / name :op1 "U0126")
                  :xref (x16 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
            :ARG1-of (x14 / describe-01
                  :ARG0 (x15 / figure :mod "3a"))))


# ::id PMC4331489.123
# ::snt The phosphorylation status of ERK5 at Ser769/773/775 was not altered by RASV12.
# ::tok The phosphorylation status of ERK5 at Ser769 @/@ 773 @/@ 775 was not altered by RASV12 .
(x9 / alter-01
      :ARG0 (x1 / phosphorylate-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "ERK5")
                  :xref (x18 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
      :ARG1 (x4 / and
            :op1 (x5 / amino-acid
                  :mod "769"
                  :name (x6 / name :op1 "serine")
                  :xref (x19 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :op2 (x7 / small-molecule
                  :name (x8 / name :op1 "773" :op2 "775")))
      :polarity "-"
      :ARG0 (x10 / and
            :op1 (x11 / enzyme
                  :name (x12 / name :op1 "ras")
                  :ARG2-of (x13 / mutate-01 :value "v12")
                  :xref (x17 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
            :op2 (x14 / enzyme
                  :name (x15 / name :op1 "ras")
                  :ARG2-of (x16 / mutate-01 :value "v12s35")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))))


# ::id PMC4331489.124
# ::snt Furthermore, RASV12 similarly promoted the phosphorylation of ERK5-KD at Thr732 in a U0126-sensitive manner ( Fig. 3B ), suggesting that phosphorylation of ERK5 at Thr732 is also induced by activated ERK1/2.
# ::tok Furthermore , RASV12 similarly promoted the phosphorylation of ERK5 @-@ KD at Thr732 in a U0126 @-@ sensitive manner ( Fig . 3B ) , suggesting that phosphorylation of ERK5 at Thr732 is also induced by activated ERK1 @/@ 2 .
(x1 / and
      :op2 (x10 / promote-01
            :ARG0 (x2 / and
                  :op1 (x3 / enzyme
                        :name (x4 / name :op1 "ras")
                        :ARG2-of (x5 / mutate-01 :value "v12")
                        :xref (x33 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "ras")
                        :ARG2-of (x8 / mutate-01 :value "v12s35")
                        :xref (x34 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203")))
            :ARG1-of (x9 / resemble-01)
            :ARG1 (x14 / dissociate-01
                  :ARG1 (x11 / phosphorylate-01
                        :ARG1 (x12 / enzyme
                              :name (x13 / name :op1 "ERK5")
                              :xref (x35 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
                  :ARG2 (x15 / amino-acid
                        :mod "732"
                        :name (x16 / name :op1 "threonine")
                        :xref (x37 / xref :value "PUBCHEM:205" :prob "11.848252"))
                  :manner (x19 / sensitive-03
                        :ARG1 (x17 / small-molecule
                              :name (x18 / name :op1 "U0126")
                              :xref (x38 / xref :value "PUBCHEM:3006531" :prob "17.656696")))
                  :ARG1-of (x20 / describe-01
                        :ARG0 (x21 / figure :mod "3b")))
            :ARG0-of (x22 / suggest-01
                  :ARG1 (x29 / induce-01
                        :ARG0 (x23 / phosphorylate-01
                              :ARG1 (x24 / protein
                                    :name (x25 / name :op1 "ERK5")
                                    :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                              :location (x26 / amino-acid
                                    :mod "732"
                                    :name (x27 / name :op1 "threonine")
                                    :xref (x36 / xref :value "PUBCHEM:205" :prob "11.848252")))
                        :mod (x28 / also)
                        :ARG0 (x30 / enzyme
                              :ARG1-of (x31 / activate-01)
                              :name (x32 / name :op1 "ERK1/2"))))))


# ::id PMC4331489.125
# ::snt ERK1/2 phosphorylates ERK5 at Thr732 in HEK293 cells.
# ::tok ERK1 @/@ 2 phosphorylates ERK5 at Thr732 in HEK293 cells .
(x3 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "ERK1/2"))
      :ARG1 (x4 / protein
            :name (x5 / name :op1 "ERK5")
            :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
      :ARG2 (x6 / amino-acid
            :mod "732"
            :name (x7 / name :op1 "threonine")
            :xref (x10 / xref :value "PUBCHEM:205" :prob "11.848252"))
      :location (x9 / cell-line
            :name (x8 / name :op1 "HEK293")))


# ::id PMC4331489.126
# ::snt The cells were incubated in the presence or absence of U0126 (20 μM) for 24 h, then ERK5 phosphorylation status at its TEY site, Thr732 and Ser769/773/775, phospho-ERK1/2 (TEY), mycERK5 and mycERK2 were examined by Western blotting.
# ::tok The cells were incubated in the presence or absence of U0126 ( 20 μM ) for 24 h , then ERK5 phosphorylation status at its TEY site , Thr732 and Ser769 @/@ 773 @/@ 775 , phospho @-@ ERK1 @/@ 2 ( TEY ) , mycERK5 and mycERK2 were examined by Western blotting .
(x1 / multi-sentence
      :snt1 (x3 / incubate-01
            :ARG1 (x2 / cell)
            :ARG2 (x4 / or
                  :op2 (x5 / absent-01)
                  :op1 (x6 / present-02
                        :ARG1 (x7 / small-molecule
                              :name (x8 / name :op1 "U0126")
                              :quant (x9 / concentration-quantity
                                    :quant "20"
                                    :unit (x10 / micromolar))
                              :xref (x40 / xref :value "PUBCHEM:3006531" :prob "17.656696"))))
            :duration (x11 / temporal-quantity
                  :quant "24"
                  :unit (x12 / hour))
            :time (x13 / then))
      :snt2 (x36 / examine-01
            :ARG0 (x17 / status
                  :mod (x16 / phosphorylate-01
                        :ARG1 (x14 / enzyme
                              :name (x15 / name :op1 "ERK5")
                              :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
                  :location (x22 / and
                        :op1 (x19 / protein-segment
                              :name (x18 / name :op1 "TEY"))
                        :op1 (x20 / amino-acid
                              :mod "732"
                              :name (x21 / name :op1 "threonine")
                              :xref (x38 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :op2 (x23 / amino-acid
                              :mod "769"
                              :name (x24 / name :op1 "serine")
                              :xref (x39 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                        :op2 (x25 / enzyme
                              :name (x26 / name :op1 "773" :op2 "775")))
                  :ARG1-of (x27 / phosphorylate-01
                        :ARG2 (x28 / enzyme
                              :name (x29 / name :op1 "ERK1/2")
                              :name (x30 / name :op1 "TEY"))))
            :ARG1 (x33 / and
                  :op1 (x31 / protein
                        :name (x32 / name :op1 "mycERK5"))
                  :op2 (x34 / enzyme
                        :name (x35 / name :op1 "mycERK2")))
            :manner (x37 / immunoblot-01)))


# ::id PMC4331489.127
# ::snt The cells were incubated in the presence or absence of U0126 (20 μM) for 24 h, then ERK5 phosphorylation status at its TEY site and Thr732, phospho-ERK1/2 (TEY), mycERK5 and mycERK2 were examined by Western blotting.
# ::tok The cells were incubated in the presence or absence of U0126 ( 20 μM ) for 24 h , then ERK5 phosphorylation status at its TEY site and Thr732 , phospho @-@ ERK1 @/@ 2 ( TEY ) , mycERK5 and mycERK2 were examined by Western blotting .
(x12 / and
      :op1 (x2 / incubate-01
            :ARG1 (x1 / cell)
            :ARG2 (x3 / or
                  :op2 (x4 / absent-01)
                  :op1 (x5 / present-02
                        :ARG1 (x6 / small-molecule
                              :name (x7 / name :op1 "U0126")
                              :quant (x8 / concentration-quantity
                                    :quant "20"
                                    :unit (x9 / micromolar))
                              :xref (x34 / xref :value "PUBCHEM:3006531" :prob "17.656696"))))
            :duration (x10 / temporal-quantity
                  :quant "24"
                  :unit (x11 / hour)))
      :op2 (x16 / status
            :mod (x15 / phosphorylate-01
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "ERK5")
                        :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
            :location (x17 / and
                  :op1 (x19 / protein-segment
                        :name (x18 / name :op1 "TEY"))
                  :op2 (x20 / amino-acid
                        :mod "732"
                        :name (x21 / name :op1 "threonine")
                        :xref (x33 / xref :value "PUBCHEM:205" :prob "11.848252")))
            :ARG1-of (x22 / phosphorylate-01
                  :ARG2 (x23 / enzyme
                        :name (x24 / name :op1 "ERK1/2")))
            :ARG1-of (x25 / tey)
            :ARG0-of (x31 / examine-01
                  :ARG1 (x28 / and
                        :op1 (x26 / protein
                              :name (x27 / name :op1 "mycERK5"))
                        :op2 (x29 / enzyme
                              :name (x30 / name :op1 "mycERK2")))
                  :manner (x32 / immunoblot-01))))


# ::id PMC4331489.128
# ::snt Because growth factors such as EGF or NGF promote phosphorylation of both ERK1/2 and ERK5 at their respective TEY sites, we examined the phosphorylation status of ERK5 at Thr732 when both ERK isoforms were physiologically activated by these growth factors.
# ::tok Because growth factors such as EGF or NGF promote phosphorylation of both ERK1 @/@ 2 and ERK5 at their respective TEY sites , we examined the phosphorylation status of ERK5 at Thr732 when both ERK isoforms were physiologically activated by these growth factors .
(x19 / examine-01
      :ARG1-of (x1 / cause-01
            :ARG0 (x8 / promote-01
                  :ARG0 (x2 / growth-factor
                        :example (x5 / or
                              :op1 (x3 / protein
                                    :name (x4 / name :op1 "EGF")
                                    :xref (x36 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                              :op2 (x6 / protein
                                    :name (x7 / name :op1 "NGF")
                                    :xref (x37 / xref :value "UNIPROT:NGF_HUMAN" :prob "1.004"))))
                  :ARG1 (x9 / phosphorylate-01
                        :ARG1 (x12 / and
                              :op1 (x10 / enzyme
                                    :name (x11 / name :op1 "ERK1/2"))
                              :op2 (x13 / enzyme
                                    :name (x14 / name :op1 "ERK5")
                                    :xref (x38 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
                        :location (x17 / site
                              :mod (x15 / respective)
                              :mod (x16 / tey)))))
      :ARG0 (x18 / we)
      :ARG1 (x20 / status
            :mod (x21 / phosphorylate-01
                  :ARG1 (x22 / protein
                        :name (x23 / name :op1 "ERK5")
                        :xref (x35 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))))
      :location (x24 / amino-acid
            :mod "732"
            :name (x25 / name :op1 "threonine")
            :xref (x39 / xref :value "PUBCHEM:205" :prob "11.848252"))
      :time (x32 / activate-01
            :ARG0 (x29 / isoform
                  :mod (x26 / both)
                  :mod (x27 / enzyme
                        :name (x28 / name :op1 "ERK")
                        :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :ARG1 (x30 / enzyme
                  :name (x31 / name :op1 "physiologically"))
            :ARG0 (x34 / growth-factor
                  :mod (x33 / this))))


# ::id PMC4331489.129
# ::snt HEK293 cells were co-transfected with mycERK2 and mycERK5-WT or mycERK5-KD, then stimulated with EGF (100 ng/ml) for 5 min in the presence or absence of U0126 (20 μM).
# ::tok HEK293 cells were co @-@ transfected with mycERK2 and mycERK5 @-@ WT or mycERK5 @-@ KD , then stimulated with EGF ( 100 ng/ml ) for 5 min in the presence or absence of U0126 ( 20 μM ) .
(x3 / cotransfect-01
      :ARG1 (x2 / cell-line
            :name (x1 / name :op1 "HEK293"))
      :ARG2 (x11 / or
            :op1 (x4 / transfect-01
                  :ARG2 (x7 / and
                        :op1 (x5 / protein
                              :name (x6 / name :op1 "mycERK2"))
                        :op2 (x10 / wild-type
                              :ARG1 (x8 / protein
                                    :name (x9 / name :op1 "mycERK5")))))
            :op2 (x14 / dissociate-01
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "mycERK5"))))
      :ARG1 (x16 / stimulate-01
            :time (x15 / then)
            :ARG2 (x17 / protein
                  :name (x18 / name :op1 "EGF")
                  :quant (x19 / concentration-quantity
                        :quant "100"
                        :unit (x20 / nanogram-per-milliliter))
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :duration (x21 / temporal-quantity
                  :quant "5"
                  :unit (x22 / minute))
            :ARG2 (x23 / or
                  :op2 (x24 / absent-01)
                  :op1 (x25 / present-02
                        :ARG1 (x26 / small-molecule
                              :name (x27 / name :op1 "U0126")
                              :quant (x28 / concentration-quantity
                                    :quant "20"
                                    :unit (x29 / micromolar))
                              :xref (x30 / xref :value "PUBCHEM:3006531" :prob "17.656696"))))))


# ::id PMC4331489.130
# ::snt EGF induced phosphorylation of ERK5 at Thr732 1.60-fold in addition to phosphorylation at the TEY sites of both ERK1/2 and ERK5 in HEK293 cells.
# ::tok EGF induced phosphorylation of ERK5 at Thr732 1.60 @-@ fold in addition to phosphorylation at the TEY sites of both ERK1 @/@ 2 and ERK5 in HEK293 cells .
(x3 / induce-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "EGF")
            :xref (x20 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :ARG2 (x4 / phosphorylate-01
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "ERK5")
                  :xref (x21 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :location (x7 / amino-acid
                  :mod "732"
                  :name (x8 / name :op1 "threonine")
                  :xref (x22 / xref :value "PUBCHEM:205" :prob "11.848252"))
            :ARG1-of (x10 / add-02
                  :ARG2 (x9 / product-of :op1 "1.60")
                  :ARG1 (x11 / phosphorylate-01
                        :ARG1 (x12 / protein-segment
                              :part-of (x13 / and
                                    :op1 (x14 / enzyme
                                          :name (x15 / name :op1 "ERK1/2"))
                                    :op2 (x16 / protein
                                          :name (x17 / name :op1 "ERK5")
                                          :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))))
                        :location (x19 / cell-line
                              :name (x18 / name :op1 "HEK293"))))))


# ::id PMC4331489.131
# ::snt U0126 blocked phosphorylation of ERK1/2 at the TEY site and ERK5 at Thr732 (reducing phosphorylation status to approximately basal levels).
# ::tok U0126 blocked phosphorylation of ERK1 @/@ 2 at the TEY site and ERK5 at Thr732 ( reducing phosphorylation status to approximately basal levels ) .
(x3 / block-01
      :ARG0 (x1 / small-molecule
            :name (x2 / name :op1 "U0126")
            :xref (x21 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
      :ARG1 (x9 / and
            :op1 (x4 / phosphorylate-01
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "ERK1/2"))
                  :location (x8 / protein-segment
                        :name (x7 / name :op1 "TEY")))
            :op2 (x10 / protein
                  :name (x11 / name :op1 "ERK5")
                  :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
      :location (x12 / amino-acid
            :mod "732"
            :name (x13 / name :op1 "threonine")
            :xref (x20 / xref :value "PUBCHEM:205" :prob "11.848252"))
      :ARG1-of (x14 / reduce-01
            :ARG1 (x16 / status
                  :mod (x15 / phosphorylate-01))
            :ARG2 (x17 / approximately
                  :op1 (x19 / level
                        :mod (x18 / basal)))))


# ::id PMC4331489.132
# ::snt ERK5-KD was also phosphorylated at both the TEY site and Thr732 ( Fig. 4A ).
# ::tok ERK5 @-@ KD was also phosphorylated at both the TEY site and Thr732 ( Fig . 4A ) .
(x1 / and
      :op1 (x2 / protein
            :name (x3 / name :op1 "ERK5")
            :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
      :op2 (x7 / phosphorylate-01
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "nik(kd)"))
            :mod (x6 / also)
            :location (x8 / and
                  :op1 (x10 / protein-segment
                        :name (x9 / name :op1 "TEY"))
                  :op2 (x11 / amino-acid
                        :mod "732"
                        :name (x12 / name :op1 "threonine")
                        :xref (x15 / xref :value "PUBCHEM:205" :prob "11.848252"))))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure :mod "4a")))


# ::id PMC4331489.133
# ::snt Experiments were also performed in PC12 cells co-transfected with mycERK2 and mycERK5-WT, then stimulated with NGF (100 ng/ml) or EGF (100 ng/ml) for 5 min in the presence or absence of U0126 (20 μM).
# ::tok Experiments were also performed in PC12 cells co @-@ transfected with mycERK2 and mycERK5 @-@ WT , then stimulated with NGF ( 100 ng/ml ) or EGF ( 100 ng/ml ) for 5 min in the presence or absence of U0126 ( 20 μM ) .
(x3 / perform-02
      :ARG1 (x1 / experiment-01)
      :mod (x2 / also)
      :location (x18 / or
            :op1 (x6 / transfect-01
                  :ARG0 (x5 / cell-line
                        :name (x4 / name :op1 "PC12"))
                  :ARG2 (x9 / and
                        :op1 (x7 / protein
                              :name (x8 / name :op1 "mycERK2"))
                        :op2 (x12 / wild-type
                              :ARG1 (x10 / protein
                                    :name (x11 / name :op1 "mycERK5"))))
                  :ARG1-of (x13 / stimulate-01
                        :ARG2 (x14 / small-molecule
                              :name (x15 / name :op1 "NGF")
                              :quant (x16 / concentration-quantity
                                    :quant "100"
                                    :unit (x17 / nanogram-per-milliliter))
                              :xref (x33 / xref :value "PUBCHEM:60160600" :prob "19.266134"))))
            :op2 (x19 / protein
                  :name (x20 / name :op1 "EGF")
                  :quant (x21 / concentration-quantity
                        :quant "100"
                        :unit (x22 / nanogram-per-milliliter))
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :duration (x23 / temporal-quantity
            :quant "5"
            :unit (x24 / minute))
      :ARG2 (x25 / or
            :op2 (x26 / absent-01)
            :op1 (x27 / present-02
                  :ARG1 (x28 / small-molecule
                        :name (x29 / name :op1 "U0126")
                        :quant (x30 / concentration-quantity
                              :quant "20"
                              :unit (x31 / micromolar))
                        :xref (x32 / xref :value "PUBCHEM:3006531" :prob "17.656696")))))


# ::id PMC4331489.134
# ::snt As in HEK293 cells, both NGF and EGF caused ERK5 phosphorylation at Thr732 in an ERK1/2-dependent manner ( Fig. 4B ).
# ::tok As in HEK293 cells , both NGF and EGF caused ERK5 phosphorylation at Thr732 in an ERK1 @/@ 2 @-@ dependent manner ( Fig . 4B ) .
(x1 / resemble-01
      :ARG2 (x4 / and
            :op1 (x3 / cell-line
                  :name (x2 / name :op1 "HEK293"))
            :op2 (x10 / cause-01
                  :ARG0 (x7 / and
                        :op1 (x5 / protein
                              :name (x6 / name :op1 "NGF")
                              :xref (x22 / xref :value "UNIPROT:NGF_HUMAN" :prob "1.004"))
                        :op2 (x8 / protein
                              :name (x9 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x13 / phosphorylate-01
                        :ARG1 (x11 / protein
                              :name (x12 / name :op1 "ERK5")
                              :xref (x21 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                        :location (x14 / amino-acid
                              :mod "732"
                              :name (x15 / name :op1 "threonine")
                              :xref (x23 / xref :value "PUBCHEM:205" :prob "11.848252")))
                  :manner (x18 / depend-01
                        :ARG1 (x16 / enzyme
                              :name (x17 / name :op1 "ERK1/2"))))
            :ARG1-of (x19 / describe-01
                  :ARG0 (x20 / figure :mod "4b"))))


# ::id PMC4331489.135
# ::snt These results strongly suggest that ERK5 Thr732 is preferentially phosphorylated by ERK1/2, but not by ERK5 itself, when both ERK isoforms are physiologically activated by growth factors.
# ::tok These results strongly suggest that ERK5 Thr732 is preferentially phosphorylated by ERK1 @/@ 2 , but not by ERK5 itself , when both ERK isoforms are physiologically activated by growth factors .
(x5 / suggest-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1-of (x4 / strong-02)
      :ARG1 (x23 / activate-01
            :ARG0 (x6 / protein
                  :name (x7 / name :op1 "ERK5")
                  :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :ARG2 (x8 / amino-acid
                  :mod "732"
                  :name (x9 / name :op1 "threonine")
                  :xref (x27 / xref :value "PUBCHEM:205" :prob "11.848252"))
            :ARG1-of (x10 / prefer-01
                  :ARG1 (x11 / phosphorylate-01
                        :ARG2 (x12 / enzyme
                              :name (x13 / name :op1 "ERK1/2")))
                  :ARG1-of (x14 / contrast-01
                        :ARG2 (x15 / protein
                              :name (x16 / name :op1 "ERK5")
                              :xref (x26 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
                  :ARG0-of (x22 / physiological
                        :ARG1 (x17 / it)
                        :time (x21 / isoform
                              :mod (x18 / both)
                              :mod (x19 / enzyme
                                    :name (x20 / name :op1 "ERK")
                                    :xref (x25 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))
            :ARG0 (x24 / growth-factor)))


# ::id PMC4331489.136
# ::snt However, ERK5 can autophosphorylate ERK5 at Thr732 when ERK5 is strongly and selectively activated by MEK5D.
# ::tok However , ERK5 can autophosphorylate ERK5 at Thr732 when ERK5 is strongly and selectively activated by MEK5D .
(x1 / have-concession-91
      :ARG1 (x4 / possible-01
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "ERK5")
                  :xref (x17 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "ERK5")
                  :xref (x18 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :location (x7 / amino-acid
                  :mod "732"
                  :name (x8 / name :op1 "threonine")
                  :xref (x19 / xref :value "PUBCHEM:205" :prob "11.848252"))
            :time (x13 / activate-01
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "ERK5")
                        :xref (x16 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :ARG1-of (x11 / strong-02)
                  :manner (x12 / selective)
                  :ARG0 (x14 / enzyme
                        :name (x15 / name :op1 "MEK5D")
                        :xref (x / xref :value "UNIPROT:MP2K5_HUMAN" :prob "0.312")))))


# ::id PMC4331489.137
# ::snt EGF and NGF promote ERK5 phosphorylation at Thr732 via ERK1/2 in HEK293 and PC12 cells.
# ::tok EGF and NGF promote ERK5 phosphorylation at Thr732 via ERK1 @/@ 2 in HEK293 and PC12 cells .
(x6 / promote-01
      :ARG0 (x3 / and
            :op1 (x1 / protein
                  :name (x2 / name :op1 "EGF")
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :op2 (x4 / protein
                  :name (x5 / name :op1 "NGF")
                  :xref (x18 / xref :value "UNIPROT:NGF_HUMAN" :prob "1.004")))
      :ARG1 (x9 / phosphorylate-01
            :ARG1 (x7 / protein
                  :name (x8 / name :op1 "ERK5")
                  :xref (x17 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :ARG1 (x10 / amino-acid
                  :mod "732"
                  :name (x11 / name :op1 "threonine")
                  :xref (x19 / xref :value "PUBCHEM:205" :prob "11.848252"))
            :ARG2 (x12 / enzyme
                  :name (x13 / name :op1 "ERK1/2"))
            :location (x14 / and
                  :op1 (x16 / cell-line
                        :name (x15 / name :op1 "PC12")))))


# ::id PMC4331489.138
# ::snt After the cells were preincubated in the presence or absence of U0126 (20 μM) for 30 min, they were stimulated with EGF (100 ng/ml) for 5 min.
# ::tok After the cells were preincubated in the presence or absence of U0126 ( 20 μM ) for 30 min , they were stimulated with EGF ( 100 ng/ml ) for 5 min .
(x14 / stimulate-01
      :time (x1 / after
            :op1 (x4 / be-located-at-91
                  :ARG1 (x2 / cell)
                  :ARG2 (x3 / preincubated)
                  :ARG2 (x5 / or
                        :op2 (x6 / absent-01)
                        :op1 (x7 / present-02
                              :ARG1 (x8 / small-molecule
                                    :name (x9 / name :op1 "U0126")
                                    :quant (x10 / concentration-quantity
                                          :quant "20"
                                          :unit (x11 / micromolar))
                                    :xref (x21 / xref :value "PUBCHEM:3006531" :prob "17.656696"))))
                  :duration (x12 / temporal-quantity
                        :quant "30"
                        :unit (x13 / minute))))
      :ARG2 (x15 / protein
            :name (x16 / name :op1 "EGF")
            :quant (x17 / concentration-quantity
                  :quant "100"
                  :unit (x18 / nanogram-per-milliliter))
            :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :duration (x19 / temporal-quantity
            :quant "5"
            :unit (x20 / minute)))


# ::id PMC4331489.140
# ::snt After the cells were preincubated in the presence or absence of U0126 (20 μM) for 30 min, they were stimulated with NGF (100 ng/ml) or EGF (100 ng/ml) for 5 min.
# ::tok After the cells were preincubated in the presence or absence of U0126 ( 20 μM ) for 30 min , they were stimulated with NGF ( 100 ng/ml ) or EGF ( 100 ng/ml ) for 5 min .
(x14 / stimulate-01
      :time (x1 / after
            :op1 (x4 / be-located-at-91
                  :ARG1 (x2 / cell)
                  :ARG2 (x3 / preincubated)
                  :ARG2 (x5 / or
                        :op2 (x6 / absent-01)
                        :op1 (x7 / present-02
                              :ARG1 (x8 / small-molecule
                                    :name (x9 / name :op1 "U0126")
                                    :quant (x10 / concentration-quantity
                                          :quant "20"
                                          :unit (x11 / micromolar))
                                    :xref (x26 / xref :value "PUBCHEM:3006531" :prob "17.656696"))))
                  :duration (x12 / temporal-quantity
                        :quant "30"
                        :unit (x13 / minute))))
      :ARG2 (x19 / or
            :op1 (x15 / small-molecule
                  :name (x16 / name :op1 "NGF")
                  :quant (x17 / concentration-quantity
                        :quant "100"
                        :unit (x18 / nanogram-per-milliliter))
                  :xref (x27 / xref :value "PUBCHEM:60160600" :prob "19.266134"))
            :op2 (x20 / protein
                  :name (x21 / name :op1 "EGF")
                  :quant (x22 / concentration-quantity
                        :quant "100"
                        :unit (x23 / nanogram-per-milliliter))
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :duration (x24 / temporal-quantity
            :quant "5"
            :unit (x25 / minute)))


# ::id PMC4331489.142
# ::snt Diaz-Rodriguez et al. examined the subcellular localization of ERK5-WT and its mutants, including those in which four Ser and Thr residues including Thr732 were substituted with Ala or Glu (i.e. 4xPA or 4xPE, respectively).
# ::tok Diaz @-@ Rodriguez et al. examined the subcellular localization of ERK5 @-@ WT and its mutants , including those in which four Ser and Thr residues including Thr732 were substituted with Ala or Glu ( i.e . 4 xPA or 4 xPE , respectively ) .
(x9 / examine-01
      :ARG0 (x3 / publication-91
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "Diaz")
                  :xref (x / xref :value "UNIPROT:DIAP2_HUMAN" :prob "0.202"))
            :ARG0 (x6 / and
                  :op1 (x4 / person
                        :name (x5 / name :op1 "rodriguez-viciana"))
                  :op2 (x7 / person
                        :mod (x8 / other))))
      :ARG1 (x11 / localize-01
            :mod (x10 / subcellular)
            :ARG1 (x15 / and
                  :op1 (x12 / enzyme
                        :name (x13 / name :op1 "ERK5")
                        :mod (x14 / wild-type)
                        :xref (x39 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :op2 (x16 / mutate-01))
            :ARG2-of (x17 / include-91
                  :ARG1 (x18 / that)))
      :ARG2-of (x25 / include-01
            :ARG0 (x21 / and
                  :op1 (x19 / cell-line
                        :quant "4"
                        :name (x20 / name :op1 "serine"))
                  :op2 (x22 / residue
                        :mod (x23 / amino-acid
                              :name (x24 / name :op1 "threonine")
                              :xref (x42 / xref :value "PUBCHEM:205" :prob "11.848252"))))
            :ARG1 (x31 / or
                  :op1 (x28 / substitute-01
                        :ARG1 (x26 / amino-acid
                              :mod "732"
                              :name (x27 / name :op1 "threonine")
                              :xref (x41 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :ARG2 (x29 / amino-acid
                              :name (x30 / name :op1 "Ala")
                              :xref (x40 / xref :value "PUBCHEM:602" :prob "11.66124")))
                  :op2 (x35 / or
                        :ARG1-of (x32 / mean-01
                              :ARG2 (x33 / protein
                                    :name (x34 / name :op1 "il-4" :op2 "xPA")))
                        :op2 (x36 / protein
                              :name (x37 / name :op1 "il-4" :op2 "xPE"))
                        :mod (x38 / respective)))))


# ::id PMC4331489.143
# ::snt While HA-tagged ERK5-WT and ERK5–4xPA maintained an essentially cytoplasmic distribution, the phospho-mimetic ERK5–4xPE had a nuclear localization [ 33 ].
# ::tok While HA @-@ tagged ERK5 @-@ WT and ERK5–4 xPA maintained an essentially cytoplasmic distribution , the phospho @-@ mimetic ERK5–4 xPE had a nuclear localization [ 33 ] .
(x1 / contrast-01
      :ARG2 (x11 / maintain-01
            :ARG0 (x8 / and
                  :op1 (x2 / enzyme
                        :ARG1-of (x5 / tag-01
                              :ARG2 (x3 / protein
                                    :name (x4 / name :op1 "HA")
                                    :xref (x24 / xref :value "UNIPROT:MORN_HUMAN" :prob "1.002")))
                        :name (x6 / name :op1 "ERK5")
                        :mod (x7 / wild-type)
                        :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :op2 (x9 / enzyme
                        :name (x10 / name :op1 "ERK5–4" :op2 "xPA")))
            :ARG1 (x14 / distribute-01
                  :mod (x12 / essential)
                  :mod (x13 / cytoplasm
                        :xref (x26 / xref :value "GO:0005737" :prob "0.8"))))
      :ARG1 (x18 / have-03
            :ARG0-of (x15 / phosphorylate-01
                  :ARG2 (x16 / enzyme
                        :name (x17 / name :op1 "ERK5–4" :op2 "xPE")))
            :ARG1 (x20 / localize-01
                  :ARG1 (x19 / nucleus
                        :xref (x25 / xref :value "GO:0005634" :prob "0.8")))
            :ARG1-of (x21 / describe-01
                  :ARG0 (x22 / publication
                        :ARG1-of (x23 / cite-01 :ARG2 "33")))))


# ::id PMC4331489.144
# ::snt In the present study, we used mycERK5-WT, mycER–32A and mycER–32E to examine the intracellular localization of ERK5.
# ::tok In the present study , we used mycERK5 @-@ WT , mycER–32A and mycER–32E to examine the intracellular localization of ERK5 .
(x4 / use-01
      :medium (x2 / study-01
            :time (x1 / present))
      :ARG0 (x3 / we)
      :ARG1 (x10 / and
            :op1 (x5 / enzyme
                  :name (x6 / name :op1 "mycERK5")
                  :mod (x7 / wild-type))
            :op1 (x8 / enzyme
                  :name (x9 / name :op1 "mycER–32A"))
            :op2 (x11 / enzyme
                  :name (x12 / name :op1 "mycER–32E")))
      :ARG2 (x13 / examine-01
            :ARG1 (x15 / be-located-at-91
                  :mod (x14 / intracellular)))
      :ARG1 (x16 / protein
            :name (x17 / name :op1 "ERK5")
            :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))


# ::id PMC4331489.145
# ::snt mycERK5-WT and mycER–32A mainly localized to the cytosol ( Fig. 5A ).
# ::tok mycERK5 @-@ WT and mycER–32A mainly localized to the cytosol ( Fig . 5A ) .
(x8 / be-located-at-91
      :ARG0 (x4 / and
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "mycERK5")
                  :mod (x3 / wild-type))
            :op2 (x5 / enzyme
                  :name (x6 / name :op1 "mycER–32A")))
      :mod (x7 / main)
      :ARG2 (x9 / cytosol
            :xref (x / xref :value "GO:0005829" :prob "0.8"))
      :ARG1-of (x10 / describe-01
            :ARG0 (x11 / figure :mod "5a")))


# ::id PMC4331489.146
# ::snt In contrast, mycER–32E was localized in both nucleus and cytosol ( Fig. 5A ).
# ::tok In contrast , mycER–32E was localized in both nucleus and cytosol ( Fig . 5A ) .
(x1 / contrast-01
      :ARG2 (x4 / localize-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "mycER–32E"))
            :location (x7 / and
                  :mod (x5 / both)
                  :op1 (x6 / nucleus
                        :xref (x11 / xref :value "GO:0005634" :prob "0.8"))
                  :op2 (x8 / cytosol
                        :xref (x / xref :value "GO:0005829" :prob "0.8")))
            :ARG1-of (x9 / describe-01
                  :ARG0 (x10 / figure :mod "5a"))))


# ::id PMC4331489.147
# ::snt There was no green fluorescence in cells transfected with empty vector alone (data not shown).
# ::tok There was no green fluorescence in cells transfected with empty vector alone ( data not shown ) .
(x2 / fluorescence
      :polarity "-"
      :ARG1-of (x1 / green-02)
      :location (x3 / cell
            :ARG1-of (x4 / transfect-01
                  :ARG2 (x6 / vector
                        :ARG1-of (x5 / empty-02)
                        :mod (x7 / alone))))
      :ARG1-of (x8 / describe-01
            :ARG0 (x9 / data
                  :ARG1-of (x10 / show-01 :polarity "-"))))


# ::id PMC4331489.148
# ::snt Next, we examined the intracellular localization of mycERK5-WT and mycERK5-KD phosphorylated at Thr732 by RASV12-ERK1/2 signaling.
# ::tok Next , we examined the intracellular localization of mycERK5 @-@ WT and mycERK5 @-@ KD phosphorylated at Thr732 by RASV12 @-@ ERK1 @/@ 2 signaling .
(x3 / examine-01
      :time (x1 / next)
      :ARG0 (x2 / we)
      :ARG1 (x24 / signal-07
            :mod (x4 / intracellular
                  :ARG0-of (x12 / dissociate-01
                        :ARG1 (x5 / be-located-at-91
                              :ARG1 (x9 / and
                                    :op1 (x6 / enzyme
                                          :name (x7 / name :op1 "mycERK5")
                                          :mod (x8 / wild-type))
                                    :op2 (x10 / protein
                                          :name (x11 / name :op1 "mycERK5"))))
                        :ARG1 (x13 / phosphorylate-01
                              :ARG1 (x14 / amino-acid
                                    :mod "732"
                                    :name (x15 / name :op1 "threonine")
                                    :xref (x26 / xref :value "PUBCHEM:205" :prob "11.848252")))
                        :ARG2 (x16 / and
                              :op1 (x17 / enzyme
                                    :name (x18 / name :op1 "ras")
                                    :ARG2-of (x19 / mutate-01 :value "v12")
                                    :xref (x25 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                              :op2 (x20 / enzyme
                                    :name (x21 / name :op1 "ras")
                                    :ARG2-of (x22 / mutate-01 :value "v12s35")
                                    :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203")))))
            :name (x23 / name :op1 "erk1/2")))


# ::id PMC4331489.149
# ::snt RASV12-ERK1/2 signaling promoted retention of ERK5 in both nucleus and cytosol probably through phosphorylation at Thr732, as demonstrated in Fig. 3 ( Fig. 5B ).
# ::tok RASV12 @-@ ERK1 @/@ 2 signaling promoted retention of ERK5 in both nucleus and cytosol probably through phosphorylation at Thr732 , as demonstrated in Fig . 3 ( Fig . 5B ) .
(x6 / promote-01
      :ARG0 (x5 / signal-07
            :mod (x1 / enzyme
                  :name (x2 / name :op1 "ras")
                  :ARG2-of (x3 / mutate-01 :value "v12")
                  :xref (x22 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
            :name (x4 / name :op1 "erk1/2"))
      :ARG1 (x12 / and
            :op1 (x7 / retain-01
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "ERK5")
                        :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :location (x11 / nucleus
                        :mod (x10 / both)
                        :xref (x23 / xref :value "GO:0005634" :prob "0.8")))
            :op2 (x13 / cytosol
                  :mod (x14 / probable)
                  :xref (x24 / xref :value "GO:0005829" :prob "0.8"))
            :manner (x15 / phosphorylate-01
                  :ARG1 (x16 / amino-acid
                        :mod "732"
                        :name (x17 / name :op1 "threonine")
                        :xref (x25 / xref :value "PUBCHEM:205" :prob "11.848252"))))
      :ARG1-of (x18 / demonstrate-01
            :ARG0 (x19 / figure :mod "3"))
      :ARG1-of (x20 / describe-01
            :ARG0 (x21 / figure :mod "5b")))


# ::id PMC4331489.150
# ::snt These results suggest that phosphorylation of Thr732 is important for ERK5 subcellular localization.
# ::tok These results suggest that phosphorylation of Thr732 is important for ERK5 subcellular localization .
(x4 / suggest-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x8 / important
            :domain (x5 / phosphorylate-01
                  :ARG1 (x6 / amino-acid
                        :mod "732"
                        :name (x7 / name :op1 "threonine")
                        :xref (x13 / xref :value "PUBCHEM:205" :prob "11.848252")))
            :purpose (x12 / localize-01
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "ERK5")
                        :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :mod (x11 / subcellular))))


# ::id PMC4331489.151
# ::snt ERK5 phosphorylation at Thr732 via ERK1/2 is required for nuclear localization in HEK293 cells.
# ::tok ERK5 phosphorylation at Thr732 via ERK1 @/@ 2 is required for nuclear localization in HEK293 cells .
(x8 / require-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "ERK5")
            :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
      :ARG1 (x3 / phosphorylate-01
            :ARG1 (x4 / amino-acid
                  :mod "732"
                  :name (x5 / name :op1 "threonine")
                  :xref (x14 / xref :value "PUBCHEM:205" :prob "11.848252"))
            :ARG2 (x6 / enzyme
                  :name (x7 / name :op1 "ERK1/2")))
      :ARG0 (x10 / localize-01
            :ARG1 (x9 / nucleus
                  :xref (x13 / xref :value "GO:0005634" :prob "0.8")))
      :location (x12 / cell-line
            :name (x11 / name :op1 "HEK293")))


# ::id PMC4331489.156
# ::snt * P < 0.05 compared with WT (n = 3).
# ::tok * P
(x3 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "*")))


# ::id PMC4331489.161
# ::snt * P < 0.05 compared with empty vector (n = 3).
# ::tok * P
(x3 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "*")))


# ::id PMC4331489.162
# ::snt Because phosphorylation of the ERK5 C-terminal is thought to enhance gene transcription independently of the phosphorylation of transcription factors [ 4 ], we next examined the role of ERK1/2-mediated phosphorylation of ERK5 at Thr732 on MEF2C-dependent gene transcription.
# ::tok Because phosphorylation of the ERK5 C @-@ terminal is thought to enhance gene transcription independently of the phosphorylation of transcription factors [ 4 ] , we next examined the role of ERK1 @/@ 2 @-@ mediated phosphorylation of ERK5 at Thr732 on MEF2C @-@ dependent gene transcription .
(x20 / examine-01
      :ARG1-of (x1 / cause-01
            :ARG0 (x5 / think-01
                  :ARG0 (x2 / phosphorylate-01
                        :ARG1 (x3 / protein
                              :name (x4 / name :op1 "ERK5")
                              :xref (x35 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
                  :ARG1 (x8 / enhance-01
                        :ARG0 (x6 / protein-segment
                              :name (x7 / name :op1 "c-terminus"))
                        :ARG1 (x10 / transcribe-01
                              :ARG1 (x9 / gene)
                              :ARG0-of (x11 / depend-01
                                    :polarity "-"
                                    :ARG1 (x12 / phosphorylate-01
                                          :ARG1 (x14 / factor
                                                :ARG0-of (x13 / transcribe-01)
                                                :ARG1-of (x15 / describe-01
                                                      :ARG0 (x16 / publication
                                                            :ARG1-of (x17 / cite-01 :ARG2 "4"))))))))))
      :ARG0 (x18 / we)
      :time (x19 / next)
      :ARG1 (x21 / role
            :poss (x25 / phosphorylate-01
                  :ARG1-of (x24 / mediate-01
                        :ARG0 (x22 / enzyme
                              :name (x23 / name :op1 "erk1/2")))
                  :ARG1 (x26 / protein
                        :name (x27 / name :op1 "ERK5")
                        :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                  :location (x28 / amino-acid
                        :mod "732"
                        :name (x29 / name :op1 "threonine")
                        :xref (x37 / xref :value "PUBCHEM:205" :prob "11.848252")))
            :topic (x34 / transcribe-01
                  :ARG0-of (x32 / depend-01
                        :ARG1 (x30 / enzyme
                              :name (x31 / name :op1 "MEF2C")
                              :xref (x36 / xref :value "UNIPROT:MEF2C_HUMAN" :prob "1.003")))
                  :ARG1 (x33 / gene))))


# ::id PMC4331489.163
# ::snt MEF2C is a transcription factor that is well known to be phosphorylated and activated by ERK5 [ 34 ].
# ::tok MEF2C is a transcription factor that is well known to be phosphorylated and activated by ERK5 [ 34 ] .
(x3 / factor
      :domain (x1 / mef2c)
      :ARG0-of (x2 / transcribe-01)
      :ARG1-of (x5 / know-02
            :degree (x4 / well)
            :ARG2 (x6 / phosphorylate-01
                  :ARG0-of (x7 / activate-01
                        :ARG0 (x8 / protein
                              :name (x9 / name :op1 "ERK5")
                              :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002")))
                  :ARG1-of (x10 / describe-01
                        :ARG0 (x11 / publication
                              :ARG1-of (x12 / cite-01 :ARG2 "34"))))))


# ::id PMC4331489.164
# ::snt HEK293 cells were transfected with a pMEF2/luciferase reporter gene, then stimulated with EGF (100 ng/ml) for 6 h in the presence or absence of U0126 (30 μM).
# ::tok HEK293 cells were transfected with a pMEF2 @/@ luciferase reporter gene , then stimulated with EGF ( 100 ng/ml ) for 6 h in the presence or absence of U0126 ( 30 μM ) .
(x3 / transfect-01
      :ARG1 (x2 / cell-line
            :name (x1 / name :op1 "HEK293"))
      :ARG2 (x6 / and
            :op1 (x4 / enzyme
                  :name (x5 / name :op1 "pMEF2"))
            :op1 (x10 / gene
                  :ARG0-of (x9 / report-01
                        :ARG1 (x7 / enzyme
                              :name (x8 / name :op1 "luciferase"))))
            :op2 (x11 / stimulate-01
                  :ARG2 (x12 / protein
                        :name (x13 / name :op1 "EGF")
                        :quant (x14 / concentration-quantity
                              :quant "100"
                              :unit (x15 / nanogram-per-milliliter))
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :duration (x16 / temporal-quantity
                        :quant "6"
                        :unit (x17 / hour))
                  :ARG2 (x18 / or
                        :op2 (x19 / absent-01)
                        :op1 (x20 / present-02
                              :ARG1 (x21 / small-molecule
                                    :name (x22 / name :op1 "U0126")
                                    :quant (x23 / concentration-quantity
                                          :quant "30"
                                          :unit (x24 / micromolar))
                                    :xref (x25 / xref :value "PUBCHEM:3006531" :prob "17.656696")))))))


# ::id PMC4331489.165
# ::snt EGF significantly increased MEF2 activity, and this effect of EGF was significantly reduced by U0126 ( Fig. 6A ).
# ::tok EGF significantly increased MEF2 activity , and this effect of EGF was significantly reduced by U0126 ( Fig . 6A ) .
(x4 / increase-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "EGF")
            :xref (x19 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :ARG2 (x3 / significant-02)
      :ARG1 (x8 / and
            :op1 (x7 / activity-06
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "MEF2")
                        :xref (x20 / xref :value "UNIPROT:MEF2A_HUMAN" :prob "1.002")))
            :op2 (x14 / reduce-01
                  :ARG1 (x10 / affect-01
                        :mod (x9 / this)
                        :ARG0 (x11 / protein
                              :name (x12 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1-of (x13 / significant-02)
                  :ARG0 (x15 / small-molecule
                        :name (x16 / name :op1 "U0126")
                        :xref (x21 / xref :value "PUBCHEM:3006531" :prob "17.656696"))))
      :ARG1-of (x17 / describe-01
            :ARG0 (x18 / figure :mod "6a")))


# ::id PMC4331489.166
# ::snt Next, HEK293 cells were co-transfected with pMEF2/luciferase and mycERK5-WT or mycERK-T732A, then stimulated with EGF (100 ng/ml) for 6 h.
# ::tok Next , HEK293 cells were co @-@ transfected with pMEF2 @/@ luciferase and mycERK5 @-@ WT or mycERK @-@ T732A , then stimulated with EGF ( 100 ng/ml ) for 6 h .
(x17 / stimulate-01
      :time (x1 / next)
      :ARG0 (x4 / cotransfect-01
            :ARG1 (x3 / cell-line
                  :name (x2 / name :op1 "HEK293"))
            :ARG2 (x5 / transfect-01
                  :ARG2 (x12 / or
                        :name (x6 / name :op1 "pMEF2")
                        :mod (x9 / and
                              :op1 (x7 / enzyme
                                    :name (x8 / name :op1 "luciferase"))
                              :op2 (x10 / protein
                                    :name (x11 / name :op1 "mycERK5"))))))
      :ARG1 (x13 / enzyme
            :name (x14 / name :op1 "mycERK")
            :ARG2-of (x15 / mutate-01 :value "T732A"))
      :time (x16 / then)
      :ARG2 (x18 / protein
            :name (x19 / name :op1 "EGF")
            :quant (x20 / concentration-quantity
                  :quant "100"
                  :unit (x21 / nanogram-per-milliliter))
            :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
      :duration (x22 / temporal-quantity
            :quant "6"
            :unit (x23 / hour)))


# ::id PMC4331489.167
# ::snt Although EGF significantly increased MEF2 activity in cells overexpressing ERK5-WT, this effect of EGF was significantly reduced in cells expressing ER–32A ( Fig. 6B ), suggesting that ERK1/2-dependent phosphorylation of ERK5 at Thr732 enhances MEF2C activation.
# ::tok Although EGF significantly increased MEF2 activity in cells overexpressing ERK5 @-@ WT , this effect of EGF was significantly reduced in cells expressing ER–32A ( Fig . 6B ) , suggesting that ERK1 @/@ 2 @-@ dependent phosphorylation of ERK5 at Thr732 enhances MEF2C activation .
(x1 / multi-sentence
      :snt1 (x2 / have-concession-91
            :ARG2 (x6 / increase-01
                  :ARG0 (x3 / protein
                        :name (x4 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :ARG2 (x5 / significant-02)
                  :ARG1 (x9 / activity-06
                        :ARG0 (x7 / protein
                              :name (x8 / name :op1 "MEF2")
                              :xref (x40 / xref :value "UNIPROT:MEF2A_HUMAN" :prob "1.002"))
                        :location (x10 / cell
                              :location-of (x11 / overexpress-01
                                    :ARG1 (x12 / enzyme
                                          :name (x13 / name :op1 "ERK5")
                                          :mod (x14 / wild-type)
                                          :xref (x43 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))))))
            :ARG1 (x15 / this))
      :snt2 (x20 / reduce-01
            :ARG1 (x16 / affect-01
                  :ARG0 (x17 / protein
                        :name (x18 / name :op1 "EGF")
                        :xref (x44 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG2 (x19 / significant-02)
            :location (x21 / cell
                  :ARG3-of (x22 / express-03
                        :ARG2 (x23 / enzyme
                              :name (x24 / name :op1 "ER–32A"))))
            :ARG1-of (x25 / describe-01
                  :ARG0 (x26 / figure :mod "6b"))
            :ARG0-of (x27 / suggest-01
                  :ARG1 (x36 / enhance-01
                        :ARG0 (x31 / phosphorylate-01
                              :ARG0-of (x30 / depend-01
                                    :ARG1 (x28 / enzyme
                                          :name (x29 / name :op1 "ERK1/2")))
                              :ARG1 (x32 / protein
                                    :name (x33 / name :op1 "ERK5")
                                    :xref (x41 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
                              :location (x34 / amino-acid
                                    :mod "732"
                                    :name (x35 / name :op1 "threonine")
                                    :xref (x45 / xref :value "PUBCHEM:205" :prob "11.848252")))
                        :ARG1 (x39 / activate-01
                              :ARG1 (x37 / enzyme
                                    :name (x38 / name :op1 "MEF2C")
                                    :xref (x42 / xref :value "UNIPROT:MEF2C_HUMAN" :prob "1.003")))))))


# ::id PMC4331489.168
# ::snt ERK5 phosphorylation at Thr732 via ERK1/2 is required for MEF2C-dependent transcription in HEK293 cells.
# ::tok ERK5 phosphorylation at Thr732 via ERK1 @/@ 2 is required for MEF2C @-@ dependent transcription in HEK293 cells .
(x8 / require-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "ERK5")
            :xref (x15 / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
      :ARG1 (x3 / phosphorylate-01
            :ARG1 (x4 / amino-acid
                  :mod "732"
                  :name (x5 / name :op1 "threonine")
                  :xref (x16 / xref :value "PUBCHEM:205" :prob "11.848252"))
            :ARG2 (x6 / enzyme
                  :name (x7 / name :op1 "ERK1/2")))
      :ARG0 (x12 / transcribe-01
            :ARG0-of (x11 / depend-01
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "MEF2C")
                        :xref (x / xref :value "UNIPROT:MEF2C_HUMAN" :prob "1.003"))))
      :location (x14 / cell-line
            :name (x13 / name :op1 "HEK293")))


# ::id PMC4331489.169
# ::snt The cells were incubated with EGF (100 ng/ml) in the presence or absence of U0126 (30 μM) for 6 h, and luciferase assays were performed.
# ::tok The cells were incubated with EGF ( 100 ng/ml ) in the presence or absence of U0126 ( 30 μM ) for 6 h , and luciferase assays were performed .
(x17 / and
      :op1 (x2 / incubate-01
            :ARG1 (x1 / cell)
            :ARG2 (x3 / protein
                  :name (x4 / name :op1 "EGF")
                  :quant (x5 / concentration-quantity
                        :quant "100"
                        :unit (x6 / nanogram-per-milliliter))
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :ARG2 (x7 / or
                  :op2 (x8 / absent-01)
                  :op1 (x9 / present-02
                        :ARG1 (x10 / and
                              :op1 (x11 / small-molecule
                                    :name (x12 / name :op1 "U0126")
                                    :xref (x22 / xref :value "PUBCHEM:3006531" :prob "17.656696"))
                              :op2 (x13 / concentration-quantity
                                    :quant "30"
                                    :unit (x14 / micromolar)))))
            :duration (x15 / temporal-quantity
                  :quant "6"
                  :unit (x16 / hour)))
      :op2 (x21 / perform-02
            :ARG1 (x20 / assay-01
                  :ARG1 (x18 / enzyme
                        :name (x19 / name :op1 "luciferase")))))


# ::id PMC4331489.171
# ::snt * P < 0.05 compared with and # P < 0.05 compared with or EGF alone (n = 6).
# ::tok * P
(x3 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "*")))


# ::id PMC4331489.172
# ::snt The cells were incubated with EGF (100 ng/ml) for 6 h, and luciferase assays were performed.
# ::tok The cells were incubated with EGF ( 100 ng/ml ) for 6 h , and luciferase assays were performed .
(x9 / and
      :op1 (x2 / incubate-01
            :ARG1 (x1 / cell)
            :ARG2 (x3 / protein
                  :name (x4 / name :op1 "EGF")
                  :quant (x5 / concentration-quantity
                        :quant "100"
                        :unit (x6 / nanogram-per-milliliter))
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
            :duration (x7 / temporal-quantity
                  :quant "6"
                  :unit (x8 / hour)))
      :op2 (x13 / perform-02
            :ARG1 (x12 / assay-01
                  :ARG1 (x10 / enzyme
                        :name (x11 / name :op1 "luciferase")))))


# ::id PMC4331489.174
# ::snt * P < 0.05 compared with and # P < 0.05 compared with ERK5-WT (n = 6).
# ::tok * P
(x3 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "*")))


# ::id PMC4331489.187
# ::snt Putative cross-talk mechanism between ERK5 and ERK1/2.
# ::tok Putative cross @-@ talk mechanism between ERK5 and ERK1 @/@ 2 .
(x1 / think-01
      :ARG0 (x2 / crosstalk-00
            :ARG0 (x3 / mechanism))
      :ARG1 (x6 / and
            :op1 (x4 / protein
                  :name (x5 / name :op1 "ERK5")
                  :xref (x / xref :value "UNIPROT:MK07_HUMAN" :prob "1.002"))
            :op2 (x7 / enzyme
                  :name (x8 / name :op1 "ERK1/2"))))


# ::id PMC4455068.0
# ::snt PI3K/mTORC2 regulates TGF-β/Activin signalling by modulating Smad2/3 activity via linker phosphorylation
# ::tok PI3K @/@ mTORC2 regulates TGF-β/Activin signalling by modulating Smad2 @/@ 3 activity via linker phosphorylation
(x9 / modulate-01
      :ARG0 (x5 / regulate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "PI3K")
                  :xref (x16 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
            :ARG2 (x3 / macro-molecular-complex
                  :name (x4 / name :op1 "mTORC2"))
            :manner (x8 / signal-07
                  :ARG0 (x6 / enzyme
                        :name (x7 / name :op1 "TGF-β/Activin"))))
      :ARG1 (x12 / activity-06
            :ARG0 (x10 / protein
                  :name (x11 / name :op1 "Smad2/3")))
      :manner (x15 / phosphorylate-01
            :ARG1 (x13 / enzyme
                  :name (x14 / name :op1 "linker")
                  :xref (x / xref :value "UNIPROT:NEUL3_HUMAN" :prob "0.202"))))


# ::id PMC4455068.2
# ::snt Crosstalk between the phosphatidylinositol 3-kinase (PI3K) and the transforming growth factor-β signalling pathways play an important role in regulating many cellular functions.
# ::tok Crosstalk between the phosphatidylinositol 3 @-@ kinase ( PI3K ) and the transforming growth factor-β signalling pathways play an important role in regulating many cellular functions .
(x1 / crosstalk-00
      :ARG0 (x2 / enzyme
            :name (x3 / name :op1 "phosphatidylinositol" :op2 "3-kinase"))
      :ARG1-of (x10 / play-02
            :ARG0 (x6 / and
                  :op1 (x4 / enzyme
                        :name (x5 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                  :op2 (x9 / pathway
                        :name (x7 / name
                              :op1 "transforming"
                              :op2 "growth"
                              :op3 "factor-β")
                        :ARG0-of (x8 / signal-07)))
            :ARG1 (x12 / role
                  :mod (x11 / important)
                  :topic (x13 / regulate-01
                        :ARG1 (x16 / function-01
                              :ARG0 (x15 / cell
                                    :quant (x14 / many)))))))


# ::id PMC4455068.3
# ::snt However, the molecular mechanisms underpinning this crosstalk remain unclear.
# ::tok However , the molecular mechanisms underpinning this crosstalk remain unclear .
(x1 / contrast-01
      :ARG2 (x6 / remain-01
            :ARG1 (x3 / mechanism
                  :mod (x2 / molecule)
                  :ARG0-of (x5 / crosstalk
                        :mod (x4 / this)))
            :ARG3 (x7 / clear-06 :polarity "-")))


# ::id PMC4455068.4
# ::snt Here, we report that PI3K signalling antagonizes the Activin-induced definitive endoderm (DE) differentiation of human embryonic stem cells by attenuating the duration of Smad2/3 activation via the mechanistic target of rapamycin complex 2 (mTORC2).
# ::tok Here , we report that PI3K signalling antagonizes the Activin @-@ induced definitive endoderm ( DE ) differentiation of human embryonic stem cells by attenuating the duration of Smad2 @/@ 3 activation via the mechanistic target of rapamycin complex 2 ( mTORC2 ) .
(x3 / report-01
      :medium (x1 / here)
      :ARG0 (x2 / we)
      :ARG1 (x7 / antagonize-02
            :ARG1 (x6 / signal-07
                  :ARG0 (x4 / enzyme
                        :name (x5 / name :op1 "PI3K")
                        :xref (x32 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
            :ARG2 (x11 / definitive
                  :ARG2-of (x10 / induce-01
                        :ARG0 (x8 / protein
                              :name (x9 / name :op1 "Activin")
                              :xref (x31 / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283"))))
            :ARG1 (x14 / differentiate-01
                  :ARG0 (x12 / country
                        :wiki "germany"
                        :name (x13 / name :op1 "endoderm"))
                  :ARG1 (x18 / cell
                        :mod (x15 / human)
                        :mod (x16 / embryo)
                        :mod (x17 / stem)))
            :ARG2 (x19 / attenuate-01
                  :ARG1 (x28 / complex
                        :mod (x20 / duration
                              :duration-of (x23 / activate-01
                                    :ARG1 (x21 / protein
                                          :name (x22 / name :op1 "Smad2/3"))
                                    :instrument (x24 / mechanism)))
                        :ARG0-of (x25 / target-01
                              :ARG1 (x26 / enzyme
                                    :name (x27 / name :op1 "rapamycin")
                                    :xref (x / xref :value "UNIPROT:MTOR_HUMAN" :prob "0.243")))
                        :mod "2"))
            :ARG1-of (x29 / macro-molecular-complex
                  :name (x30 / name :op1 "mTORC2"))))


# ::id PMC4455068.5
# ::snt Activation of mTORC2 regulates the phosphorylation of the Smad2/3-T220/T179 linker residue independent of Akt, CDK and Erk activity.
# ::tok Activation of mTORC2 regulates the phosphorylation of the Smad2 @/@ 3 @-@ T220 @/@ T179 linker residue independent of Akt , CDK and Erk activity .
(x4 / regulate-01
      :ARG0 (x1 / activate-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "mTORC2")
                  :xref (x24 / xref :value "UNIPROT:MTOR_HUMAN" :prob "0.283")))
      :ARG1 (x13 / link-01
            :ARG0 (x5 / phosphorylate-01
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "Smad2/3"))
                  :ARG2 (x8 / and
                        :op1 (x9 / amino-acid
                              :mod "220"
                              :name (x10 / name :op1 "threonine")
                              :xref (x27 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :op2 (x11 / amino-acid
                              :mod "179"
                              :name (x12 / name :op1 "threonine")
                              :xref (x28 / xref :value "PUBCHEM:205" :prob "11.848252"))))
            :ARG1 (x14 / residue)
            :ARG0-of (x15 / depend-01
                  :polarity "-"
                  :ARG1 (x23 / activity-06
                        :ARG0 (x20 / and
                              :op1 (x16 / enzyme
                                    :name (x17 / name :op1 "Akt")
                                    :xref (x26 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                              :op2 (x18 / enzyme
                                    :name (x19 / name :op1 "CDK")
                                    :xref (x25 / xref :value "UNIPROT:CDK1_HUMAN" :prob "0.262"))
                              :op3 (x21 / enzyme
                                    :name (x22 / name :op1 "Erk")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))))


# ::id PMC4455068.6
# ::snt This phosphorylation primes receptor-activated Smad2/3 for recruitment of the E3 ubiquitin ligase Nedd4L, which in turn leads to their degradation.
# ::tok This phosphorylation primes receptor @-@ activated Smad2 @/@ 3 for recruitment of the E3 ubiquitin ligase Nedd4L , which in turn leads to their degradation .
(x8 / recruit-01
      :ARG1 (x4 / receptor
            :mod (x1 / this)
            :ARG1-of (x2 / phosphorylate-01)
            :name (x3 / name :op1 "primes")
            :ARG1-of (x5 / activate-01))
      :ARG0 (x6 / protein
            :name (x7 / name :op1 "Smad2/3"))
      :ARG1 (x9 / protein
            :name (x10 / name
                  :op1 "E3"
                  :op2 "ubiquitin"
                  :op3 "ligase"))
      :ARG1 (x11 / enzyme
            :name (x12 / name :op1 "Nedd4L")
            :xref (x / xref :value "UNIPROT:NED4L_HUMAN" :prob "0.622"))
      :ARG0-of (x14 / lead-03
            :mod (x13 / in-turn)
            :ARG1 (x15 / degrade-01)))


# ::id PMC4455068.7
# ::snt Inhibition of PI3K/mTORC2 reduces this phosphorylation and increases the duration of Smad2/3 activity, promoting a more robust mesendoderm and endoderm differentiation.
# ::tok Inhibition of PI3K @/@ mTORC2 reduces this phosphorylation and increases the duration of Smad2 @/@ 3 activity , promoting a more robust mesendoderm and endoderm differentiation .
(x10 / and
      :op1 (x7 / reduce-01
            :ARG0 (x1 / inhibit-01
                  :ARG1 (x4 / slash
                        :op1 (x2 / enzyme
                              :name (x3 / name :op1 "PI3K")
                              :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                        :op2 (x5 / enzyme
                              :name (x6 / name :op1 "mTORC2")
                              :xref (x23 / xref :value "UNIPROT:MTOR_HUMAN" :prob "0.283"))))
            :ARG1 (x9 / phosphorylate-01
                  :mod (x8 / this)))
      :op2 (x11 / increase-01
            :ARG1 (x12 / duration
                  :duration-of (x15 / activity-06
                        :ARG0 (x13 / protein
                              :name (x14 / name :op1 "Smad2/3")))))
      :ARG0-of (x16 / promote-01
            :ARG1 (x20 / and
                  :op1 (x18 / robust
                        :degree (x17 / more)
                        :name (x19 / name :op1 "mesendoderm"))
                  :op2 (x22 / differentiate-01
                        :ARG1 (x21 / endoderm)))))


# ::id PMC4455068.8
# ::snt These findings present a new and direct crosstalk mechanism between these two pathways in which mTORC2 functions as a novel and critical mediator.
# ::tok These findings present a new and direct crosstalk mechanism between these two pathways in which mTORC2 functions as a novel and critical mediator .
(x4 / present-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG1-of (x3 / find-01))
      :ARG1 (x6 / and
            :ARG1-of (x5 / new-01)
            :op2 (x8 / crosstalk
                  :ARG1-of (x7 / direct-02)
                  :ARG0-of (x9 / mean-01
                        :ARG1 (x11 / pathway
                              :mod (x10 / this)
                              :quant "2")))
            :ARG1-of (x14 / function-01
                  :ARG2 (x12 / macro-molecular-complex
                        :name (x13 / name :op1 "mTORC2"))
                  :mod (x15 / novel))
            :ARG0-of (x17 / mediate-01
                  :ARG1-of (x16 / critical-02))))


# ::id PMC4455068.10
# ::snt Although crosstalk between the phosphatidylinositol 3-kinase (PI3K) and transforming growth factor-β pathways is important, the mechanism is obscure.
# ::tok Although crosstalk between the phosphatidylinositol 3 @-@ kinase ( PI3K ) and transforming growth factor-β pathways is important , the mechanism is obscure .
(x11 / obscure-02
      :concession (x1 / crosstalk-00
            :ARG0 (x2 / and
                  :op1 (x3 / enzyme
                        :name (x4 / name :op1 "phosphatidylinositol" :op2 "3-kinase"))
                  :op2 (x5 / enzyme
                        :name (x6 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
            :ARG2 (x9 / important
                  :domain (x8 / pathway
                        :name (x7 / name
                              :op1 "transforming"
                              :op2 "growth"
                              :op3 "factor-β"))))
      :ARG1 (x10 / mechanism))


# ::id PMC4455068.11
# ::snt Here, Yu et al . show that activation of mTORC2 downstream of PI3K leads to the linker phosphorylation of Smad2/3 and their ubiquitin-dependent degradation.
# ::tok Here , Yu et al. show that activation of mTORC2 downstream of PI3K leads to the linker phosphorylation of Smad2 @/@ 3 and their ubiquitin @-@ dependent degradation .
(x7 / show-01
      :medium (x1 / here)
      :ARG0 (x4 / and
            :op1 (x2 / person
                  :name (x3 / name :op1 "Yu"))
            :op2 (x5 / person
                  :mod (x6 / other)))
      :ARG1 (x15 / lead-03
            :ARG0 (x8 / activate-01
                  :ARG1 (x9 / enzyme
                        :name (x10 / name :op1 "mTORC2")
                        :xref (x24 / xref :value "UNIPROT:MTOR_HUMAN" :prob "0.283")))
            :ARG1 (x11 / relative-position
                  :direction (x12 / downstream)
                  :op1 (x13 / enzyme
                        :name (x14 / name :op1 "PI3K")
                        :xref (x25 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
            :ARG2 (x16 / phosphorylate-01
                  :ARG1 (x19 / and
                        :op1 (x17 / protein
                              :name (x18 / name :op1 "Smad2/3"))
                        :op2 (x23 / degrade-01
                              :ARG0-of (x22 / depend-01
                                    :ARG1 (x20 / protein
                                          :name (x21 / name :op1 "ubiquitin")
                                          :xref (x / xref :value "UNIPROT:RL40_HUMAN" :prob "0.702"))))))))


# ::id PMC4455068.23
# ::snt PI3K inhibits Activin-induced DE differentiation of hESCs
# ::tok PI3K inhibits Activin @-@ induced DE differentiation of hESCs
(x3 / inhibit-01
      :ARG0 (x1 / small-molecule
            :name (x2 / name :op1 "PI3K")
            :xref (x12 / xref :value "PUBCHEM:1893730" :prob "9.174922"))
      :ARG1 (x9 / differentiate-01
            :ARG2-of (x6 / induce-01
                  :ARG0 (x4 / protein
                        :name (x5 / name :op1 "Activin")
                        :xref (x / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283")))
            :ARG1 (x7 / protein
                  :name (x8 / name :op1 "DE")))
      :ARG1 (x10 / enzyme
            :name (x11 / name :op1 "hESCs")))


# ::id PMC4455068.24
# ::snt To decipher the mechanisms underlying the antagonistic impact of the PI3K pathway upon TGF-β/Activin activities and the DE differentiation of hESCs, we developed a serum-free and chemically defined culture condition to convert hESCs to DE, in which high-dosage Activin A (henceforth AA) was shown to enhance the activation of Smad2/3 signalling and DE differentiation as previously reported ( Supplementary Fig. 1a ; Fig. 1a ) 11
# ::tok To decipher the mechanisms underlying the antagonistic impact of the PI3K pathway upon TGF-β/Activin activities and the DE differentiation of hESCs , we developed a serum @-@ free and chemically defined culture condition to convert hESCs to DE , in which high @-@ dosage Activin A ( henceforth AA ) was shown to enhance the activation of Smad2 @/@ 3 signalling and DE differentiation as previously reported ( Supplementary Fig . 1a ; Fig . 1a ) 11
(x1 / multi-sentence
      :snt1 (x19 / develop-02
            :purpose (x6 / impact-01
                  :time (x2 / decipher-01)
                  :ARG1 (x3 / mechanism
                        :ARG0-of (x4 / underlie-01
                              :ARG1 (x5 / antagonistic)))
                  :ARG0 (x8 / pathway
                        :name (x7 / name :op1 "PI3K"))
                  :time (x12 / and
                        :op1 (x11 / activity-06
                              :ARG0 (x9 / protein
                                    :name (x10 / name :op1 "TGF-β/Activin")))
                        :op2 (x15 / differentiate-01
                              :ARG0 (x13 / protein
                                    :name (x14 / name :op1 "DE"))
                              :ARG1 (x16 / cell-line
                                    :name (x17 / name :op1 "hESCs")))))
            :ARG0 (x18 / we)
            :ARG1 (x25 / condition
                  :ARG1-of (x21 / free-04
                        :ARG2 (x20 / serum))
                  :ARG1-of (x23 / define-01
                        :mod (x22 / chemical))
                  :mod (x24 / culture)))
      :snt2 (x33 / show-01
            :purpose (x26 / convert-01
                  :ARG1 (x27 / small-molecule
                        :name (x28 / name :op1 "hESCs"))
                  :ARG2 (x29 / cell-line
                        :name (x30 / name :op1 "DE")
                        :location-of (x32 / dosage
                              :ARG1-of (x31 / high-02))))
            :ARG1 (x44 / and
                  :op1 (x39 / enhance-01
                        :ARG0 (x34 / protein
                              :name (x35 / name :op1 "Activin")
                              :ARG1-of (x36 / henceforth
                                    :op1 (x37 / company
                                          :wiki "-"
                                          :name (x38 / name :op1 "AA")))
                              :xref (x / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283"))
                        :ARG1 (x40 / activate-01
                              :ARG1 (x43 / signal-07
                                    :ARG0 (x41 / enzyme
                                          :name (x42 / name :op1 "Smad2/3")))))
                  :op2 (x47 / differentiate-01
                        :ARG1 (x45 / protein
                              :name (x46 / name :op1 "DE"))
                        :ARG1-of (x49 / report-01
                              :time (x48 / previous))
                        :ARG1-of (x50 / describe-01
                              :ARG0 (x52 / figure
                                    :ARG2-of (x51 / supplement-01)
                                    :mod "1a"))
                        :ARG1-of (x53 / describe-01
                              :ARG0 (x54 / figure :mod "1a"))))
            :ARG1-of (x55 / describe-01
                  :ARG0 (x56 / publication
                        :ARG1-of (x57 / cite-01 :ARG2 "11")))))


# ::id PMC4455068.25
# ::snt 12 16 .
# ::tok 12 16 .
(x1 / and
      :op2 (x2 / and :op1 "12" :op2 "16"))


# ::id PMC4455068.26
# ::snt Under this culture condition, treatment of hESCs with LY294002 (LY), a PI3K inhibitor, diminished Akt activation even in the presence of AA ( Fig. 1b ).
# ::tok Under this culture condition , treatment of hESCs with LY294002 ( LY ) , a PI3K inhibitor , diminished Akt activation even in the presence of AA ( Fig . 1b ) .
(x4 / treat-04
      :condition (x3 / condition
            :mod (x1 / this)
            :mod (x2 / culture))
      :ARG1 (x5 / cell-line
            :name (x6 / name :op1 "hESCs"))
      :ARG2 (x7 / small-molecule
            :name (x8 / name :op1 "LY294002")
            :xref (x28 / xref :value "PUBCHEM:3973" :prob "18.86067"))
      :ARG1-of (x9 / describe-01
            :ARG0 (x10 / and
                  :op1 (x11 / small-molecule
                        :name (x12 / name :op1 "LY")
                        :xref (x27 / xref :value "PUBCHEM:16196600" :prob "11.455812"))
                  :op2 (x17 / diminish-01
                        :ARG0 (x16 / molecular-physical-entity
                              :ARG0-of (x15 / inhibit-01
                                    :ARG1 (x13 / protein-family
                                          :name (x14 / name :op1 "PI3K"))))
                        :ARG1 (x20 / activate-01
                              :ARG1 (x18 / enzyme
                                    :name (x19 / name :op1 "Akt")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                              :concession (x21 / present-02
                                    :ARG1 (x22 / small-molecule
                                          :name (x23 / name :op1 "6-aa")
                                          :xref (x26 / xref :value "PUBCHEM:195491" :prob "2.046193"))))
                        :ARG1-of (x24 / describe-01
                              :ARG0 (x25 / figure :mod "1b"))))))


# ::id PMC4455068.27
# ::snt In comparison with the differentiation using AA alone, co-treatment of hESCs with AA and LY evidently enhanced the Activin-induced DE differentiation as shown by a higher expression of mesendoderm and DE markers ( Fig. 1c–f ).
# ::tok In comparison with the differentiation using AA alone , co @-@ treatment of hESCs with AA and LY evidently enhanced the Activin @-@ induced DE differentiation as shown by a higher expression of mesendoderm and DE markers ( Fig . 1c–f ) .
(x14 / enhance-01
      :ARG1-of (x1 / compare-01
            :ARG2 (x3 / and
                  :op1 (x2 / differentiate-01)
                  :op2 (x13 / evidence-01
                        :mod (x4 / alone)
                        :ARG1-of (x5 / co-culture
                              :op1 (x6 / treat-04
                                    :ARG1 (x7 / cell-line
                                          :name (x8 / name :op1 "hESCs"))
                                    :ARG2 (x9 / small-molecule
                                          :name (x10 / name :op1 "6-aa")
                                          :xref (x34 / xref :value "PUBCHEM:195491" :prob "2.046193")))
                              :op2 (x11 / small-molecule
                                    :name (x12 / name :op1 "LY")
                                    :xref (x35 / xref :value "PUBCHEM:16196600" :prob "11.455812"))))))
      :ARG1 (x20 / differentiate-01
            :ARG2-of (x17 / induce-01
                  :ARG0 (x15 / protein
                        :name (x16 / name :op1 "Activin")
                        :xref (x / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283")))
            :ARG1 (x18 / protein
                  :name (x19 / name :op1 "DE")))
      :ARG1-of (x21 / show-01
            :ARG0 (x27 / and
                  :op1 (x24 / express-03
                        :ARG1-of (x22 / high-02
                              :degree (x23 / more))
                        :ARG2 (x25 / enzyme
                              :name (x26 / name :op1 "mesendoderm")))
                  :op2 (x30 / marker
                        :mod (x28 / enzyme
                              :name (x29 / name :op1 "DE"))
                        :ARG1-of (x31 / describe-01
                              :ARG0 (x32 / figure))
                        :name (x33 / name :op1 "1c–f")))))


# ::id PMC4455068.28
# ::snt This LY-dependent enhancement of DE differentiation was further corroborated by an increase in the generation of functional hepatocyte-like cells and in multiple hESC lines ( Fig. 1g ; Supplementary Fig. 1b,c ).
# ::tok This LY @-@ dependent enhancement of DE differentiation was further corroborated by an increase in the generation of functional hepatocyte @-@ like cells and in multiple hESC lines ( Fig . 1g ; Supplementary Fig . 1b , c ) .
(x10 / corroborate-01
      :ARG1 (x4 / depend-01
            :mod (x1 / this)
            :ARG1 (x2 / small-molecule
                  :name (x3 / name :op1 "LY")
                  :xref (x27 / xref :value "PUBCHEM:16196600" :prob "11.455812"))
            :ARG0-of (x5 / enhance-01
                  :ARG1 (x8 / differentiate-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "DE")))))
      :degree (x9 / further)
      :ARG2 (x11 / increase-01
            :ARG1 (x18 / and
                  :ARG0 (x17 / cell-line
                        :ARG1-of (x16 / resemble-01
                              :ARG2 (x12 / generate-01
                                    :ARG1 (x13 / enzyme
                                          :ARG0-of (x14 / function-01)
                                          :name (x15 / name :op1 "hepatocyte")
                                          :xref (x / xref :value "UNIPROT:NOS2_HUMAN" :prob "0.352")))))
                  :location (x21 / cell-line
                        :mod (x19 / disease
                              :name (x20 / name :op1 "multiple" :op2 "hESC")))
                  :ARG1-of (x22 / describe-01
                        :ARG0 (x23 / and
                              :op1 (x24 / figure :mod "1g")
                              :op2 (x26 / figure
                                    :ARG2-of (x25 / supplement-01)
                                    :mod "1b"))))))


# ::id PMC4455068.29
# ::snt Therefore, this chemically defined culture system provides a useful platform from which to further interrogate the underlying molecular mechanisms driving the improvement of DE specification.
# ::tok Therefore , this chemically defined culture system provides a useful platform from which to further interrogate the underlying molecular mechanisms driving the improvement of DE specification .
(x1 / cause-01
      :ARG1 (x6 / system
            :mod (x3 / chemical
                  :mod (x2 / this))
            :ARG1-of (x4 / define-01)
            :mod (x5 / culture)
            :ARG0-of (x7 / provide-01
                  :ARG1 (x9 / platform
                        :ARG1-of (x8 / useful-05)))
            :ARG2-of (x11 / interrogate-01
                  :degree (x10 / further)
                  :ARG1 (x14 / mechanism
                        :ARG0-of (x12 / underlie-01)
                        :mod (x13 / molecule)
                        :ARG0-of (x15 / drive-02
                              :ARG1 (x16 / improve-01
                                    :ARG1 (x18 / follicle
                                          :name (x17 / name :op1 "DE"))))))))


# ::id PMC4455068.30
# ::snt Inhibiting PI3K prolongs Activin-induced Smad2/3 activation
# ::tok Inhibiting PI3K prolongs Activin @-@ induced Smad2 @/@ 3 activation
(x1 / inhibit-01
      :ARG1 (x2 / enzyme
            :name (x3 / name :op1 "PI3K")
            :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
      :ARG1-of (x4 / prolong-01)
      :ARG1 (x10 / activate-01
            :ARG2-of (x7 / induce-01
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "Activin")
                        :xref (x11 / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283")))
            :ARG1 (x8 / protein
                  :name (x9 / name :op1 "Smad2/3"))))


# ::id PMC4455068.31
# ::snt To interrogate the mechanisms through which PI3K signalling interferes with TGF-β activities, we first evaluated the activation status of Smad2/3 under AA±LY conditions.
# ::tok To interrogate the mechanisms through which PI3K signalling interferes with TGF-β activities , we first evaluated the activation status of Smad2 @/@ 3 under AA±LY conditions .
(x12 / evaluate-01
      :purpose (x2 / mechanism
            :ARG1-of (x1 / interrogate-01)
            :manner-of (x5 / signal-07
                  :ARG0 (x3 / enzyme
                        :name (x4 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                  :ARG2 (x6 / interfere-01)
                  :ARG1 (x9 / activity-06
                        :ARG0 (x7 / protein
                              :name (x8 / name :op1 "TGF-β")
                              :xref (x20 / xref :value "UNIPROT:TGFB1_HUMAN" :prob "0.233")))))
      :ARG0 (x10 / we)
      :ord (x11 / ordinal-entity :value "1")
      :ARG1 (x13 / status
            :mod (x14 / activate-01
                  :ARG1 (x15 / enzyme
                        :name (x16 / name :op1 "Smad2/3"))))
      :ARG1-of (x19 / condition-01
            :ARG0 (x17 / protein
                  :name (x18 / name :op1 "AA±LY"))))


# ::id PMC4455068.32
# ::snt Time-course analysis revealed that although LY treatment had no effect on the initial activation of Smad2/3 (Smad2/3-pTail), the decline of active Smad2/3 was clearly attenuated in AA–LY-treated cells compared with cells treated with AA alone ( Fig. 2a ), resulting in a marked increase of active Smad2/3 six hours post treatment ( Fig. 2b ).
# ::tok Time @-@ course analysis revealed that although LY treatment had no effect on the initial activation of Smad2 @/@ 3 ( Smad2 @/@ 3 @-@ pTail ) , the decline of active Smad2 @/@ 3 was clearly attenuated in AA–LY @-@ treated cells compared with cells treated with AA alone ( Fig . 2a ) , resulting in a marked increase of active Smad2 @/@ 3 six hours post treatment ( Fig . 2b ) .
(x1 / multi-sentence
      :snt1 (x19 / decline-01
            :ARG1 (x2 / time)
            :ARG2 (x5 / reveal-01
                  :ARG0 (x4 / analyze-01
                        :mod (x3 / of-course))
                  :ARG1 (x6 / have-concession-91
                        :ARG2 (x10 / affect-01
                              :ARG0 (x9 / treat-04
                                    :ARG2 (x7 / small-molecule
                                          :name (x8 / name :op1 "LY")
                                          :xref (x / xref :value "PUBCHEM:16196600" :prob "11.455812")))
                              :polarity "-"
                              :ARG1 (x12 / activate-01
                                    :time (x11 / initial)
                                    :ARG1 (x13 / protein
                                          :name (x14 / name :op1 "Smad2/3"))))
                        :ARG1-of (x15 / describe-01
                              :ARG0 (x16 / protein
                                    :name (x17 / name :op1 "Smad2/3")))
                        :name (x18 / name :op1 "pTail")))
            :ARG1 (x20 / activity-06))
      :snt2 (x24 / attenuate-01
            :ARG1 (x21 / protein
                  :name (x22 / name :op1 "Smad2/3"))
            :ARG1-of (x23 / clear-06)
            :location (x28 / cell
                  :ARG1-of (x27 / treat-04
                        :ARG2 (x25 / small-molecule
                              :name (x26 / name :op1 "AA–LY"))))
            :compared-to (x29 / cell
                  :ARG1-of (x30 / treat-04
                        :ARG2 (x31 / small-molecule
                              :name (x32 / name :op1 "AA")
                              :mod (x33 / alone)
                              :xref (x48 / xref :value "PUBCHEM:764" :prob "7.981792"))))
            :ARG1-of (x34 / describe-01
                  :ARG0 (x35 / figure :mod "2a"))
            :ARG0-of (x36 / result-01
                  :ARG2 (x38 / increase-01
                        :ARG1-of (x37 / mark-01)
                        :ARG1 (x39 / enzyme
                              :ARG0-of (x40 / activity-06)
                              :name (x41 / name :op1 "Smad2/3"))
                        :time (x44 / after
                              :quant (x42 / temporal-quantity
                                    :quant "6"
                                    :unit (x43 / hour))
                              :op1 (x45 / treat-04))
                        :ARG1-of (x46 / describe-01
                              :ARG0 (x47 / figure :mod "2b"))))))


# ::id PMC4455068.33
# ::snt AA–LY-treated cells also exhibited a significant increase in Smad2/3 transcriptional activity evidenced by higher luciferase reporter activity ( Fig. 2c ) and a considerable upregulation of mesendoderm markers MixL1, Eomes and goosecoid and DE marker Sox17, which are known Smad2/3 targets ( Fig. 2d ) 1 17 18 .
# ::tok AA–LY @-@ treated cells also exhibited a significant increase in Smad2 @/@ 3 transcriptional activity evidenced by higher luciferase reporter activity ( Fig . 2c ) and a considerable upregulation of mesendoderm markers MixL1 , Eomes and goosecoid and DE marker Sox17 , which are known Smad2 @/@ 3 targets ( Fig . 2d ) 1 17 18 .
(x1 / multi-sentence
      :snt1 (x7 / exhibit-01
            :ARG0 (x5 / cell
                  :ARG1-of (x4 / treat-04
                        :ARG2 (x2 / small-molecule
                              :name (x3 / name :op1 "AA–LY"))))
            :mod (x6 / also)
            :ARG1 (x9 / increase-01
                  :ARG1-of (x8 / significant-02)
                  :ARG1 (x13 / activity-06
                        :ARG0 (x10 / protein
                              :name (x11 / name :op1 "Smad2/3"))
                        :ARG1 (x12 / transcribe-01)))
            :ARG1-of (x14 / evidence-01
                  :ARG0 (x23 / and
                        :op1 (x20 / activity-06
                              :ARG1-of (x15 / high-02
                                    :degree (x16 / more))
                              :ARG0-of (x19 / report-01
                                    :ARG1 (x17 / enzyme
                                          :name (x18 / name :op1 "luciferase")))
                              :ARG1-of (x21 / describe-01
                                    :ARG0 (x22 / figure :mod "2c")))
                        :op2 (x25 / upregulate-01
                              :degree (x24 / considerable)
                              :ARG1 (x26 / enzyme
                                    :name (x27 / name :op1 "mesendoderm"))))))
      :snt2 (x35 / and
            :op1 (x28 / marker
                  :name (x29 / name :op1 "MixL1"))
            :op2 (x32 / and
                  :op1 (x30 / enzyme
                        :name (x31 / name :op1 "Eomes")
                        :xref (x / xref :value "UNIPROT:EOMES_HUMAN" :prob "0.603"))
                  :op2 (x33 / enzyme
                        :name (x34 / name :op1 "goosecoid")))
            :op2 (x37 / marker
                  :name (x36 / name :op1 "DE")
                  :mod (x38 / protein
                        :name (x39 / name :op1 "Sox17")
                        :xref (x48 / xref :value "UNIPROT:SOX17_HUMAN" :prob "0.633")))
            :ARG1-of (x43 / target-01
                  :ARG1-of (x40 / know-01)
                  :ARG0 (x41 / protein
                        :name (x42 / name :op1 "Smad2/3")))
            :ARG1-of (x44 / describe-01
                  :ARG0 (x45 / figure :mod "2d"))
            :ARG1-of (x46 / describe-01
                  :ARG0 (x47 / and :op1 "17" :op2 "18"))))


# ::id PMC4455068.34
# ::snt This finding implies preferential specification of the cells towards the mesendoderm and DE even at this early stage of differentiation.
# ::tok This finding implies preferential specification of the cells towards the mesendoderm and DE even at this early stage of differentiation .
(x4 / imply-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG1-of (x3 / find-01))
      :ARG1 (x5 / prefer-01
            :ARG1 (x6 / specify-01
                  :ARG1 (x7 / cell)))
      :direction (x8 / and
            :mod (x9 / even)
            :time (x10 / early
                  :op1 (x12 / stage
                        :mod (x11 / this)
                        :subevent-of (x13 / differentiate-01)))))


# ::id PMC4455068.35
# ::snt Furthermore, to rule out the possibility that these enhancements were due to any off-target effects of LY, we treated hESCs with two other PI3K inhibitors in the place of LY, the more commonly used wortmannin and the more selective Pictilisib (also known as GDC-0941).
# ::tok Furthermore , to rule out the possibility that these enhancements were due to any off @-@ target effects of LY , we treated hESCs with two other PI3K inhibitors in the place of LY , the more commonly used wortmannin and the more selective Pictilisib ( also known as GDC @-@ 0941 ) .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op2 (x3 / rule-out-02
                  :ARG1 (x4 / possible-01
                        :ARG1 (x5 / this))))
      :snt2 (x27 / use-01
            :ARG1 (x6 / enhance-01)
            :ARG1-of (x7 / cause-01
                  :ARG0 (x14 / treat-04
                        :mod (x8 / any)
                        :ARG1-of (x10 / affect-01
                              :mod (x9 / off-target)
                              :ARG0 (x11 / small-molecule
                                    :name (x12 / name :op1 "LY")
                                    :xref (x40 / xref :value "PUBCHEM:16196600" :prob "11.455812")))
                        :ARG0 (x13 / we)
                        :ARG1 (x15 / enzyme
                              :name (x16 / name :op1 "hESCs"))
                        :ARG2 (x21 / molecular-physical-entity
                              :quant "2"
                              :mod (x17 / other)
                              :ARG0-of (x20 / inhibit-01
                                    :ARG1 (x18 / protein-family
                                          :name (x19 / name :op1 "PI3K")))))
                  :ARG1 (x22 / place-01
                        :ARG1 (x23 / small-molecule
                              :name (x24 / name :op1 "LY")
                              :xref (x38 / xref :value "PUBCHEM:16196600" :prob "11.455812"))))
            :degree (x26 / common
                  :degree (x25 / more))
            :ARG1 (x30 / and
                  :op1 (x28 / small-molecule
                        :name (x29 / name :op1 "wortmannin")
                        :xref (x / xref :value "PUBCHEM:312145" :prob "18.013371"))
                  :op2 (x32 / selective
                        :degree (x31 / more)
                        :name (x33 / name :op1 "Pictilisib")))
            :ARG1-of (x35 / know-02
                  :mod (x34 / also)
                  :ARG2 (x36 / small-molecule
                        :name (x37 / name :op1 "GDC-0941")
                        :xref (x39 / xref :value "PUBCHEM:17755052" :prob "19.120691")))))


# ::id PMC4455068.36
# ::snt Both experiments largely replicated the changes observed using AA–LY treatment ( Supplementary Fig. 2 ) Therefore, inhibition of PI3K directly enhances Activin-induced DE formation by extending the duration of Smad2/3 activity.
# ::tok Both experiments largely replicated the changes observed using AA–LY treatment ( Supplementary Fig . 2 ) Therefore , inhibition of PI3K directly enhances Activin @-@ induced DE formation by extending the duration of Smad2 @/@ 3 activity .
(x4 / replicate-01
      :ARG0 (x2 / experiment-01
            :mod (x1 / both)
            :mod (x3 / large))
      :ARG1 (x5 / change-01
            :ARG1-of (x6 / observe-01
                  :ARG1 (x7 / use-01
                        :ARG1 (x10 / treat-04
                              :ARG2 (x8 / small-molecule
                                    :name (x9 / name :op1 "AA–LY"))))))
      :ARG1-of (x11 / describe-01
            :ARG0 (x13 / figure
                  :ARG2-of (x12 / supplement-01)
                  :mod "2"))
      :ARG0-of (x14 / cause-01
            :ARG1 (x19 / enhance-01
                  :ARG0 (x15 / inhibit-01
                        :ARG1 (x16 / enzyme
                              :name (x17 / name :op1 "PI3K")
                              :xref (x31 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                        :ARG1-of (x18 / direct-02))
                  :ARG1 (x25 / form-01
                        :ARG2-of (x22 / induce-01
                              :ARG0 (x20 / protein
                                    :name (x21 / name :op1 "Activin")
                                    :xref (x / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283")))
                        :ARG1 (x23 / protein
                              :name (x24 / name :op1 "DE"))
                        :ARG0 (x26 / extend-01
                              :ARG1 (x27 / duration
                                    :duration-of (x30 / activity-06
                                          :ARG0 (x28 / protein
                                                :name (x29 / name :op1 "Smad2/3")))))))))


# ::id PMC4455068.37
# ::snt PI3K modulates ubiquitination and degradation of Smad2/3
# ::tok PI3K modulates ubiquitination and degradation of Smad2 @/@ 3
(x5 / and
      :op1 (x4 / ubiquitinate-01
            :ARG1 (x3 / modulate-01
                  :ARG1 (x1 / enzyme
                        :name (x2 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))
      :op2 (x6 / degrade-01
            :ARG1 (x7 / protein
                  :name (x8 / name :op1 "Smad2/3"))))


# ::id PMC4455068.38
# ::snt Since inhibition of PI3K extended the duration of Smad2/3 activation rather than altering their initial response to AA, we reasoned that PI3K signalling might affect Smad2/3 activity by regulating its turnover, either via phosphatase-mediated dephosphorylation of the SxS motif or by ubiquitin-mediated proteasomal degradation of the active Smad2/3 protein 2 .
# ::tok Since inhibition of PI3K extended the duration of Smad2 @/@ 3 activation rather than altering their initial response to AA , we reasoned that PI3K signalling might affect Smad2 @/@ 3 activity by regulating its turnover , either via phosphatase @-@ mediated dephosphorylation of the SxS motif or by ubiquitin @-@ mediated proteasomal degradation of the active Smad2 @/@ 3 protein 2 .
(x1 / multi-sentence
      :snt1 (x18 / reason-01
            :ARG1-of (x2 / cause-01
                  :ARG0 (x6 / extend-01
                        :ARG0 (x3 / inhibit-01
                              :ARG1 (x4 / enzyme
                                    :name (x5 / name :op1 "PI3K")
                                    :xref (x47 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                        :ARG1 (x7 / duration
                              :duration-of (x10 / activate-01
                                    :ARG1 (x8 / protein
                                          :name (x9 / name :op1 "Smad2/3"))))
                        :ARG1-of (x11 / instead-of-91
                              :ARG2 (x12 / alter-01))
                        :ARG1 (x14 / respond-01
                              :time (x13 / initial)
                              :ARG1 (x15 / small-molecule
                                    :name (x16 / name :op1 "6-aa")
                                    :xref (x51 / xref :value "PUBCHEM:195491" :prob "2.046193")))))
            :ARG0 (x17 / we)
            :ARG1 (x21 / signal-07
                  :ARG0 (x19 / enzyme
                        :name (x20 / name :op1 "PI3K")
                        :xref (x50 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))
      :snt2 (x22 / possible-01
            :ARG1 (x23 / affect-01
                  :ARG1 (x26 / activity-06
                        :ARG0 (x24 / protein
                              :name (x25 / name :op1 "Smad2/3"))))
            :ARG0 (x37 / or
                  :op1 (x27 / regulate-01
                        :ARG1 (x30 / or
                              :op1 (x28 / enzyme
                                    :name (x29 / name :op1 "turnover"))
                              :op2 (x34 / dephosphorylate-01
                                    :ARG1-of (x33 / mediate-01
                                          :ARG0 (x31 / enzyme
                                                :name (x32 / name :op1 "phosphatase")
                                                :xref (x48 / xref :value "UNIPROT:Q59GM9_HUMAN" :prob "0.291")))
                                    :ARG1 (x36 / protein-segment
                                          :name (x35 / name :op1 "SxS")))))
                  :op2 (x43 / degrade-01
                        :ARG1-of (x40 / mediate-01
                              :ARG0 (x38 / protein
                                    :name (x39 / name :op1 "ubiquitin")
                                    :xref (x49 / xref :value "UNIPROT:RL40_HUMAN" :prob "0.702")))
                        :ARG0 (x41 / protein
                              :name (x42 / name :op1 "proteasomal")
                              :xref (x / xref :value "UNIPROT:VP113_HUMAN" :prob "0.282"))
                        :ARG1 (x46 / protein
                              :ARG0-of (x44 / activity-06)
                              :name (x45 / name :op1 "Smad2/3")
                              :mod "2")))))


# ::id PMC4455068.39
# ::snt Until recently, nuclear PPM1A was the only phosphatase identified to dephosphorylate Smad2/3 at the SxS motif 19 , which is inhibited by CLIC4 (chloride intracellular channel 4) protein 20 .
# ::tok Until recently , nuclear PPM1A was the only phosphatase identified to dephosphorylate Smad2 @/@ 3 at the SxS motif 19 , which is inhibited by CLIC4 ( chloride intracellular channel 4 ) protein 20 .
(x8 / identify-01
      :time (x1 / until
            :op1 (x2 / recent))
      :ARG0 (x3 / nucleus
            :xref (x / xref :value "GO:0005634" :prob "0.8"))
      :ARG1 (x7 / phosphatase
            :domain (x4 / protein
                  :name (x5 / name :op1 "PPM1A"))
            :mod (x6 / only))
      :ARG2 (x9 / dephosphorylate-01
            :ARG1 (x10 / protein
                  :name (x11 / name :op1 "Smad2/3")))
      :location (x13 / motif
            :name (x12 / name :op1 "SxS")
            :ARG1-of (x14 / describe-01
                  :ARG0 (x15 / publication
                        :ARG1-of (x16 / cite-01 :ARG2 "19")))
            :ARG0-of (x17 / inhibit-01
                  :ARG0 (x18 / protein
                        :name (x19 / name :op1 "CLIC4"))
                  :ARG1-of (x20 / chloride)
                  :ARG1 (x23 / protein
                        :mod (x21 / intracellular
                              :name (x22 / name :op1 "channel" :op2 "4"))
                        :ARG1-of (x24 / describe-01
                              :ARG0 (x25 / publication
                                    :ARG1-of (x26 / cite-01 :ARG2 "20")))))))


# ::id PMC4455068.40
# ::snt However, not only did LY treatment not affect the expression of either protein, PPM1A was also detected primarily in the cytoplasm ( Supplementary Fig. 3a,b ).
# ::tok However , not only did LY treatment not affect the expression of either protein , PPM1A was also detected primarily in the cytoplasm ( Supplementary Fig . 3a , b ) .
(x1 / have-concession-91
      :ARG1 (x7 / affect-01
            :ARG0 (x3 / do-02
                  :mod (x2 / only :polarity "-")
                  :ARG1 (x6 / treat-04
                        :ARG2 (x4 / small-molecule
                              :name (x5 / name :op1 "LY")
                              :xref (x19 / xref :value "PUBCHEM:16196600" :prob "11.455812")))
                  :polarity "-")
            :ARG1 (x8 / express-03
                  :ARG2 (x9 / protein))
            :ARG0-of (x13 / detect-01
                  :ARG1 (x10 / protein
                        :name (x11 / name :op1 "PPM1A"))
                  :mod (x12 / also)
                  :ARG1 (x14 / primary)
                  :location (x15 / cytoplasm
                        :xref (x / xref :value "GO:0005737" :prob "0.8")))
            :ARG1-of (x16 / describe-01
                  :ARG0 (x18 / figure
                        :ARG2-of (x17 / supplement-01)
                        :mod "3a"))))


# ::id PMC4455068.41
# ::snt It is therefore unlikely that Smad2/3 dephosphorylation by PPM1A is the mechanism accounting for the phenotypic changes associated with AA–LY treatment.
# ::tok It is therefore unlikely that Smad2 @/@ 3 dephosphorylation by PPM1A is the mechanism accounting for the phenotypic changes associated with AA–LY treatment .
(x1 / cause-01
      :ARG1 (x2 / likely-01
            :polarity "-"
            :ARG1 (x8 / mechanism
                  :domain (x5 / dephosphorylate-01
                        :ARG1 (x3 / protein
                              :name (x4 / name :op1 "Smad2/3"))
                        :ARG0 (x6 / protein
                              :name (x7 / name :op1 "PPM1A")))
                  :ARG0-of (x9 / account-01
                        :ARG1 (x11 / change-01
                              :ARG1-of (x10 / phenotypic)
                              :ARG1-of (x12 / associate-01
                                    :ARG2 (x15 / treat-04
                                          :ARG2 (x13 / small-molecule
                                                :name (x14 / name :op1 "AA–LY")))))))))


# ::id PMC4455068.42
# ::snt Although one recent study has shown that PP5, a member of the PPP phosphatase family, is able to dephosphorylate active Smad2/3 upon overexpression 21 , treatment of hESCs with okadaic acid, a potent inhibitor of PPP phosphatases, had no effect on the decay kinetics of active Smad2 ( Supplementary Fig. 3c ).
# ::tok Although one recent study has shown that PP5 , a member of the PPP phosphatase family , is able to dephosphorylate active Smad2 @/@ 3 upon overexpression 21 , treatment of hESCs with okadaic acid , a potent inhibitor of PPP phosphatases , had no effect on the decay kinetics of active Smad2 ( Supplementary Fig . 3c ) .
(x1 / multi-sentence
      :snt1 (x2 / have-concession-91
            :ARG2 (x5 / show-01
                  :ARG0 (x4 / study-01
                        :quant "1"
                        :time (x3 / recent))
                  :ARG1 (x13 / capable-01
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "PP5")
                              :ARG1-of (x8 / mean-01
                                    :ARG2 (x9 / member
                                          :ARG1-of (x10 / include-91
                                                :ARG2 (x12 / protein-family
                                                      :name (x11 / name :op1 "phosphatase")))))
                              :xref (x / xref :value "UNIPROT:PPP5_HUMAN" :prob "1.002"))
                        :ARG2 (x14 / dephosphorylate-01
                              :ARG1 (x15 / enzyme
                                    :ARG0-of (x16 / activity-06)
                                    :name (x17 / name :op1 "Smad2/3"))
                              :condition (x18 / overexpress-01
                                    :ARG1-of (x19 / describe-01
                                          :ARG0 (x20 / publication
                                                :ARG1-of (x21 / cite-01 :ARG2 "21")))))))
            :ARG1 (x31 / affect-01
                  :ARG0 (x22 / treat-04
                        :ARG1 (x23 / hescs)
                        :ARG2 (x27 / small-molecule
                              :mod (x24 / small-molecule
                                    :name (x25 / name :op1 "okadaic" :op2 "acid"))
                              :mod (x26 / potent)
                              :ARG0-of (x28 / inhibit-01
                                    :ARG1 (x29 / enzyme
                                          :name (x30 / name :op1 "PPP" :op2 "phosphatase")))))
                  :polarity "-"
                  :ARG1 (x32 / decay)))
      :snt2 (x33 / kinetics
            :mod (x34 / activate-01
                  :ARG1 (x35 / protein
                        :name (x36 / name :op1 "Smad2")
                        :xref (x40 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003"))
                  :ARG1-of (x37 / describe-01
                        :ARG0 (x39 / figure
                              :ARG2-of (x38 / supplement-01)
                              :mod "3c")))))


# ::id PMC4455068.43
# ::snt Furthermore, enhanced TGF-β-induced transcriptional responses that were observed in PP5-null mice has been shown to result from increased levels of Smad3 protein rather than through any direct effect upon the duration of their activation 21 .
# ::tok Furthermore , enhanced TGF-β-induced transcriptional responses that were observed in PP5 @-@ null mice has been shown to result from increased levels of Smad3 protein rather than through any direct effect upon the duration of their activation 21 .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op2 (x3 / show-01
                  :ARG1 (x14 / result-01
                        :ARG1 (x8 / respond-01
                              :ARG1-of (x4 / enhance-01)
                              :mod (x7 / transcribe-01
                                    :ARG1 (x5 / enzyme
                                          :name (x6 / name :op1 "TGF-β-induced")
                                          :xref (x / xref :value "UNIPROT:TGIF2_HUMAN" :prob "0.262")))
                              :ARG1-of (x9 / observe-01
                                    :location (x13 / mouse
                                          :mod (x11 / enzyme
                                                :name (x10 / name :op1 "PP5")
                                                :ARG2-of (x12 / mutate-01 :mod "-/-")
                                                :xref (x30 / xref :value "UNIPROT:PPP5_HUMAN" :prob "1.002")))))
                        :ARG2 (x16 / level
                              :ARG1-of (x15 / increase-01)
                              :quant-of (x17 / protein
                                    :name (x18 / name :op1 "Smad3")
                                    :xref (x31 / xref :value "UNIPROT:SMAD3_HUMAN" :prob "1.003"))))
                  :ARG2 (x19 / protein)
                  :ARG1-of (x20 / instead-of-91
                        :ARG2 (x21 / through))))
      :snt2 (x24 / affect-01
            :mod (x22 / any)
            :ARG1-of (x23 / direct-02)
            :ARG1 (x26 / activate-01
                  :ARG0 (x25 / duration)
                  :ARG1-of (x27 / describe-01
                        :ARG0 (x28 / publication
                              :ARG1-of (x29 / cite-01 :ARG2 "21"))))))


# ::id PMC4455068.44
# ::snt These findings therefore further discount the involvement of phosphatases in our underlying mechanism.
# ::tok These findings therefore further discount the involvement of phosphatases in our underlying mechanism .
(x6 / recommend-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG1-of (x3 / find-01)
            :ARG0-of (x4 / cause-01))
      :degree (x5 / further)
      :ARG1 (x7 / involve-01
            :ARG1 (x8 / protein
                  :name (x9 / name :op1 "phosphatase")
                  :xref (x / xref :value "UNIPROT:Q59GM9_HUMAN" :prob "0.291"))
            :ARG2 (x11 / mechanism
                  :ARG0-of (x10 / underlie-01))))


# ::id PMC4455068.45
# ::snt Given that ubiquitin-mediated proteasomal degradation is another mechanism by which Smad2/3 activity is terminated 22 , we next investigated whether LY acts to protect active Smad2 from proteasomal degradation.
# ::tok Given that ubiquitin @-@ mediated proteasomal degradation is another mechanism by which Smad2 @/@ 3 activity is terminated 22 , we next investigated whether LY acts to protect active Smad2 from proteasomal degradation .
(x1 / cause-01
      :ARG0 (x13 / terminate-01
            :ARG1 (x7 / degrade-01
                  :ARG1-of (x4 / mediate-01
                        :ARG0 (x2 / protein
                              :name (x3 / name :op1 "ubiquitin")
                              :xref (x29 / xref :value "UNIPROT:RL40_HUMAN" :prob "0.702")))
                  :ARG1 (x5 / enzyme
                        :name (x6 / name :op1 "proteasomal")
                        :xref (x30 / xref :value "UNIPROT:VP113_HUMAN" :prob "0.282")))
            :ARG1 (x9 / mechanism
                  :mod (x8 / another)
                  :instrument-of (x12 / activity-06
                        :ARG0 (x10 / protein
                              :name (x11 / name :op1 "Smad2/3"))))
            :ARG1-of (x14 / describe-01
                  :ARG0 (x15 / publication
                        :ARG1-of (x16 / cite-01 :ARG2 "22"))))
      :ARG1 (x19 / investigate-01
            :ARG0 (x17 / we)
            :time (x18 / next)
            :ARG1 (x22 / act-01
                  :mode "interrogative"
                  :ARG0 (x20 / small-molecule
                        :name (x21 / name :op1 "LY")
                        :xref (x31 / xref :value "PUBCHEM:16196600" :prob "11.455812"))
                  :purpose (x23 / protect-01
                        :ARG1 (x27 / and
                              :op1 (x24 / enzyme
                                    :ARG0-of (x25 / activity-06)
                                    :name (x26 / name :op1 "Smad2")
                                    :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003"))
                              :op2 (x28 / degrade-01))))))


# ::id PMC4455068.46
# ::snt Similar decay kinetics for active Smad2 was observed between LY- and MG132-treated cells, albeit not with the same efficacy ( Fig. 3a–c ).
# ::tok Similar decay kinetics for active Smad2 was observed between LY @- and MG132 @-@ treated cells , albeit not with the same efficacy ( Fig . 3a–c ) .
(x7 / observe-01
      :ARG1 (x3 / kinetics
            :ARG1-of (x1 / resemble-01
                  :ARG2 (x2 / decay))
            :poss (x4 / enzyme
                  :ARG0-of (x5 / activity-06)
                  :name (x6 / name :op1 "Smad2")
                  :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003")))
      :ARG1 (x10 / and
            :op1 (x8 / enzyme
                  :name (x9 / name :op1 "LY"))
            :op2 (x14 / cell
                  :ARG1-of (x13 / treat-04
                        :ARG2 (x11 / small-molecule
                              :name (x12 / name :op1 "MG132")
                              :xref (x22 / xref :value "PUBCHEM:462382" :prob "18.349844")))))
      :concession (x15 / have-03
            :polarity "-"
            :ARG1 (x17 / efficient-01
                  :ARG1-of (x16 / same-01)))
      :ARG1-of (x18 / describe-01
            :ARG0 (x19 / figure :mod "3")
            :ARG2 (x20 / protein
                  :name (x21 / name :op1 "47" :op2 "c"))))


# ::id PMC4455068.47
# ::snt In addition, inhibition of the Activin receptor by SB431542 did not abolish the effect of LY, but rather made it observable much earlier at 1 h post treatment ( Fig. 3b ).
# ::tok In addition , inhibition of the Activin receptor by SB431542 did not abolish the effect of LY , but rather made it observable much earlier at 1 h post treatment ( Fig . 3b ) .
(x1 / and
      :op2 (x8 / abolish-01
            :ARG0 (x2 / inhibit-01
                  :ARG1 (x5 / receptor
                        :mod (x3 / protein
                              :name (x4 / name :op1 "Activin")
                              :xref (x / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283")))
                  :ARG0 (x6 / small-molecule
                        :name (x7 / name :op1 "SB431542")
                        :xref (x24 / xref :value "PUBCHEM:4521392" :prob "18.349844")))
            :polarity "-"
            :ARG1 (x9 / affect-01
                  :ARG0 (x10 / small-molecule
                        :name (x11 / name :op1 "LY")
                        :xref (x25 / xref :value "PUBCHEM:16196600" :prob "11.455812"))
                  :ARG1-of (x12 / contrast-01
                        :ARG2 (x13 / make-02
                              :ARG1 (x14 / observe-01))))
            :time (x17 / early
                  :degree (x16 / more
                        :quant (x15 / much)))
            :time (x20 / after
                  :quant (x18 / temporal-quantity
                        :quant "1"
                        :unit (x19 / hour))
                  :op1 (x21 / treat-04))
            :ARG1-of (x22 / describe-01
                  :ARG0 (x23 / figure :mod "3b"))))


# ::id PMC4455068.48
# ::snt Together, this suggests that PI3K affects the TGF-β/Activin pathway independent of receptor activity and acts to promote the ubiquitin-mediated proteasomal degradation of active Smad2/3.
# ::tok Together , this suggests that PI3K affects the TGF-β/Activin pathway independent of receptor activity and acts to promote the ubiquitin @-@ mediated proteasomal degradation of active Smad2 @/@ 3 .
(x3 / suggest-01
      :mod (x1 / together)
      :ARG0 (x2 / this)
      :ARG1 (x6 / affect-01
            :ARG0 (x4 / enzyme
                  :name (x5 / name :op1 "PI3K")
                  :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
            :ARG1 (x9 / depend-01
                  :ARG1 (x7 / pathway
                        :name (x8 / name :op1 "TGF-β/Activin"))
                  :polarity "-"
                  :ARG1 (x13 / and
                        :op1 (x12 / activity-06
                              :ARG0 (x10 / enzyme
                                    :name (x11 / name :op1 "receptor")
                                    :xref (x26 / xref :value "UNIPROT:CIR1_HUMAN" :prob "0.243")))
                        :op2 (x14 / act-02))
                  :purpose (x15 / promote-01
                        :ARG1 (x21 / degrade-01
                              :ARG1-of (x18 / mediate-01
                                    :ARG0 (x16 / protein
                                          :name (x17 / name :op1 "ubiquitin")
                                          :xref (x27 / xref :value "UNIPROT:RL40_HUMAN" :prob "0.702")))
                              :ARG0 (x19 / protein
                                    :name (x20 / name :op1 "proteasomal")
                                    :xref (x25 / xref :value "UNIPROT:VP113_HUMAN" :prob "0.282"))
                              :ARG1 (x22 / enzyme
                                    :ARG0-of (x23 / activity-06)
                                    :name (x24 / name :op1 "Smad2/3")))))))


# ::id PMC4455068.49
# ::snt Although Nedd4L has been previously identified as the ubiquitin ligase responsible for Smad2/3 ubiquitination 23 , we observed no LY-dependent changes in its expression ( Supplementary Fig. 3d ).
# ::tok Although Nedd4L has been previously identified as the ubiquitin ligase responsible for Smad2 @/@ 3 ubiquitination 23 , we observed no LY @-@ dependent changes in its expression ( Supplementary Fig . 3d ) .
(x1 / have-concession-91
      :ARG2 (x4 / identify-01
            :ARG1 (x2 / nedd4l)
            :time (x3 / previous)
            :ARG2 (x7 / responsible-01
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "ubiquitin" :op2 "ligase"))
                  :ARG1 (x10 / ubiquitinate-01
                        :ARG1 (x8 / protein
                              :name (x9 / name :op1 "Smad2/3"))
                        :ARG2 "23")))
      :ARG1 (x12 / observe-01
            :ARG0 (x11 / we)
            :polarity "-"
            :ARG1 (x16 / change-01
                  :ARG0-of (x15 / depend-01
                        :ARG1 (x13 / small-molecule
                              :name (x14 / name :op1 "LY")
                              :xref (x / xref :value "PUBCHEM:16196600" :prob "11.455812")))
                  :ARG1 (x17 / express-03))
            :ARG1-of (x18 / describe-01
                  :ARG0 (x20 / figure
                        :ARG2-of (x19 / supplement-01)
                        :mod "3d"))))


# ::id PMC4455068.50
# ::snt However, LY treatment substantially reduced its interaction with Smad2 ( Fig. 3d ), which was corroborated by decreased ubiquitination of Smad2 ( Fig. 3e ).
# ::tok However , LY treatment substantially reduced its interaction with Smad2 ( Fig . 3d ) , which was corroborated by decreased ubiquitination of Smad2 ( Fig . 3e ) .
(x1 / have-concession-91
      :ARG1 (x6 / reduce-01
            :ARG0 (x4 / treat-04
                  :ARG2 (x2 / small-molecule
                        :name (x3 / name :op1 "LY")
                        :xref (x20 / xref :value "PUBCHEM:16196600" :prob "11.455812")))
            :degree (x5 / substantial)
            :ARG1 (x7 / interact-01
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "Smad2")
                        :xref (x19 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003")))
            :ARG1-of (x10 / describe-01
                  :ARG0 (x11 / figure :mod "3d"))
            :ARG0-of (x14 / ubiquitinate-01
                  :ARG1 (x12 / corroborate-01
                        :ARG0 (x13 / decrease-01))
                  :ARG2 (x15 / protein
                        :name (x16 / name :op1 "Smad2")
                        :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003")))
            :ARG1-of (x17 / describe-01
                  :ARG0 (x18 / figure :mod "3e"))))


# ::id PMC4455068.51
# ::snt These results therefore highlight the critical role PI3K signalling plays in regulating the association of Nedd4L with Smad2/3, which in turn, dictates the duration and efficacy of Smad2/3 activity.
# ::tok These results therefore highlight the critical role PI3K signalling plays in regulating the association of Nedd4L with Smad2 @/@ 3 , which in turn , dictates the duration and efficacy of Smad2 @/@ 3 activity .
(x4 / highlight-01
      :ARG0 (x2 / thing
            :mod (x1 / this)
            :ARG2-of (x3 / result-01))
      :ARG1 (x5 / role
            :ARG1-of (x6 / critical-02
                  :ARG2 (x9 / signal-07
                        :ARG0 (x7 / enzyme
                              :name (x8 / name :op1 "PI3K")
                              :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                        :ARG0-of (x10 / play-08
                              :ARG1 (x11 / regulate-01
                                    :ARG1 (x12 / associate-01
                                          :ARG1 (x13 / enzyme
                                                :name (x14 / name :op1 "Nedd4L")
                                                :xref (x25 / xref :value "UNIPROT:NED4L_HUMAN" :prob "0.622"))
                                          :ARG2 (x15 / protein
                                                :name (x16 / name :op1 "Smad2/3")))))
                        :ARG0-of (x18 / dictate-01
                              :mod (x17 / in-turn)
                              :ARG1 (x24 / activity-06
                                    :ARG0 (x20 / and
                                          :op1 (x19 / duration)
                                          :op2 (x21 / efficient-01
                                                :ARG1 (x22 / protein
                                                      :name (x23 / name :op1 "Smad2/3"))))))))))


# ::id PMC4455068.52
# ::snt PI3K primes Smad2/3 interaction with Nedd4L via pT220/T179
# ::tok PI3K primes Smad2 @/@ 3 interaction with Nedd4L via pT220 @/@ T179
(x7 / interact-01
      :ARG0 (x1 / enzyme
            :name (x2 / name :op1 "PI3K")
            :xref (x16 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
      :ARG1 (x3 / enzyme
            :name (x4 / name :op1 "primes")
            :xref (x15 / xref :value "UNIPROT:PRI1_HUMAN" :prob "0.202"))
      :ARG0 (x5 / protein
            :name (x6 / name :op1 "Smad2/3"))
      :ARG1 (x8 / protein
            :name (x9 / name :op1 "Nedd4L")
            :xref (x / xref :value "UNIPROT:NED4L_HUMAN" :prob "0.622"))
      :manner (x12 / slash
            :op1 (x10 / enzyme
                  :name (x11 / name :op1 "pT220"))
            :op2 (x13 / amino-acid
                  :mod "179"
                  :name (x14 / name :op1 "threonine")
                  :xref (x17 / xref :value "PUBCHEM:205" :prob "11.848252"))))


# ::id PMC4455068.53
# ::snt Although activation of TGF-β/Activin signalling is primarily determined by the receptor-mediated phosphorylation of Smad2/3 C-terminal SxS motif that induces their accumulation within the nucleus, it is increasingly apparent that the linker region of Smad2/3 serves a critical site through which their activity is regulated.
# ::tok Although activation of TGF-β/Activin signalling is primarily determined by the receptor @-@ mediated phosphorylation of Smad2 @/@ 3 C @-@ terminal SxS motif that induces their accumulation within the nucleus , it is increasingly apparent that the linker region of Smad2 @/@ 3 serves a critical site through which their activity is regulated .
(x1 / multi-sentence
      :snt1 (x2 / have-concession-91
            :ARG2 (x8 / determine-01
                  :ARG1 (x3 / activate-01
                        :ARG1 (x6 / signal-07
                              :ARG0 (x4 / enzyme
                                    :name (x5 / name :op1 "TGF-β/Activin"))))
                  :mod (x7 / primary)
                  :ARG0 (x12 / phosphorylate-01
                        :ARG1-of (x11 / mediate-01
                              :ARG0 (x9 / enzyme
                                    :name (x10 / name :op1 "receptor")
                                    :xref (x / xref :value "UNIPROT:CIR1_HUMAN" :prob "0.243")))
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "Smad2/3"))))
            :ARG1 (x15 / protein-segment
                  :name (x16 / name :op1 "c-terminus")))
      :snt2 (x27 / serve-01
            :ARG0 (x24 / region
                  :ARG1-of (x17 / protein-segment
                        :ARG0-of (x18 / induce-01
                              :ARG2 (x19 / accumulate-01
                                    :location (x20 / nucleus
                                          :xref (x33 / xref :value "GO:0005634" :prob "0.8"))
                                    :ARG1-of (x21 / increase-01))))
                  :ARG1-of (x22 / appear-01
                        :ARG1 (x23 / link-01))
                  :part-of (x25 / protein
                        :name (x26 / name :op1 "Smad2/3")))
            :ARG1 (x29 / protein-segment
                  :ARG1-of (x28 / critical-02)
                  :degree (x30 / more)
                  :ARG0-of (x32 / regulate-01
                        :ARG1 (x31 / activity-06)))))


# ::id PMC4455068.54
# ::snt This region contains multiple S/T residues, which are targeted by various S/T kinases stemming from other signalling pathways 24 25 26 27 28 .
# ::tok This region contains multiple S/T residues , which are targeted by various S/T kinases stemming from other signalling pathways 24 25 26 27 28 .
(x3 / contain-01
      :ARG1 (x2 / region
            :mod (x1 / this))
      :ARG1 (x6 / residue
            :mod (x4 / disease
                  :name (x5 / name :op1 "multiple" :op2 "S/T")))
      :ARG0-of (x7 / target-01
            :ARG0 (x10 / kinase
                  :mod (x8 / various)
                  :name (x9 / name :op1 "S/T"))
            :ARG1 (x11 / stem-01)
            :ARG2 (x14 / pathway
                  :mod (x12 / other)
                  :ARG0-of (x13 / signal-07)
                  :mod "24"
                  :mod "25"
                  :mod "26"
                  :name (x15 / name :op1 "27" :op2 "28"))))


# ::id PMC4455068.55
# ::snt Phosphorylation of these residues alters the interaction of Smad2/3 with other proteins, which subsequently affects Smad2/3 stability, translocation and transcriptional activity 3 23 29 30 .
# ::tok Phosphorylation of these residues alters the interaction of Smad2 @/@ 3 with other proteins , which subsequently affects Smad2 @/@ 3 stability , translocation and transcriptional activity 3 23 29 30 .
(x4 / alter-01
      :ARG1 (x1 / phosphorylate-01
            :ARG1 (x3 / residue
                  :mod (x2 / this)))
      :ARG1 (x5 / interact-01
            :ARG0 (x6 / protein
                  :name (x7 / name :op1 "Smad2/3"))
            :ARG1 (x9 / protein
                  :mod (x8 / other)))
      :ARG0-of (x11 / affect-01
            :time (x10 / subsequent)
            :ARG1 (x14 / stable-03
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "Smad2/3")))
            :ARG1 (x16 / and
                  :op1 (x15 / translocate-01)
                  :op2 (x18 / activity-06
                        :ARG1 (x17 / transcribe-01)
                        :ARG0 (x19 / and
                              :op1 "3"
                              :op2 "23"
                              :op3 "29"
                              :op4 "30")))))


# ::id PMC4455068.56
# ::snt Recruitment of Nedd4L to Smad2/3 was shown to be dependent on the phosphorylation status of their linker T220/T179 residue, which lies directly upstream of the PPXY-binding motif ( Fig. 4a ) 23 .
# ::tok Recruitment of Nedd4L to Smad2 @/@ 3 was shown to be dependent on the phosphorylation status of their linker T220 @/@ T179 residue , which lies directly upstream of the PPXY @-@ binding motif ( Fig . 4a ) 23 .
(x1 / show-01
      :ARG1 (x6 / depend-01
            :ARG0 (x2 / recruit-01
                  :ARG1 (x3 / nedd4l)
                  :ARG2 (x4 / protein
                        :name (x5 / name :op1 "Smad2/3")))
            :ARG1 (x7 / status
                  :mod (x8 / phosphorylate-01
                        :ARG1 (x15 / residue
                              :ARG1-of (x9 / link-01
                                    :ARG2 (x10 / and
                                          :op1 (x11 / amino-acid
                                                :mod "220"
                                                :name (x12 / name :op1 "threonine")
                                                :xref (x28 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                          :op2 (x13 / amino-acid
                                                :mod "179"
                                                :name (x14 / name :op1 "threonine")
                                                :xref (x29 / xref :value "PUBCHEM:205" :prob "11.848252"))))
                              :ARG0-of (x16 / lie-08
                                    :mod (x17 / direct-02)
                                    :direction (x18 / upstream)
                                    :ARG2 (x22 / protein-segment
                                          :ARG1-of (x21 / bind-01
                                                :ARG2 (x19 / protein
                                                      :name (x20 / name :op1 "PPXY")
                                                      :xref (x / xref :value "UNIPROT:PP4C_HUMAN" :prob "0.262")))))
                              :ARG1-of (x23 / describe-01
                                    :ARG0 (x24 / figure :mod "4a"))
                              :ARG1-of (x25 / describe-01
                                    :ARG0 (x26 / publication
                                          :ARG1-of (x27 / cite-01 :ARG2 "23"))))))))


# ::id PMC4455068.57
# ::snt Therefore, we anticipated that PI3K signalling might affect Smad2/3 degradation through altering the phosphorylation of this residue.
# ::tok Therefore , we anticipated that PI3K signalling might affect Smad2 @/@ 3 degradation through altering the phosphorylation of this residue .
(x1 / cause-01
      :ARG1 (x3 / anticipate-01
            :ARG0 (x2 / we)
            :ARG1 (x6 / signal-07
                  :ARG0 (x4 / enzyme
                        :name (x5 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                  :ARG1 (x7 / possible-01
                        :ARG1 (x8 / affect-01
                              :ARG1 (x11 / degrade-01
                                    :ARG1 (x9 / protein
                                          :name (x10 / name :op1 "Smad2/3"))))
                        :manner (x12 / alter-01
                              :ARG1 (x13 / phosphorylate-01
                                    :ARG1 (x15 / residue
                                          :mod (x14 / this))))))))


# ::id PMC4455068.58
# ::snt Indeed, LY treatment significantly reduced the phosphorylation of T220/T179, irrespective of Smad2/3 activation, but had negligible effects on the other linker serine residues in both hESC and tumour cell lines ( Fig. 4b–d ; Supplementary Fig. 4a–e ).
# ::tok Indeed , LY treatment significantly reduced the phosphorylation of T220/T179 , irrespective of Smad2 @/@ 3 activation , but had negligible effects on the other linker serine residues in both hESC and tumour cell lines ( Fig . 4b–d ; Supplementary Fig . 4a–e ) .
(x1 / multi-sentence
      :snt1 (x2 / indeed)
      :snt2 (x7 / reduce-01
            :ARG0 (x5 / treat-04
                  :ARG2 (x3 / small-molecule
                        :name (x4 / name :op1 "LY")
                        :xref (x37 / xref :value "PUBCHEM:16196600" :prob "11.455812")))
            :ARG2 (x6 / significant-02)
            :ARG1 (x8 / phosphorylate-01
                  :ARG1 (x9 / enzyme
                        :name (x10 / name :op1 "T220/T179")))
            :ARG1-of (x11 / regardless-91
                  :ARG2 (x14 / activate-01
                        :ARG1 (x12 / protein
                              :name (x13 / name :op1 "Smad2/3"))
                        :ARG1-of (x15 / contrast-01
                              :ARG2 (x17 / affect-01
                                    :mod (x16 / negligible)
                                    :ARG1 (x22 / residue
                                          :mod (x18 / other)
                                          :ARG0-of (x19 / link-01)
                                          :mod (x20 / amino-acid
                                                :name (x21 / name :op1 "serine")
                                                :xref (x36 / xref :value "PUBCHEM:5951" :prob "11.218784")))
                                    :location (x26 / and
                                          :mod (x23 / both)
                                          :op1 (x24 / enzyme
                                                :name (x25 / name :op1 "hESC")
                                                :xref (x / xref :value "UNIPROT:PDCD7_HUMAN" :prob "0.202"))
                                          :op2 (x28 / cell-line
                                                :mod (x27 / tumor)
                                                :ARG1-of (x29 / describe-01
                                                      :ARG0 (x30 / figure))
                                                :name (x31 / name :op1 "4b–d"))
                                          :op2 (x33 / figure
                                                :ARG2-of (x32 / supplement-01)
                                                :mod "4")))
                              :ARG1 (x34 / protein
                                    :name (x35 / name :op1 "47" :op2 "e")))))))


# ::id PMC4455068.59
# ::snt This suggests that Smad2/3 linker threonine and serine residues are differentially regulated, with PI3K specifically modulating the phosphorylation of the T220/T179 linker residue.
# ::tok This suggests that Smad2 @/@ 3 linker threonine and serine residues are differentially regulated , with PI3K specifically modulating the phosphorylation of the T220 @/@ T179 linker residue .
(x2 / suggest-01
      :ARG0 (x1 / this)
      :ARG1 (x13 / regulate-01
            :ARG1 (x8 / and
                  :op1 (x5 / link-01
                        :ARG1 (x3 / protein
                              :name (x4 / name :op1 "Smad2")
                              :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003"))
                        :ARG2 (x6 / amino-acid
                              :name (x7 / name :op1 "threonine")
                              :xref (x29 / xref :value "PUBCHEM:205" :prob "11.848252")))
                  :op2 (x9 / residue
                        :mod (x10 / amino-acid
                              :name (x11 / name :op1 "serine")
                              :xref (x30 / xref :value "PUBCHEM:5951" :prob "11.218784"))))
            :manner (x12 / differential)
            :ARG1 (x14 / enzyme
                  :name (x15 / name :op1 "PI3K")
                  :xref (x26 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
            :ARG1-of (x17 / modulate-01
                  :ARG1-of (x16 / specific-02)
                  :ARG1 (x24 / link-01
                        :ARG0 (x18 / phosphorylate-01
                              :ARG1 (x19 / and
                                    :op1 (x20 / amino-acid
                                          :mod "220"
                                          :name (x21 / name :op1 "threonine")
                                          :xref (x27 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                    :op2 (x22 / amino-acid
                                          :mod "179"
                                          :name (x23 / name :op1 "threonine")
                                          :xref (x28 / xref :value "PUBCHEM:205" :prob "11.848252"))))
                        :ARG1 (x25 / residue)))))


# ::id PMC4455068.60
# ::snt Our results also demonstrate that PI3K-mediated phosphorylation of this residue can occur in the absence of Smad2/3 activation ( Fig. 5a,d ), which raised the question as to whether Nedd4L binds to both active and inactive Smad2/3 or solely to the active form.
# ::tok Our results also demonstrate that PI3K @-@ mediated phosphorylation of this residue can occur in the absence of Smad2 @/@ 3 activation ( Fig . 5a , d ) , which raised the question as to whether Nedd4L binds to both active and inactive Smad2 @/@ 3 or solely to the active form .
(x1 / multi-sentence
      :snt1 (x6 / demonstrate-01
            :ARG0 (x3 / thing
                  :poss (x2 / we)
                  :ARG2-of (x4 / result-01))
            :mod (x5 / also)
            :ARG1 (x10 / phosphorylate-01
                  :ARG1-of (x9 / mediate-01
                        :ARG0 (x7 / enzyme
                              :name (x8 / name :op1 "PI3K")
                              :xref (x37 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                  :ARG1 (x12 / residue
                        :mod (x11 / this))))
      :snt2 (x13 / possible-01
            :ARG1 (x14 / occur-01)
            :condition (x15 / absent-01
                  :ARG1 (x18 / activate-01
                        :ARG0 (x16 / protein
                              :name (x17 / name :op1 "Smad2/3"))
                        :ARG1-of (x19 / describe-01
                              :ARG0 (x20 / and
                                    :op1 (x21 / figure :mod "5a")
                                    :op2 (x22 / figure :mod "5d")))
                        :ARG0-of (x23 / raise-01
                              :ARG1 (x24 / question-01
                                    :ARG1 (x33 / or
                                          :mode "interrogative"
                                          :op1 (x27 / bind-01
                                                :ARG0 (x25 / enzyme
                                                      :name (x26 / name :op1 "Nedd4L")
                                                      :xref (x / xref :value "UNIPROT:NED4L_HUMAN" :prob "0.622"))
                                                :ARG2 (x28 / and
                                                      :op1 (x29 / activity-06)
                                                      :op2 (x30 / activate-01 :polarity "-"))
                                                :ARG1 (x31 / protein
                                                      :name (x32 / name :op1 "Smad2/3")))
                                          :op2 (x34 / sole))
                                    :ARG2 (x36 / form
                                          :ARG0-of (x35 / activity-06))))))))


# ::id PMC4455068.61
# ::snt To address this, PC3 cells, which retain high levels of PI3K signalling even after overnight starvation due to the presence of a PTEN mutation, were used for Nedd4L co-immunoprecipitation experiments upon treatment with AA±LY post starvation.
# ::tok To address this , PC3 cells , which retain high levels of PI3K signalling even after overnight starvation due to the presence of a PTEN mutation , were used for Nedd4L co @-@ immunoprecipitation experiments upon treatment with AA±LY post starvation .
(x22 / immunoprecipitate-01
      :purpose (x1 / address-02
            :ARG1 (x2 / this))
      :ARG0 (x4 / cell-line
            :name (x3 / name :op1 "PC3")
            :ARG0-of (x5 / retain-01
                  :ARG1 (x7 / level
                        :ARG1-of (x6 / high-02)
                        :quant-of (x10 / signal-07
                              :ARG0 (x8 / enzyme
                                    :name (x9 / name :op1 "PI3K")
                                    :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                              :ARG1 (x12 / after
                                    :mod (x11 / even)
                                    :op1 (x14 / starve-01
                                          :time (x13 / overnight)
                                          :ARG1-of (x15 / cause-01
                                                :ARG0 (x16 / present-02
                                                      :ARG1 (x19 / mutate-01
                                                            :ARG1 (x17 / gene
                                                                  :name (x18 / name :op1 "PTEN")
                                                                  :xref (x29 / xref :value "UNIPROT:PTEN_HUMAN" :prob "1.004"))))))))))
            :ARG1-of (x20 / use-01
                  :ARG2 (x21 / nedd4l)))
      :ARG1 (x23 / experiment-01
            :ARG1 (x27 / after
                  :op1 (x24 / treat-04
                        :ARG2 (x25 / small-molecule
                              :name (x26 / name :op1 "AA±LY")))
                  :op2 (x28 / starve-01))))


# ::id PMC4455068.62
# ::snt This showed that Nedd4L recruitment and ubiquitination of Smad2/3 occurred most effectively only when both T220/T179 and SxS residues were phosphorylated ( Fig. 4e ), offering an explanatory mechanism by which Nedd4L selectively targets active Smad2/3 for ubiquitination and turnover.
# ::tok This showed that Nedd4L recruitment and ubiquitination of Smad2 @/@ 3 occurred most effectively only when both T220 @/@ T179 and SxS residues were phosphorylated ( Fig . 4e ) , offering an explanatory mechanism by which Nedd4L selectively targets active Smad2 @/@ 3 for ubiquitination and turnover .
(x2 / show-01
      :ARG0 (x1 / this)
      :ARG1 (x6 / and
            :op1 (x5 / recruit-01
                  :ARG1 (x3 / protein
                        :name (x4 / name :op1 "Nedd4L")
                        :xref (x / xref :value "UNIPROT:NED4L_HUMAN" :prob "0.622")))
            :op2 (x7 / ubiquitinate-01
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "Smad2/3"))))
      :time (x22 / phosphorylate-01
            :ARG1 (x18 / and
                  :op1 (x11 / effective-04
                        :degree (x10 / most)
                        :mod (x12 / only)
                        :time (x13 / and
                              :op1 (x14 / amino-acid
                                    :mod "220"
                                    :name (x15 / name :op1 "threonine")
                                    :xref (x39 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x16 / amino-acid
                                    :mod "179"
                                    :name (x17 / name :op1 "threonine")
                                    :xref (x40 / xref :value "PUBCHEM:205" :prob "11.848252"))))
                  :op2 (x21 / residue
                        :mod (x19 / amino-acid
                              :name (x20 / name :op1 "SxS")
                              :xref (x38 / xref :value "PUBCHEM:64789" :prob "18.013371")))))
      :ARG1-of (x23 / describe-01
            :ARG0 (x24 / figure :mod "4e"))
      :ARG0-of (x25 / offer-01
            :ARG1 (x27 / mechanism
                  :mod (x26 / explanatory)
                  :instrument-of (x30 / target-01
                        :ARG0 (x29 / selective
                              :name (x28 / name :op1 "Nedd4L"))
                        :ARG1 (x31 / enzyme
                              :ARG0-of (x32 / activity-06)
                              :name (x33 / name :op1 "Smad2/3"))))
            :ARG3 (x35 / and
                  :op1 (x34 / ubiquitinate-01)
                  :op2 (x36 / enzyme
                        :name (x37 / name :op1 "turnover")))))


# ::id PMC4455068.63
# ::snt We hence postulated that PI3K promotes phosphorylation of Smad2/3-T220/T179 and primes Smad2/3 for the binding of Nedd4L upon activation, resulting in increased ubiquitin-mediated Smad2/3 degradation, which acts to reduce the transcriptional activation of endoderm genes.
# ::tok We hence postulated that PI3K promotes phosphorylation of Smad2 @/@ 3 @-@ T220 @/@ T179 and primes Smad2 @/@ 3 for the binding of Nedd4L upon activation , resulting in increased ubiquitin @-@ mediated Smad2 @/@ 3 degradation , which acts to reduce the transcriptional activation of endoderm genes .
(x2 / cause-01
      :ARG0 (x1 / we)
      :ARG1 (x3 / postulate-01)
      :ARG1 (x6 / promote-02
            :ARG1 (x4 / enzyme
                  :name (x5 / name :op1 "PI3K")
                  :xref (x37 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
            :ARG1 (x15 / and
                  :op1 (x7 / phosphorylate-01
                        :ARG1 (x8 / protein
                              :name (x9 / name :op1 "Smad2/3"))
                        :ARG2 (x10 / and
                              :op1 (x11 / amino-acid
                                    :mod "220"
                                    :name (x12 / name :op1 "threonine")
                                    :xref (x39 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x13 / amino-acid
                                    :mod "179"
                                    :name (x14 / name :op1 "threonine")
                                    :xref (x40 / xref :value "PUBCHEM:205" :prob "11.848252"))))
                  :op2 (x16 / protein
                        :name (x17 / name :op1 "Smad2/3")))
            :ARG0 (x18 / bind-01
                  :ARG1 (x19 / protein
                        :name (x20 / name :op1 "Nedd4L")
                        :xref (x38 / xref :value "UNIPROT:NED4L_HUMAN" :prob "0.622")))
            :time (x21 / activate-01)
            :ARG1-of (x22 / result-01
                  :ARG2 (x23 / increase-01
                        :ARG1 (x29 / degrade-01
                              :ARG1-of (x26 / mediate-01
                                    :ARG0 (x24 / protein
                                          :name (x25 / name :op1 "ubiquitin")
                                          :xref (x / xref :value "UNIPROT:RL40_HUMAN" :prob "0.702")))
                              :ARG1 (x27 / protein
                                    :name (x28 / name :op1 "Smad2")
                                    :xref (x36 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003")))
                        :ARG0-of (x30 / act-01)))
            :ARG2 (x35 / gene
                  :ARG1-of (x31 / reduce-01
                        :ARG1 (x33 / activate-01
                              :mod (x32 / transcribe-01)
                              :ARG0 (x34 / endoderm))))))


# ::id PMC4455068.64
# ::snt If this is correct, mutagenesis of T220/T179 to a non-phosphorylatable residue should enhance the resistance of Smad2/3 to degradation independent of LY.
# ::tok If this is correct , mutagenesis of T220 @/@ T179 to a non @-@ phosphorylatable residue should enhance the resistance of Smad2 @/@ 3 to degradation independent of LY .
(x1 / have-condition-91
      :ARG2 (x3 / correct-02
            :ARG1 (x2 / this))
      :ARG1 (x4 / recommend-01
            :ARG1 (x16 / enhance-01
                  :ARG0 (x5 / enzyme
                        :name (x6 / name :op1 "mutagenesis")
                        :ARG2-of (x7 / include-91
                              :ARG1 (x8 / and
                                    :op1 (x9 / amino-acid
                                          :mod "220"
                                          :name (x10 / name :op1 "threonine")
                                          :xref (x25 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                    :op2 (x11 / amino-acid
                                          :mod "179"
                                          :name (x12 / name :op1 "threonine")
                                          :xref (x26 / xref :value "PUBCHEM:205" :prob "11.848252")))
                              :ARG2 (x15 / residue
                                    :polarity "-"
                                    :mod (x13 / enzyme
                                          :name (x14 / name :op1 "phosphorylatable")
                                          :xref (x / xref :value "UNIPROT:Q59GM9_HUMAN" :prob "0.331")))))
                  :ARG1 (x17 / resist-01
                        :ARG0 (x20 / degrade-01
                              :ARG1 (x18 / protein
                                    :name (x19 / name :op1 "Smad2/3"))
                              :ARG0-of (x21 / depend-01 :polarity "-"))
                        :ARG1 (x22 / small-molecule
                              :name (x23 / name :op1 "LY")
                              :xref (x24 / xref :value "PUBCHEM:16196600" :prob "11.455812"))))))


# ::id PMC4455068.65
# ::snt To test this, we ectopically expressed wild-type (WT) or T220V mutant Smad2 in hESCs and PC3 cells.
# ::tok To test this , we ectopically expressed wild @-@ type ( WT ) or T220V mutant Smad2 in hESCs and PC3 cells .
(x5 / express-03
      :purpose (x1 / test-01
            :ARG1 (x2 / this))
      :ARG0 (x3 / we)
      :mod (x4 / ectopic)
      :ARG2 (x7 / or
            :op1 (x6 / wild-type)
            :op2 (x8 / enzyme
                  :name (x9 / name :op1 "T220V")
                  :ARG2-of (x10 / mutate-01
                        :ARG2 (x11 / protein
                              :name (x12 / name :op1 "Smad2")
                              :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003")))))
      :location (x13 / and
            :op1 (x15 / cell-line
                  :name (x14 / name :op1 "PC3"))))


# ::id PMC4455068.66
# ::snt PC3 cells expressing Smad2-T220V showed higher Smad2/3 activation upon AA stimulation irrespective of whether LY was present ( Fig. 4f ) and correspondingly, hESCs expressing Smad2-T220V exhibited improved mesendoderm differentiation in response to AA alone ( Fig. 4g ).
# ::tok PC3 cells expressing Smad2 @-@ T220V showed higher Smad2 @/@ 3 activation upon AA stimulation irrespective of whether LY was present ( Fig . 4f ) and correspondingly , hESCs expressing Smad2 @-@ T220V exhibited improved mesendoderm differentiation in response to AA alone ( Fig . 4g ) .
(x8 / show-01
      :ARG0 (x1 / cell-line
            :name (x2 / name :op1 "PC3")
            :mod (x3 / cell
                  :ARG3-of (x4 / express-03
                        :ARG2 (x5 / protein
                              :name (x6 / name :op1 "Smad2")
                              :xref (x39 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003")))
                  :name (x7 / name :op1 "T220V")))
      :ARG1 (x13 / activate-01
            :ARG1-of (x9 / high-02
                  :degree (x10 / more))
            :ARG1 (x11 / protein
                  :name (x12 / name :op1 "Smad2/3")))
      :time (x16 / stimulate-01
            :ARG0 (x14 / protein
                  :name (x15 / name :op1 "6-aa")))
      :ARG1-of (x17 / regardless-91
            :ARG2 (x20 / present-02
                  :ARG1 (x18 / small-molecule
                        :name (x19 / name :op1 "LY")
                        :xref (x41 / xref :value "PUBCHEM:16196600" :prob "11.455812"))))
      :ARG1-of (x21 / describe-01
            :ARG0 (x22 / figure :mod "4f"))
      :ARG1-of (x23 / correspond-02
            :ARG2 (x28 / exhibit-01
                  :ARG0 (x24 / express-03
                        :ARG2 (x25 / protein
                              :name (x26 / name :op1 "Smad2")
                              :ARG2-of (x27 / mutate-01 :value "T220V")
                              :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003")))
                  :ARG1 (x32 / differentiate-01
                        :ARG1-of (x29 / improve-01)
                        :ARG1 (x30 / protein
                              :name (x31 / name :op1 "mesendoderm"))))
            :ARG2-of (x33 / respond-01
                  :ARG1 (x34 / small-molecule
                        :name (x35 / name :op1 "AA")
                        :mod (x36 / alone)
                        :xref (x40 / xref :value "PUBCHEM:764" :prob "7.981792"))))
      :ARG1-of (x37 / describe-01
            :ARG0 (x38 / figure :mod "4g")))


# ::id PMC4455068.67
# ::snt In further support of the view that Nedd4L-mediated degradation of active Smad2/3 accounts for the inhibitory effect of PI3K during Activin-induced DE differentiation, Nedd4L knockdown in PC3 cells resulted in increased Smad2/3 activation in the absence of LY ( Fig. 4h ; Supplementary Fig. 4f ), while Nedd4L-deficient hESCs expressed endoderm genes at much higher levels upon AA stimulation ( Fig. 4i ).
# ::tok In further support of the view that Nedd4L @-@ mediated degradation of active Smad2 @/@ 3 accounts for the inhibitory effect of PI3K during Activin @-@ induced DE differentiation , Nedd4L knockdown in PC3 cells resulted in increased Smad2 @/@ 3 activation in the absence of LY ( Fig . 4h ; Supplementary Fig . 4f ) , while Nedd4L @-@ deficient hESCs expressed endoderm genes at much higher levels upon AA stimulation ( Fig . 4i ) .
(x1 / multi-sentence
      :snt1 (x12 / account-01
            :ARG0 (x3 / support-01
                  :degree (x2 / further)
                  :ARG1 (x4 / view-02
                        :ARG1 (x8 / degrade-01
                              :ARG1-of (x7 / mediate-01
                                    :ARG0 (x5 / enzyme
                                          :name (x6 / name :op1 "Nedd4L")
                                          :xref (x59 / xref :value "UNIPROT:NED4L_HUMAN" :prob "0.622")))
                              :ARG1 (x9 / enzyme
                                    :ARG0-of (x10 / activity-06)
                                    :name (x11 / name :op1 "Smad2/3")))))
            :ARG1 (x14 / affect-01
                  :ARG2 (x13 / inhibit-01)
                  :ARG0 (x15 / enzyme
                        :name (x16 / name :op1 "PI3K")
                        :xref (x60 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
            :time (x20 / and
                  :op1 (x19 / induce-01
                        :ARG0 (x17 / protein
                              :name (x18 / name :op1 "Activin")
                              :xref (x61 / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283")))
                  :op2 (x21 / differentiate-01)))
      :snt2 (x27 / result-01
            :ARG1 (x24 / knock-down-02
                  :ARG1 (x22 / enzyme
                        :name (x23 / name :op1 "Nedd4L")
                        :xref (x58 / xref :value "UNIPROT:NED4L_HUMAN" :prob "0.622"))
                  :location (x26 / cell-line
                        :name (x25 / name :op1 "PC3")))
            :ARG2 (x28 / increase-01
                  :ARG1 (x31 / activate-01
                        :ARG1 (x29 / protein
                              :name (x30 / name :op1 "Smad2/3")))
                  :condition (x32 / absent-01
                        :ARG1 (x33 / small-molecule
                              :name (x34 / name :op1 "LY")
                              :xref (x62 / xref :value "PUBCHEM:16196600" :prob "11.455812")))
                  :ARG1-of (x35 / describe-01
                        :ARG0 (x36 / and
                              :op1 (x37 / figure :mod "4h")
                              :op2 (x39 / figure
                                    :ARG2-of (x38 / supplement-01)
                                    :mod "4f")))
                  :ARG1-of (x40 / contrast-01
                        :ARG2 (x43 / lack-01
                              :ARG1 (x41 / enzyme
                                    :name (x42 / name :op1 "Nedd4L")
                                    :xref (x / xref :value "UNIPROT:NED4L_HUMAN" :prob "0.622")))
                        :ARG1 (x46 / express-03
                              :ARG1 (x44 / enzyme
                                    :name (x45 / name :op1 "hESCs"))
                              :ARG1 (x48 / gene
                                    :name (x47 / name :op1 "endoderm"))
                              :location (x52 / level
                                    :ARG1-of (x51 / high-02
                                          :degree (x50 / more
                                                :degree (x49 / much)))))
                        :time (x55 / stimulate-01
                              :ARG0 (x53 / protein
                                    :name (x54 / name :op1 "6-aa")))
                        :ARG1-of (x56 / describe-01
                              :ARG0 (x57 / figure :mod "4i"))))))


# ::id PMC4455068.68
# ::snt Taken together, PI3K signalling therefore inhibits Activin-induced DE differentiation by phosphorylating the T220/T179 of Smad2/3, enabling the recruitment of Nedd4L upon their activation, which leads to the degradation and termination of active Smad2/3.
# ::tok Taken together , PI3K signalling therefore inhibits Activin @-@ induced DE differentiation by phosphorylating the T220 @/@ T179 of Smad2 @/@ 3 , enabling the recruitment of Nedd4L upon their activation , which leads to the degradation and termination of active Smad2 @/@ 3 .
(x22 / enable-01
      :ARG0 (x5 / signal-07
            :ARG1-of (x1 / take-01
                  :mod (x2 / together))
            :ARG0 (x3 / enzyme
                  :name (x4 / name :op1 "PI3K")
                  :xref (x35 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
      :ARG0-of (x6 / cause-01
            :ARG1 (x7 / inhibit-01
                  :ARG1 (x13 / differentiate-01
                        :ARG2-of (x10 / induce-01
                              :ARG0 (x8 / protein
                                    :name (x9 / name :op1 "Activin")
                                    :xref (x34 / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283")))
                        :ARG1 (x11 / protein
                              :name (x12 / name :op1 "DE")))
                  :ARG0 (x14 / phosphorylate-01
                        :ARG1 (x15 / and
                              :op1 (x16 / amino-acid
                                    :mod "220"
                                    :name (x17 / name :op1 "threonine")
                                    :xref (x37 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x18 / amino-acid
                                    :mod "179"
                                    :name (x19 / name :op1 "threonine")
                                    :xref (x36 / xref :value "PUBCHEM:205" :prob "11.848252"))))
                  :ARG1 (x20 / protein
                        :name (x21 / name :op1 "Smad2/3"))))
      :ARG1 (x23 / recruit-01
            :ARG1 (x24 / protein
                  :name (x25 / name :op1 "Nedd4L")
                  :xref (x / xref :value "UNIPROT:NED4L_HUMAN" :prob "0.622"))
            :condition (x26 / activate-01))
      :ARG0-of (x27 / lead-03
            :ARG2 (x28 / and
                  :op1 (x29 / degrade-01
                        :ARG1 (x30 / protein
                              :name (x31 / name :op1 "Smad2/3")))
                  :op2 (x32 / terminate-01
                        :ARG1 (x33 / activity-06)))))


# ::id PMC4455068.69
# ::snt Smad2/3-pT220/pT179 is a direct effect of PI3K activity
# ::tok Smad2 @/@ 3 @-@ pT220 @/@ pT179 is a direct effect of PI3K activity
(x9 / affect-01
      :domain (x5 / slash
            :op2 (x1 / protein
                  :name (x2 / name :op1 "Smad2/3"))
            :op1 (x3 / enzyme
                  :name (x4 / name :op1 "pT220"))
            :op2 (x6 / enzyme
                  :name (x7 / name :op1 "pT179")
                  :xref (x13 / xref :value "UNIPROT:PT117_HUMAN" :prob "0.212")))
      :ARG1-of (x8 / direct-02)
      :ARG1 (x12 / activity-06
            :ARG0 (x10 / enzyme
                  :name (x11 / name :op1 "PI3K")
                  :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))


# ::id PMC4455068.70
# ::snt Although many kinases including Erk (extracellular-signal-regulated kinases), p38 and CDK (cyclin-dependent kinase) have been shown to phosphorylate Smad2/3 linker residues 24 26 27 30 , inhibitors that specifically target these kinases were less effective in suppressing T220/T179 phosphorylation when compared with LY ( Fig. 5a,b ; Supplementary Fig. 5a ).
# ::tok Although many kinases including Erk ( extracellular @-@ signal @-@ regulated kinases ) , p38 and CDK ( cyclin @-@ dependent kinase ) have been shown to phosphorylate Smad2 @/@ 3 linker residues 24 26 27 30 , inhibitors that specifically target these kinases were less effective in suppressing T220 @/@ T179 phosphorylation when compared with LY ( Fig . 5a , b ; Supplementary Fig . 5a ) .
(x1 / multi-sentence
      :snt1 (x2 / have-concession-91
            :ARG2 (x4 / kinase
                  :mod (x3 / many)
                  :ARG2-of (x5 / include-91
                        :ARG1 (x6 / and
                              :op1 (x7 / enzyme
                                    :name (x8 / name :op1 "Erk")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                              :op2 (x10 / kinase
                                    :name (x9 / name :op1 "extracellular" :op2 "signal-regulated")))))
            :ARG1 (x13 / and
                  :op1 (x11 / enzyme
                        :name (x12 / name :op1 "p38")
                        :xref (x50 / xref :value "UNIPROT:CRK_HUMAN" :prob "1.003"))
                  :op2 (x14 / enzyme
                        :name (x15 / name :op1 "CDK")
                        :xref (x51 / xref :value "UNIPROT:CDK1_HUMAN" :prob "0.262"))
                  :ARG1-of (x21 / phosphorylate-01
                        :ARG1 (x19 / kinase
                              :ARG0-of (x18 / depend-01
                                    :ARG1 (x16 / protein
                                          :name (x17 / name :op1 "cyclin")
                                          :xref (x52 / xref :value "UNIPROT:PCNA_HUMAN" :prob "0.702"))))
                        :ARG1-of (x20 / show-01)
                        :ARG1 (x22 / protein
                              :name (x23 / name :op1 "Smad2/3")))))
      :snt2 (x24 / link-01
            :ARG1 (x25 / residue
                  :mod "24"
                  :mod "26"
                  :mod "27"
                  :mod "30"
                  :ARG0-of (x26 / inhibit-01
                        :ARG1 (x39 / phosphorylate-01
                              :ARG1 (x28 / target-01
                                    :ARG1-of (x27 / specific-02)
                                    :ARG1 (x30 / kinase
                                          :mod (x29 / this)))
                              :ARG1-of (x32 / effective-04
                                    :degree (x31 / less)
                                    :ARG1 (x33 / suppress-01))
                              :ARG1 (x34 / and
                                    :op1 (x35 / amino-acid
                                          :mod "220"
                                          :name (x36 / name :op1 "threonine")
                                          :xref (x55 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                    :op2 (x37 / amino-acid
                                          :mod "179"
                                          :name (x38 / name :op1 "threonine")
                                          :xref (x54 / xref :value "PUBCHEM:205" :prob "11.848252")))
                              :time (x40 / compare-01
                                    :ARG2 (x41 / small-molecule
                                          :name (x42 / name :op1 "LY")
                                          :xref (x53 / xref :value "PUBCHEM:16196600" :prob "11.455812")))
                              :ARG1-of (x43 / describe-01
                                    :ARG0 (x44 / and
                                          :op1 (x45 / figure :mod "5a")
                                          :op2 (x46 / figure :mod "1b")))))
                  :ARG1-of (x47 / describe-01
                        :ARG0 (x49 / figure
                              :ARG2-of (x48 / supplement-01)
                              :mod "5a")))))


# ::id PMC4455068.71
# ::snt Notably, flavopiridol-mediated inhibition of CDKs only diminished the phosphorylation of the linker serine residues, whereas the T220/T179 residue was unaffected.
# ::tok Notably , flavopiridol @-@ mediated inhibition of CDKs only diminished the phosphorylation of the linker serine residues , whereas the T220 @/@ T179 residue was unaffected .
(x19 / affect-01
      :ARG1-of (x1 / notable-04)
      :ARG1 (x5 / inhibit-01
            :ARG1-of (x4 / mediate-01
                  :ARG0 (x2 / enzyme
                        :name (x3 / name :op1 "flavopiridol")))
            :ARG1 (x6 / and
                  :mod (x7 / only)
                  :op1 (x8 / diminish-01
                        :ARG1 (x9 / phosphorylate-01
                              :ARG1 (x10 / link-01
                                    :ARG1 (x11 / residue
                                          :mod (x12 / amino-acid
                                                :name (x13 / name :op1 "serine")
                                                :xref (x21 / xref :value "PUBCHEM:5951" :prob "11.218784")))))
                        :ARG2 (x14 / amino-acid
                              :mod "220"
                              :name (x15 / name :op1 "threonine")
                              :xref (x / xref :value "PUBCHEM:205" :prob "11.848252")))
                  :op2 (x18 / residue
                        :mod (x16 / amino-acid
                              :mod "179"
                              :name (x17 / name :op1 "threonine")
                              :xref (x20 / xref :value "PUBCHEM:205" :prob "11.848252")))))
      :polarity "-")


# ::id PMC4455068.72
# ::snt Furthermore, PI3K-mediated phosphorylation of T220/T179 requires neither Smad2/3 activation nor nuclear localization, which thereby eliminates the direct involvement of CDK in causing this effect.
# ::tok Furthermore , PI3K @-@ mediated phosphorylation of T220 @/@ T179 requires neither Smad2 @/@ 3 activation nor nuclear localization , which thereby eliminates the direct involvement of CDK in causing this effect .
(x1 / and
      :op2 (x11 / require-01
            :ARG0 (x5 / phosphorylate-01
                  :ARG1-of (x4 / mediate-01
                        :ARG0 (x2 / enzyme
                              :name (x3 / name :op1 "PI3K")
                              :xref (x26 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                  :ARG1 (x6 / and
                        :op1 (x7 / amino-acid
                              :mod "220"
                              :name (x8 / name :op1 "threonine")
                              :xref (x29 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :op2 (x9 / amino-acid
                              :mod "179"
                              :name (x10 / name :op1 "threonine")
                              :xref (x28 / xref :value "PUBCHEM:205" :prob "11.848252"))))
            :ARG1 (x14 / activate-01
                  :polarity "-"
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "Smad2/3"))
                  :ARG1 (x16 / be-located-at-91
                        :polarity "-"
                        :ARG2 (x15 / nucleus
                              :xref (x27 / xref :value "GO:0005634" :prob "0.8")))
                  :ARG0-of (x17 / cause-01
                        :ARG1 (x18 / eliminate-01
                              :ARG1 (x20 / involve-01
                                    :ARG1-of (x19 / direct-02)
                                    :ARG1 (x21 / enzyme
                                          :name (x22 / name :op1 "CDK")
                                          :xref (x / xref :value "UNIPROT:CDK1_HUMAN" :prob "0.262")))))
                  :location (x23 / cause-01
                        :ARG1 (x25 / affect-01
                              :mod (x24 / this))))))


# ::id PMC4455068.73
# ::snt Although active Erk can phosphorylate the T220/T179 residue, inhibition of PI3K elicited a greater reduction in T220/T179 phosphorylation than that of MAPK/Erk inhibition.
# ::tok Although active Erk can phosphorylate the T220 @/@ T179 residue , inhibition of PI3K elicited a greater reduction in T220 @/@ T179 phosphorylation than that of MAPK @/@ Erk inhibition .
(x1 / have-concession-91
      :ARG2 (x2 / possible-01
            :ARG1 (x6 / phosphorylate-01
                  :ARG0 (x3 / activate-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "Erk")
                              :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))
                  :ARG1 (x11 / residue
                        :mod (x7 / amino-acid
                              :mod "220"
                              :name (x8 / name :op1 "threonine")
                              :xref (x33 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :mod (x9 / amino-acid
                              :mod "179"
                              :name (x10 / name :op1 "threonine")
                              :xref (x32 / xref :value "PUBCHEM:205" :prob "11.848252")))))
      :ARG1 (x15 / elicit-01
            :ARG0 (x12 / inhibit-01
                  :ARG1 (x13 / enzyme
                        :name (x14 / name :op1 "PI3K")
                        :xref (x29 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
            :ARG1 (x18 / reduce-01
                  :degree (x16 / great
                        :degree (x17 / more))
                  :ARG1 (x24 / phosphorylate-01
                        :ARG1 (x19 / and
                              :op1 (x20 / amino-acid
                                    :mod "220"
                                    :name (x21 / name :op1 "threonine")
                                    :xref (x30 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x22 / amino-acid
                                    :mod "179"
                                    :name (x23 / name :op1 "threonine")
                                    :xref (x31 / xref :value "PUBCHEM:205" :prob "11.848252"))))
                  :compared-to (x25 / person
                        :ARG0-of (x28 / inhibit-01
                              :ARG1 (x26 / enzyme
                                    :name (x27 / name :op1 "MAPK/Erk")))))))


# ::id PMC4455068.74
# ::snt In addition, LY treatment did not inhibit, but rather increased Erk activation under certain conditions ( Fig. 5c ; Supplementary Fig. 5a–c ) 14 , which therefore excludes the possibility of LY-induced downregulation of T220/T179 phosphorylation being an Erk-related event.
# ::tok In addition , LY treatment did not inhibit , but rather increased Erk activation under certain conditions ( Fig . 5c ; Supplementary Fig . 5a–c ) 14 , which therefore excludes the possibility of LY @-@ induced downregulation of T220 @/@ T179 phosphorylation being an Erk @-@ related event .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op2 (x6 / inhibit-01
                  :ARG0 (x5 / treat-04
                        :ARG2 (x3 / small-molecule
                              :name (x4 / name :op1 "LY")
                              :xref (x43 / xref :value "PUBCHEM:16196600" :prob "11.455812")))
                  :polarity "-"
                  :ARG1-of (x7 / contrast-01
                        :ARG2 (x8 / increase-01
                              :ARG1 (x11 / activate-01
                                    :ARG1 (x9 / enzyme
                                          :name (x10 / name :op1 "Erk")
                                          :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))
                  :condition (x13 / condition
                        :mod (x12 / certain))
                  :ARG1-of (x14 / describe-01
                        :ARG0 (x15 / and
                              :op1 (x16 / figure :mod "5c")
                              :op2 (x18 / figure
                                    :ARG2-of (x17 / supplement-01)
                                    :mod "5")))
                  :ARG1 (x19 / protein
                        :name (x20 / name :op1 "47" :op2 "c"))
                  :ARG1-of (x21 / describe-01
                        :ARG0 (x22 / publication
                              :ARG1-of (x23 / cite-01 :ARG2 "14")))
                  :ARG0-of (x24 / cause-01)))
      :snt2 (x25 / exclude-01
            :ARG1 (x26 / possible-01
                  :ARG1 (x40 / event
                        :domain (x36 / phosphorylate-01
                              :ARG2-of (x29 / induce-01
                                    :ARG0 (x27 / small-molecule
                                          :name (x28 / name :op1 "LY")
                                          :xref (x42 / xref :value "PUBCHEM:16196600" :prob "11.455812")))
                              :ARG1 (x30 / downregulate-01
                                    :ARG1 (x31 / and
                                          :op1 (x32 / amino-acid
                                                :mod "220"
                                                :name (x33 / name :op1 "threonine")
                                                :xref (x44 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                          :op2 (x34 / amino-acid
                                                :mod "179"
                                                :name (x35 / name :op1 "threonine")
                                                :xref (x45 / xref :value "PUBCHEM:205" :prob "11.848252")))))
                        :ARG1-of (x39 / relate-01
                              :ARG2 (x37 / enzyme
                                    :name (x38 / name :op1 "Erk")
                                    :xref (x41 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603")))))))


# ::id PMC4455068.75
# ::snt Furthermore, treatment of hESCs in RPMI base media along with heregulin and IGF-1 (HI), two potent stimulators of the PI3K pathway, increased T220/T179 phosphorylation ( Fig. 5d ), suggesting that this phosphorylation is regulated by the PI3K pathway itself independent of Erk and CDK activity.
# ::tok Furthermore , treatment of hESCs in RPMI base media along with heregulin and IGF @-@ 1 ( HI ) , two potent stimulators of the PI3K pathway , increased T220 @/@ T179 phosphorylation ( Fig . 5d ) , suggesting that this phosphorylation is regulated by the PI3K pathway itself independent of Erk and CDK activity .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op1 (x9 / medium
                  :ARG1-of (x3 / treat-04
                        :ARG2 (x4 / small-molecule
                              :name (x5 / name :op1 "hESCs"))
                        :location (x8 / base
                              :mod (x6 / protein
                                    :name (x7 / name :op1 "RPMI")))))
            :op2 (x21 / increase-01
                  :ARG0 (x12 / and
                        :op1 (x10 / protein
                              :name (x11 / name :op1 "heregulin")
                              :xref (x45 / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.703"))
                        :op2 (x13 / protein
                              :name (x14 / name :op1 "IGF-1")
                              :xref (x46 / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))
                        :ARG1-of (x15 / hi)
                        :op2 (x16 / person
                              :quant "2"
                              :mod (x17 / potent)
                              :name (x18 / name :op1 "stimulators"))
                        :part-of (x19 / pathway
                              :name (x20 / name :op1 "PI3K")))
                  :ARG1 (x27 / phosphorylate-01
                        :ARG1 (x22 / and
                              :op1 (x23 / amino-acid
                                    :mod "220"
                                    :name (x24 / name :op1 "threonine")
                                    :xref (x48 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x25 / amino-acid
                                    :mod "179"
                                    :name (x26 / name :op1 "threonine")
                                    :xref (x47 / xref :value "PUBCHEM:205" :prob "11.848252"))))
                  :ARG1-of (x28 / describe-01
                        :ARG0 (x29 / figure :mod "5d"))
                  :ARG0-of (x30 / suggest-01
                        :ARG1 (x33 / regulate-01
                              :ARG1 (x32 / phosphorylate-01
                                    :mod (x31 / this))
                              :ARG0 (x35 / pathway
                                    :name (x34 / name :op1 "PI3K"))))))
      :snt2 (x37 / depend-01
            :ARG0 (x36 / it)
            :polarity "-"
            :ARG1 (x43 / activity-06
                  :ARG0 (x40 / and
                        :op1 (x38 / enzyme
                              :name (x39 / name :op1 "Erk")
                              :xref (x44 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
                        :op2 (x41 / enzyme
                              :name (x42 / name :op1 "CDK")
                              :xref (x / xref :value "UNIPROT:CDK1_HUMAN" :prob "0.262"))))))


# ::id PMC4455068.76
# ::snt Since Akt is one of the principal kinases acting downstream of PI3K, we next investigated whether Akt was responsible for T220/T179 phosphorylation by ectopically expressing constitutively active (Myr-Akt-WT), partially active (S473A) and inactive (K179M/T308A/S473A) Akt in Hep3B cells, using green fluorescent protein (GFP)-expressing Hep3B as controls.
# ::tok Since Akt is one of the principal kinases acting downstream of PI3K , we next investigated whether Akt was responsible for T220 @/@ T179 phosphorylation by ectopically expressing constitutively active ( Myr @-@ Akt @-@ WT ) , partially active ( S473A ) and inactive ( K179M/T308A/S473A ) Akt in Hep3B cells , using green fluorescent protein ( GFP ) -expressing Hep3B as controls .
(x1 / multi-sentence
      :snt1 (x15 / investigate-01
            :ARG1-of (x2 / cause-01
                  :ARG0 (x8 / act-01
                        :ARG1 (x3 / enzyme
                              :name (x4 / name :op1 "Akt")
                              :xref (x50 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                        :ARG1-of (x5 / include-91
                              :ARG2 (x7 / kinase
                                    :name (x6 / name :op1 "principal"))))
                  :ARG1 (x9 / relative-position
                        :direction (x10 / downstream)
                        :op1 (x11 / enzyme
                              :name (x12 / name :op1 "PI3K")
                              :xref (x53 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))
            :ARG0 (x13 / we)
            :time (x14 / next)
            :ARG1 (x18 / responsible-01
                  :mode "interrogative"
                  :ARG0 (x16 / enzyme
                        :name (x17 / name :op1 "Akt")
                        :xref (x54 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                  :ARG1 (x24 / phosphorylate-01
                        :ARG1 (x19 / and
                              :op1 (x20 / amino-acid
                                    :mod "220"
                                    :name (x21 / name :op1 "threonine")
                                    :xref (x55 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x22 / amino-acid
                                    :mod "179"
                                    :name (x23 / name :op1 "threonine")
                                    :xref (x56 / xref :value "PUBCHEM:205" :prob "11.848252"))))
                  :ARG2 (x26 / express-03
                        :mod (x25 / ectopic)))
            :ARG1 (x28 / activity-06
                  :mod (x27 / constitutive)))
      :snt2 (x49 / control
            :ARG1-of (x29 / before
                  :op1 (x34 / activity-06
                        :ARG0 (x30 / enzyme
                              :name (x31 / name :op1 "Akt")
                              :mod (x32 / wild-type)
                              :xref (x51 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                        :degree (x33 / part)
                        :ARG1-of (x35 / mutate-01 :value "S473A"))
                  :op2 (x46 / protein
                        :ARG0-of (x36 / activity-06
                              :ARG1-of (x37 / describe-01
                                    :ARG2 (x38 / name :op1 "K179M/T308A/S473A"))
                              :ARG1 (x39 / enzyme
                                    :name (x40 / name :op1 "Akt")
                                    :xref (x52 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                              :location (x42 / cell-line
                                    :name (x41 / name :op1 "Hep3B")))
                        :ARG0-of (x43 / use-01
                              :ARG1 (x45 / fluoresce-01
                                    :ARG1-of (x44 / green-02)))
                        :name (x47 / name :op1 "GFP")
                        :xref (x / xref :value "UNIPROT:FPGT_HUMAN" :prob "0.342")))
            :ARG1-of (x48 / hep3b)))


# ::id PMC4455068.77
# ::snt In comparison with the marked upregulation and reduction of T220/T179 phosphorylation observed in control cells upon heregulin and IGF-1 and LY treatment, respectively, expression of Akt possessing varying states of activation had negligible impact on T220/T179 phosphorylation ( Fig. 5e ), suggesting that Akt is not directly responsible for this phosphorylation.
# ::tok In comparison with the marked upregulation and reduction of T220 @/@ T179 phosphorylation observed in control cells upon heregulin and IGF @-@ 1 and LY treatment , respectively , expression of Akt possessing varying states of activation had negligible impact on T220 @/@ T179 phosphorylation ( Fig . 5e ) , suggesting that Akt is not directly responsible for this phosphorylation .
(x1 / multi-sentence
      :snt1 (x18 / and
            :op1 (x2 / compare-01
                  :ARG2 (x5 / and
                        :op1 (x4 / upregulate-01
                              :degree (x3 / marked))
                        :op2 (x6 / reduce-01
                              :ARG1 (x12 / phosphorylate-01
                                    :ARG1 (x7 / and
                                          :op1 (x8 / amino-acid
                                                :mod "220"
                                                :name (x9 / name :op1 "threonine")
                                                :xref (x55 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                          :op2 (x10 / amino-acid
                                                :mod "179"
                                                :name (x11 / name :op1 "threonine")
                                                :xref (x57 / xref :value "PUBCHEM:205" :prob "11.848252")))
                                    :ARG1-of (x13 / observe-01
                                          :location (x15 / cell
                                                :ARG0-of (x14 / control-01)))
                                    :ARG2 (x16 / protein
                                          :name (x17 / name :op1 "heregulin")
                                          :xref (x52 / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.703"))))))
            :op2 (x24 / treat-04
                  :ARG1 (x21 / and
                        :op1 (x19 / protein
                              :name (x20 / name :op1 "IGF-1")
                              :xref (x51 / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673"))
                        :op2 (x22 / small-molecule
                              :name (x23 / name :op1 "LY")
                              :xref (x54 / xref :value "PUBCHEM:16196600" :prob "11.455812")))))
      :snt2 (x29 / possess-01
            :mod (x25 / respective)
            :ARG0 (x26 / express-03
                  :ARG2 (x27 / enzyme
                        :name (x28 / name :op1 "Akt")
                        :xref (x50 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :ARG1 (x34 / impact-01
                  :ARG0 (x31 / state
                        :ARG1-of (x30 / vary-01)
                        :mod (x32 / activate-01))
                  :mod (x33 / negligible)
                  :ARG1 (x40 / phosphorylate-01
                        :ARG1 (x35 / and
                              :op1 (x36 / amino-acid
                                    :mod "220"
                                    :name (x37 / name :op1 "threonine")
                                    :xref (x53 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x38 / amino-acid
                                    :mod "179"
                                    :name (x39 / name :op1 "threonine")
                                    :xref (x56 / xref :value "PUBCHEM:205" :prob "11.848252")))))
            :ARG1-of (x41 / describe-01
                  :ARG0 (x42 / figure :mod "5e"))
            :ARG0-of (x43 / suggest-01
                  :ARG1 (x47 / responsible-01
                        :ARG1 (x44 / enzyme
                              :name (x45 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
                        :polarity "-"
                        :ARG1-of (x46 / direct-02)
                        :ARG1 (x49 / phosphorylate-01
                              :mod (x48 / this))))))


# ::id PMC4455068.78
# ::snt This was further confirmed by an in vitro kinase assay that demonstrated the inability of fully active Akt to phosphorylate this residue ( Fig. 5f ), which is consistent with previous findings 8 9 10 .
# ::tok This was further confirmed by an in vitro kinase assay that demonstrated the inability of fully active Akt to phosphorylate this residue ( Fig . 5f ) , which is consistent with previous findings 8 9 10 .
(x3 / confirm-01
      :ARG1 (x1 / this)
      :degree (x2 / further)
      :ARG0 (x6 / assay-01
            :manner (x4 / in-vitro)
            :ARG1 (x5 / kinase)
            :ARG0-of (x7 / demonstrate-01
                  :ARG1 (x8 / possible-01
                        :polarity "-"
                        :ARG1 (x10 / activate-01
                              :degree (x9 / full)
                              :ARG1 (x11 / enzyme
                                    :name (x12 / name :op1 "Akt")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))
            :ARG2 (x13 / phosphorylate-01
                  :ARG1 (x15 / residue
                        :mod (x14 / this)
                        :ARG1-of (x16 / describe-01
                              :ARG0 (x17 / figure :mod "5f")))
                  :ARG1-of (x18 / consistent-01
                        :ARG2 (x20 / thing
                              :time (x19 / previous)
                              :ARG1-of (x21 / find-01)))
                  :ARG1 (x22 / and
                        :op1 "8"
                        :op2 "9"
                        :op3 "10"))))


# ::id PMC4455068.79
# ::snt mTORC2 induces the phosphorylation of Smad2/3-T220/T179
# ::tok mTORC2 induces the phosphorylation of Smad2 @/@ 3 @-@ T220 @/@ T179
(x3 / induce-01
      :ARG0 (x1 / macro-molecular-complex
            :name (x2 / name :op1 "mTORC2"))
      :ARG2 (x4 / phosphorylate-01
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "smad2/3")))
      :ARG1 (x7 / and
            :op1 (x8 / amino-acid
                  :mod "220"
                  :name (x9 / name :op1 "threonine")
                  :xref (x12 / xref :value "PUBCHEM:205" :prob "11.848252"))
            :op2 (x10 / amino-acid
                  :mod "179"
                  :name (x11 / name :op1 "threonine")
                  :xref (x / xref :value "PUBCHEM:205" :prob "11.848252"))))


# ::id PMC4455068.80
# ::snt The mTOR branches of the PI3K signalling pathway acts to regulate cell growth, differentiation and metabolism.
# ::tok The mTOR branches of the PI3K signalling pathway acts to regulate cell growth , differentiation and metabolism .
(x7 / act-01
      :ARG0 (x3 / branch
            :mod (x1 / protein
                  :name (x2 / name :op1 "mTOR")
                  :xref (x / xref :value "UNIPROT:MTOR_HUMAN" :prob "1.004"))
            :part-of (x6 / pathway
                  :name (x4 / name :op1 "PI3K")
                  :ARG0-of (x5 / signal-07)))
      :ARG1 (x8 / regulate-01
            :ARG1 (x12 / and
                  :op1 (x10 / grow-01
                        :ARG1 (x9 / cell))
                  :op2 (x11 / differentiate-01)
                  :op4 (x13 / metabolize-01))))


# ::id PMC4455068.81
# ::snt mTOR is the kinase component of two distinct multi-protein complexes, mTORC1 and mTORC2, which differ not only in their constituent components, but also in their response to rapamycin 31 .
# ::tok mTOR is the kinase component of two distinct multi @-@ protein complexes , mTORC1 and mTORC2 , which differ not only in their constituent components , but also in their response to rapamycin 31 .
(x1 / and
      :op1 (x5 / component
            :ARG0 (x2 / protein
                  :name (x3 / name :op1 "mTOR")
                  :xref (x / xref :value "UNIPROT:MTOR_HUMAN" :prob "1.004"))
            :mod (x4 / kinase)
            :poss (x6 / and
                  :op1 (x10 / macro-molecular-complex
                        :quant "2"
                        :mod (x7 / distinct)
                        :ARG0-of (x8 / multiple
                              :op1 (x9 / protein))
                        :name (x11 / name :op1 "mTORC1"))
                  :op2 (x12 / macro-molecular-complex
                        :name (x13 / name :op1 "mTORC2")))
            :ARG1-of (x14 / differ-02
                  :mod (x15 / only :polarity "-")
                  :location (x17 / component
                        :mod (x16 / constituent))))
      :op2 (x18 / contrast-01
            :mod (x19 / also)
            :ARG1 (x20 / respond-01
                  :ARG1 (x21 / small-molecule
                        :name (x22 / name :op1 "rapamycin")
                        :xref (x26 / xref :value "PUBCHEM:5040" :prob "15.003454")))
            :ARG1-of (x23 / describe-01
                  :ARG0 (x24 / publication
                        :ARG1-of (x25 / cite-01 :ARG2 "31")))))


# ::id PMC4455068.82
# ::snt mTORC1 contains an adaptor protein, raptor, as a key subunit, while mTORC2 comprises rictor as its novel component; while mTORC1 activity is rapidly inhibited by rapamycin, mTORC2 is more resistant to acute rapamycin exposure 32 .
# ::tok mTORC1 contains an adaptor protein , raptor , as a key subunit , while mTORC2 comprises rictor as its novel component ; while mTORC1 activity is rapidly inhibited by rapamycin , mTORC2 is more resistant to acute rapamycin exposure 32 .
(x3 / contain-01
      :ARG0 (x1 / macro-molecular-complex
            :name (x2 / name :op1 "mTORC1"))
      :ARG1 (x5 / protein
            :mod (x4 / adaptor)
            :name (x6 / name :op1 "raptor"))
      :time (x8 / contrast-01
            :ARG1 (x7 / subunit)
            :ARG2 (x11 / comprise-01
                  :ARG1 (x9 / macro-molecular-complex
                        :name (x10 / name :op1 "mTORC2"))
                  :ARG2 (x12 / protein
                        :name (x13 / name :op1 "rictor")
                        :xref (x / xref :value "UNIPROT:RICTR_HUMAN" :prob "0.602")))
            :ARG2 (x16 / contrast-01
                  :ARG1 (x15 / component
                        :mod (x14 / novel))
                  :ARG2 (x21 / inhibit-01
                        :ARG1 (x19 / activity-06
                              :ARG0 (x17 / enzyme
                                    :name (x18 / name :op1 "mTORC1")
                                    :xref (x36 / xref :value "UNIPROT:MTOR_HUMAN" :prob "0.283")))
                        :mod (x20 / rapid)
                        :ARG0 (x22 / small-molecule
                              :name (x23 / name :op1 "rapamycin")
                              :xref (x37 / xref :value "PUBCHEM:5040" :prob "15.003454"))))
            :ARG0-of (x27 / resist-01
                  :ARG1 (x24 / macro-molecular-complex
                        :name (x25 / name :op1 "mTORC2"))
                  :degree (x26 / more))
            :ARG1-of (x28 / key-02
                  :ARG2 (x32 / expose-01
                        :mod (x29 / acute)
                        :ARG2 (x30 / small-molecule
                              :name (x31 / name :op1 "rapamycin")
                              :xref (x38 / xref :value "PUBCHEM:5040" :prob "15.003454"))
                        :ARG1-of (x33 / describe-01
                              :ARG0 (x34 / publication
                                    :ARG1-of (x35 / cite-01 :ARG2 "32")))))))


# ::id PMC4455068.83
# ::snt To investigate whether mTOR complexes are involved in Smad2/3 regulation, PC3 cells were treated with AA in the presence of rapamycin or Torin-2 (henceforth Torin), an mTOR inhibitor that inhibits both complexes.
# ::tok To investigate whether mTOR complexes are involved in Smad2 @/@ 3 regulation , PC3 cells were treated with AA in the presence of rapamycin or Torin @-@ 2 ( henceforth Torin ) , an mTOR inhibitor that inhibits both complexes .
(x11 / treat-04
      :purpose (x1 / investigate-01
            :ARG1 (x5 / involve-01
                  :mode "interrogative"
                  :ARG1 (x4 / complex
                        :mod (x2 / protein
                              :name (x3 / name :op1 "mTOR")
                              :xref (x31 / xref :value "UNIPROT:MTOR_HUMAN" :prob "1.004")))
                  :ARG2 (x8 / regulate-01
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "Smad2/3")))))
      :ARG1 (x10 / cell-line
            :name (x9 / name :op1 "PC3"))
      :ARG2 (x12 / small-molecule
            :name (x13 / name :op1 "AA")
            :xref (x32 / xref :value "PUBCHEM:764" :prob "7.981792"))
      :location (x20 / henceforth
            :op1 (x17 / or
                  :op1 (x14 / present-02
                        :ARG1 (x15 / small-molecule
                              :name (x16 / name :op1 "rapamycin")
                              :xref (x33 / xref :value "PUBCHEM:5040" :prob "15.003454")))
                  :op2 (x18 / protein
                        :name (x19 / name :op1 "Torin-2")))
            :op1 (x21 / enzyme
                  :name (x22 / name :op1 "Torin")
                  :xref (x / xref :value "UNIPROT:TOR1A_HUMAN" :prob "0.212"))
            :op2 (x26 / molecular-physical-entity
                  :ARG0-of (x25 / inhibit-01
                        :ARG1 (x23 / protein
                              :name (x24 / name :op1 "mTOR")
                              :xref (x30 / xref :value "UNIPROT:MTOR_HUMAN" :prob "1.004")))
                  :ARG0-of (x27 / inhibit-01
                        :ARG1 (x29 / complex
                              :mod (x28 / both))))))


# ::id PMC4455068.84
# ::snt While rapamycin showed no obvious effects on both Smad2 activation and T220/T179 phosphorylation ( Fig. 6a ), Torin treatment mimicked that of LY in prolonging Smad2 activation and inhibiting T220/T179 phosphorylation ( Fig. 6b ), thereby suggesting that mTORC2, rather than mTORC1, is involved in the regulation of Smad2/3 activity.
# ::tok While rapamycin showed no obvious effects on both Smad2 activation and T220 @/@ T179 phosphorylation ( Fig . 6a ) , Torin treatment mimicked that of LY in prolonging Smad2 activation and inhibiting T220 @/@ T179 phosphorylation ( Fig . 6b ) , thereby suggesting that mTORC2 , rather than mTORC1 , is involved in the regulation of Smad2 @/@ 3 activity .
(x1 / multi-sentence
      :snt1 (x2 / contrast-01
            :ARG2 (x5 / show-01
                  :ARG0 (x3 / small-molecule
                        :name (x4 / name :op1 "rapamycin")
                        :xref (x53 / xref :value "PUBCHEM:5040" :prob "15.003454"))
                  :ARG1 (x7 / affect-01
                        :ARG1-of (x6 / obvious-01 :polarity "-")
                        :ARG1 (x8 / and
                              :op1 (x11 / activate-01
                                    :ARG1 (x9 / protein
                                          :name (x10 / name :op1 "Smad2")
                                          :xref (x51 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003")))
                              :op2 (x17 / phosphorylate-01
                                    :ARG1 (x12 / and
                                          :op1 (x13 / amino-acid
                                                :mod "220"
                                                :name (x14 / name :op1 "threonine")
                                                :xref (x56 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                          :op2 (x15 / amino-acid
                                                :mod "179"
                                                :name (x16 / name :op1 "threonine")
                                                :xref (x57 / xref :value "PUBCHEM:205" :prob "11.848252")))))))
            :ARG1-of (x18 / describe-01
                  :ARG0 (x19 / figure :mod "6a"))
            :ARG1-of (x22 / treat-04
                  :ARG2 (x20 / small-molecule
                        :name (x21 / name :op1 "Torin")
                        :xref (x52 / xref :value "PUBCHEM:49836027" :prob "11.468653"))))
      :snt2 (x24 / capable-01
            :ARG1 (x23 / mimic-01)
            :ARG1 (x25 / protein
                  :name (x26 / name :op1 "LY"))
            :location (x31 / and
                  :op1 (x30 / activate-01
                        :ARG1-of (x27 / prolong-01)
                        :ARG1 (x28 / protein
                              :name (x29 / name :op1 "Smad2")
                              :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003")))
                  :op2 (x32 / inhibit-01
                        :ARG1 (x37 / phosphorylate-01
                              :ARG1 (x33 / amino-acid
                                    :mod "220"
                                    :name (x34 / name :op1 "threonine")
                                    :xref (x54 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :ARG2 (x35 / amino-acid
                                    :mod "179"
                                    :name (x36 / name :op1 "threonine")
                                    :xref (x55 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :ARG1-of (x38 / describe-01
                                    :ARG0 (x39 / figure :mod "6b")))))
            :ARG0-of (x40 / suggest-01
                  :ARG1 (x46 / involve-01
                        :ARG1 (x43 / instead-of-91
                              :ARG1 (x41 / macro-molecular-complex
                                    :name (x42 / name :op1 "mTORC2"))
                              :ARG2 (x44 / macro-molecular-complex
                                    :name (x45 / name :op1 "mTORC1")))
                        :ARG2 (x47 / regulate-01
                              :ARG1 (x50 / activity-06
                                    :ARG0 (x48 / protein
                                          :name (x49 / name :op1 "Smad2/3"))))))))


# ::id PMC4455068.85
# ::snt In support of this notion, phosphorylation of T220/T179 was shown to be downregulated in rictor knockdown PC3 cells ( Fig. 6c ) and this reduction of pT220/pT179 appeared more evident in MEFs (mouse embryonic fibroblasts) that were derived from rictor null mice ( Fig. 6d ) 33 .
# ::tok In support of this notion , phosphorylation of T220 @/@ T179 was shown to be downregulated in rictor knockdown PC3 cells ( Fig . 6c ) and this reduction of pT220 @/@ pT179 appeared more evident in MEFs ( mouse embryonic fibroblasts ) that were derived from rictor null mice ( Fig . 6d ) 33 .
(x1 / multi-sentence
      :snt1 (x11 / show-01
            :location (x2 / support-01
                  :ARG1 (x4 / notion
                        :mod (x3 / this)))
            :ARG1 (x5 / phosphorylate-01
                  :ARG1 (x6 / and
                        :op1 (x7 / amino-acid
                              :mod "220"
                              :name (x8 / name :op1 "threonine")
                              :xref (x49 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :op2 (x9 / amino-acid
                              :mod "179"
                              :name (x10 / name :op1 "threonine")
                              :xref (x48 / xref :value "PUBCHEM:205" :prob "11.848252"))))
            :ARG1 (x12 / downregulate-01)
            :location (x17 / cell-line
                  :ARG0-of (x15 / knock-down-02
                        :ARG1 (x13 / protein
                              :name (x14 / name :op1 "rictor")
                              :xref (x47 / xref :value "UNIPROT:RICTR_HUMAN" :prob "0.602")))
                  :name (x16 / name :op1 "PC3")))
      :snt2 (x20 / and
            :ARG1-of (x18 / describe-01
                  :ARG0 (x19 / figure :mod "6c"))
            :op2 (x22 / appear-02
                  :mod (x21 / this)
                  :ARG1 (x30 / evident
                        :ARG0 (x23 / reduce-01
                              :ARG1 (x26 / slash
                                    :op1 (x24 / enzyme
                                          :name (x25 / name :op1 "pT220"))
                                    :op2 (x27 / enzyme
                                          :name (x28 / name :op1 "pT179")
                                          :xref (x / xref :value "UNIPROT:PT117_HUMAN" :prob "0.212"))))
                        :degree (x29 / more))
                  :location (x31 / cell
                        :name (x32 / name :op1 "mef"))
                  :ARG1-of (x35 / fibroblast
                        :source (x34 / embryo
                              :mod (x33 / mouse))))
            :mod (x40 / mouse
                  :ARG1-of (x36 / derive-01
                        :ARG2 (x38 / protein
                              :name (x37 / name :op1 "rictor")
                              :ARG2-of (x39 / mutate-01 :mod "-/-")
                              :xref (x46 / xref :value "UNIPROT:RICTR_HUMAN" :prob "0.602"))))
            :ARG1-of (x41 / describe-01
                  :ARG0 (x42 / figure :mod "6d"))
            :ARG1-of (x43 / describe-01
                  :ARG0 (x44 / publication
                        :ARG1-of (x45 / cite-01 :ARG2 "33")))))


# ::id PMC4455068.86
# ::snt The difference between rictor knockdown and rictor null cells could be due to the incomplete removal of rictor in the former as we have shown that PI3K/mTORC2-dependent phosphorylation of T220/179 is highly sensitive to any trace amount of PI3K/mTORC2 activity ( Fig. 5d vs Supplementary Fig. 5b ).
# ::tok The difference between rictor knockdown and rictor null cells could be due to the incomplete removal of rictor in the former as we have shown that PI3K @/@ mTORC2 @-@ dependent phosphorylation of T220 @/@ 179 is highly sensitive to any trace amount of PI3K @/@ mTORC2 activity ( Fig . 5d vs Supplementary Fig . 5b ) .
(x1 / multi-sentence
      :snt1 (x2 / possible-01
            :ARG1 (x11 / cause-01
                  :ARG1 (x10 / cell-line
                        :ARG1-of (x3 / differ-02
                              :ARG1 (x6 / knock-down-02
                                    :ARG1 (x4 / protein
                                          :name (x5 / name :op1 "rictor")
                                          :xref (x48 / xref :value "UNIPROT:RICTR_HUMAN" :prob "0.602")))
                              :ARG2 (x9 / null
                                    :mod (x7 / protein
                                          :name (x8 / name :op1 "rictor")
                                          :xref (x47 / xref :value "UNIPROT:RICTR_HUMAN" :prob "0.602")))))
                  :ARG0 (x13 / remove-01
                        :ARG1-of (x12 / complete-02)
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "rictor")
                              :xref (x51 / xref :value "UNIPROT:RICTR_HUMAN" :prob "0.602"))
                        :location (x17 / and
                              :time (x16 / former)))))
      :snt2 (x19 / show-01
            :ARG0 (x18 / we)
            :ARG1 (x31 / sensitive-03
                  :ARG1 (x26 / phosphorylate-01
                        :ARG0-of (x25 / depend-01
                              :ARG1 (x22 / slash
                                    :op1 (x20 / enzyme
                                          :name (x21 / name :op1 "PI3K")
                                          :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                                    :op2 (x23 / enzyme
                                          :name (x24 / name :op1 "mTORC2")
                                          :xref (x46 / xref :value "UNIPROT:MTOR_HUMAN" :prob "0.283"))))
                        :ARG1 (x27 / amino-acid
                              :mod "220"
                              :name (x28 / name :op1 "threonine")
                              :xref (x52 / xref :value "PUBCHEM:205" :prob "11.848252"))
                        :mod (x29 / slash :op1 "202" :op2 "179"))
                  :ARG1-of (x30 / high-02)
                  :ARG1 (x34 / amount
                        :mod (x32 / any)
                        :mod (x33 / trace)
                        :quant-of (x40 / activity-06
                              :ARG0 (x37 / slash
                                    :op1 (x35 / enzyme
                                          :name (x36 / name :op1 "PI3K")
                                          :xref (x49 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                                    :op2 (x38 / enzyme
                                          :name (x39 / name :op1 "mTORC2")
                                          :xref (x50 / xref :value "UNIPROT:MTOR_HUMAN" :prob "0.283")))))
                  :ARG1-of (x41 / describe-01
                        :ARG0 (x42 / figure :mod "5d")))
            :ARG1-of (x43 / describe-01
                  :ARG0 (x45 / figure
                        :ARG2-of (x44 / supplement-01)
                        :mod "5b"))))


# ::id PMC4455068.87
# ::snt Furthermore, this downregulation of T220/T179 phosphorylation in rictor null cells was fully rescued by the ectopic expression of human rictor ( Fig. 6d ), highlighting the important role mTORC2 plays in regulating Smad2/3-T220/T179 phosphorylation.
# ::tok Furthermore , this downregulation of T220 @/@ T179 phosphorylation in rictor null cells was fully rescued by the ectopic expression of human rictor ( Fig . 6d ) , highlighting the important role mTORC2 plays in regulating Smad2 @/@ 3 @-@ T220 @/@ T179 phosphorylation .
(x1 / and
      :op2 (x27 / play-02
            :ARG0 (x15 / rescue-01
                  :mod (x2 / this)
                  :ARG1 (x9 / phosphorylate-01
                        :ARG1 (x3 / downregulate-01
                              :ARG1 (x4 / and
                                    :op1 (x5 / amino-acid
                                          :mod "220"
                                          :name (x6 / name :op1 "threonine")
                                          :xref (x39 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                    :op2 (x7 / amino-acid
                                          :mod "179"
                                          :name (x8 / name :op1 "threonine")
                                          :xref (x38 / xref :value "PUBCHEM:205" :prob "11.848252"))))
                        :location (x13 / cell
                              :mod (x11 / protein
                                    :name (x10 / name :op1 "rictor")
                                    :ARG2-of (x12 / mutate-01 :mod "-/-")
                                    :xref (x37 / xref :value "UNIPROT:RICTR_HUMAN" :prob "0.602"))))
                  :degree (x14 / full)
                  :ARG0 (x17 / express-03
                        :mod (x16 / ectopic)
                        :ARG2 (x18 / protein
                              :mod (x19 / human)
                              :name (x20 / name :op1 "rictor")
                              :xref (x / xref :value "UNIPROT:RICTR_HUMAN" :prob "0.602")))
                  :ARG1-of (x21 / describe-01
                        :ARG0 (x22 / figure :mod "6d"))
                  :ARG0-of (x23 / highlight-01
                        :ARG1 (x25 / role
                              :mod (x24 / important)
                              :name (x26 / name :op1 "mTORC2"))))
            :ARG1 (x28 / regulate-01
                  :ARG1 (x36 / phosphorylate-01
                        :ARG2 (x29 / protein
                              :name (x30 / name :op1 "Smad2/3"))
                        :ARG1 (x31 / and
                              :op1 (x32 / amino-acid
                                    :mod "220"
                                    :name (x33 / name :op1 "threonine")
                                    :xref (x40 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x34 / amino-acid
                                    :mod "179"
                                    :name (x35 / name :op1 "threonine")
                                    :xref (x41 / xref :value "PUBCHEM:205" :prob "11.848252")))))))


# ::id PMC4455068.88
# ::snt Moreover, hESCs expressing rictor short hairpin RNA (shRNA) exhibited improved DE differentiation in response to AA treatment evidenced by rapid morphological changes and increased expression of DE markers, effects that are reminiscent of those observed upon AA–LY treatment ( Fig. 6e,f ).
# ::tok Moreover , hESCs expressing rictor short hairpin RNA ( shRNA ) exhibited improved DE differentiation in response to AA treatment evidenced by rapid morphological changes and increased expression of DE markers , effects that are reminiscent of those observed upon AA–LY treatment ( Fig . 6e , f ) .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op2 (x3 / express-03
                  :ARG2 (x4 / protein
                        :name (x5 / name :op1 "rictor")
                        :xref (x / xref :value "UNIPROT:RICTR_HUMAN" :prob "0.602"))))
      :snt2 (x30 / observe-01
            :ARG0 (x6 / protein
                  :name (x7 / name
                        :op1 "short"
                        :op2 "hairpin"
                        :op3 "RNA")
                  :ARG1-of (x10 / exhibit-01
                        :ARG0 (x8 / nucleic-acid
                              :name (x9 / name :op1 "shRNA"))
                        :ARG1 (x12 / and
                              :op1 (x11 / improve-01)
                              :op2 (x13 / differentiate-01))
                        :ARG2-of (x14 / respond-01
                              :ARG1 (x17 / treat-04
                                    :ARG2 (x15 / small-molecule
                                          :name (x16 / name :op1 "6-aa")
                                          :xref (x38 / xref :value "PUBCHEM:195491" :prob "2.046193"))))))
            :ARG1-of (x18 / evidence-01
                  :ARG0 (x22 / and
                        :op1 (x21 / change-01
                              :mod (x19 / rapid)
                              :ARG1 (x20 / morphology))
                        :op2 (x24 / express-03
                              :ARG1-of (x23 / increase-01)
                              :ARG2 (x26 / marker
                                    :name (x25 / name :op1 "DE"))))
                  :ARG0-of (x27 / affect-01)
                  :ARG0-of (x28 / reminisce-01
                        :ARG1 (x29 / that)))
            :condition (x33 / treat-04
                  :ARG2 (x31 / small-molecule
                        :name (x32 / name :op1 "AA–LY")))
            :ARG1-of (x34 / describe-01
                  :ARG0 (x35 / and
                        :op1 (x36 / figure :mod "6e")
                        :op1 (x37 / figure :mod "6f")))))


# ::id PMC4455068.89
# ::snt Therefore, these results suggest that mTORC2 plays an important role in modulating Activin-induced Smad2/3 activity by modifying the phosphorylation of the Smad2/3 linker T220/T179 residue.
# ::tok Therefore , these results suggest that mTORC2 plays an important role in modulating Activin @-@ induced Smad2 @/@ 3 activity by modifying the phosphorylation of the Smad2 @/@ 3 linker T220 @/@ T179 residue .
(x5 / suggest-01
      :ARG1-of (x1 / cause-01)
      :ARG0 (x3 / thing
            :mod (x2 / this)
            :ARG2-of (x4 / result-01))
      :ARG1 (x8 / play-02
            :ARG0 (x6 / macro-molecular-complex
                  :name (x7 / name :op1 "mTORC2"))
            :ARG1 (x10 / role
                  :mod (x9 / important)
                  :topic (x11 / modulate-01
                        :ARG1 (x17 / activity-06
                              :ARG2-of (x14 / induce-01
                                    :ARG0 (x12 / protein
                                          :name (x13 / name :op1 "Activin")
                                          :xref (x / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283")))
                              :ARG0 (x15 / protein
                                    :name (x16 / name :op1 "Smad2/3"))))))
      :manner (x18 / modify-01
            :ARG1 (x19 / phosphorylate-01
                  :ARG1 (x28 / residue
                        :ARG0-of (x22 / link-01
                              :ARG1 (x20 / protein
                                    :name (x21 / name :op1 "Smad2/3"))
                              :ARG2 (x23 / and
                                    :op1 (x24 / amino-acid
                                          :mod "220"
                                          :name (x25 / name :op1 "threonine")
                                          :xref (x29 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                    :op2 (x26 / amino-acid
                                          :mod "179"
                                          :name (x27 / name :op1 "threonine")
                                          :xref (x30 / xref :value "PUBCHEM:205" :prob "11.848252"))))))))


# ::id PMC4455068.90
# ::snt Intriguingly, immunoprecipitated mTORC2 was unable to phosphorylate Smad2-T220 in an in vitro kinase reaction ( Fig. 6g ), while inhibition of SGK1, one of the limited substrates identified to be regulated by mTORC2 (refs 34 , 35 ), exhibited considerable reduction of both active and total Smad2/3 ( Supplementary Fig. 6 ), effects that are completely different to that of either LY treatment or mTORC2 inhibition.
# ::tok Intriguingly , immunoprecipitated mTORC2 was unable to phosphorylate Smad2 @-@ T220 in an in vitro kinase reaction ( Fig . 6g ) , while inhibition of SGK1 , one of the limited substrates identified to be regulated by mTORC2 ( refs 34 , 35 ) , exhibited considerable reduction of both active and total Smad2 @/@ 3 ( Supplementary Fig . 6 ) , effects that are completely different to that of either LY treatment or mTORC2 inhibition .
(x1 / multi-sentence
      :snt1 (x16 / contrast-01
            :ARG1 (x2 / intrigue-01
                  :ARG2 (x3 / immunoprecipitate-01
                        :ARG1 (x4 / macro-molecular-complex
                              :name (x5 / name :op1 "mTORC2"))
                        :polarity "-"
                        :ARG2 (x6 / phosphorylate-01
                              :ARG1 (x7 / protein
                                    :name (x8 / name :op1 "Smad2")
                                    :xref (x49 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003"))
                              :ARG2 (x12 / kinase
                                    :mod (x9 / amino-acid
                                          :mod "220"
                                          :name (x10 / name :op1 "threonine")
                                          :xref (x52 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                    :mod (x11 / in-vitro)
                                    :ARG0-of (x13 / react-01))))
                  :ARG1-of (x14 / describe-01
                        :ARG0 (x15 / figure :mod "6g")))
            :ARG2 (x23 / regulate-01
                  :ARG1-of (x17 / inhibit-01
                        :ARG1 (x18 / protein
                              :name (x19 / name :op1 "SGK1")
                              :ARG1-of (x22 / identify-01
                                    :ARG2 (x21 / substrate
                                          :ARG1-of (x20 / limit-01)))
                              :xref (x50 / xref :value "UNIPROT:SGK1_HUMAN" :prob "1.004")))
                  :ARG0 (x24 / protein
                        :name (x25 / name :op1 "mTORC2" :op2 "refs"))))
      :snt2 (x27 / exhibit-01
            :ARG0 (x26 / and :op1 "34" :op2 "35")
            :ARG1 (x29 / reduce-01
                  :mod (x28 / considerable)
                  :ARG1 (x30 / and
                        :op1 (x31 / activity-06)
                        :op2 (x32 / enzyme
                              :mod (x33 / total)
                              :name (x34 / name :op1 "Smad2/3"))))
            :ARG1-of (x35 / describe-01
                  :ARG0 (x37 / figure
                        :ARG2-of (x36 / supplement-01)
                        :mod "6"))
            :ARG0-of (x38 / affect-01)
            :ARG1-of (x40 / differ-02
                  :ARG1-of (x39 / complete-02))
            :ARG1 (x41 / capable-01
                  :ARG1 (x42 / or
                        :op1 (x45 / treat-04
                              :ARG2 (x43 / small-molecule
                                    :name (x44 / name :op1 "LY")
                                    :xref (x51 / xref :value "PUBCHEM:16196600" :prob "11.455812")))
                        :op2 (x48 / inhibit-01
                              :ARG1 (x46 / enzyme
                                    :name (x47 / name :op1 "mTORC2")
                                    :xref (x / xref :value "UNIPROT:MTOR_HUMAN" :prob "0.283")))))))


# ::id PMC4455068.91
# ::snt Thus, the exact mechanisms by which mTORC2 regulates the phosphorylation of Smad2/3 linker residue await further elucidation.
# ::tok Thus , the exact mechanisms by which mTORC2 regulates the phosphorylation of Smad2 @/@ 3 linker residue await further elucidation .
(x1 / infer-01
      :ARG1 (x12 / await-01
            :ARG0 (x3 / mechanism
                  :mod (x2 / exact)
                  :instrument-of (x6 / regulate-01
                        :ARG0 (x4 / macro-molecular-complex
                              :name (x5 / name :op1 "mTORC2"))
                        :ARG1 (x10 / link-01
                              :ARG0 (x7 / phosphorylate-01
                                    :ARG1 (x8 / enzyme
                                          :name (x9 / name :op1 "Smad2/3"))))))
            :ARG1 (x11 / residue)
            :degree (x13 / further)
            :ARG1 (x14 / elucidate-01)))


# ::id PMC4455068.92
# ::snt Suppression of mTORC2 leads to more efficient DE formation
# ::tok Suppression of mTORC2 leads to more efficient DE formation
(x4 / lead-03
      :ARG0 (x1 / suppress-01
            :ARG1 (x2 / macro-molecular-complex
                  :name (x3 / name :op1 "mTORC2")))
      :ARG2 (x6 / efficient-01
            :degree (x5 / more)
            :ARG2 (x9 / form-01
                  :ARG1 (x7 / protein
                        :name (x8 / name :op1 "DE")))))


# ::id PMC4455068.93
# ::snt Consistent with the posited role for mTORC2 in regulating T220/T179 phosphorylation and inhibiting Smad2/3 activity, treatment of hESCs using a combination of AA and Torin yielded a substantial increase in the expression of endoderm genes ( Fig. 7a,b ), recapitulating the effects of AA–LY treatment, but with noticeably less cell death.
# ::tok Consistent with the posited role for mTORC2 in regulating T220 @/@ T179 phosphorylation and inhibiting Smad2 @/@ 3 activity , treatment of hESCs using a combination of AA and Torin yielded a substantial increase in the expression of endoderm genes ( Fig . 7a , b ) , recapitulating the effects of AA–LY treatment , but with noticeably less cell death .
(x1 / multi-sentence
      :snt1 (x18 / activity-06
            :ARG1-of (x2 / consistent-01
                  :ARG2 (x4 / role
                        :ARG1-of (x3 / posit-01)
                        :poss (x5 / macro-molecular-complex
                              :name (x6 / name :op1 "mTORC2"))
                        :topic (x7 / regulate-01)))
            :ARG0 (x14 / and
                  :op1 (x13 / phosphorylate-01
                        :ARG1 (x8 / and
                              :op1 (x9 / amino-acid
                                    :mod "220"
                                    :name (x10 / name :op1 "threonine")
                                    :xref (x48 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x11 / amino-acid
                                    :mod "179"
                                    :name (x12 / name :op1 "threonine")
                                    :xref (x49 / xref :value "PUBCHEM:205" :prob "11.848252"))))
                  :op2 (x15 / inhibit-01
                        :ARG1 (x16 / protein
                              :name (x17 / name :op1 "Smad2/3"))))
            :ARG1-of (x19 / treat-04
                  :ARG2 (x20 / small-molecule
                        :name (x21 / name :op1 "hESCs"))))
      :snt2 (x43 / contrast-01
            :ARG1 (x29 / yield-01
                  :ARG0 (x22 / use-01
                        :ARG1 (x23 / combine-01
                              :ARG1 (x26 / and
                                    :op1 (x24 / enzyme
                                          :name (x25 / name :op1 "6-aa"))
                                    :op2 (x27 / enzyme
                                          :name (x28 / name :op1 "Torin")
                                          :xref (x / xref :value "UNIPROT:TOR1A_HUMAN" :prob "0.212")))))
                  :ARG1 (x31 / increase-01
                        :degree (x30 / substantial)
                        :ARG1 (x32 / express-03
                              :ARG1 (x34 / gene
                                    :mod (x33 / endoderm))))
                  :ARG1-of (x38 / recapitulate-01
                        :ARG0 (x35 / and
                              :op1 (x36 / figure :mod "7a")
                              :op2 (x37 / figure :mod "1b"))
                        :ARG1 (x39 / affect-01
                              :ARG0 (x42 / treat-04
                                    :ARG2 (x40 / small-molecule
                                          :name (x41 / name :op1 "AA–LY"))))))
            :ARG2 (x47 / die-01
                  :ARG1 (x44 / noticeable)
                  :degree (x45 / less)
                  :ARG1 (x46 / cell))))


# ::id PMC4455068.94
# ::snt Consequently, this led to both a more efficient DE differentiation and hepatocyte generation ( Fig. 7c,d ).
# ::tok Consequently , this led to both a more efficient DE differentiation and hepatocyte generation ( Fig . 7c , d ) .
(x3 / lead-03
      :ARG1-of (x1 / cause-01)
      :ARG0 (x2 / this)
      :ARG2 (x4 / and
            :op1 (x9 / and
                  :op1 (x8 / differentiate-01
                        :ARG1 (x6 / efficient-01
                              :degree (x5 / more)
                              :name (x7 / name :op1 "DE")))
                  :op2 (x12 / generate-01
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "hepatocyte")
                              :xref (x / xref :value "UNIPROT:NOS2_HUMAN" :prob "0.352")))))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / and
                  :op1 (x15 / figure :mod "7c")
                  :op1 (x16 / figure :mod "7d"))))


# ::id PMC4455068.95
# ::snt Thus, the greater yield of DE cells in combination with the reduction in cytotoxicity makes AA–Torin a superior alternative to AA–LY treatment and provides compelling evidence to suggest that the mTORC2-mediated regulation of Smad2/3 linker phosphorylation is a critical mechanism accounting for the inhibitory effect of PI3K on Activin-induced DE differentiation.
# ::tok Thus , the greater yield of DE cells in combination with the reduction in cytotoxicity makes AA–Torin a superior alternative to AA–LY treatment and provides compelling evidence to suggest that the mTORC2 @-@ mediated regulation of Smad2 @/@ 3 linker phosphorylation is a critical mechanism accounting for the inhibitory effect of PI3K on Activin @-@ induced DE differentiation .
(x1 / multi-sentence
      :snt1 (x2 / cause-01
            :ARG1 (x5 / yield-01
                  :mod (x3 / great
                        :degree (x4 / more))
                  :ARG1 (x7 / cell-line
                        :name (x6 / name :op1 "DE")))
            :location (x19 / and
                  :op1 (x14 / superior-01
                        :ARG1-of (x8 / combine-01
                              :ARG2 (x11 / make-02
                                    :ARG1-of (x9 / reduce-01
                                          :ARG1 (x10 / cytotoxicity))
                                    :ARG1 (x12 / enzyme
                                          :name (x13 / name :op1 "AA–Torin"))))
                        :mod (x15 / alternative)
                        :ARG1-of (x18 / treat-04
                              :ARG2 (x16 / small-molecule
                                    :name (x17 / name :op1 "AA–LY"))))
                  :op2 (x20 / provide-01
                        :ARG1 (x22 / evidence-01
                              :ARG0-of (x21 / compel-01)
                              :ARG1 (x27 / regulate-01
                                    :ARG0-of (x23 / suggest-01
                                          :ARG1 (x26 / mediate-01
                                                :ARG0 (x24 / protein
                                                      :name (x25 / name :op1 "mTORC2")
                                                      :xref (x45 / xref :value "UNIPROT:MTOR_HUMAN" :prob "0.283"))))
                                    :ARG1 (x28 / protein
                                          :name (x29 / name :op1 "Smad2/3")))))))
      :snt2 (x43 / and
            :op1 (x34 / mechanism
                  :domain (x32 / phosphorylate-01
                        :ARG1 (x30 / enzyme
                              :name (x31 / name :op1 "linker")
                              :xref (x46 / xref :value "UNIPROT:NEUL3_HUMAN" :prob "0.202")))
                  :ARG1-of (x33 / critical-02)
                  :ARG0-of (x35 / account-01
                        :ARG1 (x37 / affect-01
                              :ARG2 (x36 / inhibit-01)
                              :ARG0 (x38 / enzyme
                                    :name (x39 / name :op1 "PI3K")
                                    :xref (x47 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                              :ARG1 (x42 / induce-01
                                    :ARG0 (x40 / protein
                                          :name (x41 / name :op1 "Activin")
                                          :xref (x / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283"))))))
            :op2 (x44 / differentiate-01)))


# ::id PMC4455068.128
# ::snt Cell culture and differentiation
# ::tok Cell culture and differentiation
(x3 / and
      :op1 (x2 / culture
            :mod (x1 / cell))
      :op2 (x4 / differentiate-01))


# ::id PMC4455068.156
# ::snt Transfection and lentiviral transduction
# ::tok Transfection and lentiviral transduction
(x4 / transduce-01
      :ARG1 (x1 / transfect-01
            :ARG2 (x2 / and
                  :op1 (x3 / lentiviral))))


# ::id PMC4455068.173
# ::snt Quantitative reverse transcription–PCR (qRT–PCR)
# ::tok Quantitative reverse transcription–PCR ( qRT–PCR )
(x1 / country
      :wiki "iran"
      :name (x2 / name
            :op1 "Quantitative"
            :op2 "reverse"
            :op3 "transcription–PCR"
            :op1 "qRT–PCR"))


# ::id PMC4455068.193
# ::snt Immunostaining of hESCs
# ::tok Immunostaining of hESCs
(x1 / immunostain-01
      :ARG2 (x2 / protein
            :name (x3 / name :op1 "hESCs")))


# ::id PMC4455068.214
# ::snt Smad2 ubiquitination assay
# ::tok Smad2 ubiquitination assay
(x4 / assay-01
      :ARG1 (x3 / ubiquitinate-01
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "Smad2")
                  :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003"))))


# ::id PMC4455068.221
# ::snt Generation of recombinant GST-Flag-Smad2/Smad2-T220V
# ::tok Generation of recombinant GST @-@ Flag @-@ Smad2 @/@ Smad2 @-@ T220V
(x1 / generate-01
      :ARG1 (x3 / macro-molecular-complex
            :ARG1-of (x2 / recombine-01)
            :part (x4 / enzyme
                  :name (x5 / name :op1 "GST")
                  :xref (x14 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002"))
            :part (x6 / protein
                  :name (x7 / name :op1 "Flag"))
            :part (x8 / protein
                  :name (x9 / name :op1 "Smad2")
                  :xref (x13 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003"))
            :part (x10 / protein
                  :name (x11 / name :op1 "Smad2")
                  :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003"))
            :name (x12 / name :op1 "T220V")))


# ::id PMC4455068.228
# ::snt Akt/Erk2 kinase assay
# ::tok Akt @/@ Erk2 kinase assay
(x7 / assay-01
      :ARG0 (x1 / and
            :op1 (x2 / enzyme
                  :name (x3 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :op2 (x4 / enzyme
                  :name (x5 / name :op1 "Erk2")
                  :xref (x8 / xref :value "UNIPROT:MK01_HUMAN" :prob "0.603")))
      :ARG1 (x6 / kinase))


# ::id PMC4455068.233
# ::snt mTORC2 kinase assay
# ::tok mTORC2 kinase assay
(x3 / assay-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "mTORC2")
            :xref (x / xref :value "UNIPROT:MTOR_HUMAN" :prob "0.283")))


# ::id PMC4455068.264
# ::snt Inhibition of PI3K signalling promotes differentiation of hESCs to the definitive endoderm (DE).
# ::tok Inhibition of PI3K signalling promotes differentiation of hESCs to the definitive endoderm ( DE ) .
(x5 / promote-02
      :ARG0 (x1 / inhibit-01
            :ARG1 (x4 / signal-07
                  :ARG0 (x2 / enzyme
                        :name (x3 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))
      :ARG1 (x6 / differentiate-01
            :ARG1 (x7 / cell-line
                  :name (x8 / name :op1 "hESCs"))
            :ARG2 (x9 / definitive
                  :ARG1 (x10 / country
                        :wiki "germany"
                        :name (x11 / name :op1 "endoderm")))))


# ::id PMC4455068.265
# ::snt Cell lysates were collected at indicated time points and analysed by immunoblot.
# ::tok Cell lysates were collected at indicated time points and analysed by immunoblot .
(x7 / and
      :op1 (x3 / collect-01
            :ARG1 (x2 / lysate
                  :mod (x1 / cell))
            :location (x6 / point
                  :mod (x5 / time
                        :ARG1-of (x4 / indicate-01))))
      :op2 (x8 / analyze-01
            :manner (x9 / immunoblot-01)))


# ::id PMC4455068.266
# ::snt Data represent mean±s.d. from six measurements of two independent differentiations.
# ::tok Data represent mean±s.d . from six measurements of two independent differentiations .
(x2 / represent-01
      :ARG0 (x1 / data)
      :ARG1 (x3 / person
            :wiki "-"
            :name (x4 / name :op1 "mean±s.d"))
      :ARG2 (x5 / cell-line
            :quant "6"
            :ARG1-of (x6 / measure-01)
            :quant "2"
            :ARG0-of (x7 / depend-01 :polarity "-")
            :ARG1-of (x8 / differentiate-01)))


# ::id PMC4455068.267
# ::snt Data represent mean±s.d. from three independent biological samples.
# ::tok Data represent mean±s.d . from three independent biological samples .
(x2 / represent-01
      :ARG0 (x1 / data)
      :ARG1 (x3 / person
            :wiki "-"
            :name (x4 / name :op1 "mean±s.d"))
      :ARG2 (x7 / sample-01
            :quant "3"
            :ARG0-of (x5 / depend-01 :polarity "-")
            :mod (x6 / biology)))


# ::id PMC4455068.268
# ::snt P value was calculated using the Student's t -test. ( f ) Immunostaining with Brachyury and Sox17 antibodies in hESCs treated as indicated.
# ::tok P value was calculated using the Student 's t -@ test . ( f ) Immunostaining with Brachyury and Sox17 antibodies in hESCs treated as indicated .
(x2 / calculate-01
      :ARG1 (x1 / value-01)
      :ARG2 (x3 / protein
            :name (x4 / name :op1 "student's" :op2 "t")
            :mod (x5 / test-01))
      :ARG1-of (x8 / immunostain-01
            :ARG1-of (x6 / describe-01
                  :ARG0 (x7 / figure :mod "4f"))
            :ARG2 (x14 / antibody
                  :ARG1 (x11 / and
                        :op1 (x9 / enzyme
                              :name (x10 / name :op1 "Brachyury")
                              :xref (x / xref :value "UNIPROT:BRAC_HUMAN" :prob "0.312"))
                        :op2 (x12 / protein
                              :name (x13 / name :op1 "Sox17")
                              :xref (x19 / xref :value "UNIPROT:SOX17_HUMAN" :prob "0.633")))
                  :location (x17 / treat-04
                        :ARG2 (x15 / small-molecule
                              :name (x16 / name :op1 "hESCs")))
                  :ARG1-of (x18 / indicate-01))))


# ::id PMC4455068.270
# ::snt Phase-contrast images (Phase-con) and immunostaining with AFP and albumin antibodies are presented.
# ::tok Phase @-@ contrast images ( Phase @-@ con ) and immunostaining with AFP and albumin antibodies are presented .
(x11 / present-01
      :ARG0 (x2 / image
            :name (x1 / name :op1 "Phase-contrast")
            :ARG1-of (x4 / instead-of-91
                  :ARG2 (x3 / phase)))
      :ARG1 (x5 / and
            :op1 (x6 / immunostain-01
                  :ARG2 (x7 / publication
                        :wiki "agence_france-presse"
                        :name (x8 / name :op1 "AFP")))
            :op2 (x10 / antibody
                  :name (x9 / name :op1 "albumin"))))


# ::id PMC4455068.272
# ::snt Suppression of PI3K signalling prolongs Activin-induced Smad2/3 activity.
# ::tok Suppression of PI3K signalling prolongs Activin @-@ induced Smad2 @/@ 3 activity .
(x1 / suppress-01
      :ARG1 (x4 / signal-07
            :ARG0 (x2 / enzyme
                  :name (x3 / name :op1 "PI3K")
                  :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
            :ARG1-of (x5 / prolong-01)
            :ARG1 (x11 / activity-06
                  :ARG2-of (x8 / induce-01
                        :ARG0 (x6 / protein
                              :name (x7 / name :op1 "Activin")
                              :xref (x12 / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283")))
                  :ARG0 (x9 / protein
                        :name (x10 / name :op1 "Smad2/3")))))


# ::id PMC4455068.273
# ::snt Numbers in a represent the quantification of activated Smad2 and Smad3.
# ::tok Numbers in a represent the quantification of activated Smad2 and Smad3 .
(x1 / and
      :op1 (x2 / number)
      :op2 (x3 / represent-01
            :ARG1 (x4 / quantify-01
                  :ARG1 (x8 / and
                        :op1 (x5 / enzyme
                              :ARG1-of (x6 / activate-01)
                              :name (x7 / name :op1 "Smad2")
                              :xref (x11 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003"))
                        :op2 (x9 / protein
                              :name (x10 / name :op1 "Smad3")
                              :xref (x / xref :value "UNIPROT:SMAD3_HUMAN" :prob "1.003"))))))


# ::id PMC4455068.274
# ::snt Upper panels in b are representative immunoblot and lower panels are histograms of densitometric measurements from three independent biological samples.
# ::tok Upper panels in b are representative immunoblot and lower panels are histograms of densitometric measurements from three independent biological samples .
(x13 / measure-01
      :ARG0 (x7 / and
            :op1 (x2 / panel
                  :mod (x1 / upper)
                  :location (x6 / immunoblot-01
                        :ARG0-of (x5 / represent-01
                              :ARG1 (x3 / enzyme
                                    :name (x4 / name :op1 "b-raf")
                                    :xref (x / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.701")))))
            :op2 (x10 / panel
                  :ARG1-of (x8 / low-04
                        :degree (x9 / more))))
      :mod (x11 / histogram)
      :mod (x12 / densitometric)
      :source (x16 / sample-01
            :quant "3"
            :ARG0-of (x14 / depend-01 :polarity "-")
            :mod (x15 / biology)))


# ::id PMC4455068.275
# ::snt Data show mean±s.d. of three independent transfection experiments.
# ::tok Data show mean±s.d . of three independent transfection experiments .
(x2 / show-01
      :ARG0 (x1 / data)
      :ARG1 (x6 / experiment-01
            :ARG2 (x5 / transfect-01
                  :name (x3 / name
                        :op1 "mean±s.d"
                        :op2 "of"
                        :op3 "3")
                  :ARG0-of (x4 / depend-01 :polarity "-"))))


# ::id PMC4455068.276
# ::snt Bar graphs indicate fold induction.
# ::tok Bar graphs indicate fold induction .
(x3 / indicate-01
      :ARG0 (x2 / graph
            :mod (x1 / bar))
      :ARG1 (x5 / induce-01
            :mod (x4 / product-of)))


# ::id PMC4455068.278
# ::snt ** P <0.001 and * P ≤0.05 by the Student's t -test. LY, LY294002.
# ::tok ** P
(x3 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "**")))


# ::id PMC4455068.279
# ::snt Inhibition of PI3K reduces Smad2/3 interaction with Nedd4L and subsequent ubiquitination.
# ::tok Inhibition of PI3K reduces Smad2 @/@ 3 interaction with Nedd4L and subsequent ubiquitination .
(x4 / reduce-01
      :ARG0 (x1 / inhibit-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "PI3K")
                  :xref (x13 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
      :ARG1 (x10 / and
            :op1 (x7 / interact-01
                  :ARG0 (x5 / protein
                        :name (x6 / name :op1 "Smad2/3"))
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "Nedd4L")
                        :xref (x / xref :value "UNIPROT:NED4L_HUMAN" :prob "0.622")))
            :op2 (x12 / ubiquitinate-01
                  :mod (x11 / subsequent))))


# ::id PMC4455068.280
# ::snt Graphs represent mean±s.d. from three independent experiments.
# ::tok Graphs represent mean±s.d . from three independent experiments .
(x2 / represent-01
      :ARG0 (x1 / graph)
      :ARG1 (x3 / person
            :wiki "-"
            :name (x4 / name :op1 "mean±s.d"))
      :ARG2 (x6 / experiment
            :quant "3"
            :ARG0-of (x5 / depend-01 :polarity "-")))


# ::id PMC4455068.281
# ::snt * P ≤0.05 by the Student's t -test. SB, SB431542; LY, LY294002; MG, MG132; Ub, ubiquitin.
# ::tok * P ≤0.05 by the Student 's t -@ test . SB , SB431542; LY , LY294002; MG , MG132; Ub , ubiquitin .
(x1 / phosphorylate-01
      :ARG1 (x2 / enzyme
            :name (x3 / name :op1 "≤0.05"))
      :ARG0 (x4 / and
            :op1 (x5 / protein
                  :name (x6 / name :op1 "student's" :op2 "t")
                  :mod (x7 / test-01
                        :ARG0 (x8 / sb)))
            :op2 (x9 / small-molecule
                  :name (x10 / name :op1 "LY")
                  :xref (x19 / xref :value "PUBCHEM:16196600" :prob "11.455812")))
      :ARG1 (x11 / and
            :op1 (x13 / milligram
                  :name (x12 / name :op1 "LY294002;"))
            :op2 (x14 / protein
                  :name (x15 / name :op1 "ubiquitin")
                  :xref (x / xref :value "UNIPROT:RL40_HUMAN" :prob "0.702"))
            :op3 (x16 / protein
                  :name (x17 / name :op1 "ubiquitin")
                  :xref (x18 / xref :value "UNIPROT:RL40_HUMAN" :prob "0.702"))))


# ::id PMC4455068.282
# ::snt PI3K regulates Nedd4L-mediated Smad2/3 degradation via phosphorylation of the T220/T179 linker residue.
# ::tok PI3K regulates Nedd4L @-@ mediated Smad2 @/@ 3 degradation via phosphorylation of the T220 @/@ T179 linker residue .
(x16 / link-01
      :ARG0 (x3 / regulate-01
            :ARG0 (x1 / enzyme
                  :name (x2 / name :op1 "PI3K")
                  :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
            :ARG1 (x9 / degrade-01
                  :ARG1-of (x6 / mediate-01
                        :ARG0 (x4 / enzyme
                              :name (x5 / name :op1 "Nedd4L")
                              :xref (x19 / xref :value "UNIPROT:NED4L_HUMAN" :prob "0.622")))
                  :ARG1 (x7 / protein
                        :name (x8 / name :op1 "Smad2")
                        :xref (x18 / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003"))
                  :ARG2 (x10 / phosphorylate-01
                        :ARG1 (x11 / and
                              :op1 (x12 / amino-acid
                                    :mod "220"
                                    :name (x13 / name :op1 "threonine")
                                    :xref (x21 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x14 / amino-acid
                                    :mod "179"
                                    :name (x15 / name :op1 "threonine")
                                    :xref (x20 / xref :value "PUBCHEM:205" :prob "11.848252"))))))
      :ARG1 (x17 / residue))


# ::id PMC4455068.283
# ::snt The C-terminal and linker phosphorylation sites as well as the E3 ubiquitin ligase-binding PPXY motif are indicated.
# ::tok The C @-@ terminal and linker phosphorylation sites as well as the E3 ubiquitin ligase @-@ binding PPXY motif are indicated .
(x3 / and
      :op1 (x1 / protein-segment
            :name (x2 / name :op1 "c-terminus"))
      :op2 (x4 / link-01
            :ARG1 (x7 / and
                  :op1 (x6 / site
                        :ARG1-of (x5 / phosphorylate-01))
                  :op2 (x12 / protein-segment
                        :ARG1-of (x10 / bind-01
                              :ARG2 (x8 / protein
                                    :name (x9 / name
                                          :op1 "E3"
                                          :op2 "ubiquitin"
                                          :op3 "ligase")))
                        :name (x11 / name :op1 "PPXY"))
                  :ARG1-of (x13 / indicate-01))))


# ::id PMC4455068.284
# ::snt Data in c represent mean±s.d. from three independent experiments.
# ::tok Data in c represent mean±s.d . from three independent experiments .
(x3 / represent-01
      :ARG0 (x1 / data
            :location (x2 / figure :mod "5c"))
      :ARG1 (x4 / person
            :wiki "-"
            :name (x5 / name :op1 "mean±s.d"))
      :ARG2 (x7 / experiment
            :quant "3"
            :ARG0-of (x6 / depend-01 :polarity "-")))


# ::id PMC4455068.285
# ::snt * P <0.05 (Student t -test).
# ::tok * P
(x3 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "*")))


# ::id PMC4455068.286
# ::snt PC3 cells were treated with Activin A±LY for 1 h, with MG132 added into the cultures 30 min prior to lysis.
# ::tok PC3 cells were treated with Activin A±LY for 1 h , with MG132 added into the cultures 30 min prior to lysis .
(x10 / add-02
      :ARG1 (x3 / treat-04
            :ARG1 (x2 / cell-line
                  :name (x1 / name :op1 "PC3"))
            :ARG2 (x4 / protein
                  :name (x5 / name :op1 "Activin" :op2 "A±LY"))
            :duration (x6 / temporal-quantity
                  :quant "1"
                  :unit (x7 / hour))
            :ARG2 (x8 / small-molecule
                  :name (x9 / name :op1 "MG132")
                  :xref (x / xref :value "PUBCHEM:462382" :prob "18.349844")))
      :ARG2 (x11 / culture-01
            :op2 (x12 / temporal-quantity
                  :quant "30"
                  :unit (x13 / minute))
            :time (x14 / prior
                  :op1 (x15 / lysis))))


# ::id PMC4455068.288
# ::snt PC3 cells expressing Flag-tagged WT or T220V mutant (T220V) Smad2 were starved overnight, followed by treatment for 1 h with Activin A±LY.
# ::tok PC3 cells expressing Flag @-@ tagged WT or T220V mutant ( T220V ) Smad2 were starved overnight , followed by treatment for 1 h with Activin A±LY .
(x16 / starve-01
      :ARG0 (x2 / cell-line
            :name (x1 / name :op1 "PC3")
            :ARG1-of (x3 / express-03
                  :ARG2 (x9 / or
                        :op1 (x4 / enzyme
                              :ARG1-of (x7 / tag-01
                                    :ARG2 (x5 / protein
                                          :name (x6 / name :op1 "Flag")))
                              :mod (x8 / wild-type))
                        :op2 (x11 / enzyme
                              :name (x10 / name :op1 "T220V")
                              :ARG2-of (x12 / mutate-01)
                              :ARG1-of (x13 / mutate-01 :value "T220V")))))
      :ARG1 (x14 / protein
            :name (x15 / name :op1 "Smad2")
            :xref (x / xref :value "UNIPROT:SMAD2_HUMAN" :prob "1.003"))
      :time (x17 / overnight)
      :ARG1-of (x18 / follow-01
            :ARG1 (x19 / treat-04
                  :duration (x20 / temporal-quantity
                        :quant "1"
                        :unit (x21 / hour))
                  :ARG2 (x22 / protein
                        :name (x23 / name :op1 "Activin" :op2 "A±LY")))))


# ::id PMC4455068.289
# ::snt hESCs in g and i were treated with Activin A for 2 days before the analysis, and data represent mean±s.d. from at least six measurements of two independent experiments.
# ::tok hESCs in g and i were treated with Activin A for 2 days before the analysis , and data represent mean±s.d . from at least six measurements of two independent experiments .
(x13 / and
      :op1 (x6 / treat-04
            :ARG1 (x3 / and
                  :op1 (x1 / protein
                        :name (x2 / name :op1 "g")
                        :xref (x / xref :value "UNIPROT:G_CSF_HUMAN_DNA" :prob "1.001"))
                  :op2 (x4 / enzyme
                        :name (x5 / name :op1 "i")))
            :ARG2 (x7 / protein
                  :name (x8 / name :op1 "Activin" :op2 "A"))
            :duration (x9 / temporal-quantity
                  :quant "2"
                  :unit (x10 / day)
                  :time (x11 / before
                        :op1 (x12 / analyze-01))))
      :op2 (x15 / represent-01
            :ARG0 (x14 / data)
            :ARG1 (x16 / enzyme
                  :name (x17 / name :op1 "mean±s.d"))
            :ARG2 (x18 / person
                  :quant (x19 / at-least :op1 "6")
                  :ARG0-of (x20 / measure-01
                        :ARG1 (x22 / experiment
                              :quant "2"
                              :ARG0-of (x21 / depend-01 :polarity "-"))))))


# ::id PMC4455068.290
# ::snt Phosphorylation of Smad2/3 linker residues are differentially regulated by various signalling pathways.
# ::tok Phosphorylation of Smad2 @/@ 3 linker residues are differentially regulated by various signalling pathways .
(x7 / regulate-01
      :ARG0 (x1 / phosphorylate-01
            :ARG1 (x2 / protein-segment
                  :name (x3 / name :op1 "Smad2/3")
                  :ARG0-of (x4 / link-01)))
      :ARG1 (x5 / residue)
      :mod (x6 / differential)
      :ARG0 (x10 / pathway
            :mod (x8 / various)
            :ARG0-of (x9 / signal-07)))


# ::id PMC4455068.292
# ::snt The protein mixtures were then resolved by SDS–polyacrylamide gel electrophoresis and analysed by immunoblotting with indicated antibodies.
# ::tok The protein mixtures were then resolved by SDS–polyacrylamide gel electrophoresis and analysed by immunoblotting with indicated antibodies .
(x7 / and
      :op1 (x4 / resolve-03
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "protein" :op2 "mixtures"))
            :time (x3 / then)
            :ARG3 (x6 / electrophoresis
                  :name (x5 / name :op1 "gel")))
      :op2 (x8 / analyze-01
            :manner (x9 / immunoblot-01
                  :ARG3 (x11 / antibody
                        :ARG1-of (x10 / indicate-01)))))


# ::id PMC4455068.293
# ::snt Commercially bought Erk2 and GST-GSK3 were used as positive controls.
# ::tok Commercially bought Erk2 and GST @-@ GSK3 were used as positive controls .
(x8 / use-01
      :ARG1 (x2 / buy-01
            :mod (x1 / commercial)
            :ARG1 (x5 / and
                  :op1 (x3 / enzyme
                        :name (x4 / name :op1 "Erk2")
                        :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.603"))
                  :op2 (x6 / protein
                        :name (x7 / name :op1 "GST-GSK3"))))
      :ARG2 (x10 / control
            :mod (x9 / positive)))


# ::id PMC4455068.294
# ::snt HI represents co-treatment with heregulin and IGF-1.
# ::tok HI represents co @-@ treatment with heregulin and IGF @-@ 1 .
(x6 / and
      :op1 (x2 / represent-01
            :ARG1 (x1 / hi)
            :ARG1-of (x3 / treat-04
                  :ARG2 (x4 / protein
                        :name (x5 / name :op1 "heregulin")
                        :xref (x9 / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.703"))))
      :op2 (x7 / protein
            :name (x8 / name :op1 "IGF-1")
            :xref (x / xref :value "UNIPROT:IGF1_HUMAN" :prob "0.673")))


# ::id PMC4455068.295
# ::snt mTORC2 regulates Smad2/3 activity by modulating the phosphorylation of T220/T179 residue.
# ::tok mTORC2 regulates Smad2 @/@ 3 activity by modulating the phosphorylation of T220 @/@ T179 residue .
(x3 / regulate-01
      :ARG0 (x1 / macro-molecular-complex
            :name (x2 / name :op1 "mTORC2"))
      :ARG1 (x6 / activity-06
            :ARG1 (x4 / protein
                  :name (x5 / name :op1 "Smad2/3"))
            :ARG0 (x7 / modulate-01
                  :ARG0 (x8 / phosphorylate-01
                        :ARG1 (x13 / residue
                              :mod (x9 / amino-acid
                                    :mod "220"
                                    :name (x10 / name :op1 "threonine")
                                    :xref (x / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :mod (x11 / amino-acid
                                    :mod "179"
                                    :name (x12 / name :op1 "threonine")
                                    :xref (x14 / xref :value "PUBCHEM:205" :prob "11.848252")))))))


# ::id PMC4455068.296
# ::snt PC3 cells were treated with rapamycin in the presence of Activin A or HI for 6 h and then harvested for immunoblot with indicated antibodies.
# ::tok PC3 cells were treated with rapamycin in the presence of Activin A or HI for 6 h and then harvested for immunoblot with indicated antibodies .
(x14 / and
      :op1 (x3 / treat-04
            :ARG1 (x2 / cell-line
                  :name (x1 / name :op1 "PC3"))
            :ARG2 (x4 / small-molecule
                  :name (x5 / name :op1 "rapamycin")
                  :xref (x20 / xref :value "PUBCHEM:5040" :prob "15.003454"))
            :condition (x6 / present-02
                  :ARG1 (x9 / or
                        :op1 (x7 / protein
                              :name (x8 / name :op1 "Activin")
                              :xref (x19 / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283"))
                        :op2 (x10 / enzyme
                              :name (x11 / name :op1 "HI")
                              :xref (x / xref :value "UNIPROT:AKAP4_HUMAN" :prob "1.002"))))
            :duration (x12 / temporal-quantity
                  :quant "6"
                  :unit (x13 / hour)))
      :op2 (x15 / harvest-01
            :ARG1 (x16 / immunoblot-01
                  :ARG3 (x18 / antibody
                        :ARG1-of (x17 / indicate-01)))))


# ::id PMC4455068.297
# ::snt Immunoblot of PC3 cells treated similar as in a but replacing rapamycin with Torin-2 (Torin).
# ::tok Immunoblot of PC3 cells treated similar as in a but replacing rapamycin with Torin @-@ 2 ( Torin ) .
(x6 / resemble-01
      :ARG0 (x1 / immunoblot-01
            :ARG1 (x3 / cell-line
                  :name (x2 / name :op1 "PC3")
                  :ARG1-of (x4 / treat-04)))
      :ARG1-of (x5 / resemble-01)
      :ARG1-of (x7 / contrast-01
            :ARG2 (x8 / replace-01))
      :ARG2 (x9 / protein
            :name (x10 / name :op1 "Torin-2"))
      :ARG1-of (x11 / describe-01
            :ARG2 (x12 / name :op1 "Torin")))


# ::id PMC4455068.298
# ::snt Ectopic expression of human rictor in rictor null MEF reverted the levels of Smad2/3-pT220/T179.
# ::tok Ectopic expression of human rictor in rictor null MEF reverted the levels of Smad2 @/@ 3 @-@ pT220/T179 .
(x10 / revert-01
      :ARG0 (x2 / express-03
            :mod (x1 / ectopic)
            :ARG2 (x3 / protein
                  :mod (x4 / human)
                  :name (x5 / name :op1 "rictor")
                  :location (x7 / protein
                        :name (x6 / name :op1 "rictor")
                        :ARG2-of (x8 / mutate-01 :mod "-/-")
                        :xref (x15 / xref :value "UNIPROT:RICTR_HUMAN" :prob "0.602"))
                  :name (x9 / name :op1 "MEF")
                  :xref (x14 / xref :value "UNIPROT:ELF4_HUMAN" :prob "1.002")))
      :ARG1 (x11 / level
            :quant-of (x12 / protein
                  :name (x13 / name :op1 "Smad2/3" :op2 "pT220/T179"))))


# ::id PMC4455068.299
# ::snt hESCs in f were treated with Activin A for 2 days before the analysis and data represent mean±s.d. from at least six measurements of two independent experiments.
# ::tok hESCs in f were treated with Activin A for 2 days before the analysis and data represent mean±s.d . from at least six measurements of two independent experiments .
(x10 / and
      :op1 (x3 / treat-04
            :ARG1 (x1 / protein
                  :name (x2 / name :op1 "f-actin")
                  :xref (x / xref :value "UNIPROT:NEXN_HUMAN" :prob "0.232"))
            :ARG2 (x4 / protein
                  :name (x5 / name :op1 "Activin" :op2 "A"))
            :duration (x6 / temporal-quantity
                  :quant "2"
                  :unit (x7 / day)
                  :time (x8 / before
                        :op1 (x9 / analyze-01))))
      :op2 (x12 / represent-01
            :ARG0 (x11 / data)
            :ARG1 (x13 / enzyme
                  :name (x14 / name :op1 "mean±s.d"))
            :ARG2 (x15 / person
                  :quant (x16 / at-least :op1 "6")
                  :ARG0-of (x17 / measure-01
                        :ARG1 (x19 / experiment
                              :quant "2"
                              :ARG0-of (x18 / depend-01 :polarity "-"))))))


# ::id PMC4455068.301
# ::snt The protein mixtures were then resolved by SDS–polyacrylamide gel electrophoresis and analysed by immunoblot.
# ::tok The protein mixtures were then resolved by SDS–polyacrylamide gel electrophoresis and analysed by immunoblot .
(x7 / and
      :op1 (x4 / resolve-03
            :ARG1 (x1 / enzyme
                  :name (x2 / name :op1 "protein" :op2 "mixtures"))
            :time (x3 / then)
            :ARG3 (x6 / electrophoresis
                  :name (x5 / name :op1 "gel")))
      :op2 (x8 / analyze-01
            :manner (x9 / immunoblot-01)))


# ::id PMC4455068.302
# ::snt Inhibition of mTOR enhances DE differentiation of hESCs.
# ::tok Inhibition of mTOR enhances DE differentiation of hESCs .
(x4 / enhance-01
      :ARG0 (x1 / inhibit-01
            :ARG1 (x2 / protein
                  :name (x3 / name :op1 "mTOR")
                  :xref (x / xref :value "UNIPROT:MTOR_HUMAN" :prob "1.004")))
      :ARG1 (x7 / differentiate-01
            :ARG0 (x5 / enzyme
                  :name (x6 / name :op1 "DE"))
            :ARG1 (x8 / cell-line
                  :name (x9 / name :op1 "hESCs"))))


# ::id PMC4455068.304
# ::snt Scale bar, 100 μm.
# ::tok Scale bar , 100 μm .
(x1 / bar
      :mod (x2 / distance-quantity
            :quant "100"
            :unit (x3 / micrometer)))


# ::id PMC4455068.305
# ::snt Days of differentiation are indicated.
# ::tok Days of differentiation are indicated .
(x3 / indicate-01
      :mod (x1 / day)
      :ARG1 (x2 / differentiate-01))


# ::id PMC4455068.307
# ::snt Model depicting a possible mechanism accounting for the inhibitory effect of PI3K/mTORC2 on the Activin-induced DE differentiation of hESCs.
# ::tok Model depicting a possible mechanism accounting for the inhibitory effect of PI3K @/@ mTORC2 on the Activin @-@ induced DE differentiation of hESCs .
(x16 / and
      :op1 (x1 / model
            :ARG1-of (x2 / depict-01
                  :ARG1 (x4 / mechanism
                        :ARG1-of (x3 / possible-01)
                        :ARG0-of (x5 / account-01
                              :ARG1 (x7 / affect-01
                                    :ARG2 (x6 / inhibit-01)
                                    :ARG0 (x8 / and
                                          :op1 (x9 / enzyme
                                                :name (x10 / name :op1 "PI3K")
                                                :xref (x20 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
                                          :op2 (x11 / macro-molecular-complex
                                                :name (x12 / name :op1 "mTORC2")))
                                    :ARG1 (x15 / induce-01
                                          :ARG0 (x13 / protein
                                                :name (x14 / name :op1 "Activin")
                                                :xref (x / xref :value "UNIPROT:INHBA_HUMAN" :prob "0.283"))))))))
      :op2 (x17 / differentiate-01
            :ARG1 (x18 / protein
                  :name (x19 / name :op1 "hESCs"))))


# ::id PMC5341140001.1
# ::snt Expression of wild type Gab1 rescues EGF-induced PI-3 kinase and Akt activation in Gab1 deficient MEFs.
# ::tok Expression of wild type Gab1 rescues EGF @-@ induced PI @-@ 3 kinase and Akt activation in Gab1 deficient MEFs .
(x5 / rescue-01
      :ARG0 (x1 / express-03
            :ARG2 (x2 / enzyme
                  :mod (x3 / wild-type)
                  :name (x4 / name :op1 "Gab1")
                  :xref (x21 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
      :ARG1 (x14 / activate-01
            :ARG2-of (x8 / induce-01
                  :ARG0 (x6 / protein
                        :name (x7 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x11 / and
                  :op1 (x10 / kinase
                        :name (x9 / name :op1 "PI-3"))
                  :op2 (x12 / enzyme
                        :name (x13 / name :op1 "Akt")
                        :xref (x22 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
      :location (x17 / protein
            :mod (x15 / protein
                  :name (x16 / name :op1 "Gab1")
                  :xref (x20 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG2-of (x18 / mutate-01 :mod "-/-")
            :name (x19 / name :op1 "mef")
            :xref (x23 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))


# ::id PMC5341140001.2
# ::snt The indicated cell lines were serum-starved for 24 hours and stimulated with 10 ng/ml EGF for five minutes at 37°C.
# ::tok The indicated cell lines were serum @-@ starved for 24 hours and stimulated with 10 ng @/@ ml EGF for five minutes at 37 °C .
(x4 / starve-01
      :ARG1 (x2 / cell-line
            :ARG1-of (x1 / indicate-01))
      :ARG2 (x3 / serum)
      :duration (x5 / temporal-quantity
            :quant "24"
            :unit (x6 / hour))
      :time (x7 / and
            :op1 (x8 / stimulate-01
                  :ARG2 (x9 / protein
                        :quant (x10 / concentration-quantity
                              :quant "10"
                              :unit (x11 / nanogram-per-milliliter))
                        :name (x12 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
      :duration (x13 / temporal-quantity
            :quant "5"
            :unit (x14 / minute))
      :mod (x15 / temperature-quantity
            :quant "37"
            :scale (x16 / celsius)))


# ::id PMC5341140001.3
# ::snt Cell extracts were prepared and analyzed for Gab1 tyrosine phosphorylation and Gab1 expression.
# ::tok Cell extracts were prepared and analyzed for Gab1 tyrosine phosphorylation and Gab1 expression .
(x4 / and
      :op1 (x3 / prepare-02
            :ARG1 (x2 / extract-01
                  :ARG1 (x1 / cell)))
      :op2 (x5 / analyze-01
            :ARG1 (x10 / phosphorylate-01
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "Gab1")
                        :xref (x15 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG2 (x8 / enzyme
                        :name (x9 / name :op1 "tyrosine")
                        :xref (x / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))))
      :op2 (x13 / express-03
            :ARG2 (x11 / protein
                  :name (x12 / name :op1 "Gab1")
                  :xref (x14 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))


# ::id PMC5341140001.4
# ::snt Both WT MEFs and cells expressing exogenous Gab1 show Gab1 tyrosine phosphorylation in response to EGF treatment.
# ::tok Both WT MEFs and cells expressing exogenous Gab1 show Gab1 tyrosine phosphorylation in response to EGF treatment .
(x1 / and
      :op1 (x2 / enzyme
            :mod (x3 / wild-type)
            :name (x4 / name :op1 "mef")
            :xref (x21 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
      :op2 (x10 / show-01
            :ARG0 (x5 / cell
                  :ARG3-of (x6 / express-03
                        :ARG2 (x7 / protein
                              :mod (x8 / exogenous)
                              :name (x9 / name :op1 "Gab1")
                              :xref (x22 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :ARG1 (x15 / phosphorylate-01
                  :ARG0 (x11 / protein
                        :name (x12 / name :op1 "Gab1")
                        :xref (x20 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG1 (x13 / amino-acid
                        :name (x14 / name :op1 "tyrosine")
                        :xref (x23 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2-of (x16 / respond-01
                        :ARG1 (x19 / treat-04
                              :ARG2 (x17 / protein
                                    :name (x18 / name :op1 "EGF")
                                    :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))))


# ::id PMC5341140001.5
# ::snt The indicated cell lines were serum-starved for 24 hours and stimulated with 10 ng/ml EGF for five minutes at 37°C.
# ::tok The indicated cell lines were serum @-@ starved for 24 hours and stimulated with 10 ng @/@ ml EGF for five minutes at 37 °C .
(x4 / starve-01
      :ARG1 (x2 / cell-line
            :ARG1-of (x1 / indicate-01))
      :ARG2 (x3 / serum)
      :duration (x5 / temporal-quantity
            :quant "24"
            :unit (x6 / hour))
      :time (x7 / and
            :op1 (x8 / stimulate-01
                  :ARG2 (x9 / protein
                        :quant (x10 / concentration-quantity
                              :quant "10"
                              :unit (x11 / nanogram-per-milliliter))
                        :name (x12 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
      :duration (x13 / temporal-quantity
            :quant "5"
            :unit (x14 / minute))
      :mod (x15 / temperature-quantity
            :quant "37"
            :scale (x16 / celsius)))


# ::id PMC5341140001.6
# ::snt Cell extracts were analyzed for Gab1 tyrosine phosphorylation and Gab1 expression.
# ::tok Cell extracts were analyzed for Gab1 tyrosine phosphorylation and Gab1 expression .
(x3 / analyze-01
      :ARG1 (x2 / extract-01
            :ARG1 (x1 / cell))
      :purpose (x12 / express-03
            :ARG2 (x9 / and
                  :op1 (x4 / enzyme
                        :name (x5 / name :op1 "Gab1")
                        :ARG2-of (x8 / phosphorylate-01
                              :ARG1 (x6 / enzyme
                                    :name (x7 / name :op1 "tyrosine")
                                    :xref (x13 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352")))
                        :xref (x14 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :op2 (x10 / protein
                        :name (x11 / name :op1 "Gab1")
                        :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))


# ::id PMC5341140001.7
# ::snt Cells rescued with wild type Gab1 exhibit Gab1 tyrosine phosphorylation in response to EGF treatment, while Gab1 -/- cells and Gab1-deficient cells expressing ErbB3 do not.
# ::tok Cells rescued with wild type Gab1 exhibit Gab1 tyrosine phosphorylation in response to EGF treatment , while Gab1 -/- cells and Gab1 @-@ deficient cells expressing ErbB3 do not .
(x16 / contrast-01
      :ARG1 (x6 / exhibit-01
            :ARG0 (x1 / cell
                  :ARG1-of (x2 / rescue-01
                        :ARG0 (x3 / enzyme
                              :mod (x4 / wild-type)
                              :name (x5 / name :op1 "Gab1")
                              :xref (x31 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :ARG1 (x11 / phosphorylate-01
                  :ARG2 (x7 / protein
                        :name (x8 / name :op1 "Gab1")
                        :xref (x32 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG1 (x9 / amino-acid
                        :name (x10 / name :op1 "tyrosine")
                        :xref (x35 / xref :value "PUBCHEM:1153" :prob "11.081481"))
                  :ARG2-of (x12 / respond-01
                        :ARG1 (x15 / treat-04
                              :ARG2 (x13 / protein
                                    :name (x14 / name :op1 "EGF")
                                    :xref (x33 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))
      :ARG2 (x29 / do-02
            :ARG1 (x21 / and
                  :op1 (x20 / cell
                        :mod (x17 / protein
                              :name (x18 / name :op1 "Gab1")
                              :ARG2-of (x19 / mutate-01 :mod "-/-")
                              :xref (x34 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :op2 (x24 / lack-01
                        :ARG1 (x22 / protein
                              :name (x23 / name :op1 "Gab1")
                              :xref (x30 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :ARG0 (x25 / cell
                  :ARG3-of (x26 / express-03
                        :ARG2 (x27 / protein
                              :name (x28 / name :op1 "ErbB3")
                              :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))))
            :polarity "-"))


# ::id PMC5341140001.8
# ::snt MEFs derived from Gab1-/- or wild type (WT) embryos were stimulated with EGF and assayed for Gab1 tyrosine phosphorylation, for activation of PI-3 kinase and for Akt stimulation.
# ::tok MEFs derived from Gab1-/- or wild type ( WT ) embryos were stimulated with EGF and assayed for Gab1 tyrosine phosphorylation , for activation of PI @-@ 3 kinase and for Akt stimulation .
(x12 / and
      :op1 (x9 / stimulate-01
            :ARG1 (x1 / cell
                  :name (x2 / name :op1 "mef")
                  :ARG1-of (x3 / derive-01
                        :ARG2 (x6 / or
                              :op1 (x4 / enzyme
                                    :name (x5 / name :op1 "Gab1-/-"))
                              :op2 (x8 / embryo
                                    :mod (x7 / wild-type)))))
            :ARG2 (x10 / protein
                  :name (x11 / name :op1 "EGF")
                  :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :op2 (x13 / assay-01
            :purpose (x22 / and
                  :op1 (x18 / phosphorylate-01
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "Gab1")
                              :xref (x27 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :ARG1 (x16 / enzyme
                              :name (x17 / name :op1 "tyrosine")
                              :xref (x28 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
                        :ARG2 (x19 / activate-01
                              :ARG1 (x21 / kinase
                                    :name (x20 / name :op1 "PI-3"))))
                  :op2 (x25 / stimulate-01
                        :ARG1 (x23 / enzyme
                              :name (x24 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))))


# ::id PMC5341140001.9
# ::snt As shown in Figure 1A, the endogenous Gab1 present in WT MEFs is tyrosine phosphorylated in response to EGF treatment.
# ::tok As shown in Figure 1A , the endogenous Gab1 present in WT MEFs is tyrosine phosphorylated in response to EGF treatment .
(x1 / show-01
      :ARG0 (x2 / figure :mod "1a")
      :ARG1 (x6 / present-02
            :ARG1 (x3 / enzyme
                  :mod (x4 / endogenous)
                  :name (x5 / name :op1 "Gab1")
                  :xref (x18 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG2 (x12 / phosphorylate-01
                  :ARG1 (x7 / enzyme
                        :mod (x8 / wild-type)
                        :name (x9 / name :op1 "mef")
                        :xref (x19 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
                  :ARG2 (x10 / enzyme
                        :name (x11 / name :op1 "tyrosine")
                        :xref (x17 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
                  :ARG2-of (x13 / respond-01
                        :ARG1 (x16 / treat-04
                              :ARG2 (x14 / protein
                                    :name (x15 / name :op1 "EGF")
                                    :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))))


# ::id PMC5341140002.1
# ::snt Cells were additionally stimulated with 10 ng/ml NRG and cell extracts analyzed for ErbB3 tyrosine phosphorylation.
# ::tok Cells were additionally stimulated with 10 ng @/@ ml NRG and cell extracts analyzed for ErbB3 tyrosine phosphorylation .
(x10 / analyze-01
      :ARG1 (x1 / cell)
      :manner (x2 / and
            :op1 (x3 / stimulate-01
                  :ARG2 (x4 / protein
                        :quant (x5 / concentration-quantity
                              :quant "10"
                              :unit (x6 / nanogram-per-milliliter))
                        :name (x7 / name :op1 "NRG")
                        :xref (x16 / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.263")))
            :op2 (x9 / extract-01
                  :ARG1 (x8 / cell)))
      :purpose (x15 / phosphorylate-01
            :ARG1 (x11 / amino-acid
                  :part-of (x12 / protein
                        :name (x13 / name :op1 "ErbB3")
                        :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
                  :name (x14 / name :op1 "tyrosine")
                  :xref (x17 / xref :value "PUBCHEM:1153" :prob "11.081481"))))


# ::id PMC5341140002.2
# ::snt The endogenous EGFR is tyrosine phosphorylated in response to EGF in all cell lines.
# ::tok The endogenous EGFR is tyrosine phosphorylated in response to EGF in all cell lines .
(x6 / phosphorylate-01
      :ARG1 (x1 / enzyme
            :mod (x2 / endogenous)
            :name (x3 / name :op1 "EGFR")
            :xref (x12 / xref :value "UNIPROT:EGFR_HUMAN" :prob "1.004"))
      :ARG1 (x4 / enzyme
            :name (x5 / name :op1 "tyrosine")
            :xref (x13 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
      :ARG2-of (x7 / respond-01
            :ARG1 (x8 / protein
                  :name (x9 / name :op1 "EGF")
                  :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :location (x11 / cell-line
            :mod (x10 / all)))


# ::id PMC5341140002.3
# ::snt ErbB3 exhibits weak constitutive tyrosine phosphorylation that is enhanced by NRG treatment, but is not significantly enhanced by treatment with EGF.
# ::tok ErbB3 exhibits weak constitutive tyrosine phosphorylation that is enhanced by NRG treatment , but is not significantly enhanced by treatment with EGF .
(x13 / contrast-01
      :ARG1 (x3 / exhibit-01
            :ARG0 (x1 / protein
                  :name (x2 / name :op1 "ErbB3")
                  :xref (x19 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
            :ARG1 (x8 / phosphorylate-01
                  :ARG1-of (x4 / weak-02)
                  :mod (x5 / constitutive)
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "tyrosine")
                        :xref (x20 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
                  :ARG1-of (x9 / enhance-01
                        :ARG0 (x12 / treat-04
                              :ARG2 (x10 / protein
                                    :name (x11 / name :op1 "NRG")
                                    :xref (x / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.263"))))))
      :ARG2 (x15 / enhance-01
            :polarity "-"
            :ARG1-of (x14 / significant-02)
            :ARG0 (x16 / treat-04
                  :ARG2 (x17 / small-molecule
                        :name (x18 / name :op1 "EGF")
                        :xref (x21 / xref :value "PUBCHEM:56841751" :prob "18.167522")))))


# ::id PMC5341140002.4
# ::snt Cells expressing ErbB3 show tyrosine phosphorylation in response to treatment with NRG (Figure 4A, upper and middle right panels).
# ::tok Cells expressing ErbB3 show tyrosine phosphorylation in response to treatment with NRG ( Figure 4A , upper and middle right panels ) .
(x5 / show-01
      :ARG0 (x1 / cell
            :ARG3-of (x2 / express-03
                  :ARG2 (x3 / protein
                        :name (x4 / name :op1 "ErbB3")
                        :xref (x20 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))))
      :ARG1 (x8 / phosphorylate-01
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "tyrosine")
                  :xref (x21 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
            :ARG2-of (x9 / respond-01
                  :ARG1 (x10 / treat-04
                        :ARG2 (x11 / protein
                              :name (x12 / name :op1 "NRG")
                              :xref (x / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.263")))))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure
                  :mod "4a"
                  :location (x15 / and
                        :op1 (x16 / cell-line
                              :name (x17 / name :op1 "middle"))
                        :op2 (x19 / panel
                              :ARG1-of (x18 / right-04))))))


# ::id PMC5341140002.5
# ::snt While ErbB3 is relatively ineffective at mediating EGF-stimulation of PI-3 kinase activation, it is an efficient mediator of PI-3 kinase stimulation in response to NRG stimulation.
# ::tok While ErbB3 is relatively ineffective at mediating EGF @-@ stimulation of PI @-@ 3 kinase activation , it is an efficient mediator of PI @-@ 3 kinase stimulation in response to NRG stimulation .
(x14 / mediate-01
      :ARG1 (x1 / contrast-01
            :ARG1 (x5 / effective-04
                  :ARG0 (x2 / protein
                        :name (x3 / name :op1 "ErbB3")
                        :xref (x22 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
                  :ARG1-of (x4 / relative-05)
                  :polarity "-")
            :ARG2 (x6 / mediate-01
                  :ARG1 (x9 / stimulate-01
                        :ARG0 (x7 / protein
                              :name (x8 / name :op1 "EGF")
                              :xref (x23 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                        :ARG1 (x12 / activate-01
                              :ARG1 (x11 / kinase
                                    :name (x10 / name :op1 "PI-3"))))))
      :ARG2-of (x13 / efficient-01)
      :ARG1 (x17 / stimulate-01
            :ARG0 (x15 / protein
                  :name (x16 / name :op1 "PI-3" :op2 "kinase")))
      :ARG2-of (x18 / respond-01
            :ARG1 (x21 / stimulate-01
                  :ARG0 (x19 / protein
                        :name (x20 / name :op1 "NRG")
                        :xref (x / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.263")))))


# ::id PMC5341140003.1
# ::snt The indicated cell lines were serum-starved for 24 hours and stimulated with 10 ng/ml EGF for five minutes at 37°C.
# ::tok The indicated cell lines were serum @-@ starved for 24 hours and stimulated with 10 ng @/@ ml EGF for five minutes at 37 °C .
(x4 / starve-01
      :ARG1 (x2 / cell-line
            :ARG1-of (x1 / indicate-01))
      :ARG2 (x3 / serum)
      :duration (x5 / temporal-quantity
            :quant "24"
            :unit (x6 / hour))
      :time (x7 / and
            :op1 (x8 / stimulate-01
                  :ARG2 (x9 / protein
                        :quant (x10 / concentration-quantity
                              :quant "10"
                              :unit (x11 / nanogram-per-milliliter))
                        :name (x12 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))
      :duration (x13 / temporal-quantity
            :quant "5"
            :unit (x14 / minute))
      :mod (x15 / temperature-quantity
            :quant "37"
            :scale (x16 / celsius)))


# ::id PMC5341140003.2
# ::snt Cell extracts were prepared and analyzed for Gab1 tyrosine phosphorylation, Gab1 co-immunoprecipitation with p85, p85 expression, Gab1 co-immunoprecipitation with Shp2, and Gab1 expression.
# ::tok Cell extracts were prepared and analyzed for Gab1 tyrosine phosphorylation , Gab1 co @-@ immunoprecipitation with p85 , p85 expression , Gab1 co @-@ immunoprecipitation with Shp2 , and Gab1 expression .
(x4 / and
      :op1 (x3 / prepare-02
            :ARG1 (x2 / extract-01
                  :ARG1 (x1 / cell)))
      :op2 (x5 / analyze-01
            :purpose (x6 / protein
                  :name (x7 / name :op1 "Gab1")
                  :xref (x27 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG2 (x10 / phosphorylate-01
                  :ARG1 (x8 / amino-acid
                        :name (x9 / name :op1 "tyrosine")
                        :xref (x31 / xref :value "PUBCHEM:1153" :prob "11.081481")))
            :ARG1 (x19 / and
                  :op1 (x13 / immunoprecipitate-01
                        :ARG0 (x11 / protein
                              :name (x12 / name :op1 "Gab1")
                              :xref (x28 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "p85")
                              :xref (x29 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003")))
                  :op2 (x18 / express-03
                        :ARG2 (x16 / enzyme
                              :name (x17 / name :op1 "p85")
                              :xref (x30 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003")))
                  :op2 (x20 / coimmunoprecipitate-01
                        :ARG1 (x21 / enzyme
                              :name (x22 / name :op1 "Shp2")
                              :xref (x / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003")))))
      :op2 (x25 / express-03
            :ARG2 (x23 / protein
                  :name (x24 / name :op1 "Gab1")
                  :xref (x26 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))


# ::id PMC5341140003.3
# ::snt Both Gab1 and Gab1F446/472/589 are tyrosine phosphorylated in response to EGF treatment, and both form a stable complex with Shp2.
# ::tok Both Gab1 and Gab1F446 @/@ 472 @/@ 589 are tyrosine phosphorylated in response to EGF treatment , and both form a stable complex with Shp2 .
(x16 / and
      :op1 (x11 / phosphorylate-01
            :ARG1 (x1 / and
                  :op1 (x2 / protein
                        :name (x3 / name :op1 "Gab1")
                        :xref (x23 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :op2 (x6 / slash
                        :op1 (x4 / enzyme
                              :name (x5 / name :op1 "Gab1F446")
                              :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.203"))
                        :op2 (x7 / enzyme
                              :name (x8 / name :op1 "472"))
                        :op2 "589"))
            :mod (x9 / amino-acid
                  :name (x10 / name :op1 "tyrosine")
                  :xref (x26 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :ARG2-of (x12 / respond-01
                  :ARG1 (x15 / treat-04
                        :ARG2 (x13 / protein
                              :name (x14 / name :op1 "EGF")
                              :xref (x25 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))
      :op2 (x17 / and
            :op1 (x18 / form-01
                  :ARG1 (x20 / macro-molecular-complex
                        :ARG1-of (x19 / stable-03))
                  :ARG2 (x21 / enzyme
                        :name (x22 / name :op1 "Shp2")
                        :xref (x / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003")))))


# ::id PMC5341140003.4
# ::snt However, Gab1F446/472/589 fails to associate with the p85 subunit of PI-3 kinase.
# ::tok However , Gab1F446 @/@ 472 @/@ 589 fails to associate with the p85 subunit of PI @-@ 3 kinase .
(x1 / have-concession-91
      :ARG1 (x7 / fail-01
            :ARG1 (x4 / slash
                  :op1 (x2 / enzyme
                        :name (x3 / name :op1 "Gab1F446")
                        :xref (x14 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.203"))
                  :op2 (x5 / enzyme
                        :name (x6 / name :op1 "472"))
                  :op2 "589")
            :ARG2 (x8 / associate-01
                  :ARG2 (x11 / subunit
                        :mod (x9 / protein
                              :name (x10 / name :op1 "p85")
                              :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))
                        :part-of (x13 / kinase
                              :name (x12 / name :op1 "PI-3"))))))


# ::id PMC5341140003.5
# ::snt The indicated cell lines were serum-starved for 24 hours and stimulated with 100 ng/ml EGF for five minutes at 37°C.
# ::tok The indicated cell lines were serum @-@ starved for 24 hours and stimulated with 100 ng @/@ ml EGF for five minutes at 37 °C .
(x4 / starve-01
      :ARG1 (x2 / cell-line
            :ARG1-of (x1 / indicate-01))
      :ARG2 (x3 / serum)
      :duration (x5 / temporal-quantity
            :quant "24"
            :unit (x6 / hour))
      :time (x7 / and
            :op1 (x8 / stimulate-01
                  :ARG2 (x9 / small-molecule
                        :quant (x10 / concentration-quantity
                              :quant "100"
                              :unit (x11 / nanogram-per-milliliter))
                        :name (x12 / name :op1 "EGF")
                        :xref (x / xref :value "PUBCHEM:56841751" :prob "18.167522"))))
      :duration (x13 / temporal-quantity
            :quant "5"
            :unit (x14 / minute))
      :mod (x15 / temperature-quantity
            :quant "37"
            :scale (x16 / celsius)))


# ::id PMC5341140003.6
# ::snt Cell extracts were prepared and phosphotyrosine immunoprecipitates were analyzed for PI-3 kinase activity.
# ::tok Cell extracts were prepared and phosphotyrosine immunoprecipitates were analyzed for PI @-@ 3 kinase activity .
(x4 / and
      :op1 (x3 / prepare-02
            :ARG1 (x2 / extract-01
                  :ARG1 (x1 / cell)))
      :op2 (x5 / amino-acid
            :name (x6 / name :op1 "threonine")
            :ARG3-of (x7 / phosphorylate-01)
            :xref (x / xref :value "PUBCHEM:205" :prob "11.848252"))
      :op2 (x9 / analyze-01
            :ARG1 (x8 / immunoprecipitate-01)
            :purpose (x12 / activity-06
                  :ARG0 (x11 / kinase
                        :name (x10 / name :op1 "PI-3")))))


# ::id PMC5341140003.7
# ::snt Gab1 -/- cells fail to show phosphotyrosine-associated PI-3 kinase activity, while cells expressing exogenous Gab1 display phosphotyrosine-associated PI-3 kinase activity that is augmented by EGF treatment.
# ::tok Gab1 -/- cells fail to show phosphotyrosine @-@ associated PI @-@ 3 kinase activity , while cells expressing exogenous Gab1 display phosphotyrosine @-@ associated PI @-@ 3 kinase activity that is augmented by EGF treatment .
(x14 / contrast-01
      :ARG1 (x5 / fail-01
            :ARG1 (x4 / cell
                  :mod (x1 / protein
                        :name (x2 / name :op1 "Gab1")
                        :ARG2-of (x3 / mutate-01 :mod "-/-")
                        :xref (x32 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :ARG2 (x6 / show-01
                  :ARG1 (x13 / activity-06
                        :ARG0 (x12 / kinase
                              :ARG1-of (x10 / associate-01
                                    :ARG2 (x7 / amino-acid
                                          :name (x8 / name :op1 "threonine")
                                          :ARG3-of (x9 / phosphorylate-01)
                                          :xref (x35 / xref :value "PUBCHEM:205" :prob "11.848252")))
                              :name (x11 / name :op1 "PI-3")))))
      :ARG2 (x20 / display-01
            :ARG0 (x15 / cell
                  :ARG3-of (x16 / express-03
                        :ARG2 (x17 / protein
                              :mod (x18 / exogenous)
                              :name (x19 / name :op1 "Gab1")
                              :xref (x33 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :ARG1 (x28 / augment-01
                  :ARG1 (x27 / activity-06
                        :ARG0 (x26 / kinase
                              :ARG1-of (x24 / associate-01
                                    :ARG2 (x21 / amino-acid
                                          :name (x22 / name :op1 "threonine")
                                          :ARG3-of (x23 / phosphorylate-01)
                                          :xref (x34 / xref :value "PUBCHEM:205" :prob "11.848252")))
                              :name (x25 / name :op1 "PI-3")))
                  :ARG0 (x31 / treat-04
                        :ARG2 (x29 / protein
                              :name (x30 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))


# ::id PMC5341140003.8
# ::snt Expression of wild type Gab1 in Gab1-deficient MEFs rescues the EGF-induced PI-3 kinase activity.
# ::tok Expression of wild type Gab1 in Gab1 @-@ deficient MEFs rescues the EGF @-@ induced PI @-@ 3 kinase activity .
(x8 / rescue-01
      :ARG0 (x1 / express-03
            :ARG2 (x2 / enzyme
                  :mod (x3 / wild-type)
                  :name (x4 / name :op1 "Gab1")
                  :xref (x15 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG1 (x5 / protein
                  :name (x6 / name :op1 "Gab1")
                  :ARG2-of (x7 / mutate-01 :mod "-/-")
                  :xref (x16 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
      :ARG1 (x14 / activity-06
            :ARG0 (x13 / kinase
                  :ARG1-of (x11 / induce-01
                        :ARG0 (x9 / protein
                              :name (x10 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :name (x12 / name :op1 "PI-3"))))


# ::id PMC5341140003.9
# ::snt The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway.
# ::tok The docking protein Gab1 is the primary mediator of EGF @-@ stimulated activation of the PI @-@ 3K @/@ Akt cell survival pathway .
(x5 / mediate-01
      :domain (x2 / protein
            :ARG0-of (x1 / dock-01)
            :name (x3 / name :op1 "Gab1")
            :xref (x20 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
      :mod (x4 / primary)
      :ARG1 (x8 / stimulate-01
            :ARG0 (x6 / protein
                  :name (x7 / name :op1 "EGF")
                  :xref (x21 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
      :manner (x19 / pathway
            :ARG1-of (x9 / activate-01
                  :ARG0 (x10 / small-molecule
                        :name (x11 / name :op1 "pi-103")
                        :xref (x22 / xref :value "PUBCHEM:9884685" :prob "14.194942"))
                  :ARG1 (x14 / slash
                        :op1 (x12 / enzyme
                              :name (x13 / name :op1 "3K"))
                        :op2 (x15 / enzyme
                              :name (x16 / name :op1 "Akt")
                              :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
            :mod (x18 / survive-01
                  :ARG0 (x17 / cell))))


# ::id PMC5341140003.10
# ::snt We demonstrate that Gab1 is essential for EGF stimulation of PI-3 kinase and Akt in these cells and that these responses are mediated by complex formation between p85, the regulatory subunit of PI-3 kinase, and three canonical tyrosine phosphorylation sites on Gab1.
# ::tok We demonstrate that Gab1 is essential for EGF stimulation of PI @-@ 3 kinase and Akt in these cells and that these responses are mediated by complex formation between p85 , the regulatory subunit of PI @-@ 3 kinase , and three canonical tyrosine phosphorylation sites on Gab1 .
(x2 / demonstrate-01
      :ARG0 (x1 / we)
      :ARG1 (x16 / and
            :op1 (x5 / essential
                  :domain (x3 / protein
                        :name (x4 / name :op1 "Gab1")
                        :xref (x36 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :purpose (x8 / stimulate-01
                        :ARG1 (x6 / protein
                              :name (x7 / name :op1 "EGF")
                              :xref (x37 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                        :ARG1 (x11 / and
                              :op1 (x10 / kinase
                                    :name (x9 / name :op1 "PI-3"))
                              :op2 (x12 / enzyme
                                    :name (x13 / name :op1 "Akt")
                                    :xref (x39 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                        :location (x15 / cell
                              :mod (x14 / this))))
            :op2 (x20 / mediate-01
                  :ARG1 (x18 / thing
                        :mod (x17 / this)
                        :ARG2-of (x19 / respond-01))
                  :ARG1 (x22 / form-01
                        :ARG1 (x21 / macro-molecular-complex))
                  :ARG0 (x23 / enzyme
                        :name (x24 / name :op1 "p85")
                        :xref (x / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003"))))
      :ARG1 (x29 / and
            :op1 (x26 / subunit
                  :ARG0-of (x25 / regulate-01)
                  :part-of (x28 / kinase
                        :name (x27 / name :op1 "PI-3")))
            :op2 (x33 / protein-segment
                  :quant "3"
                  :mod (x30 / canonical
                        :name (x31 / name :op1 "tyrosine"))
                  :ARG1-of (x32 / phosphorylate-01)
                  :location (x34 / protein
                        :name (x35 / name :op1 "Gab1")
                        :xref (x38 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))))


# ::id PMC5341140003.11
# ::snt The canonical p85 binding sites on Gab1 are essential for PI-3 kinase and Akt activation in response to EGF stimulation.
# ::tok The canonical p85 binding sites on Gab1 are essential for PI @-@ 3 kinase and Akt activation in response to EGF stimulation .
(x7 / essential
      :domain (x4 / site
            :mod (x1 / canonical
                  :name (x2 / name :op1 "p85"))
            :ARG2-of (x3 / bind-01)
            :location (x5 / protein
                  :name (x6 / name :op1 "Gab1")
                  :xref (x19 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
      :purpose (x13 / activate-01
            :ARG1 (x10 / and
                  :op1 (x9 / kinase
                        :name (x8 / name :op1 "PI-3"))
                  :op2 (x11 / enzyme
                        :name (x12 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :ARG2-of (x14 / respond-01
                  :ARG1 (x17 / stimulate-01
                        :ARG0 (x15 / protein
                              :name (x16 / name :op1 "EGF")
                              :xref (x18 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))


# ::id PMC5341140003.12
# ::snt Taken together, these results demonstrate that Gab1 is required for EGF-stimulation of PI-3 kinase and Akt.
# ::tok Taken together , these results demonstrate that Gab1 is required for EGF @-@ stimulation of PI @-@ 3 kinase and Akt .
(x6 / demonstrate-01
      :ARG0 (x4 / thing
            :ARG1-of (x1 / take-01
                  :mod (x2 / together))
            :mod (x3 / this)
            :ARG2-of (x5 / result-01))
      :ARG1 (x9 / require-01
            :ARG0 (x7 / protein
                  :name (x8 / name :op1 "Gab1")
                  :xref (x19 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG0 (x12 / stimulate-01
                  :ARG0 (x10 / protein
                        :name (x11 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x15 / and
                  :op1 (x14 / kinase
                        :name (x13 / name :op1 "PI-3"))
                  :op2 (x16 / enzyme
                        :name (x17 / name :op1 "Akt")
                        :xref (x18 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))


# ::id PMC5341140004.1
# ::snt Taken together, these results demonstrate that Gab1 is required for EGF-stimulation of PI-3 kinase and Akt.
# ::tok Taken together , these results demonstrate that Gab1 is required for EGF @-@ stimulation of PI @-@ 3 kinase and Akt .
(x6 / demonstrate-01
      :ARG0 (x4 / thing
            :ARG1-of (x1 / take-01
                  :mod (x2 / together))
            :mod (x3 / this)
            :ARG2-of (x5 / result-01))
      :ARG1 (x9 / require-01
            :ARG0 (x7 / protein
                  :name (x8 / name :op1 "Gab1")
                  :xref (x19 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
            :ARG0 (x12 / stimulate-01
                  :ARG0 (x10 / protein
                        :name (x11 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x15 / and
                  :op1 (x14 / kinase
                        :name (x13 / name :op1 "PI-3"))
                  :op2 (x16 / enzyme
                        :name (x17 / name :op1 "Akt")
                        :xref (x18 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))


# ::id PMC5341140004.2
# ::snt Expression of a Gab1 mutant protein deficient in Shp2 binding enhances EGF-induced activation of the PI-3 kinase/Akt signaling pathway.
# ::tok Expression of a Gab1 mutant protein deficient in Shp2 binding enhances EGF @-@ induced activation of the PI @-@ 3 kinase @/@ Akt signaling pathway .
(x10 / enhance-01
      :ARG0 (x1 / express-03
            :ARG2 (x5 / protein
                  :mod (x2 / protein
                        :name (x3 / name :op1 "Gab1")
                        :ARG2-of (x4 / mutate-01)
                        :xref (x18 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG0-of (x6 / lack-01
                        :ARG1 (x9 / bind-01
                              :ARG2 (x7 / enzyme
                                    :name (x8 / name :op1 "Shp2")
                                    :xref (x19 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))))))
      :ARG1 (x14 / activate-01
            :ARG2-of (x13 / induce-01
                  :ARG0 (x11 / protein
                        :name (x12 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x17 / signal-07
                  :ARG0 (x15 / pathway
                        :name (x16 / name :op1 "PI" :op2 "kinase")))))


# ::id PMC5341140004.3
# ::snt Furthermore, complex formation between Gab1 and the protein tyrosine phosphatase Shp2 negatively regulates Gab1 mediated PI-3 kinase and Akt activation following EGF-receptor stimulation.
# ::tok Furthermore , complex formation between Gab1 and the protein tyrosine phosphatase Shp2 negatively regulates Gab1 mediated PI @-@ 3 kinase and Akt activation following EGF @-@ receptor stimulation .
(x1 / and
      :op2 (x10 / downregulate-01
            :ARG0 (x8 / tyrosine-phosphatase
                  :ARG1-of (x2 / form-01
                        :ARG1 (x3 / macro-molecular-complex
                              :part (x4 / protein
                                    :name (x5 / name :op1 "Gab1")
                                    :xref (x24 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                              :part (x6 / enzyme
                                    :name (x7 / name :op1 "protein")
                                    :xref (x / xref :value "UNIPROT:S45A3_HUMAN" :prob "0.342"))))
                  :name (x9 / name :op1 "Shp2"))
            :ARG1 (x19 / activate-01
                  :ARG1-of (x13 / mediate-01
                        :ARG0 (x11 / protein
                              :name (x12 / name :op1 "Gab1")
                              :xref (x25 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :ARG0 (x16 / and
                        :op1 (x15 / kinase
                              :name (x14 / name :op1 "PI-3"))
                        :op2 (x17 / enzyme
                              :name (x18 / name :op1 "Akt")
                              :xref (x26 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
                  :ARG1-of (x20 / follow-01
                        :ARG2 (x23 / stimulate-01
                              :ARG2 (x21 / protein
                                    :name (x22 / name :op1 "EGF" :op2 "receptor")))))))


# ::id PMC5341140004.4
# ::snt Expression of Gab1 mutant protein deficient in Shp2 binding rescues EGF-induced PI-3 kinase/Akt activation in Gab1 -/- MEFs.
# ::tok Expression of Gab1 mutant protein deficient in Shp2 binding rescues EGF @-@ induced PI @-@ 3 kinase @/@ Akt activation in Gab1 -/- MEFs .
(x10 / rescue-01
      :ARG0 (x1 / express-03
            :ARG2 (x5 / protein
                  :mod (x2 / protein
                        :name (x3 / name :op1 "Gab1")
                        :ARG2-of (x4 / mutate-01)
                        :xref (x23 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :ARG0-of (x6 / lack-01
                        :ARG1 (x9 / bind-01
                              :ARG2 (x7 / enzyme
                                    :name (x8 / name :op1 "Shp2")
                                    :xref (x24 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))))))
      :ARG1 (x16 / activate-01
            :ARG2-of (x13 / induce-01
                  :ARG0 (x11 / protein
                        :name (x12 / name :op1 "EGF")
                        :xref (x22 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x14 / protein
                  :name (x15 / name :op1 "PI-3"))
            :location (x17 / cell
                  :mod (x18 / protein
                        :name (x19 / name :op1 "Gab1")
                        :ARG2-of (x20 / mutate-01 :mod "-/-")
                        :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                  :name (x21 / name :op1 "mef"))))


# ::id PMC5341140004.5
# ::snt Taken together, these results suggest a role for Shp2 in negatively regulating the EGF induced activation of the PI-3 kinase pathway via Gab1, possibly by dephosphorylating Gab1 at p85 binding sites.
# ::tok Taken together , these results suggest a role for Shp2 in negatively regulating the EGF induced activation of the PI @-@ 3 kinase pathway via Gab1 , possibly by dephosphorylating Gab1 at p85 binding sites .
(x6 / suggest-01
      :ARG0 (x4 / thing
            :ARG1-of (x1 / take-01
                  :mod (x2 / together))
            :mod (x3 / this)
            :ARG2-of (x5 / result-01))
      :ARG1 (x7 / role
            :topic (x11 / regulate-01
                  :ARG0 (x8 / enzyme
                        :name (x9 / name :op1 "Shp2")
                        :xref (x28 / xref :value "UNIPROT:PTN11_HUMAN" :prob "1.003"))
                  :ARG2-of (x10 / negative-01)
                  :ARG1 (x14 / induce-01
                        :ARG1 (x12 / protein
                              :name (x13 / name :op1 "EGF")
                              :xref (x30 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                        :ARG2 (x15 / activate-01
                              :ARG1 (x17 / kinase
                                    :name (x16 / name :op1 "PI-3"))
                              :ARG2 (x18 / enzyme
                                    :name (x19 / name :op1 "Gab1")
                                    :xref (x29 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                        :ARG1-of (x20 / possible-01)
                        :ARG0 (x21 / protein
                              :name (x22 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
                  :location (x26 / protein-segment
                        :ARG1-of (x25 / bind-01
                              :ARG2 (x23 / protein
                                    :name (x24 / name :op1 "p85")
                                    :xref (x27 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003")))))))


# ::id PMC5341140005.1
# ::snt We also demonstrate that tyrosine phosphorylation of ErbB3 may lead to recruitment and activation of PI-3 kinase and Akt in Gab1-/- MEFs.
# ::tok We also demonstrate that tyrosine phosphorylation of ErbB3 may lead to recruitment and activation of PI @-@ 3 kinase and Akt in Gab1-/- MEFs .
(x3 / demonstrate-01
      :ARG0 (x1 / we)
      :mod (x2 / also)
      :ARG1 (x20 / possible-01
            :ARG1 (x9 / lead-03
                  :ARG0 (x4 / phosphorylate-01
                        :ARG1 (x5 / amino-acid
                              :name (x6 / name :op1 "tyrosine")
                              :part-of (x7 / protein
                                    :name (x8 / name :op1 "ErbB3")
                                    :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
                              :xref (x22 / xref :value "PUBCHEM:1153" :prob "11.081481")))
                  :ARG2 (x10 / recruit-01
                        :ARG1 (x11 / and
                              :op2 (x12 / activate-01
                                    :ARG1 (x15 / and
                                          :op1 (x14 / kinase
                                                :name (x13 / name :op1 "PI-3"))
                                          :op2 (x16 / enzyme
                                                :name (x17 / name :op1 "Akt")
                                                :xref (x21 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
                              :location (x18 / cell
                                    :name (x19 / name :op1 "mef")))))))


# ::id PMC5341140005.2
# ::snt Expression of ErbB3 in Gab1-deficient MEFs partially rescues EGF-induced activation of the PI-3 kinase/Akt signaling pathway.
# ::tok Expression of ErbB3 in Gab1 @-@ deficient MEFs partially rescues EGF @-@ induced activation of the PI @-@ 3 kinase @/@ Akt signaling pathway .
(x8 / rescue-01
      :ARG0 (x1 / express-03
            :ARG2 (x2 / protein
                  :name (x3 / name :op1 "ErbB3")
                  :xref (x16 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
            :ARG1 (x4 / protein
                  :name (x5 / name :op1 "Gab1")
                  :ARG2-of (x6 / mutate-01 :mod "-/-")
                  :xref (x17 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
      :degree (x7 / part)
      :ARG1 (x12 / activate-01
            :ARG2-of (x11 / induce-01
                  :ARG0 (x9 / protein
                        :name (x10 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
            :ARG1 (x15 / signal-07
                  :ARG0 (x13 / pathway
                        :name (x14 / name :op1 "PI" :op2 "kinase")))))


# ::id PMC5341140005.3
# ::snt As shown in Figure 4C, both cells expressing wild type Gab1 and ErbB3 show PI-3 kinase activity, while Gab1 -/- cells do not.
# ::tok As shown in Figure 4C , both cells expressing wild type Gab1 and ErbB3 show PI @-@ 3 kinase activity , while Gab1 -/- cells do not .
(x11 / show-01
      :ARG1-of (x1 / show-01
            :ARG0 (x2 / figure :mod "4c"))
      :ARG0 (x3 / and
            :op1 (x4 / cell
                  :ARG3-of (x5 / express-03
                        :ARG2 (x6 / enzyme
                              :mod (x7 / wild-type)
                              :name (x8 / name :op1 "Gab1")
                              :xref (x20 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
            :op2 (x9 / protein
                  :name (x10 / name :op1 "ErbB3")
                  :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634")))
      :ARG1 (x14 / activity-06
            :ARG0 (x13 / kinase
                  :name (x12 / name :op1 "PI-3"))
            :ARG1-of (x15 / contrast-01
                  :ARG2 (x16 / protein
                        :name (x17 / name :op1 "Gab1")
                        :ARG2-of (x18 / mutate-01 :mod "-/-")
                        :xref (x19 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604")))
            :polarity "-"))


# ::id PMC5341140005.4
# ::snt Thus, EGF and NRG can stimulate PI-3 kinase activation in normal and transfected cells by means of Gab1 and ErbB3, respectively.
# ::tok Thus , EGF and NRG can stimulate PI @-@ 3 kinase activation in normal and transfected cells by means of Gab1 and ErbB3 , respectively .
(x1 / infer-01
      :ARG1 (x2 / possible-01
            :ARG1 (x8 / stimulate-01
                  :ARG0 (x5 / and
                        :op1 (x3 / protein
                              :name (x4 / name :op1 "EGF")
                              :xref (x23 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                        :op2 (x6 / protein
                              :name (x7 / name :op1 "NRG")
                              :xref (x24 / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.263")))
                  :ARG1 (x11 / activate-01
                        :ARG1 (x10 / kinase
                              :name (x9 / name :op1 "PI-3"))
                        :location (x13 / and
                              :ARG1-of (x12 / normal-02)
                              :op2 (x15 / cell
                                    :ARG1-of (x14 / transfect-01)
                                    :ARG1-of (x16 / mean-01
                                          :ARG2 (x19 / and
                                                :op1 (x17 / protein
                                                      :name (x18 / name :op1 "Gab1")
                                                      :xref (x25 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))
                                                :op2 (x20 / protein
                                                      :name (x21 / name :op1 "ErbB3")
                                                      :xref (x / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634")))))
                              :mod (x22 / respective))))))


# ::id PMC5341140005.5
# ::snt while only cells expressing the ectopically introduced ErbB3 protein show ErbB3 tyrosine phosphorylation in response to EGF stimulation.
# ::tok while only cells expressing the ectopically introduced ErbB3 protein show ErbB3 tyrosine phosphorylation in response to EGF stimulation .
(x1 / contrast-01
      :ARG2 (x13 / phosphorylate-01
            :mod (x2 / only)
            :ARG0 (x3 / cell
                  :ARG3-of (x4 / express-03
                        :ARG2 (x6 / introduce-02
                              :mod (x5 / ectopic))))
            :ARG1 (x8 / protein
                  :name (x7 / name :op1 "ErbB3")
                  :ARG0-of (x9 / show-01
                        :ARG1 (x10 / protein
                              :name (x11 / name :op1 "ErbB3")
                              :xref (x18 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634")))
                  :name (x12 / name :op1 "tyrosine")
                  :xref (x20 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
            :ARG2-of (x14 / respond-01
                  :ARG1 (x17 / stimulate-01
                        :ARG0 (x15 / protein
                              :name (x16 / name :op1 "EGF")
                              :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))))))


# ::id PMC5341140005.6
# ::snt Interestingly, ErbB3 reproducibly shows constitutive low-level tyrosine phosphorylation that is augmented only 1.3-fold in response to EGF treatment.
# ::tok Interestingly , ErbB3 reproducibly shows constitutive low @-@ level tyrosine phosphorylation that is augmented only 1.3 @-@ fold in response to EGF treatment .
(x3 / show-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "ErbB3" :op2 "reproducibly"))
      :ARG1 (x9 / phosphorylate-01
            :mod (x4 / constitutive)
            :ARG1 (x6 / level
                  :ARG1-of (x5 / low-04))
            :ARG1 (x7 / amino-acid
                  :name (x8 / name :op1 "tyrosine")
                  :xref (x17 / xref :value "PUBCHEM:1153" :prob "11.081481"))
            :ARG1-of (x10 / augment-01
                  :ARG1 (x12 / product-of
                        :mod (x11 / only)
                        :op1 "1.3")))
      :ARG2-of (x13 / respond-01
            :ARG1 (x16 / treat-04
                  :ARG2 (x14 / protein
                        :name (x15 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))))


# ::id PMC5341140005.7
# ::snt Cells expressing ErbB3 show tyrosine phosphorylation in response to treatment with NRG (Figure 4A, upper and middle right panels).
# ::tok Cells expressing ErbB3 show tyrosine phosphorylation in response to treatment with NRG ( Figure 4A , upper and middle right panels ) .
(x5 / show-01
      :ARG0 (x1 / cell
            :ARG3-of (x2 / express-03
                  :ARG2 (x3 / protein
                        :name (x4 / name :op1 "ErbB3")
                        :xref (x20 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))))
      :ARG1 (x8 / phosphorylate-01
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "tyrosine")
                  :xref (x21 / xref :value "UNIPROT:TYRO_HUMAN" :prob "0.352"))
            :ARG2-of (x9 / respond-01
                  :ARG1 (x10 / treat-04
                        :ARG2 (x11 / protein
                              :name (x12 / name :op1 "NRG")
                              :xref (x / xref :value "UNIPROT:NRG1_HUMAN" :prob "0.263")))))
      :ARG1-of (x13 / describe-01
            :ARG0 (x14 / figure
                  :mod "4a"
                  :location (x15 / and
                        :op1 (x16 / cell-line
                              :name (x17 / name :op1 "middle"))
                        :op2 (x19 / panel
                              :ARG1-of (x18 / right-04))))))


# ::id PMC5341140005.8
# ::snt The indicated cell lines were serum-starved for 24 hours and stimulated with 1 ng/ml EGF for varying periods of time at 37°.
# ::tok The indicated cell lines were serum @-@ starved for 24 hours and stimulated with 1 ng @/@ ml EGF for varying periods of time at 37°.
(x1 / indicate-01
      :ARG0 (x7 / and
            :op1 (x2 / cell-line
                  :ARG1-of (x4 / starve-01
                        :ARG2 (x3 / serum))
                  :duration (x5 / temporal-quantity
                        :quant "24"
                        :unit (x6 / hour)))
            :op2 (x8 / stimulate-01
                  :ARG2 (x9 / protein
                        :quant (x10 / concentration-quantity
                              :quant "1"
                              :unit (x11 / nanogram-per-milliliter))
                        :name (x12 / name :op1 "EGF")
                        :xref (x / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004"))
                  :duration (x14 / period
                        :ARG1-of (x13 / vary-01)
                        :consist-of (x15 / time))))
      :ARG1 (x16 / enzyme
            :name (x17 / name :op1 "37°.")))


# ::id PMC5341140005.9
# ::snt Cell extracts were analyzed for activation of Akt by using antibodies that specifically recognize the phosphorylated form of Akt.
# ::tok Cell extracts were analyzed for activation of Akt by using antibodies that specifically recognize the phosphorylated form of Akt .
(x3 / analyze-01
      :ARG1 (x2 / extract-01
            :ARG1 (x1 / cell))
      :purpose (x4 / activate-01
            :ARG1 (x5 / enzyme
                  :name (x6 / name :op1 "Akt")
                  :xref (x14 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))
            :ARG0 (x7 / use-01
                  :ARG1 (x8 / antibody
                        :ARG0-of (x10 / recognize-02
                              :ARG1-of (x9 / specific-02)
                              :ARG1 (x11 / enzyme
                                    :ARG3-of (x12 / phosphorylate-01)
                                    :name (x13 / name :op1 "Akt")
                                    :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))))))


# ::id PMC5341140005.10
# ::snt Membranes were subsequently stripped and immunoblotted for Akt to confirm equal loading.
# ::tok Membranes were subsequently stripped and immunoblotted for Akt to confirm equal loading .
(x8 / confirm-01
      :ARG0 (x4 / and
            :op1 (x3 / strip-01
                  :ARG1 (x1 / membrane
                        :xref (x11 / xref :value "GO:0016020" :prob "0.8"))
                  :time (x2 / subsequent))
            :op2 (x5 / immunoblot-01
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
      :ARG1 (x10 / load-01
            :ARG1-of (x9 / equal-01)))


# ::id PMC5341140005.11
# ::snt Ectopic expression of ErbB3 in Gab1 deficient cells results in a partial rescue of EGF-induced Akt activation relative to cells expressing wild type Gab1.
# ::tok Ectopic expression of ErbB3 in Gab1 deficient cells results in a partial rescue of EGF @-@ induced Akt activation relative to cells expressing wild type Gab1 .
(x9 / result-01
      :ARG0 (x2 / express-03
            :mod (x1 / ectopic)
            :ARG2 (x3 / protein
                  :name (x4 / name :op1 "ErbB3")
                  :xref (x24 / xref :value "UNIPROT:ERBB3_HUMAN" :prob "0.634"))
            :ARG3 (x8 / cell
                  :mod (x5 / enzyme
                        :name (x6 / name :op1 "Gab1")
                        :ARG2-of (x7 / mutate-01 :mod "-/-")
                        :xref (x25 / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))
      :ARG2 (x11 / rescue-01
            :degree (x10 / part)
            :ARG1 (x17 / activate-01
                  :ARG2-of (x14 / induce-01
                        :ARG0 (x12 / protein
                              :name (x13 / name :op1 "EGF")
                              :xref (x26 / xref :value "UNIPROT:EGF_HUMAN" :prob "1.004")))
                  :ARG1 (x15 / enzyme
                        :name (x16 / name :op1 "Akt")
                        :xref (x27 / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203"))))
      :ARG1-of (x18 / relative-05
            :ARG2 (x19 / cell
                  :ARG3-of (x20 / express-03
                        :ARG2 (x21 / enzyme
                              :mod (x22 / wild-type)
                              :name (x23 / name :op1 "Gab1")
                              :xref (x / xref :value "UNIPROT:GAB1_HUMAN" :prob "0.604"))))))


# ::id PMC12343350001.1
# ::snt Together these data demonstrate that E2-induced SRC-3 phosphorylation is dependent on a direct interaction between SRC-3 and ERα and can occur outside of the nucleus.
# ::tok Together these data demonstrate that E2 @-@ induced SRC @-@ 3 phosphorylation is dependent on a direct interaction between SRC @-@ 3 and ERα and can occur outside of the nucleus .
(x4 / demonstrate-01
      :ARG0 (x3 / data
            :mod (x1 / together)
            :mod (x2 / this))
      :ARG1 (x11 / depend-01
            :ARG0 (x10 / phosphorylate-01
                  :ARG2-of (x7 / induce-01
                        :ARG0 (x5 / enzyme
                              :name (x6 / name :op1 "E2")))
                  :ARG1 (x8 / protein
                        :name (x9 / name :op1 "SRC-3")))
            :ARG1 (x18 / and
                  :op1 (x13 / interact-01
                        :ARG1-of (x12 / direct-02)
                        :ARG0 (x14 / protein
                              :name (x15 / name :op1 "SRC-3"))
                        :ARG1 (x16 / protein
                              :name (x17 / name :op1 "ERα")
                              :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
                  :op2 (x19 / possible-01
                        :ARG1 (x20 / be-temporally-at-91
                              :ARG2 (x21 / outside
                                    :op1 (x22 / nucleus
                                          :xref (x23 / xref :value "GO:0005634" :prob "0.8"))))))))


# ::id PMC12343350001.2
# ::snt Mutations in the coactivator binding groove of the ERα ligand binding domain inhibit E2-stimulated SRC-3 phosphorylation, as do mutations in the nuclear receptor-interacting domain of SRC-3, suggesting that ERα must directly contact SRC-3 for this posttranslational modification to take place.
# ::tok Mutations in the coactivator binding groove of the ERα ligand binding domain inhibit E2 @-@ stimulated SRC @-@ 3 phosphorylation , as do mutations in the nuclear receptor @-@ interacting domain of SRC @-@ 3 , suggesting that ERα must directly contact SRC @-@ 3 for this posttranslational modification to take place .
(x1 / multi-sentence
      :snt1 (x5 / bind-01
            :ARG1 (x2 / mutate-01
                  :ARG1 (x3 / gene
                        :name (x4 / name :op1 "coactivator")
                        :xref (x40 / xref :value "UNIPROT:NCOA5_HUMAN" :prob "0.242")))
            :ARG1 (x6 / groove)
            :ARG2 (x7 / protein
                  :name (x8 / name :op1 "ERα")
                  :xref (x41 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))
      :snt2 (x12 / inhibit-01
            :ARG0 (x11 / domain
                  :ARG0-of (x10 / bind-01
                        :ARG1 (x9 / ligand)))
            :ARG1 (x18 / phosphorylate-01
                  :ARG1-of (x15 / stimulate-01
                        :ARG0 (x13 / protein
                              :name (x14 / name :op1 "E2")))
                  :ARG1 (x16 / protein
                        :name (x17 / name :op1 "SRC-3")))
            :ARG1-of (x37 / modify-01
                  :ARG0 (x19 / mutate-01
                        :location (x23 / domain
                              :ARG0-of (x22 / interact-01
                                    :ARG1 (x21 / receptor
                                          :mod (x20 / nucleus
                                                :xref (x42 / xref :value "GO:0005634" :prob "0.8"))))
                              :part-of (x24 / protein
                                    :name (x25 / name :op1 "SRC-3")))
                        :ARG0-of (x26 / suggest-01
                              :ARG1 (x29 / obligate-01
                                    :ARG1 (x27 / protein
                                          :name (x28 / name :op1 "ERα")
                                          :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))
                                    :ARG2 (x31 / contact-01
                                          :ARG1-of (x30 / direct-02)
                                          :ARG1 (x32 / protein
                                                :name (x33 / name :op1 "SRC-3"))))
                              :ARG0 (x34 / this)))
                  :time (x35 / after
                        :op1 (x36 / translate-02))
                  :ARG1 (x38 / take-01
                        :ARG1 (x39 / place)))))


# ::id PMC12343350001.3
# ::snt FIG. 2. Estradiol-induced SRC-3 phosphorylation requires the presence of ER. (A) HEK293T cells were transfected with Flag-tagged SRC-3 (SRC-3) or its phosphorylation mutant (A6), in the absence or presence of ER.
# ::tok FIG . 2. Estradiol @-@ induced SRC @-@ 3 phosphorylation requires the presence of ER . ( A ) HEK293T cells were transfected with Flag @-@ tagged SRC @-@ 3 ( SRC @-@ 3 ) or its phosphorylation mutant ( A6 ) , in the absence or presence of ER .
(x1 / multi-sentence
      :snt1 (x10 / require-01
            :ARG1-of (x2 / describe-01
                  :ARG0 (x3 / figure :mod "2"))
            :ARG0 (x9 / phosphorylate-01
                  :ARG2-of (x6 / induce-01
                        :ARG0 (x4 / small-molecule
                              :name (x5 / name :op1 "Estradiol")
                              :xref (x36 / xref :value "PUBCHEM:5757" :prob "13.090267")))
                  :ARG1 (x7 / protein
                        :name (x8 / name :op1 "SRC-3")))
            :ARG1 (x11 / present-02
                  :ARG1 (x12 / protein
                        :name (x13 / name :op1 "erα")
                        :xref (x35 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))))
      :snt2 (x16 / transfect-01
            :ARG1 (x14 / cell-line
                  :name (x15 / name :op1 "HEK293T"))
            :ARG2 (x24 / or
                  :ARG1-of (x19 / tag-01
                        :ARG2 (x17 / protein
                              :name (x18 / name :op1 "Flag")))
                  :op1 (x20 / protein
                        :name (x21 / name :op1 "SRC-3"))
                  :op1 (x22 / protein
                        :name (x23 / name :op1 "SRC-3"))
                  :op2 (x25 / phosphorylate-01
                        :ARG1 (x26 / enzyme
                              :ARG2-of (x27 / mutate-01)
                              :ARG1-of (x28 / mutate-01 :mod "-/-")))
                  :op2 (x29 / and
                        :op1 (x30 / or
                              :op2 (x31 / present-02)
                              :op1 (x32 / absent-01
                                    :ARG1 (x33 / protein
                                          :name (x34 / name :op1 "erα")
                                          :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))))))))


# ::id PMC12343350001.4
# ::snt FIG. 1. Estradiol induction of SRC-3 phosphorylation
# ::tok FIG . 1. Estradiol induction of SRC @-@ 3 phosphorylation
(x1 / describe-01
      :ARG0 (x2 / figure :mod "1")
      :ARG1 (x5 / induce-01
            :ARG0 (x3 / small-molecule
                  :name (x4 / name :op1 "Estradiol")
                  :xref (x / xref :value "PUBCHEM:5757" :prob "13.090267"))
            :ARG2 (x8 / phosphorylate-01
                  :ARG1 (x6 / protein
                        :name (x7 / name :op1 "SRC-3")))))


# ::id PMC12343350001.5
# ::snt we investigated the mechanisms involved in estradiol (E2)-induced SRC-3 phosphorylation and found that this occurs only when either activated estrogen receptor (ER) or activated ER is present.
# ::tok we investigated the mechanisms involved in estradiol ( E2 ) -induced SRC @-@ 3 phosphorylation and found that this occurs only when either activated estrogen receptor ( ER ) or activated ER is present .
(x2 / investigate-01
      :ARG0 (x1 / we)
      :ARG1 (x4 / involve-01
            :mod (x3 / mechanism)
            :ARG2 (x7 / and
                  :op1 (x5 / small-molecule
                        :name (x6 / name :op1 "estradiol")
                        :xref (x22 / xref :value "PUBCHEM:5757" :prob "13.090267"))
                  :op2 (x11 / find-01
                        :ARG0 (x10 / phosphorylate-01
                              :ARG1 (x8 / protein
                                    :name (x9 / name :op1 "SRC-3")))
                        :ARG1 (x12 / this)))
            :mod (x13 / only))
      :time (x21 / present-02
            :ARG1 (x14 / or
                  :op1 (x15 / activate-01
                        :ARG1 (x16 / enzyme
                              :name (x17 / name
                                    :op1 "estrogen"
                                    :op2 "receptor"
                                    :op1 "erα")))
                  :op2 (x18 / enzyme
                        :ARG1-of (x19 / activate-01)
                        :name (x20 / name :op1 "erα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593")))))


# ::id PMC12343350001.6
# ::snt Both the activation function 1 and the ligand binding domains of ERα are required for maximal induction.
# ::tok Both the activation function 1 and the ligand binding domains of ERα are required for maximal induction .
(x9 / require-01
      :ARG1 (x1 / and
            :op1 (x2 / activate-01
                  :ARG1 (x3 / function :mod "1"))
            :op2 (x6 / domain
                  :ARG0-of (x5 / bind-01
                        :ARG1 (x4 / ligand))
                  :part-of (x7 / protein
                        :name (x8 / name :op1 "ERα")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))))
      :ARG0 (x11 / induce-01
            :mod (x10 / maximal)))


# ::id PMC12343350001.7
# ::snt FIG. 4. Both AF-1 and LBD/AF-2 domains of ER are required for maximal induction of SRC-3 phosphorylation in response to E2.
# ::tok FIG . 4. Both AF @-@ 1 and LBD @/@ AF @-@ 2 domains of ER are required for maximal induction of SRC @-@ 3 phosphorylation in response to E2 .
(x2 / and
      :op1 (x1 / figure :mod "4")
      :op2 (x17 / phosphorylate-01
            :ARG1 (x5 / and
                  :op1 (x3 / protein
                        :name (x4 / name :op1 "AF")
                        :xref (x21 / xref :value "UNIPROT:PSMD4_HUMAN" :prob "1.002"))
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "LBD"))
                  :op2 (x12 / require-01
                        :ARG1 (x8 / amino-acid
                              :name (x9 / name :op1 "AF")
                              :mod "2"
                              :part-of (x10 / protein
                                    :name (x11 / name :op1 "erα")
                                    :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
                              :xref (x22 / xref :value "PUBCHEM:1983" :prob "6.800189"))
                        :ARG0 (x14 / induce-01
                              :mod (x13 / maximal)
                              :ARG1 (x15 / protein
                                    :name (x16 / name :op1 "SRC-3")))))
            :ARG2-of (x18 / respond-01
                  :ARG1 (x19 / small-molecule
                        :name (x20 / name :op1 "E2")
                        :xref (x23 / xref :value "PUBCHEM:5757" :prob "13.96532")))))


# ::id PMC12343350001.8
# ::snt Since SERMs do not promote interaction between SRC coactivators and ER in HEK293T (data not shown) and other cell lines (23, 48), the data are consistent with a requirement for a direct binding between ER and SRC-3 for induction of coactivator phosphorylation.
# ::tok Since SERMs do not promote interaction between SRC coactivators and ER in HEK293T ( data not shown ) and other cell lines ( 23 , 48 ) , the data are consistent with a requirement for a direct binding between ER and SRC @-@ 3 for induction of coactivator phosphorylation .
(x1 / multi-sentence
      :snt1 (x2 / cause-01
            :ARG0 (x4 / promote-02
                  :ARG0 (x3 / serms)
                  :polarity "-"
                  :ARG1 (x9 / and
                        :op1 (x5 / interact-01
                              :ARG0 (x6 / protein
                                    :name (x7 / name :op1 "SRC")
                                    :xref (x37 / xref :value "UNIPROT:SRC_HUMAN" :prob "1.004"))
                              :ARG0-of (x8 / coactivate-01))
                        :op2 (x10 / protein
                              :name (x11 / name :op1 "erα")
                              :xref (x39 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593")))
                  :location (x12 / cell-line
                        :name (x13 / name :op1 "HEK293T"))))
      :snt2 (x17 / and
            :ARG1-of (x14 / describe-01
                  :ARG0 (x15 / data
                        :ARG1-of (x16 / show-01 :polarity "-")))
            :op2 (x19 / cell-line
                  :mod (x18 / other))
            :ARG1-of (x20 / describe-01
                  :ARG0 (x21 / publication
                        :ARG1-of (x22 / cite-01
                              :ARG2 (x23 / and :op1 "23" :op2 "48"))))
            :op1 (x24 / data
                  :ARG1-of (x25 / consistent-01
                        :ARG2 (x26 / require-01
                              :ARG1 (x28 / bind-01
                                    :ARG1-of (x27 / direct-02)
                                    :ARG1 (x29 / protein
                                          :name (x30 / name :op1 "erα")
                                          :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.593"))
                                    :ARG2 (x31 / protein
                                          :name (x32 / name :op1 "SRC-3")))))
                  :purpose (x33 / induce-01
                        :ARG2 (x36 / phosphorylate-01
                              :ARG1 (x34 / enzyme
                                    :name (x35 / name :op1 "coactivator")
                                    :xref (x38 / xref :value "UNIPROT:NCOA5_HUMAN" :prob "0.242")))))))


# ::id PMC12343350001.9
# ::snt These data indicated that an intact coactivator-binding groove within the LBD is essential for E2-induced SRC-3 phosphorylation and imply that a direct interaction between SRC-3 and ERα is necessary.
# ::tok These data indicated that an intact coactivator @-@ binding groove within the LBD is essential for E2 @-@ induced SRC @-@ 3 phosphorylation and imply that a direct interaction between SRC @-@ 3 and ERα is necessary .
(x3 / indicate-01
      :ARG0 (x2 / data
            :mod (x1 / this))
      :ARG1 (x10 / essential
            :domain (x7 / bind-01
                  :ARG1 (x4 / nucleic-acid
                        :wiki "dna"
                        :mod (x5 / intact)
                        :name (x6 / name :op1 "coactivator"))
                  :ARG1 (x8 / groove)
                  :ARG2 (x9 / lbd))
            :purpose (x17 / and
                  :op1 (x16 / phosphorylate-01
                        :ARG2-of (x13 / induce-01
                              :ARG0 (x11 / enzyme
                                    :name (x12 / name :op1 "E2")))
                        :ARG1 (x14 / protein
                              :name (x15 / name :op1 "SRC-3")))
                  :op2 (x25 / need-01
                        :ARG1 (x18 / imply-01
                              :ARG1 (x20 / interact-01
                                    :ARG1-of (x19 / direct-02)
                                    :ARG0 (x21 / protein
                                          :name (x22 / name :op1 "SRC-3"))
                                    :ARG1 (x23 / protein
                                          :name (x24 / name :op1 "ERα")
                                          :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))))))))


# ::id PMC12343350001.10
# ::snt As shown in Fig. 2A and B, E2 induced SRC-3 phosphorylation at all six sites (T24, S505, S543, S857, S860, and S867) in cells transfected with an expression vector for wild-type ER_ (Fig. 2A, lanes 3 and 4, rows 1 to 6) or ER_ (Fig. 2B, rows 1 to 6), but not in cells transfected with an empty expression vector (Fig. 2A, lanes 1 and 2, rows 1 to 6).
# ::tok As shown in Fig . 2A and B , E2 induced SRC @-@ 3 phosphorylation at all six sites ( T24 , S505 , S543 , S857 , S860 , and S867 ) in cells transfected with an expression vector for wild @-@ type ER_ ( Fig . 2A , lanes 3 and 4 , rows 1 to 6 ) or ER_ ( Fig . 2B , rows 1 to 6 ) , but not in cells transfected with an empty expression vector ( Fig . 2A , lanes 1 and 2 , rows 1 to 6 ) .
(x1 / multi-sentence
      :snt1 (x8 / induce-01
            :ARG1-of (x2 / show-01
                  :ARG0 (x5 / and
                        :op1 (x3 / figure :mod "2a")
                        :op2 (x4 / figure :mod "1b")))
            :ARG1 (x6 / protein
                  :name (x7 / name :op1 "E2"))
            :ARG2 (x11 / phosphorylate-01
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "SRC-3"))
                  :location (x13 / protein-segment
                        :mod (x12 / all)
                        :quant "6"
                        :ARG1-of (x14 / mean-01
                              :ARG2 (x25 / and
                                    :op1 (x15 / amino-acid
                                          :mod "24"
                                          :name (x16 / name :op1 "threonine")
                                          :xref (x69 / xref :value "PUBCHEM:205" :prob "11.848252"))
                                    :op2 (x17 / amino-acid
                                          :mod "505"
                                          :name (x18 / name :op1 "serine")
                                          :xref (x70 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x19 / amino-acid
                                          :mod "543"
                                          :name (x20 / name :op1 "serine")
                                          :xref (x68 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x21 / amino-acid
                                          :mod "857"
                                          :name (x22 / name :op1 "serine")
                                          :xref (x66 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x23 / amino-acid
                                          :mod "860"
                                          :name (x24 / name :op1 "serine")
                                          :xref (x67 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                                    :op2 (x26 / amino-acid
                                          :mod "867"
                                          :name (x27 / name :op1 "serine")
                                          :xref (x65 / xref :value "PUBCHEM:5951" :prob "11.218784"))))))
            :location (x28 / cell
                  :ARG1-of (x29 / transfect-01
                        :ARG2 (x30 / vector
                              :ARG2-of (x31 / express-03
                                    :ARG1 (x32 / enzyme
                                          :mod (x33 / wild-type)
                                          :name (x34 / name :op1 "ER_")
                                          :xref (x64 / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))))
                        :ARG1-of (x35 / describe-01
                              :ARG0 (x36 / figure :mod "2a")))))
      :snt2 (x50 / contrast-01
            :ARG1 (x39 / and
                  :op1 (x37 / lane :mod "3")
                  :op2 (x38 / lane :mod "4")
                  :op2 (x40 / row
                        :mod "1"
                        :ARG2 (x43 / or
                              :op1 (x41 / protein
                                    :name (x42 / name :op1 "il-6")
                                    :xref (x63 / xref :value "UNIPROT:IL6_HUMAN" :prob "0.653"))
                              :op2 (x44 / protein
                                    :name (x45 / name :op1 "ER_")
                                    :ARG1-of (x46 / describe-01
                                          :ARG0 (x47 / figure
                                                :mod "2b"
                                                :location (x48 / row)))
                                    :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623"))))
                  :op3 (x49 / value-interval :op1 "1" :op2 "6"))
            :ARG2 (x52 / transfect-01
                  :polarity "-"
                  :ARG1 (x51 / cell)
                  :ARG2 (x55 / vector
                        :ARG1-of (x53 / empty-02)
                        :mod (x54 / express-03)
                        :ARG1-of (x56 / describe-01
                              :ARG0 (x57 / figure
                                    :mod "2a"
                                    :ARG0-of (x58 / compare-01
                                          :ARG1 (x59 / lane :mod "1")
                                          :ARG2 (x60 / lane :mod "2"))))
                        :ARG0-of (x61 / row))
                  :ARG2 (x62 / value-interval :op1 "1" :op2 "6"))))


# ::id PMC12343350001.11
# ::snt The levels of SRC-3 phosphorylated at T24, S505, and S543 were assessed.
# ::tok The levels of SRC @-@ 3 phosphorylated at T24 , S505 , and S543 were assessed .
(x12 / assess-01
      :ARG1 (x9 / and
            :op1 (x1 / level
                  :quant-of (x2 / protein
                        :name (x3 / name :op1 "SRC-3"))
                  :ARG1-of (x4 / phosphorylate-01
                        :ARG1 (x5 / amino-acid
                              :mod "24"
                              :name (x6 / name :op1 "threonine")
                              :xref (x14 / xref :value "PUBCHEM:205" :prob "11.848252"))))
            :op2 (x7 / amino-acid
                  :mod "505"
                  :name (x8 / name :op1 "serine")
                  :xref (x13 / xref :value "PUBCHEM:5951" :prob "11.218784"))
            :op2 (x10 / amino-acid
                  :mod "543"
                  :name (x11 / name :op1 "serine")
                  :xref (x / xref :value "PUBCHEM:5951" :prob "11.218784"))))


# ::id PMC12343350001.12
# ::snt (D) Cells were transfected as in panel A and treated with 10 nM E2 (_) or 0.01% ethanol (_) for various periods of time (min).
# ::tok ( D ) Cells were transfected as in panel A and treated with 10 nM E2 ( _ ) or 0.01 % ethanol ( _ ) for various periods of time ( min ) .
(x4 / transfect-01
      :ARG1-of (x1 / describe-01
            :ARG0 (x2 / figure :mod "5d"))
      :ARG1 (x3 / cell)
      :ARG2 (x13 / or
            :op1 (x5 / panel
                  :consist-of (x6 / and
                        :op1 (x7 / treat-04
                              :ARG2 (x8 / small-molecule
                                    :quant (x9 / concentration-quantity
                                          :quant "10"
                                          :unit (x10 / nanomolar))
                                    :name (x11 / name :op1 "E2")
                                    :xref (x / xref :value "PUBCHEM:5757" :prob "13.96532"))))
                  :ARG1-of (x12 / _))
            :op2 (x14 / percentage-entity :value "0.01"))
      :ARG1 (x15 / protein-segment
            :name (x16 / name :op1 "_"))
      :purpose (x18 / period
            :mod (x17 / various)
            :consist-of (x19 / time)))


# ::id PMC12343350001.13
# ::snt The level of SRC-3 phosphorylated at T24, S505, and S543 and the amount of SRC-3-bound ER_ were assessed.
# ::tok The level of SRC @-@ 3 phosphorylated at T24 , S505 , and S543 and the amount of SRC @-@ 3 @-@ bound ER_ were assessed .
(x19 / assess-01
      :ARG1 (x12 / and
            :op1 (x1 / level
                  :quant-of (x2 / protein
                        :name (x3 / name :op1 "SRC-3"))
                  :ARG1-of (x4 / phosphorylate-01
                        :ARG1 (x5 / and
                              :op1 (x6 / amino-acid
                                    :mod "24"
                                    :name (x7 / name :op1 "threonine")
                                    :xref (x22 / xref :value "PUBCHEM:205" :prob "11.848252"))
                              :op2 (x8 / amino-acid
                                    :mod "505"
                                    :name (x9 / name :op1 "serine")
                                    :xref (x21 / xref :value "PUBCHEM:5951" :prob "11.218784"))
                              :op2 (x10 / amino-acid
                                    :mod "543"
                                    :name (x11 / name :op1 "serine")
                                    :xref (x20 / xref :value "PUBCHEM:5951" :prob "11.218784")))))
            :op2 (x13 / amount
                  :quant-of (x14 / enzyme
                        :ARG1-of (x17 / bind-01
                              :ARG2 (x15 / protein
                                    :name (x16 / name :op1 "SRC-3")))
                        :name (x18 / name :op1 "ER_")
                        :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.623")))))


# ::id PMC12343350001.14
# ::snt Shown in the bottom two rows of all the panels are total cell lysates separated by SDS-PAGE and probed with the anti-ER_, anti-ER_, or anti-SRC-3 antibodies to assess the total cellular levels of ER_, ER_, and SRC-3, respectively.
# ::tok Shown in the bottom two rows of all the panels are total cell lysates separated by SDS @-@ PAGE and probed with the anti @-@ ER_, anti @-@ ER_, or anti @-@ SRC @-@ 3 antibodies to assess the total cellular levels of ER_, ER_, and SRC @-@ 3 , respectively .
(x1 / multi-sentence
      :snt1 (x4 / row
            :ARG1-of (x2 / show-01
                  :medium (x3 / bottom))
            :quant "2"
            :mod (x5 / all))
      :snt2 (x13 / and
            :op1 (x10 / separate-01
                  :ARG1 (x6 / panel)
                  :ARG1-of (x9 / lysate
                        :mod (x7 / total)
                        :mod (x8 / cell))
                  :ARG0 (x11 / thing
                        :name (x12 / name :op1 "SDS-PAGE")))
            :op2 (x14 / probe-01
                  :ARG2 (x19 / or
                        :op1 (x15 / antibody
                              :ARG0-of (x16 / counter-01
                                    :ARG1 (x17 / protein
                                          :name (x18 / name :op1 "ER_,")
                                          :xref (x / xref :value "UNIPROT:ESR1_HUMAN" :prob "0.613"))))
                        :op2 (x23 / antibody
                              :ARG0-of (x20 / counter-01
                                    :ARG1 (x21 / protein
                                          :name (x22 / name :op1 "SRC-3"))))
                        :purpose (x24 / assess-01
                              :ARG1 (x30 / and
                                    :op1 (x27 / level
                                          :mod (x25 / total)
                                          :mod (x26 / cell)
                                          :quant-of (x28 / enzyme
                                                :name (x29 / name :op1 "ER_," :op2 "ER_,")))
                                    :op2 (x31 / protein
                                          :name (x32 / name :op1 "SRC-3"))
                                    :manner (x33 / respective)))))))


# ::id PMC31784470001.1
# ::snt Figure 1. RAF inhibitors rapidly activate MEK/ERK in cells with wild-type BRAF.
# ::tok Figure 1. RAF inhibitors rapidly activate MEK @/@ ERK in cells with wild @-@ type BRAF .
(x8 / activate-01
      :ARG0 (x6 / molecular-physical-entity
            :ARG1-of (x1 / describe-01
                  :ARG0 (x2 / figure :mod "1"))
            :ARG0-of (x5 / inhibit-01
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "RAF")
                        :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))
      :manner (x7 / rapid)
      :ARG1 (x9 / pathway
            :name (x10 / name :op1 "MEK/ERK"))
      :location (x11 / cell
            :mod (x12 / wild-type)
            :name (x13 / name :op1 "BRAF")))


# ::id PMC31784470001.2
# ::snt We found that ATP-competitive RAF inhibitors inhibit ERK signaling in cells with mutant BRAF, but unexpectedly enhance signaling in cells with wild-type BRAF.
# ::tok We found that ATP @-@ competitive RAF inhibitors inhibit ERK signaling in cells with mutant BRAF , but unexpectedly enhance signaling in cells with wild @-@ type BRAF .
(x19 / contrast-01
      :ARG1 (x2 / find-01
            :ARG0 (x1 / we)
            :ARG1 (x5 / compete-01
                  :ARG2 (x3 / small-molecule
                        :name (x4 / name :op1 "ATP")
                        :xref (x28 / xref :value "PUBCHEM:5957" :prob "14.368295")))
            :ARG1 (x13 / signal-07
                  :ARG0 (x9 / molecular-physical-entity
                        :ARG0-of (x8 / inhibit-01
                              :ARG1 (x6 / enzyme
                                    :name (x7 / name :op1 "RAF")
                                    :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))
                        :ARG0-of (x10 / inhibit-01
                              :ARG1 (x11 / enzyme
                                    :name (x12 / name :op1 "ERK")
                                    :xref (x26 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))
            :location (x14 / cell
                  :ARG0-of (x15 / contain-01
                        :ARG1 (x16 / enzyme
                              :ARG2-of (x17 / mutate-01)
                              :name (x18 / name :op1 "BRAF")
                              :xref (x27 / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004")))))
      :ARG2 (x21 / enhance-01
            :ARG1-of (x20 / expect-01 :polarity "-")
            :ARG1 (x22 / signal-07)
            :location (x23 / cell
                  :mod (x24 / wild-type)
                  :name (x25 / name :op1 "BRAF"))))


# ::id PMC31784470001.3
# ::snt Six distinct ATP-competitive RAF inhibitors induced ERK activation in cells with wild-type BRAF, but inhibited signaling in mutant BRAFV600E cells (Fig. 1a, b, Supplementary Fig. 2a, b, Data Not Shown (DNS), structures of compounds shown in Supplementary Fig. 3, except that of PLX4032, which is unavailable). PLX47206, and its analog in clinical trial.
# ::tok Six distinct ATP @-@ competitive RAF inhibitors induced ERK activation in cells with wild @-@ type BRAF , but inhibited signaling in mutant BRAFV600E cells ( Fig . 1a , b, Supplementary Fig . 2a , b, Data Not Shown ( DNS ) , structures of compounds shown in Supplementary Fig . 3 , except that of PLX4032 , which is unavailable ) . PLX47206 , and its analog in clinical trial .
(x1 / multi-sentence
      :snt1 (x17 / contrast-01
            :ARG1 (x10 / induce-01
                  :ARG0 (x9 / molecular-physical-entity
                        :quant "6"
                        :mod (x2 / distinct)
                        :ARG0-of (x5 / compete-01
                              :ARG1 (x3 / small-molecule
                                    :name (x4 / name :op1 "ATP")
                                    :xref (x50 / xref :value "PUBCHEM:5957" :prob "14.368295")))
                        :ARG0-of (x8 / inhibit-01
                              :ARG1 (x6 / enzyme
                                    :name (x7 / name :op1 "RAF")
                                    :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))
                  :ARG2 (x13 / activate-01
                        :ARG1 (x11 / enzyme
                              :name (x12 / name :op1 "ERK")
                              :xref (x49 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                  :location (x14 / cell
                        :mod (x15 / wild-type)
                        :name (x16 / name :op1 "BRAF")))
            :ARG2 (x18 / inhibit-01
                  :ARG1 (x19 / signal-07)
                  :location (x23 / cell
                        :mod (x20 / enzyme
                              :ARG2-of (x21 / mutate-01)
                              :name (x22 / name :op1 "BRAFV600E"))))
            :ARG1-of (x24 / describe-01
                  :ARG0 (x25 / and
                        :op1 (x26 / figure :mod "1a")
                        :op2 (x27 / figure :mod "2b")))
            :ARG1-of (x28 / describe-01
                  :ARG0 (x30 / figure
                        :ARG2-of (x29 / supplement-01)
                        :mod "2a")))
      :snt2 (x32 / show-01
            :ARG0 (x31 / data :mod "2b")
            :polarity "-"
            :ARG1-of (x33 / dns)
            :ARG0-of (x34 / structure
                  :consist-of (x35 / compound
                        :ARG0-of (x36 / show-01
                              :ARG0 (x38 / figure
                                    :ARG2-of (x37 / supplement-01)
                                    :mod "3"))
                        :ARG2-of (x39 / except-01
                              :ARG1 (x40 / cell-line
                                    :name (x41 / name :op1 "PLX4032")
                                    :ARG0-of (x42 / available :polarity "-")))))
            :ARG1 (x45 / and
                  :op1 (x43 / enzyme
                        :name (x44 / name :op1 "PLX47206"))
                  :op2 (x46 / analog
                        :location (x48 / trial-06
                              :mod (x47 / clinic))))))


# ::id PMC31784470001.4
# ::snt Induction of ERK signaling by PLX4720 was rapid (Fig. 1c), reversible (Fig. 1d), and associated with increased phosphorylation of the ERK substrate RSK (Fig 1b).
# ::tok Induction of ERK signaling by PLX4720 was rapid ( Fig . 1c ) , reversible ( Fig . 1d ) , and associated with increased phosphorylation of the ERK substrate RSK ( Fig 1b ) .
(x14 / and
      :op1 (x7 / turn-over-12
            :ARG1 (x1 / induce-01
                  :ARG2 (x2 / enzyme
                        :name (x3 / name :op1 "ERK")
                        :ARG0-of (x4 / signal-07)
                        :xref (x25 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))
                  :ARG0 (x5 / small-molecule
                        :name (x6 / name :op1 "PLX4720")
                        :xref (x27 / xref :value "PUBCHEM:24180719" :prob "18.572987")))
            :mod (x8 / rapid)
            :ARG1-of (x9 / describe-01
                  :ARG0 (x10 / figure :mod "1c"))
            :ARG0-of (x11 / reversible)
            :ARG1-of (x12 / describe-01
                  :ARG0 (x13 / figure :mod "1d")))
      :op2 (x20 / substrate
            :ARG1-of (x15 / associate-01
                  :ARG2 (x16 / increase-01
                        :ARG1 (x17 / phosphorylate-01
                              :ARG1 (x18 / enzyme
                                    :name (x19 / name :op1 "ERK")
                                    :xref (x26 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))
            :mod (x21 / enzyme
                  :name (x22 / name :op1 "RSK")
                  :xref (x / xref :value "UNIPROT:KS6A1_HUMAN" :prob "0.262")))
      :ARG1-of (x23 / describe-01
            :ARG0 (x24 / figure :mod "1b")))


# ::id PMC31784470001.5
# ::snt MEK and ERK phosphorylation were induced at intermediate concentrations of RAF inhibitor, and inhibited at much higher doses (Fig. 1a).
# ::tok MEK and ERK phosphorylation were induced at intermediate concentrations of RAF inhibitor , and inhibited at much higher doses ( Fig . 1a ) .
(x7 / induce-01
      :ARG1 (x6 / phosphorylate-01
            :ARG1 (x3 / and
                  :op1 (x1 / enzyme
                        :name (x2 / name :op1 "MEK")
                        :xref (x21 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343"))
                  :op2 (x4 / enzyme
                        :name (x5 / name :op1 "ERK")
                        :xref (x22 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
      :location (x13 / and
            :op1 (x9 / concentrate-02
                  :degree (x8 / intermediate)
                  :ARG1 (x12 / inhibit-01
                        :ARG1 (x10 / enzyme
                              :name (x11 / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))
            :op2 (x14 / inhibit-01
                  :ARG1 (x18 / dose-01
                        :ARG1-of (x17 / high-02
                              :degree (x16 / more
                                    :mod (x15 / much))))))
      :ARG1-of (x19 / describe-01
            :ARG0 (x20 / figure :mod "1a")))


# ::id PMC31784470001.6
# ::snt PLX induced pronounced phosphorylation of MEK and ERK in wild-type MEFs and BRAF (−/−) MEFs.
# ::tok PLX induced pronounced phosphorylation of MEK and ERK in wild @-@ type MEFs and BRAF ( −/− ) MEFs .
(x3 / induce-01
      :ARG0 (x1 / protein
            :name (x2 / name :op1 "PLX")
            :xref (x23 / xref :value "UNIPROT:PLXD1_HUMAN" :prob "0.233"))
      :ARG2 (x14 / and
            :op1 (x5 / phosphorylate-01
                  :ARG1-of (x4 / pronounced-02)
                  :ARG1 (x8 / and
                        :op1 (x6 / enzyme
                              :name (x7 / name :op1 "MEK")
                              :xref (x / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343"))
                        :op2 (x9 / enzyme
                              :name (x10 / name :op1 "ERK")
                              :xref (x21 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                  :ARG2 (x11 / enzyme
                        :mod (x12 / wild-type)
                        :name (x13 / name :op1 "mef")
                        :xref (x22 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602")))
            :op2 (x15 / enzyme
                  :name (x16 / name :op1 "BRAF")
                  :ARG1-of (x17 / mutate-01 :mod "−/−")
                  :name (x18 / name :op1 "mef")
                  :xref (x20 / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))))


# ::id PMC31784470001.7
# ::snt The response was diminished markedly in CRAF (−/−) MEFs (Fig. 2b, Supplementary Fig. 6a).
# ::tok The response was diminished markedly in CRAF ( −/− ) MEFs ( Fig . 2b , Supplementary Fig . 6a ) .
(x2 / diminish-01
      :ARG1 (x1 / respond-01)
      :degree (x3 / marked)
      :location (x4 / cell-line
            :name (x5 / name :op1 "CRAF")
            :ARG1-of (x6 / mutate-01 :mod "−/−")
            :name (x7 / name :op1 "mef"))
      :ARG1-of (x8 / describe-01
            :ARG0 (x9 / and
                  :op1 (x10 / figure :mod "2b")
                  :op2 (x12 / figure
                        :ARG2-of (x11 / supplement-01)
                        :mod "6a"))))


# ::id PMC31784470001.8
# ::snt Coexpression of CRAF and active RAS in CRAF (−/−) MEFs reconstituted the wild-type phenotype (Supplementary Fig. 6b, c).
# ::tok Coexpression of CRAF and active RAS in CRAF ( −/− ) MEFs reconstituted the wild @-@ type phenotype ( Supplementary Fig . 6b , c ) .
(x4 / and
      :ARG0 (x1 / coexpress-01
            :ARG2 (x2 / enzyme
                  :name (x3 / name :op1 "CRAF")
                  :xref (x20 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603")))
      :op2 (x5 / activate-01
            :ARG1 (x6 / enzyme
                  :name (x7 / name :op1 "RAS")
                  :xref (x21 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
            :ARG2 (x8 / enzyme
                  :name (x9 / name :op1 "CRAF")
                  :xref (x19 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603")))
      :ARG1-of (x13 / reconstitute-01
            :ARG0 (x10 / enzyme
                  :ARG1-of (x11 / mutate-01 :mod "−/−")
                  :name (x12 / name :op1 "mef")
                  :xref (x / xref :value "UNIPROT:ELF4_HUMAN" :prob "0.602"))
            :ARG1 (x15 / phenotype
                  :mod (x14 / wild-type))
            :ARG1-of (x16 / describe-01
                  :ARG0 (x18 / figure
                        :ARG2-of (x17 / supplement-01)
                        :mod "6b"))))


# ::id PMC31784470001.9
# ::snt We conclude that BRAF is dispensable for MEK/ERK activation by PLX, and that CRAF expression is required for significant induction.
# ::tok We conclude that BRAF is dispensable for MEK @/@ ERK activation by PLX , and that CRAF expression is required for significant induction .
(x2 / conclude-01
      :ARG0 (x1 / we)
      :ARG1 (x5 / dispense-01
            :ARG1 (x3 / enzyme
                  :name (x4 / name :op1 "BRAF")
                  :xref (x22 / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004"))
            :ARG2 (x18 / require-01
                  :ARG1 (x11 / activate-01
                        :ARG1 (x6 / and
                              :op1 (x7 / enzyme
                                    :name (x8 / name :op1 "MEK")
                                    :xref (x24 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343"))
                              :op2 (x9 / enzyme
                                    :name (x10 / name :op1 "ERK")
                                    :xref (x21 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
                        :ARG0 (x14 / and
                              :op1 (x12 / protein
                                    :name (x13 / name :op1 "PLX")
                                    :xref (x23 / xref :value "UNIPROT:PLXD1_HUMAN" :prob "0.233"))
                              :op2 (x17 / express-03
                                    :ARG2 (x15 / enzyme
                                          :name (x16 / name :op1 "CRAF")
                                          :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603")))))
                  :ARG0 (x20 / induce-01
                        :ARG1-of (x19 / significant-02)))))


# ::id PMC31784470002.1
# ::snt We employed chemical genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors.
# ::tok We employed chemical genetic methods to show that drug @-@ mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors .
(x2 / employ-02
      :ARG0 (x1 / we)
      :ARG1 (x5 / method
            :mod (x3 / chemical)
            :mod (x4 / genetics))
      :purpose (x6 / show-01
            :ARG1 (x11 / responsible-01
                  :ARG1-of (x7 / mediate-01)
                  :ARG0 (x8 / transactivate-01
                        :ARG1 (x10 / dimer
                              :name (x9 / name :op1 "RAF")))
                  :ARG1 (x13 / activate-01
                        :manner (x12 / paradox)
                        :ARG1 (x14 / enzyme)
                        :ARG0 (x15 / molecular-physical-entity
                              :ARG0-of (x16 / inhibit-01))))))


# ::id PMC31784470002.2
# ::snt Induction of ERK signaling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity.
# ::tok Induction of ERK signaling requires direct binding of the drug to the ATP @-@ binding site of one kinase of the dimer and is dependent on RAS activity .
(x5 / require-01
      :ARG0 (x1 / induce-01
            :ARG2 (x2 / enzyme
                  :name (x3 / name :op1 "ERK")
                  :ARG0-of (x4 / signal-07)
                  :xref (x21 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
      :ARG1 (x7 / bind-01
            :ARG1-of (x6 / direct-02)
            :ARG1 (x8 / drug)
            :ARG2 (x12 / protein-segment
                  :ARG1-of (x11 / bind-01
                        :ARG2 (x9 / small-molecule
                              :name (x10 / name :op1 "ATP")
                              :xref (x22 / xref :value "PUBCHEM:5957" :prob "14.368295")))
                  :part-of (x13 / enzyme
                        :name (x14 / name :op1 "1" :op2 "kinase"))))
      :ARG2 (x17 / depend-01
            :ARG0 (x16 / and
                  :mod (x15 / dimer))
            :ARG1 (x20 / activity-06
                  :ARG0 (x18 / enzyme
                        :name (x19 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))


# ::id PMC31784470002.3
# ::snt Drug binding to one member of RAF homo-(CRAF/CRAF) or heterodimers (CRAF/BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer.
# ::tok Drug binding to one member of RAF homo- ( CRAF/CRAF ) or heterodimers ( CRAF/BRAF ) inhibits one protomer , but results in transactivation of the drug @-@ free protomer .
(x15 / contrast-01
      :ARG1 (x2 / bind-01
            :ARG1 (x1 / drug)
            :ARG2 (x7 / or
                  :op1 (x3 / member
                        :quant "1"
                        :part-of (x4 / enzyme
                              :name (x5 / name :op1 "RAF")
                              :xref (x23 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))
                        :name (x6 / name :op1 "homo-" :op2 "CRAF/CRAF"))
                  :op2 (x8 / heterodimer
                        :ARG1-of (x9 / describe-01
                              :ARG2 (x10 / name :op1 "CRAF/BRAF"))
                        :ARG0-of (x11 / inhibit-01
                              :ARG1 (x12 / enzyme
                                    :name (x13 / name :op1 "1")
                                    :xref (x24 / xref :value "UNIPROT:NOX1_HUMAN" :prob "0.573")))
                        :name (x14 / name :op1 "protomer"))))
      :ARG2 (x16 / thing
            :ARG2-of (x17 / result-01
                  :ARG1 (x18 / transactivate-01
                        :ARG1 (x20 / free-04
                              :ARG2 (x19 / drug))
                        :ARG2 (x21 / protein
                              :name (x22 / name :op1 "protomer")
                              :xref (x / xref :value "UNIPROT:CCD50_HUMAN" :prob "0.272"))))))


# ::id PMC31784470002.4
# ::snt Figure 4. MEK/ERK induction occurs via transactivation of RAF dimers
# ::tok Figure 4. MEK @/@ ERK induction occurs via transactivation of RAF dimers
(x4 / induce-01
      :ARG0 (x1 / figure :mod "4")
      :ARG1 (x2 / pathway
            :name (x3 / name :op1 "MEK/ERK"))
      :ARG2 (x5 / occur-01)
      :instrument (x6 / transactivate-01
            :ARG1 (x8 / dimer
                  :name (x7 / name :op1 "RAF"))))


# ::id PMC31784470002.5
# ::snt b, Coexpression of drug-sensitive V5-tagged catC with drug-resistant FLAG-catC reveals that activation in the homodimer occurs in trans. 293H cells expressing the indicated mutants V5-tagged catC and FLAG-tagged catC were treated with a dose of JAB34 (10μM/1 hour) that inhibits catCS428C when expressed alone.
# ::tok b , Coexpression of drug @-@ sensitive V5 @-@ tagged catC with drug @-@ resistant FLAG @-@ catC reveals that activation in the homodimer occurs in trans . 293H cells expressing the indicated mutants V5 @-@ tagged catC and FLAG @-@ tagged catC were treated with a dose of JAB34 ( 10μM/1 hour ) that inhibits catCS428C when expressed alone .
(x1 / multi-sentence
      :snt1 (x2 / and
            :li "b"
            :op1 (x3 / express-03
                  :ARG2 (x4 / and
                        :op1 (x5 / enzyme
                              :ARG1-of (x10 / tag-01
                                    :ARG2 (x6 / cell-line
                                          :ARG0-of (x8 / sensitive-03
                                                :ARG1 (x7 / drug))
                                          :name (x9 / name :op1 "V5")))
                              :name (x11 / name :op1 "catC")
                              :xref (x48 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))
                        :op2 (x13 / resist-01
                              :ARG1 (x12 / drug))))
            :op2 (x16 / reveal-01
                  :ARG0 (x14 / enzyme
                        :name (x15 / name :op1 "catC")
                        :xref (x51 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))
                  :ARG1 (x22 / express-03
                        :ARG0 (x17 / activate-01
                              :ARG1 (x18 / homodimer)
                              :mod (x19 / trans)
                              :ARG1 (x20 / cell-line
                                    :name (x21 / name :op1 "293H")))
                        :ARG2 (x23 / enzyme
                              :ARG1-of (x28 / tag-01
                                    :ARG2 (x24 / indicate-01
                                          :ARG1 (x25 / enzyme
                                                :ARG2-of (x26 / mutate-01)
                                                :name (x27 / name :op1 "V5"))))
                              :name (x29 / name :op1 "catC")
                              :xref (x47 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603")))))
      :snt2 (x36 / treat-04
            :ARG1 (x30 / and
                  :op1 (x31 / enzyme
                        :ARG1-of (x34 / tag-01
                              :ARG2 (x32 / protein
                                    :name (x33 / name :op1 "FLAG")
                                    :xref (x49 / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                        :name (x35 / name :op1 "catC")
                        :xref (x50 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603")))
            :ARG2 (x37 / dose-01
                  :ARG2 (x38 / small-molecule
                        :name (x39 / name :op1 "JAB34"))
                  :ARG4 (x41 / hour
                        :name (x40 / name :op1 "10μM/1"))
                  :ARG1 (x42 / inhibit-01
                        :ARG1 (x43 / enzyme
                              :name (x44 / name :op1 "catCS428C")
                              :xref (x / xref :value "UNIPROT:CATC_HUMAN" :prob "0.222"))
                        :condition (x45 / express-03
                              :mod (x46 / alone))))))


# ::id PMC31784470002.6
# ::snt c, Activation in the context of the heterodimer BRAF/CRAF occurs in trans.
# ::tok c , Activation in the context of the heterodimer BRAF @/@ CRAF occurs in trans .
(x3 / activate-01
      :ARG1-of (x1 / describe-01
            :ARG0 (x2 / figure :mod "4c"))
      :ARG1 (x4 / context
            :mod (x5 / heterodimer
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "BRAF")
                        :mod (x8 / enzyme
                              :name (x9 / name :op1 "CRAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
                        :xref (x11 / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004")))
            :location (x10 / trans)))


# ::id PMC31784470002.7
# ::snt c, Treatment with RAF inhibitor results in elevated phosphorylation at activating phosphorylation sites on RAF.
# ::tok c , Treatment with RAF inhibitor results in elevated phosphorylation at activating phosphorylation sites on RAF .
(x1 / and
      :op1 (x2 / figure :mod "5c")
      :op2 (x7 / result-01
            :ARG1 (x3 / treat-04
                  :ARG2 (x6 / inhibit-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "RAF")
                              :xref (x15 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))
            :ARG2 (x9 / phosphorylate-01
                  :ARG1-of (x8 / elevate-01)
                  :ARG1 (x12 / protein-segment
                        :ARG0-of (x10 / activate-01)
                        :ARG1-of (x11 / phosphorylate-01)
                        :location (x13 / enzyme
                              :name (x14 / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))))


# ::id PMC31784470002.8
# ::snt V5-tagged wild-type CRAF or kinase-dead CRAFD486N were overexpressed in 293H cells.
# ::tok V5 @-@ tagged wild @-@ type CRAF or kinase @-@ dead CRAFD486N were overexpressed in 293H cells .
(x12 / overexpress-01
      :ARG1 (x7 / or
            :ARG1-of (x3 / tag-01
                  :ARG2 (x1 / protein
                        :name (x2 / name :op1 "V5")))
            :op1 (x4 / enzyme
                  :mod (x5 / wild-type)
                  :name (x6 / name :op1 "CRAF")
                  :xref (x16 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
            :op2 (x8 / enzyme
                  :name (x9 / name :op1 "kinase")
                  :ARG1-of (x10 / die-01)
                  :name (x11 / name :op1 "CRAFD486N")
                  :xref (x15 / xref :value "UNIPROT:TRAF3_HUMAN" :prob "0.212")))
      :location (x13 / cell-line
            :name (x14 / name :op1 "293H")))


# ::id PMC31784470002.9
# ::snt After 24 hours cells were treated with vehicle or PLX4720 (5μM/1hour) and lysates were immunoblotted for p338CRAF and p621CRAF.
# ::tok After 24 hours cells were treated with vehicle or PLX4720 ( 5μM/1 hour ) and lysates were immunoblotted for p338CRAF and p621CRAF .
(x13 / and
      :op1 (x12 / hour
            :time (x1 / after
                  :quant (x2 / temporal-quantity
                        :quant "24"
                        :unit (x3 / hour))
                  :op1 (x5 / treat-04
                        :ARG1 (x4 / cell)
                        :ARG2 (x7 / or
                              :op1 (x6 / vehicle)
                              :op2 (x8 / small-molecule
                                    :name (x9 / name :op1 "PLX4720")
                                    :xref (x21 / xref :value "PUBCHEM:24180719" :prob "18.572987"))))
                  :op2 (x10 / small-molecule
                        :name (x11 / name :op1 "5μM/1"))))
      :op2 (x15 / immunoblot-01
            :ARG1 (x14 / lysate)
            :ARG3 (x18 / and
                  :op1 (x16 / enzyme
                        :name (x17 / name :op1 "p338CRAF"))
                  :op2 (x19 / enzyme
                        :name (x20 / name :op1 "p621CRAF")
                        :xref (x / xref :value "UNIPROT:MCAF1_HUMAN" :prob "0.232")))))


# ::id PMC31784470002.10
# ::snt The gatekeeper mutant CRAFT421M was used as negative control.
# ::tok The gatekeeper mutant CRAFT421M was used as negative control .
(x6 / use-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "gatekeeper")
            :ARG2-of (x3 / mutate-01
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "CRAFT421M")
                        :xref (x / xref :value "UNIPROT:CCRL2_HUMAN" :prob "0.212"))))
      :ARG2 (x8 / control-01
            :ARG2-of (x7 / negative-01)))


# ::id PMC31784470002.11
# ::snt d. Samples as in Fig. 1a, immunoblotted for pS338CRAF.
# ::tok d . Samples as in Fig . 1a , immunoblotted for pS338CRAF .
(x1 / sample-01
      :li "d"
      :ARG1-of (x2 / possible-01
            :ARG1-of (x3 / describe-01
                  :ARG0 (x4 / figure :mod "1a"))
            :ARG1 (x5 / immunoblot-01
                  :ARG3 (x6 / protein
                        :name (x7 / name :op1 "pS338CRAF")))))


# ::id PMC31784470002.12
# ::snt Note that phosphorylation at S338 steadily increased, even when concentrations were reached that inhibited MEK/ERK.
# ::tok Note that phosphorylation at S338 steadily increased , even when concentrations were reached that inhibited MEK/ERK .
(x1 / note-02
      :ARG1 (x9 / reach-01
            :ARG0 (x2 / phosphorylate-01
                  :ARG1 (x3 / amino-acid
                        :mod "338"
                        :name (x4 / name :op1 "serine")
                        :xref (x / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :ARG2 (x8 / concentrate-02
                  :ARG1-of (x6 / increase-01
                        :manner (x5 / steady))
                  :ARG1-of (x7 / even-when))
            :ARG1 (x10 / inhibit-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "MEK/ERK")))))


# ::id PMC31784470002.13
# ::snt Figure 2. MEK/ERK activation requires binding of drug to the catalytic domain of RAF
# ::tok Figure 2. MEK @/@ ERK activation requires binding of drug to the catalytic domain of RAF
(x9 / require-01
      :ARG0 (x8 / activate-01
            :ARG1-of (x1 / describe-01
                  :ARG0 (x2 / figure :mod "2"))
            :ARG1 (x3 / and
                  :op1 (x4 / enzyme
                        :name (x5 / name :op1 "MEK")
                        :xref (x16 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343"))
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "ERK")
                        :xref (x15 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
      :ARG1 (x10 / bind-01
            :ARG2 (x12 / domain
                  :mod (x11 / catalytic)
                  :part-of (x13 / enzyme
                        :name (x14 / name :op1 "RAF")
                        :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))))


# ::id PMC31784470002.14
# ::snt Figure 3. RAF inhibitor induces the active, phosphorylated state of wild-type and kinase-dead RAF
# ::tok Figure 3. RAF inhibitor induces the active , phosphorylated state of wild @-@ type and kinase @-@ dead RAF
(x14 / die-01
      :ARG1 (x8 / state
            :ARG1-of (x1 / describe-01
                  :ARG0 (x2 / figure :mod "3")
                  :ARG1 (x6 / induce-01
                        :ARG0 (x5 / inhibit-01
                              :ARG1 (x3 / enzyme
                                    :name (x4 / name :op1 "RAF")
                                    :xref (x17 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))
                        :ARG2 (x7 / activity-06)))
            :mod (x9 / phosphorylate-01
                  :ARG1 (x11 / and
                        :op1 (x10 / wild-type)
                        :op2 (x12 / enzyme
                              :name (x13 / name :op1 "kinase")
                              :xref (x18 / xref :value "UNIPROT:ITK_HUMAN" :prob "0.293")))))
      :ARG2 (x15 / enzyme
            :name (x16 / name :op1 "RAF")
            :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))


# ::id PMC31784470002.15
# ::snt Thus, activation of MEK/ERK by PLX depends on its direct binding to the RAF kinase active site.
# ::tok Thus , activation of MEK @/@ ERK by PLX depends on its direct binding to the RAF kinase active site .
(x1 / infer-01
      :ARG1 (x7 / depend-01
            :ARG0 (x2 / activate-01
                  :ARG1 (x3 / pathway
                        :name (x4 / name :op1 "MEK/ERK"))
                  :ARG0 (x5 / small-molecule
                        :name (x6 / name :op1 "PLX")
                        :xref (x14 / xref :value "PUBCHEM:449006" :prob "17.186693")))
            :ARG1 (x9 / bind-01
                  :ARG1-of (x8 / direct-02)
                  :ARG2 (x13 / protein-segment
                        :ARG1 (x12 / activity-06
                              :ARG1 (x11 / kinase
                                    :name (x10 / name :op1 "RAF")
                                    :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))))))


# ::id PMC31784470002.16
# ::snt Thus, activation of RAF by ATP-competitive inhibitors can be explained by transactivation: binding of drug to one RAF in the dimer activates the other.
# ::tok Thus , activation of RAF by ATP @-@ competitive inhibitors can be explained by transactivation : binding of drug to one RAF in the dimer activates the other .
(x1 / infer-01
      :ARG1 (x2 / possible-01
            :ARG1 (x11 / explain-01
                  :ARG0 (x3 / activate-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "RAF")
                              :xref (x19 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))
                        :ARG0 (x10 / molecular-physical-entity
                              :ARG0-of (x9 / inhibit-01
                                    :ARG1 (x8 / compete-01
                                          :ARG2 (x6 / small-molecule
                                                :name (x7 / name :op1 "ATP")
                                                :xref (x20 / xref :value "PUBCHEM:5957" :prob "14.368295"))))))
                  :ARG0 (x12 / transactivate-01)
                  :ARG1 (x13 / bind-01
                        :ARG2 (x14 / enzyme
                              :name (x15 / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))
                        :ARG1 (x16 / dimer
                              :ARG1-of (x17 / activate-01
                                    :ARG0 (x18 / other)))))))


# ::id PMC31784470002.17
# ::snt This is consistent with the enhancement of induction by active RAS, which promotes homo- and hetero-dimerization of BRAF and CRAF10,12.
# ::tok This is consistent with the enhancement of induction by active RAS , which promotes homo @- and hetero @-@ dimerization of BRAF and CRAF10,12 .
(x2 / consistent-01
      :ARG1 (x1 / this)
      :ARG2 (x3 / enhance-01
            :ARG1 (x4 / induce-01
                  :ARG0 (x5 / enzyme
                        :ARG1-of (x6 / activate-01)
                        :name (x7 / name :op1 "RAS")
                        :ARG0-of (x8 / promote-01
                              :ARG1 (x10 / and
                                    :op1 (x9 / homo)
                                    :op2 (x13 / dimerize-01
                                          :ARG1 (x11 / enzyme
                                                :name (x12 / name :op1 "hetero")))))
                        :xref (x20 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :ARG1 (x16 / and
                        :op1 (x14 / enzyme
                              :name (x15 / name :op1 "BRAF")
                              :xref (x19 / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004"))
                        :op2 (x17 / enzyme
                              :name (x18 / name :op1 "CRAF10,12")
                              :xref (x / xref :value "UNIPROT:TRAF3_HUMAN" :prob "0.282"))))))


# ::id PMC31784470002.18
# ::snt Our model suggests that transactivation will be dependent on formation of RAF dimers.
# ::tok Our model suggests that transactivation will be dependent on formation of RAF dimers .
(x3 / suggest-01
      :ARG0 (x2 / model
            :poss (x1 / we))
      :ARG1 (x5 / depend-01
            :ARG0 (x4 / transactivate-00)
            :ARG1 (x6 / form-01
                  :ARG1 (x9 / dimer
                        :mod (x7 / enzyme
                              :name (x8 / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))))


# ::id PMC31784470002.19
# ::snt All RAF inhibitors tested induced phosphorylation at p338 of endogenous CRAF (Fig. 3d).
# ::tok All RAF inhibitors tested induced phosphorylation at p338 of endogenous CRAF ( Fig . 3d ) .
(x6 / test-01
      :ARG0 (x5 / molecular-physical-entity
            :mod (x1 / all)
            :ARG0-of (x4 / inhibit-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "RAF")
                        :xref (x17 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))
      :ARG1 (x7 / induce-01
            :ARG2 (x8 / phosphorylate-01
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "p338")
                        :xref (x / xref :value "UNIPROT:C1QBP_HUMAN" :prob "0.262"))
                  :ARG2 (x11 / enzyme
                        :mod (x12 / endogenous)
                        :name (x13 / name :op1 "CRAF")
                        :xref (x16 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))))
      :ARG1-of (x14 / describe-01
            :ARG0 (x15 / figure :mod "3d")))


# ::id PMC31784470002.20
# ::snt The data suggest that binding of PLX to CRAF induces activation of the enzyme and, subsequently, ERK signaling.
# ::tok The data suggest that binding of PLX to CRAF induces activation of the enzyme and , subsequently , ERK signaling .
(x2 / suggest-01
      :ARG0 (x1 / data)
      :ARG1 (x8 / induce-01
            :ARG0 (x3 / bind-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "PLX")
                        :xref (x17 / xref :value "UNIPROT:PLXD1_HUMAN" :prob "0.233"))
                  :ARG2 (x6 / enzyme
                        :name (x7 / name :op1 "CRAF")
                        :xref (x16 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603")))
            :ARG2 (x9 / activate-01
                  :ARG1 (x11 / and
                        :op1 (x10 / enzyme)
                        :op2 (x15 / signal-07
                              :mod (x12 / subsequent)
                              :ARG1 (x13 / enzyme
                                    :name (x14 / name :op1 "ERK")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))))


# ::id PMC31784470002.21
# ::snt Six distinct ATP-competitive RAF inhibitors induced ERK activation in cells with wild-type BRAF, but inhibited signaling in mutant BRAFV600E cells (Fig. 1a, b, Supplementary Fig. 2a, b, Data Not Shown (DNS), structures of compounds shown in Supplementary Fig. 3, except that of PLX4032, which is unavailable).
# ::tok Six distinct ATP @-@ competitive RAF inhibitors induced ERK activation in cells with wild @-@ type BRAF , but inhibited signaling in mutant BRAFV600E cells ( Fig . 1a , b, Supplementary Fig . 2a , b, Data Not Shown ( DNS ) , structures of compounds shown in Supplementary Fig . 3 , except that of PLX4032 , which is unavailable ) .
(x1 / multi-sentence
      :snt1 (x10 / induce-01
            :ARG0 (x9 / molecular-physical-entity
                  :quant "6"
                  :mod (x2 / distinct)
                  :ARG0-of (x5 / compete-01
                        :ARG1 (x3 / small-molecule
                              :name (x4 / name :op1 "ATP")
                              :xref (x47 / xref :value "PUBCHEM:5957" :prob "14.368295")))
                  :ARG0-of (x8 / inhibit-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))
            :ARG2 (x13 / activate-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "ERK")
                        :xref (x46 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :location (x14 / cell
                  :mod (x15 / wild-type)
                  :name (x16 / name :op1 "BRAF"))
            :ARG1-of (x17 / contrast-01
                  :ARG2 (x18 / inhibit-01
                        :ARG1 (x19 / signal-07)
                        :location (x23 / cell
                              :mod (x20 / enzyme
                                    :ARG2-of (x21 / mutate-01)
                                    :name (x22 / name :op1 "BRAFV600E"))))
                  :ARG1-of (x24 / describe-01
                        :ARG0 (x25 / and
                              :op1 (x26 / figure :mod "1a")
                              :op2 (x27 / figure :mod "2b")))))
      :snt2 (x28 / and
            :op2 (x29 / and
                  :op1 (x30 / figure :mod "2a")
                  :op2 (x31 / figure :mod "2b"))
            :ARG1-of (x32 / describe-01
                  :ARG0 (x33 / data
                        :ARG1-of (x34 / show-01 :polarity "-")))
            :ARG1-of (x35 / describe-01
                  :ARG0 (x36 / dns))
            :ARG0-of (x37 / structure
                  :consist-of (x38 / compound
                        :ARG1-of (x39 / show-01
                              :ARG0 (x41 / figure
                                    :ARG2-of (x40 / supplement-01)
                                    :mod "3"))))
            :ARG2-of (x42 / except-01
                  :ARG1 (x43 / cell-line
                        :name (x44 / name :op1 "PLX4032")
                        :ARG0-of (x45 / available :polarity "-")))))


# ::id PMC31784470002.22
# ::snt PLX47206, and its analog in clinical trial PLX4032, were studied in more detail.
# ::tok PLX47206 , and its analog in clinical trial PLX4032 , were studied in more detail .
(x8 / study-01
      :ARG1 (x3 / and
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "PLX47206"))
            :op2 (x4 / analog
                  :location (x6 / trial-06
                        :mod (x5 / clinic)
                        :name (x7 / name :op1 "PLX4032"))))
      :manner (x10 / detail-01
            :degree (x9 / more)))


# ::id PMC31784470002.23
# ::snt Transactivation from CRAF to BRAF can occur as well.
# ::tok Transactivation from CRAF to BRAF can occur as well .
(x1 / possible-01
      :ARG1 (x7 / be-temporally-at-91
            :ARG1 (x2 / transactivate-01
                  :ARG2 (x3 / enzyme
                        :name (x4 / name :op1 "CRAF")
                        :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
                  :ARG1 (x5 / gene
                        :name (x6 / name :op1 "BRAF")
                        :xref (x9 / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004")))
            :ARG2 (x8 / as-well)))


# ::id PMC31784470003.1
# ::snt We employed chemical genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors.
# ::tok We employed chemical genetic methods to show that drug @-@ mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors .
(x2 / employ-02
      :ARG0 (x1 / we)
      :ARG1 (x5 / method
            :mod (x3 / chemical)
            :mod (x4 / genetics))
      :purpose (x6 / show-01
            :ARG1 (x11 / responsible-01
                  :ARG1-of (x7 / mediate-01)
                  :ARG0 (x8 / transactivate-01
                        :ARG1 (x10 / dimer
                              :name (x9 / name :op1 "RAF")))
                  :ARG1 (x13 / activate-01
                        :manner (x12 / paradox)
                        :ARG1 (x14 / enzyme)
                        :ARG0 (x15 / molecular-physical-entity
                              :ARG0-of (x16 / inhibit-01))))))


# ::id PMC31784470003.2
# ::snt Induction of ERK signaling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity.
# ::tok Induction of ERK signaling requires direct binding of the drug to the ATP @-@ binding site of one kinase of the dimer and is dependent on RAS activity .
(x5 / require-01
      :ARG0 (x1 / induce-01
            :ARG2 (x2 / enzyme
                  :name (x3 / name :op1 "ERK")
                  :ARG0-of (x4 / signal-07)
                  :xref (x21 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
      :ARG1 (x7 / bind-01
            :ARG1-of (x6 / direct-02)
            :ARG1 (x8 / drug)
            :ARG2 (x12 / protein-segment
                  :ARG1-of (x11 / bind-01
                        :ARG2 (x9 / small-molecule
                              :name (x10 / name :op1 "ATP")
                              :xref (x22 / xref :value "PUBCHEM:5957" :prob "14.368295")))
                  :part-of (x13 / enzyme
                        :name (x14 / name :op1 "1" :op2 "kinase"))))
      :ARG2 (x17 / depend-01
            :ARG0 (x16 / and
                  :mod (x15 / dimer))
            :ARG1 (x20 / activity-06
                  :ARG0 (x18 / enzyme
                        :name (x19 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))


# ::id PMC31784470003.3
# ::snt Drug binding to one member of RAF homo-(CRAF/CRAF) or heterodimers (CRAF/BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer.
# ::tok Drug binding to one member of RAF homo- ( CRAF/CRAF ) or heterodimers ( CRAF/BRAF ) inhibits one protomer , but results in transactivation of the drug @-@ free protomer .
(x15 / contrast-01
      :ARG1 (x2 / bind-01
            :ARG1 (x1 / drug)
            :ARG2 (x7 / or
                  :op1 (x3 / member
                        :quant "1"
                        :part-of (x4 / enzyme
                              :name (x5 / name :op1 "RAF")
                              :xref (x23 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))
                        :name (x6 / name :op1 "homo-" :op2 "CRAF/CRAF"))
                  :op2 (x8 / heterodimer
                        :ARG1-of (x9 / describe-01
                              :ARG2 (x10 / name :op1 "CRAF/BRAF"))
                        :ARG0-of (x11 / inhibit-01
                              :ARG1 (x12 / enzyme
                                    :name (x13 / name :op1 "1")
                                    :xref (x24 / xref :value "UNIPROT:NOX1_HUMAN" :prob "0.573")))
                        :name (x14 / name :op1 "protomer"))))
      :ARG2 (x16 / thing
            :ARG2-of (x17 / result-01
                  :ARG1 (x18 / transactivate-01
                        :ARG1 (x20 / free-04
                              :ARG2 (x19 / drug))
                        :ARG2 (x21 / protein
                              :name (x22 / name :op1 "protomer")
                              :xref (x / xref :value "UNIPROT:CCD50_HUMAN" :prob "0.272"))))))


# ::id PMC31784470003.4
# ::snt Figure 4. MEK/ERK induction occurs via transactivation of RAF dimers
# ::tok Figure 4. MEK @/@ ERK induction occurs via transactivation of RAF dimers
(x4 / induce-01
      :ARG0 (x1 / figure :mod "4")
      :ARG1 (x2 / pathway
            :name (x3 / name :op1 "MEK/ERK"))
      :ARG2 (x5 / occur-01)
      :instrument (x6 / transactivate-01
            :ARG1 (x8 / dimer
                  :name (x7 / name :op1 "RAF"))))


# ::id PMC31784470003.5
# ::snt b, Coexpression of drug-sensitive V5-tagged catC with drug-resistant FLAG-catC reveals that activation in the homodimer occurs in trans. 293H cells expressing the indicated mutants V5-tagged catC and FLAG-tagged catC were treated with a dose of JAB34 (10μM/1 hour) that inhibits catCS428C when expressed alone.
# ::tok b , Coexpression of drug @-@ sensitive V5 @-@ tagged catC with drug @-@ resistant FLAG @-@ catC reveals that activation in the homodimer occurs in trans . 293H cells expressing the indicated mutants V5 @-@ tagged catC and FLAG @-@ tagged catC were treated with a dose of JAB34 ( 10μM/1 hour ) that inhibits catCS428C when expressed alone .
(x1 / multi-sentence
      :snt1 (x2 / and
            :li "b"
            :op1 (x3 / express-03
                  :ARG2 (x4 / and
                        :op1 (x5 / enzyme
                              :ARG1-of (x10 / tag-01
                                    :ARG2 (x6 / cell-line
                                          :ARG0-of (x8 / sensitive-03
                                                :ARG1 (x7 / drug))
                                          :name (x9 / name :op1 "V5")))
                              :name (x11 / name :op1 "catC")
                              :xref (x48 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))
                        :op2 (x13 / resist-01
                              :ARG1 (x12 / drug))))
            :op2 (x16 / reveal-01
                  :ARG0 (x14 / enzyme
                        :name (x15 / name :op1 "catC")
                        :xref (x51 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603"))
                  :ARG1 (x22 / express-03
                        :ARG0 (x17 / activate-01
                              :ARG1 (x18 / homodimer)
                              :mod (x19 / trans)
                              :ARG1 (x20 / cell-line
                                    :name (x21 / name :op1 "293H")))
                        :ARG2 (x23 / enzyme
                              :ARG1-of (x28 / tag-01
                                    :ARG2 (x24 / indicate-01
                                          :ARG1 (x25 / enzyme
                                                :ARG2-of (x26 / mutate-01)
                                                :name (x27 / name :op1 "V5"))))
                              :name (x29 / name :op1 "catC")
                              :xref (x47 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603")))))
      :snt2 (x36 / treat-04
            :ARG1 (x30 / and
                  :op1 (x31 / enzyme
                        :ARG1-of (x34 / tag-01
                              :ARG2 (x32 / protein
                                    :name (x33 / name :op1 "FLAG")
                                    :xref (x49 / xref :value "UNIPROT:AL5AP_HUMAN" :prob "0.222")))
                        :name (x35 / name :op1 "catC")
                        :xref (x50 / xref :value "UNIPROT:CATC_HUMAN" :prob "0.603")))
            :ARG2 (x37 / dose-01
                  :ARG2 (x38 / small-molecule
                        :name (x39 / name :op1 "JAB34"))
                  :ARG4 (x41 / hour
                        :name (x40 / name :op1 "10μM/1"))
                  :ARG1 (x42 / inhibit-01
                        :ARG1 (x43 / enzyme
                              :name (x44 / name :op1 "catCS428C")
                              :xref (x / xref :value "UNIPROT:CATC_HUMAN" :prob "0.222"))
                        :condition (x45 / express-03
                              :mod (x46 / alone))))))


# ::id PMC31784470003.6
# ::snt c, Activation in the context of the heterodimer BRAF/CRAF occurs in trans.
# ::tok c , Activation in the context of the heterodimer BRAF @/@ CRAF occurs in trans .
(x3 / activate-01
      :ARG1-of (x1 / describe-01
            :ARG0 (x2 / figure :mod "4c"))
      :ARG1 (x4 / context
            :mod (x5 / heterodimer
                  :ARG1 (x6 / enzyme
                        :name (x7 / name :op1 "BRAF")
                        :mod (x8 / enzyme
                              :name (x9 / name :op1 "CRAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
                        :xref (x11 / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004")))
            :location (x10 / trans)))


# ::id PMC31784470003.7
# ::snt c, Treatment with RAF inhibitor results in elevated phosphorylation at activating phosphorylation sites on RAF.
# ::tok c , Treatment with RAF inhibitor results in elevated phosphorylation at activating phosphorylation sites on RAF .
(x1 / and
      :op1 (x2 / figure :mod "5c")
      :op2 (x7 / result-01
            :ARG1 (x3 / treat-04
                  :ARG2 (x6 / inhibit-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "RAF")
                              :xref (x15 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))
            :ARG2 (x9 / phosphorylate-01
                  :ARG1-of (x8 / elevate-01)
                  :ARG1 (x12 / protein-segment
                        :ARG0-of (x10 / activate-01)
                        :ARG1-of (x11 / phosphorylate-01)
                        :location (x13 / enzyme
                              :name (x14 / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))))


# ::id PMC31784470003.8
# ::snt V5-tagged wild-type CRAF or kinase-dead CRAFD486N were overexpressed in 293H cells.
# ::tok V5 @-@ tagged wild @-@ type CRAF or kinase @-@ dead CRAFD486N were overexpressed in 293H cells .
(x12 / overexpress-01
      :ARG1 (x7 / or
            :ARG1-of (x3 / tag-01
                  :ARG2 (x1 / protein
                        :name (x2 / name :op1 "V5")))
            :op1 (x4 / enzyme
                  :mod (x5 / wild-type)
                  :name (x6 / name :op1 "CRAF")
                  :xref (x16 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))
            :op2 (x8 / enzyme
                  :name (x9 / name :op1 "kinase")
                  :ARG1-of (x10 / die-01)
                  :name (x11 / name :op1 "CRAFD486N")
                  :xref (x15 / xref :value "UNIPROT:TRAF3_HUMAN" :prob "0.212")))
      :location (x13 / cell-line
            :name (x14 / name :op1 "293H")))


# ::id PMC31784470003.9
# ::snt After 24 hours cells were treated with vehicle or PLX4720 (5μM/1hour) and lysates were immunoblotted for p338CRAF and p621CRAF.
# ::tok After 24 hours cells were treated with vehicle or PLX4720 ( 5μM/1 hour ) and lysates were immunoblotted for p338CRAF and p621CRAF .
(x13 / and
      :op1 (x12 / hour
            :time (x1 / after
                  :quant (x2 / temporal-quantity
                        :quant "24"
                        :unit (x3 / hour))
                  :op1 (x5 / treat-04
                        :ARG1 (x4 / cell)
                        :ARG2 (x7 / or
                              :op1 (x6 / vehicle)
                              :op2 (x8 / small-molecule
                                    :name (x9 / name :op1 "PLX4720")
                                    :xref (x21 / xref :value "PUBCHEM:24180719" :prob "18.572987"))))
                  :op2 (x10 / small-molecule
                        :name (x11 / name :op1 "5μM/1"))))
      :op2 (x15 / immunoblot-01
            :ARG1 (x14 / lysate)
            :ARG3 (x18 / and
                  :op1 (x16 / enzyme
                        :name (x17 / name :op1 "p338CRAF"))
                  :op2 (x19 / enzyme
                        :name (x20 / name :op1 "p621CRAF")
                        :xref (x / xref :value "UNIPROT:MCAF1_HUMAN" :prob "0.232")))))


# ::id PMC31784470003.10
# ::snt The gatekeeper mutant CRAFT421M was used as negative control.
# ::tok The gatekeeper mutant CRAFT421M was used as negative control .
(x6 / use-01
      :ARG1 (x1 / enzyme
            :name (x2 / name :op1 "gatekeeper")
            :ARG2-of (x3 / mutate-01
                  :ARG1 (x4 / enzyme
                        :name (x5 / name :op1 "CRAFT421M")
                        :xref (x / xref :value "UNIPROT:CCRL2_HUMAN" :prob "0.212"))))
      :ARG2 (x8 / control-01
            :ARG2-of (x7 / negative-01)))


# ::id PMC31784470003.11
# ::snt d. Samples as in Fig. 1a, immunoblotted for pS338CRAF.
# ::tok d . Samples as in Fig . 1a , immunoblotted for pS338CRAF .
(x1 / sample-01
      :li "d"
      :ARG1-of (x2 / possible-01
            :ARG1-of (x3 / describe-01
                  :ARG0 (x4 / figure :mod "1a"))
            :ARG1 (x5 / immunoblot-01
                  :ARG3 (x6 / protein
                        :name (x7 / name :op1 "pS338CRAF")))))


# ::id PMC31784470003.12
# ::snt Note that phosphorylation at S338 steadily increased, even when concentrations were reached that inhibited MEK/ERK.
# ::tok Note that phosphorylation at S338 steadily increased , even when concentrations were reached that inhibited MEK/ERK .
(x1 / note-02
      :ARG1 (x9 / reach-01
            :ARG0 (x2 / phosphorylate-01
                  :ARG1 (x3 / amino-acid
                        :mod "338"
                        :name (x4 / name :op1 "serine")
                        :xref (x / xref :value "PUBCHEM:5951" :prob "11.218784")))
            :ARG2 (x8 / concentrate-02
                  :ARG1-of (x6 / increase-01
                        :manner (x5 / steady))
                  :ARG1-of (x7 / even-when))
            :ARG1 (x10 / inhibit-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "MEK/ERK")))))


# ::id PMC31784470003.13
# ::snt Figure 2. MEK/ERK activation requires binding of drug to the catalytic domain of RAF
# ::tok Figure 2. MEK @/@ ERK activation requires binding of drug to the catalytic domain of RAF
(x9 / require-01
      :ARG0 (x8 / activate-01
            :ARG1-of (x1 / describe-01
                  :ARG0 (x2 / figure :mod "2"))
            :ARG1 (x3 / and
                  :op1 (x4 / enzyme
                        :name (x5 / name :op1 "MEK")
                        :xref (x16 / xref :value "UNIPROT:M3K1_HUMAN" :prob "0.343"))
                  :op2 (x6 / enzyme
                        :name (x7 / name :op1 "ERK")
                        :xref (x15 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003"))))
      :ARG1 (x10 / bind-01
            :ARG2 (x12 / domain
                  :mod (x11 / catalytic)
                  :part-of (x13 / enzyme
                        :name (x14 / name :op1 "RAF")
                        :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))))


# ::id PMC31784470003.14
# ::snt Figure 3. RAF inhibitor induces the active, phosphorylated state of wild-type and kinase-dead RAF
# ::tok Figure 3. RAF inhibitor induces the active , phosphorylated state of wild @-@ type and kinase @-@ dead RAF
(x14 / die-01
      :ARG1 (x8 / state
            :ARG1-of (x1 / describe-01
                  :ARG0 (x2 / figure :mod "3")
                  :ARG1 (x6 / induce-01
                        :ARG0 (x5 / inhibit-01
                              :ARG1 (x3 / enzyme
                                    :name (x4 / name :op1 "RAF")
                                    :xref (x17 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))
                        :ARG2 (x7 / activity-06)))
            :mod (x9 / phosphorylate-01
                  :ARG1 (x11 / and
                        :op1 (x10 / wild-type)
                        :op2 (x12 / enzyme
                              :name (x13 / name :op1 "kinase")
                              :xref (x18 / xref :value "UNIPROT:ITK_HUMAN" :prob "0.293")))))
      :ARG2 (x15 / enzyme
            :name (x16 / name :op1 "RAF")
            :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))


# ::id PMC31784470003.15
# ::snt Thus, activation of MEK/ERK by PLX depends on its direct binding to the RAF kinase active site.
# ::tok Thus , activation of MEK @/@ ERK by PLX depends on its direct binding to the RAF kinase active site .
(x1 / infer-01
      :ARG1 (x7 / depend-01
            :ARG0 (x2 / activate-01
                  :ARG1 (x3 / pathway
                        :name (x4 / name :op1 "MEK/ERK"))
                  :ARG0 (x5 / small-molecule
                        :name (x6 / name :op1 "PLX")
                        :xref (x14 / xref :value "PUBCHEM:449006" :prob "17.186693")))
            :ARG1 (x9 / bind-01
                  :ARG1-of (x8 / direct-02)
                  :ARG2 (x13 / protein-segment
                        :ARG1 (x12 / activity-06
                              :ARG1 (x11 / kinase
                                    :name (x10 / name :op1 "RAF")
                                    :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003")))))))


# ::id PMC31784470003.16
# ::snt Thus, activation of RAF by ATP-competitive inhibitors can be explained by transactivation: binding of drug to one RAF in the dimer activates the other.
# ::tok Thus , activation of RAF by ATP @-@ competitive inhibitors can be explained by transactivation : binding of drug to one RAF in the dimer activates the other .
(x1 / infer-01
      :ARG1 (x2 / possible-01
            :ARG1 (x11 / explain-01
                  :ARG0 (x3 / activate-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "RAF")
                              :xref (x19 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))
                        :ARG0 (x10 / molecular-physical-entity
                              :ARG0-of (x9 / inhibit-01
                                    :ARG1 (x8 / compete-01
                                          :ARG2 (x6 / small-molecule
                                                :name (x7 / name :op1 "ATP")
                                                :xref (x20 / xref :value "PUBCHEM:5957" :prob "14.368295"))))))
                  :ARG0 (x12 / transactivate-01)
                  :ARG1 (x13 / bind-01
                        :ARG2 (x14 / enzyme
                              :name (x15 / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))
                        :ARG1 (x16 / dimer
                              :ARG1-of (x17 / activate-01
                                    :ARG0 (x18 / other)))))))


# ::id PMC31784470003.17
# ::snt This is consistent with the enhancement of induction by active RAS, which promotes homo- and hetero-dimerization of BRAF and CRAF10,12.
# ::tok This is consistent with the enhancement of induction by active RAS , which promotes homo @- and hetero @-@ dimerization of BRAF and CRAF10,12 .
(x2 / consistent-01
      :ARG1 (x1 / this)
      :ARG2 (x3 / enhance-01
            :ARG1 (x4 / induce-01
                  :ARG0 (x5 / enzyme
                        :ARG1-of (x6 / activate-01)
                        :name (x7 / name :op1 "RAS")
                        :ARG0-of (x8 / promote-01
                              :ARG1 (x10 / and
                                    :op1 (x9 / homo)
                                    :op2 (x13 / dimerize-01
                                          :ARG1 (x11 / enzyme
                                                :name (x12 / name :op1 "hetero")))))
                        :xref (x20 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263"))
                  :ARG1 (x16 / and
                        :op1 (x14 / enzyme
                              :name (x15 / name :op1 "BRAF")
                              :xref (x19 / xref :value "UNIPROT:BRAF_HUMAN" :prob "1.004"))
                        :op2 (x17 / enzyme
                              :name (x18 / name :op1 "CRAF10,12")
                              :xref (x / xref :value "UNIPROT:TRAF3_HUMAN" :prob "0.282"))))))


# ::id PMC31784470003.18
# ::snt Our model suggests that transactivation will be dependent on formation of RAF dimers.
# ::tok Our model suggests that transactivation will be dependent on formation of RAF dimers .
(x3 / suggest-01
      :ARG0 (x2 / model
            :poss (x1 / we))
      :ARG1 (x5 / depend-01
            :ARG0 (x4 / transactivate-00)
            :ARG1 (x6 / form-01
                  :ARG1 (x9 / dimer
                        :mod (x7 / enzyme
                              :name (x8 / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))))


# ::id PMC31784470003.19
# ::snt All RAF inhibitors tested induced phosphorylation at p338 of endogenous CRAF (Fig. 3d).
# ::tok All RAF inhibitors tested induced phosphorylation at p338 of endogenous CRAF ( Fig . 3d ) .
(x6 / test-01
      :ARG0 (x5 / molecular-physical-entity
            :mod (x1 / all)
            :ARG0-of (x4 / inhibit-01
                  :ARG1 (x2 / enzyme
                        :name (x3 / name :op1 "RAF")
                        :xref (x17 / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))
      :ARG1 (x7 / induce-01
            :ARG2 (x8 / phosphorylate-01
                  :ARG1 (x9 / protein
                        :name (x10 / name :op1 "p338")
                        :xref (x / xref :value "UNIPROT:C1QBP_HUMAN" :prob "0.262"))
                  :ARG2 (x11 / enzyme
                        :mod (x12 / endogenous)
                        :name (x13 / name :op1 "CRAF")
                        :xref (x16 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603"))))
      :ARG1-of (x14 / describe-01
            :ARG0 (x15 / figure :mod "3d")))


# ::id PMC31784470003.20
# ::snt The data suggest that binding of PLX to CRAF induces activation of the enzyme and, subsequently, ERK signaling.
# ::tok The data suggest that binding of PLX to CRAF induces activation of the enzyme and , subsequently , ERK signaling .
(x2 / suggest-01
      :ARG0 (x1 / data)
      :ARG1 (x8 / induce-01
            :ARG0 (x3 / bind-01
                  :ARG1 (x4 / protein
                        :name (x5 / name :op1 "PLX")
                        :xref (x17 / xref :value "UNIPROT:PLXD1_HUMAN" :prob "0.233"))
                  :ARG2 (x6 / enzyme
                        :name (x7 / name :op1 "CRAF")
                        :xref (x16 / xref :value "UNIPROT:RAF1_HUMAN" :prob "0.603")))
            :ARG2 (x9 / activate-01
                  :ARG1 (x11 / and
                        :op1 (x10 / enzyme)
                        :op2 (x15 / signal-07
                              :mod (x12 / subsequent)
                              :ARG1 (x13 / enzyme
                                    :name (x14 / name :op1 "ERK")
                                    :xref (x / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))))))


# ::id PMC31784470003.21
# ::snt Six distinct ATP-competitive RAF inhibitors induced ERK activation in cells with wild-type BRAF, but inhibited signaling in mutant BRAFV600E cells (Fig. 1a, b, Supplementary Fig. 2a, b, Data Not Shown (DNS), structures of compounds shown in Supplementary Fig. 3, except that of PLX4032, which is unavailable).
# ::tok Six distinct ATP @-@ competitive RAF inhibitors induced ERK activation in cells with wild @-@ type BRAF , but inhibited signaling in mutant BRAFV600E cells ( Fig . 1a , b, Supplementary Fig . 2a , b, Data Not Shown ( DNS ) , structures of compounds shown in Supplementary Fig . 3 , except that of PLX4032 , which is unavailable ) .
(x1 / multi-sentence
      :snt1 (x10 / induce-01
            :ARG0 (x9 / molecular-physical-entity
                  :quant "6"
                  :mod (x2 / distinct)
                  :ARG0-of (x5 / compete-01
                        :ARG1 (x3 / small-molecule
                              :name (x4 / name :op1 "ATP")
                              :xref (x47 / xref :value "PUBCHEM:5957" :prob "14.368295")))
                  :ARG0-of (x8 / inhibit-01
                        :ARG1 (x6 / enzyme
                              :name (x7 / name :op1 "RAF")
                              :xref (x / xref :value "UNIPROT:RAF1_HUMAN" :prob "1.003"))))
            :ARG2 (x13 / activate-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "ERK")
                        :xref (x46 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "1.003")))
            :location (x14 / cell
                  :mod (x15 / wild-type)
                  :name (x16 / name :op1 "BRAF"))
            :ARG1-of (x17 / contrast-01
                  :ARG2 (x18 / inhibit-01
                        :ARG1 (x19 / signal-07)
                        :location (x23 / cell
                              :mod (x20 / enzyme
                                    :ARG2-of (x21 / mutate-01)
                                    :name (x22 / name :op1 "BRAFV600E"))))
                  :ARG1-of (x24 / describe-01
                        :ARG0 (x25 / and
                              :op1 (x26 / figure :mod "1a")
                              :op2 (x27 / figure :mod "2b")))))
      :snt2 (x28 / and
            :op2 (x29 / and
                  :op1 (x30 / figure :mod "2a")
                  :op2 (x31 / figure :mod "2b"))
            :ARG1-of (x32 / describe-01
                  :ARG0 (x33 / data
                        :ARG1-of (x34 / show-01 :polarity "-")))
            :ARG1-of (x35 / describe-01
                  :ARG0 (x36 / dns))
            :ARG0-of (x37 / structure
                  :consist-of (x38 / compound
                        :ARG1-of (x39 / show-01
                              :ARG0 (x41 / figure
                                    :ARG2-of (x40 / supplement-01)
                                    :mod "3"))))
            :ARG2-of (x42 / except-01
                  :ARG1 (x43 / cell-line
                        :name (x44 / name :op1 "PLX4032")
                        :ARG0-of (x45 / available :polarity "-")))))


# ::id PMC31784470003.22
# ::snt PLX47206, and its analog in clinical trial PLX4032, were studied in more detail.
# ::tok PLX47206 , and its analog in clinical trial PLX4032 , were studied in more detail .
(x8 / study-01
      :ARG1 (x3 / and
            :op1 (x1 / enzyme
                  :name (x2 / name :op1 "PLX47206"))
            :op2 (x4 / analog
                  :location (x6 / trial-06
                        :mod (x5 / clinic)
                        :name (x7 / name :op1 "PLX4032"))))
      :manner (x10 / detail-01
            :degree (x9 / more)))


# ::id PMC36904800001.1
# ::snt but instead RAC1 and CDC42 from the RHO subfamily of small GTPases bind and activate p110β via its RBD.
# ::tok but instead RAC1 and CDC42 from the RHO subfamily of small GTPases bind and activate p110β via its RBD .
(x1 / contrast-01
      :ARG2 (x15 / bind-01
            :ARG1 (x10 / protein-segment
                  :ARG1-of (x2 / instead-of-91
                        :ARG1 (x5 / and
                              :op1 (x3 / protein
                                    :name (x4 / name :op1 "RAC1")
                                    :xref (x23 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                              :op2 (x6 / protein
                                    :name (x7 / name :op1 "CDC42")
                                    :xref (x25 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                        :ARG2 (x8 / protein
                              :name (x9 / name :op1 "RHO")
                              :xref (x22 / xref :value "UNIPROT:OPSD_HUMAN" :prob "1.002")))
                  :name (x11 / name :op1 "subfamily")
                  :part-of (x12 / enzyme
                        :mod (x13 / small)
                        :name (x14 / name :op1 "gtpase")
                        :xref (x24 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252")))
            :ARG2 (x16 / and
                  :op1 (x17 / activate-01
                        :ARG1 (x18 / enzyme
                              :name (x19 / name :op1 "p110β")
                              :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                        :instrument (x20 / protein-segment
                              :name (x21 / name :op1 "RBD"))))))


# ::id PMC36904800001.2
# ::snt Surprisingly, p110β bound to both RAC1 and CDC42 in a GTP-dependent manner.
# ::tok Surprisingly , p110β bound to both RAC1 and CDC42 in a GTP @-@ dependent manner .
(x4 / bind-01
      :ARG0-of (x1 / surprise-01)
      :ARG0 (x2 / small-molecule
            :name (x3 / name :op1 "p110β")
            :xref (x15 / xref :value "PUBCHEM:6511" :prob "9.430335"))
      :ARG2 (x7 / and
            :op1 (x5 / protein
                  :name (x6 / name :op1 "RAC1")
                  :xref (x13 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :op2 (x8 / protein
                  :name (x9 / name :op1 "CDC42")
                  :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :manner (x12 / depend-01
            :ARG1 (x10 / small-molecule
                  :name (x11 / name :op1 "GTP")
                  :xref (x14 / xref :value "PUBCHEM:6830" :prob "15.470645"))))


# ::id PMC36904800001.3
# ::snt Figure 2. RAC and CDC42 Directly Bind and Active p110b (A) p110b interacts with distinct RAS subfamily GTPases to non-b isoforms.
# ::tok Figure 2. RAC and CDC42 Directly Bind and Active p110b ( A ) p110b interacts with distinct RAS subfamily GTPases to non @-@ b isoforms .
(x9 / bind-01
      :ARG1 (x5 / and
            :ARG1-of (x1 / describe-01
                  :ARG0 (x2 / figure :mod "2"))
            :op1 (x3 / enzyme
                  :name (x4 / name :op1 "RAC")
                  :xref (x25 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :op2 (x6 / protein
                  :name (x7 / name :op1 "CDC42")
                  :xref (x26 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :ARG1-of (x8 / direct-02)
      :ARG1 (x10 / and
            :op1 (x16 / interact-01
                  :ARG0 (x11 / enzyme
                        :ARG0-of (x12 / activity-06)
                        :name (x13 / name :op1 "p110b")
                        :xref (x29 / xref :value "UNIPROT:PK3CB_HUMAN" :prob "0.293"))
                  :li "a"
                  :ARG1 (x14 / enzyme
                        :name (x15 / name :op1 "p110b")
                        :xref (x30 / xref :value "UNIPROT:PK3CB_HUMAN" :prob "0.293"))))
      :ARG2 (x18 / enzyme
            :mod (x17 / distinct)
            :name (x19 / name :op1 "RAS")
            :ARG0-of (x20 / subfamily)
            :name (x21 / name :op1 "gtpase")
            :xref (x28 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252"))
      :purpose (x24 / isoform
            :polarity "-"
            :mod (x22 / enzyme
                  :name (x23 / name :op1 "b-raf")
                  :xref (x / xref :value "UNIPROT:Q9NY11_HUMAN" :prob "0.701"))))


# ::id PMC36904800001.4
# ::snt Table summarizes results from GST pull-down assays (Figures S1C and S1D) probing 34 murine RAS subfamily GTPases for GTP-dependent binding of type I PI3K isoforms (_, no binding; +, specific binding;++, strong binding; +++, very strong binding).
# ::tok Table summarizes results from GST pull @-@ down assays ( Figures S1C and S1D ) probing 34 murine RAS subfamily GTPases for GTP @-@ dependent binding of type I PI3K isoforms ( _, no binding ; +, specific binding ; ++, strong binding ; +++, very strong binding ) .
(x11 / probe-01
      :ARG0 (x1 / table
            :ARG1-of (x3 / result-01
                  :ARG2-of (x2 / summarize-01)
                  :ARG2 (x6 / assay-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "GST")
                              :xref (x45 / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
                  :ARG1-of (x7 / describe-01
                        :ARG0 (x10 / and
                              :op1 (x8 / figure :mod "s1c")
                              :op2 (x9 / figure :mod "s1d")))))
      :ARG1-of (x12 / describe-01
            :ARG0 (x13 / publication
                  :ARG1-of (x14 / cite-01 :ARG2 "34")))
      :mod (x15 / organism
            :name (x16 / name :op1 "muridae"))
      :ARG1 (x17 / enzyme
            :name (x18 / name :op1 "RAS")
            :ARG0-of (x19 / subfamily)
            :name (x20 / name :op1 "gtpase")
            :xref (x48 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252"))
      :location (x24 / bind-01
            :ARG0-of (x23 / depend-01
                  :ARG1 (x21 / small-molecule
                        :name (x22 / name :op1 "GTP")
                        :xref (x47 / xref :value "PUBCHEM:6830" :prob "15.470645")))
            :ARG1 (x29 / isoform
                  :mod (x25 / type
                        :ord (x26 / ordinal-entity :value "1"))
                  :mod (x27 / enzyme
                        :name (x28 / name :op1 "PI3K")
                        :xref (x / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))
      :ARG1-of (x30 / describe-01
            :ARG0 (x34 / and
                  :op1 (x31 / enzyme
                        :name (x32 / name :op1 "_,")
                        :ARG2-of (x33 / bind-01 :polarity "-"))
                  :op1 (x38 / bind-01
                        :ARG1-of (x37 / specific-02
                              :ARG2 (x35 / protein
                                    :name (x36 / name :op1 "igf-1r")
                                    :xref (x46 / xref :value "UNIPROT:IGF1R_HUMAN" :prob "0.593"))))
                  :op2 (x41 / bind-01
                        :ARG1 (x40 / strong-02
                              :name (x39 / name :op1 "++,")))
                  :op2 (x44 / bind-01
                        :ARG1-of (x43 / strong-02
                              :degree (x42 / very))))))


# ::id PMC36904800001.5
# ::snt Taken together, these data show that the RHO family GTPases RAC1 and CDC42 bind to p110β in an isoform-specific manner and potently and directly stimulate its lipid kinase activity.
# ::tok Taken together , these data show that the RHO family GTPases RAC1 and CDC42 bind to p110β in an isoform @-@ specific manner and potently and directly stimulate its lipid kinase activity .
(x5 / show-01
      :ARG0 (x4 / data
            :ARG1-of (x1 / take-01
                  :mod (x2 / together))
            :mod (x3 / this))
      :ARG1 (x23 / stimulate-01
            :ARG0 (x19 / and
                  :ARG1-of (x6 / include-91
                        :ARG2 (x8 / protein-family
                              :name (x7 / name :op1 "RHO")))
                  :op1 (x14 / bind-01
                        :ARG0 (x11 / and
                              :op1 (x9 / protein
                                    :name (x10 / name :op1 "RAC1")
                                    :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                              :op2 (x12 / protein
                                    :name (x13 / name :op1 "CDC42")
                                    :xref (x27 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                        :ARG1 (x15 / small-molecule
                              :name (x16 / name :op1 "p110β")
                              :xref (x28 / xref :value "PUBCHEM:6511" :prob "9.430335"))
                        :manner (x18 / specific-02
                              :ARG2 (x17 / isoform)))
                  :op2 (x21 / and
                        :mod (x20 / potent)))
            :ARG1-of (x22 / direct-02)
            :ARG1 (x26 / activity-06
                  :ARG1 (x25 / kinase
                        :mod (x24 / lipid)))))


# ::id PMC36904800001.6
# ::snt (F) Binding of p110b to RAC1 and CDC42 is isoform specific.
# ::tok ( F ) Binding of p110b to RAC1 and CDC42 is isoform specific .
(x11 / isoform
      :ARG1-of (x1 / describe-01
            :ARG0 (x2 / figure :mod "1f"))
      :ARG2 (x3 / bind-01
            :ARG1 (x4 / protein
                  :name (x5 / name :op1 "p110b")
                  :xref (x14 / xref :value "UNIPROT:PK3CB_HUMAN" :prob "0.293"))
            :ARG2 (x8 / and
                  :op1 (x6 / protein
                        :name (x7 / name :op1 "RAC1")
                        :xref (x13 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x9 / protein
                        :name (x10 / name :op1 "CDC42")
                        :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))
      :ARG1-of (x12 / specific-02))


# ::id PMC36904800001.7
# ::snt Purified recombinant GDP/ GTPgS-loaded RAC1 and CDC42 were incubated with lysates from COS7 cells expressing FLAGtagged p110a/p85, p110b/p85, p110g/p101, and p110d/p85.
# ::tok Purified recombinant GDP/ GTPgS @-@ loaded RAC1 and CDC42 were incubated with lysates from COS7 cells expressing FLAGtagged p110a/p85 , p110b/p85 , p110g/p101 , and p110d/p85 .
(x13 / incubate-01
      :ARG0 (x2 / enzyme
            :ARG1-of (x1 / purify-01)
            :ARG0-of (x3 / recombine-01)
            :ARG0-of (x7 / load-01
                  :ARG2 (x4 / enzyme
                        :ARG1-of (x5 / activate-01)
                        :name (x6 / name :op1 "GTPgS"))))
      :ARG1 (x10 / and
            :op1 (x8 / protein
                  :name (x9 / name :op1 "RAC1")
                  :xref (x / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :op2 (x11 / protein
                  :name (x12 / name :op1 "CDC42")
                  :xref (x23 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :ARG2 (x14 / lysate
            :source (x16 / cell
                  :name (x15 / name :op1 "COS7")
                  :ARG3-of (x17 / express-03
                        :ARG2 (x20 / and
                              :op1 (x18 / enzyme
                                    :name (x19 / name
                                          :op1 "FLAGtagged"
                                          :op2 "p110a/p85"
                                          :op3 "p110b/p85"
                                          :op4 "p110g/p101"))
                              :op2 (x21 / enzyme
                                    :name (x22 / name :op1 "p110d/p85")))))))


# ::id PMC36904800001.8
# ::snt (E) RHO GTPases directly bind p110b in a GTPdependent manner.
# ::tok ( E ) RHO GTPases directly bind p110b in a GTPdependent manner .
(x6 / bind-01
      :ARG1-of (x1 / describe-01
            :ARG0 (x2 / figure :mod "e"))
      :ARG0 (x3 / protein
            :name (x4 / name :op1 "RHO" :op2 "gtpase"))
      :ARG1-of (x5 / direct-02)
      :ARG2 (x7 / protein
            :name (x8 / name :op1 "p110b")
            :xref (x / xref :value "UNIPROT:PK3CB_HUMAN" :prob "0.293"))
      :manner (x9 / gtpdependent))


# ::id PMC36904800001.9
# ::snt Figure 3. RAC and CDC42 Are Interactors of the p110b RAS-Binding Domain
# ::tok Figure 3. RAC and CDC42 Are Interactors of the p110b RAS @-@ Binding Domain
(x8 / interact-01
      :ARG1 (x5 / and
            :ARG1-of (x1 / describe-01
                  :ARG0 (x2 / figure :mod "3"))
            :op1 (x3 / enzyme
                  :name (x4 / name :op1 "RAC")
                  :xref (x14 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
            :op2 (x6 / protein
                  :name (x7 / name :op1 "CDC42")
                  :xref (x15 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :ARG0 (x10 / protein-segment
            :name (x9 / name :op1 "p110b")
            :ARG0-of (x13 / bind-01
                  :ARG1 (x11 / enzyme
                        :name (x12 / name :op1 "RAS")
                        :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.263")))))


# ::id PMC36904800002.1
# ::snt but instead RAC1 and CDC42 from the RHO subfamily of small GTPases bind and activate p110β via its RBD.
# ::tok but instead RAC1 and CDC42 from the RHO subfamily of small GTPases bind and activate p110β via its RBD .
(x1 / contrast-01
      :ARG2 (x15 / bind-01
            :ARG1 (x10 / protein-segment
                  :ARG1-of (x2 / instead-of-91
                        :ARG1 (x5 / and
                              :op1 (x3 / protein
                                    :name (x4 / name :op1 "RAC1")
                                    :xref (x23 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                              :op2 (x6 / protein
                                    :name (x7 / name :op1 "CDC42")
                                    :xref (x25 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
                        :ARG2 (x8 / protein
                              :name (x9 / name :op1 "RHO")
                              :xref (x22 / xref :value "UNIPROT:OPSD_HUMAN" :prob "1.002")))
                  :name (x11 / name :op1 "subfamily")
                  :part-of (x12 / enzyme
                        :mod (x13 / small)
                        :name (x14 / name :op1 "gtpase")
                        :xref (x24 / xref :value "UNIPROT:RAN_HUMAN" :prob "0.252")))
            :ARG2 (x16 / and
                  :op1 (x17 / activate-01
                        :ARG1 (x18 / enzyme
                              :name (x19 / name :op1 "p110β")
                              :xref (x / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.252"))
                        :instrument (x20 / protein-segment
                              :name (x21 / name :op1 "RBD"))))))


# ::id PMC36904800002.2
# ::snt Strikingly, GTPgS-loaded RAC1 or CDC42 strongly stimulated p110b lipid kinase activity in vitro (Figure 2G), alone and in cooperation with a phosphotyrosine peptide (pY740), or when p110b was complexed with a less inhibitory, truncated p85 (Dp85 schematic in Figure 3C).
# ::tok Strikingly , GTPgS @-@ loaded RAC1 or CDC42 strongly stimulated p110b lipid kinase activity in vitro ( Figure 2G ) , alone and in cooperation with a phosphotyrosine peptide ( pY740 ) , or when p110b was complexed with a less inhibitory , truncated p85 ( Dp85 schematic in Figure 3C ) .
(x1 / multi-sentence
      :snt1 (x2 / contrast-01
            :ARG1 (x5 / load-01
                  :ARG1 (x3 / enzyme
                        :name (x4 / name :op1 "GTPgS")))
            :ARG2 (x8 / or
                  :op1 (x6 / protein
                        :name (x7 / name :op1 "RAC1")
                        :xref (x41 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
                  :op2 (x9 / protein
                        :name (x10 / name :op1 "CDC42")
                        :xref (x40 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))))
      :snt2 (x12 / stimulate-01
            :ARG1-of (x11 / strong-02)
            :ARG1 (x16 / activity-06
                  :ARG1 (x15 / kinase
                        :mod (x14 / lipid
                              :name (x13 / name :op1 "p110b"))))
            :manner (x17 / in-vitro)
            :ARG1-of (x18 / describe-01
                  :ARG0 (x28 / or
                        :op1 (x19 / figure :mod "2g")
                        :op2 (x21 / and
                              :op1 (x20 / alone)
                              :op2 (x26 / peptide
                                    :ARG0-of (x22 / cooperate-01
                                          :ARG2 (x23 / amino-acid
                                                :name (x24 / name :op1 "threonine")
                                                :ARG3-of (x25 / phosphorylate-01)
                                                :xref (x43 / xref :value "PUBCHEM:205" :prob "11.848252")))
                                    :name (x27 / name :op1 "pY740")))
                        :op3 (x34 / truncate-01
                              :time (x31 / macro-molecular-complex
                                    :ARG1 (x29 / enzyme
                                          :name (x30 / name :op1 "p110b")
                                          :xref (x / xref :value "UNIPROT:PK3CB_HUMAN" :prob "0.293"))
                                    :ARG0-of (x33 / inhibit-01
                                          :degree (x32 / less)))
                              :ARG1 (x35 / protein
                                    :name (x36 / name :op1 "p85")
                                    :xref (x42 / xref :value "UNIPROT:ARHG7_HUMAN" :prob "1.003")))))
            :ARG1-of (x38 / schematic
                  :name (x37 / name :op1 "Dp85")
                  :location (x39 / figure :mod "3c"))))


# ::id PMC36904800002.3
# ::snt (G) RAC1 and CDC42 directly stimulate p110b lipid kinase activity.
# ::tok ( G ) RAC1 and CDC42 directly stimulate p110b lipid kinase activity .
(x9 / stimulate-01
      :ARG1-of (x1 / describe-01
            :ARG0 (x2 / figure :mod "g"))
      :ARG0 (x5 / and
            :op1 (x3 / protein
                  :name (x4 / name :op1 "RAC1")
                  :xref (x15 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
            :op2 (x6 / protein
                  :name (x7 / name :op1 "CDC42")
                  :xref (x16 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :ARG1-of (x8 / direct-02)
      :ARG1 (x12 / lipid
            :op1 (x10 / enzyme
                  :name (x11 / name :op1 "p110b")
                  :xref (x / xref :value "UNIPROT:PK3CB_HUMAN" :prob "0.293"))
            :op2 (x14 / activity-06
                  :ARG0 (x13 / kinase))))


# ::id PMC36904800002.4
# ::snt Purified recombinant GTPgSloaded RAC1/CDC42 (1 mM) were added to purified recombinant p110b/p85, and lipid kinase activity was assessed in vitro.
# ::tok Purified recombinant GTPgSloaded RAC1 @/@ CDC42 ( 1 mM ) were added to purified recombinant p110b/p85 , and lipid kinase activity was assessed in vitro .
(x20 / assess-01
      :ARG0 (x5 / or
            :op1 (x2 / enzyme
                  :ARG1-of (x1 / purify-01)
                  :ARG0-of (x3 / recombine-01)
                  :name (x4 / name :op1 "GTPgSloaded"))
            :op1 (x6 / enzyme
                  :name (x7 / name :op1 "RAC1" :op2 "1"))
            :op2 (x8 / protein
                  :name (x9 / name :op1 "CDC42")
                  :xref (x / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
      :ARG1 (x19 / activity-06
            :ARG0 (x17 / and
                  :op1 (x12 / add-02
                        :ARG1 (x10 / disease
                              :name (x11 / name :op1 "multiple" :op2 "myeloma"))
                        :ARG2 (x13 / enzyme
                              :ARG1-of (x14 / purify-01)
                              :ARG1-of (x15 / recombine-01)
                              :name (x16 / name :op1 "p110b/p85")))
                  :op2 (x18 / lipid)))
      :manner (x21 / in-vitro))


# ::id PMC36904800002.5
# ::snt Figure 4. RAC/CDC42 Binding to p110b Regulates PI3K Activity In Vivo
# ::tok Figure 4. RAC @/@ CDC42 Binding to p110b Regulates PI3K Activity In Vivo
(x11 / regulate-01
      :ARG0 (x8 / bind-01
            :ARG1-of (x1 / describe-01
                  :ARG0 (x2 / figure :mod "4"))
            :ARG0 (x3 / macro-molecular-complex
                  :part (x4 / enzyme
                        :name (x5 / name :op1 "RAC")
                        :xref (x18 / xref :value "UNIPROT:AKT1_HUMAN" :prob "1.003"))
                  :part (x6 / protein
                        :name (x7 / name :op1 "CDC42")
                        :xref (x17 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004")))
            :ARG2 (x9 / protein
                  :name (x10 / name :op1 "p110b")
                  :xref (x / xref :value "UNIPROT:PK3CB_HUMAN" :prob "0.293")))
      :ARG1 (x14 / activity-06
            :ARG0 (x12 / enzyme
                  :name (x13 / name :op1 "PI3K")
                  :xref (x16 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))
            :manner (x15 / in-vivo)))


# ::id PMC36904800002.6
# ::snt (H) RAC1 and CDC42 activate p110b in vivo.
# ::tok ( H ) RAC1 and CDC42 activate p110b in vivo .
(x5 / and
      :ARG1-of (x1 / describe-01
            :ARG0 (x2 / figure :mod "h"))
      :op2 (x3 / protein
            :name (x4 / name :op1 "RAC1")
            :xref (x12 / xref :value "UNIPROT:RAC1_HUMAN" :prob "1.004"))
      :op3 (x6 / protein
            :name (x7 / name :op1 "CDC42")
            :xref (x13 / xref :value "UNIPROT:CDC42_HUMAN" :prob "1.004"))
      :ARG1-of (x8 / activate-01
            :ARG1 (x9 / enzyme
                  :name (x10 / name :op1 "p110b")
                  :xref (x / xref :value "UNIPROT:PK3CB_HUMAN" :prob "0.293"))
            :manner (x11 / in-vivo)))


# ::id PMC36904800003.1
# ::snt (E) Gbg subunits directly bind to the N terminus of Elmo1.
# ::tok ( E ) Gbg subunits directly bind to the N terminus of Elmo1 .
(x7 / bind-01
      :ARG1-of (x1 / describe-01
            :ARG0 (x2 / figure :mod "e"))
      :ARG0 (x3 / protein
            :name (x4 / name :op1 "Gbg")
            :xref (x12 / xref :value "UNIPROT:CFAB_HUMAN" :prob "0.602"))
      :ARG2 (x5 / subunit)
      :ARG1-of (x6 / direct-02)
      :ARG2 (x8 / protein-segment
            :name (x9 / name :op1 "n-terminus")
            :part-of (x10 / protein
                  :name (x11 / name :op1 "Elmo1")
                  :xref (x / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))))


# ::id PMC36904800003.2
# ::snt GST-tagged full-length Elmo1 and fragments shown (schematic) were incubated with lysates from COS7 cells expressing Gb2 and Gg1.Bound Gb was detected by western blot.
# ::tok GST @-@ tagged full @-@ length Elmo1 and fragments shown ( schematic ) were incubated with lysates from COS7 cells expressing Gb2 and Gg1.Bound Gb was detected by western blot .
(x11 / incubate-01
      :ARG0 (x3 / tag-01
            :ARG2 (x1 / protein
                  :name (x2 / name :op1 "GST")
                  :xref (x / xref :value "UNIPROT:SO6A1_HUMAN" :prob "1.002")))
      :ARG1 (x8 / fragment-01
            :ARG1-of (x5 / long-03
                  :ARG1-of (x4 / full-09))
            :mod (x6 / protein
                  :name (x7 / name :op1 "Elmo1")
                  :xref (x24 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604"))
            :ARG1-of (x9 / show-01)
            :ARG1-of (x10 / schematic))
      :ARG2 (x22 / detect-01
            :ARG1 (x12 / lysate
                  :source (x14 / cell
                        :name (x13 / name :op1 "COS7")
                        :ARG3-of (x15 / express-03
                              :ARG2 (x18 / and
                                    :op1 (x16 / protein
                                          :name (x17 / name :op1 "Gb2"))
                                    :op2 (x19 / enzyme
                                          :name (x20 / name :op1 "Gg1.Bound")))))
                  :name (x21 / name :op1 "Gb"))
            :ARG2 (x23 / immunoblot-01)))


# ::id PMC36904800003.3
# ::snt We thus probed Gbg subunits for direct binding to purified recombinant Elmo1 (Figure 6E) and found Gbg to strongly bind to full-length Elmo and several N-terminal fragments.
# ::tok We thus probed Gbg subunits for direct binding to purified recombinant Elmo1 ( Figure 6E ) and found Gbg to strongly bind to full @-@ length Elmo and several N @-@ terminal fragments .
(x1 / cause-01
      :ARG1 (x3 / probe-01
            :ARG0 (x2 / we)
            :ARG1 (x14 / and
                  :op1 (x5 / subunit
                        :name (x4 / name :op1 "Gbg")
                        :purpose (x7 / bind-01
                              :ARG1-of (x6 / direct-02)
                              :ARG2 (x8 / enzyme
                                    :ARG1-of (x9 / purify-01)
                                    :ARG1-of (x10 / recombine-01)
                                    :name (x11 / name :op1 "Elmo1")
                                    :xref (x29 / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604")))
                        :ARG1-of (x12 / describe-01
                              :ARG0 (x13 / figure :mod "6e")))
                  :op2 (x15 / find-01
                        :ARG1 (x24 / and
                              :op1 (x16 / enzyme
                                    :name (x17 / name :op1 "Gbg")
                                    :ARG1-of (x19 / bind-01
                                          :ARG1-of (x18 / strong-02)
                                          :ARG2 (x20 / protein
                                                :ARG1-of (x22 / long-03
                                                      :ARG1-of (x21 / full-09))
                                                :name (x23 / name :op1 "Elmo")
                                                :xref (x / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.233")))
                                    :xref (x30 / xref :value "UNIPROT:CFAB_HUMAN" :prob "0.602"))
                              :op2 (x28 / protein-segment
                                    :quant (x25 / several)
                                    :mod (x26 / protein-segment
                                          :name (x27 / name :op1 "n-terminus"))))))))


# ::id PMC36904800003.4
# ::snt Reminiscent of Dictyostelium ElmoE, we find the N terminus of human Elmo1 to directly bind Gbg subunits, suggesting conservation of this pathway in mammals.
# ::tok Reminiscent of Dictyostelium ElmoE , we find the N terminus of human Elmo1 to directly bind Gbg subunits , suggesting conservation of this pathway in mammals .
(x5 / find-01
      :mod (x1 / reminisce-01
            :ARG1 (x2 / enzyme
                  :name (x3 / name :op1 "Dictyostelium" :op2 "ElmoE")))
      :ARG0 (x4 / we)
      :ARG1 (x12 / bind-01
            :ARG1 (x6 / protein-segment
                  :name (x7 / name :op1 "n-terminus")
                  :part-of (x8 / protein
                        :mod (x9 / human)
                        :name (x10 / name :op1 "Elmo1")
                        :xref (x / xref :value "UNIPROT:ELMO1_HUMAN" :prob "0.604")))
            :ARG1-of (x11 / direct-02)
            :ARG2 (x14 / subunit
                  :name (x13 / name :op1 "Gbg")))
      :ARG0-of (x15 / suggest-01
            :ARG1 (x16 / conserve-01
                  :ARG1 (x18 / pathway
                        :mod (x17 / this))
                  :location (x19 / mammal))))


# ::id PMC43455130001.1
# ::snt We found that prolonged expression of active Ras resulted in up-regulation of the MKP3 gene via the PI3K/Akt pathway.
# ::tok We found that prolonged expression of active Ras resulted in up @-@ regulation of the MKP3 gene via the PI3K @/@ Akt pathway .
(x2 / find-01
      :ARG0 (x1 / we)
      :ARG1 (x8 / result-01
            :ARG1 (x4 / express-03
                  :ARG1-of (x3 / prolong-01)
                  :ARG2 (x5 / enzyme
                        :ARG1-of (x6 / activate-01)
                        :name (x7 / name :op1 "Ras")
                        :xref (x14 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG2 (x9 / upregulate-01
                  :ARG1 (x11 / gene
                        :name (x10 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
                  :instrument (x12 / pathway
                        :name (x13 / name :op1 "PI3K/Akt")))))


# ::id PMC43455130001.2
# ::snt Role of PI3K signaling in active Ras-induced MKP3 expression. (A) NIH3T3tet-on/H-RasG12R cells were treated with doxycycline (2 μg/ml) for 12 or 48 h
# ::tok Role of PI3K signaling in active Ras @-@ induced MKP3 expression . ( A ) NIH3T3 tet @-@ on/H @-@ RasG12R cells were treated with doxycycline ( 2 μg/ml ) for 12 or 48 h
(x17 / treat-04
      :ARG0 (x4 / signal-07
            :ARG1 (x1 / role
                  :poss (x2 / enzyme
                        :name (x3 / name :op1 "PI3K")
                        :xref (x26 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
            :ARG0-of (x5 / activity-06
                  :ARG1 (x11 / express-03
                        :ARG2-of (x8 / induce-01
                              :ARG0 (x6 / enzyme
                                    :name (x7 / name :op1 "Ras")
                                    :xref (x27 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                        :ARG2 (x9 / protein
                              :name (x10 / name :op1 "MKP3")
                              :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))))
      :li "a"
      :ARG1 (x16 / cell
            :name (x12 / name :op1 "NIH3T3")
            :mod (x13 / protein
                  :name (x14 / name :op1 "tet-crkl" :op2 "on/H"))
            :name (x15 / name :op1 "RasG12R"))
      :ARG2 (x18 / small-molecule
            :name (x19 / name :op1 "doxycycline")
            :quant "2"
            :name (x20 / name :op1 "μg/ml")
            :xref (x28 / xref :value "PUBCHEM:54671203" :prob "15.91623"))
      :duration (x21 / or
            :op1 (x22 / temporal-quantity
                  :quant "12"
                  :unit (x23 / hour))
            :op2 (x24 / temporal-quantity
                  :quant "48"
                  :unit (x25 / hour))))


# ::id PMC43455130001.3
# ::snt Taking these observations into consideration, our data suggest that the PI3K/Akt pathway transmits the active Ras signal to MKP3 expression, which in turn leads to the down-regulation of the Erk1/2 activity in NIH3T3 cells
# ::tok Taking these observations into consideration , our data suggest that the PI3K @/@ Akt pathway transmits the active Ras signal to MKP3 expression , which in turn leads to the down @-@ regulation of the Erk1 @/@ 2 activity in NIH3T3 cells
(x1 / take-01
      :ARG1 (x3 / observe-01
            :mod (x2 / this))
      :ARG2 (x4 / consider-02
            :ARG1 (x7 / suggest-01
                  :ARG0 (x6 / data
                        :poss (x5 / we))
                  :ARG1 (x8 / pathway
                        :name (x9 / name :op1 "PI3K/Akt"))
                  :ARG1 (x10 / transmit-01)))
      :ARG1 (x14 / signal-07
            :ARG1 (x11 / enzyme
                  :ARG0-of (x12 / activity-06)
                  :name (x13 / name :op1 "Ras")
                  :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))
            :ARG2 (x17 / express-03
                  :ARG2 (x15 / protein
                        :name (x16 / name :op1 "MKP3")
                        :xref (x26 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))))
      :ARG0-of (x19 / lead-03
            :mod (x18 / in-turn)
            :ARG1 (x20 / downregulate-01
                  :ARG1 (x23 / activity-06
                        :ARG0 (x21 / enzyme
                              :name (x22 / name :op1 "Erk1/2")))))
      :location (x25 / cell-line
            :name (x24 / name :op1 "NIH3T3")))


# ::id PMC43455130001.4
# ::snt Transient transfection of active RasV12, p110-CAAX (constitutively active p110 subunit of PI3K), or Akt led to a strong increase in reporter activity of the pMkp3-Luc(−1597/−10) construct
# ::tok Transient transfection of active RasV12 , p110 @-@ CAAX ( constitutively active p110 subunit of PI3K ) , or Akt led to a strong increase in reporter activity of the pMkp3 @-@ Luc ( −1597/−10 ) construct
(x26 / lead-03
      :ARG0 (x23 / or
            :op1 (x2 / transfect-01
                  :ARG1-of (x1 / transient-02)
                  :ARG2 (x3 / and
                        :op1 (x4 / activity-06
                              :ARG0 (x5 / and
                                    :op1 (x6 / enzyme
                                          :name (x7 / name :op1 "ras")
                                          :ARG2-of (x8 / mutate-01 :value "v12")
                                          :xref (x40 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                                    :op2 (x9 / enzyme
                                          :name (x10 / name :op1 "ras")
                                          :ARG2-of (x11 / mutate-01 :value "v12s35")
                                          :xref (x39 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))))
                        :op2 (x12 / protein
                              :name (x13 / name :op1 "p110")
                              :xref (x41 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.262"))
                        :op3 (x14 / enzyme
                              :name (x15 / name :op1 "rlf-caax")))
                  :ARG1-of (x20 / subunit
                        :mod (x16 / enzyme
                              :ARG0-of (x18 / activity-06
                                    :mod (x17 / constitutive))
                              :name (x19 / name :op1 "p110")
                              :xref (x42 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.262"))
                        :part-of (x21 / enzyme
                              :name (x22 / name :op1 "PI3K")
                              :xref (x38 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262"))))
            :op2 (x24 / enzyme
                  :name (x25 / name :op1 "Akt")
                  :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
      :ARG2 (x28 / increase-01
            :ARG1-of (x27 / strong-02)
            :ARG1 (x29 / report-01
                  :ARG1 (x30 / activity-06
                        :ARG0 (x31 / protein
                              :name (x32 / name :op1 "pMkp3")))
                  :ARG2-of (x33 / efficient-01)
                  :ARG1-of (x34 / describe-01
                        :ARG0 (x35 / protein
                              :name (x36 / name :op1 "−1597/−10")
                              :ARG2-of (x37 / construct-01))))))


# ::id PMC43455130001.5
# ::snt Northern blot analysis revealed that prolonged expression of active Ras increased MAP kinase phosphatase 3 (MKP3) mRNA expression, a negative regulator of Erk MAPK
# ::tok Northern blot analysis revealed that prolonged expression of active Ras increased MAP kinase phosphatase 3 ( MKP3 ) mRNA expression , a negative regulator of Erk MAPK
(x4 / reveal-01
      :ARG0 (x3 / analyze-01
            :mod (x1 / thing
                  :name (x2 / name :op1 "Northern" :op2 "blot")))
      :ARG1 (x6 / express-03
            :ARG1-of (x5 / prolong-01)
            :ARG2 (x7 / enzyme
                  :ARG1-of (x8 / activate-01)
                  :name (x9 / name :op1 "Ras")
                  :xref (x23 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
      :ARG1-of (x10 / increase-01
            :ARG1 (x11 / protein
                  :name (x12 / name
                        :op1 "MAP"
                        :op2 "kinase"
                        :op3 "phosphatase"
                        :op4 "3")))
      :ARG1-of (x13 / mkp3)
      :ARG1-of (x16 / express-03
            :ARG2 (x14 / nucleic-acid
                  :name (x15 / name :op1 "mRNA")))
      :ARG1 (x17 / downregulate-01
            :ARG1 (x18 / enzyme
                  :name (x19 / name :op1 "Erk")
                  :xref (x22 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
            :ARG2 (x20 / enzyme
                  :name (x21 / name :op1 "MAPK")
                  :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))))


# ::id PMC43455130001.6
# ::snt Up-regulation of MKP3 expression by active Ras expression.
# ::tok Up @-@ regulation of MKP3 expression by active Ras expression .
(x1 / upregulate-01
      :ARG1 (x4 / express-03
            :ARG2 (x2 / protein
                  :name (x3 / name :op1 "MKP3")
                  :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))
      :ARG0 (x8 / express-03
            :ARG2 (x5 / enzyme
                  :ARG0-of (x6 / activity-06)
                  :name (x7 / name :op1 "Ras")
                  :xref (x9 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))


# ::id PMC43455130001.7
# ::snt (A) NIH3T3tet-on/H-RasG12R cells were cultured and harvested at the indicated times after the addition of doxycycline (2 μg/ml).
# ::tok ( A ) NIH3T3 tet @-@ on/H @-@ RasG12R cells were cultured and harvested at the indicated times after the addition of doxycycline ( 2 μg/ml ) .
(x8 / culture-01
      :ARG1-of (x1 / describe-01
            :ARG0 (x2 / figure :mod "a"))
      :ARG1 (x7 / cell
            :name (x3 / name :op1 "NIH3T3")
            :mod (x4 / protein
                  :name (x5 / name :op1 "tet-crkl" :op2 "on/H"))
            :name (x6 / name :op1 "RasG12R"))
      :ARG1 (x9 / and
            :op1 (x10 / harvest-01))
      :time (x12 / time
            :ARG1-of (x11 / indicate-01))
      :time (x13 / after
            :op1 (x14 / add-02
                  :ARG1 (x15 / small-molecule
                        :name (x16 / name :op1 "doxycycline")
                        :quant "2"
                        :name (x17 / name :op1 "μg/ml")
                        :xref (x / xref :value "PUBCHEM:54671203" :prob "15.91623")))))


# ::id PMC43455130001.8
# ::snt Transient co-transfection of active H-RasV12 and pMkp3-Luc(−1597/−10) into NIH3T3 cells led to a concentration-dependent increase in promoter reporter activity, while dominant-negative RasN17 had no effect (Fig. 3C).
# ::tok Transient co @-@ transfection of active H @-@ RasV12 and pMkp3 @-@ Luc ( −1597/−10 ) into NIH3T3 cells led to a concentration @-@ dependent increase in promoter reporter activity , while dominant @-@ negative RasN17 had no effect ( Fig . 3C ) .
(x1 / multi-sentence
      :snt1 (x2 / transient-02
            :ARG1 (x3 / cotransfect-01
                  :ARG2 (x4 / activate-01
                        :ARG1 (x8 / and
                              :op1 (x5 / enzyme
                                    :name (x6 / name :op1 "h-ras")
                                    :ARG2-of (x7 / mutate-01 :value "v12")
                                    :xref (x32 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601"))
                              :op2 (x9 / enzyme
                                    :name (x10 / name :op1 "pMkp3")))
                        :ARG2-of (x11 / efficient-01)
                        :ARG1-of (x13 / into
                              :name (x12 / name :op1 "−1597/−10")))))
      :snt2 (x16 / lead-03
            :ARG0 (x15 / cell-line
                  :name (x14 / name :op1 "NIH3T3"))
            :ARG2 (x24 / contrast-01
                  :ARG1 (x19 / increase-01
                        :ARG0-of (x18 / depend-01
                              :ARG1 (x17 / concentrate-02))
                        :ARG1 (x23 / activity-06
                              :ARG0 (x20 / molecular-physical-entity
                                    :ARG0-of (x21 / promote-01))
                              :ARG0-of (x22 / report-01)))
                  :ARG2 (x29 / affect-01
                        :ARG0 (x25 / enzyme
                              :ARG0-of (x26 / dominate-01)
                              :ARG2-of (x27 / mutate-01 :mod "-/-")
                              :name (x28 / name :op1 "ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                        :polarity "-")
                  :ARG1-of (x30 / describe-01
                        :ARG0 (x31 / figure :mod "3c")))))


# ::id PMC43455130001.9
# ::snt Thus, long-term activation of the Ras signaling pathway up-regulates MKP3 expression at the transcriptional level in NIH3T3 fibroblasts
# ::tok Thus , long @-@ term activation of the Ras signaling pathway up @-@ regulates MKP3 expression at the transcriptional level in NIH3T3 fibroblasts
(x1 / cause-01
      :ARG1 (x8 / regulate-01
            :ARG1-of (x2 / long-03)
            :mod (x7 / pathway
                  :ARG1-of (x3 / activate-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "Ras")
                              :xref (x16 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                  :ARG0-of (x6 / signal-07))
            :ARG1 (x11 / express-03
                  :ARG2 (x9 / protein
                        :name (x10 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
                  :ARG3 (x13 / level
                        :mod (x12 / transcribe-01)))
            :location (x15 / fibroblast
                  :name (x14 / name :op1 "NIH3T3"))))


# ::id PMC43455130002.2
# ::snt We found that prolonged expression of active Ras resulted in up-regulation of the MKP3 gene via the PI3K/Akt pathway.
# ::tok We found that prolonged expression of active Ras resulted in up @-@ regulation of the MKP3 gene via the PI3K @/@ Akt pathway .
(x2 / find-01
      :ARG0 (x1 / we)
      :ARG1 (x8 / result-01
            :ARG1 (x4 / express-03
                  :ARG1-of (x3 / prolong-01)
                  :ARG2 (x5 / enzyme
                        :ARG1-of (x6 / activate-01)
                        :name (x7 / name :op1 "Ras")
                        :xref (x14 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
            :ARG2 (x9 / upregulate-01
                  :ARG1 (x11 / gene
                        :name (x10 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
                  :instrument (x12 / pathway
                        :name (x13 / name :op1 "PI3K/Akt")))))


# ::id PMC43455130002.3
# ::snt Taking these observations into consideration, our data suggest that the PI3K/Akt pathway transmits the active Ras signal to MKP3 expression, which in turn leads to the down-regulation of the Erk1/2 activity in NIH3T3 cells.
# ::tok Taking these observations into consideration , our data suggest that the PI3K @/@ Akt pathway transmits the active Ras signal to MKP3 expression , which in turn leads to the down @-@ regulation of the Erk1 @/@ 2 activity in NIH3T3 cells .
(x1 / take-01
      :ARG1 (x3 / observe-01
            :mod (x2 / this))
      :ARG2 (x4 / consider-01)
      :ARG1 (x7 / suggest-01
            :ARG0 (x6 / data
                  :poss (x5 / we))
            :ARG1 (x11 / activity-06
                  :ARG0 (x8 / pathway
                        :name (x9 / name :op1 "PI3K/Akt"))
                  :ARG1 (x10 / transmit-01)
                  :ARG1 (x14 / signal-07
                        :ARG0 (x12 / enzyme
                              :name (x13 / name :op1 "Ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                  :ARG2 (x17 / express-03
                        :ARG2 (x15 / protein
                              :name (x16 / name :op1 "MKP3")
                              :xref (x26 / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))
                  :ARG0-of (x19 / lead-03
                        :mod (x18 / in-turn)
                        :ARG1 (x20 / downregulate-01
                              :ARG1 (x23 / activity-06
                                    :ARG0 (x21 / enzyme
                                          :name (x22 / name :op1 "Erk1/2"))
                                    :location (x25 / cell-line
                                          :name (x24 / name :op1 "NIH3T3"))))))))


# ::id PMC43455130002.4
# ::snt Transient transfection of active RasV12, p110-CAAX (constitutively active p110 subunit of PI3K), or Akt led to a strong increase in reporter activity of the pMkp3-Luc(−1597/−10) construct (Fig. 4C).
# ::tok Transient transfection of active RasV12 , p110 @-@ CAAX ( constitutively active p110 subunit of PI3K ) , or Akt led to a strong increase in reporter activity of the pMkp3 @-@ Luc ( −1597/−10 ) construct ( Fig . 4C ) .
(x1 / multi-sentence
      :snt1 (x2 / and
            :op1 (x4 / transfect-01
                  :ARG1-of (x3 / transient-02)
                  :ARG2 (x5 / activity-06
                        :ARG0 (x6 / and
                              :op1 (x7 / enzyme
                                    :name (x8 / name :op1 "ras")
                                    :ARG2-of (x9 / mutate-01 :value "v12")
                                    :xref (x42 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                              :op2 (x10 / enzyme
                                    :name (x11 / name :op1 "ras")
                                    :ARG2-of (x12 / mutate-01 :value "v12s35")
                                    :xref (x43 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203")))))
            :op2 (x13 / protein
                  :name (x14 / name :op1 "p110")
                  :xref (x44 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.262"))
            :op3 (x15 / enzyme
                  :name (x16 / name :op1 "rlf-caax")))
      :snt2 (x27 / lead-03
            :ARG0 (x24 / or
                  :op1 (x21 / subunit
                        :mod (x17 / enzyme
                              :ARG0-of (x19 / activity-06
                                    :mod (x18 / constitutive))
                              :name (x20 / name :op1 "p110")
                              :xref (x45 / xref :value "UNIPROT:EXOS6_HUMAN" :prob "0.262"))
                        :part-of (x22 / enzyme
                              :name (x23 / name :op1 "PI3K")
                              :xref (x41 / xref :value "UNIPROT:ELAF_HUMAN" :prob "0.262")))
                  :op2 (x25 / enzyme
                        :name (x26 / name :op1 "Akt")
                        :xref (x / xref :value "UNIPROT:AKT1_HUMAN" :prob "0.203")))
            :ARG2 (x29 / increase-01
                  :ARG1-of (x28 / strong-02)
                  :ARG1 (x30 / report-01
                        :ARG1 (x31 / activity-06
                              :ARG0 (x32 / protein
                                    :name (x33 / name :op1 "pMkp3")))
                        :ARG2-of (x34 / efficient-01)
                        :ARG1-of (x35 / describe-01
                              :ARG0 (x36 / protein
                                    :name (x37 / name :op1 "−1597/−10")
                                    :ARG2-of (x38 / construct-01)))))
            :ARG1-of (x39 / describe-01
                  :ARG0 (x40 / figure :mod "4c"))))


# ::id PMC43455130002.5
# ::snt Northern blot analysis revealed that prolonged expression of active Ras increased MAP kinase phosphatase 3 (MKP3) mRNA expression, a negative regulator of Erk MAPK
# ::tok Northern blot analysis revealed that prolonged expression of active Ras increased MAP kinase phosphatase 3 ( MKP3 ) mRNA expression , a negative regulator of Erk MAPK
(x4 / reveal-01
      :ARG0 (x3 / analyze-01
            :mod (x1 / thing
                  :name (x2 / name :op1 "Northern" :op2 "blot")))
      :ARG1 (x6 / express-03
            :ARG1-of (x5 / prolong-01)
            :ARG2 (x7 / enzyme
                  :ARG1-of (x8 / activate-01)
                  :name (x9 / name :op1 "Ras")
                  :xref (x23 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
      :ARG1-of (x10 / increase-01
            :ARG1 (x11 / protein
                  :name (x12 / name
                        :op1 "MAP"
                        :op2 "kinase"
                        :op3 "phosphatase"
                        :op4 "3")))
      :ARG1-of (x13 / mkp3)
      :ARG1-of (x16 / express-03
            :ARG2 (x14 / nucleic-acid
                  :name (x15 / name :op1 "mRNA")))
      :ARG1 (x17 / downregulate-01
            :ARG1 (x18 / enzyme
                  :name (x19 / name :op1 "Erk")
                  :xref (x22 / xref :value "UNIPROT:EPHB2_HUMAN" :prob "0.603"))
            :ARG2 (x20 / enzyme
                  :name (x21 / name :op1 "MAPK")
                  :xref (x / xref :value "UNIPROT:MK01_HUMAN" :prob "0.313"))))


# ::id PMC43455130002.6
# ::snt Up-regulation of MKP3 expression by active Ras expression.
# ::tok Up @-@ regulation of MKP3 expression by active Ras expression .
(x1 / upregulate-01
      :ARG1 (x4 / express-03
            :ARG2 (x2 / protein
                  :name (x3 / name :op1 "MKP3")
                  :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002")))
      :ARG0 (x8 / express-03
            :ARG2 (x5 / enzyme
                  :ARG0-of (x6 / activity-06)
                  :name (x7 / name :op1 "Ras")
                  :xref (x9 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213"))))


# ::id PMC43455130002.7
# ::snt (A) NIH3T3tet-on/H-RasG12R cells were cultured and harvested at the indicated times after the addition of doxycycline (2 μg/ml)
# ::tok ( A ) NIH3T3 tet @-@ on/H @-@ RasG12R cells were cultured and harvested at the indicated times after the addition of doxycycline ( 2 μg/ml )
(x8 / harvest-01
      :ARG0 (x6 / culture-01
            :li "a"
            :ARG1 (x5 / cell
                  :name (x1 / name :op1 "NIH3T3")
                  :mod (x2 / protein
                        :name (x3 / name :op1 "tet-crkl" :op2 "on/H"))
                  :name (x4 / name :op1 "RasG12R")))
      :mod (x7 / and)
      :time (x10 / time
            :ARG1-of (x9 / indicate-01))
      :time (x11 / after
            :op1 (x12 / add-02
                  :ARG1 (x13 / small-molecule
                        :name (x14 / name :op1 "doxycycline")
                        :quant "2"
                        :name (x15 / name :op1 "μg/ml")
                        :xref (x / xref :value "PUBCHEM:54671203" :prob "15.91623")))))


# ::id PMC43455130002.8
# ::snt Transient co-transfection of active H-RasV12 and pMkp3-Luc(−1597/−10) into NIH3T3 cells led to a concentration-dependent increase in promoter reporter activity, while dominant-negative RasN17 had no effect (Fig. 3C).
# ::tok Transient co @-@ transfection of active H @-@ RasV12 and pMkp3 @-@ Luc ( −1597/−10 ) into NIH3T3 cells led to a concentration @-@ dependent increase in promoter reporter activity , while dominant @-@ negative RasN17 had no effect ( Fig . 3C ) .
(x1 / multi-sentence
      :snt1 (x2 / transient-02
            :ARG1 (x3 / cotransfect-01
                  :ARG2 (x4 / activate-01
                        :ARG1 (x8 / and
                              :op1 (x5 / enzyme
                                    :name (x6 / name :op1 "h-ras")
                                    :ARG2-of (x7 / mutate-01 :value "v12")
                                    :xref (x32 / xref :value "UNIPROT:Q16046_HUMAN" :prob "0.601"))
                              :op2 (x9 / enzyme
                                    :name (x10 / name :op1 "pMkp3")))
                        :ARG2-of (x11 / efficient-01)
                        :ARG1-of (x13 / into
                              :name (x12 / name :op1 "−1597/−10")))))
      :snt2 (x16 / lead-03
            :ARG0 (x15 / cell-line
                  :name (x14 / name :op1 "NIH3T3"))
            :ARG2 (x24 / contrast-01
                  :ARG1 (x19 / increase-01
                        :ARG0-of (x18 / depend-01
                              :ARG1 (x17 / concentrate-02))
                        :ARG1 (x23 / activity-06
                              :ARG0 (x20 / molecular-physical-entity
                                    :ARG0-of (x21 / promote-01))
                              :ARG0-of (x22 / report-01)))
                  :ARG2 (x29 / affect-01
                        :ARG0 (x25 / enzyme
                              :ARG0-of (x26 / dominate-01)
                              :ARG2-of (x27 / mutate-01 :mod "-/-")
                              :name (x28 / name :op1 "ras")
                              :xref (x / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.203"))
                        :polarity "-")
                  :ARG1-of (x30 / describe-01
                        :ARG0 (x31 / figure :mod "3c")))))


# ::id PMC43455130002.9
# ::snt Thus, long-term activation of the Ras signaling pathway up-regulates MKP3 expression at the transcriptional level in NIH3T3 fibroblasts
# ::tok Thus , long @-@ term activation of the Ras signaling pathway up @-@ regulates MKP3 expression at the transcriptional level in NIH3T3 fibroblasts
(x1 / cause-01
      :ARG1 (x8 / regulate-01
            :ARG1-of (x2 / long-03)
            :mod (x7 / pathway
                  :ARG1-of (x3 / activate-01
                        :ARG1 (x4 / enzyme
                              :name (x5 / name :op1 "Ras")
                              :xref (x16 / xref :value "UNIPROT:RASA1_HUMAN" :prob "0.213")))
                  :ARG0-of (x6 / signal-07))
            :ARG1 (x11 / express-03
                  :ARG2 (x9 / protein
                        :name (x10 / name :op1 "MKP3")
                        :xref (x / xref :value "UNIPROT:DUS6_HUMAN" :prob "1.002"))
                  :ARG3 (x13 / level
                        :mod (x12 / transcribe-01)))
            :location (x15 / fibroblast
                  :name (x14 / name :op1 "NIH3T3"))))


